<SEC-DOCUMENT>0001650664-25-000125.txt : 20250812
<SEC-HEADER>0001650664-25-000125.hdr.sgml : 20250812
<ACCEPTANCE-DATETIME>20250812160844
ACCESSION NUMBER:		0001650664-25-000125
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250812
DATE AS OF CHANGE:		20250812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Editas Medicine, Inc.
		CENTRAL INDEX KEY:			0001650664
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				464097528
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37687
		FILM NUMBER:		251206724

	BUSINESS ADDRESS:	
		STREET 1:		11 HURLEY ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		617-401-9000

	MAIL ADDRESS:	
		STREET 1:		11 HURLEY ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>edit-20250630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1ab0433d-837b-430f-b71f-73abb830ced3,g:6d451f6e-3d6d-4567-be55-1f6fd20083c0,d:19632d208545492d9596922f4cf084ba-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:edit="http://www.editasmedicine.com/20250630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>edit-20250630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001650664</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-26">December 31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-29">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-100">http://fasb.org/us-gaap/2025#ServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-101">http://fasb.org/us-gaap/2025#ServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-102">http://fasb.org/us-gaap/2025#ServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-103">http://fasb.org/us-gaap/2025#ServiceMember</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-338">3,877</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-339">3,877</ix:nonFraction><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> As of June&#160;30, 2025 and June&#160;30, 2024, restricted cash of $3,877 and $3,877 was included in Restricted cash and other non-current assets on the Consolidated Balance Sheet, respectively.</span></div></td></tr></table></div></ix:footnote></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="edit-20250630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="security"><xbrli:measure>edit:security</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="position"><xbrli:measure>edit:position</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>edit:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:EmployeeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:EmployeeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edit:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edit:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:LicensorExpenseReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:LicensorExpenseReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:LicensorExpenseReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:LicensorExpenseReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:LicenseAndServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:LicenseAndServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:LicenseAndServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:LicenseAndServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:AmendedCollaborationAgreement2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:AmendedCollaborationAgreement2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">edit:DRIHealthcareAcquisitionsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-03</xbrli:startDate><xbrli:endDate>2024-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">edit:DRIHealthcareAcquisitionsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-03</xbrli:startDate><xbrli:endDate>2024-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">edit:DRIHealthcareAcquisitionsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-03</xbrli:startDate><xbrli:endDate>2024-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">edit:DRIHealthcareAcquisitionsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">edit:DRIHealthcareAcquisitionsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">edit:DRIHealthcareAcquisitionsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-11</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:EmployeeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:AccelerationOfExpenseChangeInUsefulLifeEstimateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:ImpairmentChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:EmployeeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:EmployeeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:AccelerationOfExpenseChangeInUsefulLifeEstimateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:AccelerationOfExpenseChangeInUsefulLifeEstimateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:ImpairmentChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:ImpairmentChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edit:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-322 f-323" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/></ix:resources></ix:header></div><div id="i19632d208545492d9596922f4cf084ba_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'null',sans-serif;font-size:10pt;font-weight:700;line-height:119%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June&#160;30, 2025</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:119%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from ____________ to ________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37687</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">EDITAS MEDICINE, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">46-4097528</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">11 Hurley Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">Massachusetts</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">02141</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">401-9000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:37.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.206%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.748%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock</ix:nonNumeric>, $0.0001 par value per share</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">EDIT</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-21">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of Common Stock outstanding as of August&#160;7, 2025 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">89,920,164</ix:nonFraction>. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Editas Medicine, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_10">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_13">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_16">Condensed Consolidated Balance Sheets as of </a>June&#160;30, 2025<a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_16"> and </a>December&#160;31, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_19">Condensed Consolidated Statements of Operations for the </a>three and six<a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_19"> months ended </a>June&#160;30, 2025<a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_19"> and </a>2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_22">Condensed Consolidated Statements of Comprehensive Loss for the </a>three and six<a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_22"> months ended </a>June&#160;30, 2025<a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_22"> and </a>2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_25">Condensed Consolidated Statements of Stockholders&#8217; Equity for the </a>three and six months ended June&#160;30, 2025 and 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_28">Condensed Consolidated Statements of Cash Flows for the </a>six<a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_28"> months ended </a>June&#160;30, 2025<a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_28"> and </a>2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_31">Notes to Condensed Consolidated Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_79">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_79">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_100">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_100">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_100">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_103">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_103">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_103">35</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_106">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_106">36</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_109">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_109">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_109">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_112">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_112">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_112">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_115">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_115">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_115">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_118">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_118">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_118">39</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_121">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i19632d208545492d9596922f4cf084ba_121">40</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i19632d208545492d9596922f4cf084ba_13"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i19632d208545492d9596922f4cf084ba_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Editas Medicine, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(amounts in thousands, except share and per share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">138,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">131,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-32">39,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">138,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ReceivablesNetCurrent" scale="3" id="f-34">588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">16,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">3,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">3,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">182,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">289,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-40">4,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-41">14,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-42">19,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-43">32,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Restricted cash and other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">4,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">5,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-46">210,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-47">341,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">6,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">5,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">48,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">45,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Liability for sale of future revenues, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">6,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">6,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">14,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">65,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">77,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">14,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">20,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Liability for sale of future revenues - non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">51,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">52,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">54,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">54,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">4,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">3,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-68">191,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-69">207,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Stockholders&#8217; equity </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-70"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-71">0.0001</ix:nonFraction></ix:nonFraction> par value per share: <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-73">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-74"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-75"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-76"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-77">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-80"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-81">0.0001</ix:nonFraction></ix:nonFraction> par value per share: <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-82">390,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83">195,000,000</ix:nonFraction> shares authorized at June&#160;30, 2025 and December&#160;31, 2024, respectively; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-85">87,388,425</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-86"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-87">82,734,696</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2025 and December&#160;31, 2024, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-88">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-89">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-90">1,616,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-91">1,602,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-92">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-93">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-94">1,597,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-95">1,468,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-96">19,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-97">134,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-98">210,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-99">341,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Editas Medicine, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(amounts in thousands, except share and per share data)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-100"><span style="-sec-ix-hidden:f-101"><span style="-sec-ix-hidden:f-102"><span style="-sec-ix-hidden:f-103">Collaboration and other research and development revenues</span></span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-104">3,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-105">513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-106">8,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-107">1,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">16,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-109">54,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-110">42,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-111">102,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-112">12,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-113">18,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-114">26,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-115">37,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-116">26,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:fixed-zero" scale="3" id="f-117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-118">66,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:fixed-zero" scale="3" id="f-119">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-120">55,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-121">72,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-122">135,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-123">140,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-124">51,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-125">71,903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-126">127,707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-127">138,893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">1,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-129">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-130">2,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-131">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest related to sale of future revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-132">2,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-134">4,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-135">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-136">2,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-137">4,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-138">4,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-139">9,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-140">1,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-141">4,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-142">1,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-143">9,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">53,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">67,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-146">129,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-147">129,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-148"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-149">0.63</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-150"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-151">0.82</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-152"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-153">1.54</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-154"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-155">1.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-156"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-157">84,412,200</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-158"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-159">82,310,368</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-160"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-161">83,737,382</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-162"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-163">82,124,603</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Editas Medicine, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(amounts in thousands)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">53,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-165">67,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-166">129,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-167">129,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss on marketable debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-168">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-169">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-170">253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-171">640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-172">53,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-173">67,723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-174">129,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-175">130,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Editas Medicine, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(amounts in thousands, except share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.573%"/><td style="width:0.1%"/></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-176">82,734,696</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-177">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-178">1,602,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-179">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-180">1,468,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">134,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock from at the market equity offering</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-182">706,236</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-183">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-184">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Vesting of restricted common stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-185">268,604</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-186">2,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-187">2,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Unrealized loss on marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-188">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-189">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-190">76,088</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-191">76,088</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-192">83,709,536</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-193">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">1,606,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-195">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-196">1,544,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-197">62,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock from at the market equity offering</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-198">3,419,836</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-199">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-200">7,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-201">7,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-202">2,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-203">2,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Vesting of restricted common stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-204">102,894</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-205">156,159</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-206">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-207">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Unrealized loss on marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-208">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-209">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-210">53,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-211">53,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-212">87,388,425</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-213">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-214">1,616,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-215">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-216">1,597,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-217">19,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.573%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.803%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.816%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-218">81,767,263</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-219">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-220">1,580,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-221">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-222">1,231,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-223">349,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-224">21,975</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-225">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-226">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Vesting of restricted common stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-227">445,713</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-228">7,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-229">7,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Unrealized loss on marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-230">524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-231">524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-232">61,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-233">61,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-234">82,234,951</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-235">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-236">1,588,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-237">326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-238">1,293,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-239">294,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-240">5,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-241">5,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Vesting of restricted common stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-242">121,643</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-243">72,920</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-244">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-245">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Unrealized loss on marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-246">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-247">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-248">67,607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-249">67,607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-250">82,429,514</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-251">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-252">1,593,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-253">442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-254">1,360,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-255">232,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Editas Medicine, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(amounts in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.647%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash flow from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-256">129,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-257">129,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-258">5,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-259">12,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-260">3,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-261">2,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="3" id="f-262">2,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net amortization of premiums and discounts on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="f-264">840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-265">3,596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest related to sale of future revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="edit:InterestRelatedToSaleOfFutureRevenues" format="ixt:num-dot-decimal" scale="3" id="f-266">4,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="edit:InterestRelatedToSaleOfFutureRevenues" format="ixt:fixed-zero" scale="3" id="f-267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of held for sale assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="3" id="f-268">3,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="3" id="f-269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other non-cash items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-270">390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-271">415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-272">15,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-273">9,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-274">418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-275">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="edit:IncreaseDecreaseInRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-276">8,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="edit:IncreaseDecreaseInRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-277">3,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-278">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-279">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-280">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-281">5,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-282">2,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-283">6,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest on sale of future revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="edit:IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues" format="ixt:num-dot-decimal" scale="3" id="f-284">2,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="edit:IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues" format="ixt:fixed-zero" scale="3" id="f-285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-286">6,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-288">9,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-289">2,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-290">1,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-291">1,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-292">98,011</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-293">106,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash flow from investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-294">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-295">5,365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the sale of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="3" id="f-296">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" format="ixt:fixed-zero" scale="3" id="f-297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-299">86,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-300">99,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-301">138,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-302">99,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-303">47,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash flow from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Repayment on sale of future revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-304">2,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" scale="3" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock from at the market equity offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-306">8,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-309">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-310">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-311">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-312">5,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-313">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-314">7,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-315">59,211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-316">135,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-317">127,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-318">142,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-319">68,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-320">138,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-321">64,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-322">3,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-323">3,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-324">142,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-325">68,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.647%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.649%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> As of June&#160;30, 2025 and June&#160;30, 2024, restricted cash of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-326">3,877</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-327">3,877</ix:nonFraction> was included in Restricted cash and other non-current assets on the Consolidated Balance Sheet, respectively.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental disclosure of cash and non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fixed asset additions included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-329">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid in connection with operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-330">11,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-331">7,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of operating lease liabilities and right-of-use assets due to lease modification</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-332">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-333">794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commencement of right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="edit:CommencementOfRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="f-334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="edit:CommencementOfRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-335">7,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash termination of right-of-use asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="edit:NonCashTerminationOfRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-336">4,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="edit:NonCashTerminationOfRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Editas Medicine, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i19632d208545492d9596922f4cf084ba_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-340" continuedAt="f-340-1" escape="true">Nature of Business</ix:nonNumeric></span></div><ix:continuation id="f-340-1"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Editas Medicine, Inc. (the &#8220;Company&#8221;) is a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, Inc. (&#8220;Juno Therapeutics&#8221;), a wholly owned subsidiary of the Bristol-Myers Squibb Company (&#8220;BMS&#8221;), payments received under its former strategic alliance with Allergan Pharmaceuticals International Limited (together with its affiliates, &#8220;Allergan&#8221;), which was terminated in August 2020, payments received under the purchase and sale agreement with DRI Healthcare Acquisitions LP (&#8220;DRI&#8221;), and payments received in conjunction with the Company&#8217;s license agreement with Vertex Pharmaceuticals, Inc (&#8220;Vertex&#8221;, and such agreement, the &#8220;Vertex License Agreement&#8221;).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of June&#160;30, 2025, the Company has raised an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="9" id="f-341">1.0</ix:nonFraction> billion in net proceeds through the sale of shares of its common stock in public offerings and at-the-market offerings. The Company also has funded its business from payments received under its purchase and sale agreement with DRI, payments received under the Vertex License Agreement, its research collaboration with BMS through its wholly owned subsidiary Juno Therapeutics and its former strategic alliance with Allergan (which was terminated in August 2020). As of June&#160;30, 2025, the Company had cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="edit:CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal" scale="6" id="f-342">178.5</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In May 2021, the Company entered into a common stock sales agreement with TD Securities (USA) LLC (as successor to Cowen and Company, LLC) (&#8220;TD Cowen&#8221;), under which the Company from time to time can issue and sell shares of the Company&#8217;s common stock through TD Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="edit:SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued" scale="6" id="f-343">300.0</ix:nonFraction> million. The Company amended the common stock sales agreement with TD Cowen in February 2024 in connection with filing a new registration statement.  In March 2025, the Company further amended its common stock sales agreement with TD Cowen in connection with amending its existing shelf registration statement following the loss of the Company&#8217;s status as a &#8220;well-known seasoned issuer&#8221; (as defined under Rule 405 of the Securities Act of 1933, as amended), reducing the amount of shares of common stock the Company may issue and sell through TD Cowen to aggregate gross sale proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="edit:SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued" format="ixt:num-dot-decimal" scale="6" id="f-344">150.0</ix:nonFraction>&#160;million (the &#8220;ATM Facility&#8221;). As of June&#160;30, 2025, the Company has sold <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-345">4,126,072</ix:nonFraction> shares of common stock under the ATM Facility for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-346">8.6</ix:nonFraction> million and has $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="edit:SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable" scale="6" id="f-347">141.4</ix:nonFraction> million available under the ATM Facility. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred annual net operating losses in every year since its inception.  As of August&#160;12, 2025, the issuance date of the consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance date of the consolidated financial statements. The Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="f-348">1.6</ix:nonFraction> billion at June&#160;30, 2025, and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations, and financial condition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-349" continuedAt="f-349-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-349-1" continuedAt="f-349-2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2024 (the &#8220;Annual Report&#8221;).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Editas Securities Corporation and Editas Medicine, LLC. All intercompany transactions and balances of the subsidiaries have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.  The three months ended June&#160;30, 2025 and 2024 are referred to as the second quarter of 2025 and 2024, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; to the consolidated financial statements included in the Annual Report. There have been no material changes to the significant accounting policies previously disclosed in the Annual Report with the exception of the following:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with restructuring activities in the period in which the liability is incurred.  Typical costs associated with restructuring activities include, employee termination benefits, contract termination costs and on-going contract costs for which there is no economic benefit.  For costs associated with employee terminations in which the employee is subject to an existing benefit arrangement, the post-employment benefits are recognized when probable and estimable.  Other employee termination costs are measured and recognized on the communication date, unless there is a required future service period, in which case, the expense is recognized over the service period.  Contract termination costs are recognized upon termination of the contract and costs for on-going contracts for which there is no future benefit, are recognized at fair value on the cease-use date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made estimates and judgments regarding the amount and timing of its restructuring expense and liability, including current and future period termination benefits and other exit costs to be incurred when related actions take place. Restructuring charges are reflected in the Company's condensed consolidated statements of operations. Actual results may differ from these estimates.  Refer to Note 12, &#8220;Restructuring and Impairment Charges&#8221; for further information.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-350" continuedAt="f-350-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company will incorporate the changes in disclosure requirements in its financial statements included in its 2025 Annual Report.     </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><ix:continuation id="f-350-1"><ix:continuation id="f-349-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income -Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve the disclosure of expenses by providing more detailed information about the types of expenses in commonly presented expense captions. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments can be applied either prospectively or retrospectively. The Company has not early adopted this ASU and is currently evaluating the impact of this new standard on its consolidated financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div id="i19632d208545492d9596922f4cf084ba_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-351" continuedAt="f-351-1" escape="true">Cash Equivalents and Marketable Securities </ix:nonNumeric></span></div><ix:continuation id="f-351-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-352" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities consisted of the following at June&#160;30, 2025 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Allowance<br/>for Credit<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-353">39,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-355">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-356">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-357">39,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-358">138,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-362">138,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-363">178,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="f-364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-365">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-366">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-367">178,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities consisted of the following at December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Allowance<br/>for Credit<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-368">131,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="f-369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-372">131,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-373">6,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-376">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-377">6,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-378">131,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-380">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-382">131,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-383">269,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-385">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-386">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-387">269,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company did <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="0" id="f-388">not</ix:nonFraction> hold any marketable securities that were in a continuous unrealized loss position for more than twelve months. Furthermore, the Company has determined that there were no material changes in the credit risk of the securities. As of June&#160;30, 2025, the Company holds <ix:nonFraction unitRef="security" contextRef="c-3" decimals="INF" name="edit:MarketableSecuritiesNoncurrentNumberOfSecurities" format="ixt:fixed-zero" scale="0" id="f-389">no</ix:nonFraction> securities with remaining maturities greater than <ix:nonNumeric contextRef="c-1" name="edit:MarketableSecuritiesRemainingMaturityTerm" format="ixt-sec:durwordsen" id="f-390">one year</ix:nonNumeric>.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-391"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-392">no</ix:nonFraction></ix:nonFraction> realized gains or losses on available-for-sale securities during the six months ended June&#160;30, 2025 or 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-393" continuedAt="f-393-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-393-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-394" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of June&#160;30, 2025 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-395">138,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-396">138,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-399">39,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-400">39,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-403">3,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-404">3,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-407">182,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-408">182,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of December&#160;31, 2024 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-411">131,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-412">131,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-415">6,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-417">6,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-418">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-419">131,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-420">131,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-423">3,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-424">3,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-427">273,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-428">267,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-429">6,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s liability for sale of future revenues approximates the amount recorded on the Company&#8217;s balance sheet as of June&#160;30, 2025 and December&#160;31, 2024, which represents a level 3 fair value measurement.</span></div></ix:continuation><div id="i19632d208545492d9596922f4cf084ba_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-431" continuedAt="f-431-1" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-432" escape="true"><ix:continuation id="f-431-1"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">External research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="edit:AccruedExternalResearchAndDevelopmentExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-433">2,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="edit:AccruedExternalResearchAndDevelopmentExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-434">11,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-435">3,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-436">11,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sublicense and license fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="edit:SublicenseAndLicenseFeesCurrent" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="edit:SublicenseAndLicenseFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-438">6,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property and patent related fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="edit:IntellectualPropertyAndPatentRelatedFeesCurrent" scale="3" id="f-439">685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="edit:IntellectualPropertyAndPatentRelatedFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-440">1,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional service expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-441">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-442">1,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:RestructuringReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-443">6,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:RestructuringReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-444">10,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RestructuringReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-445">33,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:RestructuringReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-446">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-447">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-448">808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-449">48,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-450">45,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-451" continuedAt="f-451-1" escape="true">Property and Equipment, net</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-452" escape="true"><ix:continuation id="f-451-1"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory and manufacturing equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-453">21,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-454">29,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-455">8,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-456">11,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-457">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-458">1,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-460">827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-461">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-462">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-463">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-464">2,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-465">31,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-466">46,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-467">26,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-468">31,648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-469">4,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-470">14,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i19632d208545492d9596922f4cf084ba_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-471" continuedAt="f-471-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-471-1" continuedAt="f-471-2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to a number of license agreements under which the Company licenses patents, patent applications and other intellectual property from third parties. As such, the Company is obligated to pay licensors for various costs including upfront license fees, annual license fees, certain licensor expense reimbursements, success payments, research funding payments, and milestones triggerable upon certain development, regulatory, and commercial events as well as royalties on future product sales. These contracts are generally cancellable, with notice, at the Company&#8217;s option and do not have significant cancellation penalties. The terms and conditions as well as the accounting analysis for the Company&#8217;s significant commitments and contingencies are described in Note 8, &#8220;Commitments and Contingencies&#8221; to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensor Expense Reimbursement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to reimburse The Broad Institute, Inc. (&#8220;Broad&#8221;) and the President and Fellows of Harvard College (&#8220;Harvard&#8221;) for expenses incurred by each of them associated with the prosecution and maintenance of the patent rights that the Company licenses from them pursuant to the Amended and Restated Cas9-I License Agreement by and among the Company, Broad and Harvard, including the interference and opposition proceedings involving patents licensed to the Company under the license agreement, and other license agreements between the Company and Broad. As such, the Company anticipates that it has a substantial commitment in connection with these proceedings until such time as these proceedings have been resolved, but the amount of such commitment is not determinable. The Company incurred an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:ProfessionalAndContractServicesExpense" scale="6" id="f-472">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:ProfessionalAndContractServicesExpense" scale="6" id="f-473">4.2</ix:nonFraction> million in expenses during the three and six months ended June&#160;30, 2025.  The Company incurred an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:ProfessionalAndContractServicesExpense" scale="6" id="f-474">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:ProfessionalAndContractServicesExpense" scale="6" id="f-475">4.6</ix:nonFraction> million in expense during the three months and six months ended June&#160;30, 2024, respectively, for such reimbursement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Termination </span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-471-2">In 2023, the Company entered into a license and service agreement pursuant to which it leased manufacturing space for its continued research and development activities. The lease commenced April 1, 2024. In September 2024, the Company modified the lease, and as a result of the modification the lease payments decreased and the notification period for the termination of the license and service agreement increased from <ix:nonNumeric contextRef="c-111" name="edit:OperatingLeaseTerminationNotificationPeriod" format="ixt-sec:durmonth" id="f-476">12</ix:nonNumeric> months&#8217; prior written notice to <ix:nonNumeric contextRef="c-112" name="edit:OperatingLeaseTerminationNotificationPeriod" format="ixt-sec:durmonth" id="f-477">18</ix:nonNumeric> months&#8217; prior written notice. In January 2025, the Company gave its termination notice on the license and service agreement, which resulted in the end of the term of the agreement being July 2026, and $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="f-478">8.9</ix:nonFraction> million of remaining payments owed.  In April 2025, the Company further modified the lease to terminate on April 30, 2025 with a final fixed payment of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-479">3.7</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div id="i19632d208545492d9596922f4cf084ba_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-480" continuedAt="f-480-1" escape="true">Collaboration Agreements </ix:nonNumeric></span></div><ix:continuation id="f-480-1" continuedAt="f-480-2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into multiple collaborations, out-licenses and strategic alliances with third parties that typically involve payments to or from the Company, including up-front payments, payments for research and development services, option payments, milestone payments and royalty payments to or from the Company. The terms and conditions as </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><ix:continuation id="f-480-2" continuedAt="f-480-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">well as the accounting analysis for the Company&#8217;s significant collaborations, out-licenses and strategic alliances are described in Note 9, &#8220;Collaboration Agreements&#8221; to the consolidated financial statements included in the Annual Report.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company&#8217;s contract liabilities were primarily related to the Company&#8217;s collaboration with BMS. <ix:nonNumeric contextRef="c-1" name="edit:ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" id="f-481" continuedAt="f-481-1" escape="true">The following table presents changes in the Company&#8217;s accounts receivable and contract liabilities for the six months ended June&#160;30, 2025 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-481-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-482">16,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="edit:AccountsReceivableAdditions" format="ixt:num-dot-decimal" scale="3" id="f-483">2,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="edit:AccountsReceivableDeductions" format="ixt:num-dot-decimal" scale="3" id="f-484">17,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ReceivablesNetCurrent" scale="3" id="f-485">588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-486">60,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="edit:ContractWithCustomerLiabilityAdditions" format="ixt:fixed-zero" scale="3" id="f-487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="edit:ContractWithCustomerLiabilityDeductions" format="ixt:num-dot-decimal" scale="3" id="f-488">6,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-489">54,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="edit:ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-490" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">During the three and six months ended June 30, 2025 and 2024, the Company recognized the following collaboration revenue (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.618%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.618%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.618%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognized in the period from:</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in deferred revenue at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-491">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-492">6,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="3" id="f-493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="3" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations satisfied in previous periods</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:fixed-zero" scale="3" id="f-495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:fixed-zero" scale="3" id="f-496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:fixed-zero" scale="3" id="f-497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:fixed-zero" scale="3" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Amendment to BMS Collaboration Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, the Company entered into an amendment (&#8220;2024 Amendment&#8221;) to the Second Amended and Restated Collaboration and License Agreement, dated as of November 11, 2019, by and between the Company and Juno Therapeutics (the &#8220;2019 Collaboration Agreement&#8221;) to extend the collaboration to November 2026, with options to extend the collaboration for up to an additional <ix:nonNumeric contextRef="c-115" name="edit:AgreementExtensionPeriodOptionsToExtend" format="ixt-sec:durwordsen" id="f-499">two years</ix:nonNumeric>, and provided Juno Therapeutics the ability to select up to three new gene targets for research.  The 2019 Collaboration Agreement, as amended by the 2024 Amendment, is herein referred to as the 2019 Amended Collaboration Agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s accounting assessment for the 2024 Amendment is described in Note 9, &#8220;Collaboration Agreements,&#8221; to the consolidated financial statements included in the Annual Report. </span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-480-3">As of June&#160;30, 2025, there was <ix:nonFraction unitRef="usd" contextRef="c-116" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-500">no</ix:nonFraction> short-term deferred revenue and $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-501">50.2</ix:nonFraction> million of long-term deferred revenue in the accompanying consolidated balance sheets.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-502" continuedAt="f-502-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></ix:nonNumeric></div><ix:continuation id="f-502-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-503" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations was as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-504">863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-505">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-506">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-507">5,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-508">1,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-509">2,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-510">3,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-511">7,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-512">2,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-513">5,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-514">5,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-515">12,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Awards</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-516" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of restricted stock unit awards activity for the six months ended June&#160;30, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock unit awards as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-517">2,326,523</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-518">9.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-519">1,560</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-520">1.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-521">371,498</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-522">10.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-523">1,033,046</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-524">10.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock unit awards as of June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-525">923,539</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-526">9.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="c-128" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-527">no</ix:nonFraction> restricted stock units that contained performance-based vesting provisions granted in the six months ended June&#160;30, 2025.  There was <ix:nonFraction unitRef="usd" contextRef="c-128" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-528"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-529">no</ix:nonFraction></ix:nonFraction> expense related to the vesting of performance-based restricted stock units for the three and six months ended June&#160;30, 2025 and $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-530">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-531">3.5</ix:nonFraction> million of expense related to the vesting of performance-based restricted stock units for the three and six months ended June&#160;30, 2024, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, total unrecognized compensation expense related to unvested restricted stock unit awards was $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-532">6.4</ix:nonFraction> million, which the Company expects to recognize over a remaining weighted-average period of <ix:nonNumeric contextRef="c-126" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-533">1.99</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-534" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity for the six months ended June&#160;30, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Remaining<br/>Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-535">7,656,010</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-132" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-536">14.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-133" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-537">7.19</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="f-538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-539">5,581,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-540">1.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-543">2,791,231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-544">11.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-545">10,445,817</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-135" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-546">8.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-134" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-547">7.71</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-548">2,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-549">4,026,696</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-135" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-550">16.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-134" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-551">5.23</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="f-552">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, total unrecognized compensation expense related to stock options was $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-553">15.1</ix:nonFraction> million, which the Company expects to recognize over a remaining weighted-average period of <ix:nonNumeric contextRef="c-134" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-554">2.7</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-555" continuedAt="f-555-1" escape="true">Net Loss per Share</ix:nonNumeric></span></div><ix:continuation id="f-555-1"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury stock and if converted methods. Contingently issuable shares are included in the calculation of basic loss per share as of the beginning of the period in which all the necessary conditions have been satisfied. Contingently issuable shares are included in diluted loss per share based on the number of shares, if any, that would be issuable under the terms of the arrangement if the end of the reporting period was the end of the contingency period, if the results are dilutive. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, unvested restricted stock unit awards and outstanding stock options are considered to be common stock equivalents, but they were excluded from the Company&#8217;s calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-556" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock unit awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-136" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-557">923,539</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-137" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-558">2,618,361</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-138" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-559">10,445,817</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-560">8,268,790</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-561">11,369,356</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-562">10,887,151</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i19632d208545492d9596922f4cf084ba_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-563" continuedAt="f-563-1" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="f-563-1" continuedAt="f-563-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability for the Sale of Future Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2024, the Company entered into a purchase and sale agreement (the &#8220;Purchase and Sale Agreement&#8221;) with DRI under which it sold, transferred, assigned, and conveyed to DRI certain future license fees and other payments (the &#8220;Purchased Receivables&#8221;) owed to the Company by Vertex under the terms of the Vertex License Agreement in exchange for an upfront cash payment by DRI to the Company of $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-564">57.0</ix:nonFraction>&#160;million. Under the Purchase and Sale Agreement, DRI is purchasing up to 100% of certain future fixed and sales-based annual license fees owed to the Company under the Vertex License Agreement, which fees range from $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="edit:LicenseFeeReceivable" format="ixt:num-dot-decimal" scale="6" id="f-565">5.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="edit:LicenseFeeReceivable" format="ixt:num-dot-decimal" scale="6" id="f-566">40.0</ix:nonFraction>&#160;million per year (inclusive of certain sales-based annual license fee increases) and a mid-double-digit percentage of a $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="edit:ContingentFeeReceivableThresholdAmount" format="ixt:num-dot-decimal" scale="6" id="f-567">50.0</ix:nonFraction>&#160;million contingent upfront payment that the Company may receive under the Vertex License Agreement, in each case after subtracting amounts that will be owed by the Company to Broad and Harvard (each term as defined in Note 8, respectively). The Company has retained rights to its portions of certain other sales-based annual license fees and the contingent upfront payment that may become due under the Vertex License Agreement, and the amounts that correspond to its licensor obligations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 470, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Borrower&#8217;s Accounting for Debt Modification</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has accounted for the transaction as debt. The gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="f-568">57.0</ix:nonFraction> million were recorded as a liability for the sale of future revenues, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="f-569">1.8</ix:nonFraction> million, which will be amortized over the estimated life of the arrangement using the effective interest method.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the effective interest rate used to record non-cash interest expense under the Purchase and Sale Agreement based on the estimate of future revenue payments to be made to DRI. As of June&#160;30, 2025, the estimated effective interest rate under the agreement was <ix:nonFraction unitRef="number" contextRef="c-143" decimals="3" name="edit:LiabilityForSaleOfFutureRevenuesEffectiveInterestRate" scale="-2" id="f-570">15.1</ix:nonFraction>%. Over the life of the arrangement, the actual effective interest rate will be affected by the amount and timing of the payments made to DRI and changes in the Company's revenue forecasts. At each reporting date, the Company will reassess its estimate of total future payments to be made to DRI, and prospectively adjust the effective interest rate and amortization of the liability as necessary. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-571" continuedAt="f-571-1" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the liability related to the sale of future revenues under the Purchase and Sale Agreement with DRI as of June&#160;30, 2025 (in thousands): </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><ix:continuation id="f-571-1"><ix:continuation id="f-563-2"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred royalty obligation related to the sale of future revenues, net as of December&#160;31, 2024</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-572">57,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments for sale of future revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-573">5,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense associated with sale of future revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="edit:NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues" format="ixt:num-dot-decimal" scale="3" id="f-574">4,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-575">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred royalty obligation related to the sale of future revenues, net as of June&#160;30, 2025</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-576">56,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="i19632d208545492d9596922f4cf084ba_70"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-577" continuedAt="f-577-1" escape="true">Restructuring and Impairment Charges                                  </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-577-1" continuedAt="f-577-2"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2024, the Company&#8217;s board of directors approved the discontinuation of the clinical development of the Company's reni-cel program to treat sickle cell disease and transfusion-dependent beta thalassemia (the &#8220;Discontinuation&#8221;). As a result of the Discontinuation, the Company has ceased activities towards the filing of a biologic license application and potential commercialization of reni-cel.  In connection with the Discontinuation, the Board also approved a reduction in the Company&#8217;s employee workforce by approximately <ix:nonFraction unitRef="position" contextRef="c-146" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-578">180</ix:nonFraction> positions, or approximately <ix:nonFraction unitRef="number" contextRef="c-146" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-579">65</ix:nonFraction>% (the &#8220;Reduction&#8221;).</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-580" continuedAt="f-580-1" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since the Discontinuation and Reduction started in December 2024 through the six months ended June&#160;30, 2025, the Company has incurred the following restructuring and impairment charges</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands): </span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.484%"><tr><td style="width:1.0%"/><td style="width:70.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-581">14,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs for ongoing contracts and terminated contracts </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-582">54,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Acceleration of expense for change in useful life estimate and lease termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-583">6,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-584">3,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring and impairment charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-585">79,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred the following restructuring and impairment charges for the three and six months ended June&#160;30, 2025, which are recorded in the consolidated statements of operations (in thousands): </span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"><tr><td style="width:1.0%"/><td style="width:48.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="3" id="f-586">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-587">4,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs for ongoing contracts and terminated contracts </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-588">23,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-589">52,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Acceleration of expense for change in useful life estimate and lease termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-590">1,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-591">6,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:fixed-zero" scale="3" id="f-592">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-593">3,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring and impairment charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-594">26,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-595">66,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The actions associated with the Discontinuation and Reduction commenced in December 2024 and are expected to be substantially completed by the end of 2025. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Termination Benefits</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employees affected by the Reduction received involuntary termination benefits pursuant to either a one-time benefit or arrangement or salary continuation for a set period of time in accordance with the Company&#8217;s Amended and Restated Severance Benefit Plan (the &#8220;Benefit Plan&#8221;). For employees who were notified of their termination in December 2024 and had no requirements to provide future services or were subject to the Benefit Plan, the Company recognized the liability for the termination benefits in full at fair value in the fourth quarter of 2024.  For employees who are required to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><ix:continuation id="f-577-2" continuedAt="f-577-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">render services beyond a minimum retention period to receive their one-time termination benefits or salary continuation, the Company is recognizing the termination benefits ratably over their future service periods.  The service periods began in December 2024 and all will end at various dates throughout 2025.  </span></div><ix:nonNumeric contextRef="c-1" name="edit:ScheduleOfEmployeeTerminationBenefitsTableTextBlock" id="f-596" continuedAt="f-596-1" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the liability related to employee termination benefits as of June&#160;30, 2025 (in thousands):  </span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><ix:continuation id="f-596-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.484%"><tr><td style="width:1.0%"/><td style="width:64.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Employee Termination Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued employee termination benefits as of December&#160;31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-597">10,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits charges incurred during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-598">4,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts paid or otherwise settled during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="edit:PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash" format="ixt:num-dot-decimal" scale="3" id="f-599">8,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued employee termination benefits as of June&#160;30, 2025</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-600">6,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company expects that it will incur approximately $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="f-601">15.0</ix:nonFraction> million of employee termination benefit expense to implement the Reduction.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs for Ongoing Contracts and Terminated Contracts </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Discontinuation resulted in contract termination costs from vendor contracts before the end of their term, as well as costs that continue to be incurred under certain contracts with no future economic benefit to the Company.  In accordance with ASC 420, the Company recognized these unavoidable contract costs when incurred for terminated contracts or at the cease-use date, as it relates to contract costs that continue to be incurred.  </span></div><ix:nonNumeric contextRef="c-1" name="edit:ScheduleOfContractTerminationCostsTableTextBlock" id="f-602" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the liability related to costs for ongoing contracts and contract termination costs as of June&#160;30, 2025 (in thousands): </span></div><div style="margin-top:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.060%"><tr><td style="width:1.0%"/><td style="width:63.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contract Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued contract costs as of December&#160;31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-603">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract costs incurred during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:LossOnContractTermination" format="ixt:num-dot-decimal" scale="3" id="f-604">52,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts paid or otherwise settled during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="edit:AmountsPaidOrOtherwiseSettled" format="ixt:num-dot-decimal" scale="3" id="f-605">16,364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued contract costs as of June&#160;30, 2025</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-606">37,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2025, $4.0 million of accrued contract costs was included in Other non-current liabilities on the Consolidated Balance Sheet. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These costs are subject to significant estimation based on the Company's expectation of the costs that will continue to be incurred on the contracts, as well as negotiation of contract changes and terminations with its vendors.  Changes in this estimate will be made in the period the information is known and could be material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment and Accelerated Depreciation Charges</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Discontinuation, the Company committed to a plan to actively sell specific assets within its asset group, primarily certain of its laboratory and manufacturing equipment. At March 31, 2025, the laboratory and manufacturing equipment met all of the prescribed criteria required to classify it as held for sale.  The Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" scale="6" id="f-607">0.3</ix:nonFraction> million of held for sale assets at their fair value at March 31, 2025, resulting in a $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="f-608">3.7</ix:nonFraction> million impairment charge during the three months ended March 31, 2025.  The sale was completed in April 2025.    </span></div><ix:continuation id="f-580-1" continuedAt="f-580-2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company abandoned certain other leasehold improvements, software, and right of use assets in the second quarter of 2025, and as a result, the Company accelerated depreciation and rent expense and recorded the following in the condensed consolidated statements of operations (in thousands): </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><ix:continuation id="f-580-2"><ix:continuation id="f-577-3"><div style="margin-top:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:51.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation related to leasehold improvements and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-609">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-610">1,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Charges related to termination of lease </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="edit:ChargesRelatedToTerminationOfLease" scale="3" id="f-611">731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="edit:ChargesRelatedToTerminationOfLease" format="ixt:num-dot-decimal" scale="3" id="f-612">4,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-613">1,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-614">6,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="i19632d208545492d9596922f4cf084ba_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-615" continuedAt="f-615-1" escape="true">Segments</ix:nonNumeric></span></div><ix:continuation id="f-615-1" continuedAt="f-615-2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Chief Operating Decision Maker (&#8220;CODM&#8221;) or decision-making group in making decisions on how to allocate resources and assess performance.  The Company&#8217;s CODM is its CEO.  The CEO views the Company&#8217;s operations and manages the Company&#8217;s business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-616">one</ix:nonFraction> operating segment, which is the business of developing and commercializing genome editing technology.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s CEO manages and allocates resources to the operations of the Company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with our long-term company-wide strategic goals.  In making these decisions, the Company&#8217;s CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.  The CODM performs this assessment based on the Company&#8217;s consolidated net loss.  Through this analysis, the CODM assesses performance by comparing actual consolidated net loss versus the budget, and then decides how to allocate resources to invest in the Company&#8217;s research and development programs.  The measure of segment assets is reported on the consolidated balance sheet as total assets. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-617" continuedAt="f-617-1" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains additional information on our consolidated revenue and net loss, including significant segment expenses (in thousands): </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><ix:continuation id="f-617-1"><ix:continuation id="f-615-2"><div style="margin-top:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.515%"><tr><td style="width:1.0%"/><td style="width:53.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.992%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.992%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.992%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.996%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration and other research and development revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-618">3,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-619">513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-620">8,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-621">1,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-622">8,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-623">13,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-624">22,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-625">27,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">External research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-626">25,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-627">27,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-628">60,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-629">44,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:OccupancyNet" format="ixt:num-dot-decimal" scale="3" id="f-630">4,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:OccupancyNet" format="ixt:num-dot-decimal" scale="3" id="f-631">7,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:OccupancyNet" format="ixt:num-dot-decimal" scale="3" id="f-632">13,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:OccupancyNet" format="ixt:num-dot-decimal" scale="3" id="f-633">12,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-634">863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-635">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-636">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-637">5,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sublicense and license fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="edit:SublicenseAndLicenseFees" scale="3" id="f-638">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="edit:SublicenseAndLicenseFees" scale="3" id="f-639">857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="edit:SublicenseAndLicenseFees" scale="3" id="f-640">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="edit:SublicenseAndLicenseFees" format="ixt:num-dot-decimal" scale="3" id="f-641">6,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:OtherExpenses" format="ixt:num-dot-decimal" scale="3" id="f-642">1,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:OtherExpenses" format="ixt:num-dot-decimal" scale="3" id="f-643">3,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:OtherExpenses" format="ixt:num-dot-decimal" scale="3" id="f-644">7,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:OtherExpenses" format="ixt:num-dot-decimal" scale="3" id="f-645">6,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-646">3,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-647">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-648">8,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-649">9,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional service expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="f-650">3,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="f-651">3,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="f-652">6,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="f-653">6,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property and patent related fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="edit:IntellectualPropertyAndPatentRelatedFees" format="ixt:num-dot-decimal" scale="3" id="f-654">3,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="edit:IntellectualPropertyAndPatentRelatedFees" format="ixt:num-dot-decimal" scale="3" id="f-655">3,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="edit:IntellectualPropertyAndPatentRelatedFees" format="ixt:num-dot-decimal" scale="3" id="f-656">5,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="edit:IntellectualPropertyAndPatentRelatedFees" format="ixt:num-dot-decimal" scale="3" id="f-657">7,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-658">1,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-659">2,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-660">3,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-661">7,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility and other expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:OccupancyNet" format="ixt:num-dot-decimal" scale="3" id="f-662">1,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:OccupancyNet" format="ixt:num-dot-decimal" scale="3" id="f-663">2,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:OccupancyNet" format="ixt:num-dot-decimal" scale="3" id="f-664">4,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:OccupancyNet" format="ixt:num-dot-decimal" scale="3" id="f-665">5,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-666">55,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-667">72,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-668">135,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-669">140,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-670">51,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-671">71,903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-672">127,707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-673">138,893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-674">1,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-675">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-676">2,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-677">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest related to sale of future revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-678">2,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-680">4,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-681">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-682">2,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-683">4,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-684">4,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-685">9,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-686">1,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-687">4,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-688">1,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-689">9,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-690">53,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-691">67,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-692">129,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-693">129,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The three and six months ended June&#160;30, 2025 and 2024 include $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-694">24,830</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-695">64,075</ix:nonFraction> and $- and $- of restructuring and impairment charges, respectively.   </span></div></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The three and six months ended June&#160;30, 2025 and 2024 include $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-696">1,251</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-697">2,860</ix:nonFraction> and $- and $- of restructuring and impairment charges, respectively.  </span></div></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Other expenses primarily consists of impairment charges, consultant fees and office expenses</span></div></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Facility and other expenses primarily consists of rent expense, insurance premiums, depreciation expense, software licenses and office expenses</span></div></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2024, which was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;5, 2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(the &#8220;Annual Report&#8221;).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements addressing our future operating performance and development timelines that we expect or anticipate will occur in the future, as well as expectations for cash runway, are forward-looking statements. There are a number of important risks and uncertainties that could cause our actual results to differ materially from those indicated by forward-looking statements, including uncertainties inherent in the initiation and completion of pre-clinical studies and clinical development of our product candidates; availability and timing of results from pre-clinical studies; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail in the Annual Report under the captions &#8220;Risk Factor Summary&#8221; and Part I, &#8220;Item 1A. Risk Factors,&#8221; as updated by our subsequent filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made as of the date of this Quarterly Report on Form 10-Q, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</span></div><div id="i19632d208545492d9596922f4cf084ba_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. We have developed a proprietary gene editing platform based on CRISPR technology and we continue to expand its capabilities. Our product development strategy is to target diseases where gene editing can be used to enable or enhance therapeutic outcomes for patients, while maximizing probability of technical, regulatory and commercial success. We are focused on the development of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">gene editing medicines utilizing functional upregulation, which aims to increase the expression and function of a normal gene copy and its normal protein function to treat diseases caused by genetic mutations that eliminate or disrupt normal function. We believe the ability to provide </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">gene editing, in which the medicine is injected or infused into the patient to edit the cells inside their body, and functionally upregulates normal gene expression and normal protein function in the target tissues holds the potential to significantly expand the addressable therapeutic possibilities of CRISPR-based gene editing. To that end, our preclinical efforts are also focused on the creation of a &#8220;plug &#8216;n play&#8221; lipid nanoparticle (&#8220;LNP&#8221;) platform that enables delivery of the gene editing cargo to multiple cells and tissues, including hematopoietic stem cells (&#8220;HSCs&#8221;), the liver and other cells and tissues. We will select the lead development candidate to advance towards human proof-of-concept in September 2025 and are on track to submit an investigational new drug application by mid-2026 and achieve human proof-of-concept by year-end 2026. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We previously demonstrated proof-of-concept of our functional upregulation strategy in our clinical trials of renizgamglogene autogedtemcel (&#8220;reni-cel&#8221;), an experimental </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> gene-edited medicine to treat sickle cell disease (&#8220;SCD&#8221;) and transfusion-dependent beta thalassemia (&#8220;TDT&#8221;). Despite the robust and clinically meaningful improvements observed in these trials, we determined in December 2024 not to pursue commercialization for reni-cel in order to optimize our cost structure and accelerate our intent to achieve human proof of concept of our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">gene editing medicines in approximately two years. However, leveraging our differentiated approach and the insights gained from these trials, we are pursuing next generation </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> gene editing medicines targeting HSCs for the treatment of SCD and beta thalassemia. In January 2025, we announced </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> preclinical proof of concept of editing HSCs in non-human primates (&#8220;NHPs&#8221;), and in June 2025 we shared new </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> preclinical data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in HSCs with a single dose of a novel targeted LNP (&#8220;tLNP&#8221;) in NHPs.   </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Beyond hemoglobinopathies, our discovery and development efforts are focused on </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> gene editing medicines in liver cells and other cells and tissues. In May 2025, we shared preclinical proof-of-concept data for an undisclosed liver target using </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">CRISPR editing to upregulate target protein expression and reduce a disease-associated biomarker in a relevant mouse model.   </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We previously announced </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> delivery to two additional cell types in humanized mice using our proprietary LNP targeting platform and remain on track to establish and disclose a further target cell type or tissue by the end of 2025. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are pursuing the right combination of gene editing and targeted delivery tools through internal development and the in-licensing of complementary technologies to build our preclinical pipeline and accelerate the achievement of our goal of delivering lifesaving medicines to patients with previously untreatable diseases. Through in-licensing of complementary technologies, we can expand our existing gene editing platform and further drive the development of our</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> pipeline. This was recently demonstrated with our entry in 2024 into a collaboration and license agreement to access LNPs targeting the liver, which we used in our achievement of</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> editing of liver cells in NHPs. We also actively seek opportunities to out-license and partner our robust intellectual property portfolio to drive the development of CRISPR-based medicines in therapeutic areas outside of our core focus and to provide non-dilutive capital. For example, in cellular therapy medicines, we are leveraging partnerships to progress engineered cell medicines to treat various cancers, including in our collaboration with Bristol Myers Squibb Company (&#8220;BMS&#8221;) through its wholly owned subsidiary, Juno Therapeutics, Inc. (&#8220;Juno Therapeutics&#8221;). This collaboration, which leverages our Cas9 and Cas12a platform technologies, seeks to advance alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and has resulted in 14 total programs to date.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in December 2023, we and Vertex Pharmaceuticals Incorporated (&#8220;Vertex&#8221;) entered into a license agreement, under which Vertex obtained a non-exclusive license for our Cas9 gene editing technology for</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> ex vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> gene editing medicines targeting the BCL11A gene in the fields of SCD and TDT, including Vertex&#8217;s CASGEVY</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (exagamglogene autotemcel). We received a $50.0 million upfront cash payment in the fourth quarter of 2023 and the 2024 annual license fee of $10.0 million in the first quarter of 2024. The license agreement further provides for the payment by Vertex of a potential additional $50.0 million contingent upfront payment and further future fixed and sales-based annual license fees, ranging from $10.0 million to $40.0 million annually, inclusive of certain sales-based annual license fee increases, through 2034. We are required to pay The Broad Institute, Inc. (&#8220;Broad&#8221;) and the President and Fellows of Harvard College (&#8220;Harvard&#8221;) a mid-double-digit percentage of amounts payable to us from Vertex under the license agreement as it relates to Cas9 technology licensed by us from Broad and Harvard. In October 2024, we entered into an agreement (the &#8220;DRI Agreement&#8221;) with a wholly owned subsidiary of DRI Healthcare Trust (&#8220;DRI&#8221;) providing for an upfront cash payment by DRI to us of $57.0 million in exchange for the acquisition by DRI of up to 100% of certain of the annual license fees owed to us under the Vertex license agreement, which fees range from $5.0 million to $40.0 million per year (inclusive of certain sales-based annual license fees that may become due), and a mid-double-digit percentage of the $50.0 million contingent upfront payment, in each case after subtracting amounts owed by us to Broad and Harvard. We have retained rights to our portions of certain other sales-based annual license fees and the contingent upfront payment that may become due under the license agreement with Vertex, and the amounts that correspond to our licensor obligations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in September 2013, our operations have focused on organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio, assembling our core capabilities in gene editing, seeking to identify potential product candidates, and undertaking preclinical studies and clinical trials. All of our ongoing research programs are still in the preclinical or research stage of development and the risk of failure of all of our research programs is high. We have not generated any revenue from product sales. We have primarily financed our operations through various equity financings, payments received under our research collaboration with BMS through its wholly owned subsidiary Juno Therapeutics, our former strategic alliance with Allergan Pharmaceuticals International Limited (together with its affiliates, &#8220;Allergan&#8221;), which was terminated in August 2020, payments received under the DRI Agreement in connection with our license agreement with Vertex, and payments under the Vertex license agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses. Our net losses were $129.3 million and $129.6 million for the six months ended June 30, 2025 and 2024, respectively. As of June&#160;30, 2025, we had an accumulated deficit of $1.6 billion. We expect to continue to incur significant expenses and operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and from year to year. We anticipate that our expenses will increase as we continue our current research programs and our preclinical development activities; nominate development candidates and initiate clinical trials for our current preclinical programs; seek to identify additional research programs and additional product candidates; initiate preclinical testing for other product candidates we identify and develop; maintain, expand, and protect our intellectual property portfolio, including reimbursing our licensors for such expenses related to the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">intellectual property that we in-license from such licensors; further develop our gene editing platform; hire additional personnel; and incur additional costs associated with operating as a public company.  We do not expect to be profitable for the year ending December&#160;31, 2025 or the foreseeable future.</span></div><div id="i19632d208545492d9596922f4cf084ba_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales, and we do not expect to generate any revenue from product sales for the foreseeable future. In connection with our collaboration with BMS, we have received an aggregate of $146.5 million in payments, which have primarily consisted of the initial upfront and amendment payments, development milestone payments, research funding support and certain opt-in fees. We no longer receive research funding support.  During the three and six months ended June&#160;30, 2025 and 2024 we did not recognize revenue related to our collaboration with BMS.  As of June&#160;30, 2025, we had $50.2 million of deferred revenue in relation to our collaboration with BMS, all of which was classified as long-term deferred revenue on our consolidated balance sheet. Under this collaboration, we will recognize revenue upon delivery of option packages to BMS or upon receipt of development milestone payments. We expect that our revenue will fluctuate from quarter-to-quarter and year-to-year as a result of the timing of when we deliver such option packages or receive such milestone payments.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the license agreement with Vertex, we received a $50.0 million upfront cash payment in the fourth quarter of 2023 upon execution of the agreement and the 2024 and 2025 annual license fees of $10.0 million in each of the first quarters of 2024 and 2025.  The license agreement further provides for the payment by Vertex of a potential additional $50.0 million contingent upfront payment and further annual license fees, ranging from $10.0 million to $40.0 million annually, inclusive of certain sales-based annual license fee increases, through 2034. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our revenue recognition policy related to the Vertex license agreement and BMS collaboration, see Part II, &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Estimates&#8212;Revenue Recognition&#8221; included in the Annual Report.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future we expect substantially all of our revenue will be generated from our license agreement with Vertex, collaboration with BMS, and any other collaborations or license agreements we may enter into.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research, preclinical development, process and scale-up development, manufacture and clinical development of our product candidates, and the performance of development activities under our collaboration agreements. These costs are expensed as incurred and include:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses including salaries, benefits, and stock-based compensation expense;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs incurred under clinical trial agreements with investigative sites for our former reni-cel program;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with conducting our preclinical, process and scale-up development, manufacturing, quality, clinical and regulatory activities, including fees paid to third-party professional consultants, service providers and suppliers;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of purchasing lab supplies and non-capital equipment used in our preclinical activities and in manufacturing preclinical and clinical study materials;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs incurred for the research and development activities under our collaboration agreements;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility costs including rent, depreciation, and maintenance expenses; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees for acquiring and maintaining licenses under our third-party licensing agreements, including any sublicensing or success payments made to our licensors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of any product candidates we may identify and develop. This is due to the numerous risks and uncertainties associated with developing such product candidates, including the uncertainty of:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of preclinical studies, investigational new drug application-enabling studies and natural history studies;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful initiation of, enrollment in, and completion of, clinical trials;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching commercial sales of a product, if and when approved, whether alone or in collaboration with others;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of a product, if and when approved, by patients, the medical community, and third-party payors;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies and treatment options;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety profile following approval;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enforcing and defending intellectual property and proprietary rights and claims; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieving desirable medicinal properties for the intended indications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of any product candidates we develop would significantly change the costs, timing, and viability associated with the development of that product candidate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model.  We expect research and development costs to increase for the foreseeable future as our development programs progress, including as we continue to support preclinical studies and prepare for the clinical development of our research programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation for personnel in executive, finance, investor relations, business development, legal, corporate affairs, information technology, facilities and human resource functions. Other significant costs include corporate facility costs not otherwise included in research and development expenses, legal fees related to intellectual property and corporate matters, and fees for accounting and consulting services.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will decrease or remain flat in the near future to support continued research and development activities. We anticipate that expenses associated with operating as a public company, including costs for audit, legal, regulatory, and tax-related services, director and officer insurance premiums, and investor relation costs will remain flat in the near future. With respect to reimbursement of third-party intellectual property-related expenses specifically, given the ongoing nature of the opposition and interference proceedings involving the patents licensed to us under our license agreement with Broad and Harvard, we anticipate general and administrative expenses associated with reimbursement of third-party intellectual property-related expense will continue to fluctuate as the opposition and interference proceedings continue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and Impairment Charges</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, our board of directors approved the discontinuation of the clinical development of our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> reni-cel program (the &#8220;Discontinuation&#8221;). As part of the Discontinuation, our board approved a reduction in our employee workforce by approximately 180 positions, or by approximately 65% (the &#8220;Reduction&#8221;). Restructuring charges consist </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">primarily of expenses in connection with the wind-down of various activities related to the clinical development of reni-cel, including contract termination costs, impairment charges and non-cash charges, and expenses related to the Reduction, primarily consisting of severance payments and employee benefit costs. We may also incur additional costs not currently contemplated due to events that may occur as a result of or that are associated with the Discontinuation and Reduction. We expect restructuring charges to be substantially incurred through the end of 2025, when the related activities are expected to be substantially complete.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2025 and June&#160;30, 2024, other income, net consisted primarily of interest income and the amortization of premiums or discounts on marketable securities and interest accretion related to the liability for the sale of future revenues. </span></div><div id="i19632d208545492d9596922f4cf084ba_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of our condensed consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, will be reflected in the condensed consolidated financial statements prospectively from the date of change in estimates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, we had the following material change to our critical accounting estimates as described in Part II, &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Estimates&#8221; in the Annual Report:</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We record liabilities for costs associated with restructuring activities in the period in which the liability is incurred.  Typical costs associated with restructuring activities include, employee termination benefits, contract termination costs and on-going contract costs for which there is no economic benefit.  For costs associated with employee terminations in which the employee is subject to an existing benefit arrangement, the post-employment benefits are recognized when probable and estimable.  Other employee termination costs are measured and recognized on the communication date, unless there is a required future service period, in which case, the expense is recognized over the service period.  Contract termination costs are recognized upon termination of the contract and costs for on-going contracts for which there is no future benefit, are recognized at fair value on the cease-use date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have made estimates and judgments regarding the amount and timing of our restructuring expense and liability, including current and future period termination benefits and other exit costs to be incurred when related actions take place. Restructuring charges are reflected in our consolidated statements of income. Actual results may differ from these estimates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months ended June 30, 2025 and 2024</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended June 30, 2025 and 2024, together with the changes in those items in dollars (in thousands) and the respective percentages of change:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Dollar&#160;Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration and other research and development revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38,029)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55,122&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">72,416&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(17,294)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,758)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest related to sale of future revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,020)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,020)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,691)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,987)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(53,235)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(67,607)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,372&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For our results of operations, we have included the respective percentage of changes, unless greater than 100% or less than (100)%, in which case we have denoted such changes as not meaningful (n/m).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and Other Research and Development Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration and other research and development revenues were $3.6 million for the three months ended June 30, 2025 compared to $0.5&#160;million for the same period in 2024. The increase from the three months ended June 30, 2024 is primarily attributable to the recognition of revenue related to specified deliverables that were achieved in the second quarter of 2025. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased by $38.0 million to $16.2 million for the three months ended June 30, 2025 compared to $54.2 million for the same period in 2024. The following table summarizes our research and development expenses for the three months ended June 30, 2025 and 2024, together with the changes in those items in dollars (in thousands) and the respective percentages of change:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Dollar&#160;Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,594)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">External research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(24,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sublicense and license fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,001)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16,181&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,210&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38,029)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in research and development expenses for the three months ended June 30, 2025 compared to the three months ended June 30, 2024 was primarily attributable to:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $24.4 million in decreased external research and development expenses primarily resulting from reduced clinical and manufacturing costs under our reni-cel program due to the Discontinuation, partially offset by costs attributable to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> research and discovery;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $5.6 million in decreased employee-related expenses related to reduced headcount associated with the Reduction;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $4.0 million in decreased facility expense primarily due to the end of leases for manufacturing space;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $2.0 million in decreased other expenses related to professional services to support our reni-cel program due to the Discontinuation;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $1.3 million in decreased stock-based compensation expense primarily related to reduction in the market price of common stock year-over-year, resulting in a lower valuation of equity awards, along with reduced headcount as a result of the Reduction; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.8 million in decreased sublicense and license fees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses decreased by $5.3 million to $12.9 million for the three months ended June 30, 2025 compared to $18.2 million for the three months ended June 30, 2024. The following table summarizes our general and administrative expenses for the three months ended June 30, 2025 and 2024, together with the changes in those items in dollars (in thousands) and the respective percentages of change:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Dollar&#160;Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,668)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional service expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property and patent related fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility and other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total general and administrative expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18,206&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,347)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in general and administrative expenses for the three months ended June 30, 2025 compared to the three months ended June 30, 2024 was primarily attributable to:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $1.7&#160;million in decreased employee related expenses related to reduced headcount associated with the Reduction;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $1.6 million in decreased facility and other expenses related to the end of a lease;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $1.1 million in decreased stock-based compensation expenses primarily related to reduction in the market price of common stock year-over-year, resulting in a lower valuation of equity awards, along with reduced headcount as a result of the Reduction;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.6&#160;million in decreased intellectual property and patent related legal fees; and </span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.3 million in decreased professional service expenses.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and Impairment Charges</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges were $26.1 million for the three months ended June 30, 2025, with no equivalent charges for the three months ended June 30, 2024.  The following table summarizes our restructuring charges for the three months ended June 30, 2025 and 2024, together with the changes in those items in dollars (in thousands) and the respective percentages of change: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.012%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.012%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Dollar Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100 %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs for ongoing contracts and terminated contracts </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100 %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Acceleration of expense for change in useful life estimate and lease termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100 %</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring and impairment charges</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100 %</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2025, we recorded $0.8 million, $23.5 million, and $1.8 million of expense related to employee termination benefits, reni-cel-related contract costs, and acceleration in expense due to changes in useful life estimates for leasehold improvements, software and a right of use asset, respectively, due to the Discontinuation and the Reduction.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2025, and June&#160;30, 2024 other (expense) income, net was $(1.7) million and $4.3 million, respectively, which primarily relate to interest income and accretion of discounts and premiums associated with marketable securities and interest accretion related to the liability for the sale of future revenues. The decrease is attributable to interest accretion related to the DRI Purchase and Sale Agreement and reductions in investment income due to a decrease in our investments for the three months ended June 30, 2025 compared to the three months ended June 30, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months ended June 30, 2025 and 2024</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the six months ended June 30, 2025 and 2024, together with the changes in those items in dollars (in thousands) and the respective percentages of change:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Dollar&#160;Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration and other research and development revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">102,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(60,223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(11,311)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">135,943&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">140,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4,599)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest related to sale of future revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4,528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,616)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10,952)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(129,323)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(129,557)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">234&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and Other Research and Development Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration and other research and development revenues increased by $6.6 million to $8.2 million for the six months ended June 30, 2025 compared to $1.6 million for the six months ended June 30, 2024. The increase was primarily attributable to the recognition of the remaining deferred revenue upon the closing out of a collaboration agreement with a strategic partner, and the recognition of revenue related to specified deliverables under that collaboration agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased by $60.2 million to $42.8 million for the six months ended June 30, 2025 compared to $103.0 million for the six months ended June 30, 2024. The following table summarizes our research development expenses for the six months ended June 30, 2025 and 2024, together with the changes in those items in dollars (in thousands) and the respective percentages of change:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.873%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Dollar&#160;Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7,955)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">External research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(34,547)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3,834)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sublicense and license fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3,983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">102,997&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(60,223)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in research and development expenses for the six months ended June 30, 2025 compared to the six months ended June 30, 2024 was primarily attributable to:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $34.5 million in decreased external research and development expenses primarily resulting from reduced clinical and manufacturing costs under our reni-cel program due to the Discontinuation, partially offset by costs attributable to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> research and discovery; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $8.0 million in decreased employee-related expenses related to reduced headcount associated with the Reduction;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $6.6 million in decreased sublicense and license fees related to the achievement of certain milestones in 2024 for which there was no equivalent achievement in 2025;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $4.0 million in decreased other expenses related to professional services to support our reni-cel program due to the Discontinuation; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $3.8 million in decreased facility expenses primarily due to the end of leases for manufacturing space;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $3.3 million in decreased stock-based compensation expense primarily related to expense in connection with the achievement of certain performance-based vesting milestones for restricted stock units recognized in 2024 for which there was no equivalent expense in 2025, a reduction in the market price of our common stock year-over-year resulting in lower fair value and a reduction in headcount associated with the Reduction. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses decreased by $11.3 million to $26.2 million for the six months ended June 30, 2025 compared to $37.5 million for the six months ended June 30, 2024. The following table summarizes our general and administrative expenses for the six months ended June 30, 2025 and 2024, together with the changes in those items in dollars (in thousands) and the respective percentages of change:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.696%"><tr><td style="width:1.0%"/><td style="width:52.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.140%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.140%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.140%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Dollar&#160;Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,116)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional service expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(906)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property and patent related fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3,689)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility and other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total general and administrative expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,234&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,545&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(11,311)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in general and administrative expenses for the six months ended June 30, 2025 compared to the six months ended June 30, 2024 was primarily attributable to:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $3.7&#160;million in decreased stock-based compensation expense primarily related to expense in connection with the achievement of certain performance-based vesting milestones for restricted stock units recognized in 2024 for which there was no equivalent expense in 2025, a reduction in the market price of our common stock year-over-year resulting in lower fair value and a reduction in headcount associated with the Reduction; </span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $2.6&#160;million in decreased facility and other expense primarily related to the end of a lease;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $2.1&#160;million in decreased employee related expenses related to reduced headcount associated with the Reduction;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $2.0&#160;million in decreased intellectual property and patent related fees due to reduced legal activity related to intellectual property defense; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.9&#160;million in decreased professional service expenses related to reduced licensing and strategic business activities in 2025 relative to 2024.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and Impairment Charges</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges were $66.9 million for the six months ended June 30, 2025, with no equivalent charges for the six months ended June 30, 2024.  The following table summarizes our restructuring charges for the six months ended June 30, 2025 and 2024, together with the changes in those items in dollars (in thousands) and the respective percentages of change: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.012%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.012%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Dollar Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100 %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs for ongoing contracts and terminated contracts </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100 %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Acceleration of expense for change in useful life estimate and lease termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100 %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100 %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring and impairment charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66,935&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66,935&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100 %</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2025, we recorded $4.3 million, $52.3 million, $6.5 million and $3.7 million related to employee termination benefits, reni-cel-related contract costs, acceleration in expense due to changes in useful life estimates for leasehold improvements, software and a right of use asset, and impairment charges, respectively, due to the Discontinuation and the Reduction.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2025 and June&#160;30, 2024, other (expense) income, net was $(1.6) million and $9.3 million, respectively, which primarily relates to interest income and accretion of discounts and premiums associated with marketable securities and interest accretion related to the liability for the sale of future revenues.  The decrease for the six months ended June 30, 2025 is attributable to the interest accretion related to the liability for the sale of future revenues and reductions in investment income due to a decrease in our investments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of June&#160;30, 2025, we have raised an aggregate of $1.0&#160;billion in net proceeds through the sale of shares of our common stock in public offerings and at-the-market offerings</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">.  We also have funded our business from our research collaboration with BMS through its wholly owned subsidiary Juno Therapeutics, our former strategic alliance with Allergan (which was terminated in August 2020), payments received under the DRI Agreement in connection with our license agreement with Vertex, and payments under the Vertex license agreement. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of June&#160;30, 2025, we had cash, cash equivalents and marketable securities of $178.5&#160;million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into a common stock sales agreement with TD Securities (USA) LLC (as successor to Cowen and Company, LLC) (&#8220;TD Cowen&#8221;), under which we from time to time can issue and sell shares of our common stock through TD Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $300.0 million. We amended the common stock sales agreement with TD Cowen in February 2024 in connection with filing a new registration statement.  In March 2025, we further amended our common stock sales agreement with TD Cowen in connection with amending our existing shelf registration statement following the loss of our status as a &#8220;well-known seasoned issuer&#8221; (as defined under Rule 405 of the Securities Act of 1933, as amended), reducing the amount of shares of common stock we may issue and sell through TD Cowen to aggregate gross sale proceeds of up to $150.0 million (the &#8220;ATM Facility&#8221;). As of June&#160;30, 2025, we have sold </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,126,072</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> shares of our common stock under the ATM Facility at a weighted average price of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$2.14</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> per share for aggregate gross proceeds of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$8.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and have </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$141.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of shares of our common stock remaining available for issuance and sale under the ATM Facility. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our existing cash, cash equivalents and marketable securities, we are eligible to earn milestone and other payments under our collaboration agreement with BMS and our other collaboration and license agreements. Our ability to earn applicable milestone and other payments and the timing of earning these amounts are dependent upon the timing and outcome of development, regulatory and commercial activities and, as such, are uncertain at this time. As of June&#160;30, 2025, our right to contingent payments under our collaboration agreement with BMS, as well as the retained </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">portions of the contingent upfront payment and other amounts under our license agreement with Vertex, are our only significant committed potential external source of funds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the six months ended June 30, 2025 and 2024 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(98,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(106,934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(59,211)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was approximately $98.0 million for the six months ended June 30, 2025, which primarily consisted of operating expenses that related to our ongoing research efforts, the wind-down of clinical and manufacturing activities in support of our former reni-cel program and supporting business operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was approximately $106.9 million for the six months ended June 30, 2024, which primarily consisted of operating expenses that related to increasing our research efforts, the focused progression of clinical and manufacturing activities in support of our former reni-cel program, and supporting business operations.   </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Investing Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was approximately $99.0 million for the six months ended June 30, 2025, primarily related to the proceeds from the maturities of marketable securities of $99.0 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was approximately $47.2 million for the six months ended June 30, 2024, primarily related to the proceeds from the maturities of marketable securities of $138.8&#160;million, and partially offset by the purchase of marketable securities of $86.2&#160;million, and the purchase of property and equipment of $5.4 million. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was approximately $6.0 million for the six months ended June 30, 2025, primarily related to proceeds from the issuance of common stock from our at the market offering program of $8.6 million and proceeds received from issuance of common stock under our employee stock purchase plan of $0.2 million. This was offset by the repayment of our liability for the sale of future revenues with DRI of $2.9 million.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was approximately $0.5&#160;million for the six months ended June 30, 2024, related to the proceeds received from issuance of common stock under our employee stock purchase plan of $0.3 million and exercises of options for our common stock of $0.2 million. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase for the foreseeable future as our development programs progress, including as we continue to support preclinical studies and prepare for the clinical development of our research programs; seek to identify product candidates and additional research programs; initiate preclinical testing and clinical trials for other product candidates we identify and develop; maintain, expand, and project our intellectual property portfolio, including reimbursing our licensors for expenses related to the intellectual property that we in-license from such licensors; and incur costs </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">associated with operating as a public company. In addition, if we obtain marketing approval for any product candidate that we identify and develop, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution to the extent that such sales, marketing, and distribution are not the responsibility of a collaborator. We do not expect to generate significant recurring revenue unless and until we obtain regulatory approval for and commercialize a product candidate. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our existing cash, cash equivalents and marketable securities on June&#160;30, 2025, and the retained portions of the payments payable under our license agreement with Vertex, will enable us to fund our operating expenses and capital expenditure requirements into the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">second quarter of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.  Our forecast of the period of time through which our existing cash and cash equivalents and investments will be adequate to support our operations is a forward-looking statement and involves significant risks and uncertainties. We have based this forecast on assumptions that may prove to be wrong, and actual results could vary materially from our expectations, which may adversely affect our capital resources and liquidity. We could utilize our available capital resources sooner than we currently expect. The amount and timing of future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the restructuring costs associated with the Discontinuation and Reduction;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results, and costs of drug discovery, preclinical development, laboratory testing, and any clinical or natural history study trials for product candidates we develop;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights, and defending intellectual property-related claims;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing, and outcome of regulatory review of the product candidates we develop;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing and maintaining a supply chain for the development and manufacture of our product candidates;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of future activities, including product sales, medical affairs, marketing, manufacturing, and distribution, for any product candidates for which we receive regulatory approval;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaboration with BMS, including whether BMS exercises any of its options to extend the research program term and/or to additional research programs under our collaboration;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain additional collaborations on favorable terms, if at all;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other medicines and technologies;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of reimbursing our licensors for the prosecution and maintenance of the patent rights in-licensed by us; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain healthcare coverage and adequate reimbursement for any product candidates for which we receive regulatory approval.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive, and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, even if we successfully identify and develop product candidates that are approved, we will require significant additional amounts in order to launch and commercialize our product candidates and may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of genomic medicines that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i19632d208545492d9596922f4cf084ba_97"></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, we had operating leases with future minimum lease payments for a total of $24.4 million, of which $3.9 million will be payable in 2025. These minimum lease payments exclude our share of the facility operating expenses, real-estate taxes and other costs that are reimbursable to the landlord under the leases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we entered into a license and service agreement pursuant to which we leased manufacturing space for our continued research and development activities. The lease commenced April 1, 2024. In September 2024, we modified the lease, and as a result of the modification the lease payments decreased and the notification period for the termination of the license and service agreement increased from 12 months&#8217; prior written notice to 18 months&#8217; prior written notice. In January 2025, we gave our termination notice on the license and service agreement, which resulted in the end of the term of the agreement being July 2026, and $8.9 million of remaining payments owed.  In April 2025, we modified the lease to terminate on April 30, 2025 with a final fixed payment of $3.7 million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our agreements with certain institutions to license intellectual property include potential milestone payments and success fees, sublicense fees, royalty fees, licensing maintenance fees, and reimbursement of patent maintenance costs that we may be required to pay. Our agreements to license intellectual property include potential milestone payments that are dependent upon the development of products using the intellectual property licensed under the agreements and contingent upon the achievement of development or regulatory approval milestones, as well as commercial milestones. These potential obligations are contingent upon future events and the timing and likelihood of such potential obligations are not known with certainty. For further information regarding these agreements, please see Part I, &#8220;Item 1. Business&#8212;Our Collaborations and Licensing Strategy&#8221; in the Annual Report.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into contracts in the normal course of business with contract research organizations, contract manufacturing organizations and other vendors to assist in the performance of our research and development activities and other services and products for operating purposes. These contracts generally provide for termination at any time upon prior notice.</span></div><div id="i19632d208545492d9596922f4cf084ba_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates. As of June&#160;30, 2025, we had cash and cash equivalents of $138.5 million, primarily held in money market mutual funds, and marketable securities of $40.0 million, primarily consisting of U.S. government-backed securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash equivalents, are in the form, or may be in the form of, money market funds or marketable securities and are or may be invested in U.S. Treasury and U.S. government agency obligations. Due to the short-term maturities and low risk profiles of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our investments.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While we contract with certain vendors and institutions internationally, substantially all of our total liabilities as of June&#160;30, 2025 were denominated in the United States dollar and we believe that we do not have any material exposure to foreign currency exchange rate risk.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i19632d208545492d9596922f4cf084ba_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in litigation or other legal proceedings relating to claims arising from the ordinary course of business. There can be no assurance that any proceedings that result from these third-party actions will be resolved in our favor. In addition, if they are not resolved in our favor, there can be no assurance that the result will not have a material adverse effect on our business, financial condition, results of operations, or prospects. Certain of our intellectual property rights, including ones licensed to us under our licensing agreements, are subject to, and from time to time may be subject to, priority and validity disputes. For additional information regarding these matters, see Part I, &#8220;Item 1A. Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 (the &#8220;Annual Report&#8221;). Regardless of outcome, litigation or other legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</span></div><div id="i19632d208545492d9596922f4cf084ba_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Information set forth in this Quarterly Report on Form 10-Q, including below, and in the sections entitled &#8220;Summary of Risk Factors&#8221; and Part I, &#8220;Item 1A. Risk Factors&#8221; in the Annual Report, includes risks which could materially affect our business, financial condition, results of operations, or prospects. These risks, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our common stock. Additional risks not currently known to us or that we currently deem to be immaterial may also harm our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our in-licensed patents are subject to priority and validity disputes. In addition, our owned and in-licensed patents, patent applications and other intellectual property may be subject to further priority and validity disputes, and other similar intellectual property proceedings including inventorship disputes. If we or our licensors are unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to cease the development, manufacture, and commercialization of one or more of the product candidates we develop, which could have a material adverse impact on our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain U.S. patents and a U.S. patent application directed to CRISPR/Cas9 that are co-owned by the Broad Institute and the Massachusetts Institute of Technology (&#8220;MIT&#8221;), and in some cases Harvard (collectively referred to as &#8220;Broad&#8221;), and in-licensed by us were involved in a first interference with a U.S. patent application that is co-owned by the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively referred to &#8220;CVC&#8221;). An interference is a proceeding in USPTO before the Patent Trial and Appeal Board of the USPTO (&#8220;PTAB&#8221;) to determine priority of invention of the subject matter of patent claims filed by different parties. In this first interference, the PTAB made a judgment of no interference-in-fact in favor of the Broad, which was upheld on appeal. This decision was final and bars any further interference between the same parties for claims to the same invention that was considered in the interference. As a result of this decision, the U.S. patents and application that we in-license from the Broad and others were not modified or revoked.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2019, the PTAB declared a second interference between certain pending U.S. patent applications that are co-owned by CVC and certain U.S. patents and a U.S. patent application that are co-owned by Broad and in-licensed by us. Most of the Broad U.S. patents and the patent application that are involved in the second interference were also part of the first interference. The invention that was considered in the first interference related to a method involving contacting a target DNA in a eukaryotic cell with certain defined CRISPR/Cas9 components for the purpose of cleaving or editing that target DNA molecule or modulating transcription of at least one gene encoded thereon. The second interference is directed to a different invention, namely a eukaryotic cell comprising a target DNA and certain defined CRISPR/Cas9 components including a single molecule guide RNA that are capable of cleaving or editing the target DNA molecule.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2020, the PTAB granted Broad&#8217;s motion for priority benefit while denying CVC priority benefit to their two earliest provisional patent applications. As a result, Broad entered the priority phase of the interference as &#8220;Senior Party&#8221; while CVC remained the &#8220;Junior Party&#8221; for purposes of determining which entity was the first to invent the inventions at issue. On February 28, 2022, the PTAB issued a decision regarding the priority phase of the interference determining that Broad was the first entity to invent the claims at issue. This decision was appealed by CVC and the Broad cross-appealed. On May 12, 2025, the U.S. Court of Appeals for the Federal Circuit (&#8220;CAFC&#8221;) affirmed-in-part and vacated-in-part the PTAB&#8217;s previous decision and remanded it back to the PTAB for further review. This decision does not impact our ability to grant licenses or change existing licenses we have issued to certain U.S. patents and a U.S. patent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">application that are co-owned by Broad and in-licensed by us. It is uncertain when or in what manner the PTAB will ultimately render a decision.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, the PTAB, declared two new interferences involving a pending U.S. patent application that is owned by ToolGen, Inc. (the &#8220;ToolGen application&#8221;). One of the two interferences is between the ToolGen application and certain U.S. patents and U.S. patent applications that are co-owned by Broad and in-licensed by us. Most of the Broad U.S. patents and patent applications that are involved in the interference with ToolGen are also part of the second interference with CVC. The other ToolGen interference is between the same ToolGen application and the U.S. patent applications that are co-owned by CVC and involved in the second interference with Broad. The claims in ToolGen&#8217;s patent application relate to a mammalian cell with a CRISPR/Cas system comprising a codon optimized nucleic acid encoding a Cas9 polypeptide with a nuclear localization signal and a single-molecule guide RNA that, together, are capable of forming a Cas9/RNA complex that mediates double stranded cleavage of a target nucleic acid sequence. On September 28, 2022, the PTAB suspended both of these interferences until the U.S. Court of Appeals for the Federal Circuit issues a mandate in the pending appeals related to the second interference between Broad and CVC.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2021, the PTAB declared two new interferences involving a pending U.S. patent application owned by Sigma-Aldrich (the &#8220;Sigma-Aldrich application&#8221;). One of the two new interferences is between the Sigma-Aldrich application and certain U.S. patents and U.S. patent applications that are co-owned by Broad and in-licensed by us. The other Sigma interference is between the same Sigma-Aldrich application and the U.S. patent applications that are co-owned by CVC. Most of the Broad U.S. patents and patent applications that are involved in the interference with Sigma-Aldrich are also part of the concurrent interferences with CVC and ToolGen. The claims in Sigma-Aldrich&#8217;s application relate to a method for modifying a chromosomal sequence in a eukaryotic cell by integrating a donor sequence into that chromosomal sequence. These methods use a CRISPR/Cas9 system comprising a Cas9 polypeptide with a nuclear localization signal, a guide RNA, and a donor sequence that, together, are capable of mediating double stranded cleavage and repair of a target nucleic acid sequence leading to integration of the donor sequence into the chromosomal sequence. On December 14, 2022, the PTAB suspended both of these interferences until the U.S. Court of Appeals for the Federal Circuit issues a mandate in the pending appeals related to the second interference between Broad and CVC.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these declarations of interference, five parallel adversarial proceedings in the USPTO before the PTAB have been initiated &#8211; the patent interferences between Broad and CVC, Broad and ToolGen, CVC and ToolGen, Broad and Sigma-Aldrich, and CVC and Sigma-Aldrich. We cannot predict with any certainty how long each interference proceeding will take. It is also possible that other third parties may seek to become a party to these interferences.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our owned and in-licensed patents and patent applications are, or may in the future become, subject to validity disputes in the USPTO and other foreign patent offices. For example, a request for ex parte re-examination was filed with the USPTO on February 16, 2016 against a U.S. patent that we have in-licensed from Broad, which is involved in certain of the interferences. The request for ex parte re-examination was granted on May 9, 2016 thereby initiating a re-examination procedure between the USPTO and Broad, acting on behalf of itself and MIT. The PTAB has suspended the re-examination noting that it has jurisdiction over any file that involves a patent involved in an interference. It is uncertain when the PTAB will lift the suspension. If Broad is unsuccessful during the re-examination, the patent in question may be revoked or narrowed, which could have a material adverse effect on the scope of our rights under such patent.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may also be subject to claims that former employees, collaborators, or other third parties have an interest in our owned or in-licensed patents or patent applications, or other intellectual property rights as an inventor or co-inventor. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents, patent applications or other intellectual property rights, such co-owners may be able to license their rights to other third parties, including our competitors. In addition, we may need the cooperation of any such co-owners to enforce any patents, including any patents that issue from patent applications, against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on the conduct of our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors are subject to and may in the future become a party to similar proceedings or priority disputes in Europe or other foreign jurisdictions. For example, certain European patents that we have in-licensed from Broad have been revoked in their entirety by the European Patent Office Opposition Division (the &#8220;Opposition Division&#8221;). Certain other European patents that we have in-licensed from Broad were maintained with amended patent claims. Certain of these decisions have been appealed by both Broad and the opposing party(s), and it is uncertain when or in what manner the Boards of Appeal will act on these appeals. The Opposition Division has also initiated opposition proceedings against certain other European patents that we have in-licensed from Broad. The European Patent Office opposition proceedings </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">may involve issues including, but not limited to, procedural formalities related to filing the European patent application, priority, and the patentability of the involved claims. In view of certain arguments made by the third parties against the revoked patents and similar arguments made by the third parties against other in-licensed European patents under opposition, the opposition proceedings may lead to the revocation of certain additional in-licensed European patents. The loss of priority for, or the loss of, these European patents could have a material adverse effect on the conduct of our business. One or more of the third parties that have filed oppositions against these European patents or other third parties may file future oppositions against other European patents that we in-license or own. There may be other oppositions against these European patents that have not yet been filed or that have not yet been made available to the public.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors are unsuccessful in any patent related disputes, including interference proceedings, patent oppositions, re-examinations, or other priority, inventorship, or validity disputes to which we or they are subject (including any of the proceedings discussed above), we may lose valuable intellectual property rights through the loss of one or more patents owned or licensed or our owned or licensed patent claims may be narrowed, invalidated, or held unenforceable. In addition, if we or our licensors are unsuccessful in any inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights, such as exclusive ownership of, or the exclusive right to use, our owned or in-licensed patents and patent applications. If we or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or may be non-exclusive or may not be available at all. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we develop. The loss of exclusivity or the narrowing of our owned and in-licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations, or prospects. Even if we are successful in any interference proceeding or other priority, inventorship, or validity disputes, it could result in substantial costs and be a distraction to our management and other employees.</span></div><div id="i19632d208545492d9596922f4cf084ba_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director and Officer Trading Arrangements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) is in the form of equity awards and, from time to time, directors and officers may engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other of our securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Transactions in our securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or officers <ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-698"><ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-699">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-700"><ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-701">terminated</ix:nonNumeric></ix:nonNumeric> a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit Index</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Description of Exhibit</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex31-restatedcharterasam.htm">Restated Certificate of Incorporation of the Registrant, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1650664/000165066425000086/amendedandrestated2015stoc.htm">Amended and Restated 2015 Stock Incentive Plan </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1650664/000165066425000086/amendedandrestated2015stoc.htm">(incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-37687) filed with the Securities and Exchange Commission on June 2, 2025)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="edit-20250630xex311.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="edit-20250630xex312.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="edit-20250630xex321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. &#167;1350</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following financial statements from the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2025, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets (unaudited), (ii) Condensed Consolidated Statements of Operations (unaudited), (iii) Condensed Consolidated Statements of Comprehensive Loss (unaudited), (iv) Condensed Consolidated Statements of Stockholders&#8217; Equity (unaudited), (v) Condensed Consolidated Statements of Cash Flows (unaudited) and (vi) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text and including detailed tags.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101)</span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Filed herewith</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The certifications furnished in Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications are not to be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates them by reference.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i19632d208545492d9596922f4cf084ba_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i19632d208545492d9596922f4cf084ba_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:46.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EDITAS MEDICINE, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dated: August&#160;12, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Amy Parison</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amy Parison</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer<br/>(Principal Financial Officer) </span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex31-restatedcharterasam.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>ex31-restatedcharterasam</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- ex31-restatedcharterasam001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex31-restatedcharterasam001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Exhibit 3.1      RESTATED CERTIFICATE OF INCORPORATION    OF    EDITAS MEDICINE, INC.    (originally incorporated on September 3, 2013 under the name Gengine, Inc.)  FIRST:  The name of the Corporation is Editas Medicine, Inc.  SECOND:  The address of the Corporation&#8217;s registered office in the State of Delaware is  Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle,  19801.  The name of its registered agent at that address is The Corporation Trust Company.  THIRD:  The nature of the business or purposes to be conducted or promoted by the  Corporation is to engage in any lawful act or activity for which corporations may be organized  under the General Corporation Law of the State of Delaware.  FOURTH:  The total number of shares of all classes of stock which the Corporation shall  have authority to issue is 200,000,000 shares, consisting of (i) 195,000,000 shares of Common  Stock, $0.0001 par value per share (&#8220;Common Stock&#8221;), and (ii) 5,000,000 shares of Preferred  Stock, $0.0001 par value per share (&#8220;Preferred Stock&#8221;).  The following is a statement of the designations and the powers, privileges and rights,  and the qualifications, limitations or restrictions thereof in respect of each class of capital stock  of the Corporation.  A COMMON STOCK.  1. General.  The voting, dividend and liquidation rights of the holders of the  Common Stock are subject to and qualified by the rights of the holders of the Preferred Stock of  any series as may be designated by the Board of Directors upon any issuance of the Preferred  Stock of any series.  2. Voting.  The holders of the Common Stock shall have voting rights at all  meetings of stockholders, each such holder being entitled to one vote for each share thereof held  by such holder; provided, however, that, except as otherwise required by law, holders of  Common Stock shall not be entitled to vote on any amendment to this Certificate of  Incorporation (which, as used herein, shall mean the certificate of incorporation of the  Corporation, as amended from time to time, including the terms of any certificate of designations  of any series of Preferred Stock) that relates solely to the terms of one or more outstanding series  of Preferred Stock if the holders of such affected series are entitled, either separately or together  as a class with the holders of one or more other such series, to vote thereon pursuant to this  Certificate of Incorporation.  There shall be no cumulative voting.  The number of authorized shares of Common Stock may be increased or decreased (but  not below the number of shares thereof then outstanding) by the affirmative vote of the holders  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex31-restatedcharterasam002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex31-restatedcharterasam002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of  Section 242(b)(2) of the General Corporation Law of the State of Delaware.  3. Dividends.  Dividends may be declared and paid on the Common Stock from  funds lawfully available therefor as and when determined by the Board of Directors and subject  to any preferential dividend or other rights of any then outstanding Preferred Stock.  4. Liquidation.  Upon the dissolution or liquidation of the Corporation, whether  voluntary or involuntary, holders of Common Stock will be entitled to receive all assets of the  Corporation available for distribution to its stockholders, subject to any preferential or other  rights of any then outstanding Preferred Stock.  B PREFERRED STOCK.  Preferred Stock may be issued from time to time in one or more series, each of such  series to have such terms as stated or expressed herein and in the resolution or resolutions  providing for the issue of such series adopted by the Board of Directors of the Corporation as  hereinafter provided.  Any shares of Preferred Stock which may be redeemed, purchased or  acquired by the Corporation may be reissued except as otherwise provided by law.    Authority is hereby expressly granted to the Board of Directors from time to time to issue  the Preferred Stock in one or more series, and in connection with the creation of any such series,  by adopting a resolution or resolutions providing for the issuance of the shares thereof and by  filing a certificate of designations relating thereto in accordance with the General Corporation  Law of the State of Delaware, to determine and fix the number of shares of such series and such  voting powers, full or limited, or no voting powers, and such designations, preferences and  relative participating, optional or other special rights, and qualifications, limitations or  restrictions thereof, including without limitation thereof, dividend rights, conversion rights,  redemption privileges and liquidation preferences, as shall be stated and expressed in such  resolutions, all to the full extent now or hereafter permitted by the General Corporation Law of  the State of Delaware.  Without limiting the generality of the foregoing, the resolutions providing  for issuance of any series of Preferred Stock may provide that such series shall be superior or  rank equally or be junior to any other series of Preferred Stock to the extent permitted by law.  The number of authorized shares of Preferred Stock may be increased or decreased (but  not below the number of shares then outstanding) by the affirmative vote of the holders of a  majority of the voting power of the capital stock of the Corporation entitled to vote thereon,  voting as a single class, irrespective of the provisions of Section 242(b)(2) of the General  Corporation Law of the State of Delaware.  FIFTH:  Except as otherwise provided herein, the Corporation reserves the right to  amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the  manner now or hereafter prescribed by statute and this Certificate of Incorporation, and all rights  conferred upon stockholders herein are granted subject to this reservation.  SIXTH:  In furtherance and not in limitation of the powers conferred upon it by the  General Corporation Law of the State of Delaware, and subject to the terms of any series of  Preferred Stock, the Board of Directors shall have the power to adopt, amend, alter or repeal the  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex31-restatedcharterasam003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex31-restatedcharterasam003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">By-laws of the Corporation by the affirmative vote of a majority of the directors present at any  regular or special meeting of the Board of Directors at which a quorum is present.  The  stockholders may not adopt, amend, alter or repeal the By-laws of the Corporation, or adopt any  provision inconsistent therewith, unless such action is approved, in addition to any other vote  required by this Certificate of Incorporation, by the affirmative vote of the holders of at least  seventy-five percent (75%) of the votes that all the stockholders would be entitled to cast in any  annual election of directors or class of directors.  Notwithstanding any other provisions of law,  this Certificate of Incorporation or the By-laws of the Corporation, and notwithstanding the fact  that a lesser percentage may be specified by law, the affirmative vote of the holders of at least  seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in  any annual election of directors or class of directors shall be required to amend or repeal, or to  adopt any provision inconsistent with, this Article SIXTH.  SEVENTH:  Except to the extent that the General Corporation Law of the State of  Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary  duty, no director of the Corporation shall be personally liable to the Corporation or its  stockholders for monetary damages for any breach of fiduciary duty as a director,  notwithstanding any provision of law imposing such liability.  No amendment to or repeal of this  provision shall apply to or have any effect on the liability or alleged liability of any director of  the Corporation for or with respect to any acts or omissions of such director occurring prior to  such amendment or repeal.  If the General Corporation Law of the State of Delaware is amended  to permit further elimination or limitation of the personal liability of directors, then the liability  of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by  the General Corporation Law of the State of Delaware as so amended.  EIGHTH:  The Corporation shall provide indemnification as follows:  1. Actions, Suits and Proceedings Other than by or in the Right of the Corporation.   The Corporation shall indemnify each person who was or is a party or threatened to be made a  party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal,  administrative or investigative (other than an action by or in the right of the Corporation) by  reason of the fact that he or she is or was, or has agreed to become, a director or officer of the  Corporation, or is or was serving, or has agreed to serve, at the request of the Corporation, as a  director, officer, partner, employee or trustee of, or in a similar capacity with, another  corporation, partnership, joint venture, trust or other enterprise (including any employee benefit  plan) (all such persons being referred to hereafter as an &#8220;Indemnitee&#8221;), or by reason of any action  alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217;  fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the  Employee Retirement Income Security Act of 1974), and amounts paid in settlement actually and  reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or  proceeding and any appeal therefrom, if Indemnitee acted in good faith and in a manner which  Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation,  and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or  her conduct was unlawful.  The termination of any action, suit or proceeding by judgment, order,  settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself,  create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee  reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex31-restatedcharterasam004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex31-restatedcharterasam004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">respect to any criminal action or proceeding, had reasonable cause to believe that his or her  conduct was unlawful.  2. Actions or Suits by or in the Right of the Corporation.  The Corporation shall  indemnify any Indemnitee who was or is a party to or threatened to be made a party to any  threatened, pending or completed action or suit by or in the right of the Corporation to procure a  judgment in its favor by reason of the fact that Indemnitee is or was, or has agreed to become, a  director or officer of the Corporation, or is or was serving, or has agreed to serve, at the request  of the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity  with, another corporation, partnership, joint venture, trust or other enterprise (including any  employee benefit plan), or by reason of any action alleged to have been taken or omitted in such  capacity, against all expenses (including attorneys&#8217; fees) and, to the extent permitted by law,  amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in  connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in  good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the  best interests of the Corporation, except that no indemnification shall be made under this Section  2 in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged to be  liable to the Corporation, unless, and only to the extent, that the Court of Chancery of Delaware  or the court in which such action or suit was brought shall determine upon application that,  despite the adjudication of such liability but in view of all the circumstances of the case,  Indemnitee is fairly and reasonably entitled to indemnity for such expenses (including attorneys&#8217;  fees) which the Court of Chancery of Delaware or such other court shall deem proper.  3. Indemnification for Expenses of Successful Party.  Notwithstanding any other  provisions of this Article EIGHTH, to the extent that an Indemnitee has been successful, on the  merits or otherwise, in defense of any action, suit or proceeding referred to in Sections 1 and 2 of  this Article EIGHTH, or in defense of any claim, issue or matter therein, or on appeal from any  such action, suit or proceeding, Indemnitee shall be indemnified against all expenses (including  attorneys&#8217; fees) actually and reasonably incurred by or on behalf of Indemnitee in connection  therewith.    4. Notification and Defense of Claim.  As a condition precedent to an Indemnitee&#8217;s  right to be indemnified, such Indemnitee must notify the Corporation in writing as soon as  practicable of any action, suit, proceeding or investigation involving such Indemnitee for which  indemnity will or could be sought.  With respect to any action, suit, proceeding or investigation  of which the Corporation is so notified, the Corporation will be entitled to participate therein at  its own expense and/or to assume the defense thereof at its own expense, with legal counsel  reasonably acceptable to Indemnitee.  After notice from the Corporation to Indemnitee of its  election so to assume such defense, the Corporation shall not be liable to Indemnitee for any  legal or other expenses subsequently incurred by Indemnitee in connection with such action, suit,  proceeding or investigation, other than as provided below in this Section 4.  Indemnitee shall  have the right to employ his or her own counsel in connection with such action, suit, proceeding  or investigation, but the fees and expenses of such counsel incurred after notice from the  Corporation of its assumption of the defense thereof shall be at the expense of Indemnitee unless  (i) the employment of counsel by Indemnitee has been authorized by the Corporation,  (ii) counsel to Indemnitee shall have reasonably concluded that there may be a conflict of interest  or position on any significant issue between the Corporation and Indemnitee in the conduct of  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex31-restatedcharterasam005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex31-restatedcharterasam005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">the defense of such action, suit, proceeding or investigation or (iii) the Corporation shall not in  fact have employed counsel to assume the defense of such action, suit, proceeding or  investigation, in each of which cases the fees and expenses of counsel for Indemnitee shall be at  the expense of the Corporation, except as otherwise expressly provided by this Article EIGHTH.   The Corporation shall not be entitled, without the consent of Indemnitee, to assume the defense  of any claim brought by or in the right of the Corporation or as to which counsel for Indemnitee  shall have reasonably made the conclusion provided for in clause (ii) above.  The Corporation  shall not be required to indemnify Indemnitee under this Article EIGHTH for any amounts paid  in settlement of any action, suit, proceeding or investigation effected without its written consent.   The Corporation shall not settle any action, suit, proceeding or investigation in any manner  which would impose any penalty or limitation on Indemnitee without Indemnitee&#8217;s written  consent.  Neither the Corporation nor Indemnitee will unreasonably withhold or delay its consent  to any proposed settlement.  5. Advance of Expenses.  Subject to the provisions of Section 6 of this Article  EIGHTH, in the event of any threatened or pending action, suit, proceeding or investigation of  which the Corporation receives notice under this Article EIGHTH, any expenses (including  attorneys&#8217; fees) incurred by or on behalf of Indemnitee in defending an action, suit, proceeding  or investigation or any appeal therefrom shall be paid by the Corporation in advance of the final  disposition of such matter; provided, however, that the payment of such expenses incurred by or  on behalf of Indemnitee in advance of the final disposition of such matter shall be made only  upon receipt of an undertaking by or on behalf of Indemnitee to repay all amounts so advanced  in the event that it shall ultimately be determined that Indemnitee is not entitled to be  indemnified by the Corporation as authorized in this Article EIGHTH; and provided further that  no such advancement of expenses shall be made under this Article EIGHTH if it is determined  (in the manner described in Section 6) that (i) Indemnitee did not act in good faith and in a  manner he or she reasonably believed to be in, or not opposed to, the best interests of the  Corporation, or (ii) with respect to any criminal action or proceeding, Indemnitee had reasonable  cause to believe his or her conduct was unlawful.  Such undertaking shall be accepted without  reference to the financial ability of Indemnitee to make such repayment.  6. Procedure for Indemnification and Advancement of Expenses.  In order to obtain  indemnification or advancement of expenses pursuant to Section 1, 2, 3 or 5 of this Article  EIGHTH, an Indemnitee shall submit to the Corporation a written request.  Any such  advancement of expenses shall be made promptly, and in any event within 60 days after receipt  by the Corporation of the written request of Indemnitee, unless (i) the Corporation has assumed  the defense pursuant to Section 4 of this Article EIGHTH (and none of the circumstances  described in Section 4 of this Article EIGHTH that would nonetheless entitle the Indemnitee to  indemnification for the fees and expenses of separate counsel have occurred) or (ii) the  Corporation determines within such 60-day period that Indemnitee did not meet the applicable  standard of conduct set forth in Section 1, 2 or 5 of this Article EIGHTH, as the case may be.   Any such indemnification, unless ordered by a court, shall be made with respect to requests  under Section 1 or 2 only as authorized in the specific case upon a determination by the  Corporation that the indemnification of Indemnitee is proper because Indemnitee has met the  applicable standard of conduct set forth in Section 1 or 2, as the case may be.  Such  determination shall be made in each instance (a) by a majority vote of the directors of the  Corporation consisting of persons who are not at that time parties to the action, suit or  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex31-restatedcharterasam006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex31-restatedcharterasam006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">proceeding in question (&#8220;disinterested directors&#8221;), whether or not a quorum, (b) by a committee  of disinterested directors designated by majority vote of disinterested directors, whether or not a  quorum, (c) if there are no disinterested directors, or if the disinterested directors so direct, by  independent legal counsel (who may, to the extent permitted by law, be regular legal counsel to  the Corporation) in a written opinion, or (d) by the stockholders of the Corporation.  7. Remedies.  The right to indemnification or advancement of expenses as granted  by this Article EIGHTH shall be enforceable by Indemnitee in any court of competent  jurisdiction.  Neither the failure of the Corporation to have made a determination prior to the  commencement of such action that indemnification is proper in the circumstances because  Indemnitee has met the applicable standard of conduct, nor an actual determination by the  Corporation pursuant to Section 6 of this Article EIGHTH that Indemnitee has not met such  applicable standard of conduct, shall be a defense to the action or create a presumption that  Indemnitee has not met the applicable standard of conduct.  Indemnitee&#8217;s expenses (including  attorneys&#8217; fees) reasonably incurred in connection with successfully establishing Indemnitee&#8217;s  right to indemnification, in whole or in part, in any such proceeding shall also be indemnified by  the Corporation.  Notwithstanding the foregoing, in any suit brought by Indemnitee to enforce a  right to indemnification hereunder it shall be a defense that the Indemnitee has not met any  applicable standard for indemnification set forth in the General Corporation Law of the State of  Delaware.  8. Limitations.  Notwithstanding anything to the contrary in this Article EIGHTH,  except as set forth in Section 7 of this Article EIGHTH, the Corporation shall not indemnify an  Indemnitee pursuant to this Article EIGHTH in connection with a proceeding (or part thereof)  initiated by such Indemnitee unless the initiation thereof was approved by the Board of Directors  of the Corporation.  Notwithstanding anything to the contrary in this Article EIGHTH, the  Corporation shall not indemnify an Indemnitee to the extent such Indemnitee is reimbursed from  the proceeds of insurance, and in the event the Corporation makes any indemnification payments  to an Indemnitee and such Indemnitee is subsequently reimbursed from the proceeds of  insurance, such Indemnitee shall promptly refund indemnification payments to the Corporation  to the extent of such insurance reimbursement.  9. Subsequent Amendment.  No amendment, termination or repeal of this Article  EIGHTH or of the relevant provisions of the General Corporation Law of the State of Delaware  or any other applicable laws shall adversely affect or diminish in any way the rights of any  Indemnitee to indemnification under the provisions hereof with respect to any action, suit,  proceeding or investigation arising out of or relating to any actions, transactions or facts  occurring prior to the final adoption of such amendment, termination or repeal.  10. Other Rights.  The indemnification and advancement of expenses provided by this  Article EIGHTH shall not be deemed exclusive of any other rights to which an Indemnitee  seeking indemnification or advancement of expenses may be entitled under any law (common or  statutory), agreement or vote of stockholders or disinterested directors or otherwise, both as to  action in Indemnitee&#8217;s official capacity and as to action in any other capacity while holding  office for the Corporation, and shall continue as to an Indemnitee who has ceased to be a director  or officer, and shall inure to the benefit of the estate, heirs, executors and administrators of  Indemnitee.  Nothing contained in this Article EIGHTH shall be deemed to prohibit, and the  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex31-restatedcharterasam007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex31-restatedcharterasam007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Corporation is specifically authorized to enter into, agreements with officers and directors  providing indemnification rights and procedures different from those set forth in this Article  EIGHTH.  In addition, the Corporation may, to the extent authorized from time to time by its  Board of Directors, grant indemnification rights to other employees or agents of the Corporation  or other persons serving the Corporation and such rights may be equivalent to, or greater or less  than, those set forth in this Article EIGHTH.  11. Partial Indemnification.  If an Indemnitee is entitled under any provision of this  Article EIGHTH to indemnification by the Corporation for some or a portion of the expenses  (including attorneys&#8217; fees), liabilities, losses, judgments, fines (including excise taxes and  penalties arising under the Employee Retirement Income Security Act of 1974) or amounts paid  in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with  any action, suit, proceeding or investigation and any appeal therefrom but not, however, for the  total amount thereof, the Corporation shall nevertheless indemnify Indemnitee for the portion of  such expenses (including attorneys&#8217; fees), liabilities, losses, judgments, fines (including excise  taxes and penalties arising under the Employee Retirement Income Security Act of 1974) or  amounts paid in settlement to which Indemnitee is entitled.  12. Insurance.  The Corporation may purchase and maintain insurance, at its expense,  to protect itself and any director, officer, employee or agent of the Corporation or another  corporation, partnership, joint venture, trust or other enterprise (including any employee benefit  plan) against any expense, liability or loss incurred by him or her in any such capacity, or arising  out of his or her status as such, whether or not the Corporation would have the power to  indemnify such person against such expense, liability or loss under the General Corporation Law  of the State of Delaware.  13. Savings Clause.  If this Article EIGHTH or any portion hereof shall be invalidated  on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless  indemnify each Indemnitee as to any expenses (including attorneys&#8217; fees), liabilities, losses,  judgments, fines (including excise taxes and penalties arising under the Employee Retirement  Income Security Act of 1974) and amounts paid in settlement in connection with any action, suit,  proceeding or investigation, whether civil, criminal or administrative, including an action by or  in the right of the Corporation, to the fullest extent permitted by any applicable portion of this  Article EIGHTH that shall not have been invalidated and to the fullest extent permitted by  applicable law.  14. Definitions.  Terms used herein and defined in Section 145(h) and Section 145(i)  of the General Corporation Law of the State of Delaware shall have the respective meanings  assigned to such terms in such Section 145(h) and Section 145(i).  NINTH:  This Article NINTH is inserted for the management of the business and for the  conduct of the affairs of the Corporation.  1. General Powers.  The business and affairs of the Corporation shall be managed by  or under the direction of the Board of Directors.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex31-restatedcharterasam008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex31-restatedcharterasam008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">2. Number of Directors; Election of Directors.  Subject to the rights of holders of  any series of Preferred Stock to elect directors, the number of directors of the Corporation shall  be established by the Board of Directors.  Election of directors need not be by written ballot,  except as and to the extent provided in the By-laws of the Corporation.  3. Classes of Directors.  Subject to the rights of holders of any series of Preferred  Stock to elect directors, the Board of Directors shall be and is divided into three classes,  designated Class I, Class II and Class III.  Each class shall consist, as nearly as may be possible,  of one-third of the total number of directors constituting the entire Board of Directors.  The  Board of Directors is authorized to assign members of the Board of Directors already in office to  Class I, Class II or Class III at the time such classification becomes effective.  4. Terms of Office.  Subject to the rights of holders of any series of Preferred Stock  to elect directors, each director shall serve for a term ending on the date of the third annual  meeting of stockholders following the annual meeting of stockholders at which such director was  elected; provided that each director initially assigned to Class I shall serve for a term expiring at  the Corporation&#8217;s first annual meeting of stockholders held after the effectiveness of this  Restated Certificate of Incorporation; each director initially assigned to Class II shall serve for a  term expiring at the Corporation&#8217;s second annual meeting of stockholders held after the  effectiveness of this Restated Certificate of Incorporation; and each director initially assigned to  Class III shall serve for a term expiring at the Corporation&#8217;s third annual meeting of stockholders  held after the effectiveness of this Restated Certificate of Incorporation; provided further, that the  term of each director shall continue until the election and qualification of his or her successor  and be subject to his or her earlier death, resignation or removal.  5. Quorum.  The greater of (a) a majority of the directors at any time in office and  (b) one-third of the number of directors fixed pursuant to Section 2 of this Article NINTH shall  constitute a quorum of the Board of Directors.  If at any meeting of the Board of Directors there  shall be less than such a quorum, a majority of the directors present may adjourn the meeting  from time to time without further notice other than announcement at the meeting, until a quorum  shall be present.  6. Action at Meeting.  Every act or decision done or made by a majority of the  directors present at a meeting duly held at which a quorum is present shall be regarded as the act  of the Board of Directors unless a greater number is required by law or by this Certificate of  Incorporation.  7. Removal.  Subject to the rights of holders of any series of Preferred Stock,  directors of the Corporation may be removed only for cause and only by the affirmative vote of  the holders of at least seventy-five percent (75%) of the votes which all the stockholders would  be entitled to cast in any annual election of directors or class of directors.  8. Vacancies.  Subject to the rights of holders of any series of Preferred Stock, any  vacancy or newly created directorship in the Board of Directors, however occurring, shall be  filled only by vote of a majority of the directors then in office, although less than a quorum, or  by a sole remaining director and shall not be filled by the stockholders.  A director elected to fill  a vacancy shall hold office until the next election of the class for which such director shall have  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex31-restatedcharterasam009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex31-restatedcharterasam009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">been chosen, subject to the election and qualification of a successor and to such director&#8217;s earlier  death, resignation or removal.  9. Stockholder Nominations and Introduction of Business, Etc.  Advance notice of  stockholder nominations for election of directors and other business to be brought by  stockholders before a meeting of stockholders shall be given in the manner provided by the By- laws of the Corporation.  10. Amendments to Article.  Notwithstanding any other provisions of law, this  Certificate of Incorporation or the By-laws of the Corporation, and notwithstanding the fact that  a lesser percentage may be specified by law, the affirmative vote of the holders of at least  seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in  any annual election of directors or class of directors shall be required to amend or repeal, or to  adopt any provision inconsistent with, this Article NINTH.  TENTH:  Stockholders of the Corporation may not take any action by written consent in  lieu of a meeting.  Notwithstanding any other provisions of law, this Certificate of Incorporation  or the By-laws of the Corporation, and notwithstanding the fact that a lesser percentage may be  specified by law, the affirmative vote of the holders of at least seventy-five percent (75%) of the  votes which all the stockholders would be entitled to cast in any annual election of directors or  class of directors shall be required to amend or repeal, or to adopt any provision inconsistent  with, this Article TENTH.  ELEVENTH:  Special meetings of stockholders for any purpose or purposes may be  called at any time by only the Board of Directors, the Chairman of the Board or the Chief  Executive Officer, and may not be called by any other person or persons.  Business transacted at  any special meeting of stockholders shall be limited to matters relating to the purpose or  purposes stated in the notice of meeting.  Notwithstanding any other provisions of law, this  Certificate of Incorporation or the By-laws of the Corporation, and notwithstanding the fact that  a lesser percentage may be specified by law, the affirmative vote of the holders of at least  seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in  any annual election of directors or class of directors shall be required to amend or repeal, or to  adopt any provision inconsistent with, this Article ELEVENTH.  TWELFTH:  Unless the Corporation consents in writing to the selection of an alternative  forum, the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf  of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any  director, officer or other employee of the Corporation to the Corporation or the Corporation&#8217;s  stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware  General Corporate Law or this Certificate of Incorporation or the By-Laws of the Corporation (in  each case, as they may be amended from time to time), or (iv) any action asserting a claim  governed by the internal affairs doctrine shall be the Court of Chancery in the State of Delaware  (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District  of Delaware).  Any person or entity purchasing or otherwise acquiring any interest in shares of  capital stock of the Corporation shall be deemed to have notice of and consented to the  provisions of this Article TWELFTH.     </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex31-restatedcharterasam010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex31-restatedcharterasam010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">IN WITNESS WHEREOF, this Restated Certificate of Incorporation, which restates,  integrates and amends the certificate of incorporation of the Corporation, and which has been  duly adopted in accordance with Sections 228, 242 and 245 of the General Corporation Law of  the State of Delaware, has been executed by its duly authorized officer this 8th day of February,  2016.  EDITAS MEDICINE, INC.  By: /s/ Katrine S. Bosley   Name: Katrine S. Bosley   Title:  President and Chief Executive Officer  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex31-restatedcharterasam011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex31-restatedcharterasam011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">CERTIFICATE OF AMENDMENT OF  RESTATED CERTIFICATE OF INCORPORATION  OF  EDITAS MEDICINE, INC.  (originally incorporated on September 3, 2013 under the name Gengine, Inc.)  (Pursuant to Section 242 of the  General Corporation Law of the State of Delaware)  Editas Medicine, Inc. (the &#8220;Corporation&#8221;), a corporation organized and existing under and  by virtue of the provisions of the General Corporation Law of the State of Delaware, does hereby  certify as follows:  A resolution was duly adopted by the Board of Directors of the Corporation pursuant to  Section 242 of the General Corporation Law of the State of Delaware setting forth a proposed  amendment to the Restated Certificate of Incorporation of the Corporation and declaring said  amendment to be advisable.  The stockholders of the Corporation duly approved said proposed  amendment in accordance with Section 242 of the General Corporation Law of the State of  Delaware. The resolution setting forth the amendment is as follows:  RESOLVED: That the first sentence of Article FOURTH of the Restated Certificate of  Incorporation of the Corporation be and hereby is deleted in its entirety  and the following is inserted in lieu thereof:  &#8220;FOURTH:  The total number of shares of all classes of stock which the Corporation  shall have authority to issue is 395,000,000 shares, consisting of (i) 390,000,000 shares of  Common Stock, $0.0001 par value per share (&#8220;Common Stock&#8221;), and (ii) 5,000,000  shares of Preferred Stock, $0.0001 par value per share (&#8220;Preferred Stock&#8221;).&#8221;  IN WITNESS WHEREOF, this Certificate of Amendment has been executed by a duly  authorized officer of the Corporation on this 2nd day of June, 2025.  EDITAS MEDICINE, INC.  By: /s/ Gilmore O&#8217;Neill________________  Gilmore O&#8217;Neill  President and Chief Executive Officer  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>edit-20250630xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5a0f975d996b483790ce72ce585f8be1_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Gilmore O&#8217;Neill, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">I have reviewed this Quarterly Report on Form 10-Q of Editas Medicine, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.97pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.46pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.58pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.46pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.97pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.46pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; August&#160;12, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Gilmore O&#8217;Neill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gilmore O&#8217;Neill<br>Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>edit-20250630xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4d2792b3489d4f8c9a44a3128a58d7e4_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Amy Parison, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">I have reviewed this Quarterly Report on Form 10-Q of Editas Medicine, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.97pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.46pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.58pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.46pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.97pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.46pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; August&#160;12, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Amy Parison</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amy Parison<br>Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>edit-20250630xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i8e13340c471442dc82abe993359a8584_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In connection with this Quarterly Report on Form 10-Q of Editas Medicine, Inc. (the &#8220;Company&#8221;) for the period ended June&#160;30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. (section) 1350, as adopted pursuant to (section) 906 of the Sarbanes-Oxley Act of 2002, that to the best of her or his knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.77pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.77pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:30pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; August&#160;12, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Gilmore O&#8217;Neill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gilmore O&#8217;Neill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; August&#160;12, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Amy Parison</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amy Parison</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>edit-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1ab0433d-837b-430f-b71f-73abb830ced3,g:6d451f6e-3d6d-4567-be55-1f6fd20083c0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:edit="http://www.editasmedicine.com/20250630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.editasmedicine.com/20250630">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edit-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edit-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edit-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edit-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.editasmedicine.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>9952156 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusiness" roleURI="http://www.editasmedicine.com/role/NatureofBusiness">
        <link:definition>9952157 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.editasmedicine.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecurities" roleURI="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecurities">
        <link:definition>9952159 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.editasmedicine.com/role/FairValueMeasurements">
        <link:definition>9952160 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.editasmedicine.com/role/AccruedExpenses">
        <link:definition>9952161 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnet" roleURI="http://www.editasmedicine.com/role/PropertyandEquipmentnet">
        <link:definition>9952162 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.editasmedicine.com/role/CommitmentsandContingencies">
        <link:definition>9952163 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.editasmedicine.com/role/CollaborationAgreements">
        <link:definition>9952164 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://www.editasmedicine.com/role/StockbasedCompensation">
        <link:definition>9952165 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.editasmedicine.com/role/NetLossperShare">
        <link:definition>9952166 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.editasmedicine.com/role/Debt">
        <link:definition>9952167 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandImpairmentCharges" roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentCharges">
        <link:definition>9952168 - Disclosure - Restructuring and Impairment Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://www.editasmedicine.com/role/Segments">
        <link:definition>9952169 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.editasmedicine.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesTables" roleURI="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesTables">
        <link:definition>9955512 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.editasmedicine.com/role/FairValueMeasurementsTables">
        <link:definition>9955513 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.editasmedicine.com/role/AccruedExpensesTables">
        <link:definition>9955514 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetTables" roleURI="http://www.editasmedicine.com/role/PropertyandEquipmentnetTables">
        <link:definition>9955515 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.editasmedicine.com/role/CollaborationAgreementsTables">
        <link:definition>9955516 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://www.editasmedicine.com/role/StockbasedCompensationTables">
        <link:definition>9955517 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.editasmedicine.com/role/NetLossperShareTables">
        <link:definition>9955518 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.editasmedicine.com/role/DebtTables">
        <link:definition>9955519 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandImpairmentChargesTables" roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesTables">
        <link:definition>9955520 - Disclosure - Restructuring and Impairment Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsTables" roleURI="http://www.editasmedicine.com/role/SegmentsTables">
        <link:definition>9955521 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessDetails" roleURI="http://www.editasmedicine.com/role/NatureofBusinessDetails">
        <link:definition>9955522 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>9955523 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesNarrativeDetails" roleURI="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails">
        <link:definition>9955524 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.editasmedicine.com/role/FairValueMeasurementsDetails">
        <link:definition>9955525 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.editasmedicine.com/role/AccruedExpensesDetails">
        <link:definition>9955526 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetDetails" roleURI="http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails">
        <link:definition>9955527 - Disclosure - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9955528 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails" roleURI="http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails">
        <link:definition>9955529 - Disclosure - Collaboration Agreements - Schedule of Accounts Receivable and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsChangeinContractAssetsandContractLiabilitiesDetails" roleURI="http://www.editasmedicine.com/role/CollaborationAgreementsChangeinContractAssetsandContractLiabilitiesDetails">
        <link:definition>9955530 - Disclosure - Collaboration Agreements - Change in Contract Assets and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsNarrativeDetails" roleURI="http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails">
        <link:definition>9955531 - Disclosure - Collaboration Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>9955532 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationRestrictedStockandStockOptionsDetails" roleURI="http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails">
        <link:definition>9955533 - Disclosure - Stock-based Compensation - Restricted Stock and Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareDetails" roleURI="http://www.editasmedicine.com/role/NetLossperShareDetails">
        <link:definition>9955534 - Disclosure - Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.editasmedicine.com/role/DebtNarrativeDetails">
        <link:definition>9955535 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofDebtDetails" roleURI="http://www.editasmedicine.com/role/DebtScheduleofDebtDetails">
        <link:definition>9955536 - Disclosure - Debt - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandImpairmentChargesNarrativeDetails" roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails">
        <link:definition>9955537 - Disclosure - Restructuring and Impairment Charges - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails" roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails">
        <link:definition>9955538 - Disclosure - Restructuring and Impairment Charges - Schedule of Restructuring and Related Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails" roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails">
        <link:definition>9955539 - Disclosure - Restructuring and Impairment Charges - Schedule of Employee Termination Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails" roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails">
        <link:definition>9955540 - Disclosure - Restructuring and Impairment Charges - Schedule of Contract Termination Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails" roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails">
        <link:definition>9955541 - Disclosure - Restructuring and Impairment Charges - Schedule of Accelerated Depreciation and Rent Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsNarrativeDetails" roleURI="http://www.editasmedicine.com/role/SegmentsNarrativeDetails">
        <link:definition>9955542 - Disclosure - Segments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>9955543 - Disclosure - Segments - Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="edit_InterestRelatedToSaleOfFutureRevenues" abstract="false" name="InterestRelatedToSaleOfFutureRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_IncreaseDecreaseInRightOfUseAssets" abstract="false" name="IncreaseDecreaseInRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues" abstract="false" name="IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_CommencementOfRightOfUseAsset" abstract="false" name="CommencementOfRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_NonCashTerminationOfRightOfUseAsset" abstract="false" name="NonCashTerminationOfRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_CollaborationAgreementsAbstract" abstract="true" name="CollaborationAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" abstract="false" name="ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" abstract="false" name="ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock" abstract="false" name="ScheduleOfEmployeeTerminationBenefitsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="edit_ScheduleOfContractTerminationCostsTableTextBlock" abstract="false" name="ScheduleOfContractTerminationCostsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="edit_AtMarketOfferingMember" abstract="true" name="AtMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal" abstract="false" name="CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued" abstract="false" name="SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable" abstract="false" name="SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_MarketableSecuritiesNoncurrentNumberOfSecurities" abstract="false" name="MarketableSecuritiesNoncurrentNumberOfSecurities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="edit_MarketableSecuritiesRemainingMaturityTerm" abstract="false" name="MarketableSecuritiesRemainingMaturityTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="edit_EmployeeTerminationBenefitsMember" abstract="true" name="EmployeeTerminationBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="edit_AccruedExternalResearchAndDevelopmentExpensesCurrent" abstract="false" name="AccruedExternalResearchAndDevelopmentExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_SublicenseAndLicenseFeesCurrent" abstract="false" name="SublicenseAndLicenseFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_IntellectualPropertyAndPatentRelatedFeesCurrent" abstract="false" name="IntellectualPropertyAndPatentRelatedFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_LaboratoryAndManufacturingEquipmentMember" abstract="true" name="LaboratoryAndManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="edit_LicensorExpenseReimbursementsMember" abstract="true" name="LicensorExpenseReimbursementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="edit_LicenseAndServiceAgreementMember" abstract="true" name="LicenseAndServiceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="edit_OperatingLeaseTerminationNotificationPeriod" abstract="false" name="OperatingLeaseTerminationNotificationPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="edit_ReceivablesNetCurrentRollForward" abstract="true" name="ReceivablesNetCurrentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="edit_AccountsReceivableAdditions" abstract="false" name="AccountsReceivableAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_AccountsReceivableDeductions" abstract="false" name="AccountsReceivableDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_ContractWithCustomerLiabilityRollForward" abstract="true" name="ContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="edit_ContractWithCustomerLiabilityAdditions" abstract="false" name="ContractWithCustomerLiabilityAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_ContractWithCustomerLiabilityDeductions" abstract="false" name="ContractWithCustomerLiabilityDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_BristolMyersSquibbCompanyMember" abstract="true" name="BristolMyersSquibbCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="edit_AmendedCollaborationAgreement2019Member" abstract="true" name="AmendedCollaborationAgreement2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="edit_AgreementExtensionPeriodOptionsToExtend" abstract="false" name="AgreementExtensionPeriodOptionsToExtend" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="edit_DRIHealthcareAcquisitionsLPMember" abstract="true" name="DRIHealthcareAcquisitionsLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="edit_LicenseAgreementMember" abstract="true" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="edit_LicenseFeeReceivable" abstract="false" name="LicenseFeeReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_ContingentFeeReceivableThresholdAmount" abstract="false" name="ContingentFeeReceivableThresholdAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate" abstract="false" name="LiabilityForSaleOfFutureRevenuesEffectiveInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="edit_DebtRollForward" abstract="true" name="DebtRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="edit_DebtInstrumentRollForward" abstract="true" name="DebtInstrumentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues" abstract="false" name="NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember" abstract="true" name="AccelerationOfExpenseChangeInUsefulLifeEstimateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="edit_ImpairmentChargesMember" abstract="true" name="ImpairmentChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash" abstract="false" name="PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_AmountsPaidOrOtherwiseSettled" abstract="false" name="AmountsPaidOrOtherwiseSettled" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_ChargesRelatedToTerminationOfLease" abstract="false" name="ChargesRelatedToTerminationOfLease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="edit_SublicenseAndLicenseFees" abstract="false" name="SublicenseAndLicenseFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="edit_IntellectualPropertyAndPatentRelatedFees" abstract="false" name="IntellectualPropertyAndPatentRelatedFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>edit-20250630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1ab0433d-837b-430f-b71f-73abb830ced3,g:6d451f6e-3d6d-4567-be55-1f6fd20083c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="edit-20250630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_05123125-9f82-4463-8428-d48cf76afc28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b167e0ab-64c6-4fcf-98c1-e253dbfe95f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_05123125-9f82-4463-8428-d48cf76afc28" xlink:to="loc_us-gaap_AccountsPayableCurrent_b167e0ab-64c6-4fcf-98c1-e253dbfe95f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_69316a20-1caf-44bc-88d1-9e74cee3dcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_05123125-9f82-4463-8428-d48cf76afc28" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_69316a20-1caf-44bc-88d1-9e74cee3dcc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0e0ce9fc-1ca9-4c84-a60c-198485db8032" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_05123125-9f82-4463-8428-d48cf76afc28" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0e0ce9fc-1ca9-4c84-a60c-198485db8032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4df0a5b9-179e-4883-88ca-ada73f8a46cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_05123125-9f82-4463-8428-d48cf76afc28" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4df0a5b9-179e-4883-88ca-ada73f8a46cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f42a0668-5c89-4046-b0e1-4df2bb110b95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_05123125-9f82-4463-8428-d48cf76afc28" xlink:to="loc_us-gaap_LongTermDebtCurrent_f42a0668-5c89-4046-b0e1-4df2bb110b95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_781b6148-438b-4d50-beb1-80069b9d471f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7bc75e58-7d91-4556-8048-2637f4d13d21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_781b6148-438b-4d50-beb1-80069b9d471f" xlink:to="loc_us-gaap_LiabilitiesCurrent_7bc75e58-7d91-4556-8048-2637f4d13d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5fef43a3-afd5-4833-863a-200e2fe12f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_781b6148-438b-4d50-beb1-80069b9d471f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5fef43a3-afd5-4833-863a-200e2fe12f0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e15e6f80-d930-4d22-8b6a-f790fb43e776" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_781b6148-438b-4d50-beb1-80069b9d471f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e15e6f80-d930-4d22-8b6a-f790fb43e776" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8b0cb8e7-2a2b-4fd9-ab2b-400f0d0e61c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_781b6148-438b-4d50-beb1-80069b9d471f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8b0cb8e7-2a2b-4fd9-ab2b-400f0d0e61c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_849caa28-1d44-4f03-b9c3-83c1fb9788e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_781b6148-438b-4d50-beb1-80069b9d471f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_849caa28-1d44-4f03-b9c3-83c1fb9788e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0e872125-4493-4d59-8bb6-2991dd42b37f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25623633-9281-4d1d-956f-95924fbba1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e872125-4493-4d59-8bb6-2991dd42b37f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25623633-9281-4d1d-956f-95924fbba1b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_60126c72-f3dd-4277-9ea6-d79c3ffa1223" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e872125-4493-4d59-8bb6-2991dd42b37f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_60126c72-f3dd-4277-9ea6-d79c3ffa1223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_1ca7a1b6-9d02-4f8d-b216-37b6f745b7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e872125-4493-4d59-8bb6-2991dd42b37f" xlink:to="loc_us-gaap_ReceivablesNetCurrent_1ca7a1b6-9d02-4f8d-b216-37b6f745b7a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a50df203-c23e-4618-9467-37891262edad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e872125-4493-4d59-8bb6-2991dd42b37f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a50df203-c23e-4618-9467-37891262edad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_34fe7397-ac22-4001-b6c9-f9fbf18d03fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7d64dc30-6a78-4ff4-b163-dd18ff03da98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_34fe7397-ac22-4001-b6c9-f9fbf18d03fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7d64dc30-6a78-4ff4-b163-dd18ff03da98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_49f76683-25b0-4c39-be5c-5158f8332cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_34fe7397-ac22-4001-b6c9-f9fbf18d03fa" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_49f76683-25b0-4c39-be5c-5158f8332cdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7d0e9f09-dcfb-4f9f-ba3e-d78ebc400bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_34fe7397-ac22-4001-b6c9-f9fbf18d03fa" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7d0e9f09-dcfb-4f9f-ba3e-d78ebc400bd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fa4af158-fc5b-45f0-8704-621cf4915fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_34fe7397-ac22-4001-b6c9-f9fbf18d03fa" xlink:to="loc_us-gaap_AssetsCurrent_fa4af158-fc5b-45f0-8704-621cf4915fd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e8c0c36d-340d-4ae0-ada3-c921f8ed0309" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6dea899e-3a57-42f9-939a-f873e16f8657" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e8c0c36d-340d-4ae0-ada3-c921f8ed0309" xlink:to="loc_us-gaap_PreferredStockValue_6dea899e-3a57-42f9-939a-f873e16f8657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_95a2d007-b110-4c4d-b8da-9dd9c7fc74de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e8c0c36d-340d-4ae0-ada3-c921f8ed0309" xlink:to="loc_us-gaap_CommonStockValue_95a2d007-b110-4c4d-b8da-9dd9c7fc74de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e65bca9e-bd22-4334-acbc-7b12a8c4bc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e8c0c36d-340d-4ae0-ada3-c921f8ed0309" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e65bca9e-bd22-4334-acbc-7b12a8c4bc9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_44ac1279-c29a-405a-8e58-fe86842a1285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e8c0c36d-340d-4ae0-ada3-c921f8ed0309" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_44ac1279-c29a-405a-8e58-fe86842a1285" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cab85514-bb96-4834-8ad0-75dbcf59ef88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e8c0c36d-340d-4ae0-ada3-c921f8ed0309" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cab85514-bb96-4834-8ad0-75dbcf59ef88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_408ddab2-9307-49a7-a4ee-2474108e5e63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a2f71180-0bf2-4a9f-afad-ed6cd53ada9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_408ddab2-9307-49a7-a4ee-2474108e5e63" xlink:to="loc_us-gaap_Liabilities_a2f71180-0bf2-4a9f-afad-ed6cd53ada9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ec401b13-ce3d-408e-a7d8-c563832969eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_408ddab2-9307-49a7-a4ee-2474108e5e63" xlink:to="loc_us-gaap_StockholdersEquity_ec401b13-ce3d-408e-a7d8-c563832969eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="edit-20250630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3b15b908-b300-4177-b274-d2b153cab623" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7ead97da-2966-4403-99d0-53b3fb5cf543" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3b15b908-b300-4177-b274-d2b153cab623" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7ead97da-2966-4403-99d0-53b3fb5cf543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_c797632a-3fab-412b-b53a-8f744675a4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3b15b908-b300-4177-b274-d2b153cab623" xlink:to="loc_us-gaap_InvestmentIncomeNet_c797632a-3fab-412b-b53a-8f744675a4ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a51080cd-8b56-4c27-9f91-a102471717b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3b15b908-b300-4177-b274-d2b153cab623" xlink:to="loc_us-gaap_InterestExpenseDebt_a51080cd-8b56-4c27-9f91-a102471717b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_524027be-8dc8-4f46-8914-15e97ab9cb11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b0da08f-23dc-4bd4-bfaf-3d5a29f296c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_524027be-8dc8-4f46-8914-15e97ab9cb11" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b0da08f-23dc-4bd4-bfaf-3d5a29f296c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fcc0b421-8e34-45f8-b7f1-2e7025060efc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_524027be-8dc8-4f46-8914-15e97ab9cb11" xlink:to="loc_us-gaap_OperatingExpenses_fcc0b421-8e34-45f8-b7f1-2e7025060efc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_94d8c1d3-ddb2-4383-abcb-57c0902d8669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_22364594-85e6-4dcc-8a01-0189a31a7daa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_94d8c1d3-ddb2-4383-abcb-57c0902d8669" xlink:to="loc_us-gaap_OperatingIncomeLoss_22364594-85e6-4dcc-8a01-0189a31a7daa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_57361854-c2d6-4242-8caf-5cce109b735f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_94d8c1d3-ddb2-4383-abcb-57c0902d8669" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_57361854-c2d6-4242-8caf-5cce109b735f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ebaae9f5-3319-4821-816a-a15ded388cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_734be2c4-cc58-4ff7-9dec-90a86b97b7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ebaae9f5-3319-4821-816a-a15ded388cdd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_734be2c4-cc58-4ff7-9dec-90a86b97b7c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fc79e686-96c9-471c-8d14-830dd53f402b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ebaae9f5-3319-4821-816a-a15ded388cdd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fc79e686-96c9-471c-8d14-830dd53f402b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_ef942ba8-a712-4103-976f-b715dc12d583" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ebaae9f5-3319-4821-816a-a15ded388cdd" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_ef942ba8-a712-4103-976f-b715dc12d583" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="edit-20250630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_47bf8d37-5035-42b0-8015-b2a5cfb64f29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e6ab3d4-81fc-4eb0-9ab8-24d3261358f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_47bf8d37-5035-42b0-8015-b2a5cfb64f29" xlink:to="loc_us-gaap_NetIncomeLoss_6e6ab3d4-81fc-4eb0-9ab8-24d3261358f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_68b9a864-5ca4-4836-b5dc-1997c7ec90db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_47bf8d37-5035-42b0-8015-b2a5cfb64f29" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_68b9a864-5ca4-4836-b5dc-1997c7ec90db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="edit-20250630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_952fae61-c0b3-4a12-ab5f-b048595912a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_00574a1f-3a98-4b89-a97f-2adceec3199a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_952fae61-c0b3-4a12-ab5f-b048595912a8" xlink:to="loc_us-gaap_RestrictedCash_00574a1f-3a98-4b89-a97f-2adceec3199a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a5351766-029c-48cf-9d9d-add1987b997a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_952fae61-c0b3-4a12-ab5f-b048595912a8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a5351766-029c-48cf-9d9d-add1987b997a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da6dacb3-b19a-4ea0-adc0-b6639529be6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02bc708b-2517-40cc-b579-8753029b7c20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da6dacb3-b19a-4ea0-adc0-b6639529be6f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02bc708b-2517-40cc-b579-8753029b7c20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_348bc8bc-acf0-42ee-aac6-de64ea1f6604" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da6dacb3-b19a-4ea0-adc0-b6639529be6f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_348bc8bc-acf0-42ee-aac6-de64ea1f6604" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_680d868d-56a9-452e-9b27-630f5a7a7719" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da6dacb3-b19a-4ea0-adc0-b6639529be6f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_680d868d-56a9-452e-9b27-630f5a7a7719" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fdccc51e-a3ea-4fae-adf6-50a22b7c8dea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_86dfddd9-d964-4f1d-b8f5-0f39efe9ae2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fdccc51e-a3ea-4fae-adf6-50a22b7c8dea" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_86dfddd9-d964-4f1d-b8f5-0f39efe9ae2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_5ec25b6f-b54b-49cb-aaa9-418643ecd5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fdccc51e-a3ea-4fae-adf6-50a22b7c8dea" xlink:to="loc_us-gaap_RepaymentsOfDebt_5ec25b6f-b54b-49cb-aaa9-418643ecd5ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0516af7b-e806-4c49-a09f-bd5bdb2d68ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fdccc51e-a3ea-4fae-adf6-50a22b7c8dea" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0516af7b-e806-4c49-a09f-bd5bdb2d68ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_d58cdee8-0fd4-471c-8c60-72413ea0228b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fdccc51e-a3ea-4fae-adf6-50a22b7c8dea" xlink:to="loc_us-gaap_ProceedsFromStockPlans_d58cdee8-0fd4-471c-8c60-72413ea0228b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b552cff6-e8db-4448-b1bf-1b9b52647dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_NetIncomeLoss_b552cff6-e8db-4448-b1bf-1b9b52647dbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_008676c1-8734-404c-a937-794ad50d7f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_ShareBasedCompensation_008676c1-8734-404c-a937-794ad50d7f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_365191f1-ca6d-4121-bd9c-dd5e03e40f01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_Depreciation_365191f1-ca6d-4121-bd9c-dd5e03e40f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0c40adca-2944-4f14-95f2-1f817bd204f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0c40adca-2944-4f14-95f2-1f817bd204f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_f74e548b-7070-4b79-bf8d-9077195f0d49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_f74e548b-7070-4b79-bf8d-9077195f0d49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_InterestRelatedToSaleOfFutureRevenues_d90d834a-b7dd-4de9-baad-dcd6d4e0c8d6" xlink:href="edit-20250630.xsd#edit_InterestRelatedToSaleOfFutureRevenues"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_edit_InterestRelatedToSaleOfFutureRevenues_d90d834a-b7dd-4de9-baad-dcd6d4e0c8d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_eb64e974-47b4-483e-bf3e-e87a70a53c96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_eb64e974-47b4-483e-bf3e-e87a70a53c96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5f563027-c74b-45dd-89d9-1258940bae38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_5f563027-c74b-45dd-89d9-1258940bae38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_37a7fa50-6d5a-42ab-ba33-603df36549ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_37a7fa50-6d5a-42ab-ba33-603df36549ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c64cc5ee-ebaf-4848-849e-cb109852f5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c64cc5ee-ebaf-4848-849e-cb109852f5ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_IncreaseDecreaseInRightOfUseAssets_f627233c-a57a-4d1b-bba7-18e39993a1bd" xlink:href="edit-20250630.xsd#edit_IncreaseDecreaseInRightOfUseAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_edit_IncreaseDecreaseInRightOfUseAssets_f627233c-a57a-4d1b-bba7-18e39993a1bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_cfc37d0c-65de-4927-9fcf-955a1ca06dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_cfc37d0c-65de-4927-9fcf-955a1ca06dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_aaffebe6-ad2d-4c31-8b25-e9ae30d39071" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_aaffebe6-ad2d-4c31-8b25-e9ae30d39071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_51179292-80cb-4997-921f-f7290273463d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_51179292-80cb-4997-921f-f7290273463d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues_9a3f37c6-b95f-4edd-bac7-9f7e6f440e29" xlink:href="edit-20250630.xsd#edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues_9a3f37c6-b95f-4edd-bac7-9f7e6f440e29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8c6f24d9-2bde-4ac7-a371-238011bd7080" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8c6f24d9-2bde-4ac7-a371-238011bd7080" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2bd9c1c3-60a6-4fce-bc41-772d95095a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2bd9c1c3-60a6-4fce-bc41-772d95095a7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_b71f45a6-7b46-45c2-a41f-95bd54bce67d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e46dd271-c4b5-4c75-b6fb-cac6bab7d678" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_b71f45a6-7b46-45c2-a41f-95bd54bce67d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec059b03-52fc-42ce-b89e-7c420cef9c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4023a52d-6b77-40fe-a09e-015eacf8945e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec059b03-52fc-42ce-b89e-7c420cef9c2d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4023a52d-6b77-40fe-a09e-015eacf8945e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_70c36dd3-74c2-459f-ac59-797df0105a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec059b03-52fc-42ce-b89e-7c420cef9c2d" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_70c36dd3-74c2-459f-ac59-797df0105a2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5962144c-9ab3-4648-8eba-511de9085824" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec059b03-52fc-42ce-b89e-7c420cef9c2d" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5962144c-9ab3-4648-8eba-511de9085824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c42b22b8-a77e-4d03-ace9-0b7a41e62086" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec059b03-52fc-42ce-b89e-7c420cef9c2d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c42b22b8-a77e-4d03-ace9-0b7a41e62086" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0ed2d5a8-6257-4206-be99-cdd6ad8e6610" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b9f3e000-2442-44b4-ae7c-9ec513a829d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0ed2d5a8-6257-4206-be99-cdd6ad8e6610" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b9f3e000-2442-44b4-ae7c-9ec513a829d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_16343000-da48-4dd6-b20a-b7b31c762d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0ed2d5a8-6257-4206-be99-cdd6ad8e6610" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_16343000-da48-4dd6-b20a-b7b31c762d6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_87d142d1-1c99-4002-b989-7477d95ad443" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0ed2d5a8-6257-4206-be99-cdd6ad8e6610" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_87d142d1-1c99-4002-b989-7477d95ad443" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_1d999deb-9902-4bf0-9f8b-bccebf493f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0ed2d5a8-6257-4206-be99-cdd6ad8e6610" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_1d999deb-9902-4bf0-9f8b-bccebf493f7b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.editasmedicine.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b41e61fa-a4dd-4f0f-918d-31d322991898" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_13fb9644-3265-4709-934f-0e6c042a57a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b41e61fa-a4dd-4f0f-918d-31d322991898" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_13fb9644-3265-4709-934f-0e6c042a57a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b3152348-f631-45d4-aed2-dccd16b6ca07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b41e61fa-a4dd-4f0f-918d-31d322991898" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b3152348-f631-45d4-aed2-dccd16b6ca07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_18b239c3-cf3c-48c8-abf8-9b0ba4acec67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b41e61fa-a4dd-4f0f-918d-31d322991898" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_18b239c3-cf3c-48c8-abf8-9b0ba4acec67" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.editasmedicine.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_050bca5c-f8e1-465a-87b8-dce707f58107" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent_2c2dbc24-3d80-4ef2-a9ca-3c71a314a487" xlink:href="edit-20250630.xsd#edit_AccruedExternalResearchAndDevelopmentExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_050bca5c-f8e1-465a-87b8-dce707f58107" xlink:to="loc_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent_2c2dbc24-3d80-4ef2-a9ca-3c71a314a487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_933a306f-8b1f-40e5-a9c6-9ec9f04394da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_050bca5c-f8e1-465a-87b8-dce707f58107" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_933a306f-8b1f-40e5-a9c6-9ec9f04394da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_SublicenseAndLicenseFeesCurrent_24bd5d58-c33d-4d53-9810-a5b37006f5bd" xlink:href="edit-20250630.xsd#edit_SublicenseAndLicenseFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_050bca5c-f8e1-465a-87b8-dce707f58107" xlink:to="loc_edit_SublicenseAndLicenseFeesCurrent_24bd5d58-c33d-4d53-9810-a5b37006f5bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_IntellectualPropertyAndPatentRelatedFeesCurrent_a8c20506-72b5-47f9-abf5-60d9149977d2" xlink:href="edit-20250630.xsd#edit_IntellectualPropertyAndPatentRelatedFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_050bca5c-f8e1-465a-87b8-dce707f58107" xlink:to="loc_edit_IntellectualPropertyAndPatentRelatedFeesCurrent_a8c20506-72b5-47f9-abf5-60d9149977d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_915e98a6-a566-4923-a3ce-312b7dec51da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_050bca5c-f8e1-465a-87b8-dce707f58107" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_915e98a6-a566-4923-a3ce-312b7dec51da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_b717cc6d-b822-4249-84e5-5a5ec6a5407e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_050bca5c-f8e1-465a-87b8-dce707f58107" xlink:to="loc_us-gaap_RestructuringReserveCurrent_b717cc6d-b822-4249-84e5-5a5ec6a5407e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_72d23805-a2f7-46f7-81e4-d6274a4db576" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_050bca5c-f8e1-465a-87b8-dce707f58107" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_72d23805-a2f7-46f7-81e4-d6274a4db576" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#PropertyandEquipmentnetDetails"/>
  <link:calculationLink xlink:role="http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_168f72ec-ab30-4fa2-bf19-64aac1b90072" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_dff77206-ce3d-482d-9d74-c9315279169b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_168f72ec-ab30-4fa2-bf19-64aac1b90072" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_dff77206-ce3d-482d-9d74-c9315279169b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cdf8885c-cfaf-4f7a-b644-a14fc43ad8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_168f72ec-ab30-4fa2-bf19-64aac1b90072" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cdf8885c-cfaf-4f7a-b644-a14fc43ad8e5" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>edit-20250630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1ab0433d-837b-430f-b71f-73abb830ced3,g:6d451f6e-3d6d-4567-be55-1f6fd20083c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="edit-20250630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9730f8c8-3066-4506-8767-586552dca1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_17b72221-d61d-4c52-8dfe-f8a462b37ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9730f8c8-3066-4506-8767-586552dca1ac" xlink:to="loc_us-gaap_StatementTable_17b72221-d61d-4c52-8dfe-f8a462b37ecc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bb0000c6-dc5d-400c-949c-4cefc8b1842a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_17b72221-d61d-4c52-8dfe-f8a462b37ecc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bb0000c6-dc5d-400c-949c-4cefc8b1842a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bb0000c6-dc5d-400c-949c-4cefc8b1842a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bb0000c6-dc5d-400c-949c-4cefc8b1842a" xlink:to="loc_us-gaap_EquityComponentDomain_bb0000c6-dc5d-400c-949c-4cefc8b1842a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e932bf12-fb31-449b-80ce-696e5b1bbb66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bb0000c6-dc5d-400c-949c-4cefc8b1842a" xlink:to="loc_us-gaap_EquityComponentDomain_e932bf12-fb31-449b-80ce-696e5b1bbb66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_867d2fab-701d-429b-9a85-83a698274d80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e932bf12-fb31-449b-80ce-696e5b1bbb66" xlink:to="loc_us-gaap_CommonStockMember_867d2fab-701d-429b-9a85-83a698274d80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cd3e2996-9ed6-466d-9b0a-41eb33823012" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e932bf12-fb31-449b-80ce-696e5b1bbb66" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cd3e2996-9ed6-466d-9b0a-41eb33823012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_effbe582-25b1-4b2a-80c5-e864e60517e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e932bf12-fb31-449b-80ce-696e5b1bbb66" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_effbe582-25b1-4b2a-80c5-e864e60517e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a7446b38-4483-464b-80cc-dab8e982ebb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e932bf12-fb31-449b-80ce-696e5b1bbb66" xlink:to="loc_us-gaap_RetainedEarningsMember_a7446b38-4483-464b-80cc-dab8e982ebb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9730f8c8-3066-4506-8767-586552dca1ac" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f32a907c-de4d-48ad-9598-c8e1fd05060c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_SharesOutstanding_f32a907c-de4d-48ad-9598-c8e1fd05060c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_01d28b1c-0120-4008-86dc-28398174413f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockholdersEquity_01d28b1c-0120-4008-86dc-28398174413f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d07ac737-06ac-400c-98d7-0db0713de1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d07ac737-06ac-400c-98d7-0db0713de1d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4da8f217-50da-431c-905b-24ce59c44086" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4da8f217-50da-431c-905b-24ce59c44086" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d8f65806-3faf-4d49-8055-158ac43da8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d8f65806-3faf-4d49-8055-158ac43da8c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2c67d496-8a15-42d2-98c9-cd00253c3f81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2c67d496-8a15-42d2-98c9-cd00253c3f81" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_80ec6ad0-9607-4080-9b29-60adea41509f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_80ec6ad0-9607-4080-9b29-60adea41509f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a4abfd42-5567-4561-b45e-fed0dace5869" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a4abfd42-5567-4561-b45e-fed0dace5869" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_22b02ad9-e99d-4355-94fc-43ece75ed925" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_22b02ad9-e99d-4355-94fc-43ece75ed925" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_914c5b77-ffad-4302-9379-531914c29c66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_914c5b77-ffad-4302-9379-531914c29c66" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f35476bd-5932-4d42-beb5-51a4bb9c3945" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f35476bd-5932-4d42-beb5-51a4bb9c3945" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc0d1262-635f-4943-9d9f-25d043dcffed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_NetIncomeLoss_fc0d1262-635f-4943-9d9f-25d043dcffed" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e0837327-e080-44c4-b4f4-123f42525781" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2b554bc5-164e-415c-a78d-1201f602267e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#NatureofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/NatureofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_74ea540d-f946-4db6-a5c2-bda7800695f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_74ea540d-f946-4db6-a5c2-bda7800695f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7a960c32-a35e-4fe6-b768-01940db169d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_74ea540d-f946-4db6-a5c2-bda7800695f7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7a960c32-a35e-4fe6-b768-01940db169d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7a960c32-a35e-4fe6-b768-01940db169d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7a960c32-a35e-4fe6-b768-01940db169d1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7a960c32-a35e-4fe6-b768-01940db169d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8aacdaf7-267e-4fa1-becd-7320d4868520" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7a960c32-a35e-4fe6-b768-01940db169d1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8aacdaf7-267e-4fa1-becd-7320d4868520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AtMarketOfferingMember_74e8f67c-609f-4453-83b4-f8025bb3f07f" xlink:href="edit-20250630.xsd#edit_AtMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8aacdaf7-267e-4fa1-becd-7320d4868520" xlink:to="loc_edit_AtMarketOfferingMember_74e8f67c-609f-4453-83b4-f8025bb3f07f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_232850da-06e0-44d4-9733-0aef1daf771d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_232850da-06e0-44d4-9733-0aef1daf771d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal_8cecbd1c-206e-4e90-b1e0-bd32376aab57" xlink:href="edit-20250630.xsd#edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal_8cecbd1c-206e-4e90-b1e0-bd32376aab57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued_d7090bd0-2e71-4259-ab59-0c1a1cf4c140" xlink:href="edit-20250630.xsd#edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued_d7090bd0-2e71-4259-ab59-0c1a1cf4c140" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_db64aef6-c9d9-49e2-8324-c61b02a693e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_db64aef6-c9d9-49e2-8324-c61b02a693e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7a6d2d17-20bb-417b-be3b-3ab70446092c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7a6d2d17-20bb-417b-be3b-3ab70446092c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable_6d20a0f1-f40a-4614-af0e-fff57d961454" xlink:href="edit-20250630.xsd#edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable_6d20a0f1-f40a-4614-af0e-fff57d961454" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2da2842e-3441-4c5d-881f-4b65b5447fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2da2842e-3441-4c5d-881f-4b65b5447fc7" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0b827177-6260-42d6-93f7-ceffee71d9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0b827177-6260-42d6-93f7-ceffee71d9c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f2b4332a-54fe-4164-bbfd-b29077f8ddc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0b827177-6260-42d6-93f7-ceffee71d9c2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f2b4332a-54fe-4164-bbfd-b29077f8ddc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2b4332a-54fe-4164-bbfd-b29077f8ddc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f2b4332a-54fe-4164-bbfd-b29077f8ddc1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2b4332a-54fe-4164-bbfd-b29077f8ddc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a0638897-eada-4bf9-a0c5-39e189607ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f2b4332a-54fe-4164-bbfd-b29077f8ddc1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a0638897-eada-4bf9-a0c5-39e189607ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2d910fbe-832a-4006-b3ac-e108461bbc96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a0638897-eada-4bf9-a0c5-39e189607ac8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2d910fbe-832a-4006-b3ac-e108461bbc96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b0410ade-154c-40a0-bfa8-b2b733ac34d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a0638897-eada-4bf9-a0c5-39e189607ac8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b0410ade-154c-40a0-bfa8-b2b733ac34d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f7ae5e4a-31a8-4586-96e6-1d934bb93d87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a0638897-eada-4bf9-a0c5-39e189607ac8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f7ae5e4a-31a8-4586-96e6-1d934bb93d87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_49cd5bee-e261-4d0d-813e-bd07a3e35c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_49cd5bee-e261-4d0d-813e-bd07a3e35c5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_3fbe02d1-a1c0-439f-ae6d-d52bc70269ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_3fbe02d1-a1c0-439f-ae6d-d52bc70269ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a123b942-ec55-4d8d-b274-bdefe8d4ecd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a123b942-ec55-4d8d-b274-bdefe8d4ecd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_de0f918a-9a69-4004-97ee-eb6f15ea65c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_de0f918a-9a69-4004-97ee-eb6f15ea65c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2426e469-957d-4eab-8d6b-df2fe6d98b67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2426e469-957d-4eab-8d6b-df2fe6d98b67" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dbcbe76b-1a49-495c-9774-3a0e445fbc30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_610066db-35d4-43b0-823b-192941134765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dbcbe76b-1a49-495c-9774-3a0e445fbc30" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_610066db-35d4-43b0-823b-192941134765" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d28fc9c-f915-4179-9a59-a9963075cd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_610066db-35d4-43b0-823b-192941134765" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d28fc9c-f915-4179-9a59-a9963075cd7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3d28fc9c-f915-4179-9a59-a9963075cd7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d28fc9c-f915-4179-9a59-a9963075cd7f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3d28fc9c-f915-4179-9a59-a9963075cd7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b25d7a9-0e93-4a1c-a5e1-1594d2c23b85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d28fc9c-f915-4179-9a59-a9963075cd7f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b25d7a9-0e93-4a1c-a5e1-1594d2c23b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_275ff453-f681-4901-af20-82525ab9044f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b25d7a9-0e93-4a1c-a5e1-1594d2c23b85" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_275ff453-f681-4901-af20-82525ab9044f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_424de93a-9d31-4b8f-a36b-f33ffd3a7197" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_610066db-35d4-43b0-823b-192941134765" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_424de93a-9d31-4b8f-a36b-f33ffd3a7197" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_424de93a-9d31-4b8f-a36b-f33ffd3a7197_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_424de93a-9d31-4b8f-a36b-f33ffd3a7197" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_424de93a-9d31-4b8f-a36b-f33ffd3a7197_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a777821-724b-4e36-ad43-953f48f7a464" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_424de93a-9d31-4b8f-a36b-f33ffd3a7197" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a777821-724b-4e36-ad43-953f48f7a464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4e690024-e04a-4dc6-85a8-ab761528a923" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a777821-724b-4e36-ad43-953f48f7a464" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4e690024-e04a-4dc6-85a8-ab761528a923" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8d32e5c0-4d3d-4468-aae6-9f7b3455c05d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a777821-724b-4e36-ad43-953f48f7a464" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8d32e5c0-4d3d-4468-aae6-9f7b3455c05d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_309e3632-b26b-4cac-9295-89bb71088788" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a777821-724b-4e36-ad43-953f48f7a464" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_309e3632-b26b-4cac-9295-89bb71088788" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_8ac4a6e0-3c50-4372-a0eb-a2696ef8ceb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_610066db-35d4-43b0-823b-192941134765" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_8ac4a6e0-3c50-4372-a0eb-a2696ef8ceb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8ac4a6e0-3c50-4372-a0eb-a2696ef8ceb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8ac4a6e0-3c50-4372-a0eb-a2696ef8ceb4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8ac4a6e0-3c50-4372-a0eb-a2696ef8ceb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77716b20-0108-442a-9a29-04f5cda1b5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8ac4a6e0-3c50-4372-a0eb-a2696ef8ceb4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77716b20-0108-442a-9a29-04f5cda1b5f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_30740f52-4325-40d7-9daf-15354e18f303" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77716b20-0108-442a-9a29-04f5cda1b5f6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_30740f52-4325-40d7-9daf-15354e18f303" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_82309d05-258b-4091-b2e8-5ea8efe2cdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_610066db-35d4-43b0-823b-192941134765" xlink:to="loc_us-gaap_FinancialInstrumentAxis_82309d05-258b-4091-b2e8-5ea8efe2cdf9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82309d05-258b-4091-b2e8-5ea8efe2cdf9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_82309d05-258b-4091-b2e8-5ea8efe2cdf9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82309d05-258b-4091-b2e8-5ea8efe2cdf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_457e64b5-dca7-4489-954a-e089bd2bc060" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_82309d05-258b-4091-b2e8-5ea8efe2cdf9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_457e64b5-dca7-4489-954a-e089bd2bc060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_75c97052-95f1-4118-a946-b56e0b7dccd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_457e64b5-dca7-4489-954a-e089bd2bc060" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_75c97052-95f1-4118-a946-b56e0b7dccd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5914f54f-4f1a-4452-ab59-cddbdfed0ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_457e64b5-dca7-4489-954a-e089bd2bc060" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5914f54f-4f1a-4452-ab59-cddbdfed0ec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_de48d646-e353-4d8e-bdba-1e17c885b2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dbcbe76b-1a49-495c-9774-3a0e445fbc30" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_de48d646-e353-4d8e-bdba-1e17c885b2dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1d3d8052-5275-4df3-a020-9acebc579320" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_de48d646-e353-4d8e-bdba-1e17c885b2dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1d3d8052-5275-4df3-a020-9acebc579320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_360033f7-5a5a-436a-a807-7722f93e0bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_de48d646-e353-4d8e-bdba-1e17c885b2dd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_360033f7-5a5a-436a-a807-7722f93e0bc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_d3e64dc9-9f90-4c04-8f82-27ca26e4aa63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_de48d646-e353-4d8e-bdba-1e17c885b2dd" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_d3e64dc9-9f90-4c04-8f82-27ca26e4aa63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_32e023a4-8009-4f88-bf58-e5836dbb629d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_de48d646-e353-4d8e-bdba-1e17c885b2dd" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_32e023a4-8009-4f88-bf58-e5836dbb629d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#AccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramTable_21934dcf-1e0c-447c-bc12-c18bd71f9f92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_us-gaap_SupplierFinanceProgramTable_21934dcf-1e0c-447c-bc12-c18bd71f9f92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_138fb55e-d40c-4532-9ce4-358a475b0eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SupplierFinanceProgramTable_21934dcf-1e0c-447c-bc12-c18bd71f9f92" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_138fb55e-d40c-4532-9ce4-358a475b0eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_138fb55e-d40c-4532-9ce4-358a475b0eb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_138fb55e-d40c-4532-9ce4-358a475b0eb8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_138fb55e-d40c-4532-9ce4-358a475b0eb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_cb17692b-da89-4750-9715-3cb7ccba64ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_138fb55e-d40c-4532-9ce4-358a475b0eb8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_cb17692b-da89-4750-9715-3cb7ccba64ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_EmployeeTerminationBenefitsMember_d43021d3-e670-43b0-b663-4ac03cde0701" xlink:href="edit-20250630.xsd#edit_EmployeeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cb17692b-da89-4750-9715-3cb7ccba64ec" xlink:to="loc_edit_EmployeeTerminationBenefitsMember_d43021d3-e670-43b0-b663-4ac03cde0701" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember_ed9c7cd8-dee8-4317-8b16-e330c26069f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractTerminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cb17692b-da89-4750-9715-3cb7ccba64ec" xlink:to="loc_us-gaap_ContractTerminationMember_ed9c7cd8-dee8-4317-8b16-e330c26069f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent_c21e44c6-7ebd-49c2-8846-423929511838" xlink:href="edit-20250630.xsd#edit_AccruedExternalResearchAndDevelopmentExpensesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent_c21e44c6-7ebd-49c2-8846-423929511838" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_75b5e4d2-d36e-4e6f-a2c0-a6d427d77d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_75b5e4d2-d36e-4e6f-a2c0-a6d427d77d6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_SublicenseAndLicenseFeesCurrent_9b377a85-4795-4ed2-9786-af685781f25c" xlink:href="edit-20250630.xsd#edit_SublicenseAndLicenseFeesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_edit_SublicenseAndLicenseFeesCurrent_9b377a85-4795-4ed2-9786-af685781f25c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_IntellectualPropertyAndPatentRelatedFeesCurrent_5e7a343f-2258-47d0-8041-1f312f5b5ec3" xlink:href="edit-20250630.xsd#edit_IntellectualPropertyAndPatentRelatedFeesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_edit_IntellectualPropertyAndPatentRelatedFeesCurrent_5e7a343f-2258-47d0-8041-1f312f5b5ec3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a36fbfc9-d3fe-45aa-b02a-219de938d1db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a36fbfc9-d3fe-45aa-b02a-219de938d1db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_5691d628-75cc-4ac4-bb6c-7657c8ebce08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_us-gaap_RestructuringReserveCurrent_5691d628-75cc-4ac4-bb6c-7657c8ebce08" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_03d44ea8-518a-454b-8bd5-2f326d054b65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_03d44ea8-518a-454b-8bd5-2f326d054b65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b1ac4c25-66e3-43de-9236-eb672ccf360a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b1ac4c25-66e3-43de-9236-eb672ccf360a" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#PropertyandEquipmentnetDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b22a39e-c75a-4257-b18a-d1811bc50b42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2c774a1-728e-44a6-978a-856ed6e2306f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b22a39e-c75a-4257-b18a-d1811bc50b42" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2c774a1-728e-44a6-978a-856ed6e2306f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2b0ef68b-960f-469f-8696-a69a0e9dec54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2c774a1-728e-44a6-978a-856ed6e2306f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2b0ef68b-960f-469f-8696-a69a0e9dec54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b0ef68b-960f-469f-8696-a69a0e9dec54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2b0ef68b-960f-469f-8696-a69a0e9dec54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b0ef68b-960f-469f-8696-a69a0e9dec54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2b0ef68b-960f-469f-8696-a69a0e9dec54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LaboratoryAndManufacturingEquipmentMember_cd979a9d-d07d-42fa-b56f-64d4540aa454" xlink:href="edit-20250630.xsd#edit_LaboratoryAndManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:to="loc_edit_LaboratoryAndManufacturingEquipmentMember_cd979a9d-d07d-42fa-b56f-64d4540aa454" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9d80cbb9-37eb-486a-a7bc-da430c62ad63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_9d80cbb9-37eb-486a-a7bc-da430c62ad63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_7f42440a-60ca-4115-9501-8f3054936294" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:to="loc_us-gaap_ComputerEquipmentMember_7f42440a-60ca-4115-9501-8f3054936294" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_17df4f28-108b-4a61-bcc1-c8faffc712d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:to="loc_us-gaap_ConstructionInProgressMember_17df4f28-108b-4a61-bcc1-c8faffc712d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_61acd1e1-de9c-4623-84a0-b03677d17c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_61acd1e1-de9c-4623-84a0-b03677d17c5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e58cbbcf-2c92-4607-8ac0-be11f6312f23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e58cbbcf-2c92-4607-8ac0-be11f6312f23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5c4ff359-b9e3-4c7c-b6fa-5442d6fc0746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b22a39e-c75a-4257-b18a-d1811bc50b42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5c4ff359-b9e3-4c7c-b6fa-5442d6fc0746" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bbb93ab4-564d-4736-b193-54b148dd4c57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b22a39e-c75a-4257-b18a-d1811bc50b42" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bbb93ab4-564d-4736-b193-54b148dd4c57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fd949f71-a043-4aef-b5a0-1535d062d7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b22a39e-c75a-4257-b18a-d1811bc50b42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fd949f71-a043-4aef-b5a0-1535d062d7b9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_2e4d7744-b8bb-461f-92c3-e39a76c2c3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_c6dab3ff-fdbb-4f30-9317-20699841f7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2e4d7744-b8bb-461f-92c3-e39a76c2c3a0" xlink:to="loc_us-gaap_OtherCommitmentsTable_c6dab3ff-fdbb-4f30-9317-20699841f7d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_7ee538e5-5f90-4168-9323-fc05917c9ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_c6dab3ff-fdbb-4f30-9317-20699841f7d4" xlink:to="loc_us-gaap_OtherCommitmentsAxis_7ee538e5-5f90-4168-9323-fc05917c9ae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_7ee538e5-5f90-4168-9323-fc05917c9ae0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_7ee538e5-5f90-4168-9323-fc05917c9ae0" xlink:to="loc_us-gaap_OtherCommitmentsDomain_7ee538e5-5f90-4168-9323-fc05917c9ae0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_cf9d593f-a76b-4848-b328-1618f09b53e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_7ee538e5-5f90-4168-9323-fc05917c9ae0" xlink:to="loc_us-gaap_OtherCommitmentsDomain_cf9d593f-a76b-4848-b328-1618f09b53e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicensorExpenseReimbursementsMember_952ce4c1-dd6e-463a-ad59-a24f516b7a77" xlink:href="edit-20250630.xsd#edit_LicensorExpenseReimbursementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_cf9d593f-a76b-4848-b328-1618f09b53e4" xlink:to="loc_edit_LicensorExpenseReimbursementsMember_952ce4c1-dd6e-463a-ad59-a24f516b7a77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_86ba8c7c-1ebd-473c-b0b9-786ad3072ce8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_c6dab3ff-fdbb-4f30-9317-20699841f7d4" xlink:to="loc_srt_CounterpartyNameAxis_86ba8c7c-1ebd-473c-b0b9-786ad3072ce8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86ba8c7c-1ebd-473c-b0b9-786ad3072ce8_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_86ba8c7c-1ebd-473c-b0b9-786ad3072ce8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86ba8c7c-1ebd-473c-b0b9-786ad3072ce8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82146028-eeb6-4c8a-b568-2f27d404a9a7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_86ba8c7c-1ebd-473c-b0b9-786ad3072ce8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82146028-eeb6-4c8a-b568-2f27d404a9a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicenseAndServiceAgreementMember_4124f639-2fc9-430a-bf22-06b081ed6733" xlink:href="edit-20250630.xsd#edit_LicenseAndServiceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82146028-eeb6-4c8a-b568-2f27d404a9a7" xlink:to="loc_edit_LicenseAndServiceAgreementMember_4124f639-2fc9-430a-bf22-06b081ed6733" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalAndContractServicesExpense_abd15aaf-9a3d-486c-b03c-684f97e3bdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2e4d7744-b8bb-461f-92c3-e39a76c2c3a0" xlink:to="loc_us-gaap_ProfessionalAndContractServicesExpense_abd15aaf-9a3d-486c-b03c-684f97e3bdfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_OperatingLeaseTerminationNotificationPeriod_ff382d08-8b25-45a5-873a-e5f3a1b495fa" xlink:href="edit-20250630.xsd#edit_OperatingLeaseTerminationNotificationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2e4d7744-b8bb-461f-92c3-e39a76c2c3a0" xlink:to="loc_edit_OperatingLeaseTerminationNotificationPeriod_ff382d08-8b25-45a5-873a-e5f3a1b495fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f63cdcc-0c00-4987-99ce-3d447710df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2e4d7744-b8bb-461f-92c3-e39a76c2c3a0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f63cdcc-0c00-4987-99ce-3d447710df0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_eb3aa92d-624d-4739-9996-e7b47e9360fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2e4d7744-b8bb-461f-92c3-e39a76c2c3a0" xlink:to="loc_us-gaap_OperatingLeasePayments_eb3aa92d-624d-4739-9996-e7b47e9360fb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#CollaborationAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7df2e5-e67c-439b-91a6-d65f5181b0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_299ca9ee-c03d-4da3-85f2-3ffdc78dfe99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7df2e5-e67c-439b-91a6-d65f5181b0fd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_299ca9ee-c03d-4da3-85f2-3ffdc78dfe99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9161527c-e995-475e-979e-0843055e214e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_299ca9ee-c03d-4da3-85f2-3ffdc78dfe99" xlink:to="loc_srt_CounterpartyNameAxis_9161527c-e995-475e-979e-0843055e214e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9161527c-e995-475e-979e-0843055e214e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9161527c-e995-475e-979e-0843055e214e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9161527c-e995-475e-979e-0843055e214e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b708db5e-1616-459c-9adc-0e469c4b272b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9161527c-e995-475e-979e-0843055e214e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b708db5e-1616-459c-9adc-0e469c4b272b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_BristolMyersSquibbCompanyMember_c043fc70-9355-442f-a91a-98cb5fb5df17" xlink:href="edit-20250630.xsd#edit_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b708db5e-1616-459c-9adc-0e469c4b272b" xlink:to="loc_edit_BristolMyersSquibbCompanyMember_c043fc70-9355-442f-a91a-98cb5fb5df17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_07b304de-e9cf-4dcf-9def-550a64d4dd68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_299ca9ee-c03d-4da3-85f2-3ffdc78dfe99" xlink:to="loc_us-gaap_TypeOfArrangementAxis_07b304de-e9cf-4dcf-9def-550a64d4dd68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07b304de-e9cf-4dcf-9def-550a64d4dd68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_07b304de-e9cf-4dcf-9def-550a64d4dd68" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07b304de-e9cf-4dcf-9def-550a64d4dd68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_762bf6e6-12f1-4228-b7bf-5bf764bf9e31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_07b304de-e9cf-4dcf-9def-550a64d4dd68" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_762bf6e6-12f1-4228-b7bf-5bf764bf9e31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AmendedCollaborationAgreement2019Member_b249df0f-4a95-47de-9b5e-5ef6180b94dc" xlink:href="edit-20250630.xsd#edit_AmendedCollaborationAgreement2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_762bf6e6-12f1-4228-b7bf-5bf764bf9e31" xlink:to="loc_edit_AmendedCollaborationAgreement2019Member_b249df0f-4a95-47de-9b5e-5ef6180b94dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AgreementExtensionPeriodOptionsToExtend_29cf6fff-4409-4160-8810-2f9601a1f95e" xlink:href="edit-20250630.xsd#edit_AgreementExtensionPeriodOptionsToExtend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7df2e5-e67c-439b-91a6-d65f5181b0fd" xlink:to="loc_edit_AgreementExtensionPeriodOptionsToExtend_29cf6fff-4409-4160-8810-2f9601a1f95e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0df8ba7b-b711-4404-ab6a-2d65a6e1a690" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7df2e5-e67c-439b-91a6-d65f5181b0fd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0df8ba7b-b711-4404-ab6a-2d65a6e1a690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5472c2a5-41f6-4fa2-b11e-fc3bf2b79d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7df2e5-e67c-439b-91a6-d65f5181b0fd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5472c2a5-41f6-4fa2-b11e-fc3bf2b79d9e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0b63d3e-13d6-476b-b46d-45c32f99deb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_145e34d2-42d7-4e1d-a236-1a8fd09cebd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0b63d3e-13d6-476b-b46d-45c32f99deb3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_145e34d2-42d7-4e1d-a236-1a8fd09cebd0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_96184763-91a6-43f3-8247-6ee64bfd92ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_145e34d2-42d7-4e1d-a236-1a8fd09cebd0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_96184763-91a6-43f3-8247-6ee64bfd92ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_96184763-91a6-43f3-8247-6ee64bfd92ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_96184763-91a6-43f3-8247-6ee64bfd92ba" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_96184763-91a6-43f3-8247-6ee64bfd92ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_48a1b650-6766-4a33-bed8-f8d9321f0600" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_96184763-91a6-43f3-8247-6ee64bfd92ba" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_48a1b650-6766-4a33-bed8-f8d9321f0600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_745cd47d-a892-4ced-9663-26ed886fa343" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_48a1b650-6766-4a33-bed8-f8d9321f0600" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_745cd47d-a892-4ced-9663-26ed886fa343" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_05c88ec6-0cc2-457b-b1ef-5ca7a59ce77d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_48a1b650-6766-4a33-bed8-f8d9321f0600" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_05c88ec6-0cc2-457b-b1ef-5ca7a59ce77d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_af3558c9-165e-497b-b8b3-19a3d88803f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0b63d3e-13d6-476b-b46d-45c32f99deb3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_af3558c9-165e-497b-b8b3-19a3d88803f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#StockbasedCompensationRestrictedStockandStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c388510a-9dd6-48d4-b3c3-4dfa3b26c4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c388510a-9dd6-48d4-b3c3-4dfa3b26c4d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fb8c0152-0673-440a-b630-f9ac4de28db3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c388510a-9dd6-48d4-b3c3-4dfa3b26c4d0" xlink:to="loc_us-gaap_AwardTypeAxis_fb8c0152-0673-440a-b630-f9ac4de28db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb8c0152-0673-440a-b630-f9ac4de28db3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fb8c0152-0673-440a-b630-f9ac4de28db3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb8c0152-0673-440a-b630-f9ac4de28db3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c889510-1c9c-4ecd-8d69-e07448911df9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fb8c0152-0673-440a-b630-f9ac4de28db3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c889510-1c9c-4ecd-8d69-e07448911df9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_02b093c3-8ec9-41fd-aab3-204476d905c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c889510-1c9c-4ecd-8d69-e07448911df9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_02b093c3-8ec9-41fd-aab3-204476d905c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c9cdd7ec-1888-4ae3-9888-47eff6384ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c889510-1c9c-4ecd-8d69-e07448911df9" xlink:to="loc_us-gaap_PerformanceSharesMember_c9cdd7ec-1888-4ae3-9888-47eff6384ae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e10e3144-3d04-498a-b4e1-e47e9cc4cb39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c889510-1c9c-4ecd-8d69-e07448911df9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e10e3144-3d04-498a-b4e1-e47e9cc4cb39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_e9a8ed41-8262-460d-9990-8c945880c7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c388510a-9dd6-48d4-b3c3-4dfa3b26c4d0" xlink:to="loc_us-gaap_GranteeStatusAxis_e9a8ed41-8262-460d-9990-8c945880c7cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_e9a8ed41-8262-460d-9990-8c945880c7cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_e9a8ed41-8262-460d-9990-8c945880c7cb" xlink:to="loc_us-gaap_GranteeStatusDomain_e9a8ed41-8262-460d-9990-8c945880c7cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_eeaf6ca7-4c6a-445c-b091-af16202ddd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_e9a8ed41-8262-460d-9990-8c945880c7cb" xlink:to="loc_us-gaap_GranteeStatusDomain_eeaf6ca7-4c6a-445c-b091-af16202ddd6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_412507ff-2184-4791-a539-1200772ec154" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_eeaf6ca7-4c6a-445c-b091-af16202ddd6c" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_412507ff-2184-4791-a539-1200772ec154" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bc2d2173-abe9-4d8e-9597-a21f60073fea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bc2d2173-abe9-4d8e-9597-a21f60073fea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dcdeaa41-7cfb-4af8-a301-4665bf9b37e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bc2d2173-abe9-4d8e-9597-a21f60073fea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dcdeaa41-7cfb-4af8-a301-4665bf9b37e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_63734f57-2d8d-4683-bde4-18dab9895a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bc2d2173-abe9-4d8e-9597-a21f60073fea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_63734f57-2d8d-4683-bde4-18dab9895a0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dca4fe9a-ae69-416b-8f18-273dc9282c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bc2d2173-abe9-4d8e-9597-a21f60073fea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dca4fe9a-ae69-416b-8f18-273dc9282c7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3b9f53f6-7dac-4540-bd9e-50fa081bd396" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bc2d2173-abe9-4d8e-9597-a21f60073fea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3b9f53f6-7dac-4540-bd9e-50fa081bd396" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dbc01f0b-7c26-40f0-b388-5eab76869549" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_31deeb58-9e3c-4bcc-85ca-f4d180a5c418" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_31deeb58-9e3c-4bcc-85ca-f4d180a5c418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1bc2f676-1f5a-4ba6-bd33-5f7a76419748" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1bc2f676-1f5a-4ba6-bd33-5f7a76419748" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7900fcb4-152b-4c88-942b-8ce9f9751554" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1bc2f676-1f5a-4ba6-bd33-5f7a76419748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7900fcb4-152b-4c88-942b-8ce9f9751554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78047328-505d-4fbd-b05c-7bd55e5ee8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1bc2f676-1f5a-4ba6-bd33-5f7a76419748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78047328-505d-4fbd-b05c-7bd55e5ee8d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b8628f34-cd8e-498f-b425-05db2ddf8aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1bc2f676-1f5a-4ba6-bd33-5f7a76419748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b8628f34-cd8e-498f-b425-05db2ddf8aaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fda33d6d-cf40-4ccd-9040-f1ba5796aaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1bc2f676-1f5a-4ba6-bd33-5f7a76419748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fda33d6d-cf40-4ccd-9040-f1ba5796aaa1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b852cd21-b611-4640-b0f1-489bba3a134b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d817681c-fca0-4e6a-941f-451f6a9c8b31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d817681c-fca0-4e6a-941f-451f6a9c8b31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6bbfe6d9-e579-40aa-88bb-01cf7737062e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6bbfe6d9-e579-40aa-88bb-01cf7737062e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04395de8-7421-42f9-83c4-b6758a6bf783" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04395de8-7421-42f9-83c4-b6758a6bf783" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19f0b28f-0d66-483a-add9-86086083231a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04395de8-7421-42f9-83c4-b6758a6bf783" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19f0b28f-0d66-483a-add9-86086083231a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_52824c94-14ec-4e38-a366-c8a9c301d305" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04395de8-7421-42f9-83c4-b6758a6bf783" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_52824c94-14ec-4e38-a366-c8a9c301d305" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c43b5c1-226b-422d-942d-cf3282c93a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04395de8-7421-42f9-83c4-b6758a6bf783" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c43b5c1-226b-422d-942d-cf3282c93a3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bcf868c0-76ed-496b-b9c8-5836dd68eeda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04395de8-7421-42f9-83c4-b6758a6bf783" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bcf868c0-76ed-496b-b9c8-5836dd68eeda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_416a925a-55df-424e-baf2-e7ddba16a5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ece7a8ed-d2b1-40f2-88e1-ca33c7491acf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ece7a8ed-d2b1-40f2-88e1-ca33c7491acf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45f82b40-fe51-4e77-bafc-18bc75834eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45f82b40-fe51-4e77-bafc-18bc75834eaf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_430c21ba-09ad-4bf0-bb7d-0006a2cf0d14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45f82b40-fe51-4e77-bafc-18bc75834eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_430c21ba-09ad-4bf0-bb7d-0006a2cf0d14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a8d85ce0-f3d3-4c51-9b92-ff08fd26a8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45f82b40-fe51-4e77-bafc-18bc75834eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a8d85ce0-f3d3-4c51-9b92-ff08fd26a8a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_18cbb068-3be9-49e0-ba9b-0ea59e3a96cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45f82b40-fe51-4e77-bafc-18bc75834eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_18cbb068-3be9-49e0-ba9b-0ea59e3a96cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_81cf7255-eaad-4baa-9620-44b3a1169d26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45f82b40-fe51-4e77-bafc-18bc75834eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_81cf7255-eaad-4baa-9620-44b3a1169d26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a7d0b37d-c5b6-4bf5-8ba8-48cc509538d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e67b6236-ee63-4146-9f2d-febd6551742e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e67b6236-ee63-4146-9f2d-febd6551742e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_017a9367-6a18-45f1-b36a-4a22903b68af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_017a9367-6a18-45f1-b36a-4a22903b68af" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_078d97ea-7388-4701-b0a1-8dbfed58ae28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_017a9367-6a18-45f1-b36a-4a22903b68af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_078d97ea-7388-4701-b0a1-8dbfed58ae28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3f7a3023-c522-4390-8690-8e0673131912" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_017a9367-6a18-45f1-b36a-4a22903b68af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3f7a3023-c522-4390-8690-8e0673131912" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e56a74ec-400a-4689-a259-580dbbd7c4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_017a9367-6a18-45f1-b36a-4a22903b68af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e56a74ec-400a-4689-a259-580dbbd7c4b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fedc232e-7904-4874-b636-2ed2dc5ca599" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_017a9367-6a18-45f1-b36a-4a22903b68af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fedc232e-7904-4874-b636-2ed2dc5ca599" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/NetLossperShareDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#NetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/NetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6a721e2-aaef-4f94-aeb4-beb882c0ef2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_360d1bdd-5494-4bf8-be27-bbee280d1e21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6a721e2-aaef-4f94-aeb4-beb882c0ef2a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_360d1bdd-5494-4bf8-be27-bbee280d1e21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7cea55ae-2f26-4a18-b0c2-0d0708782298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_360d1bdd-5494-4bf8-be27-bbee280d1e21" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7cea55ae-2f26-4a18-b0c2-0d0708782298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7cea55ae-2f26-4a18-b0c2-0d0708782298_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7cea55ae-2f26-4a18-b0c2-0d0708782298" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7cea55ae-2f26-4a18-b0c2-0d0708782298_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_27d51ab8-38fa-4e10-b29e-ed2e0b26b1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7cea55ae-2f26-4a18-b0c2-0d0708782298" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_27d51ab8-38fa-4e10-b29e-ed2e0b26b1cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d89d839c-eaaf-4d3e-9d70-028db4b912cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_27d51ab8-38fa-4e10-b29e-ed2e0b26b1cc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d89d839c-eaaf-4d3e-9d70-028db4b912cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_23ac8d3b-a3e8-4f36-b116-bfebdb93f9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_27d51ab8-38fa-4e10-b29e-ed2e0b26b1cc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_23ac8d3b-a3e8-4f36-b116-bfebdb93f9ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_833604d1-c8f0-4ac4-9a63-1b78f91bf52c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6a721e2-aaef-4f94-aeb4-beb882c0ef2a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_833604d1-c8f0-4ac4-9a63-1b78f91bf52c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0c9c576-9695-4250-908b-06f6f3a64b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0c9c576-9695-4250-908b-06f6f3a64b8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f6dd9eb1-37e6-4091-a32c-233ca4c9305f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0c9c576-9695-4250-908b-06f6f3a64b8c" xlink:to="loc_srt_MajorCustomersAxis_f6dd9eb1-37e6-4091-a32c-233ca4c9305f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f6dd9eb1-37e6-4091-a32c-233ca4c9305f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f6dd9eb1-37e6-4091-a32c-233ca4c9305f" xlink:to="loc_srt_NameOfMajorCustomerDomain_f6dd9eb1-37e6-4091-a32c-233ca4c9305f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5ad45079-b19b-4c62-84d9-a746ef14c8e4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f6dd9eb1-37e6-4091-a32c-233ca4c9305f" xlink:to="loc_srt_NameOfMajorCustomerDomain_5ad45079-b19b-4c62-84d9-a746ef14c8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_DRIHealthcareAcquisitionsLPMember_632854d3-e340-4108-b30c-650c8fcc6375" xlink:href="edit-20250630.xsd#edit_DRIHealthcareAcquisitionsLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5ad45079-b19b-4c62-84d9-a746ef14c8e4" xlink:to="loc_edit_DRIHealthcareAcquisitionsLPMember_632854d3-e340-4108-b30c-650c8fcc6375" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fb2dea05-f234-4458-8b3c-5dce353d0054" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0c9c576-9695-4250-908b-06f6f3a64b8c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fb2dea05-f234-4458-8b3c-5dce353d0054" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb2dea05-f234-4458-8b3c-5dce353d0054_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fb2dea05-f234-4458-8b3c-5dce353d0054" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb2dea05-f234-4458-8b3c-5dce353d0054_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8058699d-e575-49bb-a19a-adb29a5236f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fb2dea05-f234-4458-8b3c-5dce353d0054" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8058699d-e575-49bb-a19a-adb29a5236f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicenseAgreementMember_27ddfb1a-a165-4171-b1c4-1abcff00ca18" xlink:href="edit-20250630.xsd#edit_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8058699d-e575-49bb-a19a-adb29a5236f2" xlink:to="loc_edit_LicenseAgreementMember_27ddfb1a-a165-4171-b1c4-1abcff00ca18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04cd889e-2b39-41f4-add8-9d72d35714cb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0c9c576-9695-4250-908b-06f6f3a64b8c" xlink:to="loc_srt_RangeAxis_04cd889e-2b39-41f4-add8-9d72d35714cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_04cd889e-2b39-41f4-add8-9d72d35714cb_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_04cd889e-2b39-41f4-add8-9d72d35714cb" xlink:to="loc_srt_RangeMember_04cd889e-2b39-41f4-add8-9d72d35714cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fbea3c8-9c87-4bdf-83f7-ebdf5e4d0b8b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_04cd889e-2b39-41f4-add8-9d72d35714cb" xlink:to="loc_srt_RangeMember_5fbea3c8-9c87-4bdf-83f7-ebdf5e4d0b8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6bd7cd65-5de0-465d-b1db-ac85df4cf5bf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5fbea3c8-9c87-4bdf-83f7-ebdf5e4d0b8b" xlink:to="loc_srt_MinimumMember_6bd7cd65-5de0-465d-b1db-ac85df4cf5bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_182d1f39-946f-4c1d-a744-0a41495129e6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5fbea3c8-9c87-4bdf-83f7-ebdf5e4d0b8b" xlink:to="loc_srt_MaximumMember_182d1f39-946f-4c1d-a744-0a41495129e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_125b34f0-ebf9-4ed7-9111-7a0368ed585e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_125b34f0-ebf9-4ed7-9111-7a0368ed585e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicenseFeeReceivable_2a7a03e4-b18b-4153-b63e-6ed4fd5b17c9" xlink:href="edit-20250630.xsd#edit_LicenseFeeReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:to="loc_edit_LicenseFeeReceivable_2a7a03e4-b18b-4153-b63e-6ed4fd5b17c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ContingentFeeReceivableThresholdAmount_ee689ebe-043e-4e08-a5a1-199916216fa1" xlink:href="edit-20250630.xsd#edit_ContingentFeeReceivableThresholdAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:to="loc_edit_ContingentFeeReceivableThresholdAmount_ee689ebe-043e-4e08-a5a1-199916216fa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f1698680-a488-44f7-a896-fb3883252232" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f1698680-a488-44f7-a896-fb3883252232" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate_5c0e5aa2-751b-436a-a147-d9181fe0252b" xlink:href="edit-20250630.xsd#edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:to="loc_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate_5c0e5aa2-751b-436a-a147-d9181fe0252b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#DebtScheduleofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/DebtScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_15530984-3e42-479f-b776-07b6f58f3cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_71c47cb2-87c4-4c1d-9653-cbc663ccac4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15530984-3e42-479f-b776-07b6f58f3cb0" xlink:to="loc_us-gaap_DebtInstrumentTable_71c47cb2-87c4-4c1d-9653-cbc663ccac4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f82fa325-6dca-42a1-97c6-65f970659708" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_71c47cb2-87c4-4c1d-9653-cbc663ccac4e" xlink:to="loc_srt_MajorCustomersAxis_f82fa325-6dca-42a1-97c6-65f970659708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f82fa325-6dca-42a1-97c6-65f970659708_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f82fa325-6dca-42a1-97c6-65f970659708" xlink:to="loc_srt_NameOfMajorCustomerDomain_f82fa325-6dca-42a1-97c6-65f970659708_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ea8817b8-510c-461e-bbae-46fa0f709a14" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f82fa325-6dca-42a1-97c6-65f970659708" xlink:to="loc_srt_NameOfMajorCustomerDomain_ea8817b8-510c-461e-bbae-46fa0f709a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_DRIHealthcareAcquisitionsLPMember_68e7ccdf-6081-4245-bf9b-0eb9539fd3b7" xlink:href="edit-20250630.xsd#edit_DRIHealthcareAcquisitionsLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ea8817b8-510c-461e-bbae-46fa0f709a14" xlink:to="loc_edit_DRIHealthcareAcquisitionsLPMember_68e7ccdf-6081-4245-bf9b-0eb9539fd3b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1c561ad0-39cf-4fbe-8a13-61243a5c8adf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_71c47cb2-87c4-4c1d-9653-cbc663ccac4e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1c561ad0-39cf-4fbe-8a13-61243a5c8adf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c561ad0-39cf-4fbe-8a13-61243a5c8adf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1c561ad0-39cf-4fbe-8a13-61243a5c8adf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c561ad0-39cf-4fbe-8a13-61243a5c8adf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac6d795f-acc5-48bf-9d68-e0c9c216c83d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1c561ad0-39cf-4fbe-8a13-61243a5c8adf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac6d795f-acc5-48bf-9d68-e0c9c216c83d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicenseAgreementMember_67666f99-782f-46fd-a686-ebc34f0f58ed" xlink:href="edit-20250630.xsd#edit_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac6d795f-acc5-48bf-9d68-e0c9c216c83d" xlink:to="loc_edit_LicenseAgreementMember_67666f99-782f-46fd-a686-ebc34f0f58ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_DebtInstrumentRollForward_c5be974e-4e4b-49ca-af81-81ac73d13dc8" xlink:href="edit-20250630.xsd#edit_DebtInstrumentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15530984-3e42-479f-b776-07b6f58f3cb0" xlink:to="loc_edit_DebtInstrumentRollForward_c5be974e-4e4b-49ca-af81-81ac73d13dc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1a2ddb67-1780-4ab6-9e4a-5109140c78f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_edit_DebtInstrumentRollForward_c5be974e-4e4b-49ca-af81-81ac73d13dc8" xlink:to="loc_us-gaap_LongTermDebt_1a2ddb67-1780-4ab6-9e4a-5109140c78f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_592963c3-2cd5-47b9-b9fc-f26e76ed3e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_edit_DebtInstrumentRollForward_c5be974e-4e4b-49ca-af81-81ac73d13dc8" xlink:to="loc_us-gaap_RepaymentsOfDebt_592963c3-2cd5-47b9-b9fc-f26e76ed3e1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues_60fc2bf5-a542-41bb-a0dc-7e4ee69723e7" xlink:href="edit-20250630.xsd#edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_edit_DebtInstrumentRollForward_c5be974e-4e4b-49ca-af81-81ac73d13dc8" xlink:to="loc_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues_60fc2bf5-a542-41bb-a0dc-7e4ee69723e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8093d865-57a0-45eb-b41f-849605b9c586" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_edit_DebtInstrumentRollForward_c5be974e-4e4b-49ca-af81-81ac73d13dc8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_8093d865-57a0-45eb-b41f-849605b9c586" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8cc4cc57-3e15-4e04-a63d-91b63c7233b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#RestructuringandImpairmentChargesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3d974d78-1f85-42a6-9103-8c66c797595b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3d974d78-1f85-42a6-9103-8c66c797595b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77570647-8e85-40e3-af70-fba2ce902c0a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3d974d78-1f85-42a6-9103-8c66c797595b" xlink:to="loc_srt_RangeAxis_77570647-8e85-40e3-af70-fba2ce902c0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_77570647-8e85-40e3-af70-fba2ce902c0a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_77570647-8e85-40e3-af70-fba2ce902c0a" xlink:to="loc_srt_RangeMember_77570647-8e85-40e3-af70-fba2ce902c0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5ea52c0-9bb0-4cb5-afa3-87c131cbf3c0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_77570647-8e85-40e3-af70-fba2ce902c0a" xlink:to="loc_srt_RangeMember_e5ea52c0-9bb0-4cb5-afa3-87c131cbf3c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a0e5294-eff2-4cec-8ac9-81231626768b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e5ea52c0-9bb0-4cb5-afa3-87c131cbf3c0" xlink:to="loc_srt_MinimumMember_6a0e5294-eff2-4cec-8ac9-81231626768b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_888af728-1eeb-48d8-ab54-ac9b1d1842ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3d974d78-1f85-42a6-9103-8c66c797595b" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_888af728-1eeb-48d8-ab54-ac9b1d1842ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_888af728-1eeb-48d8-ab54-ac9b1d1842ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_888af728-1eeb-48d8-ab54-ac9b1d1842ac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_888af728-1eeb-48d8-ab54-ac9b1d1842ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b89bb179-84f6-4bd1-9d01-b39afe0b38d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_888af728-1eeb-48d8-ab54-ac9b1d1842ac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b89bb179-84f6-4bd1-9d01-b39afe0b38d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_EmployeeTerminationBenefitsMember_b9cab1de-a28c-4242-8d5f-c569fce87640" xlink:href="edit-20250630.xsd#edit_EmployeeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b89bb179-84f6-4bd1-9d01-b39afe0b38d2" xlink:to="loc_edit_EmployeeTerminationBenefitsMember_b9cab1de-a28c-4242-8d5f-c569fce87640" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae11fc6d-27ac-4fc7-b68c-0ee7b5073062" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3d974d78-1f85-42a6-9103-8c66c797595b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae11fc6d-27ac-4fc7-b68c-0ee7b5073062" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae11fc6d-27ac-4fc7-b68c-0ee7b5073062_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae11fc6d-27ac-4fc7-b68c-0ee7b5073062" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae11fc6d-27ac-4fc7-b68c-0ee7b5073062_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9867b274-7088-4f56-a5f9-91742cbc974c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae11fc6d-27ac-4fc7-b68c-0ee7b5073062" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9867b274-7088-4f56-a5f9-91742cbc974c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LaboratoryAndManufacturingEquipmentMember_e58fb3b7-5181-46ea-9cd9-63ea65b7a7e5" xlink:href="edit-20250630.xsd#edit_LaboratoryAndManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9867b274-7088-4f56-a5f9-91742cbc974c" xlink:to="loc_edit_LaboratoryAndManufacturingEquipmentMember_e58fb3b7-5181-46ea-9cd9-63ea65b7a7e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9d2e663a-99c1-4139-a29c-e976a6169abe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3d974d78-1f85-42a6-9103-8c66c797595b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9d2e663a-99c1-4139-a29c-e976a6169abe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9d2e663a-99c1-4139-a29c-e976a6169abe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9d2e663a-99c1-4139-a29c-e976a6169abe" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9d2e663a-99c1-4139-a29c-e976a6169abe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3d03cadc-e597-46e8-a9cf-1f810cbbf61a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9d2e663a-99c1-4139-a29c-e976a6169abe" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3d03cadc-e597-46e8-a9cf-1f810cbbf61a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_31fd9907-216e-4233-be9e-fbf71e6ad574" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3d03cadc-e597-46e8-a9cf-1f810cbbf61a" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_31fd9907-216e-4233-be9e-fbf71e6ad574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_0cb50ebb-5500-4ead-b908-d569c002c888" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_0cb50ebb-5500-4ead-b908-d569c002c888" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1c9bf794-b520-436f-b6d5-e71d983092ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1c9bf794-b520-436f-b6d5-e71d983092ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_419c1970-16c2-4bb0-8c50-d7a2fc03ce17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_419c1970-16c2-4bb0-8c50-d7a2fc03ce17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_5d1f03c8-18ba-4516-b1ce-dd3b21ce5643" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_5d1f03c8-18ba-4516-b1ce-dd3b21ce5643" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_504588d6-8c58-4674-b547-66ac47104324" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:to="loc_us-gaap_AssetImpairmentCharges_504588d6-8c58-4674-b547-66ac47104324" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6cc4edc5-b9cb-4c9d-b103-ff7421d9f6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_df63e7d9-601a-4b85-8890-269ddeb5f173" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6cc4edc5-b9cb-4c9d-b103-ff7421d9f6b1" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_df63e7d9-601a-4b85-8890-269ddeb5f173" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_18c0de47-ab47-4306-bd04-b1ebc9d636aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_df63e7d9-601a-4b85-8890-269ddeb5f173" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_18c0de47-ab47-4306-bd04-b1ebc9d636aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_18c0de47-ab47-4306-bd04-b1ebc9d636aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_18c0de47-ab47-4306-bd04-b1ebc9d636aa" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_18c0de47-ab47-4306-bd04-b1ebc9d636aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_afb833f4-5483-4a03-8c32-5c08c04f7f47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_18c0de47-ab47-4306-bd04-b1ebc9d636aa" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_afb833f4-5483-4a03-8c32-5c08c04f7f47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_EmployeeTerminationBenefitsMember_119af86b-106c-4f9a-ad4a-523044e5076a" xlink:href="edit-20250630.xsd#edit_EmployeeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_afb833f4-5483-4a03-8c32-5c08c04f7f47" xlink:to="loc_edit_EmployeeTerminationBenefitsMember_119af86b-106c-4f9a-ad4a-523044e5076a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember_de147fff-fb4c-425a-8000-68e0bea4c819" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractTerminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_afb833f4-5483-4a03-8c32-5c08c04f7f47" xlink:to="loc_us-gaap_ContractTerminationMember_de147fff-fb4c-425a-8000-68e0bea4c819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember_b98646bd-9ad2-4e25-92ae-6c1c1ee29189" xlink:href="edit-20250630.xsd#edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_afb833f4-5483-4a03-8c32-5c08c04f7f47" xlink:to="loc_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember_b98646bd-9ad2-4e25-92ae-6c1c1ee29189" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ImpairmentChargesMember_046296f3-4257-4359-91e2-eb16ac4b2082" xlink:href="edit-20250630.xsd#edit_ImpairmentChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_afb833f4-5483-4a03-8c32-5c08c04f7f47" xlink:to="loc_edit_ImpairmentChargesMember_046296f3-4257-4359-91e2-eb16ac4b2082" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9f913d08-8adf-4055-8c49-54b83064f57d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6cc4edc5-b9cb-4c9d-b103-ff7421d9f6b1" xlink:to="loc_us-gaap_RestructuringCharges_9f913d08-8adf-4055-8c49-54b83064f57d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_256a9e46-186d-4348-a6e5-ea10b538c0da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6cc4edc5-b9cb-4c9d-b103-ff7421d9f6b1" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_256a9e46-186d-4348-a6e5-ea10b538c0da" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_37a568bb-247c-4349-ac7f-9c5ebd7ec908" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa86440-e5cc-40a3-b818-4518e30074fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_37a568bb-247c-4349-ac7f-9c5ebd7ec908" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa86440-e5cc-40a3-b818-4518e30074fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a2343aef-5b59-4e07-bf39-2660787db794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa86440-e5cc-40a3-b818-4518e30074fb" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a2343aef-5b59-4e07-bf39-2660787db794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a2343aef-5b59-4e07-bf39-2660787db794_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a2343aef-5b59-4e07-bf39-2660787db794" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a2343aef-5b59-4e07-bf39-2660787db794_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a5d555ce-a0bb-4a32-9ebd-bdb899b5cb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a2343aef-5b59-4e07-bf39-2660787db794" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a5d555ce-a0bb-4a32-9ebd-bdb899b5cb2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_EmployeeTerminationBenefitsMember_5f5f5f12-b7d6-464b-81d2-5b8e2d91e84a" xlink:href="edit-20250630.xsd#edit_EmployeeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a5d555ce-a0bb-4a32-9ebd-bdb899b5cb2c" xlink:to="loc_edit_EmployeeTerminationBenefitsMember_5f5f5f12-b7d6-464b-81d2-5b8e2d91e84a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_44ba1129-3c18-4845-a3f1-1047c17cd895" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_37a568bb-247c-4349-ac7f-9c5ebd7ec908" xlink:to="loc_us-gaap_RestructuringReserveRollForward_44ba1129-3c18-4845-a3f1-1047c17cd895" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_f0765496-2b69-4df1-8976-3b9fd8e3e78f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44ba1129-3c18-4845-a3f1-1047c17cd895" xlink:to="loc_us-gaap_RestructuringReserve_f0765496-2b69-4df1-8976-3b9fd8e3e78f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_bcf4df05-b960-4cd8-bc68-4220e200e084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44ba1129-3c18-4845-a3f1-1047c17cd895" xlink:to="loc_us-gaap_RestructuringCharges_bcf4df05-b960-4cd8-bc68-4220e200e084" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash_5bb0d942-3191-48f3-b358-7e5af1b62272" xlink:href="edit-20250630.xsd#edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44ba1129-3c18-4845-a3f1-1047c17cd895" xlink:to="loc_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash_5bb0d942-3191-48f3-b358-7e5af1b62272" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_2ed67783-ca98-47e6-8849-d89f33ec5015" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_72272f3c-25ab-4cd6-8cf9-f35c24acab30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dd7fa479-99d6-4a49-a14d-662106e7815e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_72272f3c-25ab-4cd6-8cf9-f35c24acab30" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dd7fa479-99d6-4a49-a14d-662106e7815e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_caac5fb1-d58e-457f-b037-622461511cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dd7fa479-99d6-4a49-a14d-662106e7815e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_caac5fb1-d58e-457f-b037-622461511cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_caac5fb1-d58e-457f-b037-622461511cb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_caac5fb1-d58e-457f-b037-622461511cb6" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_caac5fb1-d58e-457f-b037-622461511cb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_87322383-bb2f-4324-9776-460f234422bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_caac5fb1-d58e-457f-b037-622461511cb6" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_87322383-bb2f-4324-9776-460f234422bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember_949f83ee-b3e5-44f6-9cdc-4446aadf0bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractTerminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_87322383-bb2f-4324-9776-460f234422bf" xlink:to="loc_us-gaap_ContractTerminationMember_949f83ee-b3e5-44f6-9cdc-4446aadf0bc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_2336c62f-a5c4-4b4e-8d58-fab931b60756" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_72272f3c-25ab-4cd6-8cf9-f35c24acab30" xlink:to="loc_us-gaap_RestructuringReserveRollForward_2336c62f-a5c4-4b4e-8d58-fab931b60756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_ae709f2c-5e69-487d-9b6b-095580a58a78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2336c62f-a5c4-4b4e-8d58-fab931b60756" xlink:to="loc_us-gaap_RestructuringReserve_ae709f2c-5e69-487d-9b6b-095580a58a78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_c4d21039-88dd-4c69-8390-021eea07f458" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2336c62f-a5c4-4b4e-8d58-fab931b60756" xlink:to="loc_us-gaap_LossOnContractTermination_c4d21039-88dd-4c69-8390-021eea07f458" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AmountsPaidOrOtherwiseSettled_44508554-8d20-4655-aae2-8980ab376e09" xlink:href="edit-20250630.xsd#edit_AmountsPaidOrOtherwiseSettled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2336c62f-a5c4-4b4e-8d58-fab931b60756" xlink:to="loc_edit_AmountsPaidOrOtherwiseSettled_44508554-8d20-4655-aae2-8980ab376e09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c9fe0d3f-eb63-4406-b55f-8e5728ac1a09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f4f421b5-cfca-42c9-a3c3-82241c1378f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2a04ce8b-bda4-4f2e-b34a-67886c92127c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f4f421b5-cfca-42c9-a3c3-82241c1378f7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2a04ce8b-bda4-4f2e-b34a-67886c92127c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a7e89750-8981-43b7-b2ef-1386be1f2a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2a04ce8b-bda4-4f2e-b34a-67886c92127c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a7e89750-8981-43b7-b2ef-1386be1f2a6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a7e89750-8981-43b7-b2ef-1386be1f2a6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a7e89750-8981-43b7-b2ef-1386be1f2a6e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a7e89750-8981-43b7-b2ef-1386be1f2a6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_918a995d-0aaa-4305-9591-f62c729e6693" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a7e89750-8981-43b7-b2ef-1386be1f2a6e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_918a995d-0aaa-4305-9591-f62c729e6693" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember_d3275a4c-757e-492d-96df-7ed13bdd60f2" xlink:href="edit-20250630.xsd#edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_918a995d-0aaa-4305-9591-f62c729e6693" xlink:to="loc_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember_d3275a4c-757e-492d-96df-7ed13bdd60f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_2e044002-f52d-48d2-a37a-9b36d56681a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f4f421b5-cfca-42c9-a3c3-82241c1378f7" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_2e044002-f52d-48d2-a37a-9b36d56681a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ChargesRelatedToTerminationOfLease_217ac47c-3ce2-45bf-aef8-ffa4eb1381f5" xlink:href="edit-20250630.xsd#edit_ChargesRelatedToTerminationOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f4f421b5-cfca-42c9-a3c3-82241c1378f7" xlink:to="loc_edit_ChargesRelatedToTerminationOfLease_217ac47c-3ce2-45bf-aef8-ffa4eb1381f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_bfb2ba24-20d6-483a-8716-1c30933d3244" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f4f421b5-cfca-42c9-a3c3-82241c1378f7" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_bfb2ba24-20d6-483a-8716-1c30933d3244" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#SegmentsScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0a42634-1205-4e70-8cab-90ecea8cad43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0a42634-1205-4e70-8cab-90ecea8cad43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_21657fa1-24c3-4beb-bdc5-41f2ab347233" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0a42634-1205-4e70-8cab-90ecea8cad43" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_21657fa1-24c3-4beb-bdc5-41f2ab347233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_21657fa1-24c3-4beb-bdc5-41f2ab347233_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_21657fa1-24c3-4beb-bdc5-41f2ab347233" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_21657fa1-24c3-4beb-bdc5-41f2ab347233_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b3c3f02f-ff27-419e-a7f2-5242d333b409" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_21657fa1-24c3-4beb-bdc5-41f2ab347233" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b3c3f02f-ff27-419e-a7f2-5242d333b409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b8c5d3ef-d857-4cab-85b9-58ac89131cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b3c3f02f-ff27-419e-a7f2-5242d333b409" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b8c5d3ef-d857-4cab-85b9-58ac89131cc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3723b929-6643-45d2-b63b-140656158848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b3c3f02f-ff27-419e-a7f2-5242d333b409" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3723b929-6643-45d2-b63b-140656158848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a4fb119e-9a4e-4e02-8324-59a1924a1c41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0a42634-1205-4e70-8cab-90ecea8cad43" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a4fb119e-9a4e-4e02-8324-59a1924a1c41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a4fb119e-9a4e-4e02-8324-59a1924a1c41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a4fb119e-9a4e-4e02-8324-59a1924a1c41" xlink:to="loc_us-gaap_SegmentDomain_a4fb119e-9a4e-4e02-8324-59a1924a1c41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dfc14f12-2f3c-45ed-bde2-ef96642e456b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a4fb119e-9a4e-4e02-8324-59a1924a1c41" xlink:to="loc_us-gaap_SegmentDomain_dfc14f12-2f3c-45ed-bde2-ef96642e456b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ReportableSegmentMember_383cb02f-e46b-4d79-a68b-ec5457b5c05a" xlink:href="edit-20250630.xsd#edit_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dfc14f12-2f3c-45ed-bde2-ef96642e456b" xlink:to="loc_edit_ReportableSegmentMember_383cb02f-e46b-4d79-a68b-ec5457b5c05a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b6c5ab4b-c0d5-4678-bbc7-d3c7cab68c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b6c5ab4b-c0d5-4678-bbc7-d3c7cab68c2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_3bd31099-86a2-47a1-90d9-a1bdfad51107" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_LaborAndRelatedExpense_3bd31099-86a2-47a1-90d9-a1bdfad51107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_d27991f6-5f9f-4c77-88e5-226fc3521e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_d27991f6-5f9f-4c77-88e5-226fc3521e5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OccupancyNet_e57fd2f4-a472-47a1-90dc-d552c64f1291" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OccupancyNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_OccupancyNet_e57fd2f4-a472-47a1-90dc-d552c64f1291" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_05bee6bd-6a07-409c-b487-82eadce1240d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_05bee6bd-6a07-409c-b487-82eadce1240d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_SublicenseAndLicenseFees_3f3b4fbc-392a-4272-ae6b-96eaa367de86" xlink:href="edit-20250630.xsd#edit_SublicenseAndLicenseFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_edit_SublicenseAndLicenseFees_3f3b4fbc-392a-4272-ae6b-96eaa367de86" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses_1c9d88bd-c7ef-479e-bfa6-c0fe2197bc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_OtherExpenses_1c9d88bd-c7ef-479e-bfa6-c0fe2197bc1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_b4984196-ef73-4dca-8006-c9a3fb69b4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_ProfessionalFees_b4984196-ef73-4dca-8006-c9a3fb69b4f7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_IntellectualPropertyAndPatentRelatedFees_10154a10-dabc-4e66-a109-550b77d05d02" xlink:href="edit-20250630.xsd#edit_IntellectualPropertyAndPatentRelatedFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_edit_IntellectualPropertyAndPatentRelatedFees_10154a10-dabc-4e66-a109-550b77d05d02" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1a6cecc7-4cc3-4660-a5cf-50939f182a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_OperatingExpenses_1a6cecc7-4cc3-4660-a5cf-50939f182a94" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d111a04e-7438-459f-abc9-d2aa272ae64c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:to="loc_us-gaap_OperatingIncomeLoss_d111a04e-7438-459f-abc9-d2aa272ae64c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_72df264c-9955-4c8f-a9dc-58f21476ca52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_72df264c-9955-4c8f-a9dc-58f21476ca52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_877b2442-e70e-4748-8c79-7cc26858a807" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_72df264c-9955-4c8f-a9dc-58f21476ca52" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_877b2442-e70e-4748-8c79-7cc26858a807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_4073d5d3-f5af-461e-97aa-1d27ee349cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_72df264c-9955-4c8f-a9dc-58f21476ca52" xlink:to="loc_us-gaap_InterestExpenseDebt_4073d5d3-f5af-461e-97aa-1d27ee349cd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_74251853-c1d2-49d1-92cc-269cfb87f489" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_72df264c-9955-4c8f-a9dc-58f21476ca52" xlink:to="loc_us-gaap_InvestmentIncomeNet_74251853-c1d2-49d1-92cc-269cfb87f489" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_103a1e7f-afc0-4a40-bba1-47a81131e11f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_72df264c-9955-4c8f-a9dc-58f21476ca52" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_103a1e7f-afc0-4a40-bba1-47a81131e11f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_881d7d89-2e3a-41f0-be12-572070fa6be7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:to="loc_us-gaap_NetIncomeLoss_881d7d89-2e3a-41f0-be12-572070fa6be7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9f7d7405-3a30-4781-a21a-0fa31883def6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:to="loc_us-gaap_RestructuringCharges_9f7d7405-3a30-4781-a21a-0fa31883def6" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>edit-20250630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1ab0433d-837b-430f-b71f-73abb830ced3,g:6d451f6e-3d6d-4567-be55-1f6fd20083c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_76b2ca19-ed5e-4dc9-811b-4033dcaa8d61_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_71eb4fa3-4ddf-46ff-9008-cfc044ff52ca_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_DRIHealthcareAcquisitionsLPMember_f1e746f8-1e26-4bd0-84a3-331ea8a6633a_terseLabel_en-US" xlink:label="lab_edit_DRIHealthcareAcquisitionsLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DRI Healthcare Acquisitions LP</link:label>
    <link:label id="lab_edit_DRIHealthcareAcquisitionsLPMember_label_en-US" xlink:label="lab_edit_DRIHealthcareAcquisitionsLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DRI Healthcare Acquisitions LP [Member]</link:label>
    <link:label id="lab_edit_DRIHealthcareAcquisitionsLPMember_documentation_en-US" xlink:label="lab_edit_DRIHealthcareAcquisitionsLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DRI Healthcare Acquisitions LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_DRIHealthcareAcquisitionsLPMember" xlink:href="edit-20250630.xsd#edit_DRIHealthcareAcquisitionsLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_DRIHealthcareAcquisitionsLPMember" xlink:to="lab_edit_DRIHealthcareAcquisitionsLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_108e70f4-8939-455a-a25e-44cdd1909311_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f1457e66-2dac-4485-84a5-c3d0de97a056_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_91a3f61c-0553-4056-aab4-b7685f8bf766_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_20e09e89-6fd0-4fd1-ac89-4959aa2c8720_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_5be9943c-a2b9-417f-95a6-f2dfbdf873d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_e8305c84-a4cc-43a4-8e0d-13a61cc1df27_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_46198300-61b3-4322-ae3d-6a8a2324ad66_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherExpenses_44f1c839-6cfd-47c8-ba20-eb72234c4b58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_us-gaap_OtherExpenses_label_en-US" xlink:label="lab_us-gaap_OtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenses" xlink:to="lab_us-gaap_OtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8c32d63d-0f12-474d-b22d-dfc32e57e6fd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_CollaborationAgreementsAbstract_e1f1e15a-3f68-4b0f-8d60-25f1f0a651eb_terseLabel_en-US" xlink:label="lab_edit_CollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and Profit-Sharing Agreements</link:label>
    <link:label id="lab_edit_CollaborationAgreementsAbstract_label_en-US" xlink:label="lab_edit_CollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_edit_CollaborationAgreementsAbstract_documentation_en-US" xlink:label="lab_edit_CollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_CollaborationAgreementsAbstract" xlink:href="edit-20250630.xsd#edit_CollaborationAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_CollaborationAgreementsAbstract" xlink:to="lab_edit_CollaborationAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cd07984f-d0c1-4340-9418-37935d093d21_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_37ab4f5f-d36b-4193-9f8c-f061bf1f184a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9ad3666d-6fdd-4333-bb57-f02573ff7d1d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5cd16f99-8bcd-40b2-bb3e-b243a5fd6c82_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted common stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_751e4196-a9de-4429-871f-e45faaf10ca0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, and Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_26a264ff-351e-4dec-b0cd-32589c5edb2a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_53107405-0197-46a7-8d75-1d890eb9c908_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_a2f72e28-323e-42c7-b5e4-03724dba73c5_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dab2f68-32d6-44a2-9f94-7a8b4f12e166_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_693697ae-4f0d-4bcb-a927-af3212b1f10b_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2cf182ad-eaff-4dd4-b6d0-91f33cf33de8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_bcb37e06-864d-4a83-8b8e-34579014f86e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of held for sale assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_15ebb65d-6a7f-45a2-ac1f-7f8aad8530e3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_fb8a6637-1881-45f5-88cc-204c8ca4a132_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_fe57e7ad-b849-4ecb-917a-469042b818b4_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9a3b9147-b125-4d16-9769-f7e151078dce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b294e962-6d41-47eb-a16a-44beb02a05e8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6641fc5b-8750-4329-86eb-5b787fb1a32a_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expenses</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_EmployeeTerminationBenefitsMember_61ac6510-bcd2-4365-a159-7a49941b4fa8_terseLabel_en-US" xlink:label="lab_edit_EmployeeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee termination benefits</link:label>
    <link:label id="lab_edit_EmployeeTerminationBenefitsMember_5afe32c8-dddc-4919-970e-4e5e673d8590_verboseLabel_en-US" xlink:label="lab_edit_EmployeeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Termination Benefits</link:label>
    <link:label id="lab_edit_EmployeeTerminationBenefitsMember_label_en-US" xlink:label="lab_edit_EmployeeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Termination Benefits [Member]</link:label>
    <link:label id="lab_edit_EmployeeTerminationBenefitsMember_documentation_en-US" xlink:label="lab_edit_EmployeeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_EmployeeTerminationBenefitsMember" xlink:href="edit-20250630.xsd#edit_EmployeeTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_EmployeeTerminationBenefitsMember" xlink:to="lab_edit_EmployeeTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8b6c07e6-4a33-4a34-909f-a47142e78b22_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2f126968-cf69-4dde-bbc4-4b51d1626b86_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bfab5094-5212-43ea-95a8-2d6ffeda66b7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from at the market equity offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18ac9665-5710-4e29-a0c3-65b23037afe6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d3955064-9cee-4003-aa94-3d78fa10c295_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9012d690-63ee-487d-8b28-0582954eafb8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cff199f7-8dec-4bea-a241-8f5eaaa33597_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_cd0270cb-a20c-4094-9ddd-b2c9cb75736a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_AccountsReceivableAdditions_2b231b56-abe7-4886-8b1d-2beb34354574_terseLabel_en-US" xlink:label="lab_edit_AccountsReceivableAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, additions</link:label>
    <link:label id="lab_edit_AccountsReceivableAdditions_label_en-US" xlink:label="lab_edit_AccountsReceivableAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Additions</link:label>
    <link:label id="lab_edit_AccountsReceivableAdditions_documentation_en-US" xlink:label="lab_edit_AccountsReceivableAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of additions to accounts receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AccountsReceivableAdditions" xlink:href="edit-20250630.xsd#edit_AccountsReceivableAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_AccountsReceivableAdditions" xlink:to="lab_edit_AccountsReceivableAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07bf6d5b-73f6-4ce3-85cd-839c60a39a36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41a86e4c-0b09-4163-b4c0-a85539f65171_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ee064b2f-0312-45ff-b0b8-cb86a47eb89a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0dfaa95b-0b9e-4ca2-9c49-84e9d3054f48_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9795604c-b4f4-4f82-8a9f-5c2ea7d58fa2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_51d5d4e4-8a5c-4bb2-a3d5-c8a4b3e744e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_dfb4b837-af24-47eb-b069-26eb1b582226_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_NonCashTerminationOfRightOfUseAsset_4ee23be8-d699-4a73-9083-a76b4afa5e48_terseLabel_en-US" xlink:label="lab_edit_NonCashTerminationOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash termination of right-of-use asset</link:label>
    <link:label id="lab_edit_NonCashTerminationOfRightOfUseAsset_label_en-US" xlink:label="lab_edit_NonCashTerminationOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Termination Of Right Of Use Asset</link:label>
    <link:label id="lab_edit_NonCashTerminationOfRightOfUseAsset_documentation_en-US" xlink:label="lab_edit_NonCashTerminationOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Termination Of Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_NonCashTerminationOfRightOfUseAsset" xlink:href="edit-20250630.xsd#edit_NonCashTerminationOfRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_NonCashTerminationOfRightOfUseAsset" xlink:to="lab_edit_NonCashTerminationOfRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4e826228-d92c-485b-8024-b4fc37438344_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_fbe94cea-0553-4209-8361-ad2a8f51f14f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_afa021e2-f41a-4f46-b78c-1cc61bf707b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b4277967-4e43-484e-9cfa-bc9662874c59_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_478de36a-860f-41ce-8f6d-5ee39d5b6cc7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_7c9058a6-3f61-4932-9a41-bcffd660618e_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Held-for-Sale or Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Held-for-Sale or Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_495a09c0-0fd0-4a06-ad9b-d0bd27decd2c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_17aa6712-9cd1-41bf-8d5b-0272612f8729_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of future revenues</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9ca2d5d3-140e-4e9f-a26d-8b3c10612351_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_DebtRollForward_913731fd-65a4-424e-ad08-08e74a9ad7d8_terseLabel_en-US" xlink:label="lab_edit_DebtRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt [Roll Forward]</link:label>
    <link:label id="lab_edit_DebtRollForward_label_en-US" xlink:label="lab_edit_DebtRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt [Roll Forward]</link:label>
    <link:label id="lab_edit_DebtRollForward_documentation_en-US" xlink:label="lab_edit_DebtRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_DebtRollForward" xlink:href="edit-20250630.xsd#edit_DebtRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_DebtRollForward" xlink:to="lab_edit_DebtRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_IntellectualPropertyAndPatentRelatedFeesCurrent_4de071aa-c8a9-4e87-b16d-b8db0cf33812_terseLabel_en-US" xlink:label="lab_edit_IntellectualPropertyAndPatentRelatedFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property and patent related fees</link:label>
    <link:label id="lab_edit_IntellectualPropertyAndPatentRelatedFeesCurrent_label_en-US" xlink:label="lab_edit_IntellectualPropertyAndPatentRelatedFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property And Patent Related Fees, Current</link:label>
    <link:label id="lab_edit_IntellectualPropertyAndPatentRelatedFeesCurrent_documentation_en-US" xlink:label="lab_edit_IntellectualPropertyAndPatentRelatedFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with intellectual property rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_IntellectualPropertyAndPatentRelatedFeesCurrent" xlink:href="edit-20250630.xsd#edit_IntellectualPropertyAndPatentRelatedFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_IntellectualPropertyAndPatentRelatedFeesCurrent" xlink:to="lab_edit_IntellectualPropertyAndPatentRelatedFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_659a1ed8-02dc-4050-8007-69531fd087f6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_588fc3fc-2069-4fd5-b1cc-aee7d2507ac9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for sale of future revenues, current</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_6ca66471-3d86-4286-833c-7142d3d7ed40_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_12fda3d6-7b99-446c-862d-9044472449e7_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_7238be30-4b78-409c-972c-5535f464e6d3_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_ba085e3d-8d98-4da7-9fd0-d0d9b3437a19_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_770b7438-988d-4fbd-9b23-72d71059d239_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_d690fb36-8b17-42cf-931d-3443fa64bc5d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_bea0264c-4d48-4b3d-acb0-57ad4ba28d47_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_7ce45a09-d96f-4db7-acc8-f9d9adde84e0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_34c57086-ee1a-474a-bb8a-c69bb318e651_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_db1e62ee-6b90-4cfe-a571-f7f2705a5906_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_cf2d513e-8349-4a69-b3fc-c281d1df01d9_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fce95095-7744-42b9-a833-51b798249f4f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1d63c5ec-0591-4d77-914b-d14ff910481b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_b69b9d0e-ea42-4790-9e9f-93fe496f153d_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_OperatingLeaseTerminationNotificationPeriod_c9275cc0-b52f-4680-ad44-9dae0045e6ae_terseLabel_en-US" xlink:label="lab_edit_OperatingLeaseTerminationNotificationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, termination notification period</link:label>
    <link:label id="lab_edit_OperatingLeaseTerminationNotificationPeriod_label_en-US" xlink:label="lab_edit_OperatingLeaseTerminationNotificationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Termination Notification Period</link:label>
    <link:label id="lab_edit_OperatingLeaseTerminationNotificationPeriod_documentation_en-US" xlink:label="lab_edit_OperatingLeaseTerminationNotificationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Termination Notification Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_OperatingLeaseTerminationNotificationPeriod" xlink:href="edit-20250630.xsd#edit_OperatingLeaseTerminationNotificationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_OperatingLeaseTerminationNotificationPeriod" xlink:to="lab_edit_OperatingLeaseTerminationNotificationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_5cb2b91f-53ae-494c-b5a2-a38378761eff_periodStartLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Deferred royalty obligation related to the sale of future revenues, net as of December&#160;31, 2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_c125fe55-b512-49ae-8d50-7c4ed342c305_periodEndLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Deferred royalty obligation related to the sale of future revenues, net as of June&#160;30, 2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a382d633-a0c4-4990-92dc-5d3226608af7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52b0c189-2d60-44a4-8a80-4c3a25315ba3_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d2f272a3-f6df-4787-ac73-8fd6913d8838_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_50fc6246-1e6c-4b9e-89e4-1f4343fbf98a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_59807239-8d85-4468-9c70-a65beeab72f8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c8ce46d2-a036-484f-bc37-227cdddbb826_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_2217945c-457f-47bd-bf98-f79ad7aac6d7_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Unit Awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_33f7244c-f536-4e00-b5ac-dc892c3f74de_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock unit awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ae1c5f1c-405e-460b-9324-1729f9f4351f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_83897f77-d690-4d55-a542-f741c4b2e555_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_437f650f-49a6-4478-bad4-59ef67a6d8cd_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_afed82fc-5872-46a7-a7a1-7b9b5ee8fcf8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveCurrent" xlink:to="lab_us-gaap_RestructuringReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f090c404-8fa6-4f15-9114-bbba85b56945_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b9d50639-8911-4187-92e2-f5f8d32fc4ce_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement of operating lease liabilities and right-of-use assets due to lease modification</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e415efdd-7b1c-434b-aa74-825ea6c47b0f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_43cdbf72-f4aa-425b-880e-ddb85a43ee29_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_LicenseAgreementMember_a92bf366-ce78-4018-997b-cd011461fdb5_terseLabel_en-US" xlink:label="lab_edit_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_edit_LicenseAgreementMember_label_en-US" xlink:label="lab_edit_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_edit_LicenseAgreementMember_documentation_en-US" xlink:label="lab_edit_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicenseAgreementMember" xlink:href="edit-20250630.xsd#edit_LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_LicenseAgreementMember" xlink:to="lab_edit_LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_db761dd7-b260-41bd-85d1-2446e7d8c69f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_0263ca0a-daa1-4c41-a850-74525ea46679_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash and other non-current assets:</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_eb258496-144a-4471-81ea-dad9c100eff6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_46dfd339-8f01-422b-829b-d6b3f204fa69_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eeb038e5-006c-44f4-8acf-bf3588f6a58e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_605a88e6-72b0-4eb1-9e9f-fc98b70fdcdf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_18353c11-b8f0-479c-9e70-dc62711f43d9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_de138141-8ba1-42e0-911e-ae008fbbb1ab_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_58f0bf34-8696-409a-b01e-c39c0533e7ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_563739dc-6bba-4832-8692-1f5dd35932ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f1cbf97d-f4ef-4411-bda8-4141b8b5146a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4f3f299-34e6-4a8e-a143-08eb573c58bc_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54ea8f2a-d62e-4927-aaaf-647beeca745c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90e3d103-2bf7-4d91-8de6-f8e5c80d6163_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7734be92-53b6-4f68-af17-c07187104e07_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_cf57212b-2700-4c58-b755-7d8ffc013a6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_16b25592-f94e-42cb-a73d-501c8258bb0e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities in an unrealized loss position for more than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_f70c68f6-3cd3-4f75-87b5-a48250f111a1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_350cfb19-57e6-4dd0-9253-52e04ef33ca4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_9a0eb091-5b47-4e16-8972-63b96eb954df_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_95592ff8-e8b9-4455-b7cb-c989f4a129ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate_b4658efc-fbf8-40ff-8d31-197355b66b92_terseLabel_en-US" xlink:label="lab_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for sale of future revenues, effective interest rate</link:label>
    <link:label id="lab_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate_label_en-US" xlink:label="lab_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Sale Of Future Revenues, Effective Interest Rate</link:label>
    <link:label id="lab_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate_documentation_en-US" xlink:label="lab_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Sale Of Future Revenues, Effective Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate" xlink:href="edit-20250630.xsd#edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate" xlink:to="lab_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_52c509a9-3dc4-451c-b42b-c2bbb4254d18_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8db5c214-d340-43c3-8002-41e1ff5b4638_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_197f07a7-c32b-4e6e-8dd5-5cde7eec200b_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Asset and Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Asset and Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:to="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_8e553a0f-04fd-4c51-b085-31df62b4ee4e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Impairment Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_SublicenseAndLicenseFees_b0329d1d-88b7-4037-9d65-f293d6c29936_terseLabel_en-US" xlink:label="lab_edit_SublicenseAndLicenseFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublicense and license fees</link:label>
    <link:label id="lab_edit_SublicenseAndLicenseFees_label_en-US" xlink:label="lab_edit_SublicenseAndLicenseFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublicense And License Fees</link:label>
    <link:label id="lab_edit_SublicenseAndLicenseFees_documentation_en-US" xlink:label="lab_edit_SublicenseAndLicenseFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublicense And License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_SublicenseAndLicenseFees" xlink:href="edit-20250630.xsd#edit_SublicenseAndLicenseFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_SublicenseAndLicenseFees" xlink:to="lab_edit_SublicenseAndLicenseFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_acacf58b-d073-4871-bb65-f8d1496203ad_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1f96de31-2410-4fe5-8023-891c5894fe6d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues_322491eb-8da5-453c-a794-8e2207a6ee9e_verboseLabel_en-US" xlink:label="lab_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense associated with sale of future revenues</link:label>
    <link:label id="lab_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues_label_en-US" xlink:label="lab_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash Interest Expense On Liability For Sale Of Future Revenues</link:label>
    <link:label id="lab_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues_documentation_en-US" xlink:label="lab_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-cash Interest Expense On Liability For Sale Of Future Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues" xlink:href="edit-20250630.xsd#edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues" xlink:to="lab_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1a969630-b2f2-4aa3-8a42-ad9f4a9e9a39_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4ac53f04-90e4-4c57-ba27-4bb7f15b98dc_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_23efdfaf-a4f3-458b-9e33-96f355c57186_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock unit awards, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_92a73b53-27ed-4be2-8011-429f84a2b03c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock unit awards, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e73da25d-a8bb-4e8a-910b-7621b939ba3f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3cb0674f-a6a5-4b58-a4b7-cdd74a70b8b2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9fe8aaa9-a399-45f6-b7bf-645a5801b3dc_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bb491c5-6a5b-4f73-8f06-29902ece6855_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_LicenseFeeReceivable_3b06a5eb-d87e-4006-85f3-8709df3e6979_terseLabel_en-US" xlink:label="lab_edit_LicenseFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fee receivable</link:label>
    <link:label id="lab_edit_LicenseFeeReceivable_label_en-US" xlink:label="lab_edit_LicenseFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee Receivable</link:label>
    <link:label id="lab_edit_LicenseFeeReceivable_documentation_en-US" xlink:label="lab_edit_LicenseFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicenseFeeReceivable" xlink:href="edit-20250630.xsd#edit_LicenseFeeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_LicenseFeeReceivable" xlink:to="lab_edit_LicenseFeeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2d496ead-32fc-48c3-9ebf-5c436886aea4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_28f83137-1453-4fa7-9f76-4d5b5ca12e02_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_4e071978-6d1f-4108-9750-5f5882510a2b_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_e4575944-0053-49ae-bec2-b5d3e89ed958_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d0a7d8f9-9a3d-4d6b-9e4c-9216d5fd30f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_c55c7b14-eee3-4ecf-bc4a-6c5a1f5b091c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_2f4e3588-7101-4880-83c5-66783ec800a6_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f5adc6fe-c508-4f7a-b802-849e34ca4ebb_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash and non-cash activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_91780e25-05d7-4974-8514-ff8d8170670e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_169d7a04-76f9-40fe-b848-e1f6a46d8a51_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_14f5fd41-6184-41ec-ac62-83a983364c47_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45ef036e-7343-4b81-bd7b-9b2103eede73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_7c418465-13ba-4fb1-9583-cf8d3493f5c5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities:</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_59ed1762-0ee3-4ba8-a8ae-aec0fd763bb8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_04833e1c-f1d8-476a-b4f0-e8b0cc83402c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramLineItems_a65ba670-5d48-4614-8b76-6c42b6c5a239_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Finance Program [Line Items]</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramLineItems_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems" xlink:to="lab_us-gaap_SupplierFinanceProgramLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ff1844ae-163c-403b-95d0-4dd318bad85c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_b5c960d5-45ac-4c56-a865-4375fd486e5e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, number of positions eliminated, period percent</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_4f453f71-db27-40b2-b5a7-f4de06863949_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_dee97580-2fa2-4b34-b282-f80d29c0971d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue type</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a9a6ad82-470f-4c63-a22e-0ce13cf23c46_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_AgreementExtensionPeriodOptionsToExtend_94fdbcd3-bb40-4e40-8bda-b104c4b07709_terseLabel_en-US" xlink:label="lab_edit_AgreementExtensionPeriodOptionsToExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement extension period, options to extend</link:label>
    <link:label id="lab_edit_AgreementExtensionPeriodOptionsToExtend_label_en-US" xlink:label="lab_edit_AgreementExtensionPeriodOptionsToExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement Extension Period, Options To Extend</link:label>
    <link:label id="lab_edit_AgreementExtensionPeriodOptionsToExtend_documentation_en-US" xlink:label="lab_edit_AgreementExtensionPeriodOptionsToExtend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement Extension Period, Options To Extend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AgreementExtensionPeriodOptionsToExtend" xlink:href="edit-20250630.xsd#edit_AgreementExtensionPeriodOptionsToExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_AgreementExtensionPeriodOptionsToExtend" xlink:to="lab_edit_AgreementExtensionPeriodOptionsToExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_795c7bbb-ae7e-447b-a411-f01d7a6fbf27_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4afe6d9f-e433-4cf7-b99b-fcccca493018_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c37062c5-b811-4961-ba82-e35e4d8f463c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalAndContractServicesExpense_cb717867-8b34-4269-840e-1680fe4557fe_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalAndContractServicesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense for prosecution and maintenance of patent rights</link:label>
    <link:label id="lab_us-gaap_ProfessionalAndContractServicesExpense_label_en-US" xlink:label="lab_us-gaap_ProfessionalAndContractServicesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional and Contract Services Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalAndContractServicesExpense" xlink:to="lab_us-gaap_ProfessionalAndContractServicesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_051d503b-724e-494e-9d74-c369b695f6c0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ab9a3334-a243-4673-957c-ae07f6eae7d1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_499c5f7c-a183-490c-b457-a03f91fc4aaa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_IncreaseDecreaseInRightOfUseAssets_c7a46de5-3645-455c-9cb5-a107ce713769_negatedLabel_en-US" xlink:label="lab_edit_IncreaseDecreaseInRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_edit_IncreaseDecreaseInRightOfUseAssets_label_en-US" xlink:label="lab_edit_IncreaseDecreaseInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Right Of Use Assets</link:label>
    <link:label id="lab_edit_IncreaseDecreaseInRightOfUseAssets_documentation_en-US" xlink:label="lab_edit_IncreaseDecreaseInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount represents the increase (decrease) in right of use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_IncreaseDecreaseInRightOfUseAssets" xlink:href="edit-20250630.xsd#edit_IncreaseDecreaseInRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_IncreaseDecreaseInRightOfUseAssets" xlink:to="lab_edit_IncreaseDecreaseInRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0b5a1def-8368-4169-bd2a-4cb62afc029d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0f1b7655-0890-4581-8e75-1faa202a8df5_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fc1b4818-2999-489a-abda-184f404585fd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_ContingentFeeReceivableThresholdAmount_d30b438b-11cb-4b26-b6fe-22a5210bc0b6_terseLabel_en-US" xlink:label="lab_edit_ContingentFeeReceivableThresholdAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent upfront payment</link:label>
    <link:label id="lab_edit_ContingentFeeReceivableThresholdAmount_label_en-US" xlink:label="lab_edit_ContingentFeeReceivableThresholdAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Fee Receivable, Threshold Amount</link:label>
    <link:label id="lab_edit_ContingentFeeReceivableThresholdAmount_documentation_en-US" xlink:label="lab_edit_ContingentFeeReceivableThresholdAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Fee Receivable, Threshold Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ContingentFeeReceivableThresholdAmount" xlink:href="edit-20250630.xsd#edit_ContingentFeeReceivableThresholdAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_ContingentFeeReceivableThresholdAmount" xlink:to="lab_edit_ContingentFeeReceivableThresholdAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_SublicenseAndLicenseFeesCurrent_33c5ca27-de22-41ae-b39a-1a005527600b_terseLabel_en-US" xlink:label="lab_edit_SublicenseAndLicenseFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublicense and license fees</link:label>
    <link:label id="lab_edit_SublicenseAndLicenseFeesCurrent_label_en-US" xlink:label="lab_edit_SublicenseAndLicenseFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublicense and License Fees, Current</link:label>
    <link:label id="lab_edit_SublicenseAndLicenseFeesCurrent_documentation_en-US" xlink:label="lab_edit_SublicenseAndLicenseFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublicense and License Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_SublicenseAndLicenseFeesCurrent" xlink:href="edit-20250630.xsd#edit_SublicenseAndLicenseFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_SublicenseAndLicenseFeesCurrent" xlink:to="lab_edit_SublicenseAndLicenseFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_0229fa36-9354-4f3b-b388-4e427a2f7765_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bdda223a-dac8-4e74-8374-183198ba7c6d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_b0f349a4-a56d-4f56-a64c-79a166f8af95_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_c70f3a94-23db-4526-97c6-0bcbd052b0c7_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e09afb50-c2d4-4f4c-9341-99453eb4a5b7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_639e9d1e-2562-4c27-bc06-6e8a1acf7333_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e150fab8-a8a1-4f79-9d24-34747612feab_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_ReceivablesNetCurrentRollForward_745bd778-0e90-42e7-8df0-73457e84f4db_terseLabel_en-US" xlink:label="lab_edit_ReceivablesNetCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable:</link:label>
    <link:label id="lab_edit_ReceivablesNetCurrentRollForward_label_en-US" xlink:label="lab_edit_ReceivablesNetCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current [Roll Forward]</link:label>
    <link:label id="lab_edit_ReceivablesNetCurrentRollForward_documentation_en-US" xlink:label="lab_edit_ReceivablesNetCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ReceivablesNetCurrentRollForward" xlink:href="edit-20250630.xsd#edit_ReceivablesNetCurrentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_ReceivablesNetCurrentRollForward" xlink:to="lab_edit_ReceivablesNetCurrentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_MarketableSecuritiesRemainingMaturityTerm_0f4cb7b6-0d3c-4117-afc2-240793610fb7_terseLabel_en-US" xlink:label="lab_edit_MarketableSecuritiesRemainingMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities remaining maturity term</link:label>
    <link:label id="lab_edit_MarketableSecuritiesRemainingMaturityTerm_label_en-US" xlink:label="lab_edit_MarketableSecuritiesRemainingMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities Remaining Maturity Term</link:label>
    <link:label id="lab_edit_MarketableSecuritiesRemainingMaturityTerm_documentation_en-US" xlink:label="lab_edit_MarketableSecuritiesRemainingMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable Securities Remaining Maturity Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_MarketableSecuritiesRemainingMaturityTerm" xlink:href="edit-20250630.xsd#edit_MarketableSecuritiesRemainingMaturityTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_MarketableSecuritiesRemainingMaturityTerm" xlink:to="lab_edit_MarketableSecuritiesRemainingMaturityTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f259a03-8aea-4855-bcbb-1f0f12d6829a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_AccountsReceivableDeductions_9383b189-8756-4835-a3d3-25a14ea6d5f4_negatedLabel_en-US" xlink:label="lab_edit_AccountsReceivableDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, deductions</link:label>
    <link:label id="lab_edit_AccountsReceivableDeductions_label_en-US" xlink:label="lab_edit_AccountsReceivableDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Deductions</link:label>
    <link:label id="lab_edit_AccountsReceivableDeductions_documentation_en-US" xlink:label="lab_edit_AccountsReceivableDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of deductions to accounts receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AccountsReceivableDeductions" xlink:href="edit-20250630.xsd#edit_AccountsReceivableDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_AccountsReceivableDeductions" xlink:to="lab_edit_AccountsReceivableDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_051fab2a-5e9a-4de5-9095-1d1eb1c98639_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash and other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_c4e4bfef-7050-4e6b-9529-43d7c97d152d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_75b81bce-88a1-45fa-8eb9-0ceb9a5c9851_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_LicensorExpenseReimbursementsMember_a7280fcf-6ea8-43aa-8293-9b063da94602_terseLabel_en-US" xlink:label="lab_edit_LicensorExpenseReimbursementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensor Expense Reimbursements</link:label>
    <link:label id="lab_edit_LicensorExpenseReimbursementsMember_label_en-US" xlink:label="lab_edit_LicensorExpenseReimbursementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensor Expense Reimbursements [Member]</link:label>
    <link:label id="lab_edit_LicensorExpenseReimbursementsMember_documentation_en-US" xlink:label="lab_edit_LicensorExpenseReimbursementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitment to reimburse the licensor for prosecution and maintenance of patent rights pursuant to the license agreement by and among the reporting entity, The Broad Institute Inc. and the Fellows of Harvard College.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicensorExpenseReimbursementsMember" xlink:href="edit-20250630.xsd#edit_LicensorExpenseReimbursementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_LicensorExpenseReimbursementsMember" xlink:to="lab_edit_LicensorExpenseReimbursementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fc9ea55a-0aaa-4cc8-992f-d24ce88e0ece_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9d8d9653-2520-406b-80bd-538fa54c6243_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_09000536-ab3c-47be-8000-20b9542cfcc5_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8448966b-59ca-4bbf-a8f5-6f55a19cebb2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_c2e2cd3a-d0cf-484e-b01b-cd47cdce29c7_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_2d9eaa6b-02fc-42a8-aa7c-e98ab6fbfbcd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_36a98fc3-1847-46b1-90b8-22ce9e0cbbdd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1aefc19e-fbce-4d53-b6bf-83d45a23b897_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1902a895-e280-4498-af00-89862413c4a4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f367c253-809d-4f6f-8df8-93dcc7c9aca1_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0084bad7-7c27-43ee-b2ee-0ec0dda17ea0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_c45a0234-b8c1-413b-bbbb-f6d955b43b04_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0a07f635-123c-4f81-87a5-1423a3de2143_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_1d7f0de0-66d1-4503-9c74-9a7c53747994_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for sale of future revenues - non-current</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_e062eaf6-9eb6-4a5a-85ac-42fda5583a0a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_IntellectualPropertyAndPatentRelatedFees_f3d460cc-7c74-47c1-b991-221fc0dc49b1_verboseLabel_en-US" xlink:label="lab_edit_IntellectualPropertyAndPatentRelatedFees" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property and patent related fees</link:label>
    <link:label id="lab_edit_IntellectualPropertyAndPatentRelatedFees_label_en-US" xlink:label="lab_edit_IntellectualPropertyAndPatentRelatedFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property And Patent Related Fees</link:label>
    <link:label id="lab_edit_IntellectualPropertyAndPatentRelatedFees_documentation_en-US" xlink:label="lab_edit_IntellectualPropertyAndPatentRelatedFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with intellectual property rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_IntellectualPropertyAndPatentRelatedFees" xlink:href="edit-20250630.xsd#edit_IntellectualPropertyAndPatentRelatedFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_IntellectualPropertyAndPatentRelatedFees" xlink:to="lab_edit_IntellectualPropertyAndPatentRelatedFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9aad37be-9ce0-432e-98a1-1621c31bd66a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_dabadd9b-ebbf-4407-82af-c802900200c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b3eba989-658f-4448-b8d2-1f6407f6e722_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_BristolMyersSquibbCompanyMember_183e0460-7e66-4f46-af9c-135903b463e2_terseLabel_en-US" xlink:label="lab_edit_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bristol Myers Squibb Company ("BMS")</link:label>
    <link:label id="lab_edit_BristolMyersSquibbCompanyMember_label_en-US" xlink:label="lab_edit_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bristol Myers Squibb Company ("BMS")</link:label>
    <link:label id="lab_edit_BristolMyersSquibbCompanyMember_documentation_en-US" xlink:label="lab_edit_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bristol Myers Squibb Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_BristolMyersSquibbCompanyMember" xlink:href="edit-20250630.xsd#edit_BristolMyersSquibbCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_BristolMyersSquibbCompanyMember" xlink:to="lab_edit_BristolMyersSquibbCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_33b2d77e-375e-4c81-816e-88d3d2fb6c60_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b69036f0-3709-4e5a-ab51-51edd353f3fc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ceb85b85-3332-421b-8a5f-637497792c83_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_21a9f628-9753-4a42-b989-3c1850e7acc7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues_78288f71-5061-4725-a4c3-0e8089a806e8_terseLabel_en-US" xlink:label="lab_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest on sale of future revenues</link:label>
    <link:label id="lab_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues_label_en-US" xlink:label="lab_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Interest Related To Sale Of Future Revenues</link:label>
    <link:label id="lab_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues_documentation_en-US" xlink:label="lab_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Interest Related To Sale Of Future Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues" xlink:href="edit-20250630.xsd#edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues" xlink:to="lab_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_15f5b6df-8c9e-492a-803b-504fd77fac07_netLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Restructuring and impairment charges</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_7c3dc86f-c2da-4bf2-944a-b8fd3ebb9c19_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and impairment charges</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_6bdeab21-7a99-4345-a250-7d7a8a3d52c6_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_label_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring, Settlement and Impairment Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:to="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0915dbd7-3c12-4503-9a6d-25d211340c68_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0d14d47e-63b4-4f99-8b16-af83f6069ac4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_50deb599-3d5c-437b-8a6c-5bd9f6d460fe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_ScheduleOfContractTerminationCostsTableTextBlock_28485b03-5592-419e-a918-1d6511e47697_terseLabel_en-US" xlink:label="lab_edit_ScheduleOfContractTerminationCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contract Termination Costs</link:label>
    <link:label id="lab_edit_ScheduleOfContractTerminationCostsTableTextBlock_label_en-US" xlink:label="lab_edit_ScheduleOfContractTerminationCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Contract Termination Costs [Table Text Block]</link:label>
    <link:label id="lab_edit_ScheduleOfContractTerminationCostsTableTextBlock_documentation_en-US" xlink:label="lab_edit_ScheduleOfContractTerminationCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Contract Termination Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ScheduleOfContractTerminationCostsTableTextBlock" xlink:href="edit-20250630.xsd#edit_ScheduleOfContractTerminationCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_ScheduleOfContractTerminationCostsTableTextBlock" xlink:to="lab_edit_ScheduleOfContractTerminationCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_4cc836f6-3fe8-4c58-bfa8-ebcb89265463_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee related expenses</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7d92894a-7a3a-4651-95b9-10b1fa144a4b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b172705a-b006-424d-bffa-932fab704940_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dc7e83cd-b360-4789-a0e7-086579201958_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_cfcc3e22-0fa8-47f3-a33f-0e83f2c2ebdd_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_074c2ca3-54b3-4a63-8f5e-4a0da9f616b9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b9811a7c-b2ad-4f32-8342-37a628049a20_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_d03fa817-bf2c-452b-b58c-4339696c85d8_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0fc35765-7092-4fc5-9822-f97b7a2594f9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining contractual life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued_20dadd59-ede0-412e-89ae-6b3baf78dd55_terseLabel_en-US" xlink:label="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales agreement amount of aggregate sale proceeds of common stock agreed to be issued</link:label>
    <link:label id="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued_label_en-US" xlink:label="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Agreement, Amount Of Aggregate Sale Proceeds Of Common Stock Agreed To Be Issued</link:label>
    <link:label id="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued_documentation_en-US" xlink:label="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of proceeds from common stock agreed to be issued or sold under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued" xlink:href="edit-20250630.xsd#edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued" xlink:to="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_a2616016-e484-49dd-9f1d-c3222300942f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ed818174-7e65-4f7e-86e8-d355011e6a45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_91ceaa34-56f1-4b73-8a66-c688e8a380e4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramTable_f3dc664e-21de-4f9c-a0d0-2c8e3d61c80a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Finance Program [Table]</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramTable_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramTable" xlink:to="lab_us-gaap_SupplierFinanceProgramTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_89a2abb4-013b-4ba4-a1d9-86b1bdf68942_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of held for sale assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f6647e4a-95c2-4364-ab67-e12999846f47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_a969a427-1723-4d5e-8b34-321f8d7780f5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_7a497f32-a80c-4649-a54d-9b533355b1dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_cdba61e7-c751-4ca0-983b-e72c03ea96f1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_LicenseAndServiceAgreementMember_9f3a3a35-2f22-4591-956d-cd13bfe7d61e_terseLabel_en-US" xlink:label="lab_edit_LicenseAndServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Service Agreement</link:label>
    <link:label id="lab_edit_LicenseAndServiceAgreementMember_label_en-US" xlink:label="lab_edit_LicenseAndServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Service Agreement [Member]</link:label>
    <link:label id="lab_edit_LicenseAndServiceAgreementMember_documentation_en-US" xlink:label="lab_edit_LicenseAndServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and service agreement and related manufacturing lease space.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicenseAndServiceAgreementMember" xlink:href="edit-20250630.xsd#edit_LicenseAndServiceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_LicenseAndServiceAgreementMember" xlink:to="lab_edit_LicenseAndServiceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_d7a4104d-da34-44a6-ba9d-143ae572f377_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest related to sale of future revenues</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_b785ff7e-d051-45be-a850-b4e1461a5ca0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest related to sale of future revenues</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_ae6e9f9b-3b98-4edb-9b72-b971f39c503e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e5c2bf39-5d74-46d8-b078-953981121d1c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ef63ac8-54d3-4b3e-a567-f7a5710e109a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_ae158bd4-b219-4215-83be-0efb66ad62ed_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_ff3442be-1258-4d47-baf6-bb3ac8fd470a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent_aa81c3fe-bb7f-4168-9704-086cef18d28e_terseLabel_en-US" xlink:label="lab_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">External research and development expenses</link:label>
    <link:label id="lab_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent_label_en-US" xlink:label="lab_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued External Research And Development Expenses, Current</link:label>
    <link:label id="lab_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent_documentation_en-US" xlink:label="lab_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to accrued external research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:href="edit-20250630.xsd#edit_AccruedExternalResearchAndDevelopmentExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:to="lab_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_86bc60aa-de99-406b-8ec2-c4e8af19cd5f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts included in deferred revenue at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock_910737ff-dedc-4d4c-a6a2-216412a0e64a_terseLabel_en-US" xlink:label="lab_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Receivable and Contract Liabilities</link:label>
    <link:label id="lab_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Accounts Receivable And Contract Liabilities [Table Text Block]</link:label>
    <link:label id="lab_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of account receivable and contract liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" xlink:href="edit-20250630.xsd#edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" xlink:to="lab_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ac7fc4d9-6c26-4662-85dd-55b9a822bfe0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb831e74-db40-483b-a02c-1ccbd43c6b14_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, ending of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_ed27373e-b936-4052-b001-435f95cbe4e7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_07aa2845-a216-4ea6-9cba-e20298743e02_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_845e18f7-6666-4904-b1d6-3208a8345a19_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_147879f8-0cbc-4031-8512-293ef97b35b3_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_23435268-b4aa-4b9a-87ea-bd848824b070_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e2efbe52-3b04-490b-9b37-a38333547828_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_c3d2928c-e6a1-4445-956f-6a56b00f7851_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6332bc83-4228-465b-85ca-8ca8d79c1fda_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_a8fcf648-4cb6-4a46-8975-67a5a28162f7_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e75cdb40-3f7d-4a2f-a30a-303fec83dd1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ea3c524-d2eb-4897-bab4-0f101f768156_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ebdcf318-6776-41af-87fc-44dccaf77fc8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3001c476-bca9-4da4-91ce-9610cf77241e_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_1881eb26-0298-432a-b509-66e5ef0c19d9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_610d7913-103c-4ab7-9f7a-e9dd3180d9cc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e49805f4-27be-4005-9e3f-6d36633e011b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_968d2790-5475-45e5-849b-511c4f96dedb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash paid in connection with operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_75915676-340b-4c1d-b2d6-5580932b96c0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final fixed payment</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_6de47a7e-a8c3-42b6-a22b-fdcb02f8a665_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable_fa87c187-220b-4e19-86f0-db27b771e0a8_terseLabel_en-US" xlink:label="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales agreement, amount of aggregate sale proceeds of common stock available</link:label>
    <link:label id="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable_label_en-US" xlink:label="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Agreement, Amount Of Aggregate Sale Proceeds Of Common Stock Available</link:label>
    <link:label id="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable_documentation_en-US" xlink:label="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Agreement, Amount Of Aggregate Sale Proceeds Of Common Stock Available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable" xlink:href="edit-20250630.xsd#edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable" xlink:to="lab_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_3067e28f-c99f-4006-8c5e-ae66dc57f110_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value per share: 390,000,000 and 195,000,000 shares authorized at June&#160;30, 2025 and December&#160;31, 2024, respectively; 87,388,425 and 82,734,696 shares issued and outstanding at June&#160;30, 2025 and December&#160;31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ded2fbde-c1e0-4f4e-af4e-13b81ccc172c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_509b7c45-cb99-40c3-86c1-bb030d07a55b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac6e4573-e1c0-40bc-b74f-ed874501dd35_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_ContractWithCustomerLiabilityRollForward_29cb3f00-b5ff-4128-831e-3006fd01a323_terseLabel_en-US" xlink:label="lab_edit_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities:</link:label>
    <link:label id="lab_edit_ContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_edit_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_edit_ContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_edit_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ContractWithCustomerLiabilityRollForward" xlink:href="edit-20250630.xsd#edit_ContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_ContractWithCustomerLiabilityRollForward" xlink:to="lab_edit_ContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_LaboratoryAndManufacturingEquipmentMember_5d5de12c-33cb-4dc1-b818-f85f537497bd_terseLabel_en-US" xlink:label="lab_edit_LaboratoryAndManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_edit_LaboratoryAndManufacturingEquipmentMember_label_en-US" xlink:label="lab_edit_LaboratoryAndManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory And Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_edit_LaboratoryAndManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_edit_LaboratoryAndManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory equipment used for research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LaboratoryAndManufacturingEquipmentMember" xlink:href="edit-20250630.xsd#edit_LaboratoryAndManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_LaboratoryAndManufacturingEquipmentMember" xlink:to="lab_edit_LaboratoryAndManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e0e28576-e04f-4300-a0a8-8a8ae7a7b5d4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_f12fad3c-9676-4dc5-b9f2-a27a287eb98b_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalent Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_fd639397-da8b-418c-ba21-564ab6fe2d46_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7b4cd169-4178-457d-a49e-a90d5cd90a18_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2d860d69-587b-4328-8eaf-31c08c44f31c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_DebtInstrumentRollForward_0bd0a98a-e72c-4572-8e4f-347fba764734_terseLabel_en-US" xlink:label="lab_edit_DebtInstrumentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Roll Forward]</link:label>
    <link:label id="lab_edit_DebtInstrumentRollForward_label_en-US" xlink:label="lab_edit_DebtInstrumentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Roll Forward]</link:label>
    <link:label id="lab_edit_DebtInstrumentRollForward_documentation_en-US" xlink:label="lab_edit_DebtInstrumentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_DebtInstrumentRollForward" xlink:href="edit-20250630.xsd#edit_DebtInstrumentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_DebtInstrumentRollForward" xlink:to="lab_edit_DebtInstrumentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_39928a90-bbfd-40eb-9aba-b4db94b67b88_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2185a246-9639-42f0-b0fd-70dd0ad6f48b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_93568464-a0d2-4d56-a8ec-b89ba4ac3440_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_9fa9d6d6-c58b-4ab6-bb04-6a183a7ed6a3_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, and Marketable Security [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrentAbstract_14f7ea1d-dc4c-49c6-9bec-ab6b392558ce_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable:</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract" xlink:to="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d68700ff-bc10-43aa-8f76-943e55b40004_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f7ed8299-95d8-4fa6-977f-123765770d1a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9590e85e-d633-4e42-a706-82c18dfae853_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c4e5554b-0939-45d8-b322-556bc62004d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7c04c5d0-d7bb-4bad-a5d8-9fb9319aae0b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_bc389a37-40f6-40c0-94ab-edde7847bc50_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock from at the market equity offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3d03cf9d-0ce2-46aa-8fd1-77d1ecf6264d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d293e08d-c30f-4425-becc-09eb012f86a3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and other research and development revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637d4ef2-9060-4ff2-9f7b-878e50bb2ca0_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and other research and development revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractTerminationMember_3a96d80a-f264-43bd-9369-4411d5e3209e_netLabel_en-US" xlink:label="lab_us-gaap_ContractTerminationMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Contract termination costs</link:label>
    <link:label id="lab_us-gaap_ContractTerminationMember_b5b7a076-b3c4-4e2e-bd4b-a52eda117f47_terseLabel_en-US" xlink:label="lab_us-gaap_ContractTerminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs for ongoing contracts and terminated contracts</link:label>
    <link:label id="lab_us-gaap_ContractTerminationMember_46a59a59-5683-4673-a4f3-c9821d6286a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractTerminationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract Costs</link:label>
    <link:label id="lab_us-gaap_ContractTerminationMember_label_en-US" xlink:label="lab_us-gaap_ContractTerminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Termination [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractTerminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractTerminationMember" xlink:to="lab_us-gaap_ContractTerminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_408a3903-9bfd-427e-8213-6d8b5ff326bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0a3031f6-a595-46f6-9cb2-0038b897adbc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal_037b7f1e-faa3-42d8-82a3-81b766495556_terseLabel_en-US" xlink:label="lab_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and marketable securities</link:label>
    <link:label id="lab_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal_label_en-US" xlink:label="lab_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities Investments, Total</link:label>
    <link:label id="lab_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal_documentation_en-US" xlink:label="lab_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of currency on hand as well as demand deposits with banks or financial institutions and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal" xlink:href="edit-20250630.xsd#edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal" xlink:to="lab_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_54bbb9d2-d4b8-4a1a-a01a-8ab931c5fb9d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_618b1917-82ca-418f-bbca-d9d0937dc96a_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_6d54978c-13be-4851-a9ed-c049c741604b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_47183f93-b3a9-4091-aa21-0cc0d561a524_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_98a6d9fc-a8b3-424a-bfd5-4d5e14f2fe7e_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_abda7b66-dbc0-49a8-a819-542097e2ccc5_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_989d4d68-ced3-4935-9cc5-75c3000f32a4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_bde9c708-d447-4bc2-b83f-0e6c51e2be7c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_986b57ef-fb99-45bb-b73a-6b2350ecdaf3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_MarketableSecuritiesNoncurrentNumberOfSecurities_a690b398-d986-4cc5-a43a-a9e9d1cae043_terseLabel_en-US" xlink:label="lab_edit_MarketableSecuritiesNoncurrentNumberOfSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of noncurrent securities</link:label>
    <link:label id="lab_edit_MarketableSecuritiesNoncurrentNumberOfSecurities_label_en-US" xlink:label="lab_edit_MarketableSecuritiesNoncurrentNumberOfSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Noncurrent, Number Of Securities</link:label>
    <link:label id="lab_edit_MarketableSecuritiesNoncurrentNumberOfSecurities_documentation_en-US" xlink:label="lab_edit_MarketableSecuritiesNoncurrentNumberOfSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of noncurrent marketable securities held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_MarketableSecuritiesNoncurrentNumberOfSecurities" xlink:href="edit-20250630.xsd#edit_MarketableSecuritiesNoncurrentNumberOfSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_MarketableSecuritiesNoncurrentNumberOfSecurities" xlink:to="lab_edit_MarketableSecuritiesNoncurrentNumberOfSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_ImpairmentChargesMember_3e475999-5c85-4d6b-bd21-57bcff3da065_terseLabel_en-US" xlink:label="lab_edit_ImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_edit_ImpairmentChargesMember_label_en-US" xlink:label="lab_edit_ImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment Charges [Member]</link:label>
    <link:label id="lab_edit_ImpairmentChargesMember_documentation_en-US" xlink:label="lab_edit_ImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ImpairmentChargesMember" xlink:href="edit-20250630.xsd#edit_ImpairmentChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_ImpairmentChargesMember" xlink:to="lab_edit_ImpairmentChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_bc475f9d-e15e-4dce-bd81-1a830dc09ce7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6bf93549-2421-4fa9-9e5a-a07dcdb063e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_513d8ea4-5e7f-4c16-aff8-cfb3923324e1_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_640320cc-b141-4774-a8e2-44b4392f0ec1_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_8e1c7818-58cb-44f2-9a88-e5fb9442cad3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_ContractWithCustomerLiabilityAdditions_c4852a68-0e81-45ec-99dc-961c97d9fe84_terseLabel_en-US" xlink:label="lab_edit_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, additions</link:label>
    <link:label id="lab_edit_ContractWithCustomerLiabilityAdditions_label_en-US" xlink:label="lab_edit_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer Liability Additions</link:label>
    <link:label id="lab_edit_ContractWithCustomerLiabilityAdditions_documentation_en-US" xlink:label="lab_edit_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer Liability Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ContractWithCustomerLiabilityAdditions" xlink:href="edit-20250630.xsd#edit_ContractWithCustomerLiabilityAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_ContractWithCustomerLiabilityAdditions" xlink:to="lab_edit_ContractWithCustomerLiabilityAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b95fa40a-38a1-4ab8-9485-0f8ceaca6a3d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_beb75680-10e5-494f-af43-f85b43bd6684_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated depreciation related to leasehold improvements and software</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7d075380-7ddf-400e-8933-d7c0be5009d5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e089448a-cd89-4439-ba0d-72f1b548ee87_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_9163b82f-93de-4957-8fb5-deaf525c587d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_00b786a8-5803-4319-a1b7-42f2f217a67b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3f1ee61e-50b0-4c08-981c-bd84b565d382_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7c711d48-4d4c-4872-81cd-b5d3e6a2582a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Anti-Dilutive Common Stock Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ca9b14aa-3444-431a-9f60-2ae996babb1f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e186b0b8-e991-4af6-a8e7-3217d00f7549_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_59c17f51-091b-43b7-b0e9-551146072700_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_d0b9745c-60d6-4fea-bacf-f09977688e40_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Unvested Restricted Stock</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c64b9359-7e71-42ad-84bc-908950be8c0c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b59340ee-2bd8-4ba4-a419-e0154ab40a96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_aab72739-6d3b-4a21-843c-433d0a7711c0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_bc076288-2627-4621-a289-67cc46b6217c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_7ca3123f-2a70-4437-8459-ca0b2496a20d_terseLabel_en-US" xlink:label="lab_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Change in Contract Assets and Contract Liabilities</link:label>
    <link:label id="lab_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Change in Contract with Customer Asset and Liability [Table Text Block]</link:label>
    <link:label id="lab_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Change in Contract with Customer Asset and Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="edit-20250630.xsd#edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2007fe3e-8348-4263-ad6e-18fe708ebc5c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a4e530ce-7ed8-41f3-a480-d8e19fb8b8d1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining payments owed</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_0b8d6837-e6c2-4a3d-972d-518ef39cba58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">External research and development expenses</link:label>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_ChargesRelatedToTerminationOfLease_530a33aa-1fda-4db9-bb73-87c4145a0dbb_terseLabel_en-US" xlink:label="lab_edit_ChargesRelatedToTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges related to termination of lease</link:label>
    <link:label id="lab_edit_ChargesRelatedToTerminationOfLease_label_en-US" xlink:label="lab_edit_ChargesRelatedToTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Charges Related To Termination Of Lease</link:label>
    <link:label id="lab_edit_ChargesRelatedToTerminationOfLease_documentation_en-US" xlink:label="lab_edit_ChargesRelatedToTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Charges Related To Termination Of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ChargesRelatedToTerminationOfLease" xlink:href="edit-20250630.xsd#edit_ChargesRelatedToTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_ChargesRelatedToTerminationOfLease" xlink:to="lab_edit_ChargesRelatedToTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0958a21a-2170-4375-86b6-045f76fea1db_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fd49053e-3b38-46da-acad-07bf6290473f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_1e5e6608-3a3b-4900-b271-e00c60b14e08_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_61080d62-e3b6-4a76-a543-ffbba075e22b_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8c53d6ac-667f-4187-a94a-a2c9291215b0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f8ff49cf-df50-4774-a447-2e743a66a9db_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7bf3c9c3-5471-491f-9aeb-0c0aa797e5ae_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_0596c168-6b46-4751-b636-e87b9cc16ca9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_2b056a64-d1ec-45f3-adc7-16d381810cb5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total restructuring and impairment charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_32a644d7-4e46-403f-befd-e8365def4cbf_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee termination benefits charges incurred during period</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_c8c05cc1-746f-41ef-829d-eaecaed313bb_netLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Restructuring and impairment charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ab6b2424-dc18-44b9-b8fe-425e2b71b158_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a1d6a7eb-6a23-45ff-8d3e-20172e81b0c4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e9f9720a-6569-4cf0-a9c5-3a3fceaa0175_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8803c398-1c85-41f3-9ea5-824a47978380_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_7a3e5117-4c7b-44d6-a309-413d8762decc_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_14d092c9-d082-4ce2-8801-7b61d61cc966_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnContractTermination_3663a8be-6ef4-445b-8b98-128a965f575b_verboseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract costs incurred during the period</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination" xlink:to="lab_us-gaap_LossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_83db6dbb-69e0-4c32-9b79-13d89c7ed5e9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_dfa5557c-9b52-4fdb-9af9-2871892f18a0_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2b74427f-74c6-48fc-b0e0-42ca1db48036_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_928c851f-adf0-4426-b746-cb2449f1585d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3956a6f-c209-4fe0-a325-9ad928c399ae_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_adcd1908-0240-4142-a259-d2d9c26aae1b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_2b001190-869e-48c9-b7a4-da1e6582c828_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment on sale of future revenues</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_63124c21-36d8-4b13-81cc-1b98663a18c4_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments for sale of future revenues</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash_9c73ff5a-a524-44ae-9420-2761d90bdf17_negatedTerseLabel_en-US" xlink:label="lab_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amounts paid or otherwise settled during the period</link:label>
    <link:label id="lab_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash_label_en-US" xlink:label="lab_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Restructuring And Restructuring Reserve, Settled Without Cash</link:label>
    <link:label id="lab_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash_documentation_en-US" xlink:label="lab_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Restructuring And Restructuring Reserve, Settled Without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash" xlink:href="edit-20250630.xsd#edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash" xlink:to="lab_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock_e16f937e-6552-4fa1-ac60-ebceab27fda9_terseLabel_en-US" xlink:label="lab_edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Termination Benefits</link:label>
    <link:label id="lab_edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock_label_en-US" xlink:label="lab_edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Employee Termination Benefits [Table Text Block]</link:label>
    <link:label id="lab_edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock_documentation_en-US" xlink:label="lab_edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Employee Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock" xlink:href="edit-20250630.xsd#edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock" xlink:to="lab_edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_68b4b8ec-0ed5-4754-9bb7-e347a1c1b2c2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_ReportableSegmentMember_4db651b2-d870-4135-bf93-7949a86d5aa0_terseLabel_en-US" xlink:label="lab_edit_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_edit_ReportableSegmentMember_label_en-US" xlink:label="lab_edit_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_edit_ReportableSegmentMember_documentation_en-US" xlink:label="lab_edit_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ReportableSegmentMember" xlink:href="edit-20250630.xsd#edit_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_ReportableSegmentMember" xlink:to="lab_edit_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_bd5f3c52-0d50-4223-aaee-2e34a8481d93_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional service expenses</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1af1536f-a815-44f3-92c6-11a1d26f2e4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b48a5b16-a889-414f-814b-0ae01776edc8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_12c16026-8395-42cf-a2df-7c892eecb1a6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c06eef37-5dbd-4c5e-b982-a5ddd924a1a0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_5a2b0a41-ba27-4aa0-8080-39260c63b59c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_3c715511-c74b-4aa6-8da3-195d657acb64_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_92314dd2-d0e1-42a0-9259-b440af709b7a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember_ba7c3f7e-408d-4f32-83c8-17339a08fd88_terseLabel_en-US" xlink:label="lab_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acceleration of expense for change in useful life estimate and lease termination</link:label>
    <link:label id="lab_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember_label_en-US" xlink:label="lab_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acceleration Of Expense, Change In Useful Life Estimate [Member]</link:label>
    <link:label id="lab_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember_documentation_en-US" xlink:label="lab_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acceleration Of Expense, Change In Useful Life Estimate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember" xlink:href="edit-20250630.xsd#edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember" xlink:to="lab_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_854a8c7d-6a44-4b47-8ee8-d863f61d411e_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_cb235c08-5d5e-4c04-9492-258a8065532d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_da196319-0150-45c9-a84c-121790642c92_periodEndLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, balance at end of period</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_f389b9cc-7249-4878-a784-714a468e2204_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_0d2e9475-b8d5-47ed-a3d9-d5f14ba5d2e8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, balance at end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1d170f3f-3a0c-4ac2-9393-f9c568b4a7a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_50e3c989-4248-4986-8520-a2633712b524_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_d11ba388-9199-4108-9c9d-d4cfd1ca7ccf_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4f3e6e88-615e-43e3-b2cd-986785059071_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive common stock equivalent shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fd5324d7-0aae-4823-b1f3-799567a127a3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_CommencementOfRightOfUseAsset_4d75014c-7d66-4ce7-8dc0-197629994c9a_terseLabel_en-US" xlink:label="lab_edit_CommencementOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commencement of right-of-use asset</link:label>
    <link:label id="lab_edit_CommencementOfRightOfUseAsset_label_en-US" xlink:label="lab_edit_CommencementOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commencement Of Right-Of-Use Asset</link:label>
    <link:label id="lab_edit_CommencementOfRightOfUseAsset_documentation_en-US" xlink:label="lab_edit_CommencementOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commencement Of Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_CommencementOfRightOfUseAsset" xlink:href="edit-20250630.xsd#edit_CommencementOfRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_CommencementOfRightOfUseAsset" xlink:to="lab_edit_CommencementOfRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_9daf66b4-26b5-401f-9241-96a82f783112_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c26d216-00df-4cfc-b08d-d2d616b7dd05_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a5bd67d9-04bf-48e3-8c7b-4e81cec4db37_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecf454da-5e1b-41a3-aafe-1c185fb4772b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f0acfcb-945b-4368-b944-a3b4acd47187_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_fc1627f5-4490-487b-9064-b490bf0e054d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c97d0c3d-6359-4928-b28d-3c9e09b71b34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_20e69e21-ffa0-49ed-876f-366f0d46548b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_ab3cd45c-975c-4d0f-b8b9-1061efb3b929_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0b1cf0c6-87cf-424c-adb9-2b462f53ce6b_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2c1bc49a-87e7-456a-9b38-021d5ced7f39_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_8b349828-4cca-4b7c-ad7f-bb7f11a4e0e0_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_af5a1713-c8f3-4257-ac31-ccedcf0aeed5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gains (losses) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0aa0fb70-6a15-4d82-aa32-7c4d8254967b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_610314fb-2af1-4e7d-a15c-f7be0119fc23_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80523810-4ebe-4bc7-9e06-69ab9bac6c12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_a6674c80-ff56-482e-98c0-7e183a4ebf65_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_be35c042-5dec-46d2-a9e3-33e618861ceb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_385ee126-83b1-4d6d-860d-b901a2e9b168_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OccupancyNet_c906f3d4-6b8e-4cfd-92c3-2839e3d78df6_terseLabel_en-US" xlink:label="lab_us-gaap_OccupancyNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility expenses</link:label>
    <link:label id="lab_us-gaap_OccupancyNet_label_en-US" xlink:label="lab_us-gaap_OccupancyNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Occupancy, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OccupancyNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OccupancyNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OccupancyNet" xlink:to="lab_us-gaap_OccupancyNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6167adca-57cf-4e63-a217-948b85f0802d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_AtMarketOfferingMember_78e6be49-65a7-417d-b0f0-eaca50ad554a_terseLabel_en-US" xlink:label="lab_edit_AtMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_edit_AtMarketOfferingMember_label_en-US" xlink:label="lab_edit_AtMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_edit_AtMarketOfferingMember_documentation_en-US" xlink:label="lab_edit_AtMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to at market offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AtMarketOfferingMember" xlink:href="edit-20250630.xsd#edit_AtMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_AtMarketOfferingMember" xlink:to="lab_edit_AtMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_b829d844-5086-43fa-8b5e-d75928067146_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_e3a6822c-c0b4-4ecb-b62d-1863675e95b1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_8b10bda2-170c-4c57-a097-1207fa6268fa_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_86007ed2-8788-4937-a526-f4eb9876b8a2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed asset additions included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_901db820-cad6-49e0-84c9-d2d0512ed288_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_d2eeb277-8974-4faf-a31c-d5199539194e_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_ContractWithCustomerLiabilityDeductions_ee055f5c-0344-4a91-9920-b278f9778584_negatedTerseLabel_en-US" xlink:label="lab_edit_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, deductions</link:label>
    <link:label id="lab_edit_ContractWithCustomerLiabilityDeductions_label_en-US" xlink:label="lab_edit_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer Liability Deductions</link:label>
    <link:label id="lab_edit_ContractWithCustomerLiabilityDeductions_documentation_en-US" xlink:label="lab_edit_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer Liability Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ContractWithCustomerLiabilityDeductions" xlink:href="edit-20250630.xsd#edit_ContractWithCustomerLiabilityDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_ContractWithCustomerLiabilityDeductions" xlink:to="lab_edit_ContractWithCustomerLiabilityDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_32458a50-e60c-447c-8987-f75a95abd09b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b556fe15-eaf5-446d-8110-ea054a1ceda8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a52e60ca-246e-402d-bb12-c31237c2d212_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_c03588e5-2f81-4c9a-8814-9ebb3e1dd357_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from at the market equity offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f5f29e7f-d944-4da3-a1b1-8258fb8a45a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0dabe358-f97d-4b18-8d0a-a579b70f5a3a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e124a33c-9720-4273-ba78-d91e36f784b6_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_AmendedCollaborationAgreement2019Member_dccf6131-5041-4edd-a2b0-e634462b262f_terseLabel_en-US" xlink:label="lab_edit_AmendedCollaborationAgreement2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended Collaboration Agreement 2019</link:label>
    <link:label id="lab_edit_AmendedCollaborationAgreement2019Member_label_en-US" xlink:label="lab_edit_AmendedCollaborationAgreement2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended Collaboration Agreement 2019</link:label>
    <link:label id="lab_edit_AmendedCollaborationAgreement2019Member_documentation_en-US" xlink:label="lab_edit_AmendedCollaborationAgreement2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to 2019 Amended Collaboration Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AmendedCollaborationAgreement2019Member" xlink:href="edit-20250630.xsd#edit_AmendedCollaborationAgreement2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_AmendedCollaborationAgreement2019Member" xlink:to="lab_edit_AmendedCollaborationAgreement2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_8ed2bc70-2e06-42f2-aa8d-aec013da09dc_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_520a6c2b-3dbf-4928-a4a7-64de39734f55_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_AmountsPaidOrOtherwiseSettled_dbcd3df0-6cd9-4f62-999e-166cec0ceb98_negatedTerseLabel_en-US" xlink:label="lab_edit_AmountsPaidOrOtherwiseSettled" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amounts paid or otherwise settled during the period</link:label>
    <link:label id="lab_edit_AmountsPaidOrOtherwiseSettled_label_en-US" xlink:label="lab_edit_AmountsPaidOrOtherwiseSettled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts Paid Or Otherwise Settled</link:label>
    <link:label id="lab_edit_AmountsPaidOrOtherwiseSettled_documentation_en-US" xlink:label="lab_edit_AmountsPaidOrOtherwiseSettled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amounts Paid Or Otherwise Settled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AmountsPaidOrOtherwiseSettled" xlink:href="edit-20250630.xsd#edit_AmountsPaidOrOtherwiseSettled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_AmountsPaidOrOtherwiseSettled" xlink:to="lab_edit_AmountsPaidOrOtherwiseSettled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7a08c753-20bb-45f8-bc37-6c2f4d53f42f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_52dd35de-9189-49b4-b8f3-85580a88baff_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9bbe4976-4b77-4a44-97e2-38a532222e68_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1632c37a-feec-441b-8332-0bb8c234202a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_4cffca2b-192f-41f5-9595-1adf73f65192_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate notes/bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_46a72258-0a57-44a2-a3a9-3146e916fe6e_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate notes/bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_edit_InterestRelatedToSaleOfFutureRevenues_87e68587-c489-45c7-8221-7bbd3ed38a00_terseLabel_en-US" xlink:label="lab_edit_InterestRelatedToSaleOfFutureRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest related to sale of future revenues</link:label>
    <link:label id="lab_edit_InterestRelatedToSaleOfFutureRevenues_label_en-US" xlink:label="lab_edit_InterestRelatedToSaleOfFutureRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Related To Sale Of Future Revenues</link:label>
    <link:label id="lab_edit_InterestRelatedToSaleOfFutureRevenues_documentation_en-US" xlink:label="lab_edit_InterestRelatedToSaleOfFutureRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Related To Sale Of Future Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_edit_InterestRelatedToSaleOfFutureRevenues" xlink:href="edit-20250630.xsd#edit_InterestRelatedToSaleOfFutureRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_edit_InterestRelatedToSaleOfFutureRevenues" xlink:to="lab_edit_InterestRelatedToSaleOfFutureRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_cc6e1ac0-df36-4e7d-8a77-6d2e7a9e2cb3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99bc9eb9-1e20-430f-9c40-efa5d50aefe1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_88e2aa67-d832-4c61-9e06-b89e04bf6a17_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional service expenses</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>edit-20250630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1ab0433d-837b-430f-b71f-73abb830ced3,g:6d451f6e-3d6d-4567-be55-1f6fd20083c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.editasmedicine.com/role/Cover" xlink:type="simple" xlink:href="edit-20250630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1a3cc774-5761-4231-88be-385a13645aa0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_DocumentType_1a3cc774-5761-4231-88be-385a13645aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_222ced86-9d76-4c6b-82a5-4ac945bc9b2a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_DocumentQuarterlyReport_222ced86-9d76-4c6b-82a5-4ac945bc9b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1e2a191c-c35e-45ee-8a0d-f0282e0c8c1e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_DocumentPeriodEndDate_1e2a191c-c35e-45ee-8a0d-f0282e0c8c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d4cd49b7-8b89-4774-80c0-8463730a98f6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_DocumentTransitionReport_d4cd49b7-8b89-4774-80c0-8463730a98f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b3e03588-f0d2-4fc8-bb62-772d1d7b8142" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityFileNumber_b3e03588-f0d2-4fc8-bb62-772d1d7b8142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b16d9414-1105-404b-9aab-b1cee681afe4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityRegistrantName_b16d9414-1105-404b-9aab-b1cee681afe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9c89e50a-b600-4871-acba-587596835245" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9c89e50a-b600-4871-acba-587596835245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2ec05672-f18e-4437-8274-2640a52a40f4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityTaxIdentificationNumber_2ec05672-f18e-4437-8274-2640a52a40f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ec2c84b6-509b-489f-aba4-b1baa107edcb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityAddressAddressLine1_ec2c84b6-509b-489f-aba4-b1baa107edcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0f2c6c65-2b3c-45e2-9ec9-20bc0f0bb33e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityAddressCityOrTown_0f2c6c65-2b3c-45e2-9ec9-20bc0f0bb33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0885120f-3588-4cd5-99f2-18546ba24d75" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityAddressStateOrProvince_0885120f-3588-4cd5-99f2-18546ba24d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7793dc9b-7e01-4c83-8c02-66008d66a5df" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityAddressPostalZipCode_7793dc9b-7e01-4c83-8c02-66008d66a5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ea72ef7b-9ee9-4e0b-bc1a-49ad9c157686" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_CityAreaCode_ea72ef7b-9ee9-4e0b-bc1a-49ad9c157686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1fb08aec-4166-4cbf-8625-4e161fd727cf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_LocalPhoneNumber_1fb08aec-4166-4cbf-8625-4e161fd727cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f3a693d5-caf8-40a3-82ba-565fb95995cc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_Security12bTitle_f3a693d5-caf8-40a3-82ba-565fb95995cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3536cf3e-7131-44aa-aaaf-b2416cf082eb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_TradingSymbol_3536cf3e-7131-44aa-aaaf-b2416cf082eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ada44e37-f8a4-4b37-928c-3a90b33e7e5c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_SecurityExchangeName_ada44e37-f8a4-4b37-928c-3a90b33e7e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6c0d2915-1bbf-4201-b8ca-3e38dce580d5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityCurrentReportingStatus_6c0d2915-1bbf-4201-b8ca-3e38dce580d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6b3755a4-4d70-4a65-ac1d-d10c20d50385" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityInteractiveDataCurrent_6b3755a4-4d70-4a65-ac1d-d10c20d50385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_939f708c-b520-4c95-a906-e208b1a651be" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityFilerCategory_939f708c-b520-4c95-a906-e208b1a651be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ea3684cd-ea71-4231-b677-0aecb6389579" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntitySmallBusiness_ea3684cd-ea71-4231-b677-0aecb6389579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4846b684-5c58-4367-8444-44c7bdd211f6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityEmergingGrowthCompany_4846b684-5c58-4367-8444-44c7bdd211f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ff806c55-dff8-4fe6-a129-ff8d58d84b75" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityShellCompany_ff806c55-dff8-4fe6-a129-ff8d58d84b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_35c19280-d189-41ca-86d2-c4ff2445de4d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_35c19280-d189-41ca-86d2-c4ff2445de4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8126cbd8-9602-493c-94f8-fa0d5bb19806" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_EntityCentralIndexKey_8126cbd8-9602-493c-94f8-fa0d5bb19806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1d6e21a6-8038-43f8-9657-35b91cd87b7c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_CurrentFiscalYearEndDate_1d6e21a6-8038-43f8-9657-35b91cd87b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5995481b-bdfa-487e-9a7f-06d809bc32d2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_DocumentFiscalYearFocus_5995481b-bdfa-487e-9a7f-06d809bc32d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f5669e5c-b41c-4d7e-b847-f348cb997d6a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f5669e5c-b41c-4d7e-b847-f348cb997d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_46bd4ffc-e0ea-45d0-9605-e8c9c612b156" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b2d766d-6d19-4b13-9658-ec0c18d8f9be" xlink:to="loc_dei_AmendmentFlag_46bd4ffc-e0ea-45d0-9605-e8c9c612b156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="edit-20250630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6987a920-adb3-4a18-84fd-2efd1b16eac4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_09873945-3a26-42d3-888c-580545016749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6987a920-adb3-4a18-84fd-2efd1b16eac4" xlink:to="loc_us-gaap_AssetsAbstract_09873945-3a26-42d3-888c-580545016749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_149db2b3-9988-461e-b99d-11d3dc9594d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_09873945-3a26-42d3-888c-580545016749" xlink:to="loc_us-gaap_AssetsCurrentAbstract_149db2b3-9988-461e-b99d-11d3dc9594d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c415507e-f159-4e05-a3ca-ba14e0ae511f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149db2b3-9988-461e-b99d-11d3dc9594d2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c415507e-f159-4e05-a3ca-ba14e0ae511f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_e5e554d5-ef90-4e00-98a3-721eb9c3552a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149db2b3-9988-461e-b99d-11d3dc9594d2" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_e5e554d5-ef90-4e00-98a3-721eb9c3552a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_ed238055-3b52-40d6-aa8c-cd712d347aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149db2b3-9988-461e-b99d-11d3dc9594d2" xlink:to="loc_us-gaap_ReceivablesNetCurrent_ed238055-3b52-40d6-aa8c-cd712d347aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4bd20041-d7a5-4c1e-ba0d-c453ab3f2652" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149db2b3-9988-461e-b99d-11d3dc9594d2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4bd20041-d7a5-4c1e-ba0d-c453ab3f2652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bc7dca8b-01a5-4ec0-b95d-0556927ae83a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149db2b3-9988-461e-b99d-11d3dc9594d2" xlink:to="loc_us-gaap_AssetsCurrent_bc7dca8b-01a5-4ec0-b95d-0556927ae83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_717c939c-69e3-4078-940c-eb731fc6182b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_09873945-3a26-42d3-888c-580545016749" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_717c939c-69e3-4078-940c-eb731fc6182b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b87dbac7-5358-4d6d-beaa-b4035b001af8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_09873945-3a26-42d3-888c-580545016749" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b87dbac7-5358-4d6d-beaa-b4035b001af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f9b5cd71-c870-4722-8e89-ab9333c80dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_09873945-3a26-42d3-888c-580545016749" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f9b5cd71-c870-4722-8e89-ab9333c80dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fdc377ea-2733-4eee-9e61-6defe8b64874" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_09873945-3a26-42d3-888c-580545016749" xlink:to="loc_us-gaap_Assets_fdc377ea-2733-4eee-9e61-6defe8b64874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_237a6ba8-89b8-4222-bc79-ba480b777419" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6987a920-adb3-4a18-84fd-2efd1b16eac4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_237a6ba8-89b8-4222-bc79-ba480b777419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_fc9af892-8b33-49e6-83bf-6a474d584fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_237a6ba8-89b8-4222-bc79-ba480b777419" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_fc9af892-8b33-49e6-83bf-6a474d584fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c6c03204-4c59-4cf9-87a2-c203f4292f47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc9af892-8b33-49e6-83bf-6a474d584fe1" xlink:to="loc_us-gaap_AccountsPayableCurrent_c6c03204-4c59-4cf9-87a2-c203f4292f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_57cd9e39-3b85-4b66-9668-41cd595f3e41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc9af892-8b33-49e6-83bf-6a474d584fe1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_57cd9e39-3b85-4b66-9668-41cd595f3e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_bbecdaa9-e5d2-447f-ab9a-f7cef12cfc28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc9af892-8b33-49e6-83bf-6a474d584fe1" xlink:to="loc_us-gaap_LongTermDebtCurrent_bbecdaa9-e5d2-447f-ab9a-f7cef12cfc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_03dc018e-c988-4a56-b33a-d669ec972a35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc9af892-8b33-49e6-83bf-6a474d584fe1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_03dc018e-c988-4a56-b33a-d669ec972a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d30560cf-3f7e-452e-b88e-5b47a7c26eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc9af892-8b33-49e6-83bf-6a474d584fe1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d30560cf-3f7e-452e-b88e-5b47a7c26eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3be952eb-a940-4dee-a010-13e7c4ae3329" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc9af892-8b33-49e6-83bf-6a474d584fe1" xlink:to="loc_us-gaap_LiabilitiesCurrent_3be952eb-a940-4dee-a010-13e7c4ae3329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c1bb7bfc-eb3b-4398-8fbf-83c9188c1794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_237a6ba8-89b8-4222-bc79-ba480b777419" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c1bb7bfc-eb3b-4398-8fbf-83c9188c1794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0bfd9e02-e890-4a97-a9e4-5dcd7dc99801" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_237a6ba8-89b8-4222-bc79-ba480b777419" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0bfd9e02-e890-4a97-a9e4-5dcd7dc99801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cf5d3a2e-5f23-4e40-818c-a16c843aa0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_237a6ba8-89b8-4222-bc79-ba480b777419" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cf5d3a2e-5f23-4e40-818c-a16c843aa0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_88278823-44e7-4124-8624-5fa6571d3b71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_237a6ba8-89b8-4222-bc79-ba480b777419" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_88278823-44e7-4124-8624-5fa6571d3b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9dbe8f74-f72d-443a-8b25-f785eefb158c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_237a6ba8-89b8-4222-bc79-ba480b777419" xlink:to="loc_us-gaap_Liabilities_9dbe8f74-f72d-443a-8b25-f785eefb158c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5bbf6e47-8334-4951-8cfd-2291443f890d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_237a6ba8-89b8-4222-bc79-ba480b777419" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5bbf6e47-8334-4951-8cfd-2291443f890d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f5487188-1bce-431a-81aa-d7485cd69491" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5bbf6e47-8334-4951-8cfd-2291443f890d" xlink:to="loc_us-gaap_PreferredStockValue_f5487188-1bce-431a-81aa-d7485cd69491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_419d43d5-00d2-40a6-9d32-9205bbef8fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5bbf6e47-8334-4951-8cfd-2291443f890d" xlink:to="loc_us-gaap_CommonStockValue_419d43d5-00d2-40a6-9d32-9205bbef8fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_bcf635d9-05fb-489e-b2b7-1ede1975e9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5bbf6e47-8334-4951-8cfd-2291443f890d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_bcf635d9-05fb-489e-b2b7-1ede1975e9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_018e9ac3-2e21-47e5-b3a9-a76685c1da7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5bbf6e47-8334-4951-8cfd-2291443f890d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_018e9ac3-2e21-47e5-b3a9-a76685c1da7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fc1d0456-1204-489d-8452-636d2bffcd28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5bbf6e47-8334-4951-8cfd-2291443f890d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fc1d0456-1204-489d-8452-636d2bffcd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7398b0b0-1a2c-4823-8830-828740005043" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5bbf6e47-8334-4951-8cfd-2291443f890d" xlink:to="loc_us-gaap_StockholdersEquity_7398b0b0-1a2c-4823-8830-828740005043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7717a22-6078-4a2c-a8d2-73c37ca57e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_237a6ba8-89b8-4222-bc79-ba480b777419" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7717a22-6078-4a2c-a8d2-73c37ca57e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="edit-20250630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fa6db433-f9e2-492b-ae3c-c03ad858cc97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ed449979-3581-43ac-9ff9-00e166e5337d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fa6db433-f9e2-492b-ae3c-c03ad858cc97" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ed449979-3581-43ac-9ff9-00e166e5337d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4471f75d-687c-4c3b-8c48-7a701bbac544" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fa6db433-f9e2-492b-ae3c-c03ad858cc97" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4471f75d-687c-4c3b-8c48-7a701bbac544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_bc59c449-880a-43d2-bc2f-2cf2d4540723" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fa6db433-f9e2-492b-ae3c-c03ad858cc97" xlink:to="loc_us-gaap_PreferredStockSharesIssued_bc59c449-880a-43d2-bc2f-2cf2d4540723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_67a915bb-f844-44c2-b0f6-93994de0259a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fa6db433-f9e2-492b-ae3c-c03ad858cc97" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_67a915bb-f844-44c2-b0f6-93994de0259a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_87d4649c-b8c1-4206-909f-8345b9dcf16f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fa6db433-f9e2-492b-ae3c-c03ad858cc97" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_87d4649c-b8c1-4206-909f-8345b9dcf16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_048d65e8-851b-4770-b24c-2977806cab9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fa6db433-f9e2-492b-ae3c-c03ad858cc97" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_048d65e8-851b-4770-b24c-2977806cab9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b6b7ddc7-d7f8-4b2f-b5eb-25495417f531" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fa6db433-f9e2-492b-ae3c-c03ad858cc97" xlink:to="loc_us-gaap_CommonStockSharesIssued_b6b7ddc7-d7f8-4b2f-b5eb-25495417f531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ce44f6d3-1232-453c-a5c9-6eba96bc81cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fa6db433-f9e2-492b-ae3c-c03ad858cc97" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ce44f6d3-1232-453c-a5c9-6eba96bc81cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="edit-20250630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a567f6d2-0fdf-4a8f-96fa-f18e4186b0de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6e42afa9-8133-42ef-b6ea-e10014f45bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a567f6d2-0fdf-4a8f-96fa-f18e4186b0de" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6e42afa9-8133-42ef-b6ea-e10014f45bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_536d2496-f5f2-4673-b12a-1b7f1cb82537" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6e42afa9-8133-42ef-b6ea-e10014f45bfb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_536d2496-f5f2-4673-b12a-1b7f1cb82537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4c71f92a-bb2a-49b0-b7f3-44667c0b1dca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a567f6d2-0fdf-4a8f-96fa-f18e4186b0de" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4c71f92a-bb2a-49b0-b7f3-44667c0b1dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9f50d702-25ea-4b7c-81a7-7cf78d72cbf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4c71f92a-bb2a-49b0-b7f3-44667c0b1dca" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9f50d702-25ea-4b7c-81a7-7cf78d72cbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2cab05bb-3391-4bb2-9d14-f3b1b0ebc4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4c71f92a-bb2a-49b0-b7f3-44667c0b1dca" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2cab05bb-3391-4bb2-9d14-f3b1b0ebc4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_53d3ce1c-f92e-4a4c-8458-c875d83051cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4c71f92a-bb2a-49b0-b7f3-44667c0b1dca" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_53d3ce1c-f92e-4a4c-8458-c875d83051cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4ba36e11-13e1-43b5-9d3a-af09bf1186e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4c71f92a-bb2a-49b0-b7f3-44667c0b1dca" xlink:to="loc_us-gaap_OperatingExpenses_4ba36e11-13e1-43b5-9d3a-af09bf1186e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e58728bb-98bd-4edf-a7b8-830dae021d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a567f6d2-0fdf-4a8f-96fa-f18e4186b0de" xlink:to="loc_us-gaap_OperatingIncomeLoss_e58728bb-98bd-4edf-a7b8-830dae021d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11841625-1452-4c0a-9f7b-44aa4c7fab53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a567f6d2-0fdf-4a8f-96fa-f18e4186b0de" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11841625-1452-4c0a-9f7b-44aa4c7fab53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c0d7552c-56af-45e4-acfa-3ef7a47b805c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11841625-1452-4c0a-9f7b-44aa4c7fab53" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c0d7552c-56af-45e4-acfa-3ef7a47b805c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a8dfdf74-2780-44dc-9ac9-647c3f005cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11841625-1452-4c0a-9f7b-44aa4c7fab53" xlink:to="loc_us-gaap_InterestExpenseDebt_a8dfdf74-2780-44dc-9ac9-647c3f005cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_a5ac757c-4dea-4395-ac23-f55c0fdd074e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11841625-1452-4c0a-9f7b-44aa4c7fab53" xlink:to="loc_us-gaap_InvestmentIncomeNet_a5ac757c-4dea-4395-ac23-f55c0fdd074e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0d467671-ffb9-4aa9-8971-86bca1497b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11841625-1452-4c0a-9f7b-44aa4c7fab53" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0d467671-ffb9-4aa9-8971-86bca1497b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81443c8a-ad05-457a-ba49-b28d0a074ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a567f6d2-0fdf-4a8f-96fa-f18e4186b0de" xlink:to="loc_us-gaap_NetIncomeLoss_81443c8a-ad05-457a-ba49-b28d0a074ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_87b57b43-de33-4faf-ac21-d0b43a758dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a567f6d2-0fdf-4a8f-96fa-f18e4186b0de" xlink:to="loc_us-gaap_EarningsPerShareBasic_87b57b43-de33-4faf-ac21-d0b43a758dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5787be55-2e39-41b3-bec1-a3dcfc66e3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a567f6d2-0fdf-4a8f-96fa-f18e4186b0de" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5787be55-2e39-41b3-bec1-a3dcfc66e3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3106521f-0f34-4c4b-853f-96e5ffd243b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a567f6d2-0fdf-4a8f-96fa-f18e4186b0de" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3106521f-0f34-4c4b-853f-96e5ffd243b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5fa147fd-21e8-4566-80a3-b67b1b2cf988" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a567f6d2-0fdf-4a8f-96fa-f18e4186b0de" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5fa147fd-21e8-4566-80a3-b67b1b2cf988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="edit-20250630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c241d9c7-0976-40ab-994d-e85179ba0921" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e24cbceb-fb8d-4a1b-bebf-8e6348fd5e89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c241d9c7-0976-40ab-994d-e85179ba0921" xlink:to="loc_us-gaap_NetIncomeLoss_e24cbceb-fb8d-4a1b-bebf-8e6348fd5e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_61f2cf58-571c-4e8e-82e1-0a2538b5aae7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c241d9c7-0976-40ab-994d-e85179ba0921" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_61f2cf58-571c-4e8e-82e1-0a2538b5aae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ec0e6afe-7460-4bfd-a4e8-6ab57ff1f32e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_61f2cf58-571c-4e8e-82e1-0a2538b5aae7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ec0e6afe-7460-4bfd-a4e8-6ab57ff1f32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f162b506-e5f2-44a4-85f5-03cf4a1e749f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c241d9c7-0976-40ab-994d-e85179ba0921" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f162b506-e5f2-44a4-85f5-03cf4a1e749f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="edit-20250630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_bddf5097-07de-4ce8-b682-bc069506320b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_17b72221-d61d-4c52-8dfe-f8a462b37ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_bddf5097-07de-4ce8-b682-bc069506320b" xlink:to="loc_us-gaap_StatementTable_17b72221-d61d-4c52-8dfe-f8a462b37ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bb0000c6-dc5d-400c-949c-4cefc8b1842a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_17b72221-d61d-4c52-8dfe-f8a462b37ecc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bb0000c6-dc5d-400c-949c-4cefc8b1842a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e932bf12-fb31-449b-80ce-696e5b1bbb66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bb0000c6-dc5d-400c-949c-4cefc8b1842a" xlink:to="loc_us-gaap_EquityComponentDomain_e932bf12-fb31-449b-80ce-696e5b1bbb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_867d2fab-701d-429b-9a85-83a698274d80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e932bf12-fb31-449b-80ce-696e5b1bbb66" xlink:to="loc_us-gaap_CommonStockMember_867d2fab-701d-429b-9a85-83a698274d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cd3e2996-9ed6-466d-9b0a-41eb33823012" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e932bf12-fb31-449b-80ce-696e5b1bbb66" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cd3e2996-9ed6-466d-9b0a-41eb33823012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_effbe582-25b1-4b2a-80c5-e864e60517e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e932bf12-fb31-449b-80ce-696e5b1bbb66" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_effbe582-25b1-4b2a-80c5-e864e60517e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a7446b38-4483-464b-80cc-dab8e982ebb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e932bf12-fb31-449b-80ce-696e5b1bbb66" xlink:to="loc_us-gaap_RetainedEarningsMember_a7446b38-4483-464b-80cc-dab8e982ebb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9730f8c8-3066-4506-8767-586552dca1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_17b72221-d61d-4c52-8dfe-f8a462b37ecc" xlink:to="loc_us-gaap_StatementLineItems_9730f8c8-3066-4506-8767-586552dca1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9730f8c8-3066-4506-8767-586552dca1ac" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f32a907c-de4d-48ad-9598-c8e1fd05060c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_SharesOutstanding_f32a907c-de4d-48ad-9598-c8e1fd05060c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_01d28b1c-0120-4008-86dc-28398174413f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockholdersEquity_01d28b1c-0120-4008-86dc-28398174413f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d07ac737-06ac-400c-98d7-0db0713de1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d07ac737-06ac-400c-98d7-0db0713de1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4da8f217-50da-431c-905b-24ce59c44086" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4da8f217-50da-431c-905b-24ce59c44086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d8f65806-3faf-4d49-8055-158ac43da8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d8f65806-3faf-4d49-8055-158ac43da8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2c67d496-8a15-42d2-98c9-cd00253c3f81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2c67d496-8a15-42d2-98c9-cd00253c3f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_80ec6ad0-9607-4080-9b29-60adea41509f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_80ec6ad0-9607-4080-9b29-60adea41509f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a4abfd42-5567-4561-b45e-fed0dace5869" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a4abfd42-5567-4561-b45e-fed0dace5869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_22b02ad9-e99d-4355-94fc-43ece75ed925" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_22b02ad9-e99d-4355-94fc-43ece75ed925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_914c5b77-ffad-4302-9379-531914c29c66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_914c5b77-ffad-4302-9379-531914c29c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f35476bd-5932-4d42-beb5-51a4bb9c3945" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f35476bd-5932-4d42-beb5-51a4bb9c3945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc0d1262-635f-4943-9d9f-25d043dcffed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_NetIncomeLoss_fc0d1262-635f-4943-9d9f-25d043dcffed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e0837327-e080-44c4-b4f4-123f42525781" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_SharesOutstanding_e0837327-e080-44c4-b4f4-123f42525781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2b554bc5-164e-415c-a78d-1201f602267e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_297811be-7eab-40aa-9ecc-0d22a30d5fa7" xlink:to="loc_us-gaap_StockholdersEquity_2b554bc5-164e-415c-a78d-1201f602267e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="edit-20250630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_31584753-134c-4286-beb4-eed23c50c669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c81fb4a5-4c6c-4f1a-b281-7cacf3cfb823" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_31584753-134c-4286-beb4-eed23c50c669" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c81fb4a5-4c6c-4f1a-b281-7cacf3cfb823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7f145208-f5cb-4016-899a-e1a5cfe88150" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c81fb4a5-4c6c-4f1a-b281-7cacf3cfb823" xlink:to="loc_us-gaap_NetIncomeLoss_7f145208-f5cb-4016-899a-e1a5cfe88150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bde7f32-1594-4465-9177-f082a8e2ec8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c81fb4a5-4c6c-4f1a-b281-7cacf3cfb823" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bde7f32-1594-4465-9177-f082a8e2ec8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_602beac5-7046-43b9-ab6d-22b97170317c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bde7f32-1594-4465-9177-f082a8e2ec8e" xlink:to="loc_us-gaap_ShareBasedCompensation_602beac5-7046-43b9-ab6d-22b97170317c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_40844176-a004-404e-bb2e-806823bd7699" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bde7f32-1594-4465-9177-f082a8e2ec8e" xlink:to="loc_us-gaap_Depreciation_40844176-a004-404e-bb2e-806823bd7699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_193374c3-888c-4296-81a4-348b2640abfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bde7f32-1594-4465-9177-f082a8e2ec8e" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_193374c3-888c-4296-81a4-348b2640abfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_ab067880-67b1-48dc-a77f-bc4ce915ffa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bde7f32-1594-4465-9177-f082a8e2ec8e" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_ab067880-67b1-48dc-a77f-bc4ce915ffa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_InterestRelatedToSaleOfFutureRevenues_35e49249-4741-42f7-bef7-c38bd53f5a50" xlink:href="edit-20250630.xsd#edit_InterestRelatedToSaleOfFutureRevenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bde7f32-1594-4465-9177-f082a8e2ec8e" xlink:to="loc_edit_InterestRelatedToSaleOfFutureRevenues_35e49249-4741-42f7-bef7-c38bd53f5a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f11480ca-87da-4f77-b457-5df3118ea791" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bde7f32-1594-4465-9177-f082a8e2ec8e" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f11480ca-87da-4f77-b457-5df3118ea791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_2a744838-9d10-4064-9876-ca4b847d26b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bde7f32-1594-4465-9177-f082a8e2ec8e" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_2a744838-9d10-4064-9876-ca4b847d26b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ea78881-9d54-4720-afe3-818ad418ec62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bde7f32-1594-4465-9177-f082a8e2ec8e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ea78881-9d54-4720-afe3-818ad418ec62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9f89a714-a93f-443b-a784-e070de73df7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ea78881-9d54-4720-afe3-818ad418ec62" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9f89a714-a93f-443b-a784-e070de73df7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_02c3c571-2cd2-4c85-b039-30966016a357" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ea78881-9d54-4720-afe3-818ad418ec62" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_02c3c571-2cd2-4c85-b039-30966016a357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_IncreaseDecreaseInRightOfUseAssets_0a1087bf-2154-4272-b357-a7e61a98ce56" xlink:href="edit-20250630.xsd#edit_IncreaseDecreaseInRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ea78881-9d54-4720-afe3-818ad418ec62" xlink:to="loc_edit_IncreaseDecreaseInRightOfUseAssets_0a1087bf-2154-4272-b357-a7e61a98ce56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_b54c2444-7fa4-4126-b03f-e8e4acaaf05e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ea78881-9d54-4720-afe3-818ad418ec62" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_b54c2444-7fa4-4126-b03f-e8e4acaaf05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8859161d-9061-45f5-a899-5a281ed0fa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ea78881-9d54-4720-afe3-818ad418ec62" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8859161d-9061-45f5-a899-5a281ed0fa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9152fbf5-0cec-4670-b1ca-f7f9fd6c3388" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ea78881-9d54-4720-afe3-818ad418ec62" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9152fbf5-0cec-4670-b1ca-f7f9fd6c3388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues_6577aa2e-6123-4b6f-9220-fbf4b8b31c0e" xlink:href="edit-20250630.xsd#edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ea78881-9d54-4720-afe3-818ad418ec62" xlink:to="loc_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues_6577aa2e-6123-4b6f-9220-fbf4b8b31c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8d8a8ae4-e420-47ea-8d55-746738f98658" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ea78881-9d54-4720-afe3-818ad418ec62" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8d8a8ae4-e420-47ea-8d55-746738f98658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_48e5d79a-ce11-4109-b0b4-8c0d3b294f64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ea78881-9d54-4720-afe3-818ad418ec62" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_48e5d79a-ce11-4109-b0b4-8c0d3b294f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_98e88c3a-e316-4f4a-930c-2401904a13c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ea78881-9d54-4720-afe3-818ad418ec62" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_98e88c3a-e316-4f4a-930c-2401904a13c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba408fb5-d860-4d3e-b8b6-805a2218fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c81fb4a5-4c6c-4f1a-b281-7cacf3cfb823" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba408fb5-d860-4d3e-b8b6-805a2218fa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53844afd-5f93-4015-b7f5-922dab21cbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_31584753-134c-4286-beb4-eed23c50c669" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53844afd-5f93-4015-b7f5-922dab21cbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4804b379-47a2-4b4a-acc7-e2898e6111f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53844afd-5f93-4015-b7f5-922dab21cbe5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4804b379-47a2-4b4a-acc7-e2898e6111f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_e52848c0-f54f-45c2-b9c3-9a86441171d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53844afd-5f93-4015-b7f5-922dab21cbe5" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_e52848c0-f54f-45c2-b9c3-9a86441171d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_11493399-a0ee-4b75-85b3-6d9160402ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53844afd-5f93-4015-b7f5-922dab21cbe5" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_11493399-a0ee-4b75-85b3-6d9160402ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_d1808438-04b7-43a1-af3c-c8052aa9f1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53844afd-5f93-4015-b7f5-922dab21cbe5" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_d1808438-04b7-43a1-af3c-c8052aa9f1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22af5298-e0bc-4d60-ae95-0835ebd2bf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53844afd-5f93-4015-b7f5-922dab21cbe5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22af5298-e0bc-4d60-ae95-0835ebd2bf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26908eb1-2bc4-4595-9558-406878bd2070" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_31584753-134c-4286-beb4-eed23c50c669" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26908eb1-2bc4-4595-9558-406878bd2070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_adb63f34-8b63-4caf-9412-676a71cbf0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26908eb1-2bc4-4595-9558-406878bd2070" xlink:to="loc_us-gaap_RepaymentsOfDebt_adb63f34-8b63-4caf-9412-676a71cbf0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8980595a-a530-469d-91c7-938ca9cd2075" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26908eb1-2bc4-4595-9558-406878bd2070" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8980595a-a530-469d-91c7-938ca9cd2075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_89afbd04-d890-4b21-a6e4-c082b98bfbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26908eb1-2bc4-4595-9558-406878bd2070" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_89afbd04-d890-4b21-a6e4-c082b98bfbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_42291cb1-ebf7-4165-b7d4-ddb40ed81d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26908eb1-2bc4-4595-9558-406878bd2070" xlink:to="loc_us-gaap_ProceedsFromStockPlans_42291cb1-ebf7-4165-b7d4-ddb40ed81d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_97f827ba-955f-4a51-bfc6-b3f4b91c451c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26908eb1-2bc4-4595-9558-406878bd2070" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_97f827ba-955f-4a51-bfc6-b3f4b91c451c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_53d13c49-3744-4395-aafa-89ed1d956eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_31584753-134c-4286-beb4-eed23c50c669" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_53d13c49-3744-4395-aafa-89ed1d956eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9492dde2-f33d-4b08-ba5d-8b9d609b12e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_31584753-134c-4286-beb4-eed23c50c669" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9492dde2-f33d-4b08-ba5d-8b9d609b12e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4690d726-329c-4f2e-b8c0-38c5ad95f298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_31584753-134c-4286-beb4-eed23c50c669" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4690d726-329c-4f2e-b8c0-38c5ad95f298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ac14ed2b-f02c-4dd4-a951-fd248a2dcb00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_31584753-134c-4286-beb4-eed23c50c669" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ac14ed2b-f02c-4dd4-a951-fd248a2dcb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1c32a367-4d25-4925-bd58-9a124d9b1ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ac14ed2b-f02c-4dd4-a951-fd248a2dcb00" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1c32a367-4d25-4925-bd58-9a124d9b1ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_d7f92389-0d54-4f2d-8c6b-7744817c96d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ac14ed2b-f02c-4dd4-a951-fd248a2dcb00" xlink:to="loc_us-gaap_RestrictedCash_d7f92389-0d54-4f2d-8c6b-7744817c96d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c2ca3b0-0d49-4c45-ae23-8b36c56cb64b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ac14ed2b-f02c-4dd4-a951-fd248a2dcb00" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c2ca3b0-0d49-4c45-ae23-8b36c56cb64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_931f7999-caef-4e77-91c5-eae9df359db5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_31584753-134c-4286-beb4-eed23c50c669" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_931f7999-caef-4e77-91c5-eae9df359db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c5e0ad91-f3e3-4404-a582-f29bc86af101" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_931f7999-caef-4e77-91c5-eae9df359db5" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c5e0ad91-f3e3-4404-a582-f29bc86af101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4c569fbc-3f0b-4a31-9369-9c6f828b736b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_931f7999-caef-4e77-91c5-eae9df359db5" xlink:to="loc_us-gaap_OperatingLeasePayments_4c569fbc-3f0b-4a31-9369-9c6f828b736b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_35c5cd3a-a4c6-48e8-b1fb-ad23da924980" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_931f7999-caef-4e77-91c5-eae9df359db5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_35c5cd3a-a4c6-48e8-b1fb-ad23da924980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_CommencementOfRightOfUseAsset_9b6798a7-f1c1-47e1-8d63-ed7e5c9fc671" xlink:href="edit-20250630.xsd#edit_CommencementOfRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_931f7999-caef-4e77-91c5-eae9df359db5" xlink:to="loc_edit_CommencementOfRightOfUseAsset_9b6798a7-f1c1-47e1-8d63-ed7e5c9fc671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_NonCashTerminationOfRightOfUseAsset_486e45e3-b926-44e9-b76e-077d6a57a445" xlink:href="edit-20250630.xsd#edit_NonCashTerminationOfRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_931f7999-caef-4e77-91c5-eae9df359db5" xlink:to="loc_edit_NonCashTerminationOfRightOfUseAsset_486e45e3-b926-44e9-b76e-077d6a57a445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/NatureofBusiness" xlink:type="simple" xlink:href="edit-20250630.xsd#NatureofBusiness"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/NatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91b6e632-6669-4096-970d-d6044c0a0453" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_cf16d659-2308-4a6d-bf83-3996431e0134" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91b6e632-6669-4096-970d-d6044c0a0453" xlink:to="loc_us-gaap_NatureOfOperations_cf16d659-2308-4a6d-bf83-3996431e0134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="edit-20250630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3dc414a0-ae52-479c-b633-899c2d2bc4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_aa5edfa3-b145-4b0f-b569-6394494adaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3dc414a0-ae52-479c-b633-899c2d2bc4c7" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_aa5edfa3-b145-4b0f-b569-6394494adaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="edit-20250630.xsd#CashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_cba352a7-b6ce-4aee-b957-aa36950df92d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_a2fd6fb1-0c9d-4b57-aac0-1f35a991c210" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_cba352a7-b6ce-4aee-b957-aa36950df92d" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_a2fd6fb1-0c9d-4b57-aac0-1f35a991c210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="edit-20250630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_101c2218-9b46-4e29-9f47-40733c2fe85b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c23c0a44-0201-4e37-8cc4-dfdd6a6d41e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_101c2218-9b46-4e29-9f47-40733c2fe85b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c23c0a44-0201-4e37-8cc4-dfdd6a6d41e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/AccruedExpenses" xlink:type="simple" xlink:href="edit-20250630.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ce147334-2055-4b28-b136-5ad4be71bb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7b0cc2cb-9bfb-4bd0-80d2-40d3be42d7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ce147334-2055-4b28-b136-5ad4be71bb3d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7b0cc2cb-9bfb-4bd0-80d2-40d3be42d7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="edit-20250630.xsd#PropertyandEquipmentnet"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/PropertyandEquipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4c4368bc-68e8-41c8-bc43-8619833e3a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0484e23e-5f3f-413e-a9a8-85ea467b40e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4c4368bc-68e8-41c8-bc43-8619833e3a4e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0484e23e-5f3f-413e-a9a8-85ea467b40e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="edit-20250630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5636d876-6be7-47f9-982c-8cff95a91115" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dc250cdc-d849-4245-ab44-4db590a9c181" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5636d876-6be7-47f9-982c-8cff95a91115" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dc250cdc-d849-4245-ab44-4db590a9c181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="edit-20250630.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_edit_CollaborationAgreementsAbstract_57f15824-22c7-4b60-85a2-2f88a7a576fd" xlink:href="edit-20250630.xsd#edit_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5bba4594-633f-4d2b-8aed-728be1bdb9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_CollaborationAgreementsAbstract_57f15824-22c7-4b60-85a2-2f88a7a576fd" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5bba4594-633f-4d2b-8aed-728be1bdb9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="edit-20250630.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38e30fde-a026-4535-b829-f55dd97fba92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3c2366cd-5449-456e-9cfa-182efbbca012" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38e30fde-a026-4535-b829-f55dd97fba92" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3c2366cd-5449-456e-9cfa-182efbbca012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/NetLossperShare" xlink:type="simple" xlink:href="edit-20250630.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a1eb81c7-b387-4b0f-9c50-0f0dd198df3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_77eaacd7-cb6b-4a40-92da-ad510090d8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a1eb81c7-b387-4b0f-9c50-0f0dd198df3f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_77eaacd7-cb6b-4a40-92da-ad510090d8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/Debt" xlink:type="simple" xlink:href="edit-20250630.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ff3633f7-7e8f-443d-a8b9-06c125877672" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_7708a49c-59c6-4ad0-95b5-22ea5522ee73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ff3633f7-7e8f-443d-a8b9-06c125877672" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_7708a49c-59c6-4ad0-95b5-22ea5522ee73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentCharges" xlink:type="simple" xlink:href="edit-20250630.xsd#RestructuringandImpairmentCharges"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/RestructuringandImpairmentCharges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e91c5948-2cee-417e-887c-073197f25ece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_898d5d28-07d1-4702-997e-616bcc6d88e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e91c5948-2cee-417e-887c-073197f25ece" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_898d5d28-07d1-4702-997e-616bcc6d88e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/Segments" xlink:type="simple" xlink:href="edit-20250630.xsd#Segments"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/Segments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1c9cb0e9-b991-4ace-86c9-8b53d02be57a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_bc334ab0-616c-4153-9d5a-744906ee3d89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1c9cb0e9-b991-4ace-86c9-8b53d02be57a" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_bc334ab0-616c-4153-9d5a-744906ee3d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="edit-20250630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bf46718b-ddcb-4cdb-887f-b4b3d55e796f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9a9e9aec-640a-4b1a-958a-e45e791d3afe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf46718b-ddcb-4cdb-887f-b4b3d55e796f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9a9e9aec-640a-4b1a-958a-e45e791d3afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="edit-20250630.xsd#CashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_17533881-75e5-4f85-ae9a-f42aecee42b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_24bacb0a-3862-4a59-b673-ceb0c6422b22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_17533881-75e5-4f85-ae9a-f42aecee42b6" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_24bacb0a-3862-4a59-b673-ceb0c6422b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="edit-20250630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a6c9bef6-3ed3-4305-b2ed-01f50f95cb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_262c65b3-3ba8-45e2-85ef-0bf804b738c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a6c9bef6-3ed3-4305-b2ed-01f50f95cb1e" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_262c65b3-3ba8-45e2-85ef-0bf804b738c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="edit-20250630.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_207168fb-7fe4-44ed-b91d-ddc9750e5ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_60e4f80c-caa9-4969-ab53-ccbe1455b586" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_207168fb-7fe4-44ed-b91d-ddc9750e5ef6" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_60e4f80c-caa9-4969-ab53-ccbe1455b586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="edit-20250630.xsd#PropertyandEquipmentnetTables"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/PropertyandEquipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8f5dbc4a-ee46-41b3-a625-15676c802fab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_60cfa4f1-9252-4fca-9650-fc550ff1a515" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8f5dbc4a-ee46-41b3-a625-15676c802fab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_60cfa4f1-9252-4fca-9650-fc550ff1a515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="edit-20250630.xsd#CollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_edit_CollaborationAgreementsAbstract_37141a8b-d6c9-4074-8610-2e21a9893c8f" xlink:href="edit-20250630.xsd#edit_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock_30bff040-9f51-47be-beb6-463bfe72254e" xlink:href="edit-20250630.xsd#edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_CollaborationAgreementsAbstract_37141a8b-d6c9-4074-8610-2e21a9893c8f" xlink:to="loc_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock_30bff040-9f51-47be-beb6-463bfe72254e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_38b509a9-6aa3-4c63-bf37-941340fbd170" xlink:href="edit-20250630.xsd#edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_CollaborationAgreementsAbstract_37141a8b-d6c9-4074-8610-2e21a9893c8f" xlink:to="loc_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_38b509a9-6aa3-4c63-bf37-941340fbd170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="edit-20250630.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79878699-0819-4a30-918a-5c6de2db4896" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4adf4e7a-dd74-47a4-b211-af7ea099f654" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79878699-0819-4a30-918a-5c6de2db4896" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4adf4e7a-dd74-47a4-b211-af7ea099f654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_946fb338-091b-4115-9134-5581fd569a13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79878699-0819-4a30-918a-5c6de2db4896" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_946fb338-091b-4115-9134-5581fd569a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6ccf76f3-bd52-4aee-9ffd-985e834a2b04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79878699-0819-4a30-918a-5c6de2db4896" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6ccf76f3-bd52-4aee-9ffd-985e834a2b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="edit-20250630.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2823823b-226d-4ece-9e95-d300395e1fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_81773265-cc8c-4405-8ee0-2b69456f86db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2823823b-226d-4ece-9e95-d300395e1fcf" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_81773265-cc8c-4405-8ee0-2b69456f86db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/DebtTables" xlink:type="simple" xlink:href="edit-20250630.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1afdd678-19f1-4e34-b474-481592f02144" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_bbb6be9b-d80f-4873-be6f-0e5bf62c8bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1afdd678-19f1-4e34-b474-481592f02144" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_bbb6be9b-d80f-4873-be6f-0e5bf62c8bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesTables" xlink:type="simple" xlink:href="edit-20250630.xsd#RestructuringandImpairmentChargesTables"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f407d8fb-6234-4bce-8b61-8e364f5fd9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_59928377-e6fc-44b9-8de8-12eb9ecdec79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f407d8fb-6234-4bce-8b61-8e364f5fd9ae" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_59928377-e6fc-44b9-8de8-12eb9ecdec79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock_9da40f97-dd7c-4a8f-9a1c-493e41791de3" xlink:href="edit-20250630.xsd#edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f407d8fb-6234-4bce-8b61-8e364f5fd9ae" xlink:to="loc_edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock_9da40f97-dd7c-4a8f-9a1c-493e41791de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ScheduleOfContractTerminationCostsTableTextBlock_c2e69597-01c8-40d5-9fef-c26519b92851" xlink:href="edit-20250630.xsd#edit_ScheduleOfContractTerminationCostsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f407d8fb-6234-4bce-8b61-8e364f5fd9ae" xlink:to="loc_edit_ScheduleOfContractTerminationCostsTableTextBlock_c2e69597-01c8-40d5-9fef-c26519b92851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/SegmentsTables" xlink:type="simple" xlink:href="edit-20250630.xsd#SegmentsTables"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/SegmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2801b86d-de97-4bfd-bfac-b43819da734a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f54c2773-b254-4680-b18d-a51c916fcf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2801b86d-de97-4bfd-bfac-b43819da734a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f54c2773-b254-4680-b18d-a51c916fcf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#NatureofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/NatureofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_53c65b04-f3d8-4651-bf03-069bcb8d69d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_74ea540d-f946-4db6-a5c2-bda7800695f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_53c65b04-f3d8-4651-bf03-069bcb8d69d4" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_74ea540d-f946-4db6-a5c2-bda7800695f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7a960c32-a35e-4fe6-b768-01940db169d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_74ea540d-f946-4db6-a5c2-bda7800695f7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7a960c32-a35e-4fe6-b768-01940db169d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8aacdaf7-267e-4fa1-becd-7320d4868520" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7a960c32-a35e-4fe6-b768-01940db169d1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8aacdaf7-267e-4fa1-becd-7320d4868520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AtMarketOfferingMember_74e8f67c-609f-4453-83b4-f8025bb3f07f" xlink:href="edit-20250630.xsd#edit_AtMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8aacdaf7-267e-4fa1-becd-7320d4868520" xlink:to="loc_edit_AtMarketOfferingMember_74e8f67c-609f-4453-83b4-f8025bb3f07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_74ea540d-f946-4db6-a5c2-bda7800695f7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_232850da-06e0-44d4-9733-0aef1daf771d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_232850da-06e0-44d4-9733-0aef1daf771d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal_8cecbd1c-206e-4e90-b1e0-bd32376aab57" xlink:href="edit-20250630.xsd#edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal_8cecbd1c-206e-4e90-b1e0-bd32376aab57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued_d7090bd0-2e71-4259-ab59-0c1a1cf4c140" xlink:href="edit-20250630.xsd#edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued_d7090bd0-2e71-4259-ab59-0c1a1cf4c140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_db64aef6-c9d9-49e2-8324-c61b02a693e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_db64aef6-c9d9-49e2-8324-c61b02a693e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7a6d2d17-20bb-417b-be3b-3ab70446092c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7a6d2d17-20bb-417b-be3b-3ab70446092c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable_6d20a0f1-f40a-4614-af0e-fff57d961454" xlink:href="edit-20250630.xsd#edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable_6d20a0f1-f40a-4614-af0e-fff57d961454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2da2842e-3441-4c5d-881f-4b65b5447fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0a8c2c1-f0e3-4c8f-a992-a5ee3e79b953" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2da2842e-3441-4c5d-881f-4b65b5447fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0bf9df19-c4e5-4f1e-991a-92bd359faa51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0b827177-6260-42d6-93f7-ceffee71d9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0bf9df19-c4e5-4f1e-991a-92bd359faa51" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0b827177-6260-42d6-93f7-ceffee71d9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f2b4332a-54fe-4164-bbfd-b29077f8ddc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0b827177-6260-42d6-93f7-ceffee71d9c2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f2b4332a-54fe-4164-bbfd-b29077f8ddc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a0638897-eada-4bf9-a0c5-39e189607ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f2b4332a-54fe-4164-bbfd-b29077f8ddc1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a0638897-eada-4bf9-a0c5-39e189607ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2d910fbe-832a-4006-b3ac-e108461bbc96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a0638897-eada-4bf9-a0c5-39e189607ac8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2d910fbe-832a-4006-b3ac-e108461bbc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b0410ade-154c-40a0-bfa8-b2b733ac34d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a0638897-eada-4bf9-a0c5-39e189607ac8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b0410ade-154c-40a0-bfa8-b2b733ac34d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f7ae5e4a-31a8-4586-96e6-1d934bb93d87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a0638897-eada-4bf9-a0c5-39e189607ac8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f7ae5e4a-31a8-4586-96e6-1d934bb93d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0b827177-6260-42d6-93f7-ceffee71d9c2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_49cd5bee-e261-4d0d-813e-bd07a3e35c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_49cd5bee-e261-4d0d-813e-bd07a3e35c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_3fbe02d1-a1c0-439f-ae6d-d52bc70269ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_3fbe02d1-a1c0-439f-ae6d-d52bc70269ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a123b942-ec55-4d8d-b274-bdefe8d4ecd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a123b942-ec55-4d8d-b274-bdefe8d4ecd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_de0f918a-9a69-4004-97ee-eb6f15ea65c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_de0f918a-9a69-4004-97ee-eb6f15ea65c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2426e469-957d-4eab-8d6b-df2fe6d98b67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4ccdb705-29a3-42a7-af76-c02812f25522" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2426e469-957d-4eab-8d6b-df2fe6d98b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#CashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_b1ec567b-1f40-4396-8ec0-97f4511f260b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_11359de7-68a4-4d38-a708-35d2154738bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_b1ec567b-1f40-4396-8ec0-97f4511f260b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_11359de7-68a4-4d38-a708-35d2154738bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_MarketableSecuritiesNoncurrentNumberOfSecurities_55bdd861-3a85-4f1a-8348-592d5e2b39df" xlink:href="edit-20250630.xsd#edit_MarketableSecuritiesNoncurrentNumberOfSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_b1ec567b-1f40-4396-8ec0-97f4511f260b" xlink:to="loc_edit_MarketableSecuritiesNoncurrentNumberOfSecurities_55bdd861-3a85-4f1a-8348-592d5e2b39df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_MarketableSecuritiesRemainingMaturityTerm_fd3ac3aa-6286-4661-851b-6db83ced2f6b" xlink:href="edit-20250630.xsd#edit_MarketableSecuritiesRemainingMaturityTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_b1ec567b-1f40-4396-8ec0-97f4511f260b" xlink:to="loc_edit_MarketableSecuritiesRemainingMaturityTerm_fd3ac3aa-6286-4661-851b-6db83ced2f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_c9959e2a-6e1e-4bbe-9871-8c6806c8bdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_b1ec567b-1f40-4396-8ec0-97f4511f260b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_c9959e2a-6e1e-4bbe-9871-8c6806c8bdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cc92c367-0c1e-480b-ba7a-6fe087ec71b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_610066db-35d4-43b0-823b-192941134765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cc92c367-0c1e-480b-ba7a-6fe087ec71b8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_610066db-35d4-43b0-823b-192941134765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d28fc9c-f915-4179-9a59-a9963075cd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_610066db-35d4-43b0-823b-192941134765" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d28fc9c-f915-4179-9a59-a9963075cd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b25d7a9-0e93-4a1c-a5e1-1594d2c23b85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d28fc9c-f915-4179-9a59-a9963075cd7f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b25d7a9-0e93-4a1c-a5e1-1594d2c23b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_275ff453-f681-4901-af20-82525ab9044f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b25d7a9-0e93-4a1c-a5e1-1594d2c23b85" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_275ff453-f681-4901-af20-82525ab9044f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_424de93a-9d31-4b8f-a36b-f33ffd3a7197" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_610066db-35d4-43b0-823b-192941134765" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_424de93a-9d31-4b8f-a36b-f33ffd3a7197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a777821-724b-4e36-ad43-953f48f7a464" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_424de93a-9d31-4b8f-a36b-f33ffd3a7197" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a777821-724b-4e36-ad43-953f48f7a464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4e690024-e04a-4dc6-85a8-ab761528a923" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a777821-724b-4e36-ad43-953f48f7a464" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4e690024-e04a-4dc6-85a8-ab761528a923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8d32e5c0-4d3d-4468-aae6-9f7b3455c05d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a777821-724b-4e36-ad43-953f48f7a464" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8d32e5c0-4d3d-4468-aae6-9f7b3455c05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_309e3632-b26b-4cac-9295-89bb71088788" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a777821-724b-4e36-ad43-953f48f7a464" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_309e3632-b26b-4cac-9295-89bb71088788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_8ac4a6e0-3c50-4372-a0eb-a2696ef8ceb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_610066db-35d4-43b0-823b-192941134765" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_8ac4a6e0-3c50-4372-a0eb-a2696ef8ceb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77716b20-0108-442a-9a29-04f5cda1b5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8ac4a6e0-3c50-4372-a0eb-a2696ef8ceb4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77716b20-0108-442a-9a29-04f5cda1b5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_30740f52-4325-40d7-9daf-15354e18f303" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_77716b20-0108-442a-9a29-04f5cda1b5f6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_30740f52-4325-40d7-9daf-15354e18f303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_82309d05-258b-4091-b2e8-5ea8efe2cdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_610066db-35d4-43b0-823b-192941134765" xlink:to="loc_us-gaap_FinancialInstrumentAxis_82309d05-258b-4091-b2e8-5ea8efe2cdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_457e64b5-dca7-4489-954a-e089bd2bc060" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_82309d05-258b-4091-b2e8-5ea8efe2cdf9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_457e64b5-dca7-4489-954a-e089bd2bc060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_75c97052-95f1-4118-a946-b56e0b7dccd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_457e64b5-dca7-4489-954a-e089bd2bc060" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_75c97052-95f1-4118-a946-b56e0b7dccd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5914f54f-4f1a-4452-ab59-cddbdfed0ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_457e64b5-dca7-4489-954a-e089bd2bc060" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5914f54f-4f1a-4452-ab59-cddbdfed0ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dbcbe76b-1a49-495c-9774-3a0e445fbc30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_610066db-35d4-43b0-823b-192941134765" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dbcbe76b-1a49-495c-9774-3a0e445fbc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_de48d646-e353-4d8e-bdba-1e17c885b2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dbcbe76b-1a49-495c-9774-3a0e445fbc30" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_de48d646-e353-4d8e-bdba-1e17c885b2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1d3d8052-5275-4df3-a020-9acebc579320" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_de48d646-e353-4d8e-bdba-1e17c885b2dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1d3d8052-5275-4df3-a020-9acebc579320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_360033f7-5a5a-436a-a807-7722f93e0bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_de48d646-e353-4d8e-bdba-1e17c885b2dd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_360033f7-5a5a-436a-a807-7722f93e0bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_d3e64dc9-9f90-4c04-8f82-27ca26e4aa63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_de48d646-e353-4d8e-bdba-1e17c885b2dd" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_d3e64dc9-9f90-4c04-8f82-27ca26e4aa63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_32e023a4-8009-4f88-bf58-e5836dbb629d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_de48d646-e353-4d8e-bdba-1e17c885b2dd" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_32e023a4-8009-4f88-bf58-e5836dbb629d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a0c3e5ff-16b7-48dd-991f-03b513d745f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramTable_21934dcf-1e0c-447c-bc12-c18bd71f9f92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a0c3e5ff-16b7-48dd-991f-03b513d745f6" xlink:to="loc_us-gaap_SupplierFinanceProgramTable_21934dcf-1e0c-447c-bc12-c18bd71f9f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_138fb55e-d40c-4532-9ce4-358a475b0eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramTable_21934dcf-1e0c-447c-bc12-c18bd71f9f92" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_138fb55e-d40c-4532-9ce4-358a475b0eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_cb17692b-da89-4750-9715-3cb7ccba64ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_138fb55e-d40c-4532-9ce4-358a475b0eb8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_cb17692b-da89-4750-9715-3cb7ccba64ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_EmployeeTerminationBenefitsMember_d43021d3-e670-43b0-b663-4ac03cde0701" xlink:href="edit-20250630.xsd#edit_EmployeeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cb17692b-da89-4750-9715-3cb7ccba64ec" xlink:to="loc_edit_EmployeeTerminationBenefitsMember_d43021d3-e670-43b0-b663-4ac03cde0701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember_ed9c7cd8-dee8-4317-8b16-e330c26069f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractTerminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cb17692b-da89-4750-9715-3cb7ccba64ec" xlink:to="loc_us-gaap_ContractTerminationMember_ed9c7cd8-dee8-4317-8b16-e330c26069f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramTable_21934dcf-1e0c-447c-bc12-c18bd71f9f92" xlink:to="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent_c21e44c6-7ebd-49c2-8846-423929511838" xlink:href="edit-20250630.xsd#edit_AccruedExternalResearchAndDevelopmentExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent_c21e44c6-7ebd-49c2-8846-423929511838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_75b5e4d2-d36e-4e6f-a2c0-a6d427d77d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_75b5e4d2-d36e-4e6f-a2c0-a6d427d77d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_SublicenseAndLicenseFeesCurrent_9b377a85-4795-4ed2-9786-af685781f25c" xlink:href="edit-20250630.xsd#edit_SublicenseAndLicenseFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_edit_SublicenseAndLicenseFeesCurrent_9b377a85-4795-4ed2-9786-af685781f25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_IntellectualPropertyAndPatentRelatedFeesCurrent_5e7a343f-2258-47d0-8041-1f312f5b5ec3" xlink:href="edit-20250630.xsd#edit_IntellectualPropertyAndPatentRelatedFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_edit_IntellectualPropertyAndPatentRelatedFeesCurrent_5e7a343f-2258-47d0-8041-1f312f5b5ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a36fbfc9-d3fe-45aa-b02a-219de938d1db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a36fbfc9-d3fe-45aa-b02a-219de938d1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_5691d628-75cc-4ac4-bb6c-7657c8ebce08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_us-gaap_RestructuringReserveCurrent_5691d628-75cc-4ac4-bb6c-7657c8ebce08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_03d44ea8-518a-454b-8bd5-2f326d054b65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_03d44ea8-518a-454b-8bd5-2f326d054b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b1ac4c25-66e3-43de-9236-eb672ccf360a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramLineItems_0ff4b251-b878-4b5b-ace1-54894b74fa83" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b1ac4c25-66e3-43de-9236-eb672ccf360a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#PropertyandEquipmentnetDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3084edf-026a-4d82-89db-2e7e515c125b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2c774a1-728e-44a6-978a-856ed6e2306f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3084edf-026a-4d82-89db-2e7e515c125b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2c774a1-728e-44a6-978a-856ed6e2306f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2b0ef68b-960f-469f-8696-a69a0e9dec54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2c774a1-728e-44a6-978a-856ed6e2306f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2b0ef68b-960f-469f-8696-a69a0e9dec54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2b0ef68b-960f-469f-8696-a69a0e9dec54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LaboratoryAndManufacturingEquipmentMember_cd979a9d-d07d-42fa-b56f-64d4540aa454" xlink:href="edit-20250630.xsd#edit_LaboratoryAndManufacturingEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:to="loc_edit_LaboratoryAndManufacturingEquipmentMember_cd979a9d-d07d-42fa-b56f-64d4540aa454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9d80cbb9-37eb-486a-a7bc-da430c62ad63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_9d80cbb9-37eb-486a-a7bc-da430c62ad63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_7f42440a-60ca-4115-9501-8f3054936294" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:to="loc_us-gaap_ComputerEquipmentMember_7f42440a-60ca-4115-9501-8f3054936294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_17df4f28-108b-4a61-bcc1-c8faffc712d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:to="loc_us-gaap_ConstructionInProgressMember_17df4f28-108b-4a61-bcc1-c8faffc712d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_61acd1e1-de9c-4623-84a0-b03677d17c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_61acd1e1-de9c-4623-84a0-b03677d17c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e58cbbcf-2c92-4607-8ac0-be11f6312f23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb3455d5-64d9-4332-bdfd-c638ec5f13e2" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e58cbbcf-2c92-4607-8ac0-be11f6312f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b22a39e-c75a-4257-b18a-d1811bc50b42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2c774a1-728e-44a6-978a-856ed6e2306f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b22a39e-c75a-4257-b18a-d1811bc50b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5c4ff359-b9e3-4c7c-b6fa-5442d6fc0746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b22a39e-c75a-4257-b18a-d1811bc50b42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5c4ff359-b9e3-4c7c-b6fa-5442d6fc0746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bbb93ab4-564d-4736-b193-54b148dd4c57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b22a39e-c75a-4257-b18a-d1811bc50b42" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bbb93ab4-564d-4736-b193-54b148dd4c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fd949f71-a043-4aef-b5a0-1535d062d7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b22a39e-c75a-4257-b18a-d1811bc50b42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fd949f71-a043-4aef-b5a0-1535d062d7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_746007ac-29e4-4139-a6b1-c1973f687bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_c6dab3ff-fdbb-4f30-9317-20699841f7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_746007ac-29e4-4139-a6b1-c1973f687bbb" xlink:to="loc_us-gaap_OtherCommitmentsTable_c6dab3ff-fdbb-4f30-9317-20699841f7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_7ee538e5-5f90-4168-9323-fc05917c9ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_c6dab3ff-fdbb-4f30-9317-20699841f7d4" xlink:to="loc_us-gaap_OtherCommitmentsAxis_7ee538e5-5f90-4168-9323-fc05917c9ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_cf9d593f-a76b-4848-b328-1618f09b53e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_7ee538e5-5f90-4168-9323-fc05917c9ae0" xlink:to="loc_us-gaap_OtherCommitmentsDomain_cf9d593f-a76b-4848-b328-1618f09b53e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicensorExpenseReimbursementsMember_952ce4c1-dd6e-463a-ad59-a24f516b7a77" xlink:href="edit-20250630.xsd#edit_LicensorExpenseReimbursementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_cf9d593f-a76b-4848-b328-1618f09b53e4" xlink:to="loc_edit_LicensorExpenseReimbursementsMember_952ce4c1-dd6e-463a-ad59-a24f516b7a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_86ba8c7c-1ebd-473c-b0b9-786ad3072ce8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_c6dab3ff-fdbb-4f30-9317-20699841f7d4" xlink:to="loc_srt_CounterpartyNameAxis_86ba8c7c-1ebd-473c-b0b9-786ad3072ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82146028-eeb6-4c8a-b568-2f27d404a9a7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_86ba8c7c-1ebd-473c-b0b9-786ad3072ce8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82146028-eeb6-4c8a-b568-2f27d404a9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicenseAndServiceAgreementMember_4124f639-2fc9-430a-bf22-06b081ed6733" xlink:href="edit-20250630.xsd#edit_LicenseAndServiceAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82146028-eeb6-4c8a-b568-2f27d404a9a7" xlink:to="loc_edit_LicenseAndServiceAgreementMember_4124f639-2fc9-430a-bf22-06b081ed6733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_2e4d7744-b8bb-461f-92c3-e39a76c2c3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_c6dab3ff-fdbb-4f30-9317-20699841f7d4" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_2e4d7744-b8bb-461f-92c3-e39a76c2c3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalAndContractServicesExpense_abd15aaf-9a3d-486c-b03c-684f97e3bdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2e4d7744-b8bb-461f-92c3-e39a76c2c3a0" xlink:to="loc_us-gaap_ProfessionalAndContractServicesExpense_abd15aaf-9a3d-486c-b03c-684f97e3bdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_OperatingLeaseTerminationNotificationPeriod_ff382d08-8b25-45a5-873a-e5f3a1b495fa" xlink:href="edit-20250630.xsd#edit_OperatingLeaseTerminationNotificationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2e4d7744-b8bb-461f-92c3-e39a76c2c3a0" xlink:to="loc_edit_OperatingLeaseTerminationNotificationPeriod_ff382d08-8b25-45a5-873a-e5f3a1b495fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f63cdcc-0c00-4987-99ce-3d447710df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2e4d7744-b8bb-461f-92c3-e39a76c2c3a0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f63cdcc-0c00-4987-99ce-3d447710df0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_eb3aa92d-624d-4739-9996-e7b47e9360fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2e4d7744-b8bb-461f-92c3-e39a76c2c3a0" xlink:to="loc_us-gaap_OperatingLeasePayments_eb3aa92d-624d-4739-9996-e7b47e9360fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_edit_CollaborationAgreementsAbstract_9850d35d-2d5b-49e1-ab41-a715412c3ac1" xlink:href="edit-20250630.xsd#edit_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrentAbstract_834a6226-7908-4d27-a05f-177e7fe56847" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_CollaborationAgreementsAbstract_9850d35d-2d5b-49e1-ab41-a715412c3ac1" xlink:to="loc_us-gaap_ReceivablesNetCurrentAbstract_834a6226-7908-4d27-a05f-177e7fe56847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ReceivablesNetCurrentRollForward_d8f66133-54f8-4373-aca6-fc5b5c2cc2c5" xlink:href="edit-20250630.xsd#edit_ReceivablesNetCurrentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract_834a6226-7908-4d27-a05f-177e7fe56847" xlink:to="loc_edit_ReceivablesNetCurrentRollForward_d8f66133-54f8-4373-aca6-fc5b5c2cc2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_9c072f37-f14f-4e72-8e2d-57b0d80887de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_ReceivablesNetCurrentRollForward_d8f66133-54f8-4373-aca6-fc5b5c2cc2c5" xlink:to="loc_us-gaap_ReceivablesNetCurrent_9c072f37-f14f-4e72-8e2d-57b0d80887de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AccountsReceivableAdditions_a0444a7b-f15b-4e3e-8517-fe1236b87138" xlink:href="edit-20250630.xsd#edit_AccountsReceivableAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_ReceivablesNetCurrentRollForward_d8f66133-54f8-4373-aca6-fc5b5c2cc2c5" xlink:to="loc_edit_AccountsReceivableAdditions_a0444a7b-f15b-4e3e-8517-fe1236b87138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AccountsReceivableDeductions_2d2637db-2173-4500-98a5-32f597473a33" xlink:href="edit-20250630.xsd#edit_AccountsReceivableDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_ReceivablesNetCurrentRollForward_d8f66133-54f8-4373-aca6-fc5b5c2cc2c5" xlink:to="loc_edit_AccountsReceivableDeductions_2d2637db-2173-4500-98a5-32f597473a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_ef41e06c-f18b-4594-8d15-5dac234076d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_ReceivablesNetCurrentRollForward_d8f66133-54f8-4373-aca6-fc5b5c2cc2c5" xlink:to="loc_us-gaap_ReceivablesNetCurrent_ef41e06c-f18b-4594-8d15-5dac234076d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_810ecf3f-9a89-4a61-a56b-20880529ff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_CollaborationAgreementsAbstract_9850d35d-2d5b-49e1-ab41-a715412c3ac1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_810ecf3f-9a89-4a61-a56b-20880529ff5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ContractWithCustomerLiabilityRollForward_76ab87dd-e2eb-4c6c-99ef-1212aa538d9f" xlink:href="edit-20250630.xsd#edit_ContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_810ecf3f-9a89-4a61-a56b-20880529ff5e" xlink:to="loc_edit_ContractWithCustomerLiabilityRollForward_76ab87dd-e2eb-4c6c-99ef-1212aa538d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1b0999e7-fd6c-4295-9669-a6a3cf79a9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_ContractWithCustomerLiabilityRollForward_76ab87dd-e2eb-4c6c-99ef-1212aa538d9f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1b0999e7-fd6c-4295-9669-a6a3cf79a9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ContractWithCustomerLiabilityAdditions_fb45c767-db90-4c67-99b9-700ee6a1fb4b" xlink:href="edit-20250630.xsd#edit_ContractWithCustomerLiabilityAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_ContractWithCustomerLiabilityRollForward_76ab87dd-e2eb-4c6c-99ef-1212aa538d9f" xlink:to="loc_edit_ContractWithCustomerLiabilityAdditions_fb45c767-db90-4c67-99b9-700ee6a1fb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ContractWithCustomerLiabilityDeductions_5a0667f2-4b6c-4e64-aa99-cf1cd1541014" xlink:href="edit-20250630.xsd#edit_ContractWithCustomerLiabilityDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_ContractWithCustomerLiabilityRollForward_76ab87dd-e2eb-4c6c-99ef-1212aa538d9f" xlink:to="loc_edit_ContractWithCustomerLiabilityDeductions_5a0667f2-4b6c-4e64-aa99-cf1cd1541014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_09389dfd-6c91-466d-a82e-07f3822d39cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_ContractWithCustomerLiabilityRollForward_76ab87dd-e2eb-4c6c-99ef-1212aa538d9f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_09389dfd-6c91-466d-a82e-07f3822d39cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CollaborationAgreementsChangeinContractAssetsandContractLiabilitiesDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#CollaborationAgreementsChangeinContractAssetsandContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CollaborationAgreementsChangeinContractAssetsandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_edit_CollaborationAgreementsAbstract_3c8dbaf3-dd10-4b7a-b25f-650304b9aa17" xlink:href="edit-20250630.xsd#edit_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_6ac4381e-5581-4e49-a49d-5623b64276da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_CollaborationAgreementsAbstract_3c8dbaf3-dd10-4b7a-b25f-650304b9aa17" xlink:to="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_6ac4381e-5581-4e49-a49d-5623b64276da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_13a520e4-cd87-4085-baf2-885fdc0536d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_6ac4381e-5581-4e49-a49d-5623b64276da" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_13a520e4-cd87-4085-baf2-885fdc0536d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_2a0a1824-b550-4828-bacd-43dae7ad3db3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_6ac4381e-5581-4e49-a49d-5623b64276da" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_2a0a1824-b550-4828-bacd-43dae7ad3db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#CollaborationAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_edit_CollaborationAgreementsAbstract_68c43e80-f19c-466f-ab3a-1ee6f8481d2e" xlink:href="edit-20250630.xsd#edit_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_299ca9ee-c03d-4da3-85f2-3ffdc78dfe99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_CollaborationAgreementsAbstract_68c43e80-f19c-466f-ab3a-1ee6f8481d2e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_299ca9ee-c03d-4da3-85f2-3ffdc78dfe99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9161527c-e995-475e-979e-0843055e214e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_299ca9ee-c03d-4da3-85f2-3ffdc78dfe99" xlink:to="loc_srt_CounterpartyNameAxis_9161527c-e995-475e-979e-0843055e214e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b708db5e-1616-459c-9adc-0e469c4b272b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9161527c-e995-475e-979e-0843055e214e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b708db5e-1616-459c-9adc-0e469c4b272b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_BristolMyersSquibbCompanyMember_c043fc70-9355-442f-a91a-98cb5fb5df17" xlink:href="edit-20250630.xsd#edit_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b708db5e-1616-459c-9adc-0e469c4b272b" xlink:to="loc_edit_BristolMyersSquibbCompanyMember_c043fc70-9355-442f-a91a-98cb5fb5df17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_07b304de-e9cf-4dcf-9def-550a64d4dd68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_299ca9ee-c03d-4da3-85f2-3ffdc78dfe99" xlink:to="loc_us-gaap_TypeOfArrangementAxis_07b304de-e9cf-4dcf-9def-550a64d4dd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_762bf6e6-12f1-4228-b7bf-5bf764bf9e31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_07b304de-e9cf-4dcf-9def-550a64d4dd68" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_762bf6e6-12f1-4228-b7bf-5bf764bf9e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AmendedCollaborationAgreement2019Member_b249df0f-4a95-47de-9b5e-5ef6180b94dc" xlink:href="edit-20250630.xsd#edit_AmendedCollaborationAgreement2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_762bf6e6-12f1-4228-b7bf-5bf764bf9e31" xlink:to="loc_edit_AmendedCollaborationAgreement2019Member_b249df0f-4a95-47de-9b5e-5ef6180b94dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7df2e5-e67c-439b-91a6-d65f5181b0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_299ca9ee-c03d-4da3-85f2-3ffdc78dfe99" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7df2e5-e67c-439b-91a6-d65f5181b0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AgreementExtensionPeriodOptionsToExtend_29cf6fff-4409-4160-8810-2f9601a1f95e" xlink:href="edit-20250630.xsd#edit_AgreementExtensionPeriodOptionsToExtend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7df2e5-e67c-439b-91a6-d65f5181b0fd" xlink:to="loc_edit_AgreementExtensionPeriodOptionsToExtend_29cf6fff-4409-4160-8810-2f9601a1f95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0df8ba7b-b711-4404-ab6a-2d65a6e1a690" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7df2e5-e67c-439b-91a6-d65f5181b0fd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0df8ba7b-b711-4404-ab6a-2d65a6e1a690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5472c2a5-41f6-4fa2-b11e-fc3bf2b79d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7df2e5-e67c-439b-91a6-d65f5181b0fd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5472c2a5-41f6-4fa2-b11e-fc3bf2b79d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f0584bf-ae13-4c83-af95-646e61bbc8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_145e34d2-42d7-4e1d-a236-1a8fd09cebd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f0584bf-ae13-4c83-af95-646e61bbc8d6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_145e34d2-42d7-4e1d-a236-1a8fd09cebd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_96184763-91a6-43f3-8247-6ee64bfd92ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_145e34d2-42d7-4e1d-a236-1a8fd09cebd0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_96184763-91a6-43f3-8247-6ee64bfd92ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_48a1b650-6766-4a33-bed8-f8d9321f0600" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_96184763-91a6-43f3-8247-6ee64bfd92ba" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_48a1b650-6766-4a33-bed8-f8d9321f0600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_745cd47d-a892-4ced-9663-26ed886fa343" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_48a1b650-6766-4a33-bed8-f8d9321f0600" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_745cd47d-a892-4ced-9663-26ed886fa343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_05c88ec6-0cc2-457b-b1ef-5ca7a59ce77d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_48a1b650-6766-4a33-bed8-f8d9321f0600" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_05c88ec6-0cc2-457b-b1ef-5ca7a59ce77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0b63d3e-13d6-476b-b46d-45c32f99deb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_145e34d2-42d7-4e1d-a236-1a8fd09cebd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0b63d3e-13d6-476b-b46d-45c32f99deb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_af3558c9-165e-497b-b8b3-19a3d88803f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0b63d3e-13d6-476b-b46d-45c32f99deb3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_af3558c9-165e-497b-b8b3-19a3d88803f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#StockbasedCompensationRestrictedStockandStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75c82b45-2ab5-43e1-9fb8-0fec4327eb41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c388510a-9dd6-48d4-b3c3-4dfa3b26c4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75c82b45-2ab5-43e1-9fb8-0fec4327eb41" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c388510a-9dd6-48d4-b3c3-4dfa3b26c4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fb8c0152-0673-440a-b630-f9ac4de28db3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c388510a-9dd6-48d4-b3c3-4dfa3b26c4d0" xlink:to="loc_us-gaap_AwardTypeAxis_fb8c0152-0673-440a-b630-f9ac4de28db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c889510-1c9c-4ecd-8d69-e07448911df9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fb8c0152-0673-440a-b630-f9ac4de28db3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c889510-1c9c-4ecd-8d69-e07448911df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_02b093c3-8ec9-41fd-aab3-204476d905c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c889510-1c9c-4ecd-8d69-e07448911df9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_02b093c3-8ec9-41fd-aab3-204476d905c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c9cdd7ec-1888-4ae3-9888-47eff6384ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c889510-1c9c-4ecd-8d69-e07448911df9" xlink:to="loc_us-gaap_PerformanceSharesMember_c9cdd7ec-1888-4ae3-9888-47eff6384ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e10e3144-3d04-498a-b4e1-e47e9cc4cb39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c889510-1c9c-4ecd-8d69-e07448911df9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e10e3144-3d04-498a-b4e1-e47e9cc4cb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_e9a8ed41-8262-460d-9990-8c945880c7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c388510a-9dd6-48d4-b3c3-4dfa3b26c4d0" xlink:to="loc_us-gaap_GranteeStatusAxis_e9a8ed41-8262-460d-9990-8c945880c7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_eeaf6ca7-4c6a-445c-b091-af16202ddd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_e9a8ed41-8262-460d-9990-8c945880c7cb" xlink:to="loc_us-gaap_GranteeStatusDomain_eeaf6ca7-4c6a-445c-b091-af16202ddd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_412507ff-2184-4791-a539-1200772ec154" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_eeaf6ca7-4c6a-445c-b091-af16202ddd6c" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_412507ff-2184-4791-a539-1200772ec154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c388510a-9dd6-48d4-b3c3-4dfa3b26c4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bc2d2173-abe9-4d8e-9597-a21f60073fea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bc2d2173-abe9-4d8e-9597-a21f60073fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dcdeaa41-7cfb-4af8-a301-4665bf9b37e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bc2d2173-abe9-4d8e-9597-a21f60073fea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dcdeaa41-7cfb-4af8-a301-4665bf9b37e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_63734f57-2d8d-4683-bde4-18dab9895a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bc2d2173-abe9-4d8e-9597-a21f60073fea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_63734f57-2d8d-4683-bde4-18dab9895a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dca4fe9a-ae69-416b-8f18-273dc9282c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bc2d2173-abe9-4d8e-9597-a21f60073fea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dca4fe9a-ae69-416b-8f18-273dc9282c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3b9f53f6-7dac-4540-bd9e-50fa081bd396" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bc2d2173-abe9-4d8e-9597-a21f60073fea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3b9f53f6-7dac-4540-bd9e-50fa081bd396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dbc01f0b-7c26-40f0-b388-5eab76869549" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bc2d2173-abe9-4d8e-9597-a21f60073fea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dbc01f0b-7c26-40f0-b388-5eab76869549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_31deeb58-9e3c-4bcc-85ca-f4d180a5c418" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_31deeb58-9e3c-4bcc-85ca-f4d180a5c418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1bc2f676-1f5a-4ba6-bd33-5f7a76419748" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1bc2f676-1f5a-4ba6-bd33-5f7a76419748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7900fcb4-152b-4c88-942b-8ce9f9751554" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1bc2f676-1f5a-4ba6-bd33-5f7a76419748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7900fcb4-152b-4c88-942b-8ce9f9751554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78047328-505d-4fbd-b05c-7bd55e5ee8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1bc2f676-1f5a-4ba6-bd33-5f7a76419748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78047328-505d-4fbd-b05c-7bd55e5ee8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b8628f34-cd8e-498f-b425-05db2ddf8aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1bc2f676-1f5a-4ba6-bd33-5f7a76419748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b8628f34-cd8e-498f-b425-05db2ddf8aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fda33d6d-cf40-4ccd-9040-f1ba5796aaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1bc2f676-1f5a-4ba6-bd33-5f7a76419748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fda33d6d-cf40-4ccd-9040-f1ba5796aaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b852cd21-b611-4640-b0f1-489bba3a134b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1bc2f676-1f5a-4ba6-bd33-5f7a76419748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b852cd21-b611-4640-b0f1-489bba3a134b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d817681c-fca0-4e6a-941f-451f6a9c8b31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d817681c-fca0-4e6a-941f-451f6a9c8b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6bbfe6d9-e579-40aa-88bb-01cf7737062e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6bbfe6d9-e579-40aa-88bb-01cf7737062e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04395de8-7421-42f9-83c4-b6758a6bf783" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04395de8-7421-42f9-83c4-b6758a6bf783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19f0b28f-0d66-483a-add9-86086083231a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04395de8-7421-42f9-83c4-b6758a6bf783" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19f0b28f-0d66-483a-add9-86086083231a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_52824c94-14ec-4e38-a366-c8a9c301d305" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04395de8-7421-42f9-83c4-b6758a6bf783" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_52824c94-14ec-4e38-a366-c8a9c301d305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c43b5c1-226b-422d-942d-cf3282c93a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04395de8-7421-42f9-83c4-b6758a6bf783" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c43b5c1-226b-422d-942d-cf3282c93a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bcf868c0-76ed-496b-b9c8-5836dd68eeda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04395de8-7421-42f9-83c4-b6758a6bf783" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bcf868c0-76ed-496b-b9c8-5836dd68eeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_416a925a-55df-424e-baf2-e7ddba16a5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04395de8-7421-42f9-83c4-b6758a6bf783" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_416a925a-55df-424e-baf2-e7ddba16a5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ece7a8ed-d2b1-40f2-88e1-ca33c7491acf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ece7a8ed-d2b1-40f2-88e1-ca33c7491acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45f82b40-fe51-4e77-bafc-18bc75834eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45f82b40-fe51-4e77-bafc-18bc75834eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_430c21ba-09ad-4bf0-bb7d-0006a2cf0d14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45f82b40-fe51-4e77-bafc-18bc75834eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_430c21ba-09ad-4bf0-bb7d-0006a2cf0d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a8d85ce0-f3d3-4c51-9b92-ff08fd26a8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45f82b40-fe51-4e77-bafc-18bc75834eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a8d85ce0-f3d3-4c51-9b92-ff08fd26a8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_18cbb068-3be9-49e0-ba9b-0ea59e3a96cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45f82b40-fe51-4e77-bafc-18bc75834eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_18cbb068-3be9-49e0-ba9b-0ea59e3a96cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_81cf7255-eaad-4baa-9620-44b3a1169d26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45f82b40-fe51-4e77-bafc-18bc75834eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_81cf7255-eaad-4baa-9620-44b3a1169d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a7d0b37d-c5b6-4bf5-8ba8-48cc509538d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45f82b40-fe51-4e77-bafc-18bc75834eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a7d0b37d-c5b6-4bf5-8ba8-48cc509538d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e67b6236-ee63-4146-9f2d-febd6551742e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e67b6236-ee63-4146-9f2d-febd6551742e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_017a9367-6a18-45f1-b36a-4a22903b68af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2657152-92d4-4c0b-ae48-011b83d5eeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_017a9367-6a18-45f1-b36a-4a22903b68af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_078d97ea-7388-4701-b0a1-8dbfed58ae28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_017a9367-6a18-45f1-b36a-4a22903b68af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_078d97ea-7388-4701-b0a1-8dbfed58ae28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3f7a3023-c522-4390-8690-8e0673131912" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_017a9367-6a18-45f1-b36a-4a22903b68af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3f7a3023-c522-4390-8690-8e0673131912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e56a74ec-400a-4689-a259-580dbbd7c4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_017a9367-6a18-45f1-b36a-4a22903b68af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e56a74ec-400a-4689-a259-580dbbd7c4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fedc232e-7904-4874-b636-2ed2dc5ca599" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_017a9367-6a18-45f1-b36a-4a22903b68af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fedc232e-7904-4874-b636-2ed2dc5ca599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/NetLossperShareDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#NetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/NetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_39fb9eb8-48a0-4178-8588-074661e7731e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_360d1bdd-5494-4bf8-be27-bbee280d1e21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_39fb9eb8-48a0-4178-8588-074661e7731e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_360d1bdd-5494-4bf8-be27-bbee280d1e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7cea55ae-2f26-4a18-b0c2-0d0708782298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_360d1bdd-5494-4bf8-be27-bbee280d1e21" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7cea55ae-2f26-4a18-b0c2-0d0708782298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_27d51ab8-38fa-4e10-b29e-ed2e0b26b1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7cea55ae-2f26-4a18-b0c2-0d0708782298" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_27d51ab8-38fa-4e10-b29e-ed2e0b26b1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d89d839c-eaaf-4d3e-9d70-028db4b912cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_27d51ab8-38fa-4e10-b29e-ed2e0b26b1cc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d89d839c-eaaf-4d3e-9d70-028db4b912cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_23ac8d3b-a3e8-4f36-b116-bfebdb93f9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_27d51ab8-38fa-4e10-b29e-ed2e0b26b1cc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_23ac8d3b-a3e8-4f36-b116-bfebdb93f9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6a721e2-aaef-4f94-aeb4-beb882c0ef2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_360d1bdd-5494-4bf8-be27-bbee280d1e21" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6a721e2-aaef-4f94-aeb4-beb882c0ef2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_833604d1-c8f0-4ac4-9a63-1b78f91bf52c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6a721e2-aaef-4f94-aeb4-beb882c0ef2a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_833604d1-c8f0-4ac4-9a63-1b78f91bf52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_813d3ac2-e164-41b6-94d3-9b5979b334ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0c9c576-9695-4250-908b-06f6f3a64b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_813d3ac2-e164-41b6-94d3-9b5979b334ce" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0c9c576-9695-4250-908b-06f6f3a64b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f6dd9eb1-37e6-4091-a32c-233ca4c9305f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0c9c576-9695-4250-908b-06f6f3a64b8c" xlink:to="loc_srt_MajorCustomersAxis_f6dd9eb1-37e6-4091-a32c-233ca4c9305f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5ad45079-b19b-4c62-84d9-a746ef14c8e4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f6dd9eb1-37e6-4091-a32c-233ca4c9305f" xlink:to="loc_srt_NameOfMajorCustomerDomain_5ad45079-b19b-4c62-84d9-a746ef14c8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_DRIHealthcareAcquisitionsLPMember_632854d3-e340-4108-b30c-650c8fcc6375" xlink:href="edit-20250630.xsd#edit_DRIHealthcareAcquisitionsLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5ad45079-b19b-4c62-84d9-a746ef14c8e4" xlink:to="loc_edit_DRIHealthcareAcquisitionsLPMember_632854d3-e340-4108-b30c-650c8fcc6375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fb2dea05-f234-4458-8b3c-5dce353d0054" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0c9c576-9695-4250-908b-06f6f3a64b8c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fb2dea05-f234-4458-8b3c-5dce353d0054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8058699d-e575-49bb-a19a-adb29a5236f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fb2dea05-f234-4458-8b3c-5dce353d0054" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8058699d-e575-49bb-a19a-adb29a5236f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicenseAgreementMember_27ddfb1a-a165-4171-b1c4-1abcff00ca18" xlink:href="edit-20250630.xsd#edit_LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8058699d-e575-49bb-a19a-adb29a5236f2" xlink:to="loc_edit_LicenseAgreementMember_27ddfb1a-a165-4171-b1c4-1abcff00ca18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04cd889e-2b39-41f4-add8-9d72d35714cb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0c9c576-9695-4250-908b-06f6f3a64b8c" xlink:to="loc_srt_RangeAxis_04cd889e-2b39-41f4-add8-9d72d35714cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fbea3c8-9c87-4bdf-83f7-ebdf5e4d0b8b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_04cd889e-2b39-41f4-add8-9d72d35714cb" xlink:to="loc_srt_RangeMember_5fbea3c8-9c87-4bdf-83f7-ebdf5e4d0b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6bd7cd65-5de0-465d-b1db-ac85df4cf5bf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5fbea3c8-9c87-4bdf-83f7-ebdf5e4d0b8b" xlink:to="loc_srt_MinimumMember_6bd7cd65-5de0-465d-b1db-ac85df4cf5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_182d1f39-946f-4c1d-a744-0a41495129e6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5fbea3c8-9c87-4bdf-83f7-ebdf5e4d0b8b" xlink:to="loc_srt_MaximumMember_182d1f39-946f-4c1d-a744-0a41495129e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0c9c576-9695-4250-908b-06f6f3a64b8c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_125b34f0-ebf9-4ed7-9111-7a0368ed585e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_125b34f0-ebf9-4ed7-9111-7a0368ed585e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicenseFeeReceivable_2a7a03e4-b18b-4153-b63e-6ed4fd5b17c9" xlink:href="edit-20250630.xsd#edit_LicenseFeeReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:to="loc_edit_LicenseFeeReceivable_2a7a03e4-b18b-4153-b63e-6ed4fd5b17c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ContingentFeeReceivableThresholdAmount_ee689ebe-043e-4e08-a5a1-199916216fa1" xlink:href="edit-20250630.xsd#edit_ContingentFeeReceivableThresholdAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:to="loc_edit_ContingentFeeReceivableThresholdAmount_ee689ebe-043e-4e08-a5a1-199916216fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f1698680-a488-44f7-a896-fb3883252232" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f1698680-a488-44f7-a896-fb3883252232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate_5c0e5aa2-751b-436a-a147-d9181fe0252b" xlink:href="edit-20250630.xsd#edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b05dc106-2a36-435c-a574-8d991a0ad5ee" xlink:to="loc_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate_5c0e5aa2-751b-436a-a147-d9181fe0252b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#DebtScheduleofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/DebtScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0de1d212-66ed-413c-aa45-29e4c0139e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_DebtRollForward_1a3845df-3347-4f95-acd1-775224233741" xlink:href="edit-20250630.xsd#edit_DebtRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0de1d212-66ed-413c-aa45-29e4c0139e4f" xlink:to="loc_edit_DebtRollForward_1a3845df-3347-4f95-acd1-775224233741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_71c47cb2-87c4-4c1d-9653-cbc663ccac4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0de1d212-66ed-413c-aa45-29e4c0139e4f" xlink:to="loc_us-gaap_DebtInstrumentTable_71c47cb2-87c4-4c1d-9653-cbc663ccac4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f82fa325-6dca-42a1-97c6-65f970659708" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_71c47cb2-87c4-4c1d-9653-cbc663ccac4e" xlink:to="loc_srt_MajorCustomersAxis_f82fa325-6dca-42a1-97c6-65f970659708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ea8817b8-510c-461e-bbae-46fa0f709a14" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f82fa325-6dca-42a1-97c6-65f970659708" xlink:to="loc_srt_NameOfMajorCustomerDomain_ea8817b8-510c-461e-bbae-46fa0f709a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_DRIHealthcareAcquisitionsLPMember_68e7ccdf-6081-4245-bf9b-0eb9539fd3b7" xlink:href="edit-20250630.xsd#edit_DRIHealthcareAcquisitionsLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ea8817b8-510c-461e-bbae-46fa0f709a14" xlink:to="loc_edit_DRIHealthcareAcquisitionsLPMember_68e7ccdf-6081-4245-bf9b-0eb9539fd3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1c561ad0-39cf-4fbe-8a13-61243a5c8adf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_71c47cb2-87c4-4c1d-9653-cbc663ccac4e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1c561ad0-39cf-4fbe-8a13-61243a5c8adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac6d795f-acc5-48bf-9d68-e0c9c216c83d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1c561ad0-39cf-4fbe-8a13-61243a5c8adf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac6d795f-acc5-48bf-9d68-e0c9c216c83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LicenseAgreementMember_67666f99-782f-46fd-a686-ebc34f0f58ed" xlink:href="edit-20250630.xsd#edit_LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac6d795f-acc5-48bf-9d68-e0c9c216c83d" xlink:to="loc_edit_LicenseAgreementMember_67666f99-782f-46fd-a686-ebc34f0f58ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_15530984-3e42-479f-b776-07b6f58f3cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_71c47cb2-87c4-4c1d-9653-cbc663ccac4e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_15530984-3e42-479f-b776-07b6f58f3cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_DebtInstrumentRollForward_c5be974e-4e4b-49ca-af81-81ac73d13dc8" xlink:href="edit-20250630.xsd#edit_DebtInstrumentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15530984-3e42-479f-b776-07b6f58f3cb0" xlink:to="loc_edit_DebtInstrumentRollForward_c5be974e-4e4b-49ca-af81-81ac73d13dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1a2ddb67-1780-4ab6-9e4a-5109140c78f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_DebtInstrumentRollForward_c5be974e-4e4b-49ca-af81-81ac73d13dc8" xlink:to="loc_us-gaap_LongTermDebt_1a2ddb67-1780-4ab6-9e4a-5109140c78f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_592963c3-2cd5-47b9-b9fc-f26e76ed3e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_DebtInstrumentRollForward_c5be974e-4e4b-49ca-af81-81ac73d13dc8" xlink:to="loc_us-gaap_RepaymentsOfDebt_592963c3-2cd5-47b9-b9fc-f26e76ed3e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues_60fc2bf5-a542-41bb-a0dc-7e4ee69723e7" xlink:href="edit-20250630.xsd#edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_DebtInstrumentRollForward_c5be974e-4e4b-49ca-af81-81ac73d13dc8" xlink:to="loc_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues_60fc2bf5-a542-41bb-a0dc-7e4ee69723e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8093d865-57a0-45eb-b41f-849605b9c586" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_DebtInstrumentRollForward_c5be974e-4e4b-49ca-af81-81ac73d13dc8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_8093d865-57a0-45eb-b41f-849605b9c586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8cc4cc57-3e15-4e04-a63d-91b63c7233b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_edit_DebtInstrumentRollForward_c5be974e-4e4b-49ca-af81-81ac73d13dc8" xlink:to="loc_us-gaap_LongTermDebt_8cc4cc57-3e15-4e04-a63d-91b63c7233b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#RestructuringandImpairmentChargesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e991330a-b17a-4dc2-8f34-0501585ab953" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3d974d78-1f85-42a6-9103-8c66c797595b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e991330a-b17a-4dc2-8f34-0501585ab953" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3d974d78-1f85-42a6-9103-8c66c797595b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77570647-8e85-40e3-af70-fba2ce902c0a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3d974d78-1f85-42a6-9103-8c66c797595b" xlink:to="loc_srt_RangeAxis_77570647-8e85-40e3-af70-fba2ce902c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5ea52c0-9bb0-4cb5-afa3-87c131cbf3c0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_77570647-8e85-40e3-af70-fba2ce902c0a" xlink:to="loc_srt_RangeMember_e5ea52c0-9bb0-4cb5-afa3-87c131cbf3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a0e5294-eff2-4cec-8ac9-81231626768b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e5ea52c0-9bb0-4cb5-afa3-87c131cbf3c0" xlink:to="loc_srt_MinimumMember_6a0e5294-eff2-4cec-8ac9-81231626768b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_888af728-1eeb-48d8-ab54-ac9b1d1842ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3d974d78-1f85-42a6-9103-8c66c797595b" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_888af728-1eeb-48d8-ab54-ac9b1d1842ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b89bb179-84f6-4bd1-9d01-b39afe0b38d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_888af728-1eeb-48d8-ab54-ac9b1d1842ac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b89bb179-84f6-4bd1-9d01-b39afe0b38d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_EmployeeTerminationBenefitsMember_b9cab1de-a28c-4242-8d5f-c569fce87640" xlink:href="edit-20250630.xsd#edit_EmployeeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b89bb179-84f6-4bd1-9d01-b39afe0b38d2" xlink:to="loc_edit_EmployeeTerminationBenefitsMember_b9cab1de-a28c-4242-8d5f-c569fce87640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae11fc6d-27ac-4fc7-b68c-0ee7b5073062" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3d974d78-1f85-42a6-9103-8c66c797595b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae11fc6d-27ac-4fc7-b68c-0ee7b5073062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9867b274-7088-4f56-a5f9-91742cbc974c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae11fc6d-27ac-4fc7-b68c-0ee7b5073062" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9867b274-7088-4f56-a5f9-91742cbc974c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_LaboratoryAndManufacturingEquipmentMember_e58fb3b7-5181-46ea-9cd9-63ea65b7a7e5" xlink:href="edit-20250630.xsd#edit_LaboratoryAndManufacturingEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9867b274-7088-4f56-a5f9-91742cbc974c" xlink:to="loc_edit_LaboratoryAndManufacturingEquipmentMember_e58fb3b7-5181-46ea-9cd9-63ea65b7a7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9d2e663a-99c1-4139-a29c-e976a6169abe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3d974d78-1f85-42a6-9103-8c66c797595b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9d2e663a-99c1-4139-a29c-e976a6169abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3d03cadc-e597-46e8-a9cf-1f810cbbf61a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9d2e663a-99c1-4139-a29c-e976a6169abe" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3d03cadc-e597-46e8-a9cf-1f810cbbf61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_31fd9907-216e-4233-be9e-fbf71e6ad574" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3d03cadc-e597-46e8-a9cf-1f810cbbf61a" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_31fd9907-216e-4233-be9e-fbf71e6ad574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3d974d78-1f85-42a6-9103-8c66c797595b" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_0cb50ebb-5500-4ead-b908-d569c002c888" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_0cb50ebb-5500-4ead-b908-d569c002c888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1c9bf794-b520-436f-b6d5-e71d983092ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1c9bf794-b520-436f-b6d5-e71d983092ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_419c1970-16c2-4bb0-8c50-d7a2fc03ce17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_419c1970-16c2-4bb0-8c50-d7a2fc03ce17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_5d1f03c8-18ba-4516-b1ce-dd3b21ce5643" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_5d1f03c8-18ba-4516-b1ce-dd3b21ce5643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_504588d6-8c58-4674-b547-66ac47104324" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_855eddf3-f7e1-4afa-b987-c8d384c3f097" xlink:to="loc_us-gaap_AssetImpairmentCharges_504588d6-8c58-4674-b547-66ac47104324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d668d2e5-fe68-43c9-b809-baf4d329ae97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_df63e7d9-601a-4b85-8890-269ddeb5f173" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d668d2e5-fe68-43c9-b809-baf4d329ae97" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_df63e7d9-601a-4b85-8890-269ddeb5f173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_18c0de47-ab47-4306-bd04-b1ebc9d636aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_df63e7d9-601a-4b85-8890-269ddeb5f173" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_18c0de47-ab47-4306-bd04-b1ebc9d636aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_afb833f4-5483-4a03-8c32-5c08c04f7f47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_18c0de47-ab47-4306-bd04-b1ebc9d636aa" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_afb833f4-5483-4a03-8c32-5c08c04f7f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_EmployeeTerminationBenefitsMember_119af86b-106c-4f9a-ad4a-523044e5076a" xlink:href="edit-20250630.xsd#edit_EmployeeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_afb833f4-5483-4a03-8c32-5c08c04f7f47" xlink:to="loc_edit_EmployeeTerminationBenefitsMember_119af86b-106c-4f9a-ad4a-523044e5076a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember_de147fff-fb4c-425a-8000-68e0bea4c819" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractTerminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_afb833f4-5483-4a03-8c32-5c08c04f7f47" xlink:to="loc_us-gaap_ContractTerminationMember_de147fff-fb4c-425a-8000-68e0bea4c819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember_b98646bd-9ad2-4e25-92ae-6c1c1ee29189" xlink:href="edit-20250630.xsd#edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_afb833f4-5483-4a03-8c32-5c08c04f7f47" xlink:to="loc_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember_b98646bd-9ad2-4e25-92ae-6c1c1ee29189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ImpairmentChargesMember_046296f3-4257-4359-91e2-eb16ac4b2082" xlink:href="edit-20250630.xsd#edit_ImpairmentChargesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_afb833f4-5483-4a03-8c32-5c08c04f7f47" xlink:to="loc_edit_ImpairmentChargesMember_046296f3-4257-4359-91e2-eb16ac4b2082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6cc4edc5-b9cb-4c9d-b103-ff7421d9f6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_df63e7d9-601a-4b85-8890-269ddeb5f173" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_6cc4edc5-b9cb-4c9d-b103-ff7421d9f6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9f913d08-8adf-4055-8c49-54b83064f57d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6cc4edc5-b9cb-4c9d-b103-ff7421d9f6b1" xlink:to="loc_us-gaap_RestructuringCharges_9f913d08-8adf-4055-8c49-54b83064f57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_256a9e46-186d-4348-a6e5-ea10b538c0da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6cc4edc5-b9cb-4c9d-b103-ff7421d9f6b1" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_256a9e46-186d-4348-a6e5-ea10b538c0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_476a9170-ff7f-47ce-92d8-01af8aa4dc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa86440-e5cc-40a3-b818-4518e30074fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_476a9170-ff7f-47ce-92d8-01af8aa4dc9c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa86440-e5cc-40a3-b818-4518e30074fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a2343aef-5b59-4e07-bf39-2660787db794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa86440-e5cc-40a3-b818-4518e30074fb" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a2343aef-5b59-4e07-bf39-2660787db794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a5d555ce-a0bb-4a32-9ebd-bdb899b5cb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a2343aef-5b59-4e07-bf39-2660787db794" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a5d555ce-a0bb-4a32-9ebd-bdb899b5cb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_EmployeeTerminationBenefitsMember_5f5f5f12-b7d6-464b-81d2-5b8e2d91e84a" xlink:href="edit-20250630.xsd#edit_EmployeeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a5d555ce-a0bb-4a32-9ebd-bdb899b5cb2c" xlink:to="loc_edit_EmployeeTerminationBenefitsMember_5f5f5f12-b7d6-464b-81d2-5b8e2d91e84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_37a568bb-247c-4349-ac7f-9c5ebd7ec908" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa86440-e5cc-40a3-b818-4518e30074fb" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_37a568bb-247c-4349-ac7f-9c5ebd7ec908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_44ba1129-3c18-4845-a3f1-1047c17cd895" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_37a568bb-247c-4349-ac7f-9c5ebd7ec908" xlink:to="loc_us-gaap_RestructuringReserveRollForward_44ba1129-3c18-4845-a3f1-1047c17cd895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_f0765496-2b69-4df1-8976-3b9fd8e3e78f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44ba1129-3c18-4845-a3f1-1047c17cd895" xlink:to="loc_us-gaap_RestructuringReserve_f0765496-2b69-4df1-8976-3b9fd8e3e78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_bcf4df05-b960-4cd8-bc68-4220e200e084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44ba1129-3c18-4845-a3f1-1047c17cd895" xlink:to="loc_us-gaap_RestructuringCharges_bcf4df05-b960-4cd8-bc68-4220e200e084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash_5bb0d942-3191-48f3-b358-7e5af1b62272" xlink:href="edit-20250630.xsd#edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44ba1129-3c18-4845-a3f1-1047c17cd895" xlink:to="loc_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash_5bb0d942-3191-48f3-b358-7e5af1b62272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_2ed67783-ca98-47e6-8849-d89f33ec5015" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44ba1129-3c18-4845-a3f1-1047c17cd895" xlink:to="loc_us-gaap_RestructuringReserve_2ed67783-ca98-47e6-8849-d89f33ec5015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6a801302-677e-4292-944c-3083d1bf43b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dd7fa479-99d6-4a49-a14d-662106e7815e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6a801302-677e-4292-944c-3083d1bf43b5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dd7fa479-99d6-4a49-a14d-662106e7815e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_caac5fb1-d58e-457f-b037-622461511cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dd7fa479-99d6-4a49-a14d-662106e7815e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_caac5fb1-d58e-457f-b037-622461511cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_87322383-bb2f-4324-9776-460f234422bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_caac5fb1-d58e-457f-b037-622461511cb6" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_87322383-bb2f-4324-9776-460f234422bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember_949f83ee-b3e5-44f6-9cdc-4446aadf0bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractTerminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_87322383-bb2f-4324-9776-460f234422bf" xlink:to="loc_us-gaap_ContractTerminationMember_949f83ee-b3e5-44f6-9cdc-4446aadf0bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_72272f3c-25ab-4cd6-8cf9-f35c24acab30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dd7fa479-99d6-4a49-a14d-662106e7815e" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_72272f3c-25ab-4cd6-8cf9-f35c24acab30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_2336c62f-a5c4-4b4e-8d58-fab931b60756" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_72272f3c-25ab-4cd6-8cf9-f35c24acab30" xlink:to="loc_us-gaap_RestructuringReserveRollForward_2336c62f-a5c4-4b4e-8d58-fab931b60756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_ae709f2c-5e69-487d-9b6b-095580a58a78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2336c62f-a5c4-4b4e-8d58-fab931b60756" xlink:to="loc_us-gaap_RestructuringReserve_ae709f2c-5e69-487d-9b6b-095580a58a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_c4d21039-88dd-4c69-8390-021eea07f458" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2336c62f-a5c4-4b4e-8d58-fab931b60756" xlink:to="loc_us-gaap_LossOnContractTermination_c4d21039-88dd-4c69-8390-021eea07f458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AmountsPaidOrOtherwiseSettled_44508554-8d20-4655-aae2-8980ab376e09" xlink:href="edit-20250630.xsd#edit_AmountsPaidOrOtherwiseSettled"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2336c62f-a5c4-4b4e-8d58-fab931b60756" xlink:to="loc_edit_AmountsPaidOrOtherwiseSettled_44508554-8d20-4655-aae2-8980ab376e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c9fe0d3f-eb63-4406-b55f-8e5728ac1a09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2336c62f-a5c4-4b4e-8d58-fab931b60756" xlink:to="loc_us-gaap_RestructuringReserve_c9fe0d3f-eb63-4406-b55f-8e5728ac1a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b04f5bb2-2e4c-410b-a9d0-d87ec63e32e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2a04ce8b-bda4-4f2e-b34a-67886c92127c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b04f5bb2-2e4c-410b-a9d0-d87ec63e32e5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2a04ce8b-bda4-4f2e-b34a-67886c92127c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a7e89750-8981-43b7-b2ef-1386be1f2a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2a04ce8b-bda4-4f2e-b34a-67886c92127c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a7e89750-8981-43b7-b2ef-1386be1f2a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_918a995d-0aaa-4305-9591-f62c729e6693" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a7e89750-8981-43b7-b2ef-1386be1f2a6e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_918a995d-0aaa-4305-9591-f62c729e6693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember_d3275a4c-757e-492d-96df-7ed13bdd60f2" xlink:href="edit-20250630.xsd#edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_918a995d-0aaa-4305-9591-f62c729e6693" xlink:to="loc_edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember_d3275a4c-757e-492d-96df-7ed13bdd60f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f4f421b5-cfca-42c9-a3c3-82241c1378f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2a04ce8b-bda4-4f2e-b34a-67886c92127c" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_f4f421b5-cfca-42c9-a3c3-82241c1378f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_2e044002-f52d-48d2-a37a-9b36d56681a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f4f421b5-cfca-42c9-a3c3-82241c1378f7" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_2e044002-f52d-48d2-a37a-9b36d56681a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ChargesRelatedToTerminationOfLease_217ac47c-3ce2-45bf-aef8-ffa4eb1381f5" xlink:href="edit-20250630.xsd#edit_ChargesRelatedToTerminationOfLease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f4f421b5-cfca-42c9-a3c3-82241c1378f7" xlink:to="loc_edit_ChargesRelatedToTerminationOfLease_217ac47c-3ce2-45bf-aef8-ffa4eb1381f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_bfb2ba24-20d6-483a-8716-1c30933d3244" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f4f421b5-cfca-42c9-a3c3-82241c1378f7" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_bfb2ba24-20d6-483a-8716-1c30933d3244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#SegmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/SegmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d0dd0a3b-4c09-4392-92b5-59947b23c8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cfaacfac-91c9-4ce8-89e7-5dd829a053a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d0dd0a3b-4c09-4392-92b5-59947b23c8e3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cfaacfac-91c9-4ce8-89e7-5dd829a053a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="edit-20250630.xsd#SegmentsScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_27cf175d-1f4d-426a-900f-9adb60b6406e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0a42634-1205-4e70-8cab-90ecea8cad43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_27cf175d-1f4d-426a-900f-9adb60b6406e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0a42634-1205-4e70-8cab-90ecea8cad43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_21657fa1-24c3-4beb-bdc5-41f2ab347233" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0a42634-1205-4e70-8cab-90ecea8cad43" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_21657fa1-24c3-4beb-bdc5-41f2ab347233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b3c3f02f-ff27-419e-a7f2-5242d333b409" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_21657fa1-24c3-4beb-bdc5-41f2ab347233" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b3c3f02f-ff27-419e-a7f2-5242d333b409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b8c5d3ef-d857-4cab-85b9-58ac89131cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b3c3f02f-ff27-419e-a7f2-5242d333b409" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b8c5d3ef-d857-4cab-85b9-58ac89131cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3723b929-6643-45d2-b63b-140656158848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b3c3f02f-ff27-419e-a7f2-5242d333b409" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3723b929-6643-45d2-b63b-140656158848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a4fb119e-9a4e-4e02-8324-59a1924a1c41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0a42634-1205-4e70-8cab-90ecea8cad43" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a4fb119e-9a4e-4e02-8324-59a1924a1c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dfc14f12-2f3c-45ed-bde2-ef96642e456b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a4fb119e-9a4e-4e02-8324-59a1924a1c41" xlink:to="loc_us-gaap_SegmentDomain_dfc14f12-2f3c-45ed-bde2-ef96642e456b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_ReportableSegmentMember_383cb02f-e46b-4d79-a68b-ec5457b5c05a" xlink:href="edit-20250630.xsd#edit_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dfc14f12-2f3c-45ed-bde2-ef96642e456b" xlink:to="loc_edit_ReportableSegmentMember_383cb02f-e46b-4d79-a68b-ec5457b5c05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0a42634-1205-4e70-8cab-90ecea8cad43" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b6c5ab4b-c0d5-4678-bbc7-d3c7cab68c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b6c5ab4b-c0d5-4678-bbc7-d3c7cab68c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_3bd31099-86a2-47a1-90d9-a1bdfad51107" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_LaborAndRelatedExpense_3bd31099-86a2-47a1-90d9-a1bdfad51107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_d27991f6-5f9f-4c77-88e5-226fc3521e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_d27991f6-5f9f-4c77-88e5-226fc3521e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OccupancyNet_e57fd2f4-a472-47a1-90dc-d552c64f1291" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OccupancyNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_OccupancyNet_e57fd2f4-a472-47a1-90dc-d552c64f1291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_05bee6bd-6a07-409c-b487-82eadce1240d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_05bee6bd-6a07-409c-b487-82eadce1240d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_SublicenseAndLicenseFees_3f3b4fbc-392a-4272-ae6b-96eaa367de86" xlink:href="edit-20250630.xsd#edit_SublicenseAndLicenseFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_edit_SublicenseAndLicenseFees_3f3b4fbc-392a-4272-ae6b-96eaa367de86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses_1c9d88bd-c7ef-479e-bfa6-c0fe2197bc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_OtherExpenses_1c9d88bd-c7ef-479e-bfa6-c0fe2197bc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_b4984196-ef73-4dca-8006-c9a3fb69b4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_ProfessionalFees_b4984196-ef73-4dca-8006-c9a3fb69b4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_edit_IntellectualPropertyAndPatentRelatedFees_10154a10-dabc-4e66-a109-550b77d05d02" xlink:href="edit-20250630.xsd#edit_IntellectualPropertyAndPatentRelatedFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_edit_IntellectualPropertyAndPatentRelatedFees_10154a10-dabc-4e66-a109-550b77d05d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1a6cecc7-4cc3-4660-a5cf-50939f182a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9fe74eb-c4c6-4568-8ffd-258e7a54569e" xlink:to="loc_us-gaap_OperatingExpenses_1a6cecc7-4cc3-4660-a5cf-50939f182a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d111a04e-7438-459f-abc9-d2aa272ae64c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:to="loc_us-gaap_OperatingIncomeLoss_d111a04e-7438-459f-abc9-d2aa272ae64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_72df264c-9955-4c8f-a9dc-58f21476ca52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_72df264c-9955-4c8f-a9dc-58f21476ca52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_877b2442-e70e-4748-8c79-7cc26858a807" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_72df264c-9955-4c8f-a9dc-58f21476ca52" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_877b2442-e70e-4748-8c79-7cc26858a807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_4073d5d3-f5af-461e-97aa-1d27ee349cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_72df264c-9955-4c8f-a9dc-58f21476ca52" xlink:to="loc_us-gaap_InterestExpenseDebt_4073d5d3-f5af-461e-97aa-1d27ee349cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_74251853-c1d2-49d1-92cc-269cfb87f489" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_72df264c-9955-4c8f-a9dc-58f21476ca52" xlink:to="loc_us-gaap_InvestmentIncomeNet_74251853-c1d2-49d1-92cc-269cfb87f489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_103a1e7f-afc0-4a40-bba1-47a81131e11f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_72df264c-9955-4c8f-a9dc-58f21476ca52" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_103a1e7f-afc0-4a40-bba1-47a81131e11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_881d7d89-2e3a-41f0-be12-572070fa6be7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:to="loc_us-gaap_NetIncomeLoss_881d7d89-2e3a-41f0-be12-572070fa6be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9f7d7405-3a30-4781-a21a-0fa31883def6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_df1abaeb-1450-4ea7-9f42-eb716e045e02" xlink:to="loc_us-gaap_RestructuringCharges_9f7d7405-3a30-4781-a21a-0fa31883def6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex31-restatedcharterasam001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex31-restatedcharterasam001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRSQRO/'0=/2M>B@!L:+'&J+G:HP,L2?S/-.HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUX-UG3+4XN+JSEBBR<98J< _4\5HV>GV6GQF.RL[>V0G)6&((#^ %6: ./\
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M1@SB)1(?^!8S4[11O)'(\:,\9)1B,E21@X].* 'T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 45R_B'Q+<6WB/2_#.E+$=3U!7F>652R6T"]7*@C<2>%&0,]?>IXDUK4O
M]K!J]Y>MJ.CB9(KT2Q*LL"N=HD0H " 2,J03SP: .SHKB=3UC6!\2=/T"TU%
M(K&\L)+O<8%=E96 P#Z$&NATE-42ZO!>ZA!>VORB!TB",K L'5L$@X(7GCJ1
MVH U:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$R1*_1@OR].!TZYK>\27EC%XA\-V]U<0(SW4I,<C@94V\HY![9('XUTH 4
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MH **** "BBB@ HHHH **YWP]JS^(KK4-121ET^VN9+2U13@2;.'D;URVX =
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9/"TA)\N"TNDED .V-G4;0S= 3CC-=S9V45DLNPLTDTGF2R.<L[8 R?P ''
M %6: /,()8A>_$YCP)U7RB5/[T"V"?+_ 'OFXX[UG:9J;^&9O!>NW\%R^D?\
M(^NFW$L<+2&SG^1B74 D9V[>G:O8** .:MM?TK3M*74(].FM+.]OA'#Y=FRO
M,\A'[UD"@KEL\L,D 'N*R_B% ][J_@JS@!,_]NQW/':.)'9S],$?G7<U133(
MO[6.IS-YMPL9BA)&!"A()"CU) R>^!TQ0!>HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\A;N5_-N&*PPQ1-+)(0,G:B@L<#DG&!WKR9VF\6V7@GP?/!_9BQVMIJ2W<[
MM<+$@!6#;D;N<G)! YP:[3QKH>O3:IIOB'PQ/;MJNFI)&;.Y_P!7<Q/MW+G^
M$Y48/'UXH V8_%VB26]_/]K9%T]5:[62"1'AW9V[D*ALG!XQGIZBJ_\ PG6@
MB]%EYU[]K:/SA!_9MSYA3.-VWR\[<\9Z5F>$/$VG^*=1U&*\TF?3-?MTA6^L
M;D<@(S,C*?XERQY^GMFO/_R7RT_[%M__ $H% '9Z;J5IJ]A'?6,IEMY"P5BA
M4Y5BI!# $$$$<CM5NLRZM-16]L#IMQ;6]FDSO>Q/%N:4-D_*<_*=QR3_ ).G
M0!E:AXBTW3+U;.YDN#<M'YOEP6LLQ"9(R=BG R#UJC9>._#VH1VLEK=SR0W3
M^7!-]BG$<C9(PKE-I.01U[5O211@RS! )&C"LV.2!D@?J?SKAO@]%'-\(]!6
M1 RCS& ([B=R#^! - '6:)KMAX@M)KK3I'>**=[=B\;1D.APPPP!X/J*TJ\:
ML]5USP_X,\3:[IUU:I!8:]=R/;20;S<#S\,"V1MX/& >G7T[74=>U&^U_4='
MTGSXC86\3O-##'(3)(&*@AV "@*.G)SU&.0#L**R?#-WJ][X=LY]>L%L=492
M+B!6#*K D9!!/! !QDXSBN)G\0^+9K#QG<0ZCI\)T">0Q8LRWG*D0DV$%_ES
MSDY)Y[8Y /3**X^?7=1O$T:=;F/3[*_T_P"T;HD$UP\Y"E8TCP25 +$D ]!R
M*PHO&^OWG@KP?K$)LH[C5=2BLKI&A8@Y=U)4[OE^YTP>O44 >FT5P=O?^*I?
M&&J^&6U>RREI%>PWHLOFC#,RE-F[!Y7()/ ]<Y%?2?'.I:AX:\.>9$IU75+B
MXMI'@0$ 0&3>ZJQ R=@P"<#<3SC! /1**YOPQ=^(I+[5+76K1Q:PNAL;R0(C
MSHP^8.J,0"IXSP#GI3;O6KF]\:MX9LI_LOD6(O+BX"!G^9]J(H;('0DD@]@/
M6@#I))$AB>21U2- 69F.  .I)K&T_P 5:7J6JIIT+3K<2V_VJ#S8&19HL@;T
M)&".1QUY'%<9JNO:GJ_@#QSIMY+'#J.C1W$$\L,?RW$1A+*P!/REE//)P1QU
MKM/"<4\7A;3!<7'GL;6(J?+"[5V+A>.OUH U+JZBL[:6XF+>7$N]]B%V _W5
M!)_ 57T?5K37=(MM4L'9[2Y3?$S*5)7UP>E<9H3:E+XX\<+<ZDTT-L8$6-H@
M!M: N%'H 6/U[U@^%-6US0O W@2Z2ZMFTZ\N(+"2S\@[MLA8!_,S]X$9QC';
MGJ0#U^BN"OO$/B'5%UM_#L,IETVY>UMX_*C:.>1 "PD+," 22!MQCKDYP.OC
MN[MM!2\FM##>&V$KVQ8,4DVY*9'!P>,B@""Y\1Z9;7[V'FRSW<8#2PVMO).T
M0/3?L4[<]LXSVJ;3=:T_5VN%L;@2M;L$F0JRM&Q&=K @$''8\UQWP9Q/\-[3
M4I'\R\U"XGN;N4_>DE,K D_@H%;/BK4XO"UG)J5I!&=0U*YM[*,OG8TC-M5F
MQUP"2?4*!D4 =/17'76LZKH7C+2-'NKI+RTUF.9()WA"O!/&N[!"X#(1T'4$
M=:QM%USQCJGAN[UUM2TN-+-KU&@-DS"4Q%@C9W@KRN,<\=SG@ ]*HKRT^*_%
MNGZ!X8\4WMS87&F:A]ECO+..W*O&)@!Y@?/)R<[< #..>M;UMK6L>)(?$%SH
MUW%:_P!EWDME;1/"'$\D2C<9">0I8X 7! &<G.  =I17FD7C?6M?;P7+I$EI
M:0Z_#<^:LT!D,,D<9)(.X;@&!P,#.!SS5[5]5\1Z3;7$5YJMJL]MIGGPO:V^
M][J<;BQ:+DK$,*,C'WOO#I0!WA(! )'/ ]ZIPZI;SZO=:8BS?:+:-))"T3!"
M'SC#8P3P>E>?W>JZMK>N?#>\CO\ [(FIV\MS) D89%D^REL\\G[[  ]*UV\6
M7NG>)?%L6HO%)IVCZ?%>Q+#%M?!$C,"23D_)CL/:@#MJ*\^U#Q1K>B^%M(\6
M7,\,]I<M;M?6:Q "&.; !C;J2I9<[LAN?NTLFK^*;[Q!XNTRUU*QMDTJ."2W
MD^R%B=\;/M(+>H )]N ,T >@52MM4M[O5+[3XUF$]EY?FEXF5#O&1M8C#<=<
M=*I^$M8E\0>$=)U>=%CFN[5)9%3[H8CG'MFL&+Q'KO\ ;'CBT2*"]DT>"&33
MX(HBID9XF?:W)))( XQ[ 9H [>LO6O$.F>'HHI=4G>".:01(P@=P7/1?E4\G
ML*Q/!WB6/Q%.\MIK2WL"0@3VTT(BN+:;/(90 0O4#CJ#R:SOB\6'A;32BAG&
ML6FU2< G?Z]J .JB\2:;+>V]I_ID4UPQ2(3V,\0=@I8@,Z 9PI/7M5C6-7L]
M"TJXU._=TM;="\C)$TA4#OA03^-48+C6+C7K>"_TJVALA;R2B:.X,V)0R!1R
MB[?E9_7//I7%^(=7U#Q3\,_%6KVMVEO8I%=000>4&$L4>Y'9R>=S88C& .,Y
MYH [X:Y9FZTRW G+ZE&TL#"%BNU5#'<P&%X(QGK6B""2 1D=:X>#6=2L=<\$
M:5%)!_9^I6$IE7RCY@:*%"/FSC&6Z8'3K6?X8N=?2'QS=Q7T=[=VVISQP1W(
M$<998H]I+#[J@8&/;KWH ])HKA-'\47\GC+^QQ=#4K>72&ODE,/EYE5U4A&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN0JX5R3PQ&?X<N!U^][5T-% '(Z?X+EM]<\27U]J$-W;Z^B)<VRVICVJL9C
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M HHHH **** "N1\1^))+/Q;H_AY;Z+35U"*67[7(@8LRE0(DW?+N.[.3G@8
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MHH+EI$!EECWJB9^8[<C)QD#GJ:L63VTEC;O9&,VC1*8?* ";,?+MQVQC%3T
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M9( ;GL"03[9K"\)7NLQ>*K_2->6SO+N.RAECU:S7:)X=[A5D3HK9+D8X()H
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M]M\0;6!]6M!X?ETB6\+_ "! RR(NXR9Z<GN!S3?BJZQ>#X9I&"Q1:E9O(Y.
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M&*%HG#;6'53Z$>AH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS6=M<2))-;PR.GW&= 2OT)Z4 >,:K8M+X8^)?BN=?)M-91([$2C:9(XEVK(
M>S$Y'? SWKJO$-[HFDZ)X6G%M8(EQ=VXAOY.(;9EC;;(Q4C=@94 D#GKQ7H+
MHD@PZ*P]&&::T$31>4T2&/\ N%1C\J /%+F_LCX?^*D!U!+AW_>H[[5,@,"
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MWUM97 EEL)O(N5"D>6^ <<CG@]JOT >;Z_<>*-"F\+6\GB6>2?5+]+2[*VL
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MW(3!_CR20,9&#[9Y[PSK6AZQ%X)L[CQ'I$,FC;?*1)RLT[>7Y:(590$)!^8
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M\6HES"S/:6BH X.XJIW >I&1FIY[FS'QS@\V: /'X><#<PRK>>IQ[';D_3-
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M_AS4K*.Y@U6WW,.;9G G5O[AC^]N[8QFN?NK]],^+-EJ&K VFG7VC&VM99V
M2*<2[VC8] Q7'?G;@9Q0!U4OBC0H=(35I-6LUL'.U9S*-K-G&T>ISQCK40\8
M>'3<W=O_ &S9^=:)OF4R#Y5SC/OS@<9Y..M>5^)(4@\$_$&]61%TK4=4@>R!
M/RRL'B\UT]06!Y'7:377:K<:<WQ?\+%)K4XTZZ"$,O&=FS'U&['XT =0GBWP
M\^D)JHUBS%B[^6LQD !?.-N#SNSVZT[3?%&A:QJ%S8:=JMK=7=M_K8HI 649
MQGW&>,BO(]6NK23P!\0@LL4B#Q,LA52&^0RV_.!V)#?K78:O'9W_ ,1?#.HZ
M((KG^SK.Z>[:T(8>08P(XR1QRQ^4>S&@#KK?Q+HUW>Q6D&H1/-,7$(&=LQ3[
MP1NCD<YVDXQ56Y\<>%[1)7FUVQ589?)D(E!"OQD''ID9],\UY=::[IMRG@&\
M@N8H+>'460Z?;1DQV.8Y (V."QDSQR>>H6M6.YT]K/XKMYUL6=I1G<N6'V8
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MQ$!NCR.H_P _E6%#X>UR]@6RUR\T>:R4*K?9+!HY) .@RSL$Z<X'T(ZUUE%
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M Y_6M%U75]2CB&JQ0Z$\6R[LQ;YDF.[) DSPK#"D8Z9]<C?*AE*D @]C2T4
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M0[3S&I )SC'4COF@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9- !15#2M;TW6UN6TVZ2Y6UG:WF* X60 $KR.>".E7Z "BBB@ HHHH ****
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M$;:@4,>,CIG'/UKEX_ NJQ>#_#.AK=V9?1;Z"Z,QW8F$3%@N,<9SC.3C'OP
M6-2\7:K.NLMH,"RR:;.UNEN]A/-]JD0 LOF(0J<G:,YY&3P:Z^SN9[S2H+HV
MS6UQ-"LA@FZQL5SM;Z'@UR/_  BOB32O$>H7GAW6+&#3]4E\^ZMKRW:4PRD
M,\6&&2<#AN.*[*&)K:S2%':5XXPH>5N7(&,L<=3W.* /-4\=^)QX-3Q1-!I(
MM8+\VUS;JDA>1/M'DY1MV%(XZAL^W2MSQ7XEUG1?[7FB%A;6]E9_:+07"F5[
MYPK,ZA5<% H &<'[V>@K/;P%JS?#NX\+_;++S);PW/VC#8 ,_G8V_7CK5K4?
M!NMWNI^(Y8M2LX[;7;%;>02PM));D1E-J'(&PEB>1U)XH JZEJ^L:CXM\"M9
M7D%M:ZE:SW1@D@,@5Q"I^8AUW<2$#ICKSVOQ>*=6>'QFI%EYVA,?(<0OMD'D
MB3YAOSGG'!%-_P"$.UA/^$2N(]3LA>Z'#);N6MV,<B/&J$@;LY&T'D\G/3I2
M7G@_6?[3\3'3]0LH['7HAY@FB8RQ2"+R_E(.,' .2./0T 5Y/%_B">3P9%96
M^G!_$%D\TAE#XBD$ DXP?NY/3J<8R,Y%EO$NMM/<:3NM$U:PMHFNI8;"XN87
MF<$A5"$%5P <DY.[@<4VU\':O;7'@V0WME*/#UN\+?(R>>&B$?')Q@#.>Y["
MI]6\,:]!XLD\0^&-3L[>6[A2&^M;Z%I(I=F=CC:00P!(ZT ;OAO4K[5O#UG?
M:EITFG7LJ'SK63K&P)!_ XR/8BN>_P"$HUC5-&UG6M$6R-MIT\T45O/&S-="
M'[YWA@$R0P7Y3T!/7 ZW3[::TL8H;FY:YG&3),PQN8DDX'89/ [# KE+3PCJ
MFCQ:WIVE7EJ-,U2:2=#,&\RS>08?:!PZYY )7'O0!B^(-7N?$-S\/]4TVYAA
MM+Z\$T4<T#.4?R)#\V'&0,D8&.><]J]!GAFATRX^RO;PWC(7,P@RADQ]XKN!
M/3IG\:YJ^\&SH?"L&DR6\5EH$@=4F+%I0$*8R!QP2<\\]JZ]E\R(H_&Y<'!H
M \;FNM3O?@KH-]?7$5U/<7]G*O[LHQ8W )W-N.22>H ^E=G'XJU/2O$^JZ9K
MWV)[>VTHZM'+9QLI6-6961MS'<1C@C&?0=LZ/P#K:>!=/\--J5A(+&YADBE\
MIURD4F\ C)RQX!Z 8[UL7?A6YU+QA<:K>-;FQNM(;2IK=6;?M9BQ8-C'<C'X
MY[4 4[3Q3K\][HD\>GFZL=091<QQV$\;68895_-?Y749P< >HI_Q<_Y)=K7&
M?EB_]')3O#/ASQ5HZ6VEWVO6ESHUEM$#1V[+=2(OW$=MVT 8&<#) QGDUL^+
M_#Y\4^%;_15N1;-<JH64IN"E6##(R,\KZT 8DGB'Q)I/C#3=,UB'3&L=8\R.
MTFM0^ZWE52P63<?G! Z@+SV%9\OCO6$^&EYXE$5A]LM+U[=H_*?RW5;CRLCY
M\@X.>IKHTT.^U+6]-U36VM0^FAS;P6I9E:5UVF1BP!X7("XXR3D\8YB[^'NN
MS>&-8\-P:K81Z==7C75N[0,95W3"4J_., YZ=>.E &IKGC"XL_$MWH4-U86%
MX+59;!=0B;9?.=V55]R@8("XY.3GVJ_-KVHQ?$2WT#RK7[)-IDMVKX;S-ZNJ
MX)S@#YO2JWB+POJ7B*QU'3;_ /LR\L[N,")YHV5[238%,B#G//S 9&#WYJ5/
M#%]!XPTW5XKF&2WL=,.G[)6;S),E3O+8QG*CCZT <S-X[\41>$-2\1M!I(@T
MO4)+>> )(6F1)1&=IW?(<<Y.[/H._2ZIXENVUK4-)TMECGL88W>1[":Z#2."
M57$>-HP 22>=W XK(F\!:K/X#UOPVUY9"34[R6Y$X#8C$DGF$;<<XQCKW]N;
MVI>&/$4/B9O$7A[4K"UNKN!(=0M;N)Y()2F=KJ5(8, 2* *LOCV\M;3P^=;@
MC\.R:C%+YTM]"SQQ3(R@1GYEV[@68%CT&.^18U/QC<Z,^AV^K75AIWV^&1GU
M!XFDMO-4KM0$. H8$L"S=%QWXTKK1=5DAAMYI;+5;1X'2]M[Y2JS.S;MRX#!
M0.0%P>,<\9JAIW@^]T?0;'1(VL=2TR*WDBN+2]#!79G+@J<-@+DJ 0>,<C%
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M<6\MU$HVLNWJ<<,?F_2I-7-X/C-I)LA T@T6<LDS%0R^:G&X X.<'.#TQWR
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M;HDA=E-P8MR,6PI''!#9Y.1TKJ5UO4-7\0:OIFCO:0KI0C266XB:3S)G7=M
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MG%GOMXFC:WN&!*#EFW*<$=B.OM6SXG\/VWBGPU?:)>,R174>W>G5&!#*P^C
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MJ.O:KKEGI,UO;0Z45@+S0F0S3E-Q!^880 @<<DYY&.8/A-_R2SP__P!>Q_\
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M2#GID$8J>XUGQ/J?C*^T71[_ $ZV@73H+ZWFFM&<C>Y&UAOYR%Z\8].XFMO
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MILDB0Q/+*ZI&@+,S' 4#J2>PKG/$7B*,>$=<O=!U2SDO+"RDN,HRS;"J,PR
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MW ZXR,]-'I]E#%)%%:6Z1RC$B+& ''N,<T^UL[6Q@$%G;0V\(.1'"@11^ H
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M]M73K%9EE6SMQ*@ 5Q$N5QTP<4W^R]/WRO\ 8+7?,P>5O)7+L#D%N.2#T)H
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M=2P^;)?*_D2$99/LZ?-M/;CKTKEM%NVL_!?PONYV']C173"\<GY$D(=86;T
M<]3P#BO9'LK62221[:%GE4)(QC!+J.Q/<4BV%FEL]LMI +=\[XA&-K9]1T-
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M,;CQCKUZ4MO9VMIN^S6T,.[[WEH%S]<4 3T444 %%%% !1110 4444 %%%%
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MOSX[<'=]<&N,T]6T7X+ZYX5D&=5MWNM.2W_CF>9V\LJ.I#"0$'TSZ&@#L?\
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M,& ^8NQ9B0!CDL3@#'-6XXXX8UCB1411A548 'L*STUW2[B[2RBOD^T2LZ1
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ME>2)5E64,O#%0 1@G& .ASGB@#5-K;E$0V\11!A5V#"CT'I2K;0*^]88P_\
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M7].BFM=,NM6MI=18>46 V+-*H^<+VSD'Y0210!IFTMB23;Q$GJ2@YH^QVQ4
MV\.!T&P<5DR>,_#,-P()-=T]93/]GV^>O^LQG;]>1],T^S\6^'M0O(+2SUFR
MGN+@.T,<<H8R!"0Q&.H&#^1]* -5;>!9/,6&,/\ W@HS^=-CM;>*=YX[>))I
M/OR*@#-]3WJE:>(M'OK\65MJ$$ERR&1(PW,B#JR_WA[C(KEOB3XM72O"6HOI
M.LBVU.W=$!C57&XLH:,D@@-M)./O=Z .V^R6V6/V>+YNOR#FI(XTB7;&BHOH
MHP*=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+2:]TXN!]KA0R&2//J 0V.AQ@@@XKT*'Q[X7DTW2KT:K"D&IR+#:\')D/\#
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MGB*Z=@>I5PC*?H5(KNJS1I*0ZW)JEJXCDN$6.Z0C*S!<[6]F&2,]QP>@(TJ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *YCQ_K]QX:\+/J%N3&//ABFN!'YGV:)G
M>7;WP"<#UQUKIZQ_$>K6ND6$,E]!YUG/.MO./++@(P()*@'('?VS0!G:<+Z6
M\TN_TWQ$^JZ+-O\ /WB)OX#M9715XR.1ZD=.14_A_P 8Z?XAN-52 O&EA<O
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MB9R5^H!!QUKK=:_Y 6H_]>TG_H)H S+;QSX7N]1M+"#6[5[J[0/!&&/S@C(
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M: +7B_Q-_97B?0])NM2;2-.OTE9[X*OS2+MVQ;F!5,Y))([  BM"&YOO#_\
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MC"]-N,\_0$CAO"FKGP]<PZY>31W6AR:G=VKKP6L)7F=DF4#JKKP3U Z'!(H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M836;VEK9HP9XF.Z=@6QD-]T+M.,?QCFN83QMKTWA7P9JD,6GF;6[J*WN$=7
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M) R0!P2Y;#Y .1M&/?J;1\$ZG'IOBO38=3MOLFN2W$R![=M\+3* V3NP0,<
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M7&&"J&W $%U*Y*^GKP_3O&>ISMXKLYY+%[_2YQ%9+%;NJS;SMCSESDF0%#C
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M8L@CN,@-YHP2,C/TS6N-"O+GQ FNWSVWVNUM7MK.&/<4C+D%W9C@DG:HQ@8
M/7/ !SOAWQ)XOUGP<GB:0Z/';M83RB 12%O-1CM.=WW2%(QUZ<G/#[KQAK5M
MX.\+>)&^PK9WOV7^U"T#'R5E _>*=XP Q P<]:U- \*W^B_#T^&6O+>:9()(
M([@1LJX<L<E<]MWKSCM5BQ\*+_PKV+PIJ4D<\:V(LFEC4C<H7:& /0]#]10
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M&%G= 9(FC.58J>& /4&KM>8KXV\0M\.-.UY38&]FU3[),IA8(5-R8AM^;Y>
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MA:2!<HR_/ET)XQU'K6-I/B[Q(?"USXKU.?3SI]A]L6>UA@97F,;LJ%6+';R
M,$'CG)SP >ET5QEOJ_B:'7-.,UJ]SI4\;_;I#;B'[(P7*LAW$LI.1@Y/?/:L
MZ7Q?K<O@ ^.+0V[6J[KC^SFC^];!R#\^<B3:-V>G;'>@#M]0U2UTP1"=G,DS
M%8HHD+R2$ DA5')P 34.FZ_IVK:)_:]E,TMF%<D^6P8%"0P*$;L@@C&,UQFM
MR7FH?$GP9<V=\D<%S9WDT >WW; 8XB<_,,DY]L>]=OK$UQ9Z'?7%D84N(87E
MC,J%DW $\@$'GZT 3:=?P:IIUM?VI<P7$:R1ET*':1D9!Y%6:\Z;Q=X@?0?
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MU2>268 9/ R3G&" ;_BB]T#3=.6\\000R6R.JJTMJ9@K,0!V.,D@9XK;551
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M%AM//''H:Y76/%VLZ1.DLTMKO_MB.S:QBC\Q5MG<(K/(OW)""& )'IBKR_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<_XL\/7/B"UT_['?K9W5A?1WL321>;&[)D;77(R.?7@@5T%% '#2>!-2E;Q
M67UV)O\ A(;989<V6/*81>42,/TQT'7IDGO:D\(7TDOA63^T[<'01T^RM^__
M '?E_P!_Y?E/OS77UA7WB_2M/NA#,T[(+E;22>.%GCBF;&U&8="=R^PR,XH
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M31%HY]OW7&&!5AR.X(X]ZH7G@!Y=&AL[;48XK@ZL-7NKA[<MYTP??@*&&U>
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M** .>N/#ES/XZM?$0O81#!9/9_9C 265F#$[]W7*CM61H/@?5M )TNU\0_\
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MJX4'*L &RC*<@<GC@^M4K_X=1W>AM##J3V^L'4CJRZBD8^6Z]=F?N;?EVYZ
M9)-=O10!R5SX8UK5/#.IZ?JNN0S7M_;-:F6.TVQ0HP(.U-V2QSDDGL.!BH=.
M\%7ND:[9ZII^JP0M]C2UU&$6IV7FP823&_Y6 XSS79T4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>3G '3G(W?"=SX@GL+J/Q%:"&XAN7C@E!0&XA_@<JK,%;L1GM6#)\.[J+2M
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M_$]OI^J:=;S:3=^7!_H1;S_W:N$.6.T'/)Y//;',^@^.KGQ;+X?L;4BQGO\
M3'U&[D50Q0*XCVQ[LCE]QR0< =,G(J^&([Z_\3>.XM.U6V@6340C9A\UT_<H
M-ZD..>HY!&1]0=QO =O8S:'=:#<BPNM'MS:QM)'YJ30'JD@!4GGYL@C!SUH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*.V@A8M%#&C$8)50#4M%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPHW-M(X.!S6E6?INFM:6T2W<D%S<1LQ69+98MN?0#../SK0H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:;4?%=E8V6E(VA^6ZO,\C"16B\S&!CDC SP!_M=K47C<ZA::$MG"8KK5-/\
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MC*DUG$29K%U0NJNVXAL@8/"^M1>&M5\023>,[BXN+.Z-EJ$D4411HQ\D494
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M;VZU"TFGGFLKB$R_Z-<V1_=S1;5(;[S8.XL.O:@#5ILDB11M)(ZHB@LS,<
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MI92 LWG_ +R5E#C^$ 'MSD=QTH ]@JC?:SIVF7%I;WMY#!-=RB&WC=OFD<]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEY1/YC[%5YO-/&W.1T_7VK3O?#OB"W\8+XCT2XTY'N[5+;4+6[WLAV$E71E
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M<<9%2Z=J-GJVGP7]A<)<6DZ[XY8SD,* +-%%% !1110 4444 %%%% !1110
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M9W$ +&VF^7:"#C<!MZ\9R>E;BZ%J&H:YINLZQ]C%QID,JVT-L[%&DD 5G9F
M(X& N#C)Y- '*)X\\3CP;'XHFMM*%I#?FVNH%60O(GVCR<H=V%(R.H;/MTKT
MV:/S89(]S+O4KN4\C(ZBO/F\!:LWPZG\+?:[+S);PW/VGY\ >?Y^-N/48Z].
M:[Z6.2>R>-@JR/&5(!R 2/7'3\* /(H=4NO!.A#P=XZTLOH#(;6WUNT3=$4/
MW?-7JC#U]1T.,UU5]>ZM-\6=+M+74;<:>^E2W"1F N#^\C!.0XR2.AZ 9X.<
MU+=^'?$>H^$6\,WUWIL\4UN+:;4-CB0IC!(BY&_'??C/..U6)_"=U;^)M%U/
M2KN&&&QL&T^2.>,N3$2I!4@CYODQSQ0!1;Q=J]]X5U'Q3I$=D]A:/,8[65&\
MRXBA8J[;PV%)VL0-I[9Z\7;/Q7+XCOXK/07@A4Z=#J$D]S$9-HESY:! R\X!
M).>.!WR*=IX,U/2]'U?P]87EJ-&U!Y6B>0-YUFLN=Z*H&'')*DD8SSFB[\$Z
MEI6M6.K>$+VTM7AL4TZ:UOHV>*6%/N'Y2"&7]?SR 9'BK5KNVM/ ^J>*+>'3
M+B#56>\19-Z1A8I?F!&>" #CD\XZUW.AW6IZA"U]=FU2SG.^TBC0^8(CRI=M
MY4DCG 'IS6+K/A/4M5.A>==VMT;"[-W<F=2!<$JRE%7D*N&(&<\ 9SR3:\)>
M'M1\,"[T[[5#-HHF9["(EC+;(3GR\G[R^G<=,F@"SKVIZC8WUG%;FTM;*1)#
M/?7/SA'&-D:H&4LS9/3/W<8YKE?^%@:S-X&T77+>RLC<W>IK87$;[U7_ %QB
MRG<9VYYSC/?%=#K/A_5;GQ?INNZ;?6J"VMI+9X+N)G50Y!\Q "/GXQ[CC-<]
M%\/]:@\+6>BC4;&3[)JXU&.1HV7*B8RA2!G));KQC'>@#6?Q!KEC?V^BZBUC
M_:<ZS7(FL[2>>-+=655S&#NWDOZX&#["M/PGJVK:K877]LZ>UI<V]R\*N(GC
M2YC'W955_F4$'H<XQ5+Q1X:U74=3TS7M"OX+'6;%'B*SH9()XGP6C?&#C(!!
M'_ZMO1K;4;>T9M6NXKF]E;=(8$*1)P %122<<=2<DDGT  .:U3QA<P^)[_0;
M>ZL+._BBC>R@OHV_TXLN3L?>HZ_+CDY!/TT+;7-1G\=:KX?;[*(K>QBNH)1$
MVX%V9<,-WS8V]L54\4^$[WQ/;:GIUVNGSV-T5-I-*&\ZQ.Q5+(,88Y!8<KUY
M)%23^&=6MO&*ZUI5]:B.:PCLKE;N-G<;&)5UP0"?F((/UH Y'4M?U#Q)X1\"
MZQ)!;"_F\1(!&I9(]RF=!R=Q ^49ZUTNF^(_$47BB^\-:S!IK7OV$W]C<VH=
M(I$#;2KJQ)!!(Z'D52L_A_JMGX/T32QJ=I)>:/J7]H0L86"2?-(=C'.?^6A^
M8#MTK;CL8[;Q(^MZU>6<6IW%H;.TMDE^5(E.]]I;!=B<$G P ..I(!DZ5X[N
M;[POX9N9(8H]1UL2,!%;R2I$J EB$4EFZ*,9'7.>*<GC35[&TOTU/3/](6^@
ML].N#!);Q7AF.%.U\LNTYW=>G'6L?P_X1U'4OAEX.N=/O!INMZ9']HM9)8]R
M%7!W(Z]=K*1[UT&I^$=7\2>&;BUUO5H8]5:2*:VFL8F6&UDC.Y"JL26.2<DG
MD8'&* +-[=>++0:O')]A^SQV!GM=1CA("RC.8VB,A)X&0V0/7-/^'DM]<> M
M%N+^YCN))K.*0,L95L% ?F)8[CGOQ]*DTW2O$-U9W">)-1LI))+=[=$L(61
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M\ %6^U[QEINMZ%H\\>AR7.J272B6,2A$$:%D)!.?3(YSC (SD2GQ+KC2W6E
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MEY8;/M,>QAY>_.WDC!SM/2N8\;3ZJGBKPA;V-_';P7%[('C>$N&987(+889
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MMXHB#$S(Y4!BWS  D'(Y.",=* /3Z*** "BBB@ HHHH **** "BBB@ HHHH
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M\83CU(S6G0!SOB'P_=:EK.B:Q87,,5UI3RLL4Z%DE61-C D$%3CH>?I5"_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.1D!E/'?BNOA\+7VDZYJU_HFHP00:JPFG@N+<R".;&#(A##J,94]QU[56OO
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MN[UR/F!R<CZ5>U'PCJ%^=#D.M*UQIM[]NEEFMMQGDVLN  X"+AB !G&!UYR
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ML8(+*_CM[5Y2L"X:-7V\GD\^IKJ[W5-/TV-)+Z^MK9'SM::54#8&3C)YXYH
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MD)C'I7MCVMO).L[P1-,JE%D9 6"GJ ?2JXT?3!&8QIMGL8@E?(7!(Z'&/<T
M<=>6]I8_%SPREI%# )-+NT(B 7<H,9 XZCJ?SKDK;^S-4\+MX5EUS2,QZX\_
MVV>\C61E6X+DF-CN\P\K@C!!SG'%>O/I5CD/'9VT<R+B.40*3'CH1QVKB['P
M?K(M5L-4T_PM?* 5?4I;=GGESU=XV7!8]3\^,F@#O&A@^R^28X_("[=A4;=H
M[8Z8KR[P+I>DO\$(KTV5H\_]FW2M.T:E\9?(+=<?*./8>E>F6UA;VVF0Z>$\
MRWAA6$++\VY5  SZ]*$TVQCMWMTLK98'.7C$2A6/N,8- 'EAN;>Q\"?#/49;
MZWA6U-NPAN)1''+_ *.P;YS\JLHR1G SQU(JW]ET^30?B)K]O>Z=,VI6DKB*
MUG24P(+<K\S*2 S$9(''3DUU'B+P[J%Q-I\FC1Z2UM:F3S--O82()2P #Y4'
M#*-P'RD?,:=H_A2&*\:_U#2M&MYFA,/D6$ \LJ65B78J-YRHQ\HQSUS0!R*0
M6EI_PJF:WBABD? +H "P:U.[GODXS[TMA)I<UG\1=*U+419B?5)O,96 DCC:
M*(>9C^Z/7I7I/]D:;\G_ !+[3]W]S]ROR\YXXXYJ5K&T=Y7:U@9Y@%E8Q@EP
M.@;U_&@#C?"M[K4/BVZT?7X[.[O$L$FAU:S!43P[R%61.BMDL1C@\XJ3Q-JE
MA:^.=#MY7M[2_P#LMQ)%?W<A$<4>4#JJY 9S@=3P 3STKK;2PL[!&2SM(+96
M.6$,80$^IP*=/:6UR\3W%O%*T3;XS(@8HWJ,]#0!XC:W=J/A/:*+J-EM/$R-
M*20/*3[82"P_A&.>U>VB[@DLC=PN)H-A<-%\VX#TQUI#869@E@-I 896+21^
M6-KD\DD="34ZJ%4*H 4#  Z"@#Q&WUC2GM_A_=6EY9VEA'J3&*S67>]LC)+G
MS9&))8GKT&21SC-=IX>D3_A8_P 0/G7Y18D\]/\ 1S78IIFGQC"6-LH$OG86
M)1^\_O\ 3[WOUI!I>GAY'%C;;I01(WDKEP>N>.: .7^$Q#?"SP^00?\ 1R./
M]YJ[.H;>UM[.,QVUO% A.2L2!1GUP*FH **** "BBB@ HHHH **** "BBB@
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M+W6K::6ZED5HYI3*GF%" !C Y*\<'T- 'I\?B70YK=IX=6LI8EF: O',K#S
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MR2,>% K@]9\</J'A31];\/W\<27&I6T,T>%D;RY) NUL_=)'X\UW-TC'2YD
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M.>74IG:T<JOVJ%V!B,?REF.T* %.?E&*WMT<'Q9T2W1BDB^'946.=P7!\R/
M;U/!_(T 6?B3XM&A^$=3ETK6;:VU:V"[4^1VW$CY<'C=M.<=<<UW->#76LV$
MO[/FJZ9?W,*:["[K>VLS 3_:/M&XL5/))ZY_PKW6">*Y@2>"5)8I &1T;*L/
M4$4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4R6&*8 2Q)(!TWJ#BGUR7Q!U+4-(T:QN]/O
M6MF.HVT,N$4AXWD56!R#C@]1B@#I_LEMN#?9XMPX!V#-*EM!$&$<$:!AA@J
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M9);J.-KG/DACC?@9./PYK/T*_M6TV^O#XABU.U2YE8W1*!(%!SY>Y>,*.YH
MUFM;=[;[,]O$UOC;Y10%<>F.E!M+8Q)$;>(QH,(NP84>P[5QA\3/=_$_2=.L
M=4,MA/8SRS6OE@89=FQLD;L$$XYP<<5TQ\1:.-1CT\ZC;BZD<QHA;[[CJ@/0
ML/[O6@"Y-96ES$L4]M#+&HP$>,,!^!JM?Z1;ZC]D29$\FVE654"#.Y2"N#V
M(!P.N .F0<OQ=XAMM+T/4UBU5+34(;5I48 ,8VP=FX$$ $C W=>U7/"5Y/J'
M@W0[VZD,MS<:?!++(0 6=HU)/'J2: -BH8+6WMBYM[>*(R'<_EH%W'U..IKF
MOB3J.H:1X U74M+O'M+NVC#I(J*W\0!&&![&M>P\0Z1J&H2Z;:ZE;3W\";I8
M$D!91G!./8\'T- %Y+2VC"A+>)0K%U 0##'J1[^]*;6W:Y6Y,$1G4;5E*#<!
MZ9ZU1E\1:/#>K:2:C;I,TOD@%L#S/[F[IN_V<Y]J=_;NE?;[BP^WP?:[:/S9
MH WSQI_>(Z@>] %LVEL79S;Q%FSDE!DT^.&*%2L4:("<D*H%9T7B319M*&J1
M:G;/8,XC%RKYC+$X !Z=>/KQ2W_B+1]+E$=]J,%NV5#>8V F[[NX]%SVSC-
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MD7!**9&^;(Z97\Q77^'M3T?6-$M[S0989--?(B,*;%&"01MP,<YXQ6D4PC!
MJDCKBJVG:=#IEKY$&2"[2.QQEF8Y)XP/P' &!0!PUE-I4'Q>\5_VB]I&S:=:
M;3<%1E,/OZ]ONYKDK>U@TKPOX+M[PQPVLGBEKBTAG(!2V)E*'!Z#E3_P(5V:
M>"M?_P"$RU;66UZ*."_$:A%MHW=%CW;!\R8XW'T/N:VSH6NMU\5W!^MC!_\
M$T 8=]-'HGQ=T^YO/+M])NM)DMK24X6)+DR^8X)Z!F4 ^^*KZ+X=AUU_'ULV
M#H6KW06V9>5,GE 2RIV/[S'/JE=')X?UN5"DGBJ=T/56L;<@_P#CM.&AZ\H
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M,$G\.Z-X;U"],YM+74OM&K2VV24:1) 9..=JN_X#%=,="UYA@^++DCWLH/\
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M/0736]C+)%<&+5+CI$,*&C3)V[VX^]G&.AS7;;0&+8&3U-#(K8W*#@Y&1T-
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M&.!),YPH)].I/TKHZX?XI:)?ZMX<LKO3(&N;S2-0AU%+=?O3"/.5'O@Y_#%
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M66E72S"YCU.YB@MW@!=&#L 6W+D8"Y/N1BMN9C=::[VT[Q>9%NCE11N7(R"
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M.I^(-+T<,;^Z$6Q/,DPC/Y:=-S[0=J\'DX'!JO?>+_#NFLJW>LV<9: W*CS
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M2F-Q%)("1L63&PMD$8!SD$4 ;-%<]J/CGPSI-U<VU[J\,4UJ4$R89BF\X7.
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M\L1@8 )Y/8XJU9>*='U"ZCMK:Z8S2P&XB5X)$\V(?QIN4;QR/NYZCUH V*"
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M4*Q8LW#<@8Q[]'XB\66OA[4-)LI8;B274;CRE,<#N%4*6)^4')XX YYSC -
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MI6RTU:) 'F++(! Y7AG'7C^]SUKUVB@#S*XN+;^W_ADT<D>R**8.5/" VVT
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M 2<X P-W?GTK)^U_V!\6-4NM8D$&GZG80+97<IVQ(T1;=$6/"DEBV#UKO:*
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MF)Z $*0#['!ZUS^D74"_%+Q+=RYCADT^T"O(A4$KO+KD]QD9':LCPUH$VN?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\@%)!CY""?XL"@#I:*Y;_A8?AT-"DD]W&\T\EO&DEC,K.Z#<0 5Y.,8'4Y
MS5N'Q=I=SI]O=VRWD_GQ-,D,=K(90BDJ24QE>01SUQQF@#>HK&C\5:-<:19:
MG;7@N+:^;9:^2C,\S<_*JXSD8.>.,'.,&N=\&:G+?^//&<7VF]>W@:S$4%T6
M!@)C<N K= 3SQP>,9&* .[HKA/'OB(:'K6@Q:E<W5EX?NFE6[N[=F3$H \M&
M=?F13ECD8)QUP#6E8N^C1ZIJXU.[U71#:Q2VBJ_VAE*^9O",.7!RARQ/UP.
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MN+:"ZDM)98V1+B, M&2.& /&15/0M&.CVCK/?3W]Y,P>XNYPH>5@ HX4
M  ?J220!/$Z6LGAG48[VSEO+5X&2:WA!+R(>"% Y)QTQS7G+Z/K]UI7B'P[I
MFJ7&L:7-I)-E=7D>V:&7=Q;F0@;\J#UY'&<=_7** ///#FI:/KM[87'_  C>
MI6^J6(9YWOH90+([2&VL_!)/ "\D<G&*G^'+_9?!-ZMQ!<0.E[=R,DL#HQ5I
M792 1DY!'2N\HH \6L+>_P!.^'_@74Y-*O[F#2'E34;**-TG175EWA>&.W(/
MT/I70W%OX;U;0-2NX]!U*&POI;9);Q8I8[IV5OEE (+XC^4AL>O8<^D44 <;
MX%.L176KV=_?MJEA;M$+'4Y8MDDRE261C_'LX&[N2>^0*]V9]"^*SZM>QRMI
M6H:8EK'<JA=8)4<ML; .T,&)!/&>*[JB@#RF[TNYM_ _Q!NQ;7(76YYWLK98
M6,CYC"!M@&078$\CI@FO1/#\JR^'M/*AU(MXU970JRD*,@@\@UI44 >:Q6%G
MJ?QEUA]0TPW-E)ID,,<EQ:%HFD#'<H9EVYP:O_$2UCMM!T2ULK)_*AU>TD$-
MK;E@D:2 L=J#@ 5W=% 'GOC6233/%FC>(;BPO;[1?LLMI<?8P[/;EV1EDVKR
M5.W!_P#U53\206<WPK\2-HVB75L-1!,4?V=_/NG.W,A3!89YZ\X&>]>G44 >
M;>*9WM-8\-^(WL+Z^T:.TEM+M;5)/-MR_ELKE!AL93!]/RJEXDBL9O"2W&CZ
M%>6\-UK%K<$&UD,UP$D4O*R8+ 8'5N3CW%>K44 <-XRDW^*_!<R0SRQ0WLDL
MKQP.XC1HF4,Q ^49(ZUG^(IQH'Q$FU/5M.U&ZT?4;&&%+FR21_L\L;.=K+'S
MA@^0?7\:])HH \LO8!H&L^$]>M-"N;30+=KM)K>*%FDMO. VRO&,D9P<]QGG
MGBM?PE<?:?B-XONUM;Q+:[2R:":6UDC239$0V"P'J.#SS7>44 <]K^IVT&H0
M:9J>G27.E7EO(9Y/LK31HRE<"3 . 06Y(QQ7'^%_#PTW7/$L/AI;E?#%Q8?N
MX9=PC^UG=D0[N2NW&2.,G&>./4:* /'K--07P9X#U"+3]0:/P_/&NHVS6KK(
M!Y9C9U0C+[,YX!ZG'0XU/$.B77B[Q#JNH:,76%O#DVGK.5*+--(Q*H"<9 [G
MH"P[YQZ;10!POA3Q-%J]EI=E-H-[!JEC&J7/VJS9$M"J[6*N1@YQ@!3D@\\9
MKC=$.I^']6O/$R6E]=6?]M7D-Q8-:N9%AFEW+<0KMR3_ 'L=5'M7ME% '!_$
MP?VOX7TNSM-S2W^JVL</RD$8?>3@\C"JQ/TKK->@ENO#NIV\*%Y9;25$4=68
MH0!3VTV*75(]0G)DDA4K;J?NQ;A\Q'^T>F?3@8R<W: /(GG>X\!_#V!;'4!+
M8:CIXN4>SE4Q^4F)"05SM4_Q=/0U>U>XO+?Q?XRO++29-09]$A2&&6V9HKAU
M,FY.F'X894=>E>GT4 >6:3.9OB%X<U&.#6+B"72YH'N)[.2-%D+1G;MVA8U
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M\MAQ71>&M0T/6]2M]1L] U&WN[6)_.N-0AE1K8$<QJ7^\Q/9<C ).. >[HH
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MU% 'EMOO_L?XF)]FN@UW-<-;J;9\S!K=4!3CYLL".*;I(NM'USPCKEU;W/\
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M^=N<@DC'/(:0ES%X$\!6<NGZA'/8Z\KW"/:29C4--ECQ]T;E^;ISUX./;**
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MLMO=Q/-;FYA::+:LD8*C(/K\Z\'!YY JQJ6JVNE11/<NVZ:00PQHI9Y7/15
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M3/'.@:UJ^F70^T:!]CG%E;/,L5R71RA" [1U )XXZT =7;>+M(NM)DU))I!
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MD,@RBL,,P5\@?UKO_"KV5[+/J%CX8?1HW14+W-FMO/,?0J.=H]^I/'3GIZ*
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MDGBM(5AC>0#<54 #. !T%:% 'F%E!?)J7PT:72M0C&G6,L5V3;,1 S0(B[B
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ/<V>J7EM%]I@95_=M*H9/F8$,PRO3CG)%=+H6A66E_:[BTM;BR6^99)+-Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B:IX:AU77=*U>2^O
M(9],9V@2(Q["77:V[<A)R..M;=% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4V2-98GC<91P58>H-.HH Y;3_ \.F0I:0:
M[K?]FQKL2Q:Y4QJG90VWS H'&-_2NGCC2*-8XU5$0!551@ #H!3J* "BBB@
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M,GV&: '45C^&O$,'B?1QJ5M!/!&9I(O+G #@HY0YP2.H]:V* "BBB@ HHHH
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M P!_K0!/1110 452TF^EU/3(;R:PN;"23.;:Y $B8)'."1SC/7O5V@ HHHH
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M 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-82*OGQ@Y <,"#CL?\!0!@ZEK'B/0].T6X\2Q7,]HEO(FIW.BG<8I@P"2,
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M;>J%MNYD#8(!/8 Y'%7(?"T=OK^K:Q%J-ZMQJ<212KB,J@0$+M&S/&X]2>M
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M)LE2!AN%P,,>.* /0Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M84$8!/.??K4.@>"+;P^ (M7UB[$2&.U6\N1*MJ",?NUVXSCC)!P..A.>HHH
MY%?AYIR^%;?PXNH:D+""<7"?/'OW"3S!SLZ;^?\ ZU=3)!'-:M;S@31NA202
M '>",'(Z<U+10!S-AX(L+&VL[+[9?7&FV4PFM;*=U:.)E.4YVAV"GD!F.,#T
M&"]\$V5YK6H:DM]J%L=1A6*\@@E"QS[5*JS?+D$ XX(!QR#SGIJ* .57P#ID
M>FZ'9Q7FHQ'16)M)TG'F %=A4G&,%>. /;%6+GP=:W<5S:W%_?2Z?<W N);)
MV0QE@P; .W>%R 2 W\SGHJ* .=NO!>F7FKZGJ$LMV/[4MA;7ENLV(IE",@)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex31-restatedcharterasam002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex31-restatedcharterasam002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ JO?7]KIMH]U>3+#"F 6;U)P  .222  .23
MBK%<7\2+>^.GZ+J-I!+<0Z9J]O>W<,2EG:%<AB%'+%<AL>WM0!OVGB+3+ZZN
M;6&647=M&)9;:6WDCE"'HP1E#,#TR >>.M<AH-]/XTOM3F&I:M87%CJ\D=OY
M4<L<7D1%1Y;JPV$M\Q(;YQGL!BK3K%KGQ+T?7-,F62QL-/N%N[I/N-O*[(]W
M0D89B.V!G&12_#:9&C\2)DJTFNWDZ*ZE2T;,-K@'JI]>E '4ZAK=AIEQ!;W$
MCFXN S100Q/+(X7[Q"J"<#(YZ<CUJ32]4LM:TV'4-.N%GM)@2DB@C."01@\@
M@@@@\C%<KXGU,6GC;2+6>WEMK>6UFQJ4%H992^Y?W"L%;9D#<>,G QCK3/A,
M6C\$K:207$,MO>7*NL\;*1F=V RW7@CIGK0!MW?C/0;*^O+&6\=KNS17F@AM
MY)' .<8"J2W0],XQSBH4\?>&)%L'CU,/%?,J03+#(8]S?=5GV[48^C$&LG3Y
MX8OB[K\TC!(CIEN@E;A2RLY8!NF0",BN-3Y?@)9VGER"Z745)@\L^8,7N_.W
M&?N<_2@#U+4O%>C:3+<Q7=TX:TC66Y,4$D@@1LX+E5(4'!//89Z5#J.H:6_B
M30(7UFYANIC*]K:P,?*NQY9)WX!!  +#D<UP_BS4?MTWC;3A:W$#OIH^S"SM
M6)U(& X=Y54Y52=H&0.N<YP+0F6XU?X6.J2* DZXDC*-D6A!X(!ZB@#M;_Q5
MH^F-<"ZN7"VI N9$@DDC@) (WNJD+P0>2, @GBF:GXPT'1[B&WO=01)9XFFB
M5$9]Z*,DC:#G@C ZG(Q7':'<KHNG>+M"UV.3[9->W4\*%"QOHIAE?+_OG^$J
M,D8JGI>GW&B:Y\-+#426N;'3[J.X;&X0N\:!5+=!T*CUQQ0!V%EKVB:IXEAN
M++6KR69]*^T+8(K^4T)92)=FW._D <YP<8JKIOQ(T>YT"YUJ_%U8V4-S)#YD
MMG-A0KE 6(4@$D<CL3@\U%(ZCXV0/SL&@O"7P=OF&=6"9Z;L G'7%4_ UC;Z
MEX0UGPUJ5M.I-Y>QW,<D+* KRL1AB,$D$$8SZT =O-JUG;SV4$KRK+>DK OD
MN2Q W'/'R\<_-BI;Z^M=-M'NKR9884P"S>I.  .I))  '))Q7%_#^+5KG<=<
M7,VB*^E0RD_Z\JWS3?\  E6(>N0_K5CXD6]\=.T;4;2"6XATS5[>]NX8E+.T
M*Y#$*.6(R&Q[>U &_9^(M,OKJYM(991=VT8EDMI;>2.4(>C!&4,P[9 //'6N
M0T&^G\:7VIS#4M6L+BPU>2.W\J.6.+R(BH\MU8;"6^8D-\XSV Q5IUBUWXE:
M-KFES+)8V&GW"W=TGW&WE=D>[N1AF([8YQD4OPVF1D\2IDJTFO7DZ*RE2\;,
M-K@'JI]>E &MKOBZWT3Q%HVD/;74CZ@TI+QVTD@5$C9N-H.YLA>!G R3CBN=
ML?%<.A>,?&<>M:I=R6=K):M AC>4Q(T.]R$13A03R<8'&35WQE(;+QQX+U*6
M*=K2":[262*%I-K/#M0$*">3P*S;2>(>)OB1*_RI/#;B-F'$FVVVL%/\6&^7
MC//% '<RZYIT5I:W0G,L=VH>W$$;2M,I&[*JH)(QSG'%.TC6=/UVR-WIMP)H
M0[1M\I5D=3AE96 *L/0@&O)K.X;1-,\#ZQJ-OJ+Z1#HYT^[:T,JO9RGRR&<1
MD-CY-I^@]J]'\(Q:5]BN[S1[">VM;RX,WFS^8'N6(&92)/F&>F3R<9Z8) +=
M_P")-+TQ[A+F:7_1E#3M%;R2+$#R-Q52%XYY[<]*HQ>+K>;QO<^'%MKH/;VZ
M2M*;:3:69B!@XP%P#\QX)Z'@UR/BY)+36]:U3P_J4MKK,:QI<:5<1^;!JR^6
MNT*A&2V#LROISC.:T0]Q%\4M1$L-Q;S:CHL$=NZ1,ZB0-)N^8# V[@3G% '3
M2>+M$BE1)+PK&\_V9;@POY!ESC9YN-F<@CKU&.O%3ZGXATS2&D2[FDWQ1>?*
ML,#RF./GYV" [1P>3UP<=#7F,*/>?!:7P9-:NOB*./[%]A93O,@DRL@]4Z/O
MZ=>:U8-4'@WQSK<'B**ZEL]6AMC:7:6KSK*8XA&\1" G).2!C^(^M &K?ZM)
M<?$+P>^GZI++I>HVMW(8XW'E2!40HW'7[QZUU6FZO9:O'))9/))'&[1EVA=%
M+ D'!8 -@@CC->9^,M.FU77/">GZ86T1_L5ZB"- %M=ZIY:. ,+NV[2!ZD"N
MU\%>(4US1$CEL_L%]:?N+BT";51E^7,?9HSV(XQQ0!K7^LV6G31P3O(UQ(K.
MD,$+RR%1C+;4!.!D#/3) [UB:_XRM+7P%J'B'29OM0CMY3 T<+N!(JG < 93
M!'.[&.AQ6;<S/H7Q8FU+4R8]+U#3$MX+MO\ 5PR(Y)C9NBY#9!. >E8-WI\U
MKX ^(5WY<B0:Q<W$EC!L(:3<@7<%Z_.P)''3!H [+PM9O,T&L)JNJR1S6BQS
MVEX) C2\'S5$@!7N,+A3G@<5!'XMCUK4?$6C6R7UK)IZ",3_ &9U.\H6)R5V
MJ,;<9QGJ,Y%;V@S1SZ!8/$X8?9XP<=CM&0?0^U<987*Z=XU\=PW4<\9NO(FA
M<PML9!;A2=V,?>&WKUXH F\">-=/F\+^&[/4]2EEU2^MU DE1V$DN"=IDQMW
MX_A)S[5TNJ>*='T8S&]N9$2 J)Y$@DD2#.,>8RJ0G4'DC@@]#7FD!$?PU^'4
M)5EFMM6LVGCV'=$%+;RPZJ!D9)]?>K276FZ9KOB/0_%5EJT@U&]DN+/[/]HD
MAO89 ,1A8SMW#&TY [<T >K&>(6YN/,7R0F_>#D;<9SGTQ7%>$+V]\=:8_B&
MZO;JUTZXFD6PL[9_*Q$K%=[L/F+$@\9P!CCO756UA$?#\.G&W^S0_95@\A7W
M>4NS;M![X'&?:N%^'^I1^"]"3PEXC8V-UI\LB07$J$0W43.65T?[N?FP5SD8
MH ZNS^UZ$=5N-:U8SZ<A22WGG"J8TQ@H=H&3N'7&3N Y-6+7Q)I=W>RV2SR1
M7<47GM!<020N8_[X5U!*]LC.#P:YGQ\U_K'A>*\TNRN)X;#4;:\:((0]U%&^
MYPJ$9(Z$>NTX'0E+Y[?Q%X]\+ZOI4ZR6FF0W4MY<KD*B.@58V)_BSSM/(VDG
M'% &FGQ(\)R!635E*,LKA_)DVXBSOR=N 1@\'DCD5+9^/_#%]J=GI]OJBM<7
MJ![8-$ZK+D9P'*A=V#]W.1TQFN4\,%5^#OB*(J4E4:DSHR%6PS2%3@]BI&#5
M81VWB3P+X#TS3,27]O-87#A%PUJL:@R.W]WC(&?O%AC- 'H&H>*='TQ[@75R
MX6U(%S)'!)(D&1D>8RJ0O!!Y(P"">*9J7C#0=(N+>"]U%$DN(FFA5$9_,11D
MD;0<\8P.IR,=:X_0KE=#M?%^B:\CBZGOKJY@4H6^W0S#Y?+_ +[?PE1DC JC
MI6G7&AZO\,K#4B3<V-E=I<'&X0,\:A%9N@[J/7'% '<-XX\/"S%TM[))"+5;
MQVBMI7\J%LX=P%)0'!^]CH3V-1:KXTL]-US0M.2*XN%U022K-#;R2KY:QELJ
M5!W$G;P,X!)..*Y?Q5?-/K/BW2GL[FU=M+ MC:6C%]2)B?[T@4_*A.W&1U.2
M0<56@NO(/PNU*2VO!:VMI+;S,+60E)&ME505 SRP(''./2@#N=,OM-N/%&N)
M;:O<W%S D N;.1CY-KPVTH"  6P2<$]!TJ6#Q9HMQ=6D"7; WA(M9'A=([@C
MG"2%0K<<C!Y'(S7$7=I<ZKXF^)%E8,4N;[2[:&V8_*'<12AE#=."P!QTS3+V
M1?%/@/PYHME%)%K,%S9^;;LA62R:$CS'<?P@!6 )ZY&.M '87?C[PU927T<N
MH,7L"!<I%;RR-'D9R0JD[0.2W09&3S6_;7,-Y:PW5M*LL$R"2.13D,I&01[$
M5YU:RPKXB^)4CG"310>6Q7B7%ML.W^]AN.,\\5TGP\)'P\\/QL"LD5C%'(C#
M!1E4 @@]"* +FH>+-%TN1EO+MHXTE6&2?R7:&)SC"O(%VJ>1U(QD9ZU%>>--
M L+ZZL9KYC=VJ"26"*"21PISC 526Z'IG&.:\_T^;2[4ZOX4\5:9J]Q?27]Q
M)! GVAX;^.24R(5VG8/O<[L 8R3UQT.EO#;?%C5GDVPQ+H]M$').P,C.64,>
MI (SWH TM6\>Z;8Z=HE[9B:]M]8NHH;>6&!W7:Q^8G SNP&POWLCIP:LKJFE
MR>,"$U6^-['IAE;3 C^6(MX/F%-N?,R0N.O48KS?3@]O\,O!,KP3A=/\0++=
M*(6+0IYLWS,H&0/F7MW%=@EPDWQG@N KK&_AXQAG0KAS.K!#GHVWG:>: *>I
M^,I/$/PKU[6-->^TZ>WCN&B<1-&P$;LJ_,PQDA<D*<@\<5U\6L6UCI.G&[DF
MDGFMU=8XHGFEDPHW':H+$#(R?<>M>:VDC1_!'Q%H[V]RE_#]NB>)H'!+O-(4
M5<CYB00>,U>U6^CT?Q!H.N:C'J#Z#/HZV;W%DTH-M,&#9<1G=@CCZK[4 =[#
MXHT6XT5-7AOD>RD?RU=5;<9,[=@3&[?GC;C/M7.:!K4NH?%+7+1+V]DLX=/@
M<6UPC1B&0NV<(0,<!><<YZFL'5(K;2O^$<\0Z5I%Y%X?M]7ENKM3'(TC^9%L
M%RR-\X ))Y&<8..:V-#U&WU#XMZI=VJ3R6L^D6ZQS_9W$;$.Y/S$8Z'\>U &
M]XC\60>'M2T>Q>VN99-1N/*#1V[R*BA2Q/R@Y;CA1SWZ"KE]XDTO3WD2>68O
M%$)I5AMI)6B0YPSA5)7H>N.A]#7/>/6-MK/A#4'BF:UM=4)F>*)I-@:)U!(4
M$]2!^-5=#OAX?\:^*%ULO;Q:E+%>65Q,I"S)Y84Q@_WUP!LZ\\"@#N[2[M[^
MSAN[2>.>WF0/'+&V593T(-4;#Q#IFIW]_8VDTCW-@0+F,P2*8R1D#E1G(Y&.
MHK&^&ND76B>"+6TNXWA=I9ID@<8,,;R,RJ1V.",CL216;XFT_4].\<6FH:/$
MY77;<Z9>-'_RQ=06CG^JKY@_ "@#J1XDTMK*UNUGD:.[8K;J()#)*0,G:FW<
M1@9SC&.>E9^J>.=*L?"FI:[;&6[2QWI)"D+B1)!_ ZD93MDL!@<UCZY$WA_Q
M_P"'-4>)ET&&QET\NJDI:,2I5F_NJ0H7=T&.:P];TBZU"S^)6K:?#)+9ZE91
M16PC4G[2\<1WN@[CD $=<'&: /0X?$5F=,M+N;SU>X'R0BUE\QVQD[8]NX@>
MN,>]6-(UK3]=LC=Z=<":)9&B?*E&1U.&5E8 JP]" :\ZUG58K;4O#/B2>WU.
M30!8R64\MLLT;V[MY;"0JN'*DIM]./I6Y9Z]X:\+Z%<ZY#8WMKIM[> F=H9G
MDG=AS,RM\P7@_,<9QGN,@';22)#$TDC;40%F/H*Y/2_$_AW2?"EI?/X@N+NP
MGN'BAO;S<[R.92-I.T' ;Y02,8 KK'D1(S([*J*-Q8G  ]:\3C('P7TVU>*3
MSEUH.\!C.\)]L+DE<9QL.>G0T >CK\0_"S%!_:F&DG>W56@D4F1!N88*^G3U
M[9JW#XOT6YTVWO[:>>XAN(VEC6&UE>0HIVLQC"[@ 1CD=:P/&LT+>*/!,N0\
M4>H-,[J-RHAB8!B1T&2.35'Q'>Q>'?B-)J.MQ:D-&U"PB@BO+-IML,L;N2CB
M(YY#Y'!_G0!V47BC1[BQL[RUN_M4-ZK-;_9XGE:0+]X[5!(QT.1P2 >>*KS>
M-?#UM%923ZDL2WN_[/YD;J7V9W<$9&-IZXZ5Q]_I&BBTT5-.EO?"LJ_:9].O
M>0$R4W"97XQ)D-M8@_+V.15*YU.\<?#Z^\00Q03KJMSYKQQ%4<!) )MO\(;A
M\GIG/ H ]!T?Q?H.NVMY<V&H(T=B2+KS4:%H<#.75P"!@'DC'!]*DL_$VE7V
MJ?V9%-*EZ8O.2&>WDA,B=-R[U&X?3.*\[\2:)>Z]J/C'5O#\9EBFTRWMT:,X
M%Y-')O8(1][Y $R.YQG@UHZ==:'XPVS:18ZH-9AM9X_.OS< Z>SQE2-TAVEB
M2!A<]SVH Z]?%NB->VUJ+PAKJ1HK>0PN(IG&<JDF-K'@]#SCBLW2_&MAK2:^
MLBWEE;Z=<26YG>VD0A51"S9*X5MS'"GG !Q6'X)U^QN]"T/P[>:+<?VYI0BA
MDMI[-L6[1C:9A(5VCY02"#DYP.M.\/W"V#^/;&ZBGBF?4;FZ7="P4Q/$@5@V
M,')!  .3Z4 =!I_B70],T+0E;5KR[AOU2*RNKB*21[EB.-S!?O'KS@UM2:M9
M17TMG),4FBA^T2%HV")'S\Q?&T=#W[&N!TW0IM>^!VEV-ONBU2TM(I;8D8>&
MYB^900>AR,?0U8O+35O%'PPUC4$M7@U;6+,/';-PRHJC;%_P+YC]9#0!U=IX
MHTF\U2/38[B1+N6(S0QSV\D7G(.K(74!L>V?6K]]J%KIEJ;F\F$408+D@DLQ
M. H Y))(  Y)KAO#6I^'O$VJZ9=6^EZJVK60<R?;C<?\2\LI#C=(=I).%P,D
M]>U7?B)#>1CP]JL$,MQ::9JL=S>11*681892X4<G;NS@?7M0!T%IXBTR^ENX
M(99?M-F@>>V>WD295(R"(RH9@<<8!STZUR/AJ]G\9W%S?#4]6L;FSU:41K''
M*D#6\;[?*96&PEAR<_."3TQBK2)%J_Q/M/$&GS*^G6>DR0W-VA_=R%G!5-W0
M[<,Q].,]:7X8RJ=(U:,[E=M8O)0CJ58HTA*L ><$$<T :FL^+K?2/%&DZ(]M
M=/)?"60R);2.JJBYXV@[CDKG&<#KC(KG=+\76^A>(?&":[JMU+;6MY$(MT;S
M&&,PJS':BG:@+<G 'O5WQ;*;+XA^#M0DAG:UC2]A=XH6DP[HFQ3M!Y.TX^E8
M\,L7F_$\G_EX'[G*G]Z/LP3Y?[WS<<9Y^M 'H-SK=A;06\IF:47*;X%MXVF>
M5< [E5 21@CG&.1ZT[2=8L-=T];[3;E9[=F*[@"I5@<%64@%2#U! ->50W8T
M1/!NL:I#J+:,= CT^XELVE#6DXV$^8(R&P<;3[K7HGA*#3(]-N)](T^:TM+N
MY:X#3;P]PS 9E(?YADCOR<9[T 1:AX]\-:7<7MO=:EB>QV_:(XX9)&3<"0<*
MIR,*<D=.^,BIIO&OAR"STZ[?5(OL^H_\>DBAF$G!/8<=#UQT(ZUS6G:GI^F_
M%GQ@;^>.'?:6.UY. <+)E0?4\<=3CCI7-6NER:+H/@J"Z@>%?^$B>^%NR'-M
M WFE-P_A W+G.,$^U 'IEMXOT6\L+6\M;F69+OS/(CCMY#*^P[7/E[=P /!)
M&.1ZBFS>-/#]OH3:W)?XTY)#%),(9#Y3@X*NH7<ASQA@.2*PM3EDT3XL6VL7
M^5T>[TDV27)'[N"82[\.>BAAW/4C%1:%X:35SXW-S&RZ1KMSM@4KC<!$%:50
M?5LD'OM!Z8H [.?5K.WGM8)7D62Z!:(>2_( R<G'RX'KBL?0]9T>+1;J]@UF
M[O[4WTB>;<!G<2L^/*0;02 2%  -9W@$:K<Z>MUK\317>FQMIBL__+3RVQ),
M#Z/M3_O@^M<UI,&G7G@S5K74WO+:*7Q'<21W%ON26W+2EXIAQPN0/FQC&3VH
M [76_$&C3^&=6DN-5O=,M[?]Q<7,<4D,UNQ4-\H*YSA@00#UK4FU>QT^&T26
M>61YTS"BQM)+*  2VU02>HR<8&1ZUYIJ4^L2_#CQII^H7,>JK&@AL=2@A"M?
M;D'&%X9EX7(_H:UVN&TKX@:+KUT3_8MUH?V 7.#LMY@X?YS_  A@ ,GN,4 =
M1-XT\/0:#+K4NHJMA%(8I7,;[HW!P49,;E;/8C/-2V'BK1M3UB72K2\+WD<?
MG;&B=0Z9QN1B '7/&5)%>8^)].F/A?XB:E!%(;/5[JV^PPJAS,4"!Y%7J0QS
MSW"YZ<UU>IW$$OQ5\-SQ,'A&G72-(HRH+%"JD] 3@X% '36OB32[VZMX()I6
M:YW&!S;R".4*,DJY7:1CG(//:KU]?6NFVCW5Y,L,"8RS>I.  .I))  '))Q7
MF?A,7&FZUH=OH6H2W^@78=Y-,O$W3Z3^[)!#XW*N3LVMZ\9SFN@^)%O?-IFC
MZA:02W$6F:O;WMU!$I9WA0G<0HY)&0V/;VH W[3Q%IE[=7-I%+*+NWC$LEM+
M;R1R[#T8(RAF';(!YXZUR&A7T_C2_P!4E74M6L+BPU=X[?RHY8XO(BV HZL-
MA+98D-\PSV Q5J18M=^).B:WI<RR66GV%P+NZ3[C;]NR/=W((9B.V.<9%+\-
MYD8>)DR5:37KN=%92I>-BNUP#U4^O2@#N:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHKE?B'J]]H?A*6^LA,%2:(7,L"!I(;<N!(Z@\9"Y^G7M0!U5%<?H8M]
M2N=,U;PYXAN;[2"7%S!)<F8$E#M8E\NI!QE<XY!P,5IWWB_1M-?_ $J>5(!.
M+=[KR7,$<A.-K2 ;1SP3G /!(- &[16-JGBC2]'-R+F29OLD0FNC#"\@@0Y.
MY]H.. 3CK@9QBLZY\;VB>*=)TBWAGN(;^U:[%S% [HR?+MVE1SG<"3T QZ\
M'545SND:EI,FL>(98-4NY)+=XS>QW3,L5J0G&P, %! W$C@]:GM_%FDW-[:6
MHEFB>]4M:-/ \:W  R=C, "<<XZD<CB@#;KGK;PY=/K=OJ>K:H+][*29[$"V
M$1B$HP0Q!PV%^4' ZG.3TK7'Q$\.6R7SM<W+BPE\JZ\NRF8PD $LP"Y50#]X
M\5T\4L<\*31.KQR*&1E.0P/((H ?17F_C2Q\1:)H\WBBT\27S:G!-&PT\%3:
M2!I HA";<D_, &SDGTSQV6MZA<6\$=I8A?[2N@1"&&1$ /FD8=U7(^I*CC-
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M!8DDQJ23WXH FHKA/"VH7/CV34=7FO+F#1XKM[6QMK69H3(J<&5W4AB2>@R
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M9/,6)6*L[)C(&X$<\G!QF@#HZ*Y/5_'=C8IX?DLXYKR#69E6*>&!W41E2Q/
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M<"6LGG$(VUB4QD 'C)QVQUJ_I&L6&O:9%J.FW"SVLN=K@$<@X((/(((((/-
M%ZBBB@ HHHH Y[3?#ES8>+]7UU[^*5=2CAC:W%N5*"(,%PV\Y^\<\?E70T44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %9.N>(].\/Q*]Z;AF8%A';6[S/M'5BJ D*.Y/%:U4M3
M-]#8SS:7:V\]_LQ&D\AC5L9P"P4GOT]^HH 72M5L=<TNWU+3;A;BSN%W12KG
M##IWY!R",'IBKE<;\+[B"3P7%:1V,EC<6-Q-:W=N[!BMP')D.1P02V>/7':N
MRH **** "BBB@ K D\9Z+'K,^D;[Y[^W0/+#%IUQ(54]#E4(P?6M^N!TK_DN
M'B#_ +!-M_Z$: .KTGQ#I6N-.FGWBRS6YVS0LK)+$?\ :1@&7\14VGZG%J37
MBQPW,1M;AK=O/A*;V4 [ES]Y>>".M<%XK7[#\:/!=S886[OHKJWO O\ RTA5
M R[O4 DG\/:K>G:KXGU?P]XN%M?1?VMINJ7%O9%;=0C+&B%4*G/4D\YSD]>U
M '?U2L-3BU&6]CCAN8S:3F!S-"4#D '*$_>7GJ*Y[1-?F\1V/ARXL+QP+BW-
MU>$HA^4#:4/'RMYAQQCA'^HQE\<:GIGA_P 77U^\%U<:;JQL+-5C\M/F$80$
M9)QN?)YSC- '97GB"QL=?T[19O.%YJ D,&(FV$(I9LMTZ#IG/(K5KSK5[._M
M?B=X&-WJ;WJM]MR'B1-K^1R5V@?*?0Y(QU--C\0^+=;T6WU[P_9W$WF7)*6;
M_9E@E@$A4@LS>8'P,YX&>,4 >CT5P#:CXGU'Q1XNTJVUBWM(M-BMI+:1;-69
M=Z.V/F)!Y R3Z< 4W2O&E_KMGX/LT=+:^UJT>ZNIT0'RTC4;M@;(RS$8SD 9
MX/% '6:;X@L=5U;4]-MO.^T::T:W DB9 "X)7&<9X&<].16K7EMC-K&D>(/B
M3/:;]3U&!;)HL1KO<>2?X1@%@O8 9(Z<UT_@WQ!;^(7O)[+7&U"U1(U\F>)8
MKBVER^]9%"KU^7''8]: .KJGJFIVNC:=/J%ZSI:P(7E=(FDVJ!DDA03@ 5<K
M"\:_\B'XA_[!ES_Z*:@" >/?#WV"'4)+FZAL9@K)=3V$\4)#=#O9 H!SP2<5
MJ:AK%MI^F)J&R:Z@=HU7[)&9BP<@!@%ZCG.?2LKP5!#=?#3P_;W$:RPRZ3;H
MZ.,AE,2@@CTKS3PKKNKZ)\))I]-NU$%GKIL[9Y8_,+VS3(HVDG Y=N<'I0![
MA5+5M3BTC3WO)H;F9%95*6T)D<[F"C"CG'//M7/:AJVI:3\1-*L[F[SHNJ0R
MI"OEJ-ER@#!2V,[2NX@=<CKVK-\1Z]KFF^!)]?L[],R7D9@$L"MBW>947&,<
ME6W9(/4#WH []F"(6.< 9. 2?R'6LW0M>L?$5C)>:>93"D[P'S8RC;D.&X/(
MY]:R7U>[U?QI?:!97;V4.FVL4UQ-&B-(\DN=JC>" H5<GC))'3'/'>$]:O-'
M\,164>9M0U'Q%>6IDB501AI'=E#$+G"$ $XR1UQ@@'K5%>=ZEJWC31]"\4W4
MRE+>SM?M.G7EXD+2DA27C=(FV\$<-@>X-3VVL^(+3Q1X4BO=1AN;378)1);K
M;A!"Z0B0,K=3G!!SQZ =  =9KNMV?AW1KC5;\RBUMUW.8HFD('T _4\5=@E6
MX@CF3.R10ZY]",UY7XCU74/%GPD\1:]#?FWLY$N$M[58D*M#&Y0ER1NW-M8\
M$ 9'!P<ZNL>*I-#NK"SO[Z?2--FTZ(VNHBW62$W!R"DK%3M  0CIG+<]* /0
MZ*K6C32:; S2QO.T*DRK\R%L=1C&1GFO+IO%7BR/X>ZCXG_M6W\W3+Z6-K<6
MB[+A$GV;6.<KQTQSZDYX /6J*XP:EKFF?$+3-+O=0BN[/5;6XD$2VXC^SO%L
M/RD<D$-CYL]*R6\4ZU97^@F>_CN);W5C8WEO!$&M8E;S-H27:"74*N1N/.[(
M'% 'I-!X%<3#XAO-'\7ZYINO7Y:T2R^WZ>XB5<PKD2@X'+J<?4$'%=+H2Z@-
M$M#JLOF7SQAYOE VL>=O  XZ9[XH 9HGB"Q\0+?&Q,V+*Z:TF\V(QD2* 2,-
MS_$.HK4KR;2H?$C1>-[K0-5M[-[;7+F4126HE\]A'&=K,3\JD#' SSUK8T[Q
MI?>)_P"S+>QANK>2XTF/49VM!"SJSL4"CSCMV@JV>"3\O2@#T&H;RZBL;.:Z
MFW^5$A=O+C9VP/15!)_"LGPG/K\VAK_PDEJD&HQR.A*%2)4!^5\*2%)'49Z@
MUB_VKJ'B9_$Z6-^;*VTJ1[*,+$CF658PSE]P/RY8* N#P3GD8 .HT;5K77='
MM-5LBYMKJ,21%UP2I]15ZO+?"&MW</A+P9H5BD_FW6EM<R26XB,BHA5<+YA"
MY)<<G/ /'.1I+XA\4:99V]AK%NL-[?:N+&QNY/+):!@6\QT1BH<!6&. 21QC
M- ';:EJ$&E:;<7]UYGD6\9DD,<;.P4#)X4$FDTS4(-7TFSU*UW?9[N%)XMPP
M=K $9'K@USFHV^NVND>*(]0O(KS3#8.UG*RA9P?+;>KA552,XP0,\\UF:/>W
MMKX,\#Q17R6=E-IL0N'C4/<NPA78D2%6W9.2>#@"@#T&BO+)/&?B)OAS_:L-
MQ M_!J_V"1Y+< RK]H$8)&<*<'G@^V*W+G4=>TO5K+0;B_?4+K4&N+H3VEM%
M$\,"! (U#MM)W/\ >.> >.X .WK*_P"$@L3XG'A[]]]O^RF[P8F">6&"Y#'@
MG+#IGO7)2>)/%&C::MIJ]LJ7M[J\>G:9=3>62\<G/F2)&Q&Y0&X& 3CCK2P6
MUU:_&VW6XOY+Q3X?E*-*B*Z_OX\@[  1^'K0!Z#16'XGO+VRM;-K6[@M(I+M
M$N9I,%UC(/$2D$-(3M &#U/%<9-XPUV/P;XSN8;H?:]$N62WGN;4!WCV*X#I
M\H#?-UQ]10!Z?69X@UZQ\,Z+/JVHF86L RYBB:0C\!T^IP*YF+5]>L/&?AZT
MOM0ANK/6K6=F@6W"?9WC17!5NK9!(.?J,=!S7BK5=0\5_!G6O$4=^8+2X63R
M;,1(4,"R[!N)&[>=N[(( R!CCD ]=1@Z*PZ,,BEJ",.;)!&RK(8QM9EW ''<
M9&?SKRA?$_C8_#A?&:ZG9/\ 8Y)6GL?L@ N(TF9&R^<J0!QCTY))H ]>JE=Z
MG%9W]C9O#<N]X[(CQ0ED3:NX[V'"CTSU-<9XF\1ZK:VVL7MKJ*VZ6^FK>6%M
M;PB9W.QF9K@%3L3( !RO?G-6;CQ)JK:UX&$<L,=IK2.UU"(LMD6YD&&)X&<=
ML\=: .KU;5+;1=*N=2O/,%M;1F20QQLY"@9)PH)J2PO8M2TZUOH-WDW,231[
MA@[6 (S^!KS[5M5U#Q3X'\8:A;7YM;2U2\M8(%B1A*D2$.SD@MECNQM(P,=:
M[#PC_P B7H7_ &#K?_T6M &S17G:>)=:UCP)?^,=+O5B6!KB6VL7B5HY(879
M2'.-VY@C'(8 9'''+XO$FMZYXJTBUTZ^AL]/U30O[14-;!Y(B63N3@G#>P]0
M: /0::\BIG<>=I;:!DD#K@#D]JYGP)K&H:OHMXNJ2I/=V.H7%B\Z($$OEN0&
MVC@$C'2LQ5OG^-4\1U2X^SQZ-'.L.U-J[IB&4?+T.P$GK[X   .HT+7['Q'8
MR7FGF4PQSO ?-C*-N0X;@\CGUK3KQBRU/6] \!ZYKVG7\44-AKET[6K0!_M"
MFYVL&8\KP>-N.G4YX[74=:U74?$&K:/I/VN$Z=#$3+;) Q,LBEAN$I'R@ <
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MG6PLHY(X1,CVXZ1NC'G!Y!SU_3LJ* *6E6$FG60BGNY;RX9B\UQ* #(Y[X'
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MG[N#GN>W7C6;K6_&=WH5I>26,%A913SR1*ADDDESM4;U8!0JY/&22.PYKOX
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M_#8EVBC<W%N[?*SA3A6QP0N.AP16K=?#UGM-#>PURYT_5M'MA:07\,2GS(0
M-DB'(8< _7FK=_X,DO\ 3].@EUB=[BTOX]1DN98E9IYD^[D#"JO & !P!SUR
M 0Z!J&K6_CS5] U#4FU"".SAO()'A2-H][.K)\@ (^7(SS[FK?B'6KB'Q'H/
MAZSF^SS:FTTDEP%#-'%$NXA0P(W$E1D@X&>.E6+;P[)!XQN?$+7P=[BU2U:
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MD^F,G(!R_B2/4Y['P)J5[JCSM<ZW922VXB18E9@S#9@;@!R.2<CKS79>._\
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MI7E(&"[XRWUP /TH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>,#) !<@' R<#TZ8ZRB@#F=/\&6]I'KL%U=R7MKK4LDUW#*B@9=0I"E<$#
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MI3>9HB.D($:XDWIL;?\ \!],<U0M?AY%8:E<M9:WJ5OI%U,T\^DHR^2S,<L
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M?'^SF_<-*D; Q[2HC90!E<'KUR!SP*U="T*WT**\$3%Y;VZ>[N'VA0TC8!(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJYOQIXL1?["72-6GC:;6K:W?RHCY5PAD"NHD*X;'?:WKFJ-X9KSQUXWM],F
MOY]!CBMB&P?."RX ]P67Z9K#NO$6E7GP^\'6,)9+W3=2TZ.[L_*;S;=HF ?<
MN,CH<'O0!ZE>^*=%TZ>6&ZOEC,#(DS[&*0L^-H=P-J$Y'WB.H]:JW/B^RM_&
MD'AMHYS.]JUP\@A<JOSHJ@$#!SN.3T&!D\UYIXUU6#4/#_CRQCC>QN8Y0?L4
M-L=]TH$?^D2-M)VD#C&T#;SDFNLFU*VC^+.CZ@YE%K>Z')!;R&)_WDGG(VT#
M&<XY^G- '1Z)J&GS7&MSP:\U_%%<?O@[KY=F0@RBD #'<\GK5FT\2:1>WL=G
M#=XGEC,L221O'YJ#JR%@ X]UR*\OU"WNM8T+XGV>CGSKR:^22.*,Y,L:I'O"
M^N0KKQU/%=!K5[9^,+[P9/H,R27-MJ27<^P_-;6XC;S%D'\!)VK@XR?I0!T,
MWC_PK!%)*^MVWEQ3FWD=<L$<8SD@<#YA\W3GK72 @@$'(/0UXX9[1_ ?Q042
M1&2?4;PQC(S(#&@0CU!(.,=\UZAHLGVGPQ8/!*I+6B!7!R,[0/YT 1S>*-%@
MN1!+?*A,WV?S2C>5YO389,; V>-N<YXK"\4^)DMO%FB^'S-<PP78GDNI((I-
M^$0%55E&>2P)*\C;CC-<=:21S?!2]\(WB?\ %1Q)+:MI[?ZZ2<R%D=1U922'
MWCCJ<\&N@U.9++XB^!;>\NXWGMK&[CN)"W1S'& 2>VXJV,]: .G$[>$/"<]S
MK&I7.I+9(\C7!AS*R9)4$+U(&!GCIDXKE]9\63W.G>#-9M;Z:RM[W48([V%E
MV(4:)I&!9E!(&!R#@C-==XMADN/!FNPPHTDLFGW"(BC)8F-@ !7G5WJEA>>%
M?AJ$F5E@U&R\W>I4+L@8,3GLK$ GH#QUH ](TKQ)H^M)=/I]]'*+1MMP""AB
M.,\A@"!CG/0T6?B72+_4%L(+O_2GC\V..2-X_-3^\A8 .ONN17G&NPW&IZ]\
M2;+2V$EY<Z7:+%&C<S,BR;T'J<':?]X5L>'-5\)>*M7TJ]L+?4)]7L@Y*W,M
MP38;DPX?>=N3@+CG/4< D &_XX\4/X6T*.>VA2?4+RYCL[*%SA7F<X7=CL,$
MGZ8[U(VB:TNG,8_$MTVIE#B1X8O)WXZ>7MX7/ONQW-9'Q0T2_P!3T33=0TRW
M:YO-&U&'45MD^],J$[E7WP<_ACO6Q9>-O#VHVZR6NI123L/^/,'_ $@-_=,7
MW@?;% %B/5X].TZPCU61AJ$ENK/#%&TLA8*-Y"("< GDXQR/6DE\6:!#I5OJ
MDFK6PLKEQ'#+OR'8G&T#KG/!';O7,&^?1?BM-?:V1:6.HZ5%%:W$S@1Q2(Q+
MPE^@8[L^^.*Y+6;06O@SQ#<2X6PU+Q-'<V<3#AXA+'O<+_=.UF^G/0T >E1^
M/O"DI 77;/)EDAP6Q\R+N;KV YST]ZN:/XHT37[2XNM,U*&>&V8K.<E3$1S\
MP;!'?D^E<MXZN+&'Q-X&NIWA%K_:,CF4X*<PMAL],9P<]NM<[XJT2]UZZ\<W
M_AH>9%<Z5;VY> Y6ZF1]SA2.&(C&SCNV.N: /3+3Q+I%[>1VD-X//FC,L*R1
MM'YR#JT98 ..^5S56'QOX9N+V.SAUFVDN);AK5%0DYE49*YQCH>O3MUKF-:O
M;/QA/X-ET*5'NK;4XKN94/S6L"HWFK(/X,\)@XR:=X)N;80^.98H4NY1K-U.
ML*8+3)Y:[<>H)# 'IUH ZVS\4Z+?WEO:VU\'EN59K<F-E6<+]XQL0%?'^R3Q
M69IWC;2]9778_/FLH=.F>W:YEB:/ 5%+/EA@$,Q !Y. <<UP&G:Q:76I?#N_
MCE<11RS1O:V]JRPV3-;L!"N%R6!XY))QG !K?T*]M[)_B%8W3&*X;4+BYVNA
M \IH4"MG&,$@@>M '7Z9JFGV?A?3KI]6DO;>2-%ANY1F2Y)'!"@99CZ 9J6/
MQ/HLEC>7IU"*."R)6Z,P,;0'&<.K ,IQZCFO,],GDL-$^&&LRDG2-/AD@OV'
M(MY'A"([^@!W D]-WO6CJ\<=UKOC+7K*:-M*D\._9'F1@8[BY^<C:1PQ52J\
M=VQUH [:S\8^'M0U"UL+75(9;F[B\V! &'F+MW<$C&<')7J/2MRO)6N;2/1_
MA7MEB4Q2P^9@@;!]F96SZ?,0#GO7HFD^)-*UN_U*RL+@R7&FS>3=(8V4HW([
MCD95AD>AH EEUS3H-8CTB2X(OY8S*D'EL2R#J1Q@@5!;^*-&NM.O=0AO-]I8
MLRW,OE/B(K]X'CJ._IWQ6'\089[)-(\46<$DUSHUV&DBB&7DMY?W<J@=S@JW
M_ :P]-TC5].\97&BW$;266O!-6NG7[D,J,//C'J&/DK]": -(^*!I?Q&U)-2
MU:8:4-*@N889$^XS.X(557<3A<X()'-=;'KVERZ3!JD5Y'+97 !ADCRWFYZ!
M0.2?8#-<G;W5HGQIU222:%=NB0IO9@,$2NS#/J 02/2N)TB[&F^"/!VK3I=2
M:3IU_>KJ M6<26XD>0)(0A#  -^3>] 'I.L^/M'TSPKJ6N02O="R)C>%8G#K
M-V1U(RG..6 XK-UOQ&UIXW\*RKJ<T.D7<5X;B&5/+4F-%VG!4-G+=#UXP*P/
M$L&AZG\.?&.I>&+6ZG^VV\1FO&:9_M+(?X1(<G:O4CCG'8XUM6U;3M3^(W@2
M[MYTD@\N^(=A@#=&@4\],D$ ]\<4 =CI_B31]4TJ75+2_B>RA9DEE;*>6R]0
MP;!4CT-1Q>*M$E:\4WRPO9QB6X2Y1H6C0]&*N =I]>E>7W3S3:=XTETZ.2[%
MMXD@OY+:V<AYH$\HOLP<]5/([K70V6H^$-:^W:[HYN;BXBTR6":^N)9]L*'D
M1'S#@L6YP.F/<9 .MTKQ;H.N7@M-,U**YN#;K<[$!SY1. W(]Q[\UM5R7PQ\
M@_#?0!$$W1V:1R!1RK@?,#Z'/6NMH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHK-UG7M-\/VJ76J3M! [B,.(G<;CP =H.,G@9H TJ*J2:G:Q7UM9.T@N+E
M&DB7RGY5<9).,#&1UQU%4!XLT0W%O#]M(%Q*8()FB<0RR<C:LI&PG(( !YP<
M4 ;5%<9%?W<'Q9U"SEO;J6P718[I;?&Y4<S,I*JHR3A1ZFM@>+]";1[/5A?9
ML+R40P3B)RK.6V 'Y?E^;CG% &W16!>>-?#UA>7EG/J'^DV:JT\,<+R.H.<8
M"J2>ASC.,<XJIJ_CO3=/M-#N;437D.L7$<5O+! \B;6Y)^4=< X7[V>W!H Z
MJBL2^\7:+IQF%U=2+Y$237&VVD;R$;[IDPIV9P?O8Z&FZGXQ\/Z1/'!>ZE''
M+) UPBJK.6C R2-H.>HXZG/% &[16)I/BW1-<O/LFG7C33^0EQL,$B?NV&5;
M+*!@YXK0L-3M=329[1W=896A<M&R8=3AA\P&<$$<>E %NBLK4?$>EZ7)-'<S
MR;X(Q+.(8))?)0YPS[%.T<$\XX!/:HKWQ=H&GBQ:YU.%5OUW6K+EQ*-N[(*@
M\8'XT ;5%4=*U>QUO2H=3T^?S;.8$I(5*9P2#PP!'(/45@V/B7P_I>C:MJTO
MB&>ZL(K^4337.YA _&8D 4':N1@ 'J>: .LKGV\.ZH6)'C'6E!/016?'_D"I
MK3Q;HE]JLFF6U[YEXD1F\L1.-Z X)0D8?!_NDTZS\4Z/?Z3=ZI;73O96A=9Y
M/(D&PK]X8*YX[X'% %;_ (1S5/\ H<M;_P"_-G_\8H_X1S5/^ARUO_OS9_\
MQBKUSX@TZU\I9))VEEB\Y88K:2241_WBBJ64=N0.>.M<QX\UTS?#S^V] U9U
MC-Q;[)K5P ZM,B,"<9'4C'!SUH ;H_@/6].UC5KZ3QI?G^T)%E?R;6W5R54*
M-Q:-@> /NA?I6U_PCFJ?]#EK?_?FS_\ C%:0US3SK$ND"9OM\4'VEH?*?)CS
MC<.,,,\<9YJ@_C;P['ID.HOJ:):S7!M4=T=<RAMI7!&1@\'(XH ;_P (YJG_
M $.6M_\ ?FS_ /C%)_PCFJ?]#EK?_?FS_P#C%36GB_1+][^.TN99IK%!)-"M
MO)OVG.&1=N7!QP5R#5'0O'6FZMX9MM;G\ZUCN9 D2/!)ERS$(J<?O&('\&>]
M %G_ (1S5/\ H<M;_P"_-G_\8H_X1S5/^ARUO_OS9_\ QBIO^$OT)=,OM0DO
MQ%;V#F.Z\V)T>%@,X9" W0YZ<BJ3?$7PJID!U,D1O$C,MM*0&DSL&0N.<'\1
MCK0!/_PCFJ?]#EK?_?FS_P#C%)_PCFJ?]#EK?_?FS_\ C%:TNJ6D.H6M@[N+
MFZ1GB3RG.57&XDXP,9'7'4>M7* .>_X1S5/^ARUO_OS9_P#QBMV"-HH(XWE>
M9T4*TC@!G('4X &3UX 'M7!6_BB/1/'OBZ/6-4N7L;>&SD@B*-+Y099"^U$4
MG' R<>F377MK^EKIUI?B[5[>\V_9FB4NTVX9 15!+'&3@#H#Z4 :5!&1@US]
MWK=IJ_AW6'TJ_DCN+6*19"J&.:"0*2 R.N5/U'3I53PKKJ0_#SP]J&K7;O-<
MVD +L&DDFE90< #+,QY. ">M '4L&V$)@-CY<],U@>#_  ]<^&M,N+.XO(KK
MS;J6Y5XXC'CS'+$8+'H36+X6UYKSQSXS6;4KE]/LX[1D2[4Q"VRLA<;6"[1P
M#DCH!R:Z*W\5:-<7YLA=/'<^29U2>"2'S(QU9-ZC<![9H V:*YJU^('A:]9!
M;ZO&X>*68,8W"[(B0Y+$8&,=#SCGH16K9:U9:A=R6L#3K<1QK*T<UO)$0K$@
M'YU&1D'IZ4 :%%5+_4[33$B-U*5,S^7$BHSO(V"<*J@EC@$\#H":HIXGTR?2
M[R^M999ULV*3Q)!(98W'\+1[=X/3J.G/2@#9HK@_ TMUXDT_1_$;ZKJ4=PT)
M>]M71Q;S[P=H4.-H"G&"GIR3FK%QK=[KOCZY\+Z==/9VFFVZ3ZA<1 &5W?E(
ME)!"C;R6QGL,=: .THK!_LO4[/6-.DM-4N9M.#N+JWN"KG&QMK!R-WWL9&3U
M'3',DGBS1(IDCDO2JO/]G6<Q/Y)ESC9YN-F<@C&>HQUH VJ*P[SQ?H5CJ%QI
M\U]F\MXQ+)!'$\C[2<# 4$L>O R>#Z567X@>%V@LKA-51H+QE6*58G* L=H#
ML%Q&2>,-B@#I:*Q+SQ=H=AJ4VG3WW^FPQ><\$<3R/MSC@*"6/L,G@^AJH/B#
MX6-K:72ZLC6]TP6.58I"BDMM <[<1\\?/B@#IJ*S[_6[#3IU@GDD:=D,@A@@
M>:38."VU 2!GC..O%4YO&/AZWTRRU*358!9WLBQ6\PR0[DXQP..>#G&.^* -
MRBLG2?$VD:W>75II]V9+BUVF6-HGC8!NC ,!N4XX(R*Q/B'XAE\.V&F2M/+:
M:?<7R0WU["FYK>(@G(X.,L -V#@$XYQ0!V-%<SI:7$6HQZC::Y/J?A^2RD8*
M2LVV0,A!5E&Y\KOXYY'OBF^'?&^GZ[H-QJ\JRV5M#+*"UQ"\:A%D9 =Q&"QQ
MR 203CK0!U%%9ECX@TW4-0DT^&:1+Q(Q*;>>!X9"A.-P5P"5SQD=^*@;Q9HB
MWD%LU[AKB<VT,AB<122C/R+)C86R",9Z@CJ* -JBN%\/ZX]AJ_C235]2N);+
M3[Z-8VE!;RD:)#@*H]6["NUAN$N+=9T$@1AD!XV1O^^2 1^5 $M%<^WC;P^N
MD7>JM?.MC:3&WN)3;2@12 X*L-N1@D ^A-:,FLV,4]M#))(DES&TL0:%Q\J@
M%B3CY<9'7'44 9D7AZ[3Q[-XD-Y"89+!;+[,(3N"JY<-NW=<L>,5T5>:^(]4
M$?PAUG4_#_B/4+DPO*Z7K/\ O WFX9 2H(49(&.P&#6OK=Y?6_Q"\&017UPM
MK>+=B>W# (Y2'*D\9/)[GTH [.BN4^)5U>6/P\UF\L+V>SN;> R)+"0&X(XR
M1Q^&#5G2?&>@:EJ4>CV^II)J/E;Q&RLOF #DHQ&U\<_=)[T =%16-<^*]%L[
MJ."XO#'YD_V99C"_D^;G&SS<; V>,9ZC'6M>21(8GEE=4C0%F9C@*!U)/I0
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MZ*^DLKW'V _Z6EQ&T+PC&<LK@$# )S[4^V\5:3=7UK9B:6*6\0O:^? \2W
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M3/MN(D99#:M%+=,K L=A 8@*  2.<'' Y /0+2Z2\M5N(UE56SQ+$T;?]\L
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MXWRR@=ST./:JMYY7B'Q]X:UK379K/2[>ZDN[C8RKB1%58SD#+9RQ';;SC(H
MV=)\<^']<O+:UTZ[DGDN1*8R+>0*?+)# L5P#QT/.,'N,ZNH:K::9Y*W$C>;
M.Y2&*-"[R,!DA5 ). "2>@'6N6^%0,?@E()(I89DN[EGCEC9& :9V4X('52*
M;XG%SIGQ!\.Z_+'+)I,<$]G<.B%A;,^TJ[ <A3M"D]!WH TM0\<:7:>&=5UF
MW$]S_9H99[98666.0#.UU(ROKD\8YKG]<\12'4_!&I?;;RTMKFX=;J$J\22?
MN&;E" 6^;&.N>,9JCK&CW>II\1=7T^"5[;4=,2WME5#FZD2)MS*.I'(4'OSB
MI[Z^2^N_A[/%!="*"X)E:2V==@\@KN8$94;CC)Q^5 '::;XJT?5;.^NH+EHX
M[!BEV+F)X&A(&?F5P"!CGI38?%>DS:A)8&2>&[2#[0(9[:2-I(^A9 R@M]!R
M/2O/=8L-0U.\^)$.F6\KW$S6$ULNUD%QY2H75&XS]TKP>IK?\.ZIX?UO4K;4
M[71]3CO+.)_.GU%)@;,%<,@,F0S$\87/&2>V0#=T;QOH'B"Z@M],NY)WGB>:
M-OL\BJ55MI^8J #G'!YP1ZUT-<5\)D:'X;Z7;2PR0SP^:)(I8RC*3*YY! /(
M(/XUVM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%96O>(M-\-6*WNJ2O% T
MBQ!UB9@&8@#) PHR>IP* -6BN-O_ !1H.J#3O.N=7M"-8CMH L$T'FSC[J-E
M1E"&S@\$#VK;O_$NGZ?<W-NWG32VD N+E+>,N88SG#-CUVG &2<'B@#7KG_$
M'AR?6M5T:]COTMQI=P;E$,&_S&*E<$[A@88US/BCQ):WC^#]9TW4;M+";5TB
M<@2Q)-&8W;[A W@D+@X.>U;Y\=:6^DZS>P07SRZ0NZYM'MGCF7Y=RG:P! (&
M<GC&: .GHKF](\60WWA_2+R>WG%YJ$*,END)#.WEAV*@_P (!^]G'OFMG3=1
M@U6Q6[MA((R[QXEC*,&1RC J>1AE- %NBL;4/$VGZ?-=1,+B=K-!)=?9H6D\
MA2,@MCOCG R<<XQ6!XU\6+;Z!I,VE332PZI>VL0N;5&8&%Y!NVL.C%<@=^>.
M10!W%%8V@Z5%IPNKBWNM1>WO'$J6U[(S?9SC!"AOF4$\D$]>F*KVGC31KRYL
M8XI9O*U"1XK.X,1$4[IG<%;_ ("<9P#CC- '0T5RMU\0] M?[1RU[(=-?;=K
M%92L8>-Q9AMX4#G<>/3-7W\5Z2FJZ9IPEE:?5(S+9LD+%)5"[B0^,<#GK0!M
MT52M]4M[K4KNPC$OG6FWS28R%&X9 #="<<X%8U]XM%IXXL_#@LKIA-:R7#S+
M"S#AE50N.WS')Z#CWP =-17F7AWQ=:>'AXK.KW>HW$-MKDR>84EN?L\.V, L
MPSM0'.,^^.AKN[W6[2S:.,+-<S21F9(;6,R.4'\7'0<]^O;- &E17,GQ_P"'
M!8Z9>B]=K?4I#%;.L#D%QG*GCY6&#\IYXZ5?T3Q+I^OS7L%I]HCN+)U2X@N8
M'AD3<,J2K '!'(- &O15'4-6M=->WBF+O<7+%(((E+/(0,G '8#DDX [FLQ_
M&NBQZ/?ZF\LRPZ<YCO8S WFVY']Y,9QWR,@CD4 =#165+XBTZ#5=/TV1Y1<:
MC&\EK^Z8K($7<W., @8X/K6-H7CNUU2VUJ[NK:YL[;3[R2W#2PMT3:N#CJY8
MG"CGD"@#KJ*YG5_&=MI6C:O>M8WS3Z;;B>2W:$@D,&VG/3;\C9(/&/7BI;;Q
M9:G3M*>XCN!?:@G[FV6!@\K*@9RH/\(!ZDXZ<\T =#17-R^.] @T!-:DN95L
MFG^S%C ^8Y0VPJXQ\A#<<X%6M,\5:9JNKW&EP&YCO((A/Y=Q;O%YD1.-Z;@-
MRYXR* -JBO-O'7B:&ZTS1YM+N-0CCEUBVBCNH=Z0SCS0'7(^\I .,\''!-=-
M'J.D_P#":W\:W>H-J,%@K36NV4Q+'O.'5,89B<C*YZ8H Z.BN3MOB-X<NXM/
MGAGNFMKZ;R(KDVD@B$A8JJLY&%)(X!YY&<9K5O\ Q)8:?<W-LWG336L N;E+
M>,N88SG#-CUP< 9)P<"@#7HJAI&LV.O:<E_ITKRVLGW)&B>/>,9R P!(YZCB
MN),=S??%G5=(?5]3AL8]*CNDCBNW4)(SE2PY]!T/'M0!Z+17F?@WX@^3X6GN
MO$UZTL46K2:;:Z@L!VW2@@([%1M'4C/ ./7-=?;>+=-O+82PQWID:9X$MWM7
M29V3!8A& .T CYC@<@9SQ0!NT5Q7B'QU;)\/]8UK1FF>XM4E@P8&W6\ZC!$B
MD?+M..O'3UI^D_8M-EM]56[UIIKVW$']GS-(_G2* QE5'Y!QP6R%P>>U '94
M5S$GQ \.PZ4VHRW4T<*77V.57MW#0S9 V2#'R=1R<#WIA^(>@(T*2M?PO-<O
M:Q++83*7D5=Q !7G(Q@=3G % '545@0^+].N;""ZMH;Z9IHFF%NEJ_G*BL5)
M9" 5Y! SUQQFI(O%FC7.D6.IVMU]I@OVV6BQ(6>9N<J%ZY&#G.,8.<8H VZ*
MX3P7J,E]X\\:1F:^,$+V8C@NV;,),;%@ W0$\\<'C'&*/B!X@_L/5=!&HSW=
MIX=N))5OKJU9D*R8'E*SI\RJ26/!R<#MG(!W=%<KIK#2DU/6(-3N]6T1[6*2
MTC6;[2593)O"-DEL@IRQ/3K@<+H/C2UU+PC9:Y?1RVOVH(%C,39=W/RI&,9<
M]N* .IHK)L/$>GW][=V(>2WO;1!)/;W*>6ZH>C\\%?<$BJT/B_2+F^L;,23Q
MG4E8V4KQ,J7.T9.QOIR,XR.1F@#?HKS_ ,':XNF:5KTFI75Y<B/Q%=6<&XO/
M*0'"HBCEC@#MT&3TS7?1OYD:OM9=PSAA@CZT .HHHH **** "BBB@ HHHH *
M9*ADB9 [(6&-R8R/IFGT4 0VMK#96L=M;ILBC&%7.?S)Y)]SUJ:BB@ HHHH
MP->\/7.O/+;RZJ\>DW%N;>YL1"I\P$Y+*_WE)'R]QCL#S6\B+&BH@"JHP .P
MI:* "BBB@ HHHH **** "BBB@#"L_#]S%KTVI7^LW-_&)'>SM9(T1+7<,'&T
M98XRH)/ )]2:W:** .?\.^'9]#O]8N9+Y+D:G=&[9!!L\MRH7 .XY&%%=!11
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M80_[B!$_X#6%K(GLOBKHNHM9W<UK)IL]J)((&D"RF1& 8@87(!Y; XZUVU%
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M1VNHVNGW^FS76E7EO-]HD6U:=(V4IM#@ _*0S=NU;]% 'F'A;PXFF^)O$/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_%9$C\.:*D:A476[,!5& /GJ+XUR20?#NY:+*)/<0074B\$0E^03Z9P/Q]Z
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M[[3[*\AU"^N[C4Y;F"Z\MH+9X@BVV%PP'<[CSSTK2HH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KB?&FJ:M8>(_#%EI^IR6L.J7;V\X$4;X 3<"NY3@\
M>]=M7FWQ(N+(^+_ ]O<72Q?\3%R^)S&RJ8\ Y!!') S0!=TOQ==Z;XWUGPYK
M][;26ME9I?1ZBX6':A(!67^'.3P1C([5TEIXKT"_:9;76+.4PP+<RXE'R1,,
MACZ#!'YBLS5]%T;0O"GB*[MH8XI+NSE:XN996=Y3Y9 W.Y)/7 &:Y"XV1_!7
MPUJ.GP&:*S33YKX68'F&*,JT@&.<AOF([$$T >C6WB/2+L77DW\3-: &X0Y5
MXP>A*GD ]CCFN1\-:]<^*+2'7T\1"R2"ZG:ZLV1##]E61T4$D J<*&WYZD\8
MX%GPW>>$M6\0/K^CWTU]<)9>3/>O,YCBBW!@C;L -G)QU&#G'&>-TVZ>3X(6
M\]@7NA9:J;J[@MFS(8%O&=L ?[.&^@H ]6A\3:).+LKJ=NOV10]P)6\LQ*>C
M,&Q@'L>AJD?'GA-5=F\0Z<H2%;AMTX&(VZ'\<CWY'K7,VM]X0UB6^U[2;^:^
MN4TJ6&:\DF?9#$>1&^[ #%CD \\&L&Z;3U_9F5XS;!SI:0[EVYW[@2OUSDX]
M: /48?$VAW*WC0:I:R"SD$5QMD!\MST4^YZ =SQUJ6QUS3-1MI[BTOH9(K=B
MLYW;3"0,D.#@J0.><5Q/C6YM=,M?"^N1!AH=O=AKR:Q'W$:%HTDRO55+8_&L
M3Q*FDWOA/Q!K/A7[5J0N'M&U*X21W%Q%&XW(N>"0@^;'8X/>@#I[OQ0;GXD>
M&K#3=5,EC=PW3W%L(P P6,&-P2NX@Y;!!P<>U:_CO7Y_#/A&[U6W4;XVC0R,
MA<1*SJID*CKM!)Q[5R^H^(]#U?XE>!;O3=1M;F)HKY?,B8';NC3:I]#['FNU
M\2:M::-I!N;^(26;RQP3!EW ([!"2.<@9R?;- &98'4Y;K2+W3?$1U?1[AV^
MTM)%"3M\MRK(\:J -X4$$$\CD<@V-$\8Z7KVJ:I96DHW6$WDDMD;\*&9AGL"
MV,]\9Z5PL>CZ=X<\=:)<> ]24P:E<[=0TJVG$L'D;26F !.S''XD >AAO#<W
M&G?$_1-.D/\ ;,]T\L5LN?,>(PQY('H0& /J0.] 'IUIXBTB^O$M+;4(9)Y%
M+Q(#CS5'5D)X<#U7-%[XBT?3KCR+O4((7#*C;VX1F^Z&/12<C&2,UPNL7EEX
MIT[P0V@S1->Q:E;3A(B-]O"BGS@X'*@#Y2#WP*JZ)K>AP6OB'PIXLB#ZC)JD
M\C64L19KY7DWQ-&/XLC:!CIM'04 =/;:K?1?$[5M.N;YWTV'2HKM(F10(F,C
M!CD#)X7OFNGL-0M-4M$N[&=)[=^4E3E6'J#W%>1^+9;R3XC:I)ILEO*]IH]M
M+=:<T@ NXDDD:2'=V."#[XP1@FO4?#VO:9XCT:WU'29TDMI$!"C ,9_NL.Q'
M3% $-WXO\.V+7:W&LV2-9E1<+YH)C+9P"!W^5CCKP:4>+/#[7EG:+K-DT]X%
M:W190?,##*X^HZ>O:N6T>ZTX?%3QPTL]L"+2R5B[+P DF\?A\N?PS7'6ES8P
M_!#P>?.MT=-5M6/S $,MQEC]0.OM0!Z_?>(]'TR=X;W4(87CVF7<>(MW"[ST
M3/;=C-2MK>F+JZZ2U["-09/,6VW?.5_O8]/>O*/&>LV%W9?$"QBDBL+E807@
M1=T]_B)<2G.<1@8'R@8QDL,UT7B5O+\.:#XWTL&>71D663RQS/:, LRCUP/F
M!Z?+D=: .[M]0M+NYN;:"=))K5@LZ#K&2,@'TXP?H:XZ^\4?V%\2KRVU?64@
MT9='CNE2?8JI(TS)P0,GA>ASWKH_#=K-!I(N+M"E[>R-=W"GJK/T0_[JA4_X
M#7+W<]C8_&LW&HRP6\;^'U2&6X(5683N656/&=IR0.U '80ZWI=QI*:K#?V\
ME@X!2X60%&R<  ^N>,=<\4NFZQI^KK,UA=QSF%_+E5>&C;T93RI^HKR!H)?#
MVDQZT8;F+PV/%$]YMMU(,5J\9C24 <A-Y+  ="".M=]X2_X1R^U?4M8T">:]
M>Z2-+J^,KLDA7(51G@L!UQTR,]: -74+N >)=(M?[=6UG8RM_9PV%KL;#U!^
M8!<$Y%67U[2TO%M&O8Q,TODJ.<&3^X&Z;O;.:Y7Q9<V\7Q.\"+)-$CB2]X9@
M" 8,#\SQ]:Q%NI])UQ9=%U*#5=(O-=:*ZT>X ,]I<&8[Y(B.<!@7P1C;SWS0
M!Z*^O:7'>"T>]C$S2B #G!D/\&[IN_V<YIH\1:.UI>70U&#R+)BET^[B%@,D
M/_=P.>:\[-U/I.N-/HFI0:KI5WKK17>C7(!GMK@SG?)$1S@,"^TC&WGWJ&YU
M2RTU?BAIMW<)%?7/FRP6Y_UDJ-:@!E7J1P<D<#'.* /3Y]9TZWLX+N2[C\BX
M4-"R_,901G*@9+<<\=J;'KNE2Z0NK1ZA;/I[#Y;A9 4/.,9]<\8ZYXZUY;#K
M5GI-WX0U+5;RXMM$N/#\=G'>0LP2&X&TLKD?=R !]5]CB346TC0E\-ZOIB7
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M65LLS)@#W(W?49I-#OK?1/'WBVTUN6&T%T8)[-YV"1RVRQ[=JD\80YR/]K-
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M=)N)!'%=,S-$T\?[EP)8UQED.,..1RN>H]: -8@$$$9![4U$2- B*JJ.@48
MKFM!\<Z3K7AY]::4VMLLKIF9&7@2LB=1RS8'RC)R<=:N3>+='ATS4K[[1(R:
M:N;J(0N)8^,@&,@,,CD9&* -HJ"<D#--$48D\P1KOQC=CG'UK&TGQ18ZCX:L
M=8E8PK<QQGRRC%O,90VQ1C+GGC .<59M/$.D7VGW-_!?P_9K5F6X=SL\DK]X
M.&P5(]"!0!H>5&)/,\M=^,;L<X^M#11LQ9HU)*[22.H]/I7#GQ')=_%/2=/L
M]1N392Z?/++9R0F,!@4V/AE#$')YR1P<5VEW>6UA:O<W<R0P)]YW. .<#\SQ
M0!*\:2(4=%93U5AD4I560J5!4C!!'&*S;;Q#I-VUTJ7BI):*'N(YU:%XE/1F
M5P" ?7&*KZ9XP\/:S>Q6>G:K;W-Q+$TT:1DDL@.">GK_ (]* -E8T3[B*O '
M QP*4J#U /UJK?ZG:::J&YD8,^=D:1M([XY.U%!8X[X'%9TGC#P_%I=MJ;ZI
M#]AN7\N*< E6?.-N0.&SQ@\\&@#;VKG.T?E2/%')MWHK;3D;AG!J@^O:7$]Z
MLMY'%]A4-=-("BQ C(W,1@9!!JA;>.?#%YJ-KI]OK5J]U=H'@C#'YP1D8/3)
M!!QUYZ4 ;Y4'J ?K1M7^Z/RK!E\;>&8+TV<FM6GV@7"6Q0-DB5NB\=_Y9&>M
M69O$VC6]]'9S7R)++-Y",RMY;2_\\_,QMW_[.<^U &J !T 'THVC.<#.,5FW
M'B#2[6Z-O-<D.)4@9A&Y19'P%0N!M#'<O!.>1ZT7/B#2[2Y-O-<E765(681N
MR+(^-J,X&T,=R\$YY'K0!I;%_NC\J-JYSM'Y5EZGXDTC1V<7]X(1& 96V,RQ
M ]"[ $(#ZMBIK[6+"R6)9;D[[A285A0RNX Y954$D#(YQCD4 7MJ@$8&#UXI
M$C2- D:*BCH%& *X_P"&^KW.LZ-J=Q<Z@]^(]6N889W"C=$K )]T =/0"J]U
MXC;1OB=?6VIZLZZ4NCQW*0R 820S,IVA5W,<+[GK0!W) .,@''(I&CC=E9D5
MF7[I(R1]*H1:]I<^D0:K#>Q2V,X'DRQY;S"> % Y)SQ@#.>U5&\8^'H]+N=2
MEU6"*UM9/*G:7*-$_P#<9& 8-[8S0!N4FU>>!SUXZUD6_BK0KI;PV^I0R_8Y
M5AG"9)5V^ZH&/F)[ 9S5>[\1Z-?>']3FCUM;&.!7AGN#^[DM'(ZE7&58=0"*
M -_8O]T?E1M7^Z/RK#3Q+HFFVVF6UWK<+2W-N'ADG8!YU5-QD(P,9 )Z ?RJ
M[H^N:9K]J]SI=VES%'(8G*@@HXZJ00"#R.OK0!>*(5*E5*GJ".#2JJHH50%4
M#  & *H:AKFG:7*L5W<$2M&THBCC:1]B_><JH)"C(R>G-03>*M!M[>QGEU>T
M2*_Q]E<R#$H(SD>V._04 :VU2<D#/THV+_='Y5FZ3XBTC75N6TV^BN/LS[)@
M,@QG&1D'!P1T/0UR?B'Q6LOB/PG%I.K3"&\U#RY8EBQ'<1;&.Y7*_, 0O*L1
MR/44 =^!@8%-\N/S/,V+YF,;L<X^M5-8N+>UT>\ENK\6$(B8-=%@ODY&-P)X
MR.HK,MO$>B:;I>CQ7>O12M=VRM;SW#A7N5";O,(P,9 R3@"@#?VKG.T9^E!1
M2I4J-IZC'6L_1]>TO7X9I=+O$N5AD,4NT$%&'8@@$5GZOXOL=(\2:7HLRRF>
M]$CEA$Q5$12>H')SM&!T!R<<9 .@5%10J*%4<  8 I)(TE3;(BNOHPR*X#2_
M%\&C>(/%D7B'6S]FM+V*.V,X&40Q*QP$7H"W)QZ9-=I=:O8V<$,TL^Y9AF$1
M*TK2#&<JJ@EN.>!TH N%01@@8I>E5--U2QUBQCO=.NH[FV?(62,Y&0<$'T(/
M!!Y%9=]XV\-:;<W%O>:U:Q36[(DR%LE&<D*#COP?IWH WMJ_W1^5&Q?[H_*L
MJ]\3:-IUR(+N^2)O,6%G96\M'/1&?&U6.1P2#R*??>(=+TZ62.ZN2AB"F5EC
M=ECW=-[ $*3V!(SF@#1:*-V5F1693E21DCZ4I4$Y(!/TK/U#7=.TN0QW5P1(
M(_-9(XVD9$_OL%!*K_M'BN<\:ZS/'I7A_4-&U0K;W6K6<3-;E&2>*20 C."<
M8]"* .R>-)  Z*P!R PS@TZL]-;T^2^N[%+C==VB!YX0C;U4YP<8R0<'&,YK
M&U3Q[H]A8:3>6\QNX=4NTMK>2%&93EL,Q('8!N.I(^M '3"*,2>8(UWXQNQS
MCZTIC1I%<HI=>C$<BL.'4+&Z\7K%!KCM.-/WG2QC:%+J1*PQN#<@8)'!Z58D
M\3Z-%=+;R7R*S3?9UD*MY1EZ>7YF-F_/&W.<\8H U=HSG SZXH"@'( S6+>^
M+_#^GW5S:W6JVZ7%LH>:($LR@].!DYX/'7C-:5A?VFJ6$%]8W"7%K.H>.6,Y
M#"@"=8T1F9452QRQ QGZTBQ1H[.L:JS=2!@FL_4/$&EZ4[I=W6QHT\V4)&S^
M4G/S/M!V+P>6P.#Z4R\\3Z%IXM#=:K:1B\7?;DR ^:N-VX8[8&<]* +5AIT5
M@)V0EI;B7S9G( W-@+T'  "@?ASDY)M/&DF-Z*V#D;AG!]:J:9K&GZQI4>J:
M?=1SV,@++,.%(!(/7I@@_E6=9^-/#>H7]O96FL6LUS<M(L*(V=Y3.[!Z<8/U
MP<4 ;I5202 2.1D=*-BE2I4;3G(QP:RK;Q-H]WJ$5A#>J;B9"\"LK*)U'4QL
M0 X'JI-/B\0:7/>Q6D=R6EF=XXCY;A)&4$L%?&UL;3G![4 :(1%0(JJ%'0 <
M"EVK_='Y5E7/B?1K2X,-Q?)&5E$+2%6\I)#T1I,;5;D<$@\BL74-0O[;XI:1
M9+>S'3[C3KF5[4*NW>A0 C W$\G@D^U '84U(HXEVQHJ+G.%&!62WBK0TTF;
M56U",6,$IAFGVMMC<'!#<?+@\<]ZJS^,+"#QE!X<(E,\EJUPT@B8J/F15 ('
M.=QR>@QSUH Z$*HZ #\*;)%'*NV1%<>C#-8FB:CI\K:U=0^(/M\$5TQE+NOE
MVF$!*!@ , <\D]:M6GB/2;Z[^R0W8%P8_.6.5&C+Q_WUW ;E]QD4 :3QI(NU
MT5E]",BE"@$D  DY.!UKG9/'OA6--[:Y:;/.,!<,2H<$#D@8 R0,GC/>M*_U
MS3M,=DN[@JR1^;(%C9_+3GYGV@[5X/)P.#Z&@"^L<: A$503D@#&32[%_NC\
MJ;%(DT22QMN1U#*?4'I3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M5\>06%SI5C%>ZG-I;F^0VM_$0/L\P1RK-GC:0"I!X.ZNJHH \=U#4=<D\.&\
MU*%;^+1]?BDO+[2PR?;;<18,JA3]Y"RYVG *>QK0OKGPGJ7AKQ5K>A//<R3:
M--;37\TTQ5R4.R(>8?F;/IR.!WKU(# P*  !@4 >7^(WM#^SXWDF'Y](@B4)
MC)<*OR_4'/'UHUS6+#1?&]AJNLSW46@WVDQV\%];2R+'',KLQ5C&?X@PY/\
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MUXI_B&/2IO#5YKWA:TO+NR?4K*ZU.?=+)]LBB?+A0YRP4;<D<'G^Z<>OT=*
M/-G\0:1K/Q6\,WFF7D=W ^G72>;""RY)C(4D#@]<@].^,UI_$H74-CH>HQQR
M2V6G:O;W5\D:EB(5R"^!R0I(;\,]J[4 #H*6@#@99+75/B=IFN:9>026%GI<
MZ7]W%(#$59E,:%AQG.YL=@,]Q3_@_P#9S\--($8C\V,2K( !N4F5C@]QG@_E
M7=@ # &** /.?&.HV^@>/].U36VNX=#GT][07<$DBK!/Y@;YRAR P 'U4>G"
MR6OA:7P9=Z5I]F?LOB"[<6R7,KYN97 )F'F'<J@C.?\ 9!&2PSZ*0",$9%%
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MA'KG''Z5L>(9T6^;5M"\1P6.KQ:7$TMK=[7MM1A&\JN#SN!W#*\C</6O4Z"
M>HH HZ)/+=:#IUQ/:&SFEMHW>V/_ "Q8J"4_#I^%7J** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,,D=^N,]Z ,.[NM5E^+RZ$FM7D&G/HQOO*C6+B03;."R$XP>E3>'-=U(^/\
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MF-5E8L67J  023ZCUKJ/&-]%H?CC2M;U1;TZ#+8R6CW-F\H%O*75PS>6<[6
MQWY ]* .PM_$NC76D+JL%]&]FS^6K@'<7SMV;<;M^>-N,Y[5F:KX\T?3_#VK
M:K$TUPVF#;/;+!(LJ.1E0ZE05!_O$ 8YS7'ZH++2+?1?$VB:5>?V';ZS)>7@
MVRO),)(C&;G8_P V 2?KC/0YK2\3W6G^)/A_XLO= T]I?M-E\UVELT;7;*#P
M 5#/M7OTYP.AH ["/Q#8_P!FVEW.\L9N2%CB-O()';&2%CV[FX!/ Z#/2HF\
M7Z!'H]SJLFI1QV=JYCN&=65HG'560C<&]B,UQ]UJ:Q^*_"7B1C(V@_8IK-[A
MXV5+>5PI#MD<*VW;NZ<=:R?$MJ9K/XCZS:G.GZC906]N4Y%U,B$,R?WNH7(Z
MD'TH ]#M_&?A^[>X2VU 3202)$Z1Q.S%G!90H"Y;(5C\N> ?2M/3]3M-4ADE
MM'9ECD,3AXV1E<=00P!!YKD/$46E:AX5\/K+J,VG RQFSU"U(7[+*L3X+=MN
M RD'CYL<5H> [S5;O3+X:NUO<2P7CQ1ZA;Q[$OD"KB7'3/\ "<<?+Q0!L:AK
MVG:9,8;B60RK'YK1PP/,RITW,$!('!Y/H?2L#QKXQBTKP%-K6D3^>TZ(+6XA
MC,J#>ZKNR 0,;LC=U(QSTJC87H\._$WQ,VM2BWM=4CMI;"ZE.V-EC0JT>X\!
M@3G;U.<URVI:?-I7P5U>":.2+[;JIN;*U*$.L+72.H"=1\H+8[9YH ]+T.Q:
M"YNK^'5-2GL;E5V6EZKYA=<AF7S!O /'RGCN.M<UJ7C3^W/!OB^?2WOK"XTM
M+E89OL[(28HP3DNN =Q(V\-@9XKOX9HKB)989$DC895T.0?QKR5;E+?P=\3-
M,F25+R2\U&5(VB8;ED0"/!Q@[L\ <F@#M?#?BW2KV'2M+;4?,U26R23:RM^]
M(0%\.1M8CN 21WJ_>>*M%L+@0W5YY>9A 93$YB60]$:0#8K>Q(KB9KBW&J?#
M!DD3;"D@D(Z1@VQ0;O3YOEY[\5EZ5-HPT^^\'^*M/U2XU87<Q6SW7!BO@TK2
M(Z[3L )())P 1DT >L:GJ$&D:5=ZE=,5M[6%YI".NU02<?E7,>%O[5\4:#;:
M]J6HW5H;Y?.M[2T952"(_<R2I+L1@DGCG@"MWQ#I']N^%]2T?>(S>6LD <G.
MTLI /O@URW@?Q/9Z5X9L-!\02+I6K:;"MI)!='8) @VJT;'AP0 ?ES0!T-A<
M76B6%X_B#41,JW96"<H%,B,%"*%4<MDE< <GH.:GM_$VD7"WI6\$;6(#7,<\
M;1/$",@LC@, >QQ@]JY;QK<7<C^&]=2TN#I>G:J);E/+._RBA03%,9 4L3C&
M<<_1ESY&H_$&;Q#87$;Z9;:%);7%W&P,<CL^Y$#=&( )..F0.] &P/B1X0,3
M2?VW"$6V%T6*.!Y>0,CCDY(XZ\]*NV/C/P]J6MG1[35(I+\*7$6UAO Z[21A
ML<YP3C!]*\]&P?LRRQ* KQ:64D3&"CYY!'8]_P :VM2CM/$6L^"/[':.6;3I
M_M$\D0_X]H!$0R/_ '2S;5VGG@\<&@#K+KQ7HEE*Z7%[L2.4023>4YACD.!M
M:0#8IR0,$CK46J^,_#VB7<MIJ.IQPW$,!N7CVLS",$#.%!]1QUZGH#7G^F2"
MW^%&N>$-51CX@1;R 6K+F2ZDD=VCDC'\0)=3N' P2<8K3TN Z?\ $SP_9WTJ
MRW-MX9^RRRGD&8.F1G^\0&..I% '6W'C/P_:J[RZ@!%&(VEE6)VCB$@!3>X4
MJF00?F(X(]:BN?%]K;>-;?PV8+II9+5KAI5MI&4?,BJ 0#D?,<MT&!D\UYYX
MUU 7VF>/-.^S36=U'C9:VUJ=UXH1?W\CA3D<8&"  O.2:Z+[?%'\3M!U%X[@
M6MWH4EO"_P!G?YY/-1MN,9' SSCCF@#I-%U'3);G7+BWUV6\CAN,W"S/^[LR
M$&54X "X&3R>M6;3Q-I%Y?1645TRW$\9EA2:%XO.0=60N ' '/RYXYKS/4;*
M\UK1OB=8Z1F2[N+R.2&->LR*D>X+ZYVLO'?BM_6;NV\977@Z71'W7-KJ<=Y<
M ##6L*HWF))_<))5=IY)^AH WIOB%X5@BFE?5X_+@G-O,RQNPC<8SN(4X'S#
MYCQ[UTH(90RD$$9!'>O(#+ W@?XGH&4R7%_>&%<<RAHE"%?[P)!P17IV@2K+
MX;TV2-@X^RQ]#W"C(^N: *\7BS1)KN"VCO<M<3-!#)Y3B*61<[D63&QB,'@'
ML?2I9_$>EVUT;>2>3>)TMF98)&197("H7"E0267@GN*\E;5XK[2O"MU]GN+1
MK7Q%&UQIEO9.L5B-TN00%R7)().3DDX K8U*2;3M;N]2\-ZBTDTNIHM]X=O$
MW>>_F*OFPY^93@!\C(X.?NXH ]7HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?
M\7>'9_$VF064-]':"*ZBN2[P&7<8V# 8W+CD<UT%<9\3KNZT_P )K>6E_/9O
M'>VP9H9-FY6F16!/7&">] '9)N"*'(+8Y(& 3]*6L?3/%&D:OJ=SIUG<.;NW
M02/') \99"<!UW ;ES_$,BF)XNT5[ZTM/M3JUX2MK(\#K%.1SA)"-K''(P>>
MV: -NBN<M_'GARZU!;&"_:2X:[-EM6WD^68 $JQVX7@\$\'!QT-6!XMT4WUI
M:&Z=6O',=M*\#K%.X_A20C:QXXP>>V: -NBN7M-<T2UOO$E]_;-Y,MH\9O8I
MM[1VF$Z1KMX! W'&?6I[+QQX?U&^L+.VO7:2_C\RU9H)%24;=Q"N5VE@.JYR
M.XS0!T-%84OC#0X;DP/=M@78LFF$+F)9SQY9D V@Y..O7CK6'XB\0"3QSIOA
MQVU&.SDM9YK@VD,ZN[#8$VO&,[1N))4XSC)[4 :^L:!JEUKL.L:3KGV&=+<V
MSPSVHN(67=NR%W*5;.,D-S@>E:&F:9-:2RW=]=B[OYD6-Y5B$:A5)(55R<#+
M,>23SUZ <YX,\212?VGH]Q<ZA.-'E,+7VH0,C2 +O+2/M"C 8 9P2%SWK;@\
M6://J*6'GRQ7$L+3PK/;R1><B]2A91NQUP.<<]* -JBN=TOQSX>UF]MK33[Y
MIY;GS1%B"0*3&2'!8K@$8Z'!Q@]Q5O5_$^CZ%=6MMJ5ZMO-=;O)4HQW[02>@
M/8'Z]!0!KT5S5KX^\-7>E7^I1ZB1;Z>=MV)()$DA/7YD*[AT/;L?2I;7QMX?
MO([N2&^.RU6)I6:%U!\S[FW(^<D\ +DYXZT =!161;>)=,NKFZM4DG6[MHQ-
M);26TB2[#T94*[F';*@\\=:9:^*]&OO#_P#;MM<R2Z;N*B9;>3)(;:<+MW'Y
MN.!UH VJ*P+:^TVX\;7$,6J7K7Z6"F33VW"%$W\2;2N-Y)QG/08QQ7,_$'Q5
M#_8$#Z3J-[%)_:,$"SV\;K%*?-573S,8/&[H>Q'.* /1:*R=5\2:9H_G?:Y)
MCY$8EG\FWDE\E.?F?8#M'!//8$]J?/X@TR*&SD6Y\[[:F^U6W0RM*N =RA03
MMP1STY'K0!IT5Q'PVU.;5(?$LDM]=7<<6N3Q0-<[MR1B./";2 5P2>,#!S7;
MT %%%<!I_BZ_;XF&QN\+HFIPR1:6_P#>FMV(D_[ZRQ'J%7UH [^BLG5O$VD:
M'=VEKJ-X()KLD0*48[R 2>0,#@?C5-/'/A]])OM3-W,EM82>7=[[259(#C/S
M1E=P&"#G&* .BHK-?7=/CM]/G:27R]0=4ML02$N64L. N1P"><< U9OK^VTV
MU-S=2;(PRH,*6+,Q"JH Y))(  ZDT 6:*X/X@:\9OAYXAN-)O;VRO=/1=S*C
MP2(QVG'S '!!ZC\ZZ#3?%>D:AJ@TB"Z=KT0^<%>%U65!@%D=@%< GJI- &Y1
M6%!XPT.XNK6"*[8B[F>"WF,+B*:1<[E63&TGY3WYP<9J"3QYX<BU)]/:_8W4
M=S':O&MO(=LC_=!PO .1STY'- '245B7'BW1;6ZBAGNG199_LR3F!_),N<;/
M,QMSD$=>H(Z\5+/XDTRVN6@>28E)TMG=+>1XUE<J%0N 0#EE[\9&: -:BFR2
M)%&TDCJD: LS,<!0.I)K'MO%>CW5Y:6J7$B27BEK4S0/&EP ,G8S !N.>#R.
M1Q0!M45Y[<ZL?$OC;6/#S76KV4%M:0K;R6<<\+),Y?=(S  8&U<;OE//7-6_
MB3=:CH7PQOKZRU*XCU"QBBVW2X#.V]%8L,;3D$]N_% ';T5YUJ6K:KX7\:>%
MK*'5;C4+/6#)'<6MT$9X]J@^:C*H( R<@Y'%=%:>._#E_J$5C:W[27$L\ELH
M%O( )$&65B5PO0]<9P<=* .CI#G!QU[9K%B\6Z--J%I9"Y=9+S/V5W@=8[C
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M"F=Q)]*XSQSX5FTWP7:7NF:M?7%SH4D-SIL$B1$$I@;1LC#'*Y&,\]Z]/HH
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M5UM% ''_ !!M+F.RTWQ#I]O)/?Z+=K<+%$,O+"WR2QCZJV?^ BL*RT'6-/\
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M(#!\].3^.(/$,D#3^"GM]-:QMDUC[1Y @V>5$4D'F.H'R9+ \XQNYYS7I-%
M'D^JWDUGK7Q(NK?2EU(R6MCY-O+ 9(Y]JLLG'1]F02!Z8I]G=Q-\1EOPFJ:C
M:7/AV2(3SVLB+,XE#%0-H"#:/0#ZD\^JT4 >4Z%9W]I?6^DZ!JL]_H5W83A(
MKV,^?I#;/D&_&X DA=C<C'&<&F>$KC2;_3M&T'4]"U8Z_I;PJ]K<^>887BPO
MGAB3&% !(QZX YKUFB@#QV*_?2_!7C?PUJMO=KJ[M?RQ8MW<7:2ABLBL 01S
M@^F.:]+\*N7\(Z/F.6-ELXE9)8V1E(0 @JP!'(K7HH \CTL2VGPJUGP;J5M,
M^NQK=VZ0&,EKMI6=HY4/\2DN"6[8.<8K4TJU?3/B7H-K=,TLEKX9%E)<;25,
MXDC.-V,9(5CZ_G7I%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'5-
M7LM&M4GO92BR2I!$JJ6:21SA44#DDFKU<IX\OKJPTS3I;>R>>(ZA"MQ/%:_:
M)+2/G,J)@_,"  <'&<X- &I9^)M+O(=1D\\VYTUMMZERIC,'R[LMGMMYR,BF
MV?BC3+S5DTL-/#>2P?:(8[B!HS+'G!9=P[=QU'I7F-YI.I:FGQ#LM,L=2\Z\
M%E<V;7D4@\\1HA8;G[MM(VDY&<8&,#L;?7O^$STV>/3]'OK._-G+$\]]:M";
M5V0C8K,/F.['W>,#)QP" :=SXWT6TCCGDDN3:2S"WBNDMG:&20MM"A@,')XW
M?=]ZO0^(M/GU'4=/C:9KO3D1[B+R'R%?.TKQ\V=IZ9KRJ]UKSOAAHNB3Z7J%
MGJ&FW>GVUU'-:LB(4E1<AR-K!L9&"3SZ<UUBW+Z+\4M<DN;.]=-3L;46C06S
MR+(T?F!EW ;5/S#[Q QR30!H:EXC\/ZIHVA7YU.^BM+^^A^QRVJR1^=)OPJ/
M@<*3G(;&0*LZEX\T'2]0NK"XENC=6JH\T45G*[!6. PPO*^XXZ<\BO/+&*Z3
MX3^![5]/U!;BUU:UDFB-G)N1$E+,Y&W[N"#GIS78Z:6/Q>UB<V]P(9=,MXHY
MV@<1LRLY90Y&,@$=Z -G4?&&CZ5YCW<LRVT4H@FNEA9H87)  9P,#D@$] 3@
MXJ?4M<L;>:2P8W,TXA\V1+.-G>*,Y 8[>F<''<X. <5YUIHMM/DU3PQXB\-:
ME?W4E]/+;,D,DD%[')(9%)8'8N"W.[ &*U]*N9O"OQ"\01ZI97?V;55MI+&X
MMK:2:,^7'L,7R@[2#T!ZCGO0!J?"N]N-0^&^E7=U=374TAG+33.7=_WS@$D\
M],5C6OBNW\-^-?&D>J7>HW%M!):M#$J2W)A0P[G("@[$R<D\"M7X4)-!\.]/
MMKBUN+::)Y@T<\+1D9E=@1D<@@@Y'%5["Z70_B%XPFU"VNUBOOLDEJR6SR"X
M"0[6"E006!XV]: -X^,]#\S2$CNGE&KC-C)%"[)+QG&X# ..QP:TX]4MI=7G
MTM#(;J"))I!Y;;0K$A?FQC)*MQG/!KS^V\$WT'PAM]..VUUBQ=]2L_F&+>82
M-*B9Z=&V'MR:ZOP=]HN]%&M7T/DWFK$74D6<^4A4"-/P0+GW+>M $6L^+4TG
MQ7H^A_8[F0WRRR-*D#. J+T7 Y.2N>P'7K7.:7XJM_#WB#QF-5N]1N;>UO8R
MBA);DP1&%68D*#L0$DYX%:7BOSK7X@^$-2^R7<UK"E[#(]O TNQY$CV [0<9
M*GD\>I%9$0EW?$PFTN\78/V?-K)^^_T8)\GR_-\W'% '>3Z[8PPVKQN]RUU'
MYMO';H9&D3 )8 ?P_,O)P.0.I%.T;6[#Q!IXOM.G\V'>T;94JR.IPRLIP58'
ML:\OC,^B+X0UC4=)U*YTH:#%IUTMO%)YMI,NT[F08;!P5/';Z9]#\*PV4>FS
M3Z?I+Z;;7,[3*DJ%))20,R.IY!)!Z\X )ZT 8BZM=>*?'^J:#;W4UKI6BQ1?
M:VMW*27$T@)"[QRJJ <[<$GOBMM-&O++6[*>SU*\;3E61;BTN)S*"2/E<,^7
MX(QC)'.<#%<O';S^"?B/K6JSVMS-H>O)$[7-O"TOV6>,$8=5!(5LD[L8!XKJ
M9[_^W]/NK32_-"S6\B?:WC:-4)4A=NX#<<GMP,')S@$ 8?&6BJUNS3RK:W,W
MV>&\,+""23) 4/C')! /0]B:@U#Q[H.F:C=V$\MTUU:!#-%%9RN5#G ;A>5_
MVAQR.<D5Q#VUUJ_P<A\%M87,.NQI#8M \# 1LDB_O=^-NS:N[<#@]!SQ72Z.
MKQ_%G7':"Y\J33K:*.X>!PCLA?< ^,$\CO0!:NOB9X8M([J1[FZ9+.X-O<E+
M*9O(8 9+_+\J_,!D]3G&<&MN?Q!I\*VGERM<R7D9EMH[93(TJ  EAC^'!')P
M.1W(K@-#U"TAB^(5E-!-/+-JURJ0) S^?NA1=BX&"?4=L@G J/0='U'P1X@\
M-W.J)++8_P!@+ID\T2&1;6</YGS;<X4_=W=,@9[4 =I/XYT"W\/SZW)=R"RM
MY3!.1!(7AD!P4=<90Y('..H]:$\;:+*S(DER9?M(M8HS;.K32%=PV @;EV\[
MNF.<XQ7GWB71[R3POX_U"WL[MX]:N[?[%;);N9)!'L#2; ,@,0QY'(7/<5V/
MB_5)8)_#TD5I<-837+?:+V"R:::U'EG;M7:64L3M+8R!GN: ':[\0+'3_!NI
M:[8Q3W+V<K6SPF%@8IP0-L@/W0"1D]P>,Y%6K[5=*G\0>'HY[K4[:\FDE-I;
MB.6))R$;<) 5P0 ,@'GH>]>=W&GWTW@+XAZ=!I6J>?+J;74*30N7DC/DD$%L
MESA6. 2>.<9%=7KUW_:/B[P-?V]I?&VCN+B21VM)%\M6A9%+@KE,D_Q8H Z3
M4/%FE:<;LS/.\5D0+N6&!I$M^ ?G*CL""<9P#DX%-OO&.B:?>V-I-=.TM]$T
MUKY4#R"90,_(5!#'!& ,DY''-<GH4DOA^'Q9HNL6EU)-<WUS=VK) \BWD4PR
M I (+#[I';CM5+2=&OM!U;X;6%W#<22:?97:74J1,Z0L\:[5+@8'.5'/:@#T
M+0O$&G^(K26XL'EQ!,T$T<T31R12+C*LK $'D?G4&H>+-)TS6$TFXDG^W/"T
MZ0QVTCEU! .W"_,>>@R:Q? PD77?&!>WN(EGU4S0M+"Z"1/+1=RD@9&5/2DU
M+>/B[HT_D7!@CTRXB>98',:NSH54L!@$A3WH LGXD>'!I;:AYUX8(I&CN=ME
M*6M2IP?. 7]W@^OX9K6OO$FG6-TEKNEN+E[<W0AMHS(WD@@%^.V2 /7MFO/%
MCG;P)\2+<65[YUYJ%Z]M&;60-,KQJ$*C;R"0>16BFH3_ -LZ197&GZA#:/HL
M82XM;-_-GFS@P/(!NB"XS@E>3DG% '4OXUT)(-(G%U))#J[*EE)';R,LK'HN
M0/E/7@XZ'TK4&J6QUAM*!D-TL(G8>6VT(20#NQCD@\9SP:\Z\->'Y]=^"%CI
M#P7-CJ=K'NMWN(FB:&YC<LC#<,XS@9]":ZKP/)>:GHJ^(-2@$-]JJI*T0.1'
M&%PB@^A^9_K(: ,OQCJ9T?Q[X/GDO;J*SE:\6>"-G9)=L!*?NU^\V3P,$Y(K
M<TGQGH>L:?>WEO=M&E@Q6[CN(FBD@/7YD8 CV]:R?&"R6WC/P=JSP3M8V<UT
M+F:.)I!%YD)52P4$@$\9Z#O7.^(?#VIZTWB_6])M)"+F.R6VA<&-KPV\@D<X
M.#@@;%/?''&"0#O[+Q-IU[K#:2#/!?B'SUAN8&B:2/.-RY'(SU'4=P*=K?B7
M2_#IM!J<[P_:YA!"1"[!G/09 ('0]?3BN=\+WNC:[JMO?V/AW4+:[MXV$MQJ
M$$D;6^1@QJ7^\2>NWC .3T!=\1 [R^%?+M[B;R==M[B7R8'D\N-5<%CM!P 2
M* -BV\7:9>645Q;)>R/+YFRW%I()L(VUB4(! !P,G') Z\5G:IXF\.ZIH&G7
MQU6]BM+F^BCADM!(C&8. (WP,J,\$-BLCQ9(VC>/K76[_3;Z]T2YTX6;R62.
M[6TJR,X9E3G:P;'U%5O$EK O@VP_LK0KJSAFUNVNEMTMG,I02*7E= "5)P3S
MSC&<'B@#M]1\2Z?ICW2S?:)!9H)+IH(6D$((R-V!Z#/&<#DX'-&H^)=/TQ[I
M9OM$@LXQ+=-!"T@A4@D%L#T!.!G Y.!S7$>+K63^U]6U;0+G4+#7HHD40&W:
M6VU9=@*H4(P6Y*9!RO>F>*+:Y.H:CJVE37^E^)8K>,/;+"TUKJ?[L$1E<;6(
M)9,@Y'4T =^FOV#ZU<Z.KR_;[> 7+Q>2W,9) 93C#<@C@U#:>*M(OM%AU:VN
M'DM9Y6AA A</)(&*E0A&XG*MVZ GH,UR\EU<:5\48M2U&QNPE]H<5NAMK=YE
M^T+*S-'E0<<-U.![UR=A;:E9^"O#NI-HVHSQZ3JUW+>V2Q.DIBE:4"1!QOVA
MP?E/?TS0!ZE:>+-'NK?4I6N3;G3#B]CN4,;P<9!8'L1R",@]JYF^UM[KXI>%
M(+>74K>&>"[>6WF5XHY%$8V-M/!.2W7D=P.*R?$%A'KW@_5=0\+:!=)(TEM-
M(9X7CFOQ%(&*!7^8@ <9ZG@5?NM:BUWQ_P""]1L;+4S;11WJS/)82IY+/&@
M;*\<\$]!ZT >@7M];Z=:M<W4GEQ*0N<$DDD   <DDD  <DFLJ'Q=I<LM_ ?M
M4=U81B6>U>V?S1&>CJH&6'^[FLSXD6=_<>'K2ZT^SEO7T^_AO);2(D//$A.Y
M5QWP<CZ56T35-#EDNO$-AH&I1"&T,<MS/:2B=^01"BMEGYSG' ..>3@ W=-\
M7:/J\>FO832SIJ*/);,L#X*H0&+<?* 2!\V.M-U'QCHVE">2ZGD%M;3+!<7*
MQ,T4#L0 KN!@<L,^F1G%<?X?M[GP=XP!>PD?3?$2&X/V:V=QITVXMY9('$;;
M^O'S9. #2>'=3FT%=5\*:QH-]>7;7\\UJ5M3)!>1R2%U8OC:N">=W3'X4 =Q
MJGB33])\_P [[1+]GC$UQ]G@:7R8SGYFVCCH3CK@$XJE<^//#MM-:Q&\DEDN
M[;[5;K!;R2>='QRFU3N/(X&3[5R5[*F@^.=<7Q!H^HWEAJWE36ES90RS(2(E
MC>)E3H<KQD<@T^5[/1?B%X15K'^SK9=*NU6W1"PMP60@-MR!Z$] 3UH V-4^
M).E1>![WQ%I0FO/L[_9S%Y+*T4V0N)%(!4 D9S^'6NQMKA;JW69$E16SA98V
M1ASCE6 (KR77]!OKKPQ\0=3LK&X,6JW-O):VZQ$22+#Y>^0)C/S$,1QD@9[B
MO5[&\CU"SCNHDF2.09431-&V/4JP!'X@&@#''C/13<PQB>4Q3W9L8KGR6\E[
M@$CRPV.N01GH2,9JQ=>)=/M)YXV^T2+;RI!-)%"SI'(VW:K$#K\ZGT&1DBO+
MKZZO=1TK3)[C2=4@O;+Q'%-<V5O8R+!;1B<G<H5<2DC#%AN.6/0&M77H+J#6
M-1UCPS)J%GK)N(UN-)G@9[;4AA1N (P#MX+J>-ISCK0!ZD[I'&TDC!44$LS'
M  '<UB0^+](FN;&+S9HDOSBSFEA9(K@XR K$8R1R,XW#IFG^+M,NM9\':QIM
MDX2ZNK.2*(DX!8J0!GL#T_&N*OA+XL\'>'-'@L[JWU2WN[1KB.2!D-GY)'F,
M21CH"%Y^;(Q0!O1>*EUS4O$FC1P7MK_9Z"-9A&Z,6*%RVX?=&-N,X)Z]ZSO
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MFZ_*J1P2(49HUB"-)M/*EFR1GG@&D^'MOJTT3RZYAY]*#Z1;R@Y\Y4?YY?\
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MBB@ HHHH **** ,/7/#TVMW5OG6+RVL%1H[FRA"A+E3CAF(R/0X[$]*VP H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !15+2]6L=9MI+BPN%GBCFD@9E[.C%6'YC\1@U=H
M**1F5!EF"C(&2<<DX%9<'B&QN/$ESH,8G%[;VZW$FZ(JNPMM&">O(/3CB@#5
MHHHH **KW]VNGZ?<7CQ32K!&TACA0N[ #.%4=3Z"G6]TEQ:V\^'C$Z!E25=K
MC(S@@]#CJ/8T 34444 %%4K34X[O4+ZS6WNHVLV16DEA*QR;EW?(QX8#H<=#
M5V@ HK*O_$-CIVN:9I$XG^U:DSK!MB)3Y5+'+=!P.G6M6@ HHHH **BN)TMK
M>2>0.4C4L1&A=B/8#)/X53T+6K3Q%HMKJU@7-K<J6C,B[6(R1R/PH T:***
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MK/5/%K_#67Q9+KMNTC:(;I+;["N$E5=^_=D9R!C&,#-&IS:EJ/B/X<2'5KJ
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M)69F/&2&7YB,<<5TNA:1>Z;'))J>KRZK?2 *T[Q+$H49PJHO ZDD\DYZ\
MYK68[R3XNZ%#'JEU# VG7,@B0(54AHP>"IZYY)Y],<TV#7=:\0>'-;U[2M0%
MJ;*XN([.U,*-'*L/'[W(W9<@_=*X!'7!SOZMX9;4?$FF:W;ZC+9W%E')"P2-
M7$L;[21S]TY4<U1C\%261UBVTS53:Z;JTCRSVQ@#M$[C$AB?<-N[K@JP!Z4
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MS!B,<X' ]3[XX%;0? =WH,B6<7B6]ET"&3S(-,>),ISN"&7[Q0'^'CI@\9!
M.UHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,TBC@L#SCU!'7CH1L?#_ %>_UCPOYNIS"XN[>ZN+5YP@3S?+D90Q X!( Z4
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MM[&6Q\A/+,<C,-V[&_>#@Y! ]O4 ]DHK.UZ;4;?P_J$VDPK-J*6[M;1MT:0
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M2,-NE3.-Q/;D\#'UKHJ* (+B&6>QD@$H21T*^8$R 2,9QG^M<[;>!K%? /\
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M^B K8ZC"JB15(P593PP(QD<=/KGN:* ,W1M+DTNU9;F_GU"[E;=-=3A59SC
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MH^)=0U2-(6AM1.B+Y 92NXE1EWP2,L>Y]:L1>%W.IV&I:CJ+7=UIL$D-M,L
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M*JIG:1QG/)Y).<T <IHOC'5=7T#P;;R,[7VL0SR7$L.Q'<0\$+N^4%B03@=
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MAKXPU%=5F%]I6IW<-M/Y<>X)&X"J1MP>/;-==#X03.EI>ZC/>P:7/]HM5E1
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MG(YQN(4\@$X! /-;VO:'8^)-%N=)U&-GMKA0&VG#*0<AE/8@@$?2@#G-0O\
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M;HYXW4',:!/D8$C !&>AS6=IUS/:6'Q$FMM2@TV9=9;;=SKN6+,<0SCG)P<
M8/)'!H ].K/U'5#::1-?V=I-J31G:(+0J7<[MI R0..<\]C7'Z7?7TWC75]"
M-QJ<.GR:1'=Q"YD'G1L7="RMDLH( X/((Z"N9LKG4M(_9VM]6L-6O(;L01N&
MRK8S-M(&5)&0QZ<Y[T >S45P^K2ZK<?$^TT>'6KNUL+C299WCB5,JRR(N5)7
M@D'J<XYQCJ,6'Q'KUK\.]7E6ZFN;C3=9EL)+UD#2K;),%:4@#!94)YQVSVH
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M8!NGF&3YR/\ :V@Y]A0!U<WB;['):KJ&CZC:"ZGCMXW<1NN]V"@,8W;;UZG
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MC!Z-CH5/JI(H S5^'VF2?VZ+^[O=076T1;Q;AUP2BA58;5&",9XX'8<4[2_
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MRV<]S%YT<1\HJ-A=PH)R>F6'0&MN@#D= \ 6?AZ>,0:MJT^GP/OMM.N+@-!
M>HP,9('8$D#KUP:2?X>:=<Z?K5G-J&HNFK70O)6WQJT4P*D,A"#&-B\'(XKJ
MY)XHI8HGD59)21&I/+$#)Q^ J2@#F['P;;V?B-==DU34KJ]^R"TE,TJ[9E#%
M@655 !&3PN![9YJB/AQIX\&R^%O[4U3^S7(V@R1EHT#[PBG9C&>Y!/;.,5V5
M% &$_AB.3Q-;:^VI7INX+5K15_=[&1B"<C9G)(!X-<MXB\.1^'_#5Q:PS:Y<
MVVHZLMY>7%LJO-:DOYC2*J("1N51C!QG..,'T:J5O>7,VJWMI)I\T,$ C,5T
MS*4GW DA0#D;<8.?6@#CO#"WDFL6TNG>)-=U33_F%TNJ68C0+M.W:QC0EMVW
M@9&,YQQ73^(O#UMXDL8+:XN+BW:WN8[J">W90\<B'*D;@1^8-:]% &!#X4BA
M\2?VZNIW[7?V(6.',;+Y8;=GE,[MQ)SG].*S&^&NDR>&1H<EYJ#QQW;7MO<^
M8JSV\Q8L61E48Y8]0>M=E10!RDG@6"Y\.7VD7NL:K=M?(([B\FD1IF09P@RN
MU1R>@SR>:MZSX0L=>\.P:/?W%T_V=D>"[1PD\4B?==64 !A]*Z"B@#F8O!5J
M^@ZAI>HZEJ.I&_A,$UU=2@RA,' 7  7&2>G)ZYHF\%6TT&E,VI7_ /:.EL6M
MM1+(9AD;64C;M*D  C;VSUYJWX=\1Q^(3J@2SFM6T^^>R=)BI+,JJQ/RDC'S
M>M6-5UJ/3;BQLUC\Z^OY&CMH=VW<50NQ)[  =>>HXH 72]%@TR>\NA))<7EZ
MZM<7,N-S[1M48  "@= !W)Y))JOJGAN'5==TG5Y+VZBFTMG:".+9L)==K;LJ
M2<CCJ*CT#7[_ %BXGCN_#M_I:PK_ *RZ*8=]Q!5<')' (;H0:WJ .77P1;+;
MZ_#_ &GJ!77"QNLF+*EEV'9\G'RC'.?SK<TG3DTC2+33HYI9H[6)84>7;N*J
M,#. !T'I5RL#6_%5MH\.DSK;RW<&IWL-G'-"R[$,AP&.3DCKT!_"@#'7X8Z<
MFG1:>FKZNEI;WHOK2)9DQ;.'+X7Y.1DG[V[':K5WX!LYM?EU>RU;5=,FN41+
MQ+.X"K<A1@%L@D-CC<"#^/-=;10!RVL>!+#4M0L=1L[V^TB_LX/LT=Q82*I:
M'_GFP8$$#J..M3WO@W3[RSTZ-9[J"ZTV4SVM\D@:99#G>26!#;LG<",'/TKH
MJ* .=N/!]K=V.KPW%[=/<:M#]GN[L;!(8MI4(HV[54!F[9Y)SFDO_!FGZGX3
MM_#UY/=2PVPC\BYWJLT31_<=64 !AZXKHZ* .3C\"0/JL>I:AK.IW]RMD]BY
MF:-5DB<Y((1!Z#D8/J34%K\.+*VCT9#K6L2_V/(39EYD&Q-I7R^$&1M.,_>]
M"*[.L2Q\1I?>*M3T'['/#+8112M+(5VR!RV"N">/E[X/M0!17P-:C3]?LO[3
MU Q:Y(\ET28L@NH5MOR<?* .]0WWP^L[HZ5/;ZKJ=EJ.FVXM8K^VD197A_N.
M-NUA^'6NOHH Y?5O FF:OH]G8O<WT-Q92^?;ZA%/BY24_>?>0<DYY&,?3 QJ
M:)HJZ-;.C7MW?7$A!ENKQPTCXZ#@  #L  .2>I)K4HH RO$'A[3_ !+8PVFH
MQEXHKB.X4 X^9#G'T(RI]F-$?A[3XO%,WB)8R+^:U6T9NVQ6+9^O(&?0"I=9
MUBVT/36O;K<5WI$B)]YW=@JJ/<D@5%I.J7=]=7UM>Z3<6,EJZ@.S!XIU89#1
MN,9QW&!B@"*W\-PVWBJ[\0"\NFN+J!()(6V>6$4DJ  N>"3W[UC+\-]/3PPG
MAY-5U46$4Z31+YD9,85]ZH,IT#<\\GH3@ 5V3$JI(4L0,A1U/MS6-X9\11^)
MM/GNX[6:U$-U+:M',5+!HVVG.TD=?<T -7PU$/%D?B)K^[:[2S^Q>6?+\MH]
MP8Y 7.=P!SFI?$7AZV\26$-K<3W%NT%S'=0SV[*'CD0Y4C<"/S!K7HH Y^+P
MI%#XE_MY=3OVN_L0L<.8V7RPV[/*9W;CG.?TXK,?X:Z3)X;&BR7NH,L=VU[;
MW0D19[>8L6+(RJ,<L>H/6NSHH R="T(:+#)YFH7NHW4N!)=7L@9R!G"C   &
M3P!W--U[PSI_B'[+)<^;#=V<GFVMW;OLE@;N5//![@@@]Q6Q10!S=YX1&JSZ
M<^KZK>7J:?=)=P1%8XU,J9VLQ503C)X! ]JKZGX#M;[Q%)KEGJVJ:5=W"*EW
M]@F"+<A>!N!!Y XR,'%;>L:S!H\=KYBF2>[N%MK:(''F2-D@9[  $D^@/4\4
MW1=3N=3@N#=Z7<Z=/!.T+1S8(?&"'1A]Y3GKQW':@"D?"5H->T[5H;N[A?3[
M9K6"!"AC\ML9SE2Q)VCG/:J+?#O29]'U?2[NYO;F#4[QKZ1G9%>*<D'?&54;
M2"!CK^IKKJ* .7M?!20Z3>V5UKFK7\MU ULUU=2H\D<3#!5/EVC/<X).!D\#
M"W7@BRN_"FGZ ]_?"/3FA>TNE9!-$T7W#D+M. ,<BNGK$E\1I%XRM_#C6<XD
MGM'NEN"5V$*5!  .<Y;N!^- %2S\&066KW^J1ZKJ;W=_;I#.SR(0Q0$!\;<9
MPQX^[S]VM'PWH,'AC0;;1[6XN)[>V7;$TY4L%SG&5 !_*M6B@#G]6\)VNHZQ
M#K5K=W6FZM%'Y7VNT*YDCSG8ZL"KKGU&1V-7K72-A+WUW-J,I0INN%0*JGJ
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MB;^!V95+8(."<GKD\506_EU_X@:SH4MQ<6]IIEI RI;S-$TLDNXERRD'"@
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M",X!!R".2>M+!</:^*OB9/'?PZ?)'#:,MW,NY(3]F.&([X]*V=)^'6E:+?\
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M6BRGE>6I)"@;<\$DYSFJT?@ZTB&N;;^^_P")T2;HEH^I79\OR<?*,?\ U^:
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MCB\[PSJ:>9+'FUD.Z)RC#"D\$<BO+WM3'\*OA]Y4\P>;4=+8,[E]A/\ =!X
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M6[2)(WD,H)*L&7D@]P#^%1GPW WB>#7VO;MKR&U-H 2FPQDAB" O4D YS^E
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M13A$N0H*JS@ '(!(^4@>W6F6O@*PLVT%HM0U+.B(R6F^5&X9=AW97GY0!@8
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M:"B-N&   >.#D'/&9<#Q3'JO@C2=4\0LMU=B\@OWT]AY<ACC8JP)0'=C&<C
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MBS.BQM*K[T!PKY7IN'..HKB]$TZ)OB[XKD$MVKK:6;KBZDP"PDSE2V"!V!!
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MS'EMO3)R<$9J+Q+<7&@>.- U:2]NAI%Z[6%U"9V\J.9A^ZDVYP,D%3VY!ZT
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M#;N)(+B.0QS1./XE9<8-02>"=(F\-3Z#*;N6TN6W7+R7+M+.>.7D)W'H._0
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M"[?KSGK[U9_L6P_M_P#MSR%_M#[-]E\[OY>[=C\Z .+F-]XD\0^)M%AF,?\
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MR>E/UK0;#7[:&*^C?=!*L\$L;E)(9%Z,K#D&@#@M6N-0TG7/%FA6U]>_8/[
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MW]IJUW%#++*7D2%)%!"LW<(&Q[UWVE>'+/1KS4+JTDN?-U"3SK@R2[@SXQN
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MDGOO$:VU_>7$]II8=8()FMX]/;:["1G5OF=L @8) 7G -=)X3\/_ /"/6=Y
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MOSSNR#GWS0!LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[YL=,\XS6K>V=OJ-C<65W$);:XC:*6,]&5A@C\C4]% '.Q^!]#B33%6.Z/\
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MKC&!(#NQ@ <FK%UX0T6\T>VTJ6VD%E;2K-&B3R*?,!W!BP.6.[G))R>:W:*
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M36^J+.WVCS3N0Q)N(VXQSD<Y]>*UM4DOX=,N)-,MXKB^5,PQ32;$9O0M@XH
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MRS6=O:RVZRR-((B8&)(W$X )+8Z<5/K47]CZ+X2U[0Y9#>S7EI#*XD+&^CF
M#"3^^3G<">1CBNXMO#FE6FI:AJ$5NWVG4 !=L\SN)0!@ JQ*\#CITXJ'3O"6
MC:6UO]EMI ELQ:VBDN))(X"<@E$9BJ\$C@< D# - 'GTND0W[?$A;FYOI%LI
M#):@WDO[IQ;!PP^;G!Z9R!V YKT/PI<S:AX,T2ZN9&DGN-/@DE<GEF:-23GU
MR::OA+15_M3;;S#^U/\ C]_TN7]]QCGYN...,<<5H:?I]KH^FPV-E&Z6MN@2
M*,NSE5 X +$G@=!0!Y+;^'X]6\)>,[R?4M36[TS5+\V,_P!NE_T<Q<J?O<]
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M);M/]MA\BY:XE:5I(\$;"S$G;\S<#U)ZFJ!\!^'#!I\7V!P-/)-LZW4HD3(
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M>YD+%@2K!CP1R>X]: ..A.HR^%] M+G4K]S:>+_[,BN1<,K36ZNX!;!PQR,
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MWJ"I.!AAQ@#%>GUBMX4T=I],F:"8R:6"MFQNI?W0(P?XN>..<\<5M4 %%%%
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M*[>5]XYV\ '.1C&1BG7&F6=E??$C1H81_9PTF&Z6V<ET64QRY8 YP254_44
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MH^G7=LD=UX>WC4HPN MRF8D7Z-\\G_ 5H [W4M1M=(TVXU"]E$5M;QF21SV
M_KZ"L?4_$-W8>-M"T06L+6NIQW#&<R'>IB0-C;C'<<Y/?BL?XP6T$_PPU=IH
MDD,0C="PSM;S%&1[X)_.JWB32K)OB!X(TZ.$16ACU &*$E 08T)'RXX/?UH
M]#HKQK^T)/#GAWQ19VD[6NFVWB6*VWDLRVMM(8C(!R"%^9NA&-QP0>:[71O#
M@TCQ;_:,&J6D<-Y9E3IME:F**4JP/G8WL,@,%R!SD4 ;'B/Q%:^'+&*::.2>
MXN9EM[6UBQOGE;[JC/ ]23P *I:CJOB73-'N-1?1[&Y,,32-:V]TQ< #/!*
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M$JR"0G89(XQ(RY'7A@/KD=J )8O!GA^'1[S2%TY3I]XV^>W:1V5VSG=R>#D
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M-]['S<Y[D]>^:M:/-J3Z7;G6XK6#43N$J6SEHR03@KGG!&#CMG%7R0.I ^M
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MDC!V.?<@ULE@O4@?6D+HH!+* >A)ZT 9\N@:;-K<6LR0,=0A3RXYA,XVIW4
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MIAO+:]EC&\Q[MGERCD$YY!/H>3VRO#\6C0_#+P5;/;@W5]<0,D$)6-;J50Y
MG.TY3@D\$Y48S7J.G:-I^E&9K.V6-YR#+(Q+O)CIN9B2<=LGBJ!\%>&3IIT[
M^P[(6?G>?Y0B  D'1ACH>3T]: /,;^WC'A3XI6,T=JT=O-YL4,2?NXG,"EBB
MG.#GOZY/%;]]):6GB#PIHO\ Q+[/3+JQE=(YK<-!)=8C(#*"HW;2Q&?[WKBN
MVA\+:#;M>-#H]DAO8A#<;80!+&%V[2/3  Q4=QX0\.W>AQZ+/H]H^G1G<EN8
MQM4^H[@^_6@"IX.T6#0(=2L;;41=1?;&E\E(]D=JS@,8D&3A1D';GC=[UD6
M@UWXE^*M-UNVBN4M;>U6R@N$#+Y+H3(R@\<N<$^P':NRTW3+'1["*PTVTBM;
M6(82*)=JCUJ&_P!!TS4[J*ZN[17N8E*),K%) IZKN4@[3Z=* /(=2@>X^"&M
M)?H+I-.U1[;3KB<!W\A;I$!#'GU7/H,5[3:V=M8VZV]G;PV\"YVQPH$49Y.
M.*IWOA[2-0TN/3+K3X)+", +;%<1@#I\HXXQQ5Z&%((5BCW!%&!EB3^9YH X
M7P9_R4OX@_\ 7Q9_^B*QM8GN-3^+5[JFA#SCH.A3132H-RFX;<4B]R,@X^M=
MV/!WAX7,]S_9<'GW!S-)SNE/^T<_-^-:EC86>F6JVMA:06MNOW8H(PBC\!Q0
M!YKX>TS3M9TGPKXCAUJTAGADB8S6MOB>XD8 20RMO);))W9'49IDUU8V:?%"
M;4KBZ@M/M,2226C 2@-!&H"$\ DD#GCFNZL?!WAS3-9DU>QT:SM]0DSNGCC
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M'8@!%5W985D:180S$A%9N2!G'./H.@UZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S=?UB'P_P"'
M[_5IUWI:0/-L!P7V@G:/<XQ6E7)?$^"&?X:Z^9HHY#'92.A=0=K;3@C/0^]
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MFE:C=SO=2-&&B:Y$:B(N"<9/S8S_ ! 'KS0!WFHZM:Z=HEWJKNLEM;P/.2C
M[@JEC@_A6-H.HZ]?_8=3N9-,.D7=BMQ(J!DEMI" P7))#K@G).WIGVKF[[P_
MI6G>#_'*6]['?)+:S73P"-/)MIC"_* <*QP&(ZC@]ZIW4]KI.C_#V%VMK#2K
MQ%-S*T*^49_LX\KS!P#DYY/< ]J /4UN(7@\]9HVAQGS P*X]<T>?"<XE3Y6
MV'YAPWI]>1Q7C_C3P_I>G>!/&+6M^EV9I;:Y:&-%$5K*9%!,8'W68<GG/3UK
M6\<^%="T]O#9L]-@@>Z\1VOGO&,-)E6!RW7G SZGGK0!Z2;JW6 SM/$(1UD+
MC;UQU^M/\Q#'YF]=F-V[/&/7->:W]KIFA^/],T&,6>EZ5+832V<<D*M"URTG
M[P $X#;<8] 2!UK.N;>Q\.MX;T2/4FN_#USKLHN6? A1MF^. 8X\OS#T]00>
ME ':Z9XBN[WQ]J6C,UI)806,5U!)""6)=V4ACD@_=[ 5-XE\1/I%]H^F6WD+
M>:M<-#%+<Y\J/:I8D@$%B> %R,D]16'H]M:6GQHUY;6**(R:3;22+& ,MO<$
MD#O@+6UXMTO0/$4=KX?UV(-]LWO;,&VLLB '*-U#88GZ YH GL;[6H=;DL=5
MCLFM1;&>.\MPR!R& *E&)VX!S]XYR.F#5[1]9LM>TY;_ $^82VSNZJX/#!79
M<CV)4D>U<-X:CUOP_P",G\%ZKJ)UW2)[!KJWFN5#30J&"[)/[P.>">OMTKE=
M,FATWX/>%WCCABM;K5H8M7=  3;?:) ?,(YVY 4Y[$CO0![=#/#<*6AE210<
M$HP(SZ<4">$SF 2QF8#)CW#<!ZXKSWQ!;W.D?$73IO#L"I-=:3>&\AB4!7$2
MJ8691QG>VT'KCBH_"<?AG6_"'A35);@?VE;RQR&2.3$\EV1ME5_XFRQ8L#VY
MZ4 ='X5U^^U6[\0P:C]F7^S=1-I&T*E04"(P)R3S\U=,K!@"I!![@UXJ+X6?
MB;Q"NL6Z2>%9O$#1W[]=DGEQ>491_P \L]??&>,@^SQQ0I L<2(L.W"JH 7'
ML/2@!&N($(#31J2^P L!\WI]?:G":)I6B$B&11ED##('J17B4VAZ6_PT^(,[
M6,!EL]6U VKE!F#:P*^7_<Z#ICI733Z=9Z=X^\!75G;QPW-[%=K=3(/GN!Y
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M@UXUI6G#5Y_A=_;ULL\]S87BS^<,F:,1*4#_ -X;2#@^I]373:'9V*_$C7-
MNK*$6=EIMJFE6LB;D%N0WFE0?5\ GV H ]":2-,;W5<],G&:-Z[@NY=QY SS
M7D-IX;NM:^&^M6D2":71]8N7T%Y!O/EPR9103U4D.GICZ5V/AFXL?&8'B8VD
M;6TMJMM;K+&#P1NF'(Z;CL(_Z9GUH Z#1VU#^RHCJTUG+> OYLEH"(N&.,;B
M3P, ^X-8MGXCN[GXB7&AA[273UTM;V*2$$N6,I0@G)!^Z>@[UYSH]ZMG\-/
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M6:]?-O'$RQAY"G5Y"1CJ.-V3TKG[>82? '2T\U7,>I1*,'HHOB%QZ# P/84
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MUBNH&N4&6B#@LON5SFN=\(>(KO5++6)-8FM4>RU:XL5>-?+0K&0!P2>3R>M
M&N_A[1WO)+MM-MC/(XDD?8/WCC[K,.C$8&">1@8HN_#VC7^IPZG=Z7:3WT*[
M8[B2(%U'7 /MV]*T!+&T7FAU,>-V\'C'KFL[1/$&F^(;22ZTZYCFA262+<K
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MSQ5U])TV73AI\FGVKV0&!;-"IC_[YQBI;2SM;"W6WL[:&W@7[L<*!%'T XH
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M KO[G1-*O&@:ZTRSG:WQY)E@5C%C^[D<?A2:IHFE:W"D.JZ;:7T:-N1;F%9
MI]1D<4 >9Q1Z=H&K>!]&AU"6[\-F[O-D]RRF-IP/W2Y  *AB^WW''05O>%%M
M(/BKXYCMO)0NMB[*A RWEON.!W]?K787>CZ9?Z<-.O-/M9[(  6\D*M& .F%
M(P,=J;8Z)I.F2M)8:99VLC*$+00*A*CH,@=/:@#&\7:9X=\22V?AS78E9[M)
M9K5M^QU:/:"4;KNP^<>@.17-^'8]:T7Q'JW@S4=1;7-+CTS[9;7-PH:6$%BH
MBD/<G!(S_=_ >@7VE:=J847]C;76P$+Y\2OMSC.,CCH/R%+8:5I^E1NFGV5O
M:K(VYQ#&%WGU..I^M 'CVGWD%K\-?A^N81ITE];+JA7&-IW;/,_V=X&<\<5T
M'B:+4-/\>W]QX=4K<3>'+B2Y2(<-*IQ Q']_.0.Y /I7>Q:'I$%C/8PZ791V
M<Y+30);J(Y">I9<8.?>I+#2[#2XVCL+*"V1L%A#&%W8X&<=: .'\,2>$M8T+
MPA?0SQ/?6J+]G2&7$OFLF)0X!R?XBV?3/UY;1[\6.MZD=;ACD\+3>)KV-W_A
MBN_-!C:8'JGIV#<GMCUJT\/Z-87L][9Z38V]U<9\Z:*W57DSUR0,G--_X1O0
MA:S6O]BZ=]GF</+%]E39(WJPQ@GW- &D41XRA52A&"I'!'I7B$5REA\'Y&@$
M:I_;,BZB(P XM?M;;\XYVX(!]C7ML$$-K D%O$D4*#"1QJ%51Z #I5>#2--M
MC=F#3[2+[8Q:YV0JOG$]2^!\W4]?6@#D-:MA#\3/"%UI 1&GBN8[OR<!9+54
M!4MCJ Y7!]6IWQ9CB;P,\DJ(0E[:'<P'RCSX\_3BNKT_1M,TD,-.T^UM-P"G
MR(E3('0<#H/2K%W9VVH6DEK>6\5Q;RC#Q3('1AZ$'@T <'JMGIU_\5O#]NT-
MO/:#2[O$6 T9(DCX(Z'!SQZCU%<K]K71_"FI1JQM]'MO&DD-SY: I!;;\XVX
M(V!RN1C'.,5ZXN@Z.EQ#<+I5B)H$$<4@MTW1J. JG&0/84L.AZ3;07$$&EV4
M4-SGSXTMT59<]=P ^;\: .>\/:=H\?BZ]U73];:^NKRT07$<#1&'"GY'8(/O
M') )/(!]*H^+-1CL_B'H$&HWXL=/FM+@6\SJAC^T[DX)<$ [-P!Z\D#J:[#2
M]&TS1+=K?2M/M;*%FW,EO$L8)]2 .M/U+2M/UBT-IJ=C;WEN2&\JXB#KGUP>
M] ' OX7\,GP3KFE+>3:C9W5Z[Q;-A\JZ?!"6^T ##$<#@$G/&:G\%3&XT_7-
M.UR)&\46_P"[U(N ?/0+^Z=.!F,J!@8Z[L\FNT71=*6"T@73;,0V;;K9! NV
M$^J#'RGZ4Y=(TU-2;4ET^T6_8;6NA"HE(Z8+8S^M 'C^GZA:Z=\+_ DCW$=O
MI[74(U*5%5M@*R",R @C;Y@7D]UK1\5:+H:>&/&U]::F-1FN]/$UQ&OE-#&Z
M@A' 08#D9YZG&:]+BT+2(;">PBTJRCL[@EIK=;=1'(3U++C!S[TR'PWH=OI;
M:9#H]@E@S;FMA;IY;'U*XP30!PTFFV.G>.?A_)9VL,$EU;7:3NB@-,/(5OG/
M5N>><\U?^&BVD1\2QHL"7 U^^ 50 P0.O'KCD?F*ZW^P='\VVE_LJQ\RU&+=
M_LZ9B'HIQ\OX5-;Z986EW<7=M96T-S<D&>:.)5>4CIN(&3^- '#>*=+TV^^+
M/A6.\M()5GL[T2+(H(EVB,J&'\0')P<BN3U"$^&D\9Q:>'@\,Q:SIYE6%-R1
M(VUKD*O3'* KC&"1TKOM?\.W.K^.]"U&33X+C3+&&>.;S74DM)LPRJ?[I7V/
MI740Z?9061LH;2!+4@@PK& A!ZY'3G)SZT <'+I'A^[OM3U2VUE-2GN]&DCF
M@B\EH'B7E7<(OW@3A2>V<=#7+W_A[1D_9X&J#3;4W[:-#NNC&#(>5/WNO!Z>
MG3I7K-GX;T/3[*>SL]'L+>UN#F:&*W14D_W@!@_C4AT'1SIO]FG2;$V&=WV7
M[.GE9]=N,?I0!PVM:'I,?Q)\&QI86ZI=6U\MPH0?OPJ1L/,_O_-S\V>>:RS9
M6D?A7XJV*V\*VD$UQ)%"$&R-OLRME1T'S<\=Z]..AZ0;BWN#I=D9K88@D^SI
MNB'HIQD?A3!X=T0)<(-'T\+<\SK]F3$O^]Q\WXT >?W,=I_;'PMEND@\LVLP
M=Y0,$?8\@$GWIBL+77OB=)IBPKJ2PPM8A -^\V>1L]R03QZ5Z-)H>D36EO:R
MZ79/;6S!X(6MU*1,.A48P#]*E&F6"ZDVI"RMA?,GEFY$2^85_N[L9Q[4 >=:
M!;^'-:A\*:O::^S75K@6UO;^4LA++B2-P%W$ 9+9]":YZ:YM-6^ 'B"XU'R7
MUCSIVOQ+CS$N1,=H.>00NT >@ KUZR\/Z-IU_-?66DV5M=SY\V>&!4=\\G)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M $K'MW,GR'<>2<' QCDG@="OB=G\80:$MFICN-.:_AN?./(#*NTKMX^]UR:
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M/;/6NNU#4[#2K?S]0O(+6+^_-($'KWJ>">&Z@CGMY4EAD4,DD;!E8'H01U%
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M#Y3Q@?UKMZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]W/F6\D8< A-N&SN'<8QWZ'!L/"/BF(>%))K;24GTBY=[J07+NUT6C9&F8[
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M.* *NG^+/$.JZOJ-E9^'[0IIVH"TN)'OR!LV!MZ_)R>>1CCC&><9H^(^K?\
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M=U#Q+I=E;W&E64DH\IG(EN(XF*R.IZ+]UL*0<@=1G% '77=Y;6,!GNIDAC!
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M>%=1U2;7M5E2TCU*_P!*.EVT/G,4BC.XEF?;DDLV< =%'/-+J/AG5[WX4?\
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M<D1[BVUXQCG*KD$GOTJ.3Q+XDNO$OB'1=.L=,5],A@EBEGE<AA('.&  .3M
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M?,"&!&<8SWQ6YI7B#5F\:W?AW5[:S5OL*W]O):.Q 0N4*-NZD'N ,^E9&H>
M[^709;>UEM#?WFLKJUW)(S*@975@B84D@!57)QW..<5LIH>I_P#"Q1XB?[(+
M0Z8+$QK*Q<'S/,W?=QCMC/O[4 ;EYIEGJ$UO)=P)/]G8O&L@#*K$8W8/<#(!
M[9-<;X=MK'0=7\8>(XPEKHEQ+$(UC7".\:E9)%4?WG.T8^\5[Y%;WBJT\0WU
MA';:#+81%V_TAKMI!E/[J[!D9[G(('3DY%;3-(UN]@FL?%4&@S:7Y2QQV5G
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M'G7,O"H@],[5'TR:YZT\)/X/3P/?,0T>D0R6>H,O11,N2_\ NK)U/8-D\ T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#C;QG@9[5E6WP_O[7PSX9MXKVV36/#LA:VGPQBF4@AT8=0&4XXSC&?:O0:*
M.3G\,WM]?ZGK%T;5-3N=-.FV\2.S1PQDEF)8J"Q+'/W1PH'J:H'P;JPT#PCI
MHFLMV@7$$SN6?$PB0H /E^7(;/?'O7=T4 4]5@N+K2KJWM?*\Z:)HU,K$*,@
MC)P#Z]*Y7PYH7BOPWX4L]$MI]&E:TB,<<\@EYY)!*CZ^M=M10!Q3^$]<C\1?
MVA#JMK+'-IBV,[743/)&P)+/'@@?,3D@XY ZXQ26G@BZ;X6?\(CJ-W!).EMY
M,,\*,JHR\QMR<DA@#GBNVHH XZ3P'&^J^'K_ .UL9=/5UO&Q@WFYA)EO^VRA
M\>YKL&4,I5AD$8(-+10!P-IX'U.R\*7G@Z*\MFT.8R)%<,6\^&!V):/;C:QY
M8!MPQGH<8K3U#PU>R>*O#VI6/V2.RT:&:%8'9@SB1%7@@$#;M'KGVKJZ* *>
MKV U71;[3C)Y8N[>2#?C.W<I7./QKCF\'Z]+H7A:PGN].>30[N"?<@=1(L2%
M O?D@DD]NF.]=[10!Q5[X)FU;6?$TM_) +#6[*.TVQ,3)%L#8;D8)RV<=L=Z
MM>&]*\7VC6\&OZS8W5I:#$;VL+I-<X& 923@8ZX4<G'/7/5T4 9.O6&HWT5F
MVEWD-K<VURLVZ:,NK*%8%" 1UW8Z\=>U9<WA[4-:\3:1JVKI90+I)D>".UD:
M1I'==N69E7:H'.T Y..>*ZJB@#SZY\!ZQ+HOBG28-6MH;?5KR2]@<1-O5G=&
M9'YQL^4J<=0Q^AT-/\-:Y'XUM_$-Y>:<%_LT6,UO;P. H#[QL)/ZGZ8[UV-%
M 'G,'P[U1/ ]MH)UB"*YTNZ%UI=W#"<HZNS R GG(<J0./K75:!:^(EW3^(K
MVQEG"^6D.GQND0'4L=Q)9C@>@'..IK<HH YG7?#=U<^)-+\1Z5-"FH6*/ \4
M^1'<0OU0L 2I!Y!P?<&HE\+W7E^(KYGMO[6UN(0MRWE0HL91%!QEL99B<#)/
M:NKHH Q_"NF76B>&-.TF[:%Y+*W2W$D1.'"J #@@8Z=.:Q[[P[K,GQ"A\36L
MEAY<-@UBL$K/E@7W[L@<=ACGZUV%% '*IX4N=1\3VFO:_>17$E@&^PV=O&5A
M@9N"Y))+OCOP!Z=ZSK'PIXGT/4[ZVT;6;%-!O;E[G9<0,T]HSG+B(@A2,DD;
MNF>AYSW=% '*S^&K^3QP^M1W,4=LVDG35 =C*N7W^9G&,@\8_'/:L&R\">(K
M>S\,P2:GI8.A7)=62W?]\I1E+M\W+G=G'KDY->D44 <WJ'A-+[QKI^OB<HD-
MN8;F #BXVN'BS_N-N;ZXJ/PQX/7PW;:K!%=,5NYY#;%>/LT)+,L:_P"ZSR'_
M (%7444 >;6?@/Q';Z=X<M7U32]VB7AF1UMW)F4JX+O\W+G=G'<Y.:Z/P_X?
MOM-UOQ#=WC6LEOJUPLZI&S$QX0)M.0,Y SGBNFHH X3P[X4\4>'T31(];LY/
M#D+DP,87^V)%G/E;L[<=MW)QTQQCJ[&/55U+4&OI[5[)G3[$D2$.B[?FWD\$
MYZ8K0HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG4$M(X##(61'<JK,V\ G&"0!5OP;X>C70O#&IK?7S-%81-Y,MPSQ'?"!PI.
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M3[L!]\#G8>V0:V-8U6PMOB)X8BO)8$T.>PF:Q8D" W&4VG/3/EY"_P"]QUH
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MMAK4,<TJ>1'#%,H(^R&/C:#_  EMQ..YYH ZO5=?T[1IK&"\N$CFOIA# A8
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M>L-S\3+6"%#I/]CBZ:(J-D=V8G.5'0,0%8X[X- 'JXO;0K(PNH2(U#2$2#Y
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M2IO6(H!M&""0.F:Z'QMX5T_1O#\6N:#I-M!=:+>#5!%!$%\U1@3+QZH/S44
M=^)HC*8A(AD49*!AD#Z4R"\MKHN+>YAF,9VN(W#;3Z''2O.O$UZTW@'6_%EF
MKXO?("R(G[S[ LB@_@5,K_1_:ITT_P /3:FFN6GB7=))I<T/^@"-5-OMSO8(
M,_(<8/8D"@#O8;VUN)'C@N899$)#*D@8KCKD#I536-=T_0H[5KZ=(S=7,=M"
MI8 N[L%X]AG)] #7%>%GU#1?%&E:+KEC93RG3I8M-UBP^59X%,999$_A/"'(
M..>.M7?B;!;R1>%WGBB8#Q#9J6=0<*6.1SV/% %]/$=VGQ#N='N)K,:6FDK?
MQRA2K F79\S%B",#/ '6NG\^(P>?YJ>3MW>9N&W'KGTK@'T[3-3^,;0SVUM<
MVB^'(RD3*&C_ ./A@/EZ'':N4TS4!IO@SPG'=7/V;15UR[@GE90R1@/,(0V>
M-H;'7@8![4 >TV]S!=PB:VFCFB/1XV# _B*);F"W_P!=-''P6^=@.!U//85S
M'A;2M+T_7M:NM.U9KR2]\J6YBCV>3&^" P"# 9@,GUP">U9'B71]-U+XM>'X
MKVR@G2?3;L3(Z B4 QX##^(#)QGI0!V227CZ[E;RS;36M R0JI\XR;OO[LX*
M;2!TZ]ZMB[MC=&V%Q";@#)BWC>!ZXZUPNG:=9:7\9WMK"VBMHE\-1 )$H486
M<J/R  _ 5S.G:0/$/A'2M"=K*ZGMM;:XEU%YHG2=!,Y=]I.\E@=NTK@^N,&@
M#O+;Q%=KX^U?2+Z6TCTZTL8;J*3:4(WLP.]BQ!^[[5K:KX@TW1DLFN[F-3>S
MI!;KN&9&8@9'L!R3Z"N0BT?3;_XN:O:W=C;SV\6C6H2"2,-&OSR#[IXX' XX
MKD].C@G^&_PX:Y2.0+KZ0;I #A \ZA<GM@ 8]A0![6\\4<#3O*BPJN\R,P"A
M>N<^E4=&URPU[2DU*QG5[9]Q5LC[H)&3Z XSSVJS)';SZ<T:)%);M%A5 !0K
MCC Z8KQC2KF"T^&/@)<0K83ZA NJ%0.4W.$\S_9W@9SQQB@#VNWNK>[B\RVG
MBFCSC=&X89^HJ6N&:U>S^,ELVFJ(X;K27?44084E7 B<C^]RP!ZX!]*[F@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ.:>*VA>:>5(HD&6=V"JH]R
M>E $E%5H-1LKFU:ZM[RWEMUSNFCE5D&.N2#BDCU.PEN!;QWUL\YC$HC652Q0
M]&QG./>@"U14%I?6E_$9;.Z@N8PQ4O#(' (ZC([TRUU.PO998K2^MIY(3B1(
MI58I]0#Q0!:HJF-6TYI(8QJ%J7G++"HF7,A!P0HSS@@@XHU"_MK&$":^M;22
M3*Q-<L I;Z$C/T!H N50O=#TG4KF*YOM,L[F>(YCDF@5V3Z$C(K)\ :W>^(O
M!.GZKJ)C-W.9?,,2[5^65U&!] *Z7I0!'+;PSP-!-$DD+##1NH*D>F*SD\,Z
M#%8/8QZ+IR6;G+VZVR"-CZE<8-6K;4['4#*EC?VMQ)']X12K)L/;(!KC](\<
MFT\*ZYK'B2YMU&G:E<VB^4GEB01MM55!).X_4]: .TL[&TTZV6VLK:&V@7[L
M4*!%'T XJ#4=&TO5U1=2TZTO AR@N(5D"GU&0<4^35-/ALOMLM_:I:9QY[3*
M$]/O9Q4GVZT\F&;[5!Y4Q"Q/Y@VR$] I[Y[8H 9<Z987ME]BNK*WGM<8\B6,
M,F/]T\5$-$TI=-.FKIEF+$\&V$"^7_WSC%6;:ZM[V 36MQ%/$20'B<,I(.#R
M/>I20 23@#J30!G?\(]HHL$L!I-B+-)%E2W$"B-7!R&"XP"#6E61>ZO%/HFH
M7.C7]E//;1.P8,)D5@"<,%8>GJ*J>$/$*ZQX:T6:]N[;^U+VRCN'A5@K-E<D
MA,YQ0!K:AI6G:O (=2L+:\B!R$N(ED4'Z$54B\*^'H)HIHM"TR.6%@\;K:("
MC#H0<<$5=EU/3X;Q+.6^MH[I\;(7E4.V>F%SDTZ?4+*U+BXN[>$HGF.)) NU
M,XW')X&3UH A_L72OL]U;_V;:>3=L7N8_)7;,QZEQCYC]:AG\-Z'=:4FESZ/
M8R:>ARELUNOEJ?4+C /TJ\+NV:T%V+B(VQ7?YP<;-OKNZ8]Z2VOK2]7=:W4$
MZY(S%(&&1U'% $1TG33I?]EFPM3I^SR_LOE+Y6WTVXQBN=\3>%8O^$ U3P_X
M;TRUMFO(FC2*)5B0,W5FQ]/<UTD.I6%Q=R6D%[;2W,7^LA256=/JH.15DD*I
M9B !R2>U &3H>BV6G6EO(FF6]I=B$1OL5<CU ([9&>*N6^EZ?:7MQ>VUC;0W
M=SCSYXXE5Y<=-S 9/XTZSU&QU!7:RO+>Y"'#F&57VGT.#Q21:E833)#%>VTD
MKABB+*I9MIPV!GG!X/I0!'>Z+I>I7-O<WVG6EU/;'=!)-"KM&?521Q4'_"-:
M%Y"P#1[$1+*9U5;=0%D/5Q@<,?7K5^:ZM[8H)[B*(OD()'"[L#)QGKP"?PJ"
M76-,@LXKR74K..UE_P!7,\ZA'^C9P: )[6TM[&W6"U@C@A4DA(U"C).2<#N3
MS5:^T/2M4GCGOM.M;F6-2BO+$&8*>JY/8^G2K+W=M&(R]Q$OFY,>YP-^!DX]
M> 3]*2TO;2_@\^SNH;F')'F0R!UR.HR* (KW2--U*T2TOM/M;FVC962&:%71
M2.A (P,5&-!T<7,]R-*LA/<+MFE$"[I!Z,<9(^M36FI6%^TBV=[;7+1'$@AE
M5RA]#@\40:GI]U<R6UO?6TT\?WXHY59EYQR <CF@"LWAS0VTDZ4=(L/[.)W&
MU^SKY6?7;C&:0^&]#;2X]+;1[!M/C.4M6MT,:GU"XQFLOPMK6HZEKOB:QOY(
M'73KQ(8##$4&PQJ_.2<GGUKH+N^L]/B$M[=06T9. \T@09],F@!XMX!;?9A"
M@@V[/+VC;MQC&/2F_8[7%L/L\7^C','RC]T=I7Y?3Y21QV-!O;58(IS<PB&4
MJ(Y#(-KEON@'OGMZU&FJ:?(D[I?VK);MMF99E(C/HW/!^M "7.D:;>WD%Y=:
M?:SW,'^IFEA5GC_W21D?A446@:1!>&[BTRT2X,AF,BPJ"9#U?I]XY//7FK']
MI6/V7[5]MM_L^=OF^:NS/IG.*G:1%C,C.H0#<6)X ]<T 9USX<T2]U6+5+K2
M;*:_BQY=S) K2+CIAB,\=O2KUT9%M93%$99-IVH"!D_4U%%J=A/<K;17UM).
MT8E$22J6*'D-C.<>]!U*P6<0M>VPE,GE!#*NXOC.W&>N.<=: .6^'_A&/0/"
M^F6VI:9:IJEFI5ID"OELGYU/K@XSP>W2NFAT?3+?49=0ATZTCO9?]9<)"HD?
MZMC)IXU*P-]]A%[;?;,9^S^:OF>OW<YIR7]G+<M;1W<#SKG=$L@+#'7(ZT 5
MI] T>YOS?3Z9:279VYF:%2S;?NY..<=L]*N7%M!=V[V]S$DT,@P\;J"K#T(-
M9NI7C7%G$^EZO8VY6ZC2267$BLNX;HQR,,1P/K5VYU.PLI5BN[ZV@D<95)95
M4D>H!- "W^G66J6IM=0LX+NW)!,4\8=21TX/%5;[P[HNIVT%M?:397,%N<PQ
MRP*RQ_[H(X_"G.UU_P )'$@U"U6T-JQ-D4_?,^X?O <_= XQCJ:G;4K!;X6+
M7ML+MAD0&5?,/_ <YH A@T'2+:WN8(-+LHX;K/GQI H67/7<,<_C1I>AZ3HE
ML]MI>FVEE!(=SQP0J@8^IP.:GGU"RM2XN+RWA*)YCB24+M3.-QR>!GO4T,T5
MQ"DT,B21. R.C JP]01UH R(/!_AJU<-!H&F1L)/-!6U08?GYAQUY/YUI7MC
M::E:M:WUK#<V[_>BFC#J?J#Q3;O4K'3_ "_MM[;VWF'">=*J;CZ#)YI]U>VM
MC!Y]Y<PV\.<>9-($7\S0!5_X1_1O,M9/[)L=]H,6S?9US"/]@X^7\*:WAS1'
MUA=8;2;%M27I=F!?-';.[&<X[U<:^M%LQ=M=0"V(#"8R#9@]]W2FKJ5B\EQ&
MM[;L]L,SJ)5)B'^T,_+^- $<&CZ9;:A+J$&G6D5[-_K+A(5$C_5@,FH7\.:)
M)K"ZP^DV3:DO2[,"^8.V=V,Y]ZAT7Q1I&O:7)J-E>P-:QO(K.9!@*KLNX^@.
MTD$]JOPWUM?V<DUA>V\R@%1+&XD16 [X/;TS0!$VB:2U]+>MIEF;N5"DDY@7
M>ZGL6QDCVJ#_ (1?0/L267]B:=]EC?>D'V5-BMZA<8!]Z?I=TT6C6)U'4[.Y
MN) J&YBPD<SG^X,GKZ"KEK?6E\KM:74%PJ,4<PR!PK#J#CH?:@#.M?#ME:^(
M[C6H[>WBN981!F&(*SK\O+M_$?D4#T ]ZNZAI>GZM;K!J-C;7D*N'$=Q$LBA
MAT.".M+;ZE87EQ+;VU[;3S0_ZR.*569/J <BN8^(/BJ3P]X<NI]+U"P74H&B
MS;RX=RK2*IPNX$<-G)!% '0_V#I NIKH:79"XG7;-+Y"[Y!Z,<9(^M,/AS1#
MI+:4=(L/[.8Y-J+=1%GUVXQFM.LG2[J2#2WFU35K*Y(GD7[1$!'&!O(53R>1
MP#SUH NV&G66E6:6>GVD%K;1_<B@0(H_ 4E_IUCJMHUIJ%G!=V[<F*>,.I_
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MZ/?645E=Z58W%K"<QP2VZ,B?12,#\*O1QI#$L<2*D: *JJ,!0.@ H =1110
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M@(4"KN/4<<'N* /2IM9TNWO5LIM2LX[IB%6!YU#DGH I.<GM6?+XOT6#Q/\
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M!EF##S&WDJ%R"Q4+D@'C/UK.\!^+4UGPGHLVKZE9C5[^-W$.]4>3#L/E3.2
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MR9ON_:B4+8/3<8Q@?CBN9\4V2Q^'OBDT:(=(\^![88!1;G:OG%??<1G'?(H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD,4;NZ1HK2'+E5 +'W]: .$UYX-7\8^"+[0YXYI1)+*\L+ C[&8_FW8_A)V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M45C_ /"5:#N;_B;6NQ6VM+Y@\L-TP7^[G/&,UJ03Q7-O'<02+)#*@='4Y#*1
MD$'TQ0!)1110 4444 %8FH6^N)KL5]IC6<MJ+<Q36MQ(T>]MV0P8*V,#/8YS
MVK;JC8ZSINI7EY:65Y%//9,JW"QG/EE@2 3TSP: ,+2?#M]:^)-7\37$-E'J
M%]#' EK#*WEA4S\SR; 2QS_=X  YZU1\*>'O$WA3P!'H=O\ V5+J$+2^5.\T
MGE?.[/DC9G@MC'?U%=M--%;0O-/*D448+.[L%50.Y)Z"LN/Q5H,@4KJMJ _W
M&9]HD_W2?O?AF@# U_P0^K^ AH\8A355=;F.[>9LI= Y,V\+DG.>PX...*Z/
M1AK4>C1)K LY-21-KO;R-Y<K ?>Y4%<^F#BM.B@#D_ OA[5/#EOJT.HFS?[;
MJ,]\C6\K-M\P@[2"HZ8Z_I3=,\/:M:?$35_$$PLOL=_;Q0*B3.9$\ON04 .<
MGC/'O7744 <C:^']6B^)=YXD<67V*XL4LQ&LS^8NUMV[&S'<\9_&M[2AJX6[
M_M<V1;[2_P!F^R[L>1_!OW?Q]<XXK0HH 0YP<<GMFN*T3PUK>F:GXJNY5T]Q
MK,OFPJEP_P"[(3: W[OZ'(KMJJ:GJ=GHVFSZAJ$ZV]I NZ65@<*.G:@#AD\%
M:Y'X/\*:,&TXS:+?6]S(YG<+(L1)P/DR"<]^GO7H$IE$#&)$:7'RJ[E5)]S@
MX_*GJRNBNI!5AD$=Q2T >=V_@/5F^$<O@^YN+)+M03#<1NS1LWG>:-P*@@9P
M.,^OM5^/0O$UQXRTWQ%>MI49M[&6VDMH7D899E(PQ49^[UP,>AZUVM4]1U73
M]'MC<ZE>P6D .#+/($4?B>* .;\->%M0T[P7?Z#J$EJ'N&N2DMN[. )F9N05
M7IN_'':LT^$/$<GAGPKIDKZ49=#O+:9BLL@5T@7: #L/S-G/0 >]=Y:7=M?6
MR7%I/'/"XRLD;95A['O4U '$7_@N[U?Q!XCFOFMDT[6--2Q_=2L98RN[#8*@
M=6Z9[58\.6'C6V2"UUV^TJ:VM%PDUJ)!-=8&%\S(PG8G&<D>F<]?10!P^E>$
MM:M/!&MZ&]Y;VMY>RW,MO<VTCMY9E8MSE5(P3C(_2H;#PKXC@UWP[J4IT6%-
M,LY;26WM_,VX;9RA('7;W VY_BKOJ* /-Y? NNS?#K6/#9?3A<W][)<++YSE
M%5YO-(/R9R,8_6M"Z\.^)]/\776O^'YM+QJD,2:A:7K2;5DC&U7C91D_+Q@@
M9_ET^JZ]IFB1F34+H1*$,C81G*H.KD*"0HR,L>!5VWN(;JVBN+>5)894#QR(
M<JRD9!![@B@#C-:\+^(5U32]?T+4K1]9M8'MKI;Y66&ZC9MY'RY*8;E>O89X
MYZC2(=2BLRVK3PRWDC;W6W!$4?  5,\D<=3U))XZ ;6M-76DT<WD7]HO&91;
M@Y;8,9)].HZU?H \]UGP9XAU"X\610W>FO;:W;B.&>XWF: "/;Y6 ,;,Y.0>
M,D[2:O6_AO7%\2>'=4N&TYDTVPDM9A'(X+%]O*@J>!L'4C.>W2NTJK?ZE9:7
M;B>^NHK>(L$5I&QN8]%'J?84 <!/\/M7N](U>%KJSMKZ373K>GS1NTBQR#&U
M7!4<8!Y'KTXYU;?0_$MUXUTOQ!J0TJ!;:REM9H;>620G>RG*DJO]WH>GO72Z
M?K6F:J\B6%_;W+Q@&1(W!9,]-PZKT/6K] '->-M"O_$&E6EIIYME>*]@NF-Q
M(RC$;AL#"GDXQ5.^\*7FJ^,;S4+Q;7^S+S16TJ6-)F,F&8L6'R8[D=??VKL:
M* ."B\':S=^$+/PCJTME+IEL\*/=QR-YL\$3AD4QE<*QVJ"=Q[GOQK66@:G8
M>/M6UF*:T;3]3BMQ*K;O-1HE90%'3!W9R3VZ5T]% '->-M"O_$.D6UGIYME>
M.\@N6:XD91B-P^!A3UQBHX=$U:+Q_>>("ED;>?3H[18Q.^\,C,V3\F,$MC\,
M^U=+//%;023SR)%#&I=Y';"JHY))/051T[7],U6ZN;6SN@]S:[3-"Z-&Z!N0
M2K '!['H: ,WP+H5]X:\+0Z5J#6[RQ2RN'MW9E8/(S]U&,;L?A3(=#U.+XA7
MOB#%H;2?3TLT3S6$F49F#$;,8);'7CWZ5<;QAX:2XE@?7M-6:+B2-KE R?49
MX_&M2SO;34+9;FRNH;F!ONRPR!U/T(XH \]?P+KS_#R]\.;]-%S<:@;L2^<^
MP*9Q-C[F<\;?U]JZ"YT359_'NFZ^%LEMK:QDMGC\]MY+E6)'R8P-N/?/:NIJ
MC8:SINJ7%W!87D5Q)9N(YQ&<[&(S@GIF@#A[CP1KEQX0\6:/OTY9M;OY;J)_
M/<K$LA7(;Y.2-O;KGMBMG4?#^L7'B7P_K=I)8I+96\UM<Q2L[#;)M^9" -Q!
M7H<9]176T4 >97O@7Q/<:1JVG"\TJ3[1JJZA%=2F3S90)5<))@?+M"X!&[@
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MO')R=^[)P"< *23C)YP37244 <YXMT"_UM=*ETZ\A@N-/O4NQ'<(7BEP",,
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex31-restatedcharterasam003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex31-restatedcharterasam003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M49B /?8C2*?JOI5+1+E=%TSQ=H.NQR?;9KV[GA0H6-]%,,KY?'SG^$J,D8H
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M/:13H[2F1$4AT&=H!8Y!VY/)XK3UC5F\"^!);V^GN]5EL8,>:T67F;^$OM&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-M"%QY#R$QJ_GE2P7H#@"M6S\9:+?75E!!<2$7Y<6<K0LL=P4R6V,1@\ GW
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M\Z3R6WVR));=T,L/'SKD<]1QUY'% &W17-Z;X\\/:O=06]E=RR&;S0KFVD5
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MV[IYT0Q\R9'/4<=>1Q5?PCXLC\50WLJ6MQ;B"ZEA42P,ORHVWEB,;L@\ Y%
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MWBD7JK*P!!&1U]:CU/Q+INE73VL[S27$=N;J2*"%I&CB!QO8*.!D'W.#@'%
M&I*K/"Z)(8W92%< $J?7!K'\/:%=:4LD^IZM+JVHRJL;W4D*1?(N2JJB\ 98
MD]22?IC4LKVVU*PM[ZSF6:VN(UEBD7HRD9!_*LW4/%.EZ:UT)GG=;,;KIX+=
MY5MQC/SE0<<<D=0#D\4 ;-%8UOXJTBYN]+MHYY/-U6W-S9@PN!+&%#$[L8!
M(X)SS2V_BG1[BUU*Y%WY<.F2F&[::-H_*< $@[@,\$=.N: -BBL>V\3:;<:E
M_9Q:>"\,)G2&X@>-I(QU90P^;'<#D=P*S8?B)X;N9%2WN+J4EY4S'93$*T8)
M<'Y>" #P>>* .JHK#_X2[1?L6DW@NG-MJ\B164H@?$CO]T'CY<X/WL57NO'>
M@VL^I0&:ZDGTW;]JBALY7>,$$YP%SMP,[NG(YY% '245SD?CKP]-<Z=%%>2.
MFHE4MKA;>3R'=AE4\S;M#D?PYSVZUMWT\-M83S3NZ0HA+M&I+*,<D!03GZ4
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M#.,8R3TSS3]&US3]?LWN=/F,B1RM#*K(4>*1?O(RL 58>AH T:*** "BBB@
MHHHH P9= O;KQ&;Z[UJ:;3$9)8-,\E%1)%'#%\;F&?F /0X]!6]110 4444
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M-SF-<!F[ #) Y/)/&:AB\5Z//H%IK4-R9+.[8);[8VWRN20$"XSNR",=L'/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 0.1M&T9) ]^>*PM=UV>]T?P%K<_VRTDGU.U$Z*S!)5:%G.$4D,"0,9&>,4
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M1110 4444 %%%% !1110 4444 %%%% !7#_%:3RO"-O)L9]FJ6;;4&2V)EX
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MBBB@ HHHH **** "BBB@ HHHH *Q_$GB6Q\+::M_J"7!@:5(LPQ[MI8A03V
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M$^I8#GKGBE\'Z/=Z+XD,&DRZI_PC+V98VFI(X^R3;EVI$7&XKC=D#(&.O(H
MN>.]=O;2_P##_AW3)VMKO7+HQ-<J 6AA0!I"N>-V" #VYJ]J?@^WET:XM],N
M;RROFC(CNENY"Q;'&\ECO![YSUXP>:H^/?#VH7]SH?B#1XEN-2T.Y,RVS,%\
M^)@!(@)X#$ 8SQ6O;>(VU"$)::3J<=VPQY=Y:/"L9]6=AM('^R6/I0 NJ^)[
M?3/MNRRO+W[#&)+O[*J'R5(W<[F7)V\X7)QCCD9H77Q"T:&73XK>&_OFU&U:
M[M!:6Y?SD4 D+G&6P1QV[XKG;NVN-!\;ZS)J'A&?7M.U9XY[>YM;:.9XG$:H
MT;AB-J_*"#G'ZXORV5U%X\\)SKI#V]M:V=U'.+6 F&W:39L3(&/X2"1QWXS0
M!<TWQI=:EXQ?2QHE_!:II\5T3,J+(/,)Y9=V0!M(QRV<\=*KVVO6%IX(\1:K
MX=LKXM;W%XTBS'YEN%!+MAVX4,.@_ 5,(+ZQ^+%U?'3KJ:RO-+AA2XB4%$9)
M'+!CGCA@1Z]JR-*L[Z'P%XUM9-.O5N;V\U"2VA-NVZ59MWED<=\_AWQ0!1AM
MM 70/#.OZY8:Q%=W M(2\4Q NYFV,LLNQ\'YCD%B#R>.E=_J?B:VT^:[@CM;
MJ^FLX!<7*6JH3"AR1G<RC)"DA1D\=.E<=K%I?3_#7PM91:;?/=VL^GF> 6[;
MHQ$4,A/';!^O;-63<:MX5\?:U>G0]1U32];6"6&6QC#O#*D80HZDC:" #D\#
M\\ '0)XRTVY&FKIT5S?S:C:M>6\4"JK&$8RQWLH'+ 8SG)^M96J?$!?[#\/Z
MGHUC<74&KZA%:AB$4QY<AU*LP^8[74=@><],MU2YUUO$FE17ND7CZ5+9.9$T
MXC*W!<8CD?(P@3OD*QZ\<#EK#2-:M?ASX9MY-#OEGT?7UN9X%0%VB$TK%D7.
M6 #K_P#JYH ]'OO$L=FLJIIU]=3V\"W%S!;B,O I!(#9< MP>%)/'N,WM(U6
MSUS2;74]/F$UI<H)(W QD?3L>V*\_OXKK2/'&H:GJ'A"YUG3=8B@>,P6\<\M
MI*B;#&ZD\ @ Y!QGUKO]&A-OI-O&;&"PX)%K  %B!)(7Y>,\\XXSG% &5>^,
M["R@O;O[+>7%A82F*[O($5HX67[^1N#,%SR54XY]#C&\9Z[,=2\+V-I:3W>G
MZC=AI&@:,I=1B)V"#+C()"L<X! ZGI6?I%EJ>A>%?$/A6ZTR\N;B66Z^PRQQ
M%XKI)LE2S_=0@L0VXCVS4EWHEYH__"O=/2WNKQ='<"[GAA9U0" QYR!TW'H.
M<4 =CHN@V>D:9+:6JW*6T\C3>1+*6\G=C*)@_*H] <#)Q7#>!==BT/P'K.NZ
MK-J%VEKJ%TK,9'G<1H^ !N)P ![5Z:\BQQ&0ARH&<*A)_(<UY)INF:FGPB\4
MZ5)I5^E_=SW;00-;MN<2ME".,=_7B@#N[+QI87FMV>EFTO[=[Z%IK2:XAV1W
M 4 L%.<Y .>0 1R,TVZ\<:9:K%</#=MITEV+,7Z(IA\W=MQ][<1N!7<%QGO6
M+>074WBGP%=)87AALH;@73_9W A+PA%#<?WACVZ]*J^"KG7_  [I4?@^Z\/7
MLMW9RO'!J 53:21%RRR,^<@@'E0,G'OP =9>^*+:UFOHX+*\OSIZ@W9M%5O)
MR-V#N8%FV\X7)P1ZBJMWX]T6V71WB^U7<>L FS>VA+J^%+8SQR<8QUSUQ65H
M:7WA3Q%XF@O+"]N;34KTZA9W%M TH<NH#1-M^X05 !; QWK#T[PUJ/AVV^'U
ME)9W$S:=<W%Q>-!&TB0"59,#('.&?''IF@#J%^(NGM<Q6?\ 9&N+?RVANTLV
ML2LI4/MVX)ZYYZXP.O2K6G^.]%U+0!JT+7"+]I^Q&UDBVSBXR (BG]_)'?&.
M<XS6-J%ZMC\:[622&XD1O#\BDP0M*5_TA3DJH)QQC@=Q6)=^$]85)?$EI92M
M,/$BZN-.X$CVZKY9X/ D(R^#ZXZ\4 =[;^*K274[K3)[6\M-1MX!<_9945GE
MBSC>FPL&&>.#D'K63:?$S1;O2SJHM-4BTL6KW1O9+4B(!6VE-P)^<GH/Z@@-
M>U?5_'=CXD2VNX;+3=/FB)EMWCDFDD(^4(0&(4 G.,9(QGG&1H47B'2?@<EI
M8:;,NNVL+(+::'YLF4DE0W#'821U&<#VH ZZV\4PW&J7&EMIU]#J,-H+Q;:4
M1[I8R2N5(<KG<,8)'Y<URA\96.M_"FYUOQ-I=_'ITI;S%MB,LGG,%"E&!&-J
M@D[<GZT_1+6[7XFP:I%HNKQV-QHOV<W%[@OY@F#$R98E>.@_(8K#.E:S_P *
M'OO#+:+?KJ<0:!8_+SYK&<OE,$Y7;SN.!SQF@#TZ]UN"QOX=-B@GO+Z2(S+;
M0;=PC! +$NR@#) Y/)Z9P<9%Q\0M$MO#DNMNMV8(+G[)<1"']Y!+N"E'&<*0
M2.^.1C-4;B&\TSXD1>)/LEW<:5?Z8MG*8H&>2VD5RZEHP-VT@D< X/6N=UWP
MYJ3^%_%5U#I]T]QK>K6]Q;VB1DNL4<D?S,!]TD(S8//0=>* .]T[Q99ZCX@F
MT0VE]:W:0?:8_M4.P3Q;MI9.<\$CA@#STK>KBKA+A_BMI^I)97;62:/+ TWD
M,%$C2(ZJ<C@X4_3H:W?#6O\ _"1::]TVGW>GS1RF&6VNT"R(P /./4,#^- '
M&KK(T#XF^*W%GJNH;K.SD6VM$:=A_K-Q )PHZ<9'L*WQ\0M'ET[1M0MX[NXM
M-6G%M!+&B@),21L?<PVG((_"J<8N=%^).MZC<Z?>R6=_96R6\UM TP+Q[]RG
M;DJ?F&"V![U!8>!I)_AUJ>D7^+:[U"XGOE"L#]DE>0O'@CNA"YQZ'M0!UXU2
M-M<;25@F,J0+<-* NQ5)*@'G.25;MV-8OB;Q1=Z+KV@:;;:9/<C4;AT>2-H^
MBQLVU0S#YN <G QGG/%+X#%_=>'HM:U=4&I:FB32A.550H5 /8@;L>KFJOC2
MUO?[>\*:I;6%S>0V-](TZ6ZAG57B9 <$CC)&3VH Q;'6QH'CWQQ*UIJ=ZJ1V
M4OD0 S-&OE.S'YFP!STS] :[)/$]A<:?IMU9+->'4HO.M(80 \B8!)^8@* "
M,Y(Y('4@5S6GQ7<7B_QQ>3:?>I#>V]J+=OL[$2LD3*X7 YP2![]1D5S=II&J
MZ3H7@O5)O#D^IQZ;8R6&HZ:8 TT>XJ0Z(W#$%.W8_7 !Z;H'B*R\16]S):K-
M%+:SM;7-O.H62&1>JL 2/3D$@^M5-5\86.EW&HP"UO+MM,MUNKTVZH1!&P8@
MG<PR<*QPN3@?2I?#*QO:374.A+HT,[[D@:%(I6 'WI%7@$]AUP.>N!R?BF/6
MM1U/Q/IDVD:A<VLNG;-+-KA878QMO,K9&6#$84Y&!P,GD N^./$4RV/AL:?;
MW-Q9:KJ-JKR1%%$T3!G\L;F!RP4=<#!()YQ6/?PIH_C#1=%M=&U%M+U)KF\G
MT]Y8FC9A$N$13)M"J6)*DXW8(S@5+?6^HS>%?A_#_9&H+-87UE-=1^02T4<<
M3(S-C/<CCKCM6SKJ7$OQ(\*WT5E>26EI!=B>=;=RL9D1-@/'?:?IWQ0!#X:_
MX1SPYJ?B*STZ+5VN-/BB>[-PTDN4.]HUC!)X R. .,<GK4H^)^D'17UC^S-:
M_LY;078N?L9,;#=C:&SC<._;WJ"WANH?&_C2\>PO/LUU96T=O(+=R)61'#!>
M/5A]>U9C:;J+?L__ -BC3;S^TQIXM?LIA;?YGT]/?I0!T[^.]/BU:#3I;#5(
MY;N)I;-FMOENMN"RI@YR,@\@#'.<<TZ#QWI+Z)JFJ7,=W9KI<WD7=O<1 2QN
M=NT84D'=N7!!QS67J45S<>,O ]Y%8WC6]G'<_:9/L[XAWQ!5#<=R"/;OQ61.
MOB&R/CJ[TK2[MKBZO;>6VS;_ #21!421HPPP6 #8!]C@T =G%XJBEO-1L/[.
MO8]2LK=;DVDGE[I4;."C!RO52.2,&N8/BZQUKX80ZQXFTR_CLKIHV(MSUS*-
MFUD8$ ':,MMS1HMC=K\1KN]BT;4X;&]T9(5N+LY.\.Y.\EB0<$<=?8"L5M.U
MA_@5#X?;0]034K<P0F$Q9+E)U9BN"?E"KG)P#VS0!Z.?$ELOBQ/#CVUTEV]N
M;E)&5?*>,$ D'=DD$@8QGOTYH/B2U$4SM;W*E;LV<284FXE&<B/#<]#DG &T
MYQ@XQ_'&FZA=0Z1K^@VYFU;2[E9(HG!4RQ2?)(ASR!@@G/3;5+QAX?OK?0=!
MGTZQ75Y-'NQ<7%HX&;M61UE8 \%R7+?7- '2Z/XEM-8U&_TT0W%IJ%@5^T6M
MR%#JK#*L"I92I'<'ZXHOO$EMI_B/3M$FMKKS]0#FWE"KY;;!N89W9! YQCZ9
MJGX6>"\>:^MO"[:)$R!/])M4AGE/?*J3A1[]2>V.8O'^D7>H^'EO-+C+ZMI4
MZ7]DHZNZ'E/?<NY<>XH T;GQ-8V2ZG)=I-#!I[I')*R@J[L%*J@!)+'>O&/X
MA4</BBW;6!I%S97EGJ$D#3V\,X3_ $A5^]L96*DCC()!YSTYK \4^&M5O/ L
M"V:++K%O>Q:I)!NP)I5D\QHP3VY(7/\ =45/<VLOBCQAX9U6&SO+6WTD3S3M
M=0-"VZ1 @C 8 GN21E?EZ\T 2>&?&S:KH-YJVIV,]E#%=RPIG8VXB7RUC 5B
M2Y.!TP2>":UK#Q/:WFORZ'/:W5CJ4< N5@N0G[R(G;O4HS @'@C.?:O/DT#7
M9? >HZ3%I$O]H6&LO?Q1W(40W@%QYJHIS\P9?;&>*ZWPM<0:E>"[@\&R:&8X
MBLLMW:1PR%CCY$V\E>I).!TQG)P ;^IZQ;:6UK%(LDMS=R&*WMX@"\K %CC)
M   !))( ]:IV/B>VU"34+:&SNQJ.GE1/8.$68!N5(^;801R"&QP>_%9'B^PU
M"+Q5X9\26EM+=V^FO/%=V\*[I!',@7S%7JVT@9 R2.E+IUC))XZU7Q8UO<Q6
M9T^*RA1H6$DQ5F=G\LC<,951D9.#VP2 97P\ME\3Z+I'B74+>\AU5'EF-X)5
M47(9W&PA6)9%& %8#&!BMV;Q/=_\+$'AI=+N#;C3S<O,KQC=ND5 P^8$*OS9
M_BR>!QDP?"ZUNM/^'VEZ??6EQ:W=LKK+%-&5()D8CGH>".E,O(+ZS^+-OJBZ
M==7%E/H_V/SH5!6.03;SNYX&TY]^@R: .?\ "OBRU\+Z/KKWT&I3VD&OW<<M
MRB&5;=/-"J79CDCITW$#K7?:CK\5E/+;P65WJ%Q#")Y8K0(6C0YP3N91D[6P
M 23@\5YO<Z7J<WPP\::<FEWWVV_U.ZEMH3;L&D224,K#CI@'KT[]JT-0BN-(
M\:7&KW7A6YUS2=5M8 IAM%EFM)8P5VE'P0I!!SZT =_HNLV/B#1K75=-F\VT
MN4WQOC!ZX(([$$$'Z5Y[HGB2#PO>^-IKBVU2]M[;56>0PJ9C!$(D)9F=N@YX
M!)QVP*]!T2'R-(@3^SH=.!W,+2%541 L2 0O&[!YQQG/6N!6ROCHOQ(A_LZ]
M\S4Y)S9*;=_WP:W$:XX_O#OCUH [>X\16<<MG!;)+>W-Y";B""WV[FB&,N2Q
M "_,HY(R3Q7+^+]=L_$'PP\33V<ES!/90RQS0LQBE@E0?=;:?H>I!'K5/3;'
M4M%\0^'/$$EA>2V3:#'I5Y%'"S2VLBD.&,8&X@G*G /3/2HM4\/W\N@?$#48
MK*Y\W7PL=G:",^80D00,5_A+'<><8&,X/% '90ZW!86.CV7E375]=6RM%;0;
M2[*JC<Q+$ *,CDD<D#DFN6\"ZO!9_P#"8WEW]KBACUHQK%<L7E5BD:B,<G)+
M'  )!R,4DT>IZ/XOT'Q*NEWUWI[Z,-,N8H(2TUL^\.',?WB"1@X],^E9%QH>
MO:EIWBN2VT2=9SKD.J6D%XJJEVL8CS&>3UVGVZ"@#O!XSL8]0O=/O+.^M+ZT
MM?MAMY(U=I8<XWIY;,&P>",Y%5++XB:7?627L=CJB6<L$4L-Q+;;8Y6D<(L:
MMG&_<P&.G?. 35'3[B+4;"]N[;P5<:.ZV<D;M/9(DSNPP(XPF69<YR3@=/?$
M6FZ>#\'M,TG5]#N[H)!!;7=B8F$@ 90S*."=OW@1Z<<T =CI^J?;KBYMWLKJ
MTFM]NY9POS!@2"I5B".#WIE_K<%E?PZ?'#-=W\T;3+;6^W<(U(!<EBJ@9(')
MY)XSS6!X&L-4TR[U6TDO+^[T-#%_9TFHHRSJ<'>AW ,5'RX)'KCI4>I6E]I'
MQ.A\1?9;BZTNZTW[!,;>-I7MW60NK%%RQ4Y(X!P>M $NL>-$E\!ZYJ^CQ7#7
M=C%/')$RJLEI,B$_O%8]%.#QG.1C-/\ !VC6IM['7A:WMG>R6*0S"28%;G*J
MWFL%9@S9SAC\W)SVK!N]"OE\-^/[];*Y\[Q )%M+18R9"!#Y:LRC[I8Y//08
MS@\5W'APM_PC>FI)%+%)';1QO'*A1E8* 1@^] &9?^.M+T_[?*\%W)9Z?<I:
MWEW&BF."1MO!!8,<;UR54XS]:9+XINU^(L?AQ-+N&MQ8&Z:96C^;,BH&Y8$*
MOS9[DG@<9/%>+[7Q!K>B^+;"XT/4I[P70.GB$ 6YMU9"K#D;Y" V<@L,X&!7
M42)J"?%*QUC^R+UK2ZT8VFY54^3)YP?$G.%^7GOZ#)H M?$Y2?AKKSK)+&\=
MHSJT<C(01[@C(]NE:2ZQ'9VEA:1V]Q>7LEJ)1;V^W=L  +$NRJ!D@<GGMG!Q
M3^(=M<7WP_UJRL[>6XN;BV:***)"S,QZ=/YUS.LVUW8>(=(\0OX;GUK3)-+6
MQN;5+8//;.K%E<1MUSD@_3Z9 .FMO'FD7MA8W%HMS-->W+VD5H$"S"9 2Z,&
M("E0I)R<>F<BIK?QEIMQI4]\$N(V@OO[.DMG51*+G<%$?7:22R\[L8.<USU_
M)J=M%HK6/ANXL-'N;R1[VWT^%5NHU*8C+!#\I9L[BIR!@9ZUEZ7I#IHOB;2]
M8\+:A)I]YKC3^6!N80N$VNA5B2RE<DC/3@DT =)XI\:SZ-X2UK4K?2+Q;NPQ
M&8YO+ 5F *OD,0RC<.F3GCUQU=I/)<VJ2RVTML[=8I2I8?7:2/UKRV^\/^(9
M_ 'B[189=0U.R*Q_V2;Y"MRX&&=#N 8@$84D GGVKT_3KIKVQBN&M9[4N,B*
MX4*X'N 3CZ4 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK/U;5X-(BMVF5W
MDN9UMH(D(!DD;) R2 . 3R>WKQ0!H45B_P#"20I:3RW-E=V\T=T+-;=PA>65
M@I4)AB""&'.0  2<8-4#XYM8Y-7MYM,U!+_2X1<S68$;2/"1G>A#[6'!XSG/
M&* +\GAN&3Q;#XC-[=BYBMC:K"-GE>66#$$;=V<@'.:VJQ(/$UO=:3H^HV]I
M=2QZJ4$"+Y>X!E+Y;YL8"@DX)QBJ>J^.+#2;2;4)K2[DTJWN/L]Q?Q!#'&V[
M83C=N*AOE) /.>N* .GHKE[CQO!'K.H:1:Z1JE[>V<*3%((TQ(C9P59F QQW
MQGMFLW4_'Y?2O#&HZ+83W-KK=Y'"')160')*89A\YV,/08//2@#NJ*PK+Q1#
M=^)Y_#[Z?>VU[#;+=$SB/8T9.,J5<YYX/'!J]I.JIJ]M+/';3PQI/)"#+M^<
MHQ4LNTGY<@X/?% %^BN'^(.J7=K=^'-/BLKB>VO=3C2X"-'MF4*[>5AF'4J"
M<X4@8SVJ/1+'PWH?CJ6RT_1KZVU:73Y+P*TG[J.)G3=%&-^U?GQP!@'/.* .
MAL_#-O::]<ZO)?ZC=S2NS10W5P7BMMPP?*3HN1QWXR!U-;=<WI_C.SU'P_J.
ML1V-]&FGRR0S6\BQB7S(^&4 .1GT!(SVZU/?^)TLQ<+%IM[=S6D"SW4,!CW0
M@@D*<N 6P"<*3^HR ;M%4=)U>SUS1K;5=/D,MI<QB2-L8)'ICU[8]:Y.?XHZ
M=#8WEZNC:U+:6-T]M>RQVRD6Y0@,S?-R,^F2 ,D#C(!W5%8L_B2W+1QZ=;S:
MG,]LMV$MF0?NFSL8EV4?-@X&><'TK('Q)T:2PT:\M[>_N(M6E:" 1PC*RKG*
M,">&RI'?\N: .QHKG;;Q8MVEM%%I&HC49H6G;3Y52.6&-6*;GW,% )'')SUZ
M X+'QCI^IZ1I]]9074DFH,ZP6I0)+N3(<,&( VX.3G'3&<C(!T5%<;/\2-*M
M=%U'4)[._1]-NEM;RVV*9(78@*3AMI4EA@@GK5^U\7Q7.NSZ,VE:C!>+:F[M
MUG1%^U1@[24^;@Y(X?:>><4 ='17+^ _$EYXI\.)J5Y8R6S22R[260H5$KJ%
M&#GY0H!) R>F:;>:B=5\>1^&U/\ HEI9?;;P#_EJS-MCC/\ L\,Q'?"CID$
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M;2"0<T ='17+W&OP:E/J/A^[L+VRO!I[7064KAXCE<AXV(!!X(R#]163\/\
M6UMO WA6P2UN;RZGL5=A!L/E*/XW+,, G('J0?2@#OJ*\PL-87PYXW\?31Z=
MJ%^D3VDK1VV&*)]GW,V78#J2< Y/85V9\56$EMI,EFLMW+JT7G6<$0 =X]H8
ML=Q 4 $9R>I Y- &Y17$:_KUEX@\#^+K98[BVOM.LYUN;64[)(7\IF0Y4D$'
M&002#5S1M:@TWPKX7M/*EN+V\L81!;Q8W.%B4LQ)( 4#&23W Y) H ZNBO-?
M".JV^G^(?'E]=Q7%I#%>6X,,QWR!C$HVC!.=S'C!YW"NF3QC;KK,VD7>GWMK
M?K:F[BA<(YGC!P=A1B-P/4$CUZ4 =)17&6/Q(TZ^TM=472]5BTU[83I=RPJL
M;,9!&(P=WWRS#KQUYX-=%8:H]Y>7-I+87-I+;HCGSMA5P^[!4JQS]TYSB@#1
MHK%O?$D%CXFL-"EL[HSW\<CV\P">4VP99<ELY QQC^M5+3QI:7FFZU>C3[Z/
M^R)G@N(9!'YC.H!(4!R#P1CD9SQF@#I:*Q)O$:K>/8VNG7=W?0P)/<6\1C!@
M#9VJQ9PNX[6P 3T],&J2^/=)ET_2+^".ZEMM4O%L8V5%!AF8D;)%+ J00<X!
MZ?2@#J**Q8M;M-2U[4?#CV]RD]M DLA; 1XW) *E6S_">N*Y3X=ZS;Z1\)?#
M\UT999;AF@AB3YI)Y6E?"C)'/4Y)  !)/% 'HM%>>Z).\WQGU??9W-HXT:$M
M'.X;+&5OF4AB,$8''H>*D^(<B6FO>#;TI.[)JA79$&8L/*<X"CJ<@4 =]17+
M:9X\TR];58KVWO-)N=+C\ZZM[Z,*XB(R'&TL&7CL>M6(O%MO_P )!9Z->V%Y
M87-]$\EF9]A6;8,LORL<, <X..* .AHJEJ6J0:7%"TJO)+/*(8(8\;Y7()VC
M) Z DDD  $UST_Q"TZTM=;>[L;Z&YT55>[M-J-($895U(;:5([YX[XH ZZBN
M9M/&MK<ZW8Z8^FZA;-J$#S64T\:JEQL4,RCYMP(!S\P&:RM*\72ZSHGBB?5]
M&NTL;*XN;=XXVC8^7&JJR?*^2WWCGISPW2@#NZ*X!_%?]F6?@BTT+1[EM-U1
M$\I=Z;TB$)=8QN?[V N23C /))J2PV0?&/6)&+1HVB02N)'R%/FOGO@< =..
M* .[HKF#XWL8[K2EN+.\@L]6D$5E>2!/+E=AE 0&W+N'3('OBL3X@:_#J'@7
MQ/%9V5Y<P6D,L$EU RJB3*O/\09@I(W$ @<]<' !Z%16;HC%?#6G,%+D6<1"
MKC)^0<#/%<WX=\=->:!JNLZS92V-K:7<T08E' "/L"#:Q9GS[8)/!/% ';45
M@Q>*(!KMKH]_976GW=Y&TEK]HV%9MO+*"C,-P')![=,UHZKJMKH]E]JNBV"Z
MQ1H@R\DC$*J*.Y)('_UJ +M%<R_C:PM9-6BU*UO+"72[87<RRHK;HCG#*4)!
MY!&.N:GL?%=O=:R=*N;.ZL;HV7V]!/L(>'=M)RK'!!(R#Z]Z -^BL"P\4IJ2
M6<MOIEZUO>P-/:S9CVRJ "!]_P"5B#P&QWSC!JMX$\2WGBC0CJ%Y826Q:>95
M)9"NU974*,')("@$D#)Z9H ZBBN9U&]TA?'NCVMS8W+:J;:X:TN1D1JF%\P?
M>Y/W>QK/F^)=A%I^HWPT?5WMM,NWM;V184 @*XW,<OR.>BY/&2 ,9 .VHIJ.
MLD:R(P9& 8$=Q7,6?CO3[R32F6TO$L]5F>"SNW5-DCKNZ@-N7.UL9';G% '4
MT5QUS\0[2 ZRL6BZO<MH[XNQ%$@VKMWEQN< C;SC[Q]*O/XRL5U/0[-+6[DC
MUN/S+.Z54$3#9OP26!!V\XQSVS0!T=%4+354N]5OK!+:=39%%DF;;Y;,RA@H
MPV<@$$Y ZCUJ_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5SOC*PM=3TF"RO](EU*RFN%$Z
MPY\R!=K$2K@@Y#!>G.">O2NBHH \FNO#/B9O#)6(3ZQ%I6L1WFFVVID>=<VR
MIM:-RW?+OMW#/'3H*[+PO)]M>2Z3PJ="A\O85N(8TFE8D9X0G"#'?J3T&.>G
MHH X?P5X;U#1-0OK.[4?V7IL\J:1SUBE(D.?]S[@/^]6'HVG:AH-U>Z#=^"D
MU1GNYI;'5!'$T31R.7'G,QW*5+'. 2<<#IGU2B@#BM.M[NT^)6N:A+8W(LI=
M/MX8IEB^5WC+E@ .?XABN7T_0];M/A[X+B;1[MKO1]86XN[50OF"/,O*Y(#?
MZQ>_\J]=HH X;QU8:BQT37]'V6^MP3K:JDAR&CGPC(<==I(?T^0FMF\\(V=Y
MI6GZ<M]JEI#8QA(S97KP,XP!\Y4C=T[^IJ6#PS9)XBEUQKJ^N)I#NCAFN6>"
M%MNTM''T4D9&?<],FMN@#A/$^E74$_@^VL;?4+Z'3=22XGF=C*ZQA'7<S,<L
M<L/4U9>VNV^+=MJ8LKC[ -&>U-QLPHE:57"^O0=<8[5V)(! )&3T%+0!PX\-
M7]O\1+J2!1_8&HB*_NAGI=0\  ?[7[MR>_EFL[4[&]T3Q[JFH3^%'\0:9JRP
MO&]O%%)+;2H@0J0Y'RD '.<"O2:* *>E120Z9 DMK!:/@DV\ &R+))VC'!QG
M!(ZG)KS709I[CPWXYTFVTZYN+F[UC488,)^Z<N=OS/T4#/.<<=,UZH2&#*KX
M(X)&,@UD^'_#EOX=2]6VNKJ87EU)=R^>4/[QSEB-JC&3VH X%_#M[X/UG3YS
MX>;Q)I;:3;:?,(8TDF@EA! =5<CY6#'O]>@SJ:Q8W\EUX0GAT%[=+74FNI[>
MUC4BVB*.HW;>"WS D+GOC.,GT*B@#@]976/#WQ"_X2&TTBZU;3+ZQ2TN(K/:
M9H)$=F5@K$94AB.O'\Z_BNQURYN- \2G0$U V33K=:02CR"&4+@C/REUV D#
MU(!(YKT2D9@JEF( '4F@#S7Q/97NL?#S4HM-\+2:?)=S6_D62Q1K,P25'9Y-
MIVKP#@9SQ[X&Q<07<WQ4TO4TL;HV*:7+;O.8R%61W1@#GGHI[<5V0((!!R#T
M(H) QD@9X% ''?#6TU'2O"J:1J.G3VLUG-,#)(5*R[I78%,$DC##DXZ]ZCMK
M5].^,E[<2 B'5=)0PN>A>%\,OUVNI_/TKM0P)(!!(ZCTJO>6$%\D8F4[XG$D
M4BG#1OTW*>W!(]""0<@D4 97B6TN-3DTK34A=K66]2:[<#Y5CB_> '_>=4&/
M3-6-7UF?2KFT1-'O[Z&<L'EM%5_)(QC<I(.#SR.F*UJ* ,'P_I+VNHZSJTL'
MV:75)TE^SD@E%2,(-V,C<<$G!/4#G%26EO/J.HS:I<(T0B#PV,4BX*#HTI!_
MB8CCT4#IN85M44 >9>#='U:TU7PVLMI<6\MA874.K32(56>1Y%*X8\298.^1
MG&>Q-:_ART>X^)GB[6%'^C!;:QC;L[HFZ3\BP'USZ5VDB%XV0.R%AC<O4>XJ
M*TM(+&V2WMHQ'$N2 .<DG)))Y)))))Y))- '):YI^H:?\0]+\46]K->67V&3
M3[N.$;I(5+AUD"]6&1@XYQV-54T:\63QOKOV.</K4*0VMJ%_>,(X2@8CL69C
MP>@ SBN^HH Y_P $0SVO@G1;*[MI;>YM;**":.5<%75 #[$<=167;6^H:9\3
M=;OFTVYFL=0L[81W,6THABW[@PSNS\PP #FNTHH \ACT76%^#^GZ,=(O/[1B
MU)9G@V#(071E)SG'W3Z]>*TKFSO=$\::O=3^$)-?TW6'CN+>:&*)Y8)!&J,C
MB0C"_*#G.!^>/2R0,9(&>.:6@"KIL4D.G01RP06[A/FA@'R1GKM'KCIGC/7
MKD;OPU?K\1'N;51_8NJPQS:D,])H&&S'^^"H([A#7<44 <3+9W^A?$J[US[)
M<7>EZI91P2-;IYCV\L9.W*#DJ03R <'KZU@:AX4U:+PUJ5]%82R75YXCCU?[
M$A7S%A61..N-^U=Q&>^.U>JT4 >:ZO;:AIWC237YO"4NLZ;J=I%'+ D<4EQ9
MRQEL?*QQ@AN<'J.O S;UO0[;5K/2K;5/#]Q9H%FFBN-*!$NFR978 8^[ G.
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MN,U<\;V-[->^&]0M+.:ZBT[4A<7"0X+B,QNN0I(W8+#@<UUU% 'F_B#PE?\
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MN?+U6&-;([H_WQ6#RS_%Q\WKCBF7GAW6KWX4Z'8VUFL>LZ2MI*MI<LNV62$
M%"02,-@X.?3I0!MP^.]-34]0T_4T:PGL;/[>Y=UD1X,X+JRD]#P1U],U8B\5
M,=5L["?1K^![^!YK1F"D-L )1\'"-@C /'OGBN>N],U+QIX4U;3V\-KX>:XL
MVB4SF,N\N00!LSA 1R3R<C XK9\-:QXEU);:WU7P]+IDD"XO)Y9D9)6 QB(*
M23DX.3@ <<T 4?#?CJ2Y\)W>NZW:26T<=U+$@1E?<1,8TB4 Y+9P,D $GTK8
M3Q2D>NPZ-J&GW%G>W4+S6BLR,MP$&616!P' P2#QZ$UPR^$_$-QX#N]%33S!
MJ&GZL^H6CRRIY5T1.95"X)(!4]6 P<>^.ENK*[\2>)O#NK2:;=64&D":XD6X
MVAWD=-@C4 G..23TX&,Y. !+'XCVU[92:C_8FJ1:9 MR;B[=$VPF'.Y6 8DD
M[>,9&2!GKC?T[6);V[6"73I8%DMQ<1S>8CQNI(& 5/WN03VY&":YGPGI^JZ9
MX!U6SNM$9KSSKN6.SG:,K<+([LJY#$8(.#DTGA#P[<:'XEF.E1ZA9>');0E]
M/O7W+#<[ACRADD#;NS@XR1@GL =5JNM0:7/96OEO/>WTC1VUO'@%RJ[F))(
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MU)%P#)M <C\<UY[::#KJ?#&X\!SZ;(;M4:SBO05^SO"7R)<YR,*?NXSD>^:
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M7D+S6KQW"3*^WED;;]UP.<<CK@UKZSK4&C16WF(\L]W.MM;0)C=+(V3CG@
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M:G[Y4'G)'/ R: .EHKD+SQ];)<:)%IVFW>I#6H))[*2%D57V)N*_,P(/(SD
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M:24&W8\'@#)[' '?%=39>.+9X==.JV4VF3Z*5-U%(ZR?*Z[D*E3@[AQCUXH
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MBD/L+B+JR!N">O!(!'- ':5&9X1.(#*@F8;A&6&XCUQ1+(ZV[20Q^<X7*(&
MW>@S7E7A^YMKKPM<^)-?T66ZN++5I[F&>%MTQF$YC1%VD' ^5<$[<#G@4 >L
MD9!%1P6\-K"L,$:QQKG"J.Y.2?J3SFL"W\6PIJFJ:=JD L9M-M5O97\WS(S"
M=WS!L \;3D$?3--@\5327VEQ2Z+>1V^J1N]K,I#;<+N E _U98=.3Z'% '2T
M5R7@?Q#JGB&/59=0LU@$&H3VZ;)0P7RV"[/4]"<]\UUM !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;H[+D ]&&?>M'Q5I.L>*?"E];01I87.8IK**<ACYD<@D'F%20 2H& 3CKGG
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M[=?110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5RGQ!US4M \-"ZTR*)Y9+F&!G>3;L#R*N
M0,')YQ[=><8/5US'Q T>_P!<\)RVNFQ+-=I<03I$SA-_ERJY7)X!(!ZT <_J
MDEQ:_%K1[N+2DDU&;1KD-%%(/F(D3&Z0@< =\?0&MJR\<&]\/F^72+D7RZC_
M &9)9*V_RYP^P[G QL&<EL=.U0R6.LW'Q#TG6Y-*=+6'3IK>8K/&VQW96 Z@
MG 7GCJ>,CFL)-"\66NBZI':Z>ZM<^(WU"6W%TB-<V;MDQAPWRMP,@D<9&>:
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MN(!%,5RT2ONVGTSP#0!YWX)U:Q\->$=7GF"1PKK]W;PQJ0@+--M503@ >_0
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M9UB,Z%2%Y8@%0W)7// YK#TG0-=T_1/&ED^CPI_:<\\MFEO<(5/F1*@49VX
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MDC1+@7&Z2#S/]6TB;0 #D9PQQGO5&P>TTSXK^*KN3RX($TJVGG?&!@&0LQ_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/!(,I+$X96'L1P: .(OM/\6:3XL;Q%H^G6E^FHVL<-_I[7?E&-XRVQTD*X(
M8@\?_6N:WHUWK=E9V>OZ';:O:2I*UU'#(H:WD)7R_*9BI.!N!;()Z]\5V-%
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MY_-ADF\O*R1%-P.#T/)XS75T4 <1I&D:WX5U77TM+%=0LM4NVO[=UF5/)F<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)4;C\V>@';GK3],T76O#&M:^=.MH;VPU:Z:^AWS>6T$[@!P^1RA(!!7)'3%
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M;]ZLA/&X-U!QD=ZJOX6U Z7XONA%"=5\0H4$(EPD*B'RHP6QR1R3@=\#.,D
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M.&XFVI&8\^86?'0%<# R21TR2)K+2M4M?B!K.MM:QM9W=G#!"!,-Y:,L>1C
M!W>M<Q8^"O$^E^%/#CV)LTUW09YW6*24F&YBE9BZ;@,@X(P<=10!HW?Q)N;+
MPYK^H-HR2W&C2HL@CN#Y,Z.0%>.0KSUY&.,=:VK?Q1?)XPBT/4]+BM([NUDN
M;29+GS"0A 99!M 5L,#P6'N:R_$ND>*?%/@/5+"YMK*WO[Y8XXK5+@M'"JL&
M+-)M!)/H!@8'N:N:GHFI:GXWT?5&M(UL;>RN+:X!F&\&7;]T8Y V^O>@#E_B
M#K=QXC^%MYJEKI]NVDRSQ"":24^;L$Z@2A=N "1P,YP<^U>J7$\5K;2W$[A(
M8D+NYZ*H&2?RKRN7P?XO3X;W/@A+;3YXX61;34&NBGF1"97 9-I(8 8/...,
M]_3+RS&J:/<6-XH074#0S+&^X ,I!P2!GKUP* .6N/'<]EX?L?$UUIB)H%TT
M>Z43DS0Q2$!)63;C!RN0#D9[T^?Q=K4GB?5=#TWP]%=2V"V\OF/>A%>.0G)^
M[P0!P/KST!S$\):Y>^ H/!&I1V_V:(Q0/J"2\26T;AAA,9#E5"X/ Y.3TK;T
MO1]2M/B%K>KRV\2V%];V\,3"7+@Q;N2N.AW>O:@"_P"+M=E\,^%[_68K,79M
M(S(T1E\O(^N#_*LMO&%]9K&=4TJWLOMLJ1Z<9+T8E!C9V,AV_N]H4^N20!ZU
M>\<Z5>Z[X+U32=/2-KF\A,*>8^U5SW)P:SO$F@:WJ.DZ'?:4UO;Z[I$HFCBG
M<F*3Y"CQEAV()P?Y=@"C=_$BXLM(\17+Z0D\^C!'W07),%Q&XX9)"O4="N.#
MW-75\::C:>*-,TS6-#^Q66K;ELKI;D2'>!NV2* -I(Z8)_GC)\<2:]<_"KQ)
M<ZY;VMF[6@6.TMYC*%PPRS.0,D\< 8 '4YXVI='O_$.I>'[C4+5+2VTIS<L!
M*',TVPJH7'1!N)R<$X QUH I3_$B-;>TU&VM8+K3;BY$)6&X+7*H6*B7RPOW
M>,XSG!!]A/XA\<W7A^UU+4)M)5+"PN4@S<3&.6Z!V[GB!7# ;O7G:>F*I^&=
M&\9^'+=?#4:Z?+HT#L+;4S,1-' 22%,>W#. < Y Z=>AS_$'@_Q1JMAXLL3#
MI]P^I3>99WTUPV](04*P!=OR@;3SG&3G!- &SJL:+\8_#LBHH=]-O-S <G!C
MQFNXKD;C2=9N?'>AZW):VZV]I9S07 2?)#2%3\N0-P&WJ<9]*T?#FJ:MJ$NJ
M0ZM9VUN]K=&.)K:4NKIC(R3_ ! $9^HH +O7IG\0OH6EP0SWD-L+F=YY2B1*
MQ(0< DL2#] ,^@//W/Q):'PU-J::.S7=IJ2Z;?69G ,,I<+\IQ\X^8$'C.>U
M7[K0]2TWQ[)XETR)+NWO;1;6]M3($<,ARDB$\'@D$$CUYK%U3P1JLGAW4([:
M.VDU/4]8CU.=3,5CB5'1@@;&3\J 9QU)H [?1[K5;J"=M6TZ*QE69EB2.X$P
M>/ PV<#!Y(Q[5R>D>*M2BU?QA<ZT+6/3-(E )CF8F)%B#_*I7YB<\G(YXQTK
MNT+-&K,NQB 2N<X/I7"2>#=0O+[QC87(MUTG7L.ERLA,L;>4$QLQCAE!SGI]
M> "]/XRN]-CT:]U73(X--U66.%98YR[V[R#,?F+M P>A(/!]>M=?7!GP[K>M
M:!HNA:U;V\2:?/!)<W4<VY;A8>5V+C(+$#.<8YQFN\H **** "BBB@ HHHH
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M^'^KW^EO''<Q0G]X^<H#P2N/XN>/S]J .AEU.P@U"#3Y;R!+VX!,-NT@$C@
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MRS9W*R;3NVDDC!YZ''6J!T^3P_\ $?POINEP+<1V>@30;9)-C,BO&,@X(W9
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MU&P\>3:O!!:_V:-*CT^%//;S 8V9@2-N,<XZ]JZ^B@#S_1/"VMZ9X2L]$O\
M3]*U"V$]PUY;O,622.1V=2NY/O*6Z' Z\]*JS> =5@\!R:!I[6X#:HMY!#/<
MN4M85E5UB5MI)^[Z=6/7OZ510!P_BWPO>>*(;VTO-+T^X1HP=/NC.4FLY=HR
M<A<[0PW<'GH1BK"^'-9M/&VFZQ!/;74*:2NFW<EP[+)D2!S(  0Q//!(ZYS7
M844 >?\ A[P_XQ\.(WA^VGTV304E8VUZ[/\ :8(68G9LQM9AD@'.!UYZ5>MM
M UFW\1^+M1,-FT6KQ0I;+]H;<ICC*?/\G&<YXS7944 ><VG@[7['2/!0B&GO
M?>'V=)8WG<1RHT1C+!MF<C.<8_&O15W;1N(+8Y(&!FEHH \ZE^&TDFC^)-/-
MTOEW,LDFC@<?8RS";CT_? ?@HK:UCPY?W/PXO/#]L\,M_=6KQ233,41I9,F2
M0X!ZLS'&.]=710!Q5]X=UM]1\(ZG:+8_:-)BF@N(I9F"D21JFY6"Y."N<$#.
M>HZU'%X:UM+CQK*8K$C7 /LP%PWRD0B+Y_DX]>,^E=S10!Q.F'Q'X<M?".B&
MVTV6V2W6TO2LSM+E$ #Q\ ;>"3D>W7&=CQIH<_B7P;JNCVTD<<]U 4C:3.T-
MD$9QVXK=VKOW[1NQC..<4M '&76B^(;_ ,1^%=6G@TZ,:7YYN8TN7/\ K(]@
M"$I\V.N3CT]ZJ'PKKK6GCF+R[$-K^_[-_I#83="(OG^3CIGC/I7?44 <5+X=
MO[G0-*T?5-(TW4]/BL5@NK=YCE95 "O&Q3T!_ND9&*VO".C7/A_PK8:5=W)N
M9K="I<L6P"Q(4$\D*"%!]!VK;HH YO3M$N+G5M4O]>T_3Y7F=4M=K>=L@5?E
M4[D&#N+L<?WO:LS1_#>L:#X[UK4+"VT]-#U)(V-LL[*Z3(,;PH3: PZC/O[5
MV]% ''>%?#.IZ;X(O="U'[*DTS7.R2"1I%Q,SMSE5Z;L?A65+X3\2S_#_0]!
M>/3!=:;/:$E;E]C) 5.<[,Y;;TQQZFO1J* .&NM"\3Z3XSOM<\/C3KBWU:.(
M7EK>2O'Y4L:[5=&53D;>HQV_*SJV@:U>:UX6O4DM;C^RYI9KIY)&C+ET9"$4
M*W W< GH />NPHH X*ST+Q?X>UO4X=%DTNXT;4;M[Q7NV<26CR'+@*HPZYR0
M,CZBNW,3K9&$2,\@CVAV/+'&,G'>IJ* .%U+1O$VM^"G\-ZI9:7-//;""6^^
MT,R XQYNPIG>.H&<9[BEUGPKJLFL>$)-.6UDM-!)WM<7#+)*#&(^ $(SWY-=
MS10!STUCJ^I>)8&OX+1=%M1YD2)<,SR3 _*[J4 PO89.#SR0,8]AX:US0OB#
MJ.IZ3'8C0=3"O=6LEPRN)^\J (0,\9&>>N>E=S10!R/CK0-6\0'0ETU+3;IV
MJP:C(;B9DW"/=\@PIY.>M7?&FE:AK_@S4=)L4MQ=7L!BS-*51,]3D*2?RKH:
M* .5U'1M6O/AM-H*16BW\VGFR),[>6I,>S=NV9/KC%2:7:>(M*\.^'M.A@TX
MR6HAMKXM,[#R43:S1G:/FR!@$8KIJ* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?U?Q!-;
M>(;#P_I\4#7]W#)<;[ARJ1QH0#P.68EN ,< G/'/05R/B_PSH_BZ\M]/N+B>
MSUBUC-U97EL^R6$9VDJ>XSMR/<=* -'3]3UFXNM2LKO3[:"XM$C>)UG9XYP^
M[G[H*_=QC!P<]1BLCPMXI\0>+/"MMKEII>FPK<"39#+>/D%79.2(_5:K^"M4
M\0V^OZMX5\1SPW]Q801SP:C$FTS1.2 ''9N#^O7J</X9:%>:K\(-.2#7+ZV$
MHG A01>7Q._!.PO@XY^;/)H Z7Q!XPU706\/22Z3;K;:K-%;322W#*;25P"
MPVG(SD9XZ5M^(]4O-)TZ*6PMH;JZEN(H(X)93&'+L!P0#T!+'CHIJMXHT>U\
M:>#;_3HI59;F-O(F'195/R,#Z!E'(ZCZUS_@77+CQHFG7EY&Z2Z/"T-VKC'^
MG',;?BJ G_MM[4 :>H^)]6M/&>G^'(;"RD>]M'N1,]PZA=F 5P$/KP:TX[KQ
M$9;F&33K ,L2O;R+<N4=LD%6.S*]N<'K[5ROB.WDN?C/X<CBNY[5O[,N3YD(
M0MU''SJP_2NLTBS;2;V\M[G5)KV>]F-S%Y^W>$5(T(PJ@  @=OXAWH S/ OC
MFV\:Z7+((#9ZE;D"YLW;)3(RK X&588(.*EBUO7KF*Z%MI=G)/%?FS4&X<)M
M R9&;8=O';!YP,\UR3>'+]?"OASQ=X94#7[#3HE>'HM_!L!:)O?^Z?7\,=-\
M/-9@\0:)>ZM;))'%=7\KA)!AD.%!4CU!!'X4 5K+Q5XCO_$FMZ'!I&E_:=*2
M%G=[Z0))YJEE _=9XQSFI7\6ZK'XH\/Z+)I5O&VK6C7+L\[;K<HH+H5V\G)Q
MG(JGX8_Y+!X\_P"N6G?^BFJ#Q5!)<_&#PC%%=S6CFRO#YL(0L.%_OJP_2@#<
MUOQ-?Z7XRT+08;*VECU?SMD[S,IB\I S94*<YSQS74UYKKEE<6GQ;\!>?J=U
M>[O[0Q]H6(;/W Z>6B]??/2NXM=)TVVUW4-3MUQJ%VD2W)\TG*H"$^7.%XST
M S0!I5R,WB?5CX]F\+VVGV3%+ 7ZW$EPZY0R;-I 0\Y]ZZZO.+FUEN_CQ*D-
M]<6;#PVI+P!"3_I!X.]6&/PH [73;G5);FYAU*SMX1&$:*2WE:19 <Y'*K@@
MCISU%:5<T-'L%TO4M'UJ_-^D_F7,LER5#K$>-S%0 N,$ C'W>.AKD_AS&D.L
MMI6LJS:EIMJ!I+SPA&FL68XEQ_?Z!L\C Z$MD ]1HKR[PY;:5XM\&RZMK-R]
MOJ]MJ,LEU>1,%N+:2.8[8PQ!*KL"KM'4'U-/-FOC/6_%^DZA=64=U;7 BA6X
MMC)-;0&)"DD1WKM^8LV0.O4]!0!Z=5/4]3M-'TZ6^O91%!'C)/<DX 'J22 /
MK7FZZ+::E\0M$L;^]GU2VE\-OYLKR.JW>V2,!BN>AZG'!]ZYS5-+CL_!'BW2
M2@N-,TO7K9-.,_[SR%:2$O&I.2 -Y'XGUH ]WJG8:G::F+DV<HE6WG:W=EZ;
MUQN ^A./J#4L%K:V]H+6WMX8[905$4:!4 [C X]:\8BD3P[\,O%E_I5O%:W"
MZW<VS3V\822*W-RJMM(&0 IXQTX/:@#VZJ>J:G::-ID^H7THBMX%W.Q_0#U)
M. !ZFN*UNQAT/QAX0NO#T,=N;VY>UNHK< )<0>66W,!]XKMR&Z\]>:G^,%M;
MS_#;4'FACD:*6W:,N@)0F9 2,]."1]": -?4/$%Y9^.]&T(6\!M-0@GE,VXF
M0&,*<8Z ?,/7\*Z.O//$&DZ?)\1_!^G+;1QV7V34 8(1Y:$8C)7"XX)ZCOWK
MFDOSX?\ #>M6,$PM=*@\7"S<MDQV]JVQF7@@A-QP1D<,?6@#VBBN1T+P[%HW
MBR>]@U*U1+ZS!.FV5MY4+%6'[X#>P!PVWMG/M53Q9>&3QSH&C74UK'8WEO<,
MB7<)EBFG4IM4KN4$A2Y )ZGIG& #N:"0!D\"O.)_!FE0^#]>T>^U7SK<7#2P
M>1"5.GR. 5CA&XGJ5P@/.['\53> 1#JUOJT>OV<'_"21;;34[>2)=HC"@1[5
MY!1E&[/<Y[   ';:9J5KJ]@E[92B6V=G5)!T;:Q4D>HR#@U;KQ+1+BWT;X1^
M$I(A:V<.H:A'!J-P8N&CWRX\S!4E=P4')Q@D=":W];\,PZ/HWB^>+4HE6[T:
M6?\ LZRA,$4;HAQ, '."?PW8[X- 'IU4[+4[349;R.UE$ALYS;S%>0L@56(S
M[!AGWR*\TMM,M=,U7X;:A:(R7=[$8+J4N2TR&U+;6R>0"!@=!CC%:_PUTW3[
M6]\62065K#*FO7,*-'$JLJ;8SL! X7OCI0!VEUJ=I9WUC932A;B^D:."/NQ5
M"['Z +U]QZUD:%X@O-3\4>(])NK>")-*D@6)HF+%Q(F_))Q[<8]>M87C'3=/
MO/B7X(-W96T_FF]23S8E;>JP$@'(Y .2!ZUE3:)IVM>)_B0M_ )XXXK5HU+'
M:K?9<A@!QN&.#U';K0!ZK5/4M3M-)MDGO)1&CS1P)GJSNP50/4DD5YUI-Q!K
M6F^!;:[WZCJ;Z09_LMRX^SLNQ%,LN02S#HN 3ECTY-<\MO!>?#'04O(X;G[-
MXG2WC,BAPD?VLKM7.<+@8QZ#% 'N5<AXG\9MIW@:Z\1Z(EO>QP3&+,KD*<3>
M4Q&/O?-GN,CO74+:6@LOL:V\/V388_("#9MZ%=O3';%>)I96=O\ LXWLL%M!
M#/+,ZR/'&%9@M^0N2.N!P/2@#W.BO.I[&'P_\5;8Z3"4>\T:YDG3>S?:)$="
MC-D\MR1D\\UF>'M-B\2>%_#WB7^V[2VOH9HII[R&U/VF28G#PR/YGS!F.W;C
MTP ,"@#U"^O;;3;"XOKR98;:WC:261NBJ!DFL+2M8UW7=/CU2TL+2ULYU\RV
MBNY&\V5#]UFVC$>1SCYN#^%4OBOIU[JOPQUNTT]6>X,2N$3JRHZLP'K\JGCO
M6QX;U"VUWPCIU[I\^V&>U3:\6"8S@ CD$9!!&".U %C0M0NM3TSS[VR^Q7*S
M2Q20;]^W8[*"&P,@@ YQWK2KQFT\4ZM=^!-%O=9U821WNO&SNYYX5$:0J9 H
M8)L^4LJ;LG')!X.*UM>\,PZ-H7C&:+4H@MUI,EQ_9UE"8(HG1#B4 .<$]^@;
M&><4 >H45Y7;Z;:Z5XA^'-]9JT=U?0O#=2[R6G3[+N"MD\@$ @=!CC%5["P7
MQEX9U"_N]7L[#5+/4)FGO!:DW5BT<S%5#^8,+L  &,8/KDT >N45YG#X;TS7
M/BAXFMM2CEN(!:6,PC,SJ/,RYW<'(((X';)K%UMK:33?[;TO+X\2Q[=2N''V
MAV\\(T:8 (B RH!/('3'- 'H</B"\;XAW'AR6W@6V335OHY58EVS(4P>@'W3
MZ]N:N>)/$5GX8T=M0O!(^76*&&(9>:5CA44=R36!&<_&^<C_ *%N/_TI>L_X
MLJ]N?"FL2@G3M-UN":\/:-,X#GV!_G0!T=S?^*;72IK\Z583RI$9/L$5PWF<
M#.T.5PQ]L >];MI.+JS@N ,"6-7Q]1FG-/$EN9VE00A=YD+#:%QG.?3%<-;2
MV^O_ !-UK2]7MX[BTMM.MI+"VN(\HR/N\R38PZYVKG&1C'K0!WM%>(74=S)X
M1-E<7%RUOIWC%+&QF\YMWV<3* ,Y^;:2R@G.-OM6_KOA31]-\;^#=.LH9K>T
MN[F_>>)+F3#DP$GJW&>G&.": /4**\1U@W?@>+QY8^'WGATJ&*RF1(W)^QM*
MVV79W'RY;VX-=7KUA;Z+XG\(7?AV*. WMV;2YCMOE6XMS&S%FQ]XKMW!NO/7
MF@#T.BO*_">B:-Y7B?6-0,ZOI.N7[07'G.3;(% )49Y^7/4'H/057TJ*.S\4
M?#Z>SA6WMKVVN5,CN#<7<?D!P\Y4 %B<-CYL$GF@#TR'5(M1BU)-,DBFN+.5
MK<[S\@F"*VTD=AN4''3GTJ?3S>-IUL=16!;TQKYX@),8?'.TGG&>F:\S\-Z3
MIL>@?$$Q6<$,B:G?Q(\*"-U01HP4%<$+GG XJ/3+QI+3X7:1=C.EWVG%YD?E
M)I4MU,:-ZCDG!ZD#TH ]9HKR76+5M/OO'^D68>/1UT+[<L,;%4MK@I(,(!]W
M=LW$=,BG6VFVNEZC\-=1M%:.\O(Q!<S;R6F0VI;:V3R 0"!T&.,4 >C:_J$^
MDZ!?ZE;0QS/:0//Y<CE0X52Q&0#@\>E0^%M7N=?\-6&KW-O%;F]@2=(HY"^U
M6&0"2!SSZ4WQ?_R)6O?]@ZX_]%M5/X?NJ?#;PX[L%5=,@)8G  \L4 =-17F/
MB9M-UR[\2O;(+Z6WT9&E:\($5FK([H8EQN\QAR3D8PO.>*KWO^B^$_ GC>;]
M[+I\-J+^1^2\$T:H[MZE68,/3F@#U:BO']-<6FO:UH:VD<4/BI%NM,PGW8V8
MI)U]$Q,%Z#)%>J3)_9NC2II]NN;>!O(A4<$JORK_ "H N5@ZQK<\&NV&A6'D
MK?WD,TXEG0LD:1[1RH())+ =1W/L?.9Q'<_!&V\66K_\5%$B70U!1^^:X\T!
MD)ZD$DIL/&,#' K?U+2K"[^+NA/>:99M+-I5Q+,'A5MT@:( G(Y(Z T =A9:
MC=6_AT7_ (BCMK">&-GNA'+OC0*3\P8]B!GVSBLS5O%%S9ZMX8AM;>%[+69C
M&TDC'>@\LN,*..W7/X4WXE6\-Q\-O$(GACE"6$LBAU#;6"DAAGH0>0:YC5]-
ML1_PKJT@@C@@DN\R+;_N\DVS$GY<<GN>M 'J-%>.WEP_A2W^)-MHP:UM+.2R
MDCCASB 2HOG,H!XXRW&.E=7I7AZTM?$VF:Y8ZK8Q17-N\7V;3[7RX[U=NX,W
MSMDKC.[WQGF@#;\3>(1H$%BJ1)+=:A>)96RR2;$\QLG+-@X "GH"3P.])::E
MK2>((=,U&PM?)EMI)TO+:5B"RL@V%",@_/G.3G%,\7:5HFOZ;!HNN(6BOI_+
M@*MM990C.&4]F 5OY=ZY71/^$B\)^,=/\)ZOJ UW1M3AG^QW,Z_OX?+4%DD/
M\2X(&3U)'3I0!WVGZG::K'-)9RB6.&9X&=>F]3A@/H<C\*MLRHA=F 4#))/
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M_N8YY%3GK\H;'-;QEC$?F%U"?WB>/SIP.1D4 16MK!96D-K;1+%;PHL<<:C
M50, #Z"F6EA:V F%K D(GF:>78,;Y&^\Q]S4S.B EF50.N3BE) QD@9X% &1
M>^%M&U'4TU*ZM#)>HI1)_.<,BGJ%(;@>PI]MX<TJSEGF@MV2:>,1R2^<Y<J#
MD#<6R!GT-:9EC$?F%U"?WB>/SKG/&^OWWAO04U&PBMY#]IAA<3[B LDBID 8
MY^;UH VM.TVTTFRCLK&(Q6T8PD>]F"#T&2<#VJ2ULK:R$HM8$A$TK32!!@,[
M=6^I[U,&5B0&!*\$ ]*X[Q%K_B'P[X96_GCTN6Z_M!(&$?F;!$\H1>"<[\,,
M\XS0!O6GAS2K#5;C5+:V*7UQ@3S>:Y:7 P-V3\V!TST[4ESX<TJ\U>'5I[8O
M?P K%/YKAHP>H7!X![@=:U RL2%8$@X.#TK%?5YM$T.\U'Q)/9(L$KE3:[L&
M/=B-?FZN1@8Z9/% $U[X<TK4=4M]2NK8R7MMGR)O-<-%D8.W!^7(ZXZU/;Z/
MI]KJUYJD%JB7UXJ+<3#.9 @PN?H*N,Z+C<RC)P,GJ:<"",CD4 %8L_A/1+G5
M'U26S8WSIY;7 GD#[<YVY#<+GMTJCKOBP0>$M>U;1#;W,ND^:K>:28R\:AF
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MMFI-<\/:1XDL19:Q80WEN&WJL@Y5O4$<@_2M(LJ]2!QGD]J 0RAE((/(([T
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MY#PDDN)4+98DX[#H*Z7(H **:70.$+*&/0$\FJ:G4O[<<,;/^R_LXV ;O/\
M-W'.?X=F,>^: +U%-$B,Y0.I9>H!Y%!= <%ESG&,]^M #J*,CUHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *XWXK_\DM\0_P#7M_[,*[*J6IZ38:S9M::E:QW5LWWHI.5;
MZCH?QH S;O6+'0? ZZCJ,B);0V2E@Q^^=@PH]23P![UY=X7MKWP_H?@+0M:D
M@M+>\CO)2E[#OC\XL&B1U+*,[68@'^(],@5ZQ!X5T&VEAEBTBT\R#F%FC#&/
M_=SG;^%6=7T73-?L#8ZM8P7EL2&\N9<@$="/0^XH \S\5:+;Z#\+O&MK:ZB+
MF-V$Q@BCV16K,RDH@R=HZ';GC/O70:XFGZCXS>R\M+F\AT=FE6](-M!"S_?"
M8RTA(P>0-HY/3/2#PMH2Z$NB+I5L-+!S]E"8C/.>1WYYY[TL_A?0[J\M;NXT
MNVFN+1/+@ED3<R+G(&3U /(STH \OM[<S?!OPKXH$8N;_0!%=DL-SO K$2)D
M]MG/U45/%>KIGC*_O+&T@%GXOMBFFNL609D(3<?]AU;S/<#/7->GV.A:5IFE
MOIECI]O;V+A@T$: *V[KD=\U-_9ME_H?^BQ?Z$<VWR_ZKY2GR^GRDC\: .(O
M-,T:'Q/:Z#:6T4DMEHK#R;L@VMO 7P9-F,M(2I!Y'&<D9YY&TACU+X=_#)[E
MVED.K0P,^\[O+Q,-N<YQA0/PKUR^\/:/J>HV^H7VFVUQ=VXVQ321@LHSG'TS
MS59/!OAR.VM[:/1K1(;>4SPHB;0DG]\8Z-[]: ./N;'3M*\>V'A>%+"RTIM-
M>>RM[J RPO.TI\P*"P&[;C'7 )QC-=3X+TF#0]%ETVVU)K^""YD",5PL6<$Q
MKR?E4DCJ<<CM5_6O#FC>([6.VUC3K>]BC.Y!,N2I]0>HJ[965KIUG%9V5O';
MVT*[8XHE"JH] !0!YO9>%M%U_P"(?CJRU2T6XMQ]B(B=SM4M"V6 S][K@]1D
MXZFN=TNS;4-"^'"ZHSW!.I7%LLKL=TMN%E" ^H*@?4?6NWT[PO)<>//$^I:I
MI3K9Z@MNMO+YRC<J1[75@C9VDXX.0<<UU%WX>TB^>T:XL(7-GC[-QCR<=-F/
MN_A0!Q>FZ=IUK\2Y/#+V,*:59Z0LNFV<@WQY>5O-<!LY;) ]A[$US&I1SP>!
M/$VF;W.F6?B2""QRQ_=Q^?$3&I_NJQ('IR.U>O:CHNG:M)!)>VJ2RVY)AE!*
MO&3P=K#!&>^#S45SX<T:[TV+3I].MWLHFW) 5^0-G.<>N><^O- ')66EV.E?
M&.2SL+:.WM[SP^TMQ'&,"603JH=O5L,1D\G-<D847X,3P+E8QXBV#:Q! ^W
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M'_X1K1_-L9?L$7F6"[;1LG, Z83GCCCCMQTH7PUHZ->LMA&&OABZ()S/_O\
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M\&/%6K:G#%+K(DNS<O( 9()$<A$!ZJ%4* /<^IKI;N&(?$+X?S*HWR:?=JS
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MCV]U]HBL8U?SC<8R=OFDDF3;G;OY/S8SS5ZZM8;VUDMKA!)#(-KH3PP]#[4
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MKWS70T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*Y)_'B@#U:&>&YC\R"6.5,XW(P8?F*:MW;.)2MQ$PB_UA#@[/KZ5Y5XIM(-
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M22\G6W@3(R['T]@.2:<&OSKW^OLSIAM<K$ ?/,N[ELYQLVD#IG->0:<EM?>
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M2,'.,'<.W:O-))4/P#\40+-$ZPZA.J"+A53[4,;1DX7K@9KN_$?_ "53P/\
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MM#UZVUS6X;&_M]3G:Z8QHMQ 4E)B9&/S ! H4CL"!0!ZY)<0Q$B2:-" "=S
M=3@?K2&Y@$_D&>,2X!\LN-V#TXKS>+PWH^L?%36[;4K"*ZB?2;25TF3&Z3>_
MSD#^+CKU'/K4,[76A:TD]Y:6FL>'[O7-T%]#\MU8W#3;=K _?4/\F1SCCT%
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MNXG:*;Q3);VUO'((T>3[22B.<$"/Y>>#P.!G%2E_)NOBO;O-:[CIL3&.V&U
MYMI=V!D\X49/?'04 >DZ!JG]IZ)IMQ-)%]KN+.*XDC0XP64$G'4#)K-\/:[J
M&H^*?$VEWHM_+TN:!(&A0J65X]_S9)R>0.,=*X:X\/6%EH?P_P!6T>U2#7)+
MFQ4SQ?ZR>-HP90YZLNP$G/0#C J;4[J]LI_BQ<Z<7%U&ELRF/[RC[,-Q'N!D
M_A0!ZI'<03221Q31N\9PZJP)4^X[54UG6K'0;$7=_,L<;2)$@)&7=B JCU.3
M^63VKCM(T[0;W6_#VO:;K<#.L+Q6\-E$D8GC9,E9 .<+C//0^YJ?XKP02^%K
M1YHHWV:I9C<Z@[09E!Z]B.M ':RW,$,7FRSQQQ_WV< ?G4@((!!!!Z$5P-H]
MM<?%F]TN[A@-I!I*'382@,>-Y$Q4=-V=JGV%6/AO%/:V_B&Q4L=,M-9GAT\$
MY"1#&47_ &58L!]".U '2MKEDVN2:)%<1G4$M_/9,Y" G"[N>I/;T'TK)\%>
M([G7-%>YU1[6.Z^W7%LJQ916\N0J, DDG K(AM;%?C;?O+!;!_[%MY%9D7.\
MSN-P]^@SUZ5Q%UIMB/A#KFK_ &:(ZC;:S*\%T1F2$B]&-C=5ZG@8ZF@#W*:X
M@ME#3S1Q*3@%V"@GTYJ2O-KR6VU3XB>(M%UB]MK<&S@%G'=Q*PD@9#YA3<?[
M^<XZX'IQU_A&S@T[PK865K?S7]O ACBNIB"TBAB <C@C' (Z@ T 4+;Q'>Z_
MKNHZ?H*VT=MIDGD7-]<HTBM-C)C1%9<[>,L6&"<8-7]/O-9&N3:?J5O;&!;=
M98;NWW 2G<0P*$G:1\O&3G/7L.1^%7_$IN?$_AR]8)J<&K376QN#+#)MV2#U
M!Q^'%;7Q%U6[L_ VOC2)'_M*&S,G[K.Z)20"V1T.W<1W^4GM0!U4=Q!+(\<<
MT;O&<.JL"5^H[4&XA#A#-&'+;0I89SC./KCFO.O$%K9P#P)J?AJ...:34(((
MF@ 'FVCHS2*V.J[5W<],9IG@[POH5_KWBQ[K2[:8VNO,T =,B(^5&?E'09)Y
M]<#/04 >C_:8-Z)Y\>]R0J[QEB.N/7%+-<06ZAIYHX@QP"[!<GTYKPFW\.:5
M+\!1J\5NJ:S:R2M9W:$^='(MTX1$/4 D@;1QELXR<UW.@G^UOB%XHL/$%O%-
M/%:VBV\,RAE\AHSYA0'L9"=V/0#L* ._9T0 NRJ"0!DXR3T%1/>VL< G>YA6
M(G D,@"D^F:\52R-QX3\*PWH,T$'B[[)93.<NUH'D51NZ[>,?0#VKL+C3- T
MWQG;:-I=C:V\\6F37!CGQ]D@ADE&]Q'_ !.64C@J N<GH* .PU77+#1TM&O)
MU0W=Q';0+D9=W8 8]AG)]@:<S7YUR'9/9_V8ULQ,1!\YI-PPP.<;,'GCJ17C
MNGI;7GPR^')N%AG9-=AA)<!L1^9, O/\/ &/85V3P6\'QFLY;&& %_#LNWRP
M &Q,@7IVQQ]* .[-Q +@0&:,3$9$>X;B/7'6B2>*+/F2HF%+'<P&%'4_2O'H
M%@U3X#7>JW'&NPF:XDN<8GCO4E..>H;.U0/0@=*V+;1[74?BPJZQI]O+-+X9
MAENH7C!1YO.()9>C8QWST'I0!Z8CK(BNC!E89!!R"*9-<06X4SS1Q!CM7>P7
M)]!FN-^%/R>!8X%)\N"\NXHUSG:BSN ![ 57T40:SX_\96&M6\4[Q"WCMX9U
M##[*T?\ "#V+;LX[XST% '>,Z)C>RKDX&3C)]*(Y(YHQ)$ZNAZ,IR#^->(6=
MD;WP_P"!4U)?M"+X@EM;>:4Y>2U E"J3U*D*![@"O9=,TJPT;3X[#3;6*UM(
MRQ2&,85=Q+' ^I- %%M4ET>RU?4-=O;%;.VE9XVA!4QPA00KY/+YSTZY&*T(
MM0M9+&&\::..*55*EW ZC(&?6O(YK*U3X?\ Q2A2WB$<6I731H$&$/DQG(';
MO70:CIUWLT*Y\,#2Y[NTL7,FDW"A8[B-Q'N92.%<87D]GYX/(!Z*K*Z[E((]
M0:6N?\#WUGJ/@[3[BQLI+&W*L@M9.L)5V5D]P""![8KH* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *@O;*UU&SEM+VWBN;:4;9(I4#*P
M]P:GIDTT5M"TT\J11(,L[L%51[DT 9=AX5T#2YXI['1K&WFA79'(D"AE'H#C
M(J,>#O#0:X;^P=.S<2B6;-NI\QP<@GCGGGZT_5O%&D:/H[:G<7T#6^Y8T*2*
M?,=L84<\DY'X<]*ORZA906HNIKRWCMSTF>4!#^).* *USH]D+DZI;Z99/JT,
M#1V\TD85@,'";\9"]N/4U1\/V>JRW,FL:_;VMOJ,D*VZ06TAD6&,$D_,0,EF
M.3VPJ]<9K=66-XA*DBM&1N#@Y!'KGTK'UG6=GA;5-2T:[LYYK2WDE5L^;'N1
M2V#M8>GK0 ^+P]:1^*YO$"P01W<EN;<O&F'D4E"2[=\;% '89ZYXMWVD:;JC
MP/?V%M=/ V^%IHPQC;U7/0^XJEH&M)>>&=%O;^Y@CNKVRAG8%@NYF0$X!]S6
M9X:\2W%U>^(8-:NK*,6.I_8X'4>4K#8K ?,QRWS'O0!OPZ-IEOJ$VH0V%M'>
M3C$LZQ /(/1FZFH['P]H^F3^=8Z;:V\@W;3'&!MW<MM_NY[XQFKMS=6]G"9K
MJ>*"(=7E<*H_$UA>,=9NM*\$:EK6D2VS2VULT\;2*9$8 9XPP_//YT =!)''
M-$\4J+)&ZE61AD,#U!'<5BVG@WPS8O$]KH.G1-"Y>,K;KE&/<<<?TJ]!J$2:
M/;WM[/%"KPH[R2,$4$@=S[UA^#M?O=:N/$*7LUK*EAJ)MX)+=-JM'Y:,#RQS
M][KF@#5_X1K0]EVG]D6.V\.;E?(7$Q_V^/F_&K']D:;_ &4=+^P6W]GE/+^R
MF(>7M]-O3%2VU_9WL;R6MW!/&APS12!@I]"0>*1=1L7#%+RW8)&)6Q*IPAZ,
M>>GO0!7TS0-(T6Q>RTW3;6TM9"2\44057)X.1WXXYIND>'-%T#SO[(TJSL?.
M.9#;PA-WUQ_*KEM>6M['YEK<PSI_>B<,/S%87B7Q,FDZEI&E17$$5SJ5PT9E
MD((@18V<MC/4[0!GC)[XP0#2@\/:-;6EU:P:391V]VQ:XB6!0LQ/4L,8/XTZ
MST/2]/ADBM+""))%".%3[RCH">X&3@=JJ:;>W>GV(7Q)J6F>>\S+;S1-Y0FC
M_A)#'A\=0,BM>2>&'9YLJ)O.U=S ;CZ#U- %?3M*T_1[;[/IMC;V<&=WEV\8
M1<^N!Q2ZAI=AJUNL&H6D-S&KAU65 =K#HP]"/45/!<0W4*S6\T<T3?=>-@RG
MZ$5$^HV,;*KWMNI:3RE#2J,O_='/7VH C71]-33WT];&W%G)G?#Y8VOGKN'?
M/?/6GV&G66EVRVVGVD-K OW8H4"*/H!Q4B7EM)=26J7$+7$8!>)7!=0>Y'44
MU[^SCNTM)+N!+EQE(6D =A[+U- $,^BZ7=:C'J-QI]K+>QQF)+AXE,BH<Y4-
MC(')_,^M5O\ A%?#_P!@-A_8FG_8R_F&W^SKY>[UVXQGWK1EN[:!BLUQ%&0A
MD(=P,*.K<]AD<TJ7,$ML+F.:-X"NX2JX*D>N>F* ,[4_"^@ZT;<ZGH]E>&W&
M(3/"KE!Z#/;VZ5JJJHH50 H&  . *SKKQ!I-GHUQJ\NH6QL+=2TDZ2!E&.V0
M>3[=:=;ZUI\VDPZDUW!%;2(K;Y)5 4D9P3G&>: &ZEX>T?6)HI]0TVVN)XAB
M.5T&]!Z!NH'MFK-MI]G9VAM;:UABMSG,2( ISUR.^:?]KMOLRW/VB+R&QMEW
MC:<],'I42ZKIS2>6M_:E]VS:)ESNSC&,]<T 0Z?H&D:4VZPTZVMCM* QQ@;5
M)R5'H,]AQ20:3I^CPW4FEZ7!%+-EY%MXUC,K'N3P"?<U=%S UPUN)HS,HR8P
MPW >N.O<47%S!9P--<SQP1+U>5PJC\30!Q_P^\()H7A73+;4]+@CU.S!W."K
M@OD_.I'?!QG /;I727^@Z3J=RES>Z?;SSHAC$CH"VP]5)[K['BL7PCXAN]7N
M?$2W\]H\.GWY@AE@78AB\M&!.6/][KFNCM;ZTO8FEM+J"XC4X+Q2!P#]10!7
MN]#TF_-L;O3;2<VN#!YD*MY6.FW(^7\*+O0M)O[^WO[S3;2XN[;_ %,\L*L\
M??@D<<\U.FHV4DT427ENTDR[XT65277U SR/>GV]Y;7?F?9KB&;RVV/Y;AMK
M>AQT- &>?"V@'2AI9T73_P"SQ)YHMOLZ^6'Z[MN,9]ZL)HNEQZD-233[5;X)
MY8N!$!($_N[NN/:I;?4+*[EDBMKRWFDC_P!8D<JL4^H!XI6OK1+I;5KJ!;EA
MD0F0!S^'6@"HGA[1HK]KZ/3+5;II/-:01@$R?W_][_:ZU)_8>E?;Y;_^SK7[
M9,NR2?RAO=?0MU(]JL75]:6,8DN[J"WC)P&FD" GTR:+B]M+2%9KFYAAB8@!
MY) JDGIR: (].TNPTBU^S:;96]I;Y+>5!&$7)ZG XJ!O#VCM>/=G3;8SR2"5
MW\L?.XZ,WJ1@8)Y&*T(Y(YHQ)$ZNAZ,IR#^-<AJ'B.[U'Q)J'A_1-0LK6ZL[
M2.999U$@EF=F CQG@ )SCGYO;D Z#_A']'%Q=7 TNT$UV-MQ)Y*[IAZ,<?-^
M-02>$_#LMM:VTFAZ>T%HQ>WB-LA6(GKM&,#-6K2_C_<6=Y=68U3RE::"*7/S
M8^;:#\VW.<9'2II[ZTM2PN+J"(J Q$D@7 )P#S[\4 47\,:#);7-L^C6#074
MOGSQFW4K+)UW,,<GW-3/H6DR75M=/IMJUQ:C;;RM$"T0]%/4?A5\D $D@ =2
M:@M;^SOE=K.[@N APQAD#[3[X/% $EQ;PW=O);W,,<T,B[7CD4,K#T(/!%5-
M.T32](S_ &?806Q*A,QH =HZ+GT'ITJ9=1L6DBC6\MR\V?*42KE\=<#/.,'.
M*='>6LLS0QW,+RKG<BR L,=<B@"@/#&A#6_[:&CV7]I]?M7D+YF>F<XZX[]:
M3Q3:7.H>%-6L+.'S;FZM)8(UW!1N="H))/3FM*"X@N4+V\T<J@X+1L& /IQ7
M+:%XFN)==\26>LW=E%%I]Y%;V[@>4"'C#@'<QRW/KVZ4 6_"?AVVTG1-,$NF
M0V^H6UJD+D;6VL% <J1P Q&>,9[U=N/#&A7>L1ZO<:/92ZC'@I<O ID!'0YQ
MU'8]JT9;F" J)IHXR^=N]@-V!DXSZ $_05%+J>GP6L=U+?6T=O)CRY7E4(^>
MF#G!H CCT;3(M4?4X]/MEOW&U[E8@)&'H6ZD5'%X>T>&[-U%IMLDYE,Y98P,
MR'J^.F[D_-UJW<WMI9P">ZNH8(3C$DL@5>?<\4\3PM!YXE0P[=WF!AMV^N>F
M* *-UX>T>^O3>76F6LURRA6D>,$NHZ!O[P'8'-2SZ/IMSJ$.H3V%M)>0#$4[
MQ O&/]ENHK&\6^(9;#P-JFMZ%=V4TMI"TBN1YJ';U'RL.?Q_"MC3M0ANX88S
M<0M=^2DDL2N-RY .2O4#F@"LWA;0'MKJV;1K P7;;[B/R%Q*V<Y88Y.>YI\/
MAO0[:0R0:18Q.8/LVY(%4^5UV<#[OM6H2 ,DX JO;7]G>H[VMW!.B'#M%(&"
MGWP>* *)\+Z"=.33CHU@;*-]Z6_V=?+5O4+C -9]]9:UJ>L?V9-9V,7AV)X9
M1,)2TLVS#>7LQ@#>!DY^Z,=^,^+Q%JOB+4-5B\/7VFQ-IM\MLL-R-PNE"HTC
M%E.5'S$ @'E>>O&MXO\ $J>&M)CF#0_:;BXBMH5E;@&1PNXC()"@DGZ8R.M
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MMQ::-I\'V=F>'RK9%\MFQN*X'!.!DCT% '$>#M'TC6M'\8Z-=Q6Y%SK5_$R
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MSK6G0B.01.9+I%VN>0IR>#[5I@@@$$$'H10!2&BZ4KP.-,LPUN L+"!<Q@=
MO' ^E.ATG3;?SO(T^TB\\$2[(57S >H; Y_&FC6=,:]%BNI69O"Q00><I<L!
MDC;G.0!R*Y?POXN!&M1^(]8L8I(-;GL+4RLD =5"8503R?F/<GF@#IK30='L
M#&;/2K&W,>[88;=$V[L;L8'&<#/KB@:#HXA>$:38>5(P9T^S)M8CH2,<FGW^
MKZ9I>W^T-0M;3<"R^?,J9 ZGD]!FL#QAK5_IK^&I=-NXA;WVKV]K-^[#^9$^
M2=K=!P.H'?K0!O'1M-\R.5-/LUFA&(9/LZYCQTQQQCVKB+/P9JIA^QZMH'A+
M47);?JL\9:64DDEVB,?+'.2/, ],5MVVKZD?BA>Z++<(^GII4=W%&L04J[2L
MIRW4\+[=>E=)=7EM8P&>[N(K>$$ R2N%4$\ 9- #-/LH].TRUL8F9H[:%(59
MSDD* !GWXJ&+1-)@5%ATNRC"2^<@2W0;9/[XP.&]^M"ZWI3Z>^H+J=F;*,D/
M<"=?+4CJ"V< BEM]:TJ[OYK"VU.SFO(1NEMXYU:1!ZE0<B@!!H6D!)4&E6(6
M;F0"W3#_ %XY_&LC4]'U>[NDTFS32K7PQ)"$N%5&$Y^8[T4#Y K+QGJ,GVK2
M?Q+H,;Q(^M:<K32&*)3=("[C@J.>2,CBLB^UG4;7XE:7I7VF,:9<V%Q.\?E@
M$,A0 ECV^8^E '5@8&!TKC[SPO<ZA\1UUJ\LM/N=+73/L6R9M[[_ #-^_:4Q
MTXZYYKHK?6=+N[66ZMM2LYK>'_6RQSJR)_O$' _&K"7=M)9B\2XB:U*>8)E<
M%-O7=NZ8]Z (9M)TVYMHK:?3[26"+B.)X594^@(P*DN+"SN[/['<VD$UK@#R
M9(PR8'0;2,5E^'O%ND>);&>[T^\A>**216_>#(56*[R.H4[21GM5^QU?3=3>
M1+#4+6Z:/!=8)E<KGIG!XS0!/:VEM8P""TMXK>%>D<2!%'X"GI#'&\CI&BM(
MVYRJ@%C@#)]3@ ?0"B::*WA>::1(HD&YW=@JJ/4D]*K6FKZ;?QS26>H6MPD/
M$K13*PCXS\V#QQZT -71=*43!=,L@)_]<! O[SG/S<<\\\TL6CZ9!:RVL.G6
MD=O+_K(D@4(_U &#3;77-(OKA+>TU2RN)WC,J1Q3JS,@.TL #DC/&?6L'Q!K
ME]I?CKPU9B\ABTN]6[-RKH!_JHMP)<]!DY[=* .A_LG338-8?V?:_8F^];^2
MOEGZKC%":3IT=B;%-/M5M#R8!"HC/_ <8I+;6-+O=.;4;74;2>Q7):YCG5HQ
MCKE@<<4R'7=(N+>XN(=4LI(;?'GR+.I6+TW'/'XT *=#T@K"ITNQ(A_U0^SI
M\G?Y>./PJ^0""",@]JI#6=+-@M^-2L_L;-M%QYZ^63TQNSC-)>:WI6G31PWN
MIV=M+)C8DTZH6SP, GN: '66D:;IC.UAI]I:M)]\P0JF[ZX'-%OI.FVEPUQ;
M:?:PSM]Z2.%58_4@9JY5"#6]*N;W[%!J=G+=?-^Y2=6?Y?O?*#GCOZ4 37FG
MV6H*BWMG;W*H<J)HE<*?49%,?2=-DN/M#Z?:-/Y?D^:T*EMF,;<XSMQVZ57N
M/$FA6BNUSK6G0A)?)8R72+MDQG8<GAL=NM6'U;3HK^.QDU"U2\D&4MVF42,/
M4+G)H E6RM4LULUMH5ME4*L(C 0 = %Z8J0Q1F99C&AE52JN1\P!P2 ?0X'Y
M"HXKVTFNIK6*ZADN(<>;$D@+IGIN'4?C4=_JNGZ5$)=1OK:TC.<-/*J XZ]3
M0!:=%D1D=0R,,,K#((]#6?\ V!HWV?[/_9-AY.[?Y?V9-N[UQC&:Q_&'B^U\
M/Z);7$%Y:>=>SPPV[/*NW:[JIE'/(523GITS6'>^*9]&U>QTV?Q58W5KJMSF
M"\)A66U@$;,Q8@;#EE558KCDYR: .X_LC3/M*W']G6GGHH59?(7< !@ '&<8
MKF_&7A%M3\.-IN@V&FV\DMS#-*6_<JPCD5^=J')."/QK0L-3&B6(B\2>(].E
ME>1FM[AV2 R1$_)N&0"W;*@ \5KWNIV&FPK-?7MO;1M]UYI50'C/!)]* $L-
M.L]/B/V6PMK1I #(MO&J@GZ@#.*:FCZ9'?M?IIUHMZQRUPL"B0]N6QFLW5_&
M6AZ.VF+/J%L?[2E"6Y$R[2I&2^[IM '7IG [UNHZR(KHP9& *LIR"/44 5)-
M&TN:\^V2Z;9O=9!\]H%+Y'0[L9XP/RISZ5ITEVUV]A:M<L-IF:%2Y&,8SC.,
M4R'6M*N+XV,.I6<EV,_N$G4OQU^4'/'?TJ*Z\1:)8B8W>L:? (&5)3+<HOEL
MV<!LG@G!P#Z4 ._L#1OLYM_[)L/)+;O+^S)MSZXQC-<OJGAC59-?NKD:1X=U
MG3Y5C2WAU &-[157&Q<1N"N<MT!Y]A7<(ZR(KHP96&0P.01ZUR4_C6PU*R\0
MPZ)J-K]NTR-PK$A]SK'N)"Y&0,XSTSF@#6\.:%%H-C/%%!:VYN)C.\-I'LAC
M8JJX1?3"@D]R2<#.*MG1M+:]^VG3;,W6[=YY@7?GUW8SFL?PEXFM=4T'0X[S
M5+1]:N].AN9;?S465BT88ML'(')/ Q6O<ZUI5E>1VEUJ5G!<R$*D,LZJ[$]
M 3DYH ?/I6G7-['>SV%K+=1J42>2%6=5/4!B,@<FDDTC3)=.&G2:=:/8@ "V
M:%3& /\ 9QBK4@<QL(V"N0=K$9 /KCO7">']>U+5_ABNI7VOVNF:A)-,G]H2
MPIY:;)V4?(2%^ZN.OOR: .PDT?3);.*SDTZT>UB_U<+0*43Z+C I5TG3DNDN
MET^U6X0!5E$*AU &  <9 Q27VKZ;I>W^T-0M;3<"P\^94R!U/)Z#-<]XDUZ\
MT[Q-X52VOH$TO4)I5N,H#N586<-O)X' /'YT =->6%GJ$8CO;2"Y13D+-&'
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M$N4!ZA3CC\*:=+T]HHXFL;4QQYV(85PF?08XH Y.!T/QOO5W#=_PC\/&>?\
M7O\ XBI_'>HV-C-X>2[CA$TNI+]EN;F1DAMI C_.^"-W!("DC)/48KJ%L;-;
MC[0MK )_^>@C&[TZ]:?<VMO>1>5=013QY!V2H&&1T.#0!X?J%Q9W/@[XH0?:
MX+R3[5]H0C;\V8XOWB@=L]#^IKJM7T?3G\3>!+C1+>W6Z\QWD>W4?/:&([RQ
M'522HR>[>]=-XT\.SZ[X3U72],CLXKK4(Q&\LI*#C')*J2< 8%:NFZ='86FZ
M.QL[>[=!YOD  .P]6V@GZD4 >2VFEZ%=?"_QP+BUM7GCU#4$C(0&1) Y\E5[
M@[BN /7WKHK1;FW^('@FWU!\WZ:!,L^YLDR8BW?J#6UX.\*2Z-'>OJMIITEU
M)?SW<,\.9&19'+;<L@(QGM73/8VDEP+A[6!IUQB5HP6&.G/6@#SFYM+K1/%N
MI>%;6%QIOB=OM4$B#"V[<"[&>V4^9?=J],1%CC6-%"HH 50,  =JP-"TW7/M
MAU'Q)<:?+>QQM!;I81NL:(S LQWDDLVU/8;?<UT- 'AZ7Q3X0RPP2"46FM22
M:I;QG<ZVPO&+AE'(!&,YZC/;-=KK2K>_$KP=?:3*DC^3<M=20L"&M2@V[B.J
M[RNWWSCO7;1VT$1E,<$:&5MTA5 -Y]3ZFH[/3[+3U=;*SM[97.6$,2IN/J<#
MF@#D/B9<2VEEH-T^?[+AUFVDU$_PK""<,W^R'V$_04R]MDN/B[I]S9^6\!TB
M4:F1@HT>X>3N[9SN(SV![5W+HDB,DBJR,,,K#((]#5>WTVPM;9K:WLK:&W?[
MT4<2JK?4 8H XCX/Z?IP^'6B7T5K;&[\N53<! 9,&5LC=U[#CV'I4WBZ.WG^
M)?@2&X6.12U\VQP""1"".#[UVMO:V]HA2V@BA4G)$:!03^%)+8VD\RS36L$D
MJXVN\8+#'H30!Y'<7NEZ98>/TO+5)[+^W8!Y D,4:NPBP[LO*J& )]<$5L^'
MKVUN/BUK44NIVEZ]UI5N,PA1'*0TFX*,G( Z\GOSVKOQI>GA)4%C;!91MD A
M7#CT/'-2Q6=K"ZO%;0QNL8B5D0 A!T4>WM0!YWX1MKBVU&?P/-$YM-$O#=QR
M,,J]LQWVZ9]0Y/\ WYK.6]T:YU#QEX?\6:Z^FO/?2,UO*T2"XMF51&49T+$[
M0!A3D$<5ZR(T$C2!%#L "V.2!G S^)_,U!/I]E<W$5Q/9V\L\/,4LD89D^A(
MR/PH @LO*L/#MOA+HQ06BX67F8JJ=&]7P.?>O(K36-*?_A7EU:WEE:V,=X_E
M6<<N\VJ-%(,2R,22Q/'89R,'&:]MJJFFV$8 2RME D\X!8E&'_O=/O>_6@#R
MQ++3FT[XKL;>V)1Y@#L7Y1]F4\>GS#\Q6AJ<$T'@+PGXPLD,U]H=G!<2!>6F
MMFB43I_WS\WU6O0O[*TX!P+"UP_W_P!ROS=^>.:Q=6T?6+V[33K.33+7PY+#
MLNXQ"WV@DL=RI@A0K+P21D9/M0!9\+QM-82ZM*A6;5)?M1##!6,@")2.Q$87
M(]2U<IJVKVVE_%&\@UO6'TFUO--A%C._E")PK/YJ%I%(!RRG'&>,YXKT<
M 8 [57N["SU"-8[VT@N44[@LT8< ^N#WH \PUVTTC1_AUX>M=)N)GTQ-=M3;
MR7#@[U\_<2IXRO4CVY'%;_C"6-/'W@,,ZJ3>7. 3U_T=A_,C\Z[">QM+H(+B
MU@E"<*)(PVWZ9IKZ982E3)8VSE!M4M$IP/0<4 >:2ZCI0\4^,=$\4ZXVEB[=
M6C69H4CN+5H54!6D0G@A^ >I.!G-/TS5-,\+^.[.UU.YDM-+DT*&'2KC47"
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M-&T<J*\;##*PR"/0B@#@KZU6;XKO<6OEM:G0G&I="C?/^ZW=MWWL9[ ]J?\
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MIBQB>5E\MYHHQEGA$BF0#_@(.?;- '166N:5J5PUO9:C;7$RH)#''("VP]&
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MO+BTM[RWEN;;'GPI("\6>FX#D9P>M5[?7=*O[EK*RU2UDNBA9420,<#@L!W
M/7%>7ZQ??VIKWQ"CT*Z6:[N=$M_LWDMDS!1)N\LC[W!QD=S75:!K_@_Q-)H%
MUI_D7&HVD#>3'&?GL5*8<./X1P%YZG&* &^"_&4,VD1Q^(=;M!J4VH7-O LK
M)$TH25D4*HQZ ?6NZKPN>2R'P-\0SH]N)#K,C[P1DL+P%3GUV]/:O9=7:Z?0
M;]M-;-VUK(;8J>LFT[<?CB@#E?'7BT:=9VB:1K-O'>?VE!;RQ+L=G5I%5UYS
M@@'G'(]JWUO8AXGN5.OVYCALP9-,^3,)#9,S-G< 00,'CO7E5UKVB3_!WPW;
MK=VZ7EG>62W,$C@2Q2I*HE9E/(.=Q)/K[UV4%Q:-\;+LK- 0WAZ,DAAS^_8Y
M_(@_2@#J+3Q+H5_<Q6UGK%C<3S(TD<<4ZL716*LPP>0"",^QJ6RU[2=1NWM+
M/4K6>X5/,,<<H+;>FX#N/<<5Y5H-DMU\ ;R31[:&;41'> &%09"#.VY01SDH
M ,=QBMFTOO#GBNXL-2T/5[F_URWM)_LD8=0UKOC(/FJJC SM'/?&* .\77M)
M;4%L%U*U-VS,JP^:-S,OWE'J1W'450T3Q?I&OZGJ5C8W43R6,WDGYQF3"J69
M1U*@MC/3@UQ_@S6O"^K^%?#.E721RZWIKQ+]@;(N(;F/Y7D*]<#YF)/'/K6?
M/-<2:7\3])TV;_B<RWDLD5LA_>M&88\D+UP1D ^I'<T >G6NO:1>W8M+74K6
M:X*EEC24$L!U(]0.Y'2HAXHT W4=L-:L#/)/]G2,7"DM+@'8!G[W(X]QZUP^
MLW%GX@T/P++H$L;7B:A:R0+$1NAB53YP('(4+D,#WP/2KG@6#3;GQ1XT;RK6
M6:/60ZG:K%<1)@CTP=W/KF@#OKBX@M+=[BYFCAAC&7DD8*JCU)/2J]AJVGZF
M918WL%PT)"RK&X+(3R-PZC/O7)_$J::SMO#]\X)TRUUFWFU @9"1#.';_95B
MI/T!K,\1V]WJ/CN6[\-3![D>';J.>6!@07;_ (]P2.-V[)'L#0!W<6O:3/J
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M'C#2].\3V.@RR@7-U&\I8YVHHQCGN22./_K9WI)$BC:21U2- 69F. H'4DT
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M1@DFE#&( \2[?O;#T?'?!.* -&.&*$$11H@/7:H&:;#;6]NTC0P11M(=SE$
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M)M'R@#O^M '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY"JQJ01L3)!VJ3R>0!7J94$Y(&:-JEMQ4;L8SCG% 'D7]J6,FA_"EA=Q86:
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M'6EVC.<#/K0!Y&NH:#;ZOXJ\.>,+R[M)+N^DEBAW.$O+>15"!-H^8@ +@<\
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M8M[O1)8+>106$LAFC8*I&<G'/TKH/&LT4'@?76ED5 UA.HW'&6,;  >I)[4
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M!H>+O$#R:3X<U/0=7/V6[UBT@=K<JR31O)AE)()'3'!'<&MLW]B/&$L?]O\
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MDCC <6[!!^Z3:.G?)Z9Y/6M.U\4:=+I-A>32E'O%'EPK$[.[[=S!4 W-@<Y
MZ5Y\K)>>'/BM!:L)I9)[AD2,[BX^SJ,@#KR"/J*NR^)],)\%%7CABEMI(TU=
MX2WDL(T!CCR-N]NF2"/E(P3T .GUGQUI&E^'(M9AF^UP3S+;P^4K,"Y?80V!
M\N#G.<'C'7BK$VIV%SXETB./77AG>.5DTY0!]I7;]YU(W#;@D=*\L$Z?\*RU
MM1Y[?8_$_G3F2)@R1_:U;<PP,'')';T%=GK6I65U\3O \\-PC1M!?88\<,B!
M>O9L''KVH ZJ\\3:-I\SQW5\D?ENL<LA5C'$QQA7<#:A.1PQ'4>M%]XGT/3+
MW[%>:G;0W7E&;RB_S;!@9P/<C'KGBO/-)NX+3P+XK\-ZZRC6/.O0UO)_K+OS
M2S1O&O5]VX 8SR*ETJ%M,\;>!['5)HS?6F@20S%V!*RXC&,^O#?7!H ]'TG5
M]/US3TOM,NDN;9R5$B>H.""#R"#V-)?ZQ8Z:ZQW,Q$KJ76*.-I'*CJVU03M&
M1DXQS7)_#6>"3_A*EBD1O^*ANY%"D?=;;AA['GGOS4:7PT+XM:M-K,R6]GJ5
MA;BPN9F"QCRBV^+<> V6W8[B@#3\6>,K;2/ 5YXATR>*ZS;LUI(F71WZ#)'8
M'KG'3%6O#]K<&Z?48]<N[RQGA53;7,?W9AU=6(! (_AQCT]*\YU.U;3_ (0^
M.'<^7:ZCJ-S/IT3<;HF=0NU?1B&8#T.>]>OV-Q#=6,,UO*DL3("KHV0>/6@#
MD9_&<.M:7XIATJ>XM;G2UE2.<0X)9(@Y/SJ1C)QSUQD=0:G\(>+]-OM'\/V%
MUJL<NLW6G0RLC'YI'\M6;GINYR1U]JYNUOK:R7XEV-S)Y5R]Q/.J.I&8VMU"
MMGI@D8'J>*J"ZLXO#?PJ"S0JT4]OY@# %/\ 1V5L^GS'!]Z /2+_ ,3:-IDY
MBO;Y(2KK&[LK>7&S8VJ[@;4)R,!B.HK2GN(;6W>>XE2*&-=SR.P55'J2>E>1
M6MYX?277_"WC!-1^W3ZC/)':K)<;;^*20O&8U0X)Y QQC'UQZQ'$(=,2(1F,
M)"%V%MVW"],]_K0!C0^//"MQ>V=I%KEHT]YC[.H;[^>@STR>P/)XQUJ]J?B/
M2='9A?WBPB, RML9EB!Z%R 0@/JV!7D%E'8ZY\ M'T/3W@DUF5X1;0QD>;',
M)@3(1U "[B6]/K6S)J&AZ;XE\4:'XQ:^A_M*Z,UL5DG$=Y \:)L41GEAMVXQ
MGH.U '?:CXQ\.Z3,\-]K%K#*D'VEDWY(CR!NP,^HQZYXJ5_%&C(JN;T-&PC/
MFI&[(N\ H&8#"E@RD D$Y'K7%VT>G6GQ1\.6:PI;1P>'Y((K>9][0DNFV,DD
MG=M!'7)YZU3\1SR:1K&LZEX=U2*6?[3&FH>';M0PNVVHH:'^)6*[1QD$K[8H
M ]%U#7],TMV2[N=KI'YLBI&TAC3^^^T':O!Y.!P?2F77B;0[);-KG5;2-;T9
MMF,HQ*,9W ^F.<]*Y/1M1BT+QYXM@\03QVOVZ2&ZLYKA@J30B,*54G@E2,%>
MO.:Y6TLCH_A_P%:ZAB$?V^]S%!/PT,#>:4R#T^\O7H2!0!ZKI_BC1-4M+R[M
M-2@>"R)%R['9Y.!G+;L8&.<]*=8Z_IFJW+V=I=G[2(1-Y;QM&_EG@.H<#*Y[
M@$5YQJNIVMGK_P 3)S91:FOV&S)L\Y$VU'5LXY(7(W8Y %3Z/JMG+\5=+NTU
M-KZ&XT&2..=("D1;S4)6/ ^Z ">22.YXH Z?X>ZA?ZCH^I-J%Y)=S0:M=6ZR
MR!0=B2;5&% '0=A3;^_OX/BGHU@M]+]@N=/N)7ML+LWH4 ;.,_Q'J357X73P
MS:3K0CE1S_;=X^ <_*TA*GZ$<@TFKW,"_&/PZC3(&&G72$%APS-'M'U.#CUQ
M0!L:5J^EQQZW?_\ "1K>VD%TQF>1U\NSPJYC# #@=>IZ^M6&UNSU2UU&UT^_
MDAO;>'>RF(I+%D$JVR1>AQP2"*\W;5K.ST/XB7#6D&HQ_P!LJY@<%TV$1+YC
M!>2JD%CC^Z>15_2[^"Y^*%\\6H3:A]L\/*(9_)PLI$CD[-J@;1Z\^F2: -7P
M-X\TN[\.Z!9ZKKD#ZY>6ZLR2-\SN><$] QXXZ\CBNA@N;6Z\5:C;V^OR27"6
MJ+)81E"+8Y/[SH<,<]#GITKS.VAM=:^"^A^&[$Q/KRR6ZI;ICS;65907=UZI
MM7=DG'7'<5UMC=VR_&;6R9XEQI%NI)8#E7<L/J 03Z4 4]"UU[GX4&]U[Q-+
MI\SW,\9U+Y!(-MPP 48QDA<8 Z=*Z:]\7V-CXNM?#KB4W$MN\[N(F(4 J%'
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MN%UG7Q>^/8O"[3:C;6G]G23O):13)(9C(B(0RKG: 6.?NY(R>,5J:QK#>!O
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M;)I 4C\UUB@DF*)_>8(I*KP>3@<'T-7+2[M[^SAN[29)[>9 \<L;95E/0@T
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MUN9_L\3MD$RYV["N,J0>N0,=\5#!X_\ "UQ)#''K$)>:26)%9'4EHQEQ@CC
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M;][@C)QWQTK4@F2YMXYX]VR10R[E*G!]CR/QH DHHHH **** "BBB@ HHHH
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M$STR0#@5R=KJL%VO@6^6.XB6#42LUC;V3I#8DQR#R@ N2V<=22>O .*]LHH
M\^T:[MXOB!X_DDF1(VCM"K,<!ML)#8/?!X..AK0^%1 ^&6AQGB2*WV2(>"C
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MK) OPM^'L+E0\&J6+2QD<QA&.\L.P&>2>F?>NJM[NV3XS:C,9HUB_L.)3(6
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M"]RZG*C?&@7)[9(('KBL*&:W/A#XI)O0O<7=Z81WE#0*JE?[V6! QU->MT4
M>775Q;@_# K(F(67S,'_ %8^S%/F]/FXY[\4J#[9J7Q4AM@99+FW00J@R92+
M78=OKAN..]>H44 >07&J)!X?\!ZXT-_+HVG6QM=1:V65'@9H44/A<,0K*RDC
MU(Z\4_Q!%I]SX<EU[POIU[<68U6SO;^4^<SWT<39;:LGS,%^7GH<'^[7KE%
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M!LY7E$B[_+.<;0%[\K[5Z7H/ARZT?7=<U&;4(;A=5F28Q);&,Q%4" 9WMD8
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M#/NN%616,*B3ECL#9QZ@<YXNZCXFTO7_ !=X$OM-,TL4=Q<>:%MW)A+0%=K
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MFZ<]:V)=?TR*VL[@7(F2]&ZU$"F5IAC=E54$D8YST'>N&T34],LO%'Q AO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?T'PY<
M:-K.M:A+?QW U2=9VC6W*>6P4* #N.1@#MUKH*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBLC5O$^E:'=VMKJ$TT<]VVRW1+663S&ZX&Q3D^U &O165;>(M/NKT6:?;
M$N&C:54GL9XMRKC."Z $C(X'/-)I'B72M=N+NWTZ>662SD,5P&MI(Q&XZJ2R
M@9]J -:BL8^*-+:YGM[=KF[>W8I,;2UDF6-AU4LBD;AW7.1Z4A\6:*-%N=7%
MVS6%LS)/*D$C>65&6W*%R,=\CCO0!M45E#Q'IC:!_;@EF.F^5YWG?9I?]7C=
MOV[=VW'.<8JJGC/0Y+.RNHI[J6*^5FMO*L9W:55P2P4(3CYASC'- &_17,P_
M$#PY/'++'<W;113&"67^SK@)'(" 59O+PI!(R#C%7[;Q/I-WKL^B0S3-J-NH
M>6$VLJ[%/0EBN,'L<\T :]%9$?B?29O$$FA)-,=2C3S'A-K*,)G&[=MVXSWS
MBM>@ HH)P,FN7/Q!\.!+1S<7NR\8+;-_9MSB<D9 0^7\W'/% '445S<WCK08
M(1(\UV,W<=F5>RF1EE?&T,&4;<[@<G KI* "BBD9E12S$*H&22< "@!:*PH_
M%^CS0M<0RW,MHN<W<=I*T&!U(D"[2O\ M X]ZU;&^MM3L+>^LY1+;7$:RQ2#
MHRD9!H L4444 %%%% !1110 44F1N*Y&0,D53TG5(-9TZ.^MDG2)V90L\31O
M\K%3E6Y'(H NT444 %%%5[Z]ATZQGO+DN(($+N4C9R .IVJ"3^ H L453TK4
M[;6=)M-3LV9K:ZB66(LN"5(R,CM5R@ HK+/B#3QXD&@%I?[0-LUUM,+!?+!
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M%%% !12$@ DG '4FL.R\7:5?ZG:V$+3[KR)IK25H6$5PB]2C=#V/.,@@C(H
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MW!.=JNKJ2N2< @GWJO!X#:V\'ZWH<6J#S=9FN)[JY>WR TPP^Q PP/3)/XT
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M7\S.=P*],8YQVR='Q5XKUK0K;5K_ .V0^;97L2PV,,0EC:W9HUS,X&8W;<Q
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MTMHK;1#.R9VO\VQB.AP><'T->9GQGXC_ .%8P:ZL]F;_ /M,VLN8"%9/M)B
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "HY+>&8@RPQN1TW*#BI**
M 8 P!1110 4444 %%%% !1110 4444 %%%% !1110!$;:!I?-,,9DSG>5&?S
MJ6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBN<\>:MJ6A>"]3U72WMUN;2$RCSXRX('H 1S^?TH Z
M.BH;21IK*"1SEGC5C]2*FH **** "BBB@ HHK"\7ZO=Z-X;N9]-A\_4Y!Y-E
M#C.^8@XX[@ %C[*: -VBLCPMKT/B?PQIVLP8"W4(=E'\#]&7\&!'X5.^N:3'
MJ"V#ZE:+=L_EK"9E#%L9VXSUQSCK0!H45S]CXRT74->U+28;V#SK#:)"TH&Y
MB&9@ >H4 9/O[5/HE['%X<2[N]?MM3B4R%]2 2.-@'(_A.T;?NYSVH V:*HV
MVM:7>13RVVH6LJ6_$S+*/W7&?F_N\<\U7B\4:!/=6MK#K6GR7%VI:WC6X0M*
M.>5&>1P>GH: -:BJ%SK>E6=S]FN=1M89MRKL>4 [F^Z/J>P[U?H **Y3QGXF
M;0;G1+/[5%81:G=&"2_F4,L "%@.>-S$  G@<G!Q5RT?6-/U>1=1U"&YT<6I
MDCN7B$;JX89$C#Y2,'(("]_2@#?HK/\ [>T?[+;77]JV/V>Z;9;R_:$V3-G&
M$.<,<\8%56OHHO$ERTGB"V$$%ENETTA-T)#9,S-G<!@@8/'>@#:HKG]"\9:+
MK^B-JUO>P);J[*V^4 J/,9$+#JN[;D \\UKV6HV6I1O)8W4-PD;F-S$X;:P
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M2WBD2%8XD)VX!)R0"26QCC-8NG3:=?6_PC#O;3[8VC?<0WS+:]/P; ]C[UZ
MVA:^\RS-XAMFE4%5<Z6A8 ]0#NIG_".:UA!_;MGA!A!_94?RCT'S<4 >>>(I
M)TMOBE'I@+E;FR>:* _,8C''YV /50V?QK?U?7M U#Q]\/KO3]0LI8<W85XY
M%^16@PJG^[D\ 'OQ731Z!KL3EX_$%JCG@LNEH"?_ !ZF0^&M9MB#!K=G$020
M4TF-<$]3PW?% $OQ"D2/X<^)#(ZJ#IMPH+'&28V %9G@_P -:-?^&O"VJSI)
M>3VMC ]N9KEY(X7\M<E4+%01ZXX[8K3ET3Q!.H6;Q%;R*#G#Z8A&?Q:B+1/$
M$";(O$5O&N<X33$ _P#0J .>\*6FGW7C;QUM@LY;B._@>+<BML80KAAZ8;//
MK7/VTL-]\!+[2[O_ )#<!EAFMV/[_P"W><67CJ69BI![YKOX] UV%R\6OVJ.
M>"RZ6@)_\>I#X=ULW8NSKMI]I QYW]E1[\>F[=F@#E['6[;0/'>L6?C*[AMV
MO=,M!;7%TP6*5$0B9 QX_P!8S''?-0WU_IGASQ'X9D\^XT;PT^G36UG/@;(I
M#(K#<9 VT,B@@G!^G-=?/X?URZV?:-?M9MC;D\S2D;:?49;@TL^A:]=0M#<>
M(;::)NJ2:6C*?P+4 <)J3Z1H%MI.K:7?7K>'6UV6XOKZ/;(HDDB*B5?E*^6'
M."0, YQSBD\4KI3>%_$NL^'+VYU;[4]HVK7$3J\<D2. RKL 7<$^]C^$\]:[
MTZ'KY@\@^(K?R=NWR_[,3;CTQNQBDAT+7K: 00>(;:*)>!&FEHJC\ U '-:K
MKFAW_P 3? MU8ZC93(\-ZH>.53PT:;%/IGG /O6'</:?\(%\5$#0[1J=T0 1
MP3%&!C\<_C7>P>&]9MMOD:Y9Q;<[?+TF-<9QG&&[X&?I0/#>LA2!KEG@]1_9
M,?/_ (]0!SUS]BM_&GPV%OY$8:VNU'EX&5,"G'';/ZUSUQ-I5YH_B?PC-XAT
MB 76MR2?:KN\6*6,>:KOF-N2RE2JG.#@'@=?0_\ A'=:!4C7;3*_=/\ 94?'
MT^:N:B\$>,TN?L\VL>'[NRWLS7%UI?F7#[B22P)P3SZT 2>*5N+35]0U3PYJ
MEC]HM],C^W:3>@>1=6P\PJRL#E3RXSTYY]^WTN1=4\-6<AMY+1;JS1O(<_-$
M&0?*?<9Q^%8%MX-U*ULK2U76K-X[1%CA,FE1L4"C P=W'X5H?V5XE_Z&>+_P
M7+_\50!SOPI<:#X7;PIJ;I;ZEI$TJO'(=OF1L[.LJYZH=W7V-4HK-]=\=>*/
M%%H"^FQ:,VF6\R\K<R??<I_>"D;<]">G2NGNO#>LWP47>N6=P%.5$NDQOCZ9
M:IUTCQ&BA5\2PA0, #34 '_CU 'G,E_IM[\*_A_ +FVF1-2TR*=-P8 C[RM[
M@=1^=:FNK.WC;QG:Z.0+Z;PPGE)"0&:0&0#&/XL$ ?45UA\.:T4"'7;,JI)
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M?)0,< R?W-W3=_LYS[5=N[RVT^TDNKRXBM[>(;GEE<*JCU)/ KQ[0+KP]?\
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ML22)G:ZAAD$<'V- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ.IZSINBQ12:E>P
MVJS2"*/S&P7<G  '<\T 70 .@%&T>@K'TGQ;H&NW=S:Z9JMO<SVPS*B-R!_>
M&>J^XR*=9^*-%O[N"UMKY6EN$9[?*,JSJOWC&Q 5P/\ 9)H UBBLI4J"IZ@C
M@T*H50J@ #@ =JYX^._"_GB!=9MI)3.UL%CRY,BJ&*C .3@CZG@<U3TGXB:'
M?^'5UJYG:RM7F>)6FB<# D9$R<8R0N<=B<4 =:0&!# $'J#38XHX4V1(J+Z*
M,"J\NIVD%U:6TLC+-=Y\E#&V6P,GMQ@=<UF>*?%-IX6M+2:Y21WNKJ*VC5(V
M;EW )) XP"3[XP* -SRT,@DV+O P&QSCZTN!G.!FLZXU[3K5(6EF?=,ADCB2
M%WD*#JVQ06 &1DXXR*LV%_::I8Q7MA<Q7-M*,I+$VY6'UH PM&\.W=CXKU_5
M[IK62+5)(9$C4$M"8HP@Y(YR!GMCWKI6574JRAE/!!&0:RM1\3:/I,LT=[>"
M-H$62?;&SB%#D!I"H(0'!Y;'0T7OBC0].NHK:[U2VBGFC,L:%\ED SGCMZ>O
M:@#5"JJA0H"CH .!054KM*@CT(K"_P"$T\._V&=:_M2(:<LIA><JP".#C:W&
M5.<=<=1ZUI3:I9P2V<4LC))>-M@4QMESC..G!QD\XX!]* +> "3@9/6C:N ,
M# Z<5A^*_%%KX4TE;VY221I9D@B1$9LLS #) X SG]!R16!?^)#8_$:P\[59
M8]&GTF:<P2(%4.LB*"!M#$G)X.?:@#NGC1]N]%;:<C(S@TI /4 UB_\ "8>'
MO[&AU?\ M:V%A._EQREL;GSC:!USGC&,TZV\6:%>VLUS::C'<1Q7!MF\I6=C
M*!G8J@98XY^4'CF@#8P <X%(\:2+MD16'HPS65%XGT6?2Y-2CU"(VL4ODR,0
M0R29 \LJ1N#Y(&W&>1QS4-QXOT:WTG4]1\^1TTT$W4*PN)8SC< 8R PR.02,
M8YZ4 ;F >PHVKSP.>O%8NE^)[*^\.V6K2LT(N4C_ '?EN6,C*&V(N,N>>P.<
M&D;QEX=32I-2DU:".UCE,$C295DD!QL*D;@W/0C- &V%4=%'3'3M1M'H/RK+
MT_Q-HVJZG/IUCJ$,]W F]XESG;G&X'HPSQD9%)_PD^C?VA#8F^59IY#%"61@
MDKCJBN1M9A@\ YXH UJ3:OH/RKEO&GB.VTWP[K*6^I26U_;6CR"2&+S/)?:2
M@<[65,G'WL9SQ6IX7N)KSPEHMS<2-)/-8P22.W5F,:DD_4T :NT>@IOE1EBW
MEKN.,G')QTJIJNLZ=H=F;O4[R&U@R%WRMC)/0#U/L*J:;XLT#5]5GTS3]5M[
MB]@&Z2%&YQG!([,,]QF@#7:-'QO16VG(R,X-+@$YP*RF\3Z,FH0V3WRK--*8
M8BR,(Y)!U19,;2PP1M!SD54NO'?A>S%R9M:M@+:3RYMI+[&QDYP#P,C)Z#/.
M* .@VCT'Y4;5]!^54[K5["S@@FEN%*W! @$8,C3$C/R*H);CG@'CFN%T+Q$+
MVQ\:R:AXDFALK:\:""^DVQM;*8EZ#: &5B>",Y'/- 'HVU?0?E1M'H/RK#'B
M71-,@TVVN]:A,US;B2%YF >953<7(P,9 ST'/'M5G3O$>CZKIL^HV>H0R6EN
MS+/*Q*"(J,L&W8*X'//:@"G=:-JU_P"(/,NM4A.A(T<L=BEOAS(G(W29Y7<
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M2-%;$HP$KJ2"H)'4%3QUXI7U[2I/[3@_M%()+!!]K+?(;<,#M8[ACG!(/0T
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M M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBC++G&!QGD\'!QT-<7X5U#P]K5KHFG7>F:H=?TMHC)9W+7&VSDC #298[ H
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MF549!D_-M)VG( YP#6O %\)>&+JXN;W4M2@MQ).IF4RSA.H3IN;'3+<^IXH
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ML#M%"QQ@.X!5>HZGC(SC- $%MH>M3;(M<UV&^MD=7\N"Q$!D*D,N\[VR,@'
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MTBSMX[46B10(BVX;<(@  $SWQT_"KE%% !1110 4444 %%%% !1110 4444
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M@76RG:%A'<%,E@K?0$C.,XXS6)X,:>'4_&CBRN1)-J;W%N)H'C6=?*11M9@
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M !1110 4444 %%%% !1110 4454U/4[32+%KN]DV1*RJ,*69F8@*J@<EB2
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M]AF1K=M\$V0-LG&%ZCDG![$T =516=H^LP:W;S3007D AF:%ENK=H6)&.0&
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M/($&7/S$!=O0Y(YXJ&3Q]H$.A6^L2SSI:3W/V4$P/F.7?L*OQA,'/4@<<9H
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MK:QU&3X0S^!KC2[I=:CC-BJFW?R7^?Y9A+C9LQAB<YR",9P#ZTJA%"J % P
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M;,MO;0@%Y-HRQ&2  !U)('3N17-^$(+W3O$_BJUN=/ND2ZU(WD-R4_=/&T:
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M/I=K*)[6*55D0,H.V1"C#Z@\B@#)U;Q3::4MZ_V6\NTL$#WC6J*PMUQN^;+
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M>(/LK[BGVL2[NG39S^G6NCUBPN=5^(K-%;W<=K<>'9['[6;=PB2R.I )QP<
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M>,M*O]/FN8_/6:&[-E):.F)EN/\ GGMSC/?(.,9.< FN=\8:5+I.K^'M6M-
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M'/%==0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445C>)/$MCX7L8KR_2X:&6=( 88]VUF(
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M^R/,[EHL\;L%>G(R>AYKU5%*HJEBQ P6.,GWXXHR,9R,4 >5)IFI0S_$%8M
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M)LV@Y&?X3].^*U?%]I;7^@M9WNE2:G9S2HD\$0)=4S]]<$'*G!XYXXYK>HH
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MZ5')J$EW:B\CCC94Q$>C,7( R> .N0?0D9J_$K2)-,TJ_BM-0DCU&\^PJJ1
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MC,FYN,<.?< >M>B6]P+FRBN5C=1)&) C###(S@^]1RVUDEG';2QPI:J51(F
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M_4?#ITQ;MF0A9"SG[H;=C#CMVJ7PG+XD\NRTS5?"L%C/:!4GU'S8WCE"\9C
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M<5'X1F\8165CHVKZ+#:"Q18I=16Z21+A$& 40?,"V!G=C'/? KG=1\.>)O\
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M6W%-PP>>Y&:\^C\-:_=?#8>!+W3RCH$M#J*RQF!H%<$2 ;M^[8,;2OWN^.:
M+VN7=[<_%+2-->PCN;)=/N95B>4;9"3&I<@CJ 2 /1CZUV6EZ38Z+I<6F:=!
MY%G""(XU9CM!))P2<]2?I7-W6F:BOQ*TO4H--E?3;73I;1IA+'PS,I'REMQ
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MP1Z'N.:\TU#P[XLU#3_],T-;O5;;6H[K[:UW'^^@6;<JQ GY %P"IV],\DT
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M[\'.>!_*KMGI?B'P_J7BBR@TA]0T_6;B6]MKF.XC3R9)$ 9) S X! P5#?X
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M%F8*NW'4[6/7M]*R_%NJ6FG7&@1WNCK?K=:I#!#(Y7%O,<[9!G)R &Q@?B*
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M#$DD'  _A.2.,@'8T5PD7Q+AN=)T2_M]'NI/[3OOL#1^8@,,WS9&?XOND@\
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M);V5]]GC\N=F* 1H0 "@SG)).1UQCC-;.JZZMCJ=AI5O"+C4;X.T432;%5$
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M0\(C&[YN.1D^U>B44 >>P:/XDBU#0!/I<5YIMMI26SVLURJI;W2D RL.0XP
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M('0<@_B ;UOKFLR?$[4=*DCM!IMI813#_2&!"NS9<C9@M\N,9  [G)JN?B3
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MA!MC<,0/<XXJIJND>(+SQ<UXMG:W6G2V B@2YGV_89LG<^T!@Q((Y'/&,@4
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M*[UR2XURXT+3+2"[N(+=9KHSS&..-7R$0X5B6;:QQC@#/H*P_A)G_A"GW0B
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M!KUGH5C%'+J%S"]P?,<JD42$ L< DDLP 'UY&* -NJ,.M:7<ZB^GP:C:2WJ
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MC'A/EYZYYQTJEJW@34=>NO&T5RT%O:Z[#;+;2I(6:-X1P77 X+8/!/%>BT4
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M5L9!(9(BQ=F"O\H.,.RGBO3*JV&HV6J6YN+"ZBN80[1EXF# ,IPP^H(H S=
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M&3(?EC>3;', 5.20-PY&,CK3[34];G^*NI::\EL=/MK"&1(_FR [MD^[';]
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MUVLI4X_ URGA72?&6EVEGH^IW6F/IU@%2.[@+^?<1I]Q64C"<  G)R!COF@
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ML@;,8&W'7G/X5@S^"=?G\%>*]%_XERW&LZA-=0O]H<I&LC X;]WG(QV'.>U
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M.\>7SGY1@#:W'-1ZSX=UR[N/#>HP7%E<:AI=U)-.LQ:.-Q(C*0N Q 7=P#U
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M1QC[Q';#\#U'TJPWB?4=0BUJXT*TMIX=)G>V9)G8-<RQJ"ZJ1PF,[03G)!X
MYJ3Q'H6J7OB?P]K6EM:%M--PDL=RS*"LJ*NX;0<D;<XXSZBJ>G>'=;\.7VO1
MZ4+*XL-5N7O8C/,T;6TSCYP0%.Y,@$8(/;WH Z+P_K=KXD\/V6L66[[/=Q"1
M0W5>Q4^X((_"O.-%U7Q!HUIXRO-&TFSO;>UU^\FN%FN#&[J A*Q@*1G SDD>
MP->A^&="@\,>&M/T6W<O':1"/>1@N>K-CMDDG\:YVT\-Z_IT?B2PM?L#6^L7
ML]U'=M*P:#S5"D&/;\Q7&1\PSWQ0!,OCJ+4Q:IHXC#SZ?'?E[B-W"+)G8A"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7D*EHI4,7F!E4L<-C(ZD9YY'%6I=>U31O#WA!KBWLKO^T+RTM'D;<#&)%&&
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M\:L@!Y)/)[XQF@#LJ*XSQ5XKU708]8N5@LH+73[=9;?[626U [2SK'A@5V@
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M-S;*56:%3AUV$G:X/;)R#VJY9ZIXCDO-(FFTZUDTZ_C9YS"V'L?EW+N9F_>
M]#A5P: .FHK@/^$\U.XM+#5]-TJ>]TZZN%0VT5A<&9822!*),;#QABN.A^]4
MVJ>--2\O59M#L#=_V;.T'V?['/(UTR8WA9$&U""2!D-DCG% '<.ZHC.[!549
M+$X %9/_  E.A?V-)K U2V.FQR>4UT'R@;<%QGO\Q K.A\2W>L:P=+TJ%+::
M"RBN[MKV)B83*"4B* J=V 2<GC X.>.)T/7;[P[\*-1U1;"TGECUF=9H97.Q
M2]ULXX^;!;VZ4 >O45R-_P"(M<'CIO#=A96!#::;V.XGE?@^8$^8 =.O Z\<
MBJ-OX_N&\&VVI7%E$FI3:H-):-6/DK-YICWYZ[.-WKV]Z .\JE>ZQIVG75K:
MWE[##<7<@CMXG?YI&] .IK"T_P 0ZK)XYO/#=U;6;QV]LEU]KC9T+(^0!Y9#
M#(93_%TY]JS_ (DM,D_A![>)99QK\/EH[;03Y4N,G!P/P/T- '=45P]GXG\2
M_P!N:GX<O[#3EUF*R^WV$D+N8+B/=M*MG!5@V!GWSCCF?2_%UWK'A71+^U2V
M&HZC<""2!T;;$PW>:I&<Y0(QYZX'3(H ZV>>*VMY;B=UCAB0N[MT50,DG\*9
M97MMJ5C!>V<RS6TZ"2*1.C*1D$5!K-U-8Z+>W=O#%-+! \BQRN55L#."0#_*
MN5M/&%Z;'P1.+6U6+7E1)8T!'DDQ&3Y>>G&,$4 =Q5*ZUC3K*_M+"YO88KR[
M)%O SC?)@$G ZXX/-<Q/XY.EW?B\:I%']FT!()$>$$--YJ%@N"3@YPOX]JR_
M$+:RWC#P')J2V862]D8I K!H7\A_D)).\?[6%Z=.> #TBBN#U+QS?Q:/XFUB
MPM;9[;0;M[9[>?<'GV!2[!@<)][CY6SCWXL7'BG74\0Z)I,>G:>&U.SFN YN
M'8(R;3S\H.,,.V3TXZT =I17G(\:>*'\/^(+Q-/TH7/A^>:.[+22;)UC4/\
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MHBCLP=,#Y_O$8)7IUK"@\!Z]!X!TGP_]HTZ2>QU%;PR%W52JS&7;]TY))QG
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M6RMT@WP.65PHQGD#'3I6W10!P.L>#M?OK_Q6(+S3VM-<LQ!'+<!S+;8C*>6
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MF%NF5;892,B/?C:'((^4G//2K5UJUC9:A96%Q<+'=7Q=;:,@YD*+N;'T'/-
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M/ 'B>/P%?^";>[TN33&.+*[F:03)&9 ^QU"X)'/S ^G'IM7WASQ39>*)-?\
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M4C.<G.?0=^K?7;S4?$^H:%I#VL,FG6\4MS/<Q-*-\N2B!59>RY)SW Q7/R^
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M+$\G@!>AS7+^&M<N/#]CXJEN1%-?W'BEK1#%&VQI'6)0VT$M@#+;02>,9[T
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M<@CD$?3GK0!U5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX8 !4&3L P,9W=\]2:Z.LV]U[3M/U>PTNYF9+R_++;)Y;$.54L?F P, 'J:
M.1;X=2VWAVVM-,NK>VN[76/[7MT,9-O&V3^Z"@Y"8)'&.><#I5N+PEK0UK7-
M4FU.RDEU6PCM6C%NRJC*& (.[.!N/!R3ZBNUIKN(XV=L[5!)P,_I0!P[>"M3
M_P"$:\*Z2M[:;M"NK>X,A1L3>4" ,?PYSUYJ75= O;?5O$?B&2XMS!=:0;7R
M5!W($#L&W=#G<>,5LQ^+]%F\-3>((KB2338696D6!RV5;8<)C=U]JUYH+>]M
MFAN(8YH9!\T<J!E8>X- 'GOA70KSQ!\//"=IJ$ML--@AM;IA$&WS! &1"#PH
M!"Y.3G;T&>.AL?#NH:;XOUO5[>]MVM-4\J1K=XCO61(_+ WYQM. >F:Z"UL[
M:Q@$%I;PV\(Z1PH$4?@*FH \^M?AU=0^#-)TDZE"NI:/>&]LKQ(CMW[V?:Z$
M\J=Y4@'T/M6XOA^]N-:?7;Y[7^T$LFL[:*+<8X@QRS$GDDD#L, 8YSFNEK-U
MK7M.\/VB7.I3-%%)(L2L(V?+,0 /E!QDD<GB@#D8O >IQ>#?#N@K?VA?1[V&
MZ\XQMB41/N"[<\9S@G)Z?EVNI60U/2+RPD?RQ=0/"S+SMW*02/SJW1G/2@#@
MSX+UI] \,Z;-J5B[:'=V\ZNL#*)%A0HJ_>/)!R6_(5+JG@F_U34_$MQ_:,5M
M'K.GI9+Y2MOAV;L-G/.=QR...]=O6;J6O:=I%U8VU[,T<U_,(+<"-F#N>@R!
M@=#U(Z4 <W8^$M<C\1:)J]WJFG[K"S>SDAM[1E4H=I&W+<'Y>O0#H.]:7A'P
M[>^&H;VTEOH;BS>ZFGMU2$JZB1RY#DD@D$X& /\ #I** .5\1>&M0UCQ1H&K
M6]S;11Z1+)((I%8F7>NTC(^[@9]:=:>'M2M/%>O:TL]JRZG!#$D1# Q^6& )
M/?.XYX%;>K:K::)IDVHWS.MM" 7,<;2,,D 8502>2*N@Y&: /.;7X=:EIVB^
M&?L.J6R:SX>\Q()GB8PW$4GWD=<Y&1W!.,>_%I_ -YJ=SXG?6=0MGAUZW@BD
MCMH&4Q-$I"LK%CT)SR.<#ITKO** .5T#2/%EIY:ZYKEI?):J1!Y%NT33-@@-
M,V3G@] .O/.*Q_\ A -3_P"%<?\ ")_VA:;_ +3Y_P!I\ML8\_SL;<^O'7I7
MH5% ',W.@:C-XVLO$*S6H6VL9+4P$-EBY5BV[M@J.W2L/_A -4_X5XWA;^T+
M3>;S[3]I\ML8\_SL;<^O'7I7H5% '-)H%_\ \)^OB22>V$7]F_8&MU#;OO\
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MEG1TM[9\3"154GE^#QGT'OV[7..M% &5XFTRXUOPSJ6E6TL<3WMO);F20$A
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M<UV.><52TO5;36+5[BS:1HTE>$EXV0[D8JW# 'J.M '*CP9J2V/@^V%Y:?\
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M$'4=0L--TZX@MX-?N-5GTN<@$Q(T(+22*,Y/RXP,]6]!6C-XHUC2?$&K:#/
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M+$.06(XV\9^HVX= O+O6]/U?6KFVFN-.BD2V2VB*('D #R'+$YP, =LGDYX
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M"L0<RE Q&2<!5+8SSC&1G-;T/AJ^M?&5SKMOJ<?EWEK%!<PR6^69H]VUE8,
MH.[D8/MCMD1_#EW\)S:-=:HIN%U%M3M+R&#:;>8N7!VECN )(ZC@_C0!>DUS
M5=)\:6/A^]F@N(M6MYGLKGR=K1S1#+*Z@X9=I!!&#VYZUS5MXT\4GP1IGBJX
METWR3?\ V:YM4MVS*AN3#E6+?*1Q@8/3)/.!V46@7MUK5IK.JW%K+>V-O)#:
M)!$RQHTF-[G+$DD* !V&>N<C!7X>WZ_#^'PM_;%M^ZN_M/VG[(W/[_SL;=_]
MXXSGI0!Z!6'XCO[^Q^P?9I+:WM99REW=3,,Q)M)4(I/S,S;5 YZ]#45J=='C
M2<2WT4^CFT'[A;;;Y$PVX^?/S;LN<=@!ZC+?$GAV^U;5=%U/3M1BM;G2Y9'5
M)X#-%('38<J&4Y Z'/<^M ')W/CO78_A_K^KP&U-YI.J-8AIK9T\Y-Z*&*$@
MHV)!G.>1TK<37]8TOQR-*UBXLYK&YTZ6]0P0LAMS&R@J26.\8;K@<CH.E9]S
M\.=1G\/^(=(_MZ(QZOJ'V[S'L\M&Q9&8'#C/,8 Z8!/7MN7GABZO_%UEK<]Y
M;&&"RELY+80-^\60@L=V[C[O3!H XOQAJ>J^(?A0NO--##9WEQ;2+9^5DK";
MA-GSY^_]TGMR1CO7K=>;O\.-:'A"7PG%XAM_[)25'M'ELRT\:+*) C-O 8#'
M' )]JZ:W_MY?&CK+?PW&D&S^:%;79Y,P*X._))W98[>< #VR 0^-M:U+P[:6
M&IVKP#3UO(HM0\R(L4A=@I=2",8)'4'@^U4(?%UQ;>-]?T?4;J 6=G9"[MGC
M@(8@#,@8DX8KN3@#HU=3K.EV^MZ+>Z7=#,%W"\+^P88R/<=:YH_#ZVDM_#*S
M7<CW&CRF2:<_>NMRDR!O9G"MCG@8H 2ZUOQ!INJ>#[.\>S+:I(\=\JP$%6$3
M/A3N( !&.AZ>^*SM&EU6?Q%X\6[U%9X;9EB5##C"F#<H4[N -Q['/)[UT>O^
M';K5]>T+48;V&!-*G>;RWA+F4LA0C(88X)['FJJ>%+^VUSQ#>VFJ0K;ZPJLT
M,EL6:.01^7G=N&5P,XP#G'..H!R7A?6=<T+PAX"F\ZS?3+][?3WM1"WF+O1M
MLGF;NN5Z;<<]3UKUFN%'@._7PUX8T==5MO\ B17<-R)3:M^^\H$!<;_ESN.3
MDUW7;F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJ.2"&9XWEBC=HSN1F4$J?4>E244 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !37C26-HY$5T8896&01Z$4Z
MB@""VLK6R5EM;:&!6.2(HPH/Y4U=.LDNC=)9VZW!))F$2ASGKSC-6:* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J]S8VEZ%%W:P3[/N^;&&Q],U8HH
M 155$"(H55&  , "EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex31-restatedcharterasam004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex31-restatedcharterasam004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%PBD"",1E3&Q/1F8J-O7@DCB@"WX+U.9!XN?5-2EF@L=9FC66Y<8BB6.,X[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(D4:-)+(%12[<=AD9)[GU-./C;01IFFZB+N1K34IQ;VTB6\C;I2VW8<+\IW
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M(YK1O*B\OY?.$I&W[HR"#DDX'7-:/@\R67B_Q=97%K=))<:B+J)S PC:(Q(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2:1'J>GF0VTCNBF1"C91BIX/(Y4]:TZ\8T/4];T#X:6>MV=_$MI;ZK)')9F
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M&&9E)1DV@?+D$$-DXQS0!VE%>?\ AR\\6Z_>ZLQURS@BTW6)[39]@#":-57
M/S K@D'KGKD]!7/IXM\91?#;3_';ZC9RPQ8>[TX6H'FQ&4H2'SD,.V.,#G/<
M ]@HKD+75K_Q-KFOV6G:@VGQ:4T=O&Z1([22LF\LX<'Y1D# P>#STQSB>./$
M&J:+X6N;9[6SNKW56TR^C,)==ZA\LI)^[\F<=><9[T >I4C,JC+$ 9 R3W/
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MPXW&*)I#R<#ITY[G KE-,\4:IK'A?PKJ<MY#8QZA$QO7A3=.[A?E6&,JV[+
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M-WB -+@,H^0_+@=.OO7I=% 'E2PP+X)O/"C:GKTUA+$T$,DWAN\:6&(]$W;
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M\V,<#&<XYZU4\3OINIZ9_P (#)+-<ZO)##L,=NZ^6H88GWX*KMV[NO)&.^*
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M(SVZ_O2Z;#D C V] ._))JM>^ FO8?$L3ZJ57Q 5^T8MQF,*H0;/F_N@=<T
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M()[;R(UBFC:X,9W?+G=CH00!@<=SZ;XAU8:#X<U+5FC,@L[:2?9_>*J2!^-
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MVJ00 2&P7!.>&% &U17(1:G=>(/&FO:)#?3V-OI$-N,VX3?))*K/N)93PH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7RTDF "SC:#N3!.1SCGTJ[0!A6NB)=:G9:Q>:A_:,EK$Z6;!%5%#@!GX^\Q
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MP;F2-5D5B#@J%P!QVP?>H1\/[1_#&M:#<:A<RV^K7$EU))A5>.1V#$K@8QN
M."*["F12QSPI-"ZR12*&1U.0P/((/I0!#86TMI9QPSW<MW*H^>>4*&<^N%
M^@%<ZO@A(DU:TAU6Z33-5N)+BZM@J[BTG^L"R8RJMT/4CL15X>*;8^+CX:^Q
MWGV\6_VK.U/+\G=MWYW=,\8QGVK=H X?Q8VE:Q;/X#AM+@W,B0[!';NL=O&&
M!\P28VC8%R!GD@#O7:0016MO%;P((X8D"(B]%4#  _"GL=JD@%L#.!U-9'AS
MQ#;^);&XN[>WG@6"ZEM72<*&#QG:W0D=?>@"O=>%U/B1M?TZ]DL;Z: 6]SA
M\<Z#[I93_$O8@].#FJ=WX#M)]*L+""^N+=;2_&I-,%5I)[@.7WN2,<L22 !Z
M# %=910 B@A0&.3CDXQFN7/@M2_B1_[4GSKZA;C]VG[O">7\G']WCG/K74T4
M <JW@I6M_#L/]J3A=!*M;GRTS(538-_'/RG'&*V]:TFWUW0[[2;HNL%Y"T+L
MAPP##&1[TZTOY+J^OK=[&YMTM754FE "3@J#E,'D#H<XYJU%+'/"DT3J\<BA
MD=3D,#R"#0!RY\%N\N@S3:U=S3:.Y>)WCC_>$IL^8  8V\8&/7)-)-X"L;V7
MQ%_:%S-<P:\(_M,155"%%"H4(&01@'G/(%=910!S?A[PM<:,Z/?:_J.KF%=E
ML+LKB)>F?E W-CC<V3C.,9.;'B/PX/$1TW=?2VWV"\CO8_*13ND3.W.0>.3Q
M5^_OY+*6S2.PN;H7,XA9H "(003O?)'RC';UJ[0!A:QX;_MC5]'U%KZ6%]+E
M::)$12KLRE3NSSC!/3%<#)<K+XFU>9O%&L:#?R7C!;&33EGRJ@(K1EHVR&"[
M@%..?Q/K=% '(V7AV_U.ZT#6]6U&7^T-,$X11 J"59/EW.O.UB@4D C!S0_@
M&UN-.\1V5U?W$L6O.9;C"JIC? &4X]%'!STKKJ* *FFVDMC816\UY->2H,-/
M,%#.?HH 'X#_ !K 7P1%;G5H+'4KBTT[5I'ENK1%4X=QAS&Q&4W#KU]L5U5%
M '.:EX1AOKC0WM[N2RAT5P]K!$BE<A=@!SSC:<8&*Z$INC*/\P(P?>G44 <2
MGPYBC\+VOA\:W?M9VEQ'- 76,L@C?>B_=Z ]2>3ZUJ2^$XKGQ/+K=U=O,9M/
M.G2VQC41O$6+'WR23WZ5T5% '(>'O G]@210C7]3N]+MFW6FGW#*4B(^[E@-
MS!>P)P,#C@5TNI:;9ZQIMQIU_ L]I<(8Y8VZ,#_GK5JLOQ'KD/AK0+O5[BWG
MN(+5#)(D 4M@=^2!0!GZ9X9U'2[5+"'Q+>R6$8V1K+%&TR(.B^9CD#ID@GWI
M^H>$K:YU'3=3L;B2PU#3T:**9 '#QM]Y) WW@3SUSGG-;EM,+FUBG4$+*@<
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MM&WR_=.<<8/<D\8]#K$T?PU%HVKZKJ,=]=3R:G(LLT<NS:&"A05VJ". !U-
M'(:;>^+/$.AZ-XCTN<1R3R+<3QS7*_9V@).Z/:%R"!P&SG(Y-0>+=>U;2]/U
MW4[359KBYL=0B6(6JC[-;1%HU,4N[AW.YLXW$;E^Z*W],^'5EI%\YL]5U2/2
MFF,_]D^</LP<G. ,;MN>=N<'OD<5'>_#2PO;36;(ZMJD5CJMR;N2VCD0)',6
M#%U.W=R5!VDD>W3 !2\9>(+O1M9NDU.;4=.TF:V1+'5+1=\-M,=P8S  GJ5Q
MD$8]#DUHP:K+XB\:ZIHL=]-;V6FV=O(&MG"M.\P9M^[^Z !@#@DG.>*OW?A,
MW4=_ VL7YMM0A$-U$XC<,-FPL"5^5B.IZ=, 8HD\'6D6K6VJ:7<SZ;=P6JV1
M,(5EEA7[JNK Y*]CP?J.* .&G\4>(I/#6S^TWBO].\3IH\UPL2;;J/S% 9AC
M@X89"D=_6NHT>XU+3_B5J&@W&JW.H6DFF1WZ&Y";HG,K(P7:JC:< XQQ5R\\
M"Z?=:1;Z<MW>0)%?#4'EC*&2:</OWN2I!^;G  ';H,5=C\-11^+6\1F^NGNF
MM!9F([/+\L,6' 7.=Q)SF@"CXHUJXMO$7AO0+>9K?^UYYO-G4#<L<4>\JN>A
M8E1GL,XYP12L+W4;;Q_J/A.>^N)K.73EU&TN&(,L \SRV3=CYN>03D]>M;WB
M#PY:>(8K0S2S6]U93BXM;J @20N.XR""".""""*6ST%+6\N]0>[FGU*YB6%K
MMU0%$7)554# &6)Z')/.>, ',_""V:+X?64QN9Y \EP/+<C:N+B3D8&>>_-)
M=6LLOQOM?].NT3^PI)1&KC:,3Q@@ C@' SW.!SQ72>%_#</A71H]*MKRZN;:
M-F9/M&PLI9BS<JH[L:;J'AB"^\2V>NK>W=K=V\#6S"!E"S1,P;:V5)QE0<J0
M?>@#S7=J=CX5\>ZSIVL7-E+I^NWD\44*IMD9=A(?<"6!'&!C\>W6S:QJ.N^(
M[O2+4SPQVVGV\Y^S3K$Y>7>=V2#D*%&!TR3G/%7#X!M#H>N:2VJ:@;?6;B2X
MN6_=;@TF-P4[, ' [&DU/P#;WUY8:A;:QJ>GZI:6XM?MMJZ*\T0_A<%=IYYZ
M=: -7PLNMIX>MHO$4EO+JL>4FD@.5?!.T]!@XQGCK7+Z=8O_ ,+FUIOM]WA=
M-MI,;EP09)/D/R_='Y^]=OIUA%IEC':0O*ZIDF25]SNQ.2S'N22367#X7AB\
M4WFO?;[MYKN!;>2!MGE^6I) &%W=SSGO0!QBZ]JUK=^&)UU6:^-]JS6=Y<1J
M!9S*PD(6,'!^7:N&48.#EC6M:W&K^+[7Q!-IVKR:?=V6I2V5F% ,<9B(!,BX
M^?<<YST!&!GDO@^&5E!I^FV*ZWJYM]+NQ<V*F2/]SC=\@^3YA\QY;)'8CG-J
M;X?VO]O7>IV.K:II\=^P>^M+68+'<,!C<<@LI(ZE2"?44 9EO;3R?&B0OJ-P
MP&A13%4<>629B" "#A3M!]?>K'Q<C=OA_<O'<3PE+BVR(FV[PTZ*0WJ,$\5M
MS>%;5_$]MKL%U=6LT-J+-H8"HCEB5MZJP*DC!_ND>G3BK/B/0;7Q-H-SI%Y)
M+'#/M/F0D!T96#*1D$<%1VH Y'7K&=OB9X7M(M1N(W.GWH-SA6EQF/H2-H/O
M@_UJ#3-9U8^%M:MY]>\N73M>;3UOKA TTD =#M 5?FE(8J,+R<<5U'_")HVN
MZ;K$NK:A+=6$,D*%_+(D#X+EODZG Z8 QP!6=+\.;&6RO(/[4U%9+C5!JRSJ
MT8>&Y&/F7Y,8X P0: ,&34M2NK?XA:5)=:A!;V-A'<6GG.OGQ;X78C>,G!*
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M(VN&!8#L. !@?2MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKEO&VMW&E6^CV=K*8)M6
MU.&P\\ $Q*V2Q7/&["D#/<Y[4 7QXCC/C/\ X1HV<Z3?83>B=BNQD#A,#!)S
MD]P.E7=+O;B_M&FN=/GL7$KH(IBI8A6(#?*2,$#-<5!IWV+XU"..[NF23PZY
M7SI3*T9\]0<,^3[X.1G\JPIM;UX?"*ZU)-:NAJ$&KM!]H(4ET^UB/#<<#:?X
M=M 'K]%<%J!U'1]>TK0(]6O+[^V);FY9[JX$3!8T3]TCHF5!+%N!G@@$54N[
M[Q+X7LQ9:CJ,)CU'6;>TLIQ,9IK6"4G<&9E&2-I"DYZ\YQ0!Z14<$T5S;QSP
M2+)%*H='4Y#*1D$?A7%>)=&O;'0O%##7+IM/ETN22"U>5C+%(B$LPD)W;3\N
M1[]LUF:=J$UAIWP^\/0W5Q''K-MYD\QD)=4BME;RT/\ #N)'3D '&"<T >F4
M5YO?ZGJVDZ]XF\/Q:C=&W31#JMC<,1)+;,"RF/<P.X$C(W9(YYK;\"6E_)H6
MF:U?:W?7LE]IENSP3%?+1B@.Y0!G)SR2>>OT .MHKCWU&76OB'?>'GN)[>SL
M+".<K!*8GFDD8_-N7!PH X!QDG.>*Y"]\1>(5\-W]K_:TZ7>D^(HM.6[5%S<
M0M(FWS..H#8.W&>_6@#U^BL[1],FTJVFAFU.\U R3-*)+ME+(#CY!M &T8..
M.]<AIUW?^+M-\37T6I75E<V5_<6=B(9-JP^2  77HY8\D-G@X&* .OU?6+?1
MX+=I@SRW5PEM;Q+C,DC=!D\#@$D^@-9$7B^5ITL)M%N[?5I)I8H;69E591&H
M9I%DZ%,,HSC.3C'7'%:C?S>+-"^'.M73SV\][J<*R)#(54-Y<N64=B2.#Z&M
MG7-+5OBMX7C^VWH#6%W\PG.1M$0X/OW]: .H\/:_=ZYYYN= U'2EB"X-Z%'F
M-E@P !)P"O7N""*W*\YN/$FI:)K?Q#GDNI;R'2K&VN;2"7&V,M'(Q V@<9 R
M>N!UK:L-/U!3HNM1:_-) UN6OXICO2[+H"I09Q&0W3:!D'% '645YGI<_BGQ
M)X>TCQ-IM[!!/-(+B;SKY_(:'<=T1BV;1@<;OO9')JUI=OJ^L>.?$UI+XDU*
M.UTN]M'@CB\L;@T0=D;Y>5.2,#'N30!Z%17+^.M<N-$TS3DM9/)EU+4[?3_/
MP#Y*R-\SC/&0H.,\9(JA=7%[H/Q"T;2(KNZGTS6[>X5HYI6D:WEB4-O5VRP!
M!QC.,XQB@#3N?%FVYG6PTJ[U&WM+Q;*ZEML%HI"%)PG5@N]=Q'3GK@XZ"2>*
M%XDDD56E;9&"?O-@G ]\ G\*X/X:6(AN?%4OVFY<IKUU%M>4E3PGS$=V]Z=X
MTL_M/Q"\$ W-U&LD]TI$4Q4#$#'( [\XSZ<4 =)I7B./5?$&LZ.+.>";2C")
M&E*XD\Q2P*[2>,#OSSTK:KS#^S[B]\;_ !!6#5+RQ\J"R</:L%<L(&P2Q!.!
MCH.M2:5XGU37+/P?8.X,VI:4][=.)S;M,R;%VAU4D9W,QVX/ Y R" >EUD:K
MXBM-+OK;3A'-=ZE= M#9VP!D*CJYR0JJ/5B!V&357PG::[86][:ZY>0W6VY9
MK1EE,DBP'[JR,57)'/..:YGPZS-\<_& NS^^6RM!:!O^>&T;MOMOZ^] '6)X
MBVZK9:;>:9>VEQ>%Q"SA&C.U2Q^96(!P.AP?3@$UMU6O7@A@^TS('-ONE0=]
MP4]/?!8?C7FLNLZO/\*%\=V^I3+JBH;TQ;R;<QA^83'TP%XW?>R,YH ]3HKS
M>4ZMX@\?76EIK^IZ?93:+!>HD&Q7A=I&& =O3Y><Y)]<<5#:66O^(;_Q?9+X
MKU.W;3[T)9M%Y:X;RE8!\+RN3T&,Y.<\8 /3J*\O\+^,-0\73^%]-O99+;[7
MI$E_=O"QC:=UD$04,,%1PSG;CMVSFIK>O:[INB^/]*CU6Z$FAI#<65Z-IE\N
M5=WELQ!SMP1N^]CO0!ZW39)$BC:21@J("S,QP !U)KA[^UO=+M;26;Q1?2?V
MA>0F2!@"\@V'=#;[ "FXX).> I.1R:YC5KV_OOA]\0[*[N+U$TZ=UMUEFS*D
M9B5O+9P3N&6/4G(X)- 'J5WJ$L#V'V:QFO(KJ4(\D14"%"I.]LGD< <>M7Z\
M_P!7EOM'?P1%::G>""ZOXX+B)W#"13$S8)(W=5'&<>U3Z9<W?C&\\4+_ &C=
MV+:=?/868MY"GE%$4^8P'#Y9CPV1@#CJ2 =S17DNG^)M=\16OP_NFU*>QDU.
M6ZM[Q(%3:YC20;P".I*9'4#CCBNH\&7-[%XA\5:)<W]S>P:==0_9Y;E@T@62
M%7*EL#(!)Q0!V5%%>86^K:IKWPSU#QE;:G<VNHQ?:;FWB5_W4:0NX$31_=;*
MIR2,Y;@CB@#T^D)PI(!)'8=Z\S%]J_B?Q9I-M'K5_IEIJGAS[<\-OL!AD+1_
M=)7.?FZG)Z@8S7HAMY1IPMA=S"41!/M.%+Y QNY&W/?IB@!FDWD^H:7!=W-A
M-832*2UM,07CY(P<$CW_ !JY7ENE:YXAN?A=X8UCRK[5=[M)J:6LFVYEB^<9
M3!!.&V'"D$@8Z9KL?!>J6>KZ!]KL-2GOH#/( UP")8N?]4X/.5SCGM@\YS0!
MT-%<58W<_BKQ+XGL)+V[M(=+DCMK=;:4QLK,FXRG'WCDX .5PO3DUR\/B7Q#
MJVA>$I9-4FM;N;6WTN\>!$"SA/,!< C@G8./NYSP>E 'KM%4-)TV33=*2QFU
M"[OV7=_I%RX,K DD E0.@.,^U>9WVH:Y;Z'XIT*+4[^3Q%87P?3W63+S0NOF
M(,=" BR _P"Z3UH ];HKC--UE?$$$>LZ=J#6UC;Z4)"TLI:(32+N'F9/)C49
M.>N\9Z#&/I.K:A!XL\(VZ7M_<VVIV=Q]JGN6/EW;I&K"6-&.8QDG'"@@CCO0
M!Z717FVD:_<1>*K/2_$,NI:=JS7<IC9W+6>HQD/L6,CY5(!0XP#\O.2:ZOQA
M+JT/A]Y-&@>XN5EC9X(I DDL08&148]&*YQW].<4 ;U%>8KXTA_X1^XFTB^O
M1-<:K;6+6^I%EFTXR%596WAB.C$$[AEN^,5IRV'B?3;C6)O[3$&ER::[PQF[
M-S/#<KSN0R)]PCJ#G!Z8H [NBO--)T?Q#K/PZ@U>#Q1JAU>\TB)X4WJ(UFV[
M@<8SD_=.2<Y)],;'AS61XKM]!N;2XN(HX[3[1>*)3GS#F,1OGK\ZR'_MF.Q-
M '3:=>SWANQ/I\]GY%PT,9E*GSE&,2+@GY3GOSQ5VO)KK6=;C^'GCVZ76KS[
M7INJW,5O<?)O6-%CPOW< <GH :VUFU/2?'_AN!M8O+N#6+2Y-S#.5\M6C5&5
MD4 ;>I'?(ZY/- '?45Y-?ZUKMSH.K/!J%U;^+(-8^SV]C$P_U1D4*HC(*LIB
M.[>0>YSQBO58(VAMXXGFDG9%"F63&YSZG: ,_0 4 245ROC/6[C39="T^VE:
M!M6U*.T>=<9C3!9MN>C'&T'MDGJ*S+BZU'1_'9T"#4+MM/U'3);F%I'\V2TE
MC(!*LX)*D$<-G!Z4 =[6+<^(X[7Q;8>'WLY_,O()9H[C*^7A,9'7.?F'85S_
M ,-8M3U'PYI'B'4==O[N6ZL=LEM(5\G.[(<#&=V!C.>_88 C\46TEW\4O"T$
M=U+;;[&^!DAQO _=="00#[X_7F@#OJ*\RTW5M17POKMI<:_+$VGZ^VGQ7DZ^
M9/)#NC/EKM&6D(8J"!GI]1-IVHZ_)J7C?2M.:X2:UM()=-AOY1(\4DD;\%R6
MX+*" Q.,_A0!Z/17#^#-?MM4UBZM3)JMEJ$%NOVG2-39F>,[O]:C,3N4YQD'
M'3@9YTO$T\@U;1[87\R12F4O86N5GNR%&W:X(V*I.220.@)YP0#IJ*\LMO$F
MOK\,KZ[6:>2XL]6DM)K@@/-%:K/M9N.&94SSSTSVK8TQM0O/'MY!INMWTGAZ
M.P20.DB3(MRQ92@D=6)^4!\ \'&>#B@#NZ*\ATC5M:LOA:GC6[U^]N;M+>6+
MR)MOD;FG*+(PVY)7KUZ<=*Z26'Q'H>I#5Q=1OI$=G,UW:SWSSO+(J%T:+*#:
M20<@$+CH.* .ZK-\0:PGA_0;W5I+::YBM(FFDCAV[MJC)/S$#@5QVEIXIU*T
M\.:_::A JS^5-?B:]=HIX9%RRI'LVHP)&W!'3!)ZUEZE>3^+?A?XMUR6^NH2
MJWL=O!%(52.*(,NUEZ,6 ));)&[C&!0!Z?872WVG6UXJE%GB64*>H# ''ZU)
M'/%,TBQR*YB?8X!SM; .#[X(_.J&@#=X7TM<D9LHAD=1\@KR[3-4N/"O@3Q)
MJ5K=7#7)UZXLHWGD,BQ[K@)YA#=2 <Y/4CF@#V2BN'U6XOO"_B_PW';7EU<V
M&JS/9W4%S*92'V%EE4GE3P<@?+CL*V?&,NK0:"9='MY+F=)HVE@AD"2RPALR
M+&W9BN??KCG% &_17F*>,XCX?DDTB_O#+=ZS!8M!J)9)M/WA0R,7#$?=8@G=
MRW?&*T;BR\3Z6=<G_M,0:8^FO+;QF[-S/#<(,EE:1/N$=02<'IB@#O:*\TL-
M'\0ZM\.8=7M?$^J-J]WI$,L*;U$:S! P(&.K?=)).<Y],;&A:ZGB:VT;4+.:
MX2WAL?M5U&LK9+G*+$W][#))GOE!V- '9T5YII4OBGQ%H.B^)=.OK>"::1;F
MX\V^<P/ 2=\7E;-JD#@$<Y')->ET %1S3Q6Z!YI%12RH"QQ\S$*H^I) _&N;
M\0S2-XATVS%]<&)X)G.G63%)YF!4!RX(VHN3U(!) YX%<!->7VO?#_P7=ZC?
M7377_"216TCK)L+A;ET!;;P6 1>?7F@#V>L'Q)XJMO#OA^76#;RWMO%*(7^S
MLORL9/+YR1T8X.,GVK7^S#[%]F\V;&S9YF\[^F,[NN?>O%5MS'^SC/-]HGD>
M6=<^;(7 (O\ J ?7J?6@#W&BN FO]0\.?$"2W?4[R_LY]&GO9(+AE(66)UP4
MP!M!!(P*ATH>*=6T[PYXAL[^!//,4]^);UVAFA<99%BV;489 7!SQR3UH ]%
MHKF?B%=7ECX!UJ]L+R6TNK>V>6.6+;G('3D'].?>L*\FU31(M'4:S=W<WB"Z
MAA?[3(J)!B)W81$*2N\J%YR?0YYH ]#HKS?5K_Q+X+TO7;ZXNK>2RE,"Z=%-
M<M<26TCNL;%F9060%PW)/3'>KNII=Z/X\\(V<&JZA);Z@UTMY'-.6$Q2!F5O
M]GDYPN!TXXH [NBO*9]9U5/AMXWNUU*Z%UI>J7D5I/YGSQI&P"KGN ">N:W)
MM1U#6O$\^APNRQVNFP7!V7C6SN\A8%]RJ20NT<<#+'(/& #NJCEGB@V>;(J;
MW"+D_>8] />O.[RZ\6:'H>C-K<<VKQVS3)JC:/*1,5X\I\#:QP"=P&.<'I6?
MJ$EMK<G@"[L];O;VVGU*95G$K(Q&R4C<.,.OW<X['IF@#UBBD1=B*N2<#&2<
MDTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !63XC\.6'BC23I^H"4()%EBEA?9)#(O*NC=F
M%:U% ',V?@R*VUZ+6YM8U2[U".T-H)9I$ *%MW*J@&<X[=N<U6;X=Z<WAB;P
M^=2U+[%-=?:G.^/?OW^9UV=-XS_]:NOKFI/%<LEU,--TB?4+2VOA874L,@WQ
MOQN8(1\RJ6 )R",'@@9H F\1^$;'Q/8VL%[<7<=S:2"6VOK:01SQ/C&Y6 QS
MW&,>U5YO NEWOARXT;49[V_%PP>2[N9]TY=?NL&  7;V  '7CDYZ*6XAADAC
MDD57G<I$I/+L%+8'X*Q_"LC1_$:ZOKVMZ5]BEMY-*>)':1E/F;UW C!.!C'?
MOVH BT_PA:VFG7=I>:AJ6J&Z@:VDGOY][B(@@JN  !SR0,GC).!5?_A ]._L
M/3M-:]U!WTV1)+*]:53/ 5&U=IV[<;1C!4@]\GFNIHH P6\*VTL&I">\NY;O
M48!;W%XVP2>4 0$4!=JCYFZ+U)/6K^BZ5'H>C6FEP3S306L2PQ-,5+!%&%!(
M S@#TJKJGB.VT[4K;2HH9KW5+E#)':6^-PC'!=BQ 5<\9)Y/ !--3Q!+'JUE
MIE[I5U;37A<12;E>([5+$;@<@X'0@9[9P: #4?#%M?:Y;ZU!=7-CJ<,1@^T6
MQ7,D1.=CAU8$9Y'&0>]4[WP-IM[HRZ8;F\AC^V"^EEB9/,FGW;M[DJ>=P'
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M$%Q#=1&2"19$#,FY3D;E8JP_ @C\* 'H@CC5 20H !8DG\2>33J** "BBB@
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MY]KNXUBE4LA0HN=H V\8R??GFJ:^ ]&;1M6TFY-Q=V>JW#W5PD[C/FL02ZD
M%3D ^@QQ0!G>(OMW@W3]=URSU:>>W33BT.GW3M-LF4_ZT.[%MN",KT[TZTTK
MQ FM:7J%OJD<>G21,EXLFHR7/VG<OR/&'C"HP//RX!!QBM72O!VGZ;97%M/<
MW^J">$V[OJ5P9V\H]4&< *>^!SQG.!5?0/ >G>'9%-I?:K+'$&%K!=79ECM<
M@C]VIX!P2,G/!/J: ,;X=VFH:G9QZQ?Z_JMQ);7MY (&F'E2()&4;UQR1C(/
M&.*]"KG]/\*VNB^'[_2K2YU!X+GS7.)5$JM)DL4; P222,\ ^E6O#.F7&C>'
MK6PN;F:XDAW /-)YCA2Q*JS?Q%5(7/?% '#VFF:OXDU?QC8GQ1J]M]BO%2S:
M"8)L8PJPS@<J"?NC ZYR<$)X?UZ^\2Z+X5N+Z^NGNKFQF>;3K)C#)<,K!!,T
MBLNQ!@GJ 2PP"<"K/A[29K_Q9XS:275[""\NDVE83$D\8B5259TX.=PRI!_0
MUT=QX)TF6^TV[MC=6$FGV_V2(64QB#0<?NVQSMX!XP?>@#@DUG7+KX:>&;LZ
MQ=Q7KZZEE+,K F1/M+1@.<?-PH^O?.:T=7\-I8_$#P9;2:KJ]X)IK]C)<7S[
MU'DDA5*D8 R??'!.*Z!/ASH\6DPZ9#=:C':P7OVZ-1.#LD#EUQD' #$G'?/.
M:UM8\,V>MW&FW-S-=1W.GNSPSP2^6_S+M8$CLPZXQ[8H XIX=1U'7O'UG)X@
MU:.#3U@>U$,_EF-FM]_4 <;NPP#WSQ3],\1ZIKD?A'3I'#27^BF_N#]J>V,\
M@\L8#HI8?>9B!C/'.!@]7'X1M(KS6;J.]O1+K"JMT=R'A5V+M^7C"\?_ %^:
MHW?PZT:[T32]-,]_$VE<6-Y#/Y=Q;C&,*X'3  Y!Z4 <SKL7BC0O"J17.OL)
MQKD"6[P3F1UMY)% CE9E#.1D\]QUS7H>CZ4VD6TL#:C?7WF3-*)+V42,F<?*
M#@?*,<#WK*N? ^G7>BPZ9+=Z@8X[A;IYFGW332J05=W8$DC ]!P!T %2Z[H5
MQJ6HZ)<07E]%+83B1GCG"1NF5WB1!]\L 5&!@;B?8@#?'6M3^'_"-W?VS+'*
M'BB$C' C\R14+DX/0,3T/3H:SH-&\06NO&<:F+;2[BU:*2W;4)+F3S@"5DB,
MB?*< Y XQSCBNIU33+/6=,N=-U"!9[2Y0QRQM_$#_(^]8FB>"++0HG2#4M6N
M6\HPP/=W7G&V0]HP1A>@YP3P* //[6\UG_A77A#Q'_PD&IG49[VW@EW39C=)
M)2C!D/#<'.3D^F!Q73VRWVG?$34M#CUC49;2XT07P,\WF-%,)2A*;AA01V Q
M[5JCP#IB^'-/T%;N_6QL)UG@ D3<K*VY<G;R >?YYJU=:!;6^M3>)'N;V2\6
MR-H54!E:+.[;L5<D[N>.?PXH \T^T^(+7X4Z/XYC\1:G-J-N(9);:27,$\;2
MA"C)CDG=G<23Z8XQU-U?'3/B?XCU 1F0VOAN.81C^+;)*V/TJ/X=^&!-X T*
MVU8ZD!:[9'TZ[C\M$E5BPR"H<@'# $E<X]!CK4\-VJ>)KC7O/N&NI[<6TD;%
M3&8P20N-O8DGKGF@#A-1U34[+X5Z=XYMM3NI=46.WN[B,S,89Q(RAXO+SM4#
M?@$ $;1SG-:][JC^$_'[SZI?73:+JEF\D FF9DMIX@7= ,X^9.1[J0*U[/P/
MI=E;1V,<UVVE13BXBTUW4P1N&WC'R[BH;D*6(SVJGJP3Q=K4.B3Z%?+;:;?1
MW4MY=P!87V#<OE-GYR6(!XZ;L]L@&=+=:K97/AG0I993<:L+F[N5FO9(V!4*
MP@60!F 4/VP3Y?7DY@O+GQ'X6L/L5YJ,$J:CK$%O:%KMWEMH9=V5:5DW<E"J
ML02-Q[@5U_B;PKIOBJT@AO\ SXY+>036]S;2&.:!_P"\C#I5:3P/H]SX<N-$
MOS=7\-R0TUQ=SM).[#&UM_4$8&,8 ].30!%H.F:YIOB6\:ZO8CI-Q &ALWO9
M+F6.52 S*TB@["",C)P<>M1:YJDTWCW1/#7G2P6MS;3W<S1.4:4I@*@88(')
M8X()P.V<Z?A_PQ;>'U<I?:C?S,H3S]0N3,ZH/X5)X ^@YXSG J36O#MEK<UE
M<S/-!>V,ADM;NW8+)$2,,!D$$$<$$$&@#SS7=6UG2[+Q]H\.J7HCTNTBO;&Z
M\S=-$)%),;.<D@%3@D[L=Z[[PWI<UE UY/JU_?27L<3LES(&2)@O/EC'R@YY
M&3T%177@[3[W2=2L+B:Z<ZH1]MN-RB6< ;0"=N     H&/Q.=JRM1964-J)9
M)5A0('E(+$#IG  H X6TTV.3XS:VPN+Q&_LJWD!6Y? 8O(.A.,<?=(QGMR:R
M/#]OJ>H?#RZ\0W?B369+NVAU%8T6YVH=KR!2P R2I7(.?;IQ7?7'ABRG\2?V
M\L]W!>FW%N_DR[4=02R[EQ@D$DCMZ@TFB^%K#0]$FT>&2XGLI3(6CN&#??)+
MC( X)8G\: .1;5-0_LOX:W?VZY\Z_DMX[L^:<3AK=G.X="=P!S39M;N=.\5?
M8_$+:G9?:-4']GZE#,S6<\>\;8'4':C8&TY')R<UMV_PXTF"'2X7OM6F32YA
M+9B2[/[H!2H08 ^4 _7@<X%:#>$;.0M'/>7L]F;TWWV25U,8E\SS!CY=V _.
MW=B@#B+2<^';KXEZU;-<RW%A+YD22W$CJ6^SJPW M@@$]^@X&*WK'3_$":EH
MVL0:E$+!H_\ 34EU&2X%VKJ-K(K(%1L\C;@'.,5N)X2TQ-9U/4OW['4U"W5L
MTI,$AV;,E/4KQZ>U4_#_ ("TOPW<(]I=ZG-!"2;:TN;MI(;;.1^[0]."1DY(
MR?6@#F=)D\2^)_#6D^)M/U""UN))1<S22:C*83%N.^)H=FP  8SU!&<YS76^
M.]=N/#/@?5M8M$#W%M!F($9 8D*"1W )S^%5++X=:-I^K2WEI/J,5M+-]H?3
M4NF%H9,YW>7]><9QP.*Z:]L[;4;&>RO(5FMIT,<L;CAE(P0: .'UV6]\,7'A
M;4+#4;R[2]U"&PO(IYVE2=90?W@!)",",_+@8)'2F^&]-A3XK^+W$UV3#'8L
MH-U(02R29W#=\P] <@=JZ'3_  C9V'V!'N[V\ATXYLH;J166W.TJ",*"Q"D@
M%BQ /%26GAFWL=>U'6HKN]:ZU!46X5G7:P0$( -HQ@$]"/?- &Y7$V5U)XH\
M7^*--N+N[MH-*,$$$=K<-"P+Q[S(2I!)). #D87IR:V/".BSZ#H[6<UU=SJ9
MF>+[9/YTL:'&%9^YR">.!NQSC-.NO"]K-KCZS:W5W87\L0AGEM67$Z#[H=65
M@2.Q !'3- 'G::_K^I>'O#!FU:Y@NQXC.DW,\ 51<HID&\C'4[1[9!X[5ZCH
M^F'2-.2S-_>WVUF837LOF2'))P6P,@9P/85EW7@K2[BRTJSBDN;6#2[@75LL
M+C_6C/SL6!+'+,3GKDYS71@8 &<^] 'E4NHZLGA'XCR#6;[S]-O)_LTV\;XU
M6%&"CC &2>@%7X7U#3/%W@M_[8O[E-8MYDO(9Y=T9*P"12J]%((ZCDCJ3UK?
M/@;3VL-;LVO+\PZU(TEX-Z99F 5L?+QD #CTJ=_"5K)>:+=/>WIET=66U.Y,
M89=IW?+SE>/_ *_- #O&-PUMX=D*ZH=-9Y8HQ,D9=VRZ@H@'.]AE1CD$YK%\
M)WU]_P )UXCTN8WB6<-O:SP6]W<><\1<.&^8LW7:#C<0*Z/Q#X?LO$NE_8+X
MS(BRI-'+ ^R2*1#E64]B#573?"-AI>O2ZS%<7\MY- D,S37+,)-N<,P[GYC[
M#L!0!0\;7>JV$NFW=K8WM_ID9E-_;:?,8[C&%V.H4@L%^;*@_P 0]*P+_6C-
MX:\'W^BZ]?3VMSKT$#NS$/+&TK9CDS\V1@*>><5W>H:.+^^M+U+Z[M+BV21$
M:W9<,K[=P965@?N+VXK,G\#Z7-IUA9++=0Q65[]O0QNNY[C<7\QB5.3N8G'3
MGITH Q(K:]U?XA^*-)GUS5(K*.UM9(D@G\LQE_,SM*C(Z#IR<#.:YNVU+66^
M&_AKQ7+KFH/J'VV"!T\W$4L9G\HAT'#$CDL<G/0BO28/#,%MKM_K,5[>+>7T
M212G*%=J9VX&WC&3^?.:SA\/]+7PQ:^'5N[\:?:S":)?,3<&#[Q\VW) ;G_Z
MU $4-U>I\8;BP:^N'LFT-;E;=F^1)#.5) 'L!UR>M<WH-P;?P'?;=3?3S+XC
MN(]T2%I9@;DYBCQR'89 (Z9SQU'=KX:MU\3'7_MEV;XV@LSDIL\L'=C&WKN.
M<_TXK,/P\TEM%;2S<W_E_;O[0CE$P$D-QN+%T8+P<D]<CF@#GK?4=467XA6(
MNK^TCL+.&YLUEN!-+;L\+L1O);J4!QDXR<&NA\!V%T=!TS6KS6=1O9[[3+9I
M(KB4-$K; =RKC(8YP3GGJ>:D7P'IBW&J7"W>I>=JENMO=N;DMYB@%<\@C=AB
M/;/&*V]'TN+1=(M=,MY9I(+6-8HC,06"*,*,@#. ,4 <X;M_$'CG6]"FN[FV
MM].LX&B2VG:%I'EWEI"RD$[<* ,XR3G/&*\Z7MJWA[2KWQ#<:G<K'.L\-FIA
MFO67 #EU<>6J9.<MR2._%:NN^"=.US5[?5C<W]AJ,,?D_:M/N#"[QYSL8X.1
MFENO!.EW%UIES%)>VD^G(\44EM<,K.C<LKL<ELD9)ZYYSF@#@?[:UV7X=:=.
M-7NX;N/Q"+$R[PS/']I* .V,M@<=1GOFMICJ?A7X@Q6']OWEUINIZ=<3NVHR
M"3[)+%@^8#P F&'R\#],5O&'A*VT7PQ!I^DQ:K.MSK<%W(L7FSM$OF[G*[0=
MH&2<]?<UVB^&;&Y>YN+Z2XOY;NT-HTESM4B!OO( JJ%SG)XR<#)X& #B]*U+
M4+?Q1X+2.^U"XMM3M[A;JXN96V7I6(.)4B8GRQGD<+P<8QBKNBM?>,?"O]O1
M:]<:;J'VV5PP=C#!'',R^4T6X*P*+R6YRV?05K6GP\TJU?2)/MNJRR:26%HT
MMXQ*(5V[.,?+CCC!]2:6/X>Z/!K-SJ$$^H0PW4WGW&GQ73+:S2=V:,=<]QG!
M[B@"LDEU/\5=4TJ:_NWL)-%CF6$2E!&S2LI*E<$'"CGK[URWAC1M1N?@;:W&
MB7]_#JJQR3Q!+J3$A25R8]N<#<,CC')!KT:/P[;1^*9?$(N+DWDEN+5D++Y?
ME@E@N-N>"2<YS65%:6/P[TA(]/L-;U&WEN-B6]L#<& ,6;A<C:@)//7D9]@!
MN@ZS#XMU'3M1TZXG73X+$2RH)FPTLGW4<9Y*!6SGNRUU]87A+1(]#T9HQ:QV
MT]W<2WEQ$G(221BQ7(Z[1A>/[M;M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117*_$.VU"
M3PA=7FE7%U#>V&+I%MYWC\U4(9XVVD9#*"/KB@#JJI:C=7MM]D^Q:>;SS;A(
MYL3+'Y,9SNDY^]CCY1R<UYVWBV"T\<V>N"[O'\-:A8F,%KES$ET(_.&$SCF,
MX_W@1P0:MZ_%J6CZ7X/)U&_CN;C7;9;M/M3L&$A9FC))R5& H'3 ]S0!WSWD
M0GEMHR);J.(2F!2 VTDA3SP,E2/P-9GA+Q"/%7AJVU@6K6HG:1?)9]Y79(R=
M<#KMS^-<WH>GP#XP^*I0]QN6VLI /M,F"6$F<C=@CT!X'8"N.TE+G3/A5H>O
M6FI7\5S!JH18DN&6$QO>,C(T8^5@03R03Z'% 'N%%%<QXKF']H:):_;KE#-/
M(?[/M<K)>A8SQO#+L520Q).#@#N!0!T]%>-7VIZNOPK\6O\ VE>P7.F:U);6
M[I=,SQQB6,!#(?F8 .PR:Z65[GP]\2H(HK_4+NWO-)N+B>"XN&D5I(V3#(IX
M0D$C"@#VH ] J![R%+DVH8-<^491"#\Q4'&?;DXYKRV74=0G^#\?CB#5+I=9
M2/[<6$[^2V)/FB,6=FS&5QC/&<YYK4TNTBN?C'>73BYCD?1+:X*?:9  YD?@
MC=@CC[O3VH ZGPIXB_X2?1WO_L;6A6YFMS$T@<@QN5)R![5N5X>B7.G?##4O
M$%IJ5_!>6.M3/ D5PR18-YM8,@X<$$_>S[8KL[R>_P#$?BWQ%HD;E5T^&!(0
MFHRVK(9$+&4>6IW') Y.!MZ<G(!WM%>775KK?]O^"=(U'Q%=22W,%]!?2V,Y
MC68QH #QT89()Z@YQ@XKNY0WASPI,8I+B];3[-F5[F3?)*44D;F[DXZT :U%
M<-H%E-JVA>&?$:^(;N.XD6*XO"96>*Y\Q?FBV%MJ?,0!@9&,=:S+&YN_%/@O
MQ!KIU&]M-2@N;L6WDW#HMKY).Q"@.UN%!;<#G<?; !Z917E,5YJ7BG7/"'VC
M4M1L8M7T.:>ZAM)S$-X6/#+C[I^8D'KBK5IHMSJ'CC7O#\_B+7?L%KI]F8]E
MZ5DW$.-V\<YXR<=3USTH ],HKR#0/$NL7*>&/#NIWT[B?5+ZSN+Y7*27"6P.
MP;QR"QP"0<G:>>36I?W&H:3XE\2Z!;W]Z;!M!;5+=VG9I+64,R%5=B6P=N[!
M/&#C% 'I='2O+[&UD@^'^D:S=>*=8CNM2M+&)P9FE\UF*G9$N05D<';N!SSD
M\Y-)')=3W/Q"TBZ:\CLH=/AG@MI+QY&A+Q2%AO#9&2@)4,1U[$T =]<ZG.^F
M6M[H]F-32X>(C;,(QY3$9D!;J #G'4UIUY+(LVF?"?P7<6-]?0/+-I@D"W3D
M.K[ R\DX7'\(P/:NDM;EO$GCSQ-I%Y/=16VE16T<$5O</"294+M(2A!)Z =A
MM]Z .VHKQP:QKEYH6AQ3ZM>QW-MXL_L>2YB?:;F)6<;F&,,> .1C*\CDUUGA
MCS].^(7B/11?7ES8I;6MU$EW<-,8W?>&VLQ) .T''3TH [>BBO+K/1[_ ,1W
M_C.TD\2:S;_8K_;9M#=LGE-Y*L"<=5!/W>G7OS0!ZC17E^@:S>>)=*\*RWU[
M=37MQILLLNFVK&$S$,$%Q)(K+M48Z<Y+Y .*S(M4UB\^&O@^Z?6+Z.\DUZ*S
MEF28[I$^TNF'/\?"CKUQSUH ]=FNH+>6WBEE5)+AS'$IZNP4L0/P5C^%35YA
MK'AFVL/'W@JV-_JMR)9K]C)<:A*SJ/)+;58," ">W.."32-9W6I>(/']I-K>
MKI!8I ]LL-X\?E,T!?(*D' ;G'0]P>, 'J%%>8:7XAU/6H_!VFSR"1K_ $4W
MLQ:[>V-Q*HC&-Z*3T+L0,9_#!@UVT\0Z'X<M[>?Q!-YO_"06Z0&"Y9WBMY9%
MQ%([ &3'/+=1UH ]6K"UCQ&=)\0Z'I1L7E7597B%QY@ C*H7Z=3T]NO6N:UV
MQU/PRUG)9KK.NZ2K3RWMLM^QND+E-KIR&=5PX"9_BSV&,R\GM-:D^'4NG:G=
MSVTUY<A+IR?.QY,@(8MD[A@J3UR,T >H74DL5I-)!#Y\R(S1Q;@OF,!PN3P,
MGC-,L9KBXT^WFN[7[+<R1JTMOO#^4Q'*[AP<'C(KSRRDO+./XB:/'J>H-#IB
MK+9RRW+22Q%[82$!V); ;IS503ZE>0_#",:SJ$/]HVA6[,<YS+BTW9.>K9SR
M>AYZB@#U:BN#\("_T?QWX@\./J%Y?Z;%!!>6SWDIEDA+[@R%SR1E<C/I]:[R
M@"E975[/=WT=UIQM8890MO+YRO\ :$V@EL#E>21@^E7:\GOO$FJ>'=(^(][#
M=W%S+I]W$EJ9W,GD[TC&0#Q@%RV.G%;6O_:?#&J>%;W2[Z\N(K[4(]/NXI[E
MYEG212?,PQ(#+MSE<<<=* .QL[J]GOKZ*YT\V]O"ZK;S^<K_ &A2H);:.5P<
MC!],U=KS$W.H+%\38AJE]FQ&^U?SSNA_T;S,*?X1N/:H[0WNGW/P\U%=6U&:
M75$6&\2>Y9XY5-L7'R?=!! Y R>Y- 'ID5U!/-/#%*KR6[!)5'\#%0P!_ @_
MC4U<!\/-/@@USQC(CW!,>M2( ]S(P(,49R06()]SS[U:^(3W6DPZ;XE@NKQ+
M;3;N,ZA;Q3NJ2VS':Q*@X)4D-] <\4 =K17G_B/6[C3]"UKQ):74BQ27$%E;
MLT[>5''YJQR2@'*J=S/\V#PJGG)S;@T/6;77FN/[2^RZ9<VC0R6@U&6Y=I1D
MK)&TB@JV <XZCGK0!VM0K=0/=RVBRJ9XD21XQU56+!2?KL;\J\?TRXU*+P/X
M&\1MK6J2W]SJ5K;S^9=,8Y(I)"K*R9PW'.X@G/?I6_HVEP-\2?';>;>*4CLV
M!2\E7EHG)Z-S[9Z=L4 >CT5Y+;:KJ4OPU\ ZB^I7AO+C5+.*>7[0^9D>0AE?
MGY@0.^:U;33;K6OB+XKL9]<U>*TLS83PQ0710*Q5V(_W3CE>ASST& #T6BO+
M;-M?\7>&6UNPU&.POTO)7%R^H2A(%CE(,;P!=FW8N#D\YW9KU$<@'C\* (KB
MZ@M?*\^54\V01)G^)CT J:N!^(-C#=>(_!;2-."VJF,^7.\?!BD/&TC!X'(Y
M]ZK#2[C6/B-X@TF37=9@LH+2SFB2WO&0HQ+]#Z?+R.^><X% 'H]%>6B]OAX+
M^([?VC?>9IU[=_9)/M4F^$)"C*%;.< DG&<5/K.IZI8V^E:G=VNI:CHATF+[
M4=.NF6XMI2,F8JK N"._;:3W.0#T62Z@AN(;>255FG+>6AZM@9./H*FKR_[/
M8ZE\0/!5U!?75W#/HT[+<K<RH90HBPV PQG))'?OG%=/\1-=NO#G@?4-2LV\
MN=3'$LN,^5O=4+\^@8GZXH ZFBN#UT77AGQ-X8?3;R]DM]1NC87=O-<O,'!0
ML)!O)VLNTDD8R.M5O ^G7.IW^K7MYKFKRG3=>NX8(3='RVC&%"NO\0YX],<8
MYR >BT5R/B[59X?$?A;0TED@MM5N91<2Q.48K'&6"!ARNYL<C!P".]8.J&YL
M_$GB3PR;F[GTFX\/OJ,8DN'9K>0,4*J^=VUL9P3C@CID4 =3K7BV+2X-#N;:
MV-[:ZM>P6D<Z2!502GA_4C'/3\171UX]-9K'\,OARL,TZ-/J6EL7:5I"A*=5
M#DA0.P Q[5H76J7WA'6/&L5G=WEW#::/'J%O'>3O/Y<I\P$@L2=IV@D=..U
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M?))A0@@J6QRV1@ YXKBWOM4BT?XE6OVR]M?[,C$]F/M3226Y:V\S:)#SC/.
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M;;L@F-&)"G!(SR>3ZFM/0?#UGX=M[B"Q><QSSO<.)I-_[QCEB/3)YQTK6HH
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M-6T\-?>1JTADO-UT[&0D 'DDXS@9(Y..M7/^$5LO[3TS43/=M<Z;$T-LQD&
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MC6)E& 0%(!P..: //O&][/'HWB[5-,O[RYN;"X3;="8PI8LOEYAC )WGG+<
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M)&81QCK)(7./=F))_$UY3#>7,$W@[4+*^O+J*\U=H)=2FE9#?(ZR'_4Y("#
MVYQC:,#!S7K"Q@1"-B77&#OYS]:Y6+X;>&H;:UMDM[OR;2X%Q;(;V;$#<\)\
MWRK\QR!U[]!0!RTNGOJ%[\1(I]3U7R[ H]HJ7TJ^4WV8.""&S@,<A2=OM4M]
M>7T'A/P;XYEN[R1;:"V?584G<)-%)& TA0'!*,P;IZYZ5V:>$-*C?5G47(;5
MAB\/VA_WGR[>.?E^7CC'%9>IVTVGZ7%X.TC0[NXLKBR:V2[D=7@MD(V8<LVX
MX7D#!SP/7 !I>'?]/N]2UM9I7M[J;RK5?-9H_*C^7>JYP-S!CD=5VUFZ^J7W
MBU;!;BXNY5TYF.G)(88HMSX$[R YSP54 ,>I&.375V-G!IUA;V-J@CM[>)8H
MD'\*J, ?D*R]0\)Z3J6MQ:Q<13"\2'[.S17#QB6+.=CA2 RY.<&@#@O#WB&]
MU'1OAWI^I7LQCU:*X-U,9"KSM$OR(7'/.<GG+;<<Y.9/B%H,6F_#_783J=S=
M1_;;:Y@MY)6/V17GC7:#G)7[V >G;UKJF^'7AI_#D.A&SE^QP2^= ?M#^9"^
M<@H^<KC/0'%6SX-T5_#ESH4L$LUG<D-.TL[O+*P((9I"=Q8%5P<\8':@#%UR
M-].\?^![>UNKQ+>62\22%KF1TD @9AN#$Y()."?Z"L_3&E\7:#XIO[F\NK>_
MMK^ZM[9HIWC-F(AA  "!GHQR/FSSQ@5UK^$]+DN]+NG^U-/I>XVKM=2$J6&&
M+$GYB0<$MFFS^#])GO;VZ5;B$WX O8H)V2.XXQEE!ZXX)&"1US0!P>G7VH>)
M-8\"3W]Y?6_]J:3<R7D,%P\2R%53#  _+G<3E<'GK73?#J29(/$6GO<3S0:?
MK4]M;>?*TC)$%1@NYB20"QZFMV;PSIDVL6&J>7(ES81F*V\N5E2-" "H0';@
M@#MV%/T?P_8:'+>R60F#7TYN+CS)F??(< MR>#@#IZ4 <OXGQ>Z]J5M#=7-W
M-!I6XV<<IABLR2Q$S.ISO;&% !(V]@:Q;J]N=2\$?#&\O)6FN9M6L'DD8Y+M
MY4F2?<UW-]X/T;4=:?5KB&;[3+!]GF\NX=$GC&<+(JD!@,GK5=/ >A1Z9IFG
M)'="VTR=;BU7[5)E)%X5LYR< X / '&* ,.\NY+#XH^(+R*/S)+?PU'*B?WB
MLDI _2J^BV.J:MIOAGQ);:S% S&&:[F-S)(+M7 #Q,APH)8X&/ND8 KM(_#N
MGQ^(9==43&_EA%N[F9BIC!R%VYQC))Z=ZS-)^'WAW1-4-]86LT7[PRI;_:',
M$;GJRQD[0?PX[8H Y#5CK-[8>,+;=J)\0QZAMTI[1I $B(0Q*K+\JC!.\''7
M+=JUI#=7?C ^%I9?,BMM)BN%BGO)5,K.[AWW#YFV[5 R>,_ECQ:%YVI7SZCH
M/BNTU.XNY97;2KYDMI,L=K*PD"CY0N=P!SGZ5U=QX$L-:TW2O[=:YEU2QCVI
M?0W+1SJ#U4R+@MQP3WY/&: ,".75--U/PGX.U36FO5N9KLW%U&[*\JQ(&2%G
MSDGYAGN0H!ZFK_A"RBT_XG>-X(#)Y?E:>RJ\A?;E). 22<>@[?2MZ_\ !>AZ
MAI%GILEJ\<5E();66*9DEADSG>L@.[<2222>3R<U+I7A32]'U6ZU.V%TU[=(
MB3RS74DAD"C R&.">3SVSQ@4 <WXSTZWN_B/X',OFYDDNT)2=TX$!/&TC'/<
M=>]+HP/C&_\ %D5_<W4,ECJ#6-JL,[QFW147;(NTCYF8LV3UP!T&*ZG6?#NG
M:])92WT<OFV4IE@DAG>)T)&#\R$'!!P14%QX3TN;4Y]0C%Q:W%S&L5R;6=HA
M.BC"A@#U X##! XS0!2^'.L7^O> =*U'4SNO)$99'QCS-KL@?\0H/XUP]QIP
MN=-^)EZ+N]@FLKR:>W-O<O$$D2W1@QVD;N0.&R/;K7K=K:P6-I#:6L*0V\*"
M..-!A54#  %8J^#-(6VU:W"W7E:NS->@W+_O2PVGOQD<<8XH Y_[0=;O=#BF
MN;B\NI]%6>33DD,,:E]O^D22 Y'.5  8\D@<$U@PRZOJ7P5T7Q&M[?3:EIF+
MJ4)<NINH8Y2'1\$;LHO4\Y'N:[L^!M#^U6%R([I9K*V%I&Z7<BEX <B-\-\Z
M@]CFKVA^'-+\.Z3_ &9IT#)9Y8^7)(T@ 8DD#<3@<GCIR?4T <MK&O,WA_7_
M !AI$TDD-MI^RQ(=C&S;=S2[,[3C<HZ<&-O6IM/T:^36=%UJTU>**R>,K/']
MJEG%^KKE#\W 8'YLCG&>U=1I^B:=IFAQ:+:VJ+I\<1A$##<I0]0<]<Y.?7-9
M6@> ]!\-77GZ;#<+MW>3'+<R21P ]?+5B0N?4<]LT 9OQ44OX4M55V0MJMD
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MBF91&2,,< _,2"02<YS4^G>'K#2]4U#4;83"YU!E:Y9YF8.5&%."<# XX[4
M8.HWSZA\4+7PW<O(FGII#WWEHY03RF4)@D$9"KDX]6R>@KB_$-[JEEX6^(&E
M)J-\(M&N+=K"Y%PXD190K&(OG+!0V.2>&^E>I:KX>L-8N;2[G62.\LV+6]S!
M(4DCR,, 1U!'4'(/I5:\\':-?:'<Z/<0RM:7<GFW.)W#SOD'+N#D]!W[ =!B
M@"UH^B1:.UT\=W>W#74@ED-U<-)AL8.T'[H/7 X],# KF-*;_A+?$7BVTU&>
MYC&GW*6EM%#.\1A3RP?,&TCYF8DAO0 5V\$0@@2)6=@@P&=BS'ZD]:R;KPOI
MUSJTFJ(;FUO9HA#/+:SM$9D'0/@\D=CU'8T >;66JZOK&B>!+B]U&\2YEU:6
MQGEAF9!<H@E 8J."3L'..N2*V-+T..Z\8^+?#\NH:J=+MX[6>&#^T)<H\B/N
M._=OQE0<%L9[=,=?<^$M'N4TM/(DBCTI@]FD$K1K$P& < \\$CG/4U)%X9T^
M#5M0U2(W*7FH(J7$@N'^95!"X&<#&3C&.M 'G-OJFHWOP\^'>HS:A=FZFU>T
M@G=9F'G)YC AP#AL[1US6WI>DVDWQ=\5;_/&;*T<[;F1<EO,!Z-Z=!V[8K>3
MP'H4>D:=I21W2V>FW N;2,74G[N0'*G.<G!)P#QS5]O#>F-XA&N^7*+_ ,I8
M699G"2*I)7<@.UB,G!(X_*@#R[PY='0?A7H3VLKP?VCK!LIY7N'"QQFXEZ')
MV9VA2RX/S9SGFMO7SK7@;3?$6N6]]%Y+:?OM].\QYA%,&53,I?HN'&5'&<5U
M"> _#JZ/?:2UBTFGWKL\EO+,[JI+;CL!/R?,<_+CFI-)\%Z+I&GW-E'#-<Q7
M4?DS&\G>=FCP1LRQ.%Y/ P* .2U[2;6SUOP!=07-Q.[Z@ \LEPSB?,#G><D@
MGW]"1TKL_%^\>#=:>.::&2.RFD22&0QNK*A(((((Y%9MO\.M MUL$']H/'I\
MOFV:27\Q$! ( 7YN ,]*Z+4;"#5=.N+"ZWFWN(S'*$<J2I&",CD9% 'FTK75
MS;_"\?VE?Q?;852Y\JY9?-'V4MEN<$Y_BZ\\'.*W/!0DL?%?B_14N+F6QLKF
MW>V2XG>9H_,A#, SDG&><9K7'@W2 NCJ%N0-'&+'_27_ '7R[?7YOEXYSQ5O
M3_#UAIFKZAJEL)OM>H%3<L\S,'*C"\$X&!QQ0!SOC2;5+/5;:^BTV?5](AMF
M6[LK.X*7$+%N)E4$;^%( SD<X[UF66HQ3^)OA])I>IWEQ87EA=*[23/^_P#+
MB0*9%)P6!SDGG.:[>]T.WO-174//NX+H1>1O@G*93.<$=#R>N,CL15*[\%:)
M=6>F6RPS6JZ63]C>TN'BDB!&& =3G!'7GF@#@Y]?O=&TSQ;MO[A(5\1PV0GD
MF9S:P2"(.5+$[<!FQZ$YKM)=#BTN_OKNVU.Y6WN-.>/^SI)3(C.O)F!8D@X(
M4^N1GFIH? WAZ&TU6U^PE[?5&W7<4DSLLAP!G!. >!\PYSSFC2?!6D:-93VM
MM]L831>29)KN2218_P"XC,<HOL,4 >=:/!)I7@[X;ZO:WMZMS<7MK9RJ;E_*
M:&16!3R\[,<#G&>.M>SUSG_"#Z+_ &7IFFA+H6FF3+/9H+E_W3K]TYSDXR<
MYZUT8X% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !117(^/=5DTZ'0K<SM;VNH:M#:74RL5(
MC(8[=PY7<5"D^A- '745PVNZ;I_AO3/$=RNOWFF6UW:J?)@^86I'R;XE[,Y9
M1VR>?I2TB*>#XFS:7]GDT^RN= $S6L=TQ.\3!0[%<!9,$@E2?J: /1J*\)CL
M;E/@I8>,8-5U(Z_98EAF:[D97_?E3&4SM8-GG(R3WQQ70>,Y?M%EXSN[.:XN
M;JQMD8RM,8UTUUCW;82,DN2=QZ#D GC% 'JU4M3FU&&* Z;:17,C3HLJRR^6
M$B)^9@<') [=ZXZ#4!K?CFTT357WVPT*.]C@8X6>5W(=B!][: ,#MDGZ4?$M
M@VB>&?#UG;ZS?W;6NOVL!FDN&W,C3 ^6^#AP 0.<]* /1!?6S:BU@)5-TD0F
M:,=50D@$_4@_D:L5YY8:18S?&+Q&9(22VG6LA_>,,LQD!/7T 'M6=IKRV(U3
MX>SSSO?27JFUN'E8R26<A+F3>3G<BHZ9[,$]: /5**;&B11K$@PJ* !Z"N8\
M7R0/?:%923SO+/=,8]/BP%O-L;$B0GHB\,>O0#!.* .IHKR6UN=<3X>>.X;"
MX,-W8ZM/%;*MP2((@(F9(W;&.&?;TP2,8K<L].:7QW;:C8Q:C8Z%!INZXCD:
M:VC,^X;"8R1O8+NW$@CIGF@#OJI6TVHOJE[%<6D4=C&(_LLZR[FE)!W[EQ\N
M#@#DYKRZUGD@NO!.H6$]S-#>ZD\4FI3RE9K]'21LO&.-G VY.1@<"MBW61O%
M?Q&MC=WGE):6CQ?Z3)F(F*1CL.<KSS@8H ]&HKQVP@>R\-_#;7([R];4+N[M
M+:>22Y=A)%)$^Y"I.W' [9R,]>:TM2O+C1O$<DVO64L^EW&JQO::W92EC;XD
M4""9<Y5-RE3C(.>F: /2(KZVGOKBSBE5I[94:5!_!NSMS[X!./IZU8KS_P (
M:;:0_$KQQ)'$0\5S:E3O;@O;@L>O.23UK6\5O!+K6@V3RS332RS.FFH0([H+
M'R96/1$W!N^3C@F@"[XQUZ?PQX4O]:M[1+MK2/S#$\IC!'UP?R_6H+_Q+<67
MB;PYI7V*-H=8$N9_-.Z,I$7QMQSGCG/KQ7G]Q/<R?!CQU;W+LPL[^]MHD,AD
M$:*XP@8\D#) SVKJ->_Y'KX>?[UW_P"DQH [RBN7^(6KSZ)X,N[VWE,!\V&)
MYQG]U&\JH[<<C"L>>U4['PS+:^)([W^T[=-/O+5H)=/@#[+AOO"4$N<,!U8=
M1WH [2BO*?"R"T\9?\(YJ-]<3Z?!-/=:-<2.^;P\!XV<GY_*.1COP?X15FV\
M/0>(_''C?3;^^U,VD+6AAC2^D41,\);<,'/!)(!^7GITH ]-HKQSPQKFK:Q:
M^$M'U6[CD%S:WI\RYW%;UX90B!L$%ODW-@DYX)SQ5GQ'I%_H'A&2U;7YYBNN
M6S0+!(Z&UCDE3]R<L=Z@'(#9QD4 >M45YW%;'1OB7J>G6%]/;V]SX?-V[7%P
M\JI.)2@E^<G'!Y^E9NDZO=Z%=26FK://8^(;;2;AH)(Y3+;:F4"L9 >OF94'
MYAG#'F@#U:BO-=$TJ[U33O#'B:WUV"!LPR7,ZAV:\#X5XI,OC)8X''RD< =*
MAMKRXTGQ/90>(;*5ENM3<Z?KMI*7CN"[-LAF&<K@-M Y&5&.F: /3+BXAM+:
M6YN)%BAB0O)(YP%4#))/IBLG^U-4N]#34-,TV.229D:""XF\LF(D99N#M.TD
M[?IGGBL#XORR1?#7450E4ED@BE8=HVE0-^8./QI_Q2WP>"Q-!-/ \5Y:A3#*
MR AID4@@$ C!/!H [:BO/K[3DU'XP2V%S<WILI= \Z2W6ZD5&;S]O0'C@#(&
M,XY[US^CZU<P>&_#6E75[.+*XU^XTZ6=Y3O,2-)Y<1?.>2JKUZ#% 'J&OZC-
MH_A^_P!3@MTN'M+=Y_*:38&"J6(S@XX'I3M#U!M6T#3=2>,1M=VL4Y0'(4NH
M;&?QKF-7T6VT;0/&(M;Z9HKK3I)EL&;,=KB)U)0?PAB,XZ9!QWK%M7>&?X4F
M*22,36ICE"N0)%%GD!AT.#R,T >H5S^J>(;C3O%^@Z*+.-X-5\\?:/-.Z,QQ
ME\;<<YXYSZ\5P&M:]>^'H_B--9W,L8@O+**%BY86PE2,.R@\#&YC]:V=6T>Q
MTWXF>!)+)60/]M5CYA;S,0<,<GEN3\W4]\T =S8S:C+<7JWMI%!%'-MM7CEW
MF6/ ^9A@;3G(Q5VO)93.GA;XH*+V]W6ES,T#_:I-\>VW5@ V[.,]LXJY!:G2
MO%7@&YM[J[,NIP317IDN'<3*+;>N5)VC##(P!0!Z=17DNIV^L:EI7BNU5+]_
M$8U4KIMU;;PL<64,:K*ORQ@*3N4D=\\D5ZG:P+964<.]RL28+2RM(?<EF))^
MI- $]5HK^UFO;FTCF5I[94:91_!NR1GWP,_EZUY5'</$W@[5-.N+B>*\ULPO
MJ<TI66^C<2DAHQQY? VY.1M&%%7=-T73Y/$OQ(5X"55HN/,;G=;!FSSSDD]:
M /2;&]M]2LHKRTE$MO,NZ.1>C#U'M5BO'](N?[-\#?#NPA:2"UUF:"*]E61@
M6'EDB/.?EW, .,9 ([UNW$,NE_$*ZT6QDGCTF_T62ZD@CE91;RHX4/&0<ID'
M! QDC- 'H=%>+P:0O_"CI/$AU#5#JK:(P,WVZ4#@[A\H;'&,>^3G.370):_V
M1X[\%2VUS=E]4M;E+WS;AW$VR%74E2<#!Z8 H ](HKR?2[74/%_A*+Q FM6^
MGZC%=232W>':2W*2'=$PW@;-HQMQC&#@DY.EJ%ZO@;QU>7%QYTVG:W:%K5&D
M9MEU'DF% 3A?,!! [L,4 >C5A^*=<O?#^E)?V>D/J:K*!<)',L;1Q8.7&[[Q
M&  HY)-<MJ^E:QHMCHGV2R378[6"5M1TXSE9)G;83-'N^\5(8!3T# #G&.D\
M(W&EZQX2TZYLA--: LT0O%S+&ZNP(;.3N4@C.>W6@#H:Y:Z\3:G<7>IQ:!I<
M6H?V7<1V]Q&]QY3R,RJS",D;?E##J1DY';GJ" P(/0\5Y+IX&@6/Q)U;3HC]
MLL+J8VY+,P7%NAR03SCKS0!ZW17 :;HLYO-!\166M01VYCQ*L?F/_:*NORAR
MSD%@>0V,CGM6/HEIJ'BOPGI?B:/6[>QOTF^TSW8#LZD,=\+C>!M_AVXQTXH
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MFC"]#VYXZ5RUQIT<WA+XD:EY]U'=6.L7DULT-P\8CD6.-@P"D9/3KGCIC)R
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M!G[OI6Y&BQ1K&@PB@*H] *\F\.30+\,-"MYKJYC:XUF5$MK?&Z\(N)3Y))(
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M%NZ[%8D+GV ].E-@^'_AFVUY]9ATW9=O+YS*LKB(R==_EYV;L\YQUYZUTU%
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M;F42 =-Z@A7Z#[P/2IKWP?H&HZI+J5WIL<MU-%Y,K%F"R(.@90=K8[$@D=J
M.,E;6[OP[X3U>"R@\0*FCQO>Z9/(!)*72,^<F<@N-K#G^\<=:9IFLV.LZUX-
MTJ 3G0+G3[B:.&[ZS31D+Y<@/WB@#G!R,X/.!7:0>#="M(K2.TM);86D1AA:
M"YEC94.,J65@2.!UST'I4]QX7T6YT^SL7L56&R8/:^4[1O"P_B5U(8'KD@\Y
MYH \SUY;BPL/B1HUO-<)I=E9Q7=HJ2LOV:1XR612#]W(W;>@STYK92QBTCQY
MX(FLY)UEU*UN8[UGF9O/"PJZ[@3C@],8QTZ5V<OAC2)]*N=,EM2]K=-NN0TS
MEIC@#+OG<W  Y/0 =!0WAC27NM.NF@E:?3E*VCFYD)B!&#CYN<C@YZCB@#S2
M>5#!X;UG2WDEBN/$R1_VK/)BXND>5U9, ?ZK'R@$]%'RCBM6W\-:;XF^(/CN
MVU,3O"&LMJQSO&%8V_WOE(R1VSG%=-_PKSPIY;1_V/'L-P+D+YCX20'=E!N^
M3GJ%P#W%7;CPGHMS?2WK6KQSSQK%,8)Y(1,BC #JC . ..0>..E 'FMG=WU[
MX+^'4NHSO<3#Q$L:SR'+2QKYZHQ/?*@<]^M;FIW,?@/QW=7KPM+I^NVI$"9)
MVWD8)$2YX42@].["NSOO#FDZBMBMS:92P=9+58Y'C6%E&%*A2 "!P/2LMXM3
MU_7XH=1T-;33=+O#<0W$DZ2FZ95(C95'* ;BQSSD <Y. #6\/Z4-&T.ULB0T
MJ)F9QT>0\L?IG.!V&!VKB(82?$GQ,M_/N?+6VM63_2'W(3 [':V<@9YP#BO2
MJQ_^$6TC[3J5S]GD$VI($O'%Q(#,H& #\W8<#'0<4 >:V-DEAH/PRUJ"6X_M
M"ZN+6VGF:9FWQ/ Y9""<8X'&/?KS6SI=K9^-;/Q4-5NY+?4+359H%N$<++8Q
MQD>68R?N# R2.N6S76GP?H9L]/M#:2?9].=9+-!<RXA9>%*_-V' ]*BO? WA
MK4=<_MFZTF*2_.-\FY@),=-Z@[7QQ]X'I0!B6(C;XMWD"L9+:?P]#*R..)&,
MS@L5Z9( !XKCH ]S\,_"S_:[I6/B=80\=PP.PW;C'7!P ,9SC%>JZGX7T;6-
M2M]1OK,27<"&-)!(Z90G)1@I =<_PMD55'@7PVNGQ6*:;LMHKC[4B)-(N)<Y
MWY#9R#R/3M0!R6N>%]-T[QEX.TRT:]BLKNXOFGB%[*0^82Q'+'&>>G/)IT&E
MV][XKU7PAYMLEGIUC;K96U[&\Y\M@Q>1"9%.X,0-W)&!@BNZO?#VF:AJ%E?7
M4,CW5CDVTGGR*8R1@D8;J1P3W'6JFO>#/#_B:XM[C5].2>>W&(I5=HW4>FY"
M"1['CF@#CK+SH?$GA;PAJNKG5K-+*YD>XD3:+V:-]JHX).[8N[@DY(!/2M+P
M'9P:?XO\<6MLFR%+^ J@/"@P*<#T'/ [#BNCU+PGH6JV-G9W6GIY-B0;3R6:
M)H,# V,A!7H.A[5)I7AG1]$N[J[T^R6&XNR#/*79FD(  )+$^GXGD\T <KXF
MTVWU;XJ:!9W?F&W?2[O>B2,F\;H^"5(./;//TK$M/"T^H6'C;PI975Q]ET^Y
MC;2)GE8F"5HA(8@Y.=H) (ST8UZ1J>@:;JUS;75W WVFVSY-Q#*\4B ]0'0@
MX/<9P:JW_P!H\-Z3&OA_06U!FG&^".X6-L-DM(SO]XYQG)R<YH PO"NJP>-;
MK3=46W$*:9:[)HMN/+NV.UH\?[ 0\?\ 313VJQ\0-2FLSX=L][Q6>HZO#;7<
MBL5RA!(0D= Q !]LCO6YX>THZ5IC+*D27=S-)=W7E?=\V1BS 'C(&0H/<**M
M:GI=CK.GR6&HVR7-K)C=&_L<@@]00>01R* .+EL_[+^)L6E:<KPZ5J>E2RW=
MK YC2)T8!9%VD;"=VTXQGZU'\)M%M6\'Z)X@E>YEU.2S>)YI+AV!0R$XVYV]
MNN,]?6NQM= T^T6;RDF,D\8BDFDN9))2@SA?,9BP R> >Y/>I-'T6PT#3DT_
M3(#!:1YV1>8S!<G)QN)P,]J .8U:Z^W?%/3= OU#Z8=*ENTA<92>?S N&'1M
MJ9(!_O9["N*\2_:K/PS\2='CGN1INF/;RV!69AY1E0,\0(/W1D84\#=7K6J:
M%IVLM;/?6Y>6V?S()HY&CDB8C!*NI##(ZX//>H+CPMHUWHTVDSV?F64[^9/&
M97S,V<Y=L[F/ ZD]!Z4 <L]A%HGQ5\/_ &)YU_M*QNQ>;YF?SBGEE6;)Z@D]
M.W'2K7Q67?X+1=S+NU&S&Y>H_?IR*Z)O#FEOJ5EJ+PRM=V2%+>5KB0E%/4?>
MYS@9SUQS5G5-*L=:L)+'4;9+BVDP6C?U!R"".001D$<B@#SW4M/;P=X_L9/#
MWVEDU#3KV6]M'G>57:)%:.0[B3N+,%SWS[FF:!I+:WH?ACQ1#X@M;>X5X9;B
MYBM6,MT6PLD$K>;ALL<=."!@#I7H.GZ+8Z9*\UO'(T[H$::>9YI"HZ+O<DXY
M)QG'-9FG^ _#&E:T^KV.D0PWC.7W*S;58\%E3.U3[@"@#SV[TFVO= ^)U[,9
MO/LK^YGMF29E$4B6Z,' !'S9 Y_^O71.T&NZII-O.#J5\VA+-+9W#!;:)7*Y
MF;@GS"05&!TSRO6NG'A#0UMM1MA:R>3J3%KQ#<RXF)&"6^;N.#ZCBFOX+\/2
MW%E<2:<'ELX/L\+-*Y_=9SL;YOG7V;(H \Y@N[B]^$W@">ZF>:8ZU8AI)&W,
M<3D#)/7@"NCU;2K"?XRZ.9;6-S)I=S(^1]Y@\8!_ 5OIX%\-Q:9;:=%IHCM+
M:?[3%&DTB[90<ALALY!Z>G:KLOAS3)]9AU>2&4W\,?E1S?:) 50]5QNQ@]^.
M: ,CXEZM>:'\/]4O[!WCG4(GFI]Z)6=59A[A23GMUK+UZTC\/^)O"-WH"B(7
MMY]CNHHC\MS"T;,7<?Q,NW.X\\]:[NXMX;NVEMKF))H)5*21NN592,$$'J*S
MM-\,Z3I+PO:6\F8$,<'FSR2^2AZJ@=CL' '&. !VH Y3PEI5A#\3/&CQVL:M
M;RV?E$#[FZ#G'UR:?\9_^25ZK_UTMO\ T?'7567A[3-.U2[U*UAD2\NR#<2&
M>1O-(&!N!8@X' ]*=K>@:9XCL?L6K6YN;4D,8C*ZJQ!R,A2,X(!YH Y/Q99)
M=?$OP?!)-<K#<Q7RS1I.ZJX6-,< \?>/3!.:Y:;4Y_#7AKQ78V5Q-;V4/B*.
MS202'-I!+Y1?:QY4?,V/0MFO4I/#>ES:A8W\L,SW=BK+;2M<REHPW#?Q<Y'!
MSUJ)/"6AK#J4)L1)%J1+7B2R/(LQ]2&)YX'(YX'I0!RFHZ38:5\6/"CZ?:I#
MYEC?!DCX5BJQX./4YY/4\9Z5E:#I\_BOPEI7B;^WK2RU"*<7%Q>):,9U<,=\
M+GS>5_AV8QC&!TKN++P-X=T^[LKJ"P8SV(9;:2:XDE,0.,@;V/' P.@YQC)I
M(? ?AB#7VUR+2(4U!I/-9PS;2_\ ?V9V[N^<9SS0!R$>B6>J>(_B):WK7,\$
M'V=HD>YD(1C;;LCGJ"21Z=L5G00F/PM\.O$7VBY?5[F_LH)KIYV9I(I%(9""
M<8( [>_4DGTQ/#&DQW&HW"6\JRZD +MQ<R9EP,#/S<8''';BH3X.T(Z=86!L
MY/LMA(LMK$+F4"%U^Z5^;MV].U '$'1+35/$_P 1+:]>ZF@@CMGBC:YDPC&W
M+9'/8\CL.V*B2YN+O0/A9?SW,[W$US DK&5L2 P.26&<$Y .3S7H*>%](2XU
M&X6WE$VHJ%NW%S+F4 8&?F[#@8[<5$/!VA+;:=;BSD$.FN'LT%S+B%AT*_-^
M'TH XJWABTKQ9\3-3L;2+[;96\,]MA,D2&U9C^9Z^M6=$T3[?;^&?$]KK]K#
M_JVEEAMFWWP< -'*QE.X[NY!*D=!BNV'A[25UV36Q9H-1D0(\VX_, "!E<X)
M )&<9P<50TGP)X8T/57U+3=)BM[IBS!E9BJ$\$JI.U21Q\H''% '#:987'C'
MPFVMOKMKIVIV]Y++->"U9KBT:.4YC)\T?+M &W&,$<9YKU.]A6XL)XG+A7C(
M)1RC=.Q!!%8C> _##^(&UTZ1#_:+.)&D#,%9QR&*9VEL\Y(SGGK6_/"ES \,
MF[8ZE6VL5./J,$4 >-6ZR7/PP^'$KW5TLLNK6L<CI.REE9WSG!Y/ Y/(KK?#
M5I%H_P 3O$.EV1D2R>QM;KR6D9P)275F&XGD@#/KBMT>"] 73K'3ULG6TL)A
M/:Q"YE AD'(9?FZC)QZ9/K5V#0=.MM:FUB*%Q?S1B.24S.=RCH""<8';B@#2
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBN-^(FI_V=:Z%'-*8M.N]7AM[Y\X
M'E$,=K'LI8*#[9!ZT =E17FWC2V@\'>&_%6I^')I8+ZXM(I&M("!% H8(9D4
M#Y&*ECGOLSV-2>(+&UT;5/!NI>&HTADN]0CM)?(X%U;.C,Q?'W\!=P8Y(Y/>
M@#T6BO%)]#L+CP;\2+F:.22:PU2\DM'>5B8'2*-E9>>&SCGK@8K=N+*'5_B#
MX5^W>9,MWH<SW"&1@LA_==1G&.3D=^^: /3J*\7AU!M"\*:A8Q3BVTJ'Q@]@
MYDRT=O:E@=IY!";B 1D<,1WK5\1Z=<>#M+\2:SH^IP1SW&F;Q86%MY4:%64&
MX4;F 8*QYXSC/:@#U.LDZI+JN@W5WX=>UN+A6EB@:=B(FD1BAR5YQE3R*Q[/
M0/#+WVD:M82!%N;5X$CA(,=]&R;LRC!,F "<D]2<YS7 6FFV,7[/FM30VT4,
M^+PEX1L9MEQ(%!*X) '&#Q0![7&7\I#+M$FT;MIXSWQ[4ZO/FG6_^(VCZ'J4
M:RZ9_8)N8(91F.6?>JMD'ABJ#C/3<37(^)89K7PA\1M)1Y?[*TVZMVL,.0(C
M($:2->?NKN'R]!NH ]OHKS]M-M=$^+VD?V>C1?VAIMU]K.\L9RC1E6?)Y89/
M)YK3^(^BOJ_A"YFM8E?4-/(O+7(SN:,ABGN& *X[Y% '6U2U%M35K/\ LU+5
ME-PHNOM#,,0\[BF!R_3&>.M>6GQ':6OC"Q\:VMFKZ-K%HUBI5?F>Z">8I'NQ
MW0_[R<UJ>)=%BT6S\#0( LZZ];B9HB55W979SMZ<L,CT  [4 =Y_:D$U_>Z=
M:/'+?VD,<LD;-@+OW; Q .,[#VZ8]:SO!&OW'BCPA8ZS=0Q0S7/F;HXB2J[9
M&48S[**Y_P /:;IR?%SQA-]BM5ECBL9(W\I0RNZ2;F!QP3W/>N)TW3;6V^%/
MA378D9=3AU:)8[C>=R*UVRL@YX4@G(Z'/- 'NU%4-<1I?#^HQK>?8F>UD477
M_/$E3\_X=?PKSO2!Y%_=Z%KWARVL-6_LF4)/9X:UOHE*Y;&,A@=O!YY^E 'J
M=%>/1NC?#[X7SLX-PVIV*>83\Q4AMPSUQD#(^E;&G6NF^,IO&=GKLFV]M=1D
M@23<%EL[=54Q/&3]SHS9'4YS0!TP\07@^(H\./;P"T;3&OEF#$N6$BI@C@ <
MGU[5T=>;SZ=8ZO\ %6PMKG?>6;>&22)F/[Y?/3&\<9SU(/?M6G\+24\*7%H&
M8PV>IW=M K,3LC65@JY/8#B@#M:*\L\:1V6H'QP\""[NK'35\Z6[8;;)A$SH
M+<8R&.0Q.0,[>3C LV6HQZIXN\.:3K3)/:3^'4NH8KC#)/<DJ')!X9@@R,]-
MQ- '?:AJ=IIB6[7<H3[1/';Q#N\CG  '?U^@)I&;4_[;152U_LK[.2[%F\[S
MMPP ,8V[<^^:\V\3>'M%L+'PKI]N?MT$'B>*$&Z"R&-7WLT*G'W!P-OM@\BM
MAX8[/XR6WV./"_\ "-R[(E;"?+-& %'1> !Q0!WU%>-QB/5/@C-XI=]GB*))
M;LWX&)X[A)3\F>H'&S;TQ@8K7BTJ#6?BD8=7MV<7'AJ&:YM7D;RS(9B&!7."
M..G3@=Q0!Z;17$?"^X6+P%:Q3S_)%=W-M"97YVK.ZHH)ZX  'TKJ=;0R:#J*
M+>?8BUK*!=?\\/E/S_AU_"@"]17ENC*;;4KC0M?\.VUCJO\ 94JQW%GAK6_B
M4KEL8R'!V\'GD^U9T+HWPZ^&,[.#<'5+%!(3\Q!+;AGKC@9'M0!ZK&^I+JUS
MYZVBZ6L2&%U9O-W\[]P/ 7&,8]Z?INI6NKZ?%?V4@EMILF.0=& )&1['%</!
M9V\OQ,\7VTT0F@FTFV9XIOG4Y,F>&R,<=.E7?A-:VMO\-=$D@@ACEFM5:5HT
M 9SD\L1U/UH [:BN"L5M_$7Q$\6:9KEM%<QV45JEG;SJ&58G0EW4'N6X+#G@
M#M7'!+J]\+>&H;ZYN95MO%PL+>X,S!I;97D49.>?NXSU^4<T >W45GZ1HFG:
M%IO]GZ9;_9[7<[B,.QP6))P221R3]*\D@\+Z9J?@CQI>W3SBZT[4]1>SN#</
MFV:,Y4KSUX&3U([\"@#VNBO)+?2T\2>,?#L6OQRRO?>%3)>PF5U#N6BSD C'
M)SQCD#TK6\/V-AKWB+Q9I.KVB3+ITD-G:6\WS>1;>4-C(3R"QW'<.20.>!0!
MZ+17C?AS6KR\B\#Z9XAG:>PNGOHQ)<'*W;1-M@\S/WOER0#]XA3R:V/$D=CX
M1TL6FG7[16%WKL(OEF^:"SCD!)C 7;MC)"Y7/1^>#0!Z917EOB#3I_!VE^)-
M7TO5(8Y+G3A)]@L+8Q1QX95:X4;SAMK'IC.,]JT(]'@L+^Q\3Z3J5B-UG,L=
MKI]J4341Y9==YWMN(*Y#=>Q/- &_XV\07GAG01J-G;P3D7$,3B9B,!Y%3( Z
MGYO45K!M3_MLJ4M?[*^S@AMS>=YV[IC&W9M_'->0ZC;Z?JGP6TOQ!(L=QJDU
MS:S3WIP9&E:X4."W7 )(V]!M'' KL5MT_P"%UW4>7V3>'0SCS&ZF<@D<\< =
M/2@#NJ*\)M],MH/@_I^NH)/[4M-6_P!'N6D8M$/MY0@9/ ()R.^>:[?5(//\
M?:K#J=F^J6,FE1BVAB3S3;L6<,"O\#/CA^/N=1B@#OZ*YOP'HM[H/@W3[+4W
M+ZB(PUTQE,F7/N2>@P...*\^\<M;7'A_QKJFG9FGLKM%:_N7'F6TR>7^[M\#
M*J,]21RS<&@#V6BO.]1TJSU/XQPP7:--;S>'Y&EA,C;'(G08*YP1[=.!7,V>
MHR:=X4TW1S,\>E2>+)=,E8N<);"5RL6[J%) 7Z9'>@#T=/$%X?B*_AQ[> 6G
M]F?;DF5B78^:$P1P .OKVYKHZ\_LM,L=,^-SI8VT5LDOAW>T<2A5S]H S@<#
M@#\JU/&3V<M]H%A.)9[FXO&:WLMX6&X*1L3YQ(/R*/FZ$Y P#0!UE%>'ZA&5
M^%OQ%M7946RU64010.RQQ#$1*J,_=RQXZ<]*ZN?2K/2?BEX>%G$5_M/3[Q+[
M<Q;[2$$94OG[Q&3R?I0!Z+17E%M;KH>H:W\/A%@:K.)].DVY/V:7_7#/K$%?
M&?5:]-E%KINE28(MK6WA)R@P(T4=A[ 4 6J*\?TR.*UUOX>WEC'Y-M>FX47$
MK@W5Y&T#/OG*@#).&QEL'N#Q26/A32=<TCQX=0,Q:SUB[-M*UP^;9EBC(=>>
MHXY/88H ]AHKQW2[1_$.O^"/[=,\LE[X>E>ZC:9@)B/+QN&>X.2!C/>JC3S>
M%$UW1K:Y:'PY!XAL[=9)BSI;PRH'EC)R#L#% 1D<,?4T >VTA)VG: 6[ G'-
M>;ZEI&G^&(O$&ISZ[]ALKS2V,MII-MY(0@A1/&-S .=P7MG.>V:;H=NVF?%.
MPMX[2WT^&?0'9K:!P=VV5 K2$  OR1D#N1DT =3X/U^[\0V.HS7MO#!+::C/
M9;86+*1&VW.3USSV'TK6DU.UCU:'2S*IO9H'N$BSSL4J"3Z#+ ?GZ5RWPU_X
M\/$7_8PW_P#Z,JI?:;ITWQNLI9[*U=CH<LI=XE)+K-&%;)'4#H>U &[X1\07
MFOIK/VVW@@DT_5)K%5A8L"J!3DD]2=Q["NCKQ.]TBSN_!7Q'U&:-FN[/6;V6
MUDWD&%U6-@R8/#9[]>U=&UP?$'C9M%U.2P96T>WGM;>^MC,DI8OYKJ-ZC=PH
MSR<#C'.0#TFBO([_ $"*R_X072I=7N-32+59K5K@NR;D$<A,?WCG&-N<YP,9
MXK0_LVP@\;CP=&EC#IL&EK+865]"UQ&Y:23S2H9QEA\H[D#.,#- ':^)==3P
M]HYO3'YLCS16\4><!I)'"+D^F3D^P-.TF37/M=]#J\5GY,;*;6YMB5\U2#D,
MA)*D'W.<]J\X\2^'K33OA]I=C/=QZP;/6;>".YFA!9$,Z[H@23D#[IY[8/2M
M+7/#FE7GQ/T?2Y+;;I\VD72R6L3M'&P#IQM4@ <D\8YH ]*HKSK0+"PUCQ5X
MIT35+2.:#2UMK2RMI\N(;?RN&7/.6.<MUX'/ KF+3[7J&@^!_P"T;BYF:/Q#
M)91W!F8-- OFA22#R?E W=>.M 'ME%>8Z3X6T:?Q]XMT22R4Z2(+2<66XB$2
M.KAGV9QD[1SZ\UM_"^^:;X:>'WO+G=*\1B5I7^9MKL .>IPOZ4 =C)O\MO+"
ME\';NZ9[9KG]3UZ\\.>"GU?6H+=KZ&-!)#:N?+:5F"*%+#.-S#G''/6M?5(4
MN-)NXI-VQH6!VL5/3U'->0W]K;W7[.6D3W,$4TT<=ILDD0,R[KB,-@GID<'U
MH ]3TR37AJ-Y!JD5DUJH1K:YMMRE\YW*R$G!&!SG!S69H'B:_P!7\5Z_HT]E
M;0IH[Q(TR3,QE\Q"PP"HQ@=>371VMI;6-LMO:6\5O F=L4*!%7)R< <=37!^
M%88[GXC?$6&4$QO+9*P#%3CR/4<T >A5!>230V4TEND;S*A*+(Q52?<@'^5>
M):3I]O!\,O NO('_ +5&J6J"Z,C%]CSE63K]T@G(Z'KUKL-+%IXH\0^-(=9A
MCGFL9Q;6\,HSY$'E@JZ9^Z6;<VX<\#G@4 =1X.UR;Q)X0TS6;B*.*6[A\QDC
MSM7D\#-;E>+^&[XGP_\ #K2+B:VBL+VRN#B[B,D4LRE=B,NY0>"Y )QG'&0*
ML^+/#T>@^ M;MH]4,ZKJ=K/';P*T4=F9)HP8U&X\$'.WMGIS0!Z_17FUUX=T
MN'XLVME';E;74-(FDO(1(VVY9)$VF3GYS\QY/7O7,7UND7PQ\2V<3RQP:=XG
M-O:(LC 0Q_:(AM'/0!FX/K0![A6-_:MQI&BW>H>(VLX%@D<@VS,5,>[$8^;'
MSD8&/4\5R]KIEII'QA%K81M!#?:')+<JLC'S9%F0!V).2V&(W=>:X^]M+>3X
M)ZZ)84E^SZ[((FE&\I_IBKP3S]TD9]": /<:*\\U-;:7XAVWA@IID&G?V49K
M2TN;02022F5A)M0,J[@ OJ0"WJ:RYH3X<?PWX;EUN&[TR;4+F)Y;N$M"KA T
M5NPW_,H+' +'D ?PT >KT5R_A304\/ZAK%O%J4<T<\B7 L88?+BM"P((0;FP
M&QG';'O6'XIBL=4\0:W;K$+VZM=('GK>$>1:*V\AD7&3(V.2, !1ST% 'HE4
M]3U.TTBQ:\O91'"&5 3_ !,Q"JH]220*\ST75OMI^'>FZS+YMC?:0TA$YW+<
MW*I'M#Y^\0I8@'J2#U IWC7P]HVF>#I[2U/VF./7;>413A76T,DL>Z*/CY%P
M?N^C>] 'JU%>=WD=M??$*;PS*NF164>EQR6-E<VGF1/EY!*44,HW#"CN0 <8
MYSG1Q#2M7\&^$;O5FU/2I);P/+,N%FDC'[N%LD[@I8\$G)4#MB@#LM$\07FH
M^+O$6CW-O!'%I?V8PO&Q8R"56;+9QZ#@#UY-:UZVIB[L18I:M;F4_:S,S!A'
MM.-F!@G..O:N.\'6-KIWQ*\<V]G"D,.+!A&@PJDQN3@=N>?QJ;QK&H\9>")@
M7#G49$/SG!'DN>G3KWH [BBO(I- T[4+GXF)>1/.MLPD@625F$;_ &8-N&3]
MX'D'MV[UZ%X-N)KOP/H%S<2-)-+IUN\CL<EF,:DD^^: -NBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "JNI:;9:QI\UAJ-K%<VDPQ)%*N5:K5% &3I'AG1=!TZ6PTW38(+67/F
MQXW>9QCYBV2W''/:C3O#6D:2\;V5IY9A4I"&D=Q"IZB,,2$!]%Q6HCI(NY&#
M#U!S1O0N4W+O SMSSB@#''A+0Q:7UJ++]Q?N9+N/SGQ.QZEOFY)[^M/C\,:1
M%>6EVEJPN+2+R;>3SGS''_='S=/:M5G1,;F5<G R<9-*2%!)( '4F@#(B\*Z
M)%97UF-/C:VOW,EU%(6=9G/5F#$_,>.>O ]*31?">@^';.>TTK2X+:"?_6J
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M:@!;S!C&&+9)&">#QS46A^#/#OANYFN='TFWM)IAAW0$G&<X&2=HSV&!P*W
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M)X ]*L!E)(# E>H!Z4@="Y0,N\#)7/.* '4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R7Q(6
MX;P?)]GE5<7-N9(F<)]I3S5S"">[_=QWSCH:ZVN:\;Z7?:OH\%M:6%GJ, N4
MDN[*Z?8)XER=JL00#NVGGT(SS0!@'1;F+Q3K7BC3=,%O%%I&VU@90&ENP'.\
M(IX^7:G/7Z#-8%['#+\$])\2:5@^((A;3Q7B<S2W32*DBLW5MS,RE3Q^5=/X
M9\&VMCK-OJ=KX9A\/&'=O6*Z\QIP5*["J_+MR0V22<J.!73V_AG1;6\-U!IT
M,<IE,V%'RB0]7"_=#?[0&: .4T:*V\1^-/&5CKUK%<R6SPPPP3J&"6S1Y!3/
M3<VXDCOCT%<MH&J7MQ%X$TG6YFFTNXNKY!).<BY\DD6X<GKZ@'J54\UZO?>'
M]*U*\6[N[*-[E4,7F@E6*'JA(()7V/%+J.@:3JVF)IM]IUO/91[?+A9!M3;T
MVX^[CMB@#DO"5G:6'Q1\<0V<,<,9CL',<8 4$I(3@#ID\_C2_$ZQL[E?#$EQ
M:P2N=?LXBTD88E"QRN3V/<5U.G>&M%TF[DN[#3+6WN9%"/,D8WD#MGK_ (U)
MJ>B:9K/D_P!HV<=SY#B2(29.QQT8>A'KUH X7Q':Z5<ZQK]E:VT+RV.BJDZW
M07[/:1L'9?*C SN..3D 87OQ6=(1=>%/A7>2N9+K[=9(TC-ECF!B0?R!KT6Y
M\+Z'>:A'?W6E6L]W''Y2S2QAFV=@2>OXU&OA'P^EI9VJ:3;)!9/YEM&JX$3_
M -Y<=&]^M '+^'-/T^+XH^-Y1:6J31FS,3^6H92\#;BIQP6YSCK7&Z3IEE:_
M#/P#K4,"KJ0U6T077_+0(TS*R;NNP@GY>GM7L4OA_2)]3?4I-.MVOI(O):XV
M8<ITQNZ]"1].*K_\(EH']GV^G_V7 +.WD\V&  [(WZ[E'0'//YT /\575I9>
M$M6N+^>X@M4M)/-EMCB5 5(RA[-SQ[UP>E6T=G\1?#\*V]I:076A2HUO"P+-
M&&CV>8PP&;D]!US@FO39[6"ZM)+2XA2:WE0QR1R#<KJ1@@@]1BLFV\&^&[-K
M5K;1;.)[3=Y#K& T>X $@]<\#GMB@#R,Z180?!RZUB.W4:C9:NYM;DDEX,7P
M7"$_=&"<@=>]=W826VM_%#Q/IVL0Q3BRMK9;&WG4,OE.I,CJIX.6(!/L!71?
M\(AX?_LQ]-_LJW^PN_F-;8/ELV<Y*],YY^M27_A;0]4N+:XOM,M[B>V79%+(
MN6"_W2>I'L<B@#G?A$B1_#JSCC^XES=*O.>!<28ID%I;GXT:K&8P4GT&)I5/
M1B9G!S^  KKM+T;3=$MC;:98P6D+,7984"[F/4GU-,.@Z6VIRZE]C07TL?E/
M< D.R?W<YZ>U 'C-AI5E;_"'PYK4<"C4X-5C$5T23(@-XRE0QZ*03D#@YSUK
MV;Q!<VUEX<U.YO)IH+:*UE>66#_6(H4Y*_[0[>]5O^$0\/C3(]-&E6_V&.3S
M$ML'RU;.<A>@.>?K6K);PS6K6TL:R0.AC>.0;@RD8(.>HQZT >6Z3%'8>.?!
M!MH;>S@N=*N5"1L#+)$$C*&9A@,Q// P#NY-;WQ?@CE^&>J,ZY:-H60YY4^<
M@S^1(_&MVU\&^&[%K1K;1+*-K-R]NPB&8V.,D'UX'Y"M#4])L-:LS9ZE:QW5
MLQ!:*495B.1D=^: ."U/P[I$/Q6T6WCL8UAO].NOML8SBZVM&5\W_GIR3][.
M>]8]D=,L/#/B;2;@3I8#Q5]CL[2V<(I+&)EAR00L98G=VP37I[:!I;ZA;W[V
M:->6Z[(9V)+HOH#GH>_K59_"'A^2TO+232;9X+Q_-N(V7(E?.=S9ZM[]: .$
MM;=4\0?$.PG2TCC;3;>5K:VR(UD,4N<>K85<G S@<51L]+LM/\/_  NU>U@6
M/49[FT@EN1_K'C>W?<A;J5X&!T':O2D\(^'HWD>/1[-'D@^S.R1A2T?]TD=C
MDY]>]./A70VM[.W.FP^39,'M4YQ PZ%!GY2.V* /-9/#^E7EK\3S<V4<WV:6
M22 /EA$_V96W*#T;/<<U=MM2DO\ 6?"6G:G=6HAN_#L<\'V^'S8Y[@[=_!8
MOMQC.>"WK7?CPQHJK>J-/B O_P#C['/[_P#W^?F].:CO?"/A_4M)@TJ]TFUG
ML;?'DPNN1%CCY>Z\<<4 ><ZWX=L=+T/P_IT6HO>Q1>*[=$9<H+=7;+0QD$X4
M$^O!XZBO4=)T73="L39:7:1VMJ7:3RDSMW,<GK_*J\OA?0YK&SL7TNV-I9L&
MMH0F$B8=&4#H??KS6LH"J%'0#% 'D&HZ%;0:EXG\"1VD(&NLE_IA,?$18;93
MD=/+*%@/]H#O70^!;J/Q3%IVI7%E'%/H]J;*13&!Y=WG;*!Z;0BXQVD-=PUG
M;/>QWK0H;F*-HDE(^958@L ?0E5_*FQ6%K!#-## D:3N\D@3Y=S,<LQQW)[T
M >)66F64'PC\/ZY' HU2#5X_*NNLB WK*54]E()RHX.<]:[2Z5[3XP:G-91!
MKD^&/-5>N^03L!_(#\*Z?_A$/#XTQ--&E6_V&.3S$M\'RU;.<A>F<\_6K::'
MID>JC5%M$%_Y?E?:,DOL_NYST[X]>: .%\)VOA[7?!_A?7)KHC4H9HY9+J)P
M)I;H_+)'(<98,Q.5] .PK'O-&T[4M,^*-Q>VL<\MM<3R0-)SY3K;*P9?[K9
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MJMX0\.MKPUPZ-9G5 =WVGRANW?WO][WZT <CJ_D^"/B*VJ0V:-;^(K0VX14
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MPR<J\1/!*L,%<^QKF?'?AR6_\$-H>B:6D@>XA?RE*(FU95D<MN(R3@^N2>:
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M^H!H XI!:7'Q6?0[NUM_[.M]'$EA:F-?*+&0B5@O3<.%]AGU-/\  <W]E?\
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ME/;D'K0!M-X:T)],736T>Q:P4AEMC IC!'3Y<8HU/PSH>M1V\>IZ39WBV_\
MJ1/"K[/89[<#BKL]_9VLL45Q=P0R2G$:22!2Y]@>M.EN[:!BLUQ%&50R$.X&
M%'5N>PR.: *E]H&CZG]E^WZ79W/V0YM_.A5O*_W<CCH/R%,/AO0S97=D=(L?
MLMY(9;F'R%VS.3G<PQR<\Y-6CJ5B$@<WML%N#B%O-7$I_P!GGG\*DEN[:!BL
MUQ%&0AD(=P,*.K<]AD<T 5!H&CK=6UTNEV8N+5!';R"%0T2CC:IQ\H]A39?#
MVC3:@U_)IEJUTY5GE,8RY7[I;U([$]*-6N)YM!EN-)U&RMY656BNYQYD(&1D
MG!&1C(ZTR;Q'ID'B*'0I+J(7\MNUQL+@;5#*HS[DMP.^#0!8DT;3)M274I-/
MMGOE78+EH@9 OH&ZX]J=I^DZ=I*RKIUC;V@E??(((PF]O4XZGWJ1K^S2\6S:
M[@6Z896$R .1ZA>M%Q?V=I)''<W<$+RG$:R2!2Y] #UH JW/A_2+R[DNKC3;
M:2>4 2NT8S(!T#?W@/0YI[:)I;:BVHG3K4WK)Y;7'E#S"G]W=UQ[5?JJ-0M)
MIY+6"]MFNERIC$@9E..Z@Y_"@"@_A+P[)I_V!]#TXV?F^=Y'V==F_P#O8QC/
M7FI1X:T,+=J-'L0+M52X MUQ*JC #<<@#C!K'\&>)IM6TF636+FS2\_M&XM(
MU3]V)/+<J JDDD\>IKH[K4+*Q*"[O+>W,AP@EE";C[9/- %5_#FB21VD;Z39
M,EG_ ,>RF!<0_P"YQ\OX5HNB21M'(JLC AE89!![$5S7B?6]1TG7/#5O:M;_
M &74;_[-.KQDOC8S95LX'W?0T:/K>HW7CSQ#HUTT#6MC#;2V_EQE6_>;R=Q)
M.3\HZ8^E &KI_A_1])D\S3]-M;9@"JF*,+M!.2%_N@GL.*CN?#&A7NKQ:M<Z
M/93:A%@I<O I<$=#G'4=O2L[Q9K>HZ-J/AQ+1K?[/J&J1V=PKQDOM96;*G.!
M]W'0]:Z&WN[:[1GMKB*958JS1N& (Z@X[T /FACN(7AF19(W&UD89!'H:S#X
M7T V,-B=&L/LD+^9%!]G78C>H7& ?>KD&IV%TLK6]];2K#_K#'*K!/K@\?C3
MEO[-H&G6[@,2'#2"0;5/N<T 5_["TDWYOSIMH;PQ^49S$I<I_=W8SCVZ56MO
M"/ARS%N+;0M.B^SRF:'9;(/+D/\ $..#[^PK0GU&QM4B>XO;>%)O]6TDJJ'^
MF3S5ALE3M(!QP2,B@#&NO"/AV^O9[RZT2PFN9UV2RO I:08QR<<\<?2I+_PM
MH&J64%E?:-8SVMO_ *F)X%*Q?[HQQ^%9'@_Q/-J=G??VS=6<=U%JMS8PA/W0
MD$;;1M5F))_$]:Z:ZO;6QB$MY<PV\9. \T@09],F@!\$$-M!'!;Q)%#&H5(X
MU"JH'0 #H*SKKPUH=]J1U&ZTFSFO3&8C.\(+E",8S]"1^-:$MU;P6QN9IXHX
M -QE=P% ]<GBFK>VC6JW2W4)MVZ3"0;#VZ]* **>&="C:T:/1[!&LP1;%;=1
MY.>NSCY?PJ6'0=(MWNVATRT1KP$7)6%1YP/]_CYOQJU#=VUQ++%#<1220G;*
MB."4/H0.GXTZ>>&VA::XE2*)1EGD8*H^I- &19^#O#5A)!):Z%I\3P,6B9;=
M<QDXR0<<'@5*?#&A'6_[:_L>R_M/K]J\A?,STSG'7'?K6C;W,%W L]M/'-$W
MW9(W#*?H17+7OBB8>/= TFQO+&XL+Y;D7 C^:1'B0,!N#8&=W3&>* .@MM&T
MRROI[ZUT^VAN[C_73QQ!7D_WB.3^-3WEE:ZC9RVE[;Q7%M*NV2*5 RL/0@]:
MHV5U-;OJ#:GJ=B\0NBL'E_)Y2;00CDGENI[<&M#[5;^>L'GQ><PW"/>-Q'KB
M@"C'X<T2*>UFCTFR26T39;NL"@PKZ*<?*/I3?^$8T'[/<V_]CV/DW3;[B/R%
MVRMZL,?,?<UE>/?$DGA[PMJ-WI]Y8IJ=O 9HX;CYBX'7"A@?QY''2M_^T+>W
ML8+B]N88!(JG=*X0$D9[T 5I?#FC3&$OIEMNAC\F-A& 4C_N CHOMTK1BBCM
MX4AAC2.*-0J(BX50.@ '04&6,1&4R((PNXONXQZY]*9:WEK?0^=:7,-Q%G&^
M)PZY^HH S9O"GA^XDEDET>S9I6+2GR@/-)))WX^]R3USUJUJ&C:9JNG?V??V
M%M<V?&()8PR#'3 [8KGM4\431>-_#FEZ?>6,]G?2W$5VB?/(C1Q,X^8-@<CI
MC/'6M[7M<L?#FBW.JZC,L5M;H6.3@L>RCU)/ % "PZ'I-OHYTB+3;1--*E#:
MB%?+(/4%<8.:33= T?1]/DL-.TRTM;23/F0Q1 *^1@[AWXXYJP=0LUL_MCW<
M"VW>9I $'_ LXJ:&:*XA6:&1)8G&5=&# CV(H RQX6\/BRM[(:+8?9;9_,AA
M^SKMC?\ O*,<'WZU-?:#I.I3QSWNGV\\T2E$D= 6"GJN>NT^G2L:[\07MG\1
MH-(GFM4TJ32Y;PLR;71D=%^9RV,88]A7317$$UN+B*:.2%AN$BL"I'KGIB@"
MI=:'I5Z+876FVDPM2#;AX5(A(Z;>/EQ[4Z#1]-MM0FU""PMH[V88EN$C =Q[
MMU-36M[:7T9DL[J&XC!VEH9 X!],BIZ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6JZM9:
M)I\E]?SI# F!EB!N8\!1ZDG@"KM5-0TK3M6B6+4K"UO(T;<J7,*R!3Z@,#S0
M!@^'KG2Y]7N;UM2LKC6=049AMYUE,,*?=0;2> 6))Z%G/L*SOBQ!#)X.BEDC
M1I(M1M#&[ $H3.@.#VXS74Z?H&C:3,TVFZ386<K+M9[:V2-B.N"5 XXJ>^TR
MPU2)8M0L;:[C4[E2XB60 ^N"#0!P\^DZ;=_&^9;FRMY5?P^LKH\8(=OM!&YA
MT)QQDU<^%(">"! G$4-_=Q1J.BJ)WP!["NH_L32?M?VO^S++[3L\OSOLZ[]F
M,;=V,XQVJ2QTRPTN)HM/L;:TC8[F2WB6,$^I  YH X&'P_HVJ?%SQ)!?:;:W
M$;:?:2F.2,%2Y9\N1TW<#GK^=8]HNC>(]'\1:9XCUYK&]BU2=KJ+]TDR[928
MFC+*6/R! I&>F!7JD>D:;%J#ZA'IUHEZXPURL*B1OJV,FHI] T>YU2/5)]*L
MI=0BQLNGMU,BXZ88C/% 'GOB<:AI,FO:M;K;ZWHQBB76-.N3LN8-D2G?&W3.
MTAL'OG'-6+71]%UCXMZVM[IUM/'-I-K/Y,\0(9BS@L5/!;! SU&?>N[FT+2+
MB\:\FTNSDN6*EIG@4NQ7[N3C)Q@8STQ7-CPM)=_$34=7U+3+2?3I[.*WA,I5
MV5D+$G:1P#NQU^M ' Z5<-H6E^'X+R\DMO#2^(+Z&WN7PR)&-PMRQ8$;=V_!
M/ X/8&M3Q'#IF@Z9JNH:=JD]]8W>J6,VM+&4:%(=^),"-0 6 7>.X(SUKU2X
MTVPN]/.GW%E;S614(;>2)6CVCH-I&,"F6ND:;8Z<=.M-/M8+$@J;>.%5C(/7
M*@8Y[T <OJ-OX:O7UG4-.D@N;ZXT=TE-O*'C,2@E"R@[<Y/RGK@''0U:^&[6
MI^'F@"W,.\:? 91'C.[8/O8[\=ZW=-T;2]&MVM],TZTLH7;<T=O"L:L?4@#F
MI;'3K'2[?[/I]G;VD&XMY=O$L:Y/4X  S0!Q/ATPZGXM\<V&MQ1R3^=&@CF&
M0;(Q_(!G^'.\G'<GO7)^7/)\&O#+:E^^==7MD@DF&6:#[3A.3V*!?PQ7KE]H
MFE:G.D]_IMI=2HI57FA5V"GJ,D=/:GWND:;J<<<=_IUI=1QG*+/"L@0^P(XH
M LJD=O#M1%2-!PJ+@ >P%>+#4-/DTSP+?:?-;VVGOX@WP1RR[[G8WG;WD?/&
M2>5P<9&6->U1QI%&L<:*B*,!5& !]*S%\,Z @<+HFFJ'F%PP%J@W2C.'/'WA
MD\]>: //8=$TB[U_XFB6PM98T2%HPT8*H6M 2RCH"3SD<T2V<W_"L/!_BZUB
M\_5-!LX+KIEY8/+"S)GW0D_45Z/_ &#HV^Y;^R;#==#%P?LR9F'^WQ\WXUD:
MII>KCRM'T*UTNQT2:%H[F104EASP?+11MSC.,]#SVP0";PL8]1CNO$03']J.
M&@++AOLRC;%[X(R__;2L34M5MK+XOVEMK$L<5I)I!-@TY C\_P P^8 3QOV!
M/P^M=S##';P1PPH$BC4(BJ.% & !574]&TS6H%@U33K6^B5MRI<PK( ?4 CK
M0!YYXDM-'T[P3H]KH1)TY/$-KY;>870DW +;"3]T,2...#5?QE=:?<Q_$*.V
M,$4\.GI'>R7C[C(PA9HTB3(VCG[W.6/ [UZ5<Z-I=Y;0VUUIMG/!!CRHI8%9
M8\=-H(P/PIDN@:-/=M=S:38R7+1&!IGMT+F,C!3.,[<<8Z8H X&X-O<^(/A?
M>J8I9V65&F&"Q_T4Y!/U[>M5K;1-*GN/B:DNGVKI'(2BM&"$)M@25'\))YR.
M:]'_ + T8FU)TFP_T0;;;_1D_<CT3CY?PH&@:,OVG&D6 ^U#%QBV3]]_O\?-
M^- 'F"V5I;>&?A;J<,$27\U]9++<A?WL@>W?<&;J0<#@^@KU:VU*QO;BY@M;
MRWGFM7V3QQ2!FB;T8#H?K5=O#NB-#!"VC:>8K<[H4-JFV,^JC''X5'IV@6FG
M:QJ.J0PP17%]M$GDQ!-P4L06Q]YCN.2?;TY .;\:00_\)QX%N#&GG_VA*GF8
M&[;Y+G&?3-8^HR7NA:E<7[1VNM^&KC6D>7'RW5A<^:J#'9U#A0!P<''2O1KO
M2M.O[B&>\T^UN)H3F*2:%7:/_=)&1^%1KH6D)>F\72[-;HR>:9A H8O_ 'B<
M?>]^M 'GNJ27NA:C=:B8[76_#4^LQR3J/ENK&Y$J(,=G4.JX'!P0.E21S6EK
MKGQ1CN)(8@R0MM<@;@UKCIWR>/K7?#0M(6]-XNEV8NB_FF80*&+_ -XG'WO?
MK1<Z#I%Y?B_N=+LIKP1F(7$D"M($.05W$9Q@G\S0!Y9I&JP6T?P\BO\ 419Z
M=+H>R&<A#&+H+%PQ<%0VS< 3SR1W-=YX+TO2])M-2ATC4);VVDO7F9B4,<<C
M %ECV  *#V'0D^]:T^@:/<Z6NF3Z58R6"XVVK6ZF-<=,+C JW:VEM8VL=K9V
M\5O;Q#:D42!%4>@ X% '%:-(MY\3O%]CJT:2.+>V%I',H(:U*'?M![%R=WOC
M/05Q$6GK+X2\*17L8FM8_%WV:QDDY8VF^0*H;KM..G0@#VKV2_T;2]4DCDU#
M3K2Z>+(C:>%7*@]0"1P#1=:-I=\D"7>FV=PL&/)6:!7$>.FW(X_"@!^GZ78:
M59_8]/LX+6VW,WE0H%7+')X'K7CS:-I;?#CXD2&PMB]OJFH>2QC'[K;M(V?W
M<''3%>U[0%VX&W&,8XQ6:/#FAK;S6ZZ-IPAG;=+&+5-LC>K#&"?K0!PT]C:6
M/C+X=7-K;Q0SW*7(GE10'FS;%CO;JWS<Y.>:Y_4+^PN-$TB^TZ6"WLV\5QR(
ML\F^Y=_M!$CL21L'7Y<$[=N3SBO7#H.CE[9SI-B6M1BW;[,F81_L<?+^%1MX
M9T%S<%M$TTFY<23YM4/FN#D,W')!YR: .2T%-.;XJ>+PZVI\V"P:+<%^?=')
MDKZY]JY#3+^VT[X.^%Y3*D-J-2C&J/&JL4A\Z4!G&#\H<)U';%>S'3; ZBNH
MFRMC?*GEK<^4OF!/[H;&<>U1Q:-I<%O<V\.FV<<%TQ:XC2!0LQ/4N ,,3[T
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M3;XXC:IL1O4#& ?>@#S[58FT#QMXJ7P]:QVT_P#PBHN(X;:,*&F5Y0K;1U(
M JGJ$NBS^!/AS>6KV[;=7T\B7<-P<G][D]<[LEO?DUZG'I&F17_V^/3K1+S;
MM^T+ HDQZ;L9Q51/"?AR.9YDT'3%DDD$KL+1,LXZ,>.O)YH \_5M(UV^\::+
MXCUI;&9[M@\<IA4FUV+Y3HSJ3@#D8/!Y[\V[+1]-D^*NG0R0?:D/A92SW<8,
MDQ69 K2#'+8]1U^E=Y>Z!HVHWL%Y>Z58W-U!CRIIK=7=,<C!(R*D?2-,DO\
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MX,;IY^5V#<5V[0/,53COP<5#XJT+0['P1K!TZ^:_236;6=G)0QP3/-&'$10
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M36=2\/\ @?4=6TJ6&.YME5@98MX(+!3@9&#SWS]*ZFN)^+I ^%FNDG'[N/\
M]&)0!T=V]P-<TU8]3MH(")?-LY$!DN3M^78<Y&W!)P#FIVU;35OA8MJ%J+PG
M MS,OF$XS]W.>E<CXBC@7XL^"9E2,2R0WX+@#<P$2X&>_4UQ>L:KIMSX?CN;
M&>VL[8>*4E\B63?<&47 #R,2?D'7"XX&.><4 =[9>)YK?QKXEL-9U"R@TZPB
MM'MW<"$+YH<D,S-R?E'I]*F\8ZY?Z5'H$^F7$'D7NK6UK-F/>7CD;G:V<#CO
M@]>U8EA9:-JWQ2\6'4+>RNXCI]D\?GJKKL*R;F&>,8QS[US=M;R67P_\*1.7
M%I_PED)L?,)S]F,[^7U[$<CV(H ]?O=5T[33&+Z_M;4R'">?,J;C[9/-6BP"
M[B0% SGM7E\]YIL_C+QAHOB36SIGVE8_*68PHDUH80,*TB'HWF9 /4D^M=YX
M;M;:S\-:?:V<MS-:10*D,ER<R/&!\I/ [8[#C% $>A>*=(\1O>+IMY#/]EG:
M$[) 2VT#+ ?W<G&>AQ5ZTU73K^62*SO[6YDC^^D,RN5^H!XKQZYNI(?AOX]A
MT]@;Q-<O&EAB/[W[/YZ^9@#G&PG\#76^(UANO$G@2_T%HS,UR0KP8PUD8B7S
MC^#A,=@2.] '5>(_$.G^%]%GU34IECAB'RJ6 ,C=E7U)K$U'Q-/!XV\/6MO?
MV;Z-J$%W)*Z@'F)0<^9G&,GT&,=:A^+@!^%^LD@':(CGT_>IDU4\0#3]3^)7
M@E1]GNK8Q:@0 0Z,0L?X'!'YCVH [FVO[.]M!=VEW!/;$$B:*0,AQU^8<4VR
MU.PU)7:POK:Z$9VN8)5?:?0X/%>/W4_]E^'_ !AY >+3;;Q7&]VEN@.RW_<F
M3"X(QZC&#SD8S7;:%!X?O/&!UO3=?EU2_FL/*E\J2%HA$&!4N(U&&R<#/. ?
M0X -+Q5XG;0FTVQLX%N=6U6?[/9PNVU<@99W(YVJ.3CGH/>FZB/%.GZ9)=6U
MW97\Z ,\!M&CR,_-LPY.0,D YSTS7.?$!&TGQOX.\5S@_P!EV$LUO>28R(!,
MFU9#Z+GJ>W%=Y-J=G#:I<>>DB2X$7EL&,I/0+CJ30 7FJ:?IQ07U_:VI?[@G
MF5-WTR>:DGO+6V\O[1<PQ>8<)YD@7><9XSUXKB/#DL5SXR\<6&M+&T[2QE4F
MQA[(QX7&>J9WY[98YY-<;ING^9X?^&Z:K$LV=5ECA:<99K;;+Y:DGJI7;QT(
MQ0![$-;TEH%G&IV1A:,RK(+A-I0'!;.>@/!/2IX+VUN;,7EO<PRVK*6$T<@9
M"!WW#C%>=W6@:#;_ !?T>Q72["*V;1[@K;K"JHSB53]W&#CYC^O:N8N[=]#L
M=9^QIL\*Q^+;8SHH_=K;C:9P!_<$FT$=."/6@#VBSU.PU%'>ROK:Y6,X<P2J
MX4^^#Q38M7TVXE2*'4;221U9U1)E)95.&( /(!!!/8BN0U:T$WQ9\/S6*HZ3
MZ==+J84 K) -OE;NQ^<G&?>N7\-V?AVP^"%QK%_I:7'E17T<CP +,4:9T**_
M501@<<8H ]6M]9TN\69K;4K.=85W2F*=6$8]6P>!]:Q8/%-EXD\,WUYH>LV=
MJZ>:B74Q5UBVN5$C*2/E.TD9[8KE=+O;?_A;&E>9?Z<XDT!X52U8%%_>QE(]
MQ)+G!.#QGK@5BPFQF_9_UZW<V[W$'VUVC."T;?:)-I(Z@\\4 >PR7MM8V,<]
M]>V\<> #/(XC1CCJ,G'/UH.I6(L/MYO;<69&[[095\O'KNSC%</'=O%\4?#T
M=Z<6,V@LM@S?=-SN4N!_M>6!^&?6N1\46*P^%OB:J1H=(2^@>S! VI.?+,^S
MT^8X..^?>@#V>'4;&YNYK2"\MY;F#_6PI*K/'_O*#D?C5FN NK*ST[XN>&UL
MK>&W\[3+M)!$H7> T9&<=><FNSTW5M/UFU-SIE[!>0!S&9() ZAAU&1WH >-
M1L3)/&+RW+P#,R^:N8QZL,\?C2#4K!H(9Q>VQAG<1Q2"5=LC$X"J<\G/&!7&
M)=VNG_&357O+B&W631+=E:5PH8"60$C/7'%</I\=A>?#/P(KK!(R^)EB8$#<
MH:XFRI[C(QQ0![1'J%OJ-M<?V7?VDTL1*%T82K&_HP4C\LBL3P-X@GUGP!IV
MN:O/"DTT;O-)PB+AV'T P!67HT%M8_%OQ%!:Q101/I5I(T<2A5+!I!G [XP*
MXS2-1&F_#?X>75U=26ND+>2"[N(U5A$Q\T1,VX$;0YZD<'!Z@4 >R0:II]U9
M->V]];36J9W3QS*R#'7+ XXH@U73KF"6>"_M988AF22.965![D'CH:\^NM'T
M"YM?$$VF>*)OM&HSV;2WJM%)!%<+(OE<(JKDD+N'<$9ZBHFFOM3L_$6B^(3:
MZ1K$+V.[5;+YH)F:3]PQ5NAW* RGL?2@#TBTU"RU!6:RO+>Y"?>,,JOCZX-6
M:X3P[X@N-/U#7X_%L%A8WMA%;O<ZC;N1;W$;;@C'=RK<$8/MCC%=Q#-%<01S
MP2))%(H='0Y5E(R"#W!% %8:MIK7_P!A&H6IO,D?9Q,OF<#)^7.>E)<ZQIEF
M)C=:E9P"$J)?-G5?+W9V[LGC.#C/7%>.W&K:9<Z+X6N[&XMK.P_X2A)4MI)=
MUPN9G\R25B?ER2?EQP&&2:Z+3],TJ\\=_$(R6=K*GV:T8912!N@<L?Q]: /1
MYKRVMK4W4]Q#%;@ F5W"I@].3Q7,>%O$5WK/BKQ/927EK=65@]L+22V4!2LD
M9<\Y.3GC.>W:N&\/:I]GC^%PU.8+I;V,H220_N_M00+&&)X!"[@N>Y.*Z?P=
M-8_\+,\>1VLL'SRV;[8V')\GYCQ_M9S[T =Q=WEK80>?>7,-O$#CS)I BY^I
MIAU*Q%A]O-[;"SV[OM'FKY>/7=G&*Y'4;IX/C+I$5\<6,NDS+8E_N_:O,!<#
M_:\L#\,^M</XIL5B\,?%!8XT.D)=P/:# *I<$(9RGH=Q ..^?>@#V:+4;*XN
MIK2WO;:2ZA'[V%) SQYZ;E!R/QKFO"?B:>ZM-;DUZ^LXS9ZS<6,<F!"A5-N!
MR3SU/4UGWEE9Z=\6O# LH(;?SM.O%?RE"[P#&1G'7G)JKX8T6S\2^'_'6CW@
M#076OWT9.,E#\N&'N#@CZ4 >@MJ%DGD;[N!?M!Q#F0#S?]WGGJ.E4?$7B+3O
M#&DR:CJ4Z1Q@A44L 9'/ 5??^0R>U<KX)O;[Q%-:KJT#+=>'5>TN2R_+)><I
MO4^T8SG_ *;>U6?BWM'PYOG?&$GM6)/8?:(\F@#JY-6TZ*R6]DU"U2U<X6=I
ME"'Z-G'8U8@GAN8$GMY4EA<922-@RL/4$=:X;^T(V^,5BLLD;:?-HTBZ<ZD&
M-IQ+^]"GIOV@=.PJ;P%;26NM>+X[?C2!JF;11]T.4!F"^V\XXXR#[T ;D_BK
M28/$T?AYKV!=0>!IBK2 ;/F554C/WFW9 ZX!K)\)>*GNH=577M1LHYX=9N-/
MM^1")!&5 "@DDGGU)YJI=S6UM\;;9KB2*(2: RH9"!N?[0N ,]37'7MC93?#
M;XDW<EO"]PFLWVV5E!92KJ5P>V#SQ0!['?:E8Z9$);^]MK2-C@//*L8)^I-6
M$=9$5T8,C#*LIR"/45YI+JUM%\0KJUUW6&TZ*[TFW^PR2>4(ID^?S5W2*PR2
M02!C( SG KKO!>GZ=I7A2SLM(N;BZTZ+>+>:X<,77>>00 "O]TXZ8QQ0!J7&
MJZ=:7<5I<W]K#<RX$<,DRJ[YZ84G)H.J:>+F2W-_:B>,%GB\Y=R@#))&<C K
MRNWET36;3Q5H7BG7Y;"Y_M.<W%JS0H[IOS"\99"[?($ P2> !VJ_XXTZ5KBS
MU30H[J75M-LL:D%<++-9,/FB<@?ZTX++CH58\?+D [/5O%^B:/;V,T^H6Q6^
MN$MX"LJD.2P!.<XPO))[8K0N=8TRR@BGNM1M((I@#%)+.JJX/3:2>>HZ>M<'
MXLO](OO#_@?4--: :4VN61B90%1(\.,'^[CH1VQBH9M3TR;Q[XBT_6=;&GVU
MY9VYLF<PB*XM3&0P5I%(^^6. ><^U 'H\M]9P/&LUU!&TBED#R %@!DD9Z@#
MGZ5FZIXLT72O#EQKTNH6TEA$I(DBE5A(P_@4@X+$\8K@?[$T6#Q1\.+*V#7E
MDL-^D4MX%9YHUC!3)P-R]UXZ8K-U>&*'P7\5;6WC1(8KXND2#"H3'$20.W.:
M /8[.\M[^U2YM9HYHG'#QN&'TR*J:_KMAX:T6YU74IUBMX$+')P7/95]2>@%
M16VO:*@T^U74K,37:D6T:RKF4J 6V^N,UC?%1=WPO\0_+DBT)Z=.10 W4O%%
MPGBOPK#8WMH^DZF;D7!4!CF.$N/GS@ 'KQVZUU%MJ5C>69O+6]MI[49S-%*K
M(,=?F!QQ7!:\=.U/QA\/D4V]S;-)=Y"D,C$6^?H><5B7<^DZ5:?$6"\M/,TT
M:I:C[-%)Y*;W2+DL/NKNP6/H#UZ4 >IQZWI,UI/=Q:G9R6]N,S2I.K+&,9^8
M@X''K4/A_P 0Z?XFTN/4-.G22)\D ,"RC) W#MD#.#7$:7=QR?%C6(Y=0LKF
M:XT2$8ML!&</)\H&26('OGZ5K?"6XMI?AIHD<,L3RQVP$JHP)4[FZ^G0_E0!
MM?\ "4Z5+XCG\/P7UN-1BA#L&<$*S$A5QD$MQD@<XQZUE^"/%3:IX?MI=;U"
MS74;B[N(8T!6+S=DK( BDY/ 'K5.TFMK?XSZPLTD4;RZ5:^4'(!<^9(./4UP
M[6EFGP1N]16"$7D>LETN-HWJ1?@##=1P3^9]: /:;W5-/TW9]OO[6U\PX3SY
ME3<?;)YJV"" 0<@UYA<WNG2>.O%FC^(M:.F+<Q0BW$IA6.>U,0#!6D0]'\S(
M!ZDGUKN/"]I:V/AC3[6QFN9K.&$)!+<G+O&/NDG XQC' XQ0!D:9X@U#Q7J>
MI+HTL%KI6GW!M&NI(C*]Q,OWP@R JKD#)SGMBM73)M;76;VTU,6TEJD,3VUS
M!&R;R2X<,"3@C"=#WSWP..^%#IH,.K^$M0<0ZI9W\LJQR'!GA<@K*N?O \].
MG>M/XEZA<2?#_P 01:09);B"%?/,'.U"Z^8N1_%Y>XD=0.>,C(!U=MJVFWLD
ML=KJ%K.\0S(L4RL4'N >*/[7TW[*;K^T;3[.&V&7SEV!O3.<9]JXKQ(L%WK7
M@*_T!HS*UX!&T& #8F(F3I_!@)[ D=ZY>]O+.W^'7Q+LYIX4N&U:^*PLP#G=
MM*D+UY'/X'TH ]>N=4T^S_X^KZU@_=F7][,J_(.K<GIR.?>LZT\7:+?>(;C1
M;:_MY;J"*.1MLJD$ONPHYY.%R<= 17&26&D:M\2_#GGV]I=0W&@3%@RJZRX:
M,#/9L#/7^E:&ABPT[XL^(K0"WMP;"P2VA&%R )!A![<=* .\EEC@B>6:18XT
M&6=S@*/4DU7@U33[JUDNK>_M9K>+/F2QS*R)CKD@X&*Y+XBW4EI<>%I9^-(&
ML1?;F/W5X/EE_P#9#X//&0*/LSK\9_-L@!!+HW_$Q"_=9O,Q$6_VL;@/8&@!
M-%\1:EXKN&O-'U:PCBMM2DADL9 K^9:H^POD?,'/4'[O(&.YU/$7B::PUG3/
M#^EQ13:OJ6YD,V?+@B09:1P.3Z!01D]Q69\+?+/AS4&3:?\ B;WHRO\ UV:L
M_P 38T#XP:%XEOCY>E7-@^F/<-]R"7<77<>P;.,T =->?\)+I_V1XKFTOXWN
MH8[A3;&-TC9PK,F&(X!Z'MSGC!S_  [XID>^\0PZ_J-C$MEJGV2V<X@4CRT8
M#YF.3\Q[FNIGO[:#R0T@9YV"Q(ARSY]!W ')/8<UY3-86-WHWQ8GN+:"66.6
MYV.ZABF+92,9Z<C/'<#TH ]5O=2L=-C62^O;>U1N%:>54!^A)IS7UHD<,CW4
M"I.0L+&0 2$] I[Y[8KSNSU6Q.L>'H7F@M]2/AM)9+V]D)C$#%<JB$@,Y9<D
MD\ =\XKEM,2POOAI\.4D\B=TUZ*!\X+*I>;Y#Z C''TH ]LL]1LM061K*\M[
ME8VV.895<*WH<'@^U-M]4T^[NI+6VO[6:XBYDBCF5G3G'(!R.:\NUR*XT_7?
MB'#H,8@N#H=O(D=LNT[@) 2 /XMO3'/2NCTB^\(ZXOAR_P!)DMYM1MK5TL(H
M)?F@5H\.'0'A1@ [AP<8Y- '7?VKIW]H?V?]OM?MN,_9_.7S/7[N<TV;6=+M
MI#'/J5G$X<1E7G52'(R%P3U([5Y3X;;0?$/A#1K?5?$-W'J]C=J[V"M"ERMZ
MKG.!LWDLQ))SR"<G@UN^%M$TBZ\?^-3-IUI*UO?VLD(>)6\IO)5MRC^$[N<C
MN/:@#NXM5TZ>VDN8K^UD@C^_*DRE5^IS@58BECGB66&19(W&5=#D,/4$5YB+
M.;1?$>I^!X(&&G:])]LM71?EAB;_ (^X\]N!\OIY@KT:_%Q'I-TM@JBY6!Q;
MKCC>%.T?GB@ &JZ<;_[ +^U-Y_S[^<OF>OW<YKF];\4QCQ9;>&K;5;:QEEM9
M9Y;DLC-&RE51 K<9)8G!YP..N1Q4QBU+]G^R>T+?VQ T(A(_UZWXF ;WWEBV
M>^&-=3.%_P"%T:6LHC,IT"8L .K>='_@: -F^NM=TGP+=7MU/8OJ]G:2S2.D
M3&&1D5B/ER",@#//K67I6I>,M2\&V&NVLNCW-Q<VJ7/V$VLD6[<H;8)/-;!Y
MQDKCZ5M^,2%\#Z^20 --N.3_ -<VK&\*:[IFA_"G0+[4;R&""+3(,EF&21&/
ME ZENV!S0!J^%_%MAXG\,1ZY&?LL7S+<1SL 8'4X96/MZ^A%&NZYCP;JVK:%
M?6<\EK:RRI*I$T>Y%+8.UASQZ\5Y5ID%]X9\,Z+JFM&XTS3]2\12W]V-BDVJ
MR1L(=X8$ !@K<C@XZ$"NKO+/0XM#\=:EI.L2ZE->Z7(UY(LD30AA"X7'EJ '
M(Z]\8)ZC(!U^DZU#_P (II.IZK>6\#7-I#(\DKK&I=D#'&<#UXJ\^KZ;'!#/
M)J-HL,_,,C3*%D_W3GG\*\^M=1L(6\!P,T$.H_V*98+NZD(ABC\J,/A<@.YX
MQR,#)SV.5H.F+X@^$.HV>GSQRZCI^H7-W9;,$QRQSN\> .F[!'T8T >L)J5C
M)=M:)>VS7*9W0K*I=<=<KG-,;6=+2T^UOJ5FMMNV><9U";O3=G&?:O+6\0W8
MUW2?'ME9,;/6K?\ LH6^PAFEV[X6;OS+OCSTV@'O70:F=.T/Q!X5TK=#'J,5
MM<O#?73E8D&%\UBH(#NQ.<9&,L<]B =M_:-B+2.[^VV_V:3 2;S5V-G@8;.#
MFF#5]--K+=#4+3[/"YCDE\Y=B,.JDYP#[&O$R;"Y^$]Q$TL$[6_B7"D$ QJU
MYU&/N@C/2NP\4?V;X7\7>&_FCT71KAKDO<6T4:1K=LJ!&?<I4$J'4,1GD\XH
M ]"M;NVOK9+BTN(KB!^5EB<.K?0C@U-7+^#=/T>Q;5I-%U&:_ANKLSSRET:+
MSB/F";%"^F<=_?-=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5!=V5I?P^3>6L-S%G.R:,
M.N?7!J>F2S16\+S32)'$@+,[L J@=R3TH JG2-,,L,ITZT,D  B?R%S&!TVG
M''X4UM$TES<%M+LF-RP><FW0^:P.06X^8@\\T^TU?3;])GL]0M;A(?\ 6M%,
MK!.,_-@\<>M1VNNZ1?7"6]IJEE<3R1F1(XKA69D!VE@ <D @C/K0 ^\T?3-1
MECEO=.M+F2/A'F@5ROT)'%/N]-L;\1B\LK:X$9R@FB5]OTR.*S-8\7:/H>LZ
M;I=]>017-\S[1)(%$:*C-O8GH"5"CU)]C6-IGBQK3Q3XJM=?U>R@L;":VCM7
MF*0*/,BWD9)Y/X]J .IO-'TO4'A>]TVSN6@.8C- KF/_ '<CC\*NU6N=0LK*
MU%U=7<$%N<8EDD"J<],$\4ZSO+74+5+JRN8;FWD&4EA<.C?0C@T $5C:03SS
MPVL$<TY!FD2,!I,=-Q'7\:BLM(TW37=K#3[2U:3[Y@A5"W?G YI+_5]-TL*=
M0U"UM P)7SYE3('7J:DNM1LK*W6XNKRW@A? 6260*K9Y&">M $TT,5S"\,\2
M2Q2 JZ.H96!Z@@]150:-I8DAD&FV>^ !86\A<Q@= IQP/I2-K>DI81W[:G9+
M9R'"7!N%$;?1LX-3'4;);W[$UY;B[V>9Y!E7?M_O;<YQ[T -@TK3K7S?L]A:
MP^<,2^7"J[_][ Y_&BPTO3]*B:+3K"ULXW;<R6\*Q@GU(4#FJ,_BWPY;0F67
M7=.5 CR<7*$E4.&( .3@@CCOQ4OA[7['Q+HMMJ=C+&\<T:N45PS1E@#M;'0\
M]* -)T21&2159&&&5AD$>AJA8Z!HVES--I^DV-I*W#/;VZ1L?Q J*.X(\1W8
M;6[9H([52=.VH'A.3F5FSG!&!@C'%/C\1:'+/;01ZQI[S76?L\:W*%IL$@[!
MGYN01QZ&@">]TC3=1DCDOM.M+J2/[C3PJY7Z$CBENM+T^]>-[NPM;AX_N-+"
MKE?ID<5-<W-O9V[W%U/%!!&,O)*X55'N3P*J'7M'5;<G5K$"Y_U!-RG[WG'R
M\_-SZ4 8&I^&;K4OB%9ZO<6>GW&EP6#VK1SON<LSJVX(4(XVXZ]ZZE+2VCM!
M:);Q+;!=@A5 $V^FWICVKF?'GB&;2?".M7&CZC:QZI80><R$+(R#W7/&>Q(Q
M6UI^M:=>S?8HM1M)K^*)7GMXYE,B9 Y90<CK0!+::1IEA;R6]GIUI;PR##QP
MPJBMVY &#3H-+T^UMI+:WL+6&"4$211PJJOG@Y &#531YVD;4GDUJVU&-;MM
MGE*J_95VJ?*8J3DCKDX/S4]=8LM3M[J/2-5LIKF*/.8Y%E\O/0E0>E $]OI&
MF6A@-MIUI";<,L)C@5?+#=0N!P#WQ2-HVEO'-&^FV;)._F3*8%(D?^\PQR?<
MUSG@7Q=#J_A?0VU75+/^VK^W,OD&1$DDY/*IUQ@=AVKKV940N[!549))P *
M*D^DZ;<V264^GVDMJA!2"2%612.F%(P*632M.ELDLI+"U>U3[D#0J47Z+C J
M"/Q!HLL<LD>KV#)"H>1A<(0BGH2<\#W-3'5M.#6JG4+7-V ;8><O[X'D%.?F
M_"@!!H^F+/%.-.M!-$ (Y! NY .F#C(J'1-$M=$AN4MHH8S<S&>58(A$F[:J
M_*HZ#"CZG)[U+=ZSI=A<);WFI6EO.^ L<LZHS9.!@$]S7-OXEGT[XB:C8:IJ
M5K!H\&E1W:F4+$L;-*R?,Y//W?4=>E '47&F6%Y=075S8VTUQ;G,,LD2L\9_
MV21D?A41T+2&@BA;2K$Q1$M&AMTVH3U(&.*M6]Q!=V\=Q;31S02*&22-@RL#
MT((X(JK=ZWI5A<"WO-3L[>8XQ'-.J-R<#@GN>!ZT ._L?2_/DG_LVS\Z12KR
M>0NY@>H)QR*5-)TV.QDLDT^T6TD^_ L*B-OJN,&G7VI6.F1"6_O+>UC)P&GD
M" GKWK*U?QEH>C_V9Y^H6Q_M*54MV$R[64\E]W3:!WZ=!WH TDT;2XM._LZ/
M3;-+'_GV6!1'US]W&.M"Z/I:63V:Z;9K:R'<\ @78QXY*XP>@_*JL5R9O$Q$
M6MVLEN;(,--14+[MV?.W [MI! QC'?-6?[:TK[>+#^TK/[86*BW\]?,)ZXVY
MSG':@".;1+ Z5/I]M8V,4,WWHS:JT9/')3@'H.OH*LZ=80:7IEKI]L"(+:)8
M8P>NU1@?RJ"[U[1[!IUO-5L;<VZAIA+<(OE@G +9/&3TS5R">&ZMX[BWE2:&
M10R21L&5@>A!'!% %3^P])_>_P#$KLOWT@FD_P!'3YW!R&/'+ ]^M*=&TLR3
M2'3;/S)QB5O(7,@_VCCG\:6^UG2],95O]1M+5F&5$\RH2,XSR?6G7.J:?9-$
MMU?6T#2@F,2RJI< $DC)YP 3]!0!&^B:3)IYT]]+LFLB=QMVMT,>?7;C&:EM
M=-L;%G:SLK>W9PH8PQ*A8*, ' [  #V%/L[RUU"TCN[*YAN;:49CFA<.C#U!
M'!JNNN:0]PUNFJ633+NS&)UW#;][C/;!SZ4 3WNGV6I0>1?6D%U#D-Y<\8=<
MCH<$=:8^E:=+9)926%J]HGW8&A4HOT7&!49US219QWAU2R^RRMLCG^T)L=LX
MP&S@G/&*@EN2GB55;6[:.!+-VDTUE3S"0P_?;L[@H'&,8YH L_V/I8FBF&FV
M?FQ "-_(7<@'0 XXJCJ.G7FGZ=(WA2PTB"_>12PN(S'&ZY^;)C&<XZ4>'?%>
MD^*(KB33+N*589GCPL@+$*<;\=0I.<'O6@VJZ<E\;%[^U6\"[S;F91(%QG.W
M.<8[T 0Z+ITFFV!2XE6:[FD:>YE5<!Y&.3@>@&%&>RBKL]O#=0/!<0QS0R#:
M\<BAE8>A!X-4X]=TB:SEO(M5L7M83B2=;A"B'W;.!1<Z]H]DZ)=:K90.ZJRB
M6X520W"D9/0GIZT 27&DZ;=VD=I<Z?:S6T>/+ADA5D3'3"D8&*L000VT*0P1
M)%$@PJ1J%51Z #I4%[JFGZ=M^W7UM;;P2OG2JF0.I&3VR*G25;BW66WE1TD0
M-'(/F4@C@\=10 R:QM+F>*>>U@EFASY4CQAF3/7:3R,^U5AH.CB%X1I-B(I&
M#.GV9-K$="1CDUS'A#Q@D]C<1^(=9L4OO[4N;2W61TA,JQR;0%7//ZGFNHO-
M<TG3GD2^U2RMGCC\UUFG5"J9 W')X&2!GU(H +G1-)O;:&VN]+LI[>$YBBEM
MT94_W01@?A5Y55%"J J@8  P *HW6N:38K&UWJEE;B50Z&6=5W*>A&3R/>IG
MU&QBNH;62\MTN)QF&)I5#R#_ &1G)_"@".;2-,N;^*_GTZTEO(O]7</"K2)]
M&(R*D&G6(DN)!9V^^X&)V\I<RCT8X^;\:+?4+*[>=+:\MYG@.V98Y58QGT;!
MX_&J\6O:1<R"*WU:QDE8#:JW"L3G@< \YH >-%TH6360TRR%JS;F@$"["?4K
MC&>!2WNCZ9J8B%_IUI="$YB\^!7V'VR./PKEO"WBX$:S'XCUBQBEAUN>PM3*
MR0!U0)A5!/)^8]R>:V;SQ=H]CXGMM GO8$O9H6E*O(%V %0H.>[;N!UX- &G
M-IEA<7,=S/8VTL\?W)7B5F3Z$C(ID6D:9!Y_DZ=:1^>"LVR!1Y@/4-@<_C5F
M>>&V@>>>5(HD&YY)&"JH]23TKE?&7B5K;P-K.J>'M4M'NK&$R%TVS!3Z$9P#
M]?RH UKKPYI]U/IK?9;6.+3W$D"I H9""" K?PKD D#K@=L@ZTL4<T3Q2HLD
M;@JR,,A@>H([BL[3=;T^^D%E'J-I-J$<*O/;I,ID3('+*#D=?3O4BZWI3WXL
M%U.S:\+%1;B=3)D=1MSG([B@ _L32<P'^R[+-N-L/^CI^['7"\<?A2C1-*"S
MJ-,L@+@;9@+=?WH]&XY_&L#3]6U6X^(.OZ-)=1&UM[*":V40C]VSEP<\Y;[H
M[C\*E^'FL7^O>";+4=3E66[EDG5W5 @.V9U& .G"B@#>@TS3[62.2WL;:&2.
M/R4:.)5*IG.T$#A<\XZ4^ULK6Q1DM+:&W1V+LL480%CU)QW]Z@U+5++3HL76
MHVED\BGRVN)%4<=\$C(&16!X$\13:GX L]:UN]@$KO,)9VVQIA9G1?8< "@#
MI9=/LI[E;F:TMY)U0QK*\8+!3U4$C.#Z56_L#1OLYM_[)L/)+;C']F3;GUQC
M&:H:OXST+2/#-SKS:C;3V<(*JT,RMYD@Z1J1GYB>,=N]:+ZYI,=@E^^IV:VC
MDA9S.NPD9R V<$\'\J %NM%TJ^$ O-,L[@6_^I$T"OY?^[D<?A5ZJ)UG2Q;6
MUQ_:5GY%TP6WD\]=LQ)P ISAB3Z5%%XCT.=(WAUG3Y%EW^64N4(?8"7QSS@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M..N#[UZ MM EM]F6&-8 NSR@H"[?3'3%11:9I\"(D-C;1JB%%5(E 53U P.
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M-<Q2NO,\:'="@/HT+."!W5?6O;%4(H50 H&  . *:(HP7(C7,G+\?>XQSZ\
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MZ'/_ "\25UQTZR,KRFSM_,<$._E+EL]<G'.:?;VEM:*5MK>*%2<D1H%!/X4
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MZCI@5SC(]0#^%>L)86<5I]DCM($MO^>*Q@)Z_=QBF'2].:-8S86I122JF%<
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M>&K8*9]?TR,-,8 6ND ,@ )7KU&X9],BN$M+BZT?5K!M.O;;6O#M_K+QBTE
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M<",F9,%?J,X(ZCVKD(K];#PHU['+(-+L/&-P]X;4!C#!O?:^,'Y59D;IZ$4
M>R:?JVG:LLK:?>P7/DMLE$3@E&]&'4'ZT7VJV&F!#>W<,!DSL#M@M@9.!U.!
MU]*YOPM_PCM]XAO]8T349=3N+B!([J[60-%\OW%.T ;\9]P.N,C-?Q%J^GV?
MQ!TRTFDM]/NVT^5DU*X;^ NH,,:D[2Y(!R0< =#F@#K/[5TXZ8NI"^MC8,H<
M7(E7RR#T(;.*Y32/$\E[\0-<L_[6AFTFUL(9T "J('+,&W'KG"CK7GVA:O#8
M^%? UQ<3YT>QUFZ746/2"0O*(3)_=P6#<XQ\I]*[71M1TN\^,NM?9;NUG$^D
MV^#'(K"0J[YQCK@8S0!TFCZO96NBZ:M]XEM-1EN7,4-Z6CB%T^X@! IP3VP.
MN*U8=2L;B^FL8;RWDNX &E@20%XP>A9>HKQRQ>.V^#7@2[F81VUKK=M+-*W"
MQH+AP6)[#D<UI:MJHO\ QIXM_L&\CFO9O#*K9M"^3*ZM+_JR/O$9[9Y^E '1
M>+?%HMK_ ,/P:/K-OON-9@M+F%-CF2,L0X!.>A !QTSVKHK*Y6;Q)J,::[#=
M+'%&#IR!-UJWS99B/F^;T/3%>9:AX@\/7?@SX>_9+VT4VNK:>'B+J'M]H*ON
M'5<'@DUIW;33^-/B#!I$J_VC+H< MQ$PW&39+C'ODK^8H ]!@U[2;F_%C#J5
MK)='=MB64%FV_>P.^.^.G>D&OZ0U^MB-2M3=-(8EB\T9+CDH/5AZ=:XWPIKG
MA+Q!I?AB*%89]6L(E6*T7(ELW";)"R_P@ $9/!XQR17'W.O:5=:)X<N+:YMM
M/M8?%$4C:<&R]L//?>\[,25)))_A #8YQF@#U.R\9Z-?>(M2T:*\@$U@J>86
MD W,0Q8#/7:%!)]_:IM#OH4\/?;+GQ!;ZG KREM1&R./:'/&5.WY?NY]JYOP
M]?V</Q3\96\T\:2W2V,D,;G#2((#D@'D@=SV[UQFG71M_AAX9O8V#Z79>)&E
MU'R^0D(N)2&8#^$$HWY&@#V*UUO2KU+A[?4+:1;;_7XD'[KC/S?W>.>:K1>*
M_#T]S:6T6MZ?)-> FWC6X4F4 D?*,\\@C\*YNZ2*[^+6FZAI\T3V\6DS+J4J
M,"AC+ Q!CTSG<1[ UP^GM8P?!'PA*K6\;C6+9RX(!W"Y()SZA?TH ]TK.MM>
MTB\O!9V^I6LMRP)6-)02P'4KZX[XZ51\;1:A<^!M;BTG<;V2RD$/E_>)*GA?
M<C./>N+U6XL]?\'^"?["DC-^E]9M;)$1O@"#$H('("J&##IQCTH V=1\3_VK
MXQN_#.GZ_%IKPV:O'/&8G9KEG90A#@@[=O*C!.[J*ZV.X.G:1!)J]Y!YL<:+
M/.!Y:/)P"0">,MT'OBN2T^Y@;XU:U$)HS)_9%LNT,,Y$CY&/Q'YBM/QQ;V]W
MI5E#)JS:3<M>QFSO  5CG 8KN#<$'!&.Y(H T_\ A)-$%L;AM6LEA$OD%VG5
M0)./D.3PW(XZ\U:74K%M2;35O+<WRQ^:;82#S F0-VWKC)'/O7DWB#4=2NOA
MYXGAUBUM1>Z=J=I]JO++)AN0'@/F 'H0@4,.V*UK_6+34?BK"VD:C;RRR^';
MF&VECD!1IO-0J%;H3QG ]* .]77M);4%T]=2M3=LS(L/FC<S#JH]2.XZBN4T
M'QA'9W_B*+Q+KEI%';:J;6T:X*0C;Y:-M'3/+=>:RO!>M>%]7\*^&M*NTCEU
MO39(E^P-D7$-S'\KR%>N!\S$GCGUJCNL)="^+4C-;M(9;@;B020+9=HS_O9Q
M[T >O @C(.0:X?0M:O[B+QC'JFM16ZV%^]M;WDB(BVZ^4A4D' ."V>>M=#X4
ME$_A#190X<-8P'<#G/R"N"L[BU?1_BH&FA91=7).6'3[,H_F"* .^M]5L['1
M-.EOM7AN/.A0)=':OVH[<[U4>HRV!VK"\9>(IX/#^E:IH.J0F"?4K:%I(@DB
MRQO*%8 G('<<<USMGK6FVEE\/(II;6UN'TC,.IW+_)"!#&'11D*7;C[W3'0Y
MQ7/)<6<WPRG@>9)8[;Q4&N?- &R,W><R# "@C).0* /8]/\ $6BZLURNG:M9
M71MO]?Y,ZOY?UP>!P>?:N0\3:UJ.E_"W4]7TKQ+%J%S!*S)?10QE2#*%V #*
M_*#C/M4DEE:7'Q8TN_T=8/+M]-G74I8,;"C%?)1B.,Y#$#T'TKC)KBV_X9YU
M\)-%M%].HPPQS=Y _*@#UF]N5'B73(%UV&V;9*7TTA"]T-O#<_,H7!/'7O5'
M3O'WAW4&U4C5+2&+3[@P/)-,J!@%0EQG'R[GVYZ$BLGQ%<6Q^*O@=EFB+/#?
MX(8<@QIC\^U0^"VL+O4/'&AWC1/+<:U<-):,?F:%HHAN*]=IY&>E ':-K.EI
M9V]XVHVHMKEE6"8S+LE)Z!3G!SVQ6-\0]2U#1_ >K:EI=U]FN[6'S$D\M7[]
M,-QWKGO!D.H/?Q^%]1CD:+PM*VVX<<7"E<6Q]\1L^1V*K6U\449_ACXA5%+-
M]D;@#/<4 :^G^)-&OKE["'5K*:_@C#3P),I=..<@'C'?TJ0^(]$73GU%M7L!
M9(YC:X-PGEJXZJ6S@'VKB]3L].U#Q%X'ET!;5KJVE,TDMIMPEIY1#;BO\)8J
M!ZDG'>N4U/4K&W^&/Q TJ6ZB74/[6O6%KN_>;3*&#;>NW'.>E 'J<OC#2(?%
ML7AQKJ(7CVYG;<X 4[E5$YZLVXG YX]ZN>(+A;;0KMVU>+2"8RJWTNTK"QZ-
MAN#]#7'_ -IV,7Q?TVY>[A$%WX=,=O)O&)G-PIVH?XCCL*U_B<8Q\,_$/FE0
M/L4@&[^]CC\<T ;#Z[I5BL$%[K%FL[0>;F654+H%R7QG@8YSTJSINJZ?K-DM
MYIEY!=VS$@2P.'7(ZC([UY_>O8S^//AUO:WDS8W3+D@Y/E1[3^8./I6C\/98
M#J_C6*&2,@:Y(^U".,QQY/XD'\<T =:VL:8NJ#2VU"U&H%=PM3,OFE?7;G.*
MS=>UBQ.CZA'!XFL])G@98WNV:-_L[Y!P58XR1V//-8WQ 1]'N-(\8V\;N^DS
M^7=K&N6>TEPKC'<J=K >QK,^(=O]D^#6LR7P1+NZV7$P8C(D:5#MSWVC"CV4
M4 =]J&K:?I,2OJ%[#;J02#*X&0.I^@[^E1G7]'$UG%_:MEYEZNZU3SUS./5!
MGYA]*X;5M<L]'^)MPVM:M)IUA?Z;"+"[#*(6*,YD0LRD G<I[9X]JBU31K#2
M_AS8:KX9CG:'0;HZE9^826EB#'S0I/.QD9R/7@T =_;Z[I%VUTMOJ=G,UIG[
M0(YE8PXZ[L'Y?QJW:W5O>VL=S:SQSP2KNCEC8,K#U!'!%>6XU2#Q<\D44JVO
MC6WX"KM-JT>!N/\ =8VY+'/\:XKU/R_*MO*MU5-B;8QCA<#C\* *4FO:1%?+
M92:E:I<M)Y0C:4 E^NS_ 'O;K7/^)_%EO8>)M(T :K#8_:Q,]U<"1 \*H@*C
MYP0"Q8<D= <>M<5:S07GP'O]'O/^0[ 98)K5C^_^VF4LG'4LS%6![YKHM2F-
MO\1O -O?7,9O4L;Q9LN,E_*CR?Q(/Y4 =EI,5]IVCA=:U.*\FBWE[ORQ""F2
M06 X!"XR1@4ZRUO3-4DD@T_4;>:9$#E8W#$*>C8[J>QZ&LWQY>6EAX%UFYOK
M%KZU2V;S;96*^8IXP6'('/)'09KC](U6SD^+>FS?VQ:7@GT!XD>VP(=WG(0D
M?4G R2"21R>* )/^$EU__A5_BC5?[3_XF.FWEW'%/Y"?=B?:HVXQT'H:]%LI
M3)IMO-*PW-"KNQX[9)KR(75NWP:\>%9XR#J&H#(8?Q2''YYXKUK29$ET:R>-
MU=&@0AE.0?E% '':MX[M]3\'>)KWP[J,4=WI23>6V%=F\M02VP_P[B1G!Z9[
MUT.A^(]-U!+6P_M2TFU86L<LUNLJF094$DJ.G7]:\X6_M(_A[\2[![F);M;[
M4W:$L P5ONDCT.1CU[5JRO90>)/A?Y#01@P7"C80,@VP_FWZT =[-KVD6U^E
MC-J5K'=.XC6)I0&+D9"_[Q';K6C7C&DW>@ZGX<N_#/BC4[Q-7AOI?/TP,$EF
MF\XR(T7R[FW$J<@_7BO1?'<-_<> =<ATP2&]>RD$8C^\>.0/<C(% &C:Z]I%
M[=FTMM2M9K@*7\M)025!P2/4 ]2.E9^GZU86>GZC?WWBBRO+-;R3%PS1QI;C
M@B'<#@E?4\G-9'A_7O"'B>30+G3Q!<:C:0,(8H_OV*E-KAP/NC@+SU.,5Q-_
M-:-\*?B4%DA(_MN[V@,.I=,8H ]<B\0:-,EX\6JV;K9.([DK,I$+'H&YX/:F
M?\)-H?V&6^;5[);6%_+EE>=56-_[K$GY3[&N-\83V.@OX2UI((ET.&^5KZ6"
M,%0#"R12-MZJI(Y[<>U0^,7T+5O ?C6_\/)%<R7-HK75Y;'>DS(. "."54<X
MZ9&: /07U73H[Z.Q>^MENY$,B0-*H=E R6 SD@#O5%_%_AM/)+:]IH$TIAB/
MVE,.X."!SS@D"N-O=?T?4/B-X%EM=1M9X?LMZGF)("FYHXL+NZ;O;KR/45S<
MYL#\&/';(;<EM4O,$8Y/GY3_ .M0!Z_;:]I%[JD^F6NIVDU_ ,RV\<RLZ#.#
ME0<\'\J5=>TE[P6:ZC;&X9F58_,&6*@E@/4C!SCICFN,U22RA^)'@ 6[P(&M
M;U0(R "IC0J..V<XK.T*YNM'U30(K*]MM<\-W]Y(+-7 %WI\A20G)!PRJ"ZG
M/(S0!V6B>-=$UQ-2EMKZW6&QF>-W>4+\J ;I"#T7)(R>.,]ZT;;7M)NTN&@U
M*U<6P#3_ +T#R@1D%L] 1T)ZUY9'K.DZ?X-\<6^HP1WK)X@N7ELVD*[5:X0(
M[[>0@)!SW -:>F:I8R?%;4'EUBUO1<:!'B6/:L3E99"P3&<J!ZEL<Y/' !W4
M/BKP_<7=K:PZU827%VNZWB2X4M*.>5&>>A_*I[_7=*TIPE_J-M;-@-B64+@$
MX!.>@SQD\5X_8-90?"#P!*K01N-:LW+ @'<)2&)/KCK[5T%CKFAV6N^--"\7
MSPPR7MX98Q<D@75J\:HBH?XL;2,+SD\<YH ]#U#6--TJ)9;^^@MT8%E,C@9
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M%% !1110 4444 %%%% !2,JNA1U#*PP01D$4M<WX^U&^T?P1JNJ:=<FWNK.
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MU(X(HCF.)$.T+E5 X'0?05R'B;Q3%:>*M(\/"_\ LB723R74T>-Z!$4HH)!
MR7SG'\/O5_3M8M=%MDTW6O$4-[?12^2]R\8CY8YC1]ORJY4J.V>N.: -U;*U
M21I%MH5=GWEA& 2WKGUY//O3U@A60R+%&)#U8*,_G61/>VP\600?V_'')':R
M-)I>4RPRI\UOXEQT].:2+Q7H&HW$6GV6O6CW=UYBP"&579BF=Q7J#C!]N#Z4
M :\=M!#+)+'!&DDAR[J@!;ZGO1]EM_F_<1?,P=OD'+#H3[^]<7X)\71GP%H^
MH>)-6B%W>2S1B6;">:XF=0H  &<   5U[ZC9QW\-B]PBW4Z-)%$?O.HZD#T&
M1GZCUH G:&)G+M&A8KL)*C)7T^E(D$,:,J1(JMU 4 &H;[4;/38TDO)TB$CB
M.,'EG8]%4#ECP>!Z52?Q3H,6DG59-6M([%7,9F>4* X."G/.[/\ #UH T8K2
MVMX3##;Q1Q'DHB *?P%'V.UV[?LT.!SC8*I67B'1]1U.XTVRU*VGO;<;I88Y
M 649QG\#P?0UROQ'\6+I?A>\?2=9%OJ,$\40\M58,QD4-&201NVDG .X8S0!
MW@      Z 5%':V\,TDT5O$DLGWW5 &;ZGO3IIXK:!YIY4BB0;G=V"JH]23T
MK*L_%OA[4+@06>LV4TI@-QM24']T#@O]/?\ &@#4%M )/,$$8?.=VP9S]:=+
M#%.A2:-)$/574$?K5"QU_2M2NI;6TOHI+B)!(T6<-L/1P#U7W'%-L_$>CZA=
MI:VNH0RS2(7B4'_6J."R'HX'JN: +Z6T$=O]GCAC6#!7RU0!<'MCI1%;00;?
M*@CCVKL78@&%]![53&O:6U\EF+V/SWD:%%YP[KDLJGH6&#D Y&#FFW?B+1[&
MX,%UJ,$3JZHY9OE1F^ZK-T4G(P"1G(H O+;0).\Z01K,XP\@0!F'N>II/L=L
M 1]GAP>OR#FJ-[XCT73;MK6]U6T@N%B,S1/* RH,#<1V'(^N:6#Q%HUSHPU>
M'4K9]/)P+@.-N<[<?7/&.N>* -%$2- B*JJ.@48%1BTM@"!;Q8;K\@YKG?$.
MOQS^#-?O=$U,1WFG6LLA9$!>*14+@,CCC.!U'2E\->+](U&VTW37UFUFUE[.
M*26#S1YA8H"W'KU)':@#HOLMN513!%A&W(-@^4^H]#3A#$$=!&@5R2PVC#$]
M<^M<;H_B":U\4>,X]9U3.G:9+;>4\P5%A1XMYR0!QD]372G7=+&G6^H&^A^Q
MW#*L,V?ED+<+@]\]O6@"W#:V]O#Y,,$447/R(@5>>O I/LEMMV_9XMN<XV#&
M:DDDCAB>65U2-%+,[' 4#J2>PK,@\3:)</<(FIVP:WC$LHD?84C/1SNQ\O\
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M\/B+1[B]CLXM1@:>4L(EW<2E?O!#T8CN 3BKE]/%;6,\T]TEI$J$M.[ "/\
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MS7=+L-"TH7OB2WO&N@$@NY71#=-GJ .#^% &[);PS$&6&-R. 64&G@!5"J
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M7PT+7-K(GVN)N74C MV&?^^L?CBLKQ&]Q=W?Q5M=&D$E[);6)$4+9=U"$2@
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MX/\ ND$^V*XR*]LE^!VF)]I@&S6U 7>/E OBW_H//TKW/:O]T?E1M7^Z/RH
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M^',L,/P<TTS%8DAM)8Y?,. K*SJP.>G(-<;;75@_PQ^&<<T]NRC5[4.KLI
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MI\YF5$OK*YDL[Q$^Z)4."5_V2,,/9A5HZ[IHU:72_M.;^*'SWMPC%A'_ 'L
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M ,]_$&EI>+:M<GS&F^S@B-RAE_N;\;=WMG(IH\2Z.UG?78O5\FP<I=ML;,!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ",C!Z4=***    8 P*BGCE:W=+>189&Z.
M4W;??'K4M% %33--MM)T^*RM%*Q1Y.6.69B269CW8DDD^IJW110 4444 %&
M2#CI110 4444 %%%% "$ ]1FEHHH 0J&&& (]#2T44 ( !G Z]:,#T%+10 4
M444 %(  ,  #VI:* "BBB@! H484 ?04M%% !1110 48 S@=:** $P,YQSZT
M'.#@X-+10!@:!HFI64SWFN:NNJ:@4\F.5+<0)''G) 4$\DXR?]E?3G?HHH 3
M SG'/K2T44 %%%% !0  , 8%%% !1110 8HHHH *.M%% !T&!2$ C!&:6B@
MHHHH 3 SG'/K1@'L/2EHH " 1@C(HHHH *.M%%  !@8'2BBB@ H  S@=:**
M"@@$8(R*** "D  & ,#VI:* $P/0>M+110 4A /49I:* "BBB@ HHHH *3 S
MG S2T4 ! .,CI00",$9%%% !1110 5S>D>'KS3_%VNZU-<V\D6J>1B%8R&B\
MI2HY)YSGT%=)10 4A (P1D>]+10!SWC/P_=>)M#73;:ZAMO](BF:22,O_JW#
M@  CJ5K?C#"-=X4/CYMO3/>G44 &!G..:*** #&**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBLO6_$
M6D>'+=)]7OXK5')V[LDMCK@#)('<]J -2BJ]C?6NI64-[97$=Q;3+OCEC;<K
M#U!JQ0 4444 %%%% !1167'XBTJ767T=+L-J*+O>VV-O5?[Q&.%Z<]* -2BB
MD=E1&=CA5&2?04 +15#1]:T_7K$WFF7'GVXD>+?M9?F4X88(!X-7Z "BBB@
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M$!.[:2!E2&Y!Y^E0/=:$VD>(U&N6W]J:^&%Q.;>39&#'Y:JJXR0J^IY.3QG
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M;R6[#Q6\J;3(<E<$'@>M %]Y];\-:;IVD&[M(XK3245;R5#,]U<H,;%C#!B
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M'&0,X]:UHO#6JKXNL-=FOK24VVG-9/&L3)O+,K%AR< %0 .>.] &$WC'Q,?
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MQD&]X1\/WGAVWU*&ZN8+@7=_->J8D*[#(VXJ<DYQZT ='1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%<MX\US4_#^BVUYI?V9I'O8+=TG0G<LCA>"#\IYZX/T
MH ZFBN%AUOQ/IGCF#P_J]QI]S%JMK+-8W,-LR"&2/!9&7>=RX(.<@UDZ;XW\
M10_#\>-]6ET][%+64M90PLKO+YI2,ARQP">",' YY/0 ]0HKC-4US6?#.I:
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MA)"I"L5W!3V..]>6^&?$VI:-\,X-3NKI+V\OM2EM;<2Q[?WTEU(NYR#R.K8
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M-I+HZ*_# ]&Z'TH ]#HR#GGI7"P:]X@M?$_ANVOKBRFM-<MY2(HH"K6[I$)
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M-]GAPKH+H1;1DD@8Z\Y/3-=9>ZYJ1UR70+:9_M%K9I<3W4-H'):1G" (6P
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M4H2 2IZCVIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZXR,XR*W: .5U'P5%K'AG3M,O[LK>Z:8WM+^U3RWAD0 *X!)].03@_E4.O\
MAC7/$_AJ?0-2U.P6WN JSW,%JPD<!@W"E\*3CKDCVKL** .5USPI>:KX@\/Z
MG;ZC# FC.[I$]L7,NY ARP<8X]J=XF\+WFOZOH=]#J,%LNE77VD1O;&0R-C&
M"=XP,$]JZBB@#GO&GARX\6^%+O0X[V.T%T%629H3)@!@W W#TK2-K>G13:_:
M(/M7E>7YWDG9G&,[=V?PS5^JFH:E;:9 DMRY'F2+%&BC+2.W15'<G_$]!0!C
M>$?#=YX4\(6VA+?P7+VJLL,YMRHP6+?,N\YZ]B*Q++PQKO@_X<#1-*UV+[9;
MR%K>X6PW,^YRY386().2,\8'YUUFBZ[9Z]!<26@F1K:=K>>*>(QO'(N"5(/L
M0<C(YK3H CMS,;:(W 43[!Y@3INQSCVS7#Q?#AF\(W7ARZU8O:BY:YL)8H-D
MELYE,H8DL=Y#''\/&?7CO** .=@\/WEWK.FZKK=W;W%QIL<BVZVT)C7>X"M(
M<L>=HP .!D]>,3>+O#S>)_#LVF1W7V64R12QS&/>%>-U<97(R,KCK6Y10!RY
M\-:E)XMT[7Y]4MY'M+22V>,6A4/O8,2#O^4 J !SQU)/-9+_  XEGT35+&;6
M-ES<ZLVKVEW;P%&M9R<C@L=P'3MP37?4A(49) '3F@#$T#3-;M2T^O:S'J%S
ML\M!!;^1&B\$G;DY8X'/08X YS2\4^%+S5]2T_6=&U7^S-8L0\:2M%YL<L38
MW(ZY&1D @]OY;CZI FM1:44G\^6!IU<1,8PJD @OT!YZ5=H YPZ!JL^F1VMY
MK"7#S3B2_<VY"S1C&8D4-\BD#!^]G)]:CT?PK/HOB'5[JUOHETG4G\UM.$!'
ME2[<,ZMNP-W4C;73T4 >?1_#:[7P;8:(=?*76E3K-I=[#;!3 5+8WJ6._(8@
M\@$8XZYT;KPKKFK>%]3T[5]>AGO;^W-MYT=IMBA0]=J;LECW)/8<#'/844 <
MI-X4OIM6\,7QU*W!T1)%*"U/[_?'Y9.=_P O'/?FK/ASPW<Z!J.L2#44FLK^
M]EO4@\C:\;R8+ ON.0,<<#J<YKHJI1:I!-K%QIBI.)[>))79HF$9#$@8;H3Q
MTH RM>\-W.J>(-%UBRU%+2?3?/0AX/-$B2A0V/F&&&T8/(]0>E44\'7R?\)7
M_P 32W/]OY_Y=6_<?N_+_O\ S?*/;FNO!##(((SCBEH XBT\$:II]]H5W::Y
M LNG:6-+E$EF662,%3O0;_D?Y1D\CIQQBJ\'PZO+?P?9:(FN(TVGZDNH6D[6
MGR@K*T@5U##=DL<D$=L#U[^B@"K+:27&E26<]PQDEA,;S1C8<D8+*.W7BN)L
MOA_J]M#X9CD\0V[?V!(1!Y=AMWQ&,I\V7/SX/7IZ@UZ!10!Q2^";X:3XKL3J
MMN?^$@DED+_9#^X\R,1D8W_-@ >G-=/I%E+INBV5A+,DTEM D/F*A4-M& <9
M..GK5ZB@#DM(\)ZCI6K>([_^U+:5M9<2;/LC 0L%VC_EI\PQCTJBG@"]C\)>
M'M"75[?_ (DUY#=+,;0_O?*;<JE?,XZ\G-=W10!Q8\&ZG8:SK%SH^KP06.LD
MR7=M/:F39,5VL\9#C&[N"#_2J*_#G4+71/#R:?KXMM9T.-H8+P6N8Y8F #1O
M&6Y' YS7H59>NZ_8>'+%;S46E6%Y%B!CB9_F8@ ' P,DCDX% &%JO@_5=9T&
M*SO-<C>]^V0W<UP;7Y/W;!E1$#C:N1W))R?7B\?#MZ?'*>)/M]OA=.-C]G^S
MGD%P^[=O]1TQTK6_M2#^V_[)V3_:/L_VG?Y3>7MW;<;^F[/;KCFKM 'G[_#R
M_?PY=:1_;5L/M&K'4S+]B;Y3YHDV8\SIN'7/2MP^';T^.%\2?;[?C3C8_9_L
MY[N'W;M_J.F.E=)10!P:_#VY/@*[\-2:O&9);LW<5TMJ0$?SA-@J7.1NXZCB
MK&J>#]:FUFTU_2M?CL]96W^S7;/:;X+F/<6 \O=E=I)P<DXXSWKM** .-UGP
M5?:A;Z7=VNO2P>(-.D>6/4&A#+(7 #HT><;"  !G@ =:W]$L-0L[=WU741?7
MTI&^1(O*C4#HJ)DX'7DDDD_0!=3UNUTIDBD6:>Y>-Y4M[>,R2,B8W, .PR/Q
M('4U-I6J6FM:7;ZE82&2UN$WQN5*DCW!Y% &2WAV[_X3MO$J7T 3^SOL MC;
MDG&_?NW;^N>V.E8$7P\U*UTNPAM]<@%U8ZK)J43O9DQ,9"Q973S.<;S@@@C]
M:]!HH XRS\'ZQI]UKEU;>(4$^IW,-TK&SX1TV;@0'&5(0KCC 8Y)/-:6B>&5
MTS7]4UN0VZ76HI$DL=K&4C^3=\QR?F8[N3Z #U)Z&J6K:K::)I5QJ5\TBVMN
MADE:.)I"J@9)PH)Q0!E:UX>NKWQ'I>NV%Y##=6$<L/E3Q%TD23;GD$$$;1@\
M_2L[4/A_!JFDZFES?R)JU_=1WAU"%-IAEB $6Q<G"J !@G)R><GCK+.ZBOK&
MWO("3%/&LJ9&#M89'Z&I@020""0<'VH Y2#PKJ>I:1>V/BO65U(7-LUKBVMQ
M JJW5L9.7X!ST&.!R<IX=\.>(],$,&J^)EU&UM%VVRBU\MWXPIE;<=V!V&,G
M!)KK:J:GJ,.DZ9<7]PDSQ0(7988S(Y ]%')H XM_AY?/X"O/"YUFWQ<W9N3<
M_8S\N9O.(V^9_>&,YZ5V]Q!-<:=- )Q'/)$R"5 1M8C&X#.>#SUJ:-Q+&DB@
M@, P# @\^H/2G4 <M;>%9Y/$NG:]J=Q:27UC;R0>=;6YB:XW@#,F6/ P<+S@
MG.>U82?#C54\-VWA]?$$"V%C>I<V9%EEPJR^8%D._P";!.!C;[YZ5VFHZ[8:
M7<0VT[RO<S*6C@MX7FD91C+;4!(49')XY I=*US3];6X-A,TAMY/*F5XVC:-
M\ [65@"#@C@B@#G)_!VL6GB>\UC0-?CL5U()]O@FM/.5G4;?,C^8;6QV.1ZY
MI=6\%WQUJPUOP_K7V'4K>U^Q3-=0^>EU%G=\XRIW!LG(/>NSHH X[6O!5YJ5
MGIEQ;:Y+;Z_ITSSQ:B80P9G&'5H\XV$8&,\ #KSF[%HOB!;..677HI-4$ZR2
M2?92L#1@,/*$8;(!W$[B2<\]@!OSW"6]O-,VYEA4LP12S<#. !R3CM4>GWT6
MIZ=;7T*RK%<1K(BRH4< C/*GD&@#F;+P?=:7+?WFF7MM97E]>I=RQQVY^SX5
M-A39N'WN26SU.<<4P>!F32_$T%O<6UI<:^"LOE6Y\J$&/RR53<,L<DDY&2>E
M=E10!QU_X.OKKPSH5C%J<":AHD\$UM<&V)C<QH4PZ;LX()Z-4FG^%-4L]>UK
M5Y=8@FFU2VBA=/LA54:-6 (^?.WYCQR?>NMI&8*I9B H&23T% '#1:%X@\,>
M$="T?2-8A:>RF1&_T+/VF+/*D%CL'.2V>WX'KM6TNUUO2+O2[U"UM=Q-#( <
M'!&./>HM)UW3-=2Z?3+M+E+6=K:9D!PL@ )&3UX8<CBM&@#D+;P??2Z?I&EZ
MQJ<-Y8Z5-'+&4@*23F/_ %?F$L1QP3@?,0.G()'X/OD?Q4W]IVY.O?\ 3J?W
M'[OR_P"_\WRCVYKKZ* ,SP]I<NB>'=.TJ6X2X:RMTMQ*L>P.$4*#C)P<#UKG
M_P#A";Z.W\4VEOK$26>NR32A'M-S0O*@1R6WC< !D# YZDUU&J:E;:/IEQJ-
MXTBVUO&9)62-I"J@9)PH)I^GWL.I:;:W]N28+F%)HRPP=K $9'T- '+-X-OF
MC\*+_:EN/[ *G/V5OW^(S'_?^7Y3[\U!:^"=9TK5+Y-'\2&UT.^G:XELVM@\
MD+.<N(I,_*"?4''I6E<_$#PQ9ZRNEW&J".X,OD;C$_E"3^X9=NP-[9XKIJ $
M50B!5& HP*6BJ.HZK;:9Y*2[WGN&*P01+NDE(!8X'L 3D\4 7J*S]%UFSU_3
M(]0L&D,+LRXDC*,K*2K*RD9!!!%:% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<K\0-9U/0/#0U#
M2Y($E6Z@B82Q[MRO(J'!SP?FZX-=56#XN\.R^*-$_LV.]6T!FBF:0P^83L<.
M !N'=10!AOJ'B>'QX?#QU:T>*\TYKR.;['@VQ60*0J[OF!##&X\>_0U+#QKJ
MJ>'C%=>7<ZJ->DT1)HXPHD*L3YFPL #M4\9 SBNCD\.7<GC2V\1'4808;)K/
MR/LQPP9@Q;=OX.5&..GKUK&?X<?:-"U/3[C5V$USJC:M;75O!Y;VMP3D$98Y
M _#@GGO0 VYU3QCIMIXCEEA_T*UL&N[&]O(XB_F*I+1.D3C/3(; QWS5#4=;
M\7Z=\-KKQ4VJV#N^FV]S%!]B_P!4Q W?-NY)W \C /;%= OA;6KK0M0L]7\1
MB^N[NU>T6<62QI$CC#$1JW+'CDGL, <Y74/!]QJ/PZ'A-]3C7_1H[5KH6QY1
M0!G9OZX YSCVH S-7;49OBEX;ACU.2*WDT^YE\D1J5##8">>I(;'MVZG)9>+
M9[OQ3-H]SJ7]G:I%?LBZ=<P!4N+4,0KQ.1EF*X;J>XP.M;&H>%KJ\UO1=7BU
M46]WI\,D$I6V#+,C[<X!;Y#\HP?F^AJ&[\'W&J26J:IJ,-S;VFH_;[=OLNV>
M/$A=8P^\C R%R "5&/>@"_XQ\0_\(MX6O-6$2RRQ;4B1C@-([!%S[98$^P-9
M.J:OJ_AG7]!AN[Q;ZQU:<V<A:%4:"<J2C)MQE#@@@Y(_O5O^(M!L_$^@7FC7
MX;[/=)M8H<,I!!5A[@@'\*S8?#-[<W.E3:WJ<5\VEDR6_EVQBWR[2@DDR[9(
M!/ P,DGTP 97A+4?%.O7UY/<ZG8I::?J]U92PQVA!G1/E4@[ODP<'OWR>U;'
MB37IK#5]"T6T98[O6+B2,3,NX11QH7<@=VP !GC)SSC!?X6\.S^'5U-9;^.[
M%]?RWQVVYCV-(<LOWFR/2G>)O#*Z_P#V?<PW1L]1TVX%Q:7(3>%;&&5ER-RL
M.",CZT <]?:[K%EK.N^&9KXF9=(;4[#4%B42*H)5E<8VE@W0@#@]*YV=;S_A
M67P]D>Z^T32ZGI;QF5<!21P"1R>>_6O0(O#'GW]_J6J7*3WUW9?8-\,7EI%#
MDDA02QR2Q))/8=,5C+X!O_\ A'-!TA]?1UT>[@N(9#8_>$/W%(#_ )G//;%
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MN+A+B.,80L"1\X'?_P"OGK-/LS8V,=NT\EPZY+S2XW2,22S'' R2>!P.@XH
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MSM)';KDY.,8S?#;4O^$6;PQ'XE TB*>.6U#V0::)4D#A&??A@,<?*#TYP,4
M;1UC5?\ A9LNA>?;_83HQO(AY)W+)YH3YCN^8=>F.OXUR2>+O%:^!(_%4U_9
M$6VHF":U2UP)X_M/DGYMV5P",8STY)SQVO\ PC=V/&@\1_VE$6&G?8/):V/(
MW[]Y8..=W;'3\ZQC\/+H^!)O"YUJ+RY+K[2;C[&<C]]YV,>9_>[^GYT 7;S6
MM0N_&&J:'!=C3DLM.2[BE**QF9BP+'<"-B[0#C!R>HJYX$U?4]?\'6&KZL(%
MN;Q/-$<,+1A%/08+-G.,YXX(XKB_$=S!?>-;Z*Z\5Z5I$UG!% (-8L(WCER"
MS20^8PPIW '!))7G@"N[\*76HW6DLVHSV]R4E*075O"8DN(\##A"3CDL.#@[
M<C@B@#GX=1\5:IXV\0:/:ZI8VUOIKV<B,;,L620,S(?FZD#[WL, 9-5O^$D\
M5:QHZ:YX>L9;C-TPBLF$"PS0+(4.79PX? +9X /&#U/2:7X<N-.\6ZSKC7\<
MJ:HL*M;BW*F/RE*KAMYSP3GC\JR+'P'J&E7UU!IOB6>W\/W4S3/IOV=69"YR
MZQRDY122>V1G@YYH K7%O>O\;8 NH.B_V&\@7RE.U?/3*?CZ]:8_B/Q5K&CO
MK7ARREG*W;I!9L(1#-$DIC;<[.'#D*6SP!P,'J>B?PW=-XZC\2+J,2JED;+[
M*;8G*%PY.[?UR!VQ[5DVG@/4=,U*\32_$T]KH5Y.T\NG?9U9D9SEQ'*3E 3G
MMQVYYH B&H^*]4\:Z[HUEJ=C9PV,=I/$SV>\A9-Q9"-_)(7&[/88 SFHM'UO
MQ-?7.N7=UJEE'8:)JLT,T<=F=T\*1JVT$M\IYSGG))[#%=#IWANXL/&&JZ[]
MOB>/4(HHC;"W*[!&"%PV\Y^\<\?E3?#_ (7ET=];%U>Q7D.K7<EU)&+<Q["Z
MA2N=YR,*/UH Q++6O%U_%H&KV5C+/:W[1O>6SB!8H8)%SOC??O)7(ZYW<\+T
MJCKFK:AXI^'OB[4[6]%M901WEM! (E82QQJRNSD\Y;#8P1CC.>:U_#W@C5-!
M:*P'BBXN- MW#6]B]NHD4 Y5&FSDJ#VP,].G%02?#Z]@M=?TS3-=6VT?6?.=
M[66T\QX))5(8QOO&%).<$'V(/- '3>&@3X1T@*<$V$.#C./W8KSW1?$6H>'/
M!OB76KJ]>_G36;BUA290 TAF6)&8C' XR!Q@<5Z5HVGOI6BV6GR7!N&MH5A\
MTH%W!1@' Z=*Y@?#N&;2=?T>]U*2;3-5N9;I(EB"/;R.X?(?)W%6 (X'?.:
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MMK:U1&W@G#>9U&0"" !UX.1D[][J.KZ%I_@J.WU$RPWU];VMP)84+E&C+8!
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M]#^% '545Q%W?>(+OXC7GA^VU:*TL_[*2[1UM5=XV,K)QN)!/R]3QST[C1\
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MNH5ITNY2HZ M;9Q^M 'H%8%IXOTZ]U*RM(8KHQWP<VEWY689]F=V&!XX!(W
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M$.S8VT+@'<>,**KWWA*:Y\5R:Y:ZQ/:?:+,6=S"L2OO16)!5F^X?F/8UTU%
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MZ9XFUK66OEF.JF(O"(=HC\M=BX.X]NN>_I5SP_KEKXDT&TUBR25;:Z4O&)0
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MY&?&X)V ^4=<]ZT+CPPT^N:+J\FH2F;28I(XXUB4+*'4!MWOA1C&,4 <9?\
MBG7I?#>IZA;:@]OKEOK'V.+2UC0Y0RA%3:5))*'?N_IQ7J,"21V\:2RF:15
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M;=CP-N#C'&<XR: /5Z*XNPO;OQ+XB\1:8NI75G#I!BMH3 5#M(R;FE;(.>2
M!]W@Y!SQS,/BKQ%JND>%7_M)K.[FUJ32KXQ1(4FV"3+@$$@_(#C.,]B.* /6
MJ*\[FAU^P\9Z%X>/BF_FM[FRNI)IGAA\PE67:0=F,@-C)R..E4[+Q5J]CH%W
M92WDEU=Q^)CHD%W*$$GED@@GC:7P2H)&,X)!Z4 >H45Q5OIGBQM0U2U_M*2U
MTZXM-UG+)*DL]O<@XX^7#1D$$@Y]!C-4_#VO:AKVAZ'IS7L\.M1W+PZJ1MWH
M8.)<C&,,QC P.!(".E 'H-8\'B2UF\57/A[[/>1W4, G$LD!6&9?ESL?^(C>
MH/UKD1XDN;?Q:=*UR[O]*O)=2Q8R,H-G>V^_Y8U8 @.5ZYP=W?!Q7?BSA%ZU
MYM)G*>6&9B=J]< =!D@$XZX&>@H 2^O;?3;"XOKN416UO&TLLAZ*JC)/Y"LW
M3/$+:CJ9LI-(U"T#6RW,4\R*8I$) QN4D!QG[IYQS61\4X6E^&FNE9Y8MEH[
M$1D?.,?=.0>/IBJL]_?6=YX>\.VUS=3&]M);F20R(DA5 @$:MMP!\Y/ S\O6
M@#NZ*\YEU3Q3H-K;Z;J4RRRZAJZVME/YJ&9;=E9\.=NW?\A4'!SG/45:DC\;
MZ=;Z_P#9C]HB:!9--BFG1[A) 0)%!VX((Y7=G!P.E ';7=P;6U>?R99@@R4B
M&6QWP._K@<GMD\46MU!?6D5U:RI-!,@>.1#D,IZ$5RG@KQ!::W>:B+>_O]\*
M1++IFHIMGLY/GW9R,D-E>Y''X5!\.KB07'BK2R28+#6YU@'9$?$FT>P9F_.@
M#N**X3Q9?ZA#>ZRMOJD^ZVTSSK:UL -\$@#DRS%AMV\+A2>0&PIIFF>)+W7K
MOPOI<MRULU_H@U2[EAPK2MB,!%/\(R[,<<\#IS0!W<DL<*;Y75%R%RQP,DX
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MW[U;'0@XP<@$?A7)QZUXDC^&\/BJ3Q#=275KJ1B,/E1B.:/[7Y1#@+DG![$
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M[@I\S@X[_2JT)UW2O'G_  CD^OWE[8ZKI\MQ!<2I&)K25&4$@JH4J=PX(_\
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M\.SZ5JE]?WTT[K(U_+(!.KIRC(0 %V\X &.3G.3E;3P:\6OV&MWFO:C>WMG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 445G:QJ$EE!'#:(LE_<MY5M&W3=CEF_V5')^F!R10!HT5R7PSU"^U7P#
MI]YJ-T]U=O)<"29^K;9Y%'TX &/:NMH **** "BBB@ HHKS'4_$NJ^#/'-U-
M>3SW?A-A#'<-(=[6$CYVOG&3&2,').,_0$ ].HKGKAGE\::6(KV<VD]A<3M%
M'+^[=D> (WTQ(W3@YJ6X\7Z):,3-=,L"S_9VNO)<P))G;M,F-HYXZX!X//%
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MZ62"020OV5DV[AG(P<8.: .CHK%L?%>CZEK,FDVURYO%B\Y5>%T62,'!9&8
M.,D<J2*DM?$NF7MS;0023-]JW?9Y#;N(Y0H))5R-I&!D<\]1D4 :U%8<OB[1
M8+NW@EN707$_V:*<P/Y+RY(V"3&W.01UZ@CK6Q//#:V\EQ<2I%#$I>21SA54
M#))/84 245CVOBC2KO4+>Q6:6*XN8S);+/;R1>>HY)0L &P.<#G'/2N3?4V\
M6>,-?T(WFL6$=I#;I9RVD<\)CD8.S.Y  [* '^4@<=30!Z)17)>-?$=WX9T;
M3K6R99]7U*ZBT^U>9>/,;@R,!C@=<#N15JX\-WPTJ5;/Q!J2:H8B%NY) RE\
M=3$1L SZ*#Z&@#HZ*X=KG48?B;H%K->7 BGTB9Y[7S/W?F*8QG X)Y//-;:>
M,=#DNK>%;IRMQ<M:0S^2_DR3+D%%DQM)RK#KR00.: -VBN<AU324\5:N1JUZ
M]U;6L9N;-MYA@7+8=5VXW'G."<X%11_$3PO+'82KJ+"WOFV07#6\BPECG"F0
MKM5C@\$@T =116/I7BC2=:U"YL+.:7[7;*KR136\D+%#P'4.HW*<'D9%;% !
M117 >-/%U_H7B/2YK?']B65Q''K#_P!WSP53\$X8_P"^GK0!W]%5KZ_MM-M3
M<W4FR/<J#"EBS,0JJ .222  /6HM/U:UU-[A+?SA);.$F26%XV5B P&& SP0
M<CB@"]165J7B/3=*NC:W$DK7 @-RT4$+RLL0."Y"@X&>/?G&<5=L;ZVU.P@O
MK*99K6XC$D4B]&4C(- %BBL34_%FC:0;@WERZI:E1<RI"[I 6QC>R@A>H//0
M$$\&K%YKVGV4R0M))-,\7G+%;0O,_E_W\(#@>A[]LT :=%8$_C7P[;Z59:I)
MJ<?V*^E6&"8*Q5G)Q@X'R\]=V,8.>E3Z3XHTG6KV[L[.>3[3:!6EBF@>%@K9
MPP#@94X/(XH V**\Z\9>*8IV\,MI.H7T:7&MVT/F11ND-S&7PR[\88<=C@C.
M,C-=#%JFEIXHUAH]1U"XO+6UC-Q8*KO'$H+89$V\LW.<$YP* .DHK@3XSTGQ
M!\.SJVH7FI:-:W#+^_MHY(Y$'F_(%<*0<X )&1R1QFNNOM:LM.N$MI6EDN70
MR+!!"TLFP<%MJ@D#)QD]^.M &A16!-XU\/0:-;:N^I)]AN91#'*$8C>3MVL,
M94@\'=C'>I]*\4:3K.HW.GV<\AN[95D>*6!XB4)P'7>!N4D'D9% &Q167K/B
M/2?#YMAJEXMM]ID$4196(+'L2!@< GG'2J.G^.?#VIQ:@]O?,#IPW74<MO)'
M)&O9MC*&(]P* .BHKG-/\=>'=3#M:WY9%M5NS(T+JAC8X!#%<$Y(&T<YXQFK
MEEXETN_U&XT])I(KR"(3O!<PO"_EGC> X&5SQD=#UQ0!KT5B6WBW1KK4+2RC
MN7$MZC/:&2%T2Y"C),;$ -P0>#R.1D4EQXNT6UNH89KET6:?[,DY@?R3+G&S
MS,;<Y!'7J".O% &Y17.>)?$%E::=JEJMU=)<P6QDD>TA=S;Y4E2S*I"],\\X
MYZ<U4\(:ZL?P_P##ESJ-Q/<7EW91MPK333-M!8X&2?<_G0!UU%<XWCOPXFE1
MZD^HA+9[G[)EHG#)-G!1U(RA!/.[%2VOC'1KV6_AMI+F2XL8A-+!]DE61D.<
M,BE07!P<%<B@#>HK!\'^)8_%?AZWU1()8?.!?8\3* "3MPQ&&X R5)&:@3Q?
M!)XYF\-BUN@T-LLS2FVD*LS-@8(& O!^8\9[\&@#I:*PYO%^B6[KYMVRPM/]
MF^TF%_(\W.W;YF-N<\=<9XSGBMMF5%+,P55&22< "@!:*P[+Q?HNH7=G;6]S
M)OO4>2T9X'1+A5Y8HQ #8'/TY'%4IOB+X7@AN9FOY3':3FWN&2UE80L,9+X7
MY5Y W' SGGB@#J:*:"LD8*ME6&05/4'T-<#X3U:=->\9OJFI74MEI5X(X5D8
ML(H]FX\ 9;KWR>* /0**YJS\>^'+^?3HK>^=O[1XM9#;R".1B,A-Y7:&P#\I
M.?:E\3^(+*TTO5;5+JZ2ZM[5GDDM(7<V^5)4LRJ0O3//;GIS0!TE%<EX2UU(
MO 'ARXU&XGN+RZL8FP%:::9M@+' R3[GWYJVWCKPXNFP:@^HA;>:Z^Q@M$X*
MS9VE'4C*$$\[L8H Z*BN;7QWH#W%U;"XN?M5L%9K<V<PED4YPT:;=SC@\J".
M,]*>WCCPZFB6>LMJ(6PNY1##*8W^^6V[6&,J0>#NQB@#H:*Q=.\5Z/JMY>6E
MK<2_:+-!)+'+;R1ML.<.H91N4X/(R*YQO&&F>'_ L&IZ==ZEK-O/>&"&XN$D
MD;<TQ4[CM!"J20!WP ,T =[165<^(;"UB1G%TSO&91#':2M*$!P6*!=RCZ@9
M[4D7B72+C2[34;:[^TV]Y_Q[>0C2-+UR H&>,'/'&#G% &M17.SZC;>*_#%^
M-%U*[@E5F@:2VCVW$$JD93:X&UNW..#G(ZU8M;^32-(TJUUF=[C5)(%5_)B+
MM*ZJ-[!5'3/4\#D>H% &U1573M0MM4LDO+1F:%RR@NC(<JQ4@JP!!!!'(JU0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<QJWAO6KO7WU33O$I
ML,P+"L1L8YM@!R<%CQDXSZX'H*Z>B@#S/X=S7GA+X8'4-;FNYK>.24K:)98E
MAS<.#@#YFW%@W/0>U>EJ0RAAG!&>1BEHH **** "BBB@ KEK7[#J?B;Q'87,
M:SP3P01.DB'9*-KA@">#C/..E=37/MX7D9B?^$CUP9.<"X3 _P#'* .5\*^'
M]:\-^.%T661[C0K;3KDZ7=ORT:O)!F%CZKMX]0?; RK!)D^#VH>"KZTF/B"*
M.>T6V,9)G=W8I*IQ@H=P8MT&#G%=]_PBTG_0R:[_ .!"?_$4?\(M)_T,FN_^
M!"?_ !% '.VL$^B?$[2A>)<S*_AR.Q6XCA=U>9906!8# X^;)QQ3/#-PD-OX
M]>0.BR:G/-&6C8>8AB10R\?,"00,=:Z7_A%I/^ADUW_P(3_XBC_A%I/^ADUW
M_P "$_\ B* . OMS_LYVUBL,S7BVUM$;81,9 ZRH2-F,\ $].@K;N]:'A?XD
M7NJ:E!=2Z/K%C;I;WEO;O,L3QE_W9" D;M^1Q_7'2?\ "+2?]#)KO_@0G_Q%
M'_"+2?\ 0R:[_P"!"?\ Q% '.ZIJ2V>I>&HAHLNE:=,EP5N+>PWS6^2-L2A5
M/E&0<GC/&.",CEEAN1\+]6MQ8:@)+3Q%]HD22"0OY?VL-D9&7PO)QFO2_P#A
M%I/^ADUW_P "$_\ B*/^$6D_Z&37?_ A/_B* ,/5;N.\^)G@Z[BCG\@6UX&=
MX679O5 F[(^7=M. <&L;26DTWP#XC\*:M;S/J^^\2*+RF8WPF+,CH<88$O@G
M^''.*[7_ (1:3_H9-=_\"$_^(H_X1:3_ *&37?\ P(3_ .(H Y/2K*;1_&_A
M&SO&9Y+'P\UK//M)02_N\*6Z9.TXK6^&YQ'XF!1TWZ]=S('0KNC9@589ZJ><
M&M;_ (1:3_H9-=_\"$_^(H_X1:3_ *&37?\ P(3_ .(H Y+Q5>RW&L^*]*DL
M;N!GTL"U-G:,6U$F-_ORJOW4)VA<CJ<YSBJVGSB34/A:YAN$6UL9HYS) Z^4
M3;*@W9'RY8$ GKCC-=M_PBTG_0R:[_X$)_\ $4?\(M)_T,FN_P#@0G_Q% 'G
M.L6FH7UCX\&FVTT[_P!KVUXL"H0;J&,1EPG'S<J>G7'O6]=Z[::[\0O!6H:?
M#>RVR1WJRO\ 8Y0(BZ( &RO'/!].]=1_PBTG_0R:[_X$)_\ $4?\(M)_T,FN
M_P#@0G_Q% %;XDG/P[UV%5=YI[1XHHT4LSL1@  <FJ=EXI2Q\%Z?%I]C?7^J
M)91QQVD5K(#Y@0##L0%0 ]22*U?^$6D_Z&37?_ A/_B*/^$6D_Z&37?_  (3
M_P"(H \Z3PS?> M!\(W-]!=WMO9RW+:L+!GWQM.!AQL()5",''8^]=#=-H\_
M@;Q9J&C:==11ZA8R1B>>.42WDOE.HPK_ #G&0 >_/89KI/\ A%I/^ADUW_P(
M3_XBC_A%I/\ H9-=_P# A/\ XB@#BM4DFM?#W@76A:7MUI^FPB+48;3>LT6^
M!5WX4AOE(Y'H:B\5+I5_\./$][H.EW@_M%8$$\L4WG7CJXZ*_P Y"COCU["N
MZ_X1:3_H9-=_\"$_^(H_X1:3_H9-=_\  A/_ (B@#$U.>*;XI^&+B$,\"V%T
MC2*AVJ7\O8"<8!.#@&L;PQ%=:?JVC0>'KZXN-#O!(TVEWL1:72#Y;$%7(!4;
MCMVGKGC.<CM/^$6D_P"ADUW_ ,"$_P#B*/\ A%I/^ADUW_P(3_XB@#@/"K:<
MVC67A37="U6;7K!UC^S2^>UN[(WRS!\^6$Q@Y^N >,]O\2-)O];^'NL:?I8+
M7DL0,:#_ ):;6#%/Q (_&K'_  BTG_0R:[_X$)_\11_PBTG_ $,FN_\ @0G_
M ,10!SVL3Q^-+GP@^E1RI<6FI1WUUOC9&M8T1MZ/D?*Q)5=O?KT&:L^&YT_X
M6AXQ8APEPMD(79"%E*1L'VDC!P3SBMC_ (1:3_H9-=_\"$_^(H_X1:3_ *&3
M7?\ P(3_ .(H R?B3H5_J5CI&K:5 ;F^T34([Y;8'F=%/S(OOC!'TK8L_&.D
MZA IM#<R7+#_ (\S;NLRM_=92!MYXR< >N*;_P (M)_T,FN_^!"?_$4?\(M)
M_P!#)KO_ ($)_P#$4 8^H2-_PMS0))(V&W3+B.1E!9$D9D(7=C&3@XSC-<9/
MJ$FH:5X?N9=.O[6XL_$<4EUIUO82)#9()7S@*OSL<AB?F)+'&,XKTO\ X1:3
M_H9-=_\  A/_ (BC_A%I/^ADUW_P(3_XB@#"M+F./XI^(;F572!M*MT$C(=I
M92Y90<8) 89 KE8%:/X->#[5X)A<P:C:M+#Y+;XPDVYRRXR !R3[^]>C_P#"
M+2?]#)KO_@0G_P 11_PBTG_0R:[_ .!"?_$4 8ZS(WQH:X4.T!\/B(2JA*%_
M/+;=V,;MO..N*ZK1=7M]=TF#4K6.>.&8$JMQ$8W&"1RIY'2JEGX?DM+N.<ZY
MJ]P$.?*GF4HWU 45M4 5[Z]ATZQFO+@MY4*EFV*68^P Y)]JX>'PN/$G@R\>
M_P!9O84UA'N;N )#LC=@/E.Z/?\ ( J]<_)VKT"B@#RO2=3@\1?"RUL/$D.H
MPW5M+%:W$L*2)-&R,/+N$.,D<*Q;&!SGI71>!9=8$^KV>HWJ:K:6TD:V>JB(
M(URI4DJQ'#%.!N'7)[@UV5% ' ^(+]O^$WFT^:SN8(I-, AN;.U9I;QMS9A,
MJJ2BKUQD<MDD#K>^%S-_PK?1(9(9X9(+<1.DT31D,.O# 9'O7844 >8Z1J\?
MA_5/$GAWQ!I5[<O?:E-=V82S:>.]BEP0N0"N1C!W$ <<\5>M)9O#OQ*U2[U>
M/R+#5;"V%M. 3%"\08-#NQ\N2Q89QGMSQ7H%% 'C-WI=QI_AKS9+>98[_P 8
MIJ5O!Y3;H[;S5.XKC*C"EN>FX9YK8U^WN=4\>>(8--+":[\+&UMY@"$,Q>0A
M0_3.&!Z]*].HH \=N];AU#P9X-LH[#4$OM-U33UO+3[%*6@\KANB]."1CJ/Q
MKJ--?S/BUK[JD@273+:-'9"%9U+EE!(QD;AD5W5% 'BA>1OV>/[)-G>+?VXB
MAD@:V<-O%P&*@$?-@#)QD8KK1<MHWQ1O-4ORW]DZKIT,=K>;28XGC+$QL?X<
M[BPS@'ZUWU% 'C.I:9<6GA;5+@V\ZQ:GXJCOK:W\IMPA$J9<KC(!VLW(Z$>M
M=<DJ/\:1.FYH6T#R1*%.POY^[;NZ9V\X]*[BB@#A/B;-';CPE-,"8T\0VS-A
M2V!MDYP.:J:A;QW_ (UU?Q%9_-80^'WLI+A%)6>9G+!5_OX ZC/+ =>*Z?Q-
MX=G\02Z2\=\EL-.OH[Y08/,WN@( /S# PQK?&<#/6@#RLV=_<? W1%T^TGFN
M]/2SGFLE#1R2>2ZLZ=B&XSZ\<=JEECTKQGHVK2>'--U'^TY-+FM?ME^)D:(L
M.(09#R2>NW('KR,^GT4 <-X5\2V>O6VDV?\ 8MU'JUE&$N%N;)D%BP3:Q#LN
M.<8 4Y.>0!G'+>&?[/&CP^$?$.B:K<:Y:2F,6\GGM;SD.2LP;/EJO0DG&.<
MU[%10!Y?I^H-H%_XVTC6+>Z%U?W<][92K;O(MS$\8554J#RNT @]*Q;"6;1M
M)\#ZSJ&GZJVE0:2VGWGD1S1R6LA\M@Y5<,5.S&1D=.O%>U44 >4>(XM,?PC'
M<:/I5S!!=ZW:W.9(I/-N=LBEYF5OF P.K<G&>XSMLXF^,4LL89HI/#WD+*%.
MPR><6V[NF=ISCTKO** .*^%4I'P]TNQEM[F&XLXO)G2>!H]KACD#<!G'MQS4
M$WFVWQ=O2T5RBW^BQ0V\Z0,R;UE?.6 P,!@>2*[RB@#QZUBFF^#-SX*N;.4>
M((XVLOL;1G+OYF5E4XP4Y#;^@YYKU"1)[#PXZ"(WUQ;VA C/_+=U3I_P(C]:
MT:* /&]/OOM6L?#_ %+[-J'[EIX[F&.PDB@LW:W*B%$"@ !N,\\#EL5/G=X)
M^)D(BE,MW?7C6Z>4VZ8-$JJ4&/F!(."*]=HH S= D5O#>FOG %K'G(P00H!!
MST(K@_"]Q''JWQ"DD$B)<71DA9XV E7RMN4R/FY&./;UKTZB@#QV+,?PY^',
M#12B:UU2S>>/RFW0A-V\L,94#(R3ZUH:?J+:%<>-]'U>"Z%U?W=Q>V4JV[R+
M<PR1@*%901E0H!!Z?@:]2HH \6L9I=%TSP1K.HV&JMI,.CG3[O[/'-'):R'R
MV#E5PQ4[,9&1P/:M+Q!%II\,V=QH^EW-O;W6OVMV3)%)YMP%=2\S*WS <=6Z
MXSW%>KT4 <*)HO\ A<[77/D?\(^(O.VG9O\ /+[=W3.WG'I7&_-_PK[R/(G\
MW_A*O/\ *\EMWE?:M^_;C.W;SGI7ME% '"K<1#XS2763]F_X1]8_.VG9O$Y?
M;NZ9VG./2N1AAG/P4C1;6Y,MKK N)81"WF+&+TONV8R1M.>G2O:** /,-6U2
M#2?'DFL:M:ZN=$U6QACM[JV2=3#)&S_(Z1X8;@^1D=^G7%;58+?P]<>&]9M]
M"U"V\.1+=0SP6IE6:V$K(RRLJG< 2F2.V>1GBO6** .<\))I4D%Y?Z1IT]M;
M7<HD,UPLBR7+8Y<K)\V.P)P3@]L$Y_CFRLKZ]TE9M1O-(OHQ-)9ZI;_=@8;
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MS '2&<>: Z[APPP#UX.#@FGZU;76H_$BZ%G'<QBX\+S6D5UY#B-9GD#*"^,
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M]DDWQ*DA+LPVY  /6O6KV58]/GD(8J(R<*I8GCL!R: .8T[Q5X=T7PMH<O\
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M3+.9V8!>/F&,'(R.>M=1=NTOQ,\+W26UV;>/3;A))?LTFQ&?R]H8XP"=IX-
M'06GC#1+OP_<:V+IHK*V=HI_.B9'BD4[2C(1NW9(&,9.1CK3H?%6FRZVNBN+
MJ'4FC$HMY+9\^6>C[@"H7/&2>O!YKSFXM1+X'\=QW5GJ*&77GNK;9;,KMEXO
M+D0,/G&X9(&<@'VK<\/:UI.J>.H]1N[NZ75Y++[!;Q2Z9-:1E=WF/S)D%B1G
M&> ._6@#M]5UBST:&&2\D*F>9;>%$4LTLC=%4#J>#^ )-4K?Q7I,]A?7?G21
MK8S?9[F.2)A)')QA=N,DG<N,9SD8K.\=7UU8PZ0T5G+);-?J+FZ@M?M$MHFU
MOG1 K8.?EW8. 3QDBN0LK6W9/'%GJ>C:U+I]Y>VT@W0S&1HV$2B16Y8LI^?
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MYC6225W8O+-*07E<]6;  [ <      "K58VG^);._P!6?2S%<VMZ+87:PW"
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M5I;?#B(Q;S@HIPI8G(R/3&:K^&/&\6M>%4UN\MI[19)G2-#'G?F5D1%QG<W
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MVYSNSTYJ.^T;4-:U'XEV5M;74+ZG!;I9RS0/'',R0;6 8@#&[C\?2O4:* .
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M?V2[6UDTF&%)VMG6-G61V*[B,9PPJCX<T.\T_P 97VAX4Z!ITYU.SP?NO.&
MBQ_=5O.8#W0^E=SJ-H]_IMS:1W4]H\T919X"!)&2/O*3W%5M$T9-%LFA^U7%
MY/(V^>ZN6#23-@#)( '0   =!0!7\83:A;^$-4ETJQ2^OE@;RK9TWB0]_E_B
MXR<=\8KAK:UN;[QU:W4%EKOV>]T&>S-[>P.I69G0Y8' CP 3C"@X^4&O5**
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M)IID4^;,09'8DD@=!ST R<#IR?4T <9XSTNVU+6X)!)J^EZE;VI:TU;3X9)
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M$;SQG(#)N.,$@CG&#UQ7#7,-I+X!TO2]"L-8D>RUBWEN(;FR=9UQ*)9'=<<
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M*QJD:LQ<AB<G)/ ( QSFKR>,;,76FQ7=G>V46ID+97%PB".5R,JO#$JQ'(#
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M60XM3!!G+*"2AR1ALJ1CU]N: +MEX5D@*I>^(=7U*V0@K;W;Q;3CIN*(K/\
M1B0>X-=%7/0^*UN;6-K?1M4DO&M_M$EB8TCGA0DJ-X=P 25; R2<&LJ]\4^&
M=<T_PQJ,D-Y<V][J40L7C#)Y5R"P'F<CIA\@YZ=#0!VU%<M<^.K2'5-5TV#2
MM6N[S3$CDFC@@7YE8,05+,!C"]\9SQFMO1]6M-=T>TU6Q<M:W40EC+#!P>Q'
M8T 7J*Y>\\=Z;9?;)FMKQ[*RO5L;F\14\N*4E1@@L&(!=02%/7OS33XHO3\1
MV\.+I<YMH[ 7)F#1_-NDVA^6R%&UA_>)/3H2 =51110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5R/Q TG4=0L-)OM+A-Q<Z3J<-^;4, 9T3(95SQNPQ(SZ5UU!( R: .--
ME)KOCS2O$"6UU;6>EV4Z%IX6C>627:-@0C<0H!).,9(QGG!\/H+JTCU]+RRN
M;5KG6;J[A\Z,KOB=@5;/3\.OM7944 <MX]TJ\U#0(KS2XO-U72[F.^LT!P79
M#\R?\"0LOXUAP^$-4LO&=M,A$ECJL"S:TP/!N(9/,4CV8OMQ_=7':O1:* .,
M:"Y3XNMJ1L[G[ -$^R_:!$Q7S?.W[>!D_+WZ=NM<G+H^K-\)-0TD:3>F_EU8
MSI!Y)R8S=B7=GIC8#WZ\5Z_10!Y]=RZMX:^(%[K4.BW^JZ3K-K C?8T!EMY8
MMP 9&(PI#=>QJ;6XM4O/$?@R]FTV8?9;J>:Z6%"XMT>-E0,1P3R <9YR>F*[
MNB@#CO"]M=0^.O&%U-:7$5O>S6SVTLD959 D(1L?1AWZ]J3Q1:WZ>.O"NKVN
MG7%Y;6JW<,WD;<H9%0(3DC RIY[5V5% 'G$5E?!OB(3IUX/[2S]C_<M^_P#]
M'$?'I\P[X]>E9?\ 9>I:2GA36)O#,VL6MOHL>F7]CY*O/;NNTAT1N&Y!!QVK
MUNB@#(\.)C3FE71H](CFD,B6HC1'"X S($R-QQV)P,#J*Y==-U#P?X^U;6K;
M3[B_T;7%C:X%JN^6UG0$9V=65@2>,D'M7?T4 85S)/XCTV\LH+>XM+:XMI(F
MN+F(QOEE*C:APW&<DD#I@9SD<2^DZKK'PKM_ UUIES;ZG&L%E+*8SY"QQNO[
MY9/ND;5R #NR<8[UZG10!QFCVUU#\3_$%W)9W*V=S:6L4-PT9V.T>_<,_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJZN1;1WX*%-Q)4,5W;@A(P&Q[]"#7.Z%X>O+3Q!IFH:/8ZAHJ7)=M;TV1O\
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M9G Q\O?!/8&N7T33]7\/S7GA^X\'QZD#=2R6.JXB,1CD<N/.)^8%2QS@$G&
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MCRDCA=29$8'YMP3@#G+<X S0!TP\9PM-K\ TK4#<:(JO/%B/=(K*6#1_/R"
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M6J1WUY>V5S9V=S@"5;4# D[#?EN#VVYQS@ ZD>-[6/4[W3+K3[N"_MK/[<L
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M- 'K$\,=S \,J[HW4JPSC(KS_P"&^KPZ9\*?#1E#S7%T'B@B0C?*^]V/)('
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ME$7[D(!N;[_S=3PN>!DXR*FF\8W5QXPT&QTRS^T:9J%C)>K,LB@RK\F, ]
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M[B3R> <UN:=XQ@N+_5K+4K&?2I],A6YE%RZ,# P)#Y0D<;3D=J .D9E4 LP
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M^+2XT6!Y(R%#R/ND&3P6"J..1M'2@#TBBO/_  =XK:'PC=7>I6;VMG8W3V<
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M+,JH69@% R23P!2@@C(Y%<UK<&D^&?A_=VTFFSW>CV=FR26JOO8P@'(R[ D
M>^?2LN]\3WECK/@_3-+TH_8=1ADDVB10=B0Y$8R>,94Y]L"@#N:*YY?%(GNK
MA+.PDN8+:^2PGDCD7='(S*"=G7:-XR>O!XQS70T %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$C\C7EL?A'Q#-X!ET5;#[/J&F:JVH6CRS)Y=V1.TB@8)(!5L?-C!Q[X]8HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !69KFN6N@V<=Q=,,S3+!"I<+O=N@R> , D
MGT!^E:=<MXZT?5=4TVPNM$$3ZGI=ZE[##,VU)]H96C)[95SS0!G2^*[#Q)9>
M)M N;>#[5:6+2NL<RW$,L;*<,K8&<'J" 0<4WPQXAM=%^'GA"WD:'[5>:=$(
M4FF$286-2S,QZ 9'0$Y(XK1CN/$.KZ#J37N@#37>U>&&R%S'+)([#&2P(55'
M;GG)SC KFU\/^)]+T'P9J.GZ:D^IZ%:FSNM.EG1?/C9$5MCY*@@H",__ %J
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M0^,;\XP,9]?;FN53PCXEBT&UNK?3@NIZ9K\VJ16DL\>+F*1F)4,&(5MK=^]
M&E9W!M?C-J5UJ%E#IYC\.B2:2.3>DBB8DONP"< 8.0#\OIBM2/XC6)U/2;>6
M&,6^K-Y=K)%=)(ZN1E5E0?<+=L$\\'%9USHFM>(_%]_=W6D2Z=IVH>'7TQGF
MGC:2-V=B<JC'L>Q]/<"[X4F\90VUGH^K:%;V_P!B58Y-32Z1TG1. 4C'S!F
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MZ2(WFFG4(GE?:R@%04=,95LMZGI0!T=%<-<_$7[+X8O]9?1I7^PZFVG311S
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MMQ# 8Q--'&9&"('8#<Q[#/4^U<Q8^-5^TZ];:W8_V7)H\*7,Q\X3*T+!B&!
M'/RD$8Z],US?BF\N]2U?P)?7&CQ6L<VKQ/%,9@\J*8W(1QM&TD8. S#*GVR
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M+<!@T3G)1E8HRY[X93S5O6-4AT31;[5+A7:&S@>=U098A020/?B@"[17-_\
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M=][/IQ]?;FO5** ///%WA>[\23W<J:));ZK%L.DZO;W"120'8N1*0V[ ?=P
MV0>.:EET_P 6>'/%U_J6DZ?;ZU8ZLD+7$;7*V[P3QH$W@D$%6 ' Y_+GNYIH
MK>&2::1(XHU+N[L JJ!DDD] *(9HKB".:"1)8I%#HZ,&5E/(((ZB@#C/$/A^
M;7XH+37M#75(A!O6XLY4CEM;@L2?++,IVXVC.?X1D')QO^%[+4=-\+Z=9ZO=
M?:M0AA"33%MVYOKWP,#/?&:UZ* /.D\*7L_B;3-;M]*;1]6CNLZE=03IY%Y
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MB]GS,C^;,J%56/:3\N6));:< #'/'9U6.HV*W+6QO+<7"+N:(RKN ZY(SG%
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MH9T^61)E.)&DWG SG;C(SC.>U=G39)(X8VDE=4C499F. !ZDT >;6WA;7O\
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M(2@;YA@$_+WZXJGXDT?Q'XG\#WUO/!:6^HS20RP6:S[D01R*^UI-HRS;3SC
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MPK:@3+G*1>6=WIDG/?C\J '77BRSO8?!U\=&2YAUB>,V\LS+NM':-F! P?F
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M=1TAM>_M"W6(7VK3WT)60-\C[< XZ,-O/;WH ZJBBB@ HHHH **** "BBB@
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M?.75KW[ \4L^Q[>8;LJ1M((!0\Y''.#TKKM(FU&YTN-]7LH;2\)820PS>:@
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M9)-SRY7.26 "L3VSCWH ]<HKFM"\1W][XDU30M5L+>UN[.**X1K><RI)%)N
MY*J005(/%3>(/$L6B:CI>GL]M#+J+2+'-=2;(E* ';G^\=PP..A],$ WZ*Y6
MY\4ZCI]UH%O>Z5%&^J7DEI(%N"?)*[R&'R?,I"9[=:CE\<QV-YXICU*T$4&@
MQPR&2*3>9Q*I90%(&&R .IY/6@#K7=8T9W8*JC)8G  J"ROK34;5;JQN8;FW
M8D++"X=202#@CC@@C\*R+?4];.MVUAJ&BH+2Z@:0W-O*9%@<8_=R9 SD'@CK
MCIWK@/!WB34/#/P\TJZ&EP2:0-1EMYY3<;95\RZ=0R(%((!8=2#UX[T >O45
M#=SFULY[A89)C%&SB*(9=\#.U1W)Z"N5T_QC=OXCTG1]1L;>"?4[-[D1QSEI
M+5E"L8Y5('.&Z\<@C'>@#L**Y&/Q9J5]I]MK&E:-]MTJ>[\A1'*?/,6\H9@N
M,;<C.,_=YR.@@T76->O/B!XIL98[1[6P6V2)!,R[0R.X/W3DL2,GC  QG% '
M6V5_::E;"XL;J&Y@+,HDA<.N0<$9'H015BN%T;QK;CP98:C'I,-I<7^HO8VU
MA"X"&8S.O+!1@?*S,<>O!-:<?B:\M_$Y\.ZA90+>SVK75C+',?*N IPR'*Y5
MAP>AR#GVH Z>BO.K+XC:I<Z!H>OS:%!#I>H7:6LI^UEI8R\AC5E79@J"!G)!
M//'<^BT %%<_X@\2Q:+J>EZ<SVT,NHF01S74A2(% IVY_O-N&!QT/I@U;CQ3
MJ-A>>'[:^TJ*-]5NI+60+<$^2RAR&'R_.I"9SQUH ZB21(HVDD=41 69F.
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M3D9^\>/EYH)X-N;KX51>%+]X$NX;)((YH7+*LL8&R0$@$890>E6-2\(3:IX
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M8\PEP,8QPON<GIA_AJS\:P"VL]?N=+:UM %^TVA<RW6!A=P8 )V)QG)&. :
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MY3K$T>"=O*C=G..<=!GB9_"VN-;>"HPNG[M"9#<9N'Q)MB,?R?N_?/./3WH
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M6\\TY0C&WAU"G&-W;.3QQUJ&P\*ZWH>G:YH>GFRETW4)9I;6>:5E>U\W[RE
MIW@$DCD9Z''6I;3P?>:5XE\.SV MCI>D::]C^\F82ONV?-@*1_!Z\YH H?\
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M 8GCK@]*[^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^XQ8G#@$@' 7&>,U#/XL\2S:EXILK'3],5]$$;J\TKL)%:+S,< <D8'8#WH
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M6<KN:-T:,NDB<@C([$G!'>M#P!9LW@GPW<7D5I)+%IL MI$BP\:-$F1DD\G
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M2XM9UWQRIT8>M<QI?B769M0\2:5?6=BU_I4<4T30R.L4J2*Q .02"-I!XYK
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M1@0Z,=N5W*>H!QCO7HE% '(W'AJ_O]1U36KE;1-2N-,.FVT*2LT<2$EF9GV
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M#]@/]N'= !,_[L^4(_F^3T&>/I[UTVDZUIVN6\D^G7*SI%*T,@VE6C=>JLK
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M +R=P8CY@#D9Z5>M-"U:T\;:SK8%G)!>VL,$2&9@X,>[!;Y,<[NW3'>NJHH
M\UTWP-XCTK2/"=O%<Z9-)HDDQE@E>3R9P^=L@^7(=,G&1W/(J1_ VO-X3\6:
M*UWILCZU>37$4@#H$$I!8L.>F. ,_6O1J* .1OO#^KW?B#PKJ0%BJZ0LOGH9
MGRYDC\OY?D[=>>O3CK6MXJT1O$?A74]&2<0/>0-$LA7<%)[D5L53U35;'1=/
MEO\ 4KJ.VM8AEY)#@#_&@# 70-3U6ZT236ULX8=(D$Z16LK2>=,$**Q+*NT
M,QQSDD<\<YFB^%_%GAYYM&L-3TX^'&F=X9)$?[7;([%F1<?*<$G#$\9S@]*[
MN&5+B".:)MT<BAU;U!&0:?0!E>)M,NM9\,ZCIME>&SN;F!HXYQGY"1[<^W'K
M7-:=X6\00^)M#U:=]'@BL;![*6VM5DVJI*'*9QG.WN!C/\5=U5./5K&75YM)
M2X4WT,2SR0X.51B0#Z=0: ,3P9H&I>&[.[L+N>TEM/M4TULT0;>5DD+_ #YX
M!&<8&?K1JN@:E-XWTS7]/GM D%K+:7$=P&SL=E;<N.IRO0XKIZ* . _X0[6S
MX<\8:8S:>)->NIYXG$SXB$J*F&^3G&W/'7/:EN?"OB:RU/3-;T&ZTU-1CT]-
M/OK6[+F"9$.5964;@P)/;O\ GW4\\5K \\\BQQ1C<[N<!1ZFH-,U.SUC3H=0
MT^=;BTF!,<J@X8 XR,^XH 32X+V"Q7^T;A)[QR7E:)2L8)_A0$DA0,#GD]>]
M<C#X;\5Z'K^IOX?U#2SI&IW+7<D=\DADM97^^4"\,"><$C^9/5Z?K6FZK/=P
M6%Y'<26<@CG$9R$8C.,]/RJ_0!RVL>%I/$*SZ?JXBN=*2T\NW4S-YC3$8,K_
M "X##C:1G')P<C'*^*+;Q#8^#/#%IK%Q9W6J0:[8HEQ&[%9B'^4OE00>F<9S
MR?:O4ZHZCH^FZN(AJ-C!="%Q)&)D#;&'1AGH?>@# O/"<GB#5KJ^UL0QH^FR
MZ=%!;R%]JR_ZQRQ5>2  !CC!ZYXA\,Z/XSTV*VTS5=3TR?3;(!8KB!)!<W"K
M]Q7S\J]!DC.0,=R:Z/2]9TS5A<IIMW%<"TE\B7RSD(X .W/?@CI6A0!YW)X)
MUN7P9XIT0OIXFUJ^GNHY!,^V-96!(/R9)&/Q]JO:]X7U+Q#IMQINHV.D7=K+
M;*D!EF</:S;<%U/EY(Z$?=/!]>.VJGJ&K6&E)&U]=Q0>:VV-7;YI#Z*.K'V%
M ''3^$O$FCZS:ZKX:U*RGG:QALK^+4P^VX\H864,F2'Y/MS79:;!=6]C&E]<
M+<71RTLB+M7<3G"C)PHZ#G.!SDU%9ZYI>H7/V:UOH9+C:7, ;$B@8R2IY'WA
MU'<5H4 <78^&-9T";7;;2)+*73]5N)+N,W$C*]I+(,/\H4AUSR!E?3WJ*^\$
MW4&D^$]*T9K;[+H5W#<LUS(RM+L5@1A5(!.XG/KVKN:* &$R>3D*OF[?N[N,
M^F<=/?'X5P6F>#M<L_#/B[2Y6TYI=<N;NYC=9GVQ&==NT_)SMZY[^U>@44 <
M/)X6UET\&@&PSH)4S_OG_>XB,7R_)Z'//T]ZH?\ "$^(K#1/$GAW3;C39=(U
M07#VTEPSK+;&8'<A4*0RY/!R",YP>E>CT4 >?S>$?$VGWFD:QH=_IO\ :EMI
MZ:=>P72N+>XC4Y4@C+!@2?S_  -W5_#FOZHN@2RW-C-=6.I+J%R2SQH<*R^7
M&-K$##=2>HSWXZ>YU6QM-2LM.GN%2[OM_P!FB(.9-@W-CMP.>:N4 <M9Z)JM
MIXXUG7=MD\%[;0P11^>P8&/=@M\F.=W;.,=ZY^P\"Z]9^'/"NEE]-=]$U$WL
MCB9P)5S)\H^3@_O#^7OQZ310!R,/A_5X/%7B35@+%HM4MH884,SAD,:L 6^3
MH=_;ICO66G@C68O!'AC2HY[#^T-"O8;E2SN8IA'N&"=N5R&]#TKT*B@#AKKP
MYXJTWQ3<ZWX>O=+<:E%$-0MKY9 GFHNT21[<D<<;3Z=?1VL>%_$2:MINOZ%J
M=H^L6]NUK=I?(PANHV;?_#DIALXZ\8&>.>WHH H:1#J,-EG5;B*:\D;?)Y"D
M1)P %0'G QU/4DGC.!STWAW6[;QGJFJZ9-8?9-6MH8KC[1O\R%HPP!0 88$-
MW(Y_7L** /.-/\#Z]9:%X.L'FTV1]"N?/E82.H<;67:/E//SDYXZ=*U!X:UA
M-=\6WZ_83'K5M%# IF?,9C1DRWR=]V>.F,<]:[.B@#SM_!&O6V@>%WTR^L8-
M>\/0F",R;WM[B,JJNK\!AG:#P.,?B-X67BB73DDNY=+FO7F7S[0;UMC#M8%
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M&_M-CYKZA]K\_+[0//\ .VXQUSQU]ZWI_#^I-X\MO$5O<VL<;:>+&ZAD1G(
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MH0[%LLZN6!V@<%<8_'CI0!?\0ZA?Z?;6SV,4!$EPJ7%Q<,!':Q8):1AN7=T
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MFN'N+6W>>(1(P 9$4DG=O3&3@#.?0@&YJNKZ3X7TG[7J$T=G8Q80$(2%SP
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M;Q#I4OBVTT.XTV[@2&TU"'4-TBL=_ED_)CC;U(.>1CI4J:!>)\0)?$CW%O\
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M+V>HB]\_RVP^)C*%VYXY.,YZ"MV7PW>GQR/$$-Y;I!/8)9W5N\)8D*Y<%&R
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MB811ER"[G+9).U1U&!GKG-.\%^'KCPKX8MM&GO([O[.7V2I"8\AF+<@L>[4
M4/$VM:[9>+] T?2WL5BU1+G<]Q$S&-HT!!X89'S9QQG'49K"7Q_J^A0>(]/U
MV*UN=5TJ6WCMIH%,<=R+@XC)7)VX/WN>@X]:O>,#<'XF>!EM)88Y\7Y E4E6
M'E)D<$'D=^WOTJY?> +?6M/UU=4N2;W6&B9YX%VB#RA^Z" D_=/))ZDGH.
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M!D9\@+C"\9!^;.>@K0BUO4_^%AC0)7@-K)HQO@1'\Z2B54QG."O)/3\:BO\
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MNP10,L>I..]244 %%%% "$!@00"#P0>]06UC:66[[+:P0;SEO*C"Y^N*L44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %5CIUDUT+IK.W-R#GSC$N_\ /&:LT4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex31-restatedcharterasam005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex31-restatedcharterasam005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K \7^)XO"FBB^DMYIFDE2&-8XF<!G8*"Q
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MU*LAWL<$'D<$?G0!VE%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAD6.4S$953QRNWD9[\]: .]HJIJ&IVNF11O=2$&5Q%$BJ6>1SD[54<DX!/L
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M7JE[0SP/&MP ,G86 !..<=<<XQ6AJ>IV>CZ=-J&H3K!:PC+R$$XYP.!R220
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MKZ6U9?LT<L>^9MK"/=MYC).,]".] '7:CI]MJMA+9W<>^&3&0#@@@Y# ]B"
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MMT+NB2IM$@4<G;SG'8UG^*S<>(_"SZIH&D7!2WU"UOF1K<PS7ZQ,"WR, QP
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MWKE_+_B*CY@/45TM% 'E,$D7_";:W=/8:QJ-A=^'@ ]Q;R*;G:TA9>5&S(.
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M1,9E!*LN>V"",D8R,9S63I?C2'5Y_$4-Q9WUM;:;,T!D$#EMHC4L?ER0<L<
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M2")Q(D:NR ADSAN.<< UF:2TTOQ#\/ZFEEKDT$NES027-W:O&%E+1G!4@",
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M;3P7Q:: "'*J64YX8'KU&,Y.: ._HKSNUUJP;X1Q.^O_ /$P;1Q.TAU)O/\
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M7;75G=V]DMPK*Z@&*0GA,$?Q'&">U=[X;T-/#>@6FCPW,MQ#:IY<3R@!MHZ
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M,T8"K@J%C+$*&;)&0"1P,D_J$BUHZ/?Z+HDNARVZ7L; 2VL8^S6S@%A$2.^
M>0,=^G2'XE:;>:O\/=6LM/MWN+IUC9(D^\^V16('O@&@#3F\0QPS6MH;&[;4
M;A'E6Q7RS*J*0"['?L R1_%SD=\U)H>OV6OV\\EIYB26TS6]Q!,NV2&1>JL/
MZ@D'L:Y6<:A;?$&P\6G3+XZ;=Z8=/GB$1>:V82>8CM&N3ANG&2.,XK3\)Z1/
M;Z[XEUR:)X$U:ZC:""0881QQA [#L6.XX/.,9YXH O:IXIM=-U">P6UN[RZM
M[3[9-';*F8XLD G<R@DE6P!D\4J>*K"X@TN2Q2:\?5(#<VL4056:(!26.]E
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M;M(T!(64S!PA(R,[1VR,\9S0!L6'C#3-2T*VU6W6XQ<S&VBM60"8S D&/;G
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M$:ZM;6UX%5;N-0@,?4]0K>W3F@#T&U\5V]SJMYI#6%[!JMM +G['*(]\L1.
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MDD"I].^(&CWVBZAJ$L=U9/I\PM[JTN8\3QRD@*NT$Y+$@#!YS0!U5%8,7BF
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MB6FZ+?L7 9R0^T+EE[Y^8<55T_QMIFI:;]IABN1<"\;3VLF51,+A<EH^NW(
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M!/+$?-D029CD^8Y9BP!Y(P<ENU '86_B('<][9R6=J+0W@NFD1XC&,9Y4GD
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MRER0"1G'7'7TSTK-U[PUJFI6'C?4K?3IC<ZU;16=G:DJ'*QJ1O?)PN2QX)R
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MQF:1V4C)PVU1D@#)SU)QQ0!7\.ZXNG>$?!NG1VLMS>7^F1>2BX50$A0L68\
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MSF,CPVW[N*92C(0R+\I(W9!(R,>]8NKZ)J>C>/U\7Z19M?PW-J+/4;.-U67
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M.WA=Q&,B:5CN8\* !R>>P )(% 'IE%<)-\3[&WT37+Y].GDN-%E2.[MX)4<
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M"#C\: .EHKAX_B.K6.AZC)H5^FFZNT<45P&1B)7!*+L!W$$C&>!GVP:TM/\
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MG4=%71TVA4MVE221CW8E. .P&<GG..*TX]1L9K5[J*\MY+=,[Y5E4HN.N3G
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MVWV"R\B':)MV%>-GR05^8MD C@#'?O'K>E>(+C4_"FL+9P75UI]Q.]U;QS!
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M-Q&03CCT)JMI.CZYX97Q%I=OIQO[2_NIKNQN%F15C,HY24,0P ;G*AL@^O%
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M74Z;-=W&F6TU_:BTNWC5IK<2"01N1RNX<'![T 6J*** "BBB@ HHHH ****
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MSV\EP]S/(88(U4@;2X5OF);ICH": -JBN2TWQW;ZMH.AWMI9L;S67>.WM'D
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M:UTNZ@=Q=-=*Q5U?;LV8!((!.[V/'0D ZVBBB@ HHHH **** "BBB@ HHHH
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MDD]A]:ZS1;Z74]$L;^>W^SRW$"2O%NSL)&<9[U;EBCFC,<L:R(>JN,@_A3F
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ME3(,D00;1GG!&3[>O2NSHH \H?PKXNGTZP6ZTVRN-3LM;BOI[Y[SYKR-)&8
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MNXQ_)R>2<':,8Y)Z='/XB-SK,.CZ7!%<7+V8O)6G<HD43'"YP"2S'/'H"<]
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MMG$NXKB'ROF&..>>,T )I'BRYM/"/AIM3^RG4=3MHC$\ET0K@0J[22,5&#[
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M[@O)&ZQ^9\Z[<8(SC!/O63XRUV[\0?#GQ1=Z=:VSZ7#%<6P>5SOFV95Y%P,
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MW(&2QX&1P><01^*KJZN=(TR/3C:ZQ?VC7<UO=-Q:1K@$MC[QW, !QGDG&,4
M=317 W_Q"N]/T3Q*\FEPG5O#Y7[3;_:"(Y(W&4D1MI)!'.T@8P1FM*W\4:G'
MXLTW2=2TRW@M]5MY9K22*X+NIC"EED&T 9#9X)],GK0!UE%<EX>\73>(WMY[
M)+.2U:>2*YB64^?9[0^/,7U)4#'&-PQNZUG2?$29K:SU.RT\7FFW%P(C'")&
MN%B+$"; 7:1WV^AZ]J .^HKAKCQAK\FH^)K&QT6R:31!&Q>:\8+*K1^9QA,[
MB,#'0<\U5OO%>KZEJ/@2?2D@BL]95[AXIG8,2+=F",0/NC.>G) Z4 >AT4@S
M@9QGOBEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KF?&_AV]\0:99OI5S%;ZIIUY'>VCS F-G7(V
MOCG:0Q'%=-10!QFH^'=;\8^%-3TSQ&UI8M=PB.**R=I5C<,&$C,P&3N5> .
M#R<\.DT/6=?;0%UZ*TA&E727DKP3%_M$R*0A4%1M7+;CGG@#WKL:* //!X2U
MX^&O&FFF.P$VNW5Q-;L+EMJ+*BIAODZC;GC/6K.J>%[[6-(@TK5=&TR_LTT^
M.) ;@J\%RNX,ZMLSM(V<C!&#P<UW5% 'G;>%/%.AWFCZMHE[::A?0:;'IVH1
M7SLBW*H<K(K $A@2>O8U?UO0?$6K)X>ED:PDN;'5$U"Y'FLB*%5E\N/Y23PW
M4XR03QG [6B@#BV\,:I<>)/%=W+]ECM-9L([2%EE9G0HCKEEV@8._L>U6-$L
M_%.D>%M"TT0:49[1H+:Y_?2,OV=%VLZG:/G. 0",#U-=910 5BZ]9ZC=W.E/
M8PV[I:W@N)3-,4.T(ZX7"G)^;VZ5M44 <=X[\#1^+;:WN;:46NKVA_<W )&]
M#]^)R.JL,_0_CEFN:'XCLO& \1^&6L9S<VRVM[97KM&KA"2CJR@X(W$=.E=I
M10!QFOZ!X@U:U\/DO8S75EJL6H71,C1H N[]W'\I)X;&3C.,]ZG@T36+#Q[J
M^LVR64MCJ5M;JXDE99(WB#C  4@@[NN>/0UUE% 'F47@CQ#'\--,\-[-.-Y:
M7R7#R?:7\LJLYEX.S.><=*TI-$\6:+XJU'4?#_\ 9ES8:LR37%M>RNAMY@H4
MLI53N4@#(Z\=J[NJ=[JVG:=-;0WM[!!+=2"*".1P&E<G "CJ: .<?0-:/CG1
MM89[6>WM+&6VN)&D*2.TA5BRH%( !7INZ'VKJ[B+S[:6'./,0KGTR,5)10!Y
MFG@WQ-_P@6B>'W32S-IEY;R;UN7VO'"^[.=G!;@8QQUR<X&OJ'A2_P!7\8ZC
M>W:6Z:7?Z&=)DV3$RJ2S,6 VXQ\^.O:NUHH XOPO8>-K&*TTK6)M+:QL@J"]
MMV<S7"+]T%",*3@;CD]\=<C:\6>&K7Q=X;N]&NW:-)P"DJ?>C<'*L/H0/KTJ
M]/JVG6NI6NG3WL$=[=9\BW9QYDF 22%ZX !YJY0!S6F2^+X+2.SU"QTV>XC4
M(;Y+ME23'\9CV9![E0<9[BJNH^&]3@\6Z;XGTZ6*ZNX;1K&]AG;R_/B+;P4(
M!"L&YP>".,BNOHH \[UWP-J>J:#XK,7V1=6\0O$&5I6$4$<854&X*2QP"3P.
M6QVR9?B(UX+7P:PAA%X/$-J?*,IV;MDO&[;G'OC\*[^L_4M#T[6'MGO[?SFM
MI!+"2[#RW'1A@\,/7K0!S6I>#'\3ZCJM[JX2V%UI9TN".)][1JS;VD8X SNV
MX [+UYP(QX:UO5]#T;1-<2S6#3IX9)[F&8L;D0\H I4;=Q"[LGCG&<Y'<@8
M%% '*^'M$U73O%'B74+M+5;;5)HI8#%,7=-D83# J!SC/!-<O!X+\6KI6BVT
MPTB2ZTS5UOIKIIY"][C?EW.SY6PPX^;..H P?4J* .3TW1-9TOQKK^IQK936
M.J"&4$RLLBO'%LV[=I&"0#NSQTP>W/V7@'6K;P5X?M/-LH];T&]:[MRLK-#,
M"[%D8[05!5\9P<$5Z910!R;:%J%_XB?Q#=V]O%<PZ>]G:6HG+#+MEG=]O'0
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MZ>1,J!-Z,JG<I &01GCM5S4= UJY\4>%=2#VMPFE?:#=2/(8VD:6/;\BA2
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M%L<D# S2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH0_/_:*H9"P^7Y!$3C//4L!QT% &U1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %34M+L-8LGLM2LX+NV<@M%.@=20<C@^]6(HHX(4AAC2.
M*-0J(BX50.@ '04^B@"EJ>D:?K5K]EU*TBNK?(8Q2C*DCD$CO5N.-8HUC085
M1@#.>*=10 4444 4+#1--TRXN+BRLXX)KD[IW0<R'U;U/N:OT44 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%8/BC7Y=%MK:*R2TEU*\E\JUBNIQ"C
M$#<Q+>P'8=2!WH WJ*S-"FUF?3R^NVEI:W>\@1VLQD7;Q@Y('/6M.@ HHHH
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M_9KL:HWVCZ;J6DOI5Y90S6#JJFW9/DPI! Q[$#\JN@!5"J  !@ =J %HHHH
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MN8CJ%I%&\@;YE0R;MH(!SGY"2/0CUKG_ (3,S?#325+%A&9XUR<X59G51^
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MKQD$@*?P%4="L-"U0^%M=LM<A$T(VV\5I&BR2[E^>.3&6.,$G/0@F@#T8W$
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MC@LYYP&<VXNPJ\GG!48]P!7M4$$-K"L-O%'%$OW4C4*H^@% $E%%% !1110
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M?4K&.'SGO;98M@DWF50NP]&SGI[U-Y\/V?[1YJ>3MW^9N&W;USGIB@"0  8
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M2.->KNP 'XFF17=M/-+#%<122PD"1$<%DSZCM0!3O/#NBZBMHMYI-E<+9_\
M'LLD"L(>@PH(X' X'H*:?#>AFQN[(Z18_9;R0RW,/D+MF<G.YACDYYR:N?;[
M/[;]C^UP?:L9\CS!OQZ[>M45\1Z8_B.30DNHC?10B61-X^7<<*O^\<$X],>M
M !J/A?0=6L[>TU#1[&YM[8 01R0*5B'3"C' X' J:;0=(N'M'FTRT=K, 6Q:
M%3Y(']SCY?PI-*:\V7GVZ]M+DK=2>6;==HBC_A1N3\P'4\5:M;ZTOD9K2Z@N
M%4[6,,@< ^AQ0!7@T32[:YN;F#3K6.>Z&+B18E#2C_:/\7XU%I'AO1-!:9M(
MTJSL6F.9#;PJA;ZX[>U7(+^SN9Y8(+N"6:+B2..0,R?4#I3YKF"W*":>.,N<
M*'<#<?;/6@#'/@KPN9II3X?TTO,XDD)ME.YLYR1CUYK<551 BJ%51@ #  J-
M;F!YV@6>-ID&6C#@LH]Q^-1KJ-BTD4:WEN7FSY2B5<OC@[1GG&#G% %6S\/:
M-I]S]HL],M8)=S,&CC VEOO$>A/?'6I;71M,L;V>]M-/MH+JX_UTT<05Y/\
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MTXA%NFWRH\ JC\G+CN>.HXJ6.]@OX)AIM[:RRIE=RL)51O\ :"D?ED4 5/\
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M'$DGFJ3@DN0,8].?:BQ\0:O<?$C4?#LIL?L5I:1W0=8'$C;SC;G?CC!YQ^%
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MRQ;:A;)"KG YX %:]O>PR+'&T\7V@QAVCWC<.,YQ4L-S!<QF2">.5 <%D<,
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M1\0K6Q)L-3MO[*DB6,[Y)2N]#_W]!B_#.<$5L>)M&M[.X\!Z9.D<H.J,;CC
MF=H9&=B.^YB21[XKT$6%HMM';BUA$$3*\<80;493D$#L0>:CN])TW4)HIKW3
M[6YEA.8GFA5V0_[)(X_"@#SVRL+*+7?B9IL=K EB+>VD^SJ@$89K=B3MZ#)
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M@78+A8%$@7TW8SCVI;[2=-U/R_[0T^UN_*.Z/[1"LFP^HR#@T <!J*Z7X?\
MB+I^EM+!HNES:=(]F5BC6$W+2YE'S J&*[?3CCOBLV9=(\*S>%[:'4I;GPNV
MLW!GFG93 DQC)C4%0%\M9"Q] P/]VO4-1T?3-8M5M=3T^UO+=2"L5Q"KJ".X
M!'%++I.G3Z9_9DUA:R6&T)]E:%3%M'0;<8Q0!YYXO?1]+T/6;_1I6:"?4K.;
M69+9_-01EU#X'*YV@;ACD,,\&MC2]+\/7OBE]4M=9&ISW>G>3-!$86@DA# A
MI%1>O. 3VR.QKK+72]/L=/&GVEC;066TK]GBB58\'J-H&.:AL/#^C:7:S6VG
MZ38VL$YS+%!;JBR?[P Y_&@#S/0= ;7_ ( Z7%:(IU&T5KNP;&2LT<S,H'UQ
MM_&MM=6N?$W@S5_%NEPNETVDO#IX"_.CA"TA7OGS,+]8AZUW-CIUEIEO]GL+
M.WM( 2?+MXEC7/K@#%2P6\-K"L-O$D42_=1%  []!0!YOH,'AK6AX4U:SU]W
MNK4!;6VM_)5_F3#QNJKNV@ EL^F:AT*2]T/5?#EI>QVNKZ+=3R?V1JT'RSQ,
M\;MME7^+*[LD>F3S7H-EH&CZ;>S7MCI5E;74_P#K9H;=4=^YR0,GFEL]"TC3
MYA-9:79VT@SAH8%0C/7&!QGOZT <K\7[>";X;W[RQHS1S6[1L1RA,\8R#V."
M1QZU3O;&+2/BK;#1;2"WGFT"Z^2) HE=9$*;L=3D]37>WVFV.J0>1J%E;W<.
M<^7<1+(N?7!!%1#1M*%Y'>#3+,742A8Y_(7>BCH V,@4 >42>5J'[/\ !>P%
MO[9@9)$E'^O6_P#. //7>6)'J0U='I\=LGQ?U,7J6RSOH]H<,%&YS(X.,]<D
MXKLDT+2(]0;4$TRS6\9M[3B!0Y;&-V<9SCC/6II=,L)[^._FL;:2\B0I'</$
MID13U 8C(!R>* /'/M":1X(UMDCV:3%XSD2_2)?E6T$Z[UP/X>@(]#BNK\3M
MI?\ 9GB+6/#,ZS:W+HK*7LIMRB)?NMA3@-@G:>IVG'2NTM]%TJT@G@MM,LH8
M;C/G1QP*JRYZ[@!S^-+IFCZ9HMNUOI>GVME"S;F2VA6-2?4@#K0!Q&C6_AG5
M]3\-:UIVOM-<01-':6]MY*DQLGS)(JJ#M7'0XP?<U=^*VQ?!L<TFT)%J-F[.
MW1!YZ9.>W6NFL- T?2KF:YT[2K*TGG_ULD%NJ,_?D@<U;N[2VO[62UN[>*XM
MY5VR12H&5QZ$'@T <*\EA=_&UH6>VF5_#C1R(2K!C]H4[2._!Z>AKBM.TVP@
M^#?A?4XK:%;U-6@*7(4>8O\ I97 ;KC&1CI7L4'AW1+7R_(T>PB\N(PILMD&
MV,DDJ.. 22<>])_PC6@_9$M/[$TW[,C;UA^RIL5O4+C /O0!R6AW5K?^.O&U
MGK7DFXC\J..*XQC['Y>?ES_"6+%O<\]JX[PWJL-EX5^&XO+\6FEN+I)+C"%(
M[C/[K?N! X\S&?6O8;O0-&O[JWN;S2;&XN+8 02RVZLT8'3:2.*#X?T8Z3_9
M1TFQ_LX_\NOV=?*_[YQB@#RWQAH>AV?@#Q1+I]^U^);ZVN)&S&8X)FFC#>64
M "L5(+8YY'K7JNFZ-INCK,NFV-O:"9_,E$*!=[8 R<=3@5&?#VBG38]-.D6!
ML(SE+8VR&-3ZA<8%7XHHX(EBBC6.-!A408 'H!0!P&@K9P_$;QXK+!',6M/*
M! #<VN3M_(YQZ&N1TS3[*V^&WPYU&*VB2];6+)6N0H\PAI&5@6ZXQQCIBO8Y
M='TN>[DNYM-LY+F6/R9)G@4NZ?W2Q&2OMTJ$^&]"-M%;'1=.^SPOOCB^RIM1
MO4#& ?>@#C%@M(/B7XRW,+6*31('GEA&&7/F[GX_B YS[4>%I-2T?Q1I>BZW
M:65VQTZ6/3-8L?E$L"F,LLB?PGA#D''/'4UV_P#8FDBZENO[,LOM$R&.67[.
MF]U(P0QQDC'8TMCHVF:8Y>PTZUM6*[<PPJGR]<<#IGM0!5\37\UCH[)9NJW]
MVZVMGN[2OP&QW"C+GV4UP'BJPO\ P;)X<\4G[&+/0V2RN1;JX9K23"'=DG.T
MX(]SFO3+S2M.U"2*2]L+6Y>$YB::%7*'U4D<?A3K[3K'5+?[/J%E;W<.<^7<
M1+(N?7!!% '"^*M.TS4_B?X,^T6UO<17-M?!]RAEF4)&5#?W@,D@'(I+*PTK
M2_C#+:16UI;6Z:!;K!'M50#Y[J-H]>@KLE\/:(DEO(FCZ>LEL,0,+9 8A_LG
M'R_A5B;3+"XOH;Z:RMI+N!2L4[Q*9(P>H5B,@'VH \>DF_LGP)XS:VB*6,7B
MMQ=I N,6WF1>8 !VVY!]B:]&T]?#-UXGCU72YX9K^73_ "=UK,&3[.&!4LH.
M!R< GGJ!P#C8MM&TNR2=+73;.!;C)F6*!5$N>N[ Y_&H[#0-'TNUFM=/TJRM
M;>8YEB@MU17_ -X 8/XT >1:/J*Z?\-/A_+=W)MM(:_D6[G"JRH<S>46W C:
M'P<G@$ ]A7H7A?3-(M/$&M7NF:O)?2WHBDNE1HS"C@$ @(  S 9/<\$]16ZF
MAZ1'ILFFQZ79)8R9WVRVZ")OJN,&I-.TNPTBT%IIME;V=N"2(K>((N3U.!WH
M X?XC0I<>*O L$CR(KZFX)CD*-_JST8$$?A726=A8Z%KSN+ZZEGU-(X8X+BX
M>8CRO,8D%B2!A^>V<=S5^^T+1]4E674-*L;N1/NO<6Z2%?H2#3;7P]HMC.TU
MIH^GV\K(8R\-LB,5/49 Z>U 'F.G:5<Z]X4^*.F6)S=3ZS=K&H.-S!4(7\<8
M_&NV^'VJVVM>!--2,E)K:V2TNH,E)()44(RD=5.1QT.,5N66BZ5IDLDMAIEG
M:22??>"!8RWU('-1W7A[1;ZY:YNM*LIKAQM>5X%+,/0G&2/8T >7V]Y=WOPE
M^($M[?7-TT-S?VL33S%]L:#"J,_7KU-;5YHT8^#D]S_:&HG_ (D#/L-TVS_C
MWSC'3'M7=/HFDR:>NGOIEDUDOW;8VZ&,?1<8H.BZ4=/&GG3+,V0Z6Q@7R_\
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MUCZRFD:#I]C)IVHS7F@7/B6.;5)W=&@!89(!10OE[PA;MD8]10!V-AXGFO\
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M*9VT^T>>U\1W'D.8E)APB8V_W>IZ5>^(5T]I?^%);CC2/[607K'[H.TB(O\
M[(?!YXR!0!U]KJ-C?6[7%I>V]Q"A(:2*5752.N2#BHX]8TR:XAMXM2LWFG3S
M(8UG4M(O]Y1G)''45Q&J6*M\3]2,$:-93>'V.I(0"C.'/E%ATW8#8SV%<S8V
M5E;?#OX:7L,$,=T^KV(:=5 =MVX,"W4Y'&/8>E 'J7BN^O-,\)ZMJ%A)$EU:
M6DLZ&6,NN44MC&1Z?_KIOA[7;;4M,TY)K^U?4Y;**>:!9%\P%D!)V Y Y]*9
MXVY\!>(O^P9<_P#HIJX&YT73_P"P?AY=Z/:V\>L&ZLW2:W4"1XMF9RQ')7;G
M=GOCUH ]0GU73K:\CL[B_M8KJ7 CADF57?/3"DY-<VGB2YM/B!JVFZG>VD.E
M6VGPW4;N!$$+NRG<S'G[OL.>E<;:R:'K>E^)-#\4:_-8WBZI.UU:EH4D<>9N
MB:/<A=OE"!<$G@ =JWK.QM+SXNW\=Y MQY>A6V%N5#D'S) 21TW8/)]SZT =
MU+J-E#9K>2WEO':L 5F>50A!Z8;..:PO%VO367@+4]<T*\M9'M[=IHI<"9&V
M]<8('X\_2O/_  KJ-C;^$O 5O*(Q>-=WOV*XN)2L$&QI5)8 C<=IPJY'/<8I
MD%U _P ,/B7"EY#.PU"^<&,@ J53Y@ >%))Q0!W6O^+TT?3="C>ZMXKS5)X(
M6>1E'E(ZDM)M/8!2!GC)'7I6UH*:HEO/_:6H6U_&TI>TN(4VEH2 5WX^4MUY
M7@C!KC_%GE&V^'I;82VKVHYQR/)D_P 17;ZQ]K30K_\ LY?]-%M)]F '_+3:
M=OZXH >NJZ<]\;%;^U:\&<VXF4R#'7Y<YKF]:\4H?%L'AFTU6VL9GLY+B2Y)
M1F1PRJD85N,DL20><#CKD<9>>5J/P&T:72S_ ,3B![46I'^M6^$JJ_ON)+Y]
MB2:ZF=8C\;[-6";CX?E.,#D_:$Y_0T ;-Y<ZYIG@BXN[F>Q?5[2TDFD=(F,+
MLBD\+D$ X'>F^%==FU'PAI.KZQ<V<4^H11R (/*0,X&$&YCD\XZ\U:\6D+X,
MUPD@ :?<9)_ZYM7FEY;VMS\)_AT9HXW_ -.TQ S 9 ) 8 _SH ]:M-1LK\RB
MSO+>X,+;)1#*K[&]&P>#[&N6\6^*WTZ^T2VTK4K!I)]7M[.[M^'E$;MAOXOE
MZ8Y'?M7.ZQ'+I/C7Q:F@0)!='PLLL4=N@7,JO*%8 =6 QC\*I:CJ&A7'@CX<
MSVEQ:;8M6L,'>NY"/]9GN#G[WOUH ]6NM5TZQGB@N[^UMYI3B..:949_H">:
M6XU*PM'=+F]MH62,RN))54J@(!8Y/ R0,].:\O2XT75+SQGH?B?7VT^26]<O
M#*T*"6V*KY3HSH2<*.,'@\]ZOV&EZ=_PMFPA:W,RCPLC9NT!E<B90&DXY?'4
MXH [TZWI2I:N=3L@MV<6S&X7$Q_V.?F_"I+C4K"T9UN;VVA9(S*XDE52J @;
MCD\#) S[UXM<:=IZ?!CQG*EK 'M]2NUA<(,Q!;C*!3_"!G@#U/K78&PL+OXU
MQ&>UMY2_ASS3N0'<WG@!B.YQWH ZS5[MI] :YTS6;*SW[&BOI0LD6W<,]P#D
M9 Y[TR?Q5I%OXGB\/R7L"W[V[3E&D V@,BJIS_$V_@=?E->474-L/@9JR;(M
MEKK4BP# Q$/MHX7TX)Z>M=K>36MM\;;-[F2*)9/#\B(9"!N?[1'@#/4T =C)
MJNG17Z6$E_:I>/\ =MVF42-]%SDT7FJZ=I\D<=[?VML\IQ&LTRH7^@)YKR72
M7T37_"=SI?B+Q!=6NJV^HR/<V2-"EQ]I$Q9#'E-[$_*!@GKCVJ^;G2KW7O&F
MA>)]=;37GF'[N9H466T,2A"C2(3QANAX)SU)H ]6K(T^\-O:ZA<:EK5C<0QW
M4FV5-L:V\?&(W.2-P[DXZCBIM#MX;?P]I]M"]Q+;QVR)&UUS(R!0 7X'..O%
M>0ZA;6@^$OQ%C$,/EPZ[=^6H48C(D3&/3\* /9H=1L;B[EM(+VWEN80#+"DJ
MLZ ]-R@Y'XU.[K&C.[!4499F. !ZFN N[*ST[XI^$/L4$-N9M/O5D\I0ID $
M;#..O.3S[U8^*-XUEHFDR39&EG6+4:F<?*+?<2=W^SN"9_+O0!8MO%$M[\2X
MM(L]0LKK2GTN2YQ;X9EE61%P7#'/#=..O>NF35=.DOVL$O[5KQ02UNLRF08_
MV<YKS_5;JV/Q;2;3)[9KZ7PU.L+(ZDO)YBF,>_M[5G>&6\-^(?#OA5I_$-T=
M2T^>%DL4:%9TN5X=679O*D[BV3R,DGO0!TEWXGGUGQ+JN@Z)K-E97-C;Q-#(
M^R03SN7.P@_P@(,[><M[8/46FJVKS1V$VH6+ZHL8,UO#,-P8#YL*3NQGUKC;
M ./B-X]%DJ&\6PLC",#(?RY<?J16)X9;PWXA\-^%C<^(+HZGI\\++8HT*SI=
M+PZE=F\J26+9/(R2>] 'I\NM:5;Y\[4[*/$OD'?.H_>8!V<G[V"..O-37E[:
MV$'G7EU!;1YVB2:0(N?3)(KR$Z5IC>#?BFYLK8M#>W@C/EC]WB%&&WT^;GCO
M6SIFJA/B-H,>JS*L$OAR-M/>5OE><L/-P3_&5"^^/K0!IZ!X@U36_#WB>636
M+"WFL]2GM;6_\H>2D:JA5B"V"/F)R3WKKVO[6V6)+J]MUE:,OEG"[P!EF )Z
M=_:O&YAILOPQ^)D,/V5TCU>[EC1=I"Y$>UE';G."*ZC5+&QNOB5X*\ZV@E\S
M3KHON0'?M6(KGUQR1F@#O[:^L[RT%W:W4$]L02)HI R$#K\PXIEMJFGWI(M;
M^UG(."(IE;!Z]C7DLUO%_P (!\1K2*[AL88M>EV;CMC'^I/EG'17.5]/F-=/
MI<%AXB^(D/B-7T[_ $?3/LRP+<13RF0ONWC82 %' .<G<> .H!W5Q<06L#SW
M$T<,*#+22,%5?J3TJ"'5-/N+-[R&^MI;5,AYDF5D7'7+ X&*YWQ[>V%G:Z*M
M[$KR3:K MJTDICBCF&YE>0CJHP3M[G XZCA)YK2XL_BQ!-=V=VYMQ.OEA0K,
M+7EU7)QAL#.3SWS0!Z[#JFG7%W]D@O[66Y\L2^2DRL^P]&V@YQR.:LRRQPQ/
M+*ZQQH"S.QP% [DUY?\ 8K*QUOX836L$,,LJ2J[HH#2 VN3D]\G!Y[UU'Q$O
M-.L_"$S:G;F>WDN((]GFF)=YE7:7<?=0$ D^E '0V>HV.HH[V-[;W2H=K-!*
MKA3Z'!XID>KZ;-<RVT6H6CW$(+21+,I9 .I(SD5Y5>7]V/%'CD:?J-M/JLV@
MQF$V?R[I5$O"#<26 ]R:Z3P[>^#M=L_"EU9R037UI!MLX(9?WD&Z/;('0'H
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MGQAXA\2PR6#M?^0L4<,L<LD01-K,S(2 6/8$\*,\] #MZ*** "BBB@ HHHH
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MQR*&5AZ$'@T)(/LZR.P V!F)X XKAM9\>V]_X+\1:CX:U*V^U:8LNQCMD+!
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MNFM-:TO4+A[>SU*SN)D7<T<,ZNP'3. >GO3%U_1GN$MUU:Q:>24P)&+A"S2
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M;I"ECJ4;*+?:228RJL/FR,@K_"O/% '*0Q:-X:\$:0)9=-OFNM>62*X@N/\
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MZA<VES8?%:%KVVO9&@BG1E"X;%N,NJCL#QGGMR36[J>D:?)<?#RYT2"W6_\
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M>YND/F@8;]R=JG/7YL<>M<WK4&EZ)J'Q NSIXGT!X+..YMH7,4;7);!Y7[N
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M@CD;[SI& 3]2* ..U[5=/MOB)96KR6]C?_V7(_V^Z<[1"9%!CC4D*7)7.3T
MZ'-<#X?U>"S\(?#Q[FX3^Q[;5+A+]B1MADW2^1YG]T!B#SC& ?2O<);2VGEB
MEFMXI)(3F-W0$H?4$]*:;"S-J]J;2 V[Y+Q&,;&R<G(Z')H X/2KC2KSXQ>(
M(HI[2876DVZNJNK>:0SAAQU^7&?;%1>#(+F&\D\%W,<C6_AZ[,RRL,B6 _/;
M GN06)]C"/6O0;>PL[/_ (]K2"#Y0G[J,+\HZ#CL,GBIA&BR-($4.P 9@.3C
MID_B: /$O&&K:;<>%?&,=G-;V/E:PHFMG?=<7$R2Q!I3N/R)A> HZ+G(R176
MQ1Z;??&WSD2UG5O#JRHX"L&/V@C</7@]?0UW+Z=8R/,[V=NS3@+*S1*3(!T#
M<<_C0=.L6F,IL[<RD8+F)<D8QUQZ<4 >+Z9J,>D>%/#-Y.<:%9^)+I;O;RD0
M,DHB9L=%5F!^N/:NC\7W.CR^&_$6K^&L7<DLEI+JES8N)5EC1UW*.2I81@[@
M!T//6O14TZQC@D@2SMUAE&)(Q$H5_J,<U);VMO:6ZV]M!%# O"QQ(%4?0#B@
M#B]"D\-:SXKM=;TS7Y=7U$6;1$Q/%MC@)SB545<?-T#<YSQP<'CBZ>Q\5^"[
MJZ.W1DOI5N7;[B3-$5@+>@W$\GH<5V-I86=@KK9VD%LKMN80QA Q]3@<FI)H
M(KF%X9XDEB<89'4,K#W!ZT <7I\#)\8M8NK-@+!M(A%\5/RFZ\QMF?\ :$8_
M(CUI?A%(DGPPT@HP89GZ'/\ RVDKKXK"SM[3[)#:01VW_/%(P$_[Y Q3K>SM
M;0,+:VAA#?>$:!<_E0!Q5_=V]E\:K![J>.%9=!EBC,C ;W^T)\J^I]AS7(7-
MO92_#GXGSM% \HU:]'F$ L,;"O/L>GO7LLEM!-+')+#&\D>=C,H)7/7![5 -
M)TT(R#3[4*Q!9?)7!(]>* /.YM;M]/\ 'L8UO6GTRUOM&M_L5TQB$3D%C*A>
M16 )W*>V<#.>*[#P5I^EZ9X8@M=%EGFTU7<P23,&W@L22I 'R$DXXP1R.,5K
M3Z9I]S;);3V-M+ ARD4D*LJGV!&!5D *H50  , #M0!Q%E)&WQJUB/>I;^Q+
M<%<\_P"M?M^(_.N+ODM?^%6?$M L.R/6[LH !A3F/&/2O8QIUB)S.+.W\XG)
MD\I=Q/KG&:8-)TX(R#3[78Q!*^2N"1T[>] '$7T-G9?$GP-]DCAA\RQO5(B
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M2[U;QV;5+22^35W>!BJL480KL;VPQ;GZT =N=>T@7ZV)U*U%TS^6L1E&2_\
M='^U[=:DBUC3)]2ETV+4+62^B&9+99E,B#U*YR*\F$L&I? -=)7C7(2MN+8G
M%PM\LV>G4,6^;/H2>F:Z7Q9]L\,^(=#\5PP-=2R1?V5?Q1#F7?S$1Z8EXS_M
MT =#JNKV5Q;6XL_$UG8-]M2(R!HY/-8,-T !/WCG''(S6CJ>K6&G)LN]0@M)
M)$8H9&&0!U;![#(R>@[UP_CRUATGPCX?M[B:,S)K5F\DK8&^0S;I'Y]26/XU
M)IVM6FF?%3Q3#KMU#:M<P6K:?)<N$22W5#N"$\<.6)'O[4 :?@+Q%-J'P^L]
M8UO4(FE>2=7N'VQJV)W1<8P.@ 'K71V>L:;J-G)=V=];SV\199)$D!"%>H;T
M([YKQ70]6M],\%>"[Z2ZDAT>RU.]CO9;<!C:L[RB)F&#@?,>HZ-]*UO$XTD>
M&M;UGP]<W&IVUQ>V4NL7$;^9'+$C?.%V@ D*!NP.AY[T =5+XI:Y^).B:;IV
MK0SZ?=6EQ)/!&%."@78V[K@[CCL<=Z[>O-[_ %S1=0^*_@^YL=1LIUDLKQ!)
M%*ISD1E5R._7 KM]&U[2_$-I)=:3>Q7<$<K0N\9X5UZ@Y^H_.@#FKCQ-)I/Q
M'O[/5=6@@T:+2([M1,$C6-VE9/O=3POKWKJEU73FTQ=26^MC8NH=;GS1Y9!Z
M$-TKCE>T?XYW/F-"TD?AZ/&X@E3Y[Y^G!_(UQ6B7GV3PEX*O6=3HMEKUT+PJ
M<I#NEE6)F]%!8')X&1[4 >PQZ_H\MG<7B:G:&WM3BXD,H A/^WG[OXTT^)-#
M5;1CK%@%O/\ CU)N%_?_ .YS\WX5R\=HE_\ %VZNK,I+8/H@@U H0T<DAD_=
MJV."VS=[[2/45Q\EEK*^&;G1[6.3[5X'O&NK:5UYN$4AX4![@PLX('<)ZT >
MP_VG8?:;BW^VV_G6R"2>/S!NB4]&8=AP>356'Q)HEPET\6JV;+:J&G/G+^Z4
M]&;T!]>E<1XDFN[GX<77B*&WN/\ 3+JWOYH44>8+-)$(7'/_ "S4,0>,LU:6
M@3>%M?\ $T6LZ5JLVKWWV(PR2!P5CA)SMD 4 $MT!YZ^AH ZE==TAM-74EU.
MS-B[!5N1.OEDDX #9QUXI+[7](TR58[[4K6V=MN!+*%QDX&<],G@9ZUP_A*T
MN;/5KGP3+%)]@T6\^VPRD?*]NYWP1Y[D.6/_ &QK-&HZ(-5\7^'O%VK36$EU
M>R2"!RJK=6SJHCV$J2QP-N <\#% 'H]]XET/3)98K[5[&VDAC\V1)9U5D3(&
MXC/ RP'XUI1R)-$DD;J\;@,K*<A@>A!KS6VM-+_X6QI5C+"C(GA?RE@N\/(/
MWJC:V>K;<Y_&NZLM<TF[U2\T>SO(7O; +Y]NG!B!''X8].E %37?%NE>']1T
MRPOKF..>_E*('<*$4*278G@#C'N3]:PK/Q:-/\9^*(-<UJVBTJTCLVM6FV1J
MAE60D!NK$X'<]*/'ES!8^)_!5Y=S1P6L>HRAYI6"HI,#@9)X&35/3)-/N/B5
MXYDE:W;_ (E]F,OC(4QR;AST'3(^F: .YGUC3;:V@N9KZW6&XQY+^8")<C(V
M_P![CGCM65K7C71-&\/QZRU[!/;3NL=NT4@(E8MMP".P/4]L&O.O#&MZ=:^'
MOA[%<2VMM<M97 BU.ZD^2W  #HHR%+L, ;NF.AZ51%Y;'X4:P@N=_P!D\2[Y
MBV 8T^V*0S# V\<]!]* /;XKNVGM!=0W$4EN5+"57!4@=\],5P6N^/HM1\ >
M(-5\-:E'#=:?YFQL*[$(=N[8W0$YP2*[ZUNH+VV2YMI4F@D&4D0Y5AZ@]Q[U
MXQ)?VB_!_P <6#7,0NXKV_\ ,A+#<F9SC([9SQZ]NE 'JVF>(-+O[C^SX=3M
M)]1BB5Y[=)5,B=,DJ.1R?PS4LFO:1%J*:?)J5JMV[^6L)E 8OC.T?[6.<=:X
MJ]>R@^(/P_6V>W0-8WB 1D %?+C*CCMG./QKGO#UWH.K>%X/#WB+4KP:Y9W9
M$NE[E29[E9"P9,+N.2=V[..3DXS0![#=7=M8VSW-W<16\$8R\LKA54>Y/ JA
M;>)]"O-133K;6+&:]>,2K;I.I=E(W @9STY^G-5_&JJ_@3Q &4$?V;<<$?\
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M;V%I(IC34E=2(G'LW&[VZT7WC#3-+UW2]$GN=]S>1-(9&& %5>IP,9)(X_\
MK9 -Y+:"(1B."-!'D)M0#;GKCTIPAB <"-!YAR_RCYOKZUGWOB+1].N1;WFH
MP02;U0[VP%9ONACT4G(P"1FGZEKNF:.,ZA>QP87>=V3M7^\<=%]SQ0!;DM;>
M:W^SRP1/#@#RV0%>.G'2AK:!U57AC8*,*"H.![4Z&:.XA2:&1)(I%#(Z-E6!
MY!!'45S]EKFEVHUF_N/%%M<V<5SAB[QK'9_*/W>X=3WYYYH U+_2H-1DM//"
MF.VE694V#)92&7GL 0#@=<#MD&EXOTJ_USPM?Z7IMS%;SW<+0F2497:P*MV/
M8U-:>)]#O]3_ +-M-5M9KWR_,\A) 6V^N/Q&1VJ_=WEM86DEU>3QP6\8R\DC
M!54>Y- '):'X4\0:9IEO"=?M89XX4B<P:?&VX* !\QP3T[U>CT#7HF+1^)(D
M)X)73(A_6MBPUC3]4>>.SN4DEMR%FCP5>,D9&Y3@C(Z9'-<CXI\6*FJ^&8='
MUD8NM7BMIXHU4K/$=V[#$<X( )4\9P: -4>'=;%R;D>(H?M!&#+_ &9%NQZ9
MSFI&T7Q$XPWBA6&0<'3HSR.1WK3L]<TS4+BZM[.]AGFM#BXCC.6B/HP['VJ-
MO$>CK;6]P+^)H[C=Y.S+&7;]XJ "2!W('% &=)H.OS8\WQ+&^.F[38SC]:;)
MX>UR9HVE\10N8CF,MID1V'U'/%:3>)=#2SL[QM6LQ;WKB.UD\X8F8G "^ISZ
M=*?I?B'1];EN8]+U*VNWMB%F6%PVS/3/L<'!Z'% &7_8&O>08/\ A)(O)(QY
M?]F1;<>F,XI8M!U^&$0Q>)8XXE& B:;&% ^F:TK?Q%H]U?I8P:A ]Q(&,2!O
M]9M^]L/1L=\9Q1-XBT>WOX[&;48$N))/)56; ,G]S=TW?[.<^U &=8^'M6L[
MB%QK<!BC;)C338TW*2"R@@\9Q6MIFEPZ8MP8POF7,IFF95"@M@+P!T "@?J<
MDDU>) &3P*S+7Q%H][>1VEOJ$$D\JEHE#?ZU1U*'HX'<KF@"C=Z%J\][-/#K
MD4*.Q*H=.C<J#VW$Y-1#P_KJQM&OB.((_#*-,BP?J,UDWWB(ZWXQU#PW9:VV
MFFWLT,,T"JS-<.S#!# Y"[1QQG)]L;6N^)(?"'A^UN-7N!/=.8K?<B;!+*Q"
MEL#.U<G/MT]* (X- UZUB$5OXDBBC'1(],B4#\ :?_8OB$;L>)U^;EO^)='S
MVYYK)O?$YLOB)9K+K"IH4VD2W15PJH'61%#!L;CG.,9ZFNIM=<TJ]TA=6MM0
MMY-/89%PKC9UQU]<\8]: ,T:-XB50J^*%"@8 &G1X'ZU%!X>URU4K;^(HH58
M[B(],B4$^O!K9T[6=.U9IUL;N.9[=@DT8R'C)Y 93R,^XK"\;^*4\/0Z9;I<
MI#/?W\%LSD F*)F.]P"",@ @9[F@"P-%\1!RX\4+N( )_LZ/) Z=_<U')X>U
MR:6.67Q%$\D?*.VF1$K]#GBJFC.]MXG>.;QO_:$+P//!ILB1!TB.T[W8<D#G
M!('![XK4/C;PP#"/[>L#Y\IAC(F!#.#C /UXSTS0!7.@:\9?-/B2+S.N_P#L
MR+/YYK5M=)C@U*349662[>(1%Q&$^48STZDD#.?0 8Q2:CK^E:2Y2^O8X76/
MS64Y)2/.-[8^ZN?XC@5@^+-6O;34_"<FG:@5M+_4T@F1 C+-&T;L#NP3_".A
MH ZYXTD $B*X!! 89P1T-1FUMRS,8(LMU.P<U-TK@_$?BQ?[?\+0:/K ,=YJ
M0AGA15*SQ;6)96(Y ( RIQSS0!VWV2VPH^SQ85MZC8.&]1[T[R(=CIY2;)"2
MZ[1AB>N?6L?3M0M&U;7)1XABNX8#&9+?<FRPPIR"P]<%CN/&*G'B;1=D[OJ4
M$2P1B64S-Y>Q#P&.['!P<'H>U &H    , = *C:V@;=NAC.X[FR@Y/3)K*M?
M%_AV^U.+3;76K*6]FC$L<"R@LRE=PP/H<XZXYJ>^\0Z1ILS17NH00LFWS-S<
M1[ON[ST3/;.,T 71:VX*D6\65Z'8.*7[-;_:?M/D1>?C;YNP;L>F>N*KWNK6
M.GE!<W*H74NH +$J,9; S\HR,GH,BLV\U2QN=0T(V_B**W%RWG0VR%&-_&4)
M &>=O\61Z4 7/$=A<:KX;U+3;4Q":[MI+=6E8A5WJ5R< YQG.*C\-Z/_ &/H
M=C:S06RW<%M'!++ /]9L4+G) /.,X/2J>G^-=(U'6]5TV.Y1#IQ59))#M!.T
MLV,]@,<_6IM#U"T@\*P7L_B"/4[8;LZE(459?G('W<+P?E&.N* -@VMN3(3!
M$3(07R@^8CIGUK#?2M:O?$+2ZA?6;:+!*L]K:Q0L)2X''F,3@@-\PP.H7IC!
MOV_B#2;F&ZECU" +:?\ 'SYC;##QD;PV"O'K5:W\8>';J[M+2#6;*2>\7=;H
MLH)D'M_3UH UY((9B#+$CXZ;E!Q2?9;?<6\B+<>IV#)J4D 9)P*S+7Q%H][>
M1VEMJ$$D\JEXE#?ZU1U*'HX'JN: +PMH!$\0@C\M^&38,-]12"TME@6!;>(0
MI]V,(-J_05Q%WXB?7_%VJ>';'7&TQK6UB^SS0JK,]PY?.0P.0NU1MXSD\],=
M@UTNF:;"^I7:-(%2-Y0FWS9,8^51DY)Z*,T 6!:VX96$$09>AV#(IZQHA8HB
MJ7.6(&,GU-9?_"3:*(HY6U*!8Y)_LRLS;?WO'[OGHW(XZU;CU2PEU.334NHC
M?11B5[?=\ZIG&['IGC- $T]M!=1>5<0QS1YSLD4,/R-*T$3QB-HD9%Z*5! _
M"L^+Q#I%Q?I81:C ;F7<(E#?ZPK]X(>C$=P,X[URGAGQG;V:ZW%XEUZ$21:Y
M<6=LUP4C/EJ$"C"@#'/7'4T =['''$NV-%1?11@5']CM?M N/LT/GC.)=@W#
M/7GK4K,J(7=@JJ,EB< "L(^-O#"K"QUVPVSRF*-A,"&8'&,].O&>F: -E[:W
MDE$KP1-(%*!V0$A3U&?2B2V@EM_L\D,;PX \MD!7 [8Z51L_$>C7^JSZ7::G
M;37T"EI($D!90#@GWP>#Z&DC\2:-+?)9)J,!GDD:*,9X=U^\BMT+#!R <C!H
M OM;0.BHT,91!A5*C ^E"VT"N'6&,..C!!D5SL/CS1)=8UBP-R$&EJOFN0?F
M8AF8*,<X '3J3Q5C0O%VF:YX<BUI9TAMW4,PD;!3)PH/N>./4XH W9(TEC:.
M1%=&&&5AD$>XJ-;2V6!8%MXA$GW8P@VK]!6:/%6@FPN;YM6M8[:U?9.\L@3R
MF_NL&P0?8]:GTW7M)UBXN8-.U"WNI;4J)TB<,8RPR,_D?R- %N6!"3*L$3S@
M94L,<]N<$BN<\$^&)O#NCK;:A'92W4<TTB7$.2=LDC/C)4$8W8]ZV+[7M+TV
M5X[R]CB9 "^<X0'IN(X7/;.,]JY9O$YT?XA:W;:QK"Q:3!86\\*S!5$;NS@@
M$#+<+WR: .UGMK>Y"B>"*78=R^8@;:?49[TKV\,CAWBC9QT8J"15-]<TM-/M
MK_[="UM=8%O(C;O.)&0$ Y8D9X'I6#XMU\O\.]8UGP_JBK+:P2.D\(5]KIU4
MA@<'/!!&10!U'V2VPP^SQ8;AAL'-.@MX+6(16\,<48Y"1J%'Y"N,U/5M3M]=
M\#)%?.MOJ+NEW#L7$N(&<'.,CGT-:_CF\O=.\#ZS?Z?=-:W=K:231R*JM@JI
M.,,".U &U#:6UO&\<-O%&CDEE1  Q/7('6B"TMK8N;>WBB+G+^6@7<?4XZUA
MZ!XMT;4OLNF+K%I/JXMD>6 2@ONV@MQZCG('2K]UXBT>RO%M+G48(IFD$0#-
M@!ST0MT#'C )R<T :$D,4V/-B1\=-R@XIGV6WW%OL\62,9V"EN;F"SMI+FZG
MC@@C&YY)6"JH]23P*R8O&/AR:YM;:/6K)IKM-\"^:/G&,\?AS]* -;[+;^4\
M7D1>6_#)L&&^H[TJ011P"%(D6(#:(U4!0/3%4-,\1Z-K)N?[-U.VNOLI F\N
M0'9GD$^QP<'H<46/B+2-2NEMK._AEF>/SD0''F1YQO3/WE]QD4 78[2VB55C
MMXD55**%0 !3U ]O:E%K;JC(L$05OO (,'ZUQ?Q(\5II'@_5WTS6!:ZG:J-K
M(JOA^/D)(*AB#G'!Z8KI[O6]/TNVBDU"[2(M'OP<D[0!EL#G SR>@S0!?CBC
MB7;'&J+UPHP*;!;06J%+>".%2=Q$:!03Z\46US!>VL5S:S1S02J'CDC8,KJ>
MA!'451O?$6CZ=,T-YJ$$+(5$A=N(RWW=YZ+GMG&: +BV5JDC2);0J[/O+",
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MM$OI9Y4BC6!\N[  ?*>YKQM;RQ?]G;0XI+BW8BXMD=&<'!%R"P(^F2?:O<B
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M<PZE!-"UC=0I%;)B&W8QQ;85/+%AT(8D\ X7->P;1G.!GZ4@1%  51CI@=*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[C(KEO"WBJ/2_#NL7WB/5)GAMM;NK47,R%]JK)M0':N .W0#)]Z /0*0@'J
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M]\&7OY<CDJX^O4'VKT:LS7;+5+^P6'2=7_LNY$JL9_LRSY4=5VMQSZT <OX
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MJC>(=+>%6L)WN-L$L6%\X'/EA0,L/K@#D ^N44 >56L]O_9GQ0RZ9GFG,?\
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M2?,,GC)ZXST()Z*B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;'S%4[;F<L[#9_>P-JY'=L=0:H>(&5?V;H$*,&AL+*.6,H0RNKQ!E(/.<YH
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M4 %%%% !1110 4444 %%%9>N^(=-\-V27FJ3-# \BQ!Q&S#<QP,D#CD]3@4
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M<H4!.[^]M.%W=^?2LCQG9[]=N]0TN^U'2=>MK-?*FCA:6WOU^8B%DP5=@<C
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MO/!+Y#>4R"!5)WXV_>&,9SGMUP[XC+(Z>&1%;W$QBUZTGD\F%I-D:D[F.T'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,CI&8W._:.2 P7/?!XR:XFP\/647Q.T_5O"=G<V-H\,PU@?9Y((),K^[ 5@
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M3]4NA831L<B.9E)B=?3)4J1T.0>H.=/Q)K0\.^';_5VMI;D6D+2F*(<G S^
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MC;K(SM@-(3W]<$9ZG@UW.K>*;72EOG%I>7D=@@>\>U16$ V[N=S D[?F(7)
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M(K<%2H$>]PN3DC/7@#OC.!S0!TM%>=ZEJ+67Q6TNZ:WU F;1IS]B4F1BXD0
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M'^\U:>KZ3>'7+C6/#MOJNE^(#>HDL(B<V=_&& WR'&P?)GYL@Y!QG(->H44
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MPDU*6X:S4VSYF#0"-<<?WAW^M>G44 >9Z;9:EHOB+PYK\EA>2V+Z#'I5W''
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M:*#[<KT.#BN8AM/$-Y+X1U*]\/:I)J=E?,VHR3-'U,;K^[&_"Q@D= !TZG-
M'5Z/XMN]4U'Q+!=Z/=QVNFS^0 AC8X$88@X?)9MV1C( QSG-2Z#K^A6/@S0I
M=*MKE+.] ATZS)W3.3D[?F8] &));  ZU2T:VU'2O$7C%)]+NF@O;G[5!<H%
M9'4PJNT<Y+;AC&/?-<_IGA_6[#POX#U%-.N&O/#SNEY8$ 2-'(I1V3)PQ .0
M ><GOQ0!VZ>,K+=JL%Q:7EO?:9")Y[-T5I&B(R'3:Q5EX/0\$8.*J67Q!T^]
MDT0_V=J4%KK(46MW-$JQF0IO$9^;=G /.,''!-9U_I5SJ?B35_$L5G<I#_83
M:9;Q/$5EG=G9R=AY 'R@;L<DGH,UFG3=37PE\/+3^S+PW&EWEK)>H(CF%8XF
M1B?7DCIG- 'J-9FHZW!87UMIZ0RW5_<J\D=O#MW;%QN<EB %!(')ZGC-0:7K
M\FH:[JFES:9=6;6)0I+-C;<(VX!UQVRIZ_XXQ=:L+_3?B/IWBB"UFN[!M/?3
MKM(%WO""XD60*.6&1@XR1Z&@">Y^(6E6GAW4]7EMKX?V7*8;VT$:F:%_<;MN
M#D$,"00>M;.CZU_;#W0&G7]HD#J$DNH=BSJ1D,G)R/K@CN*\]\1^&M2O=#\>
M:A;6%PUQX@-O%:6@7YRL2A=[#^')W'GG &>3BO4+67SK2*39)'N4$I(NUE]B
M* .<M]2.N^.]2TW)^PZ)%#YB=I;B0%@3ZA% P/5L]0,066IZ$U[XOD@TZ^6>
MW9!J8(.9CY7&P;N/DQTVU#X:M7TSXE>+X)A@7XMKZW)_C384?\F7]1ZU7T^U
MO8=<\>W,FGW:Q7_EM:'RC^^VP",X_P"!#OCUZ4 2O/:Q_#"TU[PU#+;)86 N
M[**5B6,2KN,3\G(901U.#@CD UUNFZC#JNCVFIVH9H;J!)XQQDJRA@/KS7%6
MHGT;X&-;WUM+#=VVCM;O Z_,9=A4*/7+$ 8ZYKJ/"6F2Z+X/T;3)_P#76MG%
M%)_O!0#^N: ,F3XAZ?%X:U#77TW4Q;:?=-:W4>R/S(G4@,2-_0$CO[].:W)-
M96/4+:S%E=/)/;/<[H]C+&JXX;YLY)8 8R#SSP:Y.]\'W-WXQU:T>,'PUK,*
M7-Z,X_?H"FP#_:_=N3_TSQWJ_P" M,U72M"9]>RU]"HLT*@DM;P%EC..Y;+-
M[[A0!C#Q;9Z-\/M-O_"VD78L[O4OLR),Z[HBUP5<G>Y)).[ S@9&<"GWUZ]E
M\7K2[%A?R33:!*?L:$.Y;SDX^]L7@==P'O63!H6LK\)[*R_LFZ^WV6KK>26N
MT!VC%T9/ER<$[3GK72[+V7XI66KOIEY%9C1I+=W:/=LD:57"G;GG:O.,C/&:
M .B\.^(+7Q+I"ZA:1S0CS'BDAG4+)%(C%65@"1D$=C65J7CNUT_6KS2(](U>
M]O;6!+AHK2W#ET9MN5RPS@@_TS4/P\L[RQT[5X[VSGMGEU>ZN8UE3&Z.1RRD
M?AVZBFVEM=K\6=1OVLK@64NEQ6R7)C^0R([L1^3#GI0!=U;QK9:3:7=\]E>S
MZ?92^5=W<*H4A;(#<%@S;20#M!QSZ'$MYXMM;=K[[+:76H+8P)/<-:^6=BLI
M9<!F!;Y1GCM[\5QMA8WV@:SJVEWO@HZREW?375CJ$<<3(5E8OMF9SE-I)YY]
MATS-XIT":[O+N\TZSU'3O$EI B6%_IJ$0W>$!$<@Y7:&R/GP ,<G!% '2:CX
MXM;'7+K18M*U6]U"WMUN/*MH ?,0DC*DL!V/)P.PR2!4FF>-]*U?0[34[);B
M0W4QMHK0H%G\Y02T94G ("DG)Q@9S7/07TMC\7[EKR":61O#UN)6M8FD"OYK
MY^49;!.<''UK(N/"&LV&FPZ[#I"7UP-=NM5GTB0J289E*;1G*EPH5L>I/7'(
M!V\'CC2V35Q>)<6-SI+(MW;3J"XW_P"K*["P;?D 8.<\42>,%BO;S3Y-(OX]
M1M[$WT=O)Y?[Z,':=KARH(/4$@^F:YK6-)O_ !'X1O)M$\-+HMS%+;W-K;W,
M4<4MQ)%('(<(2 O&!D]<YP*Z/3M7U7Q)8SI)H%YI*&W='%_M#-*1@*@4G*CG
M+''; ZX )O!.N7?B/PI8:I>6DEO+<0K(2Q3:^[G*[23CMS@^U5;3Q1>W/Q!U
M'06TR=;2SMHI/.#Q\ERWSGYLA<+@ 9/7(%+\.HKZT\#Z7I^H:=<65Q90+;NL
M^W+,O!(P3\OH>]4)=+U ?$;6G-C<M8ZMI<-NEY$5V1,ID#;LG(.&!& <T :$
MOCO38+&'5)+:[71IIA"NI[4\D9;:&(W;PA;@-MQT/0@UTMQ<16MM+<S-MBB0
MR.W7"@9)_*O+XM&UB[^%1\"7.F3QZFB+9>?LS;F,.,3"3IC:,[?O9XQ7HM^E
MY;>'[F/2U62^BM66U64\-(%.S=^.* ,G3_&ME?WNE6YLKVW&K6SW-A)*J%9D
M50Q^ZQ*G:P."!P?7BLZ;XF:=%I]_?C2=7>UTZ[>UO9! N("I +'+<C)Z+D\9
M('&>?L+369O$7@O6)O#^JF:V2XCU&>Y9"_F/$!G&[B,,&P  .>!22:3JLG@#
MQWIXTN\^UZEJ5W-:1&+F5)"-C>@Z'KC% '=_\)1:_P#"60^'C:7:W$]L;J&X
M(3R9(Q@':=V202.,9[].:NZ;JJ:G+>I';3QK:3FW,DFW;(P')7#'(&<<XYR.
MQKDO&-E=MX7T?7-.C\O6=(EADMHY@5,A;$;PG_?#8^H%=;HVG?V5I%M9L_F2
M(N99/^>DC'<[_BQ8_C0!3U+Q-!8W%Y;P65W?SV4 GN4M0F8E() .YERQ"DA1
MD\=LC.;/\0M+C;1U@L]1NSK%N]Q9B"#F0*NXK@D?-R/;GD@<UF2/K7A7Q_K-
M\FAWVK:7K2P21O8[&>"6--A5PS+A2 #G.!^=3ZI!JEQXY\'7\VGRE;1+O[8\
M"ED@,J*$7/\ %R,$@=L\4 6;76](O_&6GM+I&IVVLR:2\\9N$*;(2R[HRN[&
M_<1V/3K4+_$W3$T>35SI6K?V?!<M;74_DH!;E7V$L"^2,_W02.^*DO;:['Q8
ML-1%E<M8Q:5-;O<+&2HD:16 ]3PIY'%<K/HVKR_"/Q-I"Z5>?VA>7UQ)! 8^
M762;>IST V^IX_*@#N[;Q=;3^(X]%FT_4+26XA>:UEN(U5+E4QNVX8L",@X8
M*<5D67BGP_H^B>)M:M=-U&.&SU&7^T$V[G>8*F]@"V N".X''2GZI#=77Q"\
M)ZC#8W9M+6WNEN)3$0(C(J!0>_53TZ=ZYV?2M5E\%_$&R72KS[3JFH7$MG&8
ML&5'5%4CT^Z>N,4 =G9^,K2ZUZTTF2PU"U>]A::SGN(U6.X"@%@N&+ @$'Y@
M/Y9BB\>:=*]C(+6\%C?7S:?;WI5/+>8%EQC=O +(P!*]O3!K,O;:]G\7^![R
M/3[LV]C!<K=.8B!"7B55!_$'IG'7I7-W%IXEU*QT6ZU'P]J4VL6.O17%V^Y/
M+$2R-Q -^-NTKS@9QDD]: .HT.,1?%WQ2JLY#6-F^&<M@DR9QGI]!72:OKMO
MI$]A;/%-/=7\QAMH(0,NP4L3EB   ">3^=8.D6UXGQ/UZ_FL;B.TN;*VBBF9
M/D9TW[AGVW#GH>U3^,)=8COM$6RL[RYTIIW&HK8L!/C9^[P<@A=WWB"#@=<$
MY +-KXSTRXTBZU!TN(#:WAL);:1 9?M 8*(P%)#$EEQ@XY^M07/C5+<:Q;G2
M+Y=1TVT^V&UD,8\V,YPRN&*X!!SSGC@&N&7PUXB71=9%CHDEO=6?B4:S9V\C
MH$N$&W$8()YP#[9QR>W;KJ&J>*=!U*,:'=Z8DME+"B7^U9))67 P%8X4<\G&
M<CCB@#)F\1V6H^ O#^H>)M)O7%Y)9LOE;0#,VPI)\C\)N/0X/M74WGB".#4I
MM.M+.YU"\@A6::*VV#RU;.W)=E&6VM@9SQV%<)=V6KW7PL\.:9_8=^EY8S6"
M2PLJEL0%-[<$C;\IQGD^E;=M;WWA_P"(>M:K)9W5UI>MP6[K+!$9&@EB4IL9
M!\P!!SG& >N* +DOQ#T6/1]+U2-+R>VU&[6S3RH,M%*6V[77.000<@9/'&>*
MOZ+XI@UC5K_2VL;VQOK)4D>&[507C?.UU*LP(X/N.XKA9O#&J6&BZ<183R7%
MSXL&M3V\0#_9H3(6()'&0NW@9Y)QGK736-M=CXK:GJ#6=PME-ID-O'<-&0K2
M([L1Z]&'/2@#H-4UFWTN2T@=))KJ\D,=M;P@;Y" 6;&2   "220/Q(%9+>.=
M/AM-9DN+6]AN=&3S;RS9%,JIM+!UPQ5E(!.0>W.#53Q=INH)XI\->)+*VDO(
MM,>>*ZMHN7\N90N]1W*D D#DCI63K>B7NJ7/B[78+*Y O=#.EV<!C*R3N0Y+
ME3RHRRJ-V.A/ QD ZS0/$T?B$LT&F:C;P>1%/%<7,(6.97&?D()R1W_#J"#5
M34O&UKI^O3Z)'I>J7FH16PNA%;0 ^8A;;\I+ =0>3@<=<D Z/A=)8O"NDPSP
MR030VD44D<BX965 "/S%<M<7HL?C;,[P7$D;>'8P6@B,A4_:'QE5R>?4"@"Z
M/B7HC>'K/6E@OVM[F\6Q:,0?O+>8L%*R+G@@GMGVS5^'Q?%*((GTG4X+ZYFE
MB@L9XT2601C+2#+;=F"/FSW ZD5Q-[X:U2VT!I4TVX>YU#Q2FLO:Q*&:&$2*
M?FP<;MJ@D9ZG'.*Z7Q#8W]MXWT'Q3:6LUW9PP2VEY#$N9(TDP5D5.IP0,@<X
M[&@#2M_&FE26>JSW)FLI=*<)>V]PH\R(GE>%)#!LC;M)SGUI\/BRU.LOI=]9
MW>G7"VAO5-R$V-$#ACN1F ([@XKC=>\'ZMK_ /PE>L6$36]S>BS^P0SC893;
ML'RX/W=Q^4 X/&3C-;WVS5_&OA[4--ET*\T07%C+!+)?;?\ 6.A4",*22H)R
M6('0  Y. "^OC.S74M+M;FRO;6+5<BQN9E3RY6QN"X#%E)'(# >G!XIFH>.=
M/TV!+V>UN_[):Y^S'45"&%7W;,D;M^W<"N[;C\.:P?"'VUUL-.OO JZ?J5GM
M6YU!X8O(.SC?&P.YF;'  XSDGCG.\-Z;?Z)"WAF^\$I>W,,SK;:N88FMY(BQ
M97E8G<" >5 ).* .QUO7;>6'5M-M[*]OFM(/]+-J57RMRY"Y+*2V.<+DXQZ@
M'DO#E]I,/P]\ )K%I=7+SW%N+22,G;'<?-M9SN'&-W'/TJ]I\.K^&O$/BFSE
MT>]OK35[AKVSNK4*R[F0*T;Y(V8VC!/!%95KI.L1^ _ -C+HUZESINIV\]U'
ML#&.) X9S@G^\./O>U '7W/CFVAU35M,M](U:\O-,2.26."%?F5PQ!4LP'1>
M^"<\ \U:3QEI<VDZ/?VWG3C6"JV4**!)(2I8YR0!M )))XQWXSD:=#=VWC_Q
M9J$MA=BTNK6U2WE$1(E:-7# =^K#KUKE8+&^TKP'X(MY='U ZQIUR3Y=L$,\
M057W$(Q =2"JGGC=US@4 >B:-XIMM:U6_P!-CL[R"ZT]MERLR+M1C@@9#$'(
M((]JW:\_T#6(;-]=O(] U_\ MNZ0WLD-[;+$]T(PJ!8MK%<*"HQG/S9YS78Z
M+J:ZSHUKJ*P2V_GQAC%+C<AZ$''H<T <5X?41?%GQDI\Z2&TM[1X( [,L9>,
MEMBDX!.*OP?$S3+C3;'4UTS55TZZN?LK73PJ$@?S#&-_S9P6'500,C.#Q4&A
M07EM\3_%>ISZ?>1V-[!:K;SF$XD,2$,,=1UXR.:YU=&U<?!NWT8Z3>_VDNHB
M4V_E\A/M?FYST^Y[]>* /0]0UR WMUI5O97>H3PPB2YCM2J^4K9V@LS+\S '
M !SQVR,\K\--8BLOAEX?5DGN+J[>X6"!,&20B61B26( P!DDD?F0#-8#5/#O
MC[7KI](OK[3M<\B>WGMD!,3I&$,<@8C;T&">/Z<MI_A_7]/\)>$[^7PU)>2:
M/+=I=Z9,(R\L4SD[T!)&5PIP<'K]: .WN/B1I5II&IWUQ9W\<FF7"VUY:^6I
MDA=B I.&VE3D8(-6'\<6\>N-I$FCZLEX\!GM4,*_Z4H(!V?-\I&1]_;@=<5S
MGB:SN]9^'FJ1Z9X5ET^2\DMQ!9B!$G?9*K,T@0E5& < G/!]<5LW\-U/\3M"
MU*.RNC90V%Q%+-Y1 1Y"A4'O_">W'>@"23XBZ7#X5O-?FLM02.QN3:7=L8E,
ML,H8*0V&V]67D$]:O6?BZVNO$3Z))8:A:7!MS<P-<1!5N(P0"5PQ(()'# 'G
MI7 ZCH^KW'@CQQ81:1>M=:EK;75I'Y6/-B+1'=GH.$;@X/3UKJ[Z*ZG^)VBZ
MG'8W1L8=.GBEF\D@([LA4$=?X3VXH R[KQ99:'X \2:WX;TFZ62"_G29+A@-
MMR6 >0AF/RAB/E'Y <UV$NO&-H+<:9>/J$L;2BR#1>8J*0-S-OV $D8^;)ST
MX.//IO#^L7WPV\;Z;'IMPE[>ZI<W5M%(NTRQM*KJ1VR0#QUJ_K\6HKXGT[Q4
MWA2XU33YK$V=SI[1QO<V^'+I($)().2" >G7% '3Z?XUTS5-+@O+2.Y>::Y>
MT6R*J)A,@)=""=H*A22<XQWY%6=#\2VNN76HV2P3VM_ITBQW5K<!=Z;AN5LJ
M2"K#D$&N.\0:1J4MGHNNV'A6 K8WDDTFB;(P[P21["2!E#*,;L#V&2175^%V
M%Q'/=Q^'?[$@D"JD4T*1SN1G)<(2 .0 "<]>F10!SVN7 T[XOZ5<);W5S))I
M%P!! =Q=@\>, D*O?DD#U-;-OX[TRXT!=5^SWD;->_V=]C=%$PN=^SRR,[0<
M]]V,=ZJZA;79^*NEZ@MG<-90:;/!)<+&2JN[HRCUZ*>>E<W;P^)--T35S9Z7
M?K]I\3RW4Z1(%F>QD;):+)^\< =F STX- ';VGB[3YO[96[26PDT;!O5N=OR
M*4WA@5)!!7WSQTKE/$.IMJ'C3P+,=.U"T66\=HWG90KIY+G!56.UN0<, <?0
M@95[X3U?5E\>Z?::1<V$>KV]I)9R3R+AFC7E6.XG<Q'/7J<GUU;Z\UK7]1\'
M7?\ PC&J02V-Z7O4D5%$9,3*=I+?,N3U[CWXH [;Q#KMOX:T*ZU>[AGEM[9-
M\BP(&;'K@D#]:S[;QE;W(8G2]3AW21QV@EA"_;"ZEAY66P<!23G& .:3X@VE
MSJ'@+6;&RMY;BZN;9HHHHUR68]/I]36+XLTS4KW0?#FJ6&E?;I]*F6:?3+A0
M&F0QF-U ;C<,Y'TXSQD U3X^TJ"WUIKZ&[L[C1]GVJUD16DQ)CRRNUBK!L@#
MGZXJW!XMLVU#4;&]MKFPN;"U%Y*LX4@PG/S@HS XVD$=>*YR\GUB7PIJ-_X;
M\*/I%R1&J0R011W4J[QYA"@E1A<[=QR3SCIFI:6.H6_C34M3M_#-\;.ZT$1(
M+MU8RRJSMME)<DEL@8.3@C..P!V=CXCCO)81)8W5K#-:->1W$QC\LQC;GE7.
M#AP>>U4CXXT](=/O)[2\@TS4)%BMK^15\IBWW"0&W*&[$J!R,XS7*V'A&Z6:
M]TS07U2P\/ZCIEQ%<V5^&V6<[@!/)W<]VSM)7CKR*=-I6JZ_\-;#P;=Z7<VN
MH1&VMKF9E_=1QPNA,JR=&RJ< <Y;D 9- '27/CNVAU+5]/@TC5KNZTI8WGC@
MA7YE<%@REF Q@=\$YX!YQ97QEIUQ;:)+917%W)K,;2V<4:JK%57<Q8L0%P"
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MO97O(O"K:%$(]A%Q!''-(V0> A.$&._4GH,<@'3T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M450U;5[;1K6.:X#NTTJ0011@%Y9&.%5<D#/U(  )) % %^BN8?QM:V::U_:5
MC>6DFD0K/,NP.)$894QLIPW3&.,'\ZGM/%'GZW-HTVFW-OJ"68OHXF=&$D1;
M;PP. P;@@^O4T =!6-K/AN#6]0TR\FO+N&33IO/@6$H%WX(R=RG/!(K+3Q_I
M\GA;2_$*V-Z;/4+A;=5PF^-FD\L%ANZ;O0FKUUXICBNM1AM;"XO/[-9$NS"R
M;D9E##"D@D!6!)^N,D$4 ;]%<[J_BV#3&OQ#9S7ITY!)=B)T4H-N[:-S#<VW
M#8'8CG) K6TS5+76-(MM4L',UM<Q"6(@8+ C(X/0T 7**XCP_P".9+C2_$&J
M:W:/8VFG7L\)?<CA!&538-IW,Q.3TP2< ]*UU\51PZU8Z7J6GW.GRZ@K&T>4
MHRR,HR4)4G:^.<'@]B: -\D $DX [FEKAOB_%&_PTU.1URT30,AYR#YR#^1(
M_&M&S\;02^)HM"OM*U#39[I'DLI+M%"7*J,MMPQ(('.UL''7'2@#J*3(SC//
MI7)S?$#3H&TZ>2WF&F:A<+;6]\&0J6;.PE=VX(V.&QZ9QFL_PZJ6GQ&\?&*!
MY $L7\J/&6)B<D#) R3[B@#MX;>")Y9HD&^8[G?.2WISZ#L.@J:N-\-^(="M
MO!6BS:/8RV]G>EH["R+ .>7)R2V ,*S$D_F< DGQ%LH=-UNX?3;UKC1&7[=:
M1&-W1&&X2*=VUE(R>N>#Q0!V5%97]N(SZ4L5K-+_ &BN]"C(1&@7<6;YON\@
M9&>2/6L>Z^(&G6:VEW);S?V5=7(MDOE9"H8DJ&*[MP0D8W8]\8(- '27-A!=
M3P7#J5GMR3%*APR@_>'N#@9!XX!Z@$6000"#D'H16#XWACG\"Z\LB[@-/G8<
M]"(V(/YU@^%/%D=KIOA+1[G3+V&.^L(H[6\<)Y<DB0ABN-VX< X) SCCCF@#
MLKFRM[R:%I\R"!PZQD_*''1B.Y'49Z'GJ :M5QMIXAT'3]1\87_]GW%E/IYB
M?4I9,$S$1Y0J Q'W<8Z=>:W]/U:6\O7M9M/FMBL*S+(71XY%8D8!4GD8Y^HQ
MF@#3HK,U36X=-NK*R$3W%]>LPM[>,@%@HRS$D@!0,9/N ,DUCR>/+*#3=;N)
M[&\2ZT0;KZR 0R(FW<'4[MK*0"0<]NF>* .KI,C.,\^E8V@^('UTRL-)OK.W
M$44L,]RJA)U<$_+@D\8YR!U%<G<W#:7\9;^6STZXO9Y=!C;R+<J"[>>PR6<A
M5X ZGMQF@#T:BN:L?&VG:AH&G:I;Q3[M0D:&"U?:LGF+NWJ<G V[&R<XXXR2
M <ZY^)>G6>E:W=3Z?>"XT61$O;5#&S('^XX.[!4YZCGVH [:BLO2-7EU5[H2
M:7>V*0N%C>Z50)U(R&7!/'L<$=^<@4M3\616)U/[+875^-+0/>FWV_N_EW;0
M"1N?;AL#L1SDXH L1>&X(O%<WB(7EVUU-;BV:,E/+\L$L!C;G@DG.:V:PF\4
M6TT]G:Z?;S7EW=V@O4A&(RD)QAG+8VY)P!USGC@D9EQ\1=,M_#=QK)LKYEM+
MO['=VP1?-MIMP7#C=TRPY7.0>* .PI"0!DG ]ZY_3_%D=WXDFT.YTV\L+@6W
MVN%KG9MFA#;2PVL=I!(X;!YZ"N-^(6N1:YX-M+VUTZX>QDU*V%M>EE"G$RC?
MMSG8P! )'.1P <T >IT5B6_B2.YU_5-%CLKG[7I\4<S9*;95?=MVG=_LGKBJ
MFG^-]/U/0M)U*UM[EI-69DM+0A1*Q7=N)YV@ *23GT[D"@#IJ*X+Q)X^N;+P
M?KM]9:5<Q:AILPM94GVA8V8@+(#G#K\P(Q^(%=O;32S6JRRVLEO(<YAD92PY
M]5)'/UH FHKCI/B%:Q>'=7UEM)U$1Z3=/;7<&(O-0KC<V-^"OS YSTYK:FU^
M*"XM8VMIBDUK)=O*A5EBC0+G=@Y.=PQM!SSZ4 ,E\,6EQXC76I[J_D=0NRT:
MY;[,K+T<1]-PSU]>>O-;5<QIWC2WOK_1[:33[JV76;=[BPDDVD.JJ&(8 DJV
MU@<?UXJ>Q\4QZC+;/:V%Q+97-S);)=*R%59-^2RYR 2A X[C(&: .@HK'\3^
M(8/"N@7.LW5M//;6P!D6#;N ) SAB,\D4EUXBAM/$UIH4EI<-/=P2SPR+MV,
M(\;A][(/S#MCWH V:3(R!GDUPY^)MH-)?5CHFJ+IT%V;6ZN&6,"W(D\O)&_+
M#<?X<X'Y47D,:?&O2Y57#R:+<;CGKB2/% '<T5RD7CNTE;3IC8W:6&HWK6%M
M=,% :4%@,KG<%)1@#CZ@9J4>,XFFU^ :5?FXT15>>']WNE5E+!H_GY! /7'I
MUH Z:D+*I ) R<#)ZUA6?BF"_P!.T.]MK*XD35\&)0R9C4H7W/\ -C  YQGG
M ZFN+0+XJ\2>,+37-!NKJ"V:WCA7S8@]J!$)/E8/E6+$G*GN,GB@#U*DR,XS
MSZ5RL7CJP.@>']62SO3::S<0VL).S=&TC;5WY;IZD9JCI4*0_&77]BXWZ5;.
MW/4EY.?T% '<T453U9;U]&OETUE6_-O(+9FZ"3:=I/XXH N45Y!X8N_#FO65
MMHDZS:+XQM6B-RER[17%Q(C L2__ "U5\'@YX/3H:]%B\1Q2^)KW019W N[6
MU6ZR2FR1&8J-IW=<J>H% &U02 "2< 5S-AXWT_4=!T_5(+:ZWZA</;6MHP7S
M7D1G##[VT ;&8G.,#\*YKQ_K,.N_#GQ=9S6-Q:WFF(!)',.,G#*R,#A@0?\
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MD?,BR,Y&W=GHP&<=: ,&X\61Z9\-)]6\,Z*;-&U![=HI&4&)VG\MGP"026/
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M9N[=Y[.:5D(G"8W#:#E3A@<-CCK@\5QVJ>'/$%WX9\>V46BS^?K%[YMF#-"
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M8B^20N-CH7* >H.0>U4K'QQ9WVAVVH):3K-=7CV,%H2N]Y59E(SG&!L9B<\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI]QH=YI7F7427LGFW%Q%,4FD?()8N.<_*!Z8&  .*VE&U0!G &.3F@!:***
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MUI>EO+NY4QM6+&W:PV^^,9[YI-*EN?&%CXJN9-0O;2ZL]1N+*T^SW+Q"V$0
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MD;[=:E=@R5 7=@8))_GF@#F+?5=8O?A[X(NFUF^2ZFUU+*:9)/FEC$TJ?/\
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MASK7]LZE/<ZE+;6UVDURS12I) S'*?=R"H.[&?4FMGP'I\$/B[QG(CW):/5
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M2P>]6Z\WKM=5V[<?[77/:MZO-+RVBT'XK_:K-9GV>&KF40O*S@LLJ'C<21G
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M.",\'KS0!WE%>=_"_39+WP]IVNWFJZI<W:27<.V6[=HV7SW W*>&(QG)YY]
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MTJ#R]N5N-K'EI,YW$9& ."#GEH[+4)_A/>^)E\0ZNNJZ9-=2VTC7CE<1SO\
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M(QM)4''J,UZ#;7$=W:PW,+;HID61#C&5(R*9%?6T][<6D4JO/;!#,H_@W D
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M@P" J'=E5&>@ZX&<XK6TWPY8:3J&H7UKY_GZ@X>Y+S,P=@, X)P...,5K44
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MQ/&V""0RD-R"<\\Y]:EM_#6G6VNS:S$LHO)H%MWS*Q0QK]U=O3 R:UZI--J
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ME</*LE]-&TQG6WN+N22)'SNR$)QUY&<X/(Q6]10 5ST?@K1HC/''',MG//\
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MY4N&4!.I7:#@C))Y%1:QXBGTKQ/H&DBS22'59)8S.9<&,I&S_=QSG YS704
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MJ5OJ,X^U[G\RR\J4X3&X+M\L#(/!W$G)KJ[;X>>';4V.R"[<6$GF6BRWTSB
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M.* .!M-1M;O6OAS=:1=WC65U]LC;SY&#R!(F^64$_,RL#R<\BL[7I)/^$?\
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M;?ZU9ZO<1S-?6086\BW$BA W##:& .<#.1SBA_#^G/XA37FCE_M%(3 LHG<
M1DY*[<[<9 /3K0!X[-I%BGP*\32K"0T=]<A1YC8&VY(7C..!7<:DW_%::9X7
MC:)+)]-ENDAN'<K/)O ()SEBJY."<<DXX&-Y?!/A];35+3[ 3;:FSM<Q-,Y4
MESEMH+83)Y^7'('H*CU+P)X>U;3+2PO+.21+-M]O-]HD\Z-NY$N[>2<#J>P]
M!0!Q>MZ5J.B:%I%C+X@N;AT\3VT2-#,ZF&&1U(A;+'?M!!!;/!%;N@VXT?XI
M:QI5K-<FQETR"\,4UP\N)3(ZE@7)(R ,^M;DO@S0IM,LM/:UD%M93BYA5;B1
M2)0<ARP;+-GG))JW#X>TZ#7I-;2.;^T)(1 \K7$A!C!R%VEMN,DGIWH YGXA
MQ2/J/A)8[N[MQ/K"02B"=D#H8Y"00#C/RCGJ.Q%4A8I#XQ'@Z&;=86^F"Z@@
MOIY9#*SROO.=V6VX4#).,FNSU;P]INN36<M_',[V4PGMREQ)'LD'1L*1D\GK
MZU6\0^#]$\4-;2:I:L\]J28)XI7BDCSU =2#@^E ''P_;])U'PMX/U'6WOX+
MF>[\Z=69'=8D#1P,V23]_GG)"@'N*KW, L]4^)-G;RSI;VVDP36T0F?$#F*9
MLQ\_)\P!XQS7;7_@K0-2T6UTF>QQ:VCB2W,<C))$_7<K@[MQ)))SSGG-8/AS
M018>.?%$9TVX72[RUM88I9PSK.45Q)N9B23\PY;K[T 4)+F?R/A?<"YF\VY,
M23MYK?O5-J6.[GYN>>>]0VUKJ'C;2M9N8]6BL-1MM3GB6YW/YEEY4A"J &
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MN7<,]^<'TK*$8T'X0Z9XEMKB\74+RSL[6[O#<N?+A=UW,!G"D X#  C.<YH
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ML4<D_P =KB>($PVWAU(9F'0.]P64'WPI- '=USVB^(;K4_%/B'1[BTBA72C
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M+X8L;#4'>]BTOQM'I]G/.Q9S;B51@GOU*_AB@#W.BHX88[>!(84"1H JJ.@
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M]X9G>;2-.6WD<%<F1WV*3DJNXG:">PP.!4=GX"\,:?KCZS::3%%>LYD+*[;
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M::QIT]A?1M+:SJ4EC#LF]3U!*D'!]*H?\(IH_GZ9/]GE\W2U*6;?:I<P@C!
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M%;1"S*&U6R&5."/WR]#V-=O534M+L=8L7LM1M8[FV?!:.09&0<@CT(/0CD4
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MTJ2)[.S\OR=WD(9'=(-W7RU8D)G_ &0*D@\/Z9;:Q/JT-NRW\X"RS>:Y+@=
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MH>:LOX=TM]4.IM!)]N,'V?SQ/('\OKMSNZ9Y^O/6@#Q_2]/@@^%W@S7D,O\
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MEE%96-O';VT*A8XHQ@**L4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4M5U:ST6P:]OI1'"
MK*@]69B JCU)) J[7"?%JUM[CP9&\\$4ACU"TVF1 =N9T!QGID$@^U &M<:_
M?0?$.RT PV_V&XL);KS<L9-R,HQZ ?-[UT@(8 @@@]"*\\U72=-NOBIH>GM:
M0FQ&CW0-LJ@1D"2/Y2HX(SV/%<S#?G1/"5S9I*EMI$/C&6QE\Q2T4%KO)"L
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MD2, [9VY #>X'>@#N]ZD@;AD]!F@NH;:6 /7&:\.TO3+.V^'7P]UJ*$+J?\
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M:\*>'M+\>^"K2VTBSCMII[]I8VC#*Q\@MSNSQGD#H.U-N99]+\4_$B[TE?\
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M@&\':*.H.GP?^BUKR.[T33C\./'E\;<&ZL-9O6LY226MRDB[2A_A/ Y')[T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDW$49B29)&1PAZKN4@X/<=ZNRSPP*&FE2,$X!=@,GTYITDL<,9DE=41>K,<
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MFGZIH^G:W:K;:G90W<*2"54E7(5QT(]#U_.KU1QSPRNZ1RH[1G#JK E3[^E
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MCDFNWL+'3_\ A<FO-+:VN[^SK5U+1KG>SR D>YX&>]=1_P (GX>_L_\ L_\
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M9PSK-X==Y4D4%92)T WKT;\<]!Z"N6O[6 ? _P 3VWE)Y-AK,\=JI'$*B[4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!T!..0/>J^L7WFZ3>#3=9L+.ZA95:XFVR)"=PR'7<,$@$<D4VY\4Z3:^)(-
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MM+M]0EU"#3;.*]EXDN4@42/]6 R:(-(TRU\[[/IUI#YP(E\N!5\P?[6!S^-
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MG[!'8?V79?8XSE+?[.GEK]%Q@4 <1X_T32-,TW1);+3K.V=O$%BQ>*)5)/F
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M# =)L3#"_F11FV3:C_WE&.#[BI3I6G&"Y@-A:^3=,7N(_)7;*QZEACYB?4T
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MIXH(5QNDE<*HR<#DU+7,^-K3[;8:=##JPTN_^WHUC.R!T,X5R%=3U! 8?7%
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MZWIPM9G,<4_VI-CL/X5;."?858N-5T^*1[>34;6&?R3-M>50RI_?P3]WWZ4
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M)9E+,5^\ ,\D=P.E6[BY@L[=[BYGC@AC&7DE<*JCU)/ H C.G6)OQ?FRMS>
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M[5+IKI;:%;AAAI0@#D>YZT&SMBS,;:$LWWCL&3]: .#^'/B+2M-^''A&VO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"JE_JEAI:Q-?W<5LLKB.-I6VAF/ 4'U/I5NN)^*IV>"OM# ^5;W]I-*V,[$6
M9"6/L!0!U#:UID=]-927]NEU##Y\L3R!62/.-Y!_ASWZ52A\8^&[BXLX(=;L
M9);TD6RK,#YO)''U(('KCBN4@UW2;SXS1W-O?V\ML_AUD2=7!C<BX!.UNC8
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M,8[%O+#9 Y .#UKL-&U_PMXJU:VU+1C%?7R6K(;B-3NMXFP=CGL2<?*>>IZ
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M.KE@5902?MP(/UV<_3VH ]U)P,FLRS\1:/?W:6MKJ,$LTBEXU5O]:HX)0]&
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MV)'./3F@#V.R\0:/J6HW&GV6I6UQ>6PS-#'("R#.,X^O'UI/^$BT?^T8]/\
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M@1@C()SV(!P>AQ7-:GXJB\.?"R;6++6&UF589/LM[*@/G/O(!.T 8!X[9"T
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MN(L'U&1D=00>H[5Q'@;Q[IQ\-:7!X@U^!M8NIIT'GL%9\3R*N< !<@  <>U
M'H,<,42E8XD16.2%4#)I?+3^XOY5GZGKVF:.&-]="+:GF/A&?8G]]MH.U>OS
M' XI\^M:=;VUO<-=(\=R,P>2#*9AC.45<EN.> >* +X&!@=*:(HU "HHP<C
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M L74<JSEAGV&W/X5Q6FW=B?AMX AEG@_=^)%+HS#Y%$LW)'889>OJ/6O=**
M/.[6_L8OBEXL9KJ!4.E6VXEP 2OF;OQ (SZ9%<Q:7,,/PE^'MW)(H@LM7M&N
MI.T(!<$MZ8)'7UKVNB@#RF\UK1],\<Z['XGN+VTL-7B@ET^X#S1Q31B((T9"
MXPP.3@C/S>_,5W-I7A#7]"N+R#4-,\+R:6]I;2B68?9I/-W@2$'<N]=O#="
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M>?0/"UE8:=X:L[72[2:TL$5C!#,S%E0L2"=YW#.<X/(SCC&*UR >H!QSS2T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***KWU_:Z99R7=Y,L,$>-SM[G  '4DD@ #DDXH
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MT,<]O)%YR#J4+J V/;/K0!L4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<3\2TO8].T34K>WFN;;3=7@O+R&%2SF%=V6"CKM)!Q[9[5VU% 'E]W>
MQ^(?B+)+I!N'CNO#,]K#="VD5!*TH*Y8KQWYZ9&.M0^$[S1M5L]$T>_T75CK
M^EO#OM+K[08[:2/ ,P8DQ@  D8/.0 .:]6HH \CDL]0NM"^(NAV=M<_VI/J<
MMW#&8F598BL1&'QCYMK*!G-;?A[5O#GB'4['4;?3=3_M&Q1VFDU W _L\,A#
MC=(=I)X&%SQSVKT&B@#R[PLRQ_ [4X&1TG$-^K1-&5<L[RE!M(R205QZYJ*Y
MDC_X1_X8+@[K:XM6G&PYA"V[*Q?^[AB <]Z]6HH \^LKB*+XB^-II"5BDL;4
M*Y4[7*+(& /0D;@"!ZUS5J=GPZ^&\$D;B6VU:U>>,QG=$J"3<6&/E R.3ZBO
M9J* /+M4NWMO%_CBYM].&I%M&@6.V>,M'<LHDW)T^; 89 YQQ46DWD<_Q"\,
M7\;:A<PS:7/"9FLWCC5R8SL5=H"* #^7))%>K44 >06<C1?!OQ3H\EO<I?1&
M_C:)H'&6>1R@4D?,2"",9K46:32_%OA;7KD.=&DT0Z>\VTE;68E6R_\ =#;=
MN3T(YQ7I=% 'C/BK3II=!^)&JVT<C6>KFUBLHU0DSO&H#NB]2"3U'7:3TYKJ
MM3N(9OBEX3GA;="ME=JTBJ=JEQ'L!/09P< ^E=Y10!S'CFUT^\TBTM]1FN[5
M'O$,5[:,5>TE"L5DR <#C!)X^;FN"URXUBX^'&NV.IRQZF\>IVJ6NH6]OM-^
MBR0LS[5ZE0""PX^7VKV2B@#S[4KH+\5X+NWB-TH\/3HH4961S(CK'NZ98 X%
M<S8Z@MU>> =0^SWJ^1<R)<6T-A)'!9,T+J(40+V/&>3QDD U[/10!Y[HMQ''
MXO\ B%,Y*QR&W:-V4@2!;<*Q4_Q888X[UJ?# %/AMH4+JR2PVPCD1U*LC#J"
M#R#7744 >?Z?>VVB_$7QE)J@>&.]%H]MOB8BY5(=K!./G(/&T9/M7*V6FWG@
MBR\*7VL6>H?V7'!>0W26;2;['SIA*FX1G)& %.,@$?2O:J* .=\)1Z4UK=WN
MCV$]M:WD_FF:<2*]RV!F0B3Y@#TR>3C/3!.1#-&GQFOYG.V(:'%%YK#"[UE=
MF7=TR 0<>E=S10!XG*"?@1J=HL4GVIM1=E@$;>80;S>"%QG[O/TK8\4:E]NO
M_&&G"UN(#)I0^R-9VC,VI9A8[FD53E4)V@9'?.<XKU2B@#R/3=1?1]<\'Z[?
MP72Z*_A]=.,S6[XMKC*,2RXRH;:%SC!QZ<U3N%OKZQ\9SZ98WT[1Z];:BL*P
MR1&YBC\IF"-@?-\I.!SP/:O:** .)\+WOAW7]935M(L-0DN8K<Q2WEZ)P802
M#Y(,I^8YR2%R!CKR,I\26 @\-##,4U^SF8*I;:BOEF..@ ZFNWHH X33;B"/
MXL^(KB1@L+:;;*LK#"L5+E@&Z$@$9%3?"8-'\--)@D1XY8A(KQNI5D/F,0"#
MR."#^-=K10!Y.+K3])\0^(]$\56.K2+J-Z]Q:&W%Q)#>12*H\O;&<;AC:<CI
MBK.H7 M]7N=$;2[C3$71(H[9;.W:22ZPK#R3, <+'P,9'4DG%>GT4 >,:+J4
MV@6G@77[NSO6TBWTE]-NW%LY-K(?+.\IC.TE-N0.WTSM>,KFSO\ P?%<:?IK
MV\%SK-M.N+8QO< 2(SS,F V.#RPR0,]"*]-HH X:.9'^-1F0[H6T 1"0 ["_
MGEMN[IG:<X]*=\43GPW9(JL[_P!J6C[44L=JRJS' [ #)-=O10!PEK<0#XQ:
ME<EP(#HL*"8CY"PD=F ;ID @X]*Y;0;.QNOA]H%I>WE]H][#>7<EM?P@HUI)
MYLA&\$8",C?Q8!R!WKV2B@#R34+G69_!^C7FL0B=M/\ $\+R7=K;$"XMT<C[
M1L49 .>W7J.#5KQ%JAOM6\36!L;RT,VDJ;4V]DXEU',;GYW"Y"H2!M)7&3GT
MKU&B@#R;3;A)+SX5,8YE%K92I.9(67RS]E5!NR. 6! )ZXXS535+>^O8?'AT
MNWDN9DU:TO8[=5(^U1Q"(N%_O<H>F>1CO7LE% '!W&JV7CK0]4'A^QF^WS:7
M/;?;+BU:!H69>(=[ $G<<D*2!C)/3.;X6U#0]>_L>VFT?5CKVGE#+!>?:-ED
MZC#/N<E .#@#DY P.<>G44 <-\589&\,6-XH)BL-5M+J?_KFL@!/T&X'\*L>
M-=3.GZMX=#VS);RW$HDU*.U\^2T/EG:$^5MI?.W.#QGCN.LN;:&\M9;:YB26
M"9"DD;C(92,$$>F*CL+0V-FEKY[S)'\L;2<L%[ G^(CUZGODY) .+^&;>2?%
M%N\-Y&?[;GG4W43J61E3:2S#DG!]_7%2?">"2/P4;E@1'>7US=0@_P#/-I#M
M/T(&?QKK]0LSJ%F]J9GBBE&V4IPS(>H!_ASTSUQG&#@B:""*VMXX((UCAB4(
MB(,!5 P !Z8H X2PO+;1/B/XPEU,/!'>I9O;%XF(N D15@G'SD'C:,GVK.M/
M!NH0_".VMDC^RZQ83/JEA&W_ "PD$C2)&?JK;2.GS&O4*PM=T*^UJZ@5-;GL
M]-V-'=V<4*'[2I[;R-R<9''.#QCK0!'X/::^T@ZY=P&"ZU8BZ,3')BCV@1I^
M"@$^[-65XCU,6WCS3;2>WFMK>6QDVZA;6IEFD?>O^CJP4E 0-Q[GC!%=JJA5
M"J % P .@I: .'^$I:/X?6=I+!<0S6TUPDB3QLA!,\C <]>".1GK3-)N(8?B
MMXJGE;9$UE:*LC A6*"3> >A(R,UW=% 'B=N#'\#= M#%(MS%J,)>#RV\Q-M
MUO)*XR,+S]*T/%]^VH)XYT_['<V\QLP;>.SM&)OU\GB5Y57Y@/N@9  &#G.*
M]<HH \WFG6Y\1_#*54D4%+H8DC*-Q:XZ$ CI4&B7 T;1O%N@:Y%)]NEO+N:%
M#&6-]',"5,?'SDYVD#D8YKKK7PY<G6K?4]6U3^T)+)YS9#[.L1B$N 0Q!PQ"
MC:#@<$YR>G0T >4:/I\^B>)?A[8:@2UQ8Z3<0SO@LL4C+'M0MT'0J/7%;[.H
M^-R/@[/[ :'?M.WS//#;,]-VWG'7%=Q10!YUX"L+?5/ %]X8U*UN%837D-U'
M)"R!0\SD88C!."",9QQ[5:^'\>K70:37%S<:,KZ3%)G/G%6^>;_@06(>N5;U
MKJ-=L-1U&P6'2]8DTJX$JN;A($E)4=5VMQSZ^U6-,T^+2]/BLXF=PF2TDART
MCL2S.WN6))]S0!4\3:'#XD\-:AH\QVBZA*J_]Q^JM^# '\*Y?0X-<\1^"=1N
M[^)K/6KG3WTZ(.<%'161G]MTI8_0+7?44 >1W(;Q%\)=+\+6\$L'B"'[);-;
M-&5DM7B=-\A]%"JQ#=#D 9)K6:*X_P"$^\;6"QSQ7&K:=;+92B)MA*Q2*6W@
M8&"1U->C44 >5>$[S1M6L]$TB_T75CK^F/#OM+K[08[:2/ ,P9B8P  2,'G(
M '-=-\3+#4=0\%3KID+W$\$\-RULG+3)'(K,@'<X&<=\8KKZ* ."U%X?%GB[
MPC?Z.[2)I\DUQ<S!2/)C:/;Y;9Z,Q(&T\\$XXI_@JXC?QCXS() GOXWA+*0)
M5$*J2I/W@"",BNZHH XGXA%H+KPI?-%,]O:ZS&\[11-(8U,<BY(4$XR0/QJ#
M2[N$?%?7KN3=%"^EVRJ\B%1E2Y9<GN 1D=J[VB@#P[2&N-*\%>!]6N+/4)-/
MTU[N'48K7S$F@$C'8Y52&P,<^S>]>E^$?[&N6O\ 5-%L;B."\9"]W<B57NF4
M$9Q+\V "!D]>?2NFHH \^N-0/ASXLWMYJZ3+IVIZ?##9W2Q,Z(\;,6B)4':2
M6W>]<E<NTOPC\4VZVMVLTNO2/%$UM(K.INU?*@CG"@DXZ8YKVZB@#A)IX9/C
M/I\ZG?$=#DB64*2F]I58+NZ E03CTK$>[L-&\4^)-)\4V>K/!JET;BSDMA</
M%=1O&J&+;$<;AMQ@CD>V*]6HH \P6^3P/XVBNM1TVYM-$O=(M[6W:&)YQ9O$
M6/DML!(X;KW(J?Q T5M-X*U*#29;'3;?5)&,45JP,2/'(%9HT&5W$YQC(W<\
MUZ110!Y]H=]_PCWC/Q2FM[X(]2FCO;*XE0[9D\L*8P?[Z[0-O7G@5S5GI<^A
M:)X!M+Z*2-H]:DNVA9"3;0OYI3=_=QN7.>A/M7LU% 'GOC2WC/B)KW3]:GT3
M7;:P5HIV7=;W<>]SY+J1AB"#T^;Y\@&NO\/37=SX9TV:^LULKN2UC:6V5<")
MMHRH';'IVZ5IT4 >0Z;YD'PBU;P9J-O(WB"..ZM5MBA+7,DCLT<J?WE)<$MT
M&"3C%:][&VF^,_A]:W4QD>PLKF*ZGP2JL844%FZ#<5.,]:]'HH R_$L$MSX5
MU>W@1I)9;*9$11DLQ0@ ?C7F\][%=>"_AS&D<X:SU&P$XD@=?+\N(JY((^ZI
M(!;IGO7KE% 'DWB"RN]7\0^/K/30S7%WI%M'!C(69TWED#="<$ \]ZV/#>J>
M'_$VJ:;=0:5JIU:R#F3[?]H_XEY9<.-TAVDDX7"Y)Z]J]!HH **** "BBB@
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MG8106L8C(:Y>.([G53R>H4''.#C/%>@^';Q+[0+*:.*>-?)1<3PM$W"C/RL
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M10 4444 %%%% &!>^'9KSQAIVOB^5/L,,D*P>1G<LF-V6W=?E&../>M^BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*YMUNK=X'=U1
MQABC;21W&>HS[<T^**.&)(HD5(T4*JJ,!0.@ IU% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex31-restatedcharterasam006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex31-restatedcharterasam006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+A=/^*'C!+J.:,78M)H9#$WELB089M^-H (QR>M &OH&KZ/;^$8M0AUNYO\
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MDYQC'/2N/\475IXG^'_BJ[T'3)9/M-E@W7V1HI+IE!X 90S!1WZ<X'0TRZU
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M;)4 #)  P/88J;Q=?R^'/'FB>(KNWN)=%%I/93RPQ-)]E=V1@Y503@[,9 H
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M9VUO9FRACB58[8MN,2]E)]1^-7Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L#Q;X=F\3:;
M!917R6@BN8KDLT!E+&-@RC[RX&1S6_574-0M=+LVNKR810J0N<$DL3A5 '))
M)  '))H LH&"*'(+8Y(& 3].U+63:>)-.O+VYL5:>.]MHA-):RP.DIC/1E4C
M+#/'RYYXZUQ_A^ZD\:7VIS27^L65S8ZQ(MNT(EBC$,15?+92-A+<DAANY]J
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MOYY;!+*,<9Z^E7?B#'*)?#%ZL$TEO9:S%/<M%$TGE1^7("Q"@G )'/O7:44
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MGJT5O*^B6,$UC,(D+_9@ZJ$<@9.WY0">U=[10!Y?JNCW>JR_$#5]/@E>VO\
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M!OV@99<$L<C@=1QS6CXH:[T?XAZ'XB>TNKK25M)K*<VT+2M;,[*PD**"2#M
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M#?3"#5)HK"X:WNVBL9"("H!+/D#:O/?DX.!Q6[+XAL_+MC9)+J$ES!]IACM
MI+1<?/EB !R,9//;- &M4-U:QWEL]O-N\IQAPK%=P],CG%<V?B'X?_LW3;\2
MW+0ZA<_9(MMLY*2Y(*.,?*PP>.IQP#5W2O%NFZI+J<16XLIM,"M=1WL7E%$8
M%E?G^$@'GVYQ0!N*JH@55"JHP !@ 54ATV&VU">\@+1FYP9XQ]V1@  ^.S8
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M:)I3%%C<V!G R0*Q-%\7QW7A+2=6U"":&XOXX1'"J F>5T#8C&>1UY., $G
M% '445DZ7XAL]4U"[TX)-;:A:!6FM;A0'56^ZPP2K*?4$UG^*/%,V@ZGH=E#
M83W!U&Z\II$ (4!68@9(RQQ],9YZ9 .FHKS>WUL:-\2/%+R1ZG=I]BLY4M(0
M\[IGS"VU2<*.G<#/3J*Z^'Q1IMWI.G:A9M)=)J*[K2*)?WDO&2,$@# !R20!
MZT ;-%96A^(;'7TNA:^;'/9S&"YMYUVR0N.Q'(Z<@@D'UHU'78;":2".UNKV
MXBB\^6&U0,R1G(#') YP< ')P< XH U:*YA_'NB"ST>]C>>6RU>18K6Y2/\
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MOM-\+O:V5[-Y>LV=U(J6LA:.-&RS,,9&/0\UW-% '$P"9?BY?7YL[P6;:+'
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MT%O:3"V8[?,>$J7C.>ARI'/<5/<7M_KOCOP?JD'A_5X+:VCO%N3<0"/R6=$
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MC'>NUTG4IX5T73&TJ^VRV0:2Y,>V.!D &Q\\ACSCB@#?HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "L3_A&H?\ A+QXD^W7?VH6GV/R?D\KR]V_&-N[.><YK;HH **** "BBB@
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M23&X ^N.,T :-%%% !1378I&S!68@$[5ZGV%5M+O9-1TRWO);.XLGE3<UO<
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M2,2J%@I8@9P.IK(\-^(;?Q-ITM[;V\\"QW$MNR3@!@T;;3T)'4>M &Q1110
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MS,NUF W;E+=\'FJWA_2SX?DC2.T\9W=E;Y^R6=SY+16_ICY@6QG@,2!Z9 -
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MM#.L>V0Q*XD<%3N&6QCIA>F3576->US1(]+G\2I=II_V+;>WNC_.MO=!L%W
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MA9-((I"JAGA=BP Z')ZUN6=U+KGC37= DO+R&UT:VM43R9V22625"QD9QR<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %9FOZ#:>(]+-A>-*B>8DJ20OM>-T8,K \C(([@BM.J6K7=U8Z
M7/<V6GR:A<Q@%+6.14:3D#AFX&!D_A0!1CTF'2I9]:NIKW4[Z&V9!(Z*T@C'
MS%(T15&6('09)P,\#&9X>M[?7/$L_C :7<V3/9I9P?:XC%,ZABS,5/09*J,\
M_*>Q%=<.0,C'M10 R6-)HGBD&Y'4JP]0>M<DGP[T^/0K#1UU35?LMC<1W%ON
ME1BAC.47E,;5/MD]R>*Z/4KN[LTMVM-/DO3)<)%(J2*GE(3\TAW=0OH.35V@
M##7PS"GB:;7QJ%[]LEM!9D?N]@C!+# V=023G^G%5-/\$VVE:+8:99:KJ44=
MA<M<P2!XRX9M^Y3E,,I\QC@CTYXKI)7:.)W2-I&4$A%(!;V&2!^9KG-'\63Z
M[X5T[7-/T:>47EQY36_G(&A02,C.2>#C;G _^O0!J:1HMMHXNVA:22:\G-Q<
M328W2.0!G@ #A0, =O7)IL&BK#X@N-8-]=R2SQ+"87*>6B*20% 7(Y8GKSWS
M@5J5%)<0Q30PR2*LDQ(C4GEB!DX_ 4 8FJ>$K;5/$NGZ\U_?6][8*R0^0T87
M:WW@P*$L#[GZ8J;1_#<&C:IJ>H0WEW-)J4HEG28H5W@!05PH(X '6KMK=W<V
MIWUM-I\D%O!Y?D7+2*5N-RY; '*[3QSUJ[0!RJ^ =.31]6TJ.^U%++4WE:2(
M2J1$)"2ZIE> 2>^2.Q%&J> [#5(-*S?ZC:WVEIY=MJ%K*J3A,8*D[=I! '&/
MYFNJHH YN_\ !5CJ&A0Z3+>WXC2X2Y>82JTLTJL&#.S*<\@=,#@#H,5%K/@2
MRU?68=8BU+5--U)(A!)<V$XB:>,=G&T@_D/T%=37-ZQXUL/#_B#3M*U2WN+9
M-1<QV]XQ3R2XQ\I.[<IY Y&.>M &Y96<.GV45I;AA%&,#<Q9CZDD\DDY))Y)
M.:P(/!B6FO:EK-KKFJ0WFI>6+DKY#*PC&U  T1Q@'M^-:FL:P=(6U;[%<7(N
M)TMQY)0;68X!.YAQ],UI DJ"1@^GI0!SMSX/@O=&U/3KK5-2F&I9%S.[Q^8R
M;=NP83:JXSP .23WJ:3PEIEUX6C\.Z@LE]8Q1I&GGD!U"@!2&4+@C'4<UH7-
MW=PZI8VT6GR36TXD\ZZ610MOM&5RIY.X\<=*AU76X=,TK4[Z.-KMM.C9YH86
M4,,)OQR0/ND'\: ,N]\&C4]'?2-0UW5;K3I %DBD,.Z10<[6<1AB.!SG/O4V
MJ^$+35K_ $B[>]O;=M)??:)"R;5.-O.Y23QQR:U-&U%=8T/3]36,Q+>6T=P(
MR<E0ZAL9[XS5V@#!U[PK;^(;K3+BYOKV)M.N%N8! 8P/,'1CE#GJ>.E3^(O#
MT'B;0IM'O+JYCMIU"RF H&< @]2IQT[8K7ILCI%&TDC!44%F9C@ #J30!4AT
M]H-)2P2]N?DC$:W!V>8 !@?P[<_A6?X<\+6_A;P\FBZ=?7GV6+=Y)E,;/%EB
MQP=F#R3U!INI>*(M/UC0K%;26:/6)&2*Y5E")A"_(ZG('IWZUOT 8?A;PO:^
M$M*_LVQNKN:V#M(JW+(Q4L26P54=22>:??\ AX7U]<W2ZG?6PN;=;::&(QF-
ME&[!PR'#?.1D'T]*V:H:UJ]KH.C76J7I86]NFYMHR3S@ >Y) 'UH S(/!NGV
MFKZ;J%I<7<!TZS^PVT",AC6+C@Y4D_='.>U49/ASILEC/;'4=35I-3_M9)UD
MC$D-R>K(0F,')X((K:TW5-0N=3N[*^T>6S\E4>.X60213!L\!L AACD8_$U9
MU6[N[*R\ZRT^2_F\Q%\F.14.TL 6RW' )/X4 8UMX(LK2_U6]CU'4S<:I"D5
MRSSALE5*AP"N-V"?8=@*C;P'8-X>TG1/[0U!;72YHY[9@T>_=&<ID[.0#[?7
M-7F\1JGC6+PVUE*'DLGO%N2R["%95P #GJW?'3O6Y0 QHEDA:*3+JR[6SQD8
MYZ5S>G^![&PL[/3VO;VZTVQD62VLIV0QQE3E<D*&8*>0&)YQUP,=/10!R=]\
M/]/N_$,^LVVI:MILUT%%Y'877E1W.!@%Q@G..,J0?QYKJ(88H((X(D5(HU"(
M@' 4# %244 <AI7PZTO1K\RV=_JJZ?YWGII1N?\ 14?.<A,9QGG&<9[5:7P7
M:(FO*-1O\:WDW>3'QE=AV_)Q\O'?\^:O:KKGV'4+73+6W%UJ5U')+%"TGEKL
M3&XLV#CEE X.2?3)$^E:D]_HT6H7=E/IKLI:6WNL!HL$@Y(XQQD'TP: ,B?P
M1:3Z?H=DVI:BL6BR1R6NUH\[HUVH6^3G"DBK-WX6MYM<76K:]N['4?(%O--;
M[/W\8.0'5E*D@]" "/IQ2:EXHBT_5]"L5M)9H]8D*17*LH1,(7Y'4Y ]/QK?
MH YF[\#:;<Z=I]DES>6T=C>B_1HF3=)<!BWF.64Y)8DGMS4GB/P=9>(Y[&[D
MN[VRU&Q)^SWUE*(Y5!&&4D@@@^A%=%5#6=9L- TN74=1F\JWCP,@%F9B<!5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA5VK@  K@<<'WZ\T 4=.TK7K'Q5;7?VZ)-)FA:*>TFU"6Z:23&5>/>@VG@Y
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M9W4$\[388(665"Y.TC!R!P1VK>;PEI,^F:E8WL37JZF=U[).<O,< #) &-H
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MHEF4#:%R%P !QA0._<FE?PE:R7VBWCWMZ9M'5EM3N3&&7:V[Y><KQ_\ 7YH
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M+C6+-?W<S("&E4'.TC/MGH>171:/X<MM$O\ 4;NWN;J2349O/N%F92I? &X
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M'8;MQ);!Z9)[>E '<45YUIDMSXOT?Q1?2:A>VEY::A<VMIY%P\8M1$ $^4$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW0!R[> =';P[=Z"TEX=/NIC/-&9N6<MO)W8R,M@]:O3>%]/GUVUUJ1[DW]O
M+?S%F91*@;< X7 ;#<UM44 4-8T:PU_2YM-U* 36LP&Y<D$$'(((Y!! ((J"
MQ\/V]G=B\DN+J[O%A,$=Q<N&>.,D$JN !R0,G&3@9)Q6M10!CZ)X<L] EOI+
M.6Y/VVX:YG663<&E;&6Z<=!P./:IK_1H[[4+>_6[N[6Y@C>)'@< %6()!5@5
M/W1U'':M*H([RWEO9K-)5:X@1'D0=5#9VY^NTT 8=UX(T>YTO3[!!<VHT^8S
MVT]M,4E20YW-N[[MS9SUS1;^!M!@;5BUO-.NK(J7B3SNZR *%Y!/7C.[[V2>
M:W+J\M[)(WN)5C$DJ0IG^)V("@?4FL>U\1RS^-[WP[)9",6]FEVMQYN[S S%
M<;<<?=/<T 1Z%X+T[P]&RVEUJ,C>6887N;MIC;Q_W8PV0HX'0=AZ5$O@'1T\
M/6>A))>#3[.<3P1B;E7#;@=V,G#9.">]=110!3U+3+75])N-,OX_.M;F(Q2J
M3@LI&#R.A^E8MGX$TBSO]-OA+J$UUI\;1PRS7DCDH<?*W/(&T<=/7-=-10!R
MVG?#[0]*U1[RS%Y'$TWV@6/VI_LJ2YSO$6=N<\CL#C&,"K\?A?3X-;O]7MWN
M8;J^"^=LG;86"[0X3[N[;QG%;5% '-1^!=$C\,0>'_+G:QMI1-;$RGS('#%@
MR..0023GWQTXJ[#X<M8_M4LD]S/=W4(MY+N5P9?+&<*, !1R3P!R<]:JZ-XD
MN-6U+Q!8_P!G"*;29EA4>?N\XL@<'./EZ@=ZV--FO+C3;::_M%M+MXP9K=91
M((V[C<.#]: ,/_A!M*&D:7I0EO!::7.EQ:*)N8W3[ISC)QD\'/6M^[M(;ZQG
ML[E/,@GC:*52<;E88(X]0:GK-\0ZI)HGA[4-5CM?M)L[=YS%YFS<JJ6/.#V'
MI0!E+X$TI+'2[03WYCTN99[4O<EBCJNU3DYR O '3':I+OP1I%_<:Q-=BXF.
MKPK!>(TGRNBYV8 Z%<G!'ZUKZ1?'5-%L=0,?EFZMXYR@.=NY0V,]^M9FB^(I
M=5\1:]I,MD+=M*>%-_F[_-$B;P<8&.,<<T 16?@C2K/5+'4Q+J$U[9PF!)I[
MR1RZ$@X;)Y (! Z9YQFKNA^&M/\ #WVD:?YZQSRM+Y<DS.D99BS!%)PH))/%
M:]% &3=^'K2\\06>MR2W O+-'CAVOA55L;AMQSG Z^E9_P#P@VE'2-5TLRWA
MM-5G>XNU,W,CO]\YQD9P.!CI6_>7EO86KW-U*L4*D LWJ2 !]22!^-3T <Y=
M^"M,N[ZQOQ->V]_9P_9TN[><QR/%_<<CAA]14'_"N_#IT&^T:2WGFL[VX:ZD
M$MR[LLI.=RDGY3GN.O?-=510!S5OX'TR#1+W2WN=1N4O8_)N)[F[:69X\$;-
M[9PN">!CJ:FD\(V$IT<M/=YT?_CS/FCY#MVY/'S?+QSGBC5_$4NE>)M!TG[$
M)(]5DEC^T>;CRBD;/]W'.<>HK?H YV;P9IL\VM2O->;M:C$5]B7B1 I4 <?+
M\I(XQUIS>$-/<Z,3/=YT?_CS_>CY/EV\\?-\O'.>*Z"LKQ)J\F@>'-0U:.U^
MU&S@>=HO,V;E4$GG![#TH BM/#-I8WNJWEO<7:W&J$-<OY@.6 V@CCY2!QQ5
M1/ VDIX1;PL'N_[(9=GDF;D+DL5W8SC)]?TK;TR[.H:59WI38;B!)=F<[=R@
MXS^-6J .;UGP1I6MFPEN);V&]L%V07UK<&&=5/5=ZXR#_GJ:==^"='NX=,0"
M[@DTUW>VG@N764%_OY?.6W?Q$\FK>L:X--O=-TZ&)9K_ %*1TMT=RB?(A=F9
M@"0 !V!Y(^HFT2]U"^T[S=3TPZ==K(R-#YPE4X. RL,94]1D ^U &0/A_H T
MS5].\JY-KJLOG7"-<N</D'<N3P<JISU) SFK4OA.PFN])NGGO6GTLNUL[3EC
MN<$,S$Y+$@D<_ABMZB@#GYO!^FR7U_=0R75J-1&+Z&WEV1W'&,D8RI(X)4J3
MW-32^%]/DU?3=23S89=,B:&T2)@L<:, &7;C&" !^ QBMJB@#)T?P]::'/?S
M6LD[-?SFYN/-?<&D( +#CC@ 8''%%YX>M+W7['6I9+@7=BKI!M?"J'P'!&.<
MX'7TXQ5;3_$4M[XPU;09+(0BP@AF6;S=WFB0MVQQC;ZFM^@#!@\)6$+6RO/=
MSV]K<?:H+>:4,D<N20PXW<%C@$D#L.!6;\4;:XOOASJ]E9VMQ=7-Q&J1Q01-
M(S'>IZ*.. >:["H#>6XOULC*OVEHC,(^^P$ G\R/\B@#+T_0[4S6NHO->W$\
M,)CMFN_O6ZL!G"E0=QP 2P+<=>M/T7PU8:%:7=K;&:2"[F>::.=_,#._+GD=
M^XZ5L44 <[8>"]+TZ.UMXWNI+&SE\ZULY9=T4#Y)!48R<9X#$@=@,"N>T72)
MKWQYXRGD.K6-O>26XCD6-XDG180K89EX(.1E<-Z&O0Z* .<U?P-H6LZ786$E
MO);)IV/L4MI(8I+; Q\C#D< ?E23^!])N-'@TR22]:**X6Z,C7+-++,I!5W<
MY9B,#OC@=@*Z2B@!%!5%4L6(&-QZGWK!/A#3S<ZS<>==B368UCO")?OJ%V@#
MCY<*2./7UYK?HH YT^"]--IHUKYUX(M&97L@)?\ 5E5VKGCYL+QSGBMG4+"V
MU73;K3[R/S+:YB:&5,XW*PP1D=.#5FB@#FU\$:8J:4OVB_8Z6_F6S/<EV#;=
MN23G/R\8Z8[5,OA'2C>:Q<S++<'6$6.]CF?<DJJNU1C'&%XXQ^=;DLB0Q/+*
MZI&BEF9C@*!U)IMO<175M%<0MNBE0.C8QE2,@T 8'AWP3I?AF0/9S7\VQ2D"
MW=V\RVZ'JL:L<*.G3GWJ[XA\.:;XHTS[!JD+/$'$L;HY1XG'1U8<@BM:FN6"
M,57<P'"YQDT 8,7@_3HM!O-):>^GCO4,=U<7%RTL\RD8P7;)Q@D8&,9..M)_
MPAVG^?HLWGWGF:,A2R/F_<!7:<\?-E<#G/%2>$O$+^)]%;4)+3[(RW,T!B\S
M?@QN4SG ZXK;<L$8JNY@#A<XR?2@#GM<\%:5KVJP:I*][::A"GE"ZL;EH)'C
MSG8Q4\KFI=2\(:5J5IIUOBXM3IK[[2:UF,<D1P0?FZG()SG.:7PEXA?Q/HC:
MA):?9&%S- 8O,WX,;E,YP.N*V;BXBM;:6XGD6.&)"\CL<!5 R2?PH YO_A -
M$%OK$*_; FK@"\'VISY@"A>Y/) Y;[QR>:MR^$[&:YTBX>>[,ND BT;S!\N5
MVG/'S97CG^?-;44B30I+&<HZAE/J#3Z .=?P7ILD^J3F>]$NIR12W+K.5.^(
MJ8V4C[I&T#C\:G/A;3IH]16]\V]DU&W%K<RSL-[0@, @V@  ;F/ !R<UMT4
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MR)K6(7\N8WDA+,=^[>1D9 )(YZ5W6H>'+#5+[3KRZ^T-<:<Q>V99V7:Q&"2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?>'<PQPZI:W!>XTS8B+MD7.2I(W$CKN.<YQ6WI($OQ(\7V;2.UH;*SD$1<[
M6$FXJ,\9P,XH [JBO)O#-V+_ ,%^!8;R\NKN[N?/<6)?*WNT."978_<3(;OD
MXX/%9M]/>CX3^+%:[N89=.UZ2WM_)NG_ '2>?&/+#<%E 9@ 1C':@#VNJ]E?
M6VH0M-:RK+&LCQ%EZ;D8JP_ @C\*X<6":7\5K:RMY[MK?4M(G:[26Y=Q(ZN@
M#\G@X8CC''2G_"&QMK;P/'+#'M9[JZ0_,2,+<2 #&<#B@#M6OK9-1BT]I5^U
M2Q/,L?<HI4$_FZ_G5BO/[C3;27XYPRO$2YT%I2=[#YEN$ /7T[=*Q[.63Q%\
M*]8\33W,\&NPF\G6=)2K6CPLY2,<\*%505Z'))R30!ZQ7(0>,-0U#0Y]>TO1
M$O-*3S3'B[VW$RH2I98]FWDJ< L#CWXK=\/7MSJ7AK2KZ\C\NZN;.*:9,8VN
MR D8^I->=7GA[5?"]I<>*O &IJ^ES(;VXT6[^:"12-S&(]4..WZ]J /4K6;[
M3:0S[=OF1J^W.<9&:EKS===/BKQ%HEBJPP6-[H:ZA#:7(;;([, 5PI&XHH&!
MTY)QP"*^+SP]=>'/"^HZVUY8W>J3QRR@LI1!%OBMF8L21N8=\D8'3- 'I-]>
MV^G6$][=RK%;6\;22R-T50,DU!>3Z@EQ8BQM(IX))<7+R2[#%'M)W*,'<<X&
M*\[^(7A^STWX>^+HH[R::)UCNXK)WREH20OR#LI(8XZ C@5J>);9=.U[P.EG
M+<11/J+1O&)WV.#$[?,I.#R.IH [ZBO/=%C3QE/XO75)9DN;34Y;&VV2,C6D
M:(NQTP?E8DEMW?IT&*Y[2[_4?$:?#.ZU*\O(Y[];N.Z\FX>,3*D3A6(!P"0,
M[A@_-P1Q0!['69KFNVF@VL4MP))9IY!#;6T(S)/(>BJ/UR<  $DBN;\!H;'7
MO%VCQ2S-965_']GCEE:3RP\*LP!8DXR2<>]4M<LGU3XTZ1;75Q/#:P:+//;&
M)]A,QD". >H.PCI@^] '=V4EY+!OO;>*WD/1(YC)@>YVCGZ?G5FN-\$7FIC5
M/$NBW]U+>PZ7>K':W4W+LCQA]C'^(KN SUYJ)K@:U\4-1T/406LK/38IK>V8
MD+*SL0\A'<C"J/3G')H ZC6]7MM!T.]U:[W?9[2%IG"CD@#.![GI532[_6[C
M4FBO]*@BLGMUFANH+C> Q/,3*0#D==PX/M7F6K?:;GX6>.M/OI9KF'1KV>WL
M9Y9&+^6-I"LV<MMW$9.?TKUK2;."QTR"*W4JFP-@L6Y('<DT 5M1UM+;3]6F
MLECNKG38RTL!DV#(3?M+8.#MP>G<4_P[JC:YX:TO5GB$37MK%<&,'(4NH;&>
M_6O/]#TVTMQ\29(HBKQW4ZJ=['@VZD]^>2>35+3;0:5HWPQU2UN+H75V]M:3
MEKARCQ/;L=FS.T ;1C [9Z\T >IVTVHOJE]%<6D4=C&(_LLZR[FER#OW+CY<
M' ')S5VO.K5+Q_%7Q'L[74Y;>3[+:BVFGF9EMG>&0[ADG: QSQTJ7P;J&WQ,
M^E:GH\^C:W'99:%9/,MKI R@RQMGKGKGYN1DG% 'H%<_H'BZP\0ZOK>FVN1+
MI5P(7)/^L!'WA[;@Z_\  <]ZL^)=0N-/T29K)0VH3D6]FI[S/PI^@^\?937G
MUY%<>"_&7AO6CIQLM,EB71+US.LFX'F)VQW# Y8^M 'K%5UOK9M1>P653=)$
MLSQCJJ$D GZD'\JX7Q+IJZI\4-)T^>[ODL[O2[KSX8;J1%;#(!@ _+UZC&<<
MY&14/A_0;"T^*VNP1I,1!IEEM=IW+D_O%R6SDG ')H [O3)M1FMY6U*TBMI1
M,ZHD4OF!HP?E8G P2.<5)J-S+9Z;<W,$*S2Q1LZQL^P-@9QG!Q^5>3V6M7.F
M>"$22^N%@N?%;V%Q=/,QDCMS.P/SDY'"A=V<C/K7<OH=KI%WJT]I>S1QW=BQ
M_L[=F)2@P9%'8G<H/K0!H^%]9;Q#X7TW6'A$#7D"S&(-N"9[9[UKUY'HNH3)
MX6^&^C":**UU&U?S/-W!)&2,%(VP1P2Q.,\E0.>E=MX4T6ZT*ZU6UFU1+F"6
M59X+15;%HK @J"S$[25) X P: $UOQ3>:5XKTC08-,AN)-569H)7NC&%\I0S
M;AL..#QC/X5H6U_K#7S6MWI5O$#"TD4T5V9$9@0-K$Q@J><]#W]*Y+QG#+/\
M5O 4<-R]M(4U'$J*K$?ND[,"/TKJ]-M+O3M2NC?ZLU[]K*"W$BJC+M4[E 4
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M'$MU*[FW)4!@JL2 >,9';@'%:^GZA:ZK9+>6<HEMV9U61>C;6*DCU&0>:M4
M<U>> ?#E]/J,MQ92,-1R;J(7,@B=B,%]@;:&P/O 9]ZMQ^$]'AU2SU*."9;J
MSA\B!_M4N$C[KC=@@X&<@YQ6U6-XKUBX\/\ A;4=7M;:*YDLX&F\N20H"%&3
MR ?R_44 )<^%-)NY[R6:*=EO762ZA^T2>5,R@ ;DSMZ*H(QSCG-)?>$]&U'6
M5U:XMI/M8B$+LD[HLJ Y"R*I"N 2>&!K3T^Y:\TVUNF4*TT*2$#H"0#_ %JQ
M0!S"?#[PU'8:=91V,L<6FNSVC1W4J/$6^]APP;![C.#2O\/O##V-]8_V<5M;
MZ<3W$27$J*[@@YP&&!D X&!D#TKICTXZUSWA/Q#<^(%UG[7:Q6TFGZG+8A8I
M"X8(J'=D@==Q["@"VWAO3&UJVUAHYVO[:(PQ2M<R'"'J,;L'.!G(YQ3M(\.Z
M7H+W+:;;&'[1(TKKYKLH9CD[0Q(4$G.%P*U*S]=U>WT#0;[5[H,T%G"TSJO5
ML#.![GI0!'>^'=+U'6+35;FV+7MJI2*5977Y202K $!AD X8$9JJ_@[1)+F[
MF^RR*E[)YMU D[K#._\ >>,':2<<\<]\T_2KS7IM1*:A86BV$ELLT5S!*<JY
MZQ,IY/!SN& <=!6W0  8&!TKG$\#Z''8FPCCNX[%@0]HE[,(GSU!7=C![CH<
MG.:Z.B@#"UWP=H7B.VM8-1L0PLSFV>%VB>'MA60@@<#CIP*2[\&>'[[PZF@W
M&G(^GQMO1-[;E?).\/G=NR3\V<G)]:WJY[Q)XANM#U'08(K2&6'4K];-Y&D(
M:/*LV0N.>%/?\* )8/"&AP:!<Z(+/S+&Z!%PLLKN\N1C+.26)P!@YXP,8I'\
M'Z+(NG!X)V.G/YEJQNY=R/C&XG=ECCC+9XXK=HH Q;KPII-WJ-Q?M#-%<748
MCN6M[B2(3J. '"D!L#C)YQQTI]QX8TBZO--NWMF673 5L_*F>-801M("J0.G
M'3IQ5V^U"UTV**2[E$:RS1P)G^)W8*H'XD5:H S-.\/Z=I6H7U_9Q2I<WS![
MEWGD?S& P#AF(&!QQVJ34='LM4>VDN8V\ZU<O!-&[))&2,'#*0<$<$=#WJ_7
M.^+O$-UX<M=/GM[2&=+F_@M)#)(5,8D<+N  ^;KZC\: -BPTZUTR!H;2+8KN
M9')8LSN>K,QR23ZFJNI>'M.U2^M[^>.1+VW4I%<P3-%(%/5=RD94^AR*U**
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M:>4/8@YZ5J4 <[<>!?#MUX:A\/3Z?YFFP$-#&\SEHB.A1RVY<>QK1T70M/\
M#]C]DTZ%HXRV]V>1I'=NF69B23@ <GM6C10!B:GX3TC5]6MM4O([DWMJ&$$L
M=Y-$8@PPVW8P R.OK4EMX;TZUO6O$^V/<F$P"6:]FE94)!(7>YVY*CD8/ K7
MJK>ZC:Z>(#<RA//F2"('J[L< #]3] : *>A^&M*\.0S0Z7!+#%-(TLB/<22
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MI'.UR2=RG.5.2>A'4TY/ OAY?#\^B&SE:QN"#.K7,I>7'3<^[<1QTSBNCHH
MQY?#&ES:CI^H21W#W6GJR6LANI?W888;C=@Y  .<YQ567P-H$]OJ<$MK.T6J
M.'O%-Y-B9AW/S^P''I7144 8[^%]*DU'3[]X[AKK3D9+60W4I\L,,,,;L'(
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M$;>"1DC !.>*L7NC#1)O VNZ7<7?]HWUW;6=YNN'<7,,D9+[E)Q\H7(P !^
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M#=V\WR3E<MBXBSD$L <]SL&#7>^&KJSO?"^E7.GF1K.2TC,)E&'V;1C=[^M
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M?.,XC#MY2RG^,1YV!O<#-:^1ZBER/6@#+'A[3%U&[U!;=EN[M0D\RS.&D4=
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M++U /(H#H7*AUW#J,\B@#G[KP)X8O;F\N+C2('>]_P"/D L%E/\ >90<%O\
M:QGWI^J^"?#6MVMI;:AHUM-%:#%N I0Q#T!7! ]NE;H="Y0.NX=1GD5RE[K^
MLW^JZUIWAU+'[3I @#I>*Q%P\B[]H96&S"XYPW)Z#% &O-X9T:<6"M8HJZ?C
M[(L;,@@P,94*0 <<9IR>'=+COKV]2W=;F]4+<RK,X:4#@ \]AP/3M6DA)12X
M 8CD Y /UKF[;7]1F\>ZGH#0VH@M[".Z@<;MS%F9<,>F/E["@"S'X.T"*WLK
M>.PV0V#F2T197 @;U3YN#UZ>I]:G_P"$:TG[5?70M6$]^@2Z<3.#,H& &YZ
M9 ] <52\$:_=^)/#,>I7\<$5P;B>)EASM 25D&,DGHM='F@#%D\):#+I%MI,
MFFQ/8VL@D@A8L1$PZ%3G(QD]/4U%J_@CPSKUS;W&IZ-:W$UNH2-BI7"CHIQC
M*^QR*WR0!D\"FJZ.@=65E/<'(H R-;\)Z#XCM8+;5M+@N8K<YA!!4Q_[I7!
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MG;S>?# )7"QR9SN49X.<GZDGO5?4O$-Y:>.="T:)+5[+44N3(^29%:) <#G
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M>SF8M-$V2)2>I?NQ/OF@#@UTNRTGQOX N;&!8;B^MKF.[E7[]PHMPP#GJV"
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M3+IMK;0"6UO5S H4.HC4KTZ]3@^]8>A6=OXK\'VFJWNLVMGJEK>&:YGCMO\
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M@3=>$/A5>SL9+DW]HAE8Y)'DOG/_ 'R/RKTE?#>CI->3+8QB6]4+=."<S <
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(UC8<,@-ZX.TCD<>E=II>GV>C_&2\M--M8;2WGT&.:6*! BNXG90Q ZG'&:
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M9ZX XIUS?6EF8Q=74$!D.$$L@7<?;/6J$_B72K?7K71GO(?MEQ"TZIO'" J
M3]2W'K@^E &E);02SPSR0HTL.3$Y7)3(P<'MD4D=I;PM.T<*(UP^^8JN/,;:
M%R?4X4#\!3#J%D+T61O+<71&1!YJ[\?[N<TL]_9VPD-Q=P1>6H9_,D"[ > 3
MGH#0!0_X1;0!9367]BV'V29_,E@^SKL=O[S+C!/O4UUH.DWRVRW.GV\GV;B
ME!F(8P0IZ@8["KKW$,=N;AYHUA"[C(S *!ZYZ8KE=#\17NK>+O$NFBZLI;.R
M@MI+.:%,C]X)"=QW'=@J.F.G:@#>N=#TF\TY-.N=,M)K&/&RV>%3&N.F%QCB
MHM4\-:'K<$$.J:39WD<'^J6>$-L^F>E2:7<2QZ/9'4K^TGNG54:>#Y(Y7/\
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MEMKNVO8!/:W$4\)X$D3AE/XB@#!U/P1H5]HC:1#I.GV]I)-YSA+=1L8@@NH
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MH3627US'')>7"P0(6 +$GD\]@.2?\15NXU"RM(XY+F\MX8Y.$:255#?0D\T
M12:-IDNI#4I-/MFO@FP7)B'F!?3=UQ[57'AC019SV8T:P%M</YDT/V==DC>K
M#&"?<UK @C(.0:KW%_9VDL45S=P0R2G$:22!2Y]@>M %6/P]HT5W'=QZ79K<
MQQ^4DJPJ'5/[H.,@>U1?\(KX?-E+9'1=/^R32>;)!]G78[_WBN,$^]:,MW;0
M,5FN(HR$,A#N!A1U;GL,CFLOQ#XDL]"\+7FN>9%/%#;M+$%D&)B 2%!]Z +-
MQH&CW<UO-<:9:2RVPQ [Q*S1?[I/3\*D31]-CU-M32PMEOV78;D1CS"OINZX
M]JR-(O-5,IU"_P!4TN?1I+57+H/+>";C*YR5*8/<Y!QUK>BN[:>U^U17$4EN
M06\U'!3 [YZ4 9]IX8T*PU:75;31[*"_ESON(X%5SGKR!W[^M,N_"7AV_O9K
MV[T2PFN9T\N65X%+.N,<G'/''TK2BO;28R"*YAD,:AG"2 [01D$^@(YHM;VT
MOHS):7,-Q&#M+0R!P#Z9% #K:UM[*VCMK6"."",82*) JJ/0 <"J">'-%COV
MODTNT6Y:3S6D$0!+_P!\_P"U_M=:N6]_9WCR);7<$[Q'$BQ2!BA]#CI4D\\-
MM"TT\J11*,L\C!5'U)H Y[4[37-7UEM.GM+)/#X:*5KCS2TTNTAC'LQ@ L "
M<_=SW/'2U%;W,%W LUM/'-$WW9(W#*?H14M !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7#?
M%A(CX*$DJH0E_:'<P'RCSTSSVKN:AN[.UO[62UO+:&YMY!AXID#HP]"#P: .
M#U.TT[4/BSH4#0V\]J-)NB(\!HR1+'VZ'!S^(]17*"[72/"=\@<V^C6WC26&
MZ\M 4@MMY(^4@C8'*<8Q[5ZZ-"T=;B*X72K$3PH(XI!;IN10,!5.,@8["EAT
M/2;:WN+>#2[**&YSY\:6Z*LN>NX 8;\: .?\/:=HT?BV^U73M;>_NKRU3[2D
M+1&'"GY';RU'SD9 )/(!]*QO&@_L;XH>$O$MX=NE*DUC-.?NP.ZG8S'L"3C/
MM7=Z9H^FZ+;&WTO3[6RA+;C';1+&I/J0!UJS/!#=0/!<11S0R#:\<BAE8>A!
MZT 1W%[;VL*222#$C!8PO)=CT"CN:X3PV+75]2\>V/B".-Y_M[1RK,!Q9&,>
M5C/1<!C]23UKL=.\/:+I$GF:=I-E:/C&Z"!4('ID#I[4^\T/2=1N4N;W3+.Y
MG1=BR30*[!>N,D=,]J /(=(L6U&T^%9UZ!9[F4W4;M.N6DA$3F,-GD@KLX/7
M//6M_P#X1CP]'\8(=,&DV*V8\/%EM?*7RV87'4KT;&>^?TKT&ZT?3+ZXAN+O
M3K2XGA_U4DL"NT?^Z2,C\*YJ\\,SZA\2DUF\TZVN-,73/L8\U@SB3S-^\*1P
M,9&<YYH \_C230]-:T3*^%4\9B(@G,:6_&5/_3(2\'MD5VM_8+_PMRU%K"C6
MUYI$O]J1;04=58")G'0G)8 GG /85VAT^R.G_P!GFSM_L6SR_L_E+Y>W^[MQ
MC'M45KHNEV5M);6NG6D,$HQ)''"H5QC&",<\<<T >2Z!I_ANP^ \6MZEIWF,
MUD\$L\!"3.KS;=GF=0N=H/8#-;NF2QGXPR0W-QIS&;P\JM#;?<!$_P J')^<
M@'@X&01P*[V'1=*M]/DT^'3+**RE!$ELD"K&X/7*@8--M="TBQD@DM-*L8)+
M=#'"T5NBF-"<E5(' )["@#QHPZ?+^S+_ *NV:XBB1VX4NC?:< GN#U'YUWGV
MEF^,[VFH >2=&#:<''RD^9^^VY_BQMSWP/2NF/AS0S:RVIT;3C;S2>;)$;5-
MCO\ WB,8)]^M2W>BZ7?00P7>G6D\4!S"DD*L(ST^48X_"@#QO6-/6+P7XJM_
M+4Z9:^)(5TW_ *8@S1>8L9_A4,6''3YA7:6UA9:7\:88;"VAM8YO#\C2)"@0
M.5N$P2!U.">:["?1=*N;*.RN-,LI;2+_ %<$D"LB?12,"E71M+6]2]73;,7:
M*$2<0+YBJ.@#8R![4 2V5]::C:K=6-U#<V[$A989 ZD@X."..""*L57LK"ST
MVU6UL;6&UMU)*Q0QA%!)R< <<DDU-)%'-&T<J*\;##*PR"/<4 >;2^%9];\&
MZ-K&B3+;>(M,5I+*X[2#<=T3^J-R/;/USBWOB&_U3X6>*=7CLKBSE?4T2^M^
M?,B15@2<>N,*X^E>N66GV6FP>186=O:PYSY<$01<_0#%2+;0*)@L,8$S;I<*
M/G. ,MZ\ #Z"@#AO$5O%_P )EX)O-%6(23/)%)Y &V2R\K<<XX* [<=@2,=:
MSO"FB:7KWAOQCHDZ6ZO=:OJ$6 HWH-XP0.ORDJ1^%>@Z?HFE:46.G:;:6A88
M)@A5,C.<<#I[5);Z;86EU<75M96T-Q<D&>6.)5>4CH6(&6_&@#Q[^VKQ[#P]
MXNGMA')X6D&GZPQCRS;CY,V/79A'_P"!]L&MOQ]IT8^$.J7UW:QK>74\5[)O
M0;HW>:/ SZJFU,^U>D-86C6\UNUK"89RS2QE!M<MU)'?-)?:=8ZI;_9]0LK>
M[ASGR[B)9%SZX((H XO45LXOC3I\ERL"AM#F.Z0 9831XY/?%<?>Z987'P^^
M)5Y-:PR7,.L7QBF=06C*E"-I_AY]*]AETC39Y+62;3K21[3_ (]F>%28?]PX
M^7\*@'AS0A;S6XT73A#.V^6,6J;9&]6&,$_6@#B?$":LEY-K&DM8ZIC2(DU/
M1[SY3)#\[!HW[$Y<$$8./7%16MSIEW\0O"VH>2D%M<^''EC%R &'S1%02?X@
M*[N7PYH<S(TFCV#%(Q$I-LG"#^'I]WVZ59N-,L+N>VGN;&VFFM3NMY)(E9H3
MZH2/E/ Z4 >/:M?V%QH-K>Z=)!;VA\5I(JSR;[EY1<8=R<C8.N%P3MQDC.*Z
M33]'T?4OBMXH\^QM+F&33[.7#(K(Q829?'0DCOUP?>NS?PUH,C7+/HFG,;IP
M]P3:H?.8'(+<?,0>>>]2_P!AZ3]IFN?[+LOM$R[99?LZ;I!Z,<9(^M 'D/AS
M4O*T/X6P:C+_ ,2B5[E96E/R&9 PMU8GT.<#U ]*Z*QM]-?X@_$.V\NV9)[*
MT:6+ (=O+EW$CUZ9KN6\.Z(VEMIAT>P_L]CN-K]F3RB?7;C&?>D@\.Z):I(E
MOH]A$LD8B=4MD 9!T4\<CVH \HCL[6Z^'?PM,\,;L=2M8BQ')0I)E<]<' R/
M:M^VLK>R\9>/K'3Y(=*A?2;9Q)$H1(7*2CS,#IC@_A7<?\(YH9@@@_L73O*@
M;?#']E3;&WJHQP?I576?#T=QIVI/HT%C9:Q=0M&MZ;==V2/XB!D_TH X+1=+
MM?$\/@19+?3@NCP9G+RPRB8>4% 1 2>6P_S $8]:['XD1K)\-O$6Y VVPF89
M&<$*>:Q+/P0+MX4NO!OAK27B=&-]8R;Y05(.8P(E()QU+<>AKT*6*.:)XI46
M2-U*NCC(8'J".XH \RUB'3[RX^'5NBV\MN]T1)&F"K'[*200.N<C(/4'WK(U
MAFT5?B;#I<1@MH)]/E>&V0 +&Z)YY51QRF[/XUZFOAS0U2V1=%TX):_\>ZBU
M3$/.?DX^7GTJ:#2-,MKF>Y@TZTBGN!B:6.!5:0?[1 R?QH Y/1[/P_>>*].U
MS3M?-[=M9M"D5L8@CP=<R*B@X4XQG&"0*/B]'$WPTU-Y$0E'@VLP'RYGCSCT
MKJ=,T+2-%\W^R]+L['SCF3[- L>\^^ ,U-?Z98:I"(=0L;:\B!R$N(ED4'UP
M0: ..U&1;7XMZ#97$:1Z8VFW#62[0$-WO&[ Z;A'G'^\?6N-\3V"PZ%\4K:.
M%#H\+V\UJA4%(KED#3;/0Y*DXZ$FO8+G1],O+)+.YTZUFM8V#)"\*E$(Z$#&
M ?<4CZ+I4NGC3Y-,LWL@<BW:!3'GKG;C% ' ^*[;2O#+>'+F**'3M,N]03^T
M;J*-<,XA<1-*2"" Y!RW?!Z\U%K6CZ5%X=\;W&E>)6\Z_M%DNIMZ?9XF"D#_
M %:C#.!@XR3D''(SZ/)IEA+IQTZ2QMGL2NPVS1*8]OIMQC%8NM>&B/"<VD>&
M[;3;$,RDV[0[()5W NC!1P& *D@$\T <]8Z;:^(_&FAZW]CT^!=-T]HVA,L,
MS-(2I0)L9L!,$AN#SP.M8=CY.J_ O6YM2 &M0/=RW3GB6.]21BG/4,/W8'M@
M"NETOP<DFHVMW-X2T#0I+:99A/I[AY6(.=H(C0*IZ').1D8YR.L?0M(DU Z@
M^F6;7I(8W!@4N2.AW8SD=CVH X:W@D_X65X4EU"&,:E-X?F%X=HR[CRL@^O)
M:N4NM'TQ?A5X[N4LK<3VVKW@MY @W0[9AM"'^$#T&*]HETC39[];Z;3[22\0
M;5N'A4R*/0,1FH!X;T(6TML-%TX6\S[Y(OLJ;7;U(Q@GWH Y+5;U-/\ B5IU
M[<30W,4FB/%]D::-'B)D4^8/,95(;[IP<_+Z9JSX'T[3/!'@V 7UUIEH;BX<
MM*DB*A9W8I'OXWD [?PXXJ/7/"][-KQG'AW0-;TH6Z0V]K>8B:TQDMM_=NI#
M9'H> .U6(/ &GRZ%>:=<:;IEM#>S"62TMXM\,&%VYCR!^\QGY]H^G'(!V,D:
M31-'*BO&X*LK#(8'L17AT=I:R?!#1@T,?[K7 L1 P4!OF!VGJ./2O<6C1XS&
MZ*R$;2K#((]#6;_PC6@_9!:?V)IOV97\P0_9$V!O[VW&,^] '*V-C9Z7\:)+
M>PMH;6&7P\))(X$"*S+<8#$#O@XS6AXRN[*+5O#-K,FZ]FOF:S,LI2%'6-LM
M)_>P#\J]2V.1UKH5T?3$OEODTZS6\5=@N! HD"^F[&<>U.U#2M.U>!8-2L+6
M\B5@ZI<PK(H8=" P/- 'BFH&UN/AI\289)K2Y:/5I9H_+4!0<0Y=%R<#)/.>
M_6NTNM.L=+^*GA3[#:PVYNK"]2<QJ 9@!&PWG^+DDY.>:["3P]HLRW"RZ/I[
MK<LK3AK9")2HPI;CD@=,]*<VB:6)H;E-+L?M-NN+>0P+NC] IQE1]* //(K1
M]#UW5? ,-N5L-<E^UV;(ORQP/_Q])GM@ [?^NBUZ7<+%#ITJY,,*1$9C&"B@
M=OH*Q=!L=;FO/[5\2)81WR0FW@ALF9DC0L"[;F .6*IQV"#U-="Z+(C(ZAE8
M8*D9!'I0!YIX8;4-%U[0-%U:WLM1MI+.6+2-9LQM+1*BL4E3ME0IR#@G'<FN
M8CN;.+X%Z/!)-"LT>KHOEE@&4B])/'; /Y&O9++1-*TV3S+'3;2U?:5S#"J8
M!.2!@<#/.*A/AC0#)<R'1-.+W3B2=C:IF5@<@MQR<\\]^: .82WM3\<)62*+
M]_X;W284?O/](QD^O&!1\(_LJ^!;=(_)%P)[KS%7&_ N),9[UV"Z1IBZ@+]=
M.M!>A=@N! OF!?3=C.*=::;8:>\[V5E;6S7#^9,T,2H9'_O-@<GW- '$:AIN
MGZI\:DM]1M8+J(>'MPBG0.I/VCKM/!ZFN+N](MK?PI>VZ1#^RH?%\2::2?\
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M8Z[JNMFRN$T]/#JM%*75F-Q*5(;85QM"E@,G/3COQT= ' :J1_PO'P^,C/\
M9%SQ_P "%<Y_8>DS:7\4C)I]JY@EG,68P?*/V96RO]T[N<CT'I7J<FAZ3-?K
M?RZ79/>+]VX:W0R#_@6,TP>'M%"W"C1]/"W/^O'V9,2_[W'S?C0!P&AZF9?&
M_A.VU20&!_#$<UB93\LETQ42$9ZOL ]\$^M8!O+?2_#WBG[,ZQ:;'XP!O?(
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MYJ/C71/$FM+83-=LKQS>2I-KL7RG1G4G &3P>#SU//JJ1I%&L<:*B* JJHP
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M)/4D 4 <AI%IX<U#Q-H^N:;X@-W="U>&&&U\E5>$KG$BHH(53C&<88@=ZO\
MC:[L8KOP[;7$>^ZFU)39^9+Y<*R*C'=)Z@ G"]2V.G6MW3=!T?1GF?3-+LK)
MICF5K:!8R_UP.:EU#2]/U:W%OJ5C;7D 8.([B)9%##H<,",T <5\.+B,ZQXP
MMQ=V\S?VNT@\C"JV8H]S*N3@9]SS7H%5;;3;"SGFGM;*V@FGV^;)%$JM)M&%
MW$#G X&>E6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK7XJ>$IKJ2**(VE^"\I !.(^YH M:#XIE.J^)(->U&QABL=06UMG;$"D&-6
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M6?4?!IGAB=FUV*,EE!)0QR97Z'CB@#K!KVCFTENQJUB;:%]DLWVE-B-Z,V<
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M06P=<,MLF0F?JQ=_HX]* .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#D4S^P-&,"P?V38>2K;EC^S)M!]0,8S3[/6=+U&9X;+4K2YE1=S)#.KL!ZD
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M[VQTSN&>N!TH TUTG35N?M*Z?:"XV[?-$*[L8QC.,XQQ38-%TJU$(M],LXA
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M6Z=XD\)7E_I.O6FG$>8BW<Q1Q!M=D61D8C ;;D!L<&M^;4+2PLXIKZ^MXT8
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MF/I#C3OE6.$3M-NE"] '(VD^H^M3?#"YLI)/%\=G- P_X2&YD58F!^5ECPP
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M+%=<VG6+3-*UE;F1@0SF)<G/!R<5);VMO:(4MH(H5)R1&@4$_A0!PEM':?\
M"VO$T;)#M?1[=I%(&#\TF21^5<?IT%G!\)?A_=)'"DQUFR8R@ ,3YI!R?IQ]
M!7LS:;8O*\K65LTCYW.8E);/7)QS33I.G&,1G3[78I)"^2N 3U.,>PH A\0J
M6\,ZJJ@DFSF  [_(:\NGNM/O_AI\.(!/;SHNI:7#,@8, =F&1O?U%>Q !5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ IDD,4P EC1P.FY0<4^B@".."&'/E1(F>NU
M0*66*.>)HIHTDC889'4$'Z@T^B@"+[-!Y*P^3'Y2?=38-H^@H^SP;HV\F/='
MG8=HRN>N/2I:* &+%&D?EI&JQ\_*!@?E2[$^7Y5^3E>.G&./P-.HH 8T,3R)
M(\:,Z9V,5!*YZX/:F&TMBH4V\15<X&P8&>:FHH BGMH+F+RIX8Y8S_!(H8?D
M:<T,3JBM$C!"&0%0=I'0CTI]% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME8,[$\LWS#MT4>IJJ=1T@WG@R?\ X2KPOC08V68?VHO[TM#Y7R\<<<\_3WH
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ME8A7FD4[W) )QEB0,= !Q6;-X1U@:;X/^S3V*WWA_:KB0N8I5\DQ$@@ @XY
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MNU2X+F((^_\ =J?O84. ">N.V:9JO@GQ%?'Q5 NH::\.MP!$GF1_-B(CV^6
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M;-NM8$4@1*O("L0",#I7G/BR\L[GX>>"+C3+2Z6P76-/%K#-M\QHQD)_%CD
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M "BBB@ HHHH ***Q?$NO#0[:S")ON+ZZ6U@'ELX#$%BQ5?F8!58X'7@9&<@
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M;N-A+<P'86D1]X!X+X !^[SUKI==U"72M U#4(+5KJ:UMWF2!.LA520OXXH
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M%VKMY@2!&**%(VG ^\2?IWH ]7V+_='Y52L-3T_4Y;R.SF25[.<V]P I&R0
M$KR.>".E2:;>C4=*M+Y%*+<P),%)Z!E!Q^M<1)XUUJ+PQXQU+[)I_P!JT.\E
MAC3Y]CHD:-EN<D_-[4 >@;%_NC\JCGDM[6"2>X>.*&-2SR2$*J@=22>@KC[;
MQ-KL/BCP_9:E#IYLM;MY6B%N'\R!XXP_S,3A@03T QZGJ=7QMH5SXE\(WVEV
M5PMO=2A'B=QE=R.K@-_LDK@_7O0!8M/$NA7MU%:V^H6[7$W^JB8[7D&"<J#@
ML, G(XK7V+_='Y5YQI'C%-1\1:7HOC+1I-&\16TK26;D;H+EMC(?*?W#'C/H
M,D\5;U#QGK$UKJ-YH-D+L65V]NEF;&=VNO+?:^)5^1#D-CAN@SUP #O-B_W1
M^5&Q?[H_*N5_X2#5-7U#4['1([>"?3K>)Y!>Q,Y::1-ZQX#+MP,9))Y;IQ6-
MJ&H^)I_%_@J":2WTU[RWN9KBS:+SA'*D8!RRN-PPYQC&.ISV .VM]3T^ZU2\
MTV"9'O+(1M<1!3F,."5YQCD ]*O5Q@\9366M>,(]4A@2RT*VAN$: $O(KH[$
M'/&?E   J*]\6:QHNFZ+K6I163Z;J$L,5Q%"C"2T\W[C;RQ#@$@'Y5]1Z4 =
MQ17G\_BCQ3-?>++6QATB,Z'L='F61_,4Q>9M(!')Z9XQZ'/'7>']5_MSPYIF
MK>7Y7VVUCN/+SG;N4'&?;- %*^\<>%=,O9;.^\0Z;;W,1Q)%+<*K*>N",\5L
MVMU!>VD5U:S)-;S('CD0Y5U(R"#W%<KXOTO3[7PY<6MG86R7VIS"TBD\I2_F
M3-AI,GDD L^?]FNKM;:*SM(;6W0)##&L<:C^%0, ?D* ):K7M_;:="LES(5#
MML154NSM@G:JJ"6. 3@ \ UQ;^,]6N_!MUXPTR&RETR!I9$M)$;S9H(G*LWF
M!L*Q"LP&T]AWXJ:_>7NJ^-? -YIM[;I:WBW-Q;"6V9]N;;.6Q(-WRMQC&,]Z
M .ZTG6-/URP6]TVY2XMRQ3<H((8'!4@X((]",TFHZWINDSV<-]=QPRWDRP6Z
M-DF1VX  %5=?-QIWA75+C3'@MKN.WEG$GD;EWA2Q;;D9)QW/7KFO/+^347\
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MBDLO%WB 77A*?4(--^P:_&JE(%?S89##Y@;<3@J<'Y<<>IH [ZBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KGO&/AN7Q+I,$=G>FQU&SN4O+.YV[@DJ9QN'<$$@CW_"N
MAJGJ>JV.C63WNHW M[9/ORL#M7W) X'UH Q;2R\7G3;F2_U'3#JK1>5;K;1.
MMO%ZNP8DNW3T QCN:IV_A"ZTCQ7:ZOHLEO!!);"'4X)79C=,#E9,X^^"3\QY
M;.#BNKLKVWU"TCNK5S)!*H9'VD!@>A&>WO4] '":7X0\1Z#=WNGZ7K%FGAZZ
MN'N LD+&YMMYRZ1L"%QDG!.<9Z&I;KPOXCTWQ5?:MX9U2PBMM3V->6M_"\BI
M(JA?,CVD') &02!Q^72WNN:;I^IV.FW5R([N^8K;1[6.\@$GD# X!ZUHT >=
MZE#?6GQ5\.16TL=U<1Z1<^8UTY7S?GCR<@':<\]".,8':WJ?@*;4_#?B*W>[
MACU76YX[B28*3'&8RGEH.Y4! ">IR3@=*ZV32--EU!-0DTZT>]086Y:%3(OT
M;&15R@"O9+=K9QB^>%[G&9#"I5,^@!).![UYZGP_\1)HUCIO]KZ<XT_6%U*&
M=[=S).1(7S*=W7YB..N!R*]*JEJ>K66CPPRWTIC2:=+>,A&;,CG"C@'&3WZ4
M <MKW@^_\20M::DUA(J7:SVNH*&6YM5#ABJC'7@@'<  1P<<]7JD-Y<:7<Q:
M?.D%XR$0RN,JC=B1W%6Z* .&D^'\.IZGJU[?P6ME_:6FM87$5@Q(E9FSYS$J
MOS#''![Y)JYX:T?Q=8_9[77-:L;JQLQB)[:!TGN,#"^:2<#'7"CD@9/7/6T4
M <UX1\/7_AR._M)[NWGLY+N:XMPD9#@2.7(<DXXSC@4GB#0=1U/Q)X?U.UDM
M5BTJ:25DE9MTN]"F!@<8!)SS7344 <G#X<U+1O%&JZMHTEH\&K!'N;6Y9E\J
M91M\Q&4'((ZJ0.1U%9[^ [FTL?#=KIUQ;L-*OSJ$\D^5-Q(V_?@ ';DN<=<<
M#FN\HH YK6O#U_>>+='UW3[NWA:SBFMYDGC+;DDVG*X(^8%>_'-9:^$-5_LS
MQA:&:RSX@DE=&#-^XWQB/!^7YL 9[5W-% %#0[.;3M!L+&X,;2VUND+-&3M;
M:H7(SZXSBN0D\%:M)H/B[3C<60;7[F29'!?$(=50@\?-@*/3K7?44 <C/X;U
M2?6O"M^9+-1HL<JRIO8^:7C$9VG;Q@#//T]ZV]?L+[4M)-OIUXEI=B:&6.:2
M,NJ[)%<@J",@A2,9'6M.B@#D]1\/:GXCU'1WUA;""VTN\6]4VSN\DTB A1\R
MC8N3DCYLX S5&W\*>)M%UK41H.LV,>C:E<O=2175NSRVTCG+F(@@')Y ;@>A
MYSW5% '$W?A37M.\5W&M^&-2LXQ?PQ0WUOJ,;R*QC&U)%*D'=MX()Y]?2SJ?
MA;4Y]6\.ZG::G$UUI8G29[J(L)1,H#, I&"",A>G;M737M[;Z=937EW*(K>%
M2\CD$[0._%-T[4+75M-MM0LI/-M;F-98GVD;E89!P>1QZT <N?!LUYK?BJ;4
M7@?3]>MHK8QQL?,C"(RYR1@D[L^V.]1P^$=5N]$TK0=9NK2>PTV:)S/%N\RZ
M6(YC5E(PG(7<06S@],\=1;ZM976JWNF0REKNR6-ITV, H<$KR1@Y /0FKM '
M'1>&-4BU#Q;=>99D:XJ")=S#R2L7E?-QSQSQCT]ZVO"VEW&A^%],TFY>*22R
MMTM_,CSAPH !YZ9QTK7JO!?6MU/<P03I)+:N(YT4\QL5# '\&!_&@"C?:5+?
M>(=+O7=/LE@LL@CYW-,P"*WI@(9!_P "K6HHH X.S\$:EIOAS4O"EI=VW]AW
MC2K#*^[SK6*4DO&%QM?[S88D8SR#BK^H>%KLZ_X8N]--K'9:$DJ)#(S;I%>+
MRP,@<8 ]\^U=!INK66KQW#V4ID6WN'MI249=LB'##D#.#W'%6+FXBM+:2XG?
M9%&I9VQG % $6IV0U'2KRQ+[!<P/"6 SMW*1G]:XK_A#=>?PYX7TR:\TYWT.
M[MIPRJZB1(%VJO?E@<D]!Z&NSTK5+/6M,M]2T^;SK2X7?%)M*[AG&<$ U<H
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M!IUOJ45G);RM:,P%XS[<-)\HP%VD@?,>>O%=E4-W=P6-I+=7,@C@B4N[D$X
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M_*)5M_R$ YY#9]NE=9>>']2N_%VD:[]HM%%A;30M#M;]X9-N2&[8VCL:Q)/
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M/!YFW.PL,9QWQ7/R^%-:N)O#$]QJ-D\NC2&1]D#*LN8S'@?,<<'.3G)[ <4
M4XO&VHZ5;>*8M96VNKO1;B"**2VB:)9_/"^6"I+$89L'!/%7[/5_$K>(UL3;
M"XL)[9F%XUC);BVF'16#-\RD=,<@]ZKW?@&35)_%BZA>1BVU\0E1 I#V[1*
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M?_A))EEM]7@NXEMS]JM6@\FXMI\K\I7.0OWAR.HZF@#L:*** "BBB@ HHHH
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M0Q$*%QDL<C"CL*A\2^%[S7=;T/4(-1@METFX-PL;VQD,A(VD$[Q@8SVKIZ*
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M9+<R[FC)('#K@<\U7UGP?>^)Y]/37M5@DT^SN%NOLEI:&+SI%^[O9G8[>3P
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M"L,%SR<OTP> .<#FD\->&M>TE+:UU3Q&-0L+(;;:-;41.X POFMN.[ [ #)
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M:6-06,F>=I8X 4@@#.3G Q[7QQK.O-X(GTU[6TAUU;E;B.6$N8Y(HV)(.X9
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M97STP<XQU'7'%5K3P-J<5]X<O+CQ&)9M$BD@0)8JBR1LJKC&XX;"C)R1Z 4
M<_<>*_%J>$/$6O#4;$-HFISP>2MIQ<)'(%P26RHQGIDY[UUIUNZUCQ?<Z%87
M)LXK*SCN;F945I&>0G8B[@0  I)."3D 8J@_P_N9?">OZ$^LQ;=8NY;IYA9G
M,?F-N90/,YY'!_G5J?P??Q^(X/$&E:Q%::@UJMI>K):&2&Y1?NG9O!5AZ[C_
M (@'%Z;J^L>'?A;KNI6=Q;?;8->N%E=H25?=<A&*C/R_>)&<_P!:[#4M4U^3
MXC)X?LKZUM[.;27NU=K;>\;"5$SRV&/)QT'/(.*J/\.;E_"&J>'VU[<NH7[7
MK3-: E"91)M ##N!S]< 5MMX<O&\:0^(SJ,.^/3VL3!]E.""P<MG?P=RCCT_
M.@#F8?&^KP^!_M=T87OHM:.D3W@CVQHHG\LS%<\<=LXR1VXK:TS4];/Q"U#0
MI+R&YTVUM(KGS7M_WN7W#RRZD*.5W#Y,D?G7.Z]I)\*^%WTV[UY8(M6U@W#W
MS67[F#>QD99068%"5VX)&=P!.,UH^#Y[R'5H[:R\0:%K>G2;C<?V99+#Y!"_
M*Q:-V4DD ;3R<Y' - '1^);V]LEL/LUS!:6TMSLNKAR#(J;20(E(.YV8  8/
M4\&N*NO&VO1_#OQ5JEO/#]MT749+6*6>U(:2,>6063("OB3TQQTKL?$GANYU
MG4='U&QU+[#>:7,\D9>#SHW#IL8,NY><'@YXYK!N/AO<SZ%XCTD^(&,.MW9N
MG9[12T;'9NZ,,D[!CH!SP>M %S^T]>L?'MEH][?P36NJ64\L:Q6X0VTD97H2
M3N&&[]QVZ52T[Q-K']C^(-/O[J-O$=A>"TA"Q!4;S2/L[A>?E;.3Z8;IBMN\
M\/7,WB?2O$,^IP*--MY8FB%J0) X&XYW\?=&.#^-9.E)H?B_QU!XJTB9KBWL
M[,PO.@98YI23L&"!ED4R9]/,7TH 9 NJ?\+B:UEU>62&+1(Y@AB0+S-M8 8X
MSL!)Z_@!7+V6J:WX?\#Z_KNG7EO'!8:[=.]J\&\W"FXPP+9^7@\8';KSQZ)=
M>&IY/&D7B.TU/[.WV(6<\!@#B1 Y<$-D;>20>#D=,'FL:3X>7,O@S5_#CZU%
MLU.[DN7G%F<IODWL /,YY'!]/6@#1N]9U.'XD:?HR30?V?=:=-<;?*^<.C(!
MEL\CYN@ KDKCQ9XMC\':_P"(/[0L0=%U*>$P+:<7"1R!2"2V5&,],G/>NTF\
M-WD_B[3]?;4H0UI:/:F$6IP^\@LV=_'*C Y_&LB3X?7,OA'7= ?68MNKW<MT
M\PLSF/S&W,H'F<\C@_SH T+W6KRX\<P>'89S8POIC7PN%16:1]X38NX$84?,
M>,\CIW7X?ZSJWB#PQ'J6KO;&2261$%O T:E4=DW9+-N#;<YXZURGBJ>*?Q=%
M8WOBC3=(EL;%%']JV,;V]PSDEFB$C  @* 2&/7'8Y['P=<ZA<:=,MY>6=]!$
MX2UO;. PQS)M'1<D8!XRIP?PH PH[F\M_BMKTMQJDILK/2H)_)\M2%3=(2H_
M[YSGJ?P%077BS7(/A];^.DFC>(A+F;3/+79]G9@,*_WO,"D')."0?E%=)-X6
M=_&4VNQW^R&ZM$M+JT: -YJJS$88GY?O$$8.1Z5F6W@&2#PZ?"\FJB;P]YF5
M@: ^>(M^_P HR;L%<\9VYQQ[T =9<,]SI<CVL[0M)%NCE"@E<C@X/&?K7CV^
M^G^!>AW=Q=M=37%[9R#S0!AC<@G+#DY/.37M112A3'RD8P/2N"3X=7D?@RT\
M-#7U:WM+B.6&1[(9"QR;U4@.,G/!.>0!@#DD D'B/5="\6ZMI^L7<5]:0Z,V
MK(T5OY1CV.59!R<CC()YI+'5O%]S/H.H064MQ97I0W\+B!(X(W7(>)@^\[<C
M(.2P[#I6K/X3>\\6R:U=WL,L,VF-IDMH+<@-&S;B=V_@Y]NGYU2\.>"]6T+R
M+&7Q1/>:):,#:V;VRK(H4Y17E!RRKQP ,X Z<4 :WBS77T#1XYX$1KFYNH;.
M#S,[!)*X4,V.PR3COC'%4-0U#6O"ZZMJ>H7$5_H=KI[7"LRA)Q.N<H H"[",
M8)Y!]:T_%/ARV\5>'[C2;J22$2%7CFB.'BD4AE8>X(JA8^%K^?3[FU\3ZT=9
M$]N]KA;9;=!&PPQ(!.7.!SGCL!DY ,G4O$6MZ#HVA^(;JZCNK6]F@COK41!5
MA6;&&B8?-\I(&&+9'I4$VL^*KO4?&=I;ZI96PT7RWMW%GN+ P^9M(+?@3S[
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MD'O765S7A[P_K>G/&VM^)9-7%NNVW7[*L..,;G()+MCCL.2<$\CI: "BBB@
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MQLY50,DX4$\ 5P6E:EK>DZEX(MI=0CGT_5[4PO:B!5$)2WWJRM]XGC!R<'/
M%=AXK_Y$[7/^P?/_ .BVH LZ/J]GKNF0ZC8-(]K.H:)WB:/>IZ$!@#BKU>66
MVK:MH_PM\!R:5<PPM<RZ?:2B2+?N23 (SGC^?H16F?$^I^&_$'B.TUB]&I6E
MCI*ZK$P@6)EY<-&-O4$J,$Y(]30!U>L^(;'0I-/CO!/NO[I+2'RXBP\QS@9/
M0?B>U:M>6>)!JMWI7@?5+W4C*;K6K"66V6)!%&7RP"$#=QT^8G/7BM2[USQ)
MK::X_AY+E)]/NWM+9$6W,,KQ@;A*9&W\DD?+C P>: ._HK@SJOB:[\=6NB->
M0Z='<:$;V6)(%D:";S$5@&)(8C) [>QXK"D\2>+$\!:UK1UF 7.@WMQ;L!9I
MB\$4F"7_ +N1QA,8ZYYP #UFJ6K:E'H^F2WTMO<W"1;<QVL1ED;+ <*.3US]
M,URE[JNO77Q!MM%L]2BM+&ZT=[O_ (]@[QL)$7()/)^8XSQSR#6)<^+O$4'P
MMU?4Q?0G5-*U&2R>Y-NO[Y5G$>[;]U3AO0CCI0!ZEN4,%+ ,1D#/)I:X._CO
M9?C/I\2ZI=1P?V--*L*A"J_OHP0,J?O8&3UXX(JHGB#Q9KNBQ:[X>MKB5FNF
M\NS?[,MO+ LA0@L6\P/M!.>!GC&* /1Z*X.]UOQ!K4NOQZ MU'-ILYM;81+;
MF.258U<^;YC;L$MCY<8 SDDX'8Z9+>SZ3:RZA;K;7SPJ9X58,L<F/F (/(!S
MWH ;IVIQZD;L1V]U#]FN'MV^T0F/>5Q\R9^\ISPPZU=KSNS\3>(F\+^*+H*U
M_>:;K4EI&MK  XMU:,,43G<P5G8 YR?7I6[X.UVWU^*[NK+7/[3M R*@DC6.
M:!L'<DBA5P<XQD?RR0#IZ*XGQ'J'B#_A.M+T/3-4AL[>^L;B0N;42-&Z;<-R
M?F^]TX'UJJVK>)=1_M?3].GNGO=)"6HN+>&W5+BX\I79I%D;(4E@,+C SR>P
M!V=UJ<=IJ5C9-;W3O>%PLD<):./:NX[V'"YZ#/4U=KAY-<\10>)/!-G?""T.
MIQW U"T10^)(X2W#Y/&[GC\S62^L^*KK2_&MQ'K<,$FAW4WD>79H0ZI"L@1M
MV>#D\]>>O&* /3JRM%\0V.OM?BR$P^PW36DWG1&,^8%!. ><?,.HKDD\0:_#
M?^#M1GOXI+/7F6.:Q6W55BWPF165_O$@C!R<'T%9>EVOB*:;QQ-H.KPV$D&M
M32*CVJR^<XBC.UB3\JG ' SSU[4 >K45YYHGC'4=9UGP?('$5IK6FSW%Q;;%
M(22,)]UL9QECU)[5GZGXM\16G@OQC?07\9NM'U=K2WDD@4DQ?N@ <8&?WAYP
M?I0!ZG17":]J>O\ A6".[U/49[O39KLFYN+&P7?8P^6<#;\VY=_5B"0/>@>*
MKA['0;6PU$:K)J]S<".]M5BW>3&&?@-M3>!M4Y''S'':@#NZRKCQ#8VWB.ST
M*03_ &V[C>6+]T=A5 "WS'CN.!GK7(W7B3Q1X<TO5&U2VW^9>06VCW-UY6^0
MS':?-6(X^0\\8W#THOK2\M/BYX4^TZE+>HUE>[?-C12K 1[L;% P>.#R,'F@
M#OYYXK:WDGGD6.&)2[NQP%4#))/IBLC3?%%GJ6J+IZ6]Y#)+;"[@>:':DT1(
M&Y6&<=1\K8;GI5#XDQRR?#G7S%<R0;+&9FV!3O78V5.0>#[8/O6'>7VO:/8>
M"[2PU9634IH[>4W%NC%5,)88V@# V],9/K0!Z-17$V6H:Q)XFC\)7&M&2YM=
M/-Y=:A#;1QO*6D*QJJ$,J@*.3@YXZ<U@ZIXT\0V?A/Q*JW,"ZMH.H16S7'D
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M5B"Q"EF.YL#)ST& !SD\4>'?^$CLK.)+Q[.XLKR*]@F5 ^)$)QE3U')K<HH
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MJZ1'/K;W,_B"\MX(RUNBBR786D*<?,3@ ;LX///?8O?!,&H:3K5K/?2_:M:
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MD%6()PW' )&"1ZYK'U/P(UWJ5GJUAKM[I>K06XM9+JV1"+B(<@.C J2.Q_\
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M;=5NG79\D42JI! ;+,Q ('?%3ZAX#M;[0)=*6^N(C<7HO[FY"J9)I@X<$Y&
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MS"N(_+$BDC(('.,XR,U:L_#FS7HM:O[O[7?06IM(I!"(_D9@Q+8ZL2H] .<
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M(X *D\=V';@Y^H7?C+2M)\-P:AJZQ7TVNQV,KQ*CB:!@S*7^48? &=N ?QH
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MI]0N[;^S;I+N%8 F#*N<%MRG(Y/%=!10!@KX95?%4GB$:C=?:WLA9%-L?EA
MQ8'&W.=Q)ZUD_P#"M=._X1V#2?[1OPUK>-?6EX&036\Q8L2I"@$$L>"#U^E=
MI6+K7B.+1-2TBSEM)Y/[3N1;1RH5V(V"?FR<]%/04 4+?P1"-9N=4U#5+W49
MKNQ%A<QSK&L<L>6)!54&/O=L?CFH_#_@./P^\2)KFK7=C;9^R65S*K1P>G0
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M*['0OL&W!)Z@]0.E7=3OI["WBDM]/GO6>9(S'"5!16."YR1P.IH RU\)6_\
M;VJ:K+>W4K:G;+:SP-L">6H(&,+D'YCW[U0;X?V[^%;/P^^LZF]M:2Q/%(QB
MW@1$&-/N8P,#MD]S7844 <1XH-CXKN#X-EL;R>:.>WFGN'MV2*-%(<N), 9(
M!3 [MTP#CM@ JA5   P .U8UGXCBN_%=_H'V2>*>S@CG:60KMD5R0-N"3_">
MN/I6U0!AV/AJ.Q\4ZCKR7]T\U^D<<L+A/+ 0$)C"YXR>_>LE/AW:0:Q>75GJ
M^J6EA?2F>[TR&4""5S]X]-RANX!&?I7944 81\,I_P )9)XB34+I+E[(60B
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M+K<4<5U'O0*!']PIA<@KGU/OFGVO@FVMM;M-8?5]6N+^VMFM?-FG4^:A((W
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MLWA7P OFRR;M:TYLRON(RIX'M78?\(I826FKPW;S74NKQ&&\GD(#NFTJ%&T
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MIS:_;_:<_=Z_*&]NM=#X<\%V_AUT(U;5M02%2EM'?W D6W7&/E  YQQDY('
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MSA=GS_)S\O';\^: .EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ<A5NTL;LPI=8&!Y@'?'&00:T!X7LT\11:W#/<PW$5G]BCCC*"-(<@[0NWU
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MX:>/[5;"^^T7>J7SVT/V20/*LC H57;D@^M7+Z?^Q?%L&K:GI.I7>CZCI=O
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MQSO;01%Q!.NT;B^!M;: ,<Y!/O52;XC^'((+R<S7C16-P;>Z9+*8^0PQDO\
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MT'2K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ:@!]DCC3YY3@D@ ], '.< 8Y- %?_A$X_\ H-Z[_P"![T?\(G'_ -!O7?\
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M^NZ#!;^(-0MKF^,<.H&.[^U"3*SD(-D:MR 2R@  <F@"U_PB<?\ T&]=_P#
M]Z/^$3C_ .@WKO\ X'O1J&OV#Z3K,>HP:C9QVMMNN@(V\Q8W5OF0QYSPK<@\
M8[8IUGK>F66@Z(+=KF=;VWC%C"V7GF7RPP)R>H7DLQQZGF@!O_")Q_\ 0;UW
M_P #WH_X1./_ *#>N_\ @>](WC;1H]*U._F>XB&EDK>P- QE@.,_,H!X(Y##
MY2.]%CXUTF_U>STV-;N.2^A,MI)-;LD<X4!F",>"0#GT]": %_X1./\ Z#>N
M_P#@>]'_  B<?_0;UW_P/>I[?Q-9W5S:QPPW30W4SP070C!B=T#%AG.0/D;D
M@ XXS6AJ.HVFE6$U]>S"&WB&7<@GO@  <DDD  <DG% #--TX:9;M"MU=W(9]
MV^ZF,C#@# )[<=*NUC6WB6RGU<:5-%<VE^\)GB@N8PIF0=2A!(..XSD=Q7'Z
M=(?&^N^(;6].KV9M+Y(K.:W<Q&U"1HWK@,Q+9R#D$#L, 'I-%<SXI\5/X?O]
M%LX[&>X;4;L0EXTR$4 L0.>6(7@?4^F>?AUP:/\ $GQ(TW]IW,1T^UFCLXED
MG=2?,+;4R=HZ9Z#/U% 'HU%8T'B?3+O2-/U*TD>YBU  VD<2?/*<$X .,8 .
M<X QS4FB>(+'7ENA:&1)[28P7-O,FR2%QV8?3D$9![&@#5HKB=4U>ZUKXA1^
M$;.YEM+2UL_MNHS0MMD<%@$B5NJYSN)'.. 15S4=/LM,O+![?7I;&2.=))+>
MYU%F6XCS@@B1B?<$8R1@T =516%JOBS3M(CNYI8[F:WLL&\FMXMZ6X(#?-W/
MRD$A02 03C(J&X\;Z-!J<>G(;JYNI;3[9"EO;._G1D@ H0,-G/;@ ')&* .C
MHK#L?%NDZCH<6K022^3+*;=8FB(E\X,5,>SKNR#Q[9Z<U5?QUHT%KJTMT+NW
METD!KRW>W9I8U(RK87(*D?Q X]2* .FHKEXO'NC2Q-($OE4O!' 9+5E%R\V=
M@B)X?.#R#COG'-+>ZY:ZWX>\16]N]W:WEA#)'/&6,4L+^7O4AE/<8(()!H Z
M>BN>\!RR3_#_ ,.RS2-)(^G0,SN<EB4&22>IK$TK4+CQIXOUZ%[JX@T719Q9
MI#;2M$UQ./\ 6,[J0V%/ 4'!ZG- '>45A0:1+I>N"]CU*Y_LI;219+>YN&D6
M-]R$.&8D_=# Y.!VQDTR/QEI;S:>)!<PV^HL$LKJ6+;%<,1E0#U!(Y&X#=VS
M0!L-9PR7L=VX+2QJ5CR>$SU('J>F>N..YJQ7+R^/M&CU2YTU(M1FN;6>*"=(
M;&5C&9/NL1C(7ISWSQFJ<WQ2\-PVS79.H-:1W#6\]PMC)Y=NP;;^\./DY['G
MVH [2BLJ[U^TM[J.TA26]NI(?M"P6H#-Y6<;R20 ">G//.,X-9T_C[P_!HEK
MJ[7,IM+BX%J&6!\QR[MI608^0@]=V* .FHKFX?&NG7#0116NH?;+B:6*&TEM
MC%+)Y8!=@'P H!')(ZXZ\5GZQ\0;6W\,V6KZ9;7%TMW>I9@>7@Q,90CAP<$$
M<@#N<=N: .THKFIM2TJ;QEH\$S:C#JCVTSP0,'2(IA=V\?=8CCU(S4E[XRTJ
MQCN;F07#6-K-Y%S>QQ;HH7!P0QZD G!(! .<D8- '0T5S]]XRTFQUA-);[5-
M>R6QN8HX+9W\U 0/D(&&//;.,'.,5=T'7K'Q'I@O[ R>7O>)TE0H\;J<,K*>
MA!% &G17 Z^UP/BUX:LDOKZ.SN[6YDGMX[N1$=D4;3@-QC/;K7<W5S!96DUW
M<R+%!!&TDDC=%51DD_0"@"6BL"P\7Z??WMM:)#=137=J;RT$L87[1$,9*\\'
MYAPV#STJJWC_ $9/#TNNLEX+"&X-M*Y@.Z.0,%(9>H^8XYH ZFBJ)U2(:I;Z
M<89Q/-"TX.T%54$ [B#P<D#WSQT.#4M6M=+6#SRS2W$GE00QKN>5\$X4?0$D
MG@ $D@4 7J*QK+Q-97YOX8HKD7M@5%S9-'B9-W*G&<$$<@@D'UKD_ 0/BS2]
M,\1WDNJ0:E'--*\B2%8IU,CJ(BIR&10%XP,%>O7(!Z&X8HP1@KX.TL,@'W&1
MFL3PIX=;PQI<EA]L^U(T\DX8Q;""[%F'4Y&3Q_6JEQXK=/'\?AD6%R8S8M<O
M.J=29$12.>%&6R?7%<OX8\7V?AVP\0'59=1G@M]?NHFN"DDXMXPZJOF.<X X
M[YH ]0HK,U#7(+&8P)!<WERL7GM!:IO=8\D;CD@<D' SDX. <&I='UBQU_2;
M?5--G$]I<+NC< C/.""#R""""/:@"]17F7]OV,GCW6-%\5:C?:;=&9?[)Q=R
M6T#P;1@H5(5G+;L[L]@.A%:^HZY?>"M#T2TNENM3N[O4DLS<D!B5>4_,W3YB
MG0#O["@#MJ*Y^^\8:=8-<H\-W+)9VJW=XD40+6T39(+@D<_*W R>.E4M3\;1
MVNO>';&SL[BZM]622=;B),AHUC+ *,@DY*'V'UH ZVBL'5?%VFZ/'=33I<R6
MMFP2[N88MZ6Y.#\W<X!!.T'&><5MQRQS1)+$ZO&ZAE93D$'D$4 /HKG6\:Z1
M&EO<.9UT^XF^SQ:@8_W#/G:!NZ@$C 8@*>QK%\0ZN]U\0-.\.SVM\^G-93S3
M1PJR^<V453D$$JH9OQ(]!0!WE%<UJ>F'1OA]?V<.H:A*]I93-%=2W+>?D*S*
M2ZX)QP/H!G-8GA?1+K6?AYI%_'KVL6^K7-E',;LWLDH\PKG)C<E",]L?E0!Z
M!17#^"O'#ZMX5:XUE535+2]?3;B.!2?.G7^XON#GT&"> *GUCQ#::SX8\46E
MM)>6>I:;9R--"S&&:%O++(P*GD'&002#0!V-%<EH/B""Q\)^%+><SW.H7^G1
M-##'AI)=L*L[98@<9Y)(ZCN:G?QWHR:);:O_ *2UI/<_9,B$[HYMVS8X_A^;
MC)X]^10!TU%9$7B*SE\2S: ([A;Z* 7#!H\*8R<!@V>1GCCO5<>+M/9+()#=
M/<7TDL=K;","27R\[R,D#:,=20#QC.1D WZ*YF;Q[H-OX>77)9;A;/[0;9\P
M-NBE#["K\87#<9) ]ZL6WBVPNHF,=M?B;[0UM';RVK1R3,JAB55L?+@YW' ]
M<4 ;U%9>B>(+'7XKEK-I%EM9F@N8)DV20R#JK#^HR#V-:E !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7(_$V*>Z^'>LV=K;7%S<W$!CBBMX6D9F)'90<?C7744 <;%J]E%H
MNF,FBZG<:E:QH((CIDZ;92FSER@"CYB"2<8S5*=;C_A=MI??8KTV:Z*UHURM
MI)Y0E,V[;NQCH,YSCWKOZ* /.O"UG=^ -7UC2KNTN9M$O;Q[VQO;>%IA&7QN
MBD"@E<8&#C!YY'2IM,@ENOBYJ/B&*RN1IHT9+;[1);/'OE$NXA0P#-\N.0".
MU=_10!YW\-[%8[;Q&=1TFXBDEUJZNHOM5DZEX6(*D;EYSSQU]JF^&L,UI>>+
M(YK"[M$N-;GNK?SK5XE>)@H5E+ #L>.M=]10!P-LL_\ PNV\OC97HLVT9+5;
MDVL@C,HEW%=VW'0]>E-\=027/C/P:ZZ?=W5O:7<LER\5I)*D:M'M!8A2.IKT
M"B@#SSQU9 :_X0DL=*N'%MJJ3W#VMD["./:1EBJ^I'%==XBT^;6O"NJ:=;2>
M5->6<L,;MD;69"!GN.M:M% 'EMS;7OB7X<Z/X8.FWMIJT,EI#<"6W=4M_)9=
M\@D(VD;4.W!.=P]\;OAM)D^)/C&>2TNXX+K['Y$TELZQR[(BK[6(P<$_X5VM
M% ')?$?2M1U7PGC2XC/=6EU!>+;@X\\1N&*?7C(]P*J7L3>*O&'A;4K.VO(8
M-+,]Q<27%L\)7?&$$>' )))Y S@+SU&>XHH XGP2)D\1^+FFL[R!+K4A- \]
MK)&LB")%R"P ZJ:?X^AN1=>%[^&SN;J&RU=);@6T+2NB&-UW;5!) )'2NSHH
M X;2WFC^)^O7\UA?Q6TNG6R)(UI(59D+EE! ()&X="<]LUQFF:=JFE^#?!6I
M7'A^^O8M):ZAU#3C;-YZI*W#JC ;MN >.Q^N/;** .=\*BQF2[O[#0&TF&Y*
M\S6P@FG(!^9EZX&<#=SUXQC.9,DP^,EM=?8[LVHT5[8W MG,0D,RL%WXQT!/
M6NUHH \L5%T3Q+K^FZYX2O=6@U*\>ZL[JVL_/21)% ,3GHN""/FXQZ#KK7-I
M-!\0O"!33)8;:TTZXAE^S6[F"W9A&%0,%V@?*0/IVKO:* /(]!MDL+.;PGKG
M@JXU#4(YY!#=-9B2UND9RR2/(>%QD9SR,<9/%=)XOTG58?$VD:YH,9-S.CZ7
M>%?X(9 2DI_ZYN,^^<5W%% '$^(GN-*U?P[I]OIUZ=%6*2*2>PMVEEC(50D>
MY06C5N[#'0<@9KBULM1C\!W>G'1-62=/$WVA8VM7<F+[2'W C.X!1G=R#V)K
MVJB@#B0LTGQA6\6TO/LC:#]G%P;:01^9YV_:6(P#MY_^O3OA8EU:>!+'2[VP
MO+2ZL0\4HN(2@+;V/RY^\,8.1QSUZX[2B@#S]]0AL/C3?M.DY1]"@&Z*!Y,'
MSI.NT$C-<_/H=]8:#:3?V;>DWOC!-8^S16SR/!;^:#E@H.T[5#8Z_-CK7H</
MASRO&,_B/[:[2S6JVC0>6-@C5BPP>N<D\_I6[0!Q&OPWFG_$+1/$JVUQ<Z9]
MCEL;@0Q-(]N7(=9"@!;!*@$@<=Z?H.B&\\4^+-8N+:1=.U=(+9(IHRAF6.,J
M[E3@@'=M&<' )Z$5VE% '#> -(U:PC>TU=&\O12^G:?(_6:'<&$G_?'E*/3:
MWK638VD<NE^.(-5T34KBSO=9\P0BUE5Y86\I/,3C)VD%N.?EKT^B@#S"UM-9
ML]!\6Z;]IU+5])_LTIITUU;.;DR,C@P_=#2 ?+\V.-V.QPVVM-1TV;P#KKV-
M[)9V.F?8+Z$6[F6V9HT&_P O&XC<F#@<#GFO4:* /+==TF[O4\>ZU;6=V8M2
MTM+&TA6W?S+B148%MF-P&6"@D=B>F";MREP^O?#J9;"_,=G'-]I;['+B'=;F
M,;_E^7YN.?KTKT6B@#R[2M/O+#Q#IMYX<75+6WN[QCJ>C7EN_P!GA!#%Y8V8
M )STP?FW?45T?Q'TK4=4\*J=+B,]U9W<%Z+<'!G$;AB@]^,CW KKJ* .'O(F
M\4^,O"VIV=O=PV^E_:)[B2XMGA*[XP@C < DD\G&<!>>HR[P0)H_$'BUIK.\
M@2ZU/SH'GMI(UD3RT7(+ #JIKMJ* .,\>PW(O?"U_#9W5U#9:LLMP+:%I71#
M&Z[MJ@DC)%0Z4\T?Q.\07\UA?Q6TVGVJ)(UI(59DWEE! ()&X="<]LUW-% '
MB>EZ=JFE>#O!.I7'A^^O8M)^U0:CIWV9O/596X=48#=MV@\=C]<>E>%193)=
M7]AH#:3#<E>9K8033D _,R]<#.!NYZ\8QGHJ* . UC2;_0/B5%XPLK2:]L+R
MT^Q:C#;KOEBP04E51RPX ('.,G!J/Q;GQ-KGA$:99W=Q]BU:.ZN'>TDC6*(
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M]3'#E Q_WFWOGN&%5_&5I?6_BCPMXBM[>>ZL],FGCNX8$+NJ3($$@4<MM(Y
M!.#TKM:* .+T^T>?XAZEXJ6&YBT\:7%9+N@=7G<.SLP0C<0 5 ..<G'2E^%<
M5Q:?#[3K*\M+JUNH#*)(KF!XV&978?> SP0>/6NSHH XF_2YLOBY9ZB;"\FL
MY]&:T$T$)=5D\X/AB.%&WG)Q^=<M/9WTOPU\>6:Z9J)N;W5+N2VA-E*&E61P
M491MY!P?IWKU^B@#R^_9]&\8_P!K:AX=O]4TC4]/MXEDM[-I9;66/=\K1XW
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M*\FT! C ,< $GC&2 ,\XE^%UM<V/P^TZQO;2XM;J RK)%/$4(S(S#KUX(Z4
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M);JYD6&"%#)([G 10,DD^PK%B\7V!O-/M[BWO+-=2XLI[B,*DYQD*,$E6(Y
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ML+@P,(S(LK,5W8QT(]J +4WC_2(;.UOC%>OI]W<FUMKN*'>DLF2H"A27Y*D
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M2&VNHKC3'$=PDRJI#$9&/FY!'(/3WJ]I.I1ZOI5MJ$,4L<-P@DC$R@,5/(.
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MRL1R P&>G7BLZ7XF:9'I=YJ8TO5WL[&Z>VO)5MUQ 5(4LP+ D9/\.2,9('%
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MB6Y'S*92%"E'! &%!+;<T >DT5E7NN06=_#IL%O/>7TD)G%O!MW+&"!N8NP
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MCWXJGH^GWFAW%]H%_P"!QJDC7<TEEJ8@B>&2.1RX,SMRI4L<\$X' /&?5:*
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M@;6?'"1%_FV[=V>HSCDU#I]G-XJ^&/A#18+.Y1U%C+/-+$52**(*Q<.>&+
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M^E;=0QVL,5Q+<*G[Z7 =R220.@YZ 9/'3D^M34 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %8OB;Q-:^%K"&]O+>YEAEG2#,"!MK.P4$\CC)[9-;5</\
M5G:/PC;ND;2,NJ69"*0"Q\Y>!GB@"]I_CFWO->GT2XTG4[&_6 W-O%<QH#<Q
M@XRA#$9]B01^>*^E?$;3]3TU=5.FZE:Z1]FEN'OYXU$2>6Q4J<,3NXXP#GH,
MD'"SV,^K^.=+U[[%<PVFD6DZ@R1[9)Y9=HVA3SA0IYZ988SS6!IOA'5-3^!D
MOA6YMY+#4S%(H68C&[SC(O*DC!X!^IH ZY?%L,6I:=9:CI]W8?VED6<L^PJ[
MXSY;;6.UR.0#U]<\5#J'C>SL;6XOEL;RYTVUN?LL]W JLJON"-A<[F"L<$@>
MN,X-9E_:ZEXQ'AF.ZTNYT^73]0BU"]:8 *C1*WR(03OW,1R.,9S@X%5/#7_"
M3>%C>^&O[ FNXS=S2V&I+(GD".1R^9<G<"I8Y !)[>M '3:MXKATS[?Y-E<7
MW]GQB2[\AD'EC;NP-S#<VWYL#L1ZBA/%UC>6]G)I4<FH/>6HNXHXV5,1'@,Q
M<@#)X ZY!]"1RUS9:GX?\:ZO</X5.OZ;JSQSPS0B(R02A%1D<.1A3M!SG ]Z
M-9TO5M)\3V&OCPU#J]G-IZV=Y8VBH6MF5V=6C#X##YRIZ9QGB@#H;+QWI6HZ
M-9W]HEQ)->7+6D5EM F\Y<[D(S@;0"2<XP,YZ5SFB703XC>-II]-NH]EA:F6
MVW*S/Q)DJ=V""/<?A4NLZ9K27?AGQ/9:$J'3+F=IM)MR@D$,T80G@[6D&,X!
M[XR<9,VGQZK)XT\2:M)H5_#9WNFP1P&3R]Q= _RE0Q.3N'T[XH GT_Q?H>B>
M$?#,MAI5_'IFI/';644:AS$6R5#?,23@'IFM;3/&-K>W&L6][9W6ESZ2BS7,
M=WL.(F4L'!1F!&%/?C%<9;Z+K,7@?P%8-I%U]JTK4K>:\C 7]TB!PQSG!^\.
MF:UYK2:+Q?XOU&^TUSI5UI4<*O,RI'+Y:R;U)SE00V,D>M &F?'=LK:,7TK4
M/+UI=UBZB,[_ )=V&&[Y25^8#T]^*Z'5-3M-&TNYU&_E$5K;H7D?&<#V'<GH
M!W->7Z'</8P^'O[?\/>)EBTA L$DL,+06Y9=FYBC;R%!(!(X')!/-=MX_P!
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M;95.&0;6.<<>W(KB+R._T^/P.\&BZA+JFG:>RSK:&(S1*(T1D9'8*R,W?/\
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MP]-ISD#IWKC_ !AJ;:Q+X(O_ .R98;>?7;5[:YD9=VP[B R]5W#! YZ<X/%
M'J%%<[=>*@K:F=/TV?4(]+;9=M"Z@APH9D0$_.P4@D<=0,D\53N/B#IXDT-;
M&QO=036HI)+.2W5,/L7<5.6!#=!S@#G)&#0!UU(SJI4,P!8X&3U->?WWQ(E/
MA7Q)<VVD7%MK6B)_I%C=,H,6Y25DR"0RX&>.N/0YJY?ZQ:-_PBG]MZ)/)<W5
MY&+64LA6&;82'.&SR-W8_A0!J:AX/LK[6)-5AO=2T^]E14FDLKDQB8+]W<IR
MIQS@XS6MI^G6^FP&*#S&+-NDDED,CR-C&68\DX 'L  .!65=>*")]2BTW3I]
M1_LS NS$ZKAMN[8F3\SA2"1P.0,YXJC+\0=.*Z!)96=Y?0:YN^RRP*N,JI8J
M06!#<8Y&!SDC!H ZZBL+P[XE779]2M);">POM.F$-Q;S,K$;E#*P92000:GU
M#7$M=5M])MH&NM1GB:=80P4)&I +NQZ#) '!))Z<$@ UJ:LD;.R*ZEU^\H/(
M^M<A>>,C>>$?$%WIUK/%J>EI-%<6TA4/;R*A(;KAEZ$$=1^51^!=%LIM'T/7
M9=+-MJ::='%]I\P;KA7169GVGYLGGYN<D^M ':T5STOBD&[U"&SL9+M=.G2W
MNC'(H=&8*V0IY*@."3QT. <4^V\3+=:QKFEI8S"ZTA(I'!9=LHD#%=ISZ*>N
M* -ZD9E12S,%4=23@"N:L?&MGJ>CZ+>VEM.\^L*S6EJQ4/A1EF8YP% ZGGJ
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MWB7C69.UDV^:Y0K(1N! W'IR?44 >@7%O%=0-!.@>)^&0]&'H?4>W>I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXXM%O+N&T@$\T\;Q*@X8[1N8$D!<\#N*I:3XTEU>STR]A\/:BMEJ()AG,D)
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M@;>80, &7RG/IR>.,Y'M0!V]%>4W)U?P_J_BW08M;U*XLUT)M5M)YYS)-;2
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MG RV/IZ_3UJQ0!BZ%X8L/#TU_-9O=/)?3&><SW#29? &<'CL.>M+J/ANUO\
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M[6&UMXUC@A18XT7HJ@8 'X"I:** "BBB@ HHHH **** "BBB@ HHHH ****
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MDDVI*W]XHP*[O]H $^M%OX1TNTT_4;2$7"_VDS/>3><QDF)&"2QZ<<<8QVH
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MW7.2"<CK6[/=W/A/QCXB@LKF\N;:/PZ=46"ZN7G_ 'ZNXR"Y) ( R!Q72_\
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M[8W9[>@KL/%0U#1;RSGMK"_U;1(+=Q=6MK>R&ZB9FR)AEMTG 8 9R.<5M?\
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M\QSR>IXSTK1^*<LMMX"N[NWGF@N(9K<I+#(R,N9D4\@C@@D4 =G17%7K2?\
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MU/8V+W4-L;CROGDB4_.R#KM]6]!WZ9%2V5Y;ZC8P7MI*LUM/&LD4B]&4C(-
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M4(X/LRRFX<CR\YVE<X/(STZT:'X<TSPY#+#I<#PQ2.7V-,[JN220H8G:,DG
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MC\[Q3XHU?1+V^M)_LMA:F#SH6_>*\>7GC4.,'<<9Y(P "._2ZCX!\,:KK?\
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M,I^QH4MA-<22B!2,$('8[>...W'2@#RK2+@:!\(=.FL@UJ+W6?L=W<1,5:*
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M!\P +L49& #DDY/-:VCRQ^*/&WB2PU<BX33(K6*VA;*J!)'O:4+V8D\-U
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MF><1^2);BXDF=4SG:&<D@=.!UP,UGOX"\-2:?>6!TX_9+R7S9X5N)0K-NW<
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M\UI?LL"0^8W5MJ@9/Y5G+X.T-9YY%M'"7$WGS6XGD\B23.=S1;MA)/)XY/-
M')^'K^?Q3XKET_Q%"&^SZ)9W"6D@PC22KF63;W(;"@_PX.,9-<SJ"37GA.6Q
MU%I+N+2?%\=C93SL6<P^:G!8\D@,5S[8KUO4?#VFZI?6]_<0R+>VZE([B"9X
M9 IZKN0@E?8\4RZ\+Z+>:%_8L]BK:?N#^6'93N#;MVX'=NW<[LY)[T <EJ&D
M6=W\7+'3W61;0>'I08HY&3<//3Y20<X]L\_2M#X922?\(W>VCRR21V6JW=K
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MXDBSVVOV2:T:.&T8E+82HGF-'P,$ ELX'(SBN[@\.>'5U6RU&SE"1W=HUO\
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MYMBLOS"%GMS(R+GH%)! [9JGX@TC38_V?+&=+&W64V5A)O$8SN9H0S9]2.M
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M1CR_XC_NC@]*X&;5;WP_X>\=K"XM8K;5K=-MJQVVL4HB\WR^A'#-R ,$YP*
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M3;A?W$\1C.W@KD<$>A'4>F* +M<[XY\07?A;PC>ZS9VL-Q);!24F<J,%@N>
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M(7V!7*#<RKGD97'!J6?P#X6N3>F;1H&^VR^=.-S8:3(.X#/RDD#)7&>]=$2
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M%!JEHMQ'%*)H\L59''1E92"#]#5>V\(^'[.2^>#2;5#?H([D;,B5<8P0>,$
M9]>]:.G7\&J:9:ZA;$FWNH4FC+#!*L 1^AJR"",@Y% &+H/A'0?# E_L?3H[
M4RC#,&9SCT!8D@>PXJ$>!_#:Z1-I*Z7&MA.^^2!7<*QSN .#T!Y"] >U;Y(
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M6C^C9SV'?L* .(U!+'0KSPKX<M-05]$DN;N)GU >?$9E ,<1P5! +.%!. 5
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M#S!!:>)?!/C^^U6&*?4[>>^A_>@%[98D/E*O=0 ,\=22>YJPL2?;/A/.,[S
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M( B-Y498HI)V\D_B3737#6L7C?P?H[06Z:/+9SRI"B 127052-P'!(4DC/\
M>S0!Z,)$:/S ZE,9W \8]<TTSPA78RH%3[QW#"]^?2O&_$UB+6S^)NG01+_8
M\-I#=0PX^2"Y9"7V#MGAB!ZCUKI=2\)PV^C:;/X=%A:ZO//!<%+L,T>H/'"_
MR2>IP6;/7*YZ\T >@JZNN48,/4'-))+'" 99$0$X!9@,GTKEO -_%>Z=J2?V
M.=(O+>_>.]LPP9$FVJ24(X*D$-]2:SM-\G6?B9XLT_6K>*X%O;VJV4-P@9?L
M[(2Y4'U<X8^P'84 =)XJU]/#'AJ\U9X_-,"@)'G&YV8*HSZ989]J=I?]O+J-
MVFI2:?/8[5:VGMD:-]W.Y64LPXXP0>_2O)]0MVE^!^JI?(MS%8ZHUOIT\XWM
M]G6[1%PQYQ@%?H!7M-M:V]E;K!:V\4$*YVQQ(%49Y. .* )J*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *AN[.VU"TEM+RWBN+>5=LD4J!E8>A!ZU-6!XT
MUB\\/>$M1UBQ6!Y;.(R^7.A*N!VX(Q]>: +]GH>F6$4L=M9QQK*H20C)9E'1
M2QYP,G [9J33-)T_1K7[+IEG#:6X)(BA0*H)Z\#BHM(O9;C1K"ZOI(%GN8D?
M$8*+EESM ))-78+B"Y0O;S1RH"5+1L& (ZCB@"OJ.DV&KPI%J%I%<)&XD3>O
M*,.C*>H/N*:-&TU=.DT\64(M)<^9%M^5\]=WKGOGK6#KGB:XL_%?A[3K&XLI
M;:^NI+>[0#=(A6-G&"&P/N]"*Z9[NVCN4MWN(EG<92)G 9OH.IH H-X9T1])
M&E-I=JVG#&+4Q@Q<?[/2G3>'M'N5M1/IT$@M#NMMZY\D^J^A^E79;NV@#F:X
MBCV+N?>X&T>IST%!N[8/$AN(@\PS$I<9<?[/K^% &=J'A70-5U.'4K_1[*YO
M8<>7/+"&88Z<]\=L]*=K7AK1/$21+K&EVMZ(3F/SXPQ7UP?Z5?ENK>#?YUQ%
M'L7>V]P-J],G/054U22]:TMY--N[.$F>(O)< LKQ%AN"X(^8CH: $G\/:/<R
M6<DVFVS-9 "U/EC]P!_<_N_A4%QX=M+GQ5::\\$*W5K$8TF5?WC@AAM)_N@,
MQQW)!XQS,NOZ<_B"30TN4:^BA$TB!A\@)PH/N>3CT^HJ[]KMC=&U^T1?: -W
ME;QOQZXZT 0:IH^G:W9_9-4LH+RWW!Q',@8!AT(]#5,^$O#I^T_\22P N8UB
MG @4>8BC"J>.0 !Q["M.6[MH9XX);B*.63[D;. S_0=ZFH S#X<T8RV<ATVW
M,ED,6K%.8!Z)_=_"JUUX-\-WUY<7EUHEE+<7*[9G:(9D^OJ??K6Y7"ZCXZN?
M#OCR'1=;CMQI5U%&8=0B1D$,CLX1)<D@9\ML$>GUP =K;6T%G;1V]K#'!!&-
MJ1Q*%51Z #@50LO#>C:<4-GIT,(C5EC5!Q&&^]L'1<]\8S46HWVHP>(=+L[=
M[46UWYGF>9$Q==B@\$,!SGTX]ZTWN[:*X2WDN(DFD^Y&S@,WT'4T 9G_  B?
MA_\ L^73_P"Q[/[',_F26_E#RW;.=Q7H3GFG3>%M!N+U+V?2+*6Z2+R5EDA#
M,$Z;<GM4ESK^G6NN6NC2W,8OKB)YECW#(1<#)],D@#UY]*Q_"WB2ZU"?7HM8
MGLXS8ZJ]C T8\L.H1"/O,<L=Q[T :@\*Z"MO9P+I%FL5D=UJ@B $)]5]#[]:
MLQ:-IL&J2ZG%90I?3#;)<*N'<>A/<4V\-^-5T[[/<VD=H6D%S%*I,DOR_*(S
MG P<D\'BK,E[:PY\VYA3#A#ND PQZ#Z^U $.HZ/IVKI$FHV4-TL3B2-95W!6
M'1A[^]1C0=*6_EOUL(1>2IY<DX7YW7^Z6ZD>U79[B&UB,MQ-'%&.KR,% _$T
MY'61%=&#(PR&4Y!% &2WA30&T9M'.D6?]FEM_P!F$0"!LYR!V.><BA/"GA^/
MS-FC62F2$0.1"H)C'\'^[[=ZT[BZM[2+S;F>*&/.-TCA1GZFG/-%%"9I)42(
M#<79@% ]<T 5(-&TVWTHZ7%86ZZ>5*&V\L>7M/4;>F/:HM%\.:-X=ADBT?3+
M:R25MT@@C"[CVR>]7H[F"6W^T1S1O"1GS%8%<>N>E(EU;R3&&.XB>4*'V*X+
M;3T./3WH @U/1]-UJ".#4[&WO(HY!(B3QAPK#H1GOR?SJ*]\/:1J-RES=Z?!
M+.D?E"0KABG]PD=5_P!D\4FE>(--UJ6^2QN8YOL=PUO(58$%E52V/8;L9]0:
MN6]Y:W@8VUS#.$.&,3AL'T.* )8XTAB2*)%2- %55& H'0 =A6?-X>T>>_GO
MY=,M6O)XO)EG,0WNG3:3U(QQ]*-,FNXK&9]5O;*5UGD'F6XV(J;CM4Y)^8#
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MC(K/UKPAI6L:&-(:QMA;&7S263+(Q!S(O_33D_,3U.>>AVFO;5+D6[7,*SD
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M !1110 4444 %<E\4#CX8^(O^O-ZZVJM_IMCJEL;;4+.WNX"<F.>,.I_ \4
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MBNI-G-VL"B0YZG=C.?>M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex31-restatedcharterasam007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex31-restatedcharterasam007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 2/7( '-5RR-X'^)L04F6ZO[QH$VG=,&B4*4'\0)!P1Z4 =S?^,+:R\7Z?H
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MRF6[99D+.%D^? 4=3UP>P!/0W<\#?&+2KA75H1HTR&4<H&:1&4;NF2 2!Z4
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MXCV@GH"<' [T 5-1\9G7O!GC&;3C?V$^EK<I#+Y#QMF*,')9EP#N)^7(; '
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M$;@P )((X STYK0T[4[;5(I9+;S1Y4IAD66)HV5QC(PP![CGH>U %RHYXC/
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M@#HJ*PG\8:+%<VT3W+K'<W/V2&X,3>3)-R-@DQM)R".N,@C.:Q_#MY-'X_\
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M3?N ;&"1N'>E\<B2WU_PAJ1M[F6UM-1<SM! \I0-"ZJ2J@G&2!TKMJ* //\
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MA6;+&X<6Z?)(I1LA>A!&1SZT 9=MXUT>ZGL4C>;R+^9[>TNC$?*GD7.55O\
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M!&0 I '+$&L_4X[Z+P%XY\.#2-3EU&?4KF>)8[1RDD4DH9&5\;3D=@2WMUH
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M">>M 'I5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNP>06(4@D*&(!&14%_XYT6QFTN/?<W)U2-I;-K:W:190J;N"!@DC& .>1TH
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MZJ3[ @5B^&/$5Q8Z)9Z5KNE:G;:I9Q+!)Y5E+-%,5& Z21J5P<9Y((S79T4
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M(E!&6.222N1\O7D4 /\ ^%FZ.=._M'[%JOV%+HVL]R;;"6[!]F7R>F[TR1W
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MS/*^U68G))Z9 (SP2*[35O%5KI27T@L[R\BT]=UZ]JJ$0#;NYW,"2%(8A<D
MCU%>>VVE:I%\(_#6EOI5\+^TU*&6> 6[%D1+@NQZ8QM(-:+V\^A>+M;74/!U
MQKMAJTZW=I=6]K'*R,456BDWD; -HP2<<_D >CV=];:AI\%_:S++:SQ++'(.
MC(1D'\JX;P1*WCZPN?$NJO+):SW,D=A9B1EBAA0[02H(#.2"23G';%=OIT!A
MTRW@>V@MRL8!@@&(X^/NK[#I7">#H+WX>P7/AN^TZ^N-,CN))=/OK.W:=3$Y
MW;'5 65@2><8.: .B2"#PF^K:K>:E<'2C%$R)/*\I@*E@57.202RX')R<#L*
MFB\4VO\ ;,&E7MG>6%W<Q-+;)<*I$X7E@A1F^8#DJ<'VK&\;:=JWBKP?=QZ=
M:M%-%+#<6D,_R/.T;AR&'\(.  #@YZXIM_#-XK\0>&+^*QO;2'2Y9+NY:YMV
MB9"8]HB (^8DGDKD87KR* +-K\1=-O6?[/IFLRQ133P33)9,R0O$"6#X.1G&
M!QZ9QD5#!\3]$F&E3-:ZG#8ZFRQP7\MMM@$C=$9L\'MQD=>>#B#P=;W5KX<\
M31W=G<VSRZC?7,8GB*;XY&+*PSZCMU'>N<TJTE\5?!OP[X>MK.Z6>46OF320
MLL<,:2*[2!R-IRJX !)RW0<X /0KWQ1;6LU]'!97E^=/4&[-HJMY.1NP=S L
MVWG"Y."/455N_'NBVRZ.\7VJ[CU@$V;VT)=7PI;&>.3C&.N>N*RM#2^\*>(O
M$T%Y87MS::E>G4+.XMH&E#EU :)MOW""H +8&.]8>G>&M1\.VWP^LI+.XF;3
MKFXN+QH(VD2 2K)@9 YPSXX],T =>OCFTD11'I6JFZ%F;Z:S>%8YH(@Q7+J[
M 9)5L $DX^E5=5\<F-O"[Z383WEKK<H*S(47Y/+9]H#,/F.!UP ,\YJOXA.K
MW/BN[L9M+O[G2Y-/ M#:86-YB6W"9LC@#&%)V]>"<5@6.GZQ;>%?A[-)H>H;
M](N0MU;A 95'DLF[;GIN/?'KTH [2SU#1Y?'6H1K#=PZM%81M</,2L0AW-C
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MBQKM4YY; ;CMCDBKO@O2K_1]=N[6SNM2F\,_94:WCU)'$EO-N.8T+@,4"^O
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MG::VTI%5XI"P,:2%2-H(R6*D MU) Y +&L_$!8_"=EK.D6-Q<"[OH[,APBM
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M^L/AZ]A@U;3XULP61B[^0R;6PQ.XLV3U[DGUNRV&HFW^':C3+LG3&0WH\O\
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MJO=6[2I@21E$4$>G*G@\TW4K34;;XHZ=K$.G3W5D^ERV320E<1.94<%\D87
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUN/3K.[NL.\22B,Y8X^;;N8C/MGBM+5+ :7\5?"<@N[RX0V=\2D\QD.Y43+
MGD$Y' XXX YH ]%HKS32YO%/B/0-&\2Z;>P0332+<S^;?.8&@).^(Q;-JX'
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M4YLUM+G4KN6^GB&,HSGA3CC(4*#CC.<4 8?Q9MUG\'PLSS*4U&TQY<K(#F9
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M @.68D_-D8 'K7/6&OZWXFM_AY<3:G=V3ZH;N&\2V(19/+CD&_&.IVY'89!
MXKOIO"5F=6O=1M+N]L)K]0MXMJZA9\# )#*=K8XW+@^])/X/TV2YT6:![BT7
M1@1916Y4(F5VG(*G.5XY_G0!R@TO41\08_#!\4:VU@N@^<SFX7SF;S]N=X48
M.,?-U]^367I_B;6[.*+PU>:C/.P\3'2?[2<_O6MP@D +?\]#D+NZ\\<\UT%[
M9W%W\98[B,ZG:PIHA@%W!;GRS)YV[869"A^7FMZX\%Z-<Z$=)EBE,9N/M?GB
M0B87&[=YP?J'SW_#&.* ,22:_P!)^(0T""_O'TW4M,DN%\R4RR6LL; %E=\G
M:0PX.<'IBL/P^-1E^%T'BB]\8:C:W<^G&-I9V\V&,F3AQ'C)D_A!SG+=.@KT
M"W\/0PSSW<E[=W%_+ +?[9*4\Q(\YVJ H4<\GY>3C.<#%%/ FD+X*/A-WNI-
M,P FZ0>9'AMXVL .C#(SG\J ,329[J3XA7^AR-J<&FW&BI<B"YO&>57\UD+*
MVXLF1V#=L\&N5L6NM+_9QBU33]1OK:[\I7WI<,?^6^T@9SM!#'[N*])L?!MA
M9:]#K?VO49[^.V^RM)/=,WFINW#<.AP3T&![9JF/AUHZ^%I_#BW&H#3)G!,7
MVC.Q0^\(I(.U=W/'/J30 R;4)-8^)%SX=EGN(+*STU+G9!,T332.Y&XLI#84
M#& <98YS@8X[4]<UZ'PEX@M/[6NUN-&UR&S@O%(#S0O)'A7.,DA7P2,9XS7H
MU]X7M;W4K/5!=7=OJEK$85O8"@D>,\E'!4JPSS@KP>1BJ][X)TN^T-])>2Z2
M"6Y%W.Z./,FFW!][,0>=P!XP. .@Q0!EZ>;S2OBJVE?VI?7=G=Z.UX\=U+O"
MRK,JY08PH(;H,#VIOQ@MTF^&.L2,\H,4:D!)&4'YU'S '##V-=#_ ,(W;_\
M"31:^UW=M>QVIM!DIL,9(8@@+W8 Y_IQ3_$?A^U\3Z+-I-]+.EI/CS5A8*7
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MX+RY@6W?E"H1<E<#;V))_GFLMOAQH<GA:+P_(]XUK;SFXMI?."S6\A8L61P
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MQ;AIPQ1HSF,<J?E7L/SS0!@W.K7_ (2\0^+(8KZ\O[>UT)=4ACO)3+LE!D!
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M3G=CH!@ ]*HKS#Q-J6J:<\EYJXOKK19=/BC;4M%N'!L)MI+R&-6!*G<K!N<
M =Z])M9HKFS@G@E$L4D:ND@Z.I&0?Q% $&K75[9Z>TVGZ<=0N0R 6XF6+(+
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M0M#%-<7CL=IQP1T/0=1@]\FF/X!T>30M0T9Y+QK'4+@W5RAFY>0L&)W8R,L
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M[S/ I7<\A<@9)"[CRVT$+D]<5#;^%]/M]4U74#YLLFJJJ7B2L&2157:HVXP
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MN#>27;/<-(HPI+MDD <8Z8[<FM'3='MM-FN[A&DENKMU>XN)2"\A5=JYP
M!@  #\2:T** .>U'2'@\56?B6TC,DB6S65W$OWGA+!E9?4JPZ=PS8YP#8'AN
MT77[G6TGNDOKF 6[L)!CRP20 I&!@DG/6MFL^WO;L/J+ZC:1V=K;/^YG\\,)
M8@H)<C'R8.1@^E &.O@+1T\/6>A+)>#3[.<3P1B;E7#;A\V,G#9.":74O >C
MZGK?]KM)?VU[)&L5R]G=O!]J0=!)L(W?I71P3QW-O%<0MNBE0.C8QD$9%24
M8UQX9L+C6-,U/,T4VF(T=HL3!4C5@ PVXP00 /PXQ6=>_#[1+Z75C*UZL.JY
M:ZMH[EEA9R IDV=-V .?4 XR!755A>&/%FG^*XM0DL"<65V]J^3][;T<?[+
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MV[P6Y.<E(R< \GGD\FK=IX2L+4V2M/=W$%C+YUK!/*'2%\$!AQDX#-@$D#/
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MU%X?\":%X9N?/TV&X&W(ACFN9)4@!ZB-6)"Y]1S[T 4?BU_R2OQ!_P!>X_\
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ML\2202(8WC9<JRD8((],5CZ=X2TO3#:"(7$D=EG['%/.TB6^01\@)[ D G)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/7S/ES\PSR>>0*JW<\Y^#-GXTL[R4Z_''%>&Z#DF60R /$PS@IR5"=!@8Z4
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M^HF]TK6;S[%*;V0F'RY%"_Q?-QQ\V>*]H0"YLE$HR)8QN'3.1S0!-2,6"DJ
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M&G121BZG:XFWSO)OD;[S?,3@GOBM.B@#'O/#&F7UU=W$RW :\01W*I<R(DR
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M,P9&Y.X.#NW9)R<Y.3G.:WJ* ,[1="T_P_8_9-.A:.,MO=GD:1W;IEF8DDX
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MS/<22F%#C*IN)V\ #(YP *V*Q=:UPZ?J.E:7;HC7VJ2R1PF3.Q D9=F;')X
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M6\9/W,X9MPZ\YX%;Z_#OPFD*PKHT7EI<"YC3S'Q')DG*#=\HR>5& >XJ74/
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M,>>O->@S0Q7$$D$T:212*4='&592,$$=Q65IOA?2-)>!K2V<?9U*VZR3R2+
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MDTC0]/T*"6'38&ACED:5U,KOESR6^8GDGKZT <A!KD>OZ+>>,-+A5OL.D/\
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M>M.96W AR-[A",<;6R<\XP* *>D6IA^*%SI<EA!96-UH EDL(I-R,1-L#.
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M#>: %V <8 ())R<FE\8F&\LO&ES:N][=6-DA>XG;RUL)%BW 6X +!CPQZ#)
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MCFJ,/@/PQ;Z^VN1:1"FH-)YI<,VTO_?V9V[N^<9SS0!T=%%% !1110 4444
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MB9"PE5,$= .3Z]JXFVT]/&NF^(&O=4L[+4+/4YUDN6MR;FQ$<A\LI)Y@VKL
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M6U"]2T"&SLI3;R2GDR3#&X+Z!<X)[G(XQD@!-X;TBXN;"X>R42Z>NVT*,R"
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MWRZ;=AV!^\ D>/YG\ZY&XT+3)/ /Q%NGM$:>RU:]:TD8DFW90A!3^Z<]QR0
M.@KUP>'-&%W:72Z= D]FFRV=%V^2O<+CH#W ZU$/"FA"TN[0:9#]GO',ES%S
MMF8]6<9^8GN3UH Y>[>23QMH5Q?(-0LY=%D!M!M=HI2R$S%#U# [,]>3VS6K
M\//#LWAWPWY-U$L5Q--))LW[C'&78QH2"02JD#CCMVK(\1^$WNM<C,_A.PUW
M2(K5(+2/SUBEM2"2WW_O _+CYN-O Y.>@\(^'8_#]M<B&SCT^&X<.MC#,TJ0
MX&"<G^(]\<<#KU(!R7C!=/U"[\:K#&D]S9Z2JW4EZP9+;]V[HL"XR&;.2V0
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M#!V2/UW,.A/U]J .3NY4UGXC:GHNIS6 7^SH&LH+ZV\U9$;?YI0;E&<X![X
M]*H:KX:AT?P9HVN:?<-K-UX8F:1;B1 7N+97821Y[[5SM/;8,5W6J^$/#VN0
M6T&J:3;7:6PQ#YR[B@] >N/:J^M1ZV@M]'T+3+--.F@:&2[:8)]C&,#;$%^;
M S@<#.,X% &#/90^)M UO7+2Y@LY=7,5M8W<D?!A5PJ!NY61]V?577TJQX*N
MV.O:OIVJ:##I6M)! UP+4AK:YCRX61.,CG<"#SP/2NJ?1=.ET5-'EM(I-/2-
M(A XRNU,;1CVP/RI]CI=EIS2-:P[9)<>9(S%W8#H"S$D@9.!GC- %L
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MI=/@6>R79;.HP85[A<= >_KWJ"7PAX=GUU=<ET:S?4U(87)B&[<.C>Y'KUH
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MC6^D6L6G2MNDMU3"R'_:_O?CZ4 <:=*L=+\=^!)K*W2&6_M;J.\D'+7"B!6
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M9>P&+1B3F ?['/'''';BN 3P0]U=W!USP)I>H7\T\DCZG'>"*.7<Q()7&]<
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M-]E_:89U!V@SH#UZ9% ':2W=M!&LDUQ%&C'"L[@ GV)I[2QH0&D12>F6 S7
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M@6:,S*,M&&&X#U(ZUYGI;^)_"/B*\\*_VG)K=H^E37FGRSC-Q;LG"HY_B!)
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M!. <$_GQ4E>=?"'0M+C\#:'K"V47]I&VDB-SC+[#(?ESZ<#CM^=>BT %%%%
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MG# $=1D=Z;#?V=S-+#!=P2RQ?ZQ$D#,GU /% %:PT'2=,D5['3[>W9%*)Y:
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MMW\N9(Y QC;&=K =#CL:L57M["SLYKB6VM889+E_,G>.,*96QC<Q'4X[FK%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&^UQ^8K.^XG;GH!QUZTGA*[\0Z=966A:I<Z*MIIX6,:E%?!GN(DX51&1\I(
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MJ>G^1837%P0UEF(J\84*>68YW C/<G %6#H&O/-X'EDL[<'1@WVM4N,]83$
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M1N=R 3DD< < =\UM^'HM0M]"M(-3BMXKF*)8REO(9%&U0/O$#.<9Z<9QSC)
M.='B.[.H^-(+72K&WO\ 2887$Y<L+C=&SJ7(4'@#&.>XSWJGI'C&[T_P3X6N
M=8DM(YM52*-;R>8^6"8B^Z0X&&)& ,XR>M7[3PWJ?_"1^,+NX%M':ZU#%% R
M2EG39$8R67:!SG/!-5M,T'7;?P?I&AZII>DWUK:PBUNK4S%Q+&J *ZED W9
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M^+%06HU;Q%("RM*1'"BJJ(N[;DD*N3QU)[#-79_#VK6WBG3/$]C%!)<II_\
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M*/"]IJTMN+>:4NDL0;<%='9&P>XRIQ0!NT51UJ^FTS1+Z_MX$GEMH'F$3R%
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M<9I&6)3Y[Y/ +'GH/UJ]I_Q ^W^'-%NVM5AU#4YI8/*^:1(FB+"1OE&Y@-G
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MNSE5[*   >Y]AS:>!=?B\(PZ9'=:?]H@U@ZEL9G,%PAD9S%)\N<98=CG:.*
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M8265\ET]O=[O)N%4$;6V@G@D,.#R!0!DVOQ ,>A^*KZ[BANCH+D"2SRJ7*E
MZD D[>N#R1WJPWB;6[;Q+H&E2P:?<1ZQ;O.)8R\?D[ K./XMW##!^7)':LC4
MM-U/PSI_C+5-1U+3$BU@1B%O()"3,BPJ&#';LSCKD8.3@ BET:WUWP]?Z8US
M8^')X'\NRB:SO)WG2)B!^[$F1M'WBH(X7/:@"[=>-=4T^^TM;ZVLX?M^J"P.
MGDDW$,;,RI*6#$8.T'&T<-UXK3@UZ_F\;ZSHHLK,?9;&*X@D\QMTFYF #G'
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MK5M].\7WND7T>MW.DFYDM7MX8K+S%B+,,&1V8$Y] !QD]<C&<?!^L_\ "/\
M@[3@]@7T&X@FE<ROB41QLF!\G&0V>>F.] %NT\7W&IZ_>Z;9S6"7-E?BWET^
M=66X,(8 S*=P!&TEAA2,=\U6U+QMJAMM1O-#T]KU+"Z>W%J+*>1[HQMMDVR(
M-J'.X $-G;SC/#]8\'W^OW=O)?Q:<L]IJ(N;75(787,4(EWB/&WD[?D^]CG.
M"1RRU\,^*]"UO4DT+4M,_L74;I[MEO(W::UD<Y?RPO# G) )&/SR =O;S?:+
M:*;RY(_,0/LD7:RY&<$=C7&_%3_D2Q_V$+/_ -*$K4AN=:A\9)I^^TGT86><
MC<;B.08^:0_=PV>!U.">QIOC?0K[Q'H"Z?8O;I)]IAF+SLP $;J^. >NW% "
M3Z[=1?$6RT)K2V^S3V$MRMQN)DRK("N,8 Y]\X'2LB;QKJEC?Z.E_;6<)U'4
MOL3Z?DFXMT8N(Y&8,0<[0<;1PW!XK5N="U*X\>Z=KX-HMM;6,EJ\?FL7)=E8
MD?+C@KCW]JYF'P'XGCT;2;![_2G?3-774!<,DA>ZPS$M(>S8;ISG Y% "6DO
MB*+QOX[/AVUT^69;BU=OMLC*&Q;KA5"CJ?4D <=>U^#Q]-J>G>#]1MM.@6#6
M;S[-,)G)>WD <,%&.<%&&<_A6C!H6NZ5XEUW4=/?3YX]7\I\SN\;6[I&$SM"
ML''&<97TSWJG+X%N+/3_  I8:5+ T&B7@NY7N'*M,Q#[L *0"2[']* ':=O'
MQ<\3&)5:3^R[/:&. 3F3&3@X_*L._P#%>M:G\,M'U>T^R:?-=ZJEM/'&C, O
MVHQX4Y'7;R>^3TS76VFAZG:^.M6U[_1&M[RTBMXX_-8.#'N()^7'.[\/>L&'
MP'J\?PWM?#QN;$7]G?+>0R[G,3D3F;#< CJ1QF@#;FU_5=-\::5H^HK9?8=1
M@D,5S&C*3.@!,>"Q R,L#WP1CO6KHFH76I?;IY1#]E2Z>&U:-2"ZH=K,<D_Q
M!@,=0N>_'-^-T@U;0H=)?4[6+Q*EQ!-9BW<>9%/O^5@A.=H&[)/\(8UV&GV,
M.FZ=;6-N"(;>)8DR<G &.?>@#$?7;W4O$>IZ+HYM8Y=,BB:XFN49P9) 65 J
MLN/E&2V>XX-<\_Q&U";1=)N[32K?[7/K(T>]MY9C^YFR0P4@<CC.3TR.#6TW
MAW4M+\:7_B#1S:S1ZI#&E[:W,K1_O(QA)%95;^$X*D>^:RKCP'?QZ9ID-E-:
M/<Q:X-;O9969!+)N9F50 <#Y@ 3T"CK0!V.CMJS6 _MM+-+S>P(LV8QE<_*?
MFYSC&:X33]=MO#%[\1]9NU9H;2^C<HO5SY$8"CW)('XUZ2,X&0 >^#7"2^ [
MC5(/&%EJDMNMKK\JRQM [,\+*JJN05 ."@;K[>] %Z^\1ZKH&IZ)'K,-H]GJ
MTZVF^V5E:VG8913DG>IP1NPO3IS4>D>+[C6]6GM;2:P$MK?26]UITBLMS%$K
M%1)DM\P.%;A<8;J2.7_\(]K&L#0H_$#V132;A+LR6TC,US,BE48AE&P9.XC+
M<@"JUYX/O]7U;2[[4(M.CO-/OQ<)J5N["=X0Q(B*[1U!"G+$=3CF@";2O%]Q
MK.L7%I:36"S6E^]M<Z=*K+<QQ*Q7S02V&! #<+C#=21SN>)]0GTGPQJ>HVUO
M#<26MK)/Y4S%58*I)!P#V'2N=OO!]_K&JZ;>ZA%IT=WI^H"XBU*W=A.T(<D1
M%=HZJ0IRQ'4XKI/$FGW&K>&=3TVU,2S7EK);JTK$*N]2N3@$\9SB@#FY_%VK
MQR^#H;33[)_[=@+.7D91&X@\S  !POOR<#&.],@\=WEC8>(AK5I;M?Z/=Q6R
MK:,RQW!F">5C=DKDN >N.M2CPKK N/!DNZQ_XD$;),/-?]Z3#Y7R_)QQSS]/
M>JM_X O=8'BZ*\N8+>/6I8)[:6!V9[>2)5"$@J,\H#P?4>] &\+OQ/!JDMM<
M6ME+:-9F:.^B4JL<P/\ JF0N6;(Y##'TK$B\=7\W@_PKKPM;8'6+VWM9X3N^
M02OMW*<]L="*VM"L_%+@?\)-=Z<PCC**FGJX$I(QO<M[9^4#&3GL,<I!X#\3
MQ^&-$T)KW21#HVH0W,$H$A:9(W+#>,?*>@P,Y]1CD U_^$D\47OBS6]%TW3]
M*QIC6K>9<3R /'(&+=%^]@<<8&#US4&F>,?$%X-4O[FQTR#2M'O[JWOG$KM(
M8X5SNCXP3GUQG/08R=?1]"U.P\::]K,YM&M]3CMU54D;>AB5E!(*XYW>O'O5
M?0?"EU;:9XDT[5C;/;ZS>7-P?L\C$JDPP4.5'('?WZ4 5[;Q=K4NH:*_]DRW
M%AJ1"S"&QN%:RW#*LTC#:Z]B0%QUY%8OC'7=0\2?"WQ'J>GK:+I6R:&-9%8R
M3(C%&D# X7D,0NTY '(SQN^&-$\8Z7%:Z5J>JZ;/I5EM6*X@C<74R+]Q7S\J
M]!DC)(&.^:QSX#\1V?A/6O"-A=Z8^CW?FFSFG,@F@60EC&R@$$9)PV>_0]*
M/0M,_P"059_]<$_]!%>3>'->\1>&_AT^KV.G6%SI-E>7<EU&\K"=X_M#[F3
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MV[2_OIF!B;R?,QP.@XYYS@\5)JGA;7+GQ+K-Y:WEBUGJE@MH#<J[26F P(C
MX*L6R>1SCKBJUCX/UVV_X0HS3:=)_P (_$T<NQW7S 8?*&WY3T'.3C/3 ZT
M20>*O$<VE^)H4L;";6]#FV^7'O\ *N4,8D&W)RK$'WY'OQIV7B2;5;3PW-IK
MVTW]J(9YB4;"0JF78#=P0Q1,'/+>U1:5I\OAS7/$>M:O=Z?;V6IW$4B.9ROE
ME46,!BP YP._4XJMX"T*VT^?6=0LYVET^XNY%T]>-D4.XLX3_9,IDQZ@*: -
MGQ9KX\-:$VI,H\L311O*REDA5W"F1@.2J@YP.OJ.M8>L>+M4TKP??Z_"^EW\
M$$T(MY;?=Y=Q$[(I/#G:0S-W/W?>NGUF'49[2,::;8RB53)'<DB.6/D,AP#C
M(/7!_'I7%S_#9Y/#OB>PM#:Z;_;$D4T%I 6>"W>/:V>@^\R\X P,8SB@#H;S
MQ'/8^.;?194@^Q3:?+>&7!#Q^6R@@\X(^;/054L?$'B#4['1]9L--MY],U&9
M=UOG;-!;MG$Q<MM.!@E N>< G&:@7PWX@U#Q;I^MZK+I:QQV,UG<6UOYC##E
M2=K'&?N]3C'3!ZU'X7\,^*_#]O#H3ZK82Z#:O^XG5'^UF(-D1G^$>FX9..@!
MY !BV^H:SI6J_$2_TB"R?[)=K<2?:F;YPMNC%5"]R >2<#C@]O2-(U!=6T6P
MU)$*)=V\<ZH3DJ'4-C]:Y1/"NL*GC)2UCG7MQAQ,_P"ZS$(OF^3G@9X^GO72
M>'+"XTGPUIFFW1B,UG:QV[-$Q*ML4+D9 /.,XH P8_$NNZKI/]MZ#I]M>67V
MLPI:L=LTT2R&-Y Y8*O(8A2#P.N3@0>*_%^J^'H=8O/L]E#;:>J/;QW))>_&
MT-)L(8;=N<<JW(]*BT7PIXG\/2W6D:=J>GCP[-</-$\B/]JME=BS(F/E/).&
M)XSG!Z5#K/@G7[]O%MO#?:>UMKD8$4TZN9H<(%$7'&S/(.>,G@DT :&H^*=;
M/BRST32K"Q87FFM>137,S#:0RCY@!T^;H,DG'(YJMI7C/7+_ $O4;>72(%UW
M3=02RNT23]PB,0?/Y(.P*2V,YX[=J,D6K6GQ/\.P@64]Y%H,RS+O:.-@)$'R
MG#'CCJ.<'IGBUJ/@75+G3[JXM[NT&JWFK1:E<Q2[C;RI& JP,0,E0 #G')'0
M=@"6W^(26\/BJ2_-O=1:$L4BW%ED+<K(N5 !)P=PVYR1WK;@N_$T6LVL%U86
M<]E<6[N\T#%/LLHP0C;B2X.<;@HZ=*YZ?P%J6JW?BH:K>V0M-?MH$86\;[X9
M(U(7&3@@'!SWQT6MCP[8^+X5A3Q!?Z;*EJFU#9APURV-H:4MP..2 #S@YXP0
M#E-;\6:U>?"K6=3MEM-/NH-0>RD$*LV5\\1,5.1ACN)W8_ 'D=1J.O:OHOB7
M0K&_%BVGZF[P-=)&ZE)@"R)@L?O 8!]0>*R#X#U6?X?ZYX?EN;..YOKY[R&5
M&9D4M,)0K94'J,9&:N>-?(U#PA/I&IWUFFOR(DMI#;28=;C?^Y,:D[B-X W?
M7I0!T6E:A=:A?:GN$/V*WN/(@=%(9RH&\DYQ@,2OU4UI2RI!"\LK!8T4LS'L
M!R37-ZI!J?A[P0L&B7%G]OMU7][>JQ69LY<X7DNY+$ =2:WD1KS352]A"M-"
M!-%G(!(^9<_B10!Q=QXXU*'P=%XS6TMWT9B)'M &^T+;E]HD#YVEL88IMZ<;
MN,U+>>*/$ESXKO=#T.RTIS'817L$]S,X5U=R,-M&03@X 'X]C7MO!&K1^#)/
M!<]S:R:/N\I+S>PG^S[]VPIMV[L?+NW8QSCC%;%GX?O[7Q_<ZV!:+I\NGQV2
M1+(WF*$9F#8VX_BQC/;K0!LZS>7MAHEU=6%@;Z\CC+16RN%\QNPR>@KGM+\5
M7MUXLO/#Y?3KV2/3Q>17%L6C3=O*-&W+]#@Y'Y5J>,-&O/$'A/4-*L+L6ES<
M( DK9V\,"5;'.U@"I]B:QK+PYXAA\8P>()7TA5&E?8'M(!(JIA]X"MCI[X&/
M0]: *OA[Q9XIUSPNGB$Z9I*63VD\GE&>02&1'('8C:0#[\=LX#D\>"'P_P"%
M+J[>RTQ=:M][7,T;&W@;8K"/[PQG/&6 ^4U>\->&M4T/X=?\([,]G+=QPS11
MR)(P1M[,<G*Y&-WOTJ*P\-:O9>&-%T2XM])U"SM;-K6\MKAVV38"!'4E#@C:
MW!'\76@!VL^(]6TO3O#\UQ96$LE_JT-E,RNQ55>0JLD8[Y4 C)XS22^(O$=U
MXNUG0-.L],1K.VAGAGN)'((<M]X  Y^7H.G)R>E9_P#P@.H6OA?0M(LI[8C3
MM734BLLK[419&<0H=I) #;=Q],XYP-JTT/5;7QOJ^NXLVAO+2&".+SF#*8]Q
M!/R8P=WX8[T 9UGX^EOO"_A>_CM(XKS7KA;8!R3'"PW;R>A/W#@9&<CFM'0/
M$&J:AXJUS1+RVM FE&(-<PLRF7S%WIA"#CC(/S'G'K7'W.BW^A^$O"_@Z2[T
M<ZF+MYHOM+.(IEC+/D,,,C!G3&WDX],UT_A1]7L-9N-,U*QT=6GC:Z>XTZYD
ME<N"J_O?,&[)!^4DGA".U '94444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52U'2-.UB)(M2L;>
M[C1MZI/&'"MZ@'O5VL/Q/K_]A6UBL4:27FH7L5C;*Y^4.Y/S-CG  )P.N,<9
MS0!MHBQHJ( %48 '84M<E_PD&J6/B^+PYJ)LV>^M7N+"\BA95W)]]'0N2< @
M@AAZ5DP^.]5F\ >'O$?D62S:A>Q6UQ#L8J%>;R\H=W! YYS0!Z'17$:3=:S/
M\5?$-K+?P-96MK:E(?LYR$;S#@'?PV>K$'/' Q6UXDU]M'?3+.W1'OM4NQ:V
M_F9VIP69V Y("@\9&3@9'6@#:BBCAC$<4:QH.BJ, 5EW/B?1K348;&XOECGF
MF%NA*-L,I&1'OQM#X_A)S[5E6_B#4X?%\_A?4#:?:9K(WEA>10L$8 [65XRY
M.0<'AN1Z5E_#&"[N=%OY+^6UN(O[6NW"_9B&$HG;Y]Q<CKT&,CCDT =;>:GH
M\FI1Z!>36\MU=QLPLY%W[T YR,8Q]:JKIGACP=97>J0Z;I^EP11EYY[>V5"$
M')SM&2/:N>\5?:_^%H>$A8B'[0;2_"M-G8O$?) Y./3C/J.M1_\ ":ZTG@;Q
M/J$UMI\FJ:%<SV\FT.L,H10VX+DD9##C/XT =_#*D\,<T3!HY%#*P[@C(-/K
MB]5\9G3K_1[.YN[/3%U"S\Y;R\B9H6E^7]T"&4*>2>3Z5U6FR74NEVDE\D27
M;PHTZQ'*!R!N"^V<XH M45PS>+M7O_#.I^)='BLGL+*2;R[:9&,ES'"2'8.&
M 0G:VT;3T&>O$,OC+7-4US3;+P]!IOD:GH[:C;2WF_*'*8#A3T^;&!SWSQ@@
M'<7EY;:?9RW=W,D-O$I:21S@**;87]MJFGV]_92B6UN(Q+%( 0&4C(//-4]4
M\\^%+W[6(_M'V%_-\K.S?L.=N><9SC-<%X7U[6M$\,> A+%8-I.HI;V&Q0_G
MHS1$J^[.W'R\KMX]: /4J" 001D'M7":CXQU>:WU2YT"S6Y-A=/;+:-8SR-=
M&-MKXE7Y4.=P&0W3)ZX!=^)?%-UXK?0](L],A=])34(C?^9E"S[=CA3UX(P.
MG7/&" =AIVE:?I%L;;3;&VLX"Q8QV\2QKD]3@#K5NLK7]3N-%\,WVII;&YN+
M:W:7R8P3N(';OCOZX%<TWB;4-2\)ZWJFD:SI5U;PZ>9K:[MH&RD@5RZO&9"0
M0 N,XQGD''(!W5%<+H^IZY9^"?#$C2V3QW%O";F_G78EK%Y((+@R9=BV%R".
M3G%86O>+]9U/X8>(;R">WMKJPU%M.EEB@8":/S$7<H9LQDB0=2W0XZ@@ ])F
MT73+C4XM2FL+:2^B&([AHP9$'H&ZBKU<M+K>K6/C31]"N7LIXK^UN)GEB@:-
ME:/;C +MP=WZ5D_\)W?6V@:_?WD-O_Q*]9.G--%"Y1(LQYF=-Q)VAR2 >W:@
M#OZ*QO#NI3ZK;3W+7FGWUHSC[+<V/"R)M&<C<V&#9'7TJAXBUK5M.OI([?[#
M:VBV9ECN;I3(9Y\G$*HKJW &21GK[4 =117 O\0P-"\+:C=-;:9#K4)>2[N(
MVDA@D"J0A(*XW$G!)QA3^'8:/-=W&EPRWQMVG8ME[8_NW7<=K+R>"N#U[T 7
MJ*XJV\87.H>)+S2+>YT^"\M+Y86TZYC99Y+?<,RHQ<!LJ2PPIXXI8O%.JNGC
M*,K9>=H3?N'$3;9!Y(D^8;\]\<'WH [2J&IZWINC?9AJ%W';FZF6" -DF21B
M % 'N17.Z=XLO-8&@65JMM#J&HZ4NJ7$DB,\<*$(,*H8$DL^!\W !ZUA^,;G
M6YO"NDG6;""&_B\1VJ((I/W<ZB8;''+% P[$DB@#TVBN5T;7=7;QIJ'AW6%L
M6:.SCO;>6T1U&QF9"K!B<D%>HQGT%=50 4A(52S$  9)/:N*E\3ZS!JWBC3)
MSIT5QIUFM[8,\+A9HB&R6^?LR[3CZ^U3:#XHOM?T;PW=6[6@N-0#R7B&%L1(
M@Q(%&_(*N53G/WLX[4 :VE2>'=:O9]:TR.SN;N)VM)+U(AO!7JF_&2!GMQ6U
M7C]AK>M^'/#GC'6=.BL'M;'Q#>RSQW <O,OF@,%(("$#N=V?0=^UU#Q/<2ZS
M<Z5I;+'-;6L<\DLEC-=+NDW;%VQD8X4DDGN, \X .KJA9ZWIM_J=[IUI=QS7
M=CL^TQID^7NSMR>F?E/%<!>Z]XFU.?P.\L:Z-/>WDJ75G/;LW[Q(Y,$_,I*'
M&0O'4$DXQ4D3:TGQ'\:'1S8BZ6SL6,EVCLF0DG&U2#SZ[N/>@#TJBN%L/'LF
MJZ3X=>"$0WNKV;W3XMY+A853:&PB?,<LP Y'&23V-._\;>)M.\+7E_/H\*75
MKJ,=JKS120QW43NJK(B,=RGYN03QCO0!Z-16;H_]M>3<?VW]@\WSF\C[%OV^
M5@8W;OXLYSCCI6$GB'6-:379M %D(]*N9+1([F-G:YEC4%QE6&P9.T'#=,^U
M '7T5YXOC_4]7;PC)H=I9B#Q!%.?]*+%H7CC)(^7&0&'XX[9R.VL/[4_L>'^
MT!:'4_+_ 'OV<L(=_P#LY^;% %VBO,+?Q[XE;P?I_BB>UTI;-K[[-=0()"[*
M;@P[D.["D<<$'/)XZ5U']N:AJVOZQI6BO9PG2EC666ZB:422NI8* K+@ 8R>
M>3TXY .GHKRO4?%^JZ_HOA>[LI8M.EGUZ/3[^V>(R;94+$C<&7*90''!.1R,
M$'TNX%V--D$4\*W8BXE,1*!\==F[.,]MWXT 0ZKK>FZ)%%+J5W';K-(L4>[)
M+NQP  .3R15^O%YKO4[_ .".C:A?W,=U-<7UI,N(RC;C<@G<VX@Y)Z@#'I7:
MQ>*M3TSQ3J>EZ\MD;>WTHZK'+9HX*1JQ5T;<3N(QD$8SZ"@#LZ*X:U\5Z]/=
MZ)<1Z:;JPU%E%Q%%83QO9JXRKF5OE=1T. /44SXP:I=Z7\/;K[%*T,EW-%:M
M,IP8T=L,<]N,C\: .D/BG0A(Z_VG;E8V*/*&S&C#J"_W0?8FM.VN8+RVBN;:
M5)8)5#QR(<JRGH0?2HK+3K33],ATZV@1+2&(1)$!\H4#&,5SPO1I.LZ=X+T,
M0Q2)9/=EYT+K! KA%4*"N26; Y& IZT ;\>E:=%J<NIQV%LE_,H22Y6)1(ZC
MH"V,D<#\A5RO.-3^(&KZ;X?\5AK2R.M>'73S<AQ#-'(,HZKG()'5=W!'6K6M
M>)/%VA"PEGL]&ECU#5+>S@CC>0.B2 Y#$\;@1C<..^.U '>T5P"^-]5T#7M3
MTSQ9!9>7!IKZG;7-@'"O&APR$.2=X[=C4U[XMUC1])T;7M1BLGTR_DA2XAA1
MA):B7&UMY8AP"0#\JYSD>E '<T5P]MX@\5:EXMUK2+*#2(X=*N;8/),9"7BD
M3>P&/X\'@XQD=\Y$%QXTUC3[_24OHK"-K[518RZ>H+36\;LPCD:17*Y(4-@J
M,AN.E '?U2TK5K'6]/2_TZX6XM79E6100"58J>H!Z@BN2T*ZURX^(WBZ"2_M
MI8+-;5(HFMV4!6C=U (<XP6Y)!S[<8BTOQY=W7@[1;Z:VM5U35]0>PAB3<(D
M82NNX\Y("H2>1D\<9X ._HKD1XBU6R\6GPY?I9RSW5FUU87,2-$C%3AHW4LQ
M!&0<@\CTK L/'GB.?PYX:\17-KI:V.IWD5I/!&LGF#S)"@=6+8&#CY2#GU'0
M 'IM%4]5:_32KI]+$+7RQEH5G4E&8#(4X(//3.>,]ZX7_A8-Z=*\':GOL%MM
M9E6"\!A?=!(?E)'S\*'PA)Z$@]\4 >C45R.K>++G2;?4;MDMYH1?1:?I\85E
M,LSE5.YLD;0S$' 'W&I9_$&JZ1XLTW1-3-G-%JT<HM+J"!H_+FC7<5="[9!'
M(((Z8]Z .MJA_;6FG7/[%%W&=2\DS_9QDL(P0-Q[#DBN)?QWJZ_#2;Q,(;'[
M5;WK6[Q>6^QU%QY.1\V0><]35^[(7XTZ>Q( &@3Y)_Z[1T =/K&M:;H&G/?Z
MK=QVMJA ,CYZGH !R3]*N22I#$TLKJD:#<S,< #UKR?QQK>I>)O@]JFMVQM(
M]*N"/*@>)C*T(F"AR^[ )(W8V\ XSGFO6^U &3#+H?C'0EE5+;4]+N&.!+%O
MC<HQ'1ASAE/Y5J1QQPQ)%$BI&@"JBC 4#H .PKQ_PIKVM>'/AOHFH0Q6#Z4-
M1>WGC<.9F62[==RL"%7!;H0<XZBNK\6>*M9T&/6;E$L((+&W6:T2X!DDOL+N
MDVA7!0+]W)4\\]* .WHKD+_Q1J-GKOAG<EJFC:U^[:1XV,D4Q3>B;MV/FY .
M.HI^H>*;G3K>[NG6&6&344T[3PD+DLY(5F;!)8*V\84 G8?6@#K**Y?0];UJ
MY\2W6FW]D9+$6XG@U%+*6V3=G#1,LA)W=P0<$51\:7>KP^*O"-K87T,$%U>2
M+(DD!?<RPNP+8=<K[<<X.>,4 =/9ZWINH:E>Z=:7<<UW8[/M,:9/E[L[03TS
M\IX]JOUYK"VM1_$7QL='-B+I;2P9I+M'9,B.3C:I!Y]=W'O6C9>/)-3T?PW)
M#"(;W6+5[EL6\EPL*H%#_(GS-EF '(XR2>,$ [FBN>\*:OJVJ0WT>L:>UM-:
MW!CBG$#PI=1]5D5'^9?0@DX]:S-0\0>)9/&]YX<TJ#2TV:>EY%<71D8#+E?F
M"D9^[T&.N<\8(!TSZ+IDFJ)JCV%NU^@VK<F,&11Z!NN/:KU>>:7\1+R^TNTM
M;BR@@\02ZM)I$L0),*2QC<\@YR5"\@9R20,]ZTQXAUF'Q1=^&+@6+7\EB;W3
MKI8G6*0!MK(Z;R00<<AN0<\8Q0!V%%>:O\0]13PMX;UN0V$0O;T66HQO"^;9
MMY1B/GX"L #GU![XKH-6\47&DKJ]VZ0RV=K+!:6Z+&V][B0J,$@G*@NO1<_>
M'4<@'553?2M.EU2/4Y+"V:_C3RTNFB4R*O/ ;&0.3^9KFK;7_$7]NS6+V*7-
MH]HTT-]]AGM4CE!_U<@<G((Y!'TQWH\#:[XD\2Z9I^LW\.EPZ;=VA?RX?,\X
M2[L#J2NTC/'7I^ !V-%<1XDNM97XD^%[&TOX(K2XANY3%);EQO1%&6PXSPYQ
MTQSU[2CQ)K&KV>N7VA+9>3I=Q+;1Q7$;,UT\0&_#!@$!.5'#=,]\4 =E167X
M<URW\2^'+#6;962*\A$@1NJGNI^AR/PK4H **** "BBB@ HHHH IZEI.G:S;
M?9M3L+:]@SD1W$2R*#ZX(ZT:=I6G:/;?9M,L+:R@SGR[>)8USZX ZU<HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *Y_P 7^&CXETVV2"Y%K?V-U'>V<Y7<J2H>-P[J02"/
M>N@JEJVJV>AZ7/J6H2F*T@ ,CA&?&2 .%!)Y([4 95OH5W>>)+77M8^S+<6=
ML]O;06S,ZJ7(WN68 Y(4 #' SR<\<K'\/O$,?A6R\.KJFG+::=?QW-K+Y+EW
M193(!(,XR,XP.O'([^F Y (Z&B@#F;;P]J-IXZO-<BO+8VM_;0Q7,31-O#1;
ML;#G !W<YS_6I/%OAJ3Q!#I\]I<K;:EIETMW:2NNY-PX*.!SM8$@XYK1_MS3
M3K_]ABY!U+R#<>3M;_5@@;LXQU([UHT <[:Z'=R^)#XBU%;87L5F;2VMX9&:
M- 6W,Q<J"22%'W> .^:9X+T&_P##FF7-G>RVTWFW<UTKPEACS'+%<$=B3SFN
MEHH YO5-!OKSQOHNN126PM].BGB:-V;>_FA02.,#&T?7VK%?P5JTGA[Q=IAN
M+(-K]U+.KAF(A$BJI!X^; 7VSFN^JE=ZM966HV-A<2E;F_9UMT",=Y1=S<@8
M''KB@##N]"U.ZLH;&ZM]+O\ 3S9);SV=RS!?,7/SJ=I['IC/3D8YT_#&B_\
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M 4'*@!OE&>@&3WI]EX>U6S\4:_JYELY5U.WAA1-S*4,2L 3QWW$X'3WKJZ*
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MY?(!R =YQR<  >]=LB.;98YG#R;,.RKM!..2!SBDN;F&SMI+FX?9#$I9VQG
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MC@8V]\U5A\(:I=:#I?A[6+JTGT_3Y8F,\6X2721$&-64C"=%W$,V<'IG([4
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M6O\ Q3\31L/+;]_NB\K(Y^7CGOS0!GZ=%JTOQ:\2)]NL\+I]J,/:,PV$RE5
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M?N_,2&^3Z>@KD]'N+R6V.NV&N^#YQ<7#WB"_MV%PKLQ*AMC\2!2%X7(QCGN
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M=Y<A0KNVL5/! /4&K]>8>";V^L/A+H,ED]K"C7<B7-Q<. ((3/+N902-S9P
M/5NAZ5=M?$_B'4-$\6)IS0RZCHTY%J\UJR?:$\L2!60D$,<D9&.QQ0!Z%17G
MQ\<7#:QX.>*[@;2M<A'FGR#OCE*9C!;.%WL&7!&<J??&G<ZOK0TN2_AN+)+6
M74?*6><!!!:!BK2<G#L2/E]0R\'N ==17G!\9ZPOA_QI+#)!)<:"2UO-<6KI
MYL?E"0!TRI#<D9X!X.*MMX@\0Z;86%S?SV<[ZS);PV45O;-FW9HV>0M\WS\+
MQ]WGT% '>5332=-CO3>II]HMV3DSK"H<_P# L9K%\.W_ (@EUO4;/5+21M.1
M$DL[YXA$SD_>1E!/(/0@#BNFH **** "BBB@ HHHH **** "BBB@ HHHH *K
M7FG6.HJJWUG;W*H<J)XE< ^V15FB@!$18T5$4*BC"J!@ >E+110 4444 %%%
M% !1110 4444 %%%% !4,]I;7+1-<6\4K1-OC,B!BC>HST/O4U% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !2,JNC(ZAE88((R"*6B@"M9Z=8Z<KK965O;!SEA!$J;C[X'-
M6:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+
MQ7X:C\3Z9#!]I:UN[6YCN[2Y5=QAF0Y5L=QR01Z&MVB@#G[?0+J;78-<U6XM
MYKVUMGM[9((BL<>\@NW+$DG:H[8&1SG--\*>';OPZ-36XOX;M;Z_FOODMS&4
M:0@E>6;(&*Z*B@#G?$/ARYU?6-$U6RU!+2ZTN25E\R#S5=9$V,,;A@XZ']#5
M2'PE?0ZEXGO!J=NQUQ$0*;4_N=D?E@_?^;CGMS76T4 < _P]U"WTOP\=,UU;
M36=#@^RQ78MLQSPD %)(RW^R#UX/Z==HUC>65HW]HW_VZ]E;?+*(_+3.  J)
MD[5 'J><GO6C10!@R:5K-OK5[J&GZE;>3=!,VES 6565<;@RL"">XP>@Z5CW
M/P]6\\+>(--GOP+_ %R;[1<74<.$5P5VA4S]T;1U.3R<\UVU% '(OX6UIO$U
MGKRZ] +I;$V5TILLHRE]^Z(;_D;/'.[H,YQ6;;?#J]M?!^DZ+'K<9N-)U%;Z
MTG:TRORNS!74."<[SD@CM7H%% '%7W@[6HO$;Z[H/B%+*ZNX8XM02>T$L=P4
M&%D"[AM8#CK_ /7ZVQM6L[**!YY)W4?/-)C<[$Y+'' R2>!P.@JQ10!Q5OX(
MN]/TW5M$T_5(XM%U%Y7\MX"TML)?]8L;;L$')QD?+G^*K>H^$99M2\-SZ=>0
M6EKH6[R;=K<R;P8_+QNWC "^QKJJ* &2B4PL(F19<?*SJ2H/N,C^=<;X:\(:
M]X8\.C1K37[$H))'$YTUBZEV+''[W;G).,C\#7:T4 <:WPXTH^#[[05N+GS;
MV7[5-J#-F=[C<&$I/'((' P,<5>T+1_$5H#)K?B"+49HHRD'EVGDID_QN WS
M-], 9/KFNDHH \_MOAYJ-EX9T+3;?7(?M6C7S7<,SV9,<FXN2KQ[_P#;."",
M5M^'?#-YHFN:UJ$^J+=IJ<J3-&+<1E'"*IYR>/EX';N3UKI:* .%/PTLU\*Z
MGHL-Y+&US=&YM9P/FM,2&2-4] I+?]]-ZUJ>(?"DNHV&C0Z5>I8R:1<QSVXE
MB,L;!%*A67<">#USD5TU% '"3> =2FB\51MKL3#Q!&JR9LO]4WEB-B,/R,#@
M=NY:M#6/!TNL^$M/TJ34C;ZCIS136M_!%CRYHQA6V$G(P2",]ZZNB@#FK+1_
M$B:9>&^\0Q3:M) 8K:>*T"10'^]Y>3N)."<G'   YSOVB3Q6<$=S,)KA8U66
M4)M#L!RV.V3SBIJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!QTKC/"/B74-1N/$KZS>6<=KI.HR62.L?E#:H!WNQ8C//M7:5Y_\-)$;4_'
M#J<>(9R<'_97_ _E0!+X7\0:CXO2TU?3M:LTA^TRBZTQE1]L =T0@CYU<A0V
M2=ISTK>N?%VCVWBF+P[)?6Z7\ENTQ5Y -GS(JJ<G[S;\@=<*:Q?A&Z/\-=-*
M,K#S;GD'/_+Q)4=]=6]G\:[%[F:.%9= EBC,C!=[_:(\*,]3[4 3>%?%GF)J
MZ>(=6L8IH=;N+"U+LL =4V[54$\GGU)YKH;N64>(-.C35[>",I+YE@Z*9+G@
M;2I)R-N"3@'->4W5I93?#KXG7#PPO,-7O0)"H+#;L*\]L'GZUT]\8F^)/@&?
MY#--87A9^-S_ +J/&3W[T =M_;&F?;OL7]HVGVLMM\CSU\S.,XVYSG%7:\ML
MYK[0]3TPQ2VVM^&K[6'6W)&VZL+B1W+<CAU#&3.>0,]A7HFLZK;Z'HUWJ=TP
M$-M&7(S@L>RCW)P![F@#G+GQJUO\2;3P\\&-/N(GA%T>GVL!9/+S_P!<V!]R
MV.U=5<WMK9^7]JN88/-<1Q^;(%WN3@*,]23VKS3Q3X3\0CP&UP=1T]M0TZ4Z
MPA2S=7^T*3(P$AE([LOW<8P,"G>+]5TOQ7X/\':PJPO!=ZU8D[L'9N;YT)]N
M0?I0!U=WX]\-6NH:=9_VS82-?22*KI<H5C"*Q+,V< 97;]3[&M&UEE?Q#?I_
M;%M/"L46VP15\RW/.68@Y(;MD#I7(^)8M,T+Q[X(D2.TT^S$]^TC!5BCWM!U
M/09)_.J-TLZ^,OB&-'4+J#Z) \(B&&,I27!'^UG'Z4 >APZQIEQ?-8P:C:27
M:YW0).K2#'7*@YXK"\&ZSJ.IS^)(]3N(I?[/U62UB9(Q&JQJB$<9/]X\DFL?
MPMJG@_7M(\)M \$VIV,2K;6T4F)K9_+VR;D!!  SDMP>.I(SSMW//%X3^(LM
MH)'\KQ#OG6$ N81Y'F@ Y'W V<\8S0!ZO8ZOIFIO*EAJ-I=O%CS%@F5RF>F<
M'BN?^(VO:EX8\*2:MICP"6*:*,I/$75@[JO8@@C.:IZ(WAK6?%5EK>F^()=5
MU$6;1?NGBPD!Y_>JB*1\V,!N<]N#B#XT,@^&EX'8*#<VPZX_Y;)_3- '2/%K
M\%S:G^U+&=&F420FT,;.G\6T^8>0.>AZ5E:=KFKW'Q,U70)I[<V%G:17*;8"
M)&+G&"V[&!@]JL2VN@:1J5GJBZA,UPI-O#$]]).96D( 55=SSD#D=LYXK%T[
M9-\:_$T'F ,VD6ZG!Y')_P 1^= &IHFNZCXRDN[S2[B.RT2"=K>";RA)+=,I
MPSC)VJF>!P2<9XZ5J6(U_P"W:C:WLUL84BB:SNXH"NXDON#J6.2,+T(&".G0
M<E\(ICHV@R>#=2Q;ZOI,\H,+\&:)G+K*G]Y3N(R/3FK'A>:63XI^,X&O[N:R
MLDM/(BDNG>*(O&3)@%B!R/P]J -#X>:[JWBKP/;:SJ$UNEU=&0*((2$CVR,G
M0L<YVYZU1\(ZYXH\4>%8[];G3XKI[^2!W^RDI'%&6!.W?DL2H'7C/M69\']&
MLK[X8Z7.]Q?!B\^X0ZC/&H_?/_"C@#C':M#X,LA\  1ON5;^Z&=V[_EJ>_TQ
M0 [2]6\5ZGXM\2Z$NJ:;'_9 M_+F.GL?,,L9?D>;QC&*GEU[Q!!XZ\/Z%/+:
M)'?6#W%T! 2R2(!N56W8QD^AJOX2D1OBY\05#*3_ ,2_@'TA.:@\2V\%Y\9_
M#-M-+*F=.NC^YN'B?J,?,A!['OVH UM=US5['XA>'-$MI[=;+54N&EWP%G3R
MD#?*=P'.>XKL:\TUFQM=-^,7@=(IKEB\5_D7%W),1^Z&,;V.._3KCVK?^)HU
M$_#;71I8D-U]GX$?WBFX>9C_ (!NH W[36-+O[A[>SU*SN)D&YHX9U=E&<9(
M!R.::-<T@W"6XU2R,[RF!8Q<)N:0 $H!G)8 @XZX(KBO$9M=4N/ -]X?:,RG
M4(VA,..+(QMYPX_AVA0?? ZT?#_2M*FU?Q;*UC:/-;^(I3$QC4F+$:8*_P!W
MDMR/>@#OKJ[MK*!I[NXBMX5P#)*X11G@<GBH$UG2Y-/>_34K-K)"0]PLZF-2
M.N6S@8KG?'>H6-E)X>2[BB\Z74T^RSW$A2&WE"-AWP1NXSA<C)(Y'6O/KJXL
MKCPM\4H&O+:[?S3<(5VX;]R@WJ!VSP#^IH ]BAUG2[B\ELX=2LY+J)/,DA2=
M2Z)_>*@Y Y'-+;ZQIEU;2W-OJ5G-;P_ZR6.=65/J0<#\:X.XMK.R\<?#HVL4
M,)EMKQ6,8"EQY"MSCKSS]:BN+6YT/Q9J7A2UA<:?XG;[5;R(,+ W NQGME/F
M7W;% 'I4-Q#<6Z7$$T<L+KN61&#*P]01QBJ(\0Z(9K>$:QIYEN6*P)]I3,I!
M*D*,_,001QW%7A!$(!!Y2>2%V>7M^7;C&,>E>'VNCZ/=_ 6^9;6W;45N;A+=
MXU'G+<"Y;RE4CD'E0 .Q]Z /:;[5=.TM5;4+^UM%;.TW$RQ@XZXR:=+J-C!'
M!)->6\:7#*L+/*H$A;H%)/).>,5P_AN>XA^)?B&RUQE-U+I]F;0R=)(50B7;
MGMYA)/UKCAI\:>$- BNDC;3SXS5-.\SI]C,K!0"?X3R1V(([4 >FW7CWPU;:
MCIUF-9L)&OFD"NERA1%16)9FS@<C;]3[&M&TEE?Q!J*'5[>XA6.+98(BB2V/
MS99B#D[NV0/NG%<CXCCTS0OB#X)=4M=/LPVH,Q55B3>T2G)Z#)/YU0N$N4\6
M?$I=%4+J+:3;-"(AAC*8Y<$?[62/QQ0!Z)#K&EW%\;*'4K.2[&<P).I<8Z_*
M#GBH[K7]&LA,;O5[" 0,J2F6Y1?+9L[0V3P3@X!]*\WU)K?5?A9X/ET0I_:,
M=S9+8B/[Z2J0)5]>%\S=[ YJU::?ILOB[XE^9:VSA(+<?,BG:&MB6^F2.?I0
M!Z<K*Z!T8,K#((.017%Z!XL9-1\10^(M6L88[/4_LEJ\A6!2#&K!1D\GYCW)
MJ]\.9#)\-_#C%MQ_L^$9SGHH%<4]I97.E_%B6:""219)P'=02N+92,'MR/S'
MM0!ZG>ZC8Z; )[^\M[6$G DGE5%]>I-,;5M.6&WF;4+417) @<S+ME)Z!3GY
ML^U>86VM1:?XA\,OJ^L2:;97?AN!;6[;R_+,V09%+2*P!*^6>V<#VJ+5M'\/
M6>C^$H-,D-WIS^*8]DTY5ED#"0N$( !C+9& ,$YZB@#U#^WM'_LY=0_M:Q^Q
M,2JW/VA/+)&<@-G&>#^53_VC8_8!?_;+?[&5W"X\U?+(]=V<8KS[6KG3_#7Q
M'TZ"XNUT+2;C39%M9HHXHX1<&7=("64JI9=ISQG%9CPZ9H-]X2?3;N:X\,'6
MKAY[B5U:'SWCQ&RE0%V"0MCL&S[4 >H1:QID]E)>PZC:26D1(DG2=2B$=<L#
M@5R/ACQ!J/B];75M-UJS2(74JW.F,J/BW5V1""/G5R%#9)VG/2I+&V=/C+JL
M]E@6+Z/#]NV_=-SYAV9_VO+!_ CUH^$CH_PYL2C*P\^ZY!S_ ,O$E '67FJZ
M=IQ47U_:VI<$J)YE3('7&37-7WB.YLOB%8V<NH6J:)/I<UVS,H4 JR ,9">F
M&/H/K6=XMBU*#Q#?:IH-]9374&FH-0TB_'[NXMPTA5E;JIYD'H>,U3MI++6/
MB#X.G:S$<4OAZ2:.VG^8Q9,14'/4@=_:@#T%-5TZ731J4=_:O8$;A=+,IBQG
M&=V<=?>JUUJL5WH5]=:-J%I-)#&^V6-A,B.HS@A3U]LUY?9WVF:;X>U&*Y@B
M>(>-I8+0-(8X;:3S-R.^W^!<$XZ$X'&<C3T"^MV\5?$1#J5M<R206\@>(A5?
M%NP8J 3P.!G)[9- %L^*M</@KP/JRW4(FU2^LH+TF $NLI^;;V7\N_:N[U:2
MXAT>\EM)$CN(X6>-W3> 0,\C(S^=>5^8@^%GPU)90/[4TP9SZ,<UZIJP)T>^
M &3]GD_]!- &#X,\56^K^'=$_M#5+-M9O+-)WM_-19&)&21&#G'X5NWFLZ7I
MTT<-]J5G;2R8V)/.J,V3@8!//->0)I&GW?P=\)/IEO;?V\TUF;.6%1YOG!U\
MPDCGA0Q;/0+STK2%YH]UJ?C/0/%>O/IKSWCLT$S0H)[9D41E&="20!C"G@CC
MF@#UJL33M1BM;&]NM1\06-U MW(!."D20+GY8F.<%E'<X)S5[28(H=#LK=!.
M8DMD11<\R%0H W_[6.OO7C6I16O_  J#QR D.R+Q#<>7@#"?Z3'C'IQ0![+%
MK.ESW%U;Q:E9R3V@S<1I.I:$>KC.5_&B+6=+FLI+V+4K.2TC^_.LZE%^K9P*
MX^YMK2P^,&@):0PP"32+I&6)0NY0\9 XZ]S6?IUI+IGBC5_ RPM_9U_.-3@8
M+\J6SDF>,]@-ZA,>DOM0!WMSKND60C-UJMC!YJAX_-N$7>IZ$9/(/K6+XDUC
M4M.\5>%K2UGB6RU"ZDAN$,668")F&&SP,@=!^-<GXNU/3GN_'MG#);V5TFEI
M'=/</NDNSY+M&L2$X50&P2 223P,9J1KR"Y'PJDCN(Y07P65P<L+4@C/KGCZ
MT =]9RROK^I(=7MKB%4BV6*(HDM3@Y+$')W8XR!T.*Y[Q9XL-CJ.@VVDZM8M
M)<:Q!9W=NI623RV)#=_EZ8/'?J*P+O[3;>)OB>=&7;J']EVKQ"$?-YGE2\@#
M^+I^.*I:EJWA^X\'?#F6SN[,)#JUC@>8H:+"D/GN,'KGOUH ]3GUG2K6\6SN
M-2LX;IB%6&2=5<D] %)SSVJA)XNT:/Q6OAUKZ 7YA\UE,H&TEE54YZLVXD#K
M@>XKR[QIJVFW7A3QPEE-;V>S4E$T$DF^XN9D:(&0 GY$PHP #]W.1TKK_P"T
M;)?C1%.;N#RKGP\J0/Y@Q*WVDX"G^(\CI0!V3:SI::@NGOJ5FMZQPML9U$A.
M,\+G/2JGB#6;;2].N =3LK.],+/ +EUY(Z?*6!//'UKS'0)M#UWPC;Z3X@UZ
MZBUBSO2TVFJT*7'VM9204&S>Q8G.03U.3UK7TK5+/[9\0[+7)H(]0:YDPERP
M7?9^4!%C/5?O=.[>] '9>"M3NM9\%:-J=ZX>ZNK1)96"A06(R>!TK=KDOAC/
M%/\ #3P^8I$D"64:-M8':P'(/O76T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445'//#;0//<2I%
M#&-SR2,%51ZDGI0!)15&UUK2[Y)WM=0M95M_]<4E!\OC/S>G'/-5X_%/A^:X
MM;>+6]/>:[S]G1;E"9L$@[1GGD$<>AH UJ*0D*"20 .236?9Z]I&H3M#9ZG:
M3RK'YI2.96.SIN'/*^_2@#1HK'/BSPZK0*==TT&>4PQ#[4G[QP<%5YY.2!]:
MMKJ^F/J;:8FHVC7ZKN:U$RF4#U*9SC\* +M0W-I;7D8CNK>*= <A94##/K@T
MVVO[.\>9+6Z@G:!_+E6*0,8V_NMCH?8U%?:OIVFD"^OK>W)4OB60+\HZMSV'
M<]!0 ^33;"6Q^Q265L]I_P \&B4Q]<_=QCK4EM:6UE L%K;Q00KTCB0*H_ 5
M3/B'152)SJ]AMED\J,_:$P[_ -T<\GD<41^(M%ETZ/4(M5LY+.1BD<R3*5=A
MG(!!Y/!X'I0!=M[:"TC,=M!'"A8L5C0*,DY)P.Y/-2UG-K^C)IJ:D^K6*V+G
M"W+7"",G.,;LXSGBIGU33X[[["]];+=[#)Y#2J'V#JVW.<>] %NBL@>*_#S2
MVT8US3B]TYCMU%RF96!VD+SSSQQWXJSJ6JV.G1[;O4+>T>16*&5P.G5L$\@9
M&: +U<C>^%=5U!\W=]H5P Q91/H8?!/UEZ^]2?#K6+[7O!=MJ&HW*W-R\]PI
ME5 H8+,ZK@#CH!5&S\6C3?&7BFT\0:S:0:=9?9!:F<I"$,B.Q&3RQX'4]J -
M"?0-?NK=;>XUC1YH%P1')HVY1CIP9L<4Z/1?$<,LDL6MZ4DDN#(ZZ.07P,#)
M\[G K6EUW2()+6.;5;*-[L!K97N$!F!Z%.?F_"K O[,WYL1=0&\">8;?S!Y@
M7^]MZX]Z ,1-*\3QERFOZ8I=MS$:01N.,9/[[DX _*J@\*ZN$=!J&A!7.7']
MA##?7][S71WVIV.FJC7MW#;B0D)YC@%B!DX'?CFHFUW25M+6Z.IV8M[ME2WE
M\]=LS$X 0Y^8D^E &%_PC&LAHV_M+1-T7$9_L,93G/'[WCFN97P/XS-X8;F3
MP??VC2,SWEYIC27,FXDDLO0GGINQVKO[?Q)H=W%>2V^L6$L=D<7+I<(5A_WS
MGY>AZ^E2C7-).FC4AJED; G N?/7RB<X^]G'6@#F+?P5J=O9VEL=2T69;2)8
MH6FT0.RJHP.3+_*M7^SO%?\ T,6G?^"IO_CU= "" 000>0:HVFN:3?W;6EIJ
M5I/<!=_E1RJS;<X) !Y&>,T 8-]X7UC5"AU#4=#N]GW?M&AB3;],RG%2OH/B
M"6U%K)K&D/;@ ")M&R@ Z<>=BMAM=TE+];%M2M!=,_EB$S+N+]=N,_>QVZU(
MNK:<US<6RW]J9[9=\\0F7=$OJPSD#ZT 8'_"-ZWB ?VIHN+=MT(_L3_5'U7]
M[P?I2MX=UQ[26U;5=&:VE):2$Z+E').22/.P23S6Q_PD&BFVMKD:M8F"Z?R[
M>07"%9FSMVH<_,<\<5DS_$'PU%J.F6<6KV4_V]Y )8[A2D:HK$EFSCJ H&>2
M?:@!J>'==C#!-5T90T8A8+HN,H.BG]]]WD\=*+3P[KNG[_L6JZ-;;^7\G1=F
M[ZXFYKJLC&>U9]IKNDW]T;6TU*TGGV[_ "XYE9BO3( /(]Q0!D67A[6++4&N
MTU+1U>5@;AH=&\MY1G)!82YS[G-=%!;06P<6\$<0D<R.(T"[F/5CCJ3ZUQ%U
MXF?7O%.K>'])\0V^FS6=O#]GE0Q2F:=RY*E6!R%"J"%P>3STKL_/^Q:<LVHW
M,"&.,&>8_)'G')Y/ SZF@"PRJZE6 92,$$9!%5(](TR$.(M.M$\Q=K[85&X>
MAXY%%EJVGZE%+)97MO<)"VV4QR ^6>N&]#CUIEGKFDZA.\%GJ5I<2HGF%(Y5
M8[?[V >GOTH GM;&SL@PM+6"W#?>$483/UQ3I;6WGECEE@BDDBSY;N@)3/7!
M[5FR^+?#D*HTFNZ:BO*8$)NDPT@QE1SU&1GTS5B'7=(N-4FTN'4[.2_A7=+;
M),ID0=R5SD4 .&C:6(VC&FV81R"R^0N"1TR,4X:5IPDBD&GVH>+ C80KE,=,
M''%4Y/%OAR)HEDU[35,TABCS=)\[CJHYY(R/SJYJ&K:=I,8DU"]M[5""09I
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M_>:Z8IK"48N;*Z:<[C&P^\ ^6P?X?;)J(+8S0?%F1Q;N_P"\4L<$X^RCC/\
MO#\Q7J*V-FEU]J6U@6XY'FB,!^>O/6C[#:?-_HL'S=?W8YH \STS6].BO/",
M$EQ;V5Z_AR-QJ=P^<H?+!BC4G:9"5SDYP!T.>,"TO;4_ ?1XA<QEH-6B20%@
M"A^VDX([';@X]*]M^QVH,9%M#^Z),?R#Y">I'I2&SM60(;:$H"6"F,8R>IH
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M9\DC=-H/KGMUXKD?%NJ6V@_$6POM;N;FST:YTUK6*\B9E2*<2;BKE>@9=O\
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M)#$L0R1$S@,VXX_A!/U-<G:W<-SKWQ'@@OGOY;S1X&@D"#]^!#,"5V@ KD@
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M0*%S'(5X(8!0#P25]J9I;ZQ:S+H>G:M;:_97.CW(TO4$P+FS 5=JR%>"I.P
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MJ3Q4EGXDT:_T636+;48&T^/=YD[':J%?O!LX*D>AH TGC23&]%;!R-PS@TI
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M>HXK8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV01@$Y'.!4?A[6])M+#5O!WB>R:XU7^T;B064MNTGV\/*9(W7@@@Y')Z;<G
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M7+R1L.0H.XD,,8/!.[-=;\0]0BTWP?/<36$5Y$)H0XFC+QQ#S%_>LHY(0X;
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MGIS@X% ':7M[;:=:M<W<RQ0J0"S=R3@ #J220 !R2<53LO$>DW[7J17822Q
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MD 9W?*1MZY[<&@#KZ*\]7Q(ND_$C6Q?7U_)8_P!FV\\-J(Y)"A9GW;8E7<.
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M#0[K6;:ZD>PM-_G2FWD4IL^]\I4,<=\"M:"9+B".9 X1U#+O0J<'U! (^AH
MDHK#/B_1!+ K73+%<3?9X;DPN()),D;1)C:3D$#G!(P*KZCX\\.:7?75E=7S
MK<VNPS1I;R.4#G /"G(]QP.,]10!TE5KZQBU&V-M.7\A^)$4X$B]U;V/?&,]
M.F:LT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]GB?!&<9VFM"QM=:\4?#S5KN\MVM-:U/36M$B?Y2A6-E_#=(9&SZ,OI7?T4
M>9^%K_1M=?28)="U4:Y8%3+%>B?99.HPSAW)7G!  Y.1P!G%?04N--UW2&\.
MWEQ/I5Y<N;O1+V,L^G95BTB,0"B@Y&#P=W&<UZI10!Y9IDC6W@OQ[ID]M=)=
M?:M2<*UNX#B3=Y>TXPQ;(P!FH[^Z@TSP[\.M5?[3%<V$:Q[A:R2H@-MMD21$
M!8$XP.."">U>KU@:YX>O-1U6TU33=9FTZ]MHGA'[I9HG1RI(*-WRJ\@@\4 <
M(-7TL>%O%M_I&S7-4NYDNKJRFL)%5%)5 1"X!=44;B>Y';M>T:83?%0W4/\
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M<-A>#@'@\\=.E8?AF_TS6IM-$WA74;?6+'YIVO;>0):,!AF5VX.<8 7DYY
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M#M;.]3X,Z(C:=?":PU>.XN+?[+()5C%VSDA,;C\I!X%=5+/+'\6-/U0V%_\
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M4=M\#!F(1U[MM'0YP2169H3S>'X/%FBZO9W4LUS?7-W:LEN\BWD4PR I (+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+<2?9) L)>)%4.=ORY((YKF9Y-7U+3M!NKS0M974;+Q!%->6T5HZP6\8D?\
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M>N!NVYP<]>,ZW@DW#>*O%]Q+I][;P7=Y%-!)<6[1B11"B\9]QTZCO@\5W%%
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M3.((T&<!5+%F]!\I ]3]#B+Q#XILO#A@2XMK^ZEGW%8K&U:=PHQEB%Z#D#-
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M#*O-1U#5?$NL:'I[W-O'IEO %-H\:,'D5F#'>#D    <?>SGC&7<WGC"._\
M!6FZAJRV=[?FY@U#[*D;HQ2-BKJ2O#8YQ]T'MQ@]!KG@B/5-?CURPU>_TC4A
M$()9K-EQ-&#D!U8$$CL?_K5+/X-MY;_1+N/4+R)](:1X1E7\UI 0[2%@22<G
MICDF@#"B37XO'MMX:E\3WDML=#>XDF\B%9#()E7<IVX!P<<@]^YR,*75_$J?
M#S7=8/B.Y^UZ!?7%O$1#$!<K%+C,WR\Y''R[?Q->AR>&T?Q>OB,7UPMPMF;(
M0A4\ORRP8]LYW '.:RS\/[9O#6L:$VJWIMM5N9+F=\1[PTC;G"_+@ GV.* ,
M[Q7XENM(U17U*74=/T2>R3[/J5G$)([:X);<9A@G&"F,C'7\.XM&^T:9 PN1
M+YD*D3Q$$/E?O*>G/45C7'A>:<7"#6;D175HMI/$T4;*R@$;@-O#D,03R.!Q
MQ6SI]C;Z7IMKI]JA2VM84AB4G.$4  9^@H \RD\2ZZOP?NM;&JS?VE;:@T*S
M^7'ED%V(L,-N/NGL!6EXO\1W>CZW>0:E=7^E:=- BZ=JD$8>WBF((;SN#@[M
MO7C'3!R:MW/PSMKG2M1T@ZWJ4>EWES]J6U0Q@0N9!(VUMN2,@X#$@9S@G!K6
MO_"CW\>I6\NKW;6FI1"*ZA=(VR-@0LIV_*Q YZCT H R[S5=2UWQ%K6DZ;-<
MQ)I\$&R2TEC4F25"X<E@<C&  ..&SGC$%GK&OW.L:#X7U>XCMM1>PEO-1FM"
M#YFQPBJA(^7<3N; R,8&*OZEX MKC5K?5-)U74-%O(K=;5WLF4B:)?NJRN""
M1V-3:CX&M+N32KJSO[RPU+3-PAO8V#NX?[XD# APQR3GN<T 9G@&"2V\4>-X
M9;F2Y9=2B_>R ;B/)3&< #@8&>^*;XBMY[KXL:!#!=R6C-I=V#-&JEU&Z/[N
MX$ ^Y!^E;^@>%DT'4]4OQJ5Y=RZE(LLPGV;=RJ%R-JC!P/I[4^[\-I=>*[/Q
M!]NN$GM('@CA54\LJY!;.1G/ []J .,L?%FKVGA^:SFNY+J\7Q*^B0W;A!(4
MSD,> N_;E02,9P2#T.C=_P#"6Z9;>(IS>R1:<FFO<6;S/%+/#.BDD?=PR'@\
MY(]JNO\ #K3;C1M6TR[O+R>+4KYM0,F522"<D'?&548P0,9S^M6+;P;(ND7M
ME?:_J6H3W=NUJ;JX*;XHF&"J +@$]R02<#T% '.Q:IKNF>%-$UBXUN>\N-<6
MPM5B:*-5@>0 LZG'WB,CYLC<<].!MV-OXHM]6U))KN5-(EL]]N\\D<EQ!< \
M[<+@H1S\V<'VJY<>"M/OO!4/A:]GN)[6&*.**?(69/+QL8$ #<,#G'UI=(\+
M3Z=;3"ZU[4=2NGB,,=S=%"84/4* H&3@9)R3@4 <9%XB\07'@+P)J4>KO'>:
MGJ-O;W;F)&$JN7SD8X^Z.A'>ND\.7>I6OCO7M!O-3N-0MH;:WNH)+E4#H7WA
MERBJ",J"..*6/X?6T6@:'HZ:K?"WT:Z2ZMFQ'N9DSM#?+@@;CT K5M/#:6OB
MN\\0?;KAY[N!()(6">6%0DKC SGD]^] %?Q+=7,6J:3;QZ@8+>8R^;;6ZDW-
MR0HVB/@X4$DL> .,D#-<3)XG\0O\-?[034Y8;^VUO["TCQ1EI(_M(CPX QG!
MY*D9QUKN]:\+IJVMZ=K$.I7EA>V2R1+);[#OC?&Y2'5AV'.*R#\-K,:)<Z2N
MKZD+6?4/M^"R,4??Y@ )4\;N23DGUH K-K.H^&O&VJ6E[J=SJ6GIH3ZL4F1
MT;QR;65-JC"D=CGIUK#\1F_U3P!X:UV[U.9YKW4+"YE@4+Y($DBL$48R-N1S
MG)P<YS7=R^%(;CQ/_;EQ>3RR-8'3Y+=E3RGB+;FR,9R3[UB#X91+HT6BCQ#J
MHTJVN4N+6W_=$P;6W!0Y0D@'IG./?B@#I?$^M#P[X7U/6#'YIL[=Y53^\P'
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M#'@CQ%/KMQ/+J5];6EU;&*,1.DI92>%W;AP<YQ["NY3PJL>OZMK$>I72SZG
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ML^KB,2D,!Y92/8"G'!QSSGFH=-\-S6WV;^T]9O=6-JVZ#[2L:A6P0&.Q1N8
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MD@'I@*H]?F/3!/34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]L=* .QT[7X=0U2YTUK2[M;RVB262.X0#Y7+ %6!*M]T]"?SR*UJYGQWK?\
MPBWA+4]>@AC>]M[?;$6'=G51GU + FLK7+K4?"NH^&;J#4KF]M]1OX].O8IV
M#"0R [95X^0@KG"X&#TH [NBO._#-OK>N:KKIN/%&I1QZ9K<L,21I$-\8C3Y
M6RF"/FXP!W/.>.:34O%*_">V\;KXENY+ZS+RO:ND8@GC$[*RN N22.X(Q@
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M1G,]WNFBDE( +^7*Z G'<A1F@"T_BNW7Q>/#/V"^:^-O]J# 1^7Y.[;OSO\
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MTXZT :=8VJ^(%L+W^S[2SFO]1^S-=_9H653Y:D+G+$#))P!WP:XS5-6U;1_
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M/MX"ODW7D/YDH9MY.T[@,  =.N0<C'0^&5UE/#MG'X@FMIM512EQ+;'*.02
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MU!O&V'CA7*Y!S@Y[XXKTB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>T8-#/;7&R888G!.,$<G(((-:=AH\%CYLCRS7=S,H26XN2&=U&<+P H')X
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M-%<9Y55 )Z9+=JZF*/RH4C#,^Q0NYSECCN3W- #Z*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5CVOB73KK5(]-+3V]Y-&9H8KF!XC,@ZE=P&<=QU'<5R$-\WC/Q1XBTI[S6;
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MQS%WN+EREO!$NYY6 R<#T &23@#N:I6_BFPO+/4);9+A[C3V\NYM#$1-$W4
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MUP*NT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#SC!'4"@#6HHHH **R=,\16>JZSJNEVZ7"W&F&,3^;'L!W@E=N>3P/3N*UJ
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MN2^)_P#R3'Q%_P!>3UUM9'B?0_\ A)/#UYH[7)MXKM#'+(J;F"GKC)P#[\T
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M&P#M('3 '!S]:DUJYM-3UC3]:M;/7[+5; ,D<PTB5U>-OO1NN!N7OU!!Y!H
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M)2 "P8C./E'RY'3K0!#=1W<_QGL%75+R*$Z)+,(5\LHO[Z(%0"IX; R>O'!
MXJE-XVU31-#\<7][,EY)I.H+;68:,(J[UC"@XY(#29/.<=ZZ:3PDSZ]IFL+K
M%VMW:6K6DS;(_P#2(V8,0?EPO*CE>WIUJ!/ EK+;>(K34;DW=KKLIFN(_+">
M6V !L.3TVJ1G/(S0!5UC4M7\+:WX>,NI2:A9:I=C3[A)HHU,<KJ2DB%%&!E3
MD'/'OS7.SZYXK;PMXPU5/$'ER:%J5RD"+:1XE2-4.Q\@\8)Z8.2>3P!VEKX6
MF,NF-JNIMJ(TL[K3="$)?:5#R$$[V"D@$;1R3C.,4O\ A!&.A>(=);56,6N7
M$MQ._D#=&9  P3GI@#&<X]Z .JLK@W5A;W!7:98E?'ID9K@_"OBJZU/6[73=
M3U&YL=;C\PWND7<"(L@PV&@8+EE!P1\QR,D^_=6%L]GIUO:O+YK0QK'YFW;N
MP, XKG[;PA()M&DU#4OMKZ,&-G(UN%D+%"F9&!^88/0!<G!.<4 >?V=_K6A?
M#[6-?T[5/(2QUNY8V@@1EG4W6U@[,"1P3C:1CW[=AXLU75K.YUC[-JI@%MIO
MGV=O91+++Y@#EGFWH0J?*H'(S\W?%.?X>>9X/U'PVVKO]GOKIKF280#>I:3S
M& YQC<!VZ9JQ=^!WNM6U6]&MW4":O:I;W\,4:8D*H4#*6!*<$\#\Z ,;5M0E
MU:#X9:E.%$UW>0SR!1@!GMG8X]LFM/1O^2O>*/\ L'V7_M6I5\#.EAX;M?[8
ME?\ L%T>%Y(5)D*IL ;&/E"G''/?)K3LO#K6?B[4=?\ MI=KZ&.%X#$ %6/.
MW!SG/S'/K[4 87Q'6=[WP>EM*L4QUQ DCIN"GRI><9&?IFLJ]\6:[X*U37M/
MU:^76(X-*_M.RN)(4B93YGE^6X0 $;B#GCC-=KXC\.KKZ6#+=R6MSI]TMW;2
MHH8!P"N&4]1ACQD'WJN_A"SOUU-]8?[=<ZE;"TG<+Y:K",X2-<DJ,DMG).3U
MX  !2LCXKB\36#'[5/I$L;K>_;?LRF)\91XO*.2">"#GC%.^(6J:IHV@VUWI
M5VMO*;ZWA?=$'W*\BJ1STZ_7Z4_PYX0O-$>!;WQ)?ZK:V@VV<%PB*(AC&691
MN<@$@9.!GITQ>\4^'?\ A)M-BL3>-:I'<1W!98PQ+1L&4<GID#- '.^=XC3X
M@R^'#XAD:VNM,-\LQM8O,MV64(5C^7&#D??#8QWZU!I?B'6[GP?(UQJUM%<V
M>M2:?<7TD85Y84E*DQH%(,K# "[<$]JZ5O#DS>,(_$?V]?/2Q-EY/D?(4+!R
M?O9SN []./>L8_#G&G>0FM3QW$>KMK$%PD*YCF8MN!4Y#+\QXZCU- &4_BC7
M8]&\>K%?2K+HB+-9SW5N@E"M!YFUE  Z],C.#SS5VVU;7[+Q)X/^UZM]KMM<
M@D6>V-NB+&RP^8K(0-V<@@Y)!SP!T%R7X?&7_A(MVNW;_P!O0+#<^9%&<838
M6& .=O0=!Z'C%V3PC++>>'+EM3^?0U81 0#$NY/+.[G^[Z8YY]J .;U+Q+K>
MG7%E/_:@N9'UY+*>&VA5K5('DV!-Y4-Y@&"<,<-D$8XK2U/7M0?Q%XFT]M2.
ME1Z9I\=S9ML0^?N5BTAW@Y56 7 QW[D89_PK/;I2:9'XAODL[?4!?V<?E1GR
M7$ADP21E^2<9]>AK#UBYAD\9ZCY_BNYT&XA,4$,5[81SB=47(EC+I@ LS<*>
MH)/4  &K8^)M=FL/"UE>"X&I:Q;27<_D11))$J*AV*)#M'+@Y.3@'C/()]?\
M4:#IOV75 /M%_K$.GZ7=SB,R".4_>D6,[=R@-TP"<<=:LOX7OO%.BV%S?ZO<
M6^L:?</)8:K!;B"0H>,O$> &'!7C( Z9(J]?>!8]7\//8:KJUY=Z@TR7"ZEA
M$DBE3[C(J@*H&3QC^(]SF@#+CM+FT^-5B)]0GO$;0IRAG1 RGSH\\HJ@@\'I
MZ^V+/Q.$K:?X=$+*DI\0V.QG7< V_@D9&1[9%7K/PA>1^)K/7[_7[B[N[:U:
MU*K;QQI(K,&.0 <<@=#U[@<5H^)/#T?B.PMX&N9;:6UNHKRWFC .R6,Y4D$8
M(SU% ',P77B33O&[>&KW76O(-2L)+FSO/LL22VLB, 5P!M9?F!Y&>WO3-$\1
M:OJ7ANWTV>_>/Q,FIFPNW6./Y"C%W8+MQM,0R#CJPYKHOL$.CSW?B;6;LW-U
M!:&-I8X"JPPK\S!(QN.21D\DG Z 8K-\,VFF:QXJU'QG80RK#=V\5M#))&T?
MG;>7D"L >?D3./\ EF>QH [$#  ))]SWI:** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***YGQGK
ML^C0:1;6KB*XU74H;!9BH/E!\EF /!.%(&>,D<'I0!TU%<3+?ZII'C^ST!M0
MGN+'5[.:2"214,MM-%@L0=N"I##A@<'VXJ#X;RZ]K>@Z7X@U37Y;@2Q3)):>
M1&J,1*P5\@9! ';C&..#D [VBN3UO4[^R^(7A6Q@NW6RU!;L7$!52K>7&&4@
MXW#D]C7,ZIXBUZW\.?$"6'5Y5GT>ZQ9RF*,E$\M&VGY<'ECR1GWH ]2K)\2^
M(;;PMH%SK%Y!<36]N-SK;J&;'3N0/UKF4OM9TOQQX<M[C6);RUUFTN&F@DB1
M4B>-$<&/:-P^\1@EJYGQ+J%[XL^"6K^)6U&:%+I9'BM$5/+6%9=@0\9)(7).
M<Y/''% 'L*L&0,.A&:6N)NM5U'5?$>HZ)8O>0II]I Q>T>)7,DH8[CYG4 *,
M =\Y[5E7-]XRAG\%V&HZG'9W]_-/;W_V:.-T;;&[*XRO#8 ..F>Q'% 'I=8W
MB/Q+9>&M NM8N8YKBWM3B5;8!V!SCN0.I'>K>G65W::/%9W>I2WERB%6O&14
M=CSAL ;<CCMVKQ]HIQ\ _$LTU_<W!>>Z7$Q4\BZ(W9QDD]\D_A0![:IW*&'<
M9I:X1K_5=#\?:9:7.K37MEJ.GW$TD#Q(JPO%L(,>T @88C#%OJ:IZ=J7BW7=
M(T3Q!IC2 W,B3W,$TD(MC;M]Y%Q\X91C!ZY!SZ4 >CUCZAXBM=-\0:3HTT%P
MT^IM(L,BJ/+!1"YW'/H.P/6J_C?Q"_A;P?J&KQ(KS0JJ1*_W=[L$4GV!8$^P
MKF=;T^ZLOB)X#:?5+F\W370<3*@&_P"SM\R[0,9].G3WR =S9:@UY=WT!LKN
MW%K*(Q).@5)LJ#NC.>1SC/J*NUYNVMZXFE_$-O[6D\[1W=K.7RH\QA8!(%QM
MP>3W&:4ZGKNDZ#HU_<:S/>SZ\]G:QQ>3$HMG="SLA(Y) P-V1GGGI0!Z/17G
M6J:SXG\(6'B#5;L&?2XK59+(7DB-+'.6"$'R^L?S!N>1@BNBCTG7(M5MW7Q!
M)-I\ML\=RLJ)YGFX^62+"X7OD'(Z<4 :NH:DMCI5S?PVT]]Y ;]Q9J'D<@X*
MJ,\D'(Q[&KB-OC5MK+N .UNH]C7C^CWFK:5\ ;K6;/6;M;V-;B5'D6-]I%Q)
MGJN26SDDDG/3%=E)K-UJ/C:U\-1W4EM&FDC4)Y8L;Y2SA%4$@X ^8G'/3GKD
M ["BO)=:\5^(;#POXQM%U)UU'0+N!(KT1)F:&4J5#C;C<%8@E0.QKI8;K5]+
M^)=II=QJTM]9ZCI\T[12Q(HADC=1^[V@$+AL8)8^YH [6BN9\8Z[<:0NC6=H
M_E3ZKJ,5D)]H/E*V2S '@MA<#.1DYP<8J@=0U+2OB!;^'I;^>YL-5L99H)7"
M&6VECQNP=N"I# _,#@^W% &I-XNMDO!%!87]W;B]%A+=6T:O'%-P"&&=V 3@
ML%(!K?:1$9%=U5G.U 3@L<$X'KP"?PK@_A;:RQV&M2O?7$J_VS>IY;A-I(E/
MS\*#N/UQSTI?$MO<2_%;PHB:E=P1R6UX=D93:I54Y *D9.X@DY]L4 =+HWB*
MUUN]U2T@@N(I--G$$WG*%RQ4-D8)XP1UQ6Q7DQCU(7GQ)O=.U>?3Y+.X%PGD
M1HQ=TME8!MX/R\=!@^];</B?4=:N]$TZ)9TDNM$CU2X-HT:.2Y50 7X"@EB<
M<\KVSD [ZN?N?%UI;^)#H'V*_EU$6_VH1QQ*0T6[;O!W8QGC'7VIWA(:_'I$
MD/B)HY+N*X=8I5*EI(>"C.%^4/@X.../>N6U WJ_'F$V"6[R_P#"-'(G=E7'
MVGU /.<4 =CI'B33=:N;NTMI)$O;,@7%K/&T<L>>02I'(/8C(/K6M7E&F:G+
MHWQ0\1W?B6()K!TGS[6.T.8'M(\DX8_,7W*>H'0XJS?^(=<L?AK8^.TU%Y9M
MD-W<V)5/)>*1@#&O&5*AN&SG(YSF@#TZBO./&.MZM80>);JSU:3S;&U2>SM[
M.-6%N FYC<%EQECT7.=O(&>:FU6_UV_\7:!IUGK4EA;ZII<T\@CAC8QNH3#*
M6!Y^;OD?CS0!WTLGE1/)L=]HSM09)]A6;X<U^U\3Z#;:Q91S1V]QOV+,H#C:
MY7D GNIKGM(N]1US7-8T=M8N8ET2."V,\2(KW$[1[FE8%2 .F%''7.>,'PB#
M#X7:,&.6_?9/J?.DH [:J6JZI:Z/8F[NV(3>D:JHRSN[!54#U+$#\:Y>PO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex31-restatedcharterasam008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex31-restatedcharterasam008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/;OO@^7=RH&<;><C(QWIEEXVT/4-2L[""XF\Z]B,MLSV\BQS +N8(Y&UB!U
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MW@8=F4C/.1CUSQF@"#_A&+G_ *&C7?\ OY#_ /&J/^$8N?\ H:-=_P"_D/\
M\:K!?6Y+KXMZ-:P3ZC#!)IUQ)+:3H\2'!38VT@ G[WN/:M7XAZQ?:'X2DOK(
M3*J3Q"ZE@0-)#;EQYCJ#QD+GZ9SVH L_\(Q<_P#0T:[_ -_(?_C5'_",7/\
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M#2W7C#2+2R-XSW,D"0)<RM%;2/Y,;#<&< 97CG!YQSB@!G_",7/_ $-&N_\
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MWS;5DD7>R*NW]UC<6RQP,$G(Q0!O_P#",7/_ $-&N_\ ?R'_ .-4?\(Q<_\
M0T:[_P!_(?\ XU4^G^*]'U+2)]3AN76WMYC!,)8G22.4$#84(W;LD #&3D8Z
MU)IWB/3M3U*XTV)Y8K^W19)+:XA:)]AZ. PY7/&1WX- %3_A&+G_ *&C7?\
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MVH2^3;N(7(+\Y4\?*PP>#@\&@#I**H:/K%IKNFI?V1E\AV91YT+1,"I*D%6
M(Y!JC>>,-&L/.>>XD%M!-Y$]TL+M#%)G&UG P,$@$] >"10!NT5Q'B[Q%]F\
M3^'=$'VT6M[),]TUK#+ND1(2RJC(,GYB"=IS@<\$UT>CZ>NA:2T,NI7=U"C/
M*)KZ3<\:$Y"ECR0H[MSZF@#4K \0:!>Z\9;5M6\G2;FV:VNK/[.&9PQY99,@
MJ<<=Q[9KF?$GB5+OQ!X-.FW>H117>I*/N210W,.QCGD ,,[<9Z@Y''-;UIK6
MBV^L>);I=3OY'LQ"U]!*LC1VH"''EIM[@;CMSG@T =+'&D,211J%1%"JHZ #
MH*=7-Z?X[\/ZFC26UW(8EM4NO->WD5&1C@;6(PS9(&T9.>,9R*N67B?2[W4;
MG3Q+);WEM$)Y(;J)H6\H\>8-P&5SQD=#UQ0!L45A0^,-&FOK6T$TRR7D;RVA
M>W=5N5498QDCYN"#@=1R,BJ/AWQQ9:UI&H:G<QRV-M:3S(S7$3(%1&VY+$8W
M<= <C.* .KHK'MO$VFW&I#3BT\%XT1GCAN+=XFDC'5E##YL=P.1W%4+7X@^&
M[RX6&"\E.7F0NUM(J(T0)<.Q7"X /7'2@#IZ*R['7K/4+Q+6);E)9(3<1B:W
M>,/'D#<"1C^(<=1GD"K&HZG::7#')=2%?-D$42*I9Y'/154<D\$\=@3T% %R
MBLBT\2Z;>B]6%IS<6)"W-J;=_.CSR/W>-Q!'((!!KD_ TTOB[3M-\13:AJUO
M?)--)-&ID6WFC,CJL>UAL( "\KR".3DF@#T.BN9NO%L</CF'PS]ENLO9-</.
MMN[#.]%4 @'CYFRW0<<]:YGPOXSLM#L]=&N:C>S+!KUS )Y$DG$$8<*F]P"$
M7L,X[^] '0VOAC6M.NKD:?XG=+&XN'N##<622R(SL68+)D<9/&X''2NBL+*+
M3[-+:(L5!9F9S\SLS%F8X[EB2<>M5M1UNSTU_+D$\TWEF4PVT+2N$'\1"@X'
M7'K@XSBIM+U2RUK3+?4=.N$N+2X7='*G1A_0YXP>E %RBN&TG4[KQKXGUR);
MN>VT31[C[$L=M(8WN9Q_K&9Q\P5>  I&>I]*W;;3;S3-<-Q_:EQ)HXM'!AN9
M-WDR!E.[>?F(*[OO$XQ[T ;E%8<'B[1Y[JR@$TL?V_\ X\Y98'2.XXSA&(P2
M1R/4<C-59/'_ (>CU"6Q^TW#7,-REK*B6DK%)'^[G"\ \<].: .FHKD'^)_A
M..*.=M0D^SO,86G^RR^7$P;;AVVX3D?Q8]>G-;M]KME8W*VS&:>Y,7G>1;1-
M*XCSC<0H.!G@>O;- &E17/S^-_#MOI%EJKZB#8WLJPPS+&Y4N3MVMQ\A!SG=
MC&#Z4D'C71KI8A ]T\TTLL45O]ED65FCP7.Q@"  1R>.0.O% '0T5R&L^/\
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M5)8LQ, '(VG<%88!S7L-% 'GVKRCQI>>$9--AN(IK/44OKHRPLAMHU1MT;Y
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M[\C(Z_C7=^&;6UL]"ACL=,.F6K,SQVK+M906)RP[$]2.HSSS6O10!YOH*OX
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0+'*HR0Y(^7N.<=#Z9KF_'GB:&[T;2Y],FU!(Y-6MHHKN#>D,X\T!UR#\RD
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M!K3OKVVTVPN+Z\E$5M;QM++(>BJHR3^0H L45@V/BVQO=0CL6M[RVN)K3[;
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M<VI:?9S17=N-2!-C/-&%CN,#. <Y4XY 8*3VH Z"BJU_?V^F6C7-TY6,,J@
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M^B6.VM";>ZD+>6Q\PG;\Q4 \'Y3BMSQ/>Z3;WNA0ZFUZLLNHQBT^S[U4S8.
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MM!<I>R6YNEW*-AC! )W9YP2!CK^'-,'BBT<1K';73SS7,MM# %4-*\>=Y7+
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M?49XJ+1=(31K(P_:9[J>1_,GN;@@R3/@#<V !T   &  !6C10 4444 %%%%
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ML..IK)DT_4=:^$MMX)FTR\MM8C2"RD+V[B*,12+F82XV%=J;A@Y)XQFO5Z*
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MA#8.>=P+8&2*@GT/5+Y?B'H:6-U%-JLIFM+EDQ ZF% !OZ9++M(ZC/I7J-%
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MR!F #$L0HVDY!STJ36_#^H+X]6;3X2VF:];"VU8CHGE'(8^[QEX_Q![5WE%
M'%^)H;A_B%X-N(K2ZEM[1[HSRQ0.R1!X=BY(&!DUS, U/1O"_C3PQ>:/J<]W
M<M?36=Q;VKRQW23*Q!W@8# GD$@] ,GBO6J* /(_L]YHU]X?UC4?"U[J>G2:
M'!I]Q!':B:>TFC)(;R^NT[B#CT^F;NJV-U87GA?Q+IGAF6VT^PN[A[C3;2W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "LC6_$-OH:+OM+^]E*E_(L;=IG"CJQ Z#ZGGMFM>J>I_V@
M-/G.E):M?%<1?:F98\]MVT$X]J (]$UJP\0Z/;:KILWG6EPI9&P0>"000>A!
M!!^E:%<=\,KGS?!ZV;V'V&ZTZYFL[J(-N!F5LNP/<,6W?C78T %%%% !1110
M 5DW_B*SL=2CTQ$FN]1=/-%I:H&<)G&YB2%09XRQ&>V:UJ\Y^&[M<>+?'UQ=
M<WPU<PG=U$" B+\,9Q0!UD'B6UFU%]->UO8;]+=KDVTD/)0$+PP)5LEA]TGW
MQ4WAS7K7Q/H-MK%DDR6USNV+,H#_ "L5Y )[K5]K>%KJ.Y9 9HT:-'[A6*EA
M^)5?RKS#P==7-K\)?#!M]1BL4DNW2=MI:62,RRY2%0K9<D#MTW'B@#U2BO-[
M'Q!XDET3Q=%:)=7=[IE^L=JDBQBX\DB-F7CY2X5GVYSSC.>E26GB>ZU3PYKE
MYX:O[S4;NW6(#3[F)4NK5MQ\Q2I498KDKG=\PQSTH ]$HKS5/'<*>&]9U73=
M4N+IX6MK<65_$(Y[*:238=ZX7(^8'DG[I&:UX$\7VNN.\/FSZ;)9O^[U"2'>
MMR 2A4QX^4]"#TZB@#LZ*X'P7XE;5M8CLKS4;^WU2"S;[=I.H0JC^;E,2QD*
M,IPXX.,,.!6OXJURXL=5\/Z-:RF"75[MHFN H)CC1"[;<@C<< #(/4T =/7/
M?\)?:M>P106-_<6LMVUE]M@B#Q)*I((;#;@ P(W;=N1UK,M=0U.T\?W7A2>_
MGGM;G3?M]I=%4\ZW(?8R9VX8<@@D'TYJM\);:6/PB97O;B56O+M1$X3:I%P^
M6&%!R>^3CGH* .@UKQ79:%J5AI]U;WCSW[,EL((MXD91DC@\8'KBB#Q=I4FK
MQ:3<-<6.H3@F&"\@:+S<==C$;6/L"37/>-_^2@> /^OVY_\ 1-5?C<JKX 6Y
MBXU&"^MWL&7[XFW@#;[XW?E0!W:ZB6UI]-^Q78"VXG^U&/\ <'+$; V?O\9Q
MCI5VN.@U#57^)U[HTE^XLSHL=U'&(T_=2-*R$@XR>%[YZUS&D>(?$5O\.#XU
MU#7&NF@AN4-FUO&L<C^<R([$ $8(Y (&,#CDD ]8HKB1+XGTS68+YVN9]%6V
ME:_2\>#<&5=R-%Y?J000>,8Q1HC^(-<T7P_XAM]91#=LEQ>6LB*8?(<$F-,+
MN#+D8)/)!SZ4 =HLB.[HKJ60X8 \KWYIU>3Z=JUSX8L?B'KLE]=WK6&HR!(9
MRA61O*B"EB%!&"0, @ #I6WK&IZQX93PWJ9U.6_@OKR"SOH)$0*?-&!)'M4%
M2K=LD$'UYH [VBO/]"?Q%K'B;78G\1RQVVE:JB)$MM%^^C\M6,;'' YZCGKU
MXQ'X4\3W-_KEII>KW][8:]&'-YI=W$JQS\'YX&"\J#R,-TSG.,T >B444UU5
MHV5_ND$'Z4 <S-X[TR'3)M6^R:A)I$08_;XK??$P7@D '>5R/O;=O?..:ZBO
M()$\0_#32);>2!?$G@78PRAQ<VD#=0>SH 3SZ=U%=:FNW-S\0]*M;2_=](U#
M1Y+Q8MBXR&0*P.W=T;H30!M>(O$5KX:LX+J[AN)(YIX[<>2@;:SL%!.2,#)%
M;%>/:WJ>I:IX#U9;R\-Q-:>*DM())(U&$2XC"@A0N<?K72I<Z_H'Q!T[2+S6
MI-3T_6K>X:,RP1H]K+$ Q*[0 5(8#!S]?4 Z_2]1.IVTDQLKNSV3/%Y=U'L9
MMK8W 9/RG&0>XJ[7F6G>+M7C\)1/<7+W-_=^()-*CGV1JRKYK $# 7.U"!GC
M)&<]#9U/6O$_A&R\0:M=JUQI,-F);07DD9ECGW!=I\OK'\P//(P10!Z)34D2
M4$QNK $J2IS@@X(_ UST6EZ[#JEK*OB!I["6W=+I98TW^:1\DD6%P.^0<C&.
M#6/\)8I_^$*CN)[^YN3)=765F*G!%Q)EL@!B3U.2?PH [DR()5C+J)&!95SR
M0,9./;(_,4ZN"N+>YD^-T"C4KQ(AH;3")2A0?OT!4 J< X&3UXZU3AU_6M;^
M'=_XSL-2>WGB-S<6UIY:&'RH78>6X(R2RH23D$%N, 4 >DUC>(_$MEX:T&[U
MBY2:XM[7B5;90[ YQW( Y(ZFK.D7_P#;?AVQU% ]O]NM(YP!@M'O0'N,9&>X
MKR%HIQ\!?$\\]_=7):>Z7;,5/(N2-V0H))[Y)_"@#VU3N4,.A&:6N&%]JVC?
M$#2K&YU:6\LM3L;B5X'B15A>+808]HW8PQ&&+?6J&GZKXL\0:+I'B'23*&N)
M5FEMYI(1;&W).Y!CYPP&/FZY!SQP #TBJ6K:@=*TN>]%G=7IB /V>TCWROR!
M\JY&>N?PJAXQNKRP\&:S?6%R;:ZM;.6>.0(K89$+#A@1VKB];N_$^D_#"\\2
MKXFF>ZDL;::./[-%MA8[0^#MR<AN_<9]J /3P<@'!&>QK(\2>(K7POI)U*\A
MN)8!(D9\A Q!9@HSD@ 9(%96M:Q=1>-=*TB:Y:QTRYLYI?M*D*99U*XCW$<8
M4LV!R<>@-<1K5]K.I_!O5[S5+UKHG488K65H419(DO$59!M R&&#^''!H ]D
MIJ2)*I:-U< E25.>0<$?@017%6]QJ]G\1GT*XUJXNK6^TF2[4M%&K6\JR*G[
MO"_=PW1MW3J:YWPI<ZWI_P ([;4K&74=1E:\D:>*,(\PB%U)YK1Y7+.1D_,3
MWQB@#UFBN9\%ZU:Z[87EU9ZQ)J,'VG").@2:V&Q08G&T'(8,<D=#U-0/JMSK
M'CO4/#T-Y-96^GV44TC0!?,EDD)QRP.%4 =.I// Q0!TU[>6^G6-Q>W<JQ6U
MO&TLLC=%51DG\A69IGB)=1U1K!M+U&T;[.MS'+/$OERQD@<,K$!N1\IP?:O/
M-;U;4]9^%?C.SU&[?[7HTT]G)/$B*+M% *EA@@9##(7'(]\5Z;HMO);:1;))
M=37+&-3OF" @8''RJ!C\* *^C^(K76[_ %6S@AN(I=-F6";SD"Y8J&!7GI@C
MKBMBO*#%J7]I_$F[T[5YM/DM)DG0PQ(Q=UM58!MX/R\=  ?>MJP\47NOZMX<
MT@3M9M>Z&NKW4L(&YMVQ1&N0<#+,3WX'2@#K-=UF#P]HEWJUU%/)!:QF218$
MW-M R3@D?SJW9W*7ME!=1A@D\:R*&Z@,,C/YUYEJ^L:A+X:^(_AW49C=/I-D
M6ANV4*TD4L+,H8* -RX(R ,\<5LVNKW%SK'AWPO;7#VJ-HPU"YFC WLHV(J*
M2#C))).,X'&,T ='HOB*UUVZU.WMX;B*33KC[--YZ!<MM#9')XP1UQ6O7D>G
M:K=^&9/&&R=[F[G\0VUG'/(J!AYJQ+N/1<A3WP"0,UTH7Q9:7VI,;F=-):P9
MXI+MH7GAN5R?E"C!0CL>AZ<4 =O17F>E77B^;X?6OB:+5+G4KNYL(&:PBMXE
M/+J9'C..7\O=@'(W'IT%=#X+UZTU\7\]GJUQ=Q1LB&UNXQ'/9O@[D<;0>>H)
MSW&>* .KJ.>:*VMY)YG6.*)2[NQP%4#))_"N8O-7N;_X@#PQ!<R6D,.F_;II
M(@N^0M)L502#@#!)QR21SUSS5[JFIZCX/\?Z)J%[*USHL4R+=QHBFXA:!G0.
M-N,X."5 [8Q0!V>F>*(M3U&"U33=1ACN;7[5;74L0\J6/CNK$J<$'# 'FMVL
M+P9;R6_@_21)=37&^SA8&4(-@,:_*-JC@>^3[UR'C3Q!K.D6/B2_M-59Y].:
M-[:"TC5HH(\*2)RRXW,2?E#$X*D 4 >F45P^HW>M77Q*M]%M]9EM+"YT>2Z9
M8X8RR.)$7*LRGG![Y')XZ$8\>J^*KSX=:I=V>JRR:KHNH7,+.L,>Z\BADP00
M5(#%,X*@<@>M 'J%%<SINKGQ!K-E<:9?R'2X[!;B8!4(E:7_ %8)QD$*KD@$
M?>6F^-=5U#1[6QNK>VO9M/$Y_M!K! \\<6TX95/;=C..<4 =117GL7BQ[BPT
M"VTO5GU4:O=W 6\C$:2B) S[,,%4.!M4Y'0$XSBJ/B._\9Z!X,\4WDE\\"6O
MES:9<2>3)/M) =) !MP">#U]30!Z'JFHG3+,7 LKN\)D2/RK2/>_S,!NQD<#
M.2>P%7:\_P#%C^(O#>@2:@GB.::2;4;4!#;1!8T>14=%XSCDX)Y'J>M6[_5=
M4U?Q)K>C:<]Y --AA >T:$-YDBE@S>9U &  /1LYXP =K17G.H^(?$6AZ;HE
MQXGBN8;7[/*NIW>DHLODS!@$=Q@X0J&)P.IP>.*[/P]<B[\/6-P-134?,A!^
MV( !-_M8  &?3'% &G5#5-6M])C@,P=Y;F98((8\;I9""0HR0.@)Y(& :XVU
MU?5_$OAO7M;T_5);.:SN;B.R@5$,>(> ) 5))<@YY& 1C&,G*U6_G\4'X<:R
M+JYLS?W(<PQ!"L3F"0EEW*23U'.1CMF@#T'2=;_M:RN)UTZ_MI;>9H)+:YC"
M/N7'W3G:P.1A@2#ZUB0_$O0)=-.IR+?P:<LQ@>\EM&$2.#M(8C.T9XR>/>NN
MC4I&B,[.5 !=L9;W.,#/TKQOPOI&L^(_A;JFAV$=C'#>ZA=1274\S$QJ93N(
MC"<GT^8>M 'LB.LB*Z,&1@"K*<@CU%.KSB2UUNU\7V/@_3/$,]G81^']R.((
MW='C=(PPR.21C.<]3C!P1(^H^(]=CUV#2+F[6[TRX-E;2Q^0L;2I&I+2JW)#
M,QR ,!<8YH [34]7M]+-M'(KRW%W+Y-O!'C?*^TL0,D 852220./I3-$UA=:
ML6N!9WEF\<K0R07<6QU93@]"01Z$$@UP_B&WU*[\7?#][V]FM+R9IQ-';&-D
MBD%LQ8H64YR<CG/'I5FXU/Q!K[>((=%FNX;C3;DV=JT;0!#*D:MNE#C)!9L'
M QMZ<T >@T5YS<7/BJ_\96.B/K7]F-<Z"US.MO#'((;@.BDH6'(R>^>">AP0
MZR_X274O&FO:+_PE$T4&FI8R)(MI$68LK%U/&,-@^_3G ((!Z)4=Q-]GMY)B
MCR;%+;(QEC[ 5YU'J_BOQ'H7]MZ 9DN?M;^1#(\(M6B24H4?.7R54DGKNZ8%
M:UGJ5]XGUOQ%;0:A-80:4ZVL0@5"6E*!F=MP.0"0 .G!)SD8 .@\/:Y:^)=!
MM-8LDE2VNE+QK* &QDCD GT]:TZXOX2_\DLT#_KW/_H;5VE !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4451U?5[31-/:]O&81AEC547<\CL0JHH[L20 * +U%8<'B
M5&U:UTR[TO4;&YN@QA$Z(RL%7)^='91]"<\],<ULI+'(\B(ZLT;;7 .2IP#@
M^G!!_$4 /HHHH **QK/Q'!>>*-0T%;:XCN+&&.9Y) NQU<D#;@D_PGJ!6S0
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M#TDZ)I,&G_VA=WR0*$26[*M)M'0$JHS]3S0!P=E<R:+XR^(NK/=WEPFFP07
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M2&+40;E@K2 &-.F1MSV!(/T-=AXAT.U\2Z!>:/>M(MO=)L9HCAEP0003GD$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF0KL1MI;YLG/13T'XUQ%SXDU'P?)X\1KVYU*+2K6VNK3[8P=D>56!!( RNX
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M-/DM8X)MD,C2*PN%V@[P!T&21@^E $MG90:?IT%A:)Y-O;Q+#$J\[%48 Y]
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MK:[M9/+F@?U5L'\B,5!)X*TRZ\/7.CZA+>7ZW)#375S-NG9UQM8,,;2N!@
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MEC*?<964###U_//-16'@RSLM=@UJ34-3O+^&V-J);FYSN0MNP0H /./R]>:
M*WB_6)[76O#6BQ2O!%JUX\<\\9VL$2,ML!ZJ6.!D<XSCGFJ5K+=V/Q(N_#!N
M[N?2KS2OMT?F7#M);.)/+8+(3NVG(/)X/3%=+KN@6/B&SBM[T2*T$RSP31-M
MDAD7[KJ>Q'Y4EGH4-I<W%X;JXGU">-87O)MAD"+DJH 4* "2<!>2><T <O\
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M.5R0#QCI0!VL]U!;-"LTJH9I!%&#_$Q!.!^ )_"LC2?$9U/Q/KFBM8O VEB
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M1%MVS<,XS@9K4KR*V:[TGX:>"?$]O=7@M=-@@.H6L4[JDMLPVLQ0'!*$AO<
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MH/MEO]N%EYJ_:3$9O+[[,XS^?]?2@#!OO NBZCJ6I7LPNU;4X1#>117+I',
MNT%E!P2%XJ6V\(V=BML+&]U&V:WMA:JZW&\M&"2 V\,"1G@]1T&!6GIUQ?W
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M#6DPZ78--]CA!$22OOV DG /7J>]:E07-Y;V8B^T2K'YTJPQ@]6=N@'^>QH
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M,,]<G)R>O/6M>N8U#Q/??;=4M=#TE=3FTLQ"ZB-QY3,7&[;'E2"0I!Y(ZXH
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M#TK3T71[30-)@TRQ$HMH,[/-D:1N22<LQR>2: +]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS7-EJVI6L;3V[*!+"S9* E@06 QV&"02*Z+1=!L],MKL6J7=O#?/YK6LDQQ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7-:KX0;4M:DU2'Q%K.GRR1)$4M)(@FU<D8W1L>I)ZUTM% 'G'@.RU+P5\-V
MN;VVUF_NEDD/]F*BM(@\]P/+7 ^\&#G)/MCI7HRG*@X(R.A[4M% !1110 44
M44 %<-\5;6[O_"T%I8V5U=W'VZWEV01,^%1PS$D<#@5W-<^W@W2F8L9M8R3G
MC6;L?^U: *GCW3+W7?!LBZ5 L]W%-#=Q6TZ[1-Y<BOL8-TR 1@UGZ/=6VHPS
MWMMX(N-'DBM7666XL%CF+$8\N(+\S#.23P.!Z\;7_"%Z3_SVUC_P=7G_ ,=H
M_P"$+TG_ )[:Q_X.KS_X[0!R4.GZ@/@ VCG3KP:D--:U^RF!M_F8(QC'3WZ5
M?OX;J7Q'X!N4L;TPV2S&Z;[,_P"YW0;!NXX^;C]>E;W_  A>D_\ /;6/_!U>
M?_':/^$+TG_GMK'_ (.KS_X[0!RILFDU/QX=0T&]O=/U&XM-L/D.//B")'(4
MZ<KR1T/&1ZUJ^"-/U/2M4U*S6\U"[\/K'$;)]2C99HW.[?&"P#,@&W!([X'0
MUJ_\(7I/_/;6/_!U>?\ QVC_ (0O2?\ GMK'_@ZO/_CM &5K5I?:7\2M.\3)
M;7%UILFG/IUR+>,R/;GS!(K[%RQ!(P< XQ5(:1=+'X]UL6ER!K<2Q6EL(F\Q
MQ' 8PQ3&5+,3P<' !.*Z+_A"])_Y[:Q_X.KS_P".T?\ "%Z3_P ]M8_\'5Y_
M\=H ?X*26'P1HEK<0307%M80031S1E&5UC4,.>O(ZCBL.#2KKPI\0=7UJ.VG
MN=(UR.)IS;QF1[:>,$ E%RQ5@3R <'J,<UL_\(7I/_/;6/\ P=7G_P =H_X0
MO2?^>VL?^#J\_P#CM &/JFF3^,O%NA7(M;BWT?1IC>-+<Q-$UQ/C"*J, P"]
M22!G@#/6I-!6XA^)/BR[ELKR.UNX[1;>=K=PDAC1P^#CL2/KVS6I_P (7I/_
M #VUC_P=7G_QVC_A"])_Y[:Q_P"#J\_^.T <_P"%H[JVT;Q@EQI]]$]UJ=[<
MVZ/;.#+&X&PKQW].OM6+:V.N:-X>\!:S#I%[<OHD$EMJ&GI&1.%D15+(IQN*
ME1TZY^M=U_PA>D_\]M8_\'5Y_P#':/\ A"])_P">VL?^#J\_^.T <_XJCUCQ
M/X734+'0I%:SOH+R+3KU526[6,G>K+DA<@\ \_+[@5?\/WEM/]IU:S\%7&E>
M1:L'\ZRCAN9FX;RXP#DC@]< DKCOC1_X0O2?^>VL?^#J\_\ CM6K#PUI^FW:
MW-O+J+2*" )]2N)EY_V7<J?RH NZ;>-J&F6UX]K/:-/&LAM[A=LD9(SM8=B*
M@UVYO;/1;FXTZV:ZO(P&B@7&9#D?+SP,C//:M&B@#S'Q7HUMXFU32-0T72+^
MR\20WD,C7KVCP>5$#\XD<@*XVY  +$]N,U>9;_2?'WBF0Z1?7,6KVEM]EFMX
MMT>Z-'5E=NBGD'GJ.F>E>@44 >2Z3INJV7AOX=W-SH]^@T>1Q>Q"+?+&K1,@
M;8N6(R1P!GVK<N--FNM5\5>)F@EM[:71_L4"RH4>7:'9I"IY498*,@'@\8QG
MOJR-9T$ZS)&6U2_M81')%+!;NH2='&"'#*>?0C!&3S0!YPEC>0^%_A[K\6B-
MK5E9:4L%Y8QQK))LDCC(D1#U(*#CKS^-:.MZ=>WN@VFM>'_"WV![#5(-0&GM
M"D$]VB!E?<J\ X<[0>?E]P*](MK:&SM8;6WC6."%%CC1>BJ!@ ?@*EH XR_O
M=0\7>#M>BM=#OK$3Z;/!$E_&(II961@ %R<*,XR>I/'3G8\(2S2>%-,2>RN;
M.2&VCA:.Y38^50 G&>!G(Y]/3%;=% 'G$^B:E=^(/'^E_8[F*/7+>,6M[M_<
MC_1O+.6SU#<8Z\YZ<U!<66H^)? &C^&)M,O+/4X);6.Z:6%ECA$+*7D63&UL
MA?E"DGYA[X].HH SO$%K+?>&]4M+==TT]I+%&N<99D( _,UYY)%J-QX/\ VQ
MT;4XYM,U"R:Z1[9LHD495WP,\ GCN>H&*]4HH \OUW0-1UWQ!XUMK:VN(AJ&
ME006L\D++')+&7)7<1C'(&??O6IX6N8]4N[,R> FTB_M@3<W-Q91QI&VT@^2
MXY;)[CC&<GH#WE% ''?$JWNKSPU!!9VEQ=3?;[:79!$7.U)59CQTX!IGCR*X
MO?\ A%VM+.ZG$&M6]W-Y4#,8XE#;F88XQN''7VKM** /+];NI=.\;^('LM-U
MIH[^S@@NI;"R%VK,%8!N&!C=58#!!SD$CIE9DM;BS\#Q:%IVI?8M)U$":.6U
MD$ENJ1,A\P8R#E@??.>E=3)X.":K=WVG:[J^F_;)?.N(+>2-HW? !;$B-M)
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MH.2 <9 )SC.3TK;\9Z-<^(O!.K:3;,([JZMF2/+<;NH!/H<8S[T <EXIU?\
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M+83;6$GF98< [=H.1@<#- '6?\)182VNERV:S7<FJ0^?:01 !WCVABQW$!0
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MNH-Y4JT;JFT#!.<8.>WN:DO[34+;XK66K1Z=<7-E-I+V1EB*XBD\Y7R^2,#
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M4[^\ELXC$<RI* $([#.#UQCO6G>VM[-KO@&X33[LQ6 E^UMY)_<[H#&,_P#
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MKZ^N9+.(!6$BR*H4#!/3!R>GN:]/TDL='L]\;QL(4#)(NUE( !!% %RBBB@
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M"T?3[^UDMKNUMQ%+$^"01[@D$5FZ=::A;>,/&M])IET+:^CMA:N I\TQQ%&
M&<CD]\5W%% 'E,>B:U'\./!FF'1[HWNFZC:3740*91(GW,<[L'CI@U;2SU;P
M]XIUA&\)?VY8:I=?;+6YC,6Z%V50T<F\C"@C(//7OT'I+ND:EG8*H[L<"G4
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ML[!5'4L<"@#A?%,&N^+_ (=ZW!'H\MG-<1(+6SN'3SF*L&8M@E5SC &>W/7
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MI_"Q(/RDX/M5+PA'XHT^SL?#VH^&;=&L0D)U<31M%)$F &"_?WE1C!'7D^E
M&U>^-8[:TN-0MM,NKW3+6Z^RS7%OAFW!PC%$ZNJMP3QT. <5%:>)-2N/B+JF
MBR6(2PL[6&02>:O\9?+GV^4 #VR>O&1X<M_%GA9KWP[%HHN[1KN::QU/[0@C
MCCD<O^\4G=E2QX YZ<=:ORZ+J8^(.KSFR>73=6TR*U-VDJ*(64N&W G=G#9&
M 1GT[ %B?Q[:V^D0Z[)8SC0)91&+\,/E4MM$K)U$9..>N"#BC4/&\EKKU[HU
MGX>U&_O+6".XVPM&!)&S$;E);VZ'!/IU-<]#X>UZ?X9'P)=Z<ZW"J+,7X=#
M80X(E'S;L[1]W&=WMS6[INEZA:?$R^OO[.F73'TR"TBN3)&06C9B>-V[&&'.
M* -_Q%<V]IX;U*XO+*2\M4MI&GMX]NYX]IW#D@=,]ZY^'QA9:78^%+.ST2\\
MC5[5?L<<&PB(+#O$?+ YQ@9X'<G@UO>)X+B[\*ZM:VD#3W$]I+%%&K*"S,A
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MZ@JW-T0,#<5 48[855&/7-4_$D&M2^*=,V:;+J6@F"19[>*9$ G)&UI Q&]
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MTN83!,L*J\98-M(&",C@UYJ?!_B"[\$ZOH0LQ;7EOJLFH65Q),ICN#Y_FH
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MDTH2:?!]GC+2S+_HD8A\S((.1EB6RO\ 2O1=/2X2PA%TD23[<ND/W$)YVCU
MZ9XSC/%<59Z!J-]K'CN&]L)[.SUU$BM[@O&WRBW\ICA6)'/(XH T3XWM[73]
M,U*XT^X@T6_=(H+UG!*[_P#5M(O55;C!R3R,@42^-Y?^$@U+1K3P[J5U<Z>]
MN)BC1@;)<_.#NZ #..IR>!@FL%]!UO6OAW8^"]1TR2WFA-O;W%X)$,/DPNI\
MQ"#N)94  P""><"MS0[#4K;XB^)]0N-.ECL;^*T6WN"\9#&)7#<!BPSN&.*
M-[7-8BT+29=0FAFG",B+% NYW9F"J!^)'/:JFE>(A?ZYJ.BW%HUM?6*12N X
M='23.TJW']T@@@?C47C5-<D\-R+X?1WO/-C+QQR".1XMP\Q48X"L5R <\=N<
M5A^&M(U&Q^(&HZB- -AIM[80(K&:,LCH7R'"DDN=PZ$CONSQ0!H^,/$6I:+J
M7A^TL;/SDU"^$,C^8H. K-M /<[>IZ#Z\.U?QM;Z8M^8[7[0VFH'O$%PB,AV
MARB GYV"D'' Y'.>*9XWTW4;NX\.WVG6+WIT[4UN)H(Y$1S'L=21O('!8<9K
M&%KXC\.^*]5FA\-)K.G:O*ETK1W$:O:S;%1U8OC*_*""/RH U)_B%;M=:=;Z
M9I%_J+:E8-?6AB**)5 !V\M\I^;G=CT&3Q3H?'%Q=:C>Z9;>&M2;4;2VAN'M
MWDB7B0$XW;L#&,>N>W!-0RZ;K'_"P?#^HOIQ>VMM/F@N9X'01I)(4("J6#%1
MM(SCTJ:PL=2M?B/K^JR:9/\ 8;FSMXH90\?SM'O)&-V1G<,9 _"@"O%\2;:?
M2=+UE-'OQI%]+' ]VY1?(D=M@!7=N(#<$@8],UV=S<0V=K-<W$BQP0HTDCMT
M50,DG\!7ED?AKQ GP@TS03HT_P#:4%ZDLD0FAP%6Y\TG=OQ]WWZUZ-KFFG7/
M#>HZ86,)OK22#<>2F]"N3CTS0!A1^/[/^U-+M)K4Q1ZME;.43(YWXR%D4'*$
MCIU]#@T6WCV.YOKW31I-TFJVMVEJ;%W02.&!82+SC9M!;.>@/?@T_"LOB<0V
M>F:KX7@LYK-52?41-&\<P0<&-1\VYL=\ 9)]JJ:MI'B%]4M?&>GZ;,-;AG^S
M-IQEB DL<G*,V[;N_C!SP3C!QF@#=U+QD]EXCDT"VT*_O=06S%Y&L31A9%W;
M>&+849SRV.G .16-J?C;0]:^'EYJFH:)=75I#=+:WUA*%#P3+(H ?+#HQ4\9
MZCCK1->S0?&B.8:?<R;_  X-\:;"\?\ I!ZC=@^G!/Y<U0U?PCK$G@+Q)#;Z
M>TNIZYJ@OA:K+&/)7S(R S%@N=L>3@GDXYZT =1K'C-],\1'0[?0K^^O39->
M1"$QA955@I );CJ>N.F!DD5%8ZO8S^-+^-= N8=9CTR*661S'OEC+';&,-C@
MYZD<BF266IR?%.RU@:7.-/727M'F,D?R2-(KC(WYP I!(!YHAL=3A^)^I:P=
M,G:PDTN*VCE62/YY$=F( W9&0PP2!0!6L_B7#=Z9I&K?V)?Q:7J-RMM]J=D
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M1\ALLW;' ' '6EUOQ;+I3ZN8=*DGATBU6ZNI9)/*#*0QVQ94AV 4D\@<@9H
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M/+Y<<<1.%+-ACECG  /0YQ0!>M+.RT6R<1L8X@=\LT\I=F/3<[L22< #)/0
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MFQB80F1?-*E@F?F('!./3D4^O.M0=[#XT^?8:;]JNYO#S9CC*Q[R+@<LQZ#
MQGD]*V+/Q[8W/AJUU66 VL]Q=-9"UFE5=LZE@RE^F!L8Y]!TSQ0!UC,%4LQ
M4#))Z"D1TEC62-U=& 964Y!!Z$&O/=5\4V/B?PUXRT6XMH/M>GZ=)(ZQRK<0
MR*T3%71\#.".X!!K3T/7$T_PMX1TZ&'[1J-]IT/D0[]@"I$I=V;!PHR!T)R0
M * .N66-Y'C616=,;U!R5STR.U/KS[P"&7QMXZ#V263_ &NVW0QD%0?)Y((
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M7FB>$-3U:RMTEN;6U>81ROM VJ22<9SC'3OTR.M</KMQ<3O\/-5O+ /?F]4
MQ,KR2@V['J0,9/.#P/6@#U.BN3L_','DZ\=7LI--GT0H;F(R+*"KKN0JPX);
MICUI+#QU;7'BBUT&XB@2>\A>6UDMKM9U;:,LCX VL!SW!YP: .MHK*US7K70
MH;<SLGFW4P@@1Y BL^"W+'A0 I)/MP"2 <"V\<G5+;Q!:V=M%_:NDQAG2.Y$
MD3JRDJZ2 <C@Y! .1B@#KDN[:2Y>V2XB:>,9>)7!91[CJ*(+NVNC(+>XBE,;
M;7$;AMI]#CH:\8OXIT^"-KXA&F1IJD&EXCU%;DB7;,H$CG Y+;CP<\G.<UW+
M7.E>']4MI_[,L++7;VU,05KL11^1$1R[8QU90,*6YQT!P =I17':9\0]/U/2
MS-';O]N&H'3!9K(K;K@<_*XX*;06W>@/&>*@U_QEJVG>'O$TB:*T&H:1") [
MN6MY%920Z/M&_;@Y7 Y&,]Z .UDFBB*"21$,C;4#,!N/7 ]3P:?7%7VLQ(GA
M,:UH8N+B[O(TMY_,5U@E*$A\G!W8#=!^-:NG^)7O/%.J:#-8_9I["%)U=YLB
M='SAE&.@P0<]#ZT =!17+MXRBCL].:6&W@N]11Y;>*>Z")Y2X^=G(X!W+@ $
M_,..N,K_ (6A9_V#/J*Z9/+):ZBNG7,44J.(W+!0P8'YU.X8('/H* .]HKF;
M+Q>7\0WNCZIILNF2V]G]O1Y)4=7@W%2QV\*01R,GZU0C^(]@=0T>.2*(6FKR
MB&VECNEDD1V&4$L8Y3=[$X/!Q0!VM%<YIWBE]5DCELK%9K%KR2S>9)\R1,A8
M%G3'R@E>.<_,I(&>#3_%+ZI*LEC8K/8_;9+)Y4G_ 'D3(S*6>/'"Y7CG.&4X
M&> #HZ*S];UFTT#2+C4[TMY,('RH,L[$A551W)) 'UK-'BB2T\06.CZOI_V.
M744<V<J3>:CLHRT;' VOCGN#S@T ;DUW;6\D<<]Q%$\IVQJ[A2Y] #UJ:O--
M&M6\6>)O&%CK^DP7%I]JAA8-/DP*L2LJJ0 ?O$MD$<L:WO&FO:IHMUX?M].M
MHY$O]2CMI'>7:<89MHX/7:<GMZ<\ '5>;&9C")$\T+N*9Y ]<>E$DT4(4RR)
M&&8*I9@,D\ ?4UYQ'-<Z=\5]=ET[1OM-Y-I%K(\$4BQJ7WODLYX[ 9P2?3&<
M7[[Q?I.K>%?#FL7&B27EKJ.H01QI+L_T:8R; S9/56!Z ].V: .D'AVT'B<^
M(?.N?MQM_LOWQL\K=NV[<?WN<]?>M>N<O/%+IJ.JV6GV*WLVEHCW,7G[)3N7
M<-BX.X8(Y)'/ R:Z.@ HHHH *YRX\%:5-JEQJ,$VHV4]RV^X%E?2PI,V,;F5
M6 S@=1@UT=% $%G9P6%LEO;1[(ES@9))).223R23R2>2:GHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "N7^(&CW^M^$I;73(5GNTN()TB9PGF>7*KE<G@' /6NHI
MKR)&,NZKGU.* ..DL=8N?B'I.MR:3)':PZ=-;RD3QML=V5@/O G 7G ZGC(Y
MKGO^$3\2-HNI2VMHMOJD'B236K&.>5"DZ$GY&*L=I*EA]<<]QZDKHXRCJP]C
MFG4 86@7VO:D6GU?1TTA%3:MN;E9W=N[%EX &,#N<G.,#.9XO\-7]YK.C>)=
M$$3:MI+N!!,VQ;F%QAX]W\)QT/3)YKL** ,6VU+5K]5C&B76G,2/,ENY(6"C
MOM$;L6/IG [^QPM'TW6?"FM^(D@TV34;#5+MM0MI(I8U,<K@!TD#L"!D @C/
M'OQ7;T4 >9V/@S4_#_\ P@EI;6C7D6C/<27DT<B*H:5&!VAF!(#.>W0>O%7;
MZYGM?C;$\-E+=Y\.D,L+(&4?:.OS$ ^G7O7?UE'P]8?\)'_PD!\_^T!!]FW^
M<VWRL[MNW.,9YZ4 <-=>!=7:S;6;:.,:R-?_ +:6S:0!2@&SR2W3<4YSTW'&
M<<UOG3+W5/&%IXDN--GM4TZQEAAMI'C,LLDA&?NL5  7 RW))Z <]7!<074(
MFMYHYHB2 \;!@2#@C(]""/PITDD<,;22NJ(O)9C@#\: //-)T3Q5IOP9&B64
M!L_$%O$4C!F3#9DW':X) )0D G&#^=2:+HFK6WQ!M]83P]%I^GRZ2;253=(S
MQR>;O)?&=S'U!.>I/:N]BN(9T5X9HY$;[K(P(/TQ4E 'D_\ PB_B7_A2T_A)
MM('V^,"&(K<QE90)MY?)(PNW'7G/8=:Z2?2]5T[Q^OB>SL);NTOK!;2\M5DC
M6:%U;<CC<P5AR00&]QFNTJ*XN(+2!Y[F:.&%!EY)&"JH]R>!0!YKK'@[5YO#
M6N-;V)DU'6=7AOC;K*@$,<;H0K,2 6VH2<9&6QT&:Z%M/U*3XHVNM?V=*NGK
MI#V;2F2/*R-*K_=#9P I&1W_ #KJIIX;>!IYY4BB09:1V"J!ZDFH;74]/OF5
M;2^MKAF3S (I5?*9QNX/3((S0!#KBW#Z+=):V45]*RX^RRD!9E)&Y3GCE<CF
MN8\'^&)M \0WTNGVUWIN@SVZ[=.N)ED"7&XEFC"LP5=O!&>2?0"NWHH Y+QW
MINI:I%H::;8/=&TU>VO9L2(@$<;9;[S#)]*;?Z?J<_Q'T;5X].E-C;6,\,LG
MF1@J\A4@8W9.-O/U[UU]% '%>%--UK2M(\3)-IOE75UJ-W>VB2R1LL@DY0':
MQP<\$'\ZJ>'_  G-IGBE;_2M.N-#TZXM9!J%@\Z/"\QV[#&BL0"/FR>.,8')
MKT"B@#D_ASINJZ+X-LM'U:R6VFL4\D,LRR"7YB=PQT&",9YZ\#OC>)=$\1ZK
MJ?B:VDTN/4+*[L/*TJ:2Y18[5C$ROE#SO+'(8#I@9 KO+K4;&Q>)+N\M[=I3
MMC6654+GT&3R:G>1(\;W5<],G% 'GMGHVO#5O =Q/I#1II%E-!>;;B-MA>)$
M&/F&>4).,]>,UG:MX8\0WGAWQS8Q:1)YVLWRSVFZ>( IB,$L=_'W#^8KU165
ME#*00>X-+0!Q]]I^J77Q!\/:LFF3+9VEI<13NTD>4:39CC=DXVG./PS7)W?A
MGQ3_ ,(#K/A6#15D<Z@T\%T;J,)/&UR)1@9R"!G(;'3C)XKURB@#SO7M(\2Z
MKJNNQ7&DQ7MG=Z>(]-9[I!'9R&-@^5/)<L<A@#P ,@9I@T37SIW@%)-(82:,
M\9NU2XC.P+"8^I89.3G SQWKT>B@#*\36]Q>>%M5M+2!I[BXM)88XPRKEF0J
M.6( '-<A/H>MMHW@*W72I3+HTT$EX/.B^4)"8SCY^>3D>WY5Z)10!YSJGA+5
M-;UKQK&]N]K:ZQ8V\%K=-(A DB#<E0Q8#+#MT!Z5JZ-/XMUBU&G^(-#ATU!$
MT=U=)=)*+C*E?W:KRN2=V6Z8QSG([&B@#@?"*>--)L;/PU?:/;>18A8$UA;I
M2DD"<#$7WM^T8YXSS[&WHNFZQI'B#Q4SZ;YMG?W/VN"=)T!?,2KLVDY#97O@
M8[UUS7,"7,=NTT:SR*62(N S =2!U(&1^=2T >66OAG7[?P'X+TIM)D-WI.I
MP7%THGBP(XV8DJ=_).X8'UZ5KWEI=V?BWQ+KE]8(NDS:0D DN94\MBF\D. 2
MP4[@.GKQ7>57O["TU2PGL;Z!+BUG0I)$XR&!H \OT1-5T6WT237/".J&UTI
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MM! Z7*E9 92^\YQM&"..3GL* -;QI=ZDGBCP=:6MM;O:RWKN$>X*"1UA<@,
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MST_B;S/$%IHFG0)-=W%BVH%II"B)%N"CH"22S=.P!/L3PAXEE\4Z7+>R:?\
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MUU) /48((X/K67X.UU=*^'G@RQAA%QJ&HVR16T)?8#M0L[,V#A549Z$\@=Z
M.[CO;6:ZFM8KF%[B$ RQ+("Z YP6'49P>OI4]>8Z7JBZ%X]\=ZGJUM%:K;65
MG+(+=]XDXDP02%Y/ P>_?O6[;>-Y)/$=II$EI:3?;89'@FL;SSU1T&3'+\HV
M9'0\@X(H [&BN T_XAZE>>'Y?$$OALQ:3!%=//(MV&=6A9@ %VC<#MZ]CGC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N:\>:)>Z_X5EL].$37:SP3QI*VU7\N57*YP<9"FNEHH X34M,\66/BB+Q-H
M]G8W4EU:+:ZAILER4 VLS(Z2;>HW$'(_#GB76]'\0ZE-X:N9(+:6>QU$7MTL
M<NU$78R^6A(RQ ;J<9(/3.!VU4%UO2GU,:8NI6AOB"1;B9?,..ORYSQW]* ,
M2_TG4IOB-I6M16Z-8VME-;R-Y@#;I"I!"^@V^O>L5?#&N?\ "+>-M--I$)];
MNKF:U_?C:JRH%&\]B,9.,UVMGK>E:A=RVEGJ5I<7$2AGBBF5F5?7 /3WJ_0!
M0T2">UT*PMKF,1SPVZ1R*&W %5 .#W'%<;X:TCQGX;@'AJ*+3YM'BD86NJ-.
M1+%"6)VF+:=SC) .0.F<UZ#5>\O[/3TC>\NH;=)9%B1I7"AG8X51GJ3Z4 <?
MXH\-:KXDCO+G!M=0L'5]#>.881Q@[W_WB-I!SA>G)-9_B"YU;_A+?A[-=6$0
MU(37?FV\4P*D_9SNV,?;)&<=@<=:](K,OM TW4M3L]1NH9'N[(DV\BSR+Y9(
MP< ,!R.#ZB@#G)O#>H74OBG5WMT2^U6R%C:VQD'[M%1@"[#C)9R3C. !U-4X
M_#>N1P^ U^QQ$Z"H6[_?CYOW/E?)Z^O.*]"HH Y75](U*Z^('A_5X+=&LM/A
MN8YF,@#$RA0-H[XV\_6L$^%==?PAXTTLVD(N-:O;F>V/GC:J2A0-Y[$;><9K
MTBB@#S35(=8D\1:4NE:9:W6H:7I@2Z1+_P"SRQ&0@*"^U@RD1L0N/<XXKI?!
M<KQ6$^E2Z$-'DLF&85N1<*V_+;O,ZEB<D[N>0>]7-5\):%K5ZE[?Z>CW:+L$
M\;M%)M]"R$$CV-:-CI]IIEJMM96Z00@YVH.I[D^I]SS0!Q6N^'?$5_KOB K!
M97=G?Z?]GL9KB<J;$F-E<!-IR6)SD8[ GBHH_#?B.&+P-=I:V376AP/;W$!N
M2%PT(CW!MO."N2,=\#/6O0ZHZCK6EZ0$.I:C:V@?[IGE5,\X[GU(H 9KNGR:
MKX<U/3HW59;NTE@5FZ LA4$^W-<9)X?\1W&A>#;6:PM4FT6\MYIU2ZW I%&4
M."0/F).<= .]>A@A@"""#R"*K+J5B^HMIRWD#7JQ^:UN) 9%3(&XKU R1S[T
M <1J7@W4-;UGQ@+A5M[+6K*"WMYA(&9'B#89E],L#U[=JUO#<GC29H(/$-II
M]LEL,2W-M<&0WAQ@80J-@[G)SQC S71WU_9Z9:-=7UU#;6ZD!I9G"*"2 ,D^
MI(%6* .<\:^%AXMT$6:7'V6]MYDNK.XQGRID.5)'<<D'ZTZQO_$\MNL%YHEK
M!=@;7N%NP\!/]X#&_P!]I ],]ZZ!F5$9W8*JC)). !5"/7='ED$<>JV+N3@*
MMPA)/TS0!STN@ZII/CG_ (2*P0:A#=V26E] 76.3>ARDJYPIZD%<CU'I6/JG
M@G59?#FI);0P2:GJFL1ZE,IFVQQ*CH0F[')VH!G'4GM7I-% '!>-9;A/&/@2
M6&V\R;[9<'R2X4_ZALC/3.,X[9[CK4>M^ I_%:>)+F]865QJ=K#:VB;@QA6)
MO,5G(XR7Z@$X '.377:AH&FZIJ%G?W<,CW-DQ:W=9Y$\LD8) 5@,D<?2M.@#
MC9](UCQ++X?_ +:LHK3^RKI;V=DF#B>9$95$>.BY;<2V#P!CG(7PSHNM:=;^
M*8Y4CM9M2U"XO+.99 ^S>BJNX>H*Y[BNQHH \PT_PMXHCF\)7,VG:='<:5-(
M;V0WC.]RSQ&-IF;9DDDYP<DYQP*V--T+6],G\70BVMI;74[F6[MI1/ARTD:I
ML*D<8*Y)S] :[>JL>I6,M_)81WD#WD2AY(%D!=%/0E>H'UH X&V\&ZU9:/X+
MNX(X#J_AQ&ADMVE^2XB= D@5L<' !&1UZUH7_AK4-3N_$&M/;+%>WVD'2[2V
M:4913N):1AP"68<#. O<G [CH,FL^'7]&N)9(H-6L)9(P6=$N48J!U) /&*
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M"_O;R6:,^>/+"O-YG)QG(''3K7I]% '(ZEI&IW_CGP_JXLU6SLK:XBN TPW
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5D>(->AT&TMY'56FNKA;:!&;:I<@GDX.
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MSN9GC$<L:[0\;!3D8X((SQ^796$=U%91+>S+-<X)D=%VKN)R0H]!G SS@#-
M'+S>,;V;1M3US2M.ANM-TZ65&5IBLMPL1Q(R<$#!#8!^]CMFLGQ)K-WJNN>
M[K2A;RV%[<M<P>;*R;S]G<C< IQ@'WY[59T_POKFAZ1K?AZQ2UGT^^EG>SN9
M)2IMEFSN5TQ\VTDD8//0XZU+=^$;ZTNO!L.DQV\ECH!.\SS%'D'E&/@!2,\Y
MY(H Z^QL+:PCD^SVD%NT\AGG$*@!Y6QN8\#)..O>O+_!FLR>%_A)K.L6ME%<
MFTO[R5H6D\L$"0CJ%/3CBO5Y&D6(LB!I,<*6P"?K7FMEX*\0P?#'6_#,L=A]
MLOI9VBD6Y8Q@2MNY.S/'TYH W[;Q7J2^*-)TS4=+@M[;5[>66TDCN"[JT:JS
M+(NT 9#=B>E)%XLU._T^VUC2M'%[I<]WY"JDA\]HMY0S 8QC(SMS]WG(Z!EU
MH.L7/B7PEJ/D6JPZ3#.ERIN#N)DC"?)\O.-N><51\,^'_%WAJ ^'()-.?0XY
MG:VOVD;[1%"S%MGEXP7&2 V<#K@XQ0!M-XCO]0N=8BT*RM[D:5)Y$AGF*>=,
M%#-&F <8!4;CW.,<9K(_X6++?Q>&)M&TI+F'7O-1#-<>6T,D:,2K#:> 5P2"
M> < \5;T_0]9\-^(-=GTR&VO+#5I_MBI+.8VM[@C#Y^4Y0X!R.1TP:SK7P+J
M&C-X-AT_[-<0:))/-=222F-I7E5@Q50I[N3R>F!0!97Q=XG;75T ^'+)=5.F
MB^.=0)B7]X4PQV9 X/0'.1TY(--^(PO=&C:;33!K3:H=(:P:7Y5N!R3OQ]P+
M\V<>W-17<MW#\;MUI:K<?\4Z Z&380/M#<C(P>>QQ_0PW/P^OVT\:A;SVR:^
MNM'6@I8^26/R^26QG;L &['7G'- &Y'XHO8/$D_AZ^LH!?M:&\LI(YB(KA0<
M,I)4E&!^O'/M67H_C?Q!JWAE/$,?A<264MFTT44%UOF>4/M";=OW2,G=[$X[
M5I?V+J%_XFC\1WEK##-:6+VMK:B?=EG(+,S!< < # /4GVK)L_"?B*U^#Z^&
M(;BVMM7AB\M)HIF,;CS-Q&[:&7<N5Z<9H U;'Q3>7/B>_P##C16$E]!8K=QR
MPSDQY+%"CC&5(./J#T%<O9>+]53X,GQ+JVFV.J!\R/%),0'#3D<J4(PI*X7/
M0=1BMW2?#^N0>.;?6Y;+2[.Q.DBQ>VMIF;R")"X"_( V<_[./?'./_PA/B3_
M (5'<>#2NFF=<103"X?:Z>=YF]OD^4XP-HS]: .QN]>E;Q'_ &!ID4,EXEK]
MKGDF8A(D+;5& ,EB0>., 9] >>N_B//;^&;[4%TA3?:;J"Z??6AN,;'9U4,C
M;?G4[@1G;5^YT+5;3QM%XHT^*&4W%D+._LGFVGY6W*Z-C!(Y!!QQ63JW@;5+
MKPYK$5N+0ZIK&IQ7T^^9ECB6-T*H&VDM\J8S@<DT ;^G>)-1?QG+X>U33K>V
M9[(WUM)!<&3*!PA5\J,-D@\9'O6OH]QJ=S8F35K&*SN?-=1%%-YH*!CM;.!U
M&#BL5]&U63XCVNOF&V6RCTQ[)QYQ\P.TBOD#;@@;<=:N>%-2UC4K"Z.MVUI#
M=073P@V;L\4B@*05)YX)*GW4T 5?$/B34-)EOS#80I:V5F+DW5Y*8XYW.[$2
M''WL+R>V1QS5*;QS=NWA,V.D)-'XAA,D>^YV-$?)\S:1M(QTR<]C@'BF:QX=
M\07?BC5;F$6%S8WNGBUMI+F5@UBVU@^U I#;]P).0>!Z53T_PIXB@3P+Y\-A
M_P 2!&2X"7#?,##Y0V_)R?XCT].>M %Z#QZ]IIOB"37+&."\T6X2!XK64R+.
M9 IBV%@IRV\#D<5GZJVIM\5?!!U&UM(R8[XJUO(6P?)&4.0,XXP>^3P,<LU7
MP%JVM'Q>LDEM:G5;BVNK&5)2YCDA50-XVC@E>V<9J\VE^+-5\3^&-8O[#3+;
M^RQ<"Y2.\9]_F($W+\G'3(!_$B@#IO$&N0Z!IR7,JAWEFCMX4+;0TCG R<'
M'))P> >#TK"MO&EZ=0U6QETE[M[2R-[;RV =DN0.#$-RC$F<<<Y!S6AXT\/W
M7B+0DATZZ2UU*UN([RSED&4$L9R-P]#R/Q[UFS6?C;6_#>I07DVGZ3?R6CPV
MWV.5W'F''SLQ *], #)&XG).* )M/\83MXICT+4H+2.673S>DP3EC 5*AHY
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MKK^J:%=ZU;6UHNDR-<,D,QD\Z?85&W@809)YYS@8KK: "BBB@ HHHH ****
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M!5.P\*ZWH=CKFBZ<UE+INH3336TTTK*]KYH^=2@4AP"21R,]#CK7=4A( ))
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M%@D>!F(7<1?69 ]3YZ5V]<WXWT*^\1Z NG6+VZ.;F&9GG9@ (Y%? P#UVXH
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M"(DK;X_*0J,Y7!SG\/>@#D?#E^VDZ#XQU#5HK.[LK76[@?9U@.6E4QK&%R2
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MV>-7^R,D;;O*;/S,&YW''/ QQ3;?PGK4GB#7;^]N]/6#5].CM9$@1RT3*KJ
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M36;!!ABT>\/@<X!Q^%:]WX3?Q!J\]_KJP)&VG2Z?%;V\A?"R_P"L<L57D@
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MC0R##1DM$=I]QG% '>T5Y\?&^LWFGVFLZ1IS7MG-<!39)83^:8-Q7S%F^YG
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MQ!W3Q@!3O&T#OG.1QQUKJ-1U74M(\6>&K&6+3ISJLDT-S=) T;_NXW=0HW'
M^I/?IF@#KJ*XT^(O$&K:=J&I>'+2RN([2\>VBM)@0]UY;A9")-X6/G=C(/W1
MZX#?%/B?6=%35YXTL+6"RLQ<6HN097OG"LTBJ%<%0N ,D'KGH* .TJE;ZM8W
M>IWNFP7"O>6(C-Q$ <Q[QE><8.0#TKB=2UC6-0\7>!S97D%M::E:SW1@D@,F
M'$*GYB'7=Q(0.F#SSQB^/&DUCJOC)=4@@2ST&""=&@R7D5XV<@D\9X ' H [
M2BN(OO%6L:)9Z)JVIQ64FG:C-%#/' C+):&4?(VXL0X!P#\J^H]*JS^*O%4U
MQXMALH-(C.A,K(TRR/YJ^5YFW (Y(.-W0>A[ 'H-%9^A:F-:\/:;JHC\O[;:
MQ7&S.=N]0V/PS7,'Q7K&H^']6U_1H[)[.PEF6.WF1B]TL)(<APP"$D-M&UN@
MSUX .AUVST2>"&;6[2VN$BD4P^=%YA$A/R[%P26],#-)8^(-%OM*FU&UO(C9
MVS-',[*4,++]Y65@"I''!&:XKQ'JEUKU]\/]2TRZ@BL[Z[$\,<UNSE7,$ARV
M'&< D8&.><]J[ZX@6'2KOY(A(\3-*T:; [[<%L<^G<GZT /TZ_LM7TZ#4+"1
M9K6==\4@4@,OKSS3(=3T^?5KG2XID:]MHTEFBVG**^=ISC'.#7F?A'7M:T+P
M5X%=HK!])OI(-/:/#F<&3=MD#9VXR/NX/'?TZR/Q-J*^*O$NFO90RQZ98Q75
MNL&[S9BP<[23QGY<  =^] '6[%_NC\J-B_W1^5<GX1\42^)O)N;?4--O+-K<
MM.EO&T<UM/E<(ZLY.,%^P^[[U?\ $&OOINHZ/I-HL9O]6G>.$R@E(U1"[N0"
M"<   9&21R* -W8O]T?E1L7^Z/RKBI?%FJV&L:UH5W#9RZA:Z<=3LYD5HXIX
M@2I#+EBK!AC@G.<\5=\&ZKXBUW3K+5M3CTR*PO+"*>..WW^:LK $YR2-I'([
MCISUH V#K&EC7%T7[5$=2:(SBW RP0$ D]AU'6M *!T %<#KOV[_ (6[I T[
M[.+EM&N0KW )1/WD?) P6^F1]13K#QY=GP]OO[> :J-9DT8_9XW:)I48Y<(,
ML1M4G;G)(QD9R #O"H/4 T;%_NC\JX*Y\6^)+&T\1O)IL4T>GV+7MI>O:36T
M4NU26C9').X8XP<$>F*W?"][X@U*V2_U9-.CM+FUAFMDMM_F*S+E@^>.XQCW
M'/4@'0;%_NC\J-B_W1^5<7KGC"XL_$MUH4%SI]C>"U66Q74(VVWSG=\JOO4#
M!"C')R?:K\>NZ@?B!/X=<6WD?V4+Z.01MN5S(4VM\V&'&>,4 =+L7^Z/RHV+
M_='Y5P>D^.;[4-'TM7AM1JNI:E<6,6U6$2B)GW2$9R<*G3/)(&1UJ]>^(];\
M/V.JS:S8VTHBG@ATV>!O+6[:4A0&4LQ3:QP23R.0* .NV+_='Y4  = !7,SZ
MMKNB7-_<:Q!:3Z+;:>]V;VU0Q,DB9+1E&=BV5&0PQZ50M?$^OR:IHY_L[[38
M7_%P(K">)K+(RK&1_ED7/!("^OM0!VU%<5X=\87/B'5$@AN=/22&YFBOM-DC
M9+JV10X5LE_FRP3)"X^;VH\/^,+GQ!JHMX;G3TEANI8K[39(V2ZMXUWA6R7^
M;)"9(7&&]J .UHKA&\8:O>^$[_Q7I,5E)IUH\S1VLJ-YEQ#"Q5V$@;"D[6(&
MT]!GKPVX\8:YJ6O:=8>'H--,&IZ.=1MIKS?E3E,;PIZ?-C YYSGC! .]HJ*V
M\_[+#]J\O[1L7S?*SLWXYVYYQG.,U+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8'
MC/0)_$OAN73K6XC@N/-BFB>12R;HY%< @<X.W'XUOT4 <3JGACQ(-?MO$>B:
MI81:JUL+6^@N87-M.@8LI !W J20#GGVYS+JOAG6M0?P_,]]:S7&G7WVZX>0
M,BR-M9=B*,[% ;CDGCG)R:[&B@#F[W0;^X\=Z=KT;VPMK2TEMC$S-O;S"I+9
MQ@8VCCO[5D+X-U8>'/%NEM/9;]>N;B='#-B$2H%((Q\V ,YXS[5U^JZK9:)I
MLVH:C.(+6%=TDA4G ^@!-3174,]FEW&^8'C$BL1CY2,Y_*@"#2+6:RT:RM+@
MQF6"!(F,9)4[1C(SZXKD+/P1J6G>&=0\)6MY;?V'=&589FW>?;0RDEXPN-K'
MYFPV1C/(.*ZW1]:T_7K(WFF7'GVXD>+?M9?F4X88(!X-7Z .3U#PQ>-XB\,W
MVG&UCLM#CEC2"1FW2*\8C R =NT#WS[5MZ]H]OX@T&^TBZ+""\A:)F7JN1U'
MN#S^%:-% '(Z!HWB^WCBM-=URSGM;9"D4MI"R3S_ "E5:4DX&,YP!R0,GKG$
MM/ 7B*#3/#UF^JZ83HE]]H206SDS+AP6?YN7._..YR2:])K.DUS38=<@T5[D
M#49XVECAVMRJ]3G&!U'>@#EK+PEXCT/5M2BT76+*+1-1N7NG2>!GGMG?[_E$
M$*<GD;N!Z'G.E#X?U"W\=7.OH]L]N^G)8I"TC;_D9F#%L'J6P?SR>E;VHZA;
M:3IMSJ%[(8[:VC:65PI;:H&2< $G\*F@GCN;>*>)MT<J!T.",@C(X- &#X)T
M&[\,^&HM*O)8)GBEE<20YP0\C/T/3&['X5FQ^%=:TGQ%K-UHM[9?V=K+>=/!
M=HY:";;M+IM/S ]P<?6NTHH \]@\":Q;^$_"NCF]L9)-$OH;MI-KJ)!'NP@Z
M]=Q^;VZ5NZ9H.H6?CC6=<EDMC;:C##$(E9MZ>4& .<8.=QX[>]=+10!P>G>$
MO$VA7UY8Z3K5DGAZ[N'G"30,US:[R6=8B"%QDG!;.,]#WFF\*^(-+\5W^J^&
MM3L8K75-AO+>_A>0)(J[?,CVL,D@<@GGU].VJEJ^KV.A:9-J.I7 @M(1EY"I
M; ^@!- &#>^%]1;Q)HFKV6HQ%[&VEM;@W49=I5<J2XP0-V5Z=.?;%5+3PCJN
MCVVMZ5I=U:?V7JDLLT;3;O,LVE'SA5 Q(,\@$KC/.:[.&5+B".:,YCD4.IQC
M((R*JV&K66IRWL5I*9'LIS;S@HR[9  2.0,\$<CB@#FXO!T]AXA\.7.G-;II
MVBV3V:Q2,WF2*X4;L@8!&P'WR>E=3?Q3SZ==0VLPAN9(G6*4C[CD$!OP.#5B
MB@#CK?PI=CQ3%XDD@TZVU&.SDMY?LC,%O&8KAI/E& NTX'S'GKP*S(? >K0>
M!= \.K=61DTJ]BN3.2^)!')O QC@G..O&/?CT2B@#SG5O 6NZC9^*[!-4L1:
MZY)YRR2Q.TT9VJ!'NSC8-O!P< GCFMN3P]JTWBW0]:FN+-QI]K+!,JAE,ADV
MY*CG &T8!)S[5M6>NZ;?ZM?:7:W(DO+$(;F,*P\O?G;R1@YVGI6C0!S?AK0;
M[1]5UZZNI+=X]3O/M2"(MF/Y57:<CGA0<_I57Q+X9U:Y\1V/B3P[?6UMJEO
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M. /QK8U+PGJOB?PO?6'B#4X$OK@1F%["-EBMGC;<K*&)+'=U)(XP!C&3V-%
M'*66AZ_J>F75EXMU"RGBFMGM?+T^)HPX<;6=RQ/S8Z   9/7C$'AG0?%NEI;
M:;JFN65UI5E@0R0P,ES,J_<61B=H XS@$G&">3GLJ* .*/@^]U#5M$U#5/L
MOM+F\PZC;;A/<(%91&P(& <C)R<XX SP/X/OM1U71;_5/L O=+N/-&HV^X3S
MH P$; @8!R,G<<X. ,\=K10!PMIX+U/2]$U;PW87=K_8U^\QADDW>=:)+G>@
M7&'ZMM)(QGG-78/"=Q8^+])U&R:V33=.TTZ:D#,V\H2IW9QCC8!COZBNMHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K(\1WVH6&G1S:>EL"9XTGGN7"QV\)
M/SR')&[ [9')K7KGO%WA^\U^TT_[!>QVUS8WT5X@FC+Q2E,_*X!!QSGZ@4 <
M\OC75?[*\:-$;2>?0(_.@G>!T69##YH#)G.>",@X/!J:T\3>((M8\*?V@=/>
MRUZ)@8H8F$D#B'S V\MA@<'C:,>_4DO@?6)6\6E]7M'_ .$AMEA?_167RF\K
MRB1\QX Z#KTR?6W)X3U*2;PG)]LM!_8(^8;&_?\ [HQ\<_+QSWYH P_$NM:C
MXF^&WBK4[&6UATV.*ZMXHWB+--'&"CN6W#:20VT8XP,YSQWN@_\ (NZ9_P!>
MD7_H KBV\ :S:Z-K_A_3=6LUT75/.>)+BW9I;9I0=R A@"N3G)&1[UW&DV<V
MGZ/9V=Q,D\L$*Q-(D90-M&,[23CIZT >4Z)J7BC1?!&K:QI"Z;)96&I7T\UM
M.KF2=%F8OA@0$(&<#!SC\*ZQ_&%QJ]S-;:*3#Y5E!<^8UE)<Y:92R*0A&T!0
M,]SNXQCEMOX*U*#1=4\/?VC;_P!E:A<32O,L3"=8Y6+/&!G;GD@-VSTIVH>#
M=5LO$*:SX3U.VT]WMH[2ZM;J RPRI'PC#!!#*#CKT_'(!T'AG4-1U3P[9WFK
M:<VG:A(I\^V;^!@2./8XR/8USEAXPN-2\1W.E)>6=K?VU^T,FF7,)65[<-@2
MQL6&XE?GX!&.,=SU^G6LMG8QPW%R]U.,F29AC>Q))('89/ [# KE]0\'WFLW
M-D=4FLY?L.I?;;>\2,BX1!(76+Z8PI.>0/NYYH K)XLUDZ)XUN#]A^TZ#-,L
M#"!MDBI")!N&_.3G&01]*S-0O-3U3QCX&O;+[)%?W>CW,I:56,<99823M!R<
M9X&1]:U+WP5J[R^*;>QU2TBT[7D=W62W+2QR-%Y9 ;=C:< ]">H'K4X\(:G:
MS>&KVWU"TEO-%M'LV62!DCG1E5<\,2I&P>HZ\"@#+'C3Q#:Z!XOAO8=/_MSP
MX@E,B(_D3QM&71@N[() .1GK6O-XIN9+G3--@_=W=SIHOYY4M7GV [5 5%/=
MB>2>-N.<\9/B>QM-,\+>,EN+^WG\0:O823RPH0K,HC,<:HF2=HZ9[DGUP+VH
M>$-6F.A:QHNI1Z=K5A9+:2">+S(IXB 2C@$'AAD$4 -L?%NNO%IFF:AIT=GK
M-_?36L<DD;+$\,2%S.$)W<K@!2>IZ\52\<7OBNR^'_BMKF6V@^SJ!:WL"?-/
M"P 8;=QV,"<;OR ZUIZQX,U35M.L+DZV(_$5C=?:X;Q8/W(8KM:,1YXC*@#K
MGOW-3:CX5U37_"&K:7K6JPO?:C"(O,MH"D,('*[4+$GGDDG)]L"@#I;!+E+*
M-;N:*6;'+Q1&-3Z?*6;^=><Z1XEU#0M/\=:[J]Y'>6^G:E*GE+ 49F6.((JG
M<0J\@8P3SG)KT338KV&PB34)X9[H#YWAC*)GV!)/YG\NE<K_ ,($TZ>*-/O+
MZ.32-<F>X,2PD31R,JC._., H"..OY$ =J7B'6?#EUH,VJ-9W-EJEU'93"")
MD:VFD'R%26.Y,@@Y /0^U6OB3_R33Q'_ ->$O_H-1Q>%]2O8=%M==O;:Y@TB
M=+A'AC97N9(U(C9P3A<9W$#.2!R!P=3Q9H\_B'PMJ.CV\T<#WD+0F612P0'@
MG ZF@#GM/UO6]-\0^&=+O6L9+#5[.3RDAC826[Q1JW+EL.""?X5_QCA\9ZNF
M@^++V>UAGGT?4FM8UMH6(\H"/+E=Q+%0[,0",XQQUK1F\,:C/K?A?4#=6H&B
MQRHZ!&_?;XPA(.?EP!GO3-.\+ZUID6O-;:G:QW.I:DNH1N(F(CY3=&PS\P*I
MC(Q]XT 7_"VM'74GN[?5+'4M.*I]GGMDV,&^;>LB[C@CY3T'7I3=0UVXD\7V
M_AG3WBBN&LFOYYY4+[(PX10JY&26)Y/0+T.>$T'PNNE>(-4UHQVUO-J*1));
MV@(CRF[YSD#+'=Z#IWY-)K'AJXG\4V'B72KB*'4+:!K6:.928[B!CNVDCE2&
MY!Y^E ',:MX^UK3O#?BO]S8_VUX=EC61C&WE3Q28,;A=V5)!Y&3@CWX[G2%U
ML/=MK$EBR-(&MEM48%$QRKEC\Q![C&?0=!S&L> KC5?#_B&U^VP)J6O2(UU<
M&,E(U0*$15SDX"XR3R23[5VT'G"!!<%#-CYS'G:3[9H \[0:NWQ,\9#1I[."
M<65BWFW432#A9<#:"O7USQZ'M;T[QY<:MH_AIHX1#?:O:27,IC@><1+'M5MJ
M*<G+,,9/ SG/?5MO#NHVOBS7=:2YM674X(84B*,#'Y88 DYYSN.1@5@P_#K5
M+'P_X>CT[6H;?6M!$B6]UY!:*:)_O)(F<X/'0\8_( ;J7C#Q7I?A._OKC3K=
M+FTU".WBEF@>-+N%Y%1752V4;YN0<CBNVT=-92*X_MJ:QED,Q,!M$90(L# ;
M<3\P.>?I7.ZUX3US7O"TFGWNKVK7\\\,TLRP,(8Q&ZNJ(F[.,KR2<G)]@.RC
MW^6OF;=^/FV],^U '"ZAXLUJ[BU>;P_;B633KI[:*V:RDD%RT9 <&0$!,G('
M7& 3UP)M<\2:W:0SW"I;:;&FFBZMX[A/.EGGP6:,HK!@J  $@?Q9R,4@\(^(
M-*\0:C<^'M>M[73=4G-S<VUS:^:T,K??>([@,MC.&R,]C3KKP7J;:WJES9ZQ
M$MGJ>GQV4HN8#+-$$5E!1MP'.XDY!YYH J3^+]=NY?!8TV*PB'B&U>5Q.CMY
M+B#S."&&0">G4XQD9R$VWZ_$_P ++JCV[WXT>[$[6RD1EM\?W0><5-8^"=7M
M&\'L^I6<I\/1/$0(&7S@T0BP/F.,*,YYR>P'%;%[X?O+GQUIVOI<0+!9VTEL
M8&0[G#E23G.!C:.,4 8L'CB^MM,\37.HPV\DNFZLNG6RP(P#E_+"%ADD\R9.
M.PXJY:ZSXE_MV6S-JMQ826C2QWSV,EN(9A_ RLV64CD$8(Z<]:K-\/Y;W2_$
M^GZA?($UJ\^VQR6Z%7MI!LVXR><%%/;/-:6CZ3XJBA;^W-;L[V6*,QP""V,2
MNQ&-\O)R<=A@<GKQ@ J> ]9\2^)-*T[6]1;3(]/N[0L8((W$HEWX!R21MP#Q
MUZ<FM'4=<N'\6VOAK3FBBN&M&OKB>5"_EQ!@BA5R,LS$\G@!3P<U)X,T&X\,
M>%+'1;FXBN&M$,:RQH5#+DD9!)P>?6J>N^%[^?Q58^)M$OH+;48+=K2>.YC+
MQ7$!;=M."""&Y!% '*>'M;N?#T'BZ:Z$4]]-XE6TC\N-MC22+$H;:"3C!W%0
M2>, ]ZZ*WUSQ0FIZE;#2S?VZV#7%G<&W:T#3CCR&WD]>"&XQWJBWPZO+S3=?
MMK[6(UEU*_74;>>VMRC6TZA=K#+'(^0<?7FKK^&/$NL>'M1T_7_$$#37%H]K
M$]C;F)5W#F1P6^9N,8&  3Z\ $.E>*]2G\66FBRW5C="[TV2X\Z"!@L,Z%0R
MAMQ61?F['(QUYKD;FXU2]^"'BNYU*^CNBT]TN1"5;<LY&2=Q&.!@ # [FNSL
MO".MQ^(=#U>[U6P+:?:/9R0V]F45D.W[N7.#\O)Z8Z#O5.7X?ZHW@[7/#2:M
M:_9;^>62!S;MNB623S#N^;YB#P,8]3GH "_;ZWK=AXUTK1]1:QEL]4LYI85@
MC97@>+:2I8L0X(;KA>>U=E7+W/AW4;KQ5H&M/<VJKID$T+Q!&)D\P*"0<\8V
MC YJSX4DUN2UO1K5U!=E;IA;7$,/E+)%@$<=\$L,]\=^I ,?5M;\4/XYG\.:
M0VEQ@Z5]NAFN8G;:WF[,-AN>G;&,YYQ@PWOBO7;NWU:31($EN--G:V2W^PRR
M+<R(!O&\$!,DD#KC )/.!L_\(_>_\+"_X207-O\ 9SI_V V^P[L>9OW;LXSG
MC&*S/^$1\0:7XBU&[\/:[;VNG:I-]HNK:YM3*8I2 &>([AR<#@\9]: (=4\;
MW-OJT>FS2VVAW5QI\=Q9KJ,19)YVW;HBX90"I"C&<DG/M6I-KNIV_C_2M$D6
MV^QWEA+<.0I\P.A48SG&/F]*9K?A:]U:QO=*EEL[O3+FW6&-+U&>2W<+M\T'
M^(]#CY>1G/-)'X3NK;Q+H6HQ7L;6NDV#6.R529)0P4%BV<9^0=O6@#$U+QUK
M">%M;\1626H33-2:R%E+$S,ZK(L9)(8$.2VX#&,8'.<UIW.M>)O^$WA\.0R:
M6@ETEKPW#02-Y;B14/R[QN'/ R.O7C!Y'3[B>_EO-=L->\(O'/>R7 35+<B>
M(AB$#[9!AE4 #Y<CZUVEAI&K7WBC3_%DYM[=SI(M)+(JVY6=ED)W>Q&,$=*
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M$8RIQR.HH PH?B!JNK67A*[TRULX1K-Q+:W,-P&)AD17W88'IE#VY'IGC?\
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M7\U]!.8"RQ-(P8J5)YQ@@'WZ4 =A134#"-0Y#. -Q P"?I3J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"O+86<]U%=36D$EQ#_ *N5XP73Z$\C\*L444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!3_ +)TW[=]N_L^T^UYSY_DKYG_ 'UC-7*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN8\9^)_
M^$?M[.WM[W3+74;^4QV[ZG(4@4*,LS8(/HHP>K#MF@#IZ*R] .M'3=VNRZ=+
M=LY*MIZN(MF!C[Y))Z\_2M2@ HHHH **** "BBN4B\17NO>)M2T?1&@AM]+*
MI>7LT9DS*PSY<:@CH.K$\'C'>@#JZ*Y.#Q/=:7XMB\-Z^UN7NX'N+&]A4QI*
M$Y=&4D[64<Y!P1Z=*Z$ZKIPMEN3?VH@9MJR^<NTGT!SC- %NBJUYJ%EIT8DO
MKRWMHV. T\H0$_4FGR7EM%#'-)<0I%(55'9P Q;H >^>U $U%4X-7TRZF$-O
MJ-I-*Q("1SJQ)'48![8-/74;%XII4O;=HX?]:XE4B/\ WCGC\: +-%5$U33Y
M+EK:.^M6G6/S6B692P3^\1G./>I+.^M-0@\^RNH+F')7S(9 ZY'49% $]%%9
M^KG53!"FD-;).\P5Y+F-I$CCP23M#*2> !SWH T**X+3=;\6:EXL\1:"E]HR
M-I"6Y69M.E(E,J%N1Y_RXQCO5BR\2ZI!XV.FZY/8V]HFAQW\N%\L12M)L8%V
M8Y (..G7\: .UHJ'[9;&S^V?:8?LQ7?YV\;-OKNZ8]Z2TOK34(!/974-S"21
MYD,@=<^F1Q0!/14-U>6ME$);NYA@C)P&E<*,^F33#J%DMJ;HWEN+< $RF5=F
M#T.<XH LT55_M.P,,\WVZV\JW8I,_FKB)AU#'/!]C2PZC8W%D;V&\MY+0 DS
MI*I3 ZG<#B@"S16>^NZ0FFW&I?VG:&RMP3-.LRLB8ZY(/7VJ/2O$.G:MH$&L
MPW4*6LL*2LSR+^ZW*&PYS@$9&<T :E%5$U33Y+ W\=_:M9C.;A9E,8Q_M9Q4
ML%W;73RI;W$,K0MLE$;ABC>C8Z'V- $U%5;S4K#3R@O;VVMC(<)YTJIN^F3S
M6-XQ\41>&='2<20"YN)XH(%E8 9=U4N1D9"@Y/TZB@#HZ*Q]#75/-O'O-2M-
M0L'96LIHD"R;<'<'V_*<'&"/?-)H^L-KEU>3VQ4:=:SO;(^,F>1.'8'LH;*C
MU()Z8R ;-%4[;4]/OWDAL]0MIY4'SK#*KLGU SC\:I:1K+7.IW^CWFQ=0L=C
M,4&%FB?.R11VZ,".Q4]B* -FBH;J[MK* S7=Q%;Q X+RN$4'ZFEM[F"\MTGM
MIXYX7&5DB<,K?0C@T 2T57GU"RM6=;B[MX62,RL)) I5 <%CD],D<^]1'6-,
M"6SG4;0+='%N3.N)C_L<_-^% %VBJMYJ=AIVS[=?6UKO^[Y\JIN^F3S5;59+
MD-IQM-2M;1&ND\T3*&\^,@YC3D88G&#S0!IT55N]3L-/9%O;ZVMC(<()I53=
M],GFI)KNVMB@GN(HC)D)O<+NP,G&>O )H FHK(>\:ZU33)K+6+'^SY(Y2\(P
M[7/ VE&!Z+@DX!J#3?&.@ZJU]]GU.UV6=P8&=IE 8@*21STRVW/J* -ZBJS:
MC8K#%,UY;B*8XC<RKASZ YY_"K)( R>!0 455M-3L+\R"SOK:Y,9PXAE5]OU
MP>*X\^);_P 1:OK%AX=U;3K>?3I8H[=)L2)=DH'?=@[MN#@%>A!//0 '=45D
M:UXETSP^]C'J%U%%->SK!"C. 22>6Y_A Y)^GK6-;>)YX_'>KV%_?62:1;V$
M%U#+@1A=[,/F<L0>@YX'/2@#L**@>\M8[3[7)<PK;;0_G,X";3T.[IBEM;NV
MOK=;BTN(KB!ONR0N'4_0CB@":BJU]?6MA!YEW>6]JI^57G<*N?Q(S]*X[0M?
MUC6_!NJW4FK:?9WL&HSVT=X\(\A4CE"YVENZ@_Q=Z .ZHJM<ZC961(NKRW@*
MH9#YLJKA00"W)Z9(Y]Z9<:MIMH81<ZA:PF?'E"295\S/3;D\_A0!<HJO>7]G
MI\(FO;N"VB)QOFD"+GTR:S=5\5:/H\NG175[ KZA*$MQY@^88)+Y_N@#KTY
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MK TH-*$6W<P1HUGY2+'Y9=#PN&X!X//!->F#1M+6ZCNAIMF+B,!4E$"[U X
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M;6UET\O@K+:!#NV9ZKO))]S0!VLVHV-NL#3WEO$LY"PEY542$] N3S^%5O\
MA(=%^R17?]L:?]FE+".;[2FQ]IPV#G!P>OI7C\&GQIX8\)Q7<:/9-XN*6'F<
MYM"TNP#/53V'0@CM79Z]I-S8:_'-X0N-.M-1MK)FETJXB"P74+R%B1MP5;<#
MDCU&: .\BECN(4FAD22*10Z.C95E/(((ZBN%F\4S>(/$.LZ-H?B"QL;BP2'[
M*Q,<JW4C*SN&!R2H  ^3!!R2>U=%X/OX=3\':1>6]DUE#+:1F.V)SY:@8 ![
MC X/<8K!\,F*7XE^/8SL<;K$,IP>/(P<B@#:TG58K+1%GUGQ)IMVS32+]K0I
M#%G<?D'S$97IUSQS6M'J-C-=?9HKRW>XV"3REE4OL/1L9SCWKS;PG#H]Q\*-
M0L=2A6:RN-0N[=8$QND9IV"*G^UDKCTX-2^$KC4;"QU_PY?ON\86MIF.<ON-
MU"$(A9#@<*?E(_O9)Y8T >@1ZSI<VH'3XM2LWO5SFW6=3(,=?ESGBL/QSXE3
M0O#.J2V>JV-MJMO:O-#%,RLS$*2 $)!R<<=?H:X[PQ/X9\0Z+X4$NO7+ZGIT
ML)BTY&A2>*=1M<,H0.4^\6)."!DU2CU2SG^%/CJTU::!-;6:]-Y#.P#F3)\H
M@'DC 0+C^Z,=* /6])N)+K1;&YF;=++;QR.V,9)4$U"WB+1$DAC;6-/5YW,<
M2FY0&1P<%5&>2#V%,\.207?A72WC>.:%[.,94AE;Y "/Z5Y/:Z1H=W\(_%YF
MM+9KF*^ODB8(#(DHD;R47N#N*X _O>] 'L@U*Q-S+;"]MS<0IOEB\U=R+ZD9
MR![FHQK.EM:QW0U*S-O(XCCE$Z['<G&T'."<\8K@;"Y_LGXF::^N745O.WA2
M..26>0*'E68%QD]3WKE VGWGPRM@Y@?R_%6&#8W(K79.#W7*_I0![*-?T8VW
MVD:O8&W\PQ>:+E-N\=5SG&1W%21ZOIDTL$46HVCR7"EH46=290.I49Y'!Z>E
M<GXBT62VUO37\*7>GZ7K,45Q+'9RP 07B,8_,#!<$-E8_F'-<]'K%O=77PXU
M:XLX])@%W?121M(/+B?RY%P&Z;68';[$4 >H1:G83I.\-];2+;DB9DE4B+')
MW8/'XTRTUC3-065K/4;2Y6$ RF&=7"9&1NP>./6O)[W6M#3_ (67->*E_9R7
M-F3#'.4\Q6CC4-N'(3<1EAD8]:U]-O;2X^+MXEUJ5A>_:= 13Y(41,PF8[5&
M3NP.>23UZ"@#O8]?T::XM[>/5K!YKD%H(UN4+2@$@E1G+=#T]#5.T\7:-?>)
MKW08+Z!KRT5-Z^:,L[;\HH[E0F3CID5Y5IUM9P?!WP1>1Q0I/_;-HWG  -GS
MR#\W7IQ]*[?1+JWM_BYXM@FFCCFG@L/)C9@&DPDF=H[X[XZ4 =#XA\4:7X9C
MLVU&ZBB:[N8[>)&<*6+,%+<_PJ#N)Z #WJY<:SI5I:Q7-SJ5G#;S+NCEDG55
M<8SD$G!&*Y;XF2)#8^')Y75(HO$-B\CL<*BASDD]A4.D:@K_ !;UI+R1'CN]
M-MGTIR<K)"N[S0AZ'YR"<=L'I0!W44L<\22Q2+)&X#*Z'(8'H0>]<E+XANM1
M\=WWAJUU"#3GLK:*91)$'DNB^22H) V*  <<Y/48YA^&-M+:Z+JT:_\ (-_M
MB[.F@?=%MO\ EV_[.[?CVIGB+0_#'CK5[K2KUC;:WIFQH;FWE\NXC5E#!U/=
M<DC!R 1VS0!T6BW.IBPNVUYK:.:"=U,D*F.(QC!5_F)QD<GDX.1GBKECJNG:
MHLC:??VMVL;;7-O,LFT^AP>#7D,FLZY%X$F.KW\M_8Z1XAC@FU.&,%I[1&&9
M"""&VOC/!!VXYP36CX@BTZ]TKQ+K/A?7+C5M9GT<Q2R6TL;((PP(R(U&)-N_
M;WP#[4 >D1:[I$\D\<6JV,CP(9)E2X0F-1U9AG@#U-8MOXMT[Q+X7OKS1M<L
M[)D\U%NI61Q#M=E61E)'RG;D9QP:K:-JG@WQ#>Z!?Z7);W%]!;,MJEO)\]K$
MR#<'0'Y0,!?F'!(Q7%6LUE/^SYK=H\D$EQ;)>L\1(+1-Y\FTD?PGGB@#UR2_
MM+"QAGO[^VC0JH\^1UC1SCJ,G'/7%#:MIJ:<-1;4+06)&1<F9?+(]=V<5PUO
M=M;_ !/\/B]8"QN/#YCL'8_*;C>I<#_:*!?P%<IXGLEB\)_$MD5#I']HP/9\
M#:LV8_/*>GSG''<'WH ]EM]5TZ[O9[*VO[6:ZM_]=!',K/%_O*#D?C46LMJG
MV-8M'$ NY7">=< M'"N"2Y4$%NF ,CDCMFN2N[:TL/B_X>2TAA@$FDW2,(E"
M[E#1D#CKW-=7KFNZ=X=TQ[_4[F."$$(N]PN]ST4$D#)]S@=3@ F@#G_#6M:_
M'XLU'PQX@:UNIH+6.\M[VUB,8DC9BN&0DX8%3T/05UT]Q#:P//<31PPH,M)(
MP55'N3TKEO"^JZ%>:K=30:SI^H:U?*))ULYUF$,2<*@*]%7=U.,LQ/&<"GX_
MNI++6?"%S<'&CIJG^F,?NJY0B%F] '.<G@''M0!UD.L:9<V<MY!J-I+;0DB2
M9)U9$QURP.!CWKD?#OB'4/%TD>HZ7K=G''%?2I/IS*C[K97*!LCYU<X# YV\
M]*DM[9U^,]W<67%J^BH-0V?=,WFGRMW^WL#?A]:/A.Z2>!P496'V^\Y!S_RW
M<_R(H VK_P 7:-IWB*TT*YOK>.]N(VDVO*%V*,8SGN2>!WY]*Q_#OBPB[\01
M>(M6L81::LUG:M(5@4KY:,%&3R<L>Y-0Z]=6]E\6_#DMU-'#&VFW:*TC!06W
M1\#/4^U<U+:65QX=^+$TL$$DJW%T [*"5Q;J1@]OF'YB@#TR_EE&M:5''J]M
M:HS2>99R(I>[&PD!"3D;<%C@'@5.^L:9'>BR?4;1;HL$$!G4/N/0;<YSR*\_
ME,3^)?A7<ML,TEO/F0XW,/L?KWY/ZU$\U]H>J"XMI;;6_#=YKQ1X'&VZL;II
MR#L(^\H?)P><'TYH ]2KCM3\:MIWQ"TO0F@_XE]R&@ENCT2Z90\<>?7:#Q_M
MK73:GJ5MH^EW6HWL@CMK:)I9&/8 9_.O.]?\(^(-2\!73/?V"7YD.KH%M&\V
M.Y!WJHD\W'  C!V_= XH ](NKVUL8UDN[F&W1F"*TL@4%CP ,]SZ5A7_ (\\
M-V%U8V[:Q8R27=PT V7*$(5!+%CG  QCGN0*XWQ7KFG^+_A5HFM$0D3WUEY@
M)'[I_-42+GMC!'TK4\76^F:'XE\&2Q0VEA:G597E956)-[0.,L>!DX R?2@#
MK8)WE\1S!=9M9;?[*A73T53(C;C^]+ YVD$#&,5836-,DU V":C:->C.;=9U
M,G'7Y<YXKA+C?_PL[Q&VD[!>2^&4>$H "TI>3:?KG;^E,\(:GX2UOPMX3@D>
M*75K QB.T60BXBN57;(S("#C.YF+<$<T =#X5UC4M0U[Q19:A/%*FGWJ0P>7
M%L"H8U?U)/7N:W;/6-+U&>2"QU*SNI8AF1()U=D'N >*\MU*2Z_L_P"*9T\/
M).MW"62+EC&(H_, _P" AQ70Z++X7U[Q)HVM:=X@FU*_BMY$BBB>$>7"R\B5
M$12 #@ -T8B@#8\<ZCKFC^'GU'0OL\MU%)$@M9XBPG+R*@4$,-IRPYYI-,\5
MQ>)O!<^LZ3((+B.)_,AF3<T$R#+1NO!X/TXYJSXP=(]!1G957[?9<DX_Y>HJ
MX_QSI%]X4N[_ ,7^'X&EM[J%H]:L$Z2I@@3J/[ZYY]1GW- &CXC\1Z]I&A>%
M[NWN;1I]4OK6SG\RV)4><"2R@,,8]"32>+O%^K>#-?TQ[E([W0IXI'O6C@(E
MM55HU\S(;#+F1<C&>M9WCJ1$\+^ 2[JO_$[TT\G' !S76ZBEO<>-].M;A8Y$
METF]5XGP0ZF2V!!'<$9H DUC4KH#1IM*O+?[/?721LYC\P-&R,VY2".>!@\C
MFN=\9ZWXK\,>&K_6UO-.(CNECAMFLV/[MI@BEG$G)VD-T'I6-!IVI^"_%NC>
M&@DESX;N=0^T:;.3DVC!'+0,?3G*_CUYQM?&AU3X9WNY@N;BVQD_]-D/]* -
MB^;Q/IMIJ-Q)J%C/%%9231.MF4*2H,X8>8=RD>F,8J/PUJ^JZS\/+76I[BW6
M_N;3[0"D/[M#C(&W=DC\:U_$C*OA75W+ *+*8DD\8V&N*\$Z+8S?";2[I[F_
M!_LW<VS4IT0$*<_*'"@>V,4 =%\/]:U#Q'X*T[6=2>$W%XA<K#&45/F(P,DG
MM6U>:QIFGR".]U&TMI"-P6:=4..F<$URWPB8-\*M VD'$##CUWM6/XN-]IM_
MXDUC2[BSU&Q2%%UK1KOY6V"($-$XY!*'H1@D''- &Z_B6>P^(NHZ=J>HVD&C
MP:5'>*T@6(1LTK)\SD\_=]ASTKIGU/3X[!+Y[ZV6S< I<&51&P/3#9P<]JXF
MW2UU+XS323VZ.?\ A'8'6.9 2A,SYR#T.#C\:YGPWJ6GV?@OP;;SK")FU:\6
MSN+B0K!:LLDW+ $;OE.%7(R2.10!Z)XEUQH_ NKZSH-_:RO:VLLT<R8F0E%)
M(X.,\8]O2LJ_\0:O W@=H[F(1:K+''>*81N?,)<D'H!D= /QKD[*]MG\%?%.
M%;Z&X<S7LH*$#>&MT^< =B>A[^IK9U5T\CX8'<O-W#CGK_HS?XB@#TNBBB@
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MFGR:E:+>.VQ8&F4.6QG:!GKCG'6B^UW2=+E6*_U*TM9&QA9IE4\G ZGC)X%
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MC*;3-;\)>*[_ ,'^7>ZG<64:W5W9N7#HK#,>0<%O+W\#G&,]15GQ#/9Z]=^
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M&T.I'W@"<#.<4W0]'-IX7TO2]3AM9Y+*WBA./G0LBA0PW 8/&>G% 'DU]?\
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MO6],T^'2=+M=/M\^3;QK&F0!P!Z#@?0<5)]BM?M?VO[-#]IQCSO+&_'INZT
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MIMC$%C6//W\8(VC)R3[U@VE_9_\ "M_A@&N8E,>L6F[<P!7:L@8\]AD<^XH
M]1NO&/ANRN)K>YUNQCFAD2*5#,,H[YVJ?0G!X]JGNO$>CV5XMI<ZA#%,T@B
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D958$,
M0>Q%+6%XQU__ (1GPIJ.JJNZ:"W=H5*%@9 I*@XZ#(H VU1%4*JJ%'0 <"EP
M/05P^F:U8Z==6>H7_BR7RKZU"&QO%QNG #-*F0"HQN! &WZ8KH(/%>B76G6M
M];7PN(+L.;?R(WD>0*<,0B@L<'KQQ0!L!%&,*!@YZ=Z-H]!6/+XLT"'1TU>3
M5;9;"1MB3;^"V<;<==V>,=140\:>'#<W5L-6M_.MD$DB<YVYQE>/G&<#Y<\G
M% &\ !T%-:-'969%++RI(Y'TJGI.L:?KM@M]IETES;,Q7>N1A@<$$'D$>AK,
ME\7V,7C6/PT5E\\VIN'?RGV@EU50#C!SELGH,#F@#H'174JZAE/4$9!I0
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M$UU9KKGPO,<T(5(I@2K#"@VVT ^F6X^O%4M*NH;;X<>)O#&MD?VXKWJ-;/\
MZV[:5F:-XUZON+#!'<>U>N48YS0!Y9;N?"GB_P (/X@N/*QX=:P>X?)5K@-$
M2F>Y.#CUK"FN%E^'7BB18Y@(?%;W$@:)@5C^UH22,=@#GTP:]PHH AM;J&]M
M8[FW??#(-R-@C</49[>_>O/_  Q/#>ZO\0(+>:.26>\)B56'SCR%7(]1D$9]
MJ]&HH \1M]<L)O OP[LXI7>XL-7LDNXUC8F!D5PROQP>O'7 )Z5V'A26SG^)
MOCDJT3O))9%#QE@L !QZX;@^AKOL44 >,27L$7PQ\?Z7(Q2]6^OR8F4@_/)E
M.W\0.1Z\XZ5O7EU9_P#";?#DPSP[%M;I<HPPH:% HXZ9(P/<5Z310!XQH$_A
M^YT3_A$?$]OJ4OB"VN&5].,UP!<2>8625-IVA3D-NX Y)XYKJO#4MI+\5?&H
MW0O(ZV(3H2VV,[L>N#C/H<5WO>B@#B?BXR#X7ZTC$;I$147NQ\Q3@#N>*IZO
M<VTGQ0\,BSN8%+:9=QHZ,"H+>7L''K@X'M7H5% 'C-M+%<_!*Z\)728\1Q(]
MHVGL?WS7'FDJX7J020^\<8R<\&NCLI?[)^+20ZC*QFN/#]O"DFTD32+*^_!Q
MVSD^@Y->AXYS10!XHTD\GA/Q1<Z?&UX+3Q<U_/;0_,TUNDL;' [@[<^AVFNH
MU34M*\;^'];N/"D(N]1FTF6V^W+"48 C*P;F Y)).!TQSC(SZ'1TH \T\-:I
MX2\47FC26\&HS:W8?,;:>6XS8-MP^[<=H'&,=^/PUOB8EXNBZ5?6\4DUMI^K
MVUY>Q1J69H$8EC@=<':V/;VKM:* .#F,&O\ Q.\/:MHES%<VUG97(OKBW<,A
M1PHBC+#C.[<V/;-<0][;#]GZ[TIV(O;:Z,<T#H05;[:6V\CD[><>G->YXQ10
M!YWJT\4WQ6TU;*ZA6230KF*-T<8#,Z%!D?0D?2L/PI=^&M5T;1/#VJ6NI/XB
MTN2%6TV6:X!BGBX\WKL"CEL],''H#[!1WS0!P7@&6TF\1>--C0O(VKF12,$L
M@C0!AZC.X9]<U/\ %,^7X2@N&#>5;ZE9S2L 3L19E)8X["NVHH \^?4+&Y^,
MFF7*SQF/^PI@CO\ +AC*A'7H2H)'J.>E<Q8ZS9Z=X:N))(K>2$^+YL7,J>8E
MBK2,R3X'_CIZ9;/L?:** /%;F]MA;?%2$W4\S7-G&T,D\15ILVVT$?*!R>!@
M#/:MNXNK-==^&!CFA"I%,"5884&VVC/IEN/KQ7I]% '*_$34(M,\)/<3V,5W
M$+F .9HR\< \Q?WK*.2$^]@8Z"N0L=2M%\:^+)&U":YCN=$A:.YFBVK* )<D
M$*%V\@ ]#G&2:]9HH \:CN+2+X>_#%?-B1X=4LVD&0"F$<.3Z8)YSZ\UJ6US
M9'6?B@YF@Q)'& Q8?.!:A3CU&[(^O%>HT4 >0:#>'3+GX?:O?2 :.-"^P/.Q
M^2UN2J'YS_#G9MR>XQ2:]IEQ?Z?\3=2TU&FT^_M8%M_*&5GDCC_>.F.O89'4
M@^E>P=:* /+YO$6EZMX\\!W=A<_:+9;:]4S(C% QCCXSCJ._ID9Q6#=36C_"
M3Q^B/$9)M7O&101E]TH*$#OD#(^E>W8HH \S;Q+9>&OB'>7NN3%-+UC3K9;&
M^VEXLQ[]T60#@DONJOKEUI_A_4_#.K2Z?=Z=X66WN;;_ $99(?LC2.C)(ZIA
ME#A>A'&>1FO5** /(/$J^'5\&M=:+%(MI?ZY:W#33O(WVIA(ADD D.=N!R>A
MP>W)Z%[FS/QN@E,T! \/,H?<,;O/5@,^NW)QZ9KOJ* /$(KEH?"KZC"D]Q8Z
M=XMN+J]CM&82"W9I )!M(.!N#<>F>U;>IW'A74O"7BW6M!,]R]SH\MO+?RRS
M%9&V'9$/,/S-].F0.]>J4=* /+IKJS34OA<4FA"QHX)5AA ;4KSZ9;CZ\5K>
M +F*'6O%^FR;EO#KD]SY90_ZIDCVMG&,'!QZXKNZ* .'\4:O;6/CG1K6X"V)
MFM)O+U/R=\A.Y?W$?! 9L G(/ P!DYKA;&YCB^&.B,_G*FF^*4ENV>)AY*"[
M<DMQV!!/ID5[E10!'!/'<V\<\1)CD4,I*D9'T/->(27EN/V?]0TIV(O;>Z:.
M:!D(*L;W=MY')V\X].:]SHH \\U:>&;XK:4ME=0J\FAW,4;HXP&9D*#(^A(^
ME8/A2[\-:IHNB^'=5M=2?Q'I<D*MILDUP#'/%P)>NP+U;/3!QZ ^PT=\T <M
M\2'1?AOXA#, 7L940'^)BI  ]237-ZA<6+:_\,F$MN8XQ*<[AA ;8J/I\V /
M<5Z;10!XYK GOKGXFQ:2/M-P9K"=((6^:9(TC,H7').%93COQUK6M;GPUXQ$
ME[X:-]=:W'83Q1SSS3_Z&70C:V\[=Q; QST)'3->FT4 >3^%+_PMKMIH&FW%
MKJ3^(-+>$MI\TMP#:2Q@*SD$[0H&2,\$8&,G%6=%OK:TL/B)87+F*Y_M"\N"
MCJ1^[>) K9Z8;MZ]J]/HH \>CN;0^&OA2DDL689X#(&(^3; RG/IAL#GO6A+
M]AO/$GQ/MIIW$$^GVX<VXW2$"!PY0?Q,.!CUP#7J-9OB#26US0;O3$O);-KA
M-HGB )7D'H>"#C!'<$B@#S7PYK^A:WK'@_[5XATQ+S2+=HH8(F=7N)9(Q'@[
MU7;P/N@G)(].?1](\2:5KMWJ-KI]SYL^G3FWND*,I1P2.X&1D'D<<&J$&B:[
M=B.'7M5L+NUC=) EK8&%I"K!EW,TC #(!PH'UK:MK&.WNKBZW/)/<8#N^,A5
MSM48[#<WYF@#B_%%];:-\3O#6I:C*+>R>RN[<3N#L$A,9"D]B0#CUQ7%:E>0
M3?#;Q_$0ZO-XB=TCDC92P,L)Z$=<*W'48.>E>YT4 <%>75H?C#H+0SPE3I%P
M@*,,'+H5''J 2![5RD%Y GP,\2:6[%;VW:]CEA9""KM.Y5>1U(((%>T44 ><
M:S>VI\2_#B07$10/,Q8., &W*@GZL<?7BNB^(%Y'8>!=5N9=-34HTB&ZVD4L
MK L!E@.2%SN..RUTM% 'F.B:E;7'Q>AN$U&;4$NM "1W/D%8Y&$^2$PH&T#W
M..A)-:GQ"O6TC4_"VLW22-HUC?NU\R*6$6Z)DCD8#LI8\]LUW5% 'F=K>V^N
M_$/Q%-IKF>*?P[$L3A2!(2\N"N1R/>N>M]<L)_!'PYM(I7DGL-6LX[M%C8F!
MDCD#*_'!SGCK@$]*]+MO#UW#X\O/$+74#07%FEI]G$9#*$9F#;LX)RQXQ718
MH \W\/:C:Z+J7C/2_$DJ0RW6HRWD/G\?:K:1%5 F?OX"[2HR1P*PM%LY=%N/
MA78:RZI=VT=X9$F(S"'C/EJV>A&54>XQ7LN** //]0O[/0OC%#<W[BVMKK01
M;6[%#B259RQC7 Y;!!P.:XR.[MG^&-A%+\K+XH#,DJD?+]K9B>>H"G)].]>Y
MT4 <#]ILS\;_ #3-!@>'M@?<,;O/W8SZ[><>G-2_"R:*3P]J21NK;=7O& 4]
M%:5BI^A'(KN:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "JU]?VVG0++=2%59Q&@52S.QZ!
M5 ))]@*LURWCNVT^[TJR@U"\N;#=>H;>^MVVM:RA7*N3TV\%3GCYNW6@#+\>
M>(&;P9/J&C:E=6LEK?V\$VU#$V6EC#*P=0P^5\\8ZUTVG>*-&U;4+FPLKU9+
MFV022(R,GR$X#J6 #+_M+D>]>9:Y>ZI=?#O5[35I;>^DBU:VC@U"WAVC4$5X
MF+[1P2H!!(X^7':NAU*\C3XKBY@C6[4>&YE6-#D3/YJNL>>F6 .!Z<T =39>
M+-$U"\M;6VO"TEVKM:EH75+@+]XQN0%? YX)XYZ5SNDW>I3:QX]LY-4NV%G)
M$+5R5S"&@#X48P.3Z5R>GZG#=:G\/=047(2*6:.:V@LG2"R9K=E$*J%Z@\<D
MGC/ -='HUU GB3XBR-*JH[Q,C'@.!;A21ZX88X[T =#\/[VYU'X?Z%>7D[SW
M,UHCR2R'+,Q'))KG;3QE:>'O%_B^'Q!K4QM;>>V^S+(I<QJT(9L*B\*"W)QZ
M9-;7PR(_X5MH,9X>*T2.13P48#D$=C63IU]9:-\0?&IU8B!;PVKVZRQG_246
M *PC&/WASD;1DY[4 =B^NZ:EE;7BW(FANANMS;HTK3#&<JJ EN.>!Q3])UC3
M]<LOMFG7*SPAVC8@%2CJ<%64@%6'<$ UY#86-SX&M/"=YK]M?II26EU;W!M7
MDW6+2S"5-_EG=C: IZ\CZ5Z5X0ATC['>7FB64\%I>7!G,TQDW7+D#=)B3Y@#
MTR>N,],$@"ZCXX\-Z3<7=O>:I&D]H%::)$=V7.<<*"3T/3ICFGR>-/#D6GZ?
M?MJ]O]DU!PEK*"2)">W3CH<YQC!STKFX=1T_3OC)KKWUQ#;[])M0DDQ"C[SY
M&X\9Z<=\>U<M_9W]D^&_#RSPF""?Q@-0@MW0@PVI=]I9?X0!@\]-PSB@#U"V
M\7:)>Z?%>VEU)/%*\B1K%;R-(Q0X?$87?P>IQW'J*D@\3Z/=:;;ZA;7@GM[E
MS%#Y4;.[N,DJ$ W9&TY&.,'-<AXOOHM"\>:?K.JI??V#/I[6ANK-Y0+>;S-X
M+^6<[6&!WY J"\TWPY-I%DUA+?\ A]+C4);NQU,%PWG%,-(XDY"O\PPV,X']
MZ@#NH_$&F2:>+Y;AO),I@ ,3AS("04"$;BV0>,9X-4G\;>'8M*O-2FU)8;:R
MD\JY\V-T>)_[K(1N!]..:\]NM0UI-,T77-:MI+JSTO5KF*[N=,5XS<1,A1;I
M50@XR3G'7G'!J;Q0=!O_ (=^+=2T"TN7_M""*-KN;SB]Y(IP%59/F;:.X&.2
M.QP >A6GBS1+[5)=,MKX27D<1F\L1O\ .@."4.,/@\?*35?PIXLMO%4-Y+;P
M7,*PW,D*B6W=,A&VY)(QG.?EZCN*PM3N;:3XF>#)()$:);.[4NGW5W+'L!/0
M9P<#VJ#P5K5KH'A_Q%_:*7,;6&IWD]PHMW)5&E)4CCG(((QVYH ]&HID,J3P
M1S1YV2*&7((.",]#R*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]9^'+FU\;:AXA
M:_B>.\MX[<VPMR"BH6*G?O.3\QSQ70T44 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1145S=065M)<W4T<$$2EI))&"JH]23TH EHJM97T&H0>
M=;^:8ST,D+QY]QN R/<59H **** "BBB@ HHJ"^O;;3;"XOKR58;:WC:661N
MBJ!DG\J )Z*;'(DL:R1L&1P&5@<@@]#3J "BC(SC/-4M)U6UUK3H[^S\WR)"
MP7S8FC;*L5/RL 1R#0!=HHHH **** "B@$'.#TK+O/$>DZ?K%II5Y=B"]O"5
MMHY$8"4CJ%;&TGD=^XH U**9--';P233.J11J7=V. H R2:HZ-KFG>(;!;[2
MK@W%HQ(681LJM@D'!8#/((XH T:*** "BJ>IZG;:1I=QJ-T7^SVZEG\N,NV/
M95R35I'$B*ZYPP!&1@_E0 ZBBB@ HHIKN(XV=@Q"C)VJ6/Y#DT .HK M?&FA
MWT<DEI/<W"1NT;M#8SN%8=5)"<$>E:]C?6VI64-Y:2B6WF7<C@$9'T/- %BB
MBB@ HHHH **** "BBC(.<'IUH **** "BBH;JZBLK26YG+"*)2[E4+$ >P!)
M_"@":BJ6DZK::WI5MJ=A(9+2Y021.5*[E/?!Y%7: "BHKFXCM+6:YEW>7$C2
M-M4L< 9. .3]!3+"]AU+3[:^M]_D7$:RQ[T*-M89&0>1^- %BBJ6HZK:Z7]D
M^T^;_I5PEM%Y<3/\[9QG .!P>3P*NT %%%% !116;IFO:?K%W?VUE*[RV$HA
MN%>)DV.1G'S 9X[CB@#2HHHH **** "BBB@ HHHH **** "BJ6K:M9Z'I<^I
M:A(T=K;J7D=8V?:!U.%!-6+6YCO+2&ZA),4T:R(2,94C(_G0!+116;INO:?J
MU]J%E9RN\^GNL=RK1,FQF&0/F SQSD<4 :5%%% !1110 4444 %%%4KG5;6U
MU6RTV4R_:+T2&';$S+\@!;+ 87@]^M %VBBB@ HJD-5M3K;:0/-^UK;BY/[I
MMFPMM^_C;G(Z9S5T$'H<T %%%% !116'=^+M'LKZ*UFGD!DNA9^<L+M$LYQB
M,N!@,<C\>* -RBC(&,GKTK-TK7M/UJ>^AL97=[&;R+@/$R;7P#CY@,\$<T :
M5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5YWXJDOM;^)NB^'8! ;6TLWU:6.<GRY'#^7'N ^]M;Y@..>_%>B5A:KX>
M:ZU^PUZQN$M]1M(W@8R)N2:%\$HP!!&" P(Z'L<T 5_"?B6YUN?5M.U&TCMM
M3TFY$%PL3%HW##<CKGD CL>E=+7,CPU?6NGZQ)INJ);:YJDRSR7YM@ZH5VJ%
M$9/W0B[1DGDDUTJ@A0"<G')QUH 6BBB@ HHHH *X_P ;3Z??R6GAS4)O+L[L
M-->XSDPI]U>.A9ROU"-785P^FZ_I]CK>J7U[J<EPUVR*BQZ1<H84085,X.X9
M+'MRQH A^%6LF?PO/HUU.)+O09FLG?IOB7F)\>A3 _X#5G3-8\2>(-%TSQ#I
M+6AM[NX#-8RK@"U+$9W]?,P WIVP>IR8[O3K?X@7/B:VUF2."[MDM[FR_L:Y
M/FA3PY?^\!QG&,=JHZ$MMH#-IEKXHO/^$;$K2161T>?SD4MN,0EV_<R3VS@D
M9'6@#=\./J\_Q"\9QR:FLB6SVT<:R09"JT.]0,,, %S]?6JVD^.M2NO!GAZY
MN!;'5]:U%[)66,B*/$L@+[<Y.$3@9Y)'-%IJ6G6'B_6-:MM9G$&IB)I+9]'N
M"1)''Y:G?C[N,$C&<CJ.^/;Z=HL7@W3]%?7+HWNF7IOK&^CT>X7RY/,9_F0@
M[A\Y!&1D4 =6=<U?3O&1\-7,\$_VRQ>ZL+MX<%70X=)%4@,.001M]/>N?T[Q
MEXGD\,>%/$EU<6#6^IWL-I<6B6Y!(E<IO#[N"..,?B:T(M6TV763K=_J#/J4
M=HUI;>7I-R(H0QRS8()8D@=Q@#'J3B16FG0^#="\/)K\F-)NXKE9SH=S^\\M
M]ZJ5[<]3F@#U/4I;J#2[N6QACFNTA=H8Y'VJ[@':">P)QS7&Z1XHU&;Q;8Z.
M]]!>17NF27!G2W(2.="H/EL.)$^8]"3Q]ZK'B#7M"\0>&[_2'O[ZW^V6[0F:
M/3[C*Y&,XV<CVSTKG[.6&/7]%U>\\1R22Z=:O:/'#H4\:21G;TR#M/R\GD>@
M6@#<^&$NHW.@WES?WYNF;4;I26C"ME96&<@^W3'%5/B3X?E\1WUC;V;%-2MM
M/N[NPD'5)XY;5EQ]>5_X%1X5U+2_#27MN=7N;FRENI;B"(:1<(T?F.7(9MIW
M8)XP!WSGC%RY\1:=-XFLM534I$@MK>6 P'2+DLPD:-B=V!@CRACCN: (8/$,
M7CKPMHUO -IU2,R:A&/^6446!,A_WGVQ^X8GM6)X"UV31/@YX32WCWW-_<M:
M0_+NVDRRL6QD9PJ-@9'.*T='D\,>'[K7KO2[NYCN-5G\X>;IEPR0Y'*A0HXW
M%VX(^\!VK%MM*T:'X?6/AA_$%X+C39Q<V&H0Z1<(\,H=F#%2"&^^1C(XH Z.
M?Q3X@T"#7+G5+"2?3[:&.2QNI8UB9Y'8)Y;JI/\ $P.X <9J[;7WBL^(H;0P
MR2Z9<V[^9=RVRQFTF RI"[SN0],<D'&36$;BPUC0+_3O%6OW>H/=P>0&MM(G
M@2(9!W!=IR^X*<GC@  <YF\.ZP]@\7]N>*KO5(K9=L"IHT\)8XQND.T[C@D8
MX'.3DXP 9NC:[K^E? ZX\11ZA#<7L8GG!N+?=SY\FXG##)).1V'H:Z;5=;UY
M/&.AZ/8SV4<&HV4TS/+ S-&R!.>&&X?-TX^IKEDM-/3P!?\ A$>(IS:SET@D
M.AW&Z*-Y"Y#?WFRV,\#':M674+";Q/HNLOK#_P#$MMI+<Q#1KG][O"[CG^'[
MHP,&@!5\<:OI_@?Q'?WB6]UJ&C:D^G^<L92-QN0"5E!X $F2 ?X>M:\6K:W#
M\1(?#_VNVN;!].^W/,]M^\&'V;,JP4 ]02#T(YZUQFHZEI^C>&_$4!U^5?[;
MU'SVN/[(FC2V$A0/OWY#)M7'8G/OQ/X.\4QIKMK::;K6A:I;7$BQ3II^CRVS
MH,':Q8$K@' YXY[4 >N45GZ/;:E:6)CU74$O[GS783+ (@$+$JN!Z# SWJ](
M',;",J'Q\I89 /N* /+/ -]K-GX;\2/I>E17C)K%\T>ZYV%FW=,;3_.NC\4Z
MOJ/AJTT;4+=H(=+:[BBU(-#DQ+(V/,!R,?,0#D'K1X;\)ZYX9L[RVMM:T^5;
MJ\EO"9=.?*M(<D<3#BM:3P[]O\*7>BZO=?;7O(Y%N)Q'LR7)Y5<G:%R !DXV
MB@#/UOQ+<Z/!KNJ I+8V"Q00Q%,%[ER <M_=&^,?7=Z5%:W_ (K'B**U-NTV
MFW%NY>ZGM5C^RS 9'RA\LC=,=1ZU<;P;:7/@,^%KV>6:.2W\N:XSAWD)W&3Z
M[_FJ+0M!\26*J-7\3)J7V="MMBS\K)Q@/+ALN<$\9 YR<G! !@^'M5\=>(_!
MD&OVU]I22S6LS1VIM&.^97(7YM_ (!'MP>:UM(\3W6OZ3X9EL+B,7%^&DO T
M7^K2,8E&,\$2%4_X%WJ?0;.V^'/@>&UUC5X&L[$D?:VB,0 =R1D;FYRV*A\$
MZ/8PW^N:]8%S::I=&2U!/RA,#<R#L'DWM[C:?2@#<\1W=_8Z#<W&F"U^U)MP
MUTX2.-=P#.Q)'W5R<9&<5RD'CJ73[[Q0EY*;ZQTFPCOX9C 89) P?*] ""5&
M& QSWKH_%WAZ3Q-H)L(;TV<RS13QRF/S%W1N& 9<C<N1TS61_P (-<W>M:I?
M:MJR74&JZ<ME=V\5KY8.-PRAW$J,.>#DY[XXH NV;>*7NM)N3/93V5W"S7J;
M-OV9B@*&/G+#/!SUZ\5F_#234KBPU>>_U W1&K7<66C"L2LFT'(/3  QCBKG
MAKPQKFCI;6FI>(_[0TZR 6VB6U$;L ,+YK[CNVCT R0"<U;\,>&[GP[-J:'4
M5N+*ZO)KN*'R-K1F1MS!FW'=@], =3G/& !E[K=S<^-$\,6,RV[I8&^N+@H'
M8*7V(J@\9)R23G@ 8YR.5U7QWKUAX7\3X^QC6- NXH)',+&.>*1EV.!N^5BK
M<CYAD>_'5ZKX9FG\46?B32[N.VU&&W:TF66,O'<0$[MI (((;D$?B#6;JW@!
M]3\.:S8#4HXK[6;E+B\NS;%A\A7:J)O&  @')/<]Z .CTB'68OM1U>[M+C?+
MN@%O"8_+3 ^4Y)W8.>?_ -0P&UC4?$4OB2+3+J*UM]*=K12\6\S3! S[N>$&
MX+@8/4Y[5U\0D$2"9D:0#YF12H)]@2<?G7(CP=J-AK^K7NBZO#;66KGS+NUN
M+8R[)=NTO&P88)'4$$9_*@#GO!NO7%MX/\'Z'9+()[G2VN9)8XA(R1H57"J2
M!DEQR<X /'/&K#XI\16EG;V.JV,<&I7FK?8+.Y= $EAP7\YD#'!VJ1MR.<=J
MAC^&]_9Z)X?CT_Q +;6=#1HH+P6N4DB;&Z-XRW(X'.:T=6\$WFMZ#%#?:Y)_
M;4%TE[!J$4(5894&%"QY^Y@G()YR3F@"S<3^*-,L_$,DTUE-!;6_GZ=<R1_,
MQ"$NLB*0."."".#WK%G\<7%GX<\):CJD[65IJEDLMYJ,=OO2&8HA52.0JL6;
MD@_=QQG(WHM!UJ?1;^#5=:BN;^[MVMUE2UV0PJ002(]V23G));L.F*BL?#6J
M:;I&CZ=#J5I/;V%D;*:&>T/EW*X0*Q&_Y2 I]0=QZ4 4=5\1:QIVG>%IXKS3
M[E=1U6&SN)H8]RRQ.S$/&0V!E5'KUZ\5<AUC4O$.L:]9:3=Q6::3(MNKO#YG
MFS%-QW GA!D# P3R<U2_X5ZT&@Z#I5CJ,4$>E:D-2RUL6#N'=MBC>-B9<@#G
M@"M%/"][IOB74M8T6_@@&J*AN[>X@,B>:HP)$PPP<=1W]10!S<7CW6]4TOPK
M=V45G;2ZEJ#Z?>PRQLVR1 ^2K!ONY3.,9YQD5T'A;5]6G\2>(M"U:>"Z?3&M
MWBN(8?*WI*A;!7)Z%2,YYJNW@'R+3P[;:?J"0QZ/=F\8S0>8UQ(V[<20RXR7
M8]#V]*T]*\.W.G^+M;UQ[Z*5-46!3 L!4Q^4I5?FW'.=QSP* &ZMK=Q_PE6G
M>&K"18;BY@DNYYV7<8X4(7"@\;F9AR<@ '@UQ-CKUSX3G^(&H71CN[Q-2MH8
ML+L61WC14W#MU!;'H<8KLO$7A:YU'7=-U_2=02QU6P5XMTL/FQ31-U1U!!Z\
M@@__ %LI_AT^H0>)H-7U19X]<>.4^1;^48)$50K*2QZ%0<'\SS0!;U#6M6\.
M^)=$LKZYAO;+5W:V\P0[&@G"[EP >4.",'D8ZFN;N/%_BV/PEX@UX76FC^Q-
M2G@:$6K8N4C<*1DO\G&3_$<]Z["+PY?WE]I5WKE_;W<FE[G@$-N8Q)*5V^8^
M6/(!. ,#)SGIC)D^'][+X1\0:"VL0?\ $YO)KIIA9G]UYC;F4+YG/3@YH N7
M_B&^O==O=(TLS0M9VL4TDT=N)COEW%002 % 7)[G/!&.=CPO>ZOJ'AVTN-=T
M\6&ID$3P*05!!(R,$\$ '&>,XK"U+P;JYURWUW1->CT_4C;+:W@>U\V"Y1>5
M.PME6&3@Y]O7/4Z;:26-C'!-<R74PRTD\@ +L3DG X R> .@P* .4BU_6=?T
M_7M1T6XMX%TVZFMK:"2'>+AH@-Q<Y! 8Y VXP.3GI6:/&FM:Y<^$?[%>SM;?
M7[2XE87$#2- \: GD,-P!)XP.G7FMJW\(7VE7.M)H^IQ6]AJ\KW$D,UN7:WF
M<8=HR& YZX(X/MQ2+X(^R:KX9GTV\BM[/08)((K=X"[2JZA22^X8/RYZ=<T
M=%:QZDFCQ1W5Q;OJ0B DF6(^69,<G;D'&>V:\VM_&?BMO FA^*WGTYEN+M()
M[,6[ 2*\QCR'W';CC'!Z<YKU.42&)A$RK(1\I9<@'W&1G\ZX5/AY>1^ =/\
M"RZS!BSN4G%R;,_-ME\T#;YG'/&<]* +ECK&NVOCRXT#4+BTO4ETPZA;M% 8
M?+82!#&?F;(.0<]:SK#Q;JZ>(O#5C>7-M<-JOGQWL4,68K:5(RX6.4<-C!4@
MEC]*V+[PG=7_ (J?67U-(TDTI],:** A@';<75]_!!''%9=EX U:V7PP)?$,
M#'0&9(/+L H>(QF/G+GY\'[W3_9/< S_ !#K&H^*/AOXLU2SNHH+".*[MX83
M%N\V.,,KLS9R"2&VXQCC.:T[77KMAIN@Z?YT;Q:/!=2S10"5AO&U  2 !\C$
M]>PXZU$_P^U*WTW7]%TS6X(=%U;SG$$UH9)+=Y0=P1PX&TDYP0<?K4]WX%U2
M.YTG4]'\0+9ZO962V$TKVN^*ZA'(#1[N"#SD&@#>\*7NM7V@QR>(+ 6>HJ[)
M(JXVN >' R< C!QGCFN,M(/$-QXY\>+X?O;*TF6XM&W7,!E\QOLRX7@C:#W/
M)]J]!TNRGL;)8[J\>\N6)>:=E"[V/HHX4#@ >@[G).&OAK4[+Q%K6J:7J=O$
MNK^6TJ3VQ=H71 @9"& / Z$=>_:@#GH?'>KW/A_POXF<6]MI=Y<_9-5C,18P
M/O:,.K9X3>N#G. 179:=>7=[KNJ 2H=.MF2"-=GS&7:&<[L\@;E'3KN]*YW6
MXO"_A_P</!4\H=KFS>*VLR<S7+'/*\??+G.?7GH*Z;P[I/\ 87AZRTXRM-+#
M'^]E8Y,LAY=R?4L2?QH H:]J&HVVKVMM'=0V5C+!(WG*GFSR3 C;&D7)88W,
M< ].W6E\"Z]<^)O!>FZO>)&ES.K"01@A=RNR$@'D9VYQ[U'J7AJ_N/&-MX@T
M_54M66S-E-#+;^:"A??N0[AM?/<@C@9!Q4W@OPW/X4\.0Z/+?B]2!W,3B'R\
M*SEL$9.3ECS].* ,5=5\3ZEXI\4Z-:7^GVR:;';/;3&T9S^\1VP07Y.0!GT'
M YXR[;QGXCF\,^%_$\DEBMKJ-U;VMQ8I V2)&V%Q(6X.>0N,=LGK74V?AJ^L
MO$VOZRFHV['5HX4$36Q_<^4K*ISO^;[QSTK(3X?7D?@K1?#BZQ!C2[J*X6<V
M9_>>6^]5*^9QSU.: (_&/BG6M!@UV[CN+6+[!''+9VJQ^<9TP"[38YC4G*@_
M*..IK5U#7]1@\:^%]/B: :?JL-P\J&,^8ICC##YLXQ\WIVZUFZE\/]0OD\3V
MT>O)%9:]^\D5K3?)')L"X#EON?*/EQG' (ZU7B>/5/&G@M[+4H-4&G6]^+NX
MM\!5.V-.0"=OS' !.>._6@"ROB76M8\,ZOXCT>:WCBLIIQ;6LD6X3I"2&WMG
M(+;6QC&,C.:K'Q;KVNZSHEOH<]E:VNL:.]]&UQ;L[P.-G!PP#<MCMZ\XP=.W
M\%7FG6^LZ;IFJ1PZ3JDDDIBD@+26QD&)!&VX#!Y(R/E/KTJQ%X.:S\3:-J-C
M=PP66EV)L([0P%B8SM_CWCGY1V]: (+/5]=/CJ7P[>7-FRKHJ78EAMRN)B^P
MD@L<C() XZ_C7->';_Q5%\'Y-:T^^BO-0CENI_+GM]QD"W$OF#(8<D9(QZ8Q
M7:IX=N5\>R>)3?1&)[ 6/V7R#D*'+[M^[KD^G2L[2+>T^&V@&WUK7K<:7]I=
M;5I8?*V>8[R;6;)W');G@8'2@"]9ZY)K&H:-_95TDEE/9?;;ES'DE&P(QU^4
ML=WK]QA4GBK7Y-%72[6V$9O-4OH[.%I 2L><EG(!&<*#QD9)%4OA_H%MHNC7
M,ULDJ17US)/!'+G,4!=C$@!Z+@EL=MYK0\5>&D\2V%M&MRUI>65REW9W*KN\
MJ5.A*\;@<D$9YS0!FIK>J6'C9?#-[<1SI?V3W-C>>4 Z.APR.H.&'(8$8]#Z
MU0^%T5V=,U>2XNDFC.L7H*>5@[Q,<MG/Z5OVV@7+ZZNN:E<6\M_#:M;6ZPQ%
M8X@Q!9L%B220O<8 QZFF>$?#MUX:L[NVGOXKL7%W-=[DMS$5:1MQ'WFR,DT
M8_B:34_^%F^%+6WU'R;::*\D\HQ!E#HBC<>>3AR/;\:PH[C6[&[^(VH:/=VM
MN;*[^TD30&4RE+=&V?>&T$#KR>>V.>UU[PW<ZIK^BZQ9:BMG<:;YR$/!YHD2
M55#8^888;1@\CU!Z503P9?+!XKC.JVY_M\L2?LA_<;HQ'_ST^;Y1[<T 1_\
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MMS'0!W%-=Q'&SL&(4$G:I8_@!R:X*Q\3:M;6_BG3=4NA)K.GS*MGLB5!,DH
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MFSU)R,YK*NOAM:7>E:A#]L:UOKK4%U..ZLXO+%M<*H561,GL#G)Y+'IQCI=
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MU&:6RD,5RL6FSOY;^APAY^E:FD:YIFOVC7.EWD=S$CE'VY#(PZJRGE3[$ T
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MMYJVB064^ME[I;V*]GNI+8'S'C(*JJ!@$7Y0,<_7))J['X<N%\<'Q(]_$V;
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MWT4$X'XFKE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHQC\<U/=^$9AXLE\0Z1JSZ=<W42PWL1@$J7"K]UL$C:P' //TZY ,_X2"1?
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ML6/0D9!;(/L*30O"%_IZ+!J_B.ZUFTAC:.W@GA2/:I4K\[+S(=I(R3W/&<$
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M,]Y81Q(P:1OO-&[<QEN^.?3'&+,O@V2V\42ZYHFJOIKW4,<-Y!Y"RQS!!A&
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %&!Z444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$ ]1FEHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!ZX^7/X5@7R3:I)\5+3266>\F\@QQ1MDRA85#J,=<X9?J<4 >EV?B/2+^_\
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M+*]N_MZ1Q6)Q="96C> XS\Z, PR.1D<]JJVOCCPW?%Q:ZI'*4ABF(6-\E9"
MF!CYB20-HR<\8S0!T.,]:*I:?JMGJ9G%J[EK=_+E22)XV1L!L$, >A!_&DO]
M7LM-DCBN)',TBLR0PQ/+(RC&2$0%L#(YQCD>M %ZBN5\2>,K2P\!7WB'2IEN
MPL$AMWC1G7S #C=@?* 1SG&,8XJ7PU:323)JJ:QJ,]M/;*DMI=HP'G<$R+O
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MCETV!#MSR <XQCD\'&]8/;6WQ?E!\N!(O#D,."^X(RRL2FX]2%P?7'->@T4
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M@4, 3T&*]AHH 1'61%=&#*PR&!R"*6BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K \8>)
MXO"FBB^>WFG>25(8UCB9P&=@H+$#@<_CT')K?KC/BC%+)X(E>*&27R;NUF=8
MD+L$69"QP.3@ F@"GJ7B V/Q*TN26_ODTRXTJ>4VC1.,NKH!B+;O+<GC!/I7
M467B?1]0T3^V+:\#66\QEBC*P<-MV;"-V[=QMQDDCCFN7N+V"Z^+&AWB"06_
M]DW"^9)$R!69T*@Y'RD@$@'!Q7*%+P>'M5O;2TN[E+'QA+J$UM;[DEEM22-T
M>,$_>W CKM]J /5],\0:;J]W=6EK,XN[3;Y]O-"\4B!N5.UP#@]CTKF_%NJ3
M:5XZ\(,VHSP6,[W2W$"M\DFV$E<J!ECD\#GG&!FI_"EQH&KZK-K&BV5ZSM;B
M&:_NQ,K'D$1#S>6QR21P..3FJ_BQU'Q$\$,02D,UTTK!21&&A*J6/09;@9[T
M =!IWBG1M4TR[U&WO0MM9NR7+3QM"8&49(=7 *\'/(IUIXDTN]U%-.2:6*[D
MC,L<5Q;R0M(@ZE=ZC=COCIWKS#6;&_U6V^(<.E0O-.VH6MU%"%(^TQQK&7"?
MWN5(X[C'>NFU26'Q?XD\(7>CL[_8;E[JYEV%3;QF,@QOG[K,2HVGG@G&!0!:
M\&:E,DWC!M3U*66WL=7D19;J08BB$4;8[!5&2>U4]2\1_:_B1X.M[&]OX[:Z
M^U--;R0R0QS*(&*MAE&[!^N.#CI7-7]G?ZGX5^(EMID,DUS+K(N8X0I!N(5\
MDMM_O A&'&<].];5_P"(K'7_ !OX%U#3XKR2&*2[\X_8Y<PEH-H5OEX.2 ?3
MJ>.: .QN_%NBV-PL5S=/&K3_ &;SS YA$N<;#+C8#GCD]>.M5[KQYX;L]0N+
M&;42+FWEBAEC6"1BC2'"9PO0^O09&3R*X#0WTU=,F\'>)=(U:ZUB*XD"6I-P
MUO> R%TD!!\M5Y!).,$$UU/AIX_^%I>,FP0)DLA$Y4XDV1L'"MT."1G% '1Q
M^)-,EO(;:.65FGF>"*06\GEO(H8LH?;MXV-W[&K]Y>6VGV<MW>3)#;Q+N>1S
M@**\QTI9]-U_39/#E]-<:=>W["\T*\CW-8EMQ>:-B-R*#GKP=W!Y%=)\3++4
M+OPFDFG027,EG>V]Y);1C+3QQR!F4#N>,X[XH W+3Q'IE[J#Z?'++'>K%YWV
M>>WDB=H^FY5=06&>.,X[UQUAJ$OC76M>MDU+6--DLKU(K*2WBFB6-51&;S 5
M"$L2WROSC&!5J],/BCQUX4U/2)#+!IRW,UU<*I 1'C"K&V?XB>=O4!22!3_
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M7S$*$CUP0"/QKR1K>^O/"GC4:;;S3W*>)3J$=NFY&N84>%OD/4@[&P1U(XH
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M:#\*/#.G7D4JW*ZO!<_9PI9X8OM!DP0,XVJ1GT/%>PQR)+&KQLKHPR&4Y!%
M'F>O^-)->^&7B34M,DU#39[)I5BD6)XFPC[>6(QDG.0#D>U=AI7BO2+^_BTF
M*\9K_P"SB4*\3JLJC 9D<C:^">=I->;3.\?PF\9:.]M=+?B\O (C;N-Q>8E
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M>290J(,@$[<,QQTX[UG>$I]/O[31]'U#POJ2Z[IKQ"1+J*3R8'CP/.5R=F,
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M[@\BO)O#:6D.E+X1\0>&M2N]8MI6C4/%*UM<C>2DV_.Q5Y!)/3!P">*]@HH
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M1PDG&2RG SVST_&MNB@#R^^\SQ7X,\.:-;VES;ZK!=6C7$<D#(;,PD>8Q)&
M, A>?FR,5L6LA_X7+J$QAN! VD0VZS&%Q&9%E<E0V,$X8=Z[BB@#C/B7;:A+
MH6G7EA:RW?\ 9NJVU]<6T(W/-%&Q+!1W/0X]JSH]6AU7XIZ/J=G;7[V/]DSQ
M&=K*5%5C(A )*C' /)XSQ7HE% 'BMY%/)\)_%5HMC>M<3Z[)+%!]EDWR(;I'
M#!=N2-H)S[5UGCUIH;[PYXACL;N_TNSDF6\AM WFJDJ "0*,$[2.1Z&N^HH
M\JUNT2^\//KWA;0+K_1]2M+^5)8G2?4!"Q+ *_S' (P3UP<#@9Z)]6@\6Z)J
M\NE:3=!I--EA-Q<VC0R,Y4[8EW %L$G.. <8SDX[.B@#R2V:\CTKX=:VEC?F
MST2/[+J,+6KJ\9>!8C($(W,$(.2 >IQGFM+4[1[_ ,2>)/$5I',; ^'CIZD1
M-_I,Y9VR@QEL JN0.K8'0UZ310!YW!;6-U\(=!L-5M-06(6]I!-]GCD2>UE5
M5_>  ;@589)QTR>E:?@4ZS'+JUGJ%Z=3LK>2-;+4Y(=DEPI7+*V.&V\#=WR?
M3 [&B@#A;HSZ%\59=6OHY6TK4-,2VCN50NL$L;EMC8!VA@Q()X)XKE=;TFZA
M\(^)KI;.Z*:OK\-W:VR6[LYC66+=(4 R-VUFY'3'K7LE% #8Y%EC61#E6&0<
M8XKS32-4?PYJ_B/0-;T:_N_M^I37EFT-HTT5W'+@A"<;05Q@[B ![5Z;10!P
MD_G+\6M'E>UD5$T:6&1HXF,22,Z$)OQCHIQ7(/>76H:;X8NY]*U2"[L]?CDN
M[&"PD2"R7=)PJJN'SD'=\QR3R,XKVJB@#RO4X+JTURZU7PS-?6^HR:BBWFB7
M,+/!>_.JF5,CY3MPQ=3@;>>E+J]O=6>NWNJ^&)[V#4WU!%N]&N(6>WO_ )E7
MS4R/E.W#%U.!MYZ9KU.B@#G?'FDWNN^!-9TS3SB[N+9EC&<;CUVY]\8_&N:U
M21O&6G>$[>SM;F"]M=2MKNZ26!HS9B($N&) P<_*!WSD9&37H]% '#Z-(1\6
M?$DC0W"Q36=I'%*T+A'9-^X!B,'&X=Z=\2(;];70M4M+6:[@TO58KN[MX%W.
MT0# LJC[Q7=G'^%=M10!YY9ZI#J'Q;CU2VM[XV#: 8A<M92HF_S]V"648X!Z
M^F.M<PT4_P#PIN2R-C>FY.L^9]G^R2;RGVSS-VW;G&SG->U44 >?^.VEM-:\
M.^(?L%Y?Z1;+/#>):!S)&LH0K(%7!(!3GV-96M6RR:/:^(_#7AZ[$%IJ]O?W
M$31.MQ>HBLK,$;YCC>,9Y."<8P3ZK10!Q%_J$7BSPGXBETC2;D&XTN:!9Y[5
MH9)Y#&P6-0P#,!D\],D8SSC!$ETL7P^\0)97S:?I436M]&ULZR1&2!4\S81N
M*JP() Z9QQS7JM% 'E^N64E_J?C#7[.*<V4_AXZ?%MB;-U.0YRJXRV 57.,9
M)'8UHSVUA??#'P_9:E!J$<7EVL;2VJ.D]G*D?$F ,KM9<$XP,Y/%=_10!P/A
M[6=3T'1M;GUJ2ZUBRLKB-;2^M[0^?=HP4<H/OE20NX=<'TKO@<@&BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-Q;&,'Y1C'3'>J<GPYM;K1]8TZ\U":1=2OSJ2S1((Y+:X.,,AR>!M&,^_/-
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M$CF:W$S>8!N4X8+D@^QZUZ#8ZC)J_B+S;&^9])@LXV<*J%9I)/F7G&X83#$
M_P :^]95HVD?#;POI^AZC>3W4#L\%MBS>1Y2<L4(0$$G) Z9K3\$>'H_#/A6
MTT](C$Y!EE1FW%6;G;GOM&$!]%% #-?UBXA\1Z%H%K,;9]3,[O<!0S(D2 D*
M&!&XEEY(. #QTK \67GBWPQX(UN].L02S6]U&;*?R5,AA=T7;(-H7<-QY ["
MNB\5>%(O$J6,T=[/I^I:?*9K.]@ +1,1A@0>&4CJ#UJEJ?@F75_"]UH]]K=S
M//>,C7-Z\2;V",&54485%!'3!ZGN<T 5;^^US1=5T_2)M4GU"?5[B:2-H+:&
M)[>*.,%HTW':?F(Y;)QGJ>:C^U^+[#1M8^WW<%I''<Q?8K^_,0D$#, X98P4
M,@Y"\?,2.*V?$OA-?$MC9"2_FL]3L91-:W]J K1OC!^4Y!4CJ.]4KSP-+J6B
M"VO]?O;C5!<PW2:B8XU*/$V4 C "[02>.Y).: ,8:WJMV_C?2SJ-^D5CI\5S
M9W$D217";XY"1]T<93C*AAD^V&Z)JU[IGA+P/I4%Q>7$^K6:,'40^9%&ENK%
M8]P5>N.6W'&>IQ706W@@1ZQJFH7.L7ERVJ6:VMU&R1J'VAE##"\8#G 'XYJG
M+\.DG\,:9I3ZW?"[TID;3]01422WVKM50 ,$;>#GKZT 4;SQ!XH\-Z7J/]I)
MO\^^M[72+BZ\KS/WQVGS5B.WY#DC&-PIUY9W5I\7?"_GZE/>HUA>;?/2,%6
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MQKM"LN<$$<'IGVK,U/X?PZKINNV\U]Y5QK;Q->3P0!1B/&T(I)QTY)))R?;
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M98A(EU'G(WH"O(/(*D8Z=.*JWW@*"ZT9=/BOY87;4!J=Q<F-6>:<,&!/0 9
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M.<8XKJ[[PP7\3)XATV]^Q:@8/LT^Z+S(IX\Y&Y<@[@>A!'IR*H7_ ,/=.OM
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M^JO//9ZI%&D=K&IMH8&>-?*E+ 9D(8D[22"1T%>ES(\D+I'*T3L"!(H!*GU
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M$6TJ$0#[H&YCW.3R>E95S\.[>Z\/:;ILFL:B+O2V5K'449%F@VJ%"C"@%=H
M((Y[FNGU6^DTW2Y[R&QN+Z2)<K;6X!DDYZ#) JVIW*"01D9P>HH S-$T=])M
MW^T:C<ZC>2D>;=7.T,V.@ 4 *HR< #N3U-5+_P ,)<>(HM?L;R2QU)8#;2NJ
M!TGBSD*ZGN#R""#]16_10!S%YX)L[KPK?Z"MW<11ZC(\MY<@*99G<Y9CD8!/
M X'   K?LK=[2RAMWF:8QJ%\QE + #'..,U8K&B\1P2>+YO#AM;A+F*S%YYK
MA?+="^P;<$GKGJ!TH Y^[^&EM=6&K:>-;U**QU&[-[]G3R\13%PY8$KDC<.A
M./QYKLUAD2S$*W#F0)M\YP"Q/]X\8S^&*@TJ_EU+3UN9K"YL79G7R+D .,,0
M"<$C!QD>QJ[0!QB_#RW3P=9>&5U6\%G9SK/')M3S"5D\P G;C&[VJ_>>$(=0
M\0R:O<WT[-+ISZ;)"JJ$:)SENV0V>^:Z2D)"J68@ <DGM0!P%QX-L_#VFZ1J
M%_XBU>2#P\2;=EB1BL17R]FU$R?E(!;!('<=:FT+1(-;O?&<]Y#YVD:U/$D6
M01YT:P(K,.^-V0#ZK7<1R)-$DL;!XW4,K Y!!Z&G4 <U9>$1"FF0WVIW&H6^
ME.'LXYD4$,%*JSD#YV4$@'CU.3@U8T'PT-!N=6FCOYISJ5RUW(LB+A)" "5P
M!QA1P<]*W:* ./'P^LV\*:MX?FU"[EM]2N'NGE(0/'(SAR5P,8W '!%5_%$U
MK<:5+X(N/MVI:GJ-IA)9+8E3N8CS&=5"+L(W8X^Z,<D9[BB@"O864.FZ?;6-
MLNV"WB6*,'KM48%9.H^&([GQ#!K]E=R6.IQP&V>1%#I-$3G:ZGK@\@@@BI;[
MQ'!8>)]*T*2UN#-J2RM#.-OECRUW,#SG/([=ZV: .8O/!-I=^%]1T,7=Q&NI
M2/+>W("F69W/S'I@= .!P  *W[&W>TLH;=YVF,2!/,90"P QSCC-9WBGQ'!X
M4T"?5[FUN+B"$J'6 +D;B%!.2.,D>M;- ',OX-C&IZW>0:I>0+K" 3P*$**^
MSR]XRN<[>Q.,\XZ8@_X06+^R?#^G#5+H1:%-'-;-L3<Y12JA^.1@D<8KK:P+
M7Q7#=ZCKUBEA>"?1A'YRD)F7>I<;/FQT'<CK0!FR^ $37[S4M-UW5--@U"3S
M;ZSMG41S/W8$@E">Y7!]Q75FU@-F;0Q(;<Q^5Y>/EV8QC'ICBJ7A[6X/$?A^
MRUBVCDC@NX_,1),;@,]\<5IT <'_ ,*R0:(FAKXBU-=)AN$GM;?$1:#:X<*'
M*DD CC/3WK=7PR4\5OXA&I7!NFL18[&1-FP,6!X&=VXD^GM6_03@9- '-:1X
M+L=-\)3^&9YYK[3IA*K"<*&Q(Q9AE0.[$CN*A\/^"FT7RX[K7M2U6TMU*6MM
M>%"L*D%>< %SM) SP 3Q7412QSPI-$ZO'(H9&4Y# \@BLG1?$<&MZAJUE':W
M$$NF3K!*)MOS,5# C:3Q@B@#(T+P!'H$RPV^MZE)H\,OG6^ER,IBB;.X#=C>
M5!Y"YQGKFK2>"K$7VN22W-S-9:R2US8/M\K>4",P(&[D <9P#SZ8Z:B@#F+'
MP<EO!IEK>:G<W]GI4BR6<4RJ"&4$(78#+E0>.G8G)%6='\,KI&IZQ>K?SSMJ
MLHFF1U4*C!0HVX&<8 '.>E6=4UQ-/O(+"&VDO-0GBDFBMHF5243&YB6( &64
M>Y/U(IZ3XIDU33;R^;0-7LX[9 ZQW4*QR3?+DA06Z@@CG'M0 RS\(B*YT>:^
MU&:_;1U86;2QJKY9-A+L/O';QT'J<G!J[XE\/P>)M&;3IIYK?]['-'-#C=&Z
M,&4C((/(Z$5E'Q[9?\(YH>MBQO&MM8GA@B "9B:1MJE_FZ?3-=90!SJ^%2OB
M6UUUM5NI+JWLVM )%0AU9@S$X Y+ 'C '0"LY_AQI\^@W^E7-]>2+=7[:DEP
MI5);>X9MV]"!QSTSZFNSK&\/^(H/$/\ :8AM;BW;3[U[*59]N2ZJI)&TD8^;
MUH S4\&2RZ%?Z?J.OZA?SWMNUJ]W,$#1Q,,%44+M&>Y()/&>@Q(_@Y7D\/.=
M3N,Z$/\ 1\(G[SY-GS\?W>.,5>3Q' _C!_#9M;A+E;+[:)FV^6R;PG&#G.2>
MH'2MF@#/US2EUS0[W2GGD@CO(6@D>, L%8$'&>,X-9'_  AJ?:O#EQ_:=SOT
M&-H[<;$Q(&3RSOX_N\<8]:Z>F2S1PH'E=44LJ L<<L0 /J20/QH Q]&\.+H^
ML:OJ*WLT[ZI*LLR.JA595"C;@9Q@#KFFZMX9BU#6[+7+6ZDLM4M(VA69%#+)
M$W)C=3]Y<\CH0>]21>(X)?%\WAPVMPES%9B\\U]NQT+[!MP2>H/4#I6S0!SD
MW@^VET'5]-^USK)JY<WUWM4R2;UV''&  H"@8X ]>:BU/P:NJ^$K;P[-JERE
MO!Y0\U$02,(BI3.1CJH)P.:ZBB@#!U+PT=3UC1M3FU"9)M*=WB5$7;(SJ5;=
MD?W3CC%9@^'\4&M7UW8:UJ5E8ZC*9[W3H&7RY9#]X@D;DW=]I!/J*ZYYHXY(
MXW=5>0D(I/+$#)Q^ I] '(ZIX$2Z\0MK>E:UJ&C7<\:Q77V/84G5>%RK*0&
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MLH/)A$3J"=H&>2HW-GVQSGI+WX?QW4FO)%K-];6.MAFN;2,)M\UDV%PQ&[H
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M#LVEB"IW;E)/!([=: .:ADU:37+KPL-2O;O^S;**1KGSTAGF>5I,,2%Y"A5
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M\3ZYJMCN;[4FHV0CC";3C#F-#NW;>!GOD4 ;'C'6[C3I-$TVTE,$VKWZ6IG
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M5!Y:[2OE\(,C!QD_,.Q%:UMX5BM=7UO4X]1O?/U=46<'R]J;%VJ4&SC ]<T
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MM;M65Y8K4@M\_P H4R8!4'&.<\XK:U+P!:ZG8:8DFK:I'J.FDFVU..55G7(
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MABI(!!/3IFN/UG4;;6?"7ABXTW59[N-_%%NJ37"DRPGS&(1PW.4R!SUP.N:
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MF*GDGT QT&!Q2ZKX1@UC2;'3KK4K_P JSECF1T,8=GC(*%CLQP1G@#WKH:*
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M&=F"#N;((/6NPHH Y6+P%I\#ZI)!J.JQR:C+%/(XN<E)(RA#KD'DE%SG/<#
M.*L2^$+6X:\GEO[XWUT( UZK(LJB%]Z!<(% W9)X.<\\8QT5% &7IVA06&I7
M6I-/-<WUTB123S;0=B9VJ J@ 99CTSS[#$.N>&H->O--N9[V\@;3IQ<0+ 4
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MECE0K8RN!D#T^F*L-X.MFO-#NCJ-_P";HJ-':\QX(9=C;ODYRH [?GS71T4
M<QKO@>PUO6H=9CO]2TS4HX_):YTZ?RFECSG:^001GVS^E)JW@+2M4@TT)/?6
M-WII8VU]:3[9UW??RS [MW4YSDD^IKJ** .<O/!FG7V@)I,MS??)<)="\\[-
MP9E((D+$$$\ =, <   4^X\)6LFJVVJVU[>VFI0P?9FNHG5FGCSG;('5@W/(
M.,CZ<5T%% ',WG@;3;O2K?3Q<WD$<-X+]I(G3S);C=O\QRRG)W<\8';H *Z5
M050 L6(&"QQD^_%+10!SI\(6LA6.XO[ZYM$O3?I:S,A19=YD&"%#;0QR!GVZ
M<5&O@FT6#7H?[1U KK98W>6C_B78=OR<?+Q_]?FNFHH Y6/P'80WFFW<.HZG
M%/8V0L \4RJ9K<'(1\+V]5VGWJ%/ASI<7AJ#0([[4ULH+H74?[Y696#[U&2I
M& QSTY[DUV%% &*?#4!\4Q>(3>W9O([4V83*>68RP8@C;G)8 YS^G%/\1^';
M?Q/I8T^[N+F&#S4E/V<J"2C!EY93T(!K7HH Y^Z\(6=[KC:M=7=Y+,]BVGR1
MDH$>%CE@0%!R3SD$?E6=:_#G3;4:/_Q--8E.D.39F2Z'R(5*>7PH^7:<9^][
MUV-% &7?>']/U#7-,UBXBW7FG>8(&SP-XP<^O3CT-9_B/P78>(K^TU$W=_IV
MI6BE(KS3YO+DV'JA)!!7V(KI** *>F:=#I5BEI TKA<EI)G+R2,>2S,>22?\
MXJY110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex31-restatedcharterasam009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex31-restatedcharterasam009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>3;*$QDJ-P;CZ]JZS3=4MM3^,1O;)9Y;270%C2X%M((RWGLV-Q7'3OTX(ZT
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M-"WA]HA*O*%S.K!=W3.W)QZ<T =?J&HVFEVIN;R811;E0<%BS$X"JHR6)/
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MX'@:.,@D/AP#M(!.?:G6/BS2K^\2TB>X2>6V^UPI+;NAFAX^9,CGJ..O(XH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_;P7,,;LRA+F$Q.-K%3E3]*T*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>-E9!D$GD_-QT'J#6=I_C/5DT(6MW-#-JC>(GT)+LQ!5.&/[TH.,[0>!QG%
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MD#Q074^@RV<4 QG=AD"EL@'YCS@  <YZ_3+>YM-,MK>\O&O;F*-5EN60(96
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M4.1CY!G))))YYXM7'A.1M8L=<M=4DCUBW@:VEN)(0Z7,1.[:Z KP&Y&",>]
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MTF^^Q7=U"L-VCP^;%.%^XQ&5(=1P#G&.U5-2\!VUYX-E\-07LMO!/+Y]Q<%
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MUI=GX@N9O'$VA:VNG2P:U-(B&V203.(HSM<MG"G@< 'DG)Z5ZJNX( Y!;')
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MYU03X>*GA:+11JTP:WU :C;W*PKNCE\PR<@Y##)/% '9PQM%"D;RO,RJ 9'
M#,?4[0!GZ 5XIH=WXET#X/6'B73=7B^S:>99)-,>V4I-'Y[A@7/S!N201@<
M8[U[5;QM#;QQO,\SJN&D?&6/J< #\JY*R\!):Z&GAZ74Y+C04E,@M6A D8;]
M_EO(#RFX] H)Z9Q0!&=<O]+\?PV^I:BYT75+)IK$21QJ(I4^9XV8+D_)\PR>
MQZXK>\,R7UQHL=Y?W$DLETS3QK(BJ8HF),:$*!R%VYSWS7-^*&T7QIJ47A15
MFGO+*]BGN<0NJV\8&YB7(VD.I*8!_C]C7=@8&!0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@U'0-1DTS7-7OK&-H(8]/UD6Z?9I9=@#F;"G8Q?/'0#ICJ?1;MIQ8SO9JCW
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M:NRP&3E0WRAF"+^9P,XH ]-HKFO#*>(H-0U2'5V:33]Z/I[SO&9P"/G5]G!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;2[CO()X0I9)$/!PP((Y/!%;-% '/0^%V@\4-KXU.X>Y:Q6QVR(I4H&+!C@
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MU7\.^"7T!X8Y/$&IZA8VG_'G:7)3;#Q@9( +X' R<#TR!CK** ,CQ/H*^)M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***Y?XB7VHZ9X#U?4-+O#:75M TJR"-6/';G(H
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M'N]5FU 16=G*8;AI(G5HI!U5D(W \CC'>I;'Q7HFHZPVE6M\'O!&90AC=0Z
MX)1B K@$\[2<4 ;-%>>_$SQ7%:>"=7;2]3N[>]MF$8GM8GV"3< 4,NTJ#R1C
M((/'7BNCFOM._P"$QL[=]9N([Y+.1_[/5OW3IE<R.,=1VY'6@#?HKF'^(?A5
M(C*=67RA.;=Y!#(5C?.WYR%PHR<9; )SSQ6Q>ZS8Z?<QVT\KFXDC:5888GED
M*+C+;4!.!D#/J0.M %^BL[1]>TO7[4W.E7D=U"#@NF<9_&J^I>*='TF6XBO+
MI@UK&LMQY<$DH@1LX9RBD(#@]<< GI0!LT5C7WBS0M.N[:UNM1B2>ZC,L" %
MO,4#.1@'/48'4Y&,YJM_PG/AP:#+K9U KI\,Q@FE,$@,4@."KKMW(<D=0.H]
M10!T5%4IM6L[>6QBE>19+YMMNODN2QQNP>/EX!/..A]*EO;VVTZTDNKR988(
M\;G;W. /<DD  <DG% %BBLFW\2:7=3W5O%+-]JM8_.EMGMI$FV=F$;*&8=L@
M'GCK7":]XUFUSX8OK^ESWVFR)>1J,1M'NC-UY0!8K@Y7D[3P3@T >HT5D:;X
MHT?5]3N-.LKSS+N!!(\;1NF4)P'4L '7/\2Y%,7Q7HK7]M9_;"LETQ2W=H76
M*9AU5)"-C'CH#SVH VJ*YV/QWX:FOTL8M41[A[O[&$6-S^^P#M)Q@<'J>#SS
MP:T=7U[2]!2W?5+V.U6XF6&(OGYG8X X_GT% &C16!IOC;P[JTE['9ZFCR62
M[YT>-XV5?[P# %E]QD<CUIFG^.O#.J2^79ZK$_\ HK799D9$$2G#,68 #&1Q
MG.#GI0!T5%9%KXFTF\OH[&.XD2YEB,L4<T$D1E0=2F]1OQ[9I;#Q-I.IVM]<
MV=P\D5C(T5R?(D4QNHRRD%0<CN!TH UJ*YR35M*O?$FB!-9NXKF:"62"Q4,B
M7*%02TBE<_*!D9(Z^]7D\1Z7)>16J32,\TS01N+>3RWD7=N42;=I(VMW_A/I
M0!JT5S^C:CI<M]KT]OK<UVL,X-RD[_NK,A!E4)  7 W'D]:L6OBC2+N^@LX[
METGN(S);K-!)$)U'),9=0'P.>,\<]* -BBN8F^(?A6"&>9]64QV\YMYG2&1A
M$XQG=A?E7YA\QXSQGBM:]UW3]/D\N:61G\KSBL,+RE8_[QV X'!P3UP?0T :
M-%16UQ%=VL5S V^&9!(C8QE2,@_E65<^+-$LY&6>]*(DWV=Y_*<PI)G&UI0-
M@.>.3P>.M &U17%>+/$GV3Q3H&A'[<EO>O.UT]M;S;V5(LJJ,BY/S$$[#D8Y
MP#6W9Z9=:=X<GLWUB]NI )&BNIMOG(IR5!)') XR1F@#:HKBO!7B-$^'7AV^
MUF]DEN[V(*K,&DEGD.3@*H)8X!/ X K7D\9Z!#HTNK27Q6RAG-O-(8),PR@X
M*NNW<IR0.0.H]10!O45F?\)!IO\ ;D>C&:0:A)#YZ0F"09C_ +V=N,9..O!X
MZU9L=1M=1$QM7=A#*T+EHF3#KP0-P&<>HH M456U&^BTS3KB^G65HH$,C+#&
M9'('HHY->=ZUXOGU3PGX6UVTNKO3DN=5LEN4*-$C1R."REF4;EQW4X/- 'IM
M%8NG^*]%U1[Z.UO<O8@&X62)XV0$'#88 D'!P1D&JN@ZOI-MX5TZ>'6+O5+:
M=FCM[J=6EGN6W,2,!06QM;H.BYZ#- '2454T_4K75;=I[1W9$D:)M\;1LK*<
M$%6 ((/M5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+!;!';@2;8&5@I_BP2 <=SBN>T2\DT2#X>:Q?)-_9-MILME<R"-F^R3L%P7
M&5SMVY[5Z/\ \(S=_P#0UZ[_ -]6_P#\:H_X1F[_ .AKUW_OJW_^-4 >?7U[
M#=1_%5X4G*7EK$+=S ZK*?LNT!21R22,#OG(XK5OI[=M0^&CAT*0EC(1TC'V
M8J-W]WYN.>_%=9_PC-W_ -#7KO\ WU;_ /QJC_A&;O\ Z&O7?^^K?_XU0!P.
ML6UWJ=]\2X-*1IKF7[!+!&A(\\1(ID52.I^4J<=SBM_P]JOA;7]5M-5LK/46
MOK*)S-/?M<#["K+AE+2':23@8&>Y[5O_ /",W?\ T->N_P#?5O\ _&J/^$9N
M_P#H:]=_[ZM__C5 'F5LZ1_!'P_;E2MQ'JL3O%M(=<798DKU&%YSZ&NK6YBL
M_B7XE-S;S2PW^E6S0!(V99U02;\,!@=1U/>NB_X1F[_Z&O7?^^K?_P"-4?\
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M %%%% !1110 4444 %%%% !7+^/?$\WA;P\D]G$DNHWEQ'9622?=,TAP"WL
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M?;ZC;A >A.16_J\T?C#5O"-SI:S*UC>_;;IWB9#;1B-@T;Y'#,2J[>O!/04
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M5<R;0D>2.2,,Q';C.,B@"71_B/I5YX6AUV_2ZL[>:=HE+6<K*,RLD8W!2"2
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MR*,G;A>3R/E'(SR!4\GC'2ELEN4%U,/LJWDD<=NQ>&$@D,ZX^7H>.IP< XH
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M037D<G[Q1"%)W/WS_#U'3 Q@6_&JRMXG\'/';7,J6^HM+,\4#NL:&)URQ4$
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M*;63;*41PP4[?FP2.E=W10!X_P"'KG4-*\)^!K*ZTO48+=4GBO;B*PD>XMG
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M7$*RQ[MC#(W(5/Y'!%244 >61K=6N@?$C2Y=.U#[3=7-[/!MM)&659855-K
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MS*<@X).TC&.G3 J_:^*&U+QKJWAQK"[2"T@AS.ORY9]^6R#E5PHP>N<^U6/
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M-GY\MK)&7^5HQRH8-GZ\>M3:MH>FWEGHT!T?4= 9%N)[.ZTJ!@]BQ9<*XC!
M+@Y(/&5(SGF@#O=-U"+5+".\@618Y,X65"K @D$$'H<@UC?\)KIOV76;@P7H
M71FVWJ^3\T?R[B0,Y(V\Y';I4O@Q]8?PK:'7AG4,N'?R_+,BASM=D_A9EP2.
MQ/;I6#K6@:@?'N^RA)TS7K/[/JK@X$?E$$,?=XV:/]>U '2KKUI<V^ELD5RR
M:JO[@H.0I7=N8@Y4;><_U(%<-X.\8V>A>';@:I)J,T:ZQ<P/=LCS) #,53S)
M#G'8=2>1GJ*UO 6C:EI"W5KJB/\ 9]&:2QTUR"6D@+"3?[_+Y2#'_/,UREQ8
MZA)\'?$.G+I6I&]GU.62*W^Q2[W5KD."!MZ;><T >ARWNDM\0+:S:2]&K+82
M.B?.L!BW+D_W6;..1G%%QXUTFV>!Y//^Q3W7V)+X1YA,V2NW.<XW C=C;D=:
MR;M9KCXL:7>1VE[]D&D30M<?99 B.[HR@L5P#@'KT[UF>"+_ %31M$MO!^H>
M'-0?4K&0Q)<FWS:2)O)6;S>G .<?>R..>@ MCXAB\.^-?'/VK^T[R"W>TD2*
M)9+@Q(8-SD9)VKDD]1[5Z%8WMOJ6GV]]:2"6VN8EEB<?Q*PR#^1K@[9+A/$G
MQ#G>POQ%>10"V?['+B;;;[&V?+S\W''UZ5T'@"*:W\ :%;7,$T%Q!91Q2Q31
MLC*RJ 000#0 3>-](@E?<+@VL=Z-/DO%C!B2X) V'G=U(&[&T'O6:ID7XT36
M_P!HN#;R>'_-,1F8HK^?M+*,X4X Z8KD?$/]LZKHNJ)<Z'K!O[;68Y$@M[5A
M (%G4ATVX$K%1DGYFR3T%=9']H?XOC4&L+Y+5M!$!E:V?8LOG;]A8 C.WWQV
MH D^&TDKZ7K:2SSS^3KEY$C32M(P19,*-S$DX JY<^*Y(_B!#X973[EHVL&N
M7F51R?,1%(YSM&6R?7&*J?#F*X@LM=6YM+JV:76KNXC%Q \>^-WRK#<!D$4W
M4([JR^+=CJ?]GWD]G-H\EF)H(2ZI)YROAR.%&T$Y- &)X9\76GANR\2-JDFI
M7$%OK]S&T^R2X%O$"JJ7<YPH^I/M7>W^N064WD1P7%[<B+SS!:H&81YQN.2!
MR0<#.3@X!P:\TEL[Z3X=>/[-=+U'[3?:I=R6L1LI0TJ2%=C*-O0X/T[U<OO,
MT?Q;'J]_X;OM6TG4=-MX=T%D9I;2:/=PT9&X*0_7UH ]#T76;#Q!I%OJFFSB
M:TG7*/@@\'!!!Y!!!!'M51O$UF+AD2"ZEA6[6R:YC0&-9BP7:><\$@$XQGC.
M:E\.V\-MHT2V^DQZ5"[,Z6:1JA0$Y&X+P&/4CL3CM7!WFG7EOXBDU7PTFJV.
MHRZH$O=-EMW:SO$\S:TV6&U3L&_>#VQU/(!T^C^+SJ?B77=.EL9[:WTQTC,T
MJ@+]PN68YX!!&/;DXS@68_&6EM+I_F+<P6VI.$LKN:+;%<,1E0#G*EAR-P&>
MV:Y6?1]1O-9^(>D+:7<+:S"AM+LQ$0$?9@AR_3[PP1UYZ8YIEW;WOBCP-H7A
MXZ;>VFIP3V@NO.MW1+;R2"[AR-K A3MVDYW#WP ==JOC'3-(CO)IEN);:P95
MO;B&/<EN3CAN<D@,"0H) (SBL3[:L'Q=EE^V2&P;PY]J*O.3$#YX&\!CM7Y0
M.1@51T>^U'POK'B#1+_P]J=^E]J,U[97%M;^9#,DN#L=S\J$'@[L#'ZT?%F@
MZKK?CX2VJW5M/;Z+'Y5RMM(UJ]U'/Y@B<[<,A _EW&* -/QSK'VOPWH>K0'4
M+&(ZQ9_ZQFA+QM(,[D!Y&.S"NHTOQ7IVJ:C?6"I=6MS9HLLD=Y 828FSB0;O
MX>#].^*X_P 1:K?>)?"&A3MH6K6U\FJVDUU:-8REH@D@+G[O*X&0?Z\4_6]+
MO-:\=:]#;P7<,5]X9-C%=O;R+$)B[G!8C'1@?_KT =0GC/2R]@TBW,-IJ+B.
MRO)8\0SL?N@'.1N_AW !NV:RM*D>+XL>(XGN9C;KIUK*$EF9DC):3)4$X4<=
ML"L.YM;[Q+\.M'\+MIM[::M#):0W'FV[JEOY++OD$A&P@A#MVDYW#WQ:U+2[
M_5/&/C*WM[>ZA&H:&EG;73P.L1E DR ^,<;ASGZ4 ,\9^(H]0C\+7%A_:,=O
M<:Y:+#=(62&Y0R<C ;D'&1N ! R,UUVK>++#2$O)98KJ:"QQ]MFMXMZVV0&^
M;G)PI!(4$@$$XS7GUU?7^H>#O">F_P#"/:Q'J&E:E8_;(?L+[46$X9E;&UE(
M&1M)X/.*M*@T7Q-KMCK?@^]U>WU.[:[L[JWLA<*ZNJ@Q2$\)@C'S'&,]J .L
MO_'VB6%ZMF/MMU.]E]NB6UM7D\V+CE"!ANN>.@!SBK1\6V1622.VO988I(XI
MI4BXA=PI"L"0V<.I/! SR1@US]O:S6OQ0TAQI<UO:PZ"UH3;VSFWAD,B,(PP
M7:  I]N.U9OB+3KQ-;U#5_#2:K8:^+E$>V-N[V>IK\H#-D;!\O!;(QM/J#0!
MZ/J%ZFFZ?<7LL<LD<"&1UB7<VT<G [\=JQ?^$UTLV^B7"QW30ZT56R<1C#L1
MD G/RD@9Y_GD5T9 (P1D&O(I/!NMOX?UC1HD>*+0+I[K0'!/[QR1-']=@+1^
MGSGTH ]'N?$5A9OJ/VMI((M/56GF=?D&X9 !&26/' &>1ZC,4'B>TDU9-*GM
M[JTOY86GMX+A IN$7KL()!(XRI((SR*Y?Q%H6LZM\-VF@MO^)U-<Q:K+:;L;
MV5U?R<GNJ*JCU*"K5]$_BSQ5X5O[2UO;>'3))KFXDNK9X"FZ/:(_G R23SC(
M 4\\C(!J/XZT>/PU/X@87/V"WG:"9O*^:-U?8<KU^]QQFL^^>6/XPZ0BW$_D
MS:5<L\)E8Q[E>, A<X!P>H%<5J-OJ<?PX\5>&4T/59=1.I32ILM6,<D;W =6
M5^C9!Z#)]0 ":[*\^T3_ !4T.]6QOEMETN>)YC;/LC=V0JK,!@'"GOQWH S_
M (F^)(9OA]KK:>=0Q;YA^W6C,D:2A@"I96!(SE2<%<\$Y%>A",3V0C<N \8!
M*.5;IV(Y!]Q7C31ZM9_![5_!-SHNJR:S;K+%&T5H[Q72M*7$BR ;3D-TSG/:
MO9+*0RV4$ACDB+(#LD&&7CH1VH \Q\">/=/TCP-HL>LRZBQEEEBDU"6"1X4<
MS/M$DIXR>/7'?%=YJOB6TTK[5F"ZNOLD8ENOLL8?R$()RW(SP"<#)QSCI7G=
MCIE]=_!]O!+Z9>1ZO(TENZS6SK%$&G+^89"-A4*=W!.2,#FKEQ!_PCGC/5TU
M?PO>ZUIVI^3):W=M9_:2C+$L;1R#^'[H()XY_( ])L+^UU33[>_LIEFM;B,2
M12+T92,@UC7OC/2M/V2W N%L&N/LIOQ'F!9=VW:3G.-WR[L;<\9K3T>W6TTB
MVA2PAL$5/EM80 L(/.WCC(SSCC.:\Q\/6BV%E)X4UOP/-?ZC#,ZPWCV2R6MR
MA<LDCRGA<9&0>>.,GB@#M;KQYI-M>ZI9+!J-Q=:8J-<0P6;LP# G(X&0 ,YZ
M<C!.:JZKX[A@D\--IMK/>VVMR I/&G CV,^ "0=QP..PSFJ>GB>#QUXXNI;&
M^%O<V]JL$GV20K*4C<,%.WG!8#CKVKGM.LM1LO"?PYGETG42=*N2MY"MJYEB
MS$ZY*8SC)'/2@#MX]4TH^,[]8EU)]6ATY'EM\.$,>X[=JMA2Q.1D>G7K7(>(
M/%%QXG^"&J:XD=YI\VQI(FCD:/CSBH 93\WRC!SQFN@LUN&^+]W>-8WD=M)H
ML4 F>W81^8)78KOQMR P[XKD5LM3'P O/#S:-J:ZG!&UOY/V5R9',Q;Y,#YE
MQ@[AQSUH ]1O-9AL7CME@N+N[:+S?L]LH9]@X+')  SP,G)[9P:J6_C'1KS1
MK/4[6=YX[V7R+>)$/FR2C.4VG&"-K9S@  DG'-<GKYDTWQM;Z]=>';S5]&OM
M.CM6\BS,LUK*CLP)C(W!2'/;J*BU.SN=+U+PKXDT[PU-;:797%S]HTZTMQYT
M:3(%$IC3JV020,D XZYH TO"-])=_$KQC&WVZ-(HK+%O=NS>4Q$A8*"2 #P?
ME.*UO$/BN31O$N@Z1'I]Q/\ VB\I>2- 0%2-FVKSRV=I^F:S/#,D]Q\2?$M_
M_9U_#97EM9B">XMFB5]BON^\ 0?F'!&?:IO&$5U#XO\ !^JQ6-W=6UG<7*S_
M &6$R,GF0E5) Z#/&>@[T ;%]XJL;%KW$-W<I8 &]>VBWBWR-WS<Y)V\D*"0
M",CD5JV=Y;:A907EG,DUM.@DBD0Y#*1D$5POAYKKPOJGBFRU33[Z>.^U"34;
M26"V>99ED49C)4$*RE<8;''/2MSX?:%=>&O >D:1>D&Y@B)E .=K,Q8KGOC=
MC\* 'ZGXUTG2H[FXN//-C:3BWNKR./,4$A(&&.<G!8 E00"<'%.U3QCIFE3:
MA&Z7,XTV))K]X(PPMD8$@MR"> 3A02!S7*>&[[4_#9U/PQ?>'=1O)FOIYK.Y
MC@WVUQ'*Y<%Y.B$%CG/3MD\5!XL.KZC+XQTN?2-3??I^W3OL,#"&Y)A.YGD&
M-S!C@(QZ 84F@#O+CQ!:QS106\<][-+;_:@ELH)$/0/R1P2> ,D]AQ6->>.!
M'KWAVQM=.NY8-6@>Z$HCYV! P4 G.<LI/H/7MSMYIL>J6.C2/#KVB:O::5']
MFU*VM9&93R&AD1001E5.UN3GMWF8:\FK^ -8U;2KF6YAM+F*]6S@W^5+(B!=
MP'"@[3D_=![@4 =YKEQ:VFA7T]\TZVBP/YS0*Q=4P<D;?F!QW'3K6%;^+=!T
M;1_#D(DOC!J-O&+$O#)*[KY>X;FYRQ Z9))[5K^)P[>%=62.*661[.5$CBC+
MLS%"   "3R:X&.WO$TSX9(=-U'?IYC^UC['+F#%N8SN^7CYCC]>E '=Z%XEL
M?$#WL5M'<P7%E*(KBWNHC')&2-RD@]B#D&MBN+\-1SI\1O&-Q):7<4%T;0P3
M26[HDNR(JVUB,'!XKM* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK.UG6K30[6&:
MZWL9YX[:".,9:65SA5&<#)]20/>@#1HKFSXVTV.PUJYN(+V%]&/^FV[1!I(Q
MLW@_(2""O.<X]<4VR\<Z;>ZGIMB+74(?[3A,MG/-!MCF(7>5!SU YZ8..":
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M\V[&X$;MNW/>@#I**Y_5O&%AI*:A*;>[N8=- -]+;(K+;Y ;YLL"2%(8A02
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M)K2YA@N[F"2WDEA95D5851B"1ZBNRHH XG5K6^TGXFV?B06MQ=:9/IC:=/\
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MCW\;:=>V,ME.86CNX]I<?PNO/*GM6S4-O:0VHD\E,&1][L22S-TR2>3P /H
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ML4I4LOUVDC\B:\OUKPKJMYX7\97UM82_:M7O[>YM[+@2&*%H^2,\,P1FQUY
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M1Q<64ZJJE?ER><'L1\OT-=;X0368_"M@FOOYFIJA$KD ,PW':6QQNV[<^^:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSEHS)-('#J6)3& 0   !@ 5<U[0+#Q+H5QI&J1^=;3IM8\!@>S ]F!YH EO
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M#YB;MP)4)C(/H #W!YJ!/A[I\?AC3_#Z:EJ0L["X6XA.Z+?N5]ZY.SD!N>E
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M7#@B,F3(V@#()QP./3Z $<E49@I8@9"C&3[<USV@^,].U[6=3T98KBSU33G
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LKQ'H%KXGT2?2+Z6=+6?'F>2P5F (.,D''('2M
M6B@#$NO#,%YK>E:M->WC76F*ZP'*!3O #[AMYR /IVQ68WPZT<:W=:C!=:G;
M17DGFW=A!=%+:X<]2Z#KGN,@'O7744 8%YX1LKOQ$=;6ZOK:XDA6"XCMYMD=
MPBDE0XQGC)Y!!YJSX:\.V?A70K?1["2X>V@!"&>3>W)S]!R>@ K1EN8()8(I
M9522X<QQ*>KL%+$#\%8_A6/HWB/^UM?US2FL9+9]*>)&9W#>9YB;@0!TXQW[
M]J &R^$K0ZO>ZG9WM[I\U\BK>+:NH6? P&(93AL<;EP:;J'@W3;[3]*L$>XL
M[32YHY[6*V95"O']PG*DG'Z]\UT-% $3P)+:M;S9E1T*/N_B!&#G&.M<E;_#
M72+>WTR 7^KNFF3>;9AKP_NA@C8, ?+@D?WO>KM]XM:S\6P^'$TFXGNI[9KJ
M-TE0(44X.<D$'/;%6-*\4VNHZW=:)-:W-CJMM$)FMK@+EXB<"1&4D,N>.N0>
MHH O:UI,.NZ-=:7<RRQV]U&8I3$0&*$8(R0<9%9LOA"UFFT25KZ^WZ-G[*0R
M=UV$M\G/R\?_ %^:Z&B@#G?^$,TQ[O7)[I[BZ76T5+V&8KL8*NU<84$8''!]
M^O-1^'_!%AX?^5;[4[^-(S%#%J%R9D@0\%47  XXR<G'&<9JSI'B/^U?$>N:
M.;&2W?2C""[N&\WS%+ @#H, =^_:MV@#D]#^'NE:!>+)9WFJ-9QR&2#3I;LM
M;0,3G*I['D9)P>>O-6X?!UA;3:Q);W5]$-59Y)XUF!17< .RJ00"0!R<X[8K
MH:* .7'@6P6PT2R6^OQ#HLBR6?SIE2H*KGY.< D?C5;7O#IL+3Q+K&GQWNH:
MAJ=J(9;42* Z@%5VX (*JS'@@GUSBNQHH \OT73Y#-9KH>L^-A-"\8:#5866
MW1 1N#^9& ?ER,*Q.<8]:] T_24TZZO[A;N\G-[-YS)<3%UB. -L8_A7CI6A
M7,Z;XJN=7FT^XLM'DGT:^>1([Z.8%H]A(#/&0,*VTX()/(R!G% '35FZ7HZZ
M7->2I>74YNYC/()BA <@+D848X4#'M5Q[J%+E;7>#</&TJ1 _,RJ0"?S91^-
M9/A?Q%_PDMG>S_8WM&M;V:S:-W#$M&<$Y''7Z_6@"Q!X>TRVU?4M3BME6XU*
M...[&/EE";@"1ZX8@^H K-L? ^FV-M;V*W-[+IEM,)[>PE=6BB8-N7!V[R%/
M(#,0#CT%=-10!C1^&;*+Q1<:_%+=1W5S&B3Q++B*78"%9E[D!B.N/:GQ^&]+
MCU?4]3%L&N=3B2&Z+<AU4%0,>X.#ZX'I4%QXF0ZW+HNF6DFH7\"*]R%<)';A
MON^8YZ$]E )QS@"I;+79+C6FTFZTVXM+E;<W&]BK1.NX+\C \\GG(!'''(H
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M6%W?&UNHE0V\\^^/>,8:-/X  #GN2Q]!G:N+F"T17GE6-6D2-2W=F8*H^I)
MJ6@#(U[PY9^(/L+7$MS!-8W N()K:38ZM@@\X/!!(-06_A6VM-8U#5(+Z^6Y
MOXDAERR, J A,94\@$\G.<\YJ/Q)XMAT+0!J\%LU_!]I6W8QR!0K&3RR23Z-
MQP#TKHJ .43P!IL>A:3HZ7M^MII5RMU:X=-RNI)7)V<@$G@^O.>*MWWA&UU
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M2(R/*44#>^-S>YP /TJ2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:*.0&9F0D,H8J1M)4'![CDYZ^^\,V=WK,>L0S7%EJ*0^0;BU8 R1YSL8,"K
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MD3<5R.O4<CD"@#B;^WU'PQXX\.3VNLZE>P:M-);7EI=3>8AQ&7$B+T3&WD*
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MVD\]M.R^9'Y;L%?/WF  &2,\9ZT >I.Z11M)(P5%!9F8X  [FF6UQ%=VL-S
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MZ^UV75W@N(KBXQ]IC@N7CBN<=/,12 WX]>^:ZFFR%Q&QC4,X!VJ3@$^F><4
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ME64^M1Q6-Y<-'$T"2>8!*YP%4XY__7Z4 00^%=*BOM6NS%)*^K*%O4FD+I*
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M*V:W,[2"W!&/ES[<9.2!QG!-26/ANQT_7+[6(&N/ME]L^TLTQ99-@(7Y3P,
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M;>)SU98R=H//IQVQ4X\$Z0-/U:P_THV^K2O+>J;AOWK, &.>HR !QCI7144
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M38K^\TR&*:>*6?RMYDW%40X(W;5)R<#D>^.CA=I((W>,Q.R@LA()4XZ9''%
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M47S&^9]DIP1GGH!CMVIFAZ??:UHOAGQ-;ZY#;S%H9KJX#2.;H-Q)"XW;>6.
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MYS@FO2O^$;TW^W#K.RX_M VWV4S?:9/]5G.W&['7G.,YYJFO@;PZ/#<WA]K
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M[^ &Z\GDFECU%(=\CEVVI?A5&X\G  &3Z5Z_>S/;6-Q/&GF/'$SJG]X@9 K
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MO]2@L9&>4J8Q(V-P&/FZ'N.W6N*EU"^\->)O%;VEG%:+#X<6_CL87WQB56D
M8C  ; &<#MU/6H=6TZQ?POX U>-C->3ZOITDUV7)><N<L7/\7/0'IT&.E 'K
ME%>?:+##XPU/QA#K 8SVFH-9VZ[B&M80B['C_NLQ+-N')X[ 5S&DW.H>(X_A
MI+JUY>":]^W0W+1W#Q^>B12!6(!ZLH'S#GYN#0!['<W,-G:RW-Q(L4$*&221
MC@*H&23^%+;SI=6T5Q$28Y4#J2,<$9%>,ZSI2Z59?$?P_"TLVBV^F1WMO#-(
MT@MI61R54L2>J[L'IQ7JOAJU@L_#FGQV\8C0V\;$#U*C)H U:*\>\53K_8FN
MZSIDLMQ-:ZU$O]I32;9(7$L:-#" ,F-<D') .3PW6MZZTJWU/XOWUA=R74EE
M)H4<SV_VF0(S&9EZ \# ' P/:@#T.BO(+#3+[6?@]:W=M)-<:GH]U/+:AY&)
MG2&=QY+_ -Y61=N#[5V7AJ_L_%FJ'Q+9_-9I;1V]L?5V >0GU(W*GL0X[T =
M;17!^/X#/X@\'Q"ZNX%GU)H91!<.@9/*<XP#C/'7J.Q%<]>::WA_6/&FB:=<
MWBZ0WA\ZBD8N9";:X^=1M;.X;MI;&><>E 'KM%>174">'_ /AW5;:>\2?6#I
MEIJ-TURY*0, 68<X3CY<C& :W]1LUT7XD^'[/3(A'IVL6]U%J%F@_=$1H&63
M;T#9;:3WS0!WU4O,U'^V_*^SP?V7]FW>?YA\SSMWW=N,;=O.<]:\ZT-#:OJW
MP_N"[W"Z@)(I78EWLI/WF_<>25"M'N[,4K81/LWQF>&.:5(#X<WB,R,40B<+
ME5)PO '3'2@#NJI:;)J,BW/]I6\$#+<.L AD+[X0?D9L@88]Q7GGAB>;3/$.
MD:1XATTQ:C+'(MKK%G+OAU,;"6,AZB3 W<^^" :RO[7O-&\#>(##=7"QMXKD
MLY;EIF9X+<S*K$.3D?+\N<Y&?6@#V6BN!U6T_L'X@^&8M'5H+;5%N+>^MH6*
MHZI'N63 Z.#_ !=3G&:XJ6S$/PHU771=7K:EIVKRFTG:ZD)BQ=A>.<'()!)R
M3^ P >YU2TN349;5VU2W@@G$KA5@D+J8PQVG) Y(QD5<=0Z,AR PP=I(/X$<
MBO%+GSO^%*ZK*+N[$T&MNB2BX?=C[:J88Y^;Y21\V: /;**\UNXV\,_$:X.E
M>>WG^'KBZEADF>0331NNQCN)^;DC\:L^&M/T[6/#/A;Q+_:<\=_^ZFN+N-QN
MNI'&UXI#W7><;?X< #&* /0:*\MTU5\4^"_$^JW\CQZO;W=XD<X<K)8F+/EJ
MAZH  I('7)SG-0637/B'Q'X'FU66Z5]1T.:6[A2=T61@L?.T'Y<[B3C&<X/%
M 'K-5-4DOXM,N'TR"&>^5"88IG*(S>A(!Q7F6DVNIR^&->TK2)XG:P\2RQ6E
MG>3-LFA3;(;?<<G!&[KZ8/&:AU34;:]^&'C-8+&^T74;1O,N;$S%?L\GEH!L
M9" 8V"Y Z')XH ]<C+F-3( KX&X*<@'O@U!/J%K;7MK9RRJMQ=%A#'W;:NYC
M] ._N/6N%\3+JD-U8ZC!I4>O:=#IZK=::)-L\.XY$T8/!;"D=C\O!ZUF+;Z-
MJ_B_X>W=JC7%K/I5R%DGSYCJB1[=WN,G\2: /5J*\L@L+CQQ:>(F?5[:QO[/
M5)X5N#"QGL5C?]WM82+M!4 ] #DYS5F/2X=6^*%Q97UU<W=I+X?@FD03R)'*
MYE8%MH;Y00 =HXH ]!O=0M=.CB>ZE6,2S1P1YZL[L%4#\3_.K->(10)J/@'P
M*U]NN7A\3+:+),Q9O*$\JA<_[JJ/P%>V11)!"D42A8T4*JCL!T% #Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ JEJVD:?KNF3:=JEK'=6DPP\4@X/<>X/N.15V
MB@##T_PAH>E:3<Z99V;1VURNV;]_(7D&,8,A;=C&1C/&344G@?P]+::;:M8-
MY>F$_8R+B4-"",%0P;=M( &W...E=#5+46U-?LG]FQVKYN$%S]H=EVP\[BF!
MRW3 /% &7%X'\.6\4T=OIPMUENA=MY$TD9$O/S*58%>IX&![58?PKI$MN\3V
M\I+SK<M+]HD$K2J,*QD#;L@  <\ 5;_M."34+K3;9XY+ZWA29XBV H<L%W$
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M:1K]J8"3<L;EV.P[0%DST/W:S[?Q7XBN?%=_X>CT;2_M5G;1W#2-J$@1@Y(
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M&8L[MD_*N.3V KKM/T:PM9Q?10SFY:+RQ)<S/*Z)G.T%R=HSC..N!G.*TZ*
M.;L_ 7ABPUQ]9M=)CBO7D,I*N^P.?XA'G8&]P,TVX^'WA:[^W";2E9;Z7SYT
M\Z0*9,@[U ;",2!DK@GO7344 9*>&M)CUB'5DMG2]A@^S1R+-( L779MW;<9
M .,=>:K^%/#5MX8LKNWM(A!#<737 @65I%BRJ@@,W)R5W'W8^E;U% &7J'AW
M3-2U"'4)X9$O84,:7%O.\,FP\E2R$$KGG!XSS4-WX3T2]T^SL)K,BULY!-!'
M',\820'(?Y6&6SDY.3DD]:VJ* $50JA1G &.3D_G65#X8T:WU"_OH["/S[_/
MVK<2RR9&#E"=H)  ) Y[UK44 8VF^%='TE[=K2WD M@1;I+<22+ ",'RU9B$
MXXXQP<=*N:OI%AKVES:;J=LMS9S !XV)&<'(Y'(((!R*NT4 85IX-T"QU)-1
M@TY?MBP?9_.DD=V9.>&W$[CR>3DXXSBJ4?PY\*Q1QQ+IK>1%<"YB@-U*8XI
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MJ;W:L!/.\F0DX))SCW/)K7T#2(]"T*TTV()^Y3YRB[59R=SL!VRQ)Q[UI44
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M% D<:A54= !T%/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHKS?XF)9Q^(O!LMS&IBDU)HY_D+>8FPG:P'+#..*
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M8X_$6F6D@N$(^6==IVSQ^QXZ=#Z<5NV_A31[JQM+NYLXY2EA'%'&P^1, L6
MZ9);D]>* .IHKR_X6>'=.U3X<^'M4GA_XF*NTQN<G>Q69AACGD%1C!I/!M[I
M.D^-O&J74D4#)J"+ "I^1"@)"^@R>@H ]1HKS;P"+&X^(OCB:T6-X(I;06Y4
M<1AHB6VC^')SG'6NYT749M5TJ*\GTZYTZ1RP-M= "1,,1S@D<XS^- &A14<X
ME,$@A95E*G86Z!L<9KQG0KC0=2TV3PKXC@?1O&NQD:[N24EN93G#K,/OJQ_A
MS@C@ B@#VJBN8U3QC_9_B4Z!!HNH7M^;,WD0A\L+(H<+@,6&WDG);'3C)(!B
MTWX@:9J.A-J!@N+>X2\^P26,VU94N/\ GF<G'3G.<8!]* .LHKDK?X@:6)M8
MM]04V<^E0K/, ZRJ\3=&1E^]SQC .2!5ZW\22MK<6EW>CWEM+/;-<P-\KJP4
M\HQ!PK\C@G'O0!O*RN,JP89(R#GD4M<1H?B;1K+PH]_IFCW-M%+J;VJVBJ"[
M7#2["3@D %LDG. /RJ__ &W!KUOXCT:ZLFANM/B"7,3L'1A)&61E8=01Z@$$
M4 =.K*RAE((/0@TM<I\,O^29^'?^O&/^5,F\<.+_ %RQM- U&YN='\LS(&B4
M,K(7# EL= ,#J<].M '745QT7Q"M9DT2[72K]=*U>2.""^?8%660?*I3=NQD
M$;L8STR.:L:UXXM-)CU&6.V>[ATP_P"F&.5%9<*&8(K$%R%()Z>@).0 #J:*
MYR;QC9.L(TQ!?22VB7JKYRQ#RGSLY8CEL' ]CG'%8$OQ$DU*3PG/H5C+/9:Q
M/*LA=D1P8T?,6">"&7).<8'&<T >@[EWE-PW 9(SSBEKE;;4].;QUJL$>BW"
MZQ!I\3RSY3,\19MJK\V.N>N*H6?Q+M[O3M(U3^Q=1BTO4KA;874GE@12,Y10
M5W;B,CD@8&>IH [FBN>OO%4<%_JEG9V4M[-I5NEQ>!&"[0P+*JY^\Y52<<#I
MSS4%GXVM=2M-(EL[.<2ZNKO9Q7#HF]$4,6R&;'##CK[#!- '4453TR^;4;!+
ME[66U<LZ-#-C<I5BIS@D=L\&LFZ\5!'U/^S].N-0CTMMMVT+*,.%#%$!/SL%
M()''4#.>* .BIJ2)*@>-U=3W4Y%>>^,_$O\ :'AWPY<Z1&]UIVK:G:(SJRJ)
M8V?)B()!^;&"#QU!KK-(T?3=$CO+RUL18&\;[1<Q*V55PN"0H)4' YV]: -B
MBN>TSQ0^JPV5S;:9,]I?0-/;3+*A!  (5N?E8YZ<C@Y((Q6-X:\=37/@Q]>U
MNT> &ZEBB6)E<R,9VC2)!G);[JY.,]>E '=45@0^*$3Q##H>I6<EC>7,+3VI
M9U>.95^^ P_B4<D'MR":K+XUB==.NXM-NY=+U&Z%K!>1@-DL2%<H.1&2.&]P
M< &@#IPRDD @D=1GI064$ D GH">M>;^&[^WT#6_&WDVS2R/J\:06D& \SM"
MA(4$@>I/8 $G %2>)93;?$SP9?\ ]G2M=R6U^I@BVEVPB;5)R%XR>2<#)YH
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MC^T0^4\OG1^6F0[;AA<=<GMBI <C(Z4 %%%-$B&1HPZEU +*#R >A(_ _E0
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M@[\'KQBKD-IK_ASQ/K$<?A==:T[5+HWEO<++&C0.P 9)-_101D$9_'H/1Z*
M/.M1T[7M!\7#6;?08M<L[ZQAM[N"W9$>":/=AD#D#80Q&,_RYLZUINMRW?A/
M5H]'622QO99;BRM9(P8DDC9!@L55B,C<0>N<<5WE% '&6UGJD/Q,U/5Y-*G^
MQ2Z7%;I*CQD-(CLQ &X'^+ ) _"N9M_#NOQ?"GP]HK:+<'4+/4(9IHA+%\J)
M.9"<[\'CWZUZO)(D2[I'5%R!EC@9/ %.H \QUC[>/&>N7&F:)JD\%S:PVMW+
MIEQ!EW"DXD$O1U5P!M['GJ,6)M.TKQ!X?TK2F\)WZZ79B2!DRJ7.G2QA/+((
M?)R"3E2V>,]ZZ.?P5IDFJ7&H6]QJ5C-=/YEPME>R1),V,;F4'&< <C!K7B2Q
MT:SCB#QV\ . 9)/O,3DY9CDL3DDDY)H R_!=EJ^G^&8+76KB:XN8Y) CSL&E
M\K>?+$A'!?;C./UK%T2RU;PGK'B2 :7/J%GJ5Z^HVDT#I]^0#?$^YAMP0,'D
M8/X5W5% 'E\WA#5-%\#^#M#L[*2_FTS4[>\NFA=%50KL\F-[#/+$"O2Y'D-H
M[QQGS2A*H_KC@&G22QQ;?,D5-S!5W'&2>@'O3Z /.?#GAJZTWQ3I^H:1IUYH
MEG/'(VL:=)*K6WF%?E\I0Q&[?SE>-H[=#F0^$O$4OP_&CKI_D:CI&JG4+5I9
MD\N[(G:10,$D JW\6.<>Y'K-% '%7VD77BWQ)H>H7%A<Z=;:;#<E_M!3>TDL
M8CVJ%)X W$GITQGG%/P7_P )9HVEV?A:\T/'V$B%=5$Z&!X >&"YW;]O &.O
M)(KT&B@#R.?PQXCA\1Z[XGTS3KB'58K]9[&-Y8]E[ 41)(FP_P N=N03TP*Z
M6_@U;4O''A+5AHEW#;V<-T+K?)$3"TJ(%'#_ #<J<D9KMZ* /*+OPCKVI:;X
MH6*Q>UNY-<35M/\ /D39/L"84[6.W.T]?45TMQ87GB;Q/X=U2;3;G3X-)\Z>
M1;@IO:1TV!%VL<@9))Z<#&<G'944 >3S>$O$%_X5\36T5BUK?R>('U:Q2>1-
MLZAT95)5C@G:>N.<5L3?VYK?C;PKJS^&[VSMK2&[CNO.FAS&9%0 C#G(R.O4
M^E=]YB>;Y6]?,V[MF><>N/2G4 >9^%+'Q'H-G%X7N?#$$XM7,=OK/F1^4T.<
MAV7[VX XVXY(Z@<UN^'+'4;;QYXLOKG3IH;/4'MFMIF="'\N((W 8D<CC(KK
MZ* /-=-\-WT/B;3=8TK3+S0[N:<MK5N)5^R3IM;+!0Q&\MMQCD9.:Z[QE;75
M[X,UJQLK62YNKNRFMXHT91EG0J,EB !DUM*Z,,JRD9QD'O0LB.SJCJQ0[6 .
M=IQG!].HH \]N]#UD6G@G6;;3Y6O= 7RKFP9T#R1O$(Y"AW;2PQD#(SS4^H:
M)?ZGK>M^(ET^>-I-#.E6ELQ022EF9RQ^;"C)4#)SP3Z9[VF22QQ &214!8*"
MQQDG@#ZT 8O@NVN['P5HUC?6KVUU:V<4$L;LIPR(%."I((X]:PO$%GKM]XGO
M;>729-1T>:P"6069%ABG^;>9E8Y)^[@X;&.!DFNZHH \LTS1=?BTWX>Q3:'<
M(VC.?M8$T1V+Y)C!^]SDG.!GCWXKI/#NGZA!XZ\6WMWI\L-GJ#6QMY79")!'
M%L;@,2.?4=*Z^J&LZ1;:[I4VG7;SI#-C<T$K1N,$$89>1R* .1\"Z!/I>L:K
M;O,LNEZ5<26VE*/^6:2[99%/KM)5 >V&%6/BW_R2S7<=?*3_ -&+75Z=IUKI
M-A%96<92",' +%B23DDD\DDDDD\DFJOB#0;3Q+H\VE7[S"TGQYJQ-M+ $$#.
M,CD#I0!AWNG7?B3Q-X=O)+">SMM)>2YE:<KEI&38L:[2<]22>G QG/'(7^@^
M)?\ A O$?A:#0)Y9Y=0DG@N?.C$4T;W D7;\V=V.H( &#SV/KD,9BA2,R/(5
M&-[XR?K@ 4_I0!QD-IJ;_%5=8?2KB.P;1A:&9GC.V7S=^" Q.,=P.M9NA:A<
M67Q \>"'3;F[)N+4IY)7!;[.ORG<1C/KTZUZ!!<P749DMYHYD!P6C8,,^G%9
M>GZ!9Z+J>IZLES.9;\K)=-,Z["57:#T&W"C'% '#Z3X*U7P?)X3U"VA^WG3[
M:>UU"W@8!@)G,A:/<0"%<XQU( Q6E-H-U-?>)M>GT3[8NJ+:VJ:9*R;Y($($
MC-EMH8AF(!/&T="<#O@00"""#T(I: /*6\"ZL^@^(-(T>6ZM]*D6WFTNUU&3
M?Y4\<GF,J\DB,[4'/<GMR>K\,WFL:C/&]_X530_)4^<[R1N9'QC;'LYV]]QQ
MT P<DCJZ* .0\8Z/J,^L^'/$&EP&ZFT>YD:2U#!6EAE38^TD@;@.0"1GGFJ5
M]HM]J>O:SXC73YXR^B'2[6V8H))F9F=F(W849*@9.?O'TSWE% &#X)M;NP\$
MZ-87UJ]M=6EG%;RQNRMAD4*2"I((X]:Y_4[I[3XTV$B6LUP#H,H80@%E'GIS
M@D9&<#CGFN^K(?P[:OXGC\0&>Y%[' ;90'&SRB0Q7&.Y .>OO0!PVJ^#]6N/
M#'B.\@L\ZCJ6JPZC'8^8H;RXGCPI.=N\JA/7&2!FM2V36KGXDP^(9/#]W!8'
M17M</+%YBN90X#*&QDA3T)ZC..W=/(D>W>ZKN(5=QQDGH![TZ@#S*PT[4-'^
M NK:;JEC):7=OIU]N1W1LAO,<$%21T858ATZ\\4^'O!=I_9\]M#82VE]<3S%
M=H$4>55,$EBQ(Y[#.<'BNXU?2X=:TFYTVY>5;>YC:*7RB 61A@C.#C(-/TVQ
MCTS3;>QBDD>*WC$<9D(+;0, $@#.!0!PNDZ5K7AW2/$/A[^RYKV.ZGN)=/N8
MW3RV6;)VR9(*E23DXY'3/2J][X'A32-*T2ZTN]G;3-.C2SUC3I D\5P-P8 [
M@0#\I&05Y.<5Z93?,02B+>OF%=P3/)'KCTY% 'F4NE>+-'U'1-?N=+C\07!T
MI+#5+='02*ZL7$B;L!N6(/Y_37U?2FUS2;.UUOPL)+.>1Y'@M77S;$@#RV#!
MAEOO9V9QG'(&3W%% '.>"+#5M,\/FTU:YN+ADN)?LS73AYA;[OW8D8<%L?S%
M9VF66IVGCGQ?J,NEW'V2^AM5M9 \9\TQ(ZL,;LCEAC.*[2FJZ,"592 <'![T
M >50^'M?B^%_A71SHUP;_3[^VEN(A)%\J1R[V.=^#QTP:?XKT?Q-KMMXLL+C
M1);UIX_^)3,9XQ!%'L'RA2V1+NW<XYSC<!BO4ED1V=5=69#A@#DJ>O/I2-+&
MCHCR*KN2$4G!8@9X]>* .(\86-Y<^"+#4XH19ZWI4D-S:1R,&/F@A?*)7@[P
MVW .,D<FNKT73CI6CV]H[^9,JEII/^>DK$L[?BQ8_C56?POIMSXCCUR<7$EU
M&BJB-._D@KG#>7G;N&>#CWZ\UK3316\32S2)'&O+.[  ?4F@#D+NTU'3OB7)
MKBZ;<7=A<:4EF&MBA9)%E9_F5F!P0PY&??%<]=^#==L;"+7+&S@NM676Y]7E
MTUY!M>.53&T08_+O"8YZ9SC/&?44=)$5T961AE64Y!%.H PO#D]]>)+=76A#
M1HR J6[LC2L><LVS( Z #.>I..*W:** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *SM9UF#1K:&25'EEN)TMK>%,;I96Z*,\#H22>@!-:-<IX\T75-4T[3KS1
M!')J6E7T=]#!*VU9]H96C)[9#'F@"23Q>]DFM#4M&O(I=*A68_9U,R7"L,CR
MFPN3D8((&/IS4UCXB-YXCE\.ZAIXM[LV(O5"RB6-XBVP@\## ]1C'/4UF:E<
M>--9\):F]EIHT?4FA"6MN]RCR,VX;SO'RK\N0O/4Y..*H:/HVK6OQ MM:C\-
MBQL)-(:UE4W4;RK)YH?+D$[F('7)SQDCL <K+:6Q^ 7B>(P1^7!>WAB7:,(1
M<'&/3%>E7_B>#3)H--B^SR7QM1<%+BY6!%3H,L0>20< #L<D5QY\,Z^_PG\0
M:%_9,BZC>W5P\,9GBP5DE+@EM^!@=?ZUJ:G9>)-+\4VOB/2=%&I0W-@EG?:>
MUQ''+$R,S*ZL3M/WB",__6 -'3?B#IVL:/IEW802R7>HSO;0V;, PD3)DW,,
M@*H!)89XQ@$D"LOP:'_X6AXV\VQ2SE,5B9$C8,K-ME^8$ 9SZD ^M/UW2O$D
MVH^&_%%OI\,U]ILL_GZ7',H/DS*%(5SA2Z[0>P)) . *M^'++61X]\0:Q>:2
M]G9:A;VJQ&6>-G!C5P00A//S>I''6@#>U369;+4K'3;6Q>YNKQ9'4LQ2*-4
MR7< X)W  8.:Y/5_'UW/X+L=8T>Q*/<ZC'8S+-( 83YWEL!C(;)! /H<^U:G
MB>UUN?Q)I+0:<=2T,1R+=6JSI&/-.-CN&(WH!GY>>3G!(%<K%X3\21_#Z73/
M[)B6[M-;%]# ERF)XQ<>9\IX"_+TW8/J!0!ZI \CP(\T7E2$99 V[:?3/>N5
MMO' EGT9I]+FM[/69W@M)'?$@90Q'F1D#:&"G&">V<5TT;W,UCO:);>Y9"1&
MS;PC=@2.O;./UKRV'0/%<\?AF[O/#XDU;3]2$U_=2WL9><;7&Y3DXC&X?+P1
MT"F@#I+GX@3I_;PM?#E[.VB/BY!FC3Y F\L#DY..0!D^N.*O/XSB&I>'H4LI
M&L]=CWVUXSA44[-^UAU#%>@[UC1:-K2GQZ6TF8?VODV?[Z+]Y^X$?/S_ "\C
M//;\J75-"G;X.6EI>*UCJ>D6,,L+DJQBN8$&T@J3G)7'')#=* .OLM3>\U74
M;-;?;%9,D9GWY#NRAMH&.H##/U'X86H>(=5A^).GZ%!9QM926$MRS>: SD.B
MYQC@+D\=\]L5M>';"?3]%@2\*F^ES/=LO0S.=SX]@3@>P%8NKZ9JJ?$72-;L
MK$75JMC-9S'SE3R2SHP8YY(^4_=!/M0!!:^)=.LG\8W]OH$\-QID@>^"&/S+
MDB+=N^]CA<=\^V>*!\0'5M#DFT"]2TUF-?LLRR(Q,ICWA-N00",@,<#CG YJ
MC_8FM8^(/_$IE_XG*D67[Z+]Y^X$7/S_ "\\\]O?BBXT76FTOP%"NDS&31Y8
M7O!YT7R!(3&<?/SR<\=ORH V+/QQ!C7EU>QETR;1522Y1I%E#1NI9&4KU)P1
MCUI++QU:S^)[/0KF&**>_B>6U>"Z2=6*#+(^W[K <]P<'!K"U;PEJVMZOXVC
M^SO:0:M:6L=G=/(A7S(=QY 8L 6*]NF:WO#=_P"*K^2"/6O#T.E>0#]HG%RD
MHN&P1^[5>5!/S9)XQCG.0 9WQ12%;+PY=M;^;+!K]D4*H"_W^0OU]*O67C6X
MGUJ\T2\T"ZL=5CMC=VUO+-&PNHP<':ZDJ&SQ@_G4OCK2;_5=+TYM.@%Q-8ZI
M;7S0[PC2)&^2JEL#/ID@>]%OI=WJOC6V\17=I)90V5D]M!#,R&1WD8%F.PD!
M0%  SDDGI@9 "P\9IJ7A"UU^WL6)N9U@2T,H$@<R>7M/& 0W4=@"<UT%_?V^
MEZ;<:A?2+#;VT32S/U"J!D_6N,T?P]):_$?5O)G5M&C==16W _U=[*K(WX;0
M6QZR UT?BO0_^$E\*:GHPE\IKN!HUD/16[$^V0,T 4&\8FTFTEM3TV2SL]6D
M6*UG,H<I(PRB2KCY"W;!89X)%4+CX@SHNO&V\-WTQT20BZ!FC3Y @<L#DY.#
MD 9/'..*@GTG6O$VC>']*U32WLI+"[@N+V=I8VC?R>?W>UBQWD#J!@$YY&#'
M%HNM+'X^!TF8'5RQLOWT7SY@$8S\_P O(SSV_*@ \136FI^*OAWJ]O&I%S<2
M/'(5 ?RVMV8 _F#BN@TKQ3_:.J:WI\]E]CGTDKYHFF!#JREE<$#[A Z_7CBN
M<&AZVL/P^7^R92=&51>CSHODQ 8N/G^;DYX[>_%6O%_A^6]\8:-/8SK$U_')
M8:E'C_768'F,?;!&S/\ TUH ZW1]0DU31[74)+5[8W$8E6%VRR@C(S[XQQVK
MSZYUG4/$O@OX@1ZKI\"P6;7EO$/,#B,QP+@8QR<Y;=ZFO3P !@# %><)H6OV
MVD>/-+723*NK3W=Q9SK<1@2>=$J*N"01@@Y)Q[9H N>&?%;VEMX3TBZTFXA@
MU"Q2.UO&=<.Z0AB"@.5! .">OH*EU?XE:;I-O<7_ )<<VG6MR;>>1+E!,"'V
M,RQ=64-P>0>"0".34DT76F_X0'&E3?\ $HQ]M_?1?)^X,?'S_-R<\=O?BH]$
MM/%WAF>\T&#0[>^T][J6:RU-KE%6%)'+D2H?F)4L>G7IQUH ]!98;JWVNJ2P
MR+T8!E8'V[UXGX0E\(67PYU";6]/RT5U= SQ63F10'.W;*J_*0, '<,>U>V.
MS10$A'F91]U< M^9 KS_ ,$6WB#PSX4GTZZ\,74UTUS/,JBYM_+8.Y8 MYF1
MUY^4_C0!/X0UZ]TGX:^'IM>F-]JEZRV\ CE61IV9FV OG!(099L_PGJ:VH?%
MB1ZS>:/J=F]I?V]J;U%C;S4GA'!,9P"2#P5(!Z8S7$Z?\.=;T3P=HGV=X+C5
MM+U4ZG]D23;$RMD-"C'I\IX)XSGUS717^CZQK'B&3Q#:VS:==6FDS6M@ETR%
MFN).0S!2P"K@#KR2>,#D NV/C)KC4]'L[O2Y;7^V;5[FR/F!FPJABLBX&QMK
M XR1U&:@TOQU+JMW.L7A^\BM+2]GL[RZEEC"VYC&2Q&[D?3(''/.*Y_3]"\0
MC7?"&JR>'#%-8QSQZE+->QO-)(\:KYC,"=RY!QR3SC %:WA_P[J,F@^+]+U&
MTDL1J]_>RPR&1'_=S# /RL<$=Q0!C>-]6;7=$\-:FFDXL9]9LWM+IW'F!3*,
M,4Q\JN.F"3R,@=O3+^^MM,T^YO[R416UM&TLKG^%5&2:\PETSQ=<^"M$T";P
MZWVO2+RT+7"W<7DSQ0L,,GS;LE5&00/Z5WWBC13XE\)ZEH[2>0]Y;-&'ZA&(
MXSZC.* ,]O&7V272)-3TV2SL=6D6*UN#*&*2.,HDJX^0MVP6&>"16')Y^N?%
M'5]*U/2XKK3TTN*+RI)051'D?<X&.K #IS\HYJ:?2-:\2Z%H&CZII;V4EC=6
M\U[<&6-HW$//[O:Q8[R!U P"<\C!T+'3]3B^)VJZK)ILJZ?<6,-M'/YD9RR,
MQ)V[MP'S>G:@"I\2M-L[3X2:M:Q0+Y5G9!;<-EC&%P%P3DY '7.:?_P@VDZA
MX0M1IULFEZE]D1X+VQ'DRI)L!#%EQN&>H.<\UH?$'3K_ %CP-JNEZ;:-<W=W
M"8HU#H@!)')+$<56EF\3R^&8=+TS17LKXVRP&[O9XO+A.W:7 C9V8CJ!@=LF
M@#G-#\;0:[X$\(ZCKVD&_N;K5(K42@($BN0Y59<$YS@$\#KD<5TMYXVN8_$.
MHZ+8^&[^]NK)(96V2Q*'1R1N!+8XQT/)]!@FL>_\$W&C>%/"FA:':2WJ:7JE
MO=SR;T0E48M(WS,.26. *V-,T_4H?B7K6J3:=+'87=G;PQ3F2,_-&7)RH;<
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M>^#@ D#@$DD<=2*EM\2;*;3KJ6:"."ZMM033W4W(,!=S\KB;&/+(R<XSQC%
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MG,LTV#&?/V,H(4@@E2-W8'.#TKT&!I6@1IXTCE(^=$?< ?0' S^0H DHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KF?B!IE_K?@C5-)TVV,]U>1>4@+JBKR.221Q],UTU% '+
M1W.O1Z):6EOX>=;V*)(UFGGA,<3;=I?AB3@9.,9/3C-4?%7A[4_$R7;B.>UN
M=-VRZ-*DB9:X'/F'GH<!=IP-I)ZG"]O10!P&KV/BVZ/A[Q+::;;C6]-66*[T
MU[A0EPD@7?LDY Y0$9_'IR_Q#I'BCQ+X?MKT6]K8:O87T-_96+3"1<QY!5Y
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M"YWY\UE(.[Y< $ D<X S76QPQ0AA%&B!F+-M4#)/4GWI] 'E.G>%?$EKX/\
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M699$P2P#$D;>OJ,\=CJVEC5_#M]I,TS8N[5[9Y<#/S*5+8_'-:%% '%>$O\
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M'N10A^926P6#;>A'!/>NHHH \MC\":W9Z18RV4DCRZ1K!O=-L;RX#,MJ5"F
MR9(!^\0<D#(&:Z&32+[4O%)\23Z?+;FVTU[2VM'DC,LCNV68E6*@   ?-W/3
MC/8T4 >81>&->B\ ^$-(.FDWFDZA;7%R!-'MV1,2=IW<DYX'YXKMO%6ACQ/X
M4U+1FD,)O(#&KGG8W4$^V0,ULT4 <)-HVM>)-+T#3-7T[[&VG7<%S>7'G(Z3
M&$' BVDM\S8/S!<#/4U?\*:9J5AXB\3W-[9-#!J%XMQ;N9$;*B-4P0"2#\N:
MZRB@#A_BLTB^$[5HD#R#5+,JI. Q\Y<#/:I=2\-W'BKQ##?7]K)86EKI]S:1
MK(Z-([S@*S?(S *JCCG))Z#'._KF@Z;K]I'!JD<CP0R+,H6=X@&4Y#$J1T(S
MS5VSN+:ZM8Y;2XCN(",++')O#8.#\V3GD$4 <;X3'C:QM++0=4TNS2"Q"1'5
M8[H,)XDP %BQD,0 "20!DGVJQX3TS5]+_P"$I:>Q,#WVI37MH6D1@0R*JAL$
MX.5^G/6NQJ&>[MK9X4GN(HGG?RXED<*9&QG:N>IP#P/2@#SW3_!,K:_'>VNE
MRZ#!=VDT6L6T4Z&"X9TVJ8T5B 023NPO';DTV+POKUS\.AX$O;, (%M?[365
M#$UNK@A@N=X?:,;2N,]\5Z510!Q]CI>HV/Q"U;5?[.D.GS:?!;0,LL>6:,L>
MA;@'< ,^G.*PM'\*7L?@71_#FO\ AE-0MHOM NHUFCWQL9"T;QL6'9F!P0?Z
M^FT4 <=X>LO$7ASP]IUAY#:CF_9&^TW0\RULRS%<MSYC*NT8'K@' S78T44
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MJQ@W"NZF-6!!"Y'\7KV[U)XCL-;N?%6F3PV,6I:*D$B2VDDXC5)R1ME<$'>
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MQ*UQ#Y&G:MI*6$<PD4LCKO.XKGI\WZ4 6[;QV'U_2]/FM;5H=25O+EL[P3M
MX&0LRA0%R.,@D9&/>JLWQ+MDCLKZ""UN=-NKD09AO URBDD"4PA?N\9^]D @
MXZ@7/#9\:O';Z=K]E800VRA);Z"Y,C78 P-J;1LSP22?7 &>,[POIGC3P[:Q
M^&#;V$VEV[%+?5S<8D6#.0IBV\N < Y Z=<<@%S0]=UZ]\:>*;*>UM7MM.:&
M*)$N6! :(N, I@EMPR<C&,<XYHV/CF&R\!:#J^G^&UAM=0O1:+9V\JH(-\S)
MD?* 22"<8')Z]ZU=-TG5]*\<^(]1%K#-I^I^1,CB;$@:.$1E-I&,D@'.<8KG
M+;PCX@@^'?AW0VLHC>Z=JD=W-B==A1)C)\I[D@@=!SG\0#J=.\67#^(-3T?6
M--2PFL[1;Y'CN/.62 EAD_*,,"IR.?K6<_C^Z&FZ#J2:*KV>N3+!:XN@)%9P
M3'O!7 W 'H3@\<]:EN;2[LO'>H>)[R"*#2%T46SRS2K\I1WD+,!GY<-CC)XZ
M5RVCPZWH>CZ9=:EX.6>QTU3=1M#JZLD!()9XX64<@,VU2QQG H ]1U75+71=
M(N]4OG\NVM8FEE(Y. ,\>IK F\7W6FSZ,VKZ6EK9:M*MO%-'<>8T,KC*)(NT
M8STR"0#QTYK4\4Z$GB;POJ6BR2F(7D)C$@&=C=5..^"!7.R:'K7B'3= TW6K
M..V_LVZAN;NX28.MP80=HC YPS8)W 8&1S0!5MS?:I\4_$%A?V-E/9#3;>%X
MI+AF A=I"2!Y>"6[CCH.372ZUK%EX0TG3XUCAB@>:*QMQ))Y<460=NYL':H"
MXZ=<#OFJ&G:7JEO\1M8UB6S L+RU@MXG$JE@8RV25[ [N.IXZ5J>);6>^L(;
M9-,M]3M9)@MY:SE1OAVM]W=QN#;".G3J.M '.>+_ !)XAT_PR]Q!8VUM/_:,
M%H7^TLP>-V3#QG8.NXK[8/4UN2>(+LZPFB6UE;2:HMK]JN%:Y80PH6VJ-^S)
M)(.!M' )],\A)X"U2#P7J.F::NV+^TX;W3=/N;C=Y$2,C&,OR!DJQ !(&1SU
MK;?1]:L?&T?BFWM(YQ>6(M+^RCF&Z-E;<CHS8#8!*D''J* );7Q];7&F.[V;
MQ:HFH_V4U@9 2+G/ WXY3&6W8^Z#QGBJOB74+V_\,>+],U71/(%MIDLL5RK&
M6"8&)C\K%5^92.1CC@UG:AX"U6;3KK5+*6WB\0/K2ZS#$[$Q HNQ868#NF<G
M'4^G-;5Y%XHUWPIK$-]IEM97%U926L%G%="7YW4C>\F  .1@#/&>N0  'A/5
M[BXT;0[#3[2*Y@ATZ 7=RTY187\M<(!M.YL')&1CC.,C/+:/K5YX6M_'5[I^
MBQW5I9:U//./M A"QB*,ML&T[F !.#@>_:M/PSX9USPEJ%@^G62'3[JT1-5L
MS.H$=RBA?.B['=CYAQG@]>BCPUKA\.^.;$V*B;7+BXEM/WZX"R1*@W^A&W)Q
MGK0!TLGB<7&J6FF:5 ES>7%E]O/G2F-(H20%+$*QR2<  =CSQSR7B_7X/$OP
MN\70W%D+>_TQ7@N;9R'\N08(96P,J0<@X'TJ_:^'=8TGQ!H_B&VM1.ZZ2FF:
MA9"50P"'<LD;$[3SD8)'!]:AU7P;J5UX8\7F*&,ZKXBD!$7F )"@4(@9NY !
M)QW.!G&: .B;76AO--T.QMTN=0FL_M+K))Y:10C"[F(!.2QP !S@],5R'@W6
MH?#VG>+KJ]MH;5V\2/ MNDH">8ZQ* '( "Y.<D# R<=JU;O1->L?%NF>*-,L
MHKECIHTV^L9)PC!0VY71N5)!SQZ?IEGP5XDNM+U_BSLM0EUM=8TY_/,BB10F
M%<;1\IVD9]^E &RGC]Q>:M9MI\%Q/96)OXI+*\$L,R#AEWE1M<>F#QS3(O']
MZOA^WUV_T-++3+J"U>WN);U=N^8J,/\ +E%7=G=SD=@3BK0/BW6= U*/5-*M
M+&62SDMXK:&Z$OFR.,;RQ "*/3D\GT&5LM+U2T^'ND:/-I5M=SVUO!:W=I-(
MK1S1HH5\$\<XR,XYZXH WM*OKV\-P+NSBA$;+Y4D,QE2="H.Y3M'<D8]JS-1
M\4/!X@GT.QMK:>_ALUNQ#/<^2TP8L L?RMN(V')X R/4XJ^"?#,GAN;5E@CE
MM-)N9D>ST^27S#;87YR,$@!F.=H)QCWP*WC+PU)XDDN;>ZT2.[18 =/OHIEB
MFMI^<G<2"%SM/&>_!H S]0EN8_BUIEW9::DE]<:!*3$[B(;O-C^^^"0!TZ$^
MU;&G^-;G4?#R7L6B3-J']HG3)K2.0ND,H?8S-(%XC'4MM_"J]GH6MVOC/1M2
MN5^V1V>BFPN+GS%#2S$HQ<*>V5/7GFL=?#'BF#0KN""UB)E\0R:C-:&Y"BZM
M78L8BPZ'.,@\'&.<D4 ;G_"0Q^(M*\6Z5=6D"S:9&T4HCE$T4@:(NI!('/8@
MC@BN4FBC;X:_#*5HU,B:AI85R.0".<&M[3_#VO6FI>+YVTZRC@U:WB%M'!<?
M<98?+V8*@ #J3Q[ U#+X9UP^"/!VE+9(;K1[RTFN1YZA2L'7:>Y/;I[XH [?
M7(HY]!U".:-9$:WDRK#(/RGM7F_A;QC?>'/ WA22^T)AH4L%O;/J"W*EHV8
M*S18^YGC.[/MVKT^\A:[T^X@'R--$R#=V)&.:X.T\*ZQ>^!])\'ZE9QV]O:-
M MW=+.'6:.)@P$8'S98J,[@, GK0!?UKX@1:>FIRV4%G=IILIBFA>]$<\K*
M7$4>T[L9QR1D@@>IZVTN8=1TZ"ZC4F"YB610ZX)5AD9'T/2N)M=-\7^&O$&K
M1:196&HZ3JEVUY')<7)A:TD?&_<-IWKD9 '/O7<PK)%:QK+(9I40!GP%+L!R
M<=!F@#R[1+^WT/X:^++N32HM0M+;5K\R6;%51HQ(<@Y!&,=L&NJN_%=S9:UH
MNCVFBB4ZE:230L+@(J%%4E2,<#YAS^0/2L%?"VNGX>^*=$:RC%[JEW=2P?OU
MV!9F+#<>Q'?CZ5JR:/JTOBSPIJ7V$+;Z;9SP7.9EW!I%0#:,\@;.?K0!6'C[
M6&T;6;M/#49N-$FE2_B-^ F$4.3$VS+DJ<X*K]:T+[Q'9S:SX0_XE$=RFK%I
M+6[E*[K8F$OP,$Y*\<$=:S(?#VM+I7CFW:Q42:W+,]I^^7 #PB,;^>,$9.,\
M4X^']:W> S]A7_B2+B\_?+_SQ\KY/7GGMQ[T /TCQ9J4>I^,+K6TM8]-TB;:
M3%.S&-%B#X52@W$YR3D<G&#BK=MXZ#^(=-TV>VM3%J*OY<UG>BX,+J-VV4!0
M%R.A!(R"/>J,O@[4[RZ\::=.L":9KQ\R*[64ET8Q!,%,=F7.<]/TO^'_ /A-
M+F&+3O$-E86\,";)KVWN?,:[&,#:FT;,]22?8 9X .7^(FN2^(_A9J&I6FFP
M2:2\J""XDF_>E5F5?-5-N "1Q\V<'/M7JDQE6"0P(CS!3L61BJD]@2 <#WP:
M\IE\)>+HOAI>>!TL;.X2(A+34#=!!)$)0XW)C(8#@]N.I[^KPF5H4,R(DI W
M*C;@#[' S^0H X#POXVOSX!L]:UF"*6XOKMK>T2&8EII7G=53!4! . #EOE7
M/;%;\'B::'Q5!X?U:RCM;F[@:>SEAG,L<P3[Z<JI# $'H01W[5R-MX%\0'P#
M8Z,XLX-0T341?:?+YQ9+AUE=QN&WY 5?'<YKIQI%[K?BW1]=U"S^PII4$RQ0
MM*KN\LH56.5R-H4''<EN@QR 6O%GB63PS;6$Z:>UXMU>PVA"RA"AD8*#SU^G
M'U%9R>+M:;Q%=^'V\/0C4DM5O+?_ $_,3Q%BN7;9E2",8"MU].:L>.M(U'6;
M#3(=.MUE>WU.WNY-T@0!(W#$#/<]JC&F:F/B9)KWV(_83I LA^]7?Y@D,G3/
M3!QUZ^W- ":=XTN-4\-V.HVNBS/>7-Z;&2V#EEMY%9E=G<*<(-I^;'<#C-9N
MI>.[^3PAXLNK"UM8]2T-GB<_:#)$<(&#J0O)P?ND#D8S6?;^%_%-IX;MK-+.
M"0)K4MY=V1N0JW5O(SL$+ =BP)4C!QWZ5./!^O3V7CFRDMK"WCUN+-J8YRRJ
MWDJ@0C:, $=?R% $][X@\36^H>"K-+:QQJ#/YN;QR9=L#, S>7P/XCP>0![U
M?UGQZFGKJ9LX;*Y;3#MGADOA%+(P4,RQ)M.X@$#G&3D56O-%\1W'_"(:DMA9
M_;-(E;SK0W>!L:$QYW[>H)SC'3UIL.F^+_#7B/5&TBQL-3TO5KC[7^^NC UI
M,R@.3\K;D.T' YH L7'CN]EU:TT_1] DO9+W2CJ5L9;D0[AE1L8$';][J>^!
MWR+5OXONKV\O+2TTVW>YL)8HKNU:\Q.F\(695"'<J[^N1NVG';,?]CZPOQ$T
M[5Y(EGM8-*:QFGWJK-(SJQ<)_=^7Z\]ZS/$WA*]\07LEPFF)::Q!<JVGZU;S
M*C1Q @GS "&.!N&W# \<C)H [C5+Q].TJZO8X#.T$32"(,%W8&<9/2N2L?'U
MU+H4&NZAH8LM+N;:"2VF:\4F2:5@HC*X&T9;.\\8Y..E=5K,4T^B7T%O%YLT
ML#QHFX+DL"!R>@YKCSX1U:[^%6F:$'CLM:TU+=K>0MOC\Z$J5.1_"<>F1GI0
M!I:7XMCU;Q'/X>N[2T?=:_:(Y[2Y^TP2+G:R,=HVL.N.<CFL+X>ZG<:9\*O#
M*6>G27DUU,]NH7(2(&20EW8 [5 7KCJ0.]=-H=WXKNU:;7-*M+#R8R!!;7(F
M:X?^]D@!%ZX&2>>2,<\E8>%O%&G^!O#FDBT@F;3[MFO[$W(6.[B+.0-V.0"P
M)4C!QW[@%O6O'FH2>!O%5[IUM;0ZCH\KVTC"X,D?W01(C!1N.&'! P1R>.=3
M4]:>SN/"T6JZ):W$U[>+%',)_,%M)L8AU+(#NP#T Z]:PY?!>OW6C^.-.>WL
M(%UD^;:&.<E0WEHH3&T8 VXS^E:NKZ7K^JGPI.VFPQR:=?+=7,:7(;:H1DP"
M0-S?-GL.V: 'W'C753J7B*PL/#JSS:*(W<RWHC6160OP0I(; &!@CKDCC-M/
M&T%U:^&6LK8O<^($,EM%*^Q8U6/S'+, >@XP!R3^-4[;1M7@\0^,[YK$&'5H
MX5M,3+DE(C&=W/&2<]^/?BN?ETO5['0_!FAPZ=:W.MZ7&TSPB]\F141-F])-
MI 4LZ@@CGIC&< '9^'/$UQKFI:M8SZ:+633)S;S.)Q(K-@$%> <%2#DCVJCK
MNMZW;?$+0-(LX;5K.Y@N)F#SLC.4"CG"' &_('.3Z8IW@^:YMKV]T^^\/-I=
MW-F]DE^VK=?:&)VEF8 $'@  @# XZ8J3Q!H^JS>,_#^MZ;!;SQV<=S!.DLQC
MVB4)AAP<XV\B@ G\774MIJ]]I.EI?6>E2O#,3<>6\K1C,@C7:0<=.2,D$>YW
MM*U6VUO1K75+!_,M[J)98BW'!&<'T/8UR.EZ%KGAM?$&F65I%>66HW,UU93F
M8)Y#2CYDE!YV@\@KN)!Z5TWAG1(_#?AG3M&BD,BV<"Q;R,;R.IQVR<F@#SV[
MU75M?^'GC]M8MK,QVLE]!'Y<K/Y;1(% 52@XX)W9SDG@5OZ'XHO+2Z\,Z->Z
M2(;74[/%I<BX#.6CB#$.FWY01DC#'WQVH'PQX@B\.^-=&2TMI$U>YNYK287&
M"?/' 92/E"\Y.3VP*O3:'K$NJ^"+D6(":,D@NP9ESEH?*^7GGGGMQ[\4 -U'
MXEVUG:MJ-O!:W>GQW)@D6.\!NMH?89%A"G(!!.,@E>>*Z_5;YM.TB[OXX#<&
M"%I?+#!=P SC)Z5Q.@Z5XS\-&?P]:6UA<:09Y'M-2>X*O;1NQ8JT6T[V!8XY
M /&378>(/^19U7_KSF_] - '(1_$B]2TT'5+[PX]MHFK&&,7@NE=H9) -NY-
MOW,\;L^^!P*UX_%\\B^*$_LV,3Z"1N7[2=LP\OS.#L^7@^AYKF]"TF_\4?#7
MPEI4UF+>SCCL[B>X,JL'CC"NJH!SN;"@Y  YY/&;UWH'B&VUGQ>MC96T]IKL
M2M%</<;3"XA\LJ4QDY(R.0.>2* +4OCRZ(\*BTT-IW\0VIGB'VD*(V$/F[2=
MO(Y +>F3@]"T>-=>;65T,>%,:L=.6^,3:@GEKE]A4N%/&0>0"3QQU(I67AO7
M[:7P 9;&!AH%N\-V8[@'.Z 1 KD#)XR1^1-375Q<V_QM9[>S>Z!\.J'2-U5A
M_I#8(W$ _F* +.F_$6"_T2&X;3Y(-6?43I3:<\@RER.JE\?="_,6QT[$\5=_
MX3$V.LWVDZQ8_9KJWL6U"$V\IE2XA7.[:2JD."/ND=P<US]QX!U,62:K;/;C
M74UQM:\AG/E-N^4P[L?W !NQUSVK9GT;5-2\0MXC-JMI<VFF2VMC;S2*Y,S\
MEG*DJ%X4 9.<DG% %K2O%3WUG'J4UO:+I#V3WAO;:Z,RQ[=I*,-@P<,3U_A/
M%9\'Q"234M'B:UMGM=5<1QO;7@FE@8C*^;&%^4'H2&.#Q[UGVW@+SM7NY[;3
MSH-GJ&G3VNIVL,RM'/+( %=$4X&T;OF(4G(XY-:'A6+QO:6]GHNKVFGI;606
M,ZG%<%FN(TX4"(K\K$  DGUP,XH Z+7]<M_#^EF\G1I&:1((84(W2RNP5%&?
M4GKV&36=_P )1<V?B6UT/5=/C@N+Z&26QD@N#)',R#+QDE5*L 0>A!'Y4>./
M#EQXE\/K;V,R0W]K<Q7EH\F=GFQMD!L<X/(_&J\FE:AKGB31=:U#3S9+H\<S
MK!YRR/+-(H7@@XV@9Y)!)(X&* &>%_%^J^)F@G3P]]GT\S7$$]PUXI,3QL5&
M%P"P)&,CH?ID]A7*^ -)U'0] EL=3MUBE^V3SJ4D#AEDD9QT[C.#754 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M//\ :,2JTDS*K!-I!4$@'+ ^WJ >NT5QNL^.&M'U9=-@M;E]+.V6*:<H\[A
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M83OY>&=FR?DR, ],?C0!TDNOSS:O:Z+IT4(O7LA>RO-GRX8R=JC Y8EL\9&
MI/H#6C\0Z\^E:>]QH7V*\GN)(;EI9-T-JB!B921@E3M&!Q][KZY^I^'/$=MK
MVF>)-#;3S?QV L+VSN97$4L8;<"KA<@AL]1T/YRZSH/B:^;0[SSM/NYK2Z>>
M\L9G>.WDW+M0*=K']V>1D<G)XX  ,37?'.J7WPT\1:CIQM8;O3KUM/DGB<NC
MKN0>9&>Q(D&,GCGK74ZAXDN;/4(-'(M5U)[=KF5]LCQ1INVKPHW$DY],8/L#
MSD_@/7[KPQXPTF:YTX/J]\;ZVD0OC<3&=K#'RC]WCC=USVYT=7T+Q6=;T_Q/
MI+Z8NJI:FSO;&:1_(EB+;E"OMSN4D\[1G/;H0#=\)Z[<^(-&-U>:=+8744SP
M2Q2*P#%3]]"P!*$$$''\JJGQ!?ZGJ.KVFA6]K(=*98I&N78":8KN,:X^[@%<
ML<\GIQFMC28]12RW:K+"]Y(V]UM\^7'P %7/) QU/4DG Z#G;30-7\/^)]:O
M]*2UN['5W6X>&>9HF@G"[200K;E;@GN,=Z .=\4>)YO$W@+0M5TR-(;>[U6T
MCGAF8ATD6< H<#D!EY]L5Z-9620/+=/:VL5]<A?M,D"_ZPJ,+EL9.!TS7$WG
M@34+?P9H^AZ6]I+-:ZA'?W$UQ(T8=UE\UMH"MU)P/0>M=^ID,0+*HDQRH;(S
M]<?TH \Y\(SR66L_$:ZMH(Y9HM2WK&[[ ^(@<%@#COV-6+'QYJ\MEX6U2[TF
MTBTW7)HK;Y+AFFCDD4E6QMQMRN.N>AXZ58T7PUKNFW7BV::/3F_MF=IH ER_
MR$IM ;,?T.1FJB^#M>3PEX/TD#3C/HE[;W$S&X?;(L0(PO[O.3GOTQ0!KW/B
M;5;N#5[G0--AO8]+N&MFA=R)+J1,>8J=EQG )SD@\#@FT?$-U?Z[/HVEP0I=
M6MK'<73W1)$1DSLCPO4D*23G XZYXQK3P]XK\/Z_JPT2;2Y=)U6Z:\)NV?S+
M25_]80JC#@D9 R/PZFY_PCFIZ1XSFU_2FAO([ZTCMKZ"YE,;EX^$E5@I!."0
M1@>H]* ,Z?XCW(\.Q:A!I"->1:NNDWUJ]Q@PS;PIV';AP<@@G;U%6+OQ7XHT
MW5](TN\T+3FN=3GN(X3#?,5 CCWJ3E!@'N>3@' S@54OO FJ'0O)LVLGO[K7
M%UF[:65DC#"0-L0A"2,*JY('3..<5/XR>[7QYX#>WAB>X$]V?+>0JI_T<[AN
MP>V<<>G2@!L'Q%FTZ#Q#!XDTZ.VU'11&YCM92\=RLO$90L 1EL*<],_7&K=>
M)=1T77-)L=8M;7R=58PP3V[MB*<#(C?(Y!Y 88Y'W169J_@"3Q+!XCFU&9+6
M\U:*&*#R6+BV6$[D).!N)?D^V /6K\FB:QKUWH4VNPV4/]DS?:F%O,S_ &B<
M(54C*C:OS%NYZ#WH K:)XM\1:S/>21Z%:"TL+^YL[K9=EI#Y0X,8VC=D\<XZ
MCCJ:=9>,[X^(=$TK4+2TCGU:WEE^SQRGS;)T0/LE!ZY!(S@<@\4_0/#>MZ=H
MWB6SFGM;:XU.\NKJUN+:5G,)F'RYRJ\J>>*RM-\(^)H+SPA<2QZ-#_8HFCG6
M*61O.\R,(TN2HRQ(R0>_\7/  _P]K^O2Z)XOU"_BLKW[#?7<:P^8R*1$%&P9
M4X7:I^I//6M2P\6FXTWPK:V=I!'?ZU8K<I%DB*VC$:LQP.2 650.,^HQ5>P\
M,:[8:?XLT]3I\D&J7-U<VKF5PV9QT<;2%"\\C=GV[UX/!FL6-KX0O[9K,ZMH
M%H+*:$RMY5S"4"-A]N5/RAA\O7@T 3W7CN]L+3Q-!<:= VK:#!]J:,3%8KB
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MFZ^Q@RK#]IVG(4G9N[<XSBO(-2U+5]9^"'BB[U9[>5C+<*&CSD%;C;@ ]%&
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M3CG%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S?C+0M1UVQL%TVXM
MTEM+Z*Z:&ZW>3<*F?D?'.,D'H>5%=)10!ROA[P]J^F>*]>U:^NK*2'5/(?9#
M&P9'2,)CDXQQ]3[=*E\2Z%J&K:UX?O;1K81Z7=&YD65V!?*%,#"GLV<UTM%
M'"Q>&?%6B>(-3D\/:EI@TG4[@W4L5]$[26TK??:/:0&!QG!(_GF?Q)X4OM?L
M+W2KJ'3K^QE@5+::\=A/;2!-ID!"')SAN"O.>>>.SHH XC6O"%]J^CS:+=QZ
M=J=B;1(;>>\=EF@E";3*,*<DD!N"#G///$4_A'Q'I&M6VK>&=4LY)GL8;*_B
MU-7*7'E#"RY3D/R?;FN\HH X^_\ #>M76L>&=0:ZM+B32YII[AI"R>:TB%2J
M* =JJ&XR3T&?6NPHILD:2QM'(H9&&&4]"* /*?!FD:EXB^%(T4FUBTZ\N;E)
M+@2,95B^TOO4)MQDX(!W<9S@XYZ"[\+^(M)\4W.K^%+S34M[^**.\L]01RBM
M&NQ70ISG: ,'&<=?3I8K;1O#%@1;6UM86I<#RX(@H9V.  JCEB3T R2:JZ5X
MQT#6]2?3=/U!9;U$=Y+<QNCQA6"MN# %2"1P<'F@#.N?#FKR^*O#NJFYMITT
MR*X2=I&97F:8+N*@ A0"O R>..V:@O?#7B+3_&-[KOAF\TX1ZG'&M];:@KE0
M\8VK(A3OMX(.,^OIVM% '$:QX5\01ZQIVOZ!JMJVKP6QM+M=01O)NHRV_P#A
MY0AB2,=,XZ#F36?#>O:M9:+Y]W92WEIJL.I7!RZ1_N^D<8PQ QW)ZY..<#LZ
M* .2_P"$9U"7Q?K.J3/;+::CIZ605'8NFW=\V"H!SO/&>U8\/@SQ+!X?\,V8
MO=+DET.92('$@@N$5"BECUWC.X<8!KT6B@#S+4]*U'PSH7BV;4-4TQ4URY40
M.T!VK+*J18<,<!./?CD],58T6+7-"U:P^UV7AR>*X"VBO974[W"Q?[ DS\B_
M>(! P,]J] N;:"\MWM[J".>"08>.5 RL/0@\&J6E^'M%T1G;2M)L;%I.'-M;
MK&6^I YH Y30/"OBOP\#H=KJVGMX;61C!(\;_;(8V))C4CY>Y 8\CTZ =7X@
ML;C4_#NI:?:F(37=M) K2L0J[U*Y. 3QG-:5% '#S>$]8DTWP=;*UCNT&6*2
M4F5\2[(C'A?DXR#GGIT]ZCU3P;K.H:AXNGAOK>T76[.&VADC=B\1C# $_*.&
MW$'!X]Z[RH;FZ@LX?-GD")D*.Y)/   Y)/8#DT <99>&M=MO$^DZY>7&CV\-
MEISV4\%O&X1$W*V4)Q_=[XP.QIMEINF:S\2GU[2K^.XM([2-[H6\BO#+<#<L
M3;AD%EC9\CME#Z5NZMXP\+Z5=2:?JVMZ=;3[1O@GF4'!'<'U%2:9=^'-.\-"
M_P!+DT^UT1%:02V^U( ,X)XXZB@#6GB\^WEASCS$*Y],C%<-8^"M4;PAI_A+
M4Y;(Z7:-&))X'<R7,<;AU4H5 3)"Y.YN 0.N1TUEXJT#4K"YOK+6+.>TM?\
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MX1TN\MEN1-NFD-N7Z0P;F,<?T7<3_P "-6_"5WK-YHF_7#9O=K*Z":S#"*9
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?\
M&'B+_A&=(AOFPD+W,<,UP\32);(V<R,JD$C@#KU85T%9NL6^HW$5M_9TEN&2
M;=-%< [)HMK H2,XY(.<'IT- &#+XLGL]'AN7GL;XW]^MII]Q9(SQR(R;MY5
M69B1MDX!Y*@<9S4=OKGBN>?6;.*PBDD@MQ/I][+8S013MWB9';(;./F!Q@YQ
MQ5"3X9YT:^BL;J/2KV34TU2R6U7=#9RJH4  XW _-G@#YNG'/3Z!:>(4W3^(
MK^RFN-OEI%81,D2CJ6.XDLQP/0#MU- &;HOBB\U[0/#EY9O:_:M1^:Y4PMMB
M5 ?-P-^1M8!.2>6%9UWXUUFYTV?5="L#>Q0W3PI8BQF9[A$D,;LLP^13PS 8
M/ P>>FUX<\)1^']9UF]CG+PWMP9K> CBW#@-(!_O."?P6LFP\(^)=#U"]M-'
MUNSCT"\N'N/+FMV:XM2YRZQ$$+@DD@L#C/0]P"5M?\2WWB[5]"TZ/3(!;6D-
MQ#-<I(Q&_=PR@C)^7L1CWZ5A7OBG6M?\->!=4M9[>Q.J:I%#<P^274N-YZ[@
M=FZ/.WJ>.>.>LM- U&S\::IKJ/:O#=VD5M'"SL&7R]Q!+8.<[CGT]ZP[;P#J
MMKX-\.Z3'?V?VW0]16\CE9&,<P!DRI'!'$AZ$]/?@ V(=>U6T\?)H&JM9?9+
MFR-Q93Q0LC2NA D0Y<@$ [OH?:I]/\4VT6D1:AK^J:98Q7DDC69DD$ DA#?(
M?G8Y)7:W'3<*QO&5OIOB8Z;H4>K1'7[:\C)^RR 2PJ5_?%E!)13$6Z]RH]*[
M*;3+"YABAGLK:6*$8C22)6"#IP"..@H X?QS<W%_?^#)]+U*R>RGU>,Q.L9E
M5G\N7#;E<!EQV&.><]JUHM6U"#XA?\(^8;!8IM*:^:XCB8.\P=(\D;NGMDGH
M,\5+XC\-W>I7>@-IWV.WM])O5N_+8$;\*R[ %&%&&///TI[:#?O\08?$?F6P
MMTTYK$P[F+_,X<MG&.HQC\<]J ,S2_%FKW.C:ZEVMBFN:=?&R2!(G$;,Q40L
M07SM?<#G(P,^E3:AXFU)K[4]-TPQ?;--BC$C'3IYTFF9-X4!#\BX*\DD_-[<
MW7\)1MX]7Q(DY1&M@DUL!Q),F1'(?7".X_+TJAJ7ACQ!:>+;K7O#&IV,']H1
MQI?6M_"TD;,@VK(NT@AMO&.AQ^0!T6A:A>:IH%G?7NGR6%Y+%F6UEX,;]"/I
MD<>U<(WC'QI<:%KFK65CHQ31;ZYAFA?S"TZ0GYMAS\IP"<G.3Q@8Y]%L;>6U
MLHH9KA[F91F29Q@NQ.2<=AD\#L,"O-_"MCJNJZ1XRTVUEM8K:\UR_A:X8MYD
M(9L-A<88X/&2,'UH VT\;/K,D,.CGR"^G07[226,MUM\X,43;&1CA222?3'?
M%&3QGXG%GX8,FC6UE>ZI=O9W$%T'&Q@K$.O0[2%!YR<''O5F]\%:II>KV.J>
M#[^UM)(;&/3YK6^C9X9HH_N'Y2"&7GZ_GFUJ?AC6+Z?P]<-?VT\^FWAO)WD#
M*)6*LI1%&=B@-QR>@SDY) '66LZ_<ZHOA^:33(]6M[3[5>W,43O"-SLL:HA9
M6R0I))/&,#.<B,^*-8MK;1;'5+&*RUR_\XRI%&]U'&D75PL9R=VY,#/&XY/&
M"[7?#&LGQ7#XF\-W]I;WQMOLEU!>QL\,\8;<I^4@A@2?\]6:YX0U>_BTG4;'
M6DC\1:;))(MS+"3#*)  \90'(3  ')(QW/- &7J7C7Q-I?A/6-0GTJ!;C3[N
M***::"6&.[BD=4#JC'<I&[D$]O>M>#7-?C\;-X?O_P"S@MUI[WEI+!&Y\EE<
M*5?+#>/F!R-N<=!4.N>%_$'B'P?=Z;?ZE8G4+R2%G>*-U@A6.17"HI)))*\D
MGO[ 5H2Z%J,_CNP\0L]JL-O8O:/"&8L=[*Q8' '!7&._M0!1^%MWJFH>"K>^
MU.\BN7GFN&!$)1@?/DW9.X@CT  P..:5+U]4^+DM@YS;:/IJRHG;SYFQO^H0
M8'^\WK5[P5X>O_"^C'2KF\M[BVAED-L8XRK;7D9_G))R?FQQZ=^U6;3SI'Q,
M76SQ9ZI8BRE?LDZ/F//H&4LH]P!U(H M>)H+#1] U/48=.MI+^48C+Q!FEN'
M(2,$GD_,5'L..U4M6\(:E_PB&DZ)H-_:6_\ 9_EEA=VYECN-@X##/0MACP>0
M*W=7TJ75+[229$%I:7/VF9#G,C*I$8^@8AOJHI-737S<VDFC3:>(5+"YBO$?
M+@XP593P1SU!SF@#BHEO_%O@W5]"?3+73->TZ\A^TV\'RPS,C)*K*?[KJN!G
MIWK3M+?4[#6-;G1!;W^OW2-:P,5<V\4<21O,^"1VS@$Y)09YXZ;2=*-@]W<S
MR+->WL@EN)53:I(4*JJ,G"A0.Y[GO3;#39%FO+R^9'N[H[#L)VQQ#.Q%)^I)
M/=F/;  !3\/:UH<L=OIFF3,5\IY(&=6'VA5?:\BL?O\ S'D]]V>AS67X8O7M
M?'GBKP\/^/6%H;ZV7^YYR_O /;>"WU8U'X=\%7FDWNA&[N+=K70K2>VMFC8[
MY_,9?F<$ +A5' )R2>1BK?A?3FG\4^(O$[#$.H/%;VF?XH8EQO\ HSEB/4 '
MO0!<U+79QXJL_#>GF%+R:UDO99ID+K%$K!!A01DEF]1@ ]:Q&\2:IJ&F>+M'
MF-M;:QHT9WS)$S1RQ/&71U7<"I(!&-QP1WK6UOPW=3^)]-\2Z5/#'J%I$]M+
M%/D1W$#'.TL,E2&Y!P?<5&OA>Y%OXCNC);G5M<0)(W/E0JL?EHHXRVT$G/&2
M3TH ;\.[:;_A _#LMVUM*5T^ VY2 HT:F->"2S9/J1C/I5/2+K69_BKXBMI;
M^!K*VM;0I#]G/"-YAP#OX;/5B#GC@8KH?"^F76B>&=.TJ[>&22RMTMQ)$3AP
MB@ X(X/'3FL]/#VI6GCC4-=L[JU-M?6T,<T$J-OW1;MNU@< '=R2#]* .$\*
M:]K7ASX;Z'J$,=@^E?V@UO/$ZN9F62Z==RL" N"W0@YQU'2NOU3Q5J,MWK-K
MHB(9M+(C"R6$UP+B8H)-FZ,@(,,HR<G)/&!SG)X"U9/AY:>&/M=D9;>\%S]H
M^?# 3^=C;CU..OO5VY\+^)+#Q3>:SX;U2P@CU,(;ZTOH7E19%4+YD94J<X X
M. <?D =1I%[<ZEHEI>7-G)8W4T(:2VF&3$^.5/3.#]*YC3?%FJO;>)[;4%LU
MU;2;@0PQ10L%E#@&!L%R3O)QC(P:Z^S@>VLXH9)WGD5</*_5V[GVR>PX'05@
MWGA*.Z\<V?B-9RBQVQBN+<#B=E;,3'_=)<_7;Z4 ,76]2O/$4OAZTFLTN[*S
MCN+RY>!G3>Y(5$3>#_"226/&!WR.1UOQ?K&J^%U6*2#3]0L]?ATO4$6,NLA\
MU<%#N!",""1U(R,CJ>NN_#E[;>,SXFT>6W,MQ;"UO+6X+*DH4Y1PP!*L.G0@
MCTZUFWW@&:;PY=6]O>PKJMSJJ:M),\9\HS*ZL%P#G: H7KGC/>@"[>^(K\:M
M<Z+:S1"\L[6.6>X&G33HSR;MJA$;*C"$DECU&.^,Q_'U[::=X?DURUC\/RZC
MYR7$U["SQ0RH0%4\KM#Y+ L>BX]Q:U+POXCB\11^(=!U6PBU":V6VU""Z@<V
M\X4DJP"MN!7) YZ=^N=*YT?5Y(+6&:6QU2!HI5O[>\4HD[.5*E>&VA<, "#P
M>N>: -?2)KNXTN"6^-NUPP)9K8_NV&3M9>3P1@]>]<C+XJUV!_%UG+_9RW^C
MQ+<V:F!]MQ"REE)&_.204XZ$=\XKH/"7A\>%_#=MI"S>8(6=AC.U=SEMJYYV
MC=@9["JVJ^$X]2\7Z7KHG,8M8FBN(@/^/A0RO&#[*Z[J (-$\2W>O6/ANXLY
M;1OM]NUS=_N6^1% !"_/\K!V"\YZ,>V*XC1]>UKPSX'U+6;..P?3[36[G[1%
M*KF65&N=IVD$!"-W<-GV[][X8\)IX8GUB2"7S5O+EI;>,G"P1DE_+'H-[R'Z
M$>E8$O@+5I? &J^&C=V0DOKQ[D7 WX0-*)2-N.<$8Z]_;D WI]?O8/B+:Z$T
M5L+&;3I;L2\^8&5U7'H!\U4K'Q!XBUK2=.U[1[2SGL+NY ^R."LHMMQ7S/,+
M8W8 ;;MZ'')YJY+H.HW'CJQ\0.UJL,%B]G) &8LV]E8L#CL5QCO[5E^'O"'B
M+PZIT6VUJT/AI)6>$&%OM<<9;<8@V=H&21NP3@G&., &6EQK5KXU^(EQHIL5
ME@%G,S7:LX;;; [0JD=<?>SQZ'MWGAS5O[>\-:9JQC\HWMK'.8P<[2R@D?AF
ML.'PSJD.K^++[S;-AKB1K&FYAY)2+RQGCG(Y[>GO6OX4TFXT'PMIND7,D4DE
ME L'F1YPX48!P>GTH YC7/&>L:(\D]Q%81JFIQVRV!!>9[9G""8NKX3).0&7
MVZU9'_)<#_V+8_\ 2DUF7?P_U^?1]4TM-7L##<:H-1AFD@<RL?-63;(=W0;<
M CJ .@%=%'H&I+X]7Q%)-:R1_P!EBP:,;E9CO\POW &>-O/'>@"A\-/^0?XA
M_P"Q@O\ _P!&TVYNM9;XQ6UC'?P+8KHTEP(6MR>#/&K<AQEC@8;H!_"<DUJ^
M#]!O?#]MJ<5Y+!*;O4)[Y3#GY?-;<5.1V]>_H*;?^'K^3QS9^(K&[MXU2Q>Q
MN(IHRQ*&17RA!&#D8YX'H>E '"V.LZYX>\/^--8TR.P:WL?$%Y--'<*[-,NY
M=RJ5("''<[LGL._9W_BB>;6)M+TQA%+!:17,DSV,MT,R;MB[8R,<(223W&.^
M,Q_ ^JR>$_%&BM<V0?6[V>Y64%L0B4C*D8^;&.O&<]L<S7WA3Q#;ZW:Z]X?U
M&QMM0-FEG?6UU&\EO.J9*L-N&##)_/ZY .A\+:GJ&L>'K:\U;39-.OVW+-;N
M",,"1D9YP<9&?6L&V\87.H>);S2(+JPM[VTOEA;3KF-EFDM]PS*C%P&RI+#"
MGCCWKJ]-MKFUL4CO+K[5='+2RA=JEB<X5<G:HZ 9/ Y).37*ZQX/O=?EA343
M8L;;41=VNH)N%S!&)=XC QCI\N=V,=B10!0TW7=1T[Q'XZO]6U"&;3]),9,:
M6Y#",0>8%0[\#[QSD')].@MWWBW6-&TC1M>U"*R?3+^2%+F&%&$EJ)<;6#EB
M' ) /RC/48Z58;P9/-K?B9KBZ@?1]?C43PB,^<I$7E$!LXQT;.,YJ*#PAJES
MH.E^']8N[6?3M/EB?SXPPEN4B(,:LIX7HNX@MG!X&<T 2R>(->U:VUFZ\.06
M4O\ 9MV]I';7"G==/'CS/GW*$&20,@],GKBL;5M;@T;XNPW-X!'/<>'D@A@W
M F29[GY8P<@$Y[Y X)S6E!X3\1:-KVJ2:!K%E#I.JW!NIXKJW:26WE;[[18(
M!SC/S< ]CW-8\!G6_$<]U?>1-ILFD_V;Y3R-YH(D\Q9=^.&! _GGM0!2\>C5
MD\*:(VIM9RW_ /;5B2ELK1QAO-'RY8L<=L_I5^+Q=J&DZ_K>G^(19M#8Z8-4
MCFLXV7$66#(P9CE@5X(QGT%0W7A7Q-J/A?2=+U'4;&YN["]@N6O"'!F$3;@&
M7'WC@ MGWQ5V\\(SZIXLU#4;XVYT^_TC^RY8$9MX4LS%@<8_B(Q^.>U %.]\
M7ZQI&@:1XEOHK-M+O'A^TV\2,)+5)L;6#EB'VEE!&T9SQBHUOX-)^)WBS4;H
ME;>UT6VGE('.U3*3^@J>#P;J=QX<T_PSJUW:W&EV,D1\] PEN(HF#1HRD87[
MJY8$Y / SD6;CPA/?^)=>O+V2!M.U?3UL'B1B)$4!ANSC&3O/';WH YOQ3>:
MSJFB^#M4NC9QVUYK=A-]F2-M\(9]R#?NPQP<'Y1R>.G.WJ?BW59AK)T&!99-
M,F:!('L)YOM4BJ&91(A"IRVT9SR,G@U1/@GQ3-H.C:+<:OICPZ/>V\]O<^0Y
MDE2$_*'7< #@ <'GU'>\?"OB72?$>H7OAW6+"*PU243W5O>6S/Y4V &DBVL.
M3@'!.* ([GQ1XHNO$EIH^FV.GVLEYHQU!!?ART$@9 4<*1T+$8'U[8+AXPOY
M/$%WH1N=,M-6MGA5+*XC<&[0JA=XG+ 'DN ,$_)SUXT5\-ZA%XXL=;6YBDMK
M;33I[+*S&60%E8R$XQG*CCOZBJGB3P?>^)X+JQOS8O;M<K-9WGS"XLE!4D)Q
MR>#@[AC/(..0#JM1^VC3K@Z=Y/VT(3")U)0MV!P0<'IUK@#\0K\>'_"FKLUA
M'%J=RMK?HT#[K=]Q5B/GX57 4D^H/?%>DUP[_#FUEM_%-M+<%K?6&=K>,CBT
M+A6<K[F50_\ P%: +6L^++G1K?5KYT@FMH+B*RLHPI5I9WV@[GR1M!8 X'\+
M>E+=>(-5T7Q1I.DZFUG/;ZN)([>Y@@:/R9T7=M=2[;E(Z$$'(_&G:CX)CU3P
M$GAV>]D6Y55D^W 9;[2&WF7'?+Y)'N:E30=1U/5](U'76L]^E!VB2U+$2RLN
MWS#N V@#.%YY.<\4 8$_CO6(OAOJGB,16)O-/O9;<QF)_+D5)O+SC?D'G/4U
M?U+_ )+'H1_ZA%U_Z''67>_#[79_#>N^'8-4L(].O[Q[J"1H6,J[Y1(5;G&
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M<)G(RHP%)SD^E5O&5YXKL? WBQIY[:%;:+=9WT*?/-$5^<%=WR,"<;OQ [T
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MZB+6XTS[,'M[N)?+?S.0R,F3QW!_#FN3\&:A?V'PM\(?96MH+:2,+=WEPPQ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS?.>F/?/;:M_"VI0:KXHO?MMJYUN.-54Q,/)*1^6">?FR.>W-=<2 "2< 44
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M'BL%/">JZ9XEU74-%U.UBLM7(DNK:Y@9S'*%VEXR&'4=0?\ ZU=C10!Y_;>
M-3M_"_A?1_[4M';0[V.\\S[.P\W9NPF-W'WS\WL.*W-*\/WMAXRUO6Y;JW>'
M4T@7R5C(:/RE*@[L\YW'/ KI** .$TWP7KVBW=U8Z9XABB\.W,[S?9WMMT]N
M')9TB?=@ DG!(.,^O-32^$=;T_Q1?ZIX<UJVM+;5"KWEM=6QF"R*-OF1X888
MCL>,^O0=K5+5=5M=&LOM=WYOE>8D?[N)I#EF"CA03U- &'>^%;MO$FC:O8:D
ML;6-K)9S?:(C*TL;%26!!&'RO4Y'/3M52V\&ZAI=MK6EZ7J$$>E:I+)*!+$3
M):&08D"8.&'4C.,$]Z[2C(SC/- '(P^#I;'Q+H=]83P1:?I-@U@ELR$NR-MY
MW9QD;1VYYIOB7PC>>)K74M-OI[*73[N17MWDB)FLL*H.PYP3E20>,;CG(XKL
M** *M]I]OJ6E7&FW2F2VN(6@E!/+*PP>?7!KD[?P7?R>']/\.:IJ$%UI-C+$
MP=8B)9XXF#1QOS@8*KDCJ!T&<UVQ(&,GK10!SFD>'[W3O%^NZU+=6\D.J^3^
MY6,AHO*0J/FSSD'G@5+XO\-)XJT(V NGL[B.5+BUND&3#,ARK8[_ $]ZWJJZ
MEJ$&E:;<W]UO\BWC,DGEH7; ZX Y- &/I>F>(EMII-9U6TNKTPF&%;>W:*%<
M]68%B68X'H!T &36!9^ =6T_2/"MO:ZO:?:M >3:9;9FBG5U*Y*!@0P!."#W
M/K7>PS)/#',A.R10R[@5.",]#R/I5'3->T_5[R_M+*5WFL)!%<*\3)L8C('S
M 9X[CB@#G=*\):[HPU5K76[9GO-4.H#?:D [@H=&PW((7 QTZ\\8?8^#[S2Y
M]4O]+N+2PO-0NH9W@BB)MU$8PRXR,E\G+<=1QQSV-!.!D]* .=\.>&(]#U36
M-2"6\$FJ/&[VUJI$4912,CIEF)))P.WIDQZCX:N1XOA\3:3<PQ7?V8V=U!.I
M,<\6[<IR.58'O@Y'%:=UK^G6>MV&CSRNM]?AS;IY3%7"*6;YL;> .F<\BKE]
M>1:?87%[<;_)MXVE?8A9MJC)P!R3QT% '*W7@N:7POK^G17D(O\ 77D>[NFB
M.U=Z[<*N<X50 ,GU/>NDTBUN+'2;6TN7CDE@B6(O&" VT 9P>G3I4]K<QWEG
M!=0[O*FC61-RE3@C(R#R#ST-34 <0/!FK:=J.O?V/JEK'IFMN\\\%S SM#,Z
MX=D(8<-Z'I[U''X'U.+1O"5A_:=HYT":.;>;=E\[8A0+C<<<,>?TKLM0U"TT
MK3Y[^^G6"U@0O+*_15'>K (8 @@@\@B@#G=&\/WNF^+-?UB:ZMY(M6:%O)2,
MAHO+38.2><CGH*Q]'\%Z]H4LNF6'B&-?#3RM(ENUN3<0JQ+-&DF[ 7)/)!(S
MQSS7=U1U/5K72;:.XNC)Y<DR0J8HFD.YS@<*#QD]: .7_P"$0US3/$FI7WA[
M7+>TL-5E$UW;W%J93'+C#21'<!D@#[V1GUZ5>F\+7:>+].URQU%(U@L#I\\<
M\1D:2/>'RK;AALC&2#UZ5U%9M[KVGZ?J^GZ7<RNMWJ#,ML@B8ARJEC\V-HP!
MW- ',6O@:]T_0-2\,6FHPKH-XTH3=&?.MHI23)&O.".6PQZ9Y!Q6A#X5GM/&
MMGK-K/;QV-KIG]FI:^6VX1[E8$-GMM QCI74TUW$<;.P8A1D[5+'\ .30!R&
MO^#[SQ);W%AJ%Q9RVCW2SVUP8C]HM%# E4.>O! ;(P#T.*Z;4[>YNM+NK>RN
M?LMU)$RQ3[=WEL1PV,C.#VK*M?&NA7R2/:3W5PD<C1NT-A.X5QU4D)P1W%27
MGC#0K#3+34KF]*6=VP6";R)"'8YPO"\$X/!YH RCX.N)=:OM;<V-MJ-SIS6#
M?9HV"2EB"99.A)&  .W/)XQ6_P"$'U(>'?"NE#4+7.@W4-QYAA;]]Y2LH&,_
M+D,>>:[>*59HED4.%89 ="I_$$ BL1?&.B/?75C'/<R75J5%Q#'8SNT1897<
M G&1R/6@#F-2^'FKWNE^(]+CURV6SU:]^W(SVI:5'WHVQFW8*#8 .,XQSQBM
MY_#NHR>--.U^2]MG%K9/:21B$J9"[*S,.3MY48'/'>K5QXQT*UTF75+B\>*R
MAE,,TKV\H\I^.&&W*]1U ZBM.#4+>YTU-0A,CV[IYBD0ON9?4+C=^G- &/X5
M\/W>@2ZRUS<P3KJ.HR7X\M"IC+A1MY)SC:.>*35_#][/XJT_Q#IUS;K/:V\E
MJ\%PA*R(Y4DA@<J05'8T^3QOX?BTFWU5[V1;"X<1PSFVEVNQX 'R]ST]:L1^
M)]+DNH+;?=1RSL4B$UE-&'8 M@%D S@$X]J ,+4/A\FI:/J"2:B\6LWEZFH?
MVA%'CR9XP!'M4G[JJ ,$Y.2<\UK^']/U^!C/XAU:WO)U3RXTM(#%&!D$LP).
MYC@>@'.!R:MZ9XATK5[R[L[*[#W5F0+B!D9)(\],JP!Y]:6?7M.M=0>QFED2
MX2$SLOD28$8ZMNVXP/K0!G:[X?O=4\2Z!JMO=6\2:5)+(8Y(RQEWH4(R",8!
M]^:I:UX5U@^*?^$B\-:O!8W<T"V]Y!=0&6&=5)*M@$$,,D=?RYS<_P"$]\.>
M9;1_;)]]T";=?L4^9@!D[!L^; YXI\_CCP];:8^HSW[1VD<WV>25K:4!)./E
M8;<J?F'7UH S=5\':K+=Z/J^F:TB:YIXD22:ZAW17*2'+JR @J ?NX/&,>]8
MFDZ/)K>N?$K1;Z\5YKQ;6"6>*/:%+6H&57)X'8$GIR3UKN=4\1Z7HFEC4]2G
MDMK/C,LD$F$R<#<-N5Y('.*FT^TTW_C_ +*QAA><9,@MO*=A[Y ;\Z .5@\(
M>()-3\,W]_K%B9-$$B;(;1@LBM&(^[YW$9.<X''!IS>#-2:S\7VYO[7_ (J'
M?@^4W[C='Y9[_-P,]N:[>B@#D-4\&W&J^#=,TEM1%KJ6F&&6TOH(^$EB&U6V
MD\@C((SWIEQX0U3Q%X:U#3/%6K17+W</DI]B@,4<6"&#X))9MRJ>>., #)SV
M5% '#?\ "*>)[V^\/76IZWI\DNC3,X>.S?,X*%,ME^&(/;@'UZ5T7BG0QXE\
M+ZEHQG\C[9 T0EV[MA/0X[\UKT4 <?<>$]3EO=%UM=1MAKFFHT+L("L$\3
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M$VP,L08Y:-)<\*23SC(SQ@\UH0>%KVWUOQ+J2ZE;DZU'$@C-J?W/EH4!SO\
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M!JT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %5VL+-[D7+6D!G!!$IC&[(Z<]:L44 %%%% !1110 QH8GE25HT:1,['*@
ME<]<'M3Z** *\EA9RW N)+2!YA@B1HP6&.G/6K%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.S.LW]MYQ@,B)))R>53KCCL.U=!>ZSI>FRI%?:E:6LDF-B3SJA;)P, GUXH
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MYM8L(X9T\R*1[E KI_>!SR/>JFK^+]&T35=,TZ]OK>.>_9MF^4*$149M[$\
M$J%'J3QT- &[1659S22>(-07^V;>XA6.+;8(B[[8_-EF8')#=L@=.*GBUG2Y
M[XV,.I6<EV,Y@2=2_'7Y<YX[^E %ZBLVZ\0Z+8B8W>KV$ @94F\VY1?+9L[0
MV3P3@X!]*T4=9$5T8,C#*L#D$>M "T52N=9TNRNDM;K4;2"XD("12S*K,3TP
M"<\]J6^U;3=+"G4+^UM P)7SYE3('7J: +E%5IM1L;<0&:\MXQ<,%A+RJ/-)
MZ!>>2?:H[+5],U.*:6PU&TNHX6*RO!,KA".H8@\&@"[15.SU?3=1D:.RU"UN
M74;F6&97('8D ]*;;:UI5Y=R6MKJ5G/<1KN>**=6=1G&2 <@9H O45F?\)'H
M>^!/[9T_?<2&*%?M*9D<'!5>>2#Q@55;Q=HR>*QX=-[ +[R?-93*!M)8!4]V
M.2<=<#W% &[15*/6-+EO?L4>HVCW667R%F4OE>HVYSQ@Y]*BUZ5X=#NWBU6#
M2I/+.R]G562$_P!XAB ?Q- &E15&35;"S$<5WJ5JDIB,G[R54+*!EGP3T[YZ
M"IK&_L]3M$N["[@NK9\[98) Z-C@X(XH L453;5M-6\DLVU"T%U&A=X3,N]%
M SDKG(&.<TQ-=TB2Q>]35;%K1&VM.MPAC4^A;. : +]%9TNOZ-#*8I=6L4D#
MI&5:X0$.^=JXSU.#@=\5FOKUIHMIK>IZKX@M;FRMIB0L:J#:C:/W1P268GD9
MYY% '1T5SIUN'5[#1KW3]>LK))[B(R(Q27SP1\T .1AB2.1R,=.:T;K7]&L?
MM'VO5K&W^S[1-YMPB^7NSMW9/&<'&>N#0!HT57EOK.&T6[ENH$MF"E9FD 0Y
MZ8/3G(QZTVTU.PU#/V.^MKC&<^3*KXP<'H?7B@"U16%K'B[1]#UC3M+OKV"&
MYOBVT22A1&BHS;V)Z D!1ZD^QJ_>:SI>G2)'?:E:6SN 56:=4)!.!U/KQ0!>
MHHSQGM7&W7CBQU+1O$AT'4K0WVE1R["2)-Y2,.6"Y!*@G;GID'K0!V5%<]X7
M\1VNIZ-H\5SJ5I)K%QIT%S-;B1!*2T:L6V#D#)STQ6G<:SI=I>1V=SJ5G#=2
M$*D,DZJ[$]  3DYH O44=*I6FL:9?SF"SU&TN)0N\I#,KL%SC. >F2.: +M%
M48=9TNYOVL(-2LY;Q02T"3J9!C@_*#GBL/PCK&HZCJ?B:WU*XCE73]1\B$I&
M$"IY:-CO_>/))H ZJBJ5EK.EZE+)%8:C:74D0!D2"97*@],@'BD36=+DOS8I
MJ5FUX,Y@$ZEQCK\N<\=_2@"]17.:;XPT?Q!'JT6FZK:H]G(\/G&16 VJI,H4
MGE S8ST..O-:%A>QVWAZTNK_ %>UNE$*&34 5CBF) ^<8.T GI@]Z -.BJ<.
MK:;<6+WT.H6LEHA(>=)E*+CKELX&*9!KFDW5ZME;ZI92W3Q"98(YU9RA&0P4
M'.""#F@"_12$A022 !R2:IV>L:9J,KQ6.HVES)& SK#,KE0>A(!Z4 7:*X'_
M (2>Z\3:WK.F^'_$%C9W%A)$EH#Y<R79*!W+#[Q49V_(01@G)Z#MKJ^M=/@6
M:^NH+="0N^5PBECV&>_M0!8HJC_;6E?V<NH_VE9_86X%SYZ^6><?>SCK3K;5
MM-O;RXM+74+6>YMCB>&*96>(_P"T <C\: +E%0W5W;V5NUQ=W$4$*XW22N%4
M9X')K)U;65E\)ZIJ6B7]K+);6\KI,A$R*Z*3@X/7CI0!N45QMCXZL++P]X4?
M6K^!=0UBU@<[W6,9:+>\A[*N<CTR0*Z.[UO2=/,0O=3L[8R@&,33JF\'@$9/
M.: +]%4;S6M+T]V2]U*SMF2,RLLTZH0@(!8Y/3) S[BHIO$>AV\4LLVLZ?''
M$J-([W* ('SM).>,X./7% &G156?4["UM([N>]MHK>7'ERO*H1\C(P2<'(K+
MUKQCHFB: NL2W]O+:RL$@:.56$SDX 4C@\]3V )[4 ;U%8TM\EUJ^DO9:_9I
M;2"4M:KL=KP;>"C9R-I!)P#GO5RVUC3+U)GM=1LYU@_UIBG5A'_O8/'XT 7:
M*H3:WI-O8QWTVIV4=I)]R=IU"/\ 1LX/0U;@GANH$GMY4EAD4,DD;!E8'N".
MHH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S]=94\/:DS$!1:
MRDD]!\AK0J.>WAN8C%<0QRQGJDBA@?P- ')_"IE;X7>'BI!'V4#CU!-8'B^Q
MOM.^(MI-IL;^5XGLVTJZ9./*=?F$OU$?F8_W:])MK2VLT*6MO% I.2L2!03^
M%2-&CLC,BLR'<I(SM.",CTX)'XT >6Z3I$^D_$C4?"L%L4T2YGBUU-HPB!>&
M3ZF98R!Z*:O_ !1\A]3\%17$OEQOK:;B)3&0-C9(8$$=1R#7H?EIYGF;%\S&
MW=CG'IGTJO<:;8W<@DN;*VF<# :2)6./J10!AV<.AZ1X@1[6^DFO=11;=86N
MWG8A-S[OG8D  G/;IW(KG?A_J5C;Z_XY2:]MXV_MR0X>55.-JC/)]0?RKO8=
M*TZW<O!86L3$%24A520>HX%1_P!AZ1_T"[+_ ,!T_P * .!^*^KV.J_"O5I+
M2X26!+R"$3(X*NPFC+;2.N.1QW4^E=KI_AVQT[4SJ-K)<M(\'DMYUU)."N0P
MP78X[].N?:KK:5ISPQPO86K11YV(85*KGK@8XJQ%#%!$L4,:1QKPJ(H 'T H
M X+QY(B>.?  9U!.HS8!/_3+'\R/SI?C6RK\)M8#,!N:W R<9_?QG^E=K/IM
MA=2^;<65M-)TWR1*Q_,BG7%C:7:HMS:P3!/NB2,-M^F: ///BKHUC:_"[6KF
M.XOV(A3;YNI3R(<NN/E9R#^(KKY)]#":%_:361N9"O\ 9YF"EC)L_P"69/?'
MI6D^FV$D"0/96S0Q_<C:)2J_08XIRZ?9*(0MI;@0,6B C'[LG@E>.#R>GK0!
M8K@OBF#!9>&]3=3]ET[7K6YNI,<11#<I<^P+"N]I&571D=0RL,$$9!% '-^+
M+ZUN?#S64%S%+<:@R0VT<;AC(68<@#J ,L3T !-8UY:64WQQLO-@@=_[!E?Y
ME!)83H ?KC-=A9:-I>FRM+8Z;9VLC\,\$"H6^I J5].L9+@W$EG;O.?^6C1*
M6Z8ZXSTH \:O&BB^"7C**-D6&'6KB.-5(VHOVI< >@YKI]7UBWTSXHRQ:SK#
MZ5:7>EQ+8W#>4(F*NYE0M(K $Y0]L@#.>*[H:/I@C,8TZSV,0Q7R%P2.AQCW
M-.N-+T^[MDMKFQMIH(R"D4D*LJXZ8!&!0!YU%HEO:V/A^#P7KOV>[MOM<NFB
M_ D@O(RR>:O&#MR05*CIDCCFFVTU[K^F:!=Z5-;:#XA@EOO)M)AYMK<LL@69
M<]=I;# KR!G'3->D76FV-[&D=W96\Z)]Q98E8+] 1QT'Y4D^EZ?=01PW%C:R
MQ1C$:20JRH/8$<=!^5 &-X&U)M4\+QSR:<EA,MQ/'-#&VZ/S%E8.R'NI;)'U
MQ6%HMY;6_P 1?'MO-/%'-*;1HXV8!G M>2!W P>:[^...&)8HD5(T&%51@ >
M@%0R6-I-(\DMK \CIY;,T8)9>NTGN/:@#QG3X+2W^%OPYNHXH8YCK5D3*  Q
M)D8-D_3CZ"M7[=H]QJWC/0/%>NOIKW%VS&&9H46XM6C41E&="20!C"G@CCFO
M3#H^F&-8SIMGL4DA?(7 )ZG&/84^?3;&YGAGGLK:6:#_ %4DD2LT?^Z2./PH
M KV%G'_PC5M8Q-<+%]C6%#<?ZT+LP-W^UCK[UQ7PDO(M)\+CPEJ+QVVL:1-+
M'-;R-M9U:1G61<_>4ANH]*]'JG>Z3INIE#?Z?:713[IGA5]OTR.* .,^).J>
M=X5$]GNGT^UU&U;47C&Y&MUD!D4$=0,+N[8R.QQ)K4*7OQ/\)W>FM'*&M+K[
M<T9#*]J4&S=CJI<C;[Y]#7<+%&D(B6-1$%VA . /3'I5>VTO3[*&2&TL;:"*
M7_6)%"JJ_P!0!S0!YAX3TG2)_A1K-T;"SEGC;4PLIB5F3YI!@'''&.E5)-(T
M^X^'?P^N-*@@76#<6#030@>86 'G9(Y("ABV?[M>FZKHZOX?U*QTJTM(9KNW
M>(9'E)EE*@DJI/&?2J_A+P\N@Z!IUM<6=BFH6UK';2W%LN3)L4+G<5!YQG!H
M Y7P[-:S6OC_ $_Q"8UN!J%P]RLV,FU9 (FY_AV# ],5B:5I\AO/A5!K\*/>
M-:W@D6X4%B!$"@8'J0-O![BO6[C3+"[N(KBYLK::>+_5R21*S)]"1D4LVGV5
MQ.L\UI;R2KC;(\89ACI@D4 >:>(+K1K74?%FDV26>E20:,D,N_@W"%)"D<$>
M0H W$$@');&.]5K/4[)!\)KR6\@6WBM)8Y9FD 17^Q@8+= <\?6O5GLK26Y6
MYDM87G52@E:,%@IZC/7'M2?8+/R(8/LD'E0D-%'Y8VQD="HQQCVH \WG6Y'B
M_P"(RZ* NH/H]LT C&&,ICEP1_M9(_'%5=1:WU7X3^$6T0H-2BN+);()]^.=
M2%E![\+YF[V!S7J4=A9Q7+7,=I D[9W2K& QSUR>M-BTRPM[R2[ALK:.YD^_
M,D2AV^K 9- 'G=G8:=+XR^)7F6UL^VWMA\R*=H:V.[Z9QS]*Z;X;R&3X:^'&
M+;C]@B&<YZ*!_2MTZ5IQ:1C86NZ3[Y\E<MSGGCGFIK>V@M(O*MH(X8\YV1H%
M&?H* /+M&U3P[=:9XI\/>+Y85O6U69KFUGD*2W*EPT)C (9OE"!0O/RCVK8T
M"ZV?$SQ7::JHCDFMK5[-)L8:U"$,%SU <MN]S7:OI]E+>I>R6=N]U&,).T2E
MU'H&QD4EYIMCJ&S[;96]SY9RGG1*^T^HR.* /&(=/1/"7A*&[C1[-O%VRQ$H
M!S:%I=@YZJ>H'0@CM707EMI@\8>/[*YF%E8SZ+;"Y>'"E 5D4OCV!'X5Z3<6
M%G=[/M-I!-LX7S(PVWZ9'%,_LO3_ #'D^PVOF."';R5RP/7)QS0!YA?W7BB&
MSU_1+M;:_P!5&@R36.KV */-%G&UT'1\DE<<=<=ZT=$G\)^)[WPYJ%KKDU]>
MVT;"VLD,(:!&3#K(B(I" #'/&<8ZC/H%II]E8*ZV=G;VP<Y80Q!-Q]\#FDAT
MRPMI)Y(+&VB>?_7,D2J9/]X@<_C0!XI/:V$?P0\1W4<-NLJ:M*4E51E=MX-N
M#VP#Q]?>NZ>[MK7XW-Y\\<7GZ!&D6]@/,;[0W"^IY' KKO['TL1F,:;9["=Q
M7R%P3ZXQ4PLK57A<6T(> %8F$8S&#U"^@^E 'FF@37VBZEX<MA-;:YX<OKB3
M^S+H#;=6;F-V(<#AU"[U)ZCOT KH?BLD3_"_7S*J,%M2R[AT;(P1[UTUOI>G
MVD[3VUA:PS,,-)'"JL1[D"IKBUM[N/R[F"*:/.=LB!AGZ&@#S[4[:RN?B;X*
M\V&"0OIUTQW*#NPL14^^.2*O?#@11S^,(8=JQQ^(;C:B]%RD9X';G/ZUUHTK
M3@\;BPM0\> C>2N5QTQQQ3[>PL[-F:VM(("WWC%&%S]<4 <9XU=O#OB;0_%T
M,$DJJ6TR]CB7+R1R\Q_E*%'_  .LCPQ97^G:]=^";V,-!]HCUD2(N(Q$QW-&
MOH!<+@#NI->H/&DJA9$5P"& 89Y!R#^! -'EIYADV+YA&TMCG'IF@#SW0-+T
MJ\^*7C=9[*TG:,V#JLD:MM/E$Y /0Y .?4"L?RXE\,?%J&W1 %FN,)&!Q_HR
M]A[YKU.+3[*"X:XBM+>.9L[I$C 8YZ\XS1#I]E;,[06=O$9!ARD2KN'O@<T
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M))(;"U,DF=[&%<MGKDXYH \E\+ZM8VWA?X<QSM!%?/!<FVOKN0B&W"J5<$9
M9B"% )&.3VP<][NV/PO\3QK=QR^1XG\QVR!M0W<9#$#A0>3Z=:]I_LG3O*2+
M^S[7RT?S%3R5PK_W@,<'WJ4V-H8YHS:P>7.2TR^6,2$]2P[_ (T <1KL]E<_
M$_P)=6TD$@E&H 2QD'>!$!U'49S56_CNO#WCZ^TZQ21;?Q7"'B>,?ZBY3"RO
M[?NCOYZE,5WS:;8O)'(UE;,\0 C8Q*2@'0 XXQ5AHT9T=D4LF=K$<KGTH \X
MU;4+30/B5;6NH:FVC:9+HZ0:?-B-80RR-OCW2*P4E?+],A1[5T_@G3]*TSPZ
MMOH<\\^F^=(\,LC!@^3DE" !LW9Q@8ZXXP:VKRPL]0A$-[:07,0.X)-&'7/K
M@U.JJB!$4*JC  & !0 M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %8OBSQ##X7\,7^K2M%O@@
M=H8Y'VB60*2JCUSCM6U7*?$V1(_AGXB,CJH-C(HW'&21@"@!NB7\X6/6;KQ3
M;7>DS6R+)$ZQ#RKDX/R.F."#C:<G..:W8]=TF73Y-034[0V<1*R3^<H1".H8
MYX(]#7#ZM??9?$'P^U">5?[$$<D;S9_=QSO"!$6/09^90?<UGZ] IU7XC7UL
MT?\ 9DF@^7.P(V/=B-\8[;@FW/\ O"@#OQXN\.%V3^W=-W+LW W2 C>,IW[]
MJO-JNGK?26+7UL+N.(S/ 95#K'_>*YR%Y'/2O,_$5K8Q? RSO+2" 8MM.>6:
M)!DHLD3$DCD@?,?SK2_MK2KWXS6$EO?VL\+Z%-&LB2!D=O.0[0W0G )P* .M
M7Q9X=:2U1=<TXM=L4MP+E/WI#%2%YY^8$<=QBK%EKNDZE>W%G8ZG:7-S;?ZZ
M*&96:/MR >.>*\:QIX_9YD<?9@?[2SN&W.?MW'X[?T]J[BZ:TM_C+HB0M!'N
MT2X3:A RHD0J..W!(_&@#O:Y\>+M*G\47/AN&\B6^A@#L68<.Q(" '[S#&2!
MTXK0T;7=+\0V'V[2+V*[MMYC\R,\!AU'^?6N3M[VVLOC1JL=S/'"]SI-L(%=
ML&3$DF=H[X[XZ4 /\$>,H;K0;1?$&M6G]JW-Y<0Q+(R1-*%F=%"J,=@!_P#7
MKJM1UK2]( .HZA;6H(W?OI O'KSV]^E>-,UDGP(OKA&@$O\ ;)?S 1NW"^&#
MGUV_I71WNKZ;8_$#Q)8>(]8DTRVU""![.1V18KB 1;70,RGHQ?C/\1H ]/CD
M26-9(W5T8!E93D$'H0:I#7-*-\MD-0MOM3.8UB\P;F< DJ!W(P<CM5?PM9V6
MG^&;"TTY;A;&*/;;BX)+^7D[2<\],8!Y QTK@M.N+O1M5THV%Y;:WX<O]5=(
MH)!BZT^=RY;!'WE4E\YY /IS0!Z)<:]I%I=BTN-2M(K@L$\MY5!#'H#Z$]AW
MK$UC5=2L_B+X9TV*Z T^_ANVF@\M>6C12IW=>K=L=*XW2[BWE^%'BO2-;9/[
M7BEO5NX9/]9),[,T3*.K9RFTCK@8K0'VFU\7?#&VU28'48],NTN-[?,9/)B!
MSZG(/UP: .]N->TBTODLKC4K2*Y=Q&L3R@,6/(7ZGL.IJ^2%!)( '))KQK3K
MO0=2T/5?#'BK5;N'4DU";S]-W*DEPYF,D;1?+N;.5Q@_IBO3_$=Q!9>$M4N+
MNUDNK>*RE:6!6PTJA#E<CN1D9H FL]?TC4)S!9ZG:3RB/S=D<H)*9QN'JN>X
MXJNWBWPXIA!UW309I3#%_I*?.XX*CGDY('XUYSIVKZ?+XV\"3)J=D\#Z=<PI
M#;$&*#*1;(@QRS-V.3G@' S69=+8?\*=\>RH+?<=7N\,N,\3@IS_ "H ]FU#
M4[+38U^UWL%LT@/E^8P!.!R0.^.IKG_AYK5[KOAZXN[Z\6\=-0N84F1556C2
M0JN-O&,"L:VUNVT_XLZ@=9NXH(;K2K?^RYYG"QLBEC*JL>,EB"1UP!5CX37%
MI+X<U**UEB98]7O/DC(^53*2O'8$=* .NU'6]+T@ ZCJ%M:Y&[]](%XZ9Y[>
M_2B36]*AO+>SDU.S2ZN0#!"TZAY0>A49RWX5YY>ZKIMCX]\4:9XFU>72X+^*
M%K5Y"B17%OY05D#,IY#;^,C[QQ4^LZ)97OA?0]!\.R2P:Q:K]JTB6X?$MM&A
M_P!8^1G8P(7:1SN&1P< 'H$&JZ?=6\\]O?6TL,#,LTB2J5C*_>#$'@COGI59
M-8LM5MKN/2M3MY+B),L8V#F/(X)7T/;L:\XU+Q#;ZA\*K2[L+5DCTO4+?^V;
M!#ODC6.4&96[MDC<2>HR3WKL+#5?"VLZM<:QI$]M>7?V QSWL#Y6.+.Y4<YP
M"22<'G@YH C\#^)QJ'@K0+S6M2MQJ.HQ_+YC)&9G+'A5XR>.@%=)'JNGS7%U
M;QWUL\UH,W$:RJ6A'/+C/R]#U]*\>L+B"'X4_#:\EF1+:VUFW:>5F 6(?O5R
MQ[#) Y]:U9]0T/4O%_CM+G4%&GW.BVZO- XR8PLH=D/1MH/49% 'HT.NZ3=B
M46^IVK&*/S'Q*OR)V8^B^_0U0TS6]/T_0M/;4_$]C>O/E([YWCA6Z;<1\H!P
M?3CTKGO#=YJMMXDFT?79[#5HUTPW%OK, "%H=X&R9<E<GJ".#@^]9'AK13XD
M^ .FVMFZB^AB-Q9R*1F.XCE9D^G(Q]": /4#?6BWJ61NH1=NAD6 N-[*.K!>
MN/>J]MKVD7E\;&VU*TFN@I;R4E!8@'!('< ]<=*XR.\U'Q7\/]9\0V=O+!?W
MNEM!9PX(="J'=CN"9"X'J%0U4\.W_A3Q/+X;N;?5KJZU2Q&8+$,BO:'9MD#J
MJ@A0!CG@\ 9)% '<>)==M_#?AV^U6X>,?9X'DC21POF.JE@@]SBL3P_J5S-;
MVVO7/BFUN-+EM$%S ZQ!8;DA3A'7! ^;&UMQZ<U=^(,B1?#KQ&9'50=-N%!8
MXR3&P _.N4O[W[*WPTU*:13H<8V7,N<QI*]N%A9CT R6&3T)H [^+7=)FL9K
MV/4[0VL#%99O.4+&1U#'/RGV-51XO\-EF7^WM-!54=@;I!@.,H3SWR,?45PN
MOP(WB;QO?VKQG3&\-&.\8$;&NL/MR>A81X^@8>M0:Y:62_L_6UU:6\&_^S[!
MI98D&XJKQ,V2.3CYB?QH ]0;5-/2^:Q:^MENUC,K0&50X0=6*YSCWJE_PEGA
MTO;*-<TXM=.8[<"Y3]ZP.TA>>>01]>*Y*76])OOC#H\EMJ%K/"^CW$:R)(&1
MF,D9VANA. 3@5Q\@L!^S[JKK]G!_M)SN&,Y%[QSZ[>GM0![+9Z[I.HW]Q8V6
MIVEQ=VW^NABF5GCYQR >.>*I>,/$</A7PM?ZL[1>;#"[01R/M$L@!*K[\^G:
MN?OVL[?XP>&DMS!'NTJZ0+'@97=&5&!VX.!]:O?%*1(_AAXA+NJ@VC*-QQDG
MH* )-'OIHB-7NO%5M>:1- B%)%B'EW'&=KIC@@XVG)SCFMM-=TA].DU%=3L_
ML49*R7!F4(A'4,<X!'H:XK6+[[+XN\":A<2K_8IAFB\_/[M+AXP(RQZ#(W*#
M[GUK)\00+]J^)E];LG]ERZ,$D8$;'NQ$_3MN"[0<=R* /3+#6]+U2>:"PU&U
MN98 K2I#*&9 PRN0.F15*]UAY?$MOX?LGV3FW-W=2X!,46[:H /&YFSC/0*W
MM3?!]K8Q>%M*N+."W4RV, :6)1EP$&,D=>2?S-8>C))#\9?% GSF?3K.2WS_
M ,\QO5L?\"S0!OVTK7>M:O#!XBCFVI$JV<21EK%L-DD\D[B.C=-O%.\.ZV=7
MAO(9U2._T^X:UNT3[N\8(9<\[64JP],X[5SWAN2 ?%KQLB/'O,&GDJI&20DF
M?YC\Z/"*.WQ+\?7"Y^S--91J>QD6#Y_QY6@#K;_5].TO;]OO8+<L"RB1P"0.
MIQZ#N>U-DUO2H4M7DU*S5;S'V8F9<39Z;.?F_"N3UW5M.M_B*EE))!I]ZVDD
MF_F.6EB:7_4Q*3M+;ADDACT ![<+I5QIUW\._AI#));RF/6XHI5<@XXFRIS]
M5X]Q0!Z_!XGT&ZL;B^@UK3Y+2V;9/.MPA2,^C-G JP=9TM;&&^;4;06D[!8I
MS,NR0G@!6S@Y[8KCM'BLKGXI^-+%Q"\5Q8V2RP\8?Y9%;(^A _$55\'P7XU)
M/"-]'(UOX9G,B7#CB>(C_11[D*SY]#$M 'I!(4$D@ <DFN(U'Q9YOCWPMI^D
MZQ;S65ZUP+J"((Y8+"S(V[KC(ZC@XJQ\4_MO_"MM8^P)(\GEIYBQ_>:+>OF
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M'?SQSWBQJ)I8TV*[XY('89JS110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)(8YEVRQHZ@YPR@B
MGU%<W,%G;27%S-'#!&,O)(P55'N30 &UMV@: P1&%OO1E!M/U'2D6TMDMUMU
MMXEA7I&$ 4?ATJK::[I=]]I%O>Q.UL-TZ$X>,8R"RGD CH<<UQ^C:Y>>,;^_
M?3O$'V*6QU5XHK=(DDCFMHRH;<",DMD\@C'&.^0#O!!"(3"(D$3 @IM&T@]>
M*:EG:Q*%CMH44)Y8"H  O]WZ>U8NM>+],T/7-+TF[E"SW[.<G@1HJ,VXGW(
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MH<>]5AXT\,L]LJZ[8,;J0Q0;9U(D8';@'Z@CW- &M%8VEO&\<-K!&DARZI&
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MVR=Q"E@.GWB?3'04 >.V^M6=IX2^(.BZW<Q0:VTU_(8)R ]PCH?*9 ?O+M
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M.TOQ187_ (;L]8EE$"7$<9*,&R)'4'8HQECS@8!SVKGKW5-"\4Z!XBO_  ]
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MPVI(+>,8)/0AN.>]6+RWA2+XHZS:M&NEWU@(8I%(V3SK X<IV/+*N1U;/<4
M=YI.LPP>%-%N]1N29KFUA/(+/-(8PQ"J 2QZG 'K4K>*M#32)=5?4H5L89#%
M-*<CRG!P5<8RASV('4>M<%;7PT_5O &LW4J_V)_9!LVN-W[NWN&1,%ST7.W;
MD]^*UM$TB#6?%OC2Y"K-H6J16]L2IS'<2",K(RGH< @9'?/<4 =C)K%A%'9R
M//M6]<);DHW[QB,@#CT!/T!JO<>)=&M;U+2>^2.5Y?(5F!V&7_GGOQMW_P"S
MG/M7)^!(M4GNAINKH[?\(N7LHYVZ7+L!LD^HA*C_ +:FN:T.Y\/76B2>$?%$
M>HR:]!=2!].\Z<?:7\TNDB;3MP<@[N .2>.: /4M2\2:1I#LM_>I"$V^8Q5B
ML0;H78 A >Q8BM165U#*05(R"#P17DIU'0K#Q!XHT#QC)?0/J%X\UNHDG\N]
MMY$50JB/[S #;CKT':O2K*T-OX;M[.RB:T,=HL4,<C%C#A,*"3G)''//2@")
M_$VC1W:6SW\:N\WV=7(/EF7_ )Y^9C;OSQMSG/:L'Q+XF2'Q?I7AW[5-;0W$
M4\MU+"C;QM5=BJ0#U+Y)'H!ZUQD4T-]\#Y?"LJ@>(HE^R'3V/[_[2)<JP7J0
M3A]W3&3G@UTFI74-K\5/"4%U>1&>'3;J.9F<#YR(\9]"=I(]: .BEOF\&>#I
M;S7-2FU(V4;N]QY 6249)4%5XSC )X'&3BN?UCQ5,]SX-U&VU%[6QO;K9>Q$
M!8R/)9SEF4-@$=<XKH/'D4D_P^\111(SR-IMP%51DD^6> *XK4-7TR_C^&TD
M=U#)$EXA9FX Q;D9Y[!B!GUXZB@#T/3/$6D:S:W%SI]_#-#;,4G;.WRB!D[L
MXQQSS19>(M*U&_:QMKQ6NA'YHA=&1FCSC>H8#<O^T,BO,-:$U_J7Q0MM)(N+
MIX["1(8G^:8(@\Q5QU. 5..YQ71>&]2\(>*=>T[5-)-]>ZG:QN"TTTY-FK+A
ME?<=N2<#'/J.!F@#:\;>)Y/#6F6HLX4GU/4;J.RL8I"=AE<X!;'.T=3^ XS3
M[G1M?32IC:>)+A]4\H[&F@A\DOC@; @(7/\ M9'<GOC?$[2;ZYM=$UO3[:2[
MFT/48[V2VB&7EB!^<*.[=#CZUO6GC3P[J%NDECJMO=2./EMHG!G)_N^7]X'V
M(&.^* +4FM6NGVULNH2E+J2$2-"D;228 &YMJ G )Y.,"FS>*-"M["SOI=6M
M%M;UU2VE\T$2L3@!?7G\N]<K;ZA_8GQ5U:;79$M+;4]/MOL,\[@1KY>[S(@Y
MXW98MCN.:Y"^M8]/\(.UT4CT^]\8K=V44O ^R^<N6"G^ X9O3!![T >FQ>/?
M"DP4QZ_8G<TB@>;@YC!9^/0 9STJ[I/B71=<T^:_TW4K>XM821+(&P(R!D[L
MXV\<\UR?C*?3[;Q]X#N;E[=+;[1>.9'QLR8/E;/3KCGZ5S/B;1[W4SX_U/P[
M$9[2YBLE*P<K=O$VZ8)C[WR?*<=22.N: /4[3Q%I-]=_98+Q?/,?G+'(K1EX
M_P"^NX#<O^T,BJL'C7PU<WL-G!K5I+/-*\,:(^=SJ,L,].!7-:S>67BO7_!E
MYH-U%/):W;74TD3 F"W\LAU?'W=QVK@]\^AJ#P7=60TCQQ<1V\5])'K-_<>1
M'@M,N/EQ[,,@'W- ':6?B?1K^ZBMK:^1Y9HVDARK*)D7JT;$8<#U4FLG3_&V
MDZ[9:X4O6L(;&66W-U*ICV!54&3YA@$,QP#Z#CFN$TS6K&ZU[X<WL5X&@5+B
M(V]M 1#:,;?"PKP26!X())XS@ UK:'?VMKHOQ#L+B417*ZCJ$S1N",1NHV,3
MTPV>/7M0!W%AJ=C9^&]-N9M5-Y#+#&L5W(/GNB5X(4#)9NN ,T]?$^B-IMSJ
M!U*".UM6*7#RML,+#JKAL%3[$9KS;3KLV%E\,-9GD']C6MBUM=2Y^2VF>%55
MG_NC(9<GIDYZU/KB1S7WQ UNTFC.E7&@BV:56!CN+D(_W3T8A2J\=VQUH [Z
MS\6Z!J&I0Z=:ZI;RW<T?FQ1*3EUQDX[$@')'4=Q3_$_B&U\+>'KS6+P.T=O&
M6"(I)=NPXZ9/?H*X"2[L8S\*RD]NHCQG:P&T&V*G/I\W'UXKK/B7#)/\-?$,
M<2,[FR<A5&2<<F@#6C\0:>=-MKV2?:LY"QKL8N[XR55<;F/!Z#H,U8TW5;'5
M[=I["Y2=$<QOMX*..JL#RK#T.#7G]UK$">+_  CX@:</X?:RFM!=D$10SL%(
M9B> &"[<],Y%:WA6V,OC[Q7K%FP;2KL6R1R(<I-,B$.RGH<94$CJ<CM0!JZG
MXOL-,\4V&@R^9]HNHWE9A&Q5%7&.0.221]!UQQ7/:)XQM])U'Q/'XCUT>5;:
MIY%LUP%!6/RT.,(HP 6ZX[\FI_$MU#IWQ3\+75TQC@>TO(%?:2&D/ED(,=S@
MX'>N=6ZL7T7XKGS[<M*\X4[AEQ]F"KCU^;('O0!ZA>ZM8Z?%&]Q/_K03&L:-
M(S@#)*JH)( (R0.*?IVHV6K6$5]I]S%<VLHRDL;9![']>,5Y0-9LM&U+PQJN
MM7%S%H=UX?AM$O8)9 D-PIW,KE#QN&!SW7V./0?!UII%KHTC:%;30Z?<7#SH
MTK.3,6QND&\[@"<X]<9'!H S5UR^\1^-=2T'3+IK*PTA(_MMU&BM++,X)6--
MP*J  <G!.>!CK6M#9ZS9Z]:_\3.2\TIHI%E2>-/,23Y2AW*!E<!AC&<GJ>W(
M:;+'X%^(WB-M9<6VEZZ\=U:7\G$2R $/&[=%.3D9P"!74ZKJ2Z[H6IV?AZY2
MZN9+.98[FWD#1QR%"%&\<;LD<#IU..,@%R/Q-HTMY#:I?Q^9.YCA8@A)6'54
M<C:Q&#P"3P:K7?C;PS8W,UM<ZW9QS02)%*ADR4=\[0<=#P?IWQ7GUW/;^(/A
M%HN@Z<RIXA@:R@2TZ36L\3H)&9>JA55SD]C[UT7AZ6RF^+7C-2\$DK0V(0$@
MD[4;<!]#MSZ'% &U/\0/"5L%,OB"Q56F, 829&\8R,C@#D<]/>M>]U>QT_RA
M<3_/*"8XXT:1W ZD*H)(&1D@<9KRW3;G1F\*_$73[MK=KFXU?4$%MP99F/$8
M5>K'=TQWJWH NO"7B_1U\23"&"7PY;V4-U*V(TGC.9(BQX#'KSUQ[4 =[)XJ
MT&'28=4DU:T%E,P2*;S!AVSC:.Y.>,=14<'C#P_=1-);:G#<!;@VNV$%V:4#
M<550"6..> >.:\KU^W2V\$^+[IV1=-U+7X9K*-NDJB6+S)%'=20QR.H&>AKM
MO%^L:=IVN^&2XMK:.ZDG,>KL@86Y\L#"'[N]P< G(P.AH TM;\=:1I7A677H
MIOM4 ?R8Q$I.9=VW:W&5P>#G&/K@5//JFGW7B#1$BUYH)I!,R:>H -V-IY92
M-P"[20>/QKRR69)/A;XX@0W$DD/B!YY/,B8.$^T1-N88&#@$D8'?@5V.O:KI
M]Y\1/ -S!=1-$QO2KYP"&AVJ>>S'@'OVS0!UM]XET?399([N^2+RF59G*L4A
M+=!(X&U,Y'WB.HHOO$VB:9>+:7FJ6T-PT9E$3.-VP=\?B,>O:N T:^MK#PYX
MQT#Q Z)J3W=XY@E^_>1R@E&C'5\@A0!DY %1:7 ^E^*/AQ8:M+']OM=(N(YA
M(P)C<I&%4^_! ]<&@#TO2=9T[7;$7NF7<=S;EBF].S X((/((]#2W^K6.FLB
M7,Q$D@+)%&C2.P'4A5!.!D9.,#(KD?AQ<6\M[XP2&:-LZ_/( K Y4I'\P]B0
M>?8TR2]&A_%V[N=8E6"PU#3(HK*ZF;;&K1LQ>+<> QW;L=\4 =/+XIT&'3K7
M4)-6M!:7;B.WE\P$2L3C"^ISP?3O5C2-;TS7K:2YTN\BNX8I6A=XSD!UQD?J
M/SKQ_5;:.S\*:K/.R)INH>+([FSCDX5X?-3>Z@_P$ACZ8YZ&O;(O**!XMA1_
MGW)C#9[^] '(MXQMM97Q)8:;<3VUSIJ,B3B+DN(]Y(W*1@<#GKR1V--\%^,=
M/OM!\/6=_JT4FM7EC'(R.?FD?8&;GINQSCKCM6+9:A:V.M?$:SNI1#/))YZJ
MX(S&;90&STQD8SZ\=36/'=V4/@3X7 3P(T6HVAD 8 IB)PY/IR>?<\T >H:A
MXET?2I3'?7R0[659'96*1%ONAW VIG(QN(ZUI2S1P0//*X6)%+LQZ  9)KR.
M*^T"#4?$GAKQBU_'<W>HSS0P*\^V^@D;,>P(<,<87'L/P]-;38[GPT=+V-;Q
MR6?V?86WM&"FW&>Y'KWH YSPKJ&J>-M,.OMJ%QINGW$CBQM;9(]QB5BH>1G5
MB6)!.!@ 8Z]:V=/EO]*35)->U&*2TBE#V]TZK'B'8O#XXW!@V3QG(P!TKD_A
MWKMGX:\-0>%O$=S!I>JZ87B*74@B6=-Q*R1LV RD$=/3FK/Q O)[WP_I^I6$
M$T^G:?J]K=W112?/MT;+E5ZLH.TY[[2>@S0!UEKX@TJ\EN(H[Q5EMD$DT4RM
M$Z(>C%7 .WWZ5G)X_P#"3A"/$%CM>)Y58RX4HC%6.3QP0?KVK%NYK76?B5X>
MUG2+R":TL;&Z.H74,@:,1N%\M&8<9W9;'^R36)X5-I)\!=6\KR6F2UU/S-N-
MREFE(S]5V_AB@#O+/QIX;O\ 58=,M=9M9;V:,21PAN7!&[CWQSCK[58OO$NC
MZ;+)'>7R1>45$SE6*0ENGF,!M3.1]XCK7G4D=AKOA/X>V>D/!+J-M<V5QB C
M?;HB S,P'W1Q@YZD@=:L:)?6NG:-XRT+Q%(D>H27MW+Y,OWKN*4?(T8ZOD?*
M ,D$ 4 =WJ7BG0M'G$&H:K:V\IB:8(S_ #; ,EL#M_/M4,GC+P_';+<G4XV@
M,*7!D16=8XG^Z[D [%/."V.A]*\_TVW;2O$/PQT_6)8_MUKIMTDJR,"8V:.,
M(I]#P5'K@XIWB[5+-KGQUI"*NG7*Z6 L<,&9M1'D-ANA_=KG;\HR,$D@<4 =
MQJGC+3M+\0Z5H[L[RWZO('5&9515SG(!R22O [')[9L:7>6ESXBUE;?73>O$
M(1+9 J4LSANA SEL$D$GIVKA1JEI%K'PSU*21A9_V=<P>:4;!D,,0"CCDDJ0
M/7'%-O%GU+Q%\4+'29D-_<:?;1P*CC<["%PP'OR![$B@#T&W\2Z/=7D-I#?1
MF6X!,&056?'7RV(VOC_9)JK=>./#%E]I\_6K0?9G\N;:V[8V,X.,]._IWQ7$
MZA=VOBGP7X3L-'D0:M!>6;"W7B6S,6!*77J@4!@<XZ@=Q3[>ZL/[7^*3M/;_
M #QQC)8?,!:A3]1NR/KQ0!V/B,:O=VVEW'A[5/)/VF-V5;<3)<Q'J"W\"[<G
M</H.2*T-1U_3-*:07EUY?E1^;*1&S").<,Y4$*#@X)QG!]*S?A]*DOP[\.E'
M#E-.@1L'.&$:@@^X/%<GXRD-EK6LZEHNMP6^IPVR+>Z1? -#J,80E0H^\&(8
MK\O4X'&<D ]0!R,CH:*@L9I+C3[:>:!H)9(E=X6ZQD@$J?ITJ>@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***K7M_;:= );J0HK.$4*I9G8] J@$D^P% %@ #H *6
MN6U[QUINCZ!/J<2W%P8[A;3RQ;2 K*Q4 ."H*@;@>>O0<G%:\^O:?;QP-))-
MON S10K;R-*P7J?+"[\#(R<=QZB@#2ZC!HZ5FP>(-)N='.K17\+6(R&FS@*0
M<%2#R&SQMZYXQ61K7B*UOO#GB!-*U":WU&PLY)64Q&*:(["RG9(N<''7'T-
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M?8$UL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=V,<GFV5@+9(Q VW;EG'+X!;&>F>^!C?H \VT?4M(L?'GQ CU.:",22VV4E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT)6XC,87RU('++M V]>> :YK3]+N-!TKX=V6H1/&\&IS7,D3*3]FC<2E _\
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M-(N(_-@U8>6F-BD==IVY7^[SCK7H>L::-;\.W^F3'ROMMK) Q'.S>I7\<9H
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M6+-E7YP1@5;O##XE\?>%=5TB3S;;38KJ6[N%4A561 JQDG^(GG;U&TYQQ3O
M$Z-K'B]<E3-K+S1;E*^9'Y<:[ESU&5/(H UO$GBV#P]J6CV+VUS+)J-QY8:.
MW>144*6)^4'+<<*,GOT%<_;^)X]'\?\ BD:GJ-[)8Q6MI-!;^6\ICW"0OMC1
M20.!DXXXR:N>/6:VUGPAJ#Q3/:VNJ$S/%$TA0-$Z@D*"<9('3O5;2KJ%?B7X
MMN9=T<,EA:!7D4@$JLF]0>Y&1D#I0!UH\0:8VF6FH17/G6UX ;8PHSM-D;AM
M4 L> 2>.,'.,4_2-<T_7;>6;3YS((96AF1D9'BD'565@"I]B*\?TEY](\)>
M]7N[34)--L(;FUU%+7S%FMC(1M<JA#8&WGV/N*],\(KI$R7NHZ-8W$-O>2*[
M7-P)%>Z8#EL2?-@< $]>>P!(!0U+7+W5O'Z>$M-N6M(;:T^V:A=1@&3!("1)
MD$*3G).,XZ8/-:DFCZC::GILVGZI=M9I,?MEK<2"42(48 AF^8$,5.,XXZ5S
M6I6\WA/XI2^*);>>;1M4LEM;J:&,R&UE0C:S*H)V$#&<<'KBNOM=>L]3D1-+
M?[8K??FC!\N,>I;&,_[(Y^@R: (;KQ=HEF[^?=LD4<WV>2X\ES DF<;6E V
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MPXC42,&< ;F P"?IVIU%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEMM6/F+X?WZ99S$Y\\9#>8??R_*7Z[_6NMUS3[S4]-:VL=5GTR<NK"Y@178
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M\U30/&%D^E:C%>17ZF"TM+-UBEB5X\3LZC$K, >"3C PO&:]GHH X2[N//\
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M#EE#D!>X'7O5_0[BS\1M;^5X1O-,U:")Q)<WMH8Q9N4*GRW/WB3@?+VY..E
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MR7$@T]WF@MW=F$L:,I)/0;@"0">,TV2VNULOB7;Q:1K&-0MU-F98))&FS;A
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M2U+VLP#?+-YI^4#&">^1P">*]=H **** "BBB@ HHHH **** "BBB@ HHHH
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M6XR (MHSEB2,8R#GK0!T5%>>V&HO+\9[E)4OK2--!\R2"[ERBMYX^=0&9 ,
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MM'TV]MK/;>7<]U:M=6ZVELTOG( #\A'#'!!XS[XH Z6BJ(U(/HBZG':W+JT
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M%G VCGGICFN9MM/U&+X6>#+!]+U 7EEJEM+<0_9)"T:)*69B,= #^/:O8**
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MD<\XXKLZ* .-^%D%S9?#[3;&]M+FUNK?S!)%<0M&1F1R.HYX(/%4]9TR_P!
M^(\?C"RL9[^QN[/[%J$-LN^6+# I*J]6' ! Y[X-=]10!DVNMC4706-I>>7G
M,LMS:RP!%] '52Q/3@8'?T/G$UAJ$OPY\>V2Z7J'VJ_U2[EM8C:2!I4D92C
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MAU4D[=PY!(Z'!&1GH>>M3T >5S+?7/A/X?P?V/JD<NFW]F;I'M'W1K%$5=B
M"0 3CGD]1QS4FMZ'J.N:_P".K6VMKF+^T=*MX+6>2%TCDD0.2NXC'<#\:]0H
MH X+PO=P:O>61D\!R:5J-KDW%S=6"1I"VW!\E^K$G &.V2>P.E\28+B[^'NL
MV=I;3W-S<VYBBB@B9V9C[ <?4UU=% 'F_B>*ZBU#PWXC70;G5]/MK:2UO;(6
MVZ:,/L(D6-ADD%,'VJMKNGW,^F:7KVA^%9+.&QU>*^ET]+98KFYC565G*#^,
M;N%/.![XKU&B@#S*\AO/$OCF\FM=-U*WL[[PS+8)=7-JT*I*TA(R&P1CZ9_
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MZ@%UKD%K/Y%P\7F1,&)4[2/04SQW;7O@[0W\3^'[^]5M/9'N;&XNI)H;F(L
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MY3>(R=V=V >V#C@UTE_?VNEZ?<7][,L-K;QF261NBJ!DFO-38:@OA/X=6O\
M9M]Y^F7=J]X@MVS"L<3(Q/'."1TSGM76_$#0;OQ-X%U72;%PMU/&K1;C@,R.
MKA2>V=N/QH FC\66HU2QL+VRO;"2_4FT:Y1=LQ R5!5CM;'.UL'\>*JZ?X[L
M=4U)[*STS5Y6BOFL9Y!:?)"ZJ&W.<\*<XSZCD#C.9J45WXRF\+'^S;RQDT_4
M(]0O3<0L@B,:-^[4GA]S$#*Y& 3GIFUX"@N;6Z\4"ZL[FW%UK4UW TT3*)(F
M5 &&?=3P>: .FU'4X--CA,JO)+/((H(8P"\KD$[5R0.@)))  !)-<_/\0M*M
M+'69[NUOX)]&V_;+0Q*TJ*PRK#:Q4J1WW?7%5_B'IE_<)HVK6&F+JITN[,T^
MGL 3/$R,C;0>"PW9 K(UNW?6/ 'B'^RO"$^F/>6OD0PM:)'<SN?[RIG"CL6/
MKTXR =1:^,[*ZURWTHV6H02W<#SVDL\(1+D* 6"'.<@$=0/6L6Q\8+K7AKQ-
M<ZUI%]!IUI-=6TJQE681QC:ZY1]V[[Q)' [-Q2WT-U/XR\#W<=C>&WLX+E;F
M0V[ 0EXE50W'<@CVZGBLZRLM4M/"GCO29=(O?.NKK49;9UC#+.)L^6$P<G.>
M>,#'.* -2X\5G2V\&6&D:3=S6.J1 QDNA<1+ 65/G?[_ -TDDXP#R2:WM,\3
M6^IZ[J6CK9W<%WIZHTPG5 "'SM*D,<@X//3UP:Y":RU*"T^'5\FE7L_]EKY5
MW!''^\C)MC'RK$<!NIZ=ZN^-=*U$:]HNK:,ZP7]YNTFZ!;DPR*S;QZM&5+C\
M: .OTC5(]9TV.^A@FABD)V"8+E@#C<,$C!QQZCFN9NOB9I5M'J4D>F:S<KID
M[0WA@L\^2  2[9(PN#]>"<8&:Z^VMH;.TAM;=!'#"BQQH.BJ!@#\A7G'A_4#
M!?>/[9;"[NI9=4D$210EUE8PH-A8<+VY8@8/7K@ ZZ#Q=IMSJFE6, FD&JVS
M75G.JCRY$4 GG.0<,.H[U1NOB#I5GH>L:M/;7ZPZ3=-:748B#.' 4\88C'SC
MG(KFH/#^H^$9O 4C65UJ$6EV=Q:79LT\QDDD5"#CJ5W*1GMQ6=J.EZW<>"?'
M]D="OEN=3U1I[2,(&\Q6$0['ML.3T]": /0(_&-H_F!]/U*%S<+;6R36^PWC
M,NX&+)Y7 )).,8.<5R_CWQ!;:W\.O%MO$EY9WVEH%GAD;8Z,<%3E&*LI!]3[
MBM+QG#JC2^&_$VD:?/>MI5P\D]B%VRO%)&48JK8^9<\"J_BZXU3Q/\.==CM]
M"O[=KJ%8K2VFBQ<2-GYBRJ2%7IC)!X/J* -W3?%MG<:U;Z(]I?6\\UL9K:6X
MA"QW"K@-L.<Y&1P0..:BM_'>F7+Z>Z6]X++4;I[.TO2B^5)*I88QNW#)1L$J
M.GTK-U&*ZN?'OA"^AL;LVUK:W23R&!PL32(@0-QQRI^G>N7D@\0ZC9>'+S4/
M#VK2:O9:Y'/?<*(T0>8,0KNQLY7Y@.W))H ]%?Q1;BXE2&SO+B&&\2REN(0A
M2.5F5<$%@V 77) XJG;:IHR>,-?,-K??VG:VL)NV*N5=/FV!%SR?O<@#ZUS.
MJ:/>'79M8\/6VJ:7KYOU2:)48V=_$' +R9^0?)DYR&R#@$D&M>UBN;?XC^)K
M^2QO/LD^GV\4,H@8K(Z;]P&!S]X?7M0!/9_$?2;V+1[A++4TLM5E6""[D@ B
M$K9"HQW9R<8R 1GC.<XTM0\6V5C<:G"EM=7;:7$LUZ;=5/DJP+ '<P).T%L+
MDX^H!X*WTO4XOAEX+TY]+OOMEAJ=K+=0BW8M&D<A9F/&",$=.O;O5C69Y;3Q
M?XF%II.N/;:E!#!=2Z=:)<AV\O!898&.0*P7!!Z D<B@#T71]6MM<TJ#4K-9
M1;3J'B,L90LI&0P![$5FWWC"RLX]0G2TO;NTTYREY<6R*R0D %A@L&;:""=H
M./J"*L>%)M/E\-646EP7%O:6T8ME@N8VCEBV?+M=3R",?CUKDM%MM1\-V7B;
M0[O3+R[:ZN[FYL)H8BZ7*S<A68<(P.0=Y [T ;^H^.]*L+O3K:.&]O7U*W>X
MLS9P;Q,JJ&PIR,G!'Y\XK=L;Y;W3(+YH9K5)8A*8KE/+DC!&<..Q'>O.].\/
M7V@:W\/[-K>YN(])L;F"\N8HF:-'D1-O..1E6'L,9Q7H.LV#:IH>H:>LGE-=
M6TD D_NEE*Y_#- &,?'&FI#97DMO>1:7?2K%;ZBZ+Y+ECA"?FW*K=F90.G/(
MJ"R\276J>-];\/2Z7<I:6<, \Y9$',GF$N2'W $*H&,G@YQ7,RZ7JFN?"RT\
M$W.F75MJD:V]G-(T1\E(XG3,JR?=8%4R #G)QBMZRAO=+^)NOW<NFW<EEJ%I
M:F*YB3<B^4) P;G.?F&  2: ,'X?>+[;1_ >@07]OJ,D=Q<R6QOO+W1)(\\@
M4.Q.3G@9 (&>2*[;5O%%OI8OF6RO+U;!!)>&U5#Y V[N=S+D[?FPN3C''(SY
MW#I6JI\'M'TEM*OAJ$&I)+);^0VY4%T9"?3&T@]?;K6G/;SZ)XSUF2^\'SZ]
MIVKR)<VMS;VL<KQ/Y:HT<@<C:/E!!/'/UP =%=?$+2()[&&VM]0OWO[-KRT%
MI;E_.0 '"Y(RV"..W?%6+#QE;ZA>W=E'I6J17EM:1WC6\T2([(X^4 %^O!!'
M&""#S6,]E=P_$#PO.-)>"VMK"XAF^RP'R;=Y-A5 0,$?*1D<=^*L^+=%U63Q
M-HVKZ&-MQ(LFFWL@."EO(-PD^J,N1ZEL=Z -.Q\86>I:!I^L6EI>26]_,(8$
M 3>221DC=P!@YYR,'(XJE::]X>LM6\6WRQW=O/8^2^IR3!MK8C.S8I/]T=@,
MY'6J/A/PO>:'XEU&R,070+.=KK3!G.'F7#J/0)B0#_KK5:.UN%\0>/I[C0[J
M\L[];810O"0+M$B"2*I..>N,X]1Q0!UJ>(H4:[%_:76GI:VPNI)+G9L\OG)#
M(S#C:<CZ>M01>+;4Z[9Z1=V5[8W%]&\EF;E$"SA1E@-K$A@"#A@#7##PAJL^
MF>(- T:[U$Z!=:9BTBU175K>YW<1H7 ;R]HYZ@9')YK=\*W#:C=6GG> SH]]
M; FZN9[6)$1MI!$+ Y;)[X  SSTR =3K.MVNAP6TERLCO=7"6MO%$ 6EE;.%
M&2 .A.20.*I6WC#3);/5KBY\ZR_LF3R[R.X4;HS@,,;2P;((Q@G.<=:K>-I]
M7M[333IMK<W%NUZ@O_L:@SK!@Y*=QS@$CD G&.HX:X\,ZW?V?CBRL=(NK.2[
MN+6]L6N64K*8A&VPMN.6)0YY.#U- 'HEKXJM9=<_L>ZM+NPO&M3=QBY5-KQ
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M[TR5[)UM[S[%>WK6%O>E%\IY@67&-V\ E& )7''TK;TB\M;_ $BUN;%76V9
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MJV2VXEN 1SC)Q5[PGXL@M],\)Z-<:??0B]T^*.VO)$412R)"&91\VX< X)4
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M@OKYIE 6,Q _*C _/N8@ KD8R3CI5%-,U3^POB);_P!EW8EU6:X:R4H/WP>
M1J>O'S#OCBO3** /,;_P^FIZ9I$5[I>K66H6.E0K::I8 B:&< J\3;3R/E4\
M_+R>145UIOB+3=6T7Q!J^@+X@:728['4X($C>6&96+B15; .=Y!Q@=Z]3HH
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MM&G:C;BVUA2?O+$P>,X[EANC/^RU %BYU?3KCQ/X334-#NH]1NTGDL992O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex31-restatedcharterasam010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex31-restatedcharterasam010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX69/[>L$^0*?DOH.K0OZY['L?S'-^+5)^#7A:TE@=IR-.9[?RRSA5"E\J!G
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M6TVVU"T<M;W$8DC+*5.#Z@\@^U %JBBB@ HHHH **** "BBB@ HHHH ****
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M@O@#@9.,GJ>!DUR/P_\ $*?\(I-=7M[=79FU>YM[4R[Y)9!O;8H!Y^Z"<<8
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M[6-I6: 8_>84?=Y'USQFLO5O'NGVEIH%U8I->V^LW*10S10.RA#DDX SNPI
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M0$H(\CY\@'E<C STYH Z.BN5U3QWIUCX8UC6+>.XN'TLM'/;>2RND@&0&!'
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MJ.F!TK;\07JZC8^!9[>VO2D.K02R;K612D:Q.K.P(RJ@L!DX_+FO2:* //\
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MNH^N?2ND\0WLS>-+G3YK&\B@DTP"WN+*U9GO'W-F)IE&45>#C*_>))Q7?44
M>.:=]HM_!OPXNI=/U!8]-O%2Z'V20O'^Z=<[ NXC<0,XK?N8+C4?B3K:6Z7%
MN;KPZMK%.\3!5FWR'&[&-P# X!KT2B@#R*6"XUOX.VW@T65Q!KT:6]DUN\+
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M]8-O<:?=16TDJR!8]IC^4'# ] ?7-7_A,LL7PXTRWGMKBWFB,H:.>%HSS*[
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M,",@^N>*T=>TZ+Q;X,UN3PQX;N+.[EMT7S;RV,$MQMD5S$ W)&%(YXR0!GG
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M%9L6CBV.IDD"@[220<'G!&><X .QTSQ;I6J?VD%>:U?3,&[2\A:!HE*E@Y#
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M%G+.'0#$8)4-C/([<DUTMAXOTK4=#_M6)ITC$YM6@DB(F6<-M\HI_>SQC^E
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MFMG"21SJ <E0PP02",'J#7&:QJ@T7XNPRO\ VA<12:%*PM+<23%Y!,@&R,'
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M),6DGF8LW'S')/#'DX &3@#@ ZNBL&U\7Z5<1:D9#-;3:9*L5W;S)^\C=L;
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MI!X>NY[KP]>+)=Z?<0[3<H!(CB,'[Y <$'H>V3Q7LM% 'ENN:5_PEO@G6_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#SB87Q^.]U]@>W63_ (1Z/<9U9ACSSTP1S70W(U-?".NC6&@:[,-SM, (
M4Q[#MP"<]#S[YHE\'*_BN;Q'%K6HP7TML+0B-82@B#;@H#1GOWSFIV\,--#J
M*W&LZC/+?0BW:5Q$#%'A@0@"!1G<2202<#T% %+X9@'X9>'01D?88_Y5YC8
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MV<[O>@#?MX8;>W2&!%2*,;45>B@=A4E9C:,!J>GW4%[=V\%E$\8LHG AE#
M%QCDKCCFM.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[_9VDWFGVQN)E&4ANW8J&QTY7:6]01GK0!WUWJD<VD7MQI-[9S3PPLZL&$J
M@$C<%8>A[BJGA/6Y-4\#Z5K6IRPQR7%HDTS\(BDCGKT%<UI-_J<>I:_I?B'3
M;2+6%TI9#?V1/DW4"F15)4\JP);@^^.!7/6.I)I_ACX8F]O#9Z5) RRW!"E$
MG\H>5NW @?QX)Z'GM0!ZV-3L#;)<B^MC!)PDOFKM;Z'.#4AN[96B4W$0:7F,
M%Q\_T]:X%?!.@ZUH_BC3++4WO1J,BSN^8VBM[G;PR;  &X5F'7IZU9\%ZG<>
M+I[;4=1M3#<:-"UG.C)C%Z3ME(^BJN,=I2.U '=T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!K3;O\\2 Q[?7=TQ6)XEU\P^#-9U70K^REGL;628.")E!52V"%8<\?\ UC0
M[[/XR_Z"F@_^"Z;_ ./T?9_&7_04T'_P73?_ !^KECJT*>&[#4=3NX(!+;1/
M)+*XC7<R@GD\#FIWUG2T@@G?4K-89QF&0SJ%D'^R<\_A0!F?9_&7_04T'_P7
M3?\ Q^C[/XR_Z"F@_P#@NF_^/UM->6JW4=JUS"+B1=R1%QO8>H'4BIZ .>^S
M^,O^@IH/_@NF_P#C]'V?QE_T%-!_\%TW_P ?KH:* .>^S^,O^@IH/_@NF_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M--?4EU)M/M&OE&%N3"IE ] V,_K4RVELMX]XMO$+ET$;3!!O91R 6ZD#)XH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% "'@' R?2O/-8U;Q?HEQX8M;C4]/>?5KM;:?;8G$)*%CM_><
MX(Q7HE>?_$22-/$_@,.ZJ3K(P"<?P$?S(_.@#9O&UJSTJ_34/$5A8,98S:ZB
MUNJJJY&Y&1W(+'##.?XAW%6I_%VCVWBN+P[+>P+?/;M.0T@7;\R*J<_Q-O)
MZX7W%8?Q>6'_ (5Q?/*$RDUL59L<'SX^GX4V]N[>R^-=C)=3QPK-H$D41=@-
M[FXC(5?4^PYH T/".L:CJ&J>)[;4KF.5=/U'R(2D80*GEJV/_'CR2:W;+6=+
MU*:2&PU*TNI8@#(D$RN5!Z$@'@5Y9?R7/]A?$\V >65-41I$BP6,02+S!C_<
M#C\ZZ31)_#&O^)M+UK3M?FU748[9T18WB'E0L,D2JB*0,XP&YST[T =K9WUI
MJ-N+BQNH;F L5$D,@=<@X(R..",5,X9D958HQ'# 9Q6=H$VBSZ4KZ ;0V!D?
M;]D4"/=N.[@<9SFM.@#RVT\6^+)?"7B'Q MUIDIT:\N8C;/:,HFCA/)W!_E8
MC..",UVFG>,-'O-#L=3N;ZUL?M=FMYY-Q.JLB$ DG)' R!GI7#?#_0-,\2Z'
MXC@OI)Y[5]?N_,MX[EUCD&\$;@I&1_.M35M-TMOBYX>M)+.U,7]D7*"%HUVD
M H%&WN N0!Z"@#LKK7]&LHH9;K5K&".=0\3R7"*'4]""3R#D<^]2WFJZ=IX0
MWM_;6P<%D,TJIN ZD9/3D?G7FC7FCV?BKQ7H'B'6/[&M[A8A;1OY,4,UGY*H
M$0NA^Z0XP".2<#K5BXTZYL'LIO".J(MW8Z.BMINKC*W5GN?82>"K#!Y]U!Q0
M!V]S=B;6-'-MKMK##*)'-GA&:]4IE2ASD!<%LJ#D5G^-_$D6A^&M5DM=5LK7
M5+>T>:&.9E9B0I*C:2.N,#^1KEEO+6_\3?"V_BLA8_:+:Z*0-]Z-?LPPN>I
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MGDD8*B LS'H .IKR5+W1;J\\8^'O%FNR:=)-?RLUM*8D%Q;L%\ID+(68[0
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MB]TLHYQQRF<'Z4 >B7^KZ;I04ZAJ%K:!@2IGF5,@=3R:==ZG86%JMS=WMO!
MWW9)90JMQG@D\\5P*:WI6G_$/Q=IWBBYM[6.]@MS:/>2"..:V\HJZ*QP.'+Y
M'J352ZU'3O#_ (OT!)+VXT3P_)H[6^G3N%V(XD!*LTJMMW($/.#P ?2@#T4Z
MUI0M[:X_M*S\FZ(6WD\]=LQ/0(<_-^%2V.H66IVJW5A=P7=NQ($L$@=20<$9
M''6O)]8TOP[:Z/X:33)3=Z?/XLA<3SLK))O#;_+( 'EELC &,Y[5ZU:V=K8P
M^3:6T-O%N+;(4"+N)R3@=R>: )Z*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *K3Z?974GF7%G;ROC&Z2(,<?4BK-% $,UI;7,:QSV\,J+]U70,
M!] :/LEMNA;[/%F 8B.P?N^,?+Z<>E344 006-I;2,\%K!$[<,T<84GZXI+6
MPL['S/LEI!;^8VY_)C";CZG Y-6** (X+>&UB$5O#'%&"2$C4*,DY)P/?FG.
MB2(R2*K(PP589!%.HH KV]C:6C%K:U@A8C!,<84G\J'L;22X%P]K TX((D:,
M%ACISUJQ10!7N;"SO'B>ZM()WB.Z-I8PQ0^HR.*;=:;87SJ]W96UPR_=,L2N
M1],BK5% $$EC:33+-+:P/*N-KM&"PQTP:CFTO3[BX-Q/8VTLS(8S(\*LQ4\%
M<D9Q[5;HH KW-A9WEN+>ZM()X%P1'+&&48Z<$8HEL+*<()K2"01C"!XP=H]!
MD<58HH KQV-I%.9X[6!)FSF18P&.>O-206\-M$(K>&.*,9(2-0H&?85)10!7
M>PLY9999+2!Y)4\N1VC!+K_=)QR/:D.G6)E$IL[<R  !S$N0 ,#G'I5FB@"M
M'I]E%')''9VZ1RC$BK$H#CT(QS1;:=8V6W[+96\&U=B^5$JX7.<# Z9YJS10
M 52M]'TRUNFNK?3K2&X;.Z6.!5<_4@9J[10!6;3[)YFF>SMVE;@N8E+'C'7'
MI3/[*T[R_+_L^UV9SM\E<9]<8JY10!5N--L+N*.*YLK::.(@QI)$K!,=, CB
MGSV-I=%3<6L$Q487S(PV/IFIZ* &"*,1>4(U\O;MV8XQZ8]*J_V-I?\ T#;/
M_OPO^%7:* *XL+-?*Q:0#R?]5B,?)WX]/PI4LK2.X:XCM85F;.9%C 8YZ\]:
MGHH KV]A96DLLMM:00R3',KQQA2Y]20.?QH6PLTO'O$M(%NG&UIQ& [#T+=3
M5BB@"M+I]E-<&XEL[>28QF(R/$I8H>JYQG'M3VM+9TB1[>)EB(:-2@(0CH1Z
M8J:B@"".RM(IVGCM84F;.Z18P&.>N3UJ41H)&D"*'8 ,P') S@$_B?SIU% %
M>:PL[BYBN9[2"6>'_5RO&&9/H2,C\*L444 5+S2M.U%D:]L+6Y9/N&>%7*_3
M(XJ=X(I(3"\2-$1C85!7'IBI** *@TO3Q$T0L;81L0600K@D="1B@Z7I[1K&
M;&U,:DE5,*X!/7 Q[5;HH K3Z?971A-Q9V\QA.8O,B5O+/JN1Q^%.NK.UOH#
M!>6T-Q"3DQS('7/T-3T4 5I=/LIDC26SMY%C&U T2D*/0<<58      '0"EH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex31-restatedcharterasam011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex31-restatedcharterasam011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW&$EF,)<#D$[5W#T[FE\&^'KGPKX4M-$DO(KHVB%(YEB,>023R-Q]?6N@HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C_;.EYQ_:5GG_KNO
M^-6A/"8//$J>5C=YFX;<>N:\'MM1T?1?VA/&%YK(1-/2QS(S6[2JI(@Y(4''
M7J>Y]ZWO@M97AU'Q+K%I&UOX7U"Z9]-@) !&]OF5?X0!@?D.U 'J']M:5_T$
M[/\ [_K_ (U9CNK>: SQ3Q/",DR*X*\=>>E?._@/5;+1?$GCYI]--V9-3B@A
M M3)'&6GE7+'&$7D=<9Q@5Z+X]\(WMK\-[W3/"=L.+P79LD7B1-^]XPO<9YV
M]P,4 =[::II]^,V=];7(#;<PS*_.,XX/7 /Y4TZSI:L5;4K,$<$&=>/UKR[P
M?X^\-^-O$NDQZAIYT;Q/ISN(XG3 ES&R-&K<$?>SM8<8XSS61\=M!TW0?AMI
M5M86L46W4EW2! 'D)CD)+'N2>: /;;>_L[MREM=P3,!DB.0,0/P-3EU5E4L
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M_M"2>&]-)CT75H_--FO^KAD,9;<B]%^93T[-["@#VRJ4FL:7#>"SEU*S2Z/
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MB >8C;&PW'."G'U/K0!JIJVFR!BFH6K!!EB)E.!ZGFF_VUI7_03L_P#O^O\
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M8D@8(Z-W-16W@+6_"OQ*EU_PM]E_L;4!G4-/EE*88GDI@$<'YA]2. :]0HH
M\^^+GA+6/&WAJVTG28[<.ETMP\D\NQ0 KK@8!)/S"NPLEO+?0((WM5^UQ0*A
MB$@P6  ^]Z?A^%:-% 'F?PF\':]X"T'4;#4;>VFDFG\^(V\^0?E"[3D#'3.>
M:;\*/ FK>$-*U'3M=AM9$N;E;E'@F+ %<8!! .00#7IU% 'F_P 7_!FM>.='
ML-.TA+93!<>>\EQ+M'W2N  ">]6/'O@&X\9V6E:C:31Z=K^F.);=W.Y,@@[6
M([94$'''IS7H%% '.6][XKN[58)=(L["Z(Q)<FZ\V-3W9$ !;V!V_6FWND76
MK^*8WU*QBDTFV@*V["<[_-8_,Y4 =@%'/=O6NEHH \I?P!K6C?%J+Q1X:MK6
M/37B$5Y;RW!5I<\,5X/HC#)ZK6[\5?#&J^,?"!T;2HX/->9)&DGEV*H7/H"2
M:[FB@#(\/V]YIOA73[.YMU^UVEK' R)("K%5"Y!XX..]>>?#[P5XE\'QZTE]
MIFGWJW]TES&J7I78R,6&<IV.#GVKUJB@#(\.IK0LKB771 EY-<-((;>0O'%'
M@!5!(&>!D\=2:Y?7O UY'\0K+QQH#0M>HGE7MG,Q1;E-NW*L <,!CKP=HZ=^
M_HH \Z\3^#=2^(&O:0VL01V&A:<YF>W,HDFNG..#M^55P,=2>3^%?QIX,U[7
M?B-X<UZQ@M?L>D.C.LD^UY,/N.T $=/4UZ;10!%!#'%YCI&(VF;S)!ZM@#^0
M'Y5Q'Q8\*ZMXS\*QZ/I*0>9]H29I)Y=B@*&XX!)/(KO** .46RUJ+3?#4":?
M"TFGO&;G-R ,+"T9V'')RV><=*H?$?X>6_C:SMKJ$)#J]BZO!*>-Z@Y,;'T/
M;T/U-=U10!P'C_P!<^(=7TGQ)HES#;:[I3JT7G@^7,@;<$8CD<YY_P!HCW'0
M07GB:]2.*32K;36)'FS/="8*.^Q5 W'TW;<=<'H=^B@#S_6O ][;_$2U\<>'
MS"]UL\F^LIG*"X3;MW*V#A@,<'@[1R.<Q>(_!FI>/O$>D3:U!'8Z'IC&7[*9
M1)+<R''#;?E5> .I/)Z9X]%HH \T\4^#M>U;XJ:#XFM+>V-CI:!'5Y]LDGS,
M20,$=&[FHK;P%K?A7XE2Z_X6^R_V-J SJ&GRRE,,3R4P".#\P^I' ->H44 >
M:0>$->3XTS>,&M[;^SI;<6XC\_\ >CY%7=C&.HZ9Z5V'BWPS:>+_  S>:)>L
M4CN%&V11DQN#E6'T(Z=QD5MT4 <)HEGXQT#P9%X?2QL[J^M83;6M^+G;"5'"
M,ZD;@5&,@ YQUYJAI7PVD\,_"W5?#FG-'>:IJ<,BSW#ML0NZ%<]SM4?B>3WK
MTJB@#QR/X27M_P#"6U\-:BMO!K6FO)-8W<4NY=S.S8)P" <@'CL#SBNGAL?&
M-WX3T_1];L[*YG$B)J$T=V0)X%.3CY?O-@!AP",\\\=Y10!Y;\2/AE-KMMID
M_ABWAM=5L[@2K<2SD!5ZX[G.X*1]#7>/_:ESX89+BTA&IR6Y1XHY?W?F%<'#
M$?=SSTS6M10!Y[\(O".L>"/#5UI.KI;EWNVN$E@EWJ051<'(!S\IJI/X.U^3
MXU0>,EM[;^SHH/(,9N/WI_=LN[&,=3TSTKTVB@#SV7P1?:'\29O&/A]89X[Z
M(Q:A82/Y9;.#OC;!&<J"0<=^>>$U#P5J'B_QYIFOZ[%%::;I W6EB)/,DEES
MNW.1\H&0O )SM]Z]#HH Q=.AU%/$6J3W%I'':3B,0R+-N8[00=RXXZ\8)KG]
M(^'EOX?^)UWXFTP)%9WUE)'/;CC9,71MR^S!22.Q^O'=44 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45
MY)K_ (BOO$GQIL_ \5U/:Z1:)YU\()#&]PWE^8%+#!"\J,#KD^V&_%&_N?AQ
M-HGB+09)(8&N?LUY8^83#<+MW#Y2<!L*WS#GF@#UVBO$/BCJ*P_$+P/+%?3V
MNGZA(C7>VX:))(S(G+X('W2<GTKO/#5KHVIZRVN>'[V=[6V>6RD NY)89SA#
MN4,2,@Y&1UYZ\4 =G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN9X
MK:VDFGD6.)%RSL< 5\\_"#3M#M]$N+G7HTLM2L]32ZMI9H2)-@"Y XR0?F&/
M4YKZ+HH \=^*FM#Q/\(KBXM;>8?:;T+:PM&PEDC23:7V=0#M)Z="*J^)YKCQ
M'\(-!\)Z%:3WVIW-O:1S(D3!;8(JEC(Q&%^90,$U[910!X#\7]";2/AQX3\.
MVVZ[N;%U$@A4L>(R"V!R 6/%>U:K?6K>&[RZ6XC,#6[[9 P(/RGIZFM2B@#R
M3]GM6MO UY9W"-#<C4))/)D4J^TI& V#SC((S73F5O%/B6_%C?VBP6$36?E7
M%L91+O"F1P-ZY7[J9YY#>M=I10!XC\(KB?PAXPUWP7=2-+I[3F6QN@I\IVX!
M /(RR[>,]5(ZTGB;1O!_COPJVM7L9T?Q1]GW[0ACEFE XQ&>958@8*@G!'/:
MO;Z* .>\"0ZM;^!M'AUTN=22W F\PY8>@8_W@N ??-<IXET:S\<^'_&>D6TL
M<MX+Q;BUP>KI;P@%?4$JR$CU->F44 >#>)],U"U_9\A@U(R3:U>BV=HMI,FQ
M=H1=O7Y449]RQ[U<\;2+<_L[:390'S;O[-91^0@S(&0+N&T<Y&.?2O;:* /)
M/#6H^&_"/A>TU>RB7^UKC2;:WFLK>!M\LZ+QN '!W,02:S?B#*H^./A"[Y:W
MM$07,R*62([V^\1T_&O;:* /'==T:[^('Q>T._LK:9="T0))+?21E$ED5]^V
M/(&[D*,CCK[9K+(G_#3;7V?]#^R>5]HQ^[W^5C;NZ9SQ]>*]KHH \5TJPG^&
MWQAUK4-3AE&@:X'>._5"T<4C/OVR$?=Y+#GV/KCU.S\2:=J5RL>G2_;(0I:2
MZAYAC '=^A/L,GN<"M>B@#Q/X<RI#\:/&MU*?+M[EI#!,XVI*!)GY6/!XYX[
M5VL&E:+XX\(ZKHUVRS0O?71ROWXB9G9)%S[$$'H1ZC-=O10!Y;\)](U?PFWB
M#2O$%P2E@88K:>0X1K?]XRE2>V6/TZ=JX;X7:;HC/K-QKT:6EU!JL%[93SPE
M7PCECL.,D'&"/>OHNB@#@-5^*5II6@C7&TG4;C3Y;YK:)HH2K"-5^:1@V,#(
M;&<9 [5W9GB%OY[2*L6W=O8X 'J<U7U/38=6LVL[EG^S.<31J0!*O=&_V3W
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MLY"8G^:.:$E2[1N/O#* X^O)YH ] HKSZT\3>*-1M-$UG3M/DN+6^DC:XM#
MJK%;N,[UD+9+*,9['G %0KK7C;56\3QZ;=Z3%+H]XT40:T=OM $:L$/S_+G/
M+9.<]!CD ]'R!CGK17ED?B'4O$^O_#_4+6\%I;ZE:W<[6WE;U25(P">H+?>8
M#T'UK4O?$_B'4;?5;GP[;-))87DEM!;FW#)<&-MKAW+ KDAL8QCC.<T =_17
M#MK?B2\\<'0H9;.QBDT9+\&2W,DD#M)L*GY\.1@^@YZ'%83^,O%<?@"X\2O<
M:<'TJZ>WN8%MF(NPDWEL=V[]WD=  >1UYP #T.+7M/F\03:&DK_VA# +AXS$
MR@1EMH(8C!Y]">AK2KSK4HM4N/C#<1Z1=VUI<-X=CS//"90@^T/T0$9/U/'H
M:9IGCW59[.'3+VWB&NC5IM*F>WC+(?*C,C2HI(ZK@ $]3GH,4 >D45YUJ?B/
MQ?I'AWQ1=2VT:KIT2SV%[<VX'GH1\R,BOPRGHW0^E=7X?&N.DMSJ]W9S13I'
M);Q6\)0PY7YE8DG=SC!P._ Z  ;KGC#0?#<JQZMJ"V[, Q_=N^P$X!8J#M!/
M=L#@UM12QS1)+$ZO&ZAE=3D,#T(/I7-^.$OE\):K%I.CKJ$]U"Z2QK(J$J5V
MEN1\S!>@]A5OP=>Z?J'@W1[C2DD2P-I&L"2?>15&W:?<8Q^% &S)(D4;22.J
M(@+,S'  '4DU@:/XY\-:]J3:=INJQ3787>(BCH77U7< ''NN:W+FVAO+:2WN
M(Q)#(-KHW1AZ'U'M7+:QID>M^/-!D@09T0R7%Q.!]TNFU(L^ISN([!1G[PH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQDXRPR.HIU_XB\3>%;+7]1U*UEN-+M[=)+&:\:!91,S!/+<0G!7+ YP#@$4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G'C"9I/B]X%LKO\
MY!Y^TSHK?=:X6,[<^XXQ[FO1ZQ_$?AG3_$UE%!>^;'+;RB>VN8&VRP2#HR-V
M/UR* ,WXA>('\,^$;G4O[-AU"W!6*:WEF,>Y78)P0I_O55N]8U74O$>H:):_
M:[=K"TA>1[ P,WF2[SDF;JH"C&!R2<]JLZQX0O/$FD?V1K6M&:P+HTGD6JQ2
MR[&##<V2HY SM4?A1KW@MM2U^+7M*UJ[T;5%A^SRRVZ)(LT><@,C@@D'H?\
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MEA ;RVC!505;AA@D8-9LG@#S)/$+MKEZYUVW6"ZWQQGHA0L, 8.T\#H/0\8
M,XZMK^E:+I%]=:N][+KLEI;0PI;1)]F9D9W9"<!B0N!NX!YZ?+6[X?'B6+7[
M^+41-)H[Q*]K)=-#YZ2=&0^5P5[@GD=*74?!EKJW@^V\/WMW.?LJQ_9[R'$<
ML3Q_<<=@PQ^IZ5+I.E3Z!;RWFKZY=ZO<JGEK-+$J[4S]U$0<DG&>I) H R?A
M[<NMYXJT@G,&GZQ*+<=D23$FT>P9F_.NWKG/!^B3:397UU=ILOM4O9;ZX3.?
M++GY4SWVJ%!]\UT= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116#KOBJWT
M"_TZRGL;V>7493#;>0(R&<#.T[G&./7B@#>HK)MM;>;4HK&XTG4+-Y49TDG$
M90[<9&4=L'G.#Z'TIGBCQ'#X6T<ZG<6EQ<0K(D;>3M^4NP4$Y(XRPZ9H V:*
MI&^F&MKI_P!@N#";<S?;./*#;L>7USNQSTQBK4<T<V[RW5]C%&VG.&'4?6@!
M]%%% !16!XK\76'@[3X[_4X+HV;R")I8$5@A/3<,@XX/0&MV.1)8UDC8,C ,
MK*<@@]"* '45S_AKQAIWBR2__LN.X>"RG:W>X=5$;N/[OS9(P0<XZ&N@H **
MQO$WB.'POI:W]Q:7%Q$9HX3Y.WY"[!03DCC)'3-7/MTW]M_V?]@N/)^S^=]L
MX\K=NQY?7.['/3&* +M%%4K6^FN-2OK5["X@CMB@CN),;+C<N3LP<\=#G'-
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M** "BBL;5/$<.E:[H^E2VEP[ZI(\<4R[?+0JA8AN<YP/3\: -FBBB@ HHHH
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M6V"BTN3OD6<-RZN?X2O5>F>F*W*Y[1?"HTB&03:UJNHSM$8([B\F#/"A[)@
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M1E V@[L8'&:K:-JFHR:5<^$KS4+IO$5OJ8M7N?-(D>$DRB<>@,*L .FX8[T
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ME\2M0M=5O;&6QO9KF$6KA,R);HPW'&6' &.G7KQ@ ]?HKS]-<U'7M9TS25(
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M4]!^-;=>9>(--:VU7P#=/J-W=2R:FGG-+,625C"YWA>B=^% &#TX%6+&]O\
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M--_?FWUF9Y[O+1Y+. &P=G ( 'X<8J!?'@;PQX@UHZ1<#^Q;J>WEM_-3<WE
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M&52X!! R0<<@=*IW/@VTU*VBM-6U#4-2LH]N+6>1%C;'3>(U7>.!PV171T4
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M[>YMKB=YMK(F]9%+DE3P0<'!';-:EIX'T:U\+3>&G6:YTF7=F&X?<5+,7)#
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M_ERRRY!R64#KM P !@<8H WZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1.^(@N<;-JA2I&#G)R3FO2+'1+:QE$WFW5S,H(62ZN&E*COC)P/J!D]ZI?\
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M MI.K7ESH]U\UO-QEBG=&X/'KQD 8H ]%AUBV:+2_.=8I]14&&+.23Y9<CZ
M \_3UK0KRRZ>P\4>+/AQJ[V(C74+.ZD:)B?E'DJP7C' )-4?&-Q_Q(O$^KZ9
M--<W%EJD:C499-C6KJ\2F"$ 9*C)!SM!W'[U 'K#7]LNIIIQE7[6\+3B/OL4
MJI)].6'Z^E6:\_;3;-_CH\K0*9/[!6?.3DN+C /Y "L?1K.\\7>$;3Q&-<MM
M/U**Y:>:\$3M+"R.=T+?O -F/EV8QC'% 'K%%<]X[U6\T3P+K6I:>,W=O:LT
M1QG:>F['MG/X5RVN0KHEIX0UG099/M%Q?VMM,PD+?;89A\WF<_.?X@QR1@T
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M 6AHFFB34G%I'NU+'VPX_P!=A F#_P !&*LV=I!864%G:QB.W@C6*)!T55&
M/R%344 9FIZ!IVKW%K<W4+_:K4DP7$,K121YX(#*0<'N.AIDOAO29M%GTA[9
MOL-QN,R"9PTI;[Q=P=S$YYR>>]:U% %;3["WTRQBL[176WA4)&KR,^U0, 98
MDXP*HR>&-(EUF?5S:LM_<1B*6:.9TW  @' 8#< 2 V,@'K6O10!SP\#^'UTB
MSTI;.46-E,)[>$7<P$;@Y!!WYX/(]*9JW@+PUK>JIJ=_IHDO%0(TJS.AD4=
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M9&N)"8@1@@?-W'!SU'6JB^!?#"^(#KJZ/;C4F?S#*-V"_P#>VYV[L\YQG/-
M&_)_JG^AKY_T>"Z3X1>%9]4GFN/![2.NJVL"A'C7SFV.6 W&,-C<!@U[[<V\
M=U;O!+O\MQAMCE#CZJ016?IWAO2-)TA])LK)8].=61K9G9X]K9W !B< Y.0.
MN: .;\77Z1ZMX3TN*XM8=*U"252TL>^"0K&#$A 905.3@9P2!UJA<>%K_3=-
MUC3M+UNS>:XN[>Z@TV2%HK:/DEH?O,0DFP_*..O&#74R>"?#LV@?V%-IB2Z9
MD%;>21V6,CILR<IW^[CK3[?P=H%KHZZ3;Z>L5FLHG"I(X;S!T??G<6&!SG/
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M&,\]%%=!D8)R,#K7AVEVD,OPU^'&3(#_ ,) L.Y9&4[3+/D9!]ASUXKIM/\
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M.3@@XQP<$<$\BNRT7P_:Z7XM_M2WU.S1;RQVM8V%MY4,JJP(F(WL,C(7=W!
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MD\G';TJKXG\1-HDFE6D"P_:]4NQ:P/<,1'&=I8LV.3P,!1C)(&13[*]UR/Q
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M(8,_>V*69F]%4#)/T'4BENM3URXTG3FT:RM)+V\@$SR73LL$(VJ3G:"Q)+8
M^ISQR /;P9X;;0/[".BV9TS=N^S^7QN_O9Z[O?.:5?!WAY-"&AKI-NNF;MYM
M@"$9LYRW/S'(!YST'I53P?XEOM;?5-.U>QCL]6TJ=8;E87+Q.&7<CH3S@@]#
MS72NZQH7=@JCDLQP!0!0N]#T^]%K]HA9FM,^1()75X\C!PX.X<<=:LV5C;:=
M;"WM(5BB!+8'=B<DD]22222>233I[J&WLY+MW'DQH9"PYX SQ7-^'=7U_7$T
MG5PNG_V/J%L9I(0&6>WR,I\V2'SG!X7'4>E &M?>'-)U&^^VW-FIN3'Y32H[
M(SQ_W&*D;E]CD4M_X>TG5+>VM[RRCE@MF5H(N52,K]T@ @ CL>U._MFTDUB?
M1X)D;4(;<3NA/"!B0N[ZX/'I^%9?@CQ#<^(?#<5_J(MHKI[B>'9#D*?+D9!@
M$DGA: .C1!&BHI8A1@;F)/YGDUB/X-\.26][;MI%MY-[)YMS&%($K9S\P'7G
MG'3//6MJ26.+;YDB)N.!N.,GTI] &8?#^F-J%K?M;%KNU39!,TC%HU/4 D]#
MW]>]58O!?AN#7VUV+1;1-39BYN G.X]6QTW>^,U4M?$=[X@U?4+/04MDL].E
M-O<7]RK.KS#EHXT4KG;D98L.3@ ]:OZ?>:Q_;4]AJ5K;^2L"RPW=N6 E.XA@
M5.=A'R\9.<]>U &S6&/!V@+=RW,>G+"\S;YEAD>-)3W+(I"MGOD'-;(EC:5H
MUD0R*,LH/(^HH,T2G#2(#NV\L.OI]: *E_HNFZG8)97EE#+;1E6C3;CRROW2
MI'*D=B,8J(>']+_L^YL3:AK>ZS]H#NS--Q@[V)W-QQR3QQTK0DECA3?+(J+_
M 'F.!3BR@ E@,G R>M '%>.O#<MUX!/A_0]+,ZF6#9 )%")&DJ,1\[#C"D "
MNET[2+&R?[5#:O'</&$+32&215'(3<6; ![ XJXUS D:R--&(VX#%A@_C7/^
M,->O]!31I+)+=TO-5MK*;S020DC@$K@CG&>M %Z+POHL-X]U%81H[S?:&0%O
M+,O_ #T\O.W?_M8S[U/'H>FQ:S)JZ6P&H2)Y;S[VW,O]T\]/;I5Z21(HWDD8
M(B LS,<  =2:Y;0]?U;Q99G5-)2TL]*=V6UDNXGDDN54D;]H9=BD@XSDD<X%
M %N?P/X8NGO7GT2S=KY]]P2GWVR#N]CD DCKCFKK>'=&?4K;4#IMO]KMHO(A
ME"8,:#HHQV';T[4S0]0U"]6_74[*.TFM;HP@1R%U==B,'#$#@[O3CIVK4CEC
MF3?$ZNO]Y3D4 9MKX<T>SM+RUAL(A;WK,]S$V769F^\6!R"3W/?O2Z?X?TO2
M^;.V*,(_)5FD=V2/^XI8DJOL,"M 31$X$B$XW<,.GK0LL;.45U+  E0>0#0!
MC?\ "'Z =+FTPZ;&;":3S9;<LVQWSG)&<$YY^H!K:CC6*)8TSM48&YB3^9Y-
M(98UD6,R*)&&0I/)_"E>2.,9=U7@GYCC@=30!SK> /"CM,6T*T*S2B9XRIV%
MP<[@N< Y'.!SWJ[=>%]#O=3M]1N-,MWN[>,1Q2%<80'(7 X(!Y /3M6HTT2.
MB-*BL_W06 +?3UJG-K-C!K5MI#S+]MN(GF2($9"*0"Q]!D@#UY]* **>#?#L
M>F6NFQZ5 EG:R":&%,J%D'1^#RP_O'FJEW;ZQK.M_P!G7NDP0:':7$5PEVUR
M)'NBF&5=F,KAP"23T7'.<C:LCJ7VZ_%[)9M;B1?LBP!MZIM&?,SQG.<8[5;2
M6.1F5)%9D.& .2/K0 ^L&Z\%^&KVYO;BYT6TEEO1BX9D_P!9VR??W'-;;31+
M]Z1!\P7EAU/0?6GG.#CKVS0!P<GA>23XEV]Z-(EBT>WTC[%#-!.L7ER>;N^7
M:X<+MR/Z5+XW\-27F@Z3I6D:.)[:#4X+B:&-HT41(^Y\[F&2<GZDG-6_#/B/
M5-9\2:_IMU':1PZ1<+!OB5MTVY=P/)PN./6NK9E12SL%4#)). * ,ZVT33X(
MYRENX>Y0+,\DS/*RCHI<L6P,GC.!D^M.L-$TS3-+.F6=G%%8$%?LV,QX/4;3
MQ@Y/'3DU=66-XQ(LBLAZ,#D'\:7>N<;AD^] &;IOAS2=)='LK,1F-#'%EV<1
M(>JH&)V+P.%P.!5R2QM9KV"\D@1KFW5UBE(^9 V-P'UVC\JG# YP0<=<4V26
M.( R2*@)P"QQD^E &5KWA70O$Z0IK6F6]X(3F,R#YDSUP1S@^E.OO#&B:EI,
M.E7>F6TEC!M,,(3:(BO0IC!4CU&*9XJU]/#/AN[U5HQ*T6U8XR<;G9@B@GTR
MPS[4_2SKRZA>)J;Z?/981K6>V1HW).=RLA9AQQ@@]^E "Z;X:T71[R:\L--M
MX+F90LDRKEV &!DGG_'J:EO=$T_4+N.[N(6^TQ(8TFCE>-U4\E=RD'!XX]JR
M-8\5JGACQ#J6B26]Q/HXE#^;DH7CC#L/E.3UQVY!]*V-&OSJ&CV%S*T8N)[6
M.9T7L64$X'7&30!5N?"7A^\%B+C2+1Q8@K;#RP!&IZJ .Q]#Q49\&^'#I\UA
M_9%L+2>;SY85!"N^<Y('7GD>G:MHRQK*L1D02,,A2>3^%1WMW'86%Q>3;O*@
MB:5]HR<*,G'Y4 9^I>%]%U>6UFU"PCGFM!B&9F;S%'<;@<D'N">:GTG0]*T*
M*6+2["WM$FD,D@A0+N8G.3_GBN:MO$GB&\\*V_B6SM]+N+6XB686B,^^*-NY
MDR0[*.2NU>A&:Z8ZS8C74T;SE-\UNUR8P1\J!E7)],EN/7!H Y6'PY<7?Q+U
MC5+[3;A+&XLX8(+E+D(24W;@=CAMIR.".<<BNDNO#6C7EO96\UA$8;%E>UC7
M*K"R_=90" ".QZBM(31&4Q"1#(!DIN&0/I5.UUFQO=5O=-MYEDN+(1^>%((0
MODA?KA<D>XH -2T73M76 7UL)6MWWPR;BLD3=,JX(93]#7->//#DUY\/=0T/
M0=,\V:Z9"(U=%R?,5F9V=ADG!R>2378K+&TC1K(A=?O*#R/J*?0!F:;H]A9N
MMU#9O#<&,1CSI#(\:==@)9@JYQPIQP*C'A?15O9+M;",22RB>106$;RCI(8\
M[2^0#N(SGO6I'+'*"8Y$< X)4YP:Y-M?UO5[W5H_#PT__B5WB6KQ7@;_ $CY
M59R'4_)@/@?*W*^] &U=>&])O;J>YN+3=+<*$GQ(RK,H& KJ#AQCL01UJ'6_
M"'A[Q(T#:QI-M=M;\1,ZX*CTR.<>W2MNB@#*U+PSHNKV5M9WVFP2P6I!MU"[
M?)(X&PK@KQZ4[3/#NCZ-<7%QIVG6]M/<8\Z2-/F?  &3U[?UK3HH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "N5\=S6"V.E6]ZLLKW.J01VT"R!$FE!+*LI(/[OY22
M,$G P,UU54M4TC3M;L_L>J64%W;[@_ES(& 8="/0T >5O#']B^+%C-]E9(X!
M,L4"[8TD^R%B57)Y! R?49XZ5)<:'ID1^&US':(EQ=E(;F9"0\\;6I)5V'++
MP."<8XZ5Z+_PB?AX?:<:+8K]IB6&?; H\R-1@(<=5P!Q[4]O#6BNMFK:9;E;
M+_CU!3_4?[G]W\* /,M0+^&V^)\.A0BTAMX+*:.&U78L6^,B5T48VG:,Y&.F
M:Z33=$T2ZUW1M:L]6LF26VD@2WL;=42[A9,XD )R%QGGH>#UKKX-$TNVOKF^
MAL8$NKH;;B4)\TH[!CW_ !JKI?A+P_HDES)I>CV=F]R-LK01!2P],CH/8<4
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MIEQ=7%C86UM-=OYEP\484RMZL1UZG\S0!R>OP1+\7O"$P11)+:7ZNV.6 6/
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M06\LYRN3S@Y.?6@#SW3(X+3Q;\/FMX[:UM;C3KI517#320^2C*9G& Q)YX&
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MO<1,S1@-U7:HC  [<=ZEAT>'7_'7AY/$-DDMQ=^%B]]$XP))-T6=P'7!)^A
M]!7HLOAO1IK^2^DTVW:XD96D?9_K&7[I8=&([$Y(J631-,EU9-5DL86U"-=J
M7)7YU7T![#VH \H\80Z8WA[QR=+BC5;%(H)9KMMS1/'&NR.!>"JC@[B?O$X!
MK>N+;3[KXJ^'[BY@M92^B32/)(BG<ZO'AB3W'//:NPN?"GA^]O;F]N=&L9;F
MZC\J>5X5+2+C&"?IQ]*D?PYHDGV#?I-FW]G_ /'GF%?W'3[G''0?D* /,-0G
MN]%TCXJS:(K17$5S$4,7!0-%'O8>A +'-;GB&SL[*Y\#ZGX9BBBEFU"&V!@
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M+U.YCN;RRBEN(E*)*1APIZKN'.T^G2@#R*^@>?X'W8U!%N4LM4^SV$\X#O\
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M&.X@DAE0/'(I1U/1@1@B@#R36] F\!:7-XQ\"ZKY>EX6YN-(E;?:SHQ',?\
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M/\)^'])U.;4M/T:RMKV;.^:*$*QSU^F>^.M:EQ;PW=O);W,,<T$JE7CD4,K
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MZMW+!9XB4!+ .. /6O'K*#S_ (*^&/$-NJW&H>'A'>#HS&-&(DCSV'EY./\
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MFD9!($5P25/\6/3WKRQK&S$7Q:M_LT/D!=XCV#:&^R;LX]=W.?6D@TVQT_\
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M8V/C;QEI]G9V\%I)H<$S6\<86,N/- ;:.,\"NA^&:VJ?#O01;K"KM80M+Y8
M);:.6QWX/7TH WE-_P#V_('N;0Z>;92D 4^<)-QRQ.<;<8'3K5B*\M9Y7BBN
M89)$)#(C@E3[CM7"^3;6_P 7M=<8MUD\/1R321##9\V0%^.IP!^0JKX6:_T/
MQ'HFC:S965V&LI8M*UJQ^7S8E"L5E3L2%4Y!P3]30!Z1++'!$TLLBQQJ,L[G
M  ]S38[F":#SXIHY(<9\Q7!7'UZ5R_C:XL4G\/6MS&TMU/J2&S1I?+B,JJQS
M(<'*@<@=2VWZUQ^F0+?V/CK2EUBTM)9-9B,,T:?NO-/DX&S)^5GPK#)^\<T
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M.M2++&\CQK(C2)C>H8$KGID=J\OO7O-"U9[NXM[36O#EUK@<7$?RW5A<F8(
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M5M-M;Z.-MR+<1*X4^HSTHGT+2;J*VCFTZU=+4;;<>4/W(P!\G]W@ <8K0HH
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M(I) )8 @D 9.,]JXY]7\4I\0HO"_]IZ84?2VO_M']G/D$2;-NWSNG?.:[VN
MF=?^%_VR[AN_X1MQC/\ T\"@":;7/$&E^*?#&GZM=V*P7HOC=F*'8I$()1\L
MQV@J5)';UKKK?5=.N[ W]M?VLUF 2;B.96C '7Y@<<5Q_BV"WN?B;X&AN(XY
M4(OSL< @D1(1P>O(S^%<O)=:5I>E^.H;RU66Q_X2*%5@60Q1J["$AG8?=3<,
MGZ&@#U(:_H[6-S>IJED]K;#,\R3JRQ\9^8@\5'X>\0V'B;2(=1T^9)(I5#;0
MX+)GH& Z''8UP6FWD4GQ$\5QMJ-I=3W.CPX^SX59&7S<A1DDX'N371?"ZZMK
MCX<:"D$\4CQ64:R!&!*''0XZ'B@#27Q9I5QXCNO#UO?VPU&")68,X(#L2 F,
M@LPQD@=B/6LOP-XL&J>&K"76]2LUU2ZN+B..,LL1EV3.@")G)X4>M5K"YM[;
MXR:['/-'')/IMGY2NP!<[I,[1W_"N&2VLT^!R:@L4(NDUD.L^!O!%_@$-U^Z
M3^!H ]HOM6TW2PAU#4+6TW_<^T3+'N^F3SU%6P0P!!!!Y!%>8W.H:</'?BO2
M/$>M'2TNXH?L_G&%(Y[8Q;656D4]'\S(!ZL?>NY\+VEI8^&=/M;"2YDLXH0D
M#W)R[1C[I/ XQC' XQ0!S$GBFY\1:[K.E:!KUA9W&G^2+7>4E2[<IO?<.I4#
M ^3!!!))Z5T>CW_V;0XIM5UZPO7,KH;R+;%$QWD!!\Q&1]WKG(]:P/"HAF^(
M/CZ,B-U-Q:!E(!&/LR@@C\Q7"^19O\#++>D6R/6]J'@; ;XYP>W'IVH ]C_M
MW2/(:?\ M6Q\E93"TGVA-HD'52<_>'IUJAJ?C/0=+N=,@GU*UW:C(5A(F7;M
M 8ER<XV_+C/J0*Q/$.A-::QIC^$[C3M+UF-+B:.TD@ @O%/E"0-MP0W$?S#G
M\*Y[^V+>[_X5[J4]G%I,0U*[26)I!Y<;A)5.&Z;2P./K0!ZR'4IO##9C.[/&
M/6JMGJVG:@[)9:A:W+J-S+#,KD#U.#53Q*ME=>$=52\N6M[&:RD66>/K'&R$
M%A] <UY[=W?B>UMM;T6\BMKW5AH$TNGZOIX*--$"!M=.SY.5QQUQWH ],M]8
MTR[NY+2VU&TFN8AF2&.=6=!G'*@Y'-,.O:,'A0ZM8AII#%$#<)F1QP57GDCT
M%<+HDGA/Q+/X:U"UUV:[O+5"MK91M"&B5DQ(DB*@(0 8.>.F.HSRES96$?P5
M\674=O;K-%JT_ERA1N3;=#;@]L9XQZ^] 'K,GBW1X_%2^'6O8!?F$RLAD VG
M<JJG^\VXD#K@>XJ^=7TQ=0&GMJ-H+UNEL9E\P\9^[G/2N0GN;>V^-@,TT49F
M\/*D7F,!O?[2< >IY' KEO#LVA:_X/L-/US7KJ+6+*\W3:<K0I<B\60G*C9O
M)9B3G/<Y/!H ]5N==TBR$INM5L8!"RI*9;A%V,>@;)X)P< U9N;ZTL[;[3=7
M4,$''[V60*O/3D\5YI;Z9IDWB7XG"2SMG"10@!HU.T&URV/3)Z_2J&A:W#I=
MQ\.KG6;A8M+ET$PP3S-B..ZVQ\LQX!V!E!/J?>@#UB/4;&6P^WQWEN]GMW?:
M%E4QX]=V<8HL=1L=3A,UA>6]U$&*EX)5=01U&0>M>:>(KK1='L-,O](E>#P^
M?$!GU&[MR)8_,=&_>#=N78)"N<# 9>.173>%[70F\1:MJFD:O)J=Q>1Q?;)4
MEC>'*@A/]6H&_&??&,]1D Z>[OK33X?.O;J&VBSC?-($7/IDU1U+Q#IVF^'I
M]::[MY+2.%I$=9EVRX!(56S@DXP*YO4+I[?XSZ4E\=MC-I$L=BS_ '?M7F N
M!_M&,#\,UC0V[6MA\4O)(71B)&M@/N";[,3/M_X&1GW!H Z3PIJ&JZXFG:PN
MM65U87-FKW=FB*3;SLJL%1EYP,D$/D\>_&SXCU231]!NKRWA,]V%$=K"/^6L
MS':B_BQ'X9-5_!14^!/#Y7!!TVWY'_7-:I:B;K6O%D5KIUU:QKHRB>;SHC*#
M-(K*@PKK@JFX\G^-: +W@_Q!'XI\)Z=K" *\\0\U!_!(.'7\&!JU+XAT6 D2
MZQ81D,Z8:Y0?,HRPZ]0""1V!KA_"+2>%?B'K7A2_G@:+5%_M:R\M#&FYB5E0
M*6;'(R!GH":E^'6D:3+=>)[@V%H\]MXDN_*<Q*6BP%QM_N]3T]30!MQ^*K+Q
M)X1NM1T77;.P/S!;N?:ZP@.5#.I(P&"D@''6N@N]0L]-MUFO[VWMXSQYDT@C
M4G'J37BXELKC]F2>$O!)/;6[%TR"T3?:& R.QZUV-WK=II/Q8B&M7,5M9W&C
M*NGSSL%BWB0F50QX#$;/J * -3Q=K][I\7ARYTF[MVMK_5[6UE8()/,BD;G:
MV<#@=<'KVKH;[5]-TPH+_4+2T,GW!/,L>[MQD\UYWX@@T6R\-^$8-"01Z6OB
M>U,!WEE?,K%F0DDE22<=O3C%-FO],?QAXPT7Q-K9TP77EF)9FA2.>T,(7"M(
MIZ-OR >I)QG- 'J/5?E/4<&N&T+6_$6LZWXDLGU#3K>+2;L0(YLF;<I7=EOW
M@Z5TWARVMK+PYI]M9O<O:Q0*D+7)_>% /E)Z=L=A7GWAS0K'Q#XI^(5O<SW:
MAK\1$6U[+$,&+'*HP#=^H/3% '1ZAXGU728M&T>5+.Z\1ZK/+%"8U*P"-"29
MF7<3@)M.W.23C/>G>(M8UGP=IG]MW=Q%J6G0NHO8EM_+DC1B%WQD$YP2"5.<
MCN,5D^,;1]&\?^#_ !/-DZ99B6RNY<<0>8FU';T7)P3T'%:/Q0N5F\"WFE6P
M%QJ&JJ+:SMT.6E9B,D>P&6)Z "@!=2\1ZHGC[P]I-C<V;:9JMM-<%V@+. B@
MC:VX#!R.U;/B&\U&S?3/L$\$8N+Q+>42PE_E8$DC##!X]ZXS4K+_ (1KQG\.
MFO) +2ULYM->Y8X02^4H0$GIN*G%=;K]Q#<:KH>GQ2*]T;U;AHU.2L:(Y+D=
MES@9]6 H R9-:\0R_$FX\-6U[816R:8M^DLEFSMDR;-IQ(!COFG>&O%>K^(-
M,\1VAM;5=<TBXELU://V>:0 [& )R!GJ,\>M86KZ<VL_&;4[&WU*XL+EO#*B
M.>VE*O&_GG!XZCD'%;'PSOK2'2[CP[+9P:?KFFR%;^W3K,QZ3@GE@XP<GZ>E
M $=[J_BJR\;:/X=.IZ6XO[::9IQISC88\< >=SG/K1XFUWQ5X<TO3'DN-->Y
MN=7BL&?[*VQHY"=KA?,R"!C()/(-)KKJ/C9X34L-W]GWG&>>@_P/Y4SXNB-M
M'\/1RN45_$%F"0Y0XRV<$8(^HZ4 :7C_ %W5_#6@6E[ITUJ9GNX;:03P%E(=
MMNX888QUKKHPZQJ)'#N!RP7&3]*\Q^*FD6>G>%[*=+B^+?VI:C%QJ$TJ_P"L
M&?E=R.@]*]-F\SR9/*QYFT[,],XXH K-J^F)?BP;4;1;QC@6YF42$XSC;G/2
MN=\2>+;:P\1Z7X?75+:RDNQ,]Q<-)'NMU1 5&&R 6+#&0> >.XXB!HM1_9^N
MXKC=_;$#2"53_KUOQ,2/?>7(QWYKI=0,J_$KP+'>LAO/[/O?.Z<OLBS^H- '
M2PW\_A[PR]YXIU*T9[8.TUU&GEHR@G:=O]XC' []*P-3\8S3Q^$;_1[RV^Q:
MIJ$5O=1@"1E#QLY4L#A2, $8SS6]XT4MX$\0@#).F7.!_P!LFK@M1FL-2\+_
M  TB62"XB_M&SCE4,&7/V9LJ?S&1[T >GV.IV&J1/+I][;7<:,49K>59 K#J
M"0>#[4RUU?3+ZYDMK34;2XGB&9(HIE=D'3D Y%>8:O'<6VJ_%"#18_+G.F6C
MK';C:<^7(&*@?Q;?QZ5LZ++X5\0ZQX=U?3]?FO;ZVB=;6VB:%6BC9,,LJ(@(
M48 YX!QCK0!N^/\ 6M0\.>"]1UG36@^T6:!PD\9=7^8#'!!'6LC4?%6N>'-0
M\-?VBUC?V6M7,=HWD6[0RPR./E89=@R^O0BK'Q<8+\*O$!) _<*.?]]:YZ>"
M+PKXLT3Q!JTCW^A75O';PW-U(9/[+G*C#*2<*C]"W8]P* /3+[4[#2X1+J%[
M;6D9. ]Q*L8/XDT3:G86UK'=3WUM%;R8\N5Y557R,C!)P>.:X/5-8M;'XH7$
M.L:P=-M;O2XA83MY0B<!W\U-TBL 3E#CC( SGBJL6AQ6=CX?A\%:Z$NK07;Z
M>FH@20WD19/,7*X.W)4JRCIG'!S0!V.J>,M"TEM-6?4K4G4)O+@(F7:1SN?.
M<;1@\^N!6A<:WI-I)''<ZG90O* T:R3JI<'H1D\Y[5YE/J\-YI_@34+BRBTI
M4UZ:.>,N#$D@$P;:W3:6R1^50^,-5TN\T_X@1V<UM:R?9D6Y,S[Y;MA""GEJ
M3A4 QR <G)XQD@'HU_XMT?3?$-GHES?01WMRC2;7E"[%'0G/<D@ =^?2K\^K
MZ9;7L=E/J-I%=R$!('F578GIA2<FN ;4K(>.O!5[)=P>1)H]RHF:0;68>5D
M]SP:R+&;0M9T+7-!\4Z]/:7Z:G.UU9;HDED;SB\3190NV5V!=I/0 <8% 'JN
MI:E:6$6VXU&TLI9 1$URX )]<$C/4=ZQ_A[K-[XA\#:;JNHR))=W D,C(H53
MB1E& /8"L'0=3MHOB'XNL]=FCBN/*MA;"\91OM!'S@G@C<6+8XR:M?!Z6"3X
M7Z0D,B-Y?FJP5@=I\U^#Z<8H O'Q%>ZUXMOM T1H88M,1#?WLJ>9AW&5CC7(
M&<#)8Y Z8K0MVUZVU^"VNI;>ZTR2WD8SK"4D64%-JMR0007Y '3IZ\CX5=/#
M'Q+\5:9JDBP-K%PE_I\LAPMPI!W(I/\ $I(&.O?I77>(;^5]&U:STIVDU46,
MS0K%R8WV'9GT);&.YY]#@ OPZOIEQ?/8PZC:2W: EH$F4R+C@Y4'(J*7Q#HD
M&?-UC3XR&=<-<H.5&6'7J 03Z"O/?#LOA;Q'8>%)UUV>:_L2GV?3XVA66)]N
MV1&14#; ,[L\$#//%:'PYTC29;CQ+<&PM'GMO$=X(9#$I:+& -I_AX)Z>IH
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M"1=R2Q,&5AZ@C@B@!#:6QM/LAMXOLVS9Y.P;-OIMZ8]J;9V-IIUN+>QM8+:
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M4=KKFDWUXUG::E:3W*KN,,<RLP&<9P#TSQFN7^(_BW^PO"NH2:5K-I;ZM;E
ML;;'?)905VGOM)/0\#.* .MN=,L+V>&>ZL;:>: YBDEB5FC/JI(X_"I;>VM[
M.!8+6"."%?NQQ(%4?0"I"0JDD@ <DGM6%IFK6EII$MUJ'B6QO83<R*MWF.)%
MRQVQ9!P2OW?4XH U;W3[+4H/(O[.WNH<Y\N>)77/T(IUG8VFGVXM[*U@MH0<
MB.&,(H_ <5!9ZUI>H7EQ9V6HVEQ<VQQ/##,KO$?]H Y'XU7\13F#2CLUN#1Y
M&D0+=3*C#[PRN&(!+#(]>: +<.E:=;7<UW!86L5S/_K9DA57D_WF R?QIUKI
MUE8ES:6=O;E_O&*)4W?7 YK*D\7Z/'XM3PXUY"+XP&9@T@&TEE54YZLVXG Y
MX]Q6A'K6ERWPLH]1M6NF9E6$3*7)7.X 9R2,'/IB@!S:1IK0O"VG6AB>0RLA
MA7:SGJQ&.3[TDFD:9,8S)IUHYC 5"T"G:!T XXJU++'!$\LTBQQH"S.YP% Z
MDD]!5&WU_1[J"XF@U2RDBMO]>ZSJ1%_O'/'XT 6%TZQ2[^UK9VZW/_/81*']
M/O8S20Z9I]M>2WD%C;174W^MG2)5=_\ >8#)_&J]OXBT6[O8;*WU>QENIHA-
M%"EPK.\9&0P4')!'.?2L_3_&>BZMJ.J6%KJ-L)+!O+=VE7D[<L0#U5<@$],Y
MH U6TC3&,Y;3K0FX8/,3 O[Q@<@MQR0?6IS:6S72W36\1N44HLQ0;U7T!ZX]
MJR=+U6UM-#TXZCXBL[Z6?$:7N8XENG)P-B@X]L"K2^(M%?3EU!-6LGLV8HLZ
MSJ49AG(!S@G@\>U $\>EZ?#?O?QV%JEY(,/<+"HD8>[8R:MD9&#7/:OXUT+2
M++3KN34+:2+4;B."V=)E*ON8 ONZ;5!))Z<8[UI6VN:1>W?V2UU2RGN=@?R8
MKA6?:1D':#G&".: )+/2M.TYI&L;"UM6DY<P0JF[ZX'-$&EZ?:SF>WL;:&4]
M9(X55C^(%/M;ZTO3*+2Z@G,+F.7RI VQAU4XZ'VJQ0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 (S!5+,0 .I/:O"K22WE_9GU<EXGVR7&.0<,;@D?CR/SKW22-
M)HS'(BNC=589!_"JXTRP"%!8VVTD$CREP2/P]S0!P^II:VOQ.\'+8BWA9].O
M441X (VQE1QU&<G\ZRO!FK>&]2\&:7HNN&.37;&]S+I\CD7)O%D8[PH()R26
M+=,$YX!KTX:?9!T<6=N&3&UA&,KCICCBG"RM5NVNUMH1<L-IF$8WD>F[KB@#
M@/#=S:B[\>Z=XC>))FU"6:47! WV31JL9&>JA5(]JYW1[*2+_A4]MKR(;O;=
M[EN -VWRB8U(/H-@P>XKV">PL[J:.:XM()98CF-Y(PS)]">E++9VL\@DFMH9
M)!P&= 2/Q- 'GYT[1X/C9%:-9V4<8\.@PP^6JKD3MG:O3.,_AFN4A@DT73HK
MN)=GA9/&33C;_JTM_NJ_IY0E&?3@&O1KCPQ<WGQ#;7+NWT^?33IHL?)E8N^1
M(9-^TIM[XQGWS74F*,P^28T\K;MV;1MQZ8]* .$O($N/BS'>6;1M:C19%U)@
M04(+@Q!NV?O$9[ ]JYC11H-A^S]9ZG>Z5;WB_9A%*0=C'=.!AI%^8*&VD^RU
MZ[#865O;&V@M((H&ZQ)&%4_@!BE2SM4@>%+:%8G^_&(P%;ZCO0!YSH^I6\WQ
M?N\ZM:WLESH485[? 1V$SY5 "<X'N3UY[#FFO+&?]FB.$3P/-:I LB[@3$WV
MD<'T/!XKVR.UMX61HK>)&1/+4J@!5?[H]![4UK"S:,QM:0%"Q<J8QC<>I^OO
M0!QB7AM?C+.NH.$@N](1=-D<X5BKDRHIZ;CE21UP!Z5Q.I6<</A/6681_P!D
MR^+8FL V-NPS)YA3_8+;^G'!KVF>PL[JW6WN+2"6!<;8Y(PRC'3 (Q3I+.UF
MC1);:%T3A59 0OT]* .*A6VM_C>8H!%'N\.#*)@9Q<<<#T'Z4[Q]<R6.N^#[
MVY.-&AU(_;&/W4=HRL+-Z ,>IX!Q78K8VB2B5+6!9!T<1@$<8Z_2II(HYHFC
ME17C8896&01Z$4 <3:0$_&2^O;%E^Q'1HTOV0_(9_,/EY_V@@/T!'J*/A+-'
M+X"A,<BN!>7>=ISUN)"/T(/XUV,-E:6]M]FAM88[?G]TD8"\^PXI8+2VML_9
M[>*+=U\M N?RH XK7+NWL/B]X?FNYXX(Y-+NHT:1L!GWQ_*/4^W6N8>.RF\)
M_%B5U@>3[7=C>0">($*\_P"]G'O7K[PQ2O&\D2.T9RC,H)4^H]*@&F6 5E%E
M; -U'E+S^E 'F(UR'3/%.A3:OK$NFZ?>^'X4M;W,?E&4'=(I9U8*2"ASQG:/
M:NV\%6.DZ?H'E:'+--IS3R212R,"LFXY9DP -F[.,#'4C@@ULRZ?93VHMI;.
MWDMP<B)XE* _3&*L*H50J@!0,  < 4 >:^&I8O"/Q(\4:?J\BVR:U<+?:?<2
MG:D^0=Z!CQN4D?+UQS76Z]J$EWHFK6>B2^=J?V*8Q&%@?+DV'9D]B3C Z_@*
MV+FTMKV$PW5O%/$>2DJ!E/X&EM[:"TA6&V@CAB7HD2!5'X"@#R:^DM]8^#?A
MJ'1V4:O#-91VD:\2172.JR9'4$ 2%O;)-;>A6&EWOQ5\;1W%K:3LJ6!"2(K8
M.QB3@^X4_@*[N.PLXKI[J.T@2XDX>98P';ZGJ:!9V\4C30VL"SG)W! I)/J0
M,T >065AH5S\//B EU;VKS+JFH(OR@R*^\^4J]\[B-H'<^];/AB6^TKQ]8VG
MB)RMQ-X<MHK624\-(G^O0'N^[!/<@#TKH?"'A6;1O[0DU2VT^6XGU&>]AFBR
M[1B5MVW+*",>HZ^U=-=6=K?1"*[MH;B,'(25 XSZX- 'BFJVD4'@?Q"S^6-)
ME\4QM8;L;?+,T?F%/]@MOZ<<&NV\27.BZ)XI\.P);V&GW,YN9HK^7]W%%\BA
M_E!57=AM W'@#//0]M)9VLT:1RVT+HG"JR A?IZ4/:6TJ1));Q.L1!C5D!"$
M="/2@#Q!KNV/PH\2QI=++]F\2%Y"< JAO$(9@,;01D]!WKMM;N[*Z^*/@6YM
MIH)%EBU +(C [QY:@8/<<&NZ^RV_ERQ^1%LE),B[!AR>I([TTV-HTB2-:P%T
M "L8QE<=,'M0!Y?I$]M-\/?&FF:\R#48[F]^VQR_?8ODQ,!U((V!2/[HQTHT
MNS=/&?@*#6DC?4DT&7SQ* 7\P"/&<]6&#SZ@UZ?)86<UU'=2VD#W$?W)6C!=
M?H>HI7L[6283/;0M*.CM&"WYT <;\-6B"^+(H2FR/Q%=A50C"CY#P.W.:ANX
M[!_C<OV]+=@?#P\KSPN"PG;.W/?![=C7<P6EM;%C!;Q1%NOEH%S^5)=6-I?*
MJW=K!<*IRHEC#@'U&: /%@&\/:0FI(T]MX7'BN6='MT#"*V*%%D4$$>6)>1P
M1T([5Z#X5CT"XU_5-6T;59-4N+J.);RZ21&B)480?( N\#/3D#&>HKK7CC>(
MQ.BM&1M*$9!'IBF6]K;V<(AMH(H(EZ)$@51^ H XO7-5TZW^(\%G)+;Z??'2
MF)O[AL[H6E'[J)"=I?<N22"> ,'/'!:5)I]Y\-/AO#(]O,T>O0PRJV#CF;*M
M^!''N*]QDMH)98Y9(8WDBR8W902F>N#VJ-M.L614:SMRJY*@Q+@9.3CCUH \
MLU\W4/B#XCQ:)\MZVBVS*D'#$@2 D ?Q;>G?I2ZOKOAV\T_X<SV%[9"*+4K<
M*HD4&%/*<%2/X<':#GN!7JB6=K',9H[:%93G+K& QS[TR/3;"%R\5E;(Y?S"
MRQ*#OP1NZ=<$\^] &+\0'5?ASXD+, #IEP 2>YC;%<DRV=MK7PL: 01;HYAE
M,#<&M<GZY;'XUZ=-#%<1^7-$DB==KJ"/R-0_V=8Y0_8[?*?=_=+\O.>...:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN=;T]_@!J.DWUS%'KMN[+>VDS 3^?]HWLQ4\G.=V?\* /=BZI&7=@J@9))P
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M^YCMYKRUM'MHW.'G A=3L7JW/&!FMSX6SQ3_  R\/F*17V6B(VTYVL.H/O0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVCBD\B$SB<Q)YP&T2;1NQZ9J2B@"-H(GD$CQ(TB@J&*@D ]1FGJJHH50%4#
M & !2T4 -,4;$DHI+  DCJ*;Y$.,>4F/]T5)10!&T$+S),T2-*G"N5!*_0]J
M=Y4>_?L7=ZXYIU% $;P0O*DKQ(TB?<<J"5^A[436\-PH6>&.50<@.H8 ^O-2
M44 -9$< ,BL!ZC-)Y,7R?NT^0Y7Y1\I]1Z=:?10 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %<]=:KJD/C.+3UTR\ET^2S,D=S$
MJ^2)1NW+(QY' 0+C^\>O;H:* /+O$'B?Q%#\-[?6%_M'1M46]BMYH[F"++[G
M"L0I5OEY.T]>.<]3V/V2]M=7M6'B6ZFBA#2W5K<QP8>+:P!!2-2"'VGKT!KG
M/C-)!_P@PMY&1FDO;<B(\EE$@+<=P #FNHL?#>@P"XN=*LK2V6\M_)D:S146
M1.<'Y1@D9//O0!A^%-2U#QWIDNO&_N;#39II$L+>V"!C&C%?,D9E)+$@\#
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MN)&)VX ZYSP?3OBO/=&UNVM;/P):S[;0MHH0:F(?,E#A8P;=."%8XR<@GY<
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M>H'?'M6[=^*M%L;B2"XOE0Q2K#*_EL8XI&QM5W VJ3D<$CJ/6N.UZ2QM=2\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***S[[6K+3YQ!,TS3&,RF."!Y65
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ME5;O+PW(3[OF(Q1B/8XS^- '1T8&<XYKA;34-1\5:CXI:TOY[2+29S8V0A(
M\]$#.[C^/YB!M/&!TR<U0TSQO<>+G\(V-L[6G]J6DM[?M"<,JQ_(40]0#)GG
MK@<'G- 'I-%>9:EXZO?#>G^,;%V^U7VC2P+8R2\F1;@#RPWKL)()ZD*._-;-
MS?7GA?Q3X<L9[^>]M=7\RVG:<@E9U7<KK_=#88%1QTP!SD T_&7AZY\4:%_9
MEO>16N9XI6DDB,G^K=7  ##J5K?C#B-?,VE\?,5&!GVKF_'>OW'A_P .K)9%
M1?WES%96K,,A9)&V[B.^!DX]JHW&K2^%O&FF:5<7D]SI^J6<[JUPV]XYH '9
ML^C*3QT!7C'- ':45Y=_PDVK+\-A\0&N9O.\T7)L<CROLOF[/*QZ[/FW==W?
M'%;MOJLWBCQKJ^E07L]MI^DVT!+6[;&EFF4N&SZ*H'R]"2<YXH [2BN:\":_
M<>(?#0GO=IOK:>6SN2@P&DC8J6 [9&#CWJ_=>)-,L[B2&668F*5(97CMY'2.
M1]NU695(!.Y>IXR,XS0!K45Y[;^)DT/Q_P"+TU74KR6S@@LY(( CS>4&60N5
M1%) X&3CTR:ZQ_$VD+::?<I=^<FHC=9K!&TCSC;N)55!. .3QQWH UJ*P)/&
MOAZ'1%UB34 EBTQ@WM$X*R!MI5EQN4AN.0*?:^+]$O8)9K:ZDD$=R;78MO)O
M>4+NVJNW+?+SD C'.<4 ;E%8MMXLT:[L9+N&Z9EBN/LKQF%Q*LV<>68R-V[V
MQTYZ5=T[5+75%G-J9<V\ODRK+"\;(^T-@A@#T93GIS0!=HK.O];L=.N%MYGE
M>X:,RB"WA>:38#@L50$@9XR>IX%8'BSQK;V/P[OO$.BS_:<P,;6:.)I%#],M
M@?+@]=V.1@T =A17/>']/VW3ZG!J>K26\\*QM:7WF8$@ZR*)1N7/3 POM70T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9WLI!&_F_=*OC:1[YQ]: .NIJQHK,RHH9SEB!RQQCG\ *P[;Q;87<&^*WO\
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M.[#T% '9T5Y=81RWOBGQY;W7B#5+2VTQH#:RB^<+;!HB['!.",\X;(JWX/\
MB)N\$^'[OQ/YZ:CJ;/%$T=JY$Y4M@_*, L%X4<DG@<T >C45@P>+;*ZL8+BV
MM=0EEFC:46@MBLZHK%265L;>1@9Z]LUS_BWQO"_@*'5=!FGDCOIXH%GBC8&,
M&54<'NKX+ =\T =]17*6)L-!O+F6T_MB>6_03_V8Q:0PA,JSJK'Y-Q(R">2.
M!UI[?$'PZ-/TR^6ZF>#4I3#;LEM(<R#.4/'#9!&T\G' - '452N]-BO[FWDN
M27BMW$L</\/F#HQ]<=AT!YZ@8YX_$?0U^S(\.J)<7,4LL5LVGRB5A&<, NWD
MY[#/J<"KT_C#3H;'[8D%[-&ELEU,L5N2\$;#<"ZG!!QD[>6XZ4 ;#6<+WR7;
M[GEC4K'D\)GJ0/4],^GU-6*QV\3:8T&GR6DC7K:C&9;2.V&YI4 !+<X  R,D
MD<D#J0*YWX:WKWK^*F::\DCCUN6.);MW9XU$<?R?,21@YXH [JBO/?&?B&'2
M/&NEVVOW-Y9>'+BU8)<V\KQ(;K=]V1T(8 +TYQDDGIQHM>OX2\.ZYK?VN[UG
M3T3[59CSO.(C$8RH?/*Y!.XDG![F@#L:*Y^Q\40/H>F7=W',EU?*BQ6XB(>:
M0IN.Q?3&3D\ #DU-:>*M)N8-1D><VK:9_P ?T5RNQ[?C<"P]".01D'L: +L&
MF0VNHW%Y;DQ_:2&GC'W7<  /[-@ $]P!GI5VL*#Q)IVH:H-$D6[M;NXMS/"D
MR-$TL6<%E(.01Z'##TKF_AYKXMOA[X?^WRW=Y>7LL\:$9FE<B63)8]< #ECP
M.,GD4 =I_9L3ZJNHS$RS1H8X >D2G&[ ]3@9/H,<<YNUR$_AW4IM1\02C6-:
M2SO[=5CCCN4#PR8ZV_\ SSXXYZDGTS4%[=7_ (,T71-0U"]DN0CP6>IF1]P8
M/A!+G^\K%<G W G/., ';57M[.&WFGG7<TTY!DD8Y) Z#V R< >I/4DEFJ6K
M7NE7=JD]S TL+();5@LJ$C&4)X#>AKE[7PWKD7_",O)K>J--8%Q<[[A3'-$2
M2!,/^6CXVJ".^3]0#LZ*** "J][9Q7]N;>XW-"W^L0' D']UO4'N._0\9%6*
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWEA_Q+EL[5U2ZS"<O)( -S G;L8]!@*35NV-S+XK\!W)TS4HXK;3)XIW>SD
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MP6-N9OL,GF^8-R1@G!& 2H(R/2M7X?\ V@:CXK>:QO+9+G5WN(6N(&C$B%$
M(R/53QV[UV]% '-ZUJ-N=5GTC6-)FNM'FM$?S?LC3Q;RSAD< '' 4@XP/4<5
MQ&F>%KJS\->/['1+>\70KRU==)M)U=6,IB;S-BO\P4L5 SUQ^)];HH \P;[<
MMQX&\1IIVH&QTV"2SO8&MG$T7F1(OF"/&X@,N#QG'(R.:K^)_#.I^);GQ7JV
MD0R()["UM[5)4,9NI(I?-8X;!Q@! 3UR>U>KT4 <MH?BG^WVBN!H&I63P1DW
M+WMFR-$<<QIQER3C[HQ@<\X%>?\ @2'6O"%IH^HRZ;JEQ:WHDL[^T:RE::R(
MED=)$7;GRR&^8#N<\GBO::* $1@Z*XSAAD9!!_(]*XGXLV[ZAX$ETF 9N=1O
M+6V@ _O&9&_0*Q_"NWJI)IT,VI17LQ:22 'R%;[L1(P6 _O$<9/0$@8R<@$4
M&JK-K=UI0L[U&MXDE-R\.(9-V>%?NPQR*T*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEB!\JG!)(' ]0*HW'Q'T:TT;4=1N8+Z(Z;<"VO+8Q RPN2 -V&*[3D88-@T
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MJ* .(US6/$=]X7EOM+T2]M@;B >1)&GVPP[OWKJF2 V,!0>>"?2LO2M+O_\
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M =I&<X'?%85SI.MR_"_QEIK:+>I>WNJW$MM$%#&57F# C!Z8!Y.!Z9S7L%%
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M\;VD-AKMQ/87J3:'S>VX"%U79O#*=VU@5YZY]JM2>*[./4-"M#;76=:1FMI
M%VJ1&9"&^;(.T=@17%P>'=5G;X@V<.AS64.LV:"R:21-I;[.4VL0Q^8L>>HZ
MY/K)$FMW^H^ [@>&]0ACTHNEWYQC5E)MS'D#=RN3U)!/8&@"6X\17GB7PGX\
MAO--GMHK W<$3>8F$\N!2 2K9+;B6X!'.,G%7O"GBR"WTWPIHUQI]]"+W3XH
M[:\D11%*Z0AF4?-N' ."5 ..,U0BTW6+32_B!IC:/=.VI7%U<6DR%"DHEA5$
M4<YW9!SD #UISZ=J9M_AVHTR[W:64-Z-@_<X@,9SSS\Q[9XYH Z.]\9VMK;Z
MA>0V-Y=V.FR-'=W-N$*QE?OX!8,VW^+ ['&2"*CU'QW865]86=O8W^H2:A:O
M=VC6D:LLZ* <*2PYPPZ\>]8.D:?JWA[1?$7AR72[F\-Q<7,NGSQ &.=)LD!V
MS\A!)SNQQTS1IWAR^T+Q'X)MDMI[FUTG3)K2YNT7Y%D<)CJ<XRIZ#CB@#8L-
M8TF]\;!FTB_M=:.BK.TEPNW;;EP?+*AB-P<G/';K4ESXYCL[C2K>YT+58[C5
M)!';0_N&<\9)*B4D!1R2>E5Y;>]B^*\NK#3[J2Q70_LHF11AI1*7VCGT[],\
M9K-\/QZJ-3OO$NLZ)?/KMU^XMK?:ICLK?=\J!MW?[S,.O;I0!O:OXWL=(M;N
M^>SNY].LIO)NKN'85B8$*WRE@S!2<' ..>N#BU=^(+>:[ETVRM)]2F6W6>9;
M9E 2-\[<LS 98 X ],G Q7%Z;I^I>']6U32;GP8NKQW-[-<V.HJL13;*Q?;,
MS<KM)/(!)[#IG1LK;5_"_C_6;IM)N-0T[68K=HYK)5_<2Q1["C*S#:IZ@YP.
MGK0!8^$+!_AIIK . 9KH@/\ >'^D2=<]ZW+OQ-'%=WUK9:?=ZC+8*K70MMG[
MLD;@HW,-S[><#U'J*S/AG8ZAIG@FWL=3L)K.XBGG;9(5.X/,[@C!/9AUQ572
M;;4?"WBWQ&TUA=7FGZK.M[;3VRAR)-H5XW&?EZ#!/RXZD4 5O&7BP7W@S2K[
M1%GN;+5+VVB,T15<QM*H:,AF!!;!7ICJ"16=K-K#HWB?0K.P\/W<%GK-ZTU[
M8K)#Y4S1P/A GF;!SAFZ [1R2*;<>%-4TGX>:%I,5C+=7L>KQ7]Q';X*Q+YY
ME8 D@< XXZFNA\3PWEUXO\(WMMI]U-;65Q-+<R+'_JU>(H,@\DY/0 T 0^&[
M/PSH7C2_TW3]+NK*_6Q^TR2329B2!I"=B#<0JAMW   YK43QK9O+I;_8;T6.
MJS>39WNQ2DC$$J2 =RJP!P2/KBLJ\TB\U'XBZK*;6XBL+S0?[/6[V_*)-[DC
MKGHW7&*;X*OO$MGI6G>&K_P[/;W&GHEO+?LZ&V>%, ,A#;BQ4 8QP3D^E &I
MJGCK3])M)=0EM;J32H+C[//?1["D;;]A.W=N*A_E) ZCO3+SQY;V^M7VDV^C
M:M>W=FD4CK;0JVY)"0'7YN0,?7T'7',:)IVIZ#/>>'[KP9'J1-U-)8ZKLB,3
M1R.7!F+?,"NXYP"3C '3/0Z39WL'Q.UN]DL9TLKBRMH8KC8 C/'OW#&<C[PQ
MQB@#IM5U2TT72[C4;Z7RK:!=SMC)]  !U))  [DUF1^*84UNSTG4+&[T^YOD
M9[0S["LQ499,JQPX'.#^!-5_B#H-YXD\&7EAIS*+T-'/ '.%=XW#A3]=N/RJ
MA>VMWXMUGPS<MIMU81Z9<&\NC<J%*OL*B)>?FR3DD<87KDXH R+*WC\:^*_%
M-AKFD730V\\$5O(TD8:RQ$'^5E<LK%B3E,]1GI@=)XP\1WOAZ30X+.PEN/M^
MH16K2*Z94'+%0&(RS!2,G@<\YQ5;PI;7MOXO\67-S87,%O?W44MM)(O$BK$J
M$\'CE>^.M2>/;&_NH_#]U8V4MX=/UB&[FAA*[S&%=21N(!^\.] &(+Y],^+.
MK3P:9?7<\VBV\GV2$J7W&1\Y+,$&,#^+''&:ZBR\8Z=J6A:9JEI'/)_:1*6U
MMA5E9QNW*<G V[6R2<<=\C.790WZ?$Z_U:?3;J*SETF& 2;0P\U79F7@\\-U
MZ&N1L_#FO6/@[PQ=C03=W>BWETUUI4^S,T,SN<KG*E@"I'XT >D:#XFM==N=
M1LTAFMK[3I5BNK:;;N3<,JP*D@JPY!S7/:KJ,^O_ !.A\(K/+#IMG8&_OA$Y
M1KABP5(RPY"\[B!UZ'BMWPPS3Q3W8\/C1(9-H2"2-$F?&<LX0D <@ 9SP3WK
M%UW1=2TGQ];>,M)LWOXY+0V.HV<3*)3'NW+)'N(!(( (R.!Q0!LS^%+..[L+
MG2\V#6MPLCQ0,4BG7!!#H."<'()&<@<U!>>-[*TLKS4ELKRXTNRF:&YO854H
MA4X=@N[<RJ<@D#L<9Q6C:ZK<:C)&+;3KJWCSF66\B\O ] N<EC^0ZY.,'B-*
MTK6-&\$:WX-ETRXN9G-U%87*@&&>.8L0SMGY""YW \\<9H Z/4_'5G8:K%IM
MOIVHZA<3V37MO]CC5UG08^Z2PYYSSZ>I -9_B) ;F_L[?P_KEQ>V,4,LUM';
MKO"R*6[MC@#D=23@ \XHZ;H-YHWC;PW&EK<3V.G:$=.DO HV^9F/'?.,(><8
M&:32]0^P?%7QGFSNIU:WL"#;Q[\,(WPI Z9R<$\<<D4 ;UIXWTG4=(TJ_P!/
M\ZZ.JLR6ENB@2,R@EP02 NW:<DG''?(RP^-[&.VUIKBSO(KO1H_-N[,JID$>
MTL'7#;64@'G/;!P>*Y"Q\':QX;'A768[5KF6QN;R2_L8&!9$N3D[.<,4^7('
M7!Q6CJNB7NI7OBO7HK&X7[9HATNSMRN))F(<ERI^Z,LJC=@\$\#&0#6B^(-I
M)IZWSZ1JL5M,ML;61X5"W+S$!40[NH)YS@=\XP3--XT5++Q#Y>F7)U'1(A)/
M:.Z#<&0NK!PQ&T@'WX/'KF78\0V?PWT&#3;&[%U +2'4+>(JLXA4 2B,DXW<
M8!!Z9(.>:SM/T+4SK'C9(M"N+.VUC3HDM7ED0Y<12*0Y#$[RS ]^Y)]0"[+X
MAL[_ ,&^%KWQ+I%Y*U[<61C*; OVA@I27Y7X7<2<'GCD5T]WXB2+4;G3[*QN
M=0N[2)9;B.W*#RPV=H)=@-Q ) 'XXR,\1=6.LW7P]\)6/]AWL=UIUY8&>%MA
M8+!M\Q^&QCCCG)]*V+*UU#PYX]U[4'L;J[TS6D@FCEMTWM#+&FPHZ]0",$'H
M.AQ0!;E^(>CII.CZG#%>7%MJERMI$T4.3'*205=<Y!&UN #TK0T/Q1#K6IZC
MICV%Y87UAL:6"Z"9*."58%&8$'![\5PS>%=4T[1M C6PFEN#XF_MB[BBPPMH
MF9R1G."0&7@9YSC-=-I5I>)\3]=U"2RG2RN;*WAAG9<*S(7+#U'WAU'- &]J
M>M0:;<V=GY<EQ>WC,+>WBQN8*,LQ)( 4#&23W Y) K'D\>:?!IFM74]G>QW&
MB\WUEL4RQKMW!A\VTJ1R"#5?Q-INH6_C30?$UG;27EO:1S6MY;Q8,BQR8Q(H
M/7! R!SCIFL;6_#^H:C%XVUB"QN/,U;35L+*V*@2281AO89^7); S@X7GK0!
MTEEXVMKO6M-TZ33=0M1J<+2V5Q.BB.;:H9E&&+ @'/S 9P<4[Q]X@NO"_@K4
MM7LK8SSP1?)\R@1D\!SGJ 2.!DG]1B7-EJ$FM> +A=-NC%IR2B\;8/W):#RQ
MGGGYO3/'-;/Q%TF\USX?:UINGQ>==SP8BCR!N(8''/?B@# \2W31?$/P1J#V
M%XD[+?J;8%7D;$0VC"L5[GG.!GDCFM2X\6Z5J_@[7[C4-*OU@L/-MM2L&"^:
MH"9895\$%3G(:J^HKJ6I^-/!NJC1KV&WM1=FY\P*3#YD85-V">21VS@=<5F/
MI>J-I7Q&A&EW>_5GD-B-H_?!H!&._'S#OCB@#J[77[*WMM'L-.LII9+FP%S;
MVJNH9(%"#DLPY&]1U/\ 6MC3;X:EIMO>K#+ )D#>5, '3V8 GG\:X/4-!@U;
M1M L]6TC4X9+2P7RM0LLBXLIPJJ5&TYYQZ%>.>QKK/"4>L0^%=/CU^3S-36,
MB9SC)Y.W=CC=MVYQWS0!R/CWPI'!H&H^((M0U%?$,3>99W$5RXPY<".%8\[=
MIR%QC)SD\FNBO?%JZ3JFFZ-=Z?>W&I7ELTJ_9HU*.R ;E!+#')'7 &>2*Q[W
M7M9EUUY9_!6LW-K9R'[&J- %9L8\ULR YY(48X'/4\3WD&IW?C[PKJDNESQQ
M6]E<+=LF&6"24)A<_P 6"I!(&* -&R\<:;<^'[W5IX;FT^PW+6=Q;3*#*LX(
M C 4D,267&#SN%8$ES+<?&?1#-I]U9R'2[DD3.K*XRF,;6(!'.1_/.:Q[OPW
MK]UI/B"2TTZ5;R/Q.NM6<,Q""ZC0)A<YX)VG@XZ"MY9=4U?XB:!K"^']2MK.
M*QN(9FN1&AC9RA&1OSCY>W/H#0!U^KZQ:Z+9I<7.]C)*D$,48!>:1CA44'')
M]R !DD@"N(M+T)\9K^XNK2XLA%X>\R43,'! FR77:2,8&.WW>E:WQ TO5+J'
M1=4TFV-Y/I&HI>/:!@K31@,K!<\;L-QGWK*D.OWOCRZUS3M!O(%?PZ]M;/>"
M- +CS&= R[\XS@>OX<T ;^G^-K2_O=)MS87D"ZQ;O<6$D@3$RJH8@X8E3M((
M![>_%2:9XQL]2T_6;O[%>6PTB62*ZBN/+5PR+N;&'(QCH20#7&6%AK<_B#P7
MJ\_A[4OM-JL\>I3W,L9<R/$%W?>XC#9( P #PM:^M^'[AOB+;_8I$6PUJWSJ
MT)ZL+=E*N/\ >#",^QH [BRN3>6,%RUO+;F5 _E3 !TSV;!(S^-<[<>.]/MM
M-.KM:7;:()O);44"&-?GV%]N[=LW<;L>_3FNFEC$L+QDD!U*Y'49KR^RT36H
M?A?=> Y],F:_5)+.&Z"C[/)$SDK-NSQA3RI^;(X!H U?%FI3S^.O#>COI<U[
MIL\=U-)"#$4NBL:[>&< A=Y.&QS@C.*ZW1M%LM"TI-,L4=;2,L4CDD+[0Q)V
MC/89P!V%<M?Z9=VOCGPB]O974]AI=G<6\]R%R%+HBIWR?N<X!QFNIUV_O-+T
M:XO;#3)-3N8MI6TB<(T@W '!/<#)QWQB@#@?"U]%HNH_$#4IH;BXATV^8K&C
M!FBB6/>P0,P '4X!%=>WBZR23P^IMKO9K@!MI-J84F/S,/\ -D':.P(K TWP
MQ?S:'XX=HC#-X@DG:UBE^5E5HMBEAV).3CL,5EPPZ[>1> @/#>H1?V/*J7?F
MF-2"(#&2OS<KGN2,\8![ &_<?$>TAM]8GCT35YDTB9HKW9%&/+55#,_+C(P>
M@R>.F*VY_$5N#;1V,,M]<7-O]JCBB*K^ZXPQ+D  D@#N>>.#CC4TS5/[$^(L
M!TN[$NJRW#62E!^^#P"-3UX^8=\<55FTO5=)OM UM_#,FL6@T:+3;VR"(T]O
M(AR'56.&Y+ X/OF@#O\ PYXBLO$^DC4+'S%02-%)%*N'BD4X9& )&0?0FKU[
M!+<V4T$-PUO)(I43(,LF>X]_3WKF9-;NO#^CVET?"\D4-U=A9+>U\L-:1M@!
MY,'!;/9?4#)QSTNHW4EEI\]S#:37DL:$I;PXWR'L!D@?G0!P3>&T\-?$/P]_
MPC]Q>HMX+C^TK>:ZDF22)4XD;>3A@Y49]6^M1:<TGBW3_&.K3RR)<6MY<6>F
MNKD&U6%1M=/1B^6)[\ \#%:&A:QK<FI+)=^#]3BO;QT6XN[B2$10Q@_=7:Y;
M:H)P,<DY.,\0P:3J?AVT\5Z596$MS_:ES-=Z?*F-@:90&5SGY K G)Z@\9/%
M %C2+*#XC>$=%U36I+AH)K-6>U@G>%#-T=R4()Y' Z#GKGB#PA)KMAX$UI;7
MS]6EM;RZAT<SR#?-"IVQ[G8C(W!N2>@X[43Q:IX4\.:-X8TS1=2U&VAM5CN[
MNR:-3@#E5+.I!8YY[ \<G(U[+7-1@\/S7,?A"^MH[0I%!IZO%YSH, E5#;0
M#P,Y.#0!SGP]_L<Z_<PS6^N6/B2"'=/::I=O)O5B,RISL89XR ,9KTRN9MK*
M36?%%CX@EL)[%+*UE@C%P%664R%"<@$X50G?DECP,<ZVD:A<ZC;2RW6FSV#I
M.\2QS,I+JIP'&.QZT :%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %8UAX;M]/\1:CK<=W=/<Z@L:SHY380@(3 "@C )[]
M^<ULT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5BZ#X8LO#YG>">]NIICS->W+3NJY)"*6Z*"2<#\<UM44 %%%% !111
M0 4444 %%%% $4UM#<-&9HP_EL'4-T##H<=,CMZ5+110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% '._\ "<^'#J<VFC42U_",RVRP
M2&1!QR5"Y'4?F*LVOBO1+VQO+RVOA+!9,5N66)R8B!D[AC(P.>E>-#4+_2OV
M@O&5YING/J%U%IC,D".JY(2 YYZ].@Y/:O6IK>(>$-0OL#[5>:9OG?O(PAQD
M^^./P% #8/B%X3N;=;F/7+;[,S^6)W#)%N]-Y 7/XUKZEK6G:/IIU&^N1%9
M!C.%+( >A)4' Y'->0_!^QMM2^!NLV=VBO!+-<JX8=/W:\_4=?PK"\':G>7W
M[-_BFWN79XK-GA@9CG"$(VW\"3^= 'M:^-?#SZ7;ZFNI*;*YF\B"81/ME?GY
M5^7YC\K=/2H4^('A>2YGMDU0-/;@M-$()"T0'4L-N0/K6+\([2"X^%GAB66,
M.]N)9(B?X6+R+D?@S#\:Y7P!_P G ^-_^N;?^AI0![#8WUMJ=A!?64RS6TZ"
M2*1>C*>A%+:7MM?PM-:3I-&LCQ%D.0&1BK#\""*R-;N8/#GAQ8+-X;1I&6UM
M-[ )&[G //91EB/137F'P>U0^'_&?B'P)<WJW,8F:ZL9]X;S!QNY'4E2K8]0
MU 'K5]K^FZ=>)9SSNUTR>8(((7FD"9QN*H"0N>,GBI]-U:PUBW>?3KN*ZB1S
M&SQ-D!@ 2I]QD9';I7E/C2#QEX0\>7OC+PW;+JVGW<,<5]9@;FCV* .!\PX^
M8$9QN.1CKU_PX\5:/XOT>\U/2[9[2:6YWWML^"4F**"01U!"@Y[G/>@#6UKQ
MEX?\.7,=OK&IQV4DHS'YRL _3.#C!QD9YXK6O+VVL+&:]NYDBMH8S))*QX50
M,DUY_P#%3PL/%UN-.1-UVFF75Q:^OFI) 0!]1E?^!5S_ (-\3GQK\-+72IF+
M7&GPR?VAGJ4A7,6?=F,9]_+>@#TK3_&6@:KIUQJ&GW_VJSM\^;/%#(RI@9.2
M%[ @GVJM#\0?"US9/>P:JLMI&2'G2&1HU(ZY8+@5YW\$O^2,:W_U\77_ *)2
ML_X(ZIJ-MX9TJP@T]VL;O69TN+O>I50+?<$V]>2HYZ=N] 'KNH>,O#^E:9::
ME?:E'!8W:J\%PR-Y<@8;EPV,9(YQUJ2R\6:#J%ZEE;ZG!]KD7?'!)F.1U]55
M@"1]*\U^/EG;Z?\ "K3K*U0);V]]#%&H_A58Y !^0J'XUV\:?"W0-30^7?6<
M]N8)E.'7,9R >W*@_P# 10!Z=K/B[0O#UQ#!JVH+:23\1"2-\2'CA2!@GD=/
M6K]YJUAINFMJ-_=1VEHHRTMP?+ ^N[&#[=:\/^*EY/J6G_#"^NABXN62:48Q
M\S" G]35_P"(MR^K_'+PCX=ON=*C\NY\EON2R%GY([_<"_GZT >F)XY\.-;K
M</J!@@<9CEN8)(4E_P!QG4!SZ!<YJ6]\8Z#I^LQZ1=WXBU&7'E6QB??)DD J
M-OS#(/(]*T-4TRTUC3)]/O8A);S+M8>G<$>A!P0?45Y%XX_Y.-\&?]>J_P#H
M<M 'ILWC'P_;Z[%HEQJ<4&I2D".WF5D9R>F,@9SV]:NW>LV-E?VUC<2NMS=$
MB%!$[;R.3@@8X')]!S7GWQ'\ IXYU+4!;OY.KV-A:RV,V['S&2XRA/8' Y[$
M ^M4/AYX\N/$VH:5HFMH\7B+2IIH[E9%P9%$;+O]FSP??GOP =])XX\.Q:M)
MI3ZAC4(QE[402&0#&<[=N<8(/XU>TGQ#I6N27,>FW:SR6K!9TVLK1D\@$$ C
MI7C=]>7EA^TIJMS8:<^H7*:=E+=)%0N?)3NW%>N^&D6XTFQU>50+^^L+8W#X
MP7(3/(^KG]* -JL(^,M &N?V(;__ (FG_/IY,GF=,YQMZ8YSTQ6[7BS_ /)U
M,?\ UX?^T30!Z;#XP\/SZ\="34XAJH)'V1PR2<#/1@.W/TJ[)K-C%J\>E/*X
MO9$,B1^4YW*,9;.,8&0"<\9%>7_$+P#/XGOM6UO17>'Q%I=Q$]LR-@RJ(D;9
MGLP/*GUX[\7?AWX^7QM?V3W$1CUBPT^ZBO8=N/F\R###T#;3QV((H [K5/%.
MBZ->0V=[?*MY,,QVL2-+,X]1&@+8]\5)8>(M)U.\-E:7J/>*AD>V8%)44$#+
M(P#+]X=0,UY/\!)VUV_\4^(]0/FZK<7"([MR40@G:/0=!C_9'I7L#:9:-K$>
MJ^6!>);M;>8.\;,K8/K@KQZ9/K0!<HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#SNS^'NKV'Q'U'QE!K5EY]]%Y+6TEDQ55P@X(D!S\@_6MF/PYKCIK+7NKV<L
ME[;+:VR16;1Q6J .#A=Y+$[@3R/NBNKHH \S\/?#+6- \%W?A:'Q);BSNY':
M6=+ B8*ZA6529,#('7!ZUL77P]M8?AS-X.T29+*VFC*//,AE8DD%F.",L<?3
M\L5VE% '.^"?#ESX2\)VFARWD5W]E#+',L1CR"Q;D;CZ^M8?ASX?WVA?$#5_
M%+ZK;S_VF&62W%LR[ 6!X;>?[OI7?44 8EYH][>>);2_EN;5].MHG1;1X"6W
MMC,F[=C( (''1CZUS'B;X;W&K^.-*\4:5J=MI=SIX "BU+^: 2<-AEX(+#Z&
MO0J* .:AT;7;'7-4U&UU.UE@OY(Y#93PL%C98DC+*X.>=F2,'MTYR_PGX4A\
M,KJ4_F)+>ZG=M=W4D<>Q-QZ*JY.%'N23DFNBHH R)M.OY/$]MJ:75L+2&WD@
M\@PL7;>R,3NW8'^K'&.YK*TWP-:Z%9^(8](>.*;69Y)F>2/(CW+C: ",@$L0
M,C[U=910!P'@SX?7_@_P;J/AZ/5K:Y%TTCI.ULR["Z!3D;^>F>HJ/P9X!UWP
M3X=ETBPUO39U:=ITEN-/<E&*A>@E'I^M>AT4 ><^*?AMJ/BCP18^';C7HQ)#
M<FZGO&M2S32$N3A0X"C,AXYZ5:U3X>3>)HM*M/$FJQW&F:<59;.TMC")G5=H
M,C%V)&,\#'4\UWE% ' ^/OA[=>,[[19H-3M["+2I#+$AMC)N)*G!PPP/D[>M
M7?&/@&#Q<=.OOMC:?KFG.)+6^@3<%((."I/S+D9QG^9SV-% &!!9>);A8XM1
MU.QBC4CS&L;=EDEQV!9B$![X!/H1UK U_P"']]K7Q&TKQ:FJV\)TU%CCMC;,
MV]06/+;QS\Y[=J[ZB@#'M].U&+Q+=:E)=VS6L]O%!Y"PL'78TC [MV#GS#V[
M"J,W@JP/CVU\76^(;U8'@N% XG!&%8_[0QC/<?05TU% 'GA^'NJI\39_&L&L
MV:S2Q>3]F>S9E"[ O42 YXS5^^\.Z]+:ZO/=>)H;1Y+(6UD]G:&);(9RS#+D
MDG"C.1C'%=I10!SW@>#5K7P?80ZW<RW5\@<--,I61TWML+ \AMFW(/(/7FL%
MOA]?GXICQM_:UMN$?D_9/LS8V[-OWM_7OTKOZ* ,C3=.U"TU?4KJYNK:6"\D
M5TCCA96C*H%Y8L=V0N>@JA8^"K#3/'=YXHLL0R7UJ8;F%5^5WW*PD'H2 <^O
M7USTU% '!VGP_NO#?BF_UOPIJ$%M%J)W7>GW4)>)FR3N0J05.2>.1R?;&_)I
M>LW5A?K<:R(;RXMWA@:UAV1VQ(X< DEF!QR2.G '.=VB@#'\+:5J&B^&[/3]
M4U635+R$$27<H.Y\L2.I). 0,D]JV*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH_X2_0_^?T_]^)/_ (F@#;HK$_X2_0_^?T_]^)/_ (FC_A+]#_Y_3_WXD_\
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MAOO>8<<GVQT^E:]MKFIW7Q+U#P](+-;>VT\7*7$<)\X!VQMR6(X(SG&#@<4
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MUJ>>=S=W7E%1'&I\J-T0E 2=V!S\I (H [ZLG5O$%II-S:6;)+<W]X2+>T@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=72D23NZX%Q(!A6) /J0,GOFNDD\-V\NOV6M2W5V]Y:0M#&2RA2C8W @+SG
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EDITAS MEDICINE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4097528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 Hurley Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">401-9000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EDIT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,920,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001650664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 138,542<span></span>
</td>
<td class="nump">$ 131,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">39,959<span></span>
</td>
<td class="nump">138,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">16,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,707<span></span>
</td>
<td class="nump">3,136<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">182,796<span></span>
</td>
<td class="nump">289,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,576<span></span>
</td>
<td class="nump">14,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">19,011<span></span>
</td>
<td class="nump">32,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Restricted cash and other non-current assets</a></td>
<td class="nump">4,198<span></span>
</td>
<td class="nump">5,223<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">210,581<span></span>
</td>
<td class="nump">341,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,723<span></span>
</td>
<td class="nump">5,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">48,068<span></span>
</td>
<td class="nump">45,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Liability for sale of future revenues, current</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">6,146<span></span>
</td>
<td class="nump">14,652<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">65,937<span></span>
</td>
<td class="nump">77,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">14,989<span></span>
</td>
<td class="nump">20,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Liability for sale of future revenues - non-current</a></td>
<td class="nump">51,670<span></span>
</td>
<td class="nump">52,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">54,204<span></span>
</td>
<td class="nump">54,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">4,592<span></span>
</td>
<td class="nump">3,072<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">191,392<span></span>
</td>
<td class="nump">207,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value per share: 390,000,000 and 195,000,000 shares authorized at June&#160;30, 2025 and December&#160;31, 2024, respectively; 87,388,425 and 82,734,696 shares issued and outstanding at June&#160;30, 2025 and December&#160;31, 2024, respectively</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,616,931<span></span>
</td>
<td class="nump">1,602,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,597,766)<span></span>
</td>
<td class="num">(1,468,443)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">19,189<span></span>
</td>
<td class="nump">134,274<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 210,581<span></span>
</td>
<td class="nump">$ 341,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">390,000,000<span></span>
</td>
<td class="nump">195,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">87,388,425<span></span>
</td>
<td class="nump">82,734,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">87,388,425<span></span>
</td>
<td class="nump">82,734,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and other research and development revenues</a></td>
<td class="nump">$ 3,578<span></span>
</td>
<td class="nump">$ 513<span></span>
</td>
<td class="nump">$ 8,236<span></span>
</td>
<td class="nump">$ 1,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue type</a></td>
<td class="text">Service [Member]<span></span>
</td>
<td class="text">Service [Member]<span></span>
</td>
<td class="text">Service [Member]<span></span>
</td>
<td class="text">Service [Member]<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 16,181<span></span>
</td>
<td class="nump">$ 54,210<span></span>
</td>
<td class="nump">$ 42,774<span></span>
</td>
<td class="nump">$ 102,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,859<span></span>
</td>
<td class="nump">18,206<span></span>
</td>
<td class="nump">26,234<span></span>
</td>
<td class="nump">37,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Restructuring and impairment charges</a></td>
<td class="nump">26,082<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">66,935<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">55,122<span></span>
</td>
<td class="nump">72,416<span></span>
</td>
<td class="nump">135,943<span></span>
</td>
<td class="nump">140,542<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(51,544)<span></span>
</td>
<td class="num">(71,903)<span></span>
</td>
<td class="num">(127,707)<span></span>
</td>
<td class="num">(138,893)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(1,758)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2,183)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest related to sale of future revenues</a></td>
<td class="num">(2,020)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,236)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income, net</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="nump">4,297<span></span>
</td>
<td class="nump">4,803<span></span>
</td>
<td class="nump">9,331<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(1,691)<span></span>
</td>
<td class="nump">4,296<span></span>
</td>
<td class="num">(1,616)<span></span>
</td>
<td class="nump">9,336<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (53,235)<span></span>
</td>
<td class="num">$ (67,607)<span></span>
</td>
<td class="num">$ (129,323)<span></span>
</td>
<td class="num">$ (129,557)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
<td class="num">$ (1.54)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
<td class="num">$ (1.54)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">84,412,200<span></span>
</td>
<td class="nump">82,310,368<span></span>
</td>
<td class="nump">83,737,382<span></span>
</td>
<td class="nump">82,124,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">84,412,200<span></span>
</td>
<td class="nump">82,310,368<span></span>
</td>
<td class="nump">83,737,382<span></span>
</td>
<td class="nump">82,124,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (53,235)<span></span>
</td>
<td class="num">$ (67,607)<span></span>
</td>
<td class="num">$ (129,323)<span></span>
</td>
<td class="num">$ (129,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable debt securities</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="num">(640)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (53,308)<span></span>
</td>
<td class="num">$ (67,723)<span></span>
</td>
<td class="num">$ (129,576)<span></span>
</td>
<td class="num">$ (130,197)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning of period (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,767,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2023</a></td>
<td class="nump">$ 349,097<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 1,580,241<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="num">$ (1,231,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable debt securities</a></td>
<td class="num">(524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(61,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,950)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,234,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Mar. 31, 2024</a></td>
<td class="nump">294,400<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">1,588,018<span></span>
</td>
<td class="num">(326)<span></span>
</td>
<td class="num">(1,293,300)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning of period (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,767,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2023</a></td>
<td class="nump">349,097<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">1,580,241<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="num">(1,231,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable debt securities</a></td>
<td class="num">(640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(129,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,429,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Jun. 30, 2024</a></td>
<td class="nump">232,009<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">1,593,350<span></span>
</td>
<td class="num">(442)<span></span>
</td>
<td class="num">(1,360,907)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning of period (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,234,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Mar. 31, 2024</a></td>
<td class="nump">294,400<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">1,588,018<span></span>
</td>
<td class="num">(326)<span></span>
</td>
<td class="num">(1,293,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable debt securities</a></td>
<td class="num">(116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(67,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,607)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,429,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Jun. 30, 2024</a></td>
<td class="nump">232,009<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">1,593,350<span></span>
</td>
<td class="num">(442)<span></span>
</td>
<td class="num">(1,360,907)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning of period (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,734,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2024</a></td>
<td class="nump">134,274<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">1,602,441<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="num">(1,468,443)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from at the market equity offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from at the market equity offering</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable debt securities</a></td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(76,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,088)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,709,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Mar. 31, 2025</a></td>
<td class="nump">62,420<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">1,606,855<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="num">(1,544,531)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning of period (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,734,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2024</a></td>
<td class="nump">134,274<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">1,602,441<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="num">(1,468,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable debt securities</a></td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(129,323)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,388,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Jun. 30, 2025</a></td>
<td class="nump">19,189<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">1,616,931<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(1,597,766)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning of period (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,709,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Mar. 31, 2025</a></td>
<td class="nump">62,420<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">1,606,855<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="num">(1,544,531)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from at the market equity offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,419,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from at the market equity offering</a></td>
<td class="nump">7,185<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">7,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable debt securities</a></td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(53,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,235)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,388,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Jun. 30, 2025</a></td>
<td class="nump">$ 19,189<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 1,616,931<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="num">$ (1,597,766)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (129,323)<span></span>
</td>
<td class="num">$ (129,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,643<span></span>
</td>
<td class="nump">12,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,751<span></span>
</td>
<td class="nump">2,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,193<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Net amortization of premiums and discounts on marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(840)<span></span>
</td>
<td class="num">(3,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_InterestRelatedToSaleOfFutureRevenues', window );">Interest related to sale of future revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,236<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of held for sale assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,724<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(390)<span></span>
</td>
<td class="num">(415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,678<span></span>
</td>
<td class="nump">9,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(418)<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_IncreaseDecreaseInRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,694<span></span>
</td>
<td class="num">(3,271)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">5,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,271<span></span>
</td>
<td class="num">(6,538)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues', window );">Accrued interest on sale of future revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,128)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,221)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,048)<span></span>
</td>
<td class="nump">2,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,911<span></span>
</td>
<td class="nump">1,969<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(98,011)<span></span>
</td>
<td class="num">(106,934)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(5,365)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from the sale of equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">151<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(86,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99,000<span></span>
</td>
<td class="nump">138,795<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99,037<span></span>
</td>
<td class="nump">47,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment on sale of future revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,872)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock from at the market equity offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,619<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under employee stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,975<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,001<span></span>
</td>
<td class="num">(59,211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">135,418<span></span>
</td>
<td class="nump">127,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">142,419<span></span>
</td>
<td class="nump">68,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">138,542<span></span>
</td>
<td class="nump">64,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,877<span></span>
</td>
<td class="nump">3,877<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">142,419<span></span>
</td>
<td class="nump">68,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash and non-cash activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed asset additions included in accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid in connection with operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,048<span></span>
</td>
<td class="nump">7,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Remeasurement of operating lease liabilities and right-of-use assets due to lease modification</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">766<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_CommencementOfRightOfUseAsset', window );">Commencement of right-of-use asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_NonCashTerminationOfRightOfUseAsset', window );">Non-cash termination of right-of-use asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,849<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> As of June&#160;30, 2025 and June&#160;30, 2024, restricted cash of $3,877 and $3,877 was included in Restricted cash and other non-current assets on the Consolidated Balance Sheet, respectively.</span></div></td></tr></table></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_CommencementOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commencement Of Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_CommencementOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Interest Related To Sale Of Future Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_IncreaseDecreaseInRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represents the increase (decrease) in right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_IncreaseDecreaseInRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_InterestRelatedToSaleOfFutureRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Related To Sale Of Future Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_InterestRelatedToSaleOfFutureRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_NonCashTerminationOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Termination Of Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_NonCashTerminationOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text">Nature of Business<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Editas Medicine, Inc. (the &#8220;Company&#8221;) is a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, Inc. (&#8220;Juno Therapeutics&#8221;), a wholly owned subsidiary of the Bristol-Myers Squibb Company (&#8220;BMS&#8221;), payments received under its former strategic alliance with Allergan Pharmaceuticals International Limited (together with its affiliates, &#8220;Allergan&#8221;), which was terminated in August 2020, payments received under the purchase and sale agreement with DRI Healthcare Acquisitions LP (&#8220;DRI&#8221;), and payments received in conjunction with the Company&#8217;s license agreement with Vertex Pharmaceuticals, Inc (&#8220;Vertex&#8221;, and such agreement, the &#8220;Vertex License Agreement&#8221;).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of June&#160;30, 2025, the Company has raised an aggregate of $1.0 billion in net proceeds through the sale of shares of its common stock in public offerings and at-the-market offerings. The Company also has funded its business from payments received under its purchase and sale agreement with DRI, payments received under the Vertex License Agreement, its research collaboration with BMS through its wholly owned subsidiary Juno Therapeutics and its former strategic alliance with Allergan (which was terminated in August 2020). As of June&#160;30, 2025, the Company had cash, cash equivalents and marketable securities of $178.5 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In May 2021, the Company entered into a common stock sales agreement with TD Securities (USA) LLC (as successor to Cowen and Company, LLC) (&#8220;TD Cowen&#8221;), under which the Company from time to time can issue and sell shares of the Company&#8217;s common stock through TD Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $300.0 million. The Company amended the common stock sales agreement with TD Cowen in February 2024 in connection with filing a new registration statement.  In March 2025, the Company further amended its common stock sales agreement with TD Cowen in connection with amending its existing shelf registration statement following the loss of the Company&#8217;s status as a &#8220;well-known seasoned issuer&#8221; (as defined under Rule 405 of the Securities Act of 1933, as amended), reducing the amount of shares of common stock the Company may issue and sell through TD Cowen to aggregate gross sale proceeds of up to $150.0&#160;million (the &#8220;ATM Facility&#8221;). As of June&#160;30, 2025, the Company has sold 4,126,072 shares of common stock under the ATM Facility for gross proceeds of $8.6 million and has $141.4 million available under the ATM Facility. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred annual net operating losses in every year since its inception.  As of August&#160;12, 2025, the issuance date of the consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance date of the consolidated financial statements. The Company had an accumulated deficit of $1.6 billion at June&#160;30, 2025, and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations, and financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2024 (the &#8220;Annual Report&#8221;).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Editas Securities Corporation and Editas Medicine, LLC. All intercompany transactions and balances of the subsidiaries have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.  The three months ended June&#160;30, 2025 and 2024 are referred to as the second quarter of 2025 and 2024, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; to the consolidated financial statements included in the Annual Report. There have been no material changes to the significant accounting policies previously disclosed in the Annual Report with the exception of the following:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with restructuring activities in the period in which the liability is incurred.  Typical costs associated with restructuring activities include, employee termination benefits, contract termination costs and on-going contract costs for which there is no economic benefit.  For costs associated with employee terminations in which the employee is subject to an existing benefit arrangement, the post-employment benefits are recognized when probable and estimable.  Other employee termination costs are measured and recognized on the communication date, unless there is a required future service period, in which case, the expense is recognized over the service period.  Contract termination costs are recognized upon termination of the contract and costs for on-going contracts for which there is no future benefit, are recognized at fair value on the cease-use date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made estimates and judgments regarding the amount and timing of its restructuring expense and liability, including current and future period termination benefits and other exit costs to be incurred when related actions take place. Restructuring charges are reflected in the Company's condensed consolidated statements of operations. Actual results may differ from these estimates.  Refer to Note 12, &#8220;Restructuring and Impairment Charges&#8221; for further information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company will incorporate the changes in disclosure requirements in its financial statements included in its 2025 Annual Report.     </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income -Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve the disclosure of expenses by providing more detailed information about the types of expenses in commonly presented expense captions. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments can be applied either prospectively or retrospectively. The Company has not early adopted this ASU and is currently evaluating the impact of this new standard on its consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text">Cash Equivalents and Marketable Securities <div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities consisted of the following at June&#160;30, 2025 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Allowance<br/>for Credit<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">138,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">138,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">178,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">178,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities consisted of the following at December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Allowance<br/>for Credit<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">269,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">289&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">269,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company did not hold any marketable securities that were in a continuous unrealized loss position for more than twelve months. Furthermore, the Company has determined that there were no material changes in the credit risk of the securities. As of June&#160;30, 2025, the Company holds no securities with remaining maturities greater than one year.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no realized gains or losses on available-for-sale securities during the six months ended June&#160;30, 2025 or 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of June&#160;30, 2025 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">138,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">138,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">182,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">182,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of December&#160;31, 2024 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">273,790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">267,289&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s liability for sale of future revenues approximates the amount recorded on the Company&#8217;s balance sheet as of June&#160;30, 2025 and December&#160;31, 2024, which represents a level 3 fair value measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">External research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sublicense and license fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property and patent related fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional service expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48,068&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45,859&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">Property and Equipment, net<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory and manufacturing equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(26,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(31,648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to a number of license agreements under which the Company licenses patents, patent applications and other intellectual property from third parties. As such, the Company is obligated to pay licensors for various costs including upfront license fees, annual license fees, certain licensor expense reimbursements, success payments, research funding payments, and milestones triggerable upon certain development, regulatory, and commercial events as well as royalties on future product sales. These contracts are generally cancellable, with notice, at the Company&#8217;s option and do not have significant cancellation penalties. The terms and conditions as well as the accounting analysis for the Company&#8217;s significant commitments and contingencies are described in Note 8, &#8220;Commitments and Contingencies&#8221; to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensor Expense Reimbursement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to reimburse The Broad Institute, Inc. (&#8220;Broad&#8221;) and the President and Fellows of Harvard College (&#8220;Harvard&#8221;) for expenses incurred by each of them associated with the prosecution and maintenance of the patent rights that the Company licenses from them pursuant to the Amended and Restated Cas9-I License Agreement by and among the Company, Broad and Harvard, including the interference and opposition proceedings involving patents licensed to the Company under the license agreement, and other license agreements between the Company and Broad. As such, the Company anticipates that it has a substantial commitment in connection with these proceedings until such time as these proceedings have been resolved, but the amount of such commitment is not determinable. The Company incurred an aggregate of $2.3 million and $4.2 million in expenses during the three and six months ended June&#160;30, 2025.  The Company incurred an aggregate of $2.5 million and $4.6 million in expense during the three months and six months ended June&#160;30, 2024, respectively, for such reimbursement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Termination </span></div>In 2023, the Company entered into a license and service agreement pursuant to which it leased manufacturing space for its continued research and development activities. The lease commenced April 1, 2024. In September 2024, the Company modified the lease, and as a result of the modification the lease payments decreased and the notification period for the termination of the license and service agreement increased from 12 months&#8217; prior written notice to 18 months&#8217; prior written notice. In January 2025, the Company gave its termination notice on the license and service agreement, which resulted in the end of the term of the agreement being July 2026, and $8.9 million of remaining payments owed.  In April 2025, the Company further modified the lease to terminate on April 30, 2025 with a final fixed payment of $3.7&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_CollaborationAgreementsAbstract', window );"><strong>Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements <div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into multiple collaborations, out-licenses and strategic alliances with third parties that typically involve payments to or from the Company, including up-front payments, payments for research and development services, option payments, milestone payments and royalty payments to or from the Company. The terms and conditions as </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">well as the accounting analysis for the Company&#8217;s significant collaborations, out-licenses and strategic alliances are described in Note 9, &#8220;Collaboration Agreements&#8221; to the consolidated financial statements included in the Annual Report.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company&#8217;s contract liabilities were primarily related to the Company&#8217;s collaboration with BMS. The following table presents changes in the Company&#8217;s accounts receivable and contract liabilities for the six months ended June&#160;30, 2025 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(17,859)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6,221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">During the three and six months ended June 30, 2025 and 2024, the Company recognized the following collaboration revenue (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognized in the period from:</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in deferred revenue at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations satisfied in previous periods</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Amendment to BMS Collaboration Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, the Company entered into an amendment (&#8220;2024 Amendment&#8221;) to the Second Amended and Restated Collaboration and License Agreement, dated as of November 11, 2019, by and between the Company and Juno Therapeutics (the &#8220;2019 Collaboration Agreement&#8221;) to extend the collaboration to November 2026, with options to extend the collaboration for up to an additional two years, and provided Juno Therapeutics the ability to select up to three new gene targets for research.  The 2019 Collaboration Agreement, as amended by the 2024 Amendment, is herein referred to as the 2019 Amended Collaboration Agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s accounting assessment for the 2024 Amendment is described in Note 9, &#8220;Collaboration Agreements,&#8221; to the consolidated financial statements included in the Annual Report. </span></div>As of June&#160;30, 2025, there was no short-term deferred revenue and $50.2 million of long-term deferred revenue in the accompanying consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_CollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_CollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations was as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,643&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,595&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Awards</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of restricted stock unit awards activity for the six months ended June&#160;30, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock unit awards as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,326,523</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(371,498)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,033,046)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock unit awards as of June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">923,539</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no restricted stock units that contained performance-based vesting provisions granted in the six months ended June&#160;30, 2025.  There was no expense related to the vesting of performance-based restricted stock units for the three and six months ended June&#160;30, 2025 and $0.1 million and $3.5 million of expense related to the vesting of performance-based restricted stock units for the three and six months ended June&#160;30, 2024, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, total unrecognized compensation expense related to unvested restricted stock unit awards was $6.4 million, which the Company expects to recognize over a remaining weighted-average period of 1.99 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity for the six months ended June&#160;30, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Remaining<br/>Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,656,010</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,581,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,791,231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,445,817</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,026,696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, total unrecognized compensation expense related to stock options was $15.1 million, which the Company expects to recognize over a remaining weighted-average period of 2.7 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury stock and if converted methods. Contingently issuable shares are included in the calculation of basic loss per share as of the beginning of the period in which all the necessary conditions have been satisfied. Contingently issuable shares are included in diluted loss per share based on the number of shares, if any, that would be issuable under the terms of the arrangement if the end of the reporting period was the end of the contingency period, if the results are dilutive. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, unvested restricted stock unit awards and outstanding stock options are considered to be common stock equivalents, but they were excluded from the Company&#8217;s calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock unit awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">923,539</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,618,361</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,445,817</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,268,790</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,369,356</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,887,151</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability for the Sale of Future Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2024, the Company entered into a purchase and sale agreement (the &#8220;Purchase and Sale Agreement&#8221;) with DRI under which it sold, transferred, assigned, and conveyed to DRI certain future license fees and other payments (the &#8220;Purchased Receivables&#8221;) owed to the Company by Vertex under the terms of the Vertex License Agreement in exchange for an upfront cash payment by DRI to the Company of $57.0&#160;million. Under the Purchase and Sale Agreement, DRI is purchasing up to 100% of certain future fixed and sales-based annual license fees owed to the Company under the Vertex License Agreement, which fees range from $5.0&#160;million to $40.0&#160;million per year (inclusive of certain sales-based annual license fee increases) and a mid-double-digit percentage of a $50.0&#160;million contingent upfront payment that the Company may receive under the Vertex License Agreement, in each case after subtracting amounts that will be owed by the Company to Broad and Harvard (each term as defined in Note 8, respectively). The Company has retained rights to its portions of certain other sales-based annual license fees and the contingent upfront payment that may become due under the Vertex License Agreement, and the amounts that correspond to its licensor obligations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 470, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Borrower&#8217;s Accounting for Debt Modification</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has accounted for the transaction as debt. The gross proceeds of $57.0 million were recorded as a liability for the sale of future revenues, net of transaction costs of $1.8 million, which will be amortized over the estimated life of the arrangement using the effective interest method.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the effective interest rate used to record non-cash interest expense under the Purchase and Sale Agreement based on the estimate of future revenue payments to be made to DRI. As of June&#160;30, 2025, the estimated effective interest rate under the agreement was 15.1%. Over the life of the arrangement, the actual effective interest rate will be affected by the amount and timing of the payments made to DRI and changes in the Company's revenue forecasts. At each reporting date, the Company will reassess its estimate of total future payments to be made to DRI, and prospectively adjust the effective interest rate and amortization of the liability as necessary. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the liability related to the sale of future revenues under the Purchase and Sale Agreement with DRI as of June&#160;30, 2025 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred royalty obligation related to the sale of future revenues, net as of December&#160;31, 2024</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments for sale of future revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense associated with sale of future revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred royalty obligation related to the sale of future revenues, net as of June&#160;30, 2025</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Impairment Charges<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Impairment Charges</a></td>
<td class="text">Restructuring and Impairment Charges                                  <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2024, the Company&#8217;s board of directors approved the discontinuation of the clinical development of the Company's reni-cel program to treat sickle cell disease and transfusion-dependent beta thalassemia (the &#8220;Discontinuation&#8221;). As a result of the Discontinuation, the Company has ceased activities towards the filing of a biologic license application and potential commercialization of reni-cel.  In connection with the Discontinuation, the Board also approved a reduction in the Company&#8217;s employee workforce by approximately 180 positions, or approximately 65% (the &#8220;Reduction&#8221;).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since the Discontinuation and Reduction started in December 2024 through the six months ended June&#160;30, 2025, the Company has incurred the following restructuring and impairment charges</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands): </span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.484%"><tr><td style="width:1.0%"></td><td style="width:70.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs for ongoing contracts and terminated contracts </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Acceleration of expense for change in useful life estimate and lease termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring and impairment charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">79,167&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred the following restructuring and impairment charges for the three and six months ended June&#160;30, 2025, which are recorded in the consolidated statements of operations (in thousands): </span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"><tr><td style="width:1.0%"></td><td style="width:48.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs for ongoing contracts and terminated contracts </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Acceleration of expense for change in useful life estimate and lease termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring and impairment charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,082&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66,935&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The actions associated with the Discontinuation and Reduction commenced in December 2024 and are expected to be substantially completed by the end of 2025. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Termination Benefits</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employees affected by the Reduction received involuntary termination benefits pursuant to either a one-time benefit or arrangement or salary continuation for a set period of time in accordance with the Company&#8217;s Amended and Restated Severance Benefit Plan (the &#8220;Benefit Plan&#8221;). For employees who were notified of their termination in December 2024 and had no requirements to provide future services or were subject to the Benefit Plan, the Company recognized the liability for the termination benefits in full at fair value in the fourth quarter of 2024.  For employees who are required to </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">render services beyond a minimum retention period to receive their one-time termination benefits or salary continuation, the Company is recognizing the termination benefits ratably over their future service periods.  The service periods began in December 2024 and all will end at various dates throughout 2025.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the liability related to employee termination benefits as of June&#160;30, 2025 (in thousands):  </span></div><div style="margin-top:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.484%"><tr><td style="width:1.0%"></td><td style="width:64.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Employee Termination Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued employee termination benefits as of December&#160;31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits charges incurred during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts paid or otherwise settled during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued employee termination benefits as of June&#160;30, 2025</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,592&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company expects that it will incur approximately $15.0 million of employee termination benefit expense to implement the Reduction.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs for Ongoing Contracts and Terminated Contracts </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Discontinuation resulted in contract termination costs from vendor contracts before the end of their term, as well as costs that continue to be incurred under certain contracts with no future economic benefit to the Company.  In accordance with ASC 420, the Company recognized these unavoidable contract costs when incurred for terminated contracts or at the cease-use date, as it relates to contract costs that continue to be incurred.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the liability related to costs for ongoing contracts and contract termination costs as of June&#160;30, 2025 (in thousands): </span></div><div style="margin-top:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.060%"><tr><td style="width:1.0%"></td><td style="width:63.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contract Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued contract costs as of December&#160;31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract costs incurred during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts paid or otherwise settled during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued contract costs as of June&#160;30, 2025</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,734&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2025, $4.0 million of accrued contract costs was included in Other non-current liabilities on the Consolidated Balance Sheet. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These costs are subject to significant estimation based on the Company's expectation of the costs that will continue to be incurred on the contracts, as well as negotiation of contract changes and terminations with its vendors.  Changes in this estimate will be made in the period the information is known and could be material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment and Accelerated Depreciation Charges</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Discontinuation, the Company committed to a plan to actively sell specific assets within its asset group, primarily certain of its laboratory and manufacturing equipment. At March 31, 2025, the laboratory and manufacturing equipment met all of the prescribed criteria required to classify it as held for sale.  The Company recorded $0.3 million of held for sale assets at their fair value at March 31, 2025, resulting in a $3.7 million impairment charge during the three months ended March 31, 2025.  The sale was completed in April 2025.    </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company abandoned certain other leasehold improvements, software, and right of use assets in the second quarter of 2025, and as a result, the Company accelerated depreciation and rent expense and recorded the following in the condensed consolidated statements of operations (in thousands): </span></div><div style="margin-top:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:51.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation related to leasehold improvements and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Charges related to termination of lease </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text">Segments<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Chief Operating Decision Maker (&#8220;CODM&#8221;) or decision-making group in making decisions on how to allocate resources and assess performance.  The Company&#8217;s CODM is its CEO.  The CEO views the Company&#8217;s operations and manages the Company&#8217;s business as one operating segment, which is the business of developing and commercializing genome editing technology.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s CEO manages and allocates resources to the operations of the Company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with our long-term company-wide strategic goals.  In making these decisions, the Company&#8217;s CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.  The CODM performs this assessment based on the Company&#8217;s consolidated net loss.  Through this analysis, the CODM assesses performance by comparing actual consolidated net loss versus the budget, and then decides how to allocate resources to invest in the Company&#8217;s research and development programs.  The measure of segment assets is reported on the consolidated balance sheet as total assets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains additional information on our consolidated revenue and net loss, including significant segment expenses (in thousands): </span></div><div style="margin-top:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.515%"><tr><td style="width:1.0%"></td><td style="width:53.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.992%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.992%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.992%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.996%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration and other research and development revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">External research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sublicense and license fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional service expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property and patent related fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility and other expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55,122&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">72,416&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">135,943&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">140,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(51,544)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(71,903)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(127,707)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(138,893)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,758)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest related to sale of future revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,691)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,296&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,616)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(53,235)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(67,607)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(129,323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(129,557)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The three and six months ended June&#160;30, 2025 and 2024 include $24,830 and $64,075 and $- and $- of restructuring and impairment charges, respectively.   </span></div></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The three and six months ended June&#160;30, 2025 and 2024 include $1,251 and $2,860 and $- and $- of restructuring and impairment charges, respectively.  </span></div></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Other expenses primarily consists of impairment charges, consultant fees and office expenses</span></div></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Facility and other expenses primarily consists of rent expense, insurance premiums, depreciation expense, software licenses and office expenses</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company will incorporate the changes in disclosure requirements in its financial statements included in its 2025 Annual Report.     </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income -Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve the disclosure of expenses by providing more detailed information about the types of expenses in commonly presented expense captions. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments can be applied either prospectively or retrospectively. The Company has not early adopted this ASU and is currently evaluating the impact of this new standard on its consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities consisted of the following at June&#160;30, 2025 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Allowance<br/>for Credit<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">138,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">138,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">178,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">178,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities consisted of the following at December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Allowance<br/>for Credit<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">269,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">289&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">269,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash, cash equivalent, and investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of June&#160;30, 2025 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">138,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">138,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">182,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">182,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of December&#160;31, 2024 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">273,790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">267,289&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">External research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sublicense and license fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property and patent related fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional service expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48,068&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45,859&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory and manufacturing equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(26,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(31,648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_CollaborationAgreementsAbstract', window );"><strong>Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock', window );">Schedule of Accounts Receivable and Contract Liabilities</a></td>
<td class="text">The following table presents changes in the Company&#8217;s accounts receivable and contract liabilities for the six months ended June&#160;30, 2025 (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(17,859)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6,221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Change in Contract Assets and Contract Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">During the three and six months ended June 30, 2025 and 2024, the Company recognized the following collaboration revenue (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognized in the period from:</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in deferred revenue at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations satisfied in previous periods</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_CollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_CollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of account receivable and contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Change in Contract with Customer Asset and Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations was as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,643&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,595&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Changes in Unvested Restricted Stock</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of restricted stock unit awards activity for the six months ended June&#160;30, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock unit awards as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,326,523</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(371,498)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,033,046)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock unit awards as of June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">923,539</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity for the six months ended June&#160;30, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Remaining<br/>Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,656,010</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,581,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,791,231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,445,817</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,026,696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-Dilutive Common Stock Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock unit awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">923,539</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,618,361</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,445,817</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,268,790</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,369,356</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,887,151</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the liability related to the sale of future revenues under the Purchase and Sale Agreement with DRI as of June&#160;30, 2025 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred royalty obligation related to the sale of future revenues, net as of December&#160;31, 2024</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments for sale of future revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense associated with sale of future revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred royalty obligation related to the sale of future revenues, net as of June&#160;30, 2025</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Impairment Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring and Related Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since the Discontinuation and Reduction started in December 2024 through the six months ended June&#160;30, 2025, the Company has incurred the following restructuring and impairment charges</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands): </span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.484%"><tr><td style="width:1.0%"></td><td style="width:70.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs for ongoing contracts and terminated contracts </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Acceleration of expense for change in useful life estimate and lease termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring and impairment charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">79,167&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred the following restructuring and impairment charges for the three and six months ended June&#160;30, 2025, which are recorded in the consolidated statements of operations (in thousands): </span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"><tr><td style="width:1.0%"></td><td style="width:48.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs for ongoing contracts and terminated contracts </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Acceleration of expense for change in useful life estimate and lease termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring and impairment charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,082&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66,935&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company abandoned certain other leasehold improvements, software, and right of use assets in the second quarter of 2025, and as a result, the Company accelerated depreciation and rent expense and recorded the following in the condensed consolidated statements of operations (in thousands): </span></div><div style="margin-top:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:51.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation related to leasehold improvements and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Charges related to termination of lease </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock', window );">Schedule of Employee Termination Benefits</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the liability related to employee termination benefits as of June&#160;30, 2025 (in thousands):  </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.484%"><tr><td style="width:1.0%"></td><td style="width:64.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Employee Termination Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued employee termination benefits as of December&#160;31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee termination benefits charges incurred during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts paid or otherwise settled during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued employee termination benefits as of June&#160;30, 2025</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,592&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_ScheduleOfContractTerminationCostsTableTextBlock', window );">Schedule of Contract Termination Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the liability related to costs for ongoing contracts and contract termination costs as of June&#160;30, 2025 (in thousands): </span></div><div style="margin-top:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.060%"><tr><td style="width:1.0%"></td><td style="width:63.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contract Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued contract costs as of December&#160;31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract costs incurred during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts paid or otherwise settled during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued contract costs as of June&#160;30, 2025</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,734&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ScheduleOfContractTerminationCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Contract Termination Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ScheduleOfContractTerminationCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Employee Termination Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains additional information on our consolidated revenue and net loss, including significant segment expenses (in thousands): </span></div><div style="margin-top:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.515%"><tr><td style="width:1.0%"></td><td style="width:53.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.992%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.992%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.992%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.996%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration and other research and development revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">External research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sublicense and license fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional service expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property and patent related fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility and other expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55,122&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">72,416&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">135,943&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">140,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(51,544)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(71,903)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(127,707)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(138,893)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,758)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest related to sale of future revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,691)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,296&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,616)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(53,235)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(67,607)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(129,323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(129,557)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The three and six months ended June&#160;30, 2025 and 2024 include $24,830 and $64,075 and $- and $- of restructuring and impairment charges, respectively.   </span></div></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The three and six months ended June&#160;30, 2025 and 2024 include $1,251 and $2,860 and $- and $- of restructuring and impairment charges, respectively.  </span></div></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Other expenses primarily consists of impairment charges, consultant fees and office expenses</span></div></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Facility and other expenses primarily consists of rent expense, insurance premiums, depreciation expense, software licenses and office expenses</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate net proceeds</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">178,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">8,619<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 1,597,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,468,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edit_AtMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued', window );">Sales agreement amount of aggregate sale proceeds of common stock agreed to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued (in shares)</a></td>
<td class="nump">4,126,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable', window );">Sales agreement, amount of aggregate sale proceeds of common stock available</a></td>
<td class="nump">$ 141,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of proceeds from common stock agreed to be issued or sold under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Agreement, Amount Of Aggregate Sale Proceeds Of Common Stock Available</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=edit_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=edit_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 178,486<span></span>
</td>
<td class="nump">$ 269,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">178,501<span></span>
</td>
<td class="nump">269,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">39,944<span></span>
</td>
<td class="nump">131,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">39,959<span></span>
</td>
<td class="nump">131,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">138,542<span></span>
</td>
<td class="nump">131,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 138,542<span></span>
</td>
<td class="nump">131,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Number of securities in an unrealized loss position for more than 12 months</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_MarketableSecuritiesNoncurrentNumberOfSecurities', window );">Number of noncurrent securities | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_MarketableSecuritiesRemainingMaturityTerm', window );">Marketable securities remaining maturity term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains (losses) on available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_MarketableSecuritiesNoncurrentNumberOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of noncurrent marketable securities held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_MarketableSecuritiesNoncurrentNumberOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_MarketableSecuritiesRemainingMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities Remaining Maturity Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_MarketableSecuritiesRemainingMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">$ 178,501<span></span>
</td>
<td class="nump">$ 269,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">39,959<span></span>
</td>
<td class="nump">131,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">182,378<span></span>
</td>
<td class="nump">273,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">39,959<span></span>
</td>
<td class="nump">131,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">138,542<span></span>
</td>
<td class="nump">131,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and other non-current assets:</a></td>
<td class="nump">3,877<span></span>
</td>
<td class="nump">3,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">182,378<span></span>
</td>
<td class="nump">267,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">39,959<span></span>
</td>
<td class="nump">131,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">138,542<span></span>
</td>
<td class="nump">131,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and other non-current assets:</a></td>
<td class="nump">3,877<span></span>
</td>
<td class="nump">3,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and other non-current assets:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and other non-current assets:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramLineItems', window );"><strong>Supplier Finance Program [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent', window );">External research and development expenses</a></td>
<td class="nump">$ 2,870<span></span>
</td>
<td class="nump">$ 11,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee related expenses</a></td>
<td class="nump">3,488<span></span>
</td>
<td class="nump">11,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_SublicenseAndLicenseFeesCurrent', window );">Sublicense and license fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_IntellectualPropertyAndPatentRelatedFeesCurrent', window );">Intellectual property and patent related fees</a></td>
<td class="nump">685<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional service expenses</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">48,068<span></span>
</td>
<td class="nump">45,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=edit_EmployeeTerminationBenefitsMember', window );">Employee termination benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramLineItems', window );"><strong>Supplier Finance Program [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Restructuring reserve</a></td>
<td class="nump">6,592<span></span>
</td>
<td class="nump">10,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Contract termination costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramLineItems', window );"><strong>Supplier Finance Program [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Restructuring reserve</a></td>
<td class="nump">$ 33,743<span></span>
</td>
<td class="nump">$ 1,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_AccruedExternalResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to accrued external research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_AccruedExternalResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_IntellectualPropertyAndPatentRelatedFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with intellectual property rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_IntellectualPropertyAndPatentRelatedFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_SublicenseAndLicenseFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublicense and License Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_SublicenseAndLicenseFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=edit_EmployeeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=edit_EmployeeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 31,404<span></span>
</td>
<td class="nump">$ 46,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(26,828)<span></span>
</td>
<td class="num">(31,648)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,576<span></span>
</td>
<td class="nump">14,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=edit_LaboratoryAndManufacturingEquipmentMember', window );">Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">21,066<span></span>
</td>
<td class="nump">29,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">8,404<span></span>
</td>
<td class="nump">11,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,399<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 344<span></span>
</td>
<td class="nump">$ 2,687<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=edit_LaboratoryAndManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=edit_LaboratoryAndManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Final fixed payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,048<span></span>
</td>
<td class="nump">$ 7,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=edit_LicenseAndServiceAgreementMember', window );">License and Service Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_OperatingLeaseTerminationNotificationPeriod', window );">Operating lease, termination notification period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Remaining payments owed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Final fixed payment</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=edit_LicensorExpenseReimbursementsMember', window );">Licensor Expense Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Expense for prosecution and maintenance of patent rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_OperatingLeaseTerminationNotificationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Termination Notification Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_OperatingLeaseTerminationNotificationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=edit_LicenseAndServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=edit_LicenseAndServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=edit_LicensorExpenseReimbursementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=edit_LicensorExpenseReimbursementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Schedule of Accounts Receivable and Contract Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_ReceivablesNetCurrentRollForward', window );"><strong>Accounts receivable:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, balance at beginning of period</a></td>
<td class="nump">$ 16,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_AccountsReceivableAdditions', window );">Accounts receivable, additions</a></td>
<td class="nump">2,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_AccountsReceivableDeductions', window );">Accounts receivable, deductions</a></td>
<td class="num">(17,859)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, balance at end of period</a></td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, balance at beginning of period</a></td>
<td class="nump">60,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_ContractWithCustomerLiabilityAdditions', window );">Deferred revenue, additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_ContractWithCustomerLiabilityDeductions', window );">Deferred revenue, deductions</a></td>
<td class="num">(6,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, balance at end of period</a></td>
<td class="nump">$ 54,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_AccountsReceivableAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of additions to accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_AccountsReceivableAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_AccountsReceivableDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of deductions to accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_AccountsReceivableDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer Liability Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ContractWithCustomerLiabilityDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer Liability Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ContractWithCustomerLiabilityDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ReceivablesNetCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables, Net, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ReceivablesNetCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Change in Contract Assets and Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract', window );"><strong>Change in Contract with Customer, Asset and Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amounts included in deferred revenue at the beginning of the period</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,221<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Performance obligations satisfied in previous periods</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,221,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,204,000<span></span>
</td>
<td class="nump">$ 54,204,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=edit_BristolMyersSquibbCompanyMember', window );">Bristol Myers Squibb Company ("BMS") | Amended Collaboration Agreement 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_AgreementExtensionPeriodOptionsToExtend', window );">Agreement extension period, options to extend</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_AgreementExtensionPeriodOptionsToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Extension Period, Options To Extend</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_AgreementExtensionPeriodOptionsToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=edit_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=edit_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=edit_AmendedCollaborationAgreement2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=edit_AmendedCollaborationAgreement2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,664<span></span>
</td>
<td class="nump">$ 5,010<span></span>
</td>
<td class="nump">$ 5,643<span></span>
</td>
<td class="nump">$ 12,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">5,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,801<span></span>
</td>
<td class="nump">$ 2,885<span></span>
</td>
<td class="nump">$ 3,873<span></span>
</td>
<td class="nump">$ 7,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Restricted Stock and Stock Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,664,000<span></span>
</td>
<td class="nump">$ 5,010,000<span></span>
</td>
<td class="nump">$ 5,643,000<span></span>
</td>
<td class="nump">$ 12,595,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Unit Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock unit awards, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,326,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(371,498)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,033,046)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock unit awards, end of period (in shares)</a></td>
<td class="nump">923,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">923,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,326,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Issued (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, ending of period (in dollars per share)</a></td>
<td class="nump">$ 9.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Share-Based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,656,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,581,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,791,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">10,445,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,445,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,656,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">4,026,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,026,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (in dollars per share)</a></td>
<td class="nump">$ 8.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 16.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 2 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 2,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalent shares (in shares)</a></td>
<td class="nump">11,369,356<span></span>
</td>
<td class="nump">10,887,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock unit awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalent shares (in shares)</a></td>
<td class="nump">923,539<span></span>
</td>
<td class="nump">2,618,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalent shares (in shares)</a></td>
<td class="nump">10,445,817<span></span>
</td>
<td class="nump">8,268,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - DRI Healthcare Acquisitions LP - License Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from sale of future revenues</a></td>
<td class="nump">$ 57.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_ContingentFeeReceivableThresholdAmount', window );">Contingent upfront payment</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate', window );">Liability for sale of future revenues, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=edit_DRIHealthcareAcquisitionsLPMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_LicenseFeeReceivable', window );">License fee receivable</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=edit_DRIHealthcareAcquisitionsLPMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_LicenseFeeReceivable', window );">License fee receivable</a></td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ContingentFeeReceivableThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Fee Receivable, Threshold Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ContingentFeeReceivableThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Sale Of Future Revenues, Effective Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_LicenseFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Fee Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_LicenseFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=edit_DRIHealthcareAcquisitionsLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=edit_DRIHealthcareAcquisitionsLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=edit_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=edit_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_DebtInstrumentRollForward', window );"><strong>Debt Instrument [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments for sale of future revenues</a></td>
<td class="num">$ (2,872)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=edit_DRIHealthcareAcquisitionsLPMember', window );">DRI Healthcare Acquisitions LP | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_DebtInstrumentRollForward', window );"><strong>Debt Instrument [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Deferred royalty obligation related to the sale of future revenues, net as of December&#160;31, 2024</a></td>
<td class="nump">57,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments for sale of future revenues</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues', window );">Non-cash interest expense associated with sale of future revenues</a></td>
<td class="nump">4,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of issuance costs</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Deferred royalty obligation related to the sale of future revenues, net as of June&#160;30, 2025</a></td>
<td class="nump">$ 56,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_DebtInstrumentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_DebtInstrumentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash Interest Expense On Liability For Sale Of Future Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=edit_DRIHealthcareAcquisitionsLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=edit_DRIHealthcareAcquisitionsLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=edit_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=edit_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Impairment Charges - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Restructuring and related cost, number of positions eliminated | position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Restructuring and related cost, number of positions eliminated, period percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember', window );">Discontinued Operations, Held-for-Sale or Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of held for sale assets</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=edit_LaboratoryAndManufacturingEquipmentMember', window );">Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent', window );">Equipment held for sale</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=edit_EmployeeTerminationBenefitsMember', window );">Employee termination benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring and related cost, expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=edit_LaboratoryAndManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=edit_LaboratoryAndManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=edit_EmployeeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=edit_EmployeeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Impairment Charges - Schedule of Restructuring and Related Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Restructuring and impairment charges</a></td>
<td class="nump">$ 26,082<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 66,935<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=edit_EmployeeTerminationBenefitsMember', window );">Employee termination benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Restructuring and impairment charges</a></td>
<td class="nump">813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Costs for ongoing contracts and terminated contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Restructuring and impairment charges</a></td>
<td class="nump">23,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember', window );">Acceleration of expense for change in useful life estimate and lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Restructuring and impairment charges</a></td>
<td class="nump">1,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=edit_ImpairmentChargesMember', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Restructuring and impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=edit_EmployeeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=edit_EmployeeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=edit_ImpairmentChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=edit_ImpairmentChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Impairment Charges - Schedule of Employee Termination Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Employee termination benefits charges incurred during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=edit_EmployeeTerminationBenefitsMember', window );">Employee Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">$ 10,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Employee termination benefits charges incurred during period</a></td>
<td class="nump">4,322<span></span>
</td>
<td class="nump">14,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash', window );">Amounts paid or otherwise settled during the period</a></td>
<td class="num">(8,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 6,592<span></span>
</td>
<td class="nump">$ 6,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Restructuring And Restructuring Reserve, Settled Without Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=edit_EmployeeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=edit_EmployeeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Impairment Charges - Schedule of Contract Termination Costs (Details) - Contract Costs<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">$ 1,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Contract costs incurred during the period</a></td>
<td class="nump">52,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_AmountsPaidOrOtherwiseSettled', window );">Amounts paid or otherwise settled during the period</a></td>
<td class="num">(16,364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 37,734<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_AmountsPaidOrOtherwiseSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Paid Or Otherwise Settled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_AmountsPaidOrOtherwiseSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 275<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479072/912-275-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Impairment Charges - Schedule of Accelerated Depreciation and Rent Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation related to leasehold improvements and software</a></td>
<td class="nump">$ 1,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_ChargesRelatedToTerminationOfLease', window );">Charges related to termination of lease</a></td>
<td class="nump">731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Total</a></td>
<td class="nump">26,082<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">66,935<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember', window );">Acceleration of expense for change in useful life estimate and lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Total</a></td>
<td class="nump">$ 1,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ChargesRelatedToTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Charges Related To Termination Of Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ChargesRelatedToTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and other research and development revenues</a></td>
<td class="nump">$ 3,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,236<span></span>
</td>
<td class="nump">$ 1,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">2,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,643<span></span>
</td>
<td class="nump">12,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">55,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,943<span></span>
</td>
<td class="nump">140,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(51,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127,707)<span></span>
</td>
<td class="num">(138,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(1,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,183)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest related to sale of future revenues</a></td>
<td class="num">(2,020)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,236)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income, net</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,803<span></span>
</td>
<td class="nump">9,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(1,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,616)<span></span>
</td>
<td class="nump">9,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(53,235)<span></span>
</td>
<td class="num">$ (76,088)<span></span>
</td>
<td class="num">(67,607)<span></span>
</td>
<td class="num">$ (61,950)<span></span>
</td>
<td class="num">(129,323)<span></span>
</td>
<td class="num">(129,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=edit_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and other research and development revenues</a></td>
<td class="nump">3,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,236<span></span>
</td>
<td class="nump">1,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">55,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,943<span></span>
</td>
<td class="nump">140,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(51,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127,707)<span></span>
</td>
<td class="num">(138,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(1,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,183)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income, net</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,803<span></span>
</td>
<td class="nump">9,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(1,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,616)<span></span>
</td>
<td class="nump">9,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(53,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129,323)<span></span>
</td>
<td class="num">(129,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">5,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Employee related expenses</a></td>
<td class="nump">8,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,742<span></span>
</td>
<td class="nump">27,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">External research and development expenses</a></td>
<td class="nump">25,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466<span></span>
</td>
<td class="nump">44,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OccupancyNet', window );">Facility expenses</a></td>
<td class="nump">4,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,974<span></span>
</td>
<td class="nump">12,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">5,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_SublicenseAndLicenseFees', window );">Sublicense and license fees</a></td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">6,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses</a></td>
<td class="nump">1,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,785<span></span>
</td>
<td class="nump">6,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and impairment charges</a></td>
<td class="nump">24,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">1,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,873<span></span>
</td>
<td class="nump">7,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Employee related expenses</a></td>
<td class="nump">3,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,541<span></span>
</td>
<td class="nump">9,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OccupancyNet', window );">Facility expenses</a></td>
<td class="nump">1,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,762<span></span>
</td>
<td class="nump">5,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">1,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,873<span></span>
</td>
<td class="nump">7,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional service expenses</a></td>
<td class="nump">3,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,151<span></span>
</td>
<td class="nump">6,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edit_IntellectualPropertyAndPatentRelatedFees', window );">Intellectual property and patent related fees</a></td>
<td class="nump">3,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,767<span></span>
</td>
<td class="nump">$ 7,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and impairment charges</a></td>
<td class="nump">$ 1,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_IntellectualPropertyAndPatentRelatedFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with intellectual property rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_IntellectualPropertyAndPatentRelatedFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_SublicenseAndLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublicense And License Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_SublicenseAndLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OccupancyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net occupancy expense that may include items, such as depreciation of facilities and equipment, lease expenses, property taxes and property and casualty insurance expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481161/840-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OccupancyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=edit_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=edit_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>173</ContextCount>
  <ElementCount>249</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/NatureofBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecurities</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/PropertyandEquipmentnet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Restructuring and Impairment Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/RestructuringandImpairmentCharges</Role>
      <ShortName>Restructuring and Impairment Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecurities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/PropertyandEquipmentnetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/PropertyandEquipmentnet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/CollaborationAgreements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/StockbasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/NetLossperShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/Debt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Restructuring and Impairment Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/RestructuringandImpairmentChargesTables</Role>
      <ShortName>Restructuring and Impairment Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/RestructuringandImpairmentCharges</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/Segments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/NatureofBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/NatureofBusiness</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/AccruedExpensesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails</Role>
      <ShortName>Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/PropertyandEquipmentnetTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/CommitmentsandContingencies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Collaboration Agreements - Schedule of Accounts Receivable and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails</Role>
      <ShortName>Collaboration Agreements - Schedule of Accounts Receivable and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Collaboration Agreements - Change in Contract Assets and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CollaborationAgreementsChangeinContractAssetsandContractLiabilitiesDetails</Role>
      <ShortName>Collaboration Agreements - Change in Contract Assets and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Collaboration Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails</Role>
      <ShortName>Collaboration Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Stock-based Compensation - Restricted Stock and Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails</Role>
      <ShortName>Stock-based Compensation - Restricted Stock and Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/NetLossperShareDetails</Role>
      <ShortName>Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/NetLossperShareTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Debt - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DebtScheduleofDebtDetails</Role>
      <ShortName>Debt - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Restructuring and Impairment Charges - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails</Role>
      <ShortName>Restructuring and Impairment Charges - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Restructuring and Impairment Charges - Schedule of Restructuring and Related Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails</Role>
      <ShortName>Restructuring and Impairment Charges - Schedule of Restructuring and Related Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Restructuring and Impairment Charges - Schedule of Employee Termination Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails</Role>
      <ShortName>Restructuring and Impairment Charges - Schedule of Employee Termination Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Restructuring and Impairment Charges - Schedule of Contract Termination Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails</Role>
      <ShortName>Restructuring and Impairment Charges - Schedule of Contract Termination Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Restructuring and Impairment Charges - Schedule of Accelerated Depreciation and Rent Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails</Role>
      <ShortName>Restructuring and Impairment Charges - Schedule of Accelerated Depreciation and Rent Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Segments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/SegmentsNarrativeDetails</Role>
      <ShortName>Segments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="edit-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Segments - Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segments - Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="edit-20250630.htm">edit-20250630.htm</File>
    <File>edit-20250630.xsd</File>
    <File>edit-20250630_cal.xml</File>
    <File>edit-20250630_def.xml</File>
    <File>edit-20250630_lab.xml</File>
    <File>edit-20250630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="618">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "edit-20250630.htm": {
   "nsprefix": "edit",
   "nsuri": "http://www.editasmedicine.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "edit-20250630.htm"
     ]
    },
    "schema": {
     "local": [
      "edit-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "edit-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "edit-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "edit-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "edit-20250630_pre.xml"
     ]
    }
   },
   "keyStandard": 217,
   "keyCustom": 32,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 26,
   "memberCustom": 12,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2025": 6,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 173,
   "entityCount": 1,
   "segmentCount": 41,
   "elementCount": 501,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 618,
    "http://xbrl.sec.gov/dei/2025": 29,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.editasmedicine.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "longName": "9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-30",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-35",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "9952156 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.editasmedicine.com/role/NatureofBusiness",
     "longName": "9952157 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.editasmedicine.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecurities",
     "longName": "9952159 - Disclosure - Cash Equivalents and Marketable Securities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.editasmedicine.com/role/FairValueMeasurements",
     "longName": "9952160 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.editasmedicine.com/role/AccruedExpenses",
     "longName": "9952161 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.editasmedicine.com/role/PropertyandEquipmentnet",
     "longName": "9952162 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.editasmedicine.com/role/CommitmentsandContingencies",
     "longName": "9952163 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.editasmedicine.com/role/CollaborationAgreements",
     "longName": "9952164 - Disclosure - Collaboration Agreements",
     "shortName": "Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.editasmedicine.com/role/StockbasedCompensation",
     "longName": "9952165 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.editasmedicine.com/role/NetLossperShare",
     "longName": "9952166 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.editasmedicine.com/role/Debt",
     "longName": "9952167 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.editasmedicine.com/role/RestructuringandImpairmentCharges",
     "longName": "9952168 - Disclosure - Restructuring and Impairment Charges",
     "shortName": "Restructuring and Impairment Charges",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.editasmedicine.com/role/Segments",
     "longName": "9952169 - Disclosure - Segments",
     "shortName": "Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.editasmedicine.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesTables",
     "longName": "9955512 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.editasmedicine.com/role/FairValueMeasurementsTables",
     "longName": "9955513 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.editasmedicine.com/role/AccruedExpensesTables",
     "longName": "9955514 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.editasmedicine.com/role/PropertyandEquipmentnetTables",
     "longName": "9955515 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.editasmedicine.com/role/CollaborationAgreementsTables",
     "longName": "9955516 - Disclosure - Collaboration Agreements (Tables)",
     "shortName": "Collaboration Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "edit:ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "edit:ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.editasmedicine.com/role/StockbasedCompensationTables",
     "longName": "9955517 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.editasmedicine.com/role/NetLossperShareTables",
     "longName": "9955518 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.editasmedicine.com/role/DebtTables",
     "longName": "9955519 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesTables",
     "longName": "9955520 - Disclosure - Restructuring and Impairment Charges (Tables)",
     "shortName": "Restructuring and Impairment Charges (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.editasmedicine.com/role/SegmentsTables",
     "longName": "9955521 - Disclosure - Segments (Tables)",
     "shortName": "Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.editasmedicine.com/role/NatureofBusinessDetails",
     "longName": "9955522 - Disclosure - Nature of Business (Details)",
     "shortName": "Nature of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails",
     "longName": "9955523 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
     "longName": "9955524 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.editasmedicine.com/role/FairValueMeasurementsDetails",
     "longName": "9955525 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.editasmedicine.com/role/AccruedExpensesDetails",
     "longName": "9955526 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "edit:AccruedExternalResearchAndDevelopmentExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "edit:AccruedExternalResearchAndDevelopmentExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails",
     "longName": "9955527 - Disclosure - Property and Equipment, net (Details)",
     "shortName": "Property and Equipment, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails",
     "longName": "9955528 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-112",
      "name": "edit:OperatingLeaseTerminationNotificationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails",
     "longName": "9955529 - Disclosure - Collaboration Agreements - Schedule of Accounts Receivable and Contract Liabilities (Details)",
     "shortName": "Collaboration Agreements - Schedule of Accounts Receivable and Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "edit:AccountsReceivableAdditions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.editasmedicine.com/role/CollaborationAgreementsChangeinContractAssetsandContractLiabilitiesDetails",
     "longName": "9955530 - Disclosure - Collaboration Agreements - Change in Contract Assets and Contract Liabilities (Details)",
     "shortName": "Collaboration Agreements - Change in Contract Assets and Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "edit:ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "edit:ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails",
     "longName": "9955531 - Disclosure - Collaboration Agreements - Narrative (Details)",
     "shortName": "Collaboration Agreements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-115",
      "name": "edit:AgreementExtensionPeriodOptionsToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails",
     "longName": "9955532 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails",
     "longName": "9955533 - Disclosure - Stock-based Compensation - Restricted Stock and Stock Options (Details)",
     "shortName": "Stock-based Compensation - Restricted Stock and Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-126",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.editasmedicine.com/role/NetLossperShareDetails",
     "longName": "9955534 - Disclosure - Net Loss per Share (Details)",
     "shortName": "Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.editasmedicine.com/role/DebtNarrativeDetails",
     "longName": "9955535 - Disclosure - Debt - Narrative (Details)",
     "shortName": "Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails",
     "longName": "9955536 - Disclosure - Debt - Schedule of Debt (Details)",
     "shortName": "Debt - Schedule of Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepaymentsOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-144",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails",
     "longName": "9955537 - Disclosure - Restructuring and Impairment Charges - Narrative (Details)",
     "shortName": "Restructuring and Impairment Charges - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-146",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "position",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-146",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "position",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails",
     "longName": "9955538 - Disclosure - Restructuring and Impairment Charges - Schedule of Restructuring and Related Costs (Details)",
     "shortName": "Restructuring and Impairment Charges - Schedule of Restructuring and Related Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-151",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-152",
      "name": "us-gaap:RestructuringSettlementAndImpairmentProvisions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails",
     "longName": "9955539 - Disclosure - Restructuring and Impairment Charges - Schedule of Employee Termination Benefits (Details)",
     "shortName": "Restructuring and Impairment Charges - Schedule of Employee Termination Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-151",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails",
     "longName": "9955540 - Disclosure - Restructuring and Impairment Charges - Schedule of Contract Termination Costs (Details)",
     "shortName": "Restructuring and Impairment Charges - Schedule of Contract Termination Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-94",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "edit:ScheduleOfContractTerminationCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-94",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "edit:ScheduleOfContractTerminationCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails",
     "longName": "9955541 - Disclosure - Restructuring and Impairment Charges - Schedule of Accelerated Depreciation and Rent Expense (Details)",
     "shortName": "Restructuring and Impairment Charges - Schedule of Accelerated Depreciation and Rent Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RestructuringReserveAcceleratedDepreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RestructuringReserveAcceleratedDepreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.editasmedicine.com/role/SegmentsNarrativeDetails",
     "longName": "9955542 - Disclosure - Segments - Narrative (Details)",
     "shortName": "Segments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails",
     "longName": "9955543 - Disclosure - Segments - Schedule of Segment Reporting Information, by Segment (Details)",
     "shortName": "Segments - Schedule of Segment Reporting Information, by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-162",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250630.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "edit_AccelerationOfExpenseChangeInUsefulLifeEstimateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "AccelerationOfExpenseChangeInUsefulLifeEstimateMember",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acceleration of expense for change in useful life estimate and lease termination",
        "label": "Acceleration Of Expense, Change In Useful Life Estimate [Member]",
        "documentation": "Acceleration Of Expense, Change In Useful Life Estimate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r42",
      "r45",
      "r926"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r727"
     ]
    },
    "edit_AccountsReceivableAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "AccountsReceivableAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, additions",
        "label": "Accounts Receivable, Additions",
        "documentation": "Represents the amount of additions to accounts receivable."
       }
      }
     },
     "auth_ref": []
    },
    "edit_AccountsReceivableDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "AccountsReceivableDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, deductions",
        "label": "Accounts Receivable, Deductions",
        "documentation": "Represents the amount of deductions to accounts receivable."
       }
      }
     },
     "auth_ref": []
    },
    "edit_AccruedExternalResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "AccruedExternalResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External research and development expenses",
        "label": "Accrued External Research And Development Expenses, Current",
        "documentation": "Represents information pertaining to accrued external research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.editasmedicine.com/role/AccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails",
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities, Current [Abstract]",
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional service expenses",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r112",
      "r554"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r55",
      "r117",
      "r551",
      "r581",
      "r582",
      "r934"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10",
      "r18",
      "r439",
      "r442",
      "r497",
      "r577",
      "r578",
      "r856",
      "r857",
      "r858",
      "r871",
      "r872",
      "r873",
      "r874"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r871",
      "r872",
      "r873",
      "r874",
      "r935",
      "r1000"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r777",
      "r809"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760",
      "r770",
      "r780",
      "r812"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "edit_AgreementExtensionPeriodOptionsToExtend": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "AgreementExtensionPeriodOptionsToExtend",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement extension period, options to extend",
        "label": "Agreement Extension Period, Options To Extend",
        "documentation": "Agreement Extension Period, Options To Extend"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r771",
      "r781",
      "r805",
      "r813",
      "r817",
      "r825"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails",
      "http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expenses",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r411",
      "r412"
     ]
    },
    "edit_AmendedCollaborationAgreement2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "AmendedCollaborationAgreement2019Member",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Collaboration Agreement 2019",
        "label": "Amended Collaboration Agreement 2019",
        "documentation": "Represents information pertaining to 2019 Amended Collaboration Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r331",
      "r863",
      "r948"
     ]
    },
    "edit_AmountsPaidOrOtherwiseSettled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "AmountsPaidOrOtherwiseSettled",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amounts paid or otherwise settled during the period",
        "label": "Amounts Paid Or Otherwise Settled",
        "documentation": "Amounts Paid Or Otherwise Settled"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.editasmedicine.com/role/NetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive common stock equivalent shares (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/NetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/NetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/NetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails",
      "http://www.editasmedicine.com/role/DebtNarrativeDetails",
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of held for sale assets",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r29",
      "r729",
      "r730"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r94",
      "r114",
      "r138",
      "r141",
      "r142",
      "r175",
      "r183",
      "r201",
      "r205",
      "r243",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r429",
      "r431",
      "r477",
      "r540",
      "r541",
      "r547",
      "r611",
      "r677",
      "r678",
      "r694",
      "r727",
      "r735",
      "r736",
      "r748",
      "r895",
      "r896",
      "r950"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r118",
      "r138",
      "r141",
      "r142",
      "r243",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r429",
      "r431",
      "r477",
      "r727",
      "r895",
      "r896",
      "r950"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r713"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Assets",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "edit_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://www.editasmedicine.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At The Market Offering",
        "label": "At The Market Offering",
        "documentation": "Represents information pertaining to at market offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r251",
      "r546"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "verboseLabel": "Marketable securities:",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r251",
      "r453",
      "r472",
      "r473",
      "r474",
      "r475",
      "r536",
      "r653",
      "r713",
      "r717",
      "r724",
      "r882",
      "r939",
      "r940",
      "r941"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "edit_BristolMyersSquibbCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "BristolMyersSquibbCompanyMember",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bristol Myers Squibb Company (\"BMS\")",
        "label": "Bristol Myers Squibb Company (\"BMS\")",
        "documentation": "Bristol Myers Squibb Company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed asset additions included in accounts payable and accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Abstract]",
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents, end of period",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r110",
      "r654"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents:",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r474",
      "r475",
      "r937",
      "r938"
     ]
    },
    "edit_CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities Investments, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents and Marketable Securities",
        "label": "Cash, Cash Equivalent, and Marketable Security [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r67",
      "r135"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r67"
     ]
    },
    "us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInContractWithCustomerAssetAndLiabilityAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsChangeinContractAssetsandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Contract with Customer, Asset and Liability [Abstract]",
        "label": "Change in Contract with Customer, Asset and Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "edit_ChargesRelatedToTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "ChargesRelatedToTerminationOfLease",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charges related to termination of lease",
        "label": "Charges Related To Termination Of Lease",
        "documentation": "Charges Related To Termination Of Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "edit_CollaborationAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "CollaborationAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and Profit-Sharing Agreements",
        "label": "Collaboration Agreements [Abstract]",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r426",
      "r427"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails",
      "http://www.editasmedicine.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "edit_CommencementOfRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "CommencementOfRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commencement of right-of-use asset",
        "label": "Commencement Of Right-Of-Use Asset",
        "documentation": "Commencement Of Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r292",
      "r293",
      "r649",
      "r889",
      "r894"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r742",
      "r743",
      "r744",
      "r745",
      "r871",
      "r872",
      "r874",
      "r935",
      "r995",
      "r1000"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r599"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r49",
      "r599",
      "r617",
      "r1000",
      "r1001"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, $0.0001 par value per share: 390,000,000 and 195,000,000 shares authorized at June\u00a030, 2025 and December\u00a031, 2024, respectively; 87,388,425 and 82,734,696 shares issued and outstanding at June\u00a030, 2025 and December\u00a031, 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r341",
      "r347",
      "r550",
      "r727"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r123",
      "r125",
      "r129",
      "r538",
      "r559",
      "r560"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction-in-progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "edit_ContingentFeeReceivableThresholdAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "ContingentFeeReceivableThresholdAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent upfront payment",
        "label": "Contingent Fee Receivable, Threshold Amount",
        "documentation": "Contingent Fee Receivable, Threshold Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractTerminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractTerminationMember",
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Contract termination costs",
        "terseLabel": "Costs for ongoing contracts and terminated contracts",
        "verboseLabel": "Contract Costs",
        "label": "Contract Termination [Member]",
        "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r685",
      "r686",
      "r687",
      "r688"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Deferred revenue, balance at beginning of period",
        "periodEndLabel": "Deferred revenue, balance at end of period",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r360"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities:",
        "label": "Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "edit_ContractWithCustomerLiabilityAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "ContractWithCustomerLiabilityAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, additions",
        "label": "Contract With Customer Liability Additions",
        "documentation": "Contract With Customer Liability Additions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails",
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, current",
        "verboseLabel": "Short-term deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r360"
     ]
    },
    "edit_ContractWithCustomerLiabilityDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "ContractWithCustomerLiabilityDeductions",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred revenue, deductions",
        "label": "Contract With Customer Liability Deductions",
        "documentation": "Contract With Customer Liability Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails",
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, net of current portion",
        "verboseLabel": "Long-term deferred revenue",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r360"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsChangeinContractAssetsandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts included in deferred revenue at the beginning of the period",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "edit_ContractWithCustomerLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "ContractWithCustomerLiabilityRollForward",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities:",
        "label": "Contract with Customer, Liability [Roll Forward]",
        "documentation": "Contract with Customer, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsChangeinContractAssetsandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligations satisfied in previous periods",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate notes/bonds",
        "verboseLabel": "Corporate notes/bonds",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r701",
      "r703",
      "r713",
      "r728",
      "r737",
      "r992"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails",
      "http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r144",
      "r145",
      "r313",
      "r350",
      "r498",
      "r515",
      "r545",
      "r655",
      "r656",
      "r657",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r930",
      "r931",
      "r932",
      "r933"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "edit_DRIHealthcareAcquisitionsLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "DRIHealthcareAcquisitionsLPMember",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtNarrativeDetails",
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DRI Healthcare Acquisitions LP",
        "label": "DRI Healthcare Acquisitions LP [Member]",
        "documentation": "DRI Healthcare Acquisitions LP"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r138",
      "r140",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r298",
      "r299",
      "r309",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r325",
      "r332",
      "r333",
      "r335",
      "r437",
      "r487"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r334",
      "r437",
      "r542",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r725",
      "r865",
      "r866",
      "r867",
      "r870",
      "r947",
      "r949"
     ]
    },
    "edit_DebtInstrumentRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "DebtInstrumentRollForward",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Roll Forward]",
        "label": "Debt Instrument [Roll Forward]",
        "documentation": "Debt Instrument"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r33",
      "r34",
      "r37",
      "r80",
      "r81",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r334",
      "r437",
      "r542",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r725",
      "r865",
      "r866",
      "r867",
      "r870",
      "r947",
      "r949"
     ]
    },
    "edit_DebtRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "DebtRollForward",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt [Roll Forward]",
        "label": "Debt [Roll Forward]",
        "documentation": "Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for Credit Losses",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r251",
      "r256",
      "r257"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities in an unrealized loss position for more than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r253",
      "r683"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gains (losses) on available-for-sale securities",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r30",
      "r133",
      "r658",
      "r660",
      "r662",
      "r664"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r377",
      "r406",
      "r407",
      "r409",
      "r705"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations, Held-for-Sale or Disposed of by Sale",
        "label": "Discontinued Operations, Held-for-Sale or Disposed of by Sale [Member]",
        "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r6"
     ]
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r38",
      "r39",
      "r73",
      "r75"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r130",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r164",
      "r166",
      "r168",
      "r169",
      "r170",
      "r174",
      "r339",
      "r410",
      "r420",
      "r425",
      "r450",
      "r451",
      "r539",
      "r561",
      "r668"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r130",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r166",
      "r168",
      "r169",
      "r170",
      "r174",
      "r339",
      "r410",
      "r420",
      "r425",
      "r450",
      "r451",
      "r539",
      "r561",
      "r668"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/NetLossperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r171",
      "r172",
      "r173"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee related expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrecognized stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.editasmedicine.com/role/NetLossperShareDetails",
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "verboseLabel": "Outstanding stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "edit_EmployeeTerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "EmployeeTerminationBenefitsMember",
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee termination benefits",
        "verboseLabel": "Employee Termination Benefits",
        "label": "Employee Termination Benefits [Member]",
        "documentation": "Employee Termination Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r102",
      "r103",
      "r104",
      "r126",
      "r127",
      "r128",
      "r147",
      "r148",
      "r149",
      "r151",
      "r158",
      "r160",
      "r162",
      "r176",
      "r244",
      "r245",
      "r268",
      "r338",
      "r352",
      "r410",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r424",
      "r425",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r489",
      "r497",
      "r557",
      "r577",
      "r578",
      "r579",
      "r587",
      "r636"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r777",
      "r809"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r764",
      "r774",
      "r806"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r464",
      "r713"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r464",
      "r713"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r463",
      "r464",
      "r466",
      "r473",
      "r502",
      "r503",
      "r504",
      "r653",
      "r690",
      "r691",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r713",
      "r717",
      "r724"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r457",
      "r713",
      "r940",
      "r943"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r459",
      "r461",
      "r462",
      "r463",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r535",
      "r713",
      "r718"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r363",
      "r368",
      "r369",
      "r454",
      "r464",
      "r473",
      "r502",
      "r653",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r713",
      "r724"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r363",
      "r368",
      "r369",
      "r371",
      "r454",
      "r455",
      "r464",
      "r473",
      "r503",
      "r653",
      "r690",
      "r691",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r713",
      "r724"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r454",
      "r455",
      "r456",
      "r457",
      "r464",
      "r473",
      "r504",
      "r653",
      "r690",
      "r691",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r713",
      "r717",
      "r724"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r457",
      "r713",
      "r940",
      "r943"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r463",
      "r464",
      "r466",
      "r473",
      "r502",
      "r503",
      "r504",
      "r653",
      "r690",
      "r691",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r713",
      "r717",
      "r724"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r943"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r255",
      "r334",
      "r351",
      "r437",
      "r448",
      "r471",
      "r476",
      "r479",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r544",
      "r558",
      "r683",
      "r713",
      "r715",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r728",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r884",
      "r885",
      "r886",
      "r887",
      "r936",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r771",
      "r781",
      "r813"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r771",
      "r781",
      "r813"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r771",
      "r781",
      "r813"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r771",
      "r781",
      "r813"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r771",
      "r781",
      "r813"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and office equipment",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r620"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Axis]",
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Domain]",
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ]
    },
    "edit_ImpairmentChargesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "ImpairmentChargesMember",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Impairment Charges [Member]",
        "documentation": "Impairment Charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of held for sale assets",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r72",
      "r714"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r276",
      "r284",
      "r433",
      "r434",
      "r435",
      "r436",
      "r458",
      "r460",
      "r465",
      "r478",
      "r479",
      "r480",
      "r574",
      "r576",
      "r621",
      "r652",
      "r653",
      "r706",
      "r707",
      "r711",
      "r712",
      "r716",
      "r724",
      "r928",
      "r929",
      "r965"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r284",
      "r433",
      "r434",
      "r435",
      "r436",
      "r458",
      "r460",
      "r465",
      "r478",
      "r479",
      "r480",
      "r574",
      "r576",
      "r621",
      "r652",
      "r653",
      "r706",
      "r707",
      "r711",
      "r712",
      "r716",
      "r724",
      "r928",
      "r929",
      "r965"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r862"
     ]
    },
    "edit_IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest on sale of future revenues",
        "label": "Increase (Decrease) In Interest Related To Sale Of Future Revenues",
        "documentation": "Increase (Decrease) In Interest Related To Sale Of Future Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r862"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "edit_IncreaseDecreaseInRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "IncreaseDecreaseInRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use assets",
        "label": "Increase (Decrease) In Right Of Use Assets",
        "documentation": "Amount represents the increase (decrease) in right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity (Deficit)",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r771",
      "r781",
      "r805",
      "r813",
      "r817",
      "r825"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r829"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r829"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r829"
     ]
    },
    "edit_IntellectualPropertyAndPatentRelatedFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "IntellectualPropertyAndPatentRelatedFees",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intellectual property and patent related fees",
        "label": "Intellectual Property And Patent Related Fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with intellectual property rights."
       }
      }
     },
     "auth_ref": []
    },
    "edit_IntellectualPropertyAndPatentRelatedFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "IntellectualPropertyAndPatentRelatedFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual property and patent related fees",
        "label": "Intellectual Property And Patent Related Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with intellectual property rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest related to sale of future revenues",
        "negatedTerseLabel": "Interest related to sale of future revenues",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r329",
      "r337",
      "r692",
      "r693",
      "r997"
     ]
    },
    "edit_InterestRelatedToSaleOfFutureRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "InterestRelatedToSaleOfFutureRevenues",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest related to sale of future revenues",
        "label": "Interest Related To Sale Of Future Revenues",
        "documentation": "Interest Related To Sale Of Future Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "verboseLabel": "Interest income, net",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r63"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net amortization of premiums and discounts on marketable securities",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee related expenses",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r663",
      "r859"
     ]
    },
    "edit_LaboratoryAndManufacturingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "LaboratoryAndManufacturingEquipmentMember",
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory and manufacturing equipment",
        "label": "Laboratory And Manufacturing Equipment [Member]",
        "documentation": "Laboratory equipment used for research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r496"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining payments owed",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r866",
      "r870",
      "r960"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r138",
      "r141",
      "r142",
      "r243",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r430",
      "r431",
      "r432",
      "r477",
      "r598",
      "r671",
      "r694",
      "r748",
      "r895",
      "r950",
      "r951"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r88",
      "r553",
      "r727",
      "r735",
      "r736",
      "r865",
      "r869",
      "r888",
      "r946"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r109",
      "r138",
      "r141",
      "r142",
      "r243",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r430",
      "r431",
      "r432",
      "r477",
      "r727",
      "r895",
      "r950",
      "r951"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "edit_LiabilityForSaleOfFutureRevenuesEffectiveInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "LiabilityForSaleOfFutureRevenuesEffectiveInterestRate",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for sale of future revenues, effective interest rate",
        "label": "Liability For Sale Of Future Revenues, Effective Interest Rate",
        "documentation": "Liability For Sale Of Future Revenues, Effective Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "edit_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtNarrativeDetails",
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement",
        "label": "License Agreement [Member]",
        "documentation": "License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "edit_LicenseAndServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "LicenseAndServiceAgreementMember",
     "presentation": [
      "http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Service Agreement",
        "label": "License and Service Agreement [Member]",
        "documentation": "License and service agreement and related manufacturing lease space."
       }
      }
     },
     "auth_ref": []
    },
    "edit_LicenseFeeReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "LicenseFeeReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fee receivable",
        "label": "License Fee Receivable",
        "documentation": "License Fee Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "edit_LicensorExpenseReimbursementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "LicensorExpenseReimbursementsMember",
     "presentation": [
      "http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensor Expense Reimbursements",
        "label": "Licensor Expense Reimbursements [Member]",
        "documentation": "Commitment to reimburse the licensor for prosecution and maintenance of patent rights pursuant to the license agreement by and among the reporting entity, The Broad Institute Inc. and the Fellows of Harvard College."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Deferred royalty obligation related to the sale of future revenues, net as of December\u00a031, 2024",
        "periodEndLabel": "Deferred royalty obligation related to the sale of future revenues, net as of June\u00a030, 2025",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r87",
      "r139",
      "r146",
      "r322",
      "r336",
      "r542",
      "r690",
      "r691",
      "r725",
      "r962"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for sale of future revenues, current",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for sale of future revenues - non-current",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_LossOnContractTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossOnContractTermination",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contract costs incurred during the period",
        "label": "Loss on Contract Termination",
        "documentation": "The loss recognized on termination of a contract."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtNarrativeDetails",
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r696",
      "r698",
      "r731",
      "r734",
      "r964",
      "r966",
      "r967",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r993",
      "r994"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "edit_MarketableSecuritiesNoncurrentNumberOfSecurities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "MarketableSecuritiesNoncurrentNumberOfSecurities",
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of noncurrent securities",
        "label": "Marketable Securities, Noncurrent, Number Of Securities",
        "documentation": "Number of noncurrent marketable securities held."
       }
      }
     },
     "auth_ref": []
    },
    "edit_MarketableSecuritiesRemainingMaturityTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "MarketableSecuritiesRemainingMaturityTerm",
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities remaining maturity term",
        "label": "Marketable Securities Remaining Maturity Term",
        "documentation": "Marketable Securities Remaining Maturity Term"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r294",
      "r295",
      "r296",
      "r297",
      "r372",
      "r401",
      "r402",
      "r403",
      "r413",
      "r457",
      "r531",
      "r573",
      "r575",
      "r583",
      "r590",
      "r591",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r682",
      "r695",
      "r704",
      "r706",
      "r708",
      "r709",
      "r717",
      "r718",
      "r722",
      "r723",
      "r732",
      "r897",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtNarrativeDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r294",
      "r295",
      "r296",
      "r297",
      "r372",
      "r401",
      "r402",
      "r403",
      "r413",
      "r457",
      "r531",
      "r573",
      "r575",
      "r583",
      "r590",
      "r591",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r682",
      "r695",
      "r704",
      "r706",
      "r708",
      "r709",
      "r717",
      "r718",
      "r722",
      "r732",
      "r897",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtNarrativeDetails",
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r696",
      "r698",
      "r731",
      "r734",
      "r964",
      "r966",
      "r967",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r993",
      "r994"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.editasmedicine.com/role/NatureofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r177",
      "r669",
      "r670"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow from financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow from investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r69"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow from operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r69",
      "r90",
      "r104",
      "r107",
      "r122",
      "r124",
      "r128",
      "r138",
      "r141",
      "r142",
      "r143",
      "r150",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r167",
      "r243",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r339",
      "r342",
      "r344",
      "r348",
      "r410",
      "r420",
      "r425",
      "r451",
      "r477",
      "r556",
      "r618",
      "r634",
      "r635",
      "r661",
      "r663",
      "r665",
      "r746",
      "r895"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "edit_NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-cash interest expense associated with sale of future revenues",
        "label": "Non-cash Interest Expense On Liability For Sale Of Future Revenues",
        "documentation": "Non-cash Interest Expense On Liability For Sale Of Future Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "edit_NonCashTerminationOfRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "NonCashTerminationOfRightOfUseAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash termination of right-of-use asset",
        "label": "Non-Cash Termination Of Right Of Use Asset",
        "documentation": "Non-Cash Termination Of Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r771",
      "r781",
      "r805",
      "r813"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (expense) income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other (expense) income, net:",
        "terseLabel": "Other (expense) income, net:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Unvested Restricted Stock",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r876"
     ]
    },
    "us-gaap_OccupancyNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OccupancyNet",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility expenses",
        "label": "Occupancy, Net",
        "documentation": "Amount of net occupancy expense that may include items, such as depreciation of facilities and equipment, lease expenses, property taxes and property and casualty insurance expense."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r89",
      "r96"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "verboseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r661",
      "r665",
      "r672",
      "r875",
      "r877",
      "r878",
      "r879",
      "r880"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails",
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash paid in connection with operating lease liabilities",
        "terseLabel": "Final fixed payment",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r493"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "edit_OperatingLeaseTerminationNotificationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "OperatingLeaseTerminationNotificationPeriod",
     "presentation": [
      "http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, termination notification period",
        "label": "Operating Lease, Termination Notification Period",
        "documentation": "Operating Lease, Termination Notification Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash and other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Axis]",
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Domain]",
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on marketable debt securities",
        "verboseLabel": "Unrealized loss on marketable debt securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r557"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expenses",
        "label": "Other Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r735",
      "r736"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-cash items",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense) income, net",
        "verboseLabel": "Other (expense) income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r710"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External research and development expenses",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r769",
      "r779",
      "r811"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r772",
      "r782",
      "r814"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r772",
      "r782",
      "r814"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "edit_PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amounts paid or otherwise settled during the period",
        "label": "Payments For Restructuring And Restructuring Reserve, Settled Without Cash",
        "documentation": "Payments For Restructuring And Restructuring Reserve, Settled Without Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r349"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r599"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r349"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r599",
      "r617",
      "r1000",
      "r1001"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r341",
      "r346",
      "r549",
      "r727"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate net proceeds",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.editasmedicine.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock from at the market equity offering",
        "verboseLabel": "Gross proceeds",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of future revenues",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the sale of equipment",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "documentation": "The cash inflow from sale of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r14"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense for prosecution and maintenance of patent rights",
        "label": "Professional and Contract Services Expense",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional service expenses",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r677",
      "r746",
      "r998",
      "r999"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r496"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r98",
      "r99",
      "r100"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r111",
      "r555"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r496",
      "r543",
      "r555",
      "r727"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r496"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtNarrativeDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r294",
      "r295",
      "r296",
      "r297",
      "r362",
      "r372",
      "r401",
      "r402",
      "r403",
      "r409",
      "r413",
      "r457",
      "r505",
      "r514",
      "r531",
      "r573",
      "r575",
      "r583",
      "r590",
      "r591",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r682",
      "r695",
      "r704",
      "r706",
      "r708",
      "r709",
      "r717",
      "r718",
      "r722",
      "r723",
      "r732",
      "r740",
      "r890",
      "r897",
      "r940",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtNarrativeDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r294",
      "r295",
      "r296",
      "r297",
      "r362",
      "r372",
      "r401",
      "r402",
      "r403",
      "r409",
      "r413",
      "r457",
      "r505",
      "r514",
      "r531",
      "r573",
      "r575",
      "r583",
      "r590",
      "r591",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r682",
      "r695",
      "r704",
      "r706",
      "r708",
      "r709",
      "r717",
      "r718",
      "r722",
      "r723",
      "r732",
      "r740",
      "r890",
      "r897",
      "r940",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails",
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "periodStartLabel": "Accounts receivable, balance at beginning of period",
        "periodEndLabel": "Accounts receivable, balance at end of period",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_ReceivablesNetCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesNetCurrentAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable:",
        "label": "Receivables, Net, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "edit_ReceivablesNetCurrentRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "ReceivablesNetCurrentRollForward",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsScheduleofAccountsReceivableandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable:",
        "label": "Receivables, Net, Current [Roll Forward]",
        "documentation": "Receivables, Net, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r764",
      "r774",
      "r806"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment on sale of future revenues",
        "negatedLabel": "Payments for sale of future revenues",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "edit_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails",
      "http://www.editasmedicine.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r144",
      "r145",
      "r313",
      "r350",
      "r498",
      "r515",
      "r545",
      "r655",
      "r656",
      "r657",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r930",
      "r931",
      "r932",
      "r933"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r652",
      "r661",
      "r662",
      "r677",
      "r958"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r765",
      "r775",
      "r807"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r766",
      "r776",
      "r808"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r773",
      "r783",
      "r815"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r864",
      "r959",
      "r963"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash and other non-current assets:",
        "label": "Restricted Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r85",
      "r110",
      "r135",
      "r548"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Equivalents and Marketable Securities",
        "label": "Restricted Cash and Cash Equivalent Item [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.editasmedicine.com/role/NetLossperShareDetails",
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Stock Unit Awards",
        "terseLabel": "Unvested restricted stock unit awards",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentCharges"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Impairment Charges",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r283",
      "r286",
      "r291"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related cost, expected cost",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r285",
      "r288",
      "r290"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related cost, number of positions eliminated",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related cost, number of positions eliminated, period percent",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails",
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total restructuring and impairment charges",
        "verboseLabel": "Employee termination benefits charges incurred during period",
        "netLabel": "Restructuring and impairment charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r131",
      "r132",
      "r287",
      "r288",
      "r662",
      "r891"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r282",
      "r283",
      "r288",
      "r289",
      "r662"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r290"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r289"
     ]
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated depreciation related to leasehold improvements and software",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring reserve",
        "label": "Restructuring Reserve, Current",
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r892",
      "r893"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringSettlementAndImpairmentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringSettlementAndImpairmentProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Restructuring and impairment charges",
        "terseLabel": "Restructuring and impairment charges",
        "verboseLabel": "Total",
        "label": "Restructuring, Settlement and Impairment Provisions",
        "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.editasmedicine.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r82",
      "r552",
      "r580",
      "r582",
      "r586",
      "r600",
      "r727"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r147",
      "r148",
      "r149",
      "r151",
      "r158",
      "r160",
      "r162",
      "r244",
      "r245",
      "r268",
      "r338",
      "r410",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r424",
      "r425",
      "r438",
      "r440",
      "r441",
      "r443",
      "r449",
      "r488",
      "r489",
      "r577",
      "r579",
      "r587",
      "r1000"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and other research and development revenues",
        "verboseLabel": "Collaboration and other research and development revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r175",
      "r184",
      "r185",
      "r199",
      "r205",
      "r208",
      "r210",
      "r211",
      "r357",
      "r358",
      "r359",
      "r534",
      "r661",
      "r665"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue type",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r697"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement of operating lease liabilities and right-of-use assets due to lease modification",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r726"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales agreement amount of aggregate sale proceeds of common stock agreed to be issued",
        "label": "Sales Agreement, Amount Of Aggregate Sale Proceeds Of Common Stock Agreed To Be Issued",
        "documentation": "Represents the amount of proceeds from common stock agreed to be issued or sold under the agreement."
       }
      }
     },
     "auth_ref": []
    },
    "edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales agreement, amount of aggregate sale proceeds of common stock available",
        "label": "Sales Agreement, Amount Of Aggregate Sale Proceeds Of Common Stock Available",
        "documentation": "Sales Agreement, Amount Of Aggregate Sale Proceeds Of Common Stock Available"
       }
      }
     },
     "auth_ref": []
    },
    "edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable and Contract Liabilities",
        "label": "Schedule Of Accounts Receivable And Contract Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of account receivable and contract liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.editasmedicine.com/role/NetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/NetLossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Anti-Dilutive Common Stock Equivalents",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]",
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash Equivalents and Marketable Securities",
        "label": "Cash, Cash Equivalent, and Investment [Table Text Block]",
        "documentation": "Tabular disclosure of cash, cash equivalent, and investment."
       }
      }
     },
     "auth_ref": []
    },
    "edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Change in Contract Assets and Contract Liabilities",
        "label": "Schedule of Change in Contract with Customer Asset and Liability [Table Text Block]",
        "documentation": "Schedule of Change in Contract with Customer Asset and Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails",
      "http://www.editasmedicine.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "edit_ScheduleOfContractTerminationCostsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "ScheduleOfContractTerminationCostsTableTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contract Termination Costs",
        "label": "Schedule Of Contract Termination Costs [Table Text Block]",
        "documentation": "Schedule Of Contract Termination Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "edit_ScheduleOfEmployeeTerminationBenefitsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "ScheduleOfEmployeeTerminationBenefitsTableTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Termination Benefits",
        "label": "Schedule Of Employee Termination Benefits [Table Text Block]",
        "documentation": "Schedule Of Employee Termination Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r496"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r290"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r76",
      "r77"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails",
      "http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r409"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r83"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r175",
      "r180",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r211",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r285",
      "r290",
      "r422",
      "r423",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r674",
      "r677",
      "r678",
      "r684",
      "r733",
      "r964",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r993",
      "r994"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/Segments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r175",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r195",
      "r197",
      "r198",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r673",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested restricted stock unit awards, beginning of period (in shares)",
        "periodEndLabel": "Unvested restricted stock unit awards, end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of period (in dollars per share)",
        "periodEndLabel": "Balance, ending of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails",
      "http://www.editasmedicine.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options Additional Disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning of period (in shares)",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Employee",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining contractual life (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of period (in shares)",
        "periodEndLabel": "Balance, end of period (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.editasmedicine.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.editasmedicine.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r105",
      "r175",
      "r180",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r211",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r270",
      "r285",
      "r290",
      "r422",
      "r423",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r674",
      "r677",
      "r678",
      "r684",
      "r733",
      "r964",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r993",
      "r994"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r49",
      "r52",
      "r53",
      "r102",
      "r103",
      "r104",
      "r126",
      "r127",
      "r128",
      "r147",
      "r148",
      "r149",
      "r151",
      "r158",
      "r160",
      "r162",
      "r176",
      "r244",
      "r245",
      "r268",
      "r338",
      "r352",
      "r410",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r424",
      "r425",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r489",
      "r497",
      "r557",
      "r577",
      "r578",
      "r579",
      "r587",
      "r636"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r176",
      "r340",
      "r341",
      "r343",
      "r345",
      "r489",
      "r534",
      "r584",
      "r588",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r620",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r636",
      "r663",
      "r665",
      "r741",
      "r996"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r176",
      "r212",
      "r340",
      "r341",
      "r343",
      "r345",
      "r489",
      "r534",
      "r584",
      "r588",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r620",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r636",
      "r663",
      "r665",
      "r741",
      "r996"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r768",
      "r778",
      "r810"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48",
      "r49",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.editasmedicine.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock from at the market equity offering (in shares)",
        "terseLabel": "Number of common stock issued (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48",
      "r49",
      "r82",
      "r585",
      "r636",
      "r644"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted common stock awards (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48",
      "r49",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.editasmedicine.com/role/StockbasedCompensationRestrictedStockandStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48",
      "r49",
      "r82",
      "r386"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48",
      "r49",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from at the market equity offering",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48",
      "r49",
      "r82",
      "r587",
      "r636",
      "r644",
      "r747"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r49",
      "r52",
      "r53",
      "r82"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance, beginning of period",
        "periodEndLabel": "Balance, end of period",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r52",
      "r53",
      "r70",
      "r601",
      "r617",
      "r637",
      "r638",
      "r727",
      "r748",
      "r865",
      "r868",
      "r869",
      "r888",
      "r946",
      "r1000"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "edit_SublicenseAndLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "SublicenseAndLicenseFees",
     "crdr": "credit",
     "presentation": [
      "http://www.editasmedicine.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicense and license fees",
        "label": "Sublicense And License Fees",
        "documentation": "Sublicense And License Fees"
       }
      }
     },
     "auth_ref": []
    },
    "edit_SublicenseAndLicenseFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.editasmedicine.com/20250630",
     "localname": "SublicenseAndLicenseFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.editasmedicine.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicense and license fees",
        "label": "Sublicense and License Fees, Current",
        "documentation": "Sublicense and License Fees, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.editasmedicine.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash and non-cash activities:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierFinanceProgramLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program [Line Items]",
        "label": "Supplier Finance Program [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279"
     ]
    },
    "us-gaap_SupplierFinanceProgramTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramTable",
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program [Table]",
        "label": "Supplier Finance Program [Table]",
        "documentation": "Disclosure of information about supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.editasmedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r334",
      "r351",
      "r437",
      "r448",
      "r471",
      "r476",
      "r479",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r544",
      "r558",
      "r713",
      "r715",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r728",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r884",
      "r885",
      "r886",
      "r887",
      "r936",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.editasmedicine.com/role/CollaborationAgreementsNarrativeDetails",
      "http://www.editasmedicine.com/role/DebtNarrativeDetails",
      "http://www.editasmedicine.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.editasmedicine.com/role/AccruedExpensesDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesNarrativeDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofAcceleratedDepreciationandRentExpenseDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofContractTerminationCostsDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofEmployeeTerminationBenefitsDetails",
      "http://www.editasmedicine.com/role/RestructuringandImpairmentChargesScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r282",
      "r283",
      "r288",
      "r289",
      "r662"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.editasmedicine.com/role/CashEquivalentsandMarketableSecuritiesScheduleofCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.editasmedicine.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasuries",
        "verboseLabel": "U.S. Treasuries",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r667",
      "r699",
      "r701",
      "r703",
      "r713",
      "r961"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r170"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.editasmedicine.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r170"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1D",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481161/840-30-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "275",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479072/912-275-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001650664-25-000125-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001650664-25-000125-xbrl.zip
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M0A+KAP.9)B%@IYWZ*(!LZ^\]/MXN'"ZQ&>\;UQE+,RKL4%JBFA*2*6>DEJU
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MEP'\U8YN4UNFWC?\R(B<$,<WJ"U%WO!OLD^0NR169$Q=AP\"GP'/I6.>C;!
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MCE$EJ=;5=1%@P8CYP0W60QJLQ=,/;F&K';&]__&S;-FOY=G$GL3['T)_FBE
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MT+BQRLRRBE)H0"48V'Z:T\C^?-ZJ=37@\](=',3IOEIT_YYFRTWW[YMS;)Z
MM#&%?E-F>_=3W[M825M>3"&/,HQIQK^R3/JG2I!_&A*: C.&SV*!O>"X 08I
M/4R$$6R8U+-GC(2)X5%O#G/G@$@LS(I!L;"011<WO8?!?@ 7:-RZ(6R$Q3E5
M(70V5R'@1)$)MB?)8TR?ERY4I'3AI)(@/>GQ%L2ZX0O?0+R;<%,4[ARSL9%]
M&9CP=RJI A?A'@NDI;3>+S.!]#@32"ROYT/H&"$@@5@?UZ>9449HM>W$=OR5
MR: '(JW^/1S#*\QU WNE-;^!>4;W@SC&Z^*!-[&IH$F1F6([(;%Z07P-7T'
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M[\V_?1-].LTYQG.DTJ1$XAP#L-*$/P*;HBB&[N)&PZS9"OR9("0%=P#0]>T
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MR/K(N<7P,\D?BC9][?%""M2=$V=I+-23E\,2SI%NNJH=9WW>T%@ '4F579^
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M=VMJ?]DD*I=%]!WU>VP1:;%%!$;.S+B)-(%6EU3F#)99;Q&A'DM?1 ;*?X^
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MEX*1E9@47:D6AMWNS9WG%X>TA LXNEN:.U,L;JH_9F:T><S,QDW]Z?.Y<!F
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M._;@@1OYEFB5X6V>*JU52;7LWSHIWOWLWU&W2R6VTZ:N[7;D<0MIB1.?\GI
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M1)H&(WV4,Z%V#5(WYQ;KR[G!%*_!OV, 989)&!&OSJEDTK32.LV<G(^E6XN
M2@XQ3!)X:V5EJ8-^RSM=1.$8KY*@2!X^2&9%'9Z4G<6.:Q>B[2MG146$ZS$:
M"O7SR$RVE.W!1_CEN5PNOMAUYBPT']<\6S]);7+[/".VL4<.+MDN:2KX6[+C
M73=%-Y+%(YBRUIO]<,*HD-_.L:YD1SMP1-*K6++7&GVBO;3W)M@#S\<)J>X=
MF(=14B@7TTZJ_>%O 46J14LM1OBP%\\U9\+:I5,0+5J:^1 PSF$4"L3L->J=
M;&PDR80DU?<BU2["X7DV54<G7B^9'S@Z:^\EWNX_17K-%$VU6LC8=\U?8>D1
M]@\+M>''T6UR6'!PF$7S&*\$%3%I5%(NII]B;@^N6! ]:_B<N>\ZE"*K%+9<
MEC!GI&:3BR;FU7$IE"05N@B\)V'W<XV8IJPQAF,[X&?C2T7E:0=KJ4 _F*A.
M*'^+](BQ0IR_Z3E]?1+8S$1,Q;[#A;,*Q;L>T! #AH>_,X9V,5UM)94PCR8O
M?+$P\Q;DLH(RI9,3$!*F7P-09;ZK_?$,7]&^_CMV9C/L)J%*'1G(^/6/KTD<
M([DS4.<N?(RF^$\8N,6R5,=V0'_J&*[RJ5Y;D!86\]&S.LD#"W]/LQ&D 7(+
ME0(IR(1Y7]C+6S.<THG #SW#S*16<\H;V2W,9B1-=[4P;RG.^>V62)E+3:5T
M+8V3<H@@KEJ 5L /\1*K=>E7"]);6.3&U49O "^..+<^!"8OW\ ,:<L*-K=,
MO$KL.WT]D=,7T6!;^Q\01O9#^PR>V]*T1* MQ$/W@Y7/E;<\?/[9A*$H_B3+
M%\RBRM9%H35G O$B?R:*(DT20_8#.#U$.91?EV7DQ":Y:SI3QP4?:H\B;T$N
M<F/R &7AU[>_]WKW_+.RB-IA6-J1R2%\>_<MJWO2XZ9.R;?W7W][_S__K^EM
M'K6K_=L?+W4JK^ J64NX\VS[SW2UHI7D/)(8_#3L=KK@9[DN07.LYH%/11G@
M*:W,YV6F]63NHVVJ_9L7 @M7J)_8^V11F;S3(9$F1O?A3[WL.Q(&".!VSC]M
MP,N:B^:7-(O%'9IJ6;E&\-&DB&-T/:T6RCB9^:WR*LP'_++<M7Q8UA 7)<8T
M3I%W;IDN"X5)4-PN8H&8'MW)E)',;QTTU4^#["_X ]QGP?BDBM"MX!U 6]Z5
ME/2%>G*]&MW^("FP3 J?R>%Y)MK^2E6O'\$T=J(X8FL7+/TU7R$ W_D,MQ-U
MB]%O/C#LU.7)#S, ZP'N4KAWV4-:9B!^GSZ(*FLX?!C8/@].A+UC:*F;O/C6
M7/HQ>F.P2EZ[Y8,1S2DHCC7MFBER!]R?CIR@39<E:>^,PA9?H8)$^5Q."-R0
M6"T%%#]9D2_+#>B6RE\S7N:MV3;0=U\^:O?R+\FV1>ZGPMS!?>/W_L:PA\_"
M _L6H,7Z*GUH6@%&C$]L)8*799(*V\,G<NJAX W'><%CLO%7RD^FK41^&[X7
MK_ 9F C)<J,H,RMA>M@;YS)X;7I0XN1*;F9^)],W>?TUEY7A)E$!AN$MT*_V
M$!51=<J;++# 6;-C)M*D6YD3][*K[B!;AV&A@H5U-Y1\PC./"&$(XRJ"TXEB
MG!UAJR7,**O/ R9,EH#7.Y#7$Y #PWNP,@=$&FL;):14;U" )<3:*(#$Z/RX
M]>3Y<J>BCS) C"2?NT*X ?X4-+>2#I&VP1ALO&._.M2<1M5"F%H0$I:M2^SU
M>9(H@T? &XW2=) ?/&"H4T;<PLB<SV6T4S0^Z-H,(Z#HS6&WFD<5OH'IA+S,
MD_Q'/0UPRF]O\7NQP3:$A;KIVP*6ZT&@?L9<63$Z12(%D/0FIS=ML9%4%QV8
M-O+G=]XVP#8WJ/+:'=Z)+#QIWWOP\;O8Q8E@!*E;A"H3[C$W:;3,/IY*P<0W
M0BG*98%*;.6DIE(3G/* 7T?IVXMO!3]S 7R02BA6I8FR(A(YK!-X9-C@(9ID
M.5U(+M-OI>A"'&N"V>N\(N]TZ:#C;1[)CV/_IBX%-DPM.BZFN967N>]_?-W%
M(R]SR$4OYA(U#2_]Q!"(*YHUZ>EP> SYNL2OHX"QL,=^=Y94PO@JC\J!ZT$I
M<!W.0Q)I03PTK7%)T2YXQ: I_.?[^ &O4;C"N]44PI//W=H4=/$]CUDIF5(]
MM5';)>_8?O>=GX9+M)N>-$K"K^( C:),'7ZFM1JGP\@6)D],B\'6).Q,^JEG
M3#O]C/UK\U^-DE])RZ04'%$KX"*N8^_=TXU8!%(4J[?)AK.L>!ES'!>;80=Y
MQ-T46,:,+X/D5" 6\$[UI&6+=I_;>JZ7?)T.*8Q+I@^=>Q4%$N&5.W>Q+A6S
M'/DN!](ETEV"9<@?R5G!OY%Q%/'"2NX"I# +2?-ILM0GKC9%3Q"!+:2[I/L
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MK+Z<C;Y(HQ3/[5W&BJF[F6TB43D Y 2RDMMDKH]-AA*%[Y#Q)J@ 'F,*24)
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M03#Z&.Y_DY*4<)M*BH<"!-"[33#7_QT[_#+.MDUES8;,)2U@37+<E/]LUD[
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M_QV#1T< 1?Y<>PLO!&X!W\V\*SN\5F-D(>J41,%"A*<&(::R.%@[8;8]F1M
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MJ,]Q"'JY\R9^8IU'+(N35IRY37V'BH5*:T>HGGRQ/,'M2\KEOM^1ST=<DW-
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M^E5&M]C ,,M/7@$U4K?@0_=9)<A#4<"*IL*H;63;?K8Y.SV+JG+F(6\VL;4
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M#^F4:C7ZG<WVV?OK<'8/_UDD2_^7_P]02P,$%     @ $8$,6QT-N0F&#0
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M6N:N@4-E6H2R38KCFI#K=#(GWM&WVTBW$,7(L)Z92[88=GW0FA@BDPN-SDQ
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M2R;*[*;&WAG0BPAVRFP^&)/6.O?WTTJ_73,;-65!JZWTSH%0D8U^:-W 2RR
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M^6RQ^',Z)YPTV;1M$#]3G<VIM2>53AO=H!=DS\2P5" IT2J-DY;9.U5<[PQ
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M22GF6L>R-@+V0S)H!]U<)Y#J=1'J?OGN2U7)[.4WG*;A#/,@NV*T(RM-EE!
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MRT*] 4HF7<N$K(# ,$(0M;UT<0EC:Q-E/9H?V\MJI*4>BA'N2JO?_.YJ<=P
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M]@;3ALFL% 8'NMY&K;2*Y"UE#:)(83+3M6UP8U;<CNAQ$:.A]*]SPS3:2FX
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M_Z(Q_PKQ R8<?NU,01'JHU'1 D0&H.):UK-B" :S*EE';J_>6'^[;W3IVW]
M#K21=&O'N)X='])8Q_-+F'XGC<X^3T9Y60F$:,@L(;>$*0*FD#D:<.# /0W8
M"&[*U<;4:\BPV?-^5'KTH(T>0KW+,Z>SQ<JU6L=J,\G9H'#CG7$,@JIW>BC:
M1(/S!DJ4SDFAA9"MHV^WP/D!>=1:20U]].4*&.)P-)Q_?S69?@PU>/'JM-Z8
M^ &_XO@49R]+P52E\WH\1Z+]_$.8XT GACH$ 59S6B+K4>K E87LN>,%B1(B
M;K@9W>/Q/R"-]J2K?1XRK_-@%3*;=+-BQ]+1F[^L:?WH!G@;%9%VJ\19*_AS
M\G"M)?-. 1DH I3U!:*U!IB-IFA79(JL\8*^!LJNV];EKUW$.RU/RJ8HP-FD
M%BZ;-V1_I9B,D2F%I%H[1C? V%=Q90L=7]UG=I7JL18Z.E$";85@<@J@!%E7
MWB8#1A=OF='TQT:'FQ],H>/.>KRC4G$+>>ZO4G$#4#].I>(V&MJL4O$>XMV;
M[C$XQVUTH#E+H Q'B#&0-T7.$RN6^;!91Z#CTOF6E8K-5;Z-5 ]0J>C0II0+
M&.9JSTNE(9:NVT'T6OJ29;0;>1$/IE)Q*WUL6:FXA3#W5JG(DS8\9 ;2IWIF
MCO8^%[@$PX6202<7<NL#KD=5J=AJ%V\GY2,H-=P$[L]2PYV4O&-IV'TT= 2E
MAB&9;+TN$%+2H%PLX+-Q@+6*1G"3G,R/D5#W*C7<)Y^V4<R>2@V--<84[\&2
MT57WWPS!. ,84TW[D9N->2/;XZ&6&FZEDPU*#;<1:.N$Z>5M]F);]:0C>JMJ
M5D9%4)[LZE#(/G(\)"LSESEM5E&Z]A'[UW3+L%%#\?5@5+Z9C#_5*[07&?D@
M<H[& K>NWGX0#7A4H9K2GBN6K"NMNUQ>?/[^]-Q2)Y-& NWEPJ0OEW)B ^V%
M)P-8@DB95B0;/41?$A1AT!K,$GGKX.]5#(]"R3L)MJ%_T V1]J'G8?9YE9%Z
M^:W>H(SOQG?EL@:&E21J-[*@ZVK&:RD\RPDL*D3CK9"X67#@O@@>-!?V)_L>
M;FE_>C*9SH?_L[P,Y]5P',:IZZM0D^6.>9E=+<FT@58MC1&BX@6<\H;IZ)-V
MK;M$WH;G0;.DN<![Z(-X:<MR*2DR5RV9.%S72AM%1J;,X'FD!8YX*6/K"Y^O
MVP ]Y,*[^^M.$TU"$GL8Y]<G7\)P6E7\_'.8?JJWHNU^O=+V#VF6.]]Q?(UR
MZI=05'*3GT3OX?3KA6N^G-:8<Y%0+'*RBDJ@S=)9J'?&.95D8;ZUF;D)KG87
M*5UZ6O>D49C7Y@8TV9>7%F=:2+)UP(NKIXX"&8:<27#)F&2]U5XW;WN].;Q]
M9>>;LV7]E49M57(,*?SS,S36:LN,LN"P(F<H:5^R#$H,(J%G(K&-NAT\G--_
MC;5YX[&^;:3:XVFP36 \OF-]6PE_S;&P^TBN1T6BQJ#IF>!C)",O1;+]2Y U
M1\4E3['(M%%9V:$5N-&QOA;ZVT9@_1[K"PRU\ JP%/+5$B9P(7FR^X7D1AAK
MFAS(/))C?5N)??VQOBUDUD-8\Q;+HN.G<X[X*&A[0'*VE,L.0M3DZB0?>>:.
M-HQ>+@M?#^FQ;JI]:*2'#/LB@W<)Y+*@9!-@/>72UX(Z3-:\J0IO++MH)?\>
M8NGK 49'*R6WM+:I8NI16@X^U\Z^TH>"+$J76Q\ VC,Q[LA^'X87VXB]=<9[
M=?5]C5H-QUU0[QF.2=KS5>XW^A1H< A!N%1KQ02XK LD;7Q)Z*Q15ZR]-;'U
M.Q^U_^QH(YU,>A-H#P;%^^F$-M7Y]_>C,*[\?OG/T^&7DZXU915'Q_. G)=D
M,@@;"&))%J(AL S11LVL9*;Y2<"[83UVPZ*U9GK(MJR%6 $NI\XF$'LR,S:
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M[ M:18)(*AF:2<:!*R6#T YM(/(;W[J2<BV81\B5-H+OXTQ6B)/I>97H$MY
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M?Y _+58UO,/X<?$YORMRD5-<-)>4EJNBD5_)VW*9TYS77^1"ORQ+^O=%$I.
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MK+J4PZ8$M])=<)$#,RZ3RW3@?0+SY_<>%?!HPN[Q*^V,^COYB?@-+U?2O_O
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M%=W_)-UOWR.1+WWM+]5#T;!W2WQG$-X_OL ,\7U%&"C*T-_+@%P?:0ZTBS<
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M&" 4\X2E-,Z,TJ@':$UL7C[G=T4;9MUT0+LAZJ0,DR4''3?@QY8?$!AN38<
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M6O@Q":)(NCTB0W+3$% "<1(R&'D^38,H)<0SRJ1QR][$AF&;(U%O6%9I\+@
MJPU_0&X':_#8<]CFPS^4%>\R+_Q _D-Q;!AE<?L0-:,NK_9HS,R6XA-L&;T
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MG0.,JT(L*Q[F+< Z!Z:#PJNS%G,P@;HM[&K+R_MI2CFOMW7HV\U5RJ,HQ)Z
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MF#(<012%%.(D0S#E0> E..8\XXLG7I%2:WMMRX?)R[_+C;8.2,9@V]QR4XG
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ME/L2'*C&FG$2PBQ**,3<2T3,,4^85G_[,4)3;T>Z[CP[M($B/EI9:@;6>.3
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M^:UB]9^JHF'71?N7^MV2_58WQ=V;LF#_'W?OWMPXCN2+?A7&.3=.]$08&WR
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ME.0)BG))$.8Q02RG!$G&&<G"),8)*!^\G\S4 9+'I]7F5<I=5T]9DP4>RLY
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ME^HGFW2_\RB9N4I.9(=I8TWRRNL=>^!Z^/F 9$[GH/?1>8.1Z /B]D]''WH
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MYZGRE!-)D(CBV \"F5!LY"F_.\DFME2=$ENQ6:UH47I/R@.H,MK?34([],L
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M3G"[L_!LYP3/S$^UQ<(NZZ*5OZ%V-=P8 )Y:<5X85TD4/13F39<X+^))8L3
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MS)6!:</B^TJ^O !D<-[E);3@SL>G?VY?K_\H1'DM_JN$59_T/#JQ36OZI%5
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M9@HN0PN\JUM)[6AWA]&>=9>W@N5XM[=;!&9NRF*[^'6Y7CX^/S;[FV2"YU%
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M\H6?TC@&Y<_ R$]L;SK,U&U1NNS '0, K.9NPS1@P9V*LSA-G[9N!X-#9P1
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MSU?[7^H+Y86+),<$5#%Y"3,3*_>YB]/2\M!\$>YF9^NYT(19BPN ='[S;(+
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M#+$THBAA813[RBS1'-3F<U)N)[8B5:O5-@7!VW/2[=4Q;S+*\+LS,TSOYHW
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M4A2%02I\/T]CG $;V=OP,7W.357",MJ<PBFV9D9I!L1@QJEER&LXJL+'/45
MG8:4CKMJ.X+&78M\*R[F;IQ_"50][?0O6FZB?L'E2%O*=ERHV<3C..-!FL<!
M\K. *0>,I8CY,D-Q' 0X\=,P]7VG#82=LC]U,+VA-=-H:[=OUO"@_6[?%_ 0
M;M!ON#1M.+R3Z7W.JI[DE<S5E-@M\^^K2_$D+P;<MG@:+JSO;5YDJ=;>3TFM
M0I)UU7[5(4?Y_56P:^\S"I]E*8XY2GR1()Q+BACE.<K]+$O3A!")07N2#1,S
M!FX_/.@W5]F:WQI&NQ.**U;!ES]PU(WOA2;%$GQE= :PVLZ77LO1I!'52T!Q
M=]L$9V'NBRAKD'KNJ.S7NO3ZZH/V ]E&WY"]R*[=52<$W77XS)_OU$\EY94)
MKHO+>()9%L492F4:(!Q2@0AF'&4^R6*?2<)]T/P>]RQ.; 4/V#SH[5<=MSO_
MKK-9M\I2>H</C96YS?4NH==:;_&&8+9UAI=SP=65:_R<7UTY8_"-KJY< WS^
MZLHY)7CU<^4>WSW>ZW#.U^5:?MG*Q]&&).>>FS JJ<EY=\M'G2%S, I'$_<J
MZHXJ?@<ELQM#W[OB?-/HAP0Z&$H_^,$W"NK]HCZY-8O[L#B+L"\E"ID@"#.*
M$<5!AJ0?Q)@R[-,LF36B9\[[Q.Y&Q<A[">8!WNA,D;QIWM,;AO%J@?XU8WCP
ME_%> G@ SO^UHG?P5^(\=&?!@F69Q./3:O,J9=-*X'0ZYH)2EH9IE*%$1 QA
M&@;J\!IQA*-(^#1-@X"#@G2C%*>^ZVGH[UI0V#7"' ?.S)H[A0-F@UO2J$6B
M;TZMPW(*4TE=U56,TINWP,)4_)-*"^,'+^S:_ZND^I2A;='G0O[S6:[YZ\?-
M(UVN%XS[:1(2@L(D3!%.E!&@(5$V(>4<)TS]&S:!VH#FQ&:@0]C;4?9^KVD#
MPTPF")I9 \>XP.R!)23V_?K'A73=MW^ XMOT[Q^'X&P??X-'+5K@=L(UU755
M?R9?-=7B>KTS1L=W3"FG41!&.0IIZNLF%ZER&N(,<>JS$&<)#7VCTFQW+,U^
MSW>0X]I, =$!U=WO3%I,3_5^1B)>;X(Z\  Y#/A!4G$-?X7^OB4MX)YPJK<
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M:NL5>S9LYT:/8VEF0MPB!#,>=8+5]RXR'?)M19_CSHQ&LKILNCA,</Y^BD8
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M)"/E-F.:)HC&>L9<SACUTUB&(:CM^1"QJ6,%'=)HN49/#7&8J@ZB9::PKC
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MH$9)+&2..<MATX@O1<QJM/"NJ+N;-,+D6N;+;=G"I8=L/5=C&D2-ZE-57>\
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M'$1HV,*ZDAMF1:U$!G6P&)/)JGO%V45GZUPQ)E:W:\7H9RT\J;KYA=;J9HI
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M>IAD@N,TB24.XUAZG,0124&N\2%B$QN:+FFM#\NRW-;[+MTL&1A@/XB9V=;
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M'[:.4D2/F+HXYDVT.2<+V=9Q2I%.^*@Q@M#*:\5MT;+ULX<=I$S[@N;YL72
M GK$T?4S/:%2Q60)7$B2CR;1!)T\&(S!FY@<3R,>@(=Y6*.E6)\?48>JXCL<
M5' IW/6RG%>-T$^;I55W?/S8*=5]N&J43MU>05\N> G(H(TM=30:*[F "JZ
M-R5 X0X5=R:R_-!0VT.V\ Y2CK^B_HJ+,_R5-N9]#_-_^2.=G-6M4GLET?]R
MO84WJ$0H@8)>7NOB!)(Q-A@ .6-<%?(62^NFB >0.6TZM05R[MY@CZNK#@[.
M1UA\MUKFLU0;1G[ U==YPE_J/E_/XPF^GJ\W,UTOZI4W4'0A>VZLA,A% !YM
MX2DZH67KFXWC*)X6I*,#ZFD ;JG=#K!\6:=YWDCYJFF=2I873Y3'2'\H'RDJ
MLJ46I1AC$XL\I];AZ4YBIKT0&,-,MI%[!P!Z3[H@ NJ(B9]IYYPLAPZYYUS-
M?-$L6R8H!JI#MJ)-]6VX!9N*==F*%$OKM]4/$C2M*6ND]#L&JY4&.H#37W!!
M,CHA7E[DT_EB7N6SF7_%"W9$"K&^%@<I/2=VH@"?N8(B(X\,8U*A=3.(1TB:
MUC:- ZF66N@ 5+1#-BLZM,]6)*@/N-F<; WY(K\Z_1+FJ_H7.M>_SM<U2*,C
M/,N$/%$D+Y#LNDKUA:6KG7=U=I)IGEH_OG@:A=->98YFQ<;2T=,1Z+<(7.!F
M'"=KIF*0!CFO?57J Y*H:RE,@%"8CX63\X"MS=@=(J:]M1P'1<=)NH/WKY<,
M7!46S% [*QQ96^]B!H7D; 8;'1#,<T F>%:M[=$]9$QK=$;UP0^4=0=P>;-<
M+&]R<3$0YW)D"G>*&Z&!UR(!E5@ 7VRDW13(:-H2HF[]!N=1HJ:U/&- J:T>
MNBA^'&J==O(U2Q15:"T2:!-(6AH5A$32DEAL4+1EF&[=Z>%ABJ8-[1H#X+YF
M(6UTT8$[_FI!GT7NWCGYM9W3++A,N\XJ$-8QDDE.X$.]Y%(VR<*(@>:)@GO(
MF#:6&Q=#QTK]""_Z4[T1:P2=K\1"-=M; =5)3$&'9'5]*IMKAD-Z3>@7$HK6
MB4QY9E:UO^>Z0\:T[M'8T#E.ZAW8G-W&DV5EK+$<2HF>COUZ:^#IKW3@I\"5
MM]&T/LB..\-&<XS&!5$;#?3@<^/F6L#@:E%F<A109J;I[+5U9K+R$(7++- N
MB,T;0-P@8-HWH:/XT@?+MP-P7!1N7SQ8_2FLYVGF;-0V*@D9ZWUD(2^-C"6'
MS.B;P6J78^L(_EY"IGWD.098CI=W!X?3;29^GI^<D<<TTY880:U!U%$5BD<)
M$1.'(',JR1B45^-.1X+-.2G3ONA\#N <(O,.H/,WK#,E,;^@T#]\PC=GIQ%7
M;\N=5X3;?2$Y,UKP0@*KO062BN"TK%)#74H62L;6C3R>1."TSSS'@-EX^ND7
M?.=;Z>Y+5EW(G;.UEP5'1V>Y,>!8H UF;.11I.+=,\%O%XE[ =#_"P"PB8Z^
M\]?&-QHY#;[T#;X:/3J^N\ISOCU^A,=&3Y#O:8EUT0[K$L1)*)Y]LL"\-;7[
M7X1:'@CH-+<^!N;%".4ICY'5-AA$H5),&*%$E^L\SDC.0YUI@$8J5[)&U_I:
M]^G!X&@Y\-8H>#@P?(JL.S@K]VD=]VZY&G2UV:SF\6Q3AQY^7&[[L5R-?.6%
MC+!VH"U/H- A.($<6!!:NJA#P-:OAQN1/FUR?6QP3J'??NX)=S#^XFN8GU0V
M?UVN/H03_(#I;+7M(I7_G[-M2OFR;R(FAB84!*L, Q7)!PG$/YA P7PIO$C1
M.H_?BO:)GY5. ;TGP'\T%'1@UA\P*[/"C8CD*0(.I0 J*(KFB@8F4Z'S"JWR
M(]10[B)GV@NJL<UO*SU\A[WIKKO[]S0G'".FV=4#\9F"FL>X;-^G[H&VBC'G
MH@FQP&Q&4(EL532NMMAAQE>9"M:ZT' OPHYOW'J^R,=JNF?<1BM$S:$;GNOH
M;0$NDYDN+BC:7M)B:GU->I.";CK/-<+"W=ZM!\N[@W/PDOJM1*HY7B[J;GWQ
MQWP]BY'1_R4#.6EBAKX$7YNXD(1*<I$[)5K7DCU(4"=8.D#3NT!SM-@[P- M
M'GY>GH;Y8H9>BEBXH#A?<CJ]?03'$H*I2?'(8XS&-,;.O81T@IGC%7W[(NQH
MJ7< G6L--'[#FN&>.6.S*.1"6E9WE2 &?' :G S&.V%5=JR]\WV3B&DATT"Q
MN]N4'"#E#F"R8X;(.3,I2Q3>&_"8*?XP)H./M6,BQRBE$Y+QUM?M#Q(T;<*L
M/7S:2;\'*#T^%>2<,2PEHG:U C?68DD1JL@TA;5&H6$4VV+S$4'[$C=M4F $
MB(VBE0[@=GLPR#D7P2IEHG0D)B=ITZA!5@ERB [) &.,K2_5[J=DVI>K[8'4
M0-X=H.;2:WQ-O+RB+]<S;R4K+CF0S)"9K6DQ9XT%[8S6(J? PVAQ_"45G33X
M;AA_'2;@#B!"1G&%H=:#;/_[:G$WO_%^>7+RZW+U>UCEF?#6<1X1+)+;IU@(
M=&#3#F!9B"!9UB6TOG]\(HF=!&H'(N).Z<5XZND ?7??'Q4I@F>63"HJVHTN
MD!NH?2WL1UXR(^&QYO;IH%=@8W9E&T_EM^W74?(_&$!?<#5?UI3^JDV#A7L&
M$E$\*ESD) 8N6$V).' F)Q!.>L?I&.>R]>7;@9.AQNQ;]7Q .DX#?2%IV\_W
MYZ$5R;OM L,^>8._#S]:SS*S(5EI@9F0SA-N+M-?<V26RXP\CS+"[E'*)N_2
M\+R(:ZNI+M[3[.!K:(-_Q9;*P17!R8E@N99?TC;S3$<0*N$P[8.YUEGQO0B;
MO+7#U/@[0D\]^&,/;:KAAV^_#)V,?_D#5VF^QCS+KACMR*>5M<Q*Y3IGAFD-
M7+N0E"3^4^OTUM.IG+Q*<FI8MM)@OQ@=-M[]#(ID;*X]65W@&I3(@LZ Y"%E
M1M"221;7.DOV9"(G+\V<&J&-]-<O0+=;<.AS-T^;\VE*+ZHXAY=J)-J"\\T9
M_<[,,4PF9 ;>,$OB=?15%!X,"QF#XIHU?SEX--&3EXA.#>"1]-L[H'\Y_7*R
M_(;;K?ON;)4^D_C?G83%>A94B"4K 5H;6VO).$2E$0IF\H;( 7*F=3G,@:1.
M7GC:!W@;Z;)?R Z'S$XN9T)$)D+V@-YG\M;)"?*J4-@H,:'5F+UHW87J($(G
M+U.=&JX-]=@!6*_*(-8?ESM>20P;-(;A5?1I[9LSJ/L]DK37\PV>#R/82N<]
MIN6GQ? I@Z!FGJNDH[502JCR8.1 2>M!2UY_)'QJ_H9N;)[VR]&S?X4]T!4\
M.M@NS6J-BM3*FIA!^SI9JYYN$:,&S8.*T2?I56MS_[P59_\2=U23J+N+5/#-
M@N>26.;""#!2%U!>2?#9%Q Z,U6[TY KUABM!Q27_TO<9ATN^ [,X]T[761.
M6BDL(!O:?"9%OGM1=:!@44(+;=OGOPZ[4__7N)DZ2@%'7H7^LFC3:?6>"UT1
MM58Q:>!&(2BN$P3K,G'!>#%,"&-;%V@?>*7._W5NF Y705,@3=2A)ZP__WJR
M_'VDSCR7G_ZL'7GNYZE]S>KE0I?EB9)KIZR6P*6B8%@X4QT@!8A9R*09N?GM
M\W&[Z6G@'M7/'*;"D.1^^O97$ONKQ>58AQ=I,_^Z=08O2\P=+U$%#2H9DD#A
MH382Y6!32$6F$IUH/@WAR51V\H#Q6 3=XU2-J:X./*^;;J,MM4LR<U!TJJ:?
M&W#>UR&40:>"SG'=N@*MHV908VO[08_]*:+O #?7$CQOEHM$8AL>#G]<UDS-
M(LU/\ 9['Y=/E:R,&6VAH)=KK^H@)0V>UWP/<R(X%)A<:\]M;)XF'M7PO.CN
M"B =;)B+5L\WLYTS<H C!O*.+5.FSOKR$*+)($3TEELFN1WE[?@=2J8UO7VA
MY;[@^#C5=0# GY%63O,M[8HYI;@U$!@C<3"*S&(4"(X9VM,Q6^-;N]77UY_6
M$G8-MH/5U '$_A+FBRJQMXN:V'Y;2&8DI<VW>L$Y=($8QOS.N)?2JB3!.5<]
M\OI*B@<%4KDH3&VB55JW5MF/LFE?HG<-RQ%4>^QTIH\-"PKO# MZ<5J[#_YS
M4'YM/;U.R[-AM.N[%9[.STYG(3)CG6-0FTR#<KFFM6R!F%1"SW4IH76"^@ R
MIWW;WC6BQU;Z]/"N^;[+&6KO<6@Q\'&YW;^_GM5G?>_Q*R[JFW^I47FA/"BK
MB#%1+$2D/Y)T,6M9=+@=^-]-7NZ_W+1/V[M$Y4BZZL IN)J%_;:\7BX^O9Y_
MQ?QBO<;Z-.0GI%WV94DB?5MFA7/E6 K@;"T\*22RJ+0%G8ODW&&POKE)W9>X
M:=^Z=PG9<17< 7(O1I@.\KXQ_DW4IAI..O"9USI1H\ [<M-34-$IFX5I/I1F
M)S'3/F+O&IEM%#C]0;[[)O=2<N=OZJXFTM-F(A^<$X.:Q&8%@U"0_'+N0E:T
MUY)IW1AL?^JF?;K>-61'4G$'UO0N9R_2X%^O2>XX_SHTMO'%^6"Y@N!E(=')
M6!\+*$!F&0E5YM+\O<8^=/767:,-)AZ%WI$*ZF3\\FVN*)@CAR7_?$[1Q<#8
MQ;;]VM9QF3&19-*6@TBYCHUU&B*3'B3SQC!N@M3C]PS:A]+>^G4\$S2;*W%2
ML)Y'?[>9?%_GH+TM=.)<,!0X<S86$+S*4%@!D7B@+8B&!^\2ZEM%$3O#],?6
MZJTK1U-<C2'O3JW=I0]\MAHFIVP9BUHEH90"6P(QQH6I.Z, .E0AA5"8'O^<
MO9>TWKIQ/),].UY-G>+OPH=X%[X-#H1SVO/:M= SPT'5H2;!>0\Z",<Q,V*T
M]87WHT3UUFKCF=V[0U33:T"Q.B,ZYB'.3X:8;.:Y%B76R3D)$RAC&42> A1;
M?,DF2=E\?NL^=/76.N/Y$'>,@B8$W0Z/8;^,O='6AB 0#!<25#0%O"!)$M\J
MNBAY8H\^#3^&@-[Z7#R'+]=>,UV:O)?+Q2"ZO\TWGU^>K3?+4UQ=;*]O,Y==
M< $I/%>UGZ'% "YK70?56>F*=T:/;_T>)+&W+A;/9 C;J:U+5%Y*\77]^Q5C
MRJ'.U@=(R,G#X,R3/QL5N,2RC,*K8EHW7MN;N-X:5#Q7X-% 57UB\&9$=</G
M<.A<D@%0<@.JJ !>L@1",>Z9"ERF\9-[N^GKKD_$-#'PH1KK (W[O[6?Q:"8
M*U%#=G5X;)8(Y'B8VLXP",%=";[U$;T_==,F 9^_'F<,I34;S]H<CML7</<+
M4DNG5"@9=/&REB-IB):B-/*.<XB"IXBM^XP\G<I.9G(\4]5A*W5U8!_?A6\7
MO8'2/\[F*[SQG/C%(E^]*%:.J5@[^R@;!$5H9/E#2A90.#H4#.>\M'X4MC]U
M7=8K-L/)\EF4UD7>FEA)M#77OY*0MXF"WP))?X&K;S<80RV<(A<8BE8%E$X"
M:A>>.D'0*,6YY;EU5[(]2>NRN' T*(Z@KA[-XF]A]7?<U.3\59>H&>?*2^D]
M!(9(F\MJ<#I*,-ESPQ03*;7NM+L785TZB\]F#(]659=VD';3;V%3V?E6]]@]
M+&;NF%/2 5E\"TH&3B&@3)#(%Q8A^,*Q]2SY)Q,Y[9WRQ+:QK0H[L)+[RW,F
M1"A:> ?((GGAF8*U@%X#<U)CS'748FMP[D_=M+?.SXS*D936;W#]ZWP1%NE^
M00KCF</(0<2DR"TAYKS6KKY#=]81B\R.T&;EB51.>YP_=W#=2ET=V,?W^.7<
M.7E;?L:XF84<C2Q2@:/_@DJA@%=<@+$F6-JUA34/6F[3T&6@W$SG=P;Q'J&
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ML\V;Y>9_X:9.49XEC8QB-]JR$B4HQ6@':R> 8KF8G F%L]9U$?O2-O$PL#&
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M$T"V@L(NJ#722Z=06U_NV(OGQE:74MNH%>,X*,_JS%M1]Z@6.D3/E!K-^#U
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MS< .("HE@&S@V.J4(93>\QB\0,YXASBX?^ & E(I*4Y),$D6'Z!2K NEB8N
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MK[OLPE/ LG:;7;[P:Z'F,_YPZ2C\8.J_4$L#!!0    ( !&!#%L1>[=5=P<
M !DE   7    961I="TR,#(U,#8S,'AE>#,Q,BYH=&WM6FUOVS@2_KZ_@IOB
MNBE@.Y9C)[:3!LBF*9 /=[O;*[ ?%Y1(640D44M2=GR__IXAY;?8V;I(+W46
M5Z".)0Z'PYF'SPQ)7V:NR*\N,\G%U0^7/[;;[(-.ZD*6CB5&<B<%JZTJ)^QW
M(>T]:[<;J1M=S8V:9([UNKT!^UV;>S7EH=TIE\NKA9[+D_!\>>('N8RUF%]=
M"C5E2KP_4GW1.Q_UXM/^<"3ZZ3 9\7Z?GT:](1\,Q;GL_Q$=H2O$0Q_KYKE\
M?U2HLIU)&G_<'U3N8J:$R\91M_N/(R]W=9GJTF$P@\[A:]"QK8F;"90Y7:$[
M-#GYX-H\5Y-R[.=W%%0MQ!.=:S-^T_7_+JBEG?)"Y?/Q3S?H%1OU4\ORTK:M
M-"H- E;]1XZC",K]XRS8?8[^N2KE8AY1CXR_?<A4K!P[C3J]3<OWLSF!QZ5Y
M8:-O;C]]OOMX=W/]^>Z7?_U[7[/_9T;V=QIYUV+7Q9S]RHVRNFRQ1!JGTCES
M&7=OWPR&%WN[N^)"8$FT<YFZ\>G9(@"J%'#^N!T-7WQN46=A_,N-NNF&4>?L
MC*9]QS(^E<S(J9(SD(?+E&6_U=P E?F<?9*5-H[IDGW4IF!1M_T;TRF[%<IQ
MR_XIA4HP3(O=E4D'01F]YJ#T#B8H/W.+4,#IP/]]J6>Y%!,XV<?&A(@(+2TK
M-5@?(W!5,E[.65TZ4TM8CCS@4P)"Q5F!)Z-XSE*>X)5AN@!A.1WDM@1*F4AK
MN9F32,'O)<9=TVGQ3L 8#)G[?((Q2"!1!OD#8B6ZPQ(A#9ME*LF8K>ECU7\F
MC6R4T 0*97,D&LI9,^4R3-!6,O$&DMX*IFF!:4[13;!XONZ&UPZYT\.'G&2I
M*A%4PL<JB"W@#>)H-FOMJDS!$MPIZ%%EDM<".@&4M8BU #)%S%(AS@11@FZ>
MKS#8A-\^&AHP!^<H2@20J',( '@:Z/##66]/PFW&TES/[ *51DZ4=89C($XO
M@]VPLK4&+KLP9LO:UXZO_L'@Z_-&,-Z^&?:B\PO;(*A)[40!.DT5'GV8[A@W
MT@," 59Q+BEP3 *%<:YL1N(D5H#^B +I62B;Y-K6Z$?$:'0>D%$9G4B!UY8=
M PA" EDAVK</2<;+B637X)Q/=0Z)Z)2WH\&Q?.>[1@,1GL*CHGJM#(@D_8R(
M:0VH 3ADR]X#I1L#I1B(YOD8OI"@5/V,TN>\=P"0Y < R=$Y3?N#M*C $1R?
MH+Z,G!;ESH37=O\NE,1B"10T(X6TJ&L#!>">J;*>T2 E2Z^'BML5%Z[SJ9$Y
M][!J\N(*&JV&:ZE1@1=AB]6Y$GXS:.O8*J%01-,$5,C>GN%+TE1;RJA^%5J?
M?CW_:2MA$+:!OE.%8E E=<Z)MC$M;\0J,Z-'R//KY0F^Q9($P:SH+\4SF/0@
M8!L? &S[9]NPW9N.MM"[/Y'M#6( ?ZH$89-CR\:)L;D%KJDF),!R(Q;@ 9P5
MCU6NW)QR]:YA:2EYG'D(A56P(;I64_K$\-!,J*I-!0A;7ULDB3;"&^"KRXDL
M43+D0#):9$5+A$10.0>T8BFI"MS\VO&:?'>\1MW.P,_[=LKSVI,115.F*<H[
M-44<[(XR;5D9[$&NX7%WY>;QB8X@1AOJPUC7[FD+]J%_OI265/RF7]Z?L'A1
M5OLE)X,G8(^'%PWPBB$FOCO$EI08@K<- MH4-U67;]F)M*\@0LK..DEJ0Z%>
M2X4[M!;:.KRG\SWHL@D4_1F.5=CQ$UU28!84]4BZ,1Q[&^GW\[35+^NE7>^"
M51FWR[J!R,UC7 K/^MX?#2//L6N_EWFSN7\DWWJVBYZ)ZX/8- T. -?/V33Y
M SVQ6!*M%0<1):[#<D5'!*ROJ"2V2M"E:1QEJ-/&+I.W?P&51:&<D_(O"#_6
M* ^H72C8YY4< [S@5TO\C;]4#"]6G/RS5C#?KZZZ3/P9P+O_[XV^U=[H.D=Y
MA7)/ 5BT^Z1];*(DD-#DW>4>92;Y/2724&[Y5.H+17_0N#B>^2I\-=N)L/??
M05M<H*.52]9Z$HM->8DN !2JP%;(YA:IW-8%X  G^<DTV6+G0=;?(5,?SN;E
M&@DY-2"%%J(L/8\!)_X8N %4*^0S54YU/I64U$H^:4ZS34-]LJAR/9=HG64Z
M\!W?@"O@]4TR?N<K[L:<W^\TS3'@)DT;+LYY9>5X\>4"O%SE?#Y6I7>8[W31
M*(NU<[H8T_WHE,@=54!S2^@!%)J;J]/1J#/L#^GVU!G\%XN!FXO5CK]8/7%B
MNZU_UAD.HB>;NYVGV_Y*;:\S&IU_<ZW>V-Y>:D^\(X(SX&Y;\?+]T>G1HD,#
MQW&O>F#1YATL(?2QQX.SUR^G7V#9^.OP#U@(/I&QZWI26Z V.NM>1+V6O[E_
M=#O>..4;SO<EI_KS?#-CO^[9O'W3![GXS_6;ZXW9[0G2+DWR:"^/["':D)'G
MJ@KNH,-!1GZX> UN77=E;*YN,B53]G')U;^$VO?[>_DU^/+XUW# !;]M>?#=
MM@M/?'K:D?W6?\I3:>LOYL;AA'HJMW[<L\*ASV_=51<> XRUV^[RA=\#-9_A
MITDG_B=1_P502P,$%     @ $8$,6_NS^1S=!   S!<  !<   !E9&ET+3(P
M,C4P-C,P>&5X,S(Q+FAT;>U8;6_;-A#^OE]Q<[ V 2Q'DNW:EMP KN-L&;:X
MC5UT^S30$F43H4F-I))XOWY'2LIKL_E#F\;#C,"P<B^\>^[X'*GARJSYT7!%
M27KTW?![SX-CF11K*@PDBA)#4R@T$TOXE%)] 9Y7:8UEOE%LN3(0^F$7/DEU
MP2Y)*3?,<'I4^QD>EL_#0[?(<"'3S=$P99? TK<-UJ=!N]WQDTXOZ'3"-.F'
M9$$'@W:[.R#];K_S1]! 4U0O;;39</JVL6;"6U&[?M3IYB:^8JE918'O_]!P
M>D?#3 J#BRDT+G^6/AY[(FJ)SHS,T1P]&7IM/,+94D0NOT;IJE9/))<JVO/=
M)[82+R-KQC?1ZS%:+11[W=1$:$]3Q;)20;._:!0$Z-P]7I5Q]]">,T'K/(+0
M!C^Y7K$%,] .6\']R+>+.4'$J7H0]((D%TLE"Y%Z5?R9^\1?.YOQY'Q^>G(Z
M'LU/IV<SF)[ >#*%T=DQC$^F\/[C^>SCZ&P.\RD$??C8FK7&+9A-QE8;@G;7
M;SX)P8M->32#T?'T_7QR?#>_W<NC+L/ ?V/K-O]I K/1^;O1V63F37_[9?([
MC,9S*PE]/]RV4Y\_N<YGDSL5D$@A:&*8%'#%S K,BFGX4!"%-> ;.*>Y5 90
M>B+5&@+?^P R@TG*#-'P*TU9@EZ;<"J2%NR;%857>_TP]..Q7.=$;-Q3$!]
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M&"$+4LN[SUUE%8=Y(% 7^!>-\Q031;RVH*WVG6)?%WBG)F/=VH$BC?!Z)XX
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M*@<6_#<S-IX#4#T"(/)U%7K+CE!)9Y*\OJ:'-12&(_Y,FX0% 0#GJM8&&G!
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M93N;Y6N,%K)96.RM3EVA]MO0AO@B$V(S&^)K3(BM-,P7*9A--(R40Q#GE=7
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M_,8&G[V=N,XFC^FIW)*,/$E]-"3,I#0F$@K><!NX\7BC4D%Q2X(( :S_?:P
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M+3(P,C4P-C,P7W!R92YX;6Q02P$"% ,4    "  1@0Q;@07)+( '   W)0
M%P              @ $3W ( 961I="TR,#(U,#8S,'AE>#,Q,2YH=&U02P$"
M% ,4    "  1@0Q;$7NW57<'   9)0  %P              @ '(XP( 961I
M="TR,#(U,#8S,'AE>#,Q,BYH=&U02P$"% ,4    "  1@0Q;^[/Y'-T$  #,
M%P  %P              @ %TZP( 961I="TR,#(U,#8S,'AE>#,R,2YH=&U0
M2P$"% ,4    "  1@0Q;QT"!:]DE  #DF   '               @ &&\ (
M97@S,2UR97-T871E9&-H87)T97)A<V%M+FAT;5!+!08     "@ * *,"  "9
%%@,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>edit-20250630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:edit="http://www.editasmedicine.com/20250630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="edit-20250630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2025-08-07</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:EmployeeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:EmployeeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edit:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edit:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:LicensorExpenseReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:LicensorExpenseReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:LicensorExpenseReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:LicensorExpenseReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:LicenseAndServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:LicenseAndServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:LicenseAndServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:LicenseAndServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:AmendedCollaborationAgreement2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:AmendedCollaborationAgreement2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">edit:DRIHealthcareAcquisitionsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-03</startDate>
            <endDate>2024-10-03</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">edit:DRIHealthcareAcquisitionsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-03</startDate>
            <endDate>2024-10-03</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">edit:DRIHealthcareAcquisitionsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-03</startDate>
            <endDate>2024-10-03</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">edit:DRIHealthcareAcquisitionsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">edit:DRIHealthcareAcquisitionsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">edit:DRIHealthcareAcquisitionsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2024-12-11</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:EmployeeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:AccelerationOfExpenseChangeInUsefulLifeEstimateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:ImpairmentChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:EmployeeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:EmployeeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:AccelerationOfExpenseChangeInUsefulLifeEstimateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:AccelerationOfExpenseChangeInUsefulLifeEstimateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:ImpairmentChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">edit:ImpairmentChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edit:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">edit:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="security">
        <measure>edit:security</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="position">
        <measure>edit:position</measure>
    </unit>
    <unit id="segment">
        <measure>edit:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001650664</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-1" id="f-100">http://fasb.org/us-gaap/2025#ServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-5" id="f-101">http://fasb.org/us-gaap/2025#ServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-6" id="f-102">http://fasb.org/us-gaap/2025#ServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-7" id="f-103">http://fasb.org/us-gaap/2025#ServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RestrictedCash contextRef="c-3" decimals="-3" id="f-338" unitRef="usd">3877000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-53" decimals="-3" id="f-339" unitRef="usd">3877000</us-gaap:RestrictedCash>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37687</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">EDITAS MEDICINE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">46-4097528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">11 Hurley Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">02141</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">401-9000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">EDIT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">89920164</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">138542000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">131541000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">39959000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">138372000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">588000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">16266000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">3707000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">3136000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">182796000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">289315000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">4576000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">14497000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">19011000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">32554000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">4198000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">5223000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">210581000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">341589000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">6723000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">5493000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">48068000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">45859000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">5000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">5000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">6221000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">6146000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">14652000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">65937000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">77225000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">14989000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">20380000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">51670000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">52434000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">54204000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">54204000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">4592000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">3072000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">191392000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">207315000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-70"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-71"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-72" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-73" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-74" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-75" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-76" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-77" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-80"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-81"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-82" unitRef="shares">390000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-83" unitRef="shares">195000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-84" unitRef="shares">87388425</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-85" unitRef="shares">87388425</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-86" unitRef="shares">82734696</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-87" unitRef="shares">82734696</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-88" unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-90" unitRef="usd">1616931000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">1602441000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-92" unitRef="usd">15000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">268000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-94" unitRef="usd">-1597766000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">-1468443000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-96" unitRef="usd">19189000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">134274000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-98" unitRef="usd">210581000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-99" unitRef="usd">341589000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">3578000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-105" unitRef="usd">513000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">8236000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-107" unitRef="usd">1649000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-108" unitRef="usd">16181000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-109" unitRef="usd">54210000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">42774000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-111" unitRef="usd">102997000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-112" unitRef="usd">12859000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-113" unitRef="usd">18206000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">26234000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-115" unitRef="usd">37545000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">26082000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-6" decimals="-3" id="f-117" unitRef="usd">0</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">66935000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-7" decimals="-3" id="f-119" unitRef="usd">0</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-120" unitRef="usd">55122000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-121" unitRef="usd">72416000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">135943000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-123" unitRef="usd">140542000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-124" unitRef="usd">-51544000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-125" unitRef="usd">-71903000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">-127707000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-127" unitRef="usd">-138893000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-128" unitRef="usd">-1758000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-129" unitRef="usd">-1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">-2183000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-131" unitRef="usd">5000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt contextRef="c-5" decimals="-3" id="f-132" unitRef="usd">2020000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-6" decimals="-3" id="f-133" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">4236000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-7" decimals="-3" id="f-135" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InvestmentIncomeNet contextRef="c-5" decimals="-3" id="f-136" unitRef="usd">2087000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-6" decimals="-3" id="f-137" unitRef="usd">4297000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">4803000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-7" decimals="-3" id="f-139" unitRef="usd">9331000</us-gaap:InvestmentIncomeNet>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-140" unitRef="usd">-1691000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-141" unitRef="usd">4296000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">-1616000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-143" unitRef="usd">9336000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-144" unitRef="usd">-53235000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-145" unitRef="usd">-67607000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">-129323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-147" unitRef="usd">-129557000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-148"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">-0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-151"
      unitRef="usdPerShare">-0.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-152"
      unitRef="usdPerShare">-1.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-153"
      unitRef="usdPerShare">-1.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-154"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-155"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-156" unitRef="shares">84412200</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-157" unitRef="shares">84412200</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-158" unitRef="shares">82310368</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-159" unitRef="shares">82310368</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-160" unitRef="shares">83737382</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-161" unitRef="shares">83737382</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-162" unitRef="shares">82124603</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-163" unitRef="shares">82124603</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-164" unitRef="usd">-53235000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-165" unitRef="usd">-67607000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">-129323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-167" unitRef="usd">-129557000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-168" unitRef="usd">-73000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-169" unitRef="usd">-116000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">-253000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-7" decimals="-3" id="f-171" unitRef="usd">-640000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-172" unitRef="usd">-53308000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-173" unitRef="usd">-67723000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-174" unitRef="usd">-129576000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-3" id="f-175" unitRef="usd">-130197000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding contextRef="c-8" decimals="INF" id="f-176" unitRef="shares">82734696</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-177" unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-178" unitRef="usd">1602441000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-179" unitRef="usd">268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-180" unitRef="usd">-1468443000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-181" unitRef="usd">134274000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-12"
      decimals="INF"
      id="f-182"
      unitRef="shares">706236</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-13" decimals="-3" id="f-183" unitRef="usd">1435000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-14" decimals="-3" id="f-184" unitRef="usd">1435000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-12"
      decimals="INF"
      id="f-185"
      unitRef="shares">268604</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-186" unitRef="usd">2979000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-187" unitRef="usd">2979000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-188" unitRef="usd">-180000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-14" decimals="-3" id="f-189" unitRef="usd">-180000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-190" unitRef="usd">-76088000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-191" unitRef="usd">-76088000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-17"
      decimals="INF"
      id="f-192"
      unitRef="shares">83709536</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-193" unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-194" unitRef="usd">1606855000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-195" unitRef="usd">88000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-196" unitRef="usd">-1544531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-197" unitRef="usd">62420000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-22"
      decimals="INF"
      id="f-198"
      unitRef="shares">3419836</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-22" decimals="-3" id="f-199" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-23" decimals="-3" id="f-200" unitRef="usd">7184000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-5" decimals="-3" id="f-201" unitRef="usd">7185000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="-3" id="f-202" unitRef="usd">2664000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-203" unitRef="usd">2664000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-22"
      decimals="INF"
      id="f-204"
      unitRef="shares">102894</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-22"
      decimals="INF"
      id="f-205"
      unitRef="shares">156159</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-23" decimals="-3" id="f-206" unitRef="usd">228000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-5" decimals="-3" id="f-207" unitRef="usd">228000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-24" decimals="-3" id="f-208" unitRef="usd">-73000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-209" unitRef="usd">-73000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-3" id="f-210" unitRef="usd">-53235000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-211" unitRef="usd">-53235000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-26"
      decimals="INF"
      id="f-212"
      unitRef="shares">87388425</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-213" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-214" unitRef="usd">1616931000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-215" unitRef="usd">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-216" unitRef="usd">-1597766000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-217" unitRef="usd">19189000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-30"
      decimals="INF"
      id="f-218"
      unitRef="shares">81767263</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-219" unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-220" unitRef="usd">1580241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-221" unitRef="usd">198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-222" unitRef="usd">-1231350000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-223" unitRef="usd">349097000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-35"
      decimals="INF"
      id="f-224"
      unitRef="shares">21975</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-36" decimals="-3" id="f-225" unitRef="usd">192000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-37" decimals="-3" id="f-226" unitRef="usd">192000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-35"
      decimals="INF"
      id="f-227"
      unitRef="shares">445713</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-36" decimals="-3" id="f-228" unitRef="usd">7585000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-37" decimals="-3" id="f-229" unitRef="usd">7585000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-38" decimals="-3" id="f-230" unitRef="usd">-524000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-37" decimals="-3" id="f-231" unitRef="usd">-524000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-39" decimals="-3" id="f-232" unitRef="usd">-61950000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-37" decimals="-3" id="f-233" unitRef="usd">-61950000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-40"
      decimals="INF"
      id="f-234"
      unitRef="shares">82234951</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-235" unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-236" unitRef="usd">1588018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-237" unitRef="usd">-326000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-238" unitRef="usd">-1293300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-239" unitRef="usd">294400000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-45" decimals="-3" id="f-240" unitRef="usd">5010000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-241" unitRef="usd">5010000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-46"
      decimals="INF"
      id="f-242"
      unitRef="shares">121643</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-46"
      decimals="INF"
      id="f-243"
      unitRef="shares">72920</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-45" decimals="-3" id="f-244" unitRef="usd">322000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-6" decimals="-3" id="f-245" unitRef="usd">322000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-47" decimals="-3" id="f-246" unitRef="usd">-116000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-247" unitRef="usd">-116000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-48" decimals="-3" id="f-248" unitRef="usd">-67607000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-249" unitRef="usd">-67607000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-49"
      decimals="INF"
      id="f-250"
      unitRef="shares">82429514</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-251" unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-252" unitRef="usd">1593350000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-253" unitRef="usd">-442000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-254" unitRef="usd">-1360907000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-255" unitRef="usd">232009000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-256" unitRef="usd">-129323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-257" unitRef="usd">-129557000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">5643000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-259" unitRef="usd">12595000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-260" unitRef="usd">3751000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-261" unitRef="usd">2829000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-262" unitRef="usd">-2193000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-7" decimals="-3" id="f-263" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">840000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-7" decimals="-3" id="f-265" unitRef="usd">3596000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <edit:InterestRelatedToSaleOfFutureRevenues contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">4236000</edit:InterestRelatedToSaleOfFutureRevenues>
    <edit:InterestRelatedToSaleOfFutureRevenues contextRef="c-7" decimals="-3" id="f-267" unitRef="usd">0</edit:InterestRelatedToSaleOfFutureRevenues>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">3724000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c-7" decimals="-3" id="f-269" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">390000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-7" decimals="-3" id="f-271" unitRef="usd">415000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-272" unitRef="usd">-15678000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-7" decimals="-3" id="f-273" unitRef="usd">-9943000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-274" unitRef="usd">418000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-275" unitRef="usd">-535000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <edit:IncreaseDecreaseInRightOfUseAssets contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">-8694000</edit:IncreaseDecreaseInRightOfUseAssets>
    <edit:IncreaseDecreaseInRightOfUseAssets contextRef="c-7" decimals="-3" id="f-277" unitRef="usd">3271000</edit:IncreaseDecreaseInRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-278" unitRef="usd">-1025000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-7" decimals="-3" id="f-279" unitRef="usd">-443000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">1231000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-281" unitRef="usd">5967000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">2271000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="-3" id="f-283" unitRef="usd">-6538000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <edit:IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">-2128000</edit:IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues>
    <edit:IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues contextRef="c-7" decimals="-3" id="f-285" unitRef="usd">0</edit:IncreaseDecreaseInInterestRelatedToSaleOfFutureRevenues>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">-6221000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-7" decimals="-3" id="f-287" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">-9048000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-289" unitRef="usd">2162000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">1911000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-7" decimals="-3" id="f-291" unitRef="usd">1969000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-292" unitRef="usd">-98011000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-293" unitRef="usd">-106934000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">114000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-295" unitRef="usd">5365000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">151000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="c-7" decimals="-3" id="f-297" unitRef="usd">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-7" decimals="-3" id="f-299" unitRef="usd">86221000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">99000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-7" decimals="-3" id="f-301" unitRef="usd">138795000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">99037000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-303" unitRef="usd">47209000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfDebt contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">2872000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-7" decimals="-3" id="f-305" unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">8619000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-307" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-309" unitRef="usd">192000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">228000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-7" decimals="-3" id="f-311" unitRef="usd">322000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">5975000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-313" unitRef="usd">514000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">7001000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-315" unitRef="usd">-59211000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-316" unitRef="usd">135418000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-34" decimals="-3" id="f-317" unitRef="usd">127529000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-318" unitRef="usd">142419000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-53" decimals="-3" id="f-319" unitRef="usd">68318000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-320" unitRef="usd">138542000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-53" decimals="-3" id="f-321" unitRef="usd">64441000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-3" decimals="-3" id="f-322" unitRef="usd">3877000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-53" decimals="-3" id="f-323" unitRef="usd">3877000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-324" unitRef="usd">142419000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-53" decimals="-3" id="f-325" unitRef="usd">68318000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCash contextRef="c-3" decimals="-3" id="f-326" unitRef="usd">3877000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-53" decimals="-3" id="f-327" unitRef="usd">3877000</us-gaap:RestrictedCash>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-7" decimals="-3" id="f-329" unitRef="usd">54000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">11048000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-7" decimals="-3" id="f-331" unitRef="usd">7683000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">766000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-333" unitRef="usd">794000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <edit:CommencementOfRightOfUseAsset contextRef="c-1" decimals="-3" id="f-334" unitRef="usd">0</edit:CommencementOfRightOfUseAsset>
    <edit:CommencementOfRightOfUseAsset contextRef="c-7" decimals="-3" id="f-335" unitRef="usd">7844000</edit:CommencementOfRightOfUseAsset>
    <edit:NonCashTerminationOfRightOfUseAsset contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">4849000</edit:NonCashTerminationOfRightOfUseAsset>
    <edit:NonCashTerminationOfRightOfUseAsset contextRef="c-7" decimals="-3" id="f-337" unitRef="usd">0</edit:NonCashTerminationOfRightOfUseAsset>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-340">Nature of Business&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Editas Medicine, Inc. (the &#x201c;Company&#x201d;) is a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, Inc. (&#x201c;Juno Therapeutics&#x201d;), a wholly owned subsidiary of the Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;), payments received under its former strategic alliance with Allergan Pharmaceuticals International Limited (together with its affiliates, &#x201c;Allergan&#x201d;), which was terminated in August 2020, payments received under the purchase and sale agreement with DRI Healthcare Acquisitions LP (&#x201c;DRI&#x201d;), and payments received in conjunction with the Company&#x2019;s license agreement with Vertex Pharmaceuticals, Inc (&#x201c;Vertex&#x201d;, and such agreement, the &#x201c;Vertex License Agreement&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of June&#160;30, 2025, the Company has raised an aggregate of $1.0 billion in net proceeds through the sale of shares of its common stock in public offerings and at-the-market offerings. The Company also has funded its business from payments received under its purchase and sale agreement with DRI, payments received under the Vertex License Agreement, its research collaboration with BMS through its wholly owned subsidiary Juno Therapeutics and its former strategic alliance with Allergan (which was terminated in August 2020). As of June&#160;30, 2025, the Company had cash, cash equivalents and marketable securities of $178.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2021, the Company entered into a common stock sales agreement with TD Securities (USA) LLC (as successor to Cowen and Company, LLC) (&#x201c;TD Cowen&#x201d;), under which the Company from time to time can issue and sell shares of the Company&#x2019;s common stock through TD Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $300.0 million. The Company amended the common stock sales agreement with TD Cowen in February 2024 in connection with filing a new registration statement.  In March 2025, the Company further amended its common stock sales agreement with TD Cowen in connection with amending its existing shelf registration statement following the loss of the Company&#x2019;s status as a &#x201c;well-known seasoned issuer&#x201d; (as defined under Rule 405 of the Securities Act of 1933, as amended), reducing the amount of shares of common stock the Company may issue and sell through TD Cowen to aggregate gross sale proceeds of up to $150.0&#160;million (the &#x201c;ATM Facility&#x201d;). As of June&#160;30, 2025, the Company has sold 4,126,072 shares of common stock under the ATM Facility for gross proceeds of $8.6 million and has $141.4 million available under the ATM Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred annual net operating losses in every year since its inception.  As of August&#160;12, 2025, the issuance date of the consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance date of the consolidated financial statements. The Company had an accumulated deficit of $1.6 billion at June&#160;30, 2025, and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#x2019;s business, results of operations, and financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-1" decimals="-8" id="f-341" unitRef="usd">1000000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <edit:CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal contextRef="c-3" decimals="-5" id="f-342" unitRef="usd">178500000</edit:CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal>
    <edit:SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued contextRef="c-54" decimals="-5" id="f-343" unitRef="usd">300000000.0</edit:SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued>
    <edit:SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued contextRef="c-55" decimals="-5" id="f-344" unitRef="usd">150000000</edit:SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-56"
      decimals="INF"
      id="f-345"
      unitRef="shares">4126072</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-56" decimals="-5" id="f-346" unitRef="usd">8600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <edit:SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable contextRef="c-57" decimals="-5" id="f-347" unitRef="usd">141400000</edit:SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAvailable>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-8" id="f-348" unitRef="usd">-1600000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-349">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2024 (the &#x201c;Annual Report&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Editas Securities Corporation and Editas Medicine, LLC. All intercompany transactions and balances of the subsidiaries have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.  The three months ended June&#160;30, 2025 and 2024 are referred to as the second quarter of 2025 and 2024, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are described in Note 2, &#x201c;Summary of Significant Accounting Policies,&#x201d; to the consolidated financial statements included in the Annual Report. There have been no material changes to the significant accounting policies previously disclosed in the Annual Report with the exception of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records liabilities for costs associated with restructuring activities in the period in which the liability is incurred.  Typical costs associated with restructuring activities include, employee termination benefits, contract termination costs and on-going contract costs for which there is no economic benefit.  For costs associated with employee terminations in which the employee is subject to an existing benefit arrangement, the post-employment benefits are recognized when probable and estimable.  Other employee termination costs are measured and recognized on the communication date, unless there is a required future service period, in which case, the expense is recognized over the service period.  Contract termination costs are recognized upon termination of the contract and costs for on-going contracts for which there is no future benefit, are recognized at fair value on the cease-use date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has made estimates and judgments regarding the amount and timing of its restructuring expense and liability, including current and future period termination benefits and other exit costs to be incurred when related actions take place. Restructuring charges are reflected in the Company's condensed consolidated statements of operations. Actual results may differ from these estimates.  Refer to Note 12, &#x201c;Restructuring and Impairment Charges&#x201d; for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company will incorporate the changes in disclosure requirements in its financial statements included in its 2025 Annual Report.     &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income -Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is intended to improve the disclosure of expenses by providing more detailed information about the types of expenses in commonly presented expense captions. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments can be applied either prospectively or retrospectively. The Company has not early adopted this ASU and is currently evaluating the impact of this new standard on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-350">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company will incorporate the changes in disclosure requirements in its financial statements included in its 2025 Annual Report.     &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income -Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is intended to improve the disclosure of expenses by providing more detailed information about the types of expenses in commonly presented expense captions. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments can be applied either prospectively or retrospectively. The Company has not early adopted this ASU and is currently evaluating the impact of this new standard on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-351">Cash Equivalents and Marketable Securities &lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and marketable securities consisted of the following at June&#160;30, 2025 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Allowance&lt;br/&gt;for Credit&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;178,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;178,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and marketable securities consisted of the following at December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Allowance&lt;br/&gt;for Credit&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;269,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;269,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company did not hold any marketable securities that were in a continuous unrealized loss position for more than twelve months. Furthermore, the Company has determined that there were no material changes in the credit risk of the securities. As of June&#160;30, 2025, the Company holds no securities with remaining maturities greater than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no realized gains or losses on available-for-sale securities during the six months ended June&#160;30, 2025 or 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-352">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and marketable securities consisted of the following at June&#160;30, 2025 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Allowance&lt;br/&gt;for Credit&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;178,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;178,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and marketable securities consisted of the following at December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Allowance&lt;br/&gt;for Credit&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;269,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;269,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-58" decimals="-3" id="f-353" unitRef="usd">39944000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-58" decimals="-3" id="f-354" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-58" decimals="-3" id="f-355" unitRef="usd">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-58" decimals="-3" id="f-356" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-58" decimals="-3" id="f-357" unitRef="usd">39959000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-59" decimals="-3" id="f-358" unitRef="usd">138542000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-59" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-59" decimals="-3" id="f-360" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-59" decimals="-3" id="f-361" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-59" decimals="-3" id="f-362" unitRef="usd">138542000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-363" unitRef="usd">178486000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-3" decimals="-3" id="f-364" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-365" unitRef="usd">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-366" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-367" unitRef="usd">178501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-60" decimals="-3" id="f-368" unitRef="usd">131541000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-60" decimals="-3" id="f-369" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-60" decimals="-3" id="f-370" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-60" decimals="-3" id="f-371" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-60" decimals="-3" id="f-372" unitRef="usd">131541000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-61" decimals="-3" id="f-373" unitRef="usd">6522000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-61" decimals="-3" id="f-374" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-61" decimals="-3" id="f-375" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-61" decimals="-3" id="f-376" unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-61" decimals="-3" id="f-377" unitRef="usd">6501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-62" decimals="-3" id="f-378" unitRef="usd">131582000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-62" decimals="-3" id="f-379" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-62" decimals="-3" id="f-380" unitRef="usd">289000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-62" decimals="-3" id="f-381" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-62" decimals="-3" id="f-382" unitRef="usd">131871000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-383" unitRef="usd">269645000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-384" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-385" unitRef="usd">289000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-386" unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-387" unitRef="usd">269913000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-3" decimals="INF" id="f-388" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <edit:MarketableSecuritiesNoncurrentNumberOfSecurities
      contextRef="c-3"
      decimals="INF"
      id="f-389"
      unitRef="security">0</edit:MarketableSecuritiesNoncurrentNumberOfSecurities>
    <edit:MarketableSecuritiesRemainingMaturityTerm contextRef="c-1" id="f-390">P1Y</edit:MarketableSecuritiesRemainingMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-1" decimals="INF" id="f-391" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-7" decimals="INF" id="f-392" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-393">Fair Value Measurements&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured at fair value on a recurring basis as of June&#160;30, 2025 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured at fair value on a recurring basis as of December&#160;31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;273,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;267,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s liability for sale of future revenues approximates the amount recorded on the Company&#x2019;s balance sheet as of June&#160;30, 2025 and December&#160;31, 2024, which represents a level 3 fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-394">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured at fair value on a recurring basis as of June&#160;30, 2025 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured at fair value on a recurring basis as of December&#160;31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;273,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;267,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-63" decimals="-3" id="f-395" unitRef="usd">138542000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-64" decimals="-3" id="f-396" unitRef="usd">138542000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-397" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-66" decimals="-3" id="f-398" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-67" decimals="-3" id="f-399" unitRef="usd">39959000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-68" decimals="-3" id="f-400" unitRef="usd">39959000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-69" decimals="-3" id="f-401" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-70" decimals="-3" id="f-402" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-63" decimals="-3" id="f-403" unitRef="usd">3877000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-64" decimals="-3" id="f-404" unitRef="usd">3877000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-65" decimals="-3" id="f-405" unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-66" decimals="-3" id="f-406" unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-407" unitRef="usd">182378000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-408" unitRef="usd">182378000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-409" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-74" decimals="-3" id="f-410" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-75" decimals="-3" id="f-411" unitRef="usd">131541000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-76" decimals="-3" id="f-412" unitRef="usd">131541000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-77" decimals="-3" id="f-413" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-78" decimals="-3" id="f-414" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-79" decimals="-3" id="f-415" unitRef="usd">6501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-80" decimals="-3" id="f-416" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-81" decimals="-3" id="f-417" unitRef="usd">6501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-82" decimals="-3" id="f-418" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-83" decimals="-3" id="f-419" unitRef="usd">131871000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-84" decimals="-3" id="f-420" unitRef="usd">131871000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-85" decimals="-3" id="f-421" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-86" decimals="-3" id="f-422" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-75" decimals="-3" id="f-423" unitRef="usd">3877000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-76" decimals="-3" id="f-424" unitRef="usd">3877000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-77" decimals="-3" id="f-425" unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-78" decimals="-3" id="f-426" unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-87" decimals="-3" id="f-427" unitRef="usd">273790000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-88" decimals="-3" id="f-428" unitRef="usd">267289000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-89" decimals="-3" id="f-429" unitRef="usd">6501000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-90" decimals="-3" id="f-430" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-431">Accrued Expenses&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;External research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublicense and license fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property and patent related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional service expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract termination costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-432">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;External research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublicense and license fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property and patent related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional service expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract termination costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <edit:AccruedExternalResearchAndDevelopmentExpensesCurrent contextRef="c-3" decimals="-3" id="f-433" unitRef="usd">2870000</edit:AccruedExternalResearchAndDevelopmentExpensesCurrent>
    <edit:AccruedExternalResearchAndDevelopmentExpensesCurrent contextRef="c-4" decimals="-3" id="f-434" unitRef="usd">11630000</edit:AccruedExternalResearchAndDevelopmentExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-435" unitRef="usd">3488000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-436" unitRef="usd">11516000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <edit:SublicenseAndLicenseFeesCurrent contextRef="c-3" decimals="-3" id="f-437" unitRef="usd">0</edit:SublicenseAndLicenseFeesCurrent>
    <edit:SublicenseAndLicenseFeesCurrent contextRef="c-4" decimals="-3" id="f-438" unitRef="usd">6609000</edit:SublicenseAndLicenseFeesCurrent>
    <edit:IntellectualPropertyAndPatentRelatedFeesCurrent contextRef="c-3" decimals="-3" id="f-439" unitRef="usd">685000</edit:IntellectualPropertyAndPatentRelatedFeesCurrent>
    <edit:IntellectualPropertyAndPatentRelatedFeesCurrent contextRef="c-4" decimals="-3" id="f-440" unitRef="usd">1471000</edit:IntellectualPropertyAndPatentRelatedFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-3" decimals="-3" id="f-441" unitRef="usd">432000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-442" unitRef="usd">1593000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:RestructuringReserveCurrent contextRef="c-91" decimals="-3" id="f-443" unitRef="usd">6592000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:RestructuringReserveCurrent contextRef="c-92" decimals="-3" id="f-444" unitRef="usd">10475000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:RestructuringReserveCurrent contextRef="c-93" decimals="-3" id="f-445" unitRef="usd">33743000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:RestructuringReserveCurrent contextRef="c-94" decimals="-3" id="f-446" unitRef="usd">1757000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-447" unitRef="usd">258000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-448" unitRef="usd">808000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-449" unitRef="usd">48068000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-450" unitRef="usd">45859000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-451">Property and Equipment, net&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(26,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(31,648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-452">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(26,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(31,648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-95" decimals="-3" id="f-453" unitRef="usd">21066000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-96" decimals="-3" id="f-454" unitRef="usd">29128000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-97" decimals="-3" id="f-455" unitRef="usd">8404000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-98" decimals="-3" id="f-456" unitRef="usd">11749000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-99" decimals="-3" id="f-457" unitRef="usd">1399000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-100" decimals="-3" id="f-458" unitRef="usd">1490000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-101" decimals="-3" id="f-459" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-102" decimals="-3" id="f-460" unitRef="usd">827000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-103" decimals="-3" id="f-461" unitRef="usd">191000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-104" decimals="-3" id="f-462" unitRef="usd">264000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-105" decimals="-3" id="f-463" unitRef="usd">344000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-106" decimals="-3" id="f-464" unitRef="usd">2687000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-465" unitRef="usd">31404000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-466" unitRef="usd">46145000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-467" unitRef="usd">26828000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-468" unitRef="usd">31648000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-469" unitRef="usd">4576000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-470" unitRef="usd">14497000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-471">Commitments and Contingencies&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to a number of license agreements under which the Company licenses patents, patent applications and other intellectual property from third parties. As such, the Company is obligated to pay licensors for various costs including upfront license fees, annual license fees, certain licensor expense reimbursements, success payments, research funding payments, and milestones triggerable upon certain development, regulatory, and commercial events as well as royalties on future product sales. These contracts are generally cancellable, with notice, at the Company&#x2019;s option and do not have significant cancellation penalties. The terms and conditions as well as the accounting analysis for the Company&#x2019;s significant commitments and contingencies are described in Note 8, &#x201c;Commitments and Contingencies&#x201d; to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensor Expense Reimbursement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is obligated to reimburse The Broad Institute, Inc. (&#x201c;Broad&#x201d;) and the President and Fellows of Harvard College (&#x201c;Harvard&#x201d;) for expenses incurred by each of them associated with the prosecution and maintenance of the patent rights that the Company licenses from them pursuant to the Amended and Restated Cas9-I License Agreement by and among the Company, Broad and Harvard, including the interference and opposition proceedings involving patents licensed to the Company under the license agreement, and other license agreements between the Company and Broad. As such, the Company anticipates that it has a substantial commitment in connection with these proceedings until such time as these proceedings have been resolved, but the amount of such commitment is not determinable. The Company incurred an aggregate of $2.3 million and $4.2 million in expenses during the three and six months ended June&#160;30, 2025.  The Company incurred an aggregate of $2.5 million and $4.6 million in expense during the three months and six months ended June&#160;30, 2024, respectively, for such reimbursement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Termination &lt;/span&gt;&lt;/div&gt;In 2023, the Company entered into a license and service agreement pursuant to which it leased manufacturing space for its continued research and development activities. The lease commenced April 1, 2024. In September 2024, the Company modified the lease, and as a result of the modification the lease payments decreased and the notification period for the termination of the license and service agreement increased from 12 months&#x2019; prior written notice to 18 months&#x2019; prior written notice. In January 2025, the Company gave its termination notice on the license and service agreement, which resulted in the end of the term of the agreement being July 2026, and $8.9 million of remaining payments owed.  In April 2025, the Company further modified the lease to terminate on April 30, 2025 with a final fixed payment of $3.7&#160;million.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ProfessionalAndContractServicesExpense contextRef="c-107" decimals="-5" id="f-472" unitRef="usd">2300000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense contextRef="c-108" decimals="-5" id="f-473" unitRef="usd">4200000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense contextRef="c-109" decimals="-5" id="f-474" unitRef="usd">2500000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense contextRef="c-110" decimals="-5" id="f-475" unitRef="usd">4600000</us-gaap:ProfessionalAndContractServicesExpense>
    <edit:OperatingLeaseTerminationNotificationPeriod contextRef="c-111" id="f-476">P12M</edit:OperatingLeaseTerminationNotificationPeriod>
    <edit:OperatingLeaseTerminationNotificationPeriod contextRef="c-112" id="f-477">P18M</edit:OperatingLeaseTerminationNotificationPeriod>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-113" decimals="-5" id="f-478" unitRef="usd">8900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeasePayments contextRef="c-114" decimals="-3" id="f-479" unitRef="usd">3700000</us-gaap:OperatingLeasePayments>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-480">Collaboration Agreements &lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into multiple collaborations, out-licenses and strategic alliances with third parties that typically involve payments to or from the Company, including up-front payments, payments for research and development services, option payments, milestone payments and royalty payments to or from the Company. The terms and conditions as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;well as the accounting analysis for the Company&#x2019;s significant collaborations, out-licenses and strategic alliances are described in Note 9, &#x201c;Collaboration Agreements&#x201d; to the consolidated financial statements included in the Annual Report.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no other material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company&#x2019;s contract liabilities were primarily related to the Company&#x2019;s collaboration with BMS. The following table presents changes in the Company&#x2019;s accounts receivable and contract liabilities for the six months ended June&#160;30, 2025 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three and six months ended June 30, 2025 and 2024, the Company recognized the following collaboration revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue recognized in the period from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts included in deferred revenue at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance obligations satisfied in previous periods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Amendment to BMS Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2024, the Company entered into an amendment (&#x201c;2024 Amendment&#x201d;) to the Second Amended and Restated Collaboration and License Agreement, dated as of November 11, 2019, by and between the Company and Juno Therapeutics (the &#x201c;2019 Collaboration Agreement&#x201d;) to extend the collaboration to November 2026, with options to extend the collaboration for up to an additional two years, and provided Juno Therapeutics the ability to select up to three new gene targets for research.  The 2019 Collaboration Agreement, as amended by the 2024 Amendment, is herein referred to as the 2019 Amended Collaboration Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s accounting assessment for the 2024 Amendment is described in Note 9, &#x201c;Collaboration Agreements,&#x201d; to the consolidated financial statements included in the Annual Report. &lt;/span&gt;&lt;/div&gt;As of June&#160;30, 2025, there was no short-term deferred revenue and $50.2 million of long-term deferred revenue in the accompanying consolidated balance sheets.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <edit:ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock contextRef="c-1" id="f-481">The following table presents changes in the Company&#x2019;s accounts receivable and contract liabilities for the six months ended June&#160;30, 2025 (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</edit:ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock>
    <us-gaap:ReceivablesNetCurrent contextRef="c-4" decimals="-3" id="f-482" unitRef="usd">16266000</us-gaap:ReceivablesNetCurrent>
    <edit:AccountsReceivableAdditions contextRef="c-1" decimals="-3" id="f-483" unitRef="usd">2181000</edit:AccountsReceivableAdditions>
    <edit:AccountsReceivableDeductions contextRef="c-1" decimals="-3" id="f-484" unitRef="usd">17859000</edit:AccountsReceivableDeductions>
    <us-gaap:ReceivablesNetCurrent contextRef="c-3" decimals="-3" id="f-485" unitRef="usd">588000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-3" id="f-486" unitRef="usd">60425000</us-gaap:ContractWithCustomerLiability>
    <edit:ContractWithCustomerLiabilityAdditions contextRef="c-1" decimals="-3" id="f-487" unitRef="usd">0</edit:ContractWithCustomerLiabilityAdditions>
    <edit:ContractWithCustomerLiabilityDeductions contextRef="c-1" decimals="-3" id="f-488" unitRef="usd">6221000</edit:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability contextRef="c-3" decimals="-3" id="f-489" unitRef="usd">54204000</us-gaap:ContractWithCustomerLiability>
    <edit:ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-490">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three and six months ended June 30, 2025 and 2024, the Company recognized the following collaboration revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue recognized in the period from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts included in deferred revenue at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance obligations satisfied in previous periods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</edit:ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-5" decimals="-3" id="f-491" unitRef="usd">2000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-3" id="f-492" unitRef="usd">6221000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-6" decimals="-3" id="f-493" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-7" decimals="-3" id="f-494" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="c-5" decimals="-3" id="f-495" unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="c-1" decimals="-3" id="f-496" unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="c-6" decimals="-3" id="f-497" unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="c-7" decimals="-3" id="f-498" unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <edit:AgreementExtensionPeriodOptionsToExtend contextRef="c-115" id="f-499">P2Y</edit:AgreementExtensionPeriodOptionsToExtend>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-116" decimals="INF" id="f-500" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-116" decimals="-5" id="f-501" unitRef="usd">50200000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-502">&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Unit Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of restricted stock unit awards activity for the six months ended June&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock unit awards as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,326,523&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,560&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(371,498)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,033,046)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock unit awards as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;923,539&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no restricted stock units that contained performance-based vesting provisions granted in the six months ended June&#160;30, 2025.  There was no expense related to the vesting of performance-based restricted stock units for the three and six months ended June&#160;30, 2025 and $0.1 million and $3.5 million of expense related to the vesting of performance-based restricted stock units for the three and six months ended June&#160;30, 2024, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, total unrecognized compensation expense related to unvested restricted stock unit awards was $6.4 million, which the Company expects to recognize over a remaining weighted-average period of 1.99 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option activity for the six months ended June&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;br/&gt;Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,656,010&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,581,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,791,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,445,817&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,026,696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, total unrecognized compensation expense related to stock options was $15.1 million, which the Company expects to recognize over a remaining weighted-average period of 2.7 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-503">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-117" decimals="-3" id="f-504" unitRef="usd">863000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="-3" id="f-505" unitRef="usd">2125000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-119" decimals="-3" id="f-506" unitRef="usd">1770000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-120" decimals="-3" id="f-507" unitRef="usd">5033000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-121" decimals="-3" id="f-508" unitRef="usd">1801000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-122" decimals="-3" id="f-509" unitRef="usd">2885000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-123" decimals="-3" id="f-510" unitRef="usd">3873000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-124" decimals="-3" id="f-511" unitRef="usd">7562000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-512" unitRef="usd">2664000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-513" unitRef="usd">5010000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-514" unitRef="usd">5643000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-515" unitRef="usd">12595000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-516">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of restricted stock unit awards activity for the six months ended June&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock unit awards as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,326,523&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,560&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(371,498)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,033,046)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock unit awards as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;923,539&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-125"
      decimals="INF"
      id="f-517"
      unitRef="shares">2326523</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-125"
      decimals="2"
      id="f-518"
      unitRef="usdPerShare">9.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-126"
      decimals="INF"
      id="f-519"
      unitRef="shares">1560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-126"
      decimals="2"
      id="f-520"
      unitRef="usdPerShare">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-126"
      decimals="INF"
      id="f-521"
      unitRef="shares">371498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-126"
      decimals="2"
      id="f-522"
      unitRef="usdPerShare">10.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-126"
      decimals="INF"
      id="f-523"
      unitRef="shares">1033046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-126"
      decimals="2"
      id="f-524"
      unitRef="usdPerShare">10.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-127"
      decimals="INF"
      id="f-525"
      unitRef="shares">923539</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-127"
      decimals="2"
      id="f-526"
      unitRef="usdPerShare">9.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-128"
      decimals="INF"
      id="f-527"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-128" decimals="INF" id="f-528" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-129" decimals="INF" id="f-529" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-130" decimals="-5" id="f-530" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-131" decimals="-5" id="f-531" unitRef="usd">3500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-127" decimals="-5" id="f-532" unitRef="usd">6400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-126" id="f-533">P1Y11M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-534">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option activity for the six months ended June&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;br/&gt;Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,656,010&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,581,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,791,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,445,817&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,026,696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-132"
      decimals="INF"
      id="f-535"
      unitRef="shares">7656010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-132"
      decimals="2"
      id="f-536"
      unitRef="usdPerShare">14.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-133" id="f-537">P7Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-132" decimals="-3" id="f-538" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-134"
      decimals="INF"
      id="f-539"
      unitRef="shares">5581038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-134"
      decimals="2"
      id="f-540"
      unitRef="usdPerShare">1.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-134"
      decimals="INF"
      id="f-541"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-134"
      decimals="2"
      id="f-542"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-134"
      decimals="INF"
      id="f-543"
      unitRef="shares">2791231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-134"
      decimals="2"
      id="f-544"
      unitRef="usdPerShare">11.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-135"
      decimals="INF"
      id="f-545"
      unitRef="shares">10445817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-135"
      decimals="2"
      id="f-546"
      unitRef="usdPerShare">8.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-134" id="f-547">P7Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-135" decimals="-3" id="f-548" unitRef="usd">2505000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-135"
      decimals="INF"
      id="f-549"
      unitRef="shares">4026696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-135"
      decimals="2"
      id="f-550"
      unitRef="usdPerShare">16.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-134" id="f-551">P5Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-135" decimals="-3" id="f-552" unitRef="usd">120000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-135" decimals="-5" id="f-553" unitRef="usd">15100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-134" id="f-554">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-555">Net Loss per Share&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury stock and if converted methods. Contingently issuable shares are included in the calculation of basic loss per share as of the beginning of the period in which all the necessary conditions have been satisfied. Contingently issuable shares are included in diluted loss per share based on the number of shares, if any, that would be issuable under the terms of the arrangement if the end of the reporting period was the end of the contingency period, if the results are dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of the diluted net loss per share calculation, unvested restricted stock unit awards and outstanding stock options are considered to be common stock equivalents, but they were excluded from the Company&#x2019;s calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;923,539&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,618,361&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,445,817&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,268,790&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,369,356&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,887,151&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-556">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;923,539&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,618,361&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,445,817&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,268,790&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,369,356&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,887,151&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-136" decimals="0" id="f-557" unitRef="shares">923539</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-137" decimals="0" id="f-558" unitRef="shares">2618361</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-138" decimals="0" id="f-559" unitRef="shares">10445817</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-139" decimals="0" id="f-560" unitRef="shares">8268790</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-561" unitRef="shares">11369356</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="0" id="f-562" unitRef="shares">10887151</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-563">Debt &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability for the Sale of Future Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 3, 2024, the Company entered into a purchase and sale agreement (the &#x201c;Purchase and Sale Agreement&#x201d;) with DRI under which it sold, transferred, assigned, and conveyed to DRI certain future license fees and other payments (the &#x201c;Purchased Receivables&#x201d;) owed to the Company by Vertex under the terms of the Vertex License Agreement in exchange for an upfront cash payment by DRI to the Company of $57.0&#160;million. Under the Purchase and Sale Agreement, DRI is purchasing up to 100% of certain future fixed and sales-based annual license fees owed to the Company under the Vertex License Agreement, which fees range from $5.0&#160;million to $40.0&#160;million per year (inclusive of certain sales-based annual license fee increases) and a mid-double-digit percentage of a $50.0&#160;million contingent upfront payment that the Company may receive under the Vertex License Agreement, in each case after subtracting amounts that will be owed by the Company to Broad and Harvard (each term as defined in Note 8, respectively). The Company has retained rights to its portions of certain other sales-based annual license fees and the contingent upfront payment that may become due under the Vertex License Agreement, and the amounts that correspond to its licensor obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 470, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Borrower&#x2019;s Accounting for Debt Modification&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has accounted for the transaction as debt. The gross proceeds of $57.0 million were recorded as a liability for the sale of future revenues, net of transaction costs of $1.8 million, which will be amortized over the estimated life of the arrangement using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the effective interest rate used to record non-cash interest expense under the Purchase and Sale Agreement based on the estimate of future revenue payments to be made to DRI. As of June&#160;30, 2025, the estimated effective interest rate under the agreement was 15.1%. Over the life of the arrangement, the actual effective interest rate will be affected by the amount and timing of the payments made to DRI and changes in the Company's revenue forecasts. At each reporting date, the Company will reassess its estimate of total future payments to be made to DRI, and prospectively adjust the effective interest rate and amortization of the liability as necessary. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the liability related to the sale of future revenues under the Purchase and Sale Agreement with DRI as of June&#160;30, 2025 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred royalty obligation related to the sale of future revenues, net as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments for sale of future revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense associated with sale of future revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred royalty obligation related to the sale of future revenues, net as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-140" decimals="-5" id="f-564" unitRef="usd">57000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <edit:LicenseFeeReceivable contextRef="c-141" decimals="-5" id="f-565" unitRef="usd">5000000</edit:LicenseFeeReceivable>
    <edit:LicenseFeeReceivable contextRef="c-142" decimals="-5" id="f-566" unitRef="usd">40000000</edit:LicenseFeeReceivable>
    <edit:ContingentFeeReceivableThresholdAmount contextRef="c-140" decimals="-5" id="f-567" unitRef="usd">50000000</edit:ContingentFeeReceivableThresholdAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-140" decimals="-5" id="f-568" unitRef="usd">57000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-140" decimals="-5" id="f-569" unitRef="usd">1800000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <edit:LiabilityForSaleOfFutureRevenuesEffectiveInterestRate contextRef="c-143" decimals="3" id="f-570" unitRef="number">0.151</edit:LiabilityForSaleOfFutureRevenuesEffectiveInterestRate>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-571">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the liability related to the sale of future revenues under the Purchase and Sale Agreement with DRI as of June&#160;30, 2025 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred royalty obligation related to the sale of future revenues, net as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments for sale of future revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense associated with sale of future revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred royalty obligation related to the sale of future revenues, net as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt contextRef="c-144" decimals="-3" id="f-572" unitRef="usd">57434000</us-gaap:LongTermDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-143" decimals="-3" id="f-573" unitRef="usd">5000000</us-gaap:RepaymentsOfDebt>
    <edit:NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues contextRef="c-143" decimals="-3" id="f-574" unitRef="usd">4117000</edit:NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-143" decimals="-3" id="f-575" unitRef="usd">119000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:LongTermDebt contextRef="c-145" decimals="-3" id="f-576" unitRef="usd">56670000</us-gaap:LongTermDebt>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-577">Restructuring and Impairment Charges                                  &lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 11, 2024, the Company&#x2019;s board of directors approved the discontinuation of the clinical development of the Company's reni-cel program to treat sickle cell disease and transfusion-dependent beta thalassemia (the &#x201c;Discontinuation&#x201d;). As a result of the Discontinuation, the Company has ceased activities towards the filing of a biologic license application and potential commercialization of reni-cel.  In connection with the Discontinuation, the Board also approved a reduction in the Company&#x2019;s employee workforce by approximately 180 positions, or approximately 65% (the &#x201c;Reduction&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the Discontinuation and Reduction started in December 2024 through the six months ended June&#160;30, 2025, the Company has incurred the following restructuring and impairment charges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.484%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.219%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs for ongoing contracts and terminated contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acceleration of expense for change in useful life estimate and lease termination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred the following restructuring and impairment charges for the three and six months ended June&#160;30, 2025, which are recorded in the consolidated statements of operations (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.593%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs for ongoing contracts and terminated contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acceleration of expense for change in useful life estimate and lease termination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actions associated with the Discontinuation and Reduction commenced in December 2024 and are expected to be substantially completed by the end of 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Termination Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employees affected by the Reduction received involuntary termination benefits pursuant to either a one-time benefit or arrangement or salary continuation for a set period of time in accordance with the Company&#x2019;s Amended and Restated Severance Benefit Plan (the &#x201c;Benefit Plan&#x201d;). For employees who were notified of their termination in December 2024 and had no requirements to provide future services or were subject to the Benefit Plan, the Company recognized the liability for the termination benefits in full at fair value in the fourth quarter of 2024.  For employees who are required to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;render services beyond a minimum retention period to receive their one-time termination benefits or salary continuation, the Company is recognizing the termination benefits ratably over their future service periods.  The service periods began in December 2024 and all will end at various dates throughout 2025.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the liability related to employee termination benefits as of June&#160;30, 2025 (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.484%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Termination Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued employee termination benefits as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee termination benefits charges incurred during period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts paid or otherwise settled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued employee termination benefits as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company expects that it will incur approximately $15.0 million of employee termination benefit expense to implement the Reduction.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Costs for Ongoing Contracts and Terminated Contracts &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Discontinuation resulted in contract termination costs from vendor contracts before the end of their term, as well as costs that continue to be incurred under certain contracts with no future economic benefit to the Company.  In accordance with ASC 420, the Company recognized these unavoidable contract costs when incurred for terminated contracts or at the cease-use date, as it relates to contract costs that continue to be incurred.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the liability related to costs for ongoing contracts and contract termination costs as of June&#160;30, 2025 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.060%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued contract costs as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract costs incurred during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts paid or otherwise settled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued contract costs as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2025, $4.0 million of accrued contract costs was included in Other non-current liabilities on the Consolidated Balance Sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These costs are subject to significant estimation based on the Company's expectation of the costs that will continue to be incurred on the contracts, as well as negotiation of contract changes and terminations with its vendors.  Changes in this estimate will be made in the period the information is known and could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment and Accelerated Depreciation Charges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the Discontinuation, the Company committed to a plan to actively sell specific assets within its asset group, primarily certain of its laboratory and manufacturing equipment. At March 31, 2025, the laboratory and manufacturing equipment met all of the prescribed criteria required to classify it as held for sale.  The Company recorded $0.3 million of held for sale assets at their fair value at March 31, 2025, resulting in a $3.7 million impairment charge during the three months ended March 31, 2025.  The sale was completed in April 2025.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company abandoned certain other leasehold improvements, software, and right of use assets in the second quarter of 2025, and as a result, the Company accelerated depreciation and rent expense and recorded the following in the condensed consolidated statements of operations (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accelerated depreciation related to leasehold improvements and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges related to termination of lease &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-146"
      decimals="INF"
      id="f-578"
      unitRef="position">180</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="c-146"
      decimals="INF"
      id="f-579"
      unitRef="number">0.65</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-580">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the Discontinuation and Reduction started in December 2024 through the six months ended June&#160;30, 2025, the Company has incurred the following restructuring and impairment charges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.484%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.219%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs for ongoing contracts and terminated contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acceleration of expense for change in useful life estimate and lease termination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred the following restructuring and impairment charges for the three and six months ended June&#160;30, 2025, which are recorded in the consolidated statements of operations (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.593%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs for ongoing contracts and terminated contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acceleration of expense for change in useful life estimate and lease termination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company abandoned certain other leasehold improvements, software, and right of use assets in the second quarter of 2025, and as a result, the Company accelerated depreciation and rent expense and recorded the following in the condensed consolidated statements of operations (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accelerated depreciation related to leasehold improvements and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges related to termination of lease &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-147" decimals="-3" id="f-581" unitRef="usd">14797000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-148" decimals="-3" id="f-582" unitRef="usd">54098000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-149" decimals="-3" id="f-583" unitRef="usd">6548000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-150" decimals="-3" id="f-584" unitRef="usd">3724000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-151" decimals="-3" id="f-585" unitRef="usd">79167000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-152" decimals="-3" id="f-586" unitRef="usd">813000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-153" decimals="-3" id="f-587" unitRef="usd">4322000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-154" decimals="-3" id="f-588" unitRef="usd">23466000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-155" decimals="-3" id="f-589" unitRef="usd">52341000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-156" decimals="-3" id="f-590" unitRef="usd">1803000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-157" decimals="-3" id="f-591" unitRef="usd">6548000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-158" decimals="-3" id="f-592" unitRef="usd">0</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-159" decimals="-3" id="f-593" unitRef="usd">3724000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-5" decimals="-3" id="f-594" unitRef="usd">26082000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-1" decimals="-3" id="f-595" unitRef="usd">66935000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <edit:ScheduleOfEmployeeTerminationBenefitsTableTextBlock contextRef="c-1" id="f-596">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the liability related to employee termination benefits as of June&#160;30, 2025 (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.484%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Termination Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued employee termination benefits as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee termination benefits charges incurred during period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts paid or otherwise settled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued employee termination benefits as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</edit:ScheduleOfEmployeeTerminationBenefitsTableTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-92" decimals="-3" id="f-597" unitRef="usd">10475000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-153" decimals="-3" id="f-598" unitRef="usd">4322000</us-gaap:RestructuringCharges>
    <edit:PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash contextRef="c-153" decimals="-3" id="f-599" unitRef="usd">8205000</edit:PaymentsForRestructuringAndRestructuringReserveSettledWithoutCash>
    <us-gaap:RestructuringReserve contextRef="c-91" decimals="-3" id="f-600" unitRef="usd">6592000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-91" decimals="-5" id="f-601" unitRef="usd">15000000.0</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <edit:ScheduleOfContractTerminationCostsTableTextBlock contextRef="c-1" id="f-602">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the liability related to costs for ongoing contracts and contract termination costs as of June&#160;30, 2025 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.060%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued contract costs as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract costs incurred during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts paid or otherwise settled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued contract costs as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</edit:ScheduleOfContractTerminationCostsTableTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-94" decimals="-3" id="f-603" unitRef="usd">1757000</us-gaap:RestructuringReserve>
    <us-gaap:LossOnContractTermination contextRef="c-155" decimals="-3" id="f-604" unitRef="usd">52341000</us-gaap:LossOnContractTermination>
    <edit:AmountsPaidOrOtherwiseSettled contextRef="c-155" decimals="-3" id="f-605" unitRef="usd">16364000</edit:AmountsPaidOrOtherwiseSettled>
    <us-gaap:RestructuringReserve contextRef="c-93" decimals="-3" id="f-606" unitRef="usd">37734000</us-gaap:RestructuringReserve>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent contextRef="c-160" decimals="-5" id="f-607" unitRef="usd">300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:AssetImpairmentCharges contextRef="c-161" decimals="-5" id="f-608" unitRef="usd">3700000</us-gaap:AssetImpairmentCharges>
    <us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="c-5" decimals="-3" id="f-609" unitRef="usd">1072000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="c-1" decimals="-3" id="f-610" unitRef="usd">1790000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <edit:ChargesRelatedToTerminationOfLease contextRef="c-5" decimals="-3" id="f-611" unitRef="usd">731000</edit:ChargesRelatedToTerminationOfLease>
    <edit:ChargesRelatedToTerminationOfLease contextRef="c-1" decimals="-3" id="f-612" unitRef="usd">4758000</edit:ChargesRelatedToTerminationOfLease>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-156" decimals="-3" id="f-613" unitRef="usd">1803000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c-157" decimals="-3" id="f-614" unitRef="usd">6548000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-615">Segments&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) or decision-making group in making decisions on how to allocate resources and assess performance.  The Company&#x2019;s CODM is its CEO.  The CEO views the Company&#x2019;s operations and manages the Company&#x2019;s business as one operating segment, which is the business of developing and commercializing genome editing technology.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s CEO manages and allocates resources to the operations of the Company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with our long-term company-wide strategic goals.  In making these decisions, the Company&#x2019;s CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.  The CODM performs this assessment based on the Company&#x2019;s consolidated net loss.  Through this analysis, the CODM assesses performance by comparing actual consolidated net loss versus the budget, and then decides how to allocate resources to invest in the Company&#x2019;s research and development programs.  The measure of segment assets is reported on the consolidated balance sheet as total assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table contains additional information on our consolidated revenue and net loss, including significant segment expenses (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.515%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.462%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.462%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration and other research and development revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;External research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Facility expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublicense and license fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional service expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property and patent related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Facility and other expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(51,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(71,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(127,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(138,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (expense) income, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest related to sale of future revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(53,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(67,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(129,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(129,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The three and six months ended June&#160;30, 2025 and 2024 include $24,830 and $64,075 and $- and $- of restructuring and impairment charges, respectively.   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The three and six months ended June&#160;30, 2025 and 2024 include $1,251 and $2,860 and $- and $- of restructuring and impairment charges, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other expenses primarily consists of impairment charges, consultant fees and office expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Facility and other expenses primarily consists of rent expense, insurance premiums, depreciation expense, software licenses and office expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-616"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-617">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table contains additional information on our consolidated revenue and net loss, including significant segment expenses (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.515%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.462%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.462%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration and other research and development revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;External research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Facility expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublicense and license fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional service expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property and patent related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Facility and other expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(51,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(71,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(127,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(138,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (expense) income, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest related to sale of future revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(53,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(67,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(129,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(129,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The three and six months ended June&#160;30, 2025 and 2024 include $24,830 and $64,075 and $- and $- of restructuring and impairment charges, respectively.   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The three and six months ended June&#160;30, 2025 and 2024 include $1,251 and $2,860 and $- and $- of restructuring and impairment charges, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other expenses primarily consists of impairment charges, consultant fees and office expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Facility and other expenses primarily consists of rent expense, insurance premiums, depreciation expense, software licenses and office expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-162" decimals="-3" id="f-618" unitRef="usd">3578000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-163" decimals="-3" id="f-619" unitRef="usd">513000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-164" decimals="-3" id="f-620" unitRef="usd">8236000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-165" decimals="-3" id="f-621" unitRef="usd">1649000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LaborAndRelatedExpense contextRef="c-166" decimals="-3" id="f-622" unitRef="usd">8575000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-167" decimals="-3" id="f-623" unitRef="usd">13661000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-168" decimals="-3" id="f-624" unitRef="usd">22742000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-169" decimals="-3" id="f-625" unitRef="usd">27344000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-166" decimals="-3" id="f-626" unitRef="usd">25111000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-167" decimals="-3" id="f-627" unitRef="usd">27025000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-168" decimals="-3" id="f-628" unitRef="usd">60466000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-169" decimals="-3" id="f-629" unitRef="usd">44613000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OccupancyNet contextRef="c-166" decimals="-3" id="f-630" unitRef="usd">4581000</us-gaap:OccupancyNet>
    <us-gaap:OccupancyNet contextRef="c-167" decimals="-3" id="f-631" unitRef="usd">7370000</us-gaap:OccupancyNet>
    <us-gaap:OccupancyNet contextRef="c-168" decimals="-3" id="f-632" unitRef="usd">13974000</us-gaap:OccupancyNet>
    <us-gaap:OccupancyNet contextRef="c-169" decimals="-3" id="f-633" unitRef="usd">12589000</us-gaap:OccupancyNet>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-166" decimals="-3" id="f-634" unitRef="usd">863000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-167" decimals="-3" id="f-635" unitRef="usd">2125000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-168" decimals="-3" id="f-636" unitRef="usd">1770000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-169" decimals="-3" id="f-637" unitRef="usd">5033000</us-gaap:AllocatedShareBasedCompensationExpense>
    <edit:SublicenseAndLicenseFees contextRef="c-166" decimals="-3" id="f-638" unitRef="usd">95000</edit:SublicenseAndLicenseFees>
    <edit:SublicenseAndLicenseFees contextRef="c-167" decimals="-3" id="f-639" unitRef="usd">857000</edit:SublicenseAndLicenseFees>
    <edit:SublicenseAndLicenseFees contextRef="c-168" decimals="-3" id="f-640" unitRef="usd">112000</edit:SublicenseAndLicenseFees>
    <edit:SublicenseAndLicenseFees contextRef="c-169" decimals="-3" id="f-641" unitRef="usd">6753000</edit:SublicenseAndLicenseFees>
    <us-gaap:OtherExpenses contextRef="c-166" decimals="-3" id="f-642" unitRef="usd">1787000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c-167" decimals="-3" id="f-643" unitRef="usd">3172000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c-168" decimals="-3" id="f-644" unitRef="usd">7785000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c-169" decimals="-3" id="f-645" unitRef="usd">6665000</us-gaap:OtherExpenses>
    <us-gaap:LaborAndRelatedExpense contextRef="c-170" decimals="-3" id="f-646" unitRef="usd">3436000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-171" decimals="-3" id="f-647" unitRef="usd">4800000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-172" decimals="-3" id="f-648" unitRef="usd">8541000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-173" decimals="-3" id="f-649" unitRef="usd">9690000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ProfessionalFees contextRef="c-170" decimals="-3" id="f-650" unitRef="usd">3711000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c-171" decimals="-3" id="f-651" unitRef="usd">3893000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c-172" decimals="-3" id="f-652" unitRef="usd">6151000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c-173" decimals="-3" id="f-653" unitRef="usd">6808000</us-gaap:ProfessionalFees>
    <edit:IntellectualPropertyAndPatentRelatedFees contextRef="c-170" decimals="-3" id="f-654" unitRef="usd">3221000</edit:IntellectualPropertyAndPatentRelatedFees>
    <edit:IntellectualPropertyAndPatentRelatedFees contextRef="c-171" decimals="-3" id="f-655" unitRef="usd">3845000</edit:IntellectualPropertyAndPatentRelatedFees>
    <edit:IntellectualPropertyAndPatentRelatedFees contextRef="c-172" decimals="-3" id="f-656" unitRef="usd">5767000</edit:IntellectualPropertyAndPatentRelatedFees>
    <edit:IntellectualPropertyAndPatentRelatedFees contextRef="c-173" decimals="-3" id="f-657" unitRef="usd">7790000</edit:IntellectualPropertyAndPatentRelatedFees>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-170" decimals="-3" id="f-658" unitRef="usd">1801000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-171" decimals="-3" id="f-659" unitRef="usd">2885000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-172" decimals="-3" id="f-660" unitRef="usd">3873000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-173" decimals="-3" id="f-661" unitRef="usd">7562000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:OccupancyNet contextRef="c-170" decimals="-3" id="f-662" unitRef="usd">1941000</us-gaap:OccupancyNet>
    <us-gaap:OccupancyNet contextRef="c-171" decimals="-3" id="f-663" unitRef="usd">2783000</us-gaap:OccupancyNet>
    <us-gaap:OccupancyNet contextRef="c-172" decimals="-3" id="f-664" unitRef="usd">4762000</us-gaap:OccupancyNet>
    <us-gaap:OccupancyNet contextRef="c-173" decimals="-3" id="f-665" unitRef="usd">5695000</us-gaap:OccupancyNet>
    <us-gaap:OperatingExpenses contextRef="c-162" decimals="-3" id="f-666" unitRef="usd">55122000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-163" decimals="-3" id="f-667" unitRef="usd">72416000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-164" decimals="-3" id="f-668" unitRef="usd">135943000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-165" decimals="-3" id="f-669" unitRef="usd">140542000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-162" decimals="-3" id="f-670" unitRef="usd">-51544000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-163" decimals="-3" id="f-671" unitRef="usd">-71903000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-164" decimals="-3" id="f-672" unitRef="usd">-127707000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-165" decimals="-3" id="f-673" unitRef="usd">-138893000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-162" decimals="-3" id="f-674" unitRef="usd">-1758000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-163" decimals="-3" id="f-675" unitRef="usd">-1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-164" decimals="-3" id="f-676" unitRef="usd">-2183000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-165" decimals="-3" id="f-677" unitRef="usd">5000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt contextRef="c-5" decimals="-3" id="f-678" unitRef="usd">2020000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-6" decimals="-3" id="f-679" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-3" id="f-680" unitRef="usd">4236000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-7" decimals="-3" id="f-681" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InvestmentIncomeNet contextRef="c-162" decimals="-3" id="f-682" unitRef="usd">2087000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-163" decimals="-3" id="f-683" unitRef="usd">4297000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-164" decimals="-3" id="f-684" unitRef="usd">4803000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-165" decimals="-3" id="f-685" unitRef="usd">9331000</us-gaap:InvestmentIncomeNet>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-162" decimals="-3" id="f-686" unitRef="usd">-1691000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-163" decimals="-3" id="f-687" unitRef="usd">4296000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-164" decimals="-3" id="f-688" unitRef="usd">-1616000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-165" decimals="-3" id="f-689" unitRef="usd">9336000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-162" decimals="-3" id="f-690" unitRef="usd">-53235000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-163" decimals="-3" id="f-691" unitRef="usd">-67607000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-164" decimals="-3" id="f-692" unitRef="usd">-129323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-165" decimals="-3" id="f-693" unitRef="usd">-129557000</us-gaap:NetIncomeLoss>
    <us-gaap:RestructuringCharges contextRef="c-166" decimals="-3" id="f-694" unitRef="usd">24830000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-167" decimals="-3" id="f-695" unitRef="usd">64075000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-170" decimals="-3" id="f-696" unitRef="usd">1251000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-171" decimals="-3" id="f-697" unitRef="usd">2860000</us-gaap:RestructuringCharges>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-5" id="f-698">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-5" id="f-699">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-5" id="f-700">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-5" id="f-701">false</ecd:Rule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-323"
          xlink:label="f-323"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-322"
          xlink:label="f-322"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div><xhtml:table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"><xhtml:tr><xhtml:td style="width:1.0%"/><xhtml:td style="width:98.900%"/><xhtml:td style="width:0.1%"/></xhtml:tr><xhtml:tr style="height:15pt"><xhtml:td colspan="3" style="padding:0 1pt"/></xhtml:tr><xhtml:tr><xhtml:td
              colspan="3"
              style="padding:2px 1pt;text-align:left;vertical-align:top"><xhtml:div><xhtml:span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> As of June&#160;30, 2025 and June&#160;30, 2024, restricted cash of $3,877 and $3,877 was included in Restricted cash and other non-current assets on the Consolidated Balance Sheet, respectively.</xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-323"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-322"
          xlink:to="fn-1"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
